PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ho, M; Kreitman, RJ; Onda, M; Pastan, I				Ho, M; Kreitman, RJ; Onda, M; Pastan, I			In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIMICKING SOMATIC HYPERMUTATION; B-CELL LEUKEMIAS; PHAGE DISPLAY; RECOMBINANT IMMUNOTOXIN; AFFINITY MATURATION; CYTOTOXIC ACTIVITY; PSEUDOMONAS EXOTOXIN; DIRECTED EVOLUTION; BINDING-AFFINITY; FV FRAGMENT	Recombinant immunotoxin BL22, containing the Fv portion of an anti-CD22 antibody, produced complete remissions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias with low CD22 expression. Complementarity-determining region (CDR) mutagenesis is used to increase antibody affinity but can be difficult to perform successfully. We previously showed that antibodies with increased affinity and immunotoxins with increased activity could be obtained by directing mutations at specific DNA residues called hot spots. Because hot spots can arise either by somatic mutation or be present in the germline, we examined which type of hot spot is preferred for increasing antibody affinity. Initially, a second generation antibody phage-display library targeting a germline hot spot (Ser(30)-Asn(31)) within CDR1 of the antibody light chain was mutated. Substitution of serine 30 or asparagine 31 with arginine produced mutant immunotoxins with an affinity (0.8 nM) increased 7-fold over BL22 (5.8 nM) and 3-fold over the first generation mutant HA22 (2.3 nM). More importantly, a 10-fold increase in activity over BL22 and a 2-3-fold increase over HA22 were observed in various B lymphoma cell lines including WSU-CLL that contains only 5500 CD22 sites per cell. For comparison, two phage-display libraries targeting non-germline hot spots in heavy chain CDR1 and CDR3 were generated but did not produce Fv with increased affinity. Our results demonstrate that germline hot spots but not non-germline hot spots are effective for in vitro antibody affinity maturation.	NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Rm 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	Ho, Mitchell/F-5059-2015; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ho, Mitchell/0000-0002-9152-5405	NATIONAL CANCER INSTITUTE [ZIABC008753, Z01BC008753] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Beers R, 2000, CLIN CANCER RES, V6, P2835; Benedict CA, 1997, J IMMUNOL METHODS, V201, P223, DOI 10.1016/S0022-1759(96)00227-X; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; CAMPANA D, 1985, J IMMUNOL, V134, P1524; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; Frankel AE, 2000, CLIN CANCER RES, V6, P326; Ghetie V, 2001, MOL BIOTECHNOL, V18, P251, DOI 10.1385/MB:18:3:251; Graff CP, 2004, PROTEIN ENG DES SEL, V17, P293, DOI 10.1093/protein/gzh038; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; Jolly C J, 1996, Semin Immunol, V8, P159, DOI 10.1006/smim.1996.0020; Kabat E. A., 1991, NIH PUBLICATION; Krauss J, 2003, PROTEIN ENG, V16, P753, DOI 10.1093/protein/gzg096; Kreitman RJ, 1999, INT J CANCER, V81, P148; Kreitman RJ, 2000, CLIN CANCER RES, V6, P1476; KREITMAN RJ, 1995, SEMIN CANCER BIOL, V6, P297, DOI 10.1006/scbi.1995.0038; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Lavoie TB, 1999, MOL IMMUNOL, V36, P1189, DOI 10.1016/S0161-5890(99)00130-3; Lefranc MP, 2001, NUCLEIC ACIDS RES, V29, P207, DOI 10.1093/nar/29.1.207; Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Mansfield E, 1997, BLOOD, V90, P2020, DOI 10.1182/blood.V90.5.2020; Mohammad RM, 1996, LEUKEMIA, V10, P130; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Neuberger MS, 2002, BIOCHEM SOC T, V30, P341, DOI 10.1042/bst0300341; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; NEWMAN MA, 1992, J IMMUNOL, V149, P3260; Pastan I, 2003, CANCER IMMUNOL IMMUN, V52, P338, DOI 10.1007/s00262-002-0353-8; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rossmann E D, 2001, Hematol J, V2, P300, DOI 10.1038/sj.thj.6200119; Salvatore G, 2002, CLIN CANCER RES, V8, P995; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEN GL, 1988, INT J CANCER, V42, P792, DOI 10.1002/ijc.2910420527; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Wang CL, 2004, P NATL ACAD SCI USA, V101, P7352, DOI 10.1073/pnas.0402009101; Whitelegg NRJ, 2000, PROTEIN ENG, V13, P819, DOI 10.1093/protein/13.12.819; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	44	80	100	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					607	617		10.1074/jbc.M409783200	http://dx.doi.org/10.1074/jbc.M409783200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15491997	hybrid			2022-12-27	WOS:000226025100072
J	Matlhagela, K; Borsick, M; Rajkhowa, T; Taub, M				Matlhagela, K; Borsick, M; Rajkhowa, T; Taub, M			Identification of a prostaglandin-responsive element in the Na,K-ATPase beta(1) promoter that is regulated by cAMP and Ca2+ - Evidence for an interactive role of cAMP regulatory element-binding protein and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE BETA-1 GENE; RNA POLYMERASE-II; TRANSCRIPTION FACTORS; MDCK-CELLS; KINASE-II; SUBUNIT GENE; CREB; EXPRESSION; ACTIVATION; RAT	The Na,K-ATPase is a transmembrane protein responsible for maintaining electrochemical gradients across the plasma membrane in all mammalian cells, a process that is subject to regulation at the transcriptional as well as post-transcriptional level. Included among physiologic regulators in the kidney are prostaglandins. Previously, we demonstrated that prostaglandin E-1 (PGE(1)) increases the activity and expression of the Na,K-ATPase in Madin-Darby canine kidney cells (Taub, M., Borsick, M., Geisel, J., Matlhagela, K., Rajkhowa, T., and Allen, C. ( 2004) Exp. Cell Res. 299, 1-14; Taub, M. L., Wang, Y., Yang, I. S., Fiorella, P., and Lee, S. M. ( 1992) J. Cell. Physiol. 151, 337-346). In this work, we present evidence that transcription of the Na, K-ATPase beta(1) subunit is stimulated by PGE1, an effect that may be mediated through the cAMP and Ca2+ pathways. Transient transfection studies using 5'-deletion mutants of the human beta(1) subunit promoter indicated that region -100 to -92 containing the sequence AGTCCCTGC (a prostaglandin-responsive element (PGRE)) is required to elicit the stimulatory effects of PGE1, 8-bromo-cAMP, phorbol 12-myristate 13-acetate, and okadaic acid. Electrophoretic mobility shift assays indicated that both the cAMP regulatory element-binding protein ( CREB) and Sp1 bind to the PGRE present within this region of the beta(1) subunit promoter. The involvement of the PGRE and Sp1 sites in regulation by PGE1 was further confirmed by the increased PGE1 stimulation that was observed following insertion of the PGRE into a promoter/luciferase construct containing a portion of a heterologous promoter and the fibronectin promoter with four GC boxes. Further evidence suggesting an interaction between Sp1 and CREB was obtained from experiments conducted with pLuc-MCS-beta72-167, which contains region -167 to -72 in the human beta(1) subunit promoter. The PGE1 stimulation observed in Madin-Darby canine kidney cells transiently transfected with pLuc-MCS-beta72-167 was reduced when the two GC boxes immediately upstream from the PGRE were translocated farther upstream. Also consistent with an interaction between CREB and Sp1 are the results of our immunoprecipitation studies indicating that CREB co-immunoprecipitated with Sp1 when an antibody against CREB, Sp1, or the CREB-binding protein was used.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Taub, M (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	biochtau@buffalo.edu		Herman, Maryann/0000-0002-9652-8517; Taub, Mary/0000-0003-1382-3885	NHLBI NIH HHS [1R01HL6976-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABOOLIAN A, 1989, AM J PHYSIOL, V256, pF1135, DOI 10.1152/ajprenal.1989.256.6.F1135; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; BONVALET JP, 1987, AM J PHYSIOL, V253, pF377, DOI 10.1152/ajprenal.1987.253.3.F377; BONVENTRE JV, 1991, KIDNEY INT, V39, P438, DOI 10.1038/ki.1991.55; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breyer MD, 1998, KIDNEY INT, V54, pS88, DOI 10.1046/j.1523-1755.1998.06718.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CARER EP, 1997, AM J PHYSIOL, V272, pL542; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; CORTHESYTHEULAZ I, 1991, AM J PHYSIOL, V261, pC124, DOI 10.1152/ajpcell.1991.261.1.C124; Derfoul A, 1998, J BIOL CHEM, V273, P20702, DOI 10.1074/jbc.273.33.20702; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FENG JI, 1993, NUCLEIC ACIDS RES, V21, P2619, DOI 10.1093/nar/21.11.2619; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GICK GG, 1988, J BIOL CHEM, V263, P16610; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hocker M, 1998, J BIOL CHEM, V273, P34000, DOI 10.1074/jbc.273.51.34000; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Kim E, 2004, J BIOL CHEM, V279, P11188, DOI 10.1074/jbc.M313291200; KIM KS, 1994, J NEUROCHEM, V63, P834; KITAGAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P339, DOI 10.1016/0167-4781(91)90174-K; Kobayashi M, 1997, BIOCHEM BIOPH RES CO, V241, P169, DOI 10.1006/bbrc.1997.7781; KURSTJENS NP, 1990, BIOCHEM BIOPH RES CO, V167, P1162, DOI 10.1016/0006-291X(90)90645-4; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MAMIYA N, 1993, BIOCHEM BIOPH RES CO, V195, P608, DOI 10.1006/bbrc.1993.2089; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAIER MH, 1986, MINER ELECTROL METAB, V12, P42; SCHERZER P, 1992, CLIN SCI, V83, P307, DOI 10.1042/cs0830307; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Shell SA, 2002, BIOL REPROD, V66, P659, DOI 10.1095/biolreprod66.3.659; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; TAORMINO JP, 1990, J BIOL CHEM, V265, P4116; Taub M, 2004, EXP CELL RES, V299, P1, DOI 10.1016/j.yexcr.2004.04.046; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; TAUB ML, 1992, J CELL PHYSIOL, V151, P337, DOI 10.1002/jcp.1041510215; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; Uchida C, 2002, J BIOL CHEM, V277, P39082, DOI 10.1074/jbc.M201380200; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wendt CH, 2000, J BIOL CHEM, V275, P41396, DOI 10.1074/jbc.M004759200; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200; Zhuang Y, 2000, J BIOL CHEM, V275, P24173, DOI 10.1074/jbc.M002953200	57	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					334	346		10.1074/jbc.M411415200	http://dx.doi.org/10.1074/jbc.M411415200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15485816	hybrid			2022-12-27	WOS:000226025100041
J	Altroff, H; Schlinkert, R; van der Walle, CF; Bernini, A; Campbell, ID; Werner, JM; Mardon, HJ				Altroff, H; Schlinkert, R; van der Walle, CF; Bernini, A; Campbell, ID; Werner, JM; Mardon, HJ			Interdomain tilt angle determines integrin-dependent function of the ninth and tenth FIII domains of human fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; DIPOLAR COUPLINGS; CRYSTAL-STRUCTURE; POLYACRYLAMIDE GELS; HETERONUCLEAR NMR; PROTEINS; ALIGNMENT; COMPLEX; SEGMENT; SITE	Integrins are an important family of signaling receptors that mediate diverse cellular processes. The binding of the abundant extracellular matrix ligand fibronectin to integrins alpha(5)beta(1) and alpha(v)beta(3) is known to depend upon the Arg-Gly-Asp (RGD) motif on the tenth fibronectin FIII domain. The adjacent ninth FIII domain provides a synergistic effect on RGD-mediated integrin alpha(5)beta(1) binding and downstream function. The precise molecular basis of this synergy remains elusive. Here we have dissected further the function of FIII9 in integrin binding by analyzing the biological activity of the FIII9-10 interdomain interface variants and by determining their structural and dynamic properties in solution. We demonstrate that the contribution of FIII9 to both alpha(5)beta(1) and alpha(v)beta(3) binding and downstream function critically depends upon the interdomain tilt between the FIII9 and FIII10 domains. Our data suggest that modulation of integrin binding by FIII9 may arise in part from its steric properties that determine accessibility of the RGD motif. These findings have wider implications for mechanisms of integrin-ligand binding in the physiological context.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Mardon, HJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.	helen.mardon@obs-gyn.ox.ac.uk	Bernini, Andrea/H-9412-2012; Werner, Joern/E-1148-2013; Altroff, Harri/B-3544-2011; van der Walle, Chris/AAB-9641-2022	Bernini, Andrea/0000-0002-7528-2749; van der Walle, Christopher/0000-0002-1561-1213; Werner, Jorn/0000-0002-4712-1833	Wellcome Trust [073028] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Altroff H, 2003, J BIOL CHEM, V278, P491, DOI 10.1074/jbc.M209992200; AOTA S, 1994, J BIOL CHEM, V269, P24756; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Copie V, 1998, J MOL BIOL, V277, P663; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Ishii Y, 2001, J BIOMOL NMR, V21, P141, DOI 10.1023/A:1012417721455; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; Kauf ACW, 2001, BIOCHEMISTRY-US, V40, P9159, DOI 10.1021/bi010503x; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; OBARA M, 1995, EXP CELL RES, V216, P273, DOI 10.1006/excr.1995.1033; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Sass HJ, 2000, J BIOMOL NMR, V18, P303, DOI 10.1023/A:1026703605147; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; van der Walle CF, 2002, PROTEIN ENG, V15, P1021, DOI 10.1093/protein/15.12.1021; Werner Jorn M, 2002, Methods Mol Biol, V173, P285; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	44	54	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55995	56003		10.1074/jbc.M406976200	http://dx.doi.org/10.1074/jbc.M406976200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485890	hybrid, Green Accepted			2022-12-27	WOS:000225960800123
J	Ballou, CE				Ballou, CE			My brief encounter with the phosphoinositides and IP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							BEEF BRAIN PHOSPHOINOSITIDE; MYO-INOSITOL PHOSPHATES; MYCOBACTERIUM-TUBERCULOSIS; OX BRAIN; TRIPHOSPHOINOSITIDE; COMPLEX; DIPHOSPHOINOSITIDE; PHOSPHOLIPIDS; 1-PHOSPHATE; EXCHANGE		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ballou, CE (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	ceba@berkeley.edu						Anderson RJ, 1930, J AM CHEM SOC, V52, P1607, DOI 10.1021/ja01367a050; BALLOU CE, 1955, J AM CHEM SOC, V77, P5967, DOI 10.1021/ja01627a053; BALLOU CE, 1963, J BIOL CHEM, V238, P69; BALLOU CE, 1960, J AM CHEM SOC, V82, P3333, DOI 10.1021/ja01498a026; BALLOU CE, 1952, J CHEM SOC, P1054, DOI 10.1039/jr9520001054; BALLOU CE, 1953, J AM CHEM SOC, V75, P648, DOI 10.1021/ja01099a039; BALLOU CE, 1959, J AM CHEM SOC, V81, P4745, DOI 10.1021/ja01526a074; BALLOU CE, 1964, BIOCHEMISTRY-US, V3, P682, DOI 10.1021/bi00893a014; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1954, ADV CARBOHYD CHEM, V9, P59, DOI 10.1016/S0096-5332(08)60372-0; BALLOU CE, 1968, ACCOUNTS CHEM RES, V1, P366, DOI 10.1021/ar50012a003; BALLOU CE, 1964, 6 INT C BIOCH NEW YO, P547; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P1764; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P49; BROCKERHOFF H, 1961, J BIOL CHEM, V236, P1907; BROWN DM, 1952, J CHEM SOC, P52, DOI 10.1039/jr9520000052; BROWN DM, 1966, BIOCHIM BIOPHYS ACTA, V125, P413, DOI 10.1016/0005-2760(66)90029-4; BROWN DM, 1961, J CHEM SOC, P3774, DOI 10.1039/jr9610003774; CHANG M, 1967, BIOCHEM BIOPH RES CO, V26, P199, DOI 10.1016/0006-291X(67)90234-3; DAWSON RMC, 1954, BIOCHIM BIOPHYS ACTA, V14, P374, DOI 10.1016/0006-3002(54)90195-X; DITTMER JC, 1960, BIOCHIM BIOPHYS ACTA, V40, P379, DOI 10.1016/0006-3002(60)91375-5; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Fischer E., 1894, BER DTSCH CHEM GES, V27, P2478; FOLCH J, 1949, J BIOL CHEM, V177, P505; FOLCH J, 1949, J BIOL CHEM, V177, P497; GRADO C, 1961, J BIOL CHEM, V236, P54; GRAY GR, 1970, J BIOL CHEM, V246, P6835; HANAHAN DJ, 1958, J BIOL CHEM, V231, P813; HAWTHORNE JN, 1954, J BIOL CHEM, V206, P27; HAWTHORNE JN, 1955, BIOCHIM BIOPHYS ACTA, V18, P389, DOI 10.1016/0006-3002(55)90102-5; HENDRICKSON HS, 1964, J BIOL CHEM, V239, P1369; HEUBNER CF, 1944, J AM CHEM SOC, V66, P906; HOKIN LE, 1958, J BIOL CHEM, V233, P818; HOKIN MR, 1953, J BIOL CHEM, V203, P967; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; KABAT EA, 1953, J AM CHEM SOC, V75, P4507, DOI 10.1021/ja01114a034; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; MCKIBBIN JM, 1956, J BIOL CHEM, V220, P537; Moore S, 1940, J BIOL CHEM, V133, P293; PIZER FL, 1959, J AM CHEM SOC, V81, P915, DOI 10.1021/ja01513a040; TOMLINSON R, 1961, J BIOL CHEM, V236, P1902; TOMLINSON RV, 1962, BIOCHEMISTRY-US, V1, P166, DOI 10.1021/bi00907a025; VILKAS E, 1961, B SOC CHIM BIOL, V42, P1013; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Woolley D. W., 1943, JOUR BIOL CHEM, V147, P581	49	3	3	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					54975	54982		10.1074/jbc.X400010200	http://dx.doi.org/10.1074/jbc.X400010200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475347	hybrid			2022-12-27	WOS:000225960800001
J	Galigniana, MD; Morishima, Y; Gallay, PA; Pratt, WB				Galigniana, MD; Morishima, Y; Gallay, PA; Pratt, WB			Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; GLUCOCORTICOID-RECEPTOR; HSP90-BINDING IMMUNOPHILINS; MAMMALIAN PROTEIN; BINDING-PROTEIN; HIV-1 VIRIONS; CYCLOSPORIN-A; IN-VIVO; FKBP52; RAPAMYCIN	Although cyclophilin A (CyP-A) is a relatively abundant small immunophilin present in the cytoplasm of all mammalian cells, its general function(s) in the absence of the immunosuppressant drug cyclosporin A is not known. In contrast, the high molecular weight hsp90-binding immunophilins appear to play a role in protein trafficking in that they have been shown to link glucocorticoid receptor-hsp90 and p53.hsp90 complexes to the dynein motor protein for retrograde movement along microtubules. These immunophilins link to cytoplasmic dynein indirectly through the association of the immunophilin peptidylprolyl isomerase (PPIase) domain with dynamitin, a component of the dynein-associated dynactin complex (Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004) J. Biol. Chem. 279, 22483-22489). Here, we show that CyP-A exists in native heterocomplexes containing cytoplasmic dynein that can be formed in cell-free systems. Prolyl isomerase activity is not required for forming the dynein complex, but the PPIase domain fragment of FKBP52 blocks complex formation and CyP-A binds to dynamitin in a PPIase domain-dependent manner. CyP-A heterocomplexes containing tubulin and dynein can be formed in cytosol prepared under microtubule-stabilizing conditions, and CyP-A colocalizes in mouse fibroblasts with microtubules. Colocalization with microtubules is disrupted by overexpression of the PPIase domain fragment. Thus, we conclude that CyP-A associates in vitro and in vivo with the dynein/dynactin motor protein complex and we suggest that CyP-A may perform a general function related to the binding of cargo for retrograde movement along microtubules.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol,Programa Regulac Hormonal & Metab, Consejo Nacl Invest Cient & Tecn Argentina, Buenos Aires C1428EGA, DF, Argentina	University of Michigan System; University of Michigan; Scripps Research Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	mgali@umich.edu		GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28010] Funding Source: Medline; NIAID NIH HHS [AI 054196] Funding Source: Medline; NIDDK NIH HHS [P60 DK 20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899; FISCHER G, 1985, BIOCHIM BIOPHYS ACTA, V828, P39, DOI 10.1016/0167-4838(85)90006-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051	31	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55754	55759		10.1074/jbc.M406259200	http://dx.doi.org/10.1074/jbc.M406259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496417	hybrid, Green Published			2022-12-27	WOS:000225960800097
J	Jastrzebska, B; Maeda, T; Zhu, L; Fotiadis, D; Filipek, S; Engel, A; Stenkamp, RE; Palczewski, K				Jastrzebska, B; Maeda, T; Zhu, L; Fotiadis, D; Filipek, S; Engel, A; Stenkamp, RE; Palczewski, K			Functional characterization of rhodopsin monomers and dimers in detergents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BLUE NATIVE ELECTROPHORESIS; CYTOCHROME-C-OXIDASE; TRANSMEMBRANE HELICES; 3-DIMENSIONAL STRUCTURE; TRANSDUCIN ACTIVATION; LATERAL DIFFUSION; MEMBRANE-PROTEIN; LIGHT; DIMERIZATION	Rhodopsin (Rho) is a G protein-coupled receptor that initiates phototransduction in rod photoreceptors. High expression levels of Rho in the disc membranes of rod outer segments and the propensity of Rho to form higher oligomeric structures are evident from atomic force microscopy, transmission electron microscopy, and chemical cross-linking experiments. To explore the structural and functional properties of Rho in n-dodecyl-beta-maltoside, frequently used to purify heterologously expressed Rho and its mutants, we used gel filtration techniques, blue native gel electrophoresis, and functional assays. Here, we show that in micelles containing n-dodecyl-beta-maltoside at concentrations greater than 3 mM, Rho is present as a single monomer per detergent micelle. In contrast, in 12 mM 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS), micelles contain mostly dimeric Rho. The cognate G protein transducin (Gt) appears to have a preference for binding to the Rho dimer, and the complexes fall apart in the presence of guanosine 5'-3-O-(thio)triphosphate. Cross-linked Rho dimers release the chromophore at a slower rate than monomers and are much more resistant to heat denaturation. Both Rho* monomers and dimers are capable of activating Gt, and both of them are phosphorylated by Rho kinase. Rho expressed in HEK293 cells is also readily cross-linked by a bifunctional reagent. These studies provide an explanation of how detergent influences the oligomer-dimer-monomer equilibrium of Rho and describe the functional characterization of Rho monomers and dimers in detergent.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Basel; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, P30EY001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; APPLEBURY ML, 1974, BIOCHEMISTRY-US, V13, P3448, DOI 10.1021/bi00714a005; Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; Butler PJG, 2004, J MOL BIOL, V340, P797, DOI 10.1016/j.jmb.2004.05.014; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; Dupuy C, 1997, LANGMUIR, V13, P3965, DOI 10.1021/la9604285; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV BIOPH BIOM, V32, P375, DOI 10.1146/annurev.biophys.32.110601.142520; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P485, DOI 10.1016/0003-2697(83)90621-8; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Krebs A, 2003, J BIOL CHEM, V278, P50217, DOI 10.1074/jbc.M307995200; KUSUMI A, 1982, BIOCHEMISTRY-US, V21, P5978, DOI 10.1021/bi00266a039; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; PREININGER AM, 2004, SCI STKE; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; SAIBIL H, 1976, NATURE, V262, P266, DOI 10.1038/262266a0; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Sakmar TP, 2002, CURR OPIN CELL BIOL, V14, P189, DOI 10.1016/S0955-0674(02)00306-X; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Vogel R, 2004, J MOL BIOL, V338, P597, DOI 10.1016/j.jmb.2004.03.006	66	119	124	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54663	54675		10.1074/jbc.M408691200	http://dx.doi.org/10.1074/jbc.M408691200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489507	hybrid, Green Accepted			2022-12-27	WOS:000225793600093
J	Nalvarte, I; Damdimopoulos, AE; Nystom, C; Nordman, T; Miranda-Vizuete, A; Olsson, JM; Eriksson, L; Bjornstedt, M; Arner, ESJ; Spyrou, G				Nalvarte, I; Damdimopoulos, AE; Nystom, C; Nordman, T; Miranda-Vizuete, A; Olsson, JM; Eriksson, L; Bjornstedt, M; Arner, ESJ; Spyrou, G			Overexpression of enzymatically active human cytosolic and mitochondrial thioredoxin reductase in HEK-293 cells - Effect on cell growth and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; ALTERNATIVE SPLICING VARIANT; MAMMALIAN THIOREDOXIN; GLUTATHIONE-PEROXIDASE; REDOX REGULATION; BINDING PROTEIN; LEUKEMIA-CELLS; RNA; MECHANISM; EXPRESSION	The mammalian thioredoxin reductases (TrxR) are selenoproteins containing a catalytically active selenocysteine residue ( Sec) and are important enzymes in cellular redox control. The cotranslational incorporation of Sec, necessary for activity, is governed by a stem-loop structure in the 3'-untranslated region of the mRNA and demands adequate selenium availability. The complicated translation machinery required for Sec incorporation is a major obstacle in isolating mammalian cell lines stably overexpressing selenoproteins. In this work we report on the development and characterization of stably transfected human embryonic kidney 293 cells that overexpress enzymatically active selenocysteine-containing cytosolic TrxR1 or mitochondrial TrxR2. We demonstrate that the overexpression of selenium-containing TrxR1 results in lower expression and activity of the endogenous selenoprotein glutathione peroxidase and that the activity of overexpressed TrxRs, rather than the protein amount, can be increased by selenium supplementation in the cell growth media. We also found that the TrxR-overexpressing cells grew slower over a wide range of selenium concentrations, which was an effect apparently not related to increased apoptosis nor to fatally altered intracellular levels of reactive oxygen species. Most surprisingly, the TrxR1- or TrxR2-overexpressing cells also induced novel expression of the epithelial markers CK18, CK-Cam5.2, and BerEP4, suggestive of a stimulation of cellular differentiation.	Karolinska Inst, Ctr Biotechnol, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Pathol, Dept Lab Med, SE-14186 Huddinge, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Acad Athens, Inst Biomed Res, Athens 11527, Greece	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Academy of Athens	Spyrou, G (corresponding author), Karolinska Inst, Ctr Biotechnol, Novum, Dept Biosci, SE-14157 Huddinge, Sweden.	giannis.spyrou@cbt.ki.se	Nalvarte, Ivan/V-3849-2019; Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Nalvarte, Ivan/0000-0001-6828-2583; Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; BEHNE D, 1993, AM J CLIN NUTR, V57, P310, DOI 10.1093/ajcn/57.2.310S; Berry MJ, 2002, METHOD ENZYMOL, V347, P17; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2001, BIOFACTORS, V14, P11, DOI 10.1002/biof.5520140103; Damdimopoulos AE, 2004, J BIOL CHEM, V279, P38721, DOI 10.1074/jbc.M402753200; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Fletcher JE, 2001, RNA, V7, P1442; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 2002, J BIOL CHEM, V277, P9701, DOI 10.1074/jbc.M109234200; HAINAUT P, 1993, CANCER RES, V53, P4469; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Karimpour S, 2002, ONCOGENE, V21, P6317, DOI 10.1038/sj.onc.1205749; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; Koishi R, 1997, J BIOL CHEM, V272, P2570; Krol A, 2002, BIOCHIMIE, V84, P765, DOI 10.1016/S0300-9084(02)01405-0; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lescure A, 2002, CURR PROTEIN PEPT SC, V3, P143, DOI 10.2174/1389203023380783; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 2002, MOL CELLS, V13, P488; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Muller C, 2003, BIOL CHEM, V384, P11, DOI 10.1515/BC.2003.002; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nalvarte I, 2004, FREE RADICAL BIO MED, V36, P1270, DOI 10.1016/j.freeradbiomed.2004.02.072; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Oertel Martin, 1993, American Journal of Clinical Nutrition, V57, p313S, DOI 10.1093/ajcn/57.2.313S; Patenaude A, 2004, J BIOL CHEM, V279, P27302, DOI 10.1074/jbc.M402496200; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 1997, ONCOL RES, V9, P303; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakurai A, 2004, J CELL PHYSIOL, V198, P22, DOI 10.1002/jcp.10377; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Schutze N, 1999, BIOFACTORS, V10, P329, DOI 10.1002/biof.5520100403; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Spyrou G, 1996, CANCER RES, V56, P4407; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Sun XJ, 2000, DIFFERENTIATION, V66, P181, DOI 10.1111/j.1432-0436.2000.660404.x; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Walczak R, 1996, RNA, V2, P367; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	75	53	54	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54510	54517		10.1074/jbc.M408494200	http://dx.doi.org/10.1074/jbc.M408494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471857	hybrid			2022-12-27	WOS:000225793600075
J	Pei, ZT; Fraisl, P; Berger, J; Jia, ZZ; Forss-Petter, S; Watkins, PA				Pei, ZT; Fraisl, P; Berger, J; Jia, ZZ; Forss-Petter, S; Watkins, PA			Mouse very long-chain acyl-CoA synthetase 3/fatty acid transport protein 3 catalyzes fatty acid activation but not fatty acid transport in MA-10 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; PHOSPHOLIPID-BILAYERS; BETA-OXIDATION; CDNA CLONING; FLIP-FLOP; FAMILY; RAT; BUBBLEGUM; MEMBRANE; EXPRESSION	The family of proteins that includes very long-chain acyl-CoA synthetases (ACSVL) consists of six members. These enzymes have also been designated fatty acid transport proteins. We cloned full-length mouse Acsvl3 cDNA and characterized its protein product ACSVL3/fatty acid transport protein 3. The predicted amino acid sequence contains two highly conserved motifs characteristic of acyl-CoA synthetases. Northern blot analysis revealed that the mouse Acsvl3 mRNA is highly expressed in adrenal gland, testis, and ovary, with lower expression in the brain of adult mice. A developmental Northern blot revealed that Acsvl3 mRNA levels were significantly higher in embryonic mouse brain (embryonic days 12-14) than in newborn or adult mice, suggesting a possible role in nervous system development. Immunohistochemistry revealed high ACSVL3 expression in adrenal cortical cells, spermatocytes and interstitial cells of the testis, theca cells of the ovary, cerebral cortical neurons, and cerebellar Purkinje cells. Endogenous ACSVL3 was found primarily in mitochondria of MA-10 and Neuro2a cells by both Western blot analysis of subcellular fractions and immunofluorescence analysis. In MA-10 cells, loss-of-function studies using RNA interference confirmed that endogenous ACSVL3 is an acyl-CoA synthetase capable of activating both long-chain (C16:0) and very long-chain (C24:0) fatty acids. However, despite decreased acyl-CoA synthetase activity, initial rates of fatty acid uptake were unaffected by knockdown of Acsvl3 expression in MA-10 cells. These studies cast doubt on the designation of ACSVL3 as a fatty acid transport protein.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Med Univ Vienna, Ctr Brain Res, A-1090 Vienna, Austria	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Medical University of Vienna	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, 707 N Broadway, Baltimore, MD 21205 USA.	watkins@kennedykrieger.org	Berger, Johannes/A-9122-2014	Berger, Johannes/0000-0003-0182-2658; Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD24061] Funding Source: Medline; NINDS NIH HHS [NS37355] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Berger J, 1998, FEBS LETT, V425, P305, DOI 10.1016/S0014-5793(98)00255-5; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Fraisl P, 2004, BIOCHEM J, V377, P85, DOI 10.1042/BJ20031062; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Hui T.Y., 1997, FRONT BIOSCI, V2, P222; Jia ZZ, 2004, MOL GENET METAB, V83, P117, DOI 10.1016/j.ymgme.2004.06.015; Kamp F, 2003, J BIOL CHEM, V278, P7988, DOI 10.1074/jbc.M206648200; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moriya-Sato A, 2000, BIOCHEM BIOPH RES CO, V279, P62, DOI 10.1006/bbrc.2000.3897; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pei ZT, 2003, J BIOL CHEM, V278, P47070, DOI 10.1074/jbc.M310075200; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Spector D. L., 1998, CELLS LAB MANUAL; Stahl A, 2004, PFLUG ARCH EUR J PHY, V447, P722, DOI 10.1007/s00424-003-1106-z; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; Trotter PJ, 1996, J LIPID RES, V37, P336; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; *US NAT RES COUNC, 1996, NIH GUID CAR US LAB; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2	47	58	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54454	54462		10.1074/jbc.M410091200	http://dx.doi.org/10.1074/jbc.M410091200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15469937	hybrid			2022-12-27	WOS:000225793600068
J	Porter, SL; Armitage, JP				Porter, SL; Armitage, JP			Chemotaxis in Rhodobacter sphaeroides requires an atypical histidine protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION SYSTEM; BACTERIAL CHEMOTAXIS; CHEA; PHOSPHOTRANSFER; PHOSPHORYLATION; BINDING; IDENTIFICATION; LOCALIZATION; ACTIVATION; DOMAIN	Rhodobacter sphaeroides has a complex chemosensory system comprising two classic CheAs, two atypical CheAs, and eight response regulators (six CheYs and two CheBs). The classic CheAs, CheA(1) and CheA(2), have similar domain structures to Escherichia coli CheA, whereas the atypical CheAs, CheA(3) and CheA(4), lack some of the domains found in E. coli CheA. CheA(2), CheA(3), and CheA(4) are all essential for chemotaxis. Here we demonstrate that CheA(3) and CheA(4) are both unable to undergo ATP-dependent autophosphorylation, however, CheA(4) is able to phosphorylate CheA(3). The in vitro kinetics of this phosphorylation reaction were consistent with a reaction mechanism in which CheA(3) associates with a CheA(4) dimer forming a complex, CheA(3)A(4). To the best of our knowledge, CheA(3)A(4) is the first characterized histidine protein kinase where the subunits are encoded by distinct genes. Selective phosphotransfer was observed from CheA(3)-P to the response regulators CheY(1), CheY(6), and CheB(2). Using phosphorylation site and kinase domain mutants of CheA we show that phosphosignaling involving CheA(2), CheA(3), and CheA(4) is essential for chemotaxis in R. sphaeroides. Interestingly, CheA(3) was not phosphorylated in vitro by CheA(1) or CheA(2), although CheA(1) and CheA(2) mutants with defective kinase domains were phosphorylated by CheA(4). Because in vivo CheA(3) and CheA(4) localize to the cytoplasmic chemotaxis cluster, while CheA(2) localizes to the polar chemotaxis cluster, it is likely that the physical separation of CheA(2) and CheA(4) prevents unwanted cross-talk between these CheAs.	Univ Oxford, Dept Biochem, Microbiol Unit, Oxford OX1 3QU, England	University of Oxford	Armitage, JP (corresponding author), Univ Oxford, Dept Biochem, Microbiol Unit, S Parks Rd, Oxford OX1 3QU, England.	armitage@bioch.ox.ac.uk		Porter, Steven/0000-0002-7851-236X				ANDREWS P, 1962, NATURE, V196, P36, DOI 10.1038/196036a0; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; Hamblin PA, 1997, MOL MICROBIOL, V26, P1083, DOI 10.1046/j.1365-2958.1997.6502022.x; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jahreis K, 2004, J BACTERIOL, V186, P2664, DOI 10.1128/JB.186.9.2664-2672.2004; Levit M, 1996, J BIOL CHEM, V271, P32057, DOI 10.1074/jbc.271.50.32057; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Martin AC, 2003, J BACTERIOL, V185, P4667, DOI 10.1128/JB.185.16.4667-4671.2003; Martin AC, 2001, MOL MICROBIOL, V40, P1261, DOI 10.1046/j.1365-2958.2001.02468.x; Martin AC, 2001, J BACTERIOL, V183, P7135, DOI 10.1128/JB.183.24.7135-7144.2001; MCCLEARY WR, 1990, P NATL ACAD SCI USA, V87, P5898, DOI 10.1073/pnas.87.15.5898; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5485, DOI 10.1073/pnas.91.12.5485; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; Porter SL, 2002, J MOL BIOL, V324, P35, DOI 10.1016/S0022-2836(02)01031-8; Porter SL, 2002, MOL MICROBIOL, V46, P1081, DOI 10.1046/j.1365-2958.2002.03218.x; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Shah DSH, 2000, EMBO J, V19, P4601, DOI 10.1093/emboj/19.17.4601; Shah DSH, 2000, MOL MICROBIOL, V35, P101, DOI 10.1046/j.1365-2958.2000.01680.x; Skidmore JM, 2000, J BACTERIOL, V182, P967, DOI 10.1128/JB.182.4.967-973.2000; SOCKETT RE, 1990, FEMS SYMP, V53, P473; Sourjik V, 1998, BIOCHEMISTRY-US, V37, P2327, DOI 10.1021/bi972330a; Stewart RC, 2000, BIOCHEMISTRY-US, V39, P13157, DOI 10.1021/bi001100k; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; TAWA P, 1994, BIOCHEMISTRY-US, V33, P7917, DOI 10.1021/bi00191a019; Verhamme DT, 2002, MICROBIOL-SGM, V148, P69, DOI 10.1099/00221287-148-1-69; Wadhams GH, 2000, MOL MICROBIOL, V36, P1222, DOI 10.1046/j.1365-2958.2000.01936.x; Wadhams GH, 2003, MOL MICROBIOL, V50, P763, DOI 10.1046/j.1365-2958.2003.03716.x; Wadhams GH, 2002, MOL MICROBIOL, V46, P1211, DOI 10.1046/j.1365-2958.2002.03252.x; WARD MJ, 1995, MOL MICROBIOL, V17, P357, DOI 10.1111/j.1365-2958.1995.mmi_17020357.x; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; Whitchurch CB, 2004, MOL MICROBIOL, V52, P873, DOI 10.1111/j.1365-2958.2004.04026.x	43	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54573	54580		10.1074/jbc.M408855200	http://dx.doi.org/10.1074/jbc.M408855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485885	hybrid			2022-12-27	WOS:000225793600083
J	Shahied, LS; Tang, Y; Alpaugh, RK; Somer, R; Greenspon, D; Weiner, LM				Shahied, LS; Tang, Y; Alpaugh, RK; Somer, R; Greenspon, D; Weiner, LM			Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; METASTATIC BREAST-CANCER; NON-HODGKINS-LYMPHOMA; FC-GAMMA-RIII; ANTI-CD20 MONOCLONAL-ANTIBODY; IN-VIVO; PHASE-I; NK CELLS; 1ST-LINE TREATMENT; CHEMOTHERAPY	Unconjugated monoclonal antibodies have emerged as important therapeutic agents for selected malignancies. One mechanism by which antibodies can exert cytotoxic effects is antibody-dependent cellular cytotoxicity (ADCC). In an effort to increase the efficiency of ADCC at tumor sites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER2/neu and the FcgammaRIII-activating receptor (CD16) found on NK cells, mononuclear phagocytes, and neutrophils. Here, we describe the production of bispecific minibodies in two distinct binding formats. The parent minibody was constructed such that the IgG1 C(H)3 constant domain serves as the oligomerization domain and is attached to an anti-CD16 and an anti-HER2/neu single-chain Fv via 19- and 29-amino acid linkers, respectively. This molecule can be expressed in mammalian cells from a dicistronic vector and has been purified using sequential affinity purification techniques. Analysis by surface plasmon resonance shows that the bispecific minibody can bind to HER2/neu and CD16, both individually and simultaneously. Furthermore, cytotoxicity studies show that the minibody can induce significant tumor cell lysis at a concentration as low as 20 nM. A trimeric, bispecific minibody (TriBi) that binds dimerically to HER2/neu and monomerically to CD16 induces equivalent cytotoxicity at lower antibody concentrations than either the parent minibody or the corresponding single-chain dimer. Both minibody constructs are stable in mouse and human serum for up to 72 h at 37degreesC. These minibodies have the potential to target solid tumors and promote tumor lysis by natural killer cells and mononuclear phagocytes.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Weiner, LM (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Louis.Weiner@fccc.edu	Alpaugh, R. Katherine/AAO-6697-2021	Alpaugh, R. Katherine/0000-0002-6775-5323	NCI NIH HHS [CA009035, CA07125, CA50633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS GP, 1993, CANCER RES, V53, P4026; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; Atwell JL, 1999, PROTEIN ENG, V12, P597, DOI 10.1093/protein/12.7.597; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clark JI, 1997, CANCER IMMUNOL IMMUN, V44, P265, DOI 10.1007/s002620050382; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coiffier B, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.32749; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; DEPALAZZO IG, 1990, CANCER RES, V50, P7123; Figlin R, 2002, P AN M AM SOC CLIN, V21, P35; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Goldstein J, 1997, J IMMUNOL, V158, P872; Heijnen I A, 1997, Int Rev Immunol, V16, P29, DOI 10.3109/08830189709045702; HOMBACH A, 1993, INT J CANCER, V55, P830, DOI 10.1002/ijc.2910550523; HSIEHMA ST, 1992, CANCER RES, V52, P6832; Hu SZ, 1996, CANCER RES, V56, P3055; James ND, 2001, BRIT J CANCER, V85, P152, DOI 10.1054/bjoc.2001.1878; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kortt AA, 2001, BIOMOL ENG, V18, P95, DOI 10.1016/S1389-0344(01)00090-9; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; Le Gall F, 1999, FEBS LETT, V453, P164, DOI 10.1016/S0014-5793(99)00713-9; Leonard JP, 2002, SEMIN ONCOL, V29, P81, DOI 10.1053/sonc.2002.30149; LI S, 1986, J IMMUNOL, V137, P3378; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; McCall AM, 1999, MOL IMMUNOL, V36, P433, DOI 10.1016/S0161-5890(99)00057-7; McCall AM, 2001, J IMMUNOL, V166, P6112, DOI 10.4049/jimmunol.166.10.6112; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; OEGEN JG, 2002, NAT IMMUNOL, V3, P611; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; Pullarkat V, 1999, CANCER IMMUNOL IMMUN, V48, P9, DOI 10.1007/s002620050543; RENNER C, 1995, EUR J IMMUNOL, V25, P2027, DOI 10.1002/eji.1830250734; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Schiedt K., 1995, ISOLATION ANAL, V1A, P81; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Schoonjans R, 2001, BIOMOL ENG, V17, P193, DOI 10.1016/S1389-0344(01)00066-1; SCONOCCHIA G, 1994, J IMMUNOL, V153, P5473; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAVINCHIORINI DC, 1993, INT J CANCER, V53, P97, DOI 10.1002/ijc.2910530119; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Sulica A, 2001, Int Rev Immunol, V20, P371, DOI 10.3109/08830180109054414; TITUS JA, 1987, J IMMUNOL, V139, P3153; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; VALONE FH, 1995, J CLIN ONCOL, V13, P2281, DOI 10.1200/JCO.1995.13.9.2281; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; WEINER GJ, 1994, J IMMUNOL, V152, P2385; WEINER LM, 1995, CANCER RES, V55, P4586; Weiner LM, 1996, CANCER IMMUNOL IMMUN, V42, P141, DOI 10.1007/s002620050264; WEINER LM, 1993, CANCER RES, V53, P94; WEINER LM, 1993, J IMMUNOL, V151, P2877; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Xie ZG, 2003, BIOCHEM BIOPH RES CO, V311, P307, DOI 10.1016/j.bbrc.2003.09.211; Yusa S, 2002, J IMMUNOL, V168, P5047, DOI 10.4049/jimmunol.168.10.5047	62	97	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53907	53914		10.1074/jbc.M407888200	http://dx.doi.org/10.1074/jbc.M407888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471859	hybrid			2022-12-27	WOS:000225793600003
J	Rafaeloff-Phail, R; Ding, LY; Conner, L; Yeh, WK; McClure, D; Guo, HH; Emerson, K; Brooks, H				Rafaeloff-Phail, R; Ding, LY; Conner, L; Yeh, WK; McClure, D; Guo, HH; Emerson, K; Brooks, H			Biochemical regulation of mammalian AMP-activated protein kinase activity by NAD and NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; RAT-LIVER; GLUCOSE; SUBFAMILY; ISOFORMS; LKB1	AMP-activated protein kinase ( AMPK) serves as an energy-sensing protein kinase that is activated by a variety of metabolic stresses that lower cellular energy levels. When activated, AMPK modulates a network of metabolic pathways that result in net increased substrate oxidation, generation of reduced nucleotide co-factors, and production of ATP. AMPK is activated by a high AMP: ATP ratio and phosphorylation on threonine 172 by an upstream kinase. Recent studies suggest that mechanisms that do not involve changes in adenine nucleotide levels can activate AMPK. Another sensor of the metabolic state of the cell is the NAD/NADH redox potential. To test whether the redox state might have an effect on AMPK activity, we examined the effect of beta-NAD and NADH on this enzyme. The recombinant T172D-AMPK, which was mutated to mimic the phosphorylated state, was activated by beta-NAD in a dose-dependent manner, whereas NADH inhibited its activity. We explored the effect of NADH on AMPK by systematically varying the concentrations of ATP, NADH, peptide substrate, and AMP. Based on our findings and established activation of AMPK by AMP, we proposed a model for the regulation by NADH. Key features of this model are as follows. ( a) NADH has an apparent competitive behavior with respect to ATP and uncompetitive behavior with respect to AMP resulting in improved binding constant in the presence of AMP, and (b) the binding of the peptide is not significantly altered by NADH. In the absence of AMP, the binding constant of NADH becomes higher than physiologically relevant. We conclude that AMPK senses both components of cellular energy status, redox potential, and phosphorylation potential.	Lilly Corp Ctr, Lilly Res Labs, Endocrine Discovery Res, Indianapolis, IN 46285 USA	Eli Lilly	Rafaeloff-Phail, R (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Endocrine Discovery Res, DC0424, Indianapolis, IN 46285 USA.	PHAIL_RONIT_R@Lilly.com						Barron JT, 1999, MOL CELL BIOCHEM, V194, P283, DOI 10.1023/A:1006928516648; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Hardie D. G., 1999, ASSAY PURIFICATION P, P201; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Kahn AM, 2002, AM J HYPERTENS, V15, P273, DOI 10.1016/S0895-7061(01)02289-0; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SEGEL IH, 1975, ENZYME KINETICS BEHA, P330; TRUS MD, 1978, LIFE SCI, V22, P809, DOI 10.1016/0024-3205(78)90251-5; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xavier GD, 2003, BIOCHEM J, V371, P761; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	30	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52934	52939		10.1074/jbc.M409574200	http://dx.doi.org/10.1074/jbc.M409574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465812	hybrid			2022-12-27	WOS:000225680600017
J	Rivera, MA; Blackburn, EH				Rivera, MA; Blackburn, EH			Processive utilization of the human telomerase template - Lack of a requirement for template switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY IN-VITRO; REPEAT ADDITION PROCESSIVITY; TETRAHYMENA-TELOMERASE; RNA TEMPLATE; REVERSE-TRANSCRIPTASE; SECONDARY STRUCTURE; CHROMOSOME SEPARATION; BINDING PROTEIN; END PROTECTION; DNA	The ribonucleoprotein telomerase is a specialized reverse transcriptase minimally composed of an RNA, TER, and a protein catalytic subunit, TERT. The TER and TERT subunits of telomerase associate to form a dimeric enzyme in several organisms, including human. A small portion of TER, the template domain, is used by telomerase for the synthesis of tandem repeats of telomeric DNA. We studied some of the requirements for processive template usage by human telomerase. A blunt-ended duplex DNA primer was not utilized by telomerase. With a duplex telomeric DNA primer, a single-stranded 3' overhang with a minimum length of similar to6 bases was required for efficient priming activity. Large substitutions in the human TER templating domain did not abolish enzymatic activity, although insertion of two residues into this sequence reduced processivity, as did a template mutation that results in a mismatch between the template region used for copying DNA and the region used for alignment of the substrate primer. Finally, by using a complementary pair of catalytically inactive telomerase RNA pseudoknot mutants in combination with a marked template, we demonstrated that processive synthesis by an obligatory dimer of human telomerase does not require template switching. These results indicate that processive template usage by human telomerase, like that of Tetrahymena telomerase, is strongly dependent on the base identities in the template domain and that a dimeric human telomerase can processively utilize a single template.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu						Aigner S, 2004, RNA, V10, P1108, DOI 10.1261/rna.7400704; Autexier C, 1998, NUCLEIC ACIDS RES, V26, P787, DOI 10.1093/nar/26.3.787; AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COOKE H, 1995, TELOMERES, P219; de Lange T, 2001, SCIENCE, V292, P1075; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gavory G, 2002, NUCLEIC ACIDS RES, V30, P4470, DOI 10.1093/nar/gkf575; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Gilley D, 1996, MOL CELL BIOL, V16, P66; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Lai CK, 2003, MOL CELL, V11, P1673, DOI 10.1016/S1097-2765(03)00232-6; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LERMAN LS, 1984, ANNU REV BIOPHYS BIO, V13, P399; Lin J, 2004, P NATL ACAD SCI USA, V101, P14713, DOI 10.1073/pnas.0405879101; Lin J, 2004, MOL BIOL CELL, V15, P1623, DOI 10.1091/mbc.E03-10-0740; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lue NF, 2004, BIOESSAYS, V26, P955, DOI 10.1002/bies.20093; Ly H, 2003, MOL CELL BIOL, V23, P6849, DOI 10.1128/MCB.23.19.6849-6856.2003; Ly H, 2003, GENE DEV, V17, P1078, DOI 10.1101/gad.1060803; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Mason DX, 2003, MOL CELL BIOL, V23, P5606, DOI 10.1128/MCB.23.16.5606-5613.2003; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; Melek M, 1996, MOL CELL BIOL, V16, P3437; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Seto AG, 2003, RNA, V9, P1323, DOI 10.1261/rna.5570803; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Tatematsu K, 1996, ONCOGENE, V13, P2265; TENDAM E, 1991, NUCLEIC ACIDS RES, V19, P6951; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Wang H, 1998, EMBO J, V17, P1152, DOI 10.1093/emboj/17.4.1152; Wang H, 1997, EMBO J, V16, P866, DOI 10.1093/emboj/16.4.866; Wang LB, 2002, NUCLEIC ACIDS RES, V30, P4032, DOI 10.1093/nar/gkf513; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	74	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53770	53781		10.1074/jbc.M407768200	http://dx.doi.org/10.1074/jbc.M407768200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456773	hybrid			2022-12-27	WOS:000225680600115
J	Agniswamy, J; Lei, BF; Musser, JM; Sun, PD				Agniswamy, J; Lei, BF; Musser, JM; Sun, PD			Insight of host immune evasion mediated by two variants of group A Streptococcus Mac protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RECEPTOR; CRYSTAL-STRUCTURE; COMPLEX; BINDING; SURFACE; IGG; IDENTIFICATION	Group A Streptococcus has evolved numerous mechanisms to evade the host immune system to survive, disseminate, and cause disease. Recently a secreted protein named Mac-1 was identified and shown to enhance survival of the pathogen. A new variant of Mac-1 (designated Mac-2) also was recently described and shown to differ from Mac-1 by similar to50% amino acid sequence divergence in the middle one-third of the molecule. To gain new information about the role of Mac-1 and Mac-2 in host-pathogen interactions, solution binding experiments were performed using surface plasmon resonance and purified Mac proteins. Mac-1 bound the same lower hinge region of human IgG as Fc receptors with 2.5 muM affinity, which lead to proteolytic cleavage of the antibody. Similar K-m (6.8-18.9 muM) and k(cat) (0.02-0.13 s(-1)) values of the Mac-1 endopeptidase activity were obtained for IgG(1), IgG(2), IgG(3), and IgG(4). Mac-2 variant, in contrast, bound human IgG poorly (K-D = 16 mM) and had weak endopeptidase activity against IgG. Instead, Mac-2 bound FcgammaRII and FcgammaRIII with 5 and 75 muM affinity, respectively. This binding competitively blocked IgG from recognition by Fc receptors. Taken together, Mac proteins block immunoglobulin recognition by Fc receptors and degrade immunoglobulins, thereby enhancing survival of the pathogen through the inhibition of phagocytosis, endocytosis of IgG-opsonized particles, and antibody-dependent cell-mediated cytotoxicity. Consequently, these proteins may be potential therapeutic targets.	NIAAA, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA; NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Montana State University System; Montana State University Bozeman; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Sun, PD (corresponding author), NIAAA, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.	psun@nih.gov		Agniswamy, Johnson/0000-0002-3053-5677; Lei, Benfang Lei/0000-0001-8133-6021				Berge A, 1997, J BIOL CHEM, V272, P20774, DOI 10.1074/jbc.272.33.20774; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 1996, INFECT IMMUN, V64, P1495, DOI 10.1128/IAI.64.5.1495-1501.1996; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Fernie-King BA, 2001, IMMUNOLOGY, V103, P390, DOI 10.1046/j.1365-2567.2001.01249.x; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; Frank MM, 2001, NAT MED, V7, P1285, DOI 10.1038/nm1201-1285; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Lei BF, 2001, NAT MED, V7, P1298, DOI 10.1038/nm1201-1298; Lei BF, 2003, INFECT IMMUN, V71, P2881, DOI 10.1128/IAI.71.5.2881-2884.2003; Lei BF, 2002, INFECT IMMUN, V70, P6880, DOI 10.1128/IAI.70.12.6880-6890.2002; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MUSSER JM, 1988, EMERG INFECT DIS, P185; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Perez-Caballero D, 2000, EUR J IMMUNOL, V30, P1243, DOI 10.1002/(SICI)1521-4141(200004)30:4<1243::AID-IMMU1243>3.0.CO;2-D; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; von Pawel-Rammingen U, 2002, EMBO J, V21, P1607, DOI 10.1093/emboj/21.7.1607	23	51	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52789	52796		10.1074/jbc.M410698200	http://dx.doi.org/10.1074/jbc.M410698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466462	hybrid			2022-12-27	WOS:000225493400126
J	Arokium, H; Camougrand, N; Vallette, FM; Manon, S				Arokium, H; Camougrand, N; Vallette, FM; Manon, S			Studies of the interaction of substituted mutants of BAX with yeast mitochondria reveal that the C-terminal hydrophobic alpha-helix is a second ART sequence and plays a role in the interaction with anti-apoptotic BCL-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PROTEIN FAMILY; CYTOCHROME-C; CELL-DEATH; MEMBRANE ANCHOR; INTRACELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; RELEASE; SIGNAL; PERMEABILITY; CONFORMATION	The role of the two ends of the pro-apoptotic protein BAX in its interaction with mitochondria was challenged by assaying substituted mutants in yeast cells for the ability to bind and insert into the mitochondrial membrane and to promote the release of cytochrome c. Mutations at the N-terminal end confirmed the inhibitory function of this zone, known as apoptotic regulation of targeting ( ART). On the other hand, mutations at the C-terminal end of the protein support the hypothesis that the hydrophobic helix alpha9 is not required for the insertion of BAX. In addition, three mutations ( a T174D single substitution in the helix alpha9, a K189E/K190E double substitution at the end of the protein, and a P168A mutation in the loop before alpha9) exhibited a strong binding capacity, a strong insertion, as well as high ability to induce cytochrome c release. Considering the positions of these mutations and their potential effect on the movement of helix alpha9, we propose that the C-terminal end of the protein behaves like a second ART. Also, opposite to a mutation that changes the conformation of the N-terminal ART, the mutations in the C-terminal part of the protein impaired the inhibitory effect of antiapoptotic BCL-x(L) over BAX insertion, suggesting that the conformation of the alpha9-helix plays a significant role in BAX/BCL-x(L) interaction.	Univ Bordeaux 2, CNRS, UMR5095, F-33077 Bordeaux, France; Univ Nantes, INSERM, UMR601, F-44035 Nantes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Manon, S (corresponding author), Univ Bordeaux 2, CNRS, UMR5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	manon@ibgc.u-bordeaux2.fr	Manon, Stéphen/C-7088-2017; Vallette, Francois/N-2361-2018; Vallette, Francois M/K-9047-2015	Vallette, Francois M/0000-0002-3296-8572; Manon, Stephen/0000-0002-5792-1084; Vallette, Francois/0000-0003-0802-0519				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Clow A, 1998, EUR J BIOCHEM, V258, P19, DOI 10.1046/j.1432-1327.1998.2580019.x; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kissova I, 2000, FEBS LETT, V471, P113, DOI 10.1016/S0014-5793(00)01379-X; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Lewis S, 1998, PROTEIN EXPRES PURIF, V13, P120, DOI 10.1006/prep.1997.0871; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Manon S, 2001, BIOCHEM BIOPH RES CO, V289, P1314, DOI 10.1006/bbrc.2001.6120; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martinez-Senac MD, 2001, BIOCHEMISTRY-US, V40, P9983; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Polcic P, 2003, BIOCHEM J, V374, P393, DOI 10.1042/BJ20030690; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Priault M, 2003, FEMS YEAST RES, V4, P15, DOI 10.1016/S1567-1356(03)00143-0; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Zha HB, 1996, MOL CELL BIOL, V16, P6494	40	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52566	52573		10.1074/jbc.M408373200	http://dx.doi.org/10.1074/jbc.M408373200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459197	hybrid			2022-12-27	WOS:000225493400103
J	Boue-Grabot, E; Toulme, E; Emerit, MB; Garret, M				Boue-Grabot, E; Toulme, E; Emerit, MB; Garret, M			Subunit-specific coupling between gamma-aminobutyric acid type A and P2X(2) receptor channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-GATED CHANNELS; GABA(A) RECEPTORS; CROSS-TALK; GUINEA-PIG; IONOTROPIC RECEPTORS; INTERNATIONAL UNION; SUBMUCOSAL NEURONS; NMDA RECEPTORS; DORSAL-HORN; TRAFFICKING	ATP and gamma-aminobutyric acid (GABA) are two fast neurotransmitters co-released at central synapses, where they co-activate excitatory P2X and inhibitory GABA(A) (GABA type A) receptors. We report here that co-activation of P2X(2) and various GABA(A) receptors, coexpressed in Xenopus oocytes, leads to a functional cross-inhibition dependent on GABA(A) subunit composition. Sequential applications of GABA and ATP revealed that alphabeta- or alphabetagamma-containing GABA(A) receptors inhibited P2X2 channels, whereas P2X2 channels failed to inhibit gamma-containing GABA(A) receptors. This functional crosstalk is independent of membrane potential, changes in current direction, and calcium. Non-additive responses observed between cation-selective GABA(A) and P2X(2) receptors further indicate the chloride independence of this process. Overexpression of minigenes encoding either the C-terminal fragment of P2X(2) or the intracellular loop of the beta3 subunit disrupted the functional cross-inhibition. We previously demonstrated functional and physical cross-talk between rho1 and P2X(2) receptors, which induced a retargeting of rho1 channels to surface clusters when co-expressed in hippocampal neurons (Boue-Grabot, E., Emerit, M. B., Toulme, E., Seguela, P., and Garret, M. ( 2004) J. Biol. Chem. 279, 6967 - 6975). Co-expression of P2X(2) and chimeric rho1 receptors with the C-terminal sequences of alpha2, beta3, or gamma2 subunits indicated that only rho1-beta3 and P2X(2) channels exhibit both functional cross-inhibition in Xenopus oocytes and coclustering/ retargeting in hippocampal neurons. Therefore, the C-terminal domain of P2X(2) and the intracellular loop of beta GABA(A) subunits are required for the functional interaction between ATP- and GABA-gated channels. This gamma subunit-dependent cross-talk may contribute to the regulation of synaptic activity.	Univ Bordeaux 2, Neurophysiol Lab, CNRS, UMR 5543, F-33076 Bordeaux, France; Hop La Pitie Salpetriere, INSERM, U288, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Boue-Grabot, E (corresponding author), Univ Bordeaux 2, Neurophysiol Lab, CNRS, UMR 5543, F-33076 Bordeaux, France.	eric.boue-grabot@umr5543.u-bordeaux2.fr	Boué-Grabot, Eric/AAQ-2061-2020	Boué-Grabot, Eric/0000-0003-2187-9037				Barajas-Lopez C, 2002, AM J PHYSIOL-GASTR L, V283, pG1238, DOI 10.1152/ajpgi.00054.2002; Barajas-Lopez C, 1998, J PHYSIOL-LONDON, V513, P671, DOI 10.1111/j.1469-7793.1998.671ba.x; Bardoni R, 1997, J NEUROSCI, V17, P5297; Barnard EA, 1998, PHARMACOL REV, V50, P291; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; Boue-Grabot E, 1998, J NEUROCHEM, V70, P899; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Bray D, 2004, ANNU REV BIOPH BIOM, V33, P53, DOI 10.1146/annurev.biophys.33.110502.132703; Brunig I, 2002, J NEUROSCI, V22, P4805, DOI 10.1523/JNEUROSCI.22-12-04805.2002; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Cheng Q, 2001, J NEUROPHYSIOL, V86, P2605, DOI 10.1152/jn.2001.86.5.2605; Cotrina ML, 2000, J NEUROSCI, V20, P2835; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Fisher JL, 1997, J PHYSIOL-LONDON, V505, P283, DOI 10.1111/j.1469-7793.1997.283bb.x; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; GRAHAM B, 1994, J NEUROPHYSIOL, V71, P538, DOI 10.1152/jn.1994.71.2.538; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Illes P, 2004, CURR TOP MED CHEM, V4, P831, DOI 10.2174/1568026043451032; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Jo YH, 2002, J NEUROSCI, V22, P4794, DOI 10.1523/JNEUROSCI.22-12-04794.2002; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Lee FS, 2003, EXP NEUROL, V183, P269, DOI 10.1016/S0014-4886(03)00249-8; Li Y, 2003, J BIOL CHEM, V278, P38637, DOI 10.1074/jbc.M303735200; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Lorez Matthias, 2000, Journal of Physiology (Cambridge), V527, P11, DOI 10.1111/j.1469-7793.2000.t01-1-00011.x; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nusser Z, 1998, J NEUROSCI, V18, P1693; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Salter MW, 2003, TRENDS NEUROSCI, V26, P235, DOI 10.1016/S0166-2236(03)00081-X; Searl TJ, 1998, J PHYSIOL-LONDON, V510, P783, DOI 10.1111/j.1469-7793.1998.783bj.x; Sokolova E, 2001, J NEUROSCI, V21, P4958, DOI 10.1523/JNEUROSCI.21-14-04958.2001; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	43	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52517	52525		10.1074/jbc.M410223200	http://dx.doi.org/10.1074/jbc.M410223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456793	hybrid			2022-12-27	WOS:000225493400097
J	Jiang, CL; Jin, SG; Pfeifer, GP				Jiang, CL; Jin, SG; Pfeifer, GP			MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-binding protein 2 (MBD2) and components of the NuRD complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; CHROMOSOMAL-PROTEIN; DNA METHYLATION; MAMMALIAN PROTEIN; CHROMATIN; MECP2; DOMAIN; IDENTIFICATION; SITES; MCPG	Methyl-CpG-binding domain proteins 2 and 3 (MBD2 and MBD3) are transcriptional repressors that contain methyl-CpG binding domains and are components of a CpG-methylated DNA binding complex named MeCP1. Methyl-CpG-binding protein 3-like 1 ( MBD3L1) is a protein with substantial homology to MBD2 and MBD3, but it lacks the methyl-CpG binding domain. MBD3L1 interacts with MBD2 and MBD3 in vitro and in yeast two-hybrid assays. Gel shift experiments with a CpG-methylated DNA probe indicate that recombinant MBD3L1 can supershift an MBD2-methylated DNA complex. In vivo, MBD3L1 associates with and colocalizes with MBD2 but not with MBD3 and is recruited to 5-methylcytosine-rich pericentromeric heterochromatin in mouse cells. In glutathione S-transferase pull-down assays MBD3L1 is found associated with several known components of the MeCP1 . NuRD complex, including HDAC1, HDAC2, MTA2, MBD2, RbAp46, and RbAp48, but MBD3 is not found in the MBD3L1-bound fraction. MBD3L1 enhances transcriptional repression of methylated DNA by MBD2. The data are consistent with a role of MBD3L1 as a methylation-dependent transcriptional repressor that may interchange with MBD3 as an MBD2-interacting component of the NuRD complex. MBD3L1 knockout mice were created and were found to be viable and fertile, indicating that MBD3L1 may not be essential or there is functional redundancy ( through MBD3) in this pathway. Overall, this study reveals additional complexities in the mechanisms of transcriptional repression by the MBD family proteins.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	gpfeifer@coh.org		Jin, Seung-Gi/0000-0001-5041-0559	NCI NIH HHS [CA104967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Feng Q, 2001, GENE DEV, V15, P827; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Jiang CL, 2002, GENOMICS, V80, P621, DOI 10.1006/geno.2002.7001; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	32	45	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52456	52464		10.1074/jbc.M409149200	http://dx.doi.org/10.1074/jbc.M409149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456747	hybrid			2022-12-27	WOS:000225493400090
J	Scarlett, GP; Elgar, SJ; Cary, PD; Noble, AM; Orford, RL; Kneale, GG; Guille, MJ				Scarlett, GP; Elgar, SJ; Cary, PD; Noble, AM; Orford, RL; Kneale, GG; Guille, MJ			Intact RNA-binding domains are necessary for structure-specific DNA binding and transcription control by CBTF122 during Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HEMATOPOIETIC DEFECT; PROTEIN; GATA-2; IDENTIFICATION; EXPRESSION	CBTF122 is a subunit of the Xenopus CCAAT box transcription factor complex and a member of a family of double-stranded RNA-binding proteins that function in both transcriptional and post-transcriptional control. Here we identify a region of CBTF122 containing the double-stranded RNA-binding domains that is capable of binding either RNA or DNA. We show that these domains bind A-form DNA in preference to B-form DNA and that the -59 to -31 region of the GATA-2 promoter ( an in vivo target of CCAAT box transcription factor) adopts a partial A-form structure. Mutations in the RNA-binding domains that inhibit RNA binding also affect DNA binding in vitro. In addition, these mutations alter the ability of CBTF122 fusions with engrailed transcription repressor and VP16 transcription activator domains to regulate transcription of the GATA-2 gene in vivo. These data support the hypothesis that the double-stranded RNA-binding domains of this family of proteins are important for their DNA binding both in vitro and in vivo.	Univ Portsmouth, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; Natl Inst Med Res, Ridgeway, London NW7 1AA, England	University of Portsmouth; Cardiff University	Guille, MJ (corresponding author), Univ Portsmouth, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England.	matthew.guille@port.ac.uk		Guille, Matthew/0000-0001-6865-4519; Scarlett, Garry/0000-0001-8338-2398				BASHAM B, 1995, P NATL ACAD SCI USA, V92, P6464, DOI 10.1073/pnas.92.14.6464; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; Brzostowski J, 2000, EMBO J, V19, P3683, DOI 10.1093/emboj/19.14.3683; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P4385; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; Connolly KM, 1998, NAT STRUCT BIOL, V5, P546, DOI 10.1038/799; Coolidge CJ, 2000, NUCLEIC ACIDS RES, V28, P1407, DOI 10.1093/nar/28.6.1407; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; ELGAR SJ, 2001, THESIS U PORTSMOUTH; Fleenor DE, 1996, GENE, V179, P219, DOI 10.1016/S0378-1119(96)00355-1; Green J, 1999, METH MOL B, V127, P1, DOI 10.1385/1-59259-678-9:1; Guille M, 1999, METH MOL B, V127, P111, DOI 10.1385/1-59259-678-9:111; Guille MJ, 1997, MOL BIOTECHNOL, V8, P35, DOI 10.1007/BF02762338; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Krovat BC, 1996, J BIOL CHEM, V271, P28112, DOI 10.1074/jbc.271.45.28112; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Liu WC, 2003, MOL CELL BIOL, V23, P4083, DOI 10.1128/MCB.23.12.4083-4093.2003; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Moore W, 1999, METH MOL B, V127, P99, DOI 10.1385/1-59259-678-9:99; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Reichman TW, 2003, RNA, V9, P543, DOI 10.1261/rna.2181103; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Robinson C, 1999, METH MOL B, V127, P89, DOI 10.1385/1-59259-678-9:89; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Saunders LR, 2001, GENOMICS, V71, P256, DOI 10.1006/geno.2000.6423; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; Steinbach OC, 1999, METH MOL B, V127, P41, DOI 10.1385/1-59259-678-9:41; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sykes TG, 1998, DEVELOPMENT, V125, P4595; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	45	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52447	52455		10.1074/jbc.M406107200	http://dx.doi.org/10.1074/jbc.M406107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452137	hybrid			2022-12-27	WOS:000225493400089
J	Shi, Q; Bao, SD; Maxwell, JA; Reese, ED; Friedman, HS; Bigner, DD; Wang, XF; Rich, JN				Shi, Q; Bao, SD; Maxwell, JA; Reese, ED; Friedman, HS; Bigner, DD; Wang, XF; Rich, JN			Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING EF-HAND; IN-VITRO; PROGNOSTIC-SIGNIFICANCE; MATRICELLULAR PROTEIN; MALIGNANT GLIOMAS; SIGNALING PATHWAY; ENHANCED GROWTH; TUMOR-GROWTH; NULL MICE; EXPRESSION	Secreted protein acidic, rich in cysteine (SPARC), is an extracellular matrix protein expressed in many advanced cancers, including malignant gliomas. We and others have previously shown that human glioma cell lines engineered to overexpress SPARC adopt an invasive phenotype. We now show that SPARC expression increases cell survival under stress initiated by serum withdrawal through a decrease in apoptosis. Phosphatidylinositol 3-OH kinase/AKT is a potent pro-survival pathway that contributes to the malignancy of gliomas. Cells expressing SPARC display increased AKT activation with decreased caspase 3/7 activity. Exogenous SPARC rapidly induces AKT phosphorylation, an effect that is blocked by a neutralizing SPARC antibody. Furthermore, AKT activation is essential for the anti-apoptotic effects of SPARC as the decreased apoptosis and caspase activity associated with SPARC expression can be blocked with dominant-negative AKT or a specific AKT inhibitor. As tumor cells face stressful microenvironments particularly during the process of invasion, these results suggest that SPARC functions, in part, to promote tumor progression by enabling tumor cells to survive under stressful conditions.	Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu	Rich, Jeremy/AAM-1445-2021		NINDS NIH HHS [NS047409] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS047409] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Aycock RL, 2004, J INVEST DERMATOL, V123, P592, DOI 10.1111/j.0022-202X.2004.23316.x; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bogler O, 2002, FRONT BIOSCI, V7, pE339, DOI 10.2741/bogler; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Choe G, 2003, CANCER RES, V63, P2742; Davies MA, 1998, CANCER RES, V58, P5285; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Golembieski WA, 1999, INT J DEV NEUROSCI, V17, P463, DOI 10.1016/S0736-5748(99)00009-X; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heesters MAAM, 1999, J NEURO-ONCOL, V44, P255, DOI 10.1023/A:1006398613605; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaufmann B, 2004, GLYCOBIOLOGY, V14, P609, DOI 10.1093/glycob/cwh063; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kubiatowski T, 2001, J NEUROSURG, V95, P480, DOI 10.3171/jns.2001.95.3.0480; Kuriyama H, 2002, NEURO-ONCOLOGY, V4, P179, DOI 10.1093/neuonc/4.3.179; Loging WT, 2000, GENOME RES, V10, P1393, DOI 10.1101/gr.138000; Menon PM, 2000, INT J ONCOL, V17, P683; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rich JN, 2001, CANCER RES, V61, P3556; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Schultz C, 2002, CANCER RES, V62, P6270; Scott CB, 1998, INT J RADIAT ONCOL, V40, P51, DOI 10.1016/S0360-3016(97)00485-9; Shingu T, 2003, J NEUROSURG, V98, P154, DOI 10.3171/jns.2003.98.1.0154; Sweetwyne MT, 2004, J HISTOCHEM CYTOCHEM, V52, P723, DOI 10.1369/jhc.3A6153.2004; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Vadlamuri SV, 2003, NEURO-ONCOLOGY, V5, P244, DOI 10.1093/neuonc/5.4.244; Vaquero J, 2002, ACTA NEUROCHIR, V144, P151, DOI 10.1007/s007010200018; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343	48	95	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52200	52209		10.1074/jbc.M409630200	http://dx.doi.org/10.1074/jbc.M409630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469933	hybrid			2022-12-27	WOS:000225493400060
J	Zheng, W; Xie, YX; Li, G; Kong, J; Feng, JQ; Li, YC				Zheng, W; Xie, YX; Li, G; Kong, J; Feng, JQ; Li, YC			Critical role of calbindin-D28k in calcium homeostasis revealed by mice lacking both vitamin D receptor and calbindin-D28k	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,25-DIHYDROXYVITAMIN D-3; GENE-EXPRESSION; KNOCKOUT MICE; PARATHYROID-HORMONE; BINDING PROTEINS; CA2+ TRANSPORT; KIDNEY; CELLS; ABSORPTION; CHANNEL	Calbindin (CaBP)-D28k and CaBP-D9k are cytosolic vitamin D-dependent calcium-binding proteins long thought to play an important role in transepithelial calcium transport. However, recent genetic studies suggest that CaBP-D28k is not essential for calcium metabolism. Genetic ablation of this gene in mice leads to no calcemic abnormalities. Genetic inactivation of the vitamin D receptor (VDR) gene leads to hypocalcemia, secondary hyperparathyroidism, rickets, and osteomalacia, accompanied by 90% reduction in renal CaBP-D9k expression but little change in CaBP-D28k. To address whether the role of CaBP-D28k in calcium homeostasis is compensated by CaBP-D9k, we generated VDR/CaBP-D28k double knockout ( KO) mice, which expressed no CaBP-D28k and only 10% of CaBP-D9k in the kidney. On a regular diet, the double KO mice were more growth-retarded and 42% smaller in body weight than VDRKO mice and died prematurely at 2.5 - 3 months of age. Compared with VDRKO mice, the double KO mice had higher urinary calcium excretion and developed more severe secondary hyperparathyroidism and rachitic skeletal phenotype, which were manifested by larger parathyroid glands, higher serum parathyroid hormone levels, much lower bone mineral density, and more distorted growth plate with more osteoid formation in the trabecular region. On high calcium, high lactose diet, blood-ionized calcium levels were normalized in both VDRKO and the double KO mice; however, in contrast to VDRKO mice, the skeletal abnormalities were not completely corrected in the double KO mice. These results directly demonstrate that CaBP-D28k plays a critical role in maintaining calcium homeostasis and skeletal mineralization and suggest that its calcemic role can be mostly compensated by CaBP-D9k.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Queens Univ Belfast, Musgrave Pk Hosp, Sch Med, Dept Traumat & Orthopaed Surg, Belfast BT9 7JB, Antrim, North Ireland	University of Chicago; University of Missouri System; University of Missouri Kansas City; Queens University Belfast	Li, YC (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 4076, Chicago, IL 60637 USA.	cyan@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059327] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR51587] Funding Source: Medline; NIDDK NIH HHS [DK59327] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; AN YH, 2003, HDB HISTOLOGY METHOD, P295; Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756-3282(96)00047-6; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Breslau Neil A., 1996, P49; Bronner F, 1999, J NUTR, V129, P9, DOI 10.1093/jn/129.1.9; BUSHINSKY DA, 1999, PRIMER METABOLIC BON, P67; Cao LP, 2002, ARCH BIOCHEM BIOPHYS, V400, P118, DOI 10.1006/abbi.2002.2775; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; Faucheux C, 1998, BIOCHEM J, V333, P817, DOI 10.1042/bj3330817; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; FERRARI S, 1992, EXP CELL RES, V200, P528, DOI 10.1016/0014-4827(92)90205-M; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; FULLMER CS, 1992, J NUTR, V122, P644, DOI 10.1093/jn/122.suppl_3.644; GAGNON AM, 1994, KIDNEY INT, V45, P95, DOI 10.1038/ki.1994.11; Hoenderop JGJ, 2000, AM J PHYSIOL-RENAL, V278, pF352, DOI 10.1152/ajprenal.2000.278.3.F352; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HUANG YC, 1989, J BIOL CHEM, V264, P17454; JOHNSON JA, 1994, SEMIN NEPHROL, V14, P119; Lee CT, 2002, KIDNEY INT, V62, P2055, DOI 10.1046/j.1523-1755.2002.00670.x; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Li YC, 2001, AM J PHYSIOL-ENDOC M, V281, pE558, DOI 10.1152/ajpendo.2001.281.3.E558; Peng JB, 2002, CURR OPIN NEPHROL HY, V11, P555, DOI 10.1097/00041552-200209000-00012; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; SILVER J, 1986, J CLIN INVEST, V78, P1296, DOI 10.1172/JCI112714; Silver J, 2001, J CLIN INVEST, V107, P1079, DOI 10.1172/JCI12824; Song YR, 2003, ENDOCRINOLOGY, V144, P3885, DOI 10.1210/en.2003-0314; Sooy K, 2000, CURR OPIN NEPHROL HY, V9, P341, DOI 10.1097/00041552-200007000-00004; Sooy K, 1999, J BIOL CHEM, V274, P34343, DOI 10.1074/jbc.274.48.34343; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; VARGHESE S, 1989, MOL ENDOCRINOL, V3, P495, DOI 10.1210/mend-3-3-495; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121; Zeitz U, 2003, FASEB J, V17, P509, DOI 10.1096/fj.02-0424fje	39	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52406	52413		10.1074/jbc.M405562200	http://dx.doi.org/10.1074/jbc.M405562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456794	hybrid			2022-12-27	WOS:000225493400085
J	Fueger, PT; Hess, HS; Posey, KA; Bracy, DP; Pencek, RR; Charron, MJ; Wasserman, DH				Fueger, PT; Hess, HS; Posey, KA; Bracy, DP; Pencek, RR; Charron, MJ; Wasserman, DH			Control of exercise-stimulated muscle glucose uptake by GLUT4 is dependent on glucose phosphorylation capacity in the conscious mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; TRANSGENIC MICE; HEXOKINASE-II; INSULIN-RESISTANCE; KNOCKOUT MICE; TRANSPORT; OVEREXPRESSION; GENE; HOMEOSTASIS; LIMITATIONS	Previous work suggests that normal GLUT4 content is sufficient for increases in muscle glucose uptake (MGU) during exercise because GLUT4 overexpression does not increase exercise-stimulated MGU. Instead of glucose transport, glucose phosphorylation is a primary limitation of exercise-stimulated MGU. It was hypothesized that a partial ablation of GLUT4 would not impair exercise-stimulated MGU when glucose phosphorylation capacity is normal but would do so when glucose phosphorylation capacity was increased. Thus, C57BL/6J mice with hexokinase II (HKII) overexpression (HKTg), a GLUT4 partial knock-out (G4(+/-)), or both (HKTg + G4(+/-)) and wild-type (WT) littermates were implanted with carotid artery and jugular vein catheters for sampling and infusions at 4 months of age. After a 7-day recovery, 5-h fasted mice remained sedentary or ran on a treadmill at 0.6 mph for 30 min ( n = 9 - 12 per group) and received a bolus of 2-deoxy[H-3] glucose to provide an index of MGU (R-g). Arterial blood glucose and plasma insulin concentrations were similar in WT, G4(+/-), HKTg, and HKTg + G4(+/-) mice. Sedentary R-g values were the same in all genotypes in all muscles studied, confirming that glucose transport is a significant barrier to basal glucose uptake. Gastrocnemius and soleus Rg were greater in exercising compared with sedentary mice in all genotypes. During exercise, G4(+/-) mice had a marked increase in blood glucose that was corrected by the addition of HK II overexpression. Exercise R-g (mumol/100g/min) was not different between WT and G4(+/-) mice in the gastrocnemius ( 24 +/- 5 versus 21 +/- 2) or the soleus ( 54 +/- 6 versus 70 +/- 7). In contrast, the enhanced exercise R-g observed in HKTg mice compared with that in WT mice was absent in HKTg + G4(+/-) mice in both the gastrocnemius (39 +/- 7 versus 22 +/- 6) and the soleus ( 98 +/- 13 versus 65 +/- 13). Thus, glucose transport is not a significant barrier to exercise-stimulated MGU despite a 50% reduction in GLUT4 content when glucose phosphorylation capacity is normal. However, when glucose phosphorylation capacity is increased by HK II overexpression, GLUT4 availability becomes a marked limitation to exercise-stimulated MGU.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Mouse Metab Phenotyping Ctr, Nashville, TN 37232 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Vanderbilt University; Yeshiva University; Albert Einstein College of Medicine	Fueger, PT (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	patrick.fueger@duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637, R01DK047425, R01DK054902] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-54902, R01 DK-47425, U24 DK-59637] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; FERNANDO P, 1993, CAN J PHYSIOL PHARM, V71, P854, DOI 10.1139/y93-128; Fueger PT, 2004, AM J PHYSIOL-ENDOC M, V286, pE77, DOI 10.1152/ajpendo.00309.2003; Fueger PT, 2003, AM J PHYSIOL-ENDOC M, V285, pE958, DOI 10.1152/ajpendo.00190.2003; GOODYEAR LJ, 1990, J APPL PHYSIOL, V68, P193, DOI 10.1152/jappl.1990.68.1.193; GULVE EA, 1994, J BIOL CHEM, V269, P18366; Halseth AE, 1999, AM J PHYSIOL-ENDOC M, V276, pE70, DOI 10.1152/ajpendo.1999.276.1.E70; Halseth AE, 2001, AM J PHYSIOL-ENDOC M, V280, pE994, DOI 10.1152/ajpendo.2001.280.6.E994; Halseth AE, 1998, J APPL PHYSIOL, V85, P2305, DOI 10.1152/jappl.1998.85.6.2305; Halseth AE, 2000, AM J PHYSIOL-ENDOC M, V279, pE1064, DOI 10.1152/ajpendo.2000.279.5.E1064; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hansen PA, 2000, J BIOL CHEM, V275, P22381, DOI 10.1074/jbc.M001946200; Heikkinen S, 1999, J BIOL CHEM, V274, P22517, DOI 10.1074/jbc.274.32.22517; HONIG CR, 1980, AM J PHYSIOL, V238, pH31, DOI 10.1152/ajpheart.1980.238.1.H31; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P865, DOI 10.1073/pnas.92.3.865; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE361, DOI 10.1152/ajpendo.1999.277.2.E361; Kelley DE, 1996, J CLIN INVEST, V97, P2705, DOI 10.1172/JCI118724; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Li J, 2000, FASEB J, V14, P1117, DOI 10.1096/fasebj.14.9.1117; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Lombardi AM, 1997, FASEB J, V11, P1137, DOI 10.1096/fasebj.11.13.9367348; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MORGAN CR, 1965, DIABETES, V14, P669, DOI 10.2337/diab.14.10.669; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; PALM T, 1983, CLIN PHYSIOL, V3, P445, DOI 10.1111/j.1475-097X.1983.tb00852.x; REN JM, 1993, J BIOL CHEM, V268, P16113; Rottman JN, 2002, AM J PHYSIOL-ENDOC M, V283, pE116, DOI 10.1152/ajpendo.00545.2001; Rudich A, 2003, DIABETOLOGIA, V46, P649, DOI 10.1007/s00125-003-1080-1; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1999, DIABETES, V48, P775, DOI 10.2337/diabetes.48.4.775	39	49	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50956	50961		10.1074/jbc.M408312200	http://dx.doi.org/10.1074/jbc.M408312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456776	hybrid			2022-12-27	WOS:000225355800039
J	Mizukami, Y; Iwamatsu, A; Aki, T; Kimura, M; Nakamura, K; Nao, T; Okusa, T; Matsuzaki, M; Yoshida, K; Kobayashi, S				Mizukami, Y; Iwamatsu, A; Aki, T; Kimura, M; Nakamura, K; Nao, T; Okusa, T; Matsuzaki, M; Yoshida, K; Kobayashi, S			ERK1/2 regulates intracellular ATP levels through alpha-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; MAP KINASE; NUCLEAR TRANSLOCATION; CELL-DEATH; C-MYC; SIGNALING PATHWAY; CARDIAC MYOCYTES; COUPLED RECEPTOR; GENE-EXPRESSION; DOMAIN PROTEIN	Extracellular signal-regulated kinase 1/2 (ERK1/2) is known to function in cell survival in response to various stresses; however, the mechanism of cell survival by ERK1/2 remains poorly elucidated in ischemic heart. Here we applied functional proteomics by two-dimensional electrophoresis to identify a cellular target of ERK1/2 in response to ischemic hypoxia. Approximately 1500 spots were detected by Coomassie Brilliant Blue staining of a sample from unstimulated cells. The staining intensities of at least 50 spots increased at 6-h reoxygenation after 2-h ischemic hypoxia. Of the 50 spots that increased, at least 4 spots were inhibited in the presence of PD98059, a MEK inhibitor. A protein with a molecular mass of 52 kDa that is strongly induced by ERK1/2 activation in response to ischemic hypoxia and reoxygenation was identified as alpha-enolase, a rate-limiting enzyme in the glycolytic pathway, by liquid chromatography-mass spectrometry and amino acid sequencing. The expressions of the alpha-enolase mRNA and protein are inhibited during reoxygenation after ischemic hypoxia in the cells containing a dominant negative mutant of MEK1 and treated with a MEK inhibitor, PD98059, leading to a decrease in ATP levels. alpha-Enolase expression is also observed in rat heart subjected to ischemia-reperfusion. The induction of alpha-enolase by ERK1/2 appears to be mediated by c-Myc. The introduction of the alpha-enolase protein into the cells restores ATP levels and prevents cell death during ischemic hypoxia and reoxygenation in these cells. These results show that alpha-enolase expression by ERK1/2 participates in the production of ATP during reoxygenation after ischemic hypoxia, and a decrease in ATP induces apoptotic cell death. Furthermore, alpha-enolase improves the contractility of cardiomyocytes impaired by ischemic hypoxia. Our results reveal that ERK1/2 plays a role in the contractility of cardiomyocytes and cell survival through alpha-enolase expression during ischemic hypoxia and reoxygenation.	Yamaguchi Univ, Ctr Gene Res, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Mol Physiol, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Cardiovasc Med, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Biochem, Yamaguchi 7558505, Japan; Univ Tokyo, Sch Med, Dept Legal Med, Tokyo 1130033, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Tokyo 2360004, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University; Yamaguchi University; University of Tokyo; Kirin Brewery Company Limited	Mizukami, Y (corresponding author), Yamaguchi Univ, Ctr Gene Res, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	mizukami@yamaguchi-u.ac.jp	Kobayashi, Sei/E-7175-2010	Mizukami, Yoichi/0000-0002-3290-0754				AARONSON RM, 1995, J BIOL CHEM, V270, P27752, DOI 10.1074/jbc.270.46.27752; Abas L, 2000, BIOCHEM J, V349, P119, DOI 10.1042/0264-6021:3490119; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Di Lisa F, 1998, BBA-BIOENERGETICS, V1366, P69, DOI 10.1016/S0005-2728(98)00121-2; Eguchi Y, 1997, CANCER RES, V57, P1835; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837, DOI 10.1152/ajprenal.1999.276.6.F837; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Fujimoto K, 2001, BBA-GENE STRUCT EXPR, V1518, P173, DOI 10.1016/S0167-4781(00)00309-2; GORG A, 1988, ELECTROPHORESIS, V9, P37, DOI 10.1002/elps.1150090108; Guerra S, 1999, CIRC RES, V85, P856, DOI 10.1161/01.RES.85.9.856; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kang PM, 2000, CIRC RES, V86, P1107; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Kawata H, 2001, CIRC RES, V88, P696, DOI 10.1161/hh0701.088842; Kimura M, 2001, J BIOL CHEM, V276, P26453, DOI 10.1074/jbc.M101289200; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 2000, J BIOL CHEM, V275, P19921, DOI 10.1074/jbc.M907901199; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1999, J BIOL CHEM, V274, P24941, DOI 10.1074/jbc.274.35.24941; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Noshita N, 2002, J NEUROSCI, V22, P7923; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Saraste A, 1999, EUR J CLIN INVEST, V29, P380; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang XQ, 2003, J CELL SCI, V116, P2099, DOI 10.1242/jcs.00420; Webster KA, 2000, ADV EXP MED BIOL, V475, P161; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang BS, 1996, MOL CELL BIOL, V16, P538; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081; Yonemochi H, 2000, CIRCULATION, V101, P2625, DOI 10.1161/01.CIR.101.22.2625; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X	67	77	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50120	50131		10.1074/jbc.M402299200	http://dx.doi.org/10.1074/jbc.M402299200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15459207	hybrid			2022-12-27	WOS:000225229500071
J	Wessells, J; Baer, M; Young, HA; Claudio, E; Brown, K; Siebenlist, U; Johnson, PF				Wessells, J; Baer, M; Young, HA; Claudio, E; Brown, K; Siebenlist, U; Johnson, PF			BCL-3 and NF-kappa B p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; CANDIDATE PROTOONCOGENE BCL-3; IL-10 GENE-EXPRESSION; ONCOPROTEIN BCL-3; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; THERAPEUTIC TARGET; IMMUNE-RESPONSES	Lipopolysaccharide (LPS) induces expression of tumor necrosis factor alpha (TNFalpha) and other pro-inflammatory cytokines in macrophages. Following its induction, TNFalpha gene transcription is rapidly attenuated, in part due to the accumulation of NF-kappaB p50 homodimers that bind to three kappaB sites in the TNFalpha promoter. Here we have investigated the inhibitory role of BCL-3, an IkappaB-like protein that interacts exclusively with p50 and p52 homodimers. BCL-3 was induced by LPS with delayed kinetics and was associated with p50 in the nucleus. Forced expression of BCL-3 suppressed LPS-induced transcription from the TNFalpha promoter and inhibited two artificial promoters composed of TNFalpha kappaB sites that preferentially bind p50 dimers. BCL-3-mediated repression was reversed by trichostatin A and was enhanced by overexpression of HDAC-1, indicating that transcriptional attenuation involves recruitment of histone deacetylase. Analysis of macrophages from p50 and BCL-3 knock-out mice revealed that both transcription factors negatively regulate TNFalpha expression and that BCL-3 inhibits IL-1alpha and IL-1beta. In contrast, induction of the anti-inflammatory cytokine IL-10 was reduced in BCL-3 null macrophages. BCL-3 was not required for the production of p50 homodimers but BCL-3 expression was severely diminished in p50-deficient cells. Together, these findings indicate that p50 and BCL-3 function as anti-inflammatory regulators in macrophages by attenuating transcription of pro-inflammatory cytokines and activating IL-10 expression.	NCI Frederick, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA; NCI Frederick, Expt Immunol Lab, Frederick, MD 21702 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Johnson, PF (corresponding author), NCI Frederick, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA.	johnsopf@ncifcrf.gov	Young, Howard/A-6350-2008; Johnson, Peter/A-1940-2012	Young, Howard/0000-0002-3118-5111; Johnson, Peter/0000-0002-4145-4725	NATIONAL CANCER INSTITUTE [ZIABC010328, Z01BC010328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000723] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; BHATIA K, 1991, ONCOGENE, V6, P1569; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CERAMI A, 1993, BLOOD PURIFICAT, V11, P108, DOI 10.1159/000170104; DE WMR, 1991, J EXP MED, V174, P1209; Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gerondakis S, 2001, NAT IMMUNOL, V2, P377, DOI 10.1038/87669; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; SCHATTNER A, 1994, CLIN IMMUNOL IMMUNOP, V70, P177, DOI 10.1006/clin.1994.1027; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; TRACEY KJ, 1991, CIRC SHOCK, V35, P123; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	45	160	167	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49995	50003		10.1074/jbc.M404246200	http://dx.doi.org/10.1074/jbc.M404246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15465827	hybrid			2022-12-27	WOS:000225229500056
J	Fan, CY; Ren, HY; Lee, P; Caplan, AJ; Cyr, DM				Fan, CY; Ren, HY; Lee, P; Caplan, AJ; Cyr, DM			The type I Hsp40 zinc finger-like region is required for Hsp70 to capture non-native polypeptides from Ydj1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE YDJ1; SACCHAROMYCES-CEREVISIAE; DNAJ PROTEIN; SUBSTRATE-BINDING; ATPASE ACTIVITY; YEAST HOMOLOG; DOMAIN; SIS1; SPECIFICITY; MECHANISM	The cytosolic yeast Hsp40 Ydj1 contains a conserved zinc finger-like region (ZFLR), which has two zinc-binding domains (ZBD), that helps regulate and specify Hsp70 function. To investigate the mechanism for Ydj1 ZFLR action, ZBDI and ZBDII mutants were constructed and characterized. ZBDII mutants exhibited temperature-sensitive growth defects, but yeast tolerated mutation of ZBDI. However, ZBDI and ZBDII mutants were defective at facilitating androgen receptor (AR) folding. Defective AR folding was associated with the accumulation of complexes between AR and Ydj1 ZFLR mutants and a reduction in Hsp70.AR complex formation. Purified Ydj1 ZBDI and ZBDII mutants could bind non-native polypeptides but could not deliver luciferase to Hsp70 and were defective at luciferase refolding. Interestingly, the ability of Ydj1 to synergize with Hsp70 to suppress thermally induced protein aggregation was blocked by mutation of ZBDII, but not ZBDI. Hence, ZBDII is required for yeast to survive heat stress because it is essential for Ydj1 to cooperate with Hsp70 to suppress protein aggregation. On the other hand, protein folding is dependent upon the action of both ZBDI and ZBDII because each is required for Hsp70 to capture non-native polypeptides from Ydj1.	Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cyr, DM (corresponding author), Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	DMCYR@med.unc.edu	Caplan, Avrom/GPT-0824-2022	Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060598] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60598] Funding Source: Medline; NIGMS NIH HHS [R01 GM056981, R01 GM067785] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Fan CY, 2004, MOL BIOL CELL, V15, P761, DOI 10.1091/mbc.E03-03-0146; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; WALL D, 1994, J BIOL CHEM, V269, P5446; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679	34	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					695	702		10.1074/jbc.M410645200	http://dx.doi.org/10.1074/jbc.M410645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15496404	Green Published, hybrid			2022-12-27	WOS:000226025100082
J	Lee, HJ; Barry, CH; Borisova, SN; Seto, NOL; Zheng, RXB; Blancher, A; Evans, SV; Palcic, MM				Lee, HJ; Barry, CH; Borisova, SN; Seto, NOL; Zheng, RXB; Blancher, A; Evans, SV; Palcic, MM			Structural basis for the inactivity of human blood group O-2 glycosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOR SUBSTRATE-SPECIFICITY; GROUP-B TRISACCHARIDE; GROUP-A; O-ALLELE; RECOMBINANT; ABO; SYSTEM; GENE; TRANSFERASES; RECOGNITION	The human ABO( H) blood group antigens are carbohydrate structures generated by glycosyltransferase enzymes. Glycosyltransferase A (GTA) uses UDP-GalNAc as a donor to transfer a monosaccharide residue to Fucalpha1-2Galbeta-R (H)-terminating acceptors. Similarly, glycosyltransferase B (GTB) catalyzes the transfer of a monosaccharide residue from UDP-Gal to the same acceptors. These are highly homologous enzymes differing in only four of 354 amino acids, Arg/Gly-176, Gly/Ser-235, Leu/Met-266, and Gly/Ala-268. Blood group O usually stems from the expression of truncated inactive forms of GTA or GTB. Recently, an O-2 enzyme was discovered that was a full-length form of GTA with three mutations, P74S, R176G, and G268R. We showed previously that the R176G mutation increased catalytic activity with minor effects on substrate binding. Enzyme kinetics and high resolution structural studies of mutant enzymes based on the O2 blood group transferase reveal that whereas the P74S mutation in the stem region of the protein does not appear to play a role in enzyme inactivation, the G268R mutation completely blocks the donor GalNAc-binding site leaving the acceptor binding site unaffected.	Univ Victoria, Dept Biochem & Mol Biol, Victoria, BC V8W 3P6, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Toulouse 3, Hop Rangeuil, Immunogenet Mol Lab, F-31059 Toulouse 9, France	University of Victoria; University of Alberta; National Research Council Canada; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Evans, SV (corresponding author), Univ Victoria, Dept Biochem & Mol Biol, Victoria, BC V8W 3P6, Canada.	svevans@uvic.ca; monica.palcic@ualberta.ca		Evans, Stephen/0000-0002-0366-4027				Amado M, 2000, VOX SANG, V79, P219, DOI 10.1046/j.1423-0410.2000.7940219.x; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Nguyen HP, 2003, J BIOL CHEM, V278, P49191, DOI 10.1074/jbc.M308770200; Palcic MM, 2001, TRANSFUSION MED, V11, P315, DOI 10.1046/j.1365-3148.2001.00314.x; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; SETO NOL, 1995, EUR J BIOCHEM, V234, P323, DOI 10.1111/j.1432-1033.1995.323_c.x; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P175, DOI 10.1111/j.1423-0410.1993.tb05158.x	25	48	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					525	529		10.1074/jbc.M410245200	http://dx.doi.org/10.1074/jbc.M410245200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15475562	hybrid			2022-12-27	WOS:000226025100062
J	Bhattacharyya, M; Ray, S; Bhattacharya, S; Chakrabarti, A				Bhattacharyya, M; Ray, S; Bhattacharya, S; Chakrabarti, A			Chaperone activity and prodan binding at the self-associating domain of erythroid spectrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MEMBRANE SKELETON; ALPHA-CRYSTALLIN; IN-VITRO; FLUORESCENCE; SURFACE; HEMOGLOBIN; ORGANIZATION; EVOLUTION; SYNUCLEIN	Spectrin, the major constituent protein of the erythrocyte membrane skeleton, exhibits chaperone activity by preventing the irreversible aggregation of insulin at 25degreesC and that of alcohol dehydrogenase at 50degreesC. The dimeric spectrin and the two subunits, alpha-spectrin and beta-spectrin prevent such aggregation appreciably better, 70% in presence of dimeric spectrin at an insulin: spectrin ratio of 1:1, than that in presence of the tetramer of 25%. Our results also show that spectrin binds to denatured enzymes alpha-glucosidase and alkaline phosphatase during refolding and the reactivation yields are increased in the presence of the spectrin derivatives when compared with those refolded in their absence. The unique hydrophobic binding site on spectrin for the fluorescence probe, 6-propionyl-2-(dimethylamino)naphthalene (Prodan) has been established to localize at the self-associating domain with the binding stoichiometry of one Prodan/both dimeric and tetrameric spectrin. The other fluorescence probe, 1-anilinonaphthalene-8-sulfonic acid, does not show such specificity for spectrin, and the binding stoichiometry is between 3 and 5 1-anilinonaphthalene-8-sulfonic acid/dimeric and tetrameric spectrin, respectively. Regions in alpha- and beta-spectrins have been found to have sequence homology with known chaperone proteins. More than 50% similarities in alpha-spectrin near the N terminus with human Hsp90 and in beta-spectrin near the C terminus with human Hsp90 and Escherichia coli DnaJ have been found, indicating a potential chaperone-like sequence to be present near the self-associating domain that is formed by portions of alpha-spectrin near the N terminus and the beta-spectrin near the C terminus. There are other patches of sequences also in both the spectrin polypeptides, at the other termini as well as in the middle of the rod domain having significant homology with well known chaperone proteins.	Saha Inst Nucl Phys, Div Biophys, Kolkata 700064, India	Saha Institute of Nuclear Physics	Chakrabarti, A (corresponding author), Saha Inst Nucl Phys, Div Biophys, 1-AF Bidhannagar, Kolkata 700064, India.	abhijitc@petal.saha.ernet.in	Ray, Sibnath/C-7369-2008	Ray, Sibnath/0000-0002-6313-3930				[Anonymous], METHODS ENZYMOL B; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BEAVEN GH, 1978, ACTA HAEMATOL-BASEL, V60, P321, DOI 10.1159/000207731; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; Beissinger M, 1998, BIOL CHEM, V379, P245; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BERGLUND A, 1986, FEBS LETT, V201, P306, DOI 10.1016/0014-5793(86)80629-9; Bhattacharyya J, 1999, J BIOL CHEM, V274, P15505, DOI 10.1074/jbc.274.22.15505; BHOWN AS, 1989, BIOCHEM BIOPH RES CO, V164, P894, DOI 10.1016/0006-291X(89)91543-X; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHAIMANEE P, 1977, FEBS LETT, V78, P119, DOI 10.1016/0014-5793(77)80287-1; Chakrabarti A, 2001, BIOCHEM BIOPH RES CO, V282, P1189, DOI 10.1006/bbrc.2001.4715; Chakrabarti A, 1996, BIOCHEM BIOPH RES CO, V226, P495, DOI 10.1006/bbrc.1996.1383; Chattopadhyay A, 2003, PROTEIN SCI, V12, P2389, DOI 10.1110/ps.03302003; COHEN AM, 1986, BLOOD, V68, P920; COLE N, 1993, INT J BIOCHEM, V25, P1555, DOI 10.1016/0020-711X(93)90511-C; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Datta P, 2003, BLOOD CELL MOL DIS, V30, P248, DOI 10.1016/S1079-9796(03)00019-6; DE M, 2000, J CELL SCI, V113, P2331; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DIAKOWSKI W, 1995, BIOCHEMISTRY-US, V34, P13252, DOI 10.1021/bi00040a041; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gallagher PG, 1997, J CLIN INVEST, V99, P267, DOI 10.1172/JCI119155; GRATZER WB, 1982, METHOD ENZYMOL, V85, P475; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; GUAGLIARDI A, 1995, J BIOL CHEM, V270, P28126; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; Haque ME, 2000, J FLUORESC, V10, P1, DOI 10.1023/A:1009402126863; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703; HAUGHLAND RP, 1996, HDB FLUORESCENT PROB, P320; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL ZD, 1986, J CHEM EDUC, V63, P162, DOI 10.1021/ed063p162; Hinton A, 2003, J BIOL CHEM, V278, P34110, DOI 10.1074/jbc.M305353200; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KAHANA E, 1992, BIOCHEM J, V282, P75, DOI 10.1042/bj2820075; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majee S, 1999, EUR J BIOCHEM, V260, P619, DOI 10.1046/j.1432-1327.1999.00159.x; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; MARIK T, 1984, CELL BIOCHEM FUNCT, V2, P21, DOI 10.1002/cbf.290020107; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mondal M, 2002, FEBS LETT, V532, P396, DOI 10.1016/S0014-5793(02)03721-3; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Nardai G, 2000, ARCH BIOCHEM BIOPHYS, V384, P59, DOI 10.1006/abbi.2000.2075; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Ray S, 2004, MOL MEMBR BIOL, V21, P93, DOI 10.1080/09687680310001625800; Ray S, 2003, CELL MOTIL CYTOSKEL, V54, P16, DOI 10.1002/cm.10082; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAMBROOK J, 1997, GUIDEBOOK MOL CHAPER; SCATCHARD G, 1957, J AM CHEM SOC, V79, P12, DOI 10.1021/ja01558a003; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; SUBBARAO NK, 1994, CELL MOTIL CYTOSKEL, V29, P72, DOI 10.1002/cm.970290107; WALLIS CJ, 1992, J BIOL CHEM, V267, P4333; WANG JL, 1971, J BIOL CHEM, V246, P1185; Wichterle H, 1996, J CLIN INVEST, V98, P2300, DOI 10.1172/JCI119041; WILLIAMSON P, 1982, CELL, V30, P725, DOI 10.1016/0092-8674(82)90277-X; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YOSHINO H, 1984, J BIOL CHEM, V259, P4496	78	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55080	55088		10.1074/jbc.M406418200	http://dx.doi.org/10.1074/jbc.M406418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492010	hybrid			2022-12-27	WOS:000225960800013
J	Leiros, HKS; Kozielski-Stuhrmann, S; Kapp, U; Terradot, L; Leonard, GA; McSweeney, SM				Leiros, HKS; Kozielski-Stuhrmann, S; Kapp, U; Terradot, L; Leonard, GA; McSweeney, SM			Structural basis of 5-nitroimidazole antibiotic resistance - The crystal structure of NimA from Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METRONIDAZOLE-RESISTANCE; NITROIMIDAZOLE RESISTANCE; HELICOBACTER-PYLORI; FERREDOXIN GENE; BACTEROIDES; PROTEIN; RDXA; STRAINS; OXIDOREDUCTASE; MECHANISMS	5-Nitroimidazole-based antibiotics are compounds extensively used for treating infections in humans and animals caused by several important pathogens. They are administered as prodrugs, and their activation depends upon an anaerobic 1-electron reduction of the nitro group by a reduction pathway in the cells. Bacterial resistance toward these drugs is thought to be caused by decreased drug uptake and/or an altered reduction efficiency. One class of resistant strains, identified in Bacteroides, has been shown to carry Nim genes (NimA, -B, -C, -D, and -E), which encode for reductases that convert the nitro group on the antibiotic into a non-bactericidal amine. In this paper, we have described the crystal structure of NimA from Deinococcus radiodurans (drNimA) at 1.6 Angstrom resolution. We have shown that drNimA is a homodimer in which each monomer adopts a beta-barrel fold. We have identified the catalytically important His-71 along with the cofactor pyruvate and antibiotic binding sites, all of which are found at the monomer-monomer interface. We have reported three additional crystal structures of drNimA, one in which the antibiotic metronidazole is bound to the protein, one with pyruvate covalently bound to His-71, and one with lactate covalently bound to His-71. Based on these structures, a reaction mechanism has been proposed in which the 2-electron reduction of the antibiotic prevents accumulation of the toxic nitro radical. This mechanism suggests that Nim proteins form a new class of reductases, conferring resistance against 5-nitroimidazole-based antibiotics.	European Synchrotron Radiat Facil, Macromol Crystallog Grp, F-38043 Grenoble 09, France	European Synchrotron Radiation Facility (ESRF)	McSweeney, SM (corresponding author), European Synchrotron Radiat Facil, Macromol Crystallog Grp, BP 220,6 Rue Jules Horowitz, F-38043 Grenoble 09, France.	mcsweeney@esrf.fr	Leiros, Hanna-Kirsti S/E-4000-2016; Leonard, Gordon/D-2160-2019	Leiros, Hanna-Kirsti S/0000-0002-2726-6322; Leonard, Gordon/0000-0001-5030-0122; McSweeney, Sean/0000-0002-3758-3161				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BREUIL J, 1989, PLASMID, V21, P151, DOI 10.1016/0147-619X(89)90060-7; Carlier JP, 1997, ANTIMICROB AGENTS CH, V41, P1495, DOI 10.1128/AAC.41.7.1495; Chiu HJ, 2001, STRUCTURE, V9, P311, DOI 10.1016/S0969-2126(01)00589-5; DECLERCK PJ, 1986, BIOCHEM PHARMACOL, V35, P59, DOI 10.1016/0006-2952(86)90555-1; DECLERCK PJ, 1983, FEBS LETT, V164, P145, DOI 10.1016/0014-5793(83)80038-6; Diniz CG, 2003, MICROBES INFECT, V5, P19, DOI 10.1016/S1286-4579(02)00052-7; EDWARDS DI, 1993, J ANTIMICROB CHEMOTH, V31, P201, DOI 10.1093/jac/31.2.201; EDWARDS DI, 1993, J ANTIMICROB CHEMOTH, V31, P9, DOI 10.1093/jac/31.1.9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fang H, 2002, INT J ANTIMICROB AG, V19, P361, DOI 10.1016/S0924-8579(02)00019-5; Goodwin A, 1998, MOL MICROBIOL, V28, P383, DOI 10.1046/j.1365-2958.1998.00806.x; HAGGOUD A, 1992, FEMS MICROBIOL LETT, V95, P1; HAGGOUD A, 1994, ANTIMICROB AGENTS CH, V38, P1047, DOI 10.1128/AAC.38.5.1047; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047; Jamal WY, 2004, MED PRIN PRACT, V13, P147, DOI 10.1159/000076954; Jenks PJ, 1999, J ANTIMICROB CHEMOTH, V43, P753, DOI 10.1093/jac/43.6.753; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koder RL, 2002, BIOCHEMISTRY-US, V41, P14197, DOI 10.1021/bi025805t; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kulda J, 1999, INT J PARASITOL, V29, P199, DOI 10.1016/S0020-7519(98)00155-6; Kwon DH, 2000, ANTIMICROB AGENTS CH, V44, P2133, DOI 10.1128/AAC.44.8.2133-2142.2000; Land KM, 2004, MOL MICROBIOL, V51, P115, DOI 10.1046/j.1365-2958.2003.03791.x; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P975, DOI 10.1038/nsb1297-975; Liepinsh E, 1998, NAT STRUCT BIOL, V5, P102, DOI 10.1038/nsb0298-102; LOCKERBY DL, 1985, ANTIMICROB AGENTS CH, V27, P863, DOI 10.1128/AAC.27.5.863; Marais A, 2003, RES MICROBIOL, V154, P137, DOI 10.1016/S0923-2508(03)00030-5; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Musayev FN, 2003, PROTEIN SCI, V12, P1455, DOI 10.1110/ps.0356203; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; QUON DVK, 1992, P NATL ACAD SCI USA, V89, P4402, DOI 10.1073/pnas.89.10.4402; Rafii F, 2003, FEMS MICROBIOL LETT, V225, P195, DOI 10.1016/S0378-1097(03)00513-5; Ragsdale SW, 2003, CHEM REV, V103, P2333, DOI 10.1021/cr020423e; Stubbs SLJ, 2000, J CLIN MICROBIOL, V38, P3209, DOI 10.1128/JCM.38.9.3209-3213.2000; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P1688, DOI 10.1107/S0907444903015142; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRINH S, 1995, MICROBIOL-UK, V141, P927, DOI 10.1099/13500872-141-4-927; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	42	55	56	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55840	55849		10.1074/jbc.M408044200	http://dx.doi.org/10.1074/jbc.M408044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492014	hybrid			2022-12-27	WOS:000225960800107
J	Lloyd, LJ; Jones, SE; Jovanovic, G; Gyaneshwar, P; Rolfe, MD; Thompson, A; Hinton, JC; Buck, M				Lloyd, LJ; Jones, SE; Jovanovic, G; Gyaneshwar, P; Rolfe, MD; Thompson, A; Hinton, JC; Buck, M			Identification of a new member of the phage shock protein response in Escherichia coli, the phage shock protein g (PspG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; COMPLETE GENOME SEQUENCE; INTEGRATION HOST FACTOR; GENE-EXPRESSION; YERSINIA-ENTEROCOLITICA; SALMONELLA-ENTERICA; PROTONMOTIVE FORCE; STRESS PROTEIN; ROTARY MOTOR; OPERON	The phage shock protein operon (pspABCDE) of Escherichia coli is strongly up-regulated in response to overexpression of the filamentous phage secretin protein IV (pIV) and by many other stress conditions including defects in protein export. PspA has an established role in maintenance of the proton-motive force of the cell under stress conditions. Here we present evidence for a new member of the phage shock response in E. coli. Using transcriptional profiling, we show that the synthesis of pIV in E. coli leads to a highly restricted response limited to the up-regulation of the psp operon genes and yjbO. The psp operon and yjbO are also up-regulated in response to pIV in Salmonella enterica serovar Typhimurium. yjbO is a highly conserved gene found exclusively in bacteria that contain a psp operon but is physically unlinked to the psp operon. yjbO encodes a putative inner membrane protein that is co-controlled with the psp operon genes and is predicted to be an effector of the psp response in E. coli. We present evidence that yjbO expression is driven by sigma(54)-RNA polymerase, activated by PspF and integration host factor, and negatively regulated by PspA. PspF specifically regulates only members of the PspF regulon: pspABCDE and yjbO. We found that increased expression of YjbO results in decreased motility of bacteria. Because yjbO is co-conserved and co-regulated with the psp operon and is a member of the phage shock protein F regulon, we propose that yjbO be renamed pspG.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Inst Food Res, Inst Food Res, Mol Microbiol Grp, Norwich NR4 7UA, Norfolk, England	Imperial College London; University of California System; University of California Berkeley; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	m.buck@imperial.ac.uk	Hinton, Jay C. D./B-2142-2008	Hinton, Jay C. D./0000-0003-2671-6026; Jovanovic, Goran/0000-0001-6587-7645; Jones, Susan/0000-0002-7801-9786	NIGMS NIH HHS [GM 38361] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038361, R01GM038361] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams H, 2002, FEBS LETT, V518, P173, DOI 10.1016/S0014-5793(02)02695-9; Anjum MF, 2003, INFECT IMMUN, V71, P4674, DOI 10.1128/IAI.71.8.4674-4683.2003; Arends SJR, 2004, J BACTERIOL, V186, P880, DOI 10.1128/JB.186.3.880-884.2004; Beloin C, 2004, MOL MICROBIOL, V51, P659, DOI 10.1046/j.1365-2958.2003.03865.x; Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRISSETTE JL, 1991, J MOL BIOL, V220, P35, DOI 10.1016/0022-2836(91)90379-K; BRISSETTE JL, 1990, P NATL ACAD SCI USA, V87, P862, DOI 10.1073/pnas.87.3.862; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Clements MO, 2002, P NATL ACAD SCI USA, V99, P8784, DOI 10.1073/pnas.132047099; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; Darwin AJ, 2001, MOL MICROBIOL, V39, P429, DOI 10.1046/j.1365-2958.2001.02235.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; Dworkin J, 1997, J MOL BIOL, V273, P377, DOI 10.1006/jmbi.1997.1317; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; FUNG DC, 1995, NATURE, V375, P809, DOI 10.1038/375809a0; Gabel CV, 2003, P NATL ACAD SCI USA, V100, P8748, DOI 10.1073/pnas.1533395100; Green RC, 2004, J BACTERIOL, V186, P4910, DOI 10.1128/JB.186.15.4910-4920.2004; HALES LM, 1994, J BACTERIOL, V176, P2999, DOI 10.1128/JB.176.10.2999-3006.1994; Jones SE, 2003, J BACTERIOL, V185, P6707, DOI 10.1128/JB.185.22.6707-6711.2003; Jovanovic G, 1997, J BACTERIOL, V179, P5232, DOI 10.1128/jb.179.16.5232-5237.1997; Jovanovic G, 1996, J BACTERIOL, V178, P1936, DOI 10.1128/jb.178.7.1936-1945.1996; Jovanovic G, 1997, MOL MICROBIOL, V25, P473, DOI 10.1046/j.1365-2958.1997.4791844.x; Kao KC, 2004, P NATL ACAD SCI USA, V101, P641, DOI 10.1073/pnas.0305287101; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; KLEEREBEZEM M, 1993, MOL MICROBIOL, V7, P947, DOI 10.1111/j.1365-2958.1993.tb01186.x; Kleerebezem M, 1996, EMBO J, V15, P162, DOI 10.1002/j.1460-2075.1996.tb00344.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSTU S, 1979, P NATL ACAD SCI USA, V76, P4576, DOI 10.1073/pnas.76.9.4576; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Martinez-Antonio A, 2003, CURR OPIN MICROBIOL, V6, P482, DOI 10.1016/j.mib.2003.09.002; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Model P, 1997, MOL MICROBIOL, V24, P255, DOI 10.1046/j.1365-2958.1997.3481712.x; MONOD J, 1952, ADV ENZYMOL REL S BI, V13, P67; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; POSSOT O, 1992, MOL MICROBIOL, V6, P95, DOI 10.1111/j.1365-2958.1992.tb00841.x; RUSSEL M, 1993, J BACTERIOL, V175, P3998, DOI 10.1128/JB.175.13.3998-4007.1993; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Thompson A, 2001, TRENDS MICROBIOL, V9, P154, DOI 10.1016/S0966-842X(01)01977-1; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Wang QF, 2004, MOL MICROBIOL, V52, P169, DOI 10.1111/j.1365-2958.2003.03977.x; WEINER L, 1991, GENE DEV, V5, P1912, DOI 10.1101/gad.5.10.1912; WEINER L, 1995, NUCLEIC ACIDS RES, V23, P2030, DOI 10.1093/nar/23.11.2030; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	56	71	75	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55707	55714		10.1074/jbc.M408994200	http://dx.doi.org/10.1074/jbc.M408994200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485810	hybrid			2022-12-27	WOS:000225960800091
J	Nagata, K; Asano, T; Nozawa, Y; Inagaki, M				Nagata, K; Asano, T; Nozawa, Y; Inagaki, M			Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; DIVISION CYCLE; OVARIAN-TUMORS; GENE; CYTOSKELETAL; MLL; FILAMENTS; PROTEIN; MSF; CYTOKINESIS	Septins are members of a conserved family of cytoskeletal GTPases present in organisms as diverse as yeast and mammals. Unlike lower eukaryotic cells, the physiological significance of mammalian septin complexes is largely unknown. Using specific antibodies, we found at least five septins, Sept2, Sept7, Sept8, Sept9b, and Sept11, in septin complexes affinity-purified with anti-Sept7 antibody-conjugated column from rat embryonic fibroblast REF52 cells. Immunofluorescence studies revealed co-localization of Sept7, Sept9b, and Sept11 along stress fibers in REF52 cells. Biochemical and immunoprecipitation analyses revealed that the three septins directly bind with each other through their N- or C-terminal divergent regions. These septins per se formed distinct and characteristic filament structures when transiently expressed in COS7 cells. When two of the three septins were coexpressed in COS7 cells, combination-dependent filament elongation, bundling, or disruption was observed. Taken together, our results suggest that septin filament structures may be affected by interactions with other septins included in the complex.	Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Aichi 4800392, Japan; Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Int Inst Biotechnol, Gifu 5040838, Japan	Aichi Cancer Center	Nagata, K (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya Cho, Aichi 4800392, Japan.	knagata@inst-hsc.jp	Inagaki, Masaki/B-9920-2016					Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; Dent J, 2002, P NATL ACAD SCI USA, V99, P3064, DOI 10.1073/pnas.052715199; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Hanai N, 2004, FEBS LETT, V568, P83, DOI 10.1016/j.febslet.2004.05.030; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Ihara M, 2003, J BIOL CHEM, V278, P24095, DOI 10.1074/jbc.M301352200; Joberty G, 2001, NAT CELL BIOL, V3, P861, DOI 10.1038/ncb1001-861; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kinoshita N, 2004, GENES CELLS, V9, P1, DOI 10.1111/j.1356-9597.2004.00696.x; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Russell SEH, 2000, CANCER RES, V60, P4729; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	33	116	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55895	55904		10.1074/jbc.M406153200	http://dx.doi.org/10.1074/jbc.M406153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485874	hybrid			2022-12-27	WOS:000225960800113
J	O'Neil, CH; Boffa, MB; Hancock, MA; Pickering, JG				O'Neil, CH; Boffa, MB; Hancock, MA; Pickering, JG			Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN ACTIVATION; ENDOTHELIAL-CELLS; COLLAGEN-SYNTHESIS; RECOMBINANT FORM; GLU-PLASMINOGEN; LYS-PLASMINOGEN; LIPOPROTEIN(A); EXPRESSION; SURFACE; ATHEROSCLEROSIS	Elevated plasma concentrations of lipoprotein(a) are a risk factor for the development of a variety of atherosclerotic disorders. Despite intensive study, the mechanisms by which lipoprotein(a) promotes these disorders remain to be unequivocally defined. It has been demonstrated that lipoprotein(a), through its unique constituent apolipoprotein(a) ( apo(a)), stimulates vascular smooth muscle cell (SMC) migration and proliferation. These effects arise from the ability of apo(a) to inhibit the formation of active transforming growth factor beta (TGF-beta) from its latent precursor, which in turn is caused by the ability of apo(a) to decrease the formation of plasmin from its precursor plasminogen. We utilized a battery of recombinant apo(a) variants that represent systematic deletions of the various domains in the molecule to further probe the mechanism underlying the effect of apo(a) on SMC responses. All recombinant apo(a) variants that contained kringle IV type 9 were able to stimulate SMC proliferation and migration and to decrease the formation of active TGF-beta; conversely all recombinant apo( a) variants lacking kringle IV type 9 had no effect on these parameters. The kringle IV type 9-dependent effects of apo(a) on SMC proliferation required the presence of plasminogen, suggesting for the first time that this kringle mediates the ability of apo(a) to inhibit pericellular plasmin formation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada	Queens University - Canada; Western University (University of Western Ontario)	Hancock, MA (corresponding author), Queens Univ, Dept Biochem, Rm A208,Botterell Hall, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca	Pickering, J. Geoffrey/G-3341-2011; Boffa, Michael/N-6539-2019	Pickering, J. Geoffrey/0000-0001-6474-3274; Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; Angelin B, 1997, CURR OPIN LIPIDOL, V8, P337, DOI 10.1097/00041433-199712000-00003; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; Caplice NM, 2001, BLOOD, V98, P2980, DOI 10.1182/blood.V98.10.2980; Ford CM, 1999, ARTERIOSCL THROM VAS, V19, P1843, DOI 10.1161/01.ATV.19.8.1843; GABEL BR, 1995, BIOCHEMISTRY-US, V34, P15777, DOI 10.1021/bi00048a023; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gazzaruso C, 2003, INT J CARDIOL, V87, P91, DOI 10.1016/S0167-5273(02)00202-4; Gong Y, 2001, J BIOL CHEM, V276, P19078, DOI 10.1074/jbc.M101387200; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Grainger DJ, 2004, ARTERIOSCL THROM VAS, V24, P399, DOI 10.1161/01.ATV.0000114567.76772.33; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hancock MA, 2003, J BIOL CHEM, V278, P23260, DOI 10.1074/jbc.M302780200; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Keesler GA, 1996, J BIOL CHEM, V271, P32096, DOI 10.1074/jbc.271.50.32096; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; Koschinsky ML, 2004, CURR OPIN LIPIDOL, V15, P167, DOI 10.1097/00041433-200404000-00009; Kraft HG, 1996, ATHEROSCLEROSIS, V125, P53, DOI 10.1016/0021-9150(96)05844-3; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; Mallat Z, 2002, CURR OPIN LIPIDOL, V13, P523, DOI 10.1097/00041433-200210000-00008; Marcovina SM, 1996, CLIN CHEM, V42, P436; Marcovina SM, 2003, CLIN CHEM, V49, P1785, DOI 10.1373/clinchem.2003.023689; Marcovina SM, 2003, CURR OPIN LIPIDOL, V14, P361, DOI 10.1097/00041433-200308000-00004; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Miles LA, 2003, TRENDS CARDIOVAS MED, V13, P21, DOI 10.1016/S1050-1738(02)00190-1; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Morishita R, 1998, HYPERTENSION, V32, P215, DOI 10.1161/01.HYP.32.2.215; Pellegrino M, 2004, J BIOL CHEM, V279, P6526, DOI 10.1074/jbc.M309705200; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; Rahman M, 1998, PROTEIN ENG, V11, P1249, DOI 10.1093/protein/11.12.1249; Rand ML, 1998, ARTERIOSCL THROM VAS, V18, P1393, DOI 10.1161/01.ATV.18.9.1393; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Scanu A M, 2001, Curr Cardiol Rep, V3, P385; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Yu H, 2003, CHINESE MED J-PEKING, V116, P721	43	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55187	55195		10.1074/jbc.M409860200	http://dx.doi.org/10.1074/jbc.M409860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498766	hybrid			2022-12-27	WOS:000225960800026
J	Six, EM; Ndiaye, D; Sauer, G; Laabi, Y; Athman, R; Cumano, A; Brou, C; Israel, A; Logeat, F				Six, EM; Ndiaye, D; Sauer, G; Laabi, Y; Athman, R; Cumano, A; Brou, C; Israel, A; Logeat, F			The Notch ligand Delta1 recruits Dlg1 at cell-cell contacts and regulates cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE; DROSOPHILA MASTERMIND; INTRACELLULAR DOMAIN; HUMAN HOMOLOG; MAGUK FAMILY; PDZ DOMAINS; PROTEIN; CLEAVAGE; SERRATE; RECEPTOR	Delta1 acts as a membrane-bound ligand that interacts with the Notch receptor and plays a critical role in cell fate specification. By using peptide affinity chromatography followed by mass spectrometry, we have identified Dlg1 as a partner of the Delta1 C-terminal region. Dlg1 is a human homolog of the Drosophila Discs large tumor suppressor, a member of the membrane-associated guanylate kinase family of molecular scaffolds. We confirmed this interaction by co-immunoprecipitation experiments between endogenous Dlg1 and transduced Delta1 in a 3T3 cell line stably expressing Delta1. Moreover, we showed that deletion of a canonical C-terminal PDZ-binding motif (ATEV) in Delta1 abrogated this interaction. Delta4 also interacted with Dlg1, whereas Jagged1, another Notch ligand, did not. In HeLa cells, transfected Delta1 triggered the accumulation of endogenous Dlg1 at sites of cell-cell contact. Expression of Delta1 also reduced the motility of 3T3 cells. Finally, deletion of the ATEV motif totally abolished these effects but did not interfere with the ability of Delta1 to induce Notch signaling and T cell differentiation in co-culture experiments. These results point to a new, probably cell-autonomous function of Delta1, which is independent of its activity as a Notch ligand.	Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1961, Unite Dev Lymphocytes, F-75724 Paris 15, France; Max Planck Inst Biochem, Abt Zellbiol, D-82152 Martinsried, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society	Israel, A (corresponding author), Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, 25 Rue Dr Roux, F-75724 Paris 15, France.	aisrael@pasteur.fr	Six, Emmanuelle/H-7891-2017	Six, Emmanuelle/0000-0001-7806-0968; Cumano, Ana/0000-0002-4578-959X				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bilder D, 2001, TRENDS GENET, V17, P511, DOI 10.1016/S0168-9525(01)02407-6; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Brenner M, 2000, NAT MED, V6, P1210, DOI 10.1038/81297; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; De Bellard ME, 2002, DEV BIOL, V249, P121, DOI 10.1006/dbio.2002.0756; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Harris BZ, 2001, J CELL SCI, V114, P3219; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hukriede NA, 1997, GENETICS, V145, P359; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; Klueg KM, 1999, J CELL SCI, V112, P3289; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lendahl U, 1998, BIOESSAYS, V20, P103, DOI 10.1002/(SICI)1521-1878(199802)20:2<103::AID-BIES1>3.0.CO;2-U; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Lowell S, 2001, MECH DEVELOP, V107, P133, DOI 10.1016/S0925-4773(01)00459-2; Mantovani F, 2001, J CELL SCI, V114, P4285; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Pfister S, 2003, J MOL BIOL, V333, P229, DOI 10.1016/j.jmb.2003.08.043; Pourquie O, 2000, CURR BIOL, V10, pR425, DOI 10.1016/S0960-9822(00)00510-8; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Reuver SM, 1998, J CELL SCI, V111, P1071; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Sun X, 1996, DEVELOPMENT, V122, P2465; Szafranski P, 2004, DEVELOPMENT, V131, P2023, DOI 10.1242/dev.01097; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Zeng CY, 1998, GENE DEV, V12, P1086, DOI 10.1101/gad.12.8.1086; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	54	49	50	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55818	55826		10.1074/jbc.M408022200	http://dx.doi.org/10.1074/jbc.M408022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485825	hybrid			2022-12-27	WOS:000225960800104
J	Zhang, XM; Azhar, G; Zhong, Y; Wei, JY				Zhang, XM; Azhar, G; Zhong, Y; Wei, JY			Identification of a novel serum response factor cofactor in cardiac gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; NATRIURETIC-FACTOR GENE; TRANSCRIPTION FACTOR; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; EXPRESSION; SRF; ELEMENT; MYOCARDIN; HEART	The transcription factor serum response factor (SRF) plays an important role in the regulation of a variety of cardiac genes during development and during adult aging. A novel SRF cofactor, herein called p49/STRAP, for SRF-dependent transcription regulation-associated protein, was recently identified in our laboratory. This protein interacted mainly with the transcriptional activation domain of the SRF protein and was found to bind to SRF or to the complex of SRF and another cofactor, such as myocardin or Nkx2.5. The expression of p49/STRAP affected the promoter activity of SRF target genes in a non-uniform manner. For example, p49 activated MLC2v and cardiac actin promoters when it was co-transfected with SRF, but it repressed atrial natriuretic factor promoter activity, which was strongly induced by myocardin. The p49/STRAP mRNA was observed to be highly expressed in fetal, adult, and senescent human hearts, and also in hearts of young adult and old mice, suggesting that p49/STRAP may be an important SRF cofactor in the transcriptional regulation of mammalian cardiac muscle genes throughout the life span.	Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Zhang, XM (corresponding author), Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, 4301 W Markham 748, Little Rock, AR 72205 USA.	zhangxiaomin@uams.edu; jwei@uams.edu			NIA NIH HHS [AG 18388, AG 19946] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG019946, R01AG018388] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bodyak N, 2002, NUCLEIC ACIDS RES, V30, P3788, DOI 10.1093/nar/gkf497; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Groisman R, 1996, J BIOL CHEM, V271, P5258; Helfand SL, 2002, NAT REV GENET, V3, P149, DOI 10.1038/nrg726; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Li X, 2004, NATURE, V427, P687, DOI 10.1038/427687a; Lu XG, 1998, J GERONTOL A-BIOL, V53, pB3, DOI 10.1093/gerona/53A.1.B3; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Muller JG, 2002, J MOL CELL CARDIOL, V34, P807, DOI 10.1006/jmcc.2002.2019; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Pardee AB, 2003, GENE, V321, P17, DOI 10.1016/S0378-1119(03)00839-4; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pugh KG, 2001, DRUG AGING, V18, P263, DOI 10.2165/00002512-200118040-00004; Schratt G, 2004, EMBO J, V23, P1834, DOI 10.1038/sj.emboj.7600188; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsou H, 1996, EXP CELL RES, V229, P432, DOI 10.1006/excr.1996.0388; Vaitkevicius PV, 2001, P NATL ACAD SCI USA, V98, P1171, DOI 10.1073/pnas.98.3.1171; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang XM, 2003, AM J PHYSIOL-REG I, V285, pR552, DOI 10.1152/ajpregu.00631.2002; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhang XM, 2001, J BIOL CHEM, V276, P40033, DOI 10.1074/jbc.M104934200; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	42	37	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55626	55632		10.1074/jbc.M405945200	http://dx.doi.org/10.1074/jbc.M405945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492011	hybrid			2022-12-27	WOS:000225960800081
J	Agou, F; Courtois, G; Chiaravalli, J; Baleux, F; Coic, YM; Traincard, F; Israel, A; Veron, M				Agou, F; Courtois, G; Chiaravalli, J; Baleux, F; Coic, YM; Traincard, F; Israel, A; Veron, M			Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (NEMO) oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-GAMMA; ECTODERMAL DYSPLASIA; KINASE COMPLEX; COILED-COIL; THERAPEUTIC PEPTIDES; PROTEIN; RECEPTOR; DOMAIN; APOPTOSIS; EXPRESSION	NF-kappaB essential modulator/IKK-gamma (NEMO/IKK-gamma) plays a key role in the activation of the NF-kappaB pathway in response to proinflammatory stimuli. Previous studies suggested that the signal-dependent activation of the IKK complex involves the trimerization of NEMO. The minimal oligomerization domain of this protein consists of two coiled-coil subdomains named Coiled-coil 2 (CC2) and leucine zipper (LZ) (Agou, F., Traincard, F., Vinolo, E., Courtois, G., Yamaoka, S., Israel, A., and Veron, M. (2004) J. Biol. Chem. 279, 27861-27869). To search for drugs inhibiting NF-kappaB activation, we have rationally designed cell-permeable peptides corresponding to the CC2 and LZ subdomains that mimic the contact areas between NEMO subunits. The peptides were tagged with the Antennapedia/Penetratin motif and delivered to cells prior to stimulation with lipopolysaccharide. Peptide transduction was monitored by fluorescence-activated cell sorter, and their effect on lipopolysaccharide-induced NF-kappaB activation was quantified using an NF-kappaB-dependent beta-galactosidase assay in stably transfected pre-B 70Z/3 lymphocytes. We show that the peptides corresponding to the LZ and CC2 subdomains inhibit NF-kappaB activation with an IC50 in the muM range. Control peptides, including mutated CC2 and LZ peptides and a heterologous coiled-coil peptide, had no inhibitory effect. The designed peptides are able to induce cell death in human retinoblastoma Y79 cells exhibiting constitutive NF-kappaB activity. Our results provide the "proof of concept" for a new and promising strategy for the inhibition of NF-kappaB pathway activation through targeting the oligomerization state of the NEMO protein.	Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Genet, F-75724 Paris, France; Inst Pasteur, CNRS, URA 2128, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Agou, F (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	fagou@pasteur.fr	, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Agou F, 1999, J BIOL CHEM, V274, P19630, DOI 10.1074/jbc.274.28.19630; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRONSTEIN I, 1989, J BIOLUM CHEMILUM, V4, P99, DOI 10.1002/bio.1170040116; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Inohara N, 2000, J BIOL CHEM, V275, P27823; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Latham PW, 1999, NAT BIOTECHNOL, V17, P755, DOI 10.1038/11686; Lien S, 2003, TRENDS BIOTECHNOL, V21, P556, DOI 10.1016/j.tibtech.2003.10.005; Liu WK, 2004, BIOCHEM J, V378, P867, DOI 10.1042/BJ20031736; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mousson F, 2002, BIOCHEMISTRY-US, V41, P13611, DOI 10.1021/bi026274b; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Poulaki V, 2002, AM J PATHOL, V161, P2229, DOI 10.1016/S0002-9440(10)64499-9; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	49	59	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54248	54257		10.1074/jbc.M406423200	http://dx.doi.org/10.1074/jbc.M406423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15466857	hybrid			2022-12-27	WOS:000225793600045
J	Clausen, JD; Andersen, JP				Clausen, JD; Andersen, JP			Functional consequences of alterations to Thr(247), Pro(248), Glu(340), Asp(813), Arg(819), and Arg(822) at the interfaces between domain P, M3, and L6-7 of sarcoplasmic reticulum Ca2+-ATPase - Roles in Ca2+ interaction and phosphoenzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; INTRAMOLECULAR COMMUNICATION; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; SEGMENT M3; A-DOMAIN; BINDING; LOOP	Point mutants with alterations to amino acid residues Thr(247), Pro(248), Glu(340), Asp(813), Arg(819), and Arg(822) of sarcoplasmic reticulum Ca2+-ATPase were analyzed by transient kinetic measurements. In the Ca2+-ATPase crystal structures, most of these residues participate in a hydrogen-bonding network between the phosphorylation domain (domain P), the third transmembrane helix (M3), and the cytoplasmic loop connecting the sixth and the seventh transmembrane helices (L6-7). In several of the mutants, a pronounced phosphorylation "overshoot" was observed upon reaction of the Ca2+-bound enzyme with ATP, because of accumulation of dephosphoenzyme at steady state. Mutations of Glu(340) and its partners, Thr(247) and Arg(822), in the bonding network markedly slowed the Ca2+ binding transition (E2-->E1-->Ca(2)E1) as well as Ca2+ dissociation from Ca2+ site II back toward the cytosol but did not affect the apparent affinity for vanadate. These mutations may have caused a slowing, in both directions, of the conformational change associated directly with Ca2+ interaction at Ca2+ site II. Because mutation of Asp(813) inhibited the Ca2+ binding transition, but not Ca2+ dissociation, and increased the apparent affinity for vanadate, the effect on the Ca2+ binding transition seems in this case to be exerted by slowing the E2-->E1 conformational change. Because the rate was not significantly enhanced by a 10-fold increase of the Ca2+ concentration, the slowing is not the consequence of reduced affinity of any pre-binding site for Ca2+. Furthermore, the mutations interfered in specific ways with the phosphoenzyme processing steps of the transport cycle; the transition from ADP-sensitive phosphoenzyme to ADP-insensitive phosphoenzyme (Ca(2)E1P-->E2P) was accelerated by mutations perturbing the interactions mediated by Glu(340) and Asp(813) and inhibited by mutation of Pro(248), and mutations of Thr(247) induced charge-specific changes of the rate of dephosphorylation of E2P.	Aarhus Univ, Inst Physiol & Biophys, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Inst Physiol & Biophys, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2003, ANN NY ACAD SCI, V986, P72, DOI 10.1111/j.1749-6632.2003.tb07141.x; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lenoir G, 2004, J BIOL CHEM, V279, P32125, DOI 10.1074/jbc.M402934200; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Menguy T, 2002, J BIOL CHEM, V277, P13016, DOI 10.1074/jbc.M108899200; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	47	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54426	54437		10.1074/jbc.M410204200	http://dx.doi.org/10.1074/jbc.M410204200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485864	hybrid			2022-12-27	WOS:000225793600065
J	Collier, J; Bohn, C; Bouloc, P				Collier, J; Bohn, C; Bouloc, P			SsrA tagging of Escherichia coli SecM at its translation arrest sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANS-TRANSLATION; STOP CODONS; PROTEIN SECRETION; NASCENT-PEPTIDE; FIMBRIAL OPERON; QUALITY-CONTROL; 10SA RNA; GENE; RIBOSOME	SecM is expressed from the secM-secA operon and activates the expression of secA in response to secretion defects. The 3'-end of secM encodes an "arrest sequence," which can interact with the ribosomal exit tunnel, preventing complete secM translation under secretion-defective conditions. In a cis-acting manner, ribosome stalling enhances secA translation. Pro(166) is the last residue incorporated when SecM elongation is arrested. We report that secretion deficiencies lead to SsrA tagging of SecM after Pro(166), Gly(165), and likely Arg(163). Northern blot analysis revealed the presence of a truncated secM transcript, likely issued from a secM-secA cleavage. The level of secM transcripts was decreased either when secM translation was totally prevented or when Pro(166) was mutated. However, the accumulation of a truncated secM transcript required secM translation and was prevented when the SecM arrest sequence was inactivated by a point mutation changing Pro(166) to Ala. We suggest that ribosome pausing at the site encoding the arrest sequence is required for formation of the truncated secM mRNA. SsrA tagging affected neither the presence of the secM mRNA nor secA expression, even under translocation-defective conditions. It is therefore likely that SsrA tagging of SecM occurs only after cleavage of secM-secA mRNA within the secM open reading frame encoding the SecM arrest sequence. Accumulation of transcripts expressing arrested SecM generated growth inhibition that was alleviated by the SsrA tagging system. Therefore, SsrA tagging of SecM would rescue ribosomes to avoid excessive jamming of the translation apparatus on stop-less secM mRNA.	Univ Paris 11, Inst Genet & Microbiol, Lab Res Regulat & Biogenese Enveloppe Bacterienne, CNRS,UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Collier, J (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.	justinec@stanford.edu	Bouloc, Philippe/ABA-5732-2021	Bouloc, Philippe/0000-0003-4601-3387; Bohn, Chantal/0000-0003-1569-9072; Collier, Justine/0000-0003-4213-9687				Abo T, 2002, GENES CELLS, V7, P629, DOI 10.1046/j.1365-2443.2002.00549.x; Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Bohn C, 2002, MOL GENET GENOMICS, V266, P827, DOI 10.1007/s00438-001-0601-1; Bollag D.M., 1991, PROTEIN METHODS; Butkus ME, 2003, J BACTERIOL, V185, P6719, DOI 10.1128/JB.185.22.6719-6722.2003; CHITTUM HS, 1994, J BACTERIOL, V176, P6192, DOI 10.1128/jb.176.20.6192-6198.1994; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Collier J, 2002, MOL MICROBIOL, V45, P745, DOI 10.1046/j.1365-2958.2002.03045.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Drider D, 2002, MOL MICROBIOL, V43, P1319, DOI 10.1046/j.1365-2958.2002.02830.x; FORTIN Y, 1990, J BACTERIOL, V172, P6607, DOI 10.1128/jb.172.11.6607-6610.1990; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Hayes CS, 2002, P NATL ACAD SCI USA, V99, P3440, DOI 10.1073/pnas.052707199; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; ITO K, 1981, CELL, V25, P143, DOI 10.1016/0092-8674(81)90238-5; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Koo JT, 2004, MOL MICROBIOL, V52, P1813, DOI 10.1111/j.1365-2958.2004.04099.x; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Loomis WP, 2001, MOL MICROBIOL, V39, P693, DOI 10.1046/j.1365-2958.2001.02241.x; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Murakami A, 2004, P NATL ACAD SCI USA, V101, P12330, DOI 10.1073/pnas.0404907101; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nakatogawa H, 2004, CURR OPIN MICROBIOL, V7, P145, DOI 10.1016/j.mib.2004.01.001; Nakatogawa H, 2004, CHEMBIOCHEM, V5, P48, DOI 10.1002/cbic.200300751; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Oliver D, 1998, J BACTERIOL, V180, P5240, DOI 10.1128/JB.180.19.5240-5242.1998; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; RAJAPANDI T, 1994, J BACTERIOL, V176, P4444, DOI 10.1128/jb.176.14.4444-4447.1994; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RIGGS PD, 1988, GENETICS, V118, P571; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Salavati R, 1997, J MOL BIOL, V265, P142, DOI 10.1006/jmbi.1996.0724; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarker S, 2000, J BACTERIOL, V182, P5592, DOI 10.1128/JB.182.19.5592-5595.2000; Sarker S, 2002, J BACTERIOL, V184, P2360, DOI 10.1128/JB.184.9.2360-2369.2002; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sunohara T, 2004, J BIOL CHEM, V279, P15368, DOI 10.1074/jbc.M312805200; Sunohara T, 2004, RNA, V10, P378, DOI 10.1261/rna.5169404; Sunohara T, 2002, RNA, V8, P1416, DOI 10.1017/S1355838202020198; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Ueda K, 2002, GENES CELLS, V7, P509, DOI 10.1046/j.1365-2443.2002.00537.x; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Withey JH, 2003, ANNU REV MICROBIOL, V57, P101, DOI 10.1146/annurev.micro.57.030502.090945; Yamamoto Y, 2003, RNA, V9, P408, DOI 10.1261/rna.2174803; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	62	26	27	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54193	54201		10.1074/jbc.M314012200	http://dx.doi.org/10.1074/jbc.M314012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494397	hybrid			2022-12-27	WOS:000225793600038
J	Henderson, NC; Collis, EA; Mackinnon, AC; Simpson, KJ; Haslett, C; Zent, R; Ginsberg, M; Sethi, T				Henderson, NC; Collis, EA; Mackinnon, AC; Simpson, KJ; Haslett, C; Zent, R; Ginsberg, M; Sethi, T			CD98hc (SLC3A2) interaction with beta(1) Integrins is required for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; AMINO-ACID-TRANSPORT; LYMPHOCYTE-ACTIVATION; SURFACE-ANTIGEN; CELL CARCINOMA; HEAVY-CHAIN; EXPRESSION; 4F2; ASSOCIATION; SUBUNIT	CD98hc (SLC3A2) constitutively and specifically associates with beta(1) integrins and is highly expressed on the surface of human tumor cells irrespective of the tissue of origin. We have found here that expression of CD98hc promotes both anchorage- and serum-independent growth. This oncogenic activity is dependent on beta(1) integrin-mediated phosphoinositol 3-hydroxykinase stimulation and the level of surface expression of CD98hc. Using chimeras of CD98hc and the type II membrane protein CD69, we show that the transmembrane domain of CD98hc is necessary and sufficient for integrin association in cells. Furthermore, CD98hc/beta(1) integrin association is required for focal adhesion kinase-dependent phosphoinositol 3-hydroxykinase activation and cellular transformation. Amino acids 82-87 in the putative cytoplasmic/transmembrane region appear to be critical for the oncogenic potential of CD98hc and provide a novel mechanism for tumor promotion by integrins. These results explain how high expression of CD98hc in human cancers contributes to transformation; furthermore, the transmembrane association of CD98hc and beta(1) integrins may provide a new target for cancer therapy.	Univ Edinburgh, Sch Med, MRC,Ctr Inflammat Res, Lung Inflammat Grp, Edinburgh EH8 9XD, Midlothian, Scotland; Vanderbilt Univ, Med Ctr, Vet Affairs Med Ctr, Div Nephrol, Nashville, TN 37232 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Edinburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; University of California System; University of California San Diego	Sethi, T (corresponding author), Univ Edinburgh, Sch Med, MRC,Ctr Inflammat Res, Lung Inflammat Grp, Hugh Robson Bldg,Rm 219,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.	t.sethi@ed.ac.uk						AZZARONE B, 1985, EXP CELL RES, V159, P451, DOI 10.1016/S0014-4827(85)80018-5; BELLONE G, 1989, EUR J IMMUNOL, V19, P1, DOI 10.1002/eji.1830190102; Bouck N, 1979, Methods Enzymol, V58, P296; CARNEY DN, 1980, CANCER RES, V40, P1820; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; DIXON WT, 1990, INT J CANCER, V45, P59, DOI 10.1002/ijc.2910450113; ESTEBAN F, 1990, CANCER, V66, P1493, DOI 10.1002/1097-0142(19901001)66:7<1493::AID-CNCR2820660710>3.0.CO;2-0; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kolesnikova TV, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-10; Liu SC, 2000, J CELL SCI, V113, P3563; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; Miyamoto YJ, 2003, MOL IMMUNOL, V39, P739, DOI 10.1016/S0161-5890(02)00255-9; Moore SM, 1998, CANCER RES, V58, P5239; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; SUOMALAINEN HA, 1986, J IMMUNOL, V137, P422; VANDERKAAY J, 1999, PHOSPHOLIPID SIGNALI, P109; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Yoon JH, 2003, ANTICANCER RES, V23, P3877; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	45	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54731	54741		10.1074/jbc.M408700200	http://dx.doi.org/10.1074/jbc.M408700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485886	hybrid			2022-12-27	WOS:000225793600101
J	Liu, W; Xu, DR; Yang, HM; Xu, H; Shi, ZQ; Cao, XM; Takeshita, S; Liu, JZ; Teale, M; Feng, X				Liu, W; Xu, DR; Yang, HM; Xu, H; Shi, ZQ; Cao, XM; Takeshita, S; Liu, JZ; Teale, M; Feng, X			Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; OSTEOPROTEGERIN-LIGAND; TERMINAL KINASE; DENDRITIC-CELL; TRAF FAMILY; SIGNAL-TRANSDUCTION; MATURE OSTEOCLASTS; BONE-RESORPTION; T-CELLS	Receptor activator of NF-kappaB ligand (RANKL) and its receptor activator of NF-kappaB (RANK) play pivotal roles in osteoclast differentiation and function. However, the structural determinants of the RANK that mediate osteoclast formation and function have not been definitively identified. To address this issue, we developed a chimeric receptor approach that permits a structure/function study of the RANK cytoplasmic domain in osteoclasts. Using this approach, we examined the role of six RANK putative tumor necrosis factor receptor-associated factor-binding motifs (PTM) (PTM1, ILLMT-REE286-293; PTM2, PSQPS(349-353); PTM3, PFQEP(369-373); PTM4, VYVSQTSQE(537-545); PTM5, PVQEET(559-564); and PTM6, PVQEQG(604-609)) in osteoclast formation and function. Our data revealed that the RANK cytoplasmic domain possesses three functional motifs (PFQEP(369-373), PVQEET(559-564), and PVQEQG(604-609)) capable of mediating osteoclast formation and function. Moreover, we demonstrated that these motifs play distinct roles in activating intracellular signaling. PFQEP(369-373) initiates NF-kappaB, c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38 signaling pathways and PVQEET(559-564) activates NF-kappaB and p38 pathways in osteoclasts, whereas PVQEQG(604-609) is only capable of activating NF-kappaB pathway. Significantly, the revelation of these functional RANK cytoplasmic motifs has not only laid a foundation for further delineating RANK signaling pathways in osteoclasts, but, more importantly, these RANK motifs themselves represent potential therapeutic targets for bone disorders such as osteoporosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Guangdong Prov, Peoples R China; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Sun Yat Sen University; Washington University (WUSTL)	Feng, X (corresponding author), Univ Alabama, Dept Pathol, 1670 Univ Blvd,VH G046B, Birmingham, AL 35294 USA.	xfeng@path.uab.edu	Xu, Hui/A-8167-2009		NIAMS NIH HHS [P30AR46031, AR 47830] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031, R01AR047830] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; GREENFIELD EM, 1992, CALCIFIED TISSUE INT, V51, P317, DOI 10.1007/BF00334494; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Jimi E, 1999, J IMMUNOL, V163, P434; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peschon JJ, 1998, J IMMUNOL, V160, P943; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	41	43	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54759	54769		10.1074/jbc.M404687200	http://dx.doi.org/10.1074/jbc.M404687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485878	hybrid			2022-12-27	WOS:000225793600104
J	Cui, NG; Kang, YH; He, Y; Leung, YM; Xie, HL; Pasyk, EA; Gao, XD; Sheu, L; Hansen, JB; Wahl, P; Tsushima, RG; Gaisano, HY				Cui, NG; Kang, YH; He, Y; Leung, YM; Xie, HL; Pasyk, EA; Gao, XD; Sheu, L; Hansen, JB; Wahl, P; Tsushima, RG; Gaisano, HY			H3 domain of syntaxin 1A inhibits K-ATP channels by its actions on the sulfonylurea receptor 1 nucleotide-binding folds-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; BETA-CELL; 3-DIMENSIONAL STRUCTURE; MOLECULAR DETERMINANTS; EXOCYTOSIS; MODULATION; DIAZOXIDE; TERMINUS; SUBUNIT; COMPLEX	The ATP-sensitive potassium (K-ATP) channel in pancreatic islet beta cells consists of four pore-forming (Kir6.2) subunits and four regulatory sulfonylurea receptor (SUR1) subunits. In beta cells, the KATP channel links intracellular metabolism to the dynamic regulation of the cell membrane potential that triggers insulin secretion. Syntaxin 1A (Syn-1A) is a SNARE protein that not only plays a direct role in exocytosis, but also binds and modulates voltage-gated K+ and Ca2+ channels to fine tune exocytosis. We recently reported that wild type Syn-1A inhibits rat islet beta cell KATP channels and binds both nucleotide-binding folds (NBF-1 and NBF-2) of SUR1. However, wild type Syn-1A inhibition of rat islet beta cell KATP channels seems to be mediated primarily via NBF-1. During exocytosis, Syn-1A undergoes a conformational change from a closed form to an open form, which would fully expose its active domain, the C-terminal H3 domain. Here, we show that the constitutively open form Syn-1A mutant ( L165A/E166A) has a similar affinity to NBF-1 and NBF-2 as wild type Syn-1A and was equally effective in inhibiting the KATP channels of rat pancreatic beta cells and a cell line (BA8) stably expressing SUR1/Kir6.2. Although dialysis of NBF-1 into BA8 and islet beta cells effectively blocked wild type and open form Syn-1A inhibition of the KATP current, NBF-2 was also effective in blocking the open form Syn-1A inhibition. This prompted us to examine the specific domains within Syn-1A that would mediate its action on the KATP channels. The C-terminal H3 domain of Syn-1A (Syn-1A-H3), but not the N-terminal H-ABC domain (Syn-1A-H-ABC), binds the SUR1 protein of BA8 cells, causing an inhibition of KATP currents, and this inhibition was mediated via both NBF-1 and NBF-2. It therefore appears that the H3 domain of Syn-1A is the putative domain, which binds SUR1, but its distinct actions on the NBFs may depend on the conformation of Syn-1A occurring during exocytosis.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; NovoNordisk, DK-2760 Malov, Denmark	University of Toronto; University of Toronto	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Rm 7226 Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	Herbert.gaisano@utoronto.ca						Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Dabrowski M, 2001, DIABETOLOGIA, V44, P747, DOI 10.1007/s001250051684; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fox JEM, 2003, METABOLISM, V52, P1313, DOI 10.1016/S0026-0495(03)00199-9; Gribble FM, 2000, MOL PHARMACOL, V57, P1256; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jarvis SE, 2002, J BIOL CHEM, V277, P44399, DOI 10.1074/jbc.M206902200; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Matsuo M, 2002, EMBO J, V21, P4250, DOI 10.1093/emboj/cdf419; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Pasyk EA, 2004, J BIOL CHEM, V279, P4234, DOI 10.1074/jbc.M309667200; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	29	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53259	53265		10.1074/jbc.M410171200	http://dx.doi.org/10.1074/jbc.M410171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485808	hybrid			2022-12-27	WOS:000225680600056
J	Heitmeier, MR; Kelly, CB; Ensor, NJ; Gibson, KA; Mullis, KG; Corbett, JA; Maziasz, TJ				Heitmeier, MR; Kelly, CB; Ensor, NJ; Gibson, KA; Mullis, KG; Corbett, JA; Maziasz, TJ			Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; INSULIN-SECRETION; INDUCED INHIBITION; EXPRESSION; COX-2; LANGERHANS; INTERLEUKIN-1; DESTRUCTION; PATHOGENESIS; SENSITIVITY	Type I diabetes mellitus is an autoimmune disease characterized by the selective destruction of the insulin-secreting beta-cell found in pancreatic islets of Langerhans. Cytokines such as interleukin-1 (IL-1), interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) mediate beta-cell dysfunction and islet degeneration, in part, through the induction of the inducible isoform of nitric-oxide synthase and the production of nitric oxide by beta-cells. Cytokines also stimulate the expression of the inducible isoform of cyclooxygenase, COX-2, and the production of prostaglandin E-2 (PGE(2)) by rat and human islets; however, the role of increased COX-2 expression and PGE(2) production in mediating cytokine-induced inhibition of islet metabolic function and viability has been incompletely characterized. In this study, we have shown that treatment of rat islets with IL-1beta or human islets with a cytokine mixture containing IL-1beta + IFN-gamma +/- TNF-alpha stimulates COX-2 expression and PGE(2) formation in a time-dependent manner. Co-incubation of rat and human islets with selective COX-2 inhibitors SC-58236 and Celecoxib, respectively, attenuated cytokine-induced PGE(2) formation. However, these inhibitors failed to prevent cytokine-mediated inhibition of insulin secretion or islet degeneration. These findings indicate that selective inhibition of COX-2 activity does not protect rat and human islets from cytokine-induced beta-cell dysfunction and islet degeneration and, furthermore, that islet production of PGE(2) does not mediate these inhibitory and destructive effects.	Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, St Louis, MO 63017 USA; Pfizer Global Res & Dev, Dept Arthrit & Inflammat, St Louis, MO 63017 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Pfizer; Pfizer; Saint Louis University	Heitmeier, MR (corresponding author), Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, 700 Chesterfield Pkwy W,Mail Code T2C, St Louis, MO 63017 USA.	Monique.R.Heitmeier@Pfizer.com			NIDDK NIH HHS [DK 52194, DK 68839] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK068839, R01DK052194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; Cosentino F, 2003, CIRCULATION, V107, P1017, DOI 10.1161/01.CIR.0000051367.92927.07; DAYERMETROZ MD, 1989, J AUTOIMMUN, V2, P163, DOI 10.1016/0896-8411(89)90152-2; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Flodstrom M, 1999, DIABETES, V48, P706, DOI 10.2337/diabetes.48.4.706; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeyer M. R, 2000, NITRIC OXIDE BIOL PA, P785; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; Kwon G, 1997, MOL PHARMACOL, V52, P398, DOI 10.1124/mol.52.3.398; LACY PE, 1991, AM J PATHOL, V138, P1183; Lee SH, 2000, LIFE SCI, V68, P57, DOI 10.1016/S0024-3205(00)00920-6; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; MANDRUPPOULSEN T, 1993, DIABETOLOGIA, V36, P470, DOI 10.1007/BF00402286; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Persaud SJ, 2004, DIABETES, V53, pS190, DOI 10.2337/diabetes.53.2007.S190; ROBERTSON R P, 1986, Diabetes Metabolism Reviews, V2, P261; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Scarim AL, 1997, ENDOCRINOLOGY, V138, P5301, DOI 10.1210/en.138.12.5301; Shanmugam N, 2004, DIABETES, V53, P795, DOI 10.2337/diabetes.53.3.795; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; Tran POT, 2002, DIABETES, V51, P1772, DOI 10.2337/diabetes.51.6.1772; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	41	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53145	53151		10.1074/jbc.M410978200	http://dx.doi.org/10.1074/jbc.M410978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471850	hybrid			2022-12-27	WOS:000225680600043
J	Sarg, B; Helliger, W; Talasz, H; Koutzamani, E; Lindner, HH				Sarg, B; Helliger, W; Talasz, H; Koutzamani, E; Lindner, HH			Histone H4 hyperacetylation precludes histone H4 lysine 20 trimethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHILIC-INTERACTION CHROMATOGRAPHY; INTERACTION LIQUID-CHROMATOGRAPHY; DNA METHYLATION; ERYTHROLEUKEMIC CELLS; HORMONE-RECEPTOR; ACTIVE GENES; ACETYLATION; H3; HETEROCHROMATIN; CHROMATIN	Posttranslational modification of histones is a common means of regulating chromatin structure and thus diverse nuclear processes. Using a hydrophilic interaction liquid chromatographic separation method in combination with mass spectrometric analysis, the present study investigated the alterations in histone H4 methylation/ acetylation status and the interplay between H4 methylation and acetylation during in vitro differentiation of mouse erythroleukemia cells and how these modifications affect the chromatin structure. Independently of the type of inducer used ( dimethyl sulfoxide, hexamethylenebisacetamide, butyrate, and trichostatin A), we observed a strong increase in non- and monoacetylated H4 lysine 20 (H4-Lys(20)) trimethylation. An increase in H4-Lys(20) trimethylation, however, to a clearly lesser extent, was also found when cells accumulated in the stationary phase. Since we show that trimethylated H4-Lys(20) is localized to heterochromatin, the increase in H4-Lys(20) trimethylation observed indicates an accumulation of chromatin-dense and transcriptionally silent regions during differentiation and during the accumulation of control cells in the stationary phase, respectively. When using the deacetylase inhibitors butyrate or trichostatin A, we found that H4 hyperacetylation prevents H4-Lys(20) trimethylation, but not mono- or dimethylation, and that the nonacetylated unmethylated H4-Lys(20) is therefore the most suitable substrate for H4-Lys(20) trimethylase. Summarizing, histone H4-Lys(20) hypotrimethylation correlates with H4 hyperacetylation and H4-Lys(20) hypertrimethylation correlates with H4 hypoacetylation. The results provide a model for how transcriptionally active euchromatin might be converted to the compacted, transcriptionally silent heterochromatin.	Med Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden	Medical University of Innsbruck; Linkoping University	Lindner, HH (corresponding author), Med Univ Innsbruck, Dept Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	herbert.lindner@uibk.ac.at	Koutzamani, Elisavet/N-4112-2015	Koutzamani, Elisavet/0000-0003-3059-5191				ALPERT AJ, 1990, J CHROMATOGR, V499, P177, DOI 10.1016/S0021-9673(00)96972-3; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Czermin B, 2003, GENETICA, V117, P159, DOI 10.1023/A:1022927725945; FRIEND C, 1987, CANCER RES, V47, P378; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HELLIGER W, 1992, BIOCHEM J, V288, P747, DOI 10.1042/bj2880747; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kristjuhan A, 2003, P NATL ACAD SCI USA, V100, P7551, DOI 10.1073/pnas.1332299100; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; LINDNER H, 1988, J CHROMATOGR, V450, P309, DOI 10.1016/S0021-9673(01)83585-8; Lindner H, 1998, J BIOL CHEM, V273, P13324, DOI 10.1074/jbc.273.21.13324; Lindner Herbert, 2004, Methods Mol Biol, V251, P75; Marks PA, 2001, CLIN CANCER RES, V7, P759; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Sarg B, 1999, ARCH BIOCHEM BIOPHYS, V372, P333, DOI 10.1006/abbi.1999.1503; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Van Holde KE., 1988, SPRINGER SERIES MOL, P111; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	45	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53458	53464		10.1074/jbc.M409099200	http://dx.doi.org/10.1074/jbc.M409099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456746	hybrid			2022-12-27	WOS:000225680600080
J	Srivastava, S; Spite, M; Trent, JO; West, MB; Ahmed, Y; Bhatnagar, A				Srivastava, S; Spite, M; Trent, JO; West, MB; Ahmed, Y; Bhatnagar, A			Aldose reductase-catalyzed reduction of aldehyde phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; FACTOR-ACETYLHYDROLASE; OXIDIZED PHOSPHOLIPIDS; LIPID-PEROXIDATION; OXIDATIVE STRESS; STRUCTURAL-CHARACTERIZATION; METABOLISM; PRODUCTS	Oxidation of unsaturated phospholipids results in the generation of aldehyde side chains that remain esterified to the phospholipid backbone. Such "core" aldehydes elicit immune responses and promote inflammation. However, the biochemical mechanisms by which phospholipid aldehydes are metabolized or detoxified are not well understood. In the studies reported here, we examined whether aldose reductase (AR), which reduces hydrophobic aldehydes, metabolizes phospholipid aldehydes. Incubation with AR led to the reduction of 5-oxovaleroyl, 7-oxo-5-heptenoyl, 5-hydroxy-6-oxo-caproyl, and 5-hydroxy-8-oxo-6-octenoyl phospholipids generated upon oxidation of 1-palmitoyl-2-arachidonoyl-sn- glycero-3-phosphocholine (PAPC). The enzyme also catalyzed the reduction of phospholipid aldehydes generated from the oxidation of 1-alkyl, and 1-alkenyl analogs of PAPC, and 1-palmitoyl-2-arachidonoyl phosphatidic acid or phosphoglycerol. Aldose reductase catalyzed the reduction of chemically synthesized 1-palmitoyl-2-( 5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine (POVPC) with a K-m of 10 muM. Addition of POVPC to the culture medium led to incorporation and reduction of the aldehyde in COS-7 and THP-1 cells. Reduction of POVPC in these cells was prevented by the AR inhibitors sorbinil and tolrestat and was increased in COS-7 cells overexpressing AR. Together, these observations suggest that AR may be a significant participant in the metabolism of several structurally diverse phospholipid aldehydes. This metabolism may be a critical regulator of the pro-inflammatory and immunogenic effects of oxidized phospholipids.	Univ Louisville, Dept Med, Div Cardiol, Inst Mol Cardiol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, James Graham Brown Canc Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Bhatnagar, A (corresponding author), Univ Louisville, Dept Med, Div Cardiol, Inst Mol Cardiol, Delia Baxter Bldg,580 S Preston St,Room 421F, Louisville, KY 40202 USA.	aruni@louisville.edu	Srivastava, Sanjay/D-3921-2012; Bhatnagar, Aruni/H-7791-2013; Spite, Matthew/B-3337-2010	trent, John/0000-0002-7346-4231	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055477, R01HL065618, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011860] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CARPER DA, 1995, BBA-PROTEIN STRUCT M, V1246, P67, DOI 10.1016/0167-4838(94)00182-G; Chan H., 1987, AUTOXIDATION UNSATUR; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Gaut JP, 2001, TRENDS CARDIOVAS MED, V11, P103, DOI 10.1016/S1050-1738(01)00101-3; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goyal J, 1997, J BIOL CHEM, V272, P16231, DOI 10.1074/jbc.272.26.16231; Harman D, 2001, ANN NY ACAD SCI, V928, P1, DOI 10.1111/j.1749-6632.2001.tb05631.x; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Hoff HF, 2003, ARTERIOSCL THROM VAS, V23, P275, DOI 10.1161/01.ATV.0000051407.42536.73; Itabe H, 1999, J BIOCHEM-TOKYO, V126, P153, DOI 10.1093/oxfordjournals.jbchem.a022416; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; KAMIDO H, 1995, J LIPID RES, V36, P1876; KAYGANICHHARRISON KA, 1994, ANAL BIOCHEM, V221, P16, DOI 10.1006/abio.1994.1372; Keightley JA, 2004, MOL CELL PROTEOMICS, V3, P167, DOI 10.1074/mcp.M300119-MCP200; Khaselev N, 2000, FREE RADICAL BIO MED, V29, P620, DOI 10.1016/S0891-5849(00)00361-0; Khaselev N, 2000, J LIPID RES, V41, P564; KINOSHITA JH, 1990, EXP EYE RES, V50, P567, DOI 10.1016/0014-4835(90)90096-D; Kloner RA, 2001, CIRCULATION, V104, P2981, DOI 10.1161/hc4801.100038; Lamensdorf I, 2000, BRAIN RES, V868, P191, DOI 10.1016/S0006-8993(00)02309-X; Lee YS, 1998, BIOPHYS CHEM, V70, P203, DOI 10.1016/S0301-4622(97)00115-4; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Maack C, 2003, CIRCULATION, V108, P1567, DOI 10.1161/01.CIR.0000091084.46500.BB; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; Mezzetti A, 2000, CARDIOVASC RES, V47, P475, DOI 10.1016/S0008-6363(00)00118-8; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; NAKAMURA Y, 1994, B CHEM SOC JPN, V67, P2151, DOI 10.1246/bcsj.67.2151; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Quarck R, 2001, CIRCULATION, V103, P2495; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shinmura K, 2002, CIRC RES, V91, P240, DOI 10.1161/01.RES.0000029970.97247.57; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 2002, AM J PHYSIOL-HEART C, V283, pH2612, DOI 10.1152/ajpheart.00592.2002; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; Srivastava S, 2001, CHEM-BIOL INTERACT, V130, P563, DOI 10.1016/S0009-2797(00)00299-4; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Srivastava S, 1998, BIOCHEM J, V329, P469, DOI 10.1042/bj3290469; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; Steckelbroeck S, 2004, J BIOL CHEM, V279, P10784, DOI 10.1074/jbc.M313308200; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; Subramanian VS, 1999, BBA-MOL CELL BIOL L, V1439, P95, DOI 10.1016/S1388-1981(99)00072-4; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; West M, 2003, PROG EXP CARDIOL, V6, P465; WILSON DK, 1995, BIOCHEMISTRY-US, V34, P14323, DOI 10.1021/bi00044a009; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; Zacarias A, 2002, ANAL BIOCHEM, V308, P152, DOI 10.1016/S0003-2697(02)00209-9	80	63	66	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53395	53406		10.1074/jbc.M403416200	http://dx.doi.org/10.1074/jbc.M403416200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465833	Green Accepted, hybrid			2022-12-27	WOS:000225680600073
J	Al-Anouti, F; Tomavo, S; Parmley, S; Ananvoranich, S				Al-Anouti, F; Tomavo, S; Parmley, S; Ananvoranich, S			The expression of lactate dehydrogenase is important for the cell cycle of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED GENES; DOUBLE-STRANDED-RNA; DIFFERENTIAL EXPRESSION; STAGE CONVERSION; IDENTIFICATION; INTERFERENCE; BRADYZOITES; ENZYMES; MEDIATE; CLONING	In Toxoplasma gondii, lactate dehydrogenase is encoded by two independent and developmentally regulated genes LDH1 and LDH2. These genes and their products have been implicated in the control of a metabolic flux during parasite differentiation. To investigate the significance of LDH1 and LDH2 in this process, we generated stable transgenic parasite lines in which the expression of these two expressed isoforms of lactate dehydrogenase was knocked down in a stage-specific manner. These LDH knockdown parasites exhibited variable growth rates in either the tachyzoite or the bradyzoite stage, as compared with the parental parasites. Their differentiation processes were impaired when the parasites were grown under in vitro conditions. In vivo studies in a murine model system revealed that tachyzoites of these parasite lines were unable to form significant numbers of tissue cysts and to establish a chronic infection. Most importantly, all mice that were initially infected with tachyzoites of either of the four LDH knockdown lines survived a subsequent challenge with tachyzoites of the parental parasites ( 104), a dose that usually causes 100% mortality, suggesting that live vaccination of mice with the LDH knockdown tachyzoites can confer protection against T. gondii. Thus, we conclude that LDH expression is essential for parasite differentiation. The knockdown of LDH1 and LDH2 expression gave rise to virulence-attenuated parasites that were unable to exhibit a significant brain cyst burden in a murine model of chronic infection.	Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; Univ Sci & Technol Lille, CNRS UMR 8576, Equip Parasitol Mol, Lab Chim Biol,UGSF, F-59655 Villeneuve Dascq, France; Palo Alto Med Fdn, Dept Immunol & Infect Dis, Palo Alto, CA 94305 USA	University of Windsor; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Palo Alto Medical Foundation Research Institute	Ananvoranich, S (corresponding author), Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.	anans@uwindsor.ca	Al Anouti, Fatme/ADY-7764-2022	Al Anouti, Fatme/0000-0002-1993-6656				Al-Anouti F, 2003, BIOCHEM BIOPH RES CO, V302, P316, DOI 10.1016/S0006-291X(03)00172-4; Al-Anouti F, 2002, ANTISENSE NUCLEIC A, V12, P275, DOI 10.1089/108729002320351593; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Black MW, 1998, J BIOL CHEM, V273, P3972, DOI 10.1074/jbc.273.7.3972; BOHNE W, 1995, MOL MICROBIOL, V16, P1221, DOI 10.1111/j.1365-2958.1995.tb02344.x; Boothroyd JC, 1997, PHILOS T ROY SOC B, V352, P1347, DOI 10.1098/rstb.1997.0119; Cleary MD, 2002, EUKARYOT CELL, V1, P329, DOI 10.1128/EC.1.3.329-340.2002; Dando C, 2001, MOL BIOCHEM PARASIT, V118, P23, DOI 10.1016/S0166-6851(01)00360-7; Denton H, 1996, FEMS MICROBIOL LETT, V137, P103, DOI 10.1111/j.1574-6968.1996.tb08090.x; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; DUBEY JP, 1994, J AM VET MED ASSOC, V205, P1593; Dzierszinski F, 2001, J MOL BIOL, V309, P1017, DOI 10.1006/jmbi.2001.4730; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freyre A, 1995, J PARASITOL, V81, P1008, DOI 10.2307/3284058; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jijakli H, 1996, ARCH BIOCHEM BIOPHYS, V327, P260, DOI 10.1006/abbi.1996.0119; Kavanagh KL, 2004, BIOCHEMISTRY-US, V43, P879, DOI 10.1021/bi035108g; Manger ID, 1998, INFECT IMMUN, V66, P1632, DOI 10.1128/IAI.66.4.1632-1637.1998; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; PARMLEY SF, 1995, MOL BIOCHEM PARASIT, V73, P253, DOI 10.1016/0166-6851(95)00100-F; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SOETE M, 1993, EXP PARASITOL, V76, P259, DOI 10.1006/expr.1993.1031; Soldati D, 1995, MOL BIOCHEM PARASIT, V74, P87, DOI 10.1016/0166-6851(95)02487-5; Tomavo S, 2001, INT J PARASITOL, V31, P1023, DOI 10.1016/S0020-7519(01)00193-X; Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x; Voinnet O, 2002, CURR OPIN PLANT BIOL, V5, P444, DOI 10.1016/S1369-5266(02)00291-1; Winter VJ, 2003, MOL BIOCHEM PARASIT, V131, P1, DOI 10.1016/S0166-6851(03)00170-1; Yahiaoui B, 1999, MOL BIOCHEM PARASIT, V99, P223, DOI 10.1016/S0166-6851(99)00019-5; Yang SM, 1997, GENE, V184, P1, DOI 10.1016/S0378-1119(96)00566-5; Zhang YW, 2001, INFECT IMMUN, V69, P501, DOI 10.1128/IAI.69.1.501-507.2001	32	50	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52300	52311		10.1074/jbc.M409175200	http://dx.doi.org/10.1074/jbc.M409175200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459194	hybrid			2022-12-27	WOS:000225493400071
J	Carrier, JC; Deblois, GV; Champigny, C; Levy, E; Giguere, V				Carrier, JC; Deblois, GV; Champigny, C; Levy, E; Giguere, V			Estrogen-related receptor alpha (ERR alpha) is a transcriptional regulator of apolipoprotein A-IV and controls lipid handling in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; DIETARY-FAT ABSORPTION; GENE-EXPRESSION; COACTIVATOR-1-ALPHA PGC-1-ALPHA; PANCREATIC LIPASE; NUCLEAR RECEPTORS; GAMMA; LIVER; IDENTIFICATION; OVEREXPRESSION	The estrogen-related receptor alpha (ERRalpha) is an orphan member of the superfamily of nuclear receptors involved in the control of energy metabolism. In particular, ERRalpha induces a high energy expenditure in the presence of the coactivator PGC-1alpha. However, ERRalpha knockout mice have reduced fat mass and are resistant to diet-induced obesity. ERRalpha is expressed in epithelial cells of the small intestine, and because the intestine is the first step in the energy chain, we investigated whether ERRalpha plays a function in dietary energy handling. Gene expression profiling in the intestine identified a subset of genes involved in oxidative phosphorylation that were down-regulated in the absence of ERRalpha. In support of the physiological role of ERRalpha in this pathway, isolated enterocytes from ERRalpha knockout mice display lower capacity for beta-oxidation. Microarray results also show altered expression of genes involved in dietary lipid digestion and absorption, such as pancreatic lipase-related protein 2 (PLRP2), fatty acid-binding protein 1 and 2 ( L-FABP and I-FABP), and apolipoprotein A-IV (apoA-IV). In agreement, we found that ERRalpha(-/-) pups exhibit significant lipid malabsorption. We further show that the apoA-IV promoter is a direct target of ERRalpha and that its presence is required to maintain basal level but not feeding-induced regulation of the apoA-IV gene in mice. ERRalpha, in cooperation with PGC-1alpha, activates the apoA-IV promoter via interaction with the apoC-III enhancer in both human and mouse. Our results demonstrate that apoA-IV is a direct ERRalpha target gene and suggest a function for ERRalpha in intestinal fat transport, a crucial step in energy balance.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Hop St Justine, Ctr Rech, Dept Nutr, Montreal, PQ H3C 1C5, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; Universite de Montreal; McGill University; McGill University; McGill University	Giguere, V (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Room H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	vincent.giguere@mcgill.ca		Giguere, Vincent/0000-0001-9567-3694; Deblois, Genevieve/0000-0002-3067-2807				Ariazi EA, 2002, CANCER RES, V62, P6510; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; Bonnelye E, 2002, ENDOCRINOLOGY, V143, P3658, DOI 10.1210/en.2002-220095; Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; D'Agostino D, 2004, J NUTR, V134, P132, DOI 10.1093/jn/134.1.132; Darimont C, 2000, J LIPID RES, V41, P84; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Ek-von Mentzer BA, 2001, J BIOL CHEM, V276, P15575, DOI 10.1074/jbc.M011623200; FUJIMOTO K, 1993, J CLIN INVEST, V91, P1830, DOI 10.1172/JCI116395; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Jove M, 2004, J LIPID RES, V45, P113, DOI 10.1194/jlr.M300208-JLR200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Laganiere J, 2003, METHOD ENZYMOL, V364, P339; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Levy E, 1996, CLIN INVEST MED, V19, P317; Liang Y, 2004, MOL ENDOCRINOL, V18, P2000, DOI 10.1210/me.2003-0477; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu M, 2003, EXP BIOL MED, V228, P1181, DOI 10.1177/153537020322801013; Lowe ME, 1998, J BIOL CHEM, V273, P31215, DOI 10.1074/jbc.273.47.31215; Lu S, 2002, J BIOL CHEM, V277, P31929, DOI 10.1074/jbc.M201418200; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Murase T, 2002, J LIPID RES, V43, P1312, DOI 10.1194/jlr.M200094-JLR200; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poirier H, 1997, AM J PHYSIOL-GASTR L, V273, pG289, DOI 10.1152/ajpgi.1997.273.2.G289; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Stan S, 2003, BBA-MOL CELL BIOL L, V1631, P177, DOI 10.1016/S1388-1981(03)00004-0; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vassileva G, 2000, FASEB J, V14, P2040, DOI 10.1096/fj.99-0959com; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Weinstock PH, 1997, J LIPID RES, V38, P1782; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis	50	84	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52052	52058		10.1074/jbc.M410337200	http://dx.doi.org/10.1074/jbc.M410337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466464	hybrid			2022-12-27	WOS:000225493400042
J	Kim, KH; Song, MJ; Yoo, EJ; Choe, SS; Park, SD; Kim, JB				Kim, KH; Song, MJ; Yoo, EJ; Choe, SS; Park, SD; Kim, JB			Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; STIMULATED GLUCOSE-METABOLISM; INSULIN-RECEPTOR SUBSTRATE-1; RABBIT SKELETAL-MUSCLE; GENE-EXPRESSION; IN-VITRO; NUTRITIONAL REGULATION; STEROL REGULATION; RAT HEPATOCYTES; BETA-CATENIN	Adipocyte determination- and differentiation-dependent factor 1 (ADD1) plays important roles in lipid metabolism and insulin-dependent gene expression. Because insulin stimulates carbohydrate and lipid synthesis, it would be important to decipher how the transcriptional activity of ADD1/SREBP1c is regulated in the insulin signaling pathway. In this study, we demonstrated that glycogen synthase kinase (GSK)-3 negatively regulates the transcriptional activity of ADD1/SREBP1c. GSK3 inhibitors enhanced a transcriptional activity of ADD1/ SREBP1c and expression of ADD1/ SREBP1c target genes including fatty acid synthase (FAS), acetyl-CoA carboxylase 1 (ACC1), and steroyl-CoA desaturase 1 (SCD1) in adipocytes and hepatocytes. In contrast, overexpression of GSK3beta down-regulated the transcriptional activity of ADD1/ SREBP1c. GSK3 inhibitor-mediated ADD1/ SREBP1c target gene activation did not require de novo protein synthesis, implying that GSK3 might affect transcriptional activity of ADD1/ SREBP1c at the level of post-translational modification. Additionally, we demonstrated that GSK3 efficiently phosphorylated ADD1/ SREBP1c in vitro and in vivo. Therefore, these data suggest that GSK3 inactivation is crucial to confer stimulated transcriptional activity of ADD1/ SREBP1c for insulin-dependent gene expression, which would coordinate lipid and glucose metabolism.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Int Vaccine Inst, Seoul 151742, South Korea	Seoul National University (SNU); International Vaccine Institute	Kim, JB (corresponding author), Seoul Natl Univ, Sch Biol Sci, San 56-1 Sillim Dong, Seoul 151742, South Korea.	jaebkim@snu.ac.kr	Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935; Min, Jeong-Ki/0000-0003-4924-8739				Aiston S, 2003, EUR J BIOCHEM, V270, P2773, DOI 10.1046/j.1432-1033.2003.03648.x; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Bene H, 2001, BIOCHEM BIOPH RES CO, V284, P1194, DOI 10.1006/bbrc.2001.5102; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHESNOKOV V N, 1990, Biokhimiya, V55, P1276; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Guillet-Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Iynedjian PB, 2000, BIOCHEM J, V351, P621, DOI 10.1042/0264-6021:3510621; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Lan H, 2003, DIABETES, V52, P688, DOI 10.2337/diabetes.52.3.688; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TABATA I, 1994, DIABETES, V43, P903, DOI 10.2337/diabetes.43.7.903; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Tsakiridis T, 2001, BIOCHEM BIOPH RES CO, V288, P205, DOI 10.1006/bbrc.2001.5762; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhen XC, 2002, PSYCHOPHARMACOLOGY, V162, P379, DOI 10.1007/s00213-002-1126-y	64	79	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51999	52006		10.1074/jbc.M405522200	http://dx.doi.org/10.1074/jbc.M405522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466874	hybrid			2022-12-27	WOS:000225493400036
J	Sugioka, R; Shimizu, S; Tsujimoto, Y				Sugioka, R; Shimizu, S; Tsujimoto, Y			Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; CYTOCHROME-C RELEASE; OUTER-MEMBRANE; CELL-DEATH; FISSION; MORPHOLOGY; BCL-2; CARDIOLIPIN; YEAST; BAX	Mitochondrial morphology and physiology are regulated by the processes of fusion and fission. Some forms of apoptosis are reported to be associated with mitochondrial fragmentation. We showed that overexpression of Fzo1A/B ( rat) proteins involved in mitochondrial fusion, or silencing of Dnm1 (rat)/Drp1 (human) (a mitochondrial fission protein), increased elongated mitochondria in healthy cells. After apoptotic stimulation, these interventions inhibited mitochondrial fragmentation and cell death, suggesting that a process involved in mitochondrial fusion/fission might play a role in the regulation of apoptosis. Consistently, silencing of Fzo1A/B or Mfn1/2 (a human homolog of Fzo1A/B) led to an increase of shorter mitochondria and enhanced apoptotic death. Overexpression of Fzo1 inhibited cytochrome c release and activation of Bax/Bak, as assessed from conformational changes and oligomerization. Silencing of Mfn or Drp1 caused an increase or decrease of mitochondrial sensitivity to apoptotic stimulation, respectively. These results indicate that some of the proteins involved in mitochondrial fusion/fission modulate apoptotic cell death at the mitochondrial level.	Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp						Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; KJER P, 1983, ACTA OPHTHALMOL, V61, P300; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Malisan F, 2003, CURR MED CHEM, V10, P1573, DOI 10.2174/0929867033457188; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Messerschmitt M, 2003, J CELL BIOL, V160, P553, DOI 10.1083/jcb.200211113; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nomura M, 1999, CANCER RES, V59, P5542; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Santel A, 2001, J CELL SCI, V114, P867; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Shimizu S, 1996, ONCOGENE, V12, P2251; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	38	275	291	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52726	52734		10.1074/jbc.M408910200	http://dx.doi.org/10.1074/jbc.M408910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459195	hybrid			2022-12-27	WOS:000225493400119
J	Drisaldi, B; Coomaraswamy, J; Mastrangelo, P; Strome, B; Yang, J; Watts, JC; Chishti, MA; Marvi, M; Windl, O; Ahrens, R; Major, F; Sy, MS; Kretzschmar, H; Fraser, PE; Mount, HTJ; Westaway, D				Drisaldi, B; Coomaraswamy, J; Mastrangelo, P; Strome, B; Yang, J; Watts, JC; Chishti, MA; Marvi, M; Windl, O; Ahrens, R; Major, F; Sy, MS; Kretzschmar, H; Fraser, PE; Mount, HTJ; Westaway, D			Genetic mapping of activity determinants within cellular prion proteins - N-terminal modules in PrPC offset pro-apoptotic activity of the Doppel helix B/B ' region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURKINJE-CELLS; COPPER-BINDING; MICE DEFICIENT; TRUNCATED PRP; KNOCKOUT MICE; GRANULE CELLS; NMR STRUCTURE; SCRAPIE; EXPRESSION; IDENTIFICATION	The PrP-like Doppel (Dpl) protein causes apoptotic death of cerebellar neurons in transgenic mice, a process prevented by expression of the wild type (wt) cellular prion protein, PrPC. Internally deleted forms of PrPC resembling Dpl such as PrPDelta32-121 produce a similar PrPC-sensitive pro-apoptotic phenotype in transgenic mice. Here we demonstrate that these phenotypic attributes of wt Dpl, wt PrPC, and PrPDelta132-121 can be accurately recapitulated by transfected mouse cerebellar granule cell cultures. This system was then explored by mutagenesis of the co-expressed prion proteins to reveal functional determinants. By this means, neuroprotective activity of wt PrPC was shown to be nullified by a deletion of the N-terminal charged region implicated in endocytosis and retrograde axonal transport (PrPDelta23-28), by deletion of all five octarepeats (PrPDelta51-90), or by glycine replacement of four octarepeat histidine residues required for selective binding of copper ions (Prnp"H/G"). In the case of Dpl, overlapping deletions defined a requirement for the gene interval encoding helices B and B' (DplDelta101-125). These data suggest contributions of copper binding and neuronal trafficking to wt PrPC function in vivo and place constraints upon current hypotheses to explain Dpl/PrPC antagonism by competitive ligand binding. Further implementation of this assay should provide a fuller understanding of the attributes and subcellular localizations required for activity of these enigmatic proteins.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Vet Labs Agcy, Weybridge KT15 3NB, Surrey, England; Univ Montreal, Dept Informat & Rech Operat, Montreal, PQ H3C 3J7, Canada; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Univ Munich, D-81377 Munich, Germany	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Veterinary Laboratories Agency; Universite de Montreal; Case Western Reserve University; University of Munich	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	david.westaway@utoronto.ca	Mount, Howard/B-4097-2013; Windl, Otto/C-6760-2011	Watts, Joel/0000-0002-2604-2925				Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Anderson L, 2004, P NATL ACAD SCI USA, V101, P3644, DOI 10.1073/pnas.0308681101; Atarashi R, 2003, J BIOL CHEM, V278, P28944, DOI 10.1074/jbc.M303655200; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Behrens A, 2001, EMBO REP, V2, P347, DOI 10.1093/embo-reports/kve088; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chesebro Bruce, 2002, EMBO Reports, V3, P1123, DOI 10.1093/embo-reports/kvf256; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Cui T, 2003, MOL CELL NEUROSCI, V23, P144, DOI 10.1016/S1044-7431(03)00017-4; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Flechsig E, 2003, EMBO J, V22, P3095, DOI 10.1093/emboj/cdg285; FONCIN JF, 1982, REV NEUROL, V138, P123; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Hachiya NS, 2004, BIOCHEM BIOPH RES CO, V315, P802, DOI 10.1016/j.bbrc.2004.01.126; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Legname G, 2002, P NATL ACAD SCI USA, V99, P16285, DOI 10.1073/pnas.242611999; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Levkovitz Y, 2001, J NEUROSCI, V21, P5893, DOI 10.1523/JNEUROSCI.21-16-05893.2001; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Liu T, 2002, J BIOL CHEM, V277, P47671, DOI 10.1074/jbc.M207458200; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; Luck R, 1996, J MOL BIOL, V258, P813, DOI 10.1006/jmbi.1996.0289; Luhrs T, 2003, J MOL BIOL, V326, P1549, DOI 10.1016/S0022-2836(02)01471-7; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Mastrangelo P, 2001, GENE, V275, P1, DOI 10.1016/S0378-1119(01)00627-8; Miller TM, 1996, J NEUROSCI, V16, P7487; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; Nishida N, 1999, LAB INVEST, V79, P689; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Qin KF, 2003, J BIOL CHEM, V278, P8888, DOI 10.1074/jbc.M210875200; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakudo A, 2003, BIOCHEM BIOPH RES CO, V308, P660, DOI 10.1016/S0006-291X(03)01459-1; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Supattapone S, 2004, PRIONS AND PRION DISEASES: CURRENT PERSPECTIVES, P83; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; WESTAWAY D, 1994, P NATL ACAD SCI USA, V91, P6418, DOI 10.1073/pnas.91.14.6418; Westaway D, 2002, TRENDS BIOCHEM SCI, V27, P301, DOI 10.1016/S0968-0004(02)02106-0; Westaway David, 2004, VVolume 41, P283; WILLS PR, 1992, J THEOR BIOL, V159, P523, DOI 10.1016/S0022-5193(05)80696-4; WILLS PR, 1990, J ACQ IMMUN DEF SYND, V3, P95; Wong BS, 2001, MOL CELL NEUROSCI, V17, P768, DOI 10.1006/mcne.2001.0963; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	85	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55443	55454		10.1074/jbc.M404794200	http://dx.doi.org/10.1074/jbc.M404794200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15459186	hybrid			2022-12-27	WOS:000225960800059
J	Hsieh, TJ; Farh, L; Huang, WM; Chan, NL				Hsieh, TJ; Farh, L; Huang, WM; Chan, NL			Structure of the topoisomerase IVC-terminal domain - A broken beta-propeller implies a role as geometry facilitator in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II DNA TOPOISOMERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GYRASE-A; BINDING PROTEIN; SINGLE-MOLECULE; REPLICATION; MECHANISM; CHROMOSOME; UNLINKING	Bacteria possess two closely related yet functionally distinct essential type IIA topoisomerases (Topos). DNA gyrase supports replication and transcription with its unique supercoiling activity, whereas Topo IV preferentially relaxes (+) supercoils and is a decatenating enzyme required for chromosome segregation. Here we report the crystal structure of the C-terminal domain of Topo IV ParC subunit (ParC-CTD) from Bacillus stearothermophilus and provide a structure-based explanation for how Topo IV and DNA gyrase execute distinct activities. Although the topological connectivity of ParC-CTD is similar to the recently determined CTD structure of DNA gyrase GyrA subunit (GyrA-CTD), ParC-CTD surprisingly folds as a previously unseen broken form of a six-bladed beta-propeller. Propeller breakage is due to the absence of a DNA gyrase-specific GyrA box motif, resulting in the reduction of curvature of the proposed DNA binding region, which explains why ParC-CTD is less efficient than GyrA-CTD in mediating DNA bending, a difference that leads to divergent activities of the two homologous enzymes. Moreover, we found that the topology of the propeller blades observed in ParC-CTD and GyrA-CTD can be achieved from a concerted beta-hairpin invasion-induced fold change event of a canonical six-bladed beta-propeller; hence, we proposed to name this new fold as "hairpin-invaded beta-propeller" to highlight the high degree of similarity and a potential evolutionary linkage between them. The possible role of ParC-CTD as a geometry facilitator during various catalytic events and the evolutionary relationships between prokaryotic type IIA Topos have also been discussed according to these new structural insights.	Natl Chung Hsing Univ, Coll Life Sci, Inst Biochem, Taichung 402, Taiwan; Natl Pingtung Teachers Coll, Dept Nat Sci Educ, Pingtung 900, Taiwan; Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA	National Chung Hsing University; Utah System of Higher Education; University of Utah	Chan, NL (corresponding author), Natl Chung Hsing Univ, Coll Life Sci, Inst Biochem, Taichung 402, Taiwan.	nlchan@dragon.nchu.edu.tw	huang, wen/GXW-0661-2022	CHAN, NEI-LI/0000-0003-0139-6513				Adachi N, 1997, NUCLEIC ACIDS RES, V25, P3135, DOI 10.1093/nar/25.15.3135; ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BATES AD, 1993, DNA TOPOLOGY, P26; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P764; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Edwards TA, 2003, GENE DEV, V17, P2508, DOI 10.1101/gad.1119403; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x; Espeli O, 2003, J BIOL CHEM, V278, P44639, DOI 10.1074/jbc.M308926200; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Gadelle D, 2003, BIOESSAYS, V25, P232, DOI 10.1002/bies.10245; Grishin NV, 2001, J STRUCT BIOL, V134, P167, DOI 10.1006/jsbi.2001.4335; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hsieh TJ, 2004, ACTA CRYSTALLOGR D, V60, P564, DOI 10.1107/S0907444903029779; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; Kang SH, 2003, J BIOL CHEM, V278, P48779, DOI 10.1074/jbc.M308843200; KATO J, 1992, J BIOL CHEM, V267, P25676; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; Knight SW, 1999, EMBO J, V18, P4875, DOI 10.1093/emboj/18.17.4875; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MILLER WG, 1993, MOL MICROBIOL, V10, P675, DOI 10.1111/j.1365-2958.1993.tb00939.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Prescott L., 1996, MICROBIOLOGY, V3rd ed; Qi Y, 2002, PROTEINS, V47, P258, DOI 10.1002/prot.10090; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Ward D, 1997, MOL MICROBIOL, V26, P897, DOI 10.1046/j.1365-2958.1997.6242005.x; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	56	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55587	55593		10.1074/jbc.M408934200	http://dx.doi.org/10.1074/jbc.M408934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15466871	hybrid			2022-12-27	WOS:000225960800076
J	Llano, M; Delgado, S; Vanegas, M; Poeschla, EM				Llano, M; Delgado, S; Vanegas, M; Poeschla, EM			Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SUBCELLULAR-LOCALIZATION; TRANSCRIPTIONAL ACTIVATION; ORNITHINE-DECARBOXYLASE; KARYOPHILIC PROPERTIES; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; HUMAN GENOME; HUMAN-CELLS; RAT-LIVER	The transcriptional coactivator lens epithelium-derived growth factor (LEDGF)/p75 acts as a chromatin tethering factor for human immunodeficiency virus type 1 (HIV-1) integrase protein, determining its nuclear localization and its tight association with nuclear DNA. Here we identify a second function for the LEDGF/p75-integrase interaction. We observed that stable introduction of HIV-1 integrase ( IN) transcription units into cells made stringently LEDGF/p75-deficient by RNAi resulted in much lower steady state levels of IN protein than introduction into LEDGF/p75 wild type cells. The same LEDGF/p75-dependent disparity was observed for feline immunodeficiency virus IN. However, IN mRNA levels were equivalent in the presence and absence of LEDGF/p75. A post-translational mechanism was confirmed when the half-life of HIV-1 IN protein was found to be much shorter in LEDGF/p75-deficient cells. Proteasome inhibition fully countered this extreme instability, increasing IN protein levels to those seen in LEDGF/p75 wild type cells and implicating proteasomal destruction as the main cause of IN instability. Consistent with these data, increased ubiquitinated HIV-1 IN was found in the LEDGF/p75 knock-down cells. Moreover, restoration of LEDGF/p75 to knocked down clones rescued HIV-1 IN stability. Subcellular fractionation showed that HIV-1 IN is exclusively cytoplasmic in LEDGF/p75-deficient cells, but mainly nuclear in LEDGF/p75 wild type cells, and that cytoplasmic HIV-1 IN has a shorter half-life than nuclear HIV-1 IN. However, using LEDGF proteins defective for nuclear localization and IN interaction, we further determined that protection of HIV-1 IN from the proteasome requires neither chromatin tethering nor nuclear residence. Protection requires only interaction with LEDGF/p75, and it is independent of the subcellular localization of the IN-LEDGF complex.	Mayo Clin, Coll Med, Program Mol Med, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Poeschla, EM (corresponding author), Mayo Clin, Coll Med, Program Mol Med, Guggenheim 18,200 1st St SW, Rochester, MN 55905 USA.	emp@mayo.edu						Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Ganapathy V, 2003, AUTOIMMUN REV, V2, P290, DOI 10.1016/S1568-9972(03)00063-6; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Han YF, 2004, J VIROL, V78, P6122, DOI 10.1128/JVI.78.12.6122-6133.2004; Hautbergue G, 2001, J BIOL CHEM, V276, P8005, DOI 10.1074/jbc.M010162200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirai I, 2004, ONCOGENE, V23, P5124, DOI 10.1038/sj.onc.1207658; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nguyen KL, 2004, VIROLOGY, V319, P163, DOI 10.1016/j.virol.2003.11.021; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Petit C, 2000, J VIROL, V74, P7119, DOI 10.1128/JVI.74.15.7119-7126.2000; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Sharma P, 2000, BIOCHEM BIOPH RES CO, V276, P1320, DOI 10.1006/bbrc.2000.3606; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	48	131	138	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55570	55577		10.1074/jbc.M408508200	http://dx.doi.org/10.1074/jbc.M408508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475359	hybrid			2022-12-27	WOS:000225960800074
J	Luo, Q; Kang, Q; Si, WK; Jiang, W; Park, JK; Peng, Y; Li, XM; Luu, HH; Luo, J; Montag, AG; Haydon, RC; He, TC				Luo, Q; Kang, Q; Si, WK; Jiang, W; Park, JK; Peng, Y; Li, XM; Luu, HH; Luo, J; Montag, AG; Haydon, RC; He, TC			Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; RECEPTOR-RELATED PROTEIN-5; BETA-CATENIN; TGF-BETA; BOYDEN CHAMBER; CCN FAMILY; CYCLIN D1; GENE; EXPRESSION; BMP	Osteoblast lineage-specific differentiation of mesenchymal stem cells is a well regulated but poorly understood process. Both bone morphogenetic proteins (BMPs) and Wnt signaling are implicated in regulating osteoblast differentiation and bone formation. Here we analyzed the expression profiles of mesenchymal stem cells stimulated with Wnt3A and osteogenic BMPs, and we identified connective tissue growth factor (CTGF) as a potential target of Wnt and BMP signaling. We confirmed the microarray results, and we demonstrated that CTGF was up-regulated at the early stage of BMP-9 and Wnt3A stimulations and that Wnt3A-regulated CTGF expression was beta-catenin-dependent. RNA interference-mediated knockdown of CTGF expression significantly diminished BMP-9-induced, but not Wnt3A-induced, osteogenic differentiation, suggesting that Wnt3A may also regulate osteoblast differentiation in a CTGF-independent fashion. However, constitutive expression of CTGF was shown to inhibit both BMP-9- and Wnt3A-induced osteogenic differentiation. Exogenous expression of CTGF was shown to promote cell migration and recruitment of mesenchymal stem cells. Our findings demonstrate that CTGF is up-regulated by Wnt3A and BMP-9 at the early stage of osteogenic differentiation, which may regulate the proliferation and recruitment of osteoprogenitor cells; however, CTGF is down-regulated as the differentiation potential of committed pre-osteoblasts increases, strongly suggesting that tight regulation of CTGF expression may be essential for normal osteoblast differentiation of mesenchymal stem cells.	Univ Chicago, Med Ctr, Dept Surg, Oncol Mol Lab, Chicago, IL 60637 USA; Chongqing Univ Med Sci, Childrens Hosp, Chongqing 400016, Peoples R China; Third Mil Med Univ, Dept Clin Biochem, Chongqing 400038, Peoples R China; Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Surg, Seoul, South Korea; Univ Chicago Hosp, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Funct Genom Facil, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; Chongqing Medical University; Army Medical University; Catholic University of Korea; University of Chicago; University of Illinois System; University of Chicago; University of Chicago	He, TC (corresponding author), Univ Chicago, Med Ctr, Dept Surg, Oncol Mol Lab, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.	tche@surgery.bsd.uchicago.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT002014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR050142] Funding Source: NIH RePORTER; NCCIH NIH HHS [F05 AT 002014-01] Funding Source: Medline; NIAMS NIH HHS [1K08 AR 50142-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Baker JC, 1999, GENE DEV, V13, P3149, DOI 10.1101/gad.13.23.3149; Ball DK, 2003, J ENDOCRINOL, V176, pR1, DOI 10.1677/joe.0.176R001; Bergwitz C, 2001, BBA-MOL CELL RES, V1538, P129, DOI 10.1016/S0167-4889(00)00123-3; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Bloomfield KL, 2001, BIOTECHNIQUES, V31, P1242, DOI 10.2144/01316bm02; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Christian JL, 2000, CURR OPIN CELL BIOL, V12, P244, DOI 10.1016/S0955-0674(99)00082-4; Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Haider AS, 2003, CYTOM PART A, V53A, P1, DOI 10.1002/cyto.a.10032; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kingsley D M, 2001, Novartis Found Symp, V232, P213; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lam S, 2003, DIABETES, V52, P2975, DOI 10.2337/diabetes.52.12.2975; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V234, P206, DOI 10.1006/bbrc.1997.6528; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; URIST MR, 1987, CLIN ORTHOP RELAT R, P295; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu LF, 2000, GENE DEV, V14, P585; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	74	259	273	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55958	55968		10.1074/jbc.M407810200	http://dx.doi.org/10.1074/jbc.M407810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496414	hybrid			2022-12-27	WOS:000225960800119
J	Gomez, E; Powell, ML; Greenman, IC; Herbert, TP				Gomez, E; Powell, ML; Greenman, IC; Herbert, TP			Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP center dot Met-tRNAi) and the dephosphorylation of eIF2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; INSULIN-BIOSYNTHESIS; MESSENGER-RNA; PHAS-I; PROINSULIN BIOSYNTHESIS; MAMMALIAN TRANSLATION; REGULATED KINASE; GENE-EXPRESSION; AMINO-ACIDS; INITIATION	In pancreatic beta-cells, glucose causes a rapid increase in the rate of protein synthesis. However, the mechanism by which this occurs is poorly understood. In this report, we demonstrate, in the pancreatic beta-cell line MIN6, that glucose stimulates the recruitment of ribosomes onto the mRNA, indicative of an increase in the rate of the initiation step of protein synthesis. This increase in the rate of initiation is not mediated through an increase in the availability of the initiation complex eIF4F, because glucose is unable to stimulate eIF4F assembly or, in the absence of amino acids, modulate the phosphorylation status of 4E-BP1. Moreover, in MIN6 cells and isolated islets of Langerhans, rapamycin, an inhibitor of the mammalian target of rapamycin, only partially inhibited glucose-stimulated protein synthesis. However, we show that glucose stimulates the dephosphorylation of eIF2alpha in MIN6 cells and the assembly of the translational ternary complex, eIF2-GTP.Met-tRNAi, in both MIN6 cells and islets of Langerhans. The changes in the phosphorylation of eIF2alpha are not mediated by the PKR-like endoplasmic reticulum eIF2alpha kinase (PERK), because PERK is not phosphorylated at low glucose concentrations and overexpression of a dominant negative form of PERK has no significant effect on either glucose-stimulated protein synthesis or the phosphorylation of eIF2alpha. Taken together, these results indicate that glucose-stimulated protein synthesis in pancreatic beta-cells is regulated by a mechanism largely independent of the activity of mammalian target of rapamycin, but which is likely to be dependent on the availability of the translational ternary complex, regulated by the phosphorylation status of eIF2alpha.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Herbert, TP (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	tph4@le.ac.uk		Herbert, Terence/0000-0001-5402-0814				ALARCON C, 1993, J BIOL CHEM, V268, P4276; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHEN JJ, 1994, BIOCHIMIE, V76, P761, DOI 10.1016/0300-9084(94)90080-9; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; ITOH N, 1978, FEBS LETT, V93, P343, DOI 10.1016/0014-5793(78)81136-3; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jefferson LS, 2003, J NUTR, V133, p2046S, DOI 10.1093/jn/133.6.2046S; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; MARTIN SK, 1994, FEBS LETT, V356, P279, DOI 10.1016/0014-5793(94)01284-9; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Sood R, 2000, GENETICS, V154, P787; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Tokunaga C, 2004, BIOCHEM BIOPH RES CO, V313, P443, DOI 10.1016/j.bbrc.2003.07.019; WANG SY, 1988, ENDOCRINOLOGY, V123, P1008, DOI 10.1210/endo-123-2-1008; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH N, 1987, BIOCHEM J, V246, P245, DOI 10.1042/bj2460245; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yan LM, 2003, J BIOL CHEM, V278, P18177, DOI 10.1074/jbc.M301116200; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002	57	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53937	53946		10.1074/jbc.M408682200	http://dx.doi.org/10.1074/jbc.M408682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475356	hybrid, Green Accepted			2022-12-27	WOS:000225793600007
J	Khyrul, WAKM; LaLonde, DP; Brown, MC; Levinson, H; Turner, CE				Khyrul, WAKM; LaLonde, DP; Brown, MC; Levinson, H; Turner, CE			The integrin-linked kinase regulates cell morphology and motility in a Rho-associated kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PHOSPHATASE TARGET SUBUNIT; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; C-SRC; PAXILLIN; ILK; PHOSPHORYLATION	The integrin-linked kinase ( ILK) is a multidomain focal adhesion protein implicated in signal transmission from integrin and growth factor receptors. We have determined that ILK regulates U2OS osteosarcoma cell spreading and motility in a manner requiring both kinase activity and localization. Overexpression of wildtype (WT) ILK resulted in suppression of cell spreading, polarization, and motility to fibronectin. Cell lines over-expressing kinase-dead (S343A) or paxillin binding site mutant ILK proteins display inhibited haptotaxis to fibronectin. Conversely, spreading and motility was potentiated in cells expressing the "dominant negative," non-targeting, kinase-deficient E359K ILK protein. Suppression of cell spreading and motility of WT ILK U2OS cells could be rescued by treatment with the Rho-associated kinase ( ROCK) inhibitor Y-27632 or introduction of dominant negative ROCK or RhoA, suggesting these cells have increased RhoA signaling. Activation of focal adhesion kinase (FAK), a negative regulator of RhoA, was reduced in WT ILK cells, whereas overexpression of FAK rescued the observed defects in spreading and cell polarity. Thus, ILK-dependent effects on ROCK and/or RhoA signaling may be mediated through FAK.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA; Brookdale Univ Hosp, Dept Surg, Brooklyn, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	Turnerce@upstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kiss E, 2002, BIOCHEM J, V365, P79, DOI 10.1042/BJ20011295; Labouesse M, 2003, CURR BIOL, V13, pR528, DOI 10.1016/S0960-9822(03)00448-2; Li FG, 1999, J CELL SCI, V112, P4589; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Medley QG, 2003, J BIOL CHEM, V278, P13265, DOI 10.1074/jbc.M300277200; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 2000, J CELL SCI, V113, P3673; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 1999, J CELL SCI, V112, P1655; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200	60	50	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54131	54139		10.1074/jbc.M410051200	http://dx.doi.org/10.1074/jbc.M410051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485819				2022-12-27	WOS:000225793600032
J	Tie, JK; Jin, DY; Loiselle, DR; Pope, RM; Straight, DL; Stafford, DW				Tie, JK; Jin, DY; Loiselle, DR; Pope, RM; Straight, DL; Stafford, DW			Chemical modification of cysteine residues is a misleading indicator of their status as active site residues in the vitamin K-dependent gamma-glutamyl carboxylation reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PROPEPTIDE; PROTEINS; ENZYME; IDENTIFICATION; COAGULATION; EPOXIDATION; MEGAPRIMER; BINDING; SYSTEM	The enzymatic activity of the vitamin K-dependent proteins requires the post-translational conversion of specific glutamic acids to gamma-carboxy-glutamic acid by the integral membrane enzyme, gamma-glutamyl carboxylase. Whether or not cysteine residues are important for carboxylase activity has been the subject of a number of studies. In the present study we used carboxylase with point mutations at cysteines, chemical modification, and mass spectrometry to examine this question. Mutation of any of the free cysteine residues to alanine or serine had little effect on carboxylase activity, although C343A mutant carboxylase had only 38% activity compared with that of wild type. In contrast, treatment with either thiol-reactive reagent 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, disodium salt, or sodium tetrathionate, caused complete loss of activity. We identified the residues modified, using matrix-assisted laser desorption/ionization time of flight mass spectrometry, as Cys(323) and Cys(343). According to our results, these residues are on the cytoplasmic side of the microsomal membrane, whereas catalytic residues are expected to be on the lumenal side of the membrane. Carboxylase was partially protected from chemical modification by factor IXs propeptide. Although all mutant carboxylases bound propeptide with normal affinity, chemical modification caused a >100-fold decrease in carboxylase affinity for the consensus propeptide. We conclude that cysteine residues are not directly involved in carboxylase catalysis, but chemical modification of Cys(323) and Cys(343) may disrupt the three-dimensional structure, resulting in inactivation.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Invitrogen Corp, Res & Dev, Carlsbad, CA 92008 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Thermo Fisher Scientific	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	dws@email.unc.edu		Tie, Jian-Ke/0000-0002-8447-3408	NHLBI NIH HHS [HL78318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R13HL078318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouchard BA, 1999, BIOCHEMISTRY-US, V38, P9517, DOI 10.1021/bi9907375; Bristol JA, 1996, BLOOD, V88, P2585, DOI 10.1182/blood.V88.7.2585.bloodjournal8872585; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; CANFIELD LM, 1980, ARCH BIOCHEM BIOPHYS, V202, P515, DOI 10.1016/0003-9861(80)90457-9; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; FRIEDMAN PA, 1976, BIOCHEM BIOPH RES CO, V70, P647, DOI 10.1016/0006-291X(76)91096-2; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P148; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kuster B, 1999, ANAL CHEM, V71, P1431, DOI 10.1021/ac981012u; LIU TY, 1967, J BIOL CHEM, V242, P4029; MACK DO, 1976, J BIOL CHEM, V251, P3269; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Rishavy MA, 2004, P NATL ACAD SCI USA, V101, P13732, DOI 10.1073/pnas.0404989101; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE JW, 1979, BIOCHEM BIOPH RES CO, V86, P500, DOI 10.1016/0006-291X(79)91742-X; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; Tie JK, 2003, J BIOL CHEM, V278, P45468, DOI 10.1074/jbc.M309164200; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WALLIN R, 1982, ARCH BIOCHEM BIOPHYS, V214, P155, DOI 10.1016/0003-9861(82)90017-0; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718	29	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54079	54087		10.1074/jbc.M408945200	http://dx.doi.org/10.1074/jbc.M408945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492002	hybrid			2022-12-27	WOS:000225793600025
J	Foster, DB; Huang, RJ; Hatch, V; Craig, R; Graceffa, P; Lehman, W; Wang, CLA				Foster, DB; Huang, RJ; Hatch, V; Craig, R; Graceffa, P; Lehman, W; Wang, CLA			Modes of caldesmon binding to actin - Sites of caldesmon contact and modulation of interactions by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; ACTIVATED PROTEIN-KINASE; LIGHT-CHAIN KINASE; FILAMENT-ASSOCIATED PROTEINS; ERK MAP KINASES; THIN-FILAMENTS; CALMODULIN-BINDING; CROSS-LINKING; F-ACTIN; SIGNAL-TRANSDUCTION	Smooth muscle caldesmon binds actin and inhibits actomyosin ATPase activity. Phosphorylation of caldesmon by extracellular signal-regulated kinase (ERK) reverses this inhibitory effect and weakens actin binding. To better understand this function, we have examined the phosphorylation-dependent contact sites of caldesmon on actin by low dose electron microscopy and three-dimensional reconstruction of actin filaments decorated with a C-terminal fragment, hH32K, of human caldesmon containing the principal actin-binding domains. Helical reconstruction of negatively stained filaments demonstrated that hH32K is located on the inner portion of actin subdomain 1, traversing its upper surface toward the C-terminal segment of actin, and forms a bridge to the neighboring actin monomer of the adjacent long pitch helical strand by connecting to its subdomain 3. Such lateral binding was supported by cross-linking experiments using a mutant isoform, which was capable of cross-linking actin subunits. Upon ERK phosphorylation, however, the mutant no longer cross-linked actin to polymers. Three-dimensional reconstruction of ERK-phosphorylated hH32K indeed indicated loss of the interstrand connectivity. These results, together with fluorescence quenching data, are consistent with a phosphorylation-dependent conformational change that moves the C-terminal end segment of caldesmon near the phosphorylation site but not the upstream region around Cys(595), away from F-actin, thus neutralizing its inhibitory effect on actomyosin interactions. The binding pattern of hH32K suggests a mechanism by which unphosphorylated, but not ERK-phosphorylated, caldesmon could stabilize actin filaments and resist F-actin severing or depolymerization in both smooth muscle and nonmuscle cells.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Boston Biomedical Research Institute; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Wang, CLA (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	wang@bbri.org	Foster, D. Brian/S-9108-2019; Foster, D. Brian/C-6350-2009	Foster, D. Brian/0000-0002-9290-9590; Foster, D. Brian/0000-0002-9290-9590; Lehman, William/0000-0002-9430-9521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062468, R01HL036153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62468, R01-HL36153] Funding Source: Medline; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAMS S, 1990, J BIOL CHEM, V265, P19652; AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARANY M, 1996, BIOCH SMOOTH MUSCLE, P321; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; Chalovich JM, 1998, ACTA PHYSIOL SCAND, V164, P427; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; CHILDS TJ, 1993, BIOCHEM CELL BIOL, V71, P544, DOI 10.1139/o93-078; Cook AK, 2000, AM J PHYSIOL-GASTR L, V278, pG429, DOI 10.1152/ajpgi.2000.278.3.G429; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; D'Angelo G, 1999, J BIOL CHEM, V274, P30115, DOI 10.1074/jbc.274.42.30115; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; Earley JJ, 1998, CIRC RES, V83, P661, DOI 10.1161/01.RES.83.6.661; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; Franklin MT, 1997, AM J PHYSIOL-CELL PH, V273, pC1819, DOI 10.1152/ajpcell.1997.273.6.C1819; FUJII T, 1987, J BIOL CHEM, V262, P2757; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; Geguchadze R, 2004, FEBS LETT, V557, P121, DOI 10.1016/S0014-5793(03)01456-X; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Graceffa P, 1999, BIOCHEMISTRY-US, V38, P11984, DOI 10.1021/bi9825495; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1995, J BIOL CHEM, V270, P30187; Guo HQ, 1999, J MUSCLE RES CELL M, V20, P725, DOI 10.1023/A:1005537132581; Hatch V, 2001, J CELL BIOL, V154, P611, DOI 10.1083/jcb.200105079; HAYASHI K, 1991, J BIOL CHEM, V266, P355; Hedges JC, 2000, AM J PHYSIOL-CELL PH, V278, pC718, DOI 10.1152/ajpcell.2000.278.4.C718; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; Hnath EJ, 1996, BIOPHYS J, V71, P1920, DOI 10.1016/S0006-3495(96)79391-8; Hodgkinson JL, 1997, BIOPHYS J, V72, P2398, DOI 10.1016/S0006-3495(97)78885-4; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; Huang RJ, 2003, BIOCHEMISTRY-US, V42, P2513, DOI 10.1021/bi0268605; Hulvershorn J, 2001, AM J PHYSIOL-HEART C, V280, pH1422, DOI 10.1152/ajpheart.2001.280.3.H1422; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1990, J BIOL CHEM, V265, P17607; Isotani E, 2004, P NATL ACAD SCI USA, V101, P6279, DOI 10.1073/pnas.0308742101; KHALIL RA, 1995, CIRC RES, V76, P1101, DOI 10.1161/01.RES.76.6.1101; KOLAKOWSKI J, 1992, FEBS LETT, V309, P65, DOI 10.1016/0014-5793(92)80740-8; Krueger JK, 2000, BIOCHEMISTRY-US, V39, P3979, DOI 10.1021/bi992638x; Lehman W, 1997, J MOL BIOL, V274, P310, DOI 10.1006/jmbi.1997.1422; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lehrer S S, 1978, Methods Enzymol, V49, P222; LI Y, 2004, J CELL SCI, P29; Li YH, 2000, J BIOL CHEM, V275, P10989, DOI 10.1074/jbc.275.15.10989; Li YP, 2003, AM J PHYSIOL-REG I, V284, pR192, DOI 10.1152/ajpregu.00290.2002; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; NIXON GF, 1995, J PHYSIOL-LONDON, V487, P283, DOI 10.1113/jphysiol.1995.sp020879; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Patchell VB, 2002, BBA-PROTEIN STRUCT M, V1596, P121, DOI 10.1016/S0167-4838(02)00210-8; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; Tran QK, 2003, J BIOL CHEM, V278, P24247, DOI 10.1074/jbc.C300165200; TSURUDA TS, 1995, BIOCHEM J, V309, P951, DOI 10.1042/bj3090951; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1990, BIOPHYS J, V57, pA162; WANG CLA, 1991, J BIOL CHEM, V266, P13958; Wang Z, 1997, P NATL ACAD SCI USA, V94, P11899, DOI 10.1073/pnas.94.22.11899; Wang Z, 1997, J BIOL CHEM, V272, P16896, DOI 10.1074/jbc.272.27.16896; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V280, pC1680, DOI 10.1152/ajpcell.2001.280.6.C1680; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	86	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53387	53394		10.1074/jbc.M410109200	http://dx.doi.org/10.1074/jbc.M410109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456752	hybrid			2022-12-27	WOS:000225680600072
J	Lemieux, AM; Pare, ME; Audet, B; Legault, E; Lefort, S; Boucher, N; Landry, S; van Opijnen, T; Berkhout, B; Naghavi, MH; Tremblay, MJ; Barbeau, B				Lemieux, AM; Pare, ME; Audet, B; Legault, E; Lefort, S; Boucher, N; Landry, S; van Opijnen, T; Berkhout, B; Naghavi, MH; Tremblay, MJ; Barbeau, B			T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappa B and NFAT with its enhancer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; TYPE-1 SUBTYPES; DIFFERENTIAL REGULATION; REGULATORY ELEMENTS; GENE-EXPRESSION; IN-VIVO; ALPHA; REPLICATION; PROTEINS	The enhancer region in the human immunodeficiency virus type 1 (HIV-1) 5'-long terminal repeat (LTR) is very important for viral transcription. This promoter sequence binds both nuclear factor-kappaB and NFAT, two important modulators of HIV-1 gene expression. Previous studies have indicated that the enhancer regions of the different HIV-1 clade LTRs differ in their number of NF-kappaB-binding sites. In this study, we have compared the activation potential of the different HIV-1 clade and HIV-2 LTRs and assessed their interaction with NFAT and NF-kappaB. In T-cell lines and primary CD4(+) T-cells, the results showed that the HIV-1 clade LTR (with a single NF-kappaB-binding site) was the weakest LTR regardless of the tested activators, whereas the HIV-2 LTR was the most responsive LTR. The clade E enhancer region was also demonstrated to be the weakest enhancer region in transfection experiments with luciferase reporter-based vectors. Electrophoretic mobility shift assays with extracts from activated CD4(+) T-cells indicated that, although NF-kappaB and NFAT bound all enhancers, HIV-1 clade E and HIV-2 LTR enhancers were poor binding targets for these two factors. Weak NFAT binding to clade E enhancers was also confirmed using NFAT1-expressing 293T cells in competition experiments. We have also shown the absence of interaction of NF-kappaB or NFAT with the third NF-kappaB repeat present in clade C. However, the clade C enhancer bound NFAT more efficiently than all other enhancer regions tested. Our results hence demonstrate for the first time that differences in the binding of NF-kappaB and NFAT to the enhancer regions could be responsible for some of the observed variation in HIV-1 clade LTR activation, whereas HIV-2 LTR activation seems mostly independent of these interactions.	Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada; Univ Amsterdam, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Laval University; Laval University; University of Amsterdam; Columbia University; Howard Hughes Medical Institute	Barbeau, B (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Infectiol, RC709,Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	benoit.barbeau@crchul.ulaval.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155; Lefort, Sylvain/0000-0001-7320-4256; van Opijnen, Tim/0000-0001-6895-6795				ARYA S K, 1990, New Biologist, V2, P57; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Barbeau B, 2001, J IMMUNOL, V167, P2700, DOI 10.4049/jimmunol.167.5.2700; Berry N, 2001, AIDS RES HUM RETROV, V17, P263, DOI 10.1089/088922201750063197; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; Fortin JF, 1999, VIROLOGY, V257, P228, DOI 10.1006/viro.1999.9687; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HANNIBAL MC, 1993, J VIROL, V67, P5035, DOI 10.1128/JVI.67.8.5035-5040.1993; HANNIBAL MC, 1994, BLOOD, V83, P1839; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Montano MA, 1997, J VIROL, V71, P8657, DOI 10.1128/JVI.71.11.8657-8665.1997; Montano MA, 1998, J VIROL, V72, P8446, DOI 10.1128/JVI.72.10.8446-8452.1998; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Naghavi MH, 1999, AIDS RES HUM RETROV, V15, P1293, DOI 10.1089/088922299310197; Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robichaud GA, 2002, J BIOL CHEM, V277, P23733, DOI 10.1074/jbc.M201563200; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roof P, 2002, VIROLOGY, V296, P77, DOI 10.1006/viro.2001.1397; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH SD, 1984, CANCER RES, V44, P5657; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348; TRAENCKER E, 1995, EMBO J, P2876; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004; Verhoef K, 1999, J VIROL, V73, P1331, DOI 10.1128/JVI.73.2.1331-1340.1999; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; West MJ, 2001, J VIROL, V75, P8524, DOI 10.1128/JVI.75.18.8524-8537.2001	53	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52949	52960		10.1074/jbc.M409896200	http://dx.doi.org/10.1074/jbc.M409896200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466412	hybrid			2022-12-27	WOS:000225680600019
J	Westmeyer, GG; Willem, M; Lichtenthaler, SF; Lurman, G; Multhaup, G; Assafalg-Machleidt, I; Reiss, K; Saftig, P; Haass, C				Westmeyer, GG; Willem, M; Lichtenthaler, SF; Lurman, G; Multhaup, G; Assafalg-Machleidt, I; Reiss, K; Saftig, P; Haass, C			Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; SECRETASE CLEAVAGE; BIOCHEMICAL-PROPERTIES; PEPTIDE PRODUCTION; ASPARTYL PROTEASE; KNOCKOUT MICE; PRO-DOMAIN; BACE; EXPRESSION; RECOMBINANT	Cleavage of the beta-amyloid precursor protein (APP) by the aspartyl protease beta-site APP-cleaving enzyme ( BACE) is the first step in the generation of the amyloid beta-peptide, which is deposited in the brain of Alzheimer's disease patients. Whereas the subsequent cleavage by gamma-secretase was shown to originate from the cooperation of a multicomponent complex, it is currently unknown whether in a cellular environment BACE is enzymatically active as a monomer or in concert with other proteins. Using blue native gel electrophoresis we found that endogenous and overexpressed BACE has a molecular mass of 140 kDa instead of the expected mass of 70 kDa under denaturing conditions. This suggests that under native conditions BACE exists as a homodimer. Homodimerization was confirmed by co-immunoprecipitation of full-length BACE carrying different epitope tags. In contrast, the soluble active BACE ectodomain was exclusively present as a monomer both under native and denaturing conditions. A domain analysis revealed that the BACE ectodomain dimerized as long as it was attached to the membrane, whereas the cytoplasmic domain and the transmembrane domain were dispensable for dimerization. By adding a KKXX-endoplasmic reticulum retention signal to BACE, we demonstrate that dimerization of BACE occurs already before full maturation and pro-peptide cleavage. Furthermore, kinetic analysis of the purified native BACE dimer revealed a higher affinity and turnover rate in comparison to the monomeric soluble BACE. Dimerization of BACE might, thus, facilitate binding and cleavage of physiological substrates.	Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany	University of Munich; Free University of Berlin; University of Kiel	Willem, M (corresponding author), Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	mwillem@med.uni-muenchen.de; chaass@med.uni-muenchen.de	Saftig, Paul/A-7966-2010; Reiss, Karina/B-3175-2010; Lichtenthaler, Stefan F/B-6587-2016	Lichtenthaler, Stefan F/0000-0003-2211-2575; Westmeyer, Gil Gregor/0000-0001-7224-8919				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Andra K, 1996, NEUROBIOL AGING, V17, P183, DOI 10.1016/0197-4580(95)02066-7; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bowman MJ, 2002, BIOPOLYMERS, V66, P126, DOI 10.1002/bip.10232; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Dunn BM, 2002, CHEM REV, V102, P4431, DOI 10.1021/cr010167q; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Fluhrer R, 2003, J BIOL CHEM, V278, P5531, DOI 10.1074/jbc.M211485200; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803; Gorelick FS, 2001, MOL CELL ENDOCRINOL, V177, P13, DOI 10.1016/S0303-7207(01)00438-5; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong HS, 2003, BIOCHEM BIOPH RES CO, V307, P922, DOI 10.1016/S0006-291X(03)01270-1; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEMISTRY-US, V41, P10963, DOI 10.1021/bi026232n; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Kopcho LM, 2003, ARCH BIOCHEM BIOPHYS, V410, P307, DOI 10.1016/S0003-9861(02)00690-2; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mallender WD, 2001, MOL PHARMACOL, V59, P619, DOI 10.1124/mol.59.3.619; Marcinkeviciene J, 2001, J BIOL CHEM, V276, P23790, DOI 10.1074/jbc.M101896200; Marlow L, 2003, J MOL NEUROSCI, V20, P233, DOI 10.1385/JMN:20:3:233; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shi XP, 2003, J BIOL CHEM, V278, P21286, DOI 10.1074/jbc.M209859200; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Shultz MD, 2000, ANGEW CHEM INT EDIT, V39, P2710, DOI 10.1002/1521-3773(20000804)39:15<2710::AID-ANIE2710>3.0.CO;2-P; Sidera C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-25; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Toulokhonova L, 2003, J BIOL CHEM, V278, P4582, DOI 10.1074/jbc.M210471200; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; TSUKUBA T, 1995, ADV EXP MED BIOL, V362, P331; Tsukuba T, 1996, J BIOCHEM, V119, P126; Turner RT, 2002, BIOCHEMISTRY-US, V41, P8742, DOI 10.1021/bi025926t; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3	67	97	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53205	53212		10.1074/jbc.M410378200	http://dx.doi.org/10.1074/jbc.M410378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485862	hybrid			2022-12-27	WOS:000225680600050
J	Luciano, BS; Hsu, S; Channavajhala, PL; Lin, LL; Cuozzo, JW				Luciano, BS; Hsu, S; Channavajhala, PL; Lin, LL; Cuozzo, JW			Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL LYMPHOMAS; PROTEIN-KINASE; FACTOR-ALPHA; TNF-ALPHA; RHEUMATOID-ARTHRITIS; NF-KAPPA-B1 P105; CROHNS-DISEASE; B-RAF; TPL-2	Cot/Tpl2/MAP3K8 is a serine/threonine kinase known to activate the ERK, p38, and JNK kinase pathways. Studies of Tpl2 knock-out mice reveal a clear defect in tumor necrosis factor-alpha production, although very little detail is known about its regulation and the signaling events involved. In the present study we demonstrated that phosphorylation of Cot was required for its maximal activity as phosphatase treatment of Cot decreased its kinase activity. The Cot sequence contains a conserved threonine at position 290 in the activation loop of the kinase domain. We found that mutation of this residue to alanine eliminated its ability to activate MEK/ ERK and NF-kappaB pathways, whereas a phosphomimetic mutation to aspartic acid could rescue the ability to activate MEK. Thr-290 was also required for robust autophosphorylation of Cot. Antibody generated to phospho-Thr-290-Cot recognized both wild-type and kinase-dead Cot, suggesting that phosphorylation of Thr-290 did not occur through autophosphorylation but via another kinase. We showed that Cot was constitutively phosphorylated at Thr-290 in transfected human embryonic kidney 293T cells as well as human monocytes as this residue was phosphorylated in unstimulated and lipopolysaccharide-stimulated cells to the same degree. Treatment with herbimycin A inhibited Cot activity in the MEK/ ERK pathway but did not inhibit phosphorylation at Thr-290. Together these results showed that phosphorylation of Cot at Thr-290 is necessary but not sufficient for full kinase activity in the MEK/ ERK pathway.	Wyeth Ayerst Res, Dept Mol Inflammat Inflammat Signaling, Cambridge, MA 02140 USA	Pfizer	Cuozzo, JW (corresponding author), Wyeth Ayerst Res, Dept Mol Inflammat Inflammat Signaling, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	jcuozzo@wyeth.com		Cuozzo, John/0000-0002-6229-0395				Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bondeson J, 2001, INT J CLIN PRACT, V55, P211; Caivano M, 2003, J BIOL CHEM, V278, P52124, DOI 10.1074/jbc.M306583200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Channavajhala PL, 2003, J BIOL CHEM, V278, P47089, DOI 10.1074/jbc.M306002200; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Creange A, 1996, J NEUROIMMUNOL, V68, P95, DOI 10.1016/0165-5728(96)00075-6; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Gandara ML, 2003, MOL CELL BIOL, V23, P7377, DOI 10.1128/MCB.23.20.7377-7390.2003; Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kapp Alexander, 1993, Journal of Dermatological Science, V5, P133, DOI 10.1016/0923-1811(93)90760-M; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lang V, 2004, MOL CELL BIOL, V24, P5235, DOI 10.1128/MCB.24.12.5235-5248.2004; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MAURY CPJ, 1989, ARTHRITIS RHEUM, V32, P146, DOI 10.1002/anr.1780320206; MAURY CPJ, 1989, INT J TISSUE REACT, V11, P189; Mizutani H, 1997, J DERMATOL SCI, V14, P145, DOI 10.1016/S0923-1811(96)00562-2; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Rask-Madsen C, 2003, CIRCULATION, V108, P1815, DOI 10.1161/01.CIR.0000091406.72832.11; Raza A, 2000, MICROSC RES TECHNIQ, V50, P229, DOI 10.1002/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955	40	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52117	52123		10.1074/jbc.M403716200	http://dx.doi.org/10.1074/jbc.M403716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466476	hybrid			2022-12-27	WOS:000225493400050
J	Tang, DD; Gunst, SJ				Tang, DD; Gunst, SJ			The small GTPase Cdc42 regulates actin polymerization and tension development during contractile stimulation of smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; LENGTH-DEPENDENT MODULATION; FORCE DEVELOPMENT; CELL-ADHESION; ACTIVATION; PROTEIN; RHO; PHOSPHORYLATION; CYTOCHALASIN; NUCLEATION	Contractile stimulation induces actin polymerization in smooth muscle tissues and cells, and the inhibition of actin polymerization depresses smooth muscle force development. In the present study, the role of Cdc42 in the regulation of actin polymerization and tension development in smooth muscle was evaluated. Acetylcholine stimulation of tracheal smooth muscle tissues increased the activation of Cdc42. Plasmids encoding wild type Cdc42 or a dominant negative Cdc42 mutant, Asn-17 Cdc42, were introduced into tracheal smooth muscle strips by reversible permeabilization, and tissues were incubated for 2 days to allow for protein expression. Expression of recombinant proteins was confirmed by immunoblot analysis. The expression of the dominant negative Cdc42 mutant inhibited contractile force and the increase in actin polymerization in response to acetylcholine stimulation but did not inhibit the increase in myosin light chain phosphorylation. The expression of wild type Cdc42 had no significant effect on force, actin polymerization, or myosin light chain phosphorylation. Contractile stimulation increased the association of neuronal Wiskott-Aldrich syndrome protein with Cdc42 and the Arp2/3 (actin-related protein) complex in smooth muscle tissues expressing wild type Cdc42. The agonist-induced increase in these protein interactions was inhibited in tissues expressing the inactive Cdc42 mutant. We conclude that Cdc42 activation regulates active tension development and actin polymerization during contractile stimulation. Cdc42 may regulate the activation of neuronal Wiskott-Aldrich syndrome protein and the actin related protein complex, which in turn regulate actin filament polymerization initiated by the contractile stimulation of smooth muscle.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Gunst, SJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	sgunst@iupui.edu	T, Dale/AAE-9643-2020	T, Dale/0000-0002-7339-9249; Gunst, Susan/0000-0001-9836-4782	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075388, R23HL029289, R01HL029289, R01HL074099] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL029289, HL-75388, R01 HL074099, R01 HL029289-19, HL-74099, HL-29289, R01 HL074099-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1983, CELL MOTIL CYTOSKEL, V3, P545, DOI 10.1002/cm.970030521; Allen WE, 1997, J CELL SCI, V110, P707; Barany M, 2001, J BIOL CHEM, V276, P48398, DOI 10.1074/jbc.M106227200; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Herrera AM, 2004, AM J PHYSIOL-LUNG C, V286, pL1161, DOI 10.1152/ajplung.00298.2003; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; Hirshman CA, 1998, AM J PHYSIOL-LUNG C, V275, pL911, DOI 10.1152/ajplung.1998.275.5.L911; Jones KA, 1999, J PHYSIOL-LONDON, V519, P527, DOI 10.1111/j.1469-7793.1999.0527m.x; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; Mehta D, 1996, AM J PHYSIOL-CELL PH, V270, pC243, DOI 10.1152/ajpcell.1996.270.1.C243; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Murthy KS, 2003, BIOCHEM J, V374, P145, DOI 10.1042/BJ20021274; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OBARA K, 1994, EUR J PHARMACOL, V255, P139, DOI 10.1016/0014-2999(94)90092-2; OPAZO SA, 2004, AM J PHYSIOL-CELL PH, V286, pC433; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tang DD, 2003, HYPERTENSION, V42, P858, DOI 10.1161/01.HYP.0000085333.76141.33; Tang DD, 2003, AM J PHYSIOL-HEART C, V285, pH1528, DOI 10.1152/ajpheart.00188.2003; Tang DD, 2002, J PHYSIOL-LONDON, V542, P501, DOI 10.1113/jphysiol.2002.021006; Tang DD, 2001, AM J PHYSIOL-CELL PH, V280, pC874, DOI 10.1152/ajpcell.2001.280.4.C874; Tang DD, 2003, J PHYSIOL-LONDON, V553, P21, DOI 10.1113/jphysiol.2003.045047; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001; Youn T, 1998, AM J PHYSIOL-CELL PH, V274, pC1601, DOI 10.1152/ajpcell.1998.274.6.C1601; Zhang WW, 2004, FASEB J, V18, pA1086; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	34	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51722	51728		10.1074/jbc.M408351200	http://dx.doi.org/10.1074/jbc.M408351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456777	hybrid			2022-12-27	WOS:000225493400003
J	Choi, HJ; Smithgall, TE				Choi, HJ; Smithgall, TE			HIV-1 Nef promotes survival of TF-1 macrophages by inducing Bcl-X-L expression in an extracellular signal-regulated kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VIRUS TYPE-1 NEF; NF-KAPPA-B; SH3 DOMAIN; SERINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; TRANSGENIC MICE; GM-CSF; CELL; STAT3	The Nef protein of human immunodeficiency virus-1 (HIV-1) is essential for the progression from human and simian immunodeficiency virus infection to full-blown AIDS. Recent studies indicate that Nef generates antiapoptotic signals in HIV-infected T cells, suppressing cell death early in infection to allow productive viral replication. Previous work from our laboratory has shown that Nef also promotes proliferation of myeloid cells through a signal transducer and activator of transcription 3-dependent pathway. Here we demonstrate that Nef suppresses cell death induced by cytokine deprivation in the human macrophage precursor cell line, TF-1. Nef selectively induced up-regulation of Bcl-X-L, an anti-apoptotic gene that is also regulated by granulocyte/ macrophage-colony stimulating factor in this cell line. Activation of the extracellular signal-regulated kinase (Erk) mitogen-activated protein kinase pathway also correlated with the survival of TF-1/Nef cells. Using the selective mitogen-activated protein kinase kinase inhibitor PD98059, we found that Nef-induced Erk signaling is essential for Bcl-X-L up-regulation and cell survival. In contrast, expression of Bcl-X-L and TF-1 survival was not affected by dominant-negative signal transducer and activator of transcription 3. These data suggest that Nef produces survival signals in myeloid cells through Erk-mediated Bcl-X-L induction, a pathway distinct from Nef survival pathways recently reported in T lymphocytes.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057083] Funding Source: NIH RePORTER; NCI NIH HHS [CA81398] Funding Source: Medline; NIAID NIH HHS [AI57083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; Arold S, 2000, PROTEIN SCI, V9, P1137, DOI 10.1110/ps.9.6.1137; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hanna Z, 2001, J VIROL, V75, P9378, DOI 10.1128/JVI.75.19.9378-9392.2001; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Orenstein JM, 2001, IMMUNOBIOLOGY, V204, P598, DOI 10.1078/0171-2985-00098; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; SCHUITEMAKER H, 1993, J INFECT DIS, V168, P1140, DOI 10.1093/infdis/168.5.1140; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walk SF, 2001, J VIROL, V75, P834, DOI 10.1128/JVI.75.2.834-843.2001; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	49	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51688	51696		10.1074/jbc.M410068200	http://dx.doi.org/10.1074/jbc.M410068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459189	hybrid			2022-12-27	WOS:000225355800125
J	Zhao, GJ; Mao, GZ; Tan, JX; Dong, YZ; Cui, MZ; Kim, SH; Xu, XM				Zhao, GJ; Mao, GZ; Tan, JX; Dong, YZ; Cui, MZ; Kim, SH; Xu, XM			Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; NOTCH; APP; PEPTIDES; MUTATION	gamma-Secretase cleavage of beta-amyloid precursor protein (APP) is crucial in the pathogenesis of Alzheimer disease, because it is the decisive step in the formation of the C terminus of beta-amyloid protein (Abeta). To better understand the molecular events involved in gamma-secretase cleavage of APP, in this study we report the identification of a new intracellular long Abeta species containing residues 1 - 46 (Abeta(46)), which led to the identification of a novel zeta-cleavage site between the known gamma- and epsilon-cleavage sites within the transmembrane domain of APP. Our data clearly demonstrate that the new zeta-cleavage is a presenilin-dependent event. It is also noted that the new zeta-cleavage site at Abeta46 is the APP717 mutation site. Furthermore, we show that the new zeta-cleavage is inhibited by gamma-secretase inhibitors known as transition state analogs but less affected by inhibitors known as non-transition state gamma-secretase inhibitors. Thus, the identification of Abeta(46) establishes a system to determine the specificity or the preference of the known gamma-secretase inhibitors by examining their effects on the formation or turnover of Abeta(46).	Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Chicago	Xu, XM (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, 2407 River Dr, Knoxville, TN 37996 USA.	xmx@utk.edu		Cui, Mei-Zhen/0000-0003-4745-6999; xu, xuemin/0000-0002-7426-272X	NINDS NIH HHS [NS42314] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736; Kuo YM, 2000, AM J PATHOL, V156, P797, DOI 10.1016/S0002-9440(10)64947-4; Roher AE, 2004, J BIOL CHEM, V279, P5829, DOI 10.1074/jbc.M311380200; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	20	132	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50647	50650		10.1074/jbc.C400473200	http://dx.doi.org/10.1074/jbc.C400473200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485850	hybrid			2022-12-27	WOS:000225355800003
J	Buddha, MR; Tao, T; Parry, RJ; Crane, BR				Buddha, MR; Tao, T; Parry, RJ; Crane, BR			Regioselective nitration of tryptophan by a complex between bacterial nitric-oxide synthase and tryptophanyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE NITRATION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; PEROXYNITRITE; TETRAHYDROBIOPTERIN; PROTEIN; MECHANISM; MYELOPEROXIDASE; NITROTYROSINE; DERIVATIVES	Bacterial nitric-oxide synthase proteins (NOSs) from certain Streptomyces strains have been shown to participate in biosynthetic nitration of tryptophanyl moieties in vivo (Kers, J.A., Wach, M.J., Krasnoff, S. B., Cameron, K. D., Widom, J., Bukhaid, R. A., Gibson, D. M., and Crane, B. R., and Loria, R. (2004) Nature 429, 79-82). We report that the complex between Deinococcus radiodurans NOS (deiNOS) and an unusual tryptophanyl-tRNA synthetase (TrpRS II) catalyzes the regioselective nitration of tryptophan (Trp) at the 4-position. Unlike non-enzymatic Trp nitration, and similar reactions catalyzed by globins and peroxidases, deiNOS only produces the otherwise unfavorable 4-nitro-Trp isomer. Although deiNOS alone will catalyze 4-nitro-Trp production, yields are significantly enhanced by TrpRS II and ATP. 4-Nitro-Trp formation exhibits saturation behavior with Trp (but not tyrosine) and is completely inhibited by the addition of the mammalian NOS cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin (H4B). Trp stimulates deiNOS oxidation of substrate L-arginine (Arg) to the same degree as H4B. These observations are consistent with a mechanism where Trp or a derivative thereof binds in the NOS pterin site, participates in Arg oxidation, and becomes nitrated at the 4-position.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	Cornell University; Rice University	Crane, BR (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	bc69@cornell.edu						Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; BONNETT R, 1977, HETEROCYCLES, V7, P637, DOI 10.3987/S-1977-01-0637; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; BUDDHA MR, 2004, IN PRESS P NATL ACAD; CASTRO A, 1986, J CHEM SOC P2, V2, P1165; DA SETTIMO ANTONIO, 1962, ANN CHIM, V52, P17; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; Healy FG, 2000, MOL MICROBIOL, V38, P794, DOI 10.1046/j.1365-2958.2000.02170.x; Herold S, 2004, FREE RADICAL BIO MED, V36, P565, DOI 10.1016/j.freeradbiomed.2003.10.014; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; Ischiropoulos H, 2002, FREE RADICAL BIO MED, V33, P727, DOI 10.1016/S0891-5849(02)00889-4; Kato Y, 1997, BIOCHEM BIOPH RES CO, V234, P82, DOI 10.1006/bbrc.1997.6587; Kers JA, 2004, NATURE, V429, P79, DOI 10.1038/nature02504; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; MELHADO LL, 1988, J ORG CHEM, V53, P3852, DOI 10.1021/jo00251a037; Padmaja S, 1996, REDOX REP, V2, P173, DOI 10.1080/13510002.1996.11747045; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sala A, 2004, EUR J BIOCHEM, V271, P2841, DOI 10.1111/j.1432-1033.2004.04219.x; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Tommos C, 1999, BIOCHEMISTRY-US, V38, P9495, DOI 10.1021/bi990609g; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350	31	53	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49567	49570		10.1074/jbc.C400418200	http://dx.doi.org/10.1074/jbc.C400418200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15466862	hybrid			2022-12-27	WOS:000225229500004
J	Qian, Y; Liu, KJ; Chen, Y; Flynn, DC; Castranova, V; Shi, XL				Qian, Y; Liu, KJ; Chen, Y; Flynn, DC; Castranova, V; Shi, XL			Cdc42 regulates arsenic-induced NADPH oxidase activation and cell migration through actin filament reorganizatlion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; IN-VITRO; P47(PHOX); TRANSLOCATION; LOCALIZATION; CYTOSKELETON; MECHANISM; INTEGRITY; AFAP-110; DYNAMICS	Although arsenic is a human carcinogen, the molecular mechanisms of its action remain to be understood. The present study reports that exposure to arsenic induced actin filament reorganization, resulting in lamel-lipodia and filopodia structures through the activation of Cdc42 in SVEC4-10 endothelial cells. It was also found that arsenic induced the formation of the superoxide anion (O-2(.-)) in SVEC4-10 cells. Immunoprecipitation and Western blotting analysis demonstrated that arsenic stimulation induced serine phosphorylation of p47(phox) a key component of NADPH oxidase, indicating that arsenic induces O-2(.-) formation through NADPH oxidase activation. Inhibition of arsenic-induced actin filament reorganization by either overexpression of a dominant negative Cdc42 or pretreatment of an actin filament stabilizing regent, jasplakinolide, abrogated arsenic-induced NADPH oxidase activation, showing that the activation of NADPH oxidase was regulated by Cdc42-mediated actin filament reorganization. This study also showed that overexpression of a dominant negative Rac1 was sufficient to abolish arsenic-induced O-2(.-) production, implying that Rac1 activities area required for Cdc42-mediated NADPH oxidase activation in response to arsenic stimulation. Furthermore, arsenic stimulation induced cell migration, which can be inhibited by the inactivation of either Cdc42 or NADPH oxidase. Taken together, the results indicate that arsenic is able to activate NADPH oxidase through Cdc42-mediated actin filament reorganization, leading to the induction of an increase in cell migration in SVEC4-10 endothelial cells.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; W Virginia Univ, Sch Med, Ctr Canc, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of New Mexico; Indiana University System; Indiana University-Purdue University Indianapolis; West Virginia University; West Virginia University	Qian, Y (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA.	YAQ2@CDC.GOV	Shi, Xianglin/B-8588-2012		NCI NIH HHS [CA060731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Barchowsky A, 1999, FREE RADICAL BIO MED, V27, P1405, DOI 10.1016/S0891-5849(99)00186-0; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Brown MD, 2000, J NEUROBIOL, V43, P352, DOI 10.1002/1097-4695(20000615)43:4<352::AID-NEU4>3.0.CO;2-T; Chou I N, 1989, Biomed Environ Sci, V2, P358; Chou WC, 2004, P NATL ACAD SCI USA, V101, P4578, DOI 10.1073/pnas.0306687101; Corsini E, 1999, J INVEST DERMATOL, V113, P760, DOI 10.1046/j.1523-1747.1999.00748.x; Cramer, 1997, FRONT BIOSCI, V2, pd260, DOI DOI 10.2741/A189; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Faisal A, 2004, J BIOL CHEM, V279, P3202, DOI 10.1074/jbc.M310010200; Fenteany G, 2003, CURR TOP MED CHEM, V3, P593, DOI 10.2174/1568026033452348; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; LI WD, 1992, TOXICOL APPL PHARM, V114, P132, DOI 10.1016/0041-008X(92)90105-2; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Ochi T, 1998, ARCH TOXICOL, V72, P566, DOI 10.1007/s002040050544; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2003, J INORG BIOCHEM, V96, P271, DOI 10.1016/S0162-0134(03)00235-6; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Smith KR, 2001, AM J PHYSIOL-LUNG C, V280, pL442, DOI 10.1152/ajplung.2001.280.3.L442; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tamura M, 2000, BIOCHEM BIOPH RES CO, V276, P1186, DOI 10.1006/bbrc.2000.3598; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zhao QQ, 1998, TOXICOL APPL PHARM, V149, P99, DOI 10.1006/taap.1997.8352; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	44	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3875	3884		10.1074/jbc.M403788200	http://dx.doi.org/10.1074/jbc.M403788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15492012	hybrid, Green Submitted			2022-12-27	WOS:000226983900090
J	Yaworsky, DC; Baker, BY; Bose, HS; Best, KB; Jensen, LB; Bell, JD; Baldwin, MA; Miller, WL				Yaworsky, DC; Baker, BY; Bose, HS; Best, KB; Jensen, LB; Bell, JD; Baldwin, MA; Miller, WL			pH-dependent interactions of the carboxyl-terminal helix of steroidogenic acute regulatory protein with synthetic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; CIRCULAR-DICHROISM SPECTROSCOPY; MOLTEN-GLOBULE; MITOCHONDRIAL PROTEIN; STAR; CHOLESTEROL; MECHANISM; VESICLES; BINDING; DOMAIN	Steroidogenic acute regulatory ( StAR) protein facilitates import of cholesterol into adrenal and gonadal mitochondria where cholesterol is converted to pregnenolone, initiating steroidogenesis. StAR acts exclusively on the outer mitochondrial membrane (OMM) by unknown mechanisms. To identify StAR domains involved in membrane association, we reacted N-62 StAR with small unilamellar vesicles (SUVs) composed of lipids resembling the OMM. Solvent-exposed domains were digested with trypsin, Asp-N, or pepsin at different pH levels, and StAR peptides protected from proteolysis were identified by mass spectrometry. At pH 4 SUVs completely protected residues 259-282; at pH 6.5 this region was partially digested into 254-272, 254-273, and 254-274. Computer-graphic modeling of N-62 StAR indicated these peptides correspond to the C-terminal alpha4 helix and that residues Leu(275), Thr(263), and Arg(272) in alpha4 form stabilizing interactions with Gln(128), Asp(150), and Asp(106) in adjacent loops. CD spectroscopy of a 37-mer model of alpha4 (residues 247-287) indicated a random coil in aqueous buffer, but in 40% methanol the peptide was alpha-helical and achieved maximal alpha-helicity at pH 5.0 in the presence of SUVs. Reacting the 37-mer with diethyl pyrocarbamate incorporated into SUVs increased the number of modified residues. Thus the C-terminal alpha4 helix is critically involved in the membrane association of StAR with OMM lipids. The membrane association and the alpha-helical structure of the C terminus in the presence of OMM lipids are also pH-dependent. These results further support StAR undergoing a pH-dependent change in its conformation when interacting with the acidic phospholipid head groups of a membrane.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA; Brigham Young Univ, Dept Physiol & Dev Biol, Provo, UT 84602 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Brigham Young University	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR 4,Rm 205,Box 0978, San Francisco, CA 94143 USA.	wlmlab@itsa.ucsf.edu	Miller, Walter L/J-3696-2012; Baker, Bo/C-1466-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, T32DK007161, K01DK002762] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK37922, KO1 DK02762, DK07161] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1998, BIOCHEMISTRY-US, V37, P9768, DOI 10.1021/bi980588a; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; Mills RL, 2003, J PLASMA PHYS, V69, P131, DOI 10.1017/S0022377803002113; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Safarian S, 2003, J PROTEIN CHEM, V22, P643, DOI 10.1023/B:JOPC.0000008729.20730.59; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUBBARAO NK, 1991, BIOCHIM BIOPHYS ACTA, V1063, P147, DOI 10.1016/0005-2736(91)90364-E; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	28	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2045	2054		10.1074/jbc.M410937200	http://dx.doi.org/10.1074/jbc.M410937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15489236	hybrid			2022-12-27	WOS:000226341700039
J	Zaim, J; Speina, E; Kierzek, AM				Zaim, J; Speina, E; Kierzek, AM			Identification of new genes regulated by the Crt1 transcription factor, an effector of the DNA damage checkpoint pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; BINDING PROTEIN; YEAST; EXPRESSION; GENOME; REPLICATION; TREHALOSE; INHIBITION; REDUCTASE; REPAIR	The Crt1 (RFX1) protein in Saccharomyces cerevisiae is an effector of the DNA damage checkpoint pathway. It recognizes a 13-bp cis-regulatory element in the 5'-untranslated region (5'-UTR) of the ribonucleotide reductase genes RNR2, RNR3, and RNR4; the HUG1 gene; and itself. We calculated the weight matrix representing the Crt1p binding site motif according to analysis of the 5'-UTR sequences of the genes that are under its regulation. We subsequently searched the 5'-UTR sequences of all the genes in the yeast genome for the occurrence of this motif. The motif was found in regulatory regions of 30 genes. A statistical analysis showed that it is unlikely that a random gene cluster contains the motif conserved as well as the Crt1p binding site. Analysis of microarray data provided supporting evidence for five putative Crt1p targets: FSH3, YLR345W, UBC5, NDE2, and NTH2. We used reverse transcription-PCR to compare the expression levels of these genes in wild-type and crt1Delta strains. Our results indicated that FSH3, YLR345W, and NTH2 are indeed under the regulation of Crt1p. Sequence analysis of the FSH3p indicated that this protein may be involved in folate metabolism either by carrying serine hydrolase activity required for the novel metabolic pathway involving dihydrofolate reductase (DHFR) or by directly interacting with the DHFR enzyme. We postulate that Crt1p may influence deoxyribonucleotide synthesis not only by regulating expression of the RNR genes but also by modulating DHFR activity. FSH3p shares significant sequence similarity with the product of the human tumor suppressor gene OVCA2. YLR345Wp and NTH2p are enzymes involved in the central metabolism under stress conditions.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Kierzek, AM (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	andrzejk@ibb.waw.pl	Speina, Elzbieta/ABB-3371-2021	Elzbieta, Speina/0000-0002-0734-9390; Kierzek, Andrzej/0000-0002-2605-9057				BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Baxter SM, 2004, MOL CELL PROTEOMICS, V3, P209, DOI 10.1074/mcp.M300082-MCP200; BERTANI LE, 1994, GENE, V147, P131, DOI 10.1016/0378-1119(94)90052-3; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; DURBIN R, 1998, BIOL SEQUENCE ANAL P, P308; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jensen MR, 2004, GENE DEV, V18, P245, DOI 10.1101/gad.1184004; KITAMURA K, 1989, J BIOL CHEM, V264, P6344; Le Crom S, 2002, NUCLEIC ACIDS RES, V30, P76, DOI 10.1093/nar/30.1.76; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mercier G, 2001, MUTAT RES-DNA REPAIR, V487, P157, DOI 10.1016/S0921-8777(01)00116-1; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Schultz DC, 1996, CANCER RES, V56, P1997; Sebollela A, 2004, INT J BIOCHEM CELL B, V36, P900, DOI 10.1016/j.biocel.2003.10.006; STRYER L, 1995, BIOCHEMISTRY-US, P748; Voit EO, 2003, J THEOR BIOL, V223, P55, DOI 10.1016/S0022-5193(03)00072-9; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	32	41	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					28	37		10.1074/jbc.M404669200	http://dx.doi.org/10.1074/jbc.M404669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494396	hybrid			2022-12-27	WOS:000226025100005
J	Akhtar, MW; Srinivas, V; Raman, B; Ramakrishna, T; Inobe, T; Maki, K; Arai, M; Kuwajima, K; Rao, CM				Akhtar, MW; Srinivas, V; Raman, B; Ramakrishna, T; Inobe, T; Maki, K; Arai, M; Kuwajima, K; Rao, CM			Oligomeric Hsp33 with enhanced chaperone activity - Gel filtration, cross-linking, and small angle X-ray scattering (SAXS) analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; OXIDATIVE STRESS; BIOLOGICAL MACROMOLECULES; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ALPHA-CRYSTALLIN; REDOX SWITCH; ACTIVATION; RESOLUTION; MECHANISM	Hsp33, an Escherichia coli cytosolic chaperone, is inactive under normal conditions but becomes active upon oxidative stress. It was previously shown to dimerize upon activation in a concentration- and temperature-dependent manner. This dimer was thought to bind to aggregation-prone target proteins, preventing their aggregation. In the present study, we report small angle x-ray scattering (SAXS), steady state and time-resolved fluorescence, gel filtration, and glutaraldehyde cross-linking analysis of full-length Hsp33. Our circular dichroism and fluorescence results show that there are significant structural changes in oxidized Hsp33 at different temperatures. SAXS, gel filtration, and glutaraldehyde cross-linking results indicate, in addition to the dimers, the presence of oligomeric species. Oxidation in the presence of physiological salt concentration leads to significant increases in the oligomer population. Our results further show that under conditions that mimic the crowded milieu of the cytosol, oxidized Hsp33 exists predominantly as an oligomeric species. Interestingly, chaperone activity studies show that the oligomeric species is much more efficient compared with the dimers in preventing aggregation of target proteins. Taken together, these results indicate that in the cell, Hsp33 undergoes conformational and quaternary structural changes leading to the formation of oligomeric species in response to oxidative stress. Oligomeric Hsp33 thus might be physiologically relevant under oxidative stress.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Prot Design Res Grp, Tsukuba, Ibaraki 3058566, Japan	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.res.in	Arai, Munehito/A-1258-2012	Arai, Munehito/0000-0002-1223-2242; Tangirala, Ramakrishna/0000-0002-0738-329X; Inobe, Tomonao/0000-0002-5864-6889				AMEMIYA Y, 1983, NUCL INSTRUM METHODS, V208, P471, DOI 10.1016/0167-5087(83)91170-5; AMEMIYA Y, 1995, REV SCI INSTRUM, V66, P2290, DOI 10.1063/1.1145667; Arai M, 2002, J MOL BIOL, V321, P121, DOI 10.1016/S0022-2836(02)00566-1; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Graf PCF, 2004, J BIOL CHEM, V279, P20529, DOI 10.1074/jbc.M401764200; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Hoffmann JH, 2004, EMBO J, V23, P160, DOI 10.1038/sj.emboj.7600016; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lakshmikanth GS, 1999, BIOPHYS J, V77, P1100, DOI 10.1016/S0006-3495(99)76960-2; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Raman B, 2001, FEBS LETT, V489, P19, DOI 10.1016/S0014-5793(01)02074-9; Rao C. M., 2002, PINSA-A (Proceedings of the Indian National Science Academy) Part A (Physical Sciences), V68, P349; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	34	25	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55760	55769		10.1074/jbc.M406333200	http://dx.doi.org/10.1074/jbc.M406333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494414	hybrid			2022-12-27	WOS:000225960800098
J	Ikeda, K; Quertermous, T				Ikeda, K; Quertermous, T			Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCAM CD166; IN-VITRO; EXPRESSION; IDENTIFICATION; MELANOMA; CLONING; ATHEROSCLEROSIS; RECEPTORS; SELECTIN; ANTIGEN	Cell adhesion molecules regulate a variety of endothelial cell functions such as migration, response to inflammation, and angiogenesis. Recently, activated leukocyte cell adhesion molecule ( ALCAM), a member of the Ig superfamily, has been detected in the primitive subsets of hematopoietic cells and endothelial cells during embryogenesis. ALCAM supports the development of hematopoietic cells as well as enhancing capillary tube formation in vitro. Here, we isolated a novel soluble isoform of ALCAM (sALCAM) that is produced via alternative splicing. sALCAM contains the single amino-terminal Ig-like domain of ALCAM and lacks a transmembrane domain. When expressed in cultured cells, sALCAM was properly secreted into the media. Both ALCAM and sALCAM are expressed in a variety of cultured human endothelial cells. Notably, their transcripts were differentially regulated in human microvascular endothelial cells (HMVEC) upon tumor necrosis factor-alpha stimulation. ALCAM significantly enhanced tube formation of endothelial-like yolk sac cells on Matrigel, whereas it inhibited their migration in vitro. sALCAM completely abolished these effects of ALCAM. Furthermore, sALCAM enhanced migration of mock-transfected endothelial-like yolk sac cells that do not express ALCAM, indicating that sALCAM has an independent effect on cell migration in addition to modulating ALCAM function. In addition, sALCAM significantly enhanced migration of HMVEC, whereas it inhibited tube formation of HMVEC on Matrigel. sALCAM demonstrated an ability to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic interactions. Taken together, these data characterize a novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providing further insights regarding the role of this adhesion molecule in the regulation of endothelial cell function.	Stanford Univ, Sch Med, Div Cardiovasc Med,Falk CVRC, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA	Stanford University	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med,Falk CVRC, Donald W Reynolds Cardiovasc Clin Res Ctr, 300 Pasteur Dr, Stanford, CA 94305 USA.	tomq1@stanford.edu		Quertermous, Thomas/0000-0002-7645-9067; ikeda, Koji/0000-0002-9972-7255				Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Bowen MA, 1997, EUR J IMMUNOL, V27, P1469, DOI 10.1002/eji.1830270625; Bowen MA, 2000, PROTEINS, V40, P420; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CHEDOTAL A, 1995, EUR J NEUROSCI, V7, P198, DOI 10.1111/j.1460-9568.1995.tb01056.x; DEBERNARDO AP, 1995, DEV BIOL, V169, P65, DOI 10.1006/dbio.1995.1127; DeBernardo AP, 1996, J CELL BIOL, V133, P657, DOI 10.1083/jcb.133.3.657; Degen WGJ, 1998, AM J PATHOL, V152, P805; Gho YS, 2001, CANCER RES, V61, P4253; Gho YS, 1999, CANCER RES, V59, P5128; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Ikeda K, 2003, J BIOL CHEM, V278, P3514, DOI 10.1074/jbc.M204563200; Ishida T, 2003, J BIOL CHEM, V278, P34598, DOI 10.1074/jbc.M304890200; ISHIWATA N, 1994, J BIOL CHEM, V269, P23708; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Levesque MC, 1998, ARTHRITIS RHEUM, V41, P2221, DOI 10.1002/1529-0131(199812)41:12<2221::AID-ART18>3.0.CO;2-I; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Meager A, 1996, J IMMUNOL METHODS, V191, P97, DOI 10.1016/0022-1759(96)00005-1; Morbidelli L, 1997, LIFE SCI, V62, pPL7, DOI 10.1016/S0024-3205(97)01042-4; Nelissen JMDT, 2000, MOL BIOL CELL, V11, P2057, DOI 10.1091/mbc.11.6.2057; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; POURQUIE O, 1990, DEVELOPMENT, V109, P743; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHWARTZ CJ, 1985, ANN NY ACAD SCI, V454, P115, DOI 10.1111/j.1749-6632.1985.tb11849.x; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; Uchida N, 1997, BLOOD, V89, P2706, DOI 10.1182/blood.V89.8.2706; van Kempen LCLT, 2004, J INVEST DERMATOL, V122, P1293, DOI 10.1111/j.0022-202X.2004.22531.x; van Kempen LCLT, 2001, J BIOL CHEM, V276, P25783, DOI 10.1074/jbc.M011272200; van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7; Zimmerman AW, 2004, J CELL SCI, V117, P2841, DOI 10.1242/jcs.01139	36	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55315	55323		10.1074/jbc.M407776200	http://dx.doi.org/10.1074/jbc.M407776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496415	hybrid			2022-12-27	WOS:000225960800043
J	Kamath-Loeb, AS; Welcsh, P; Waite, M; Adman, ET; Loeb, LA				Kamath-Loeb, AS; Welcsh, P; Waite, M; Adman, ET; Loeb, LA			The enzymatic activities of the Werner syndrome protein are disabled by the amino acid polymorphism R834C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; NUCLEAR-LOCALIZATION; SYNDROME GENE; AGING PROCESS; MUTATIONS; SEQUENCE; EXONUCLEASE; PROGRAM; DENSITY; VARIANT	The Werner syndrome protein, WRN, is a member of the RecQ family of DNA helicases. It possesses both 3' -->5' DNA helicase and 3' -->5' DNA exonuclease activities. Mutations in WRN are causally associated with a rare, recessive disorder, Werner syndrome (WS), distinguished by premature aging and genomic instability; all are reported to result in loss of protein expression. In addition to WS-linked mutations, single nucleotide polymorphisms, with frequencies that exceed those of WS-associated mutations, are also present in WRN. We have initiated studies to determine if six of these polymorphisms affect the enzymatic activities of WRN. We show that two common polymorphisms, F1074L and C1367R, and two infrequent polymorphisms, Q724L and S1079L, exhibit little change in activity relative to wild-type WRN; the polymorphism, T172P, shows a small but consistent reduction of activity. However, an infrequent polymorphism, R834C, located in the helicase domain dramatically reduces WRN helicase and helicase-coupled exonuclease activity. The structure of the E. coli helicase core suggests that R834 may be involved in interactions with ATP. As predicted, substitution of Arg with Cys interferes with ATP hydrolysis that is absolutely required for unwinding DNA. R834C thus represents the first missense amino acid polymorphism in WRN that nearly abolishes enzymatic activity while leaving expression largely unaffected.	Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Box 357705,1959 NE Pacific St, Seattle, WA 98195 USA.	laloeb@u.washington.edu	Hess, Maureen/E-9769-2013		NATIONAL CANCER INSTITUTE [P01CA077852] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77852] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Castro E, 2000, AM J MED GENET, V95, P374, DOI 10.1002/1096-8628(20001211)95:4<374::AID-AJMG14>3.3.CO;2-W; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; Matsumoto T, 1998, INT J MOL MED, V1, P71; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Ogata N, 2001, J BONE MINER METAB, V19, P296, DOI 10.1007/s007740170013; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; Passarino G, 2001, GENOMICS, V71, P118, DOI 10.1006/geno.2000.6405; Rong SB, 2000, MOL MED, V6, P155, DOI 10.1007/BF03402111; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Ye L, 1997, AM J MED GENET, V68, P494, DOI 10.1002/(SICI)1096-8628(19970211)68:4<494::AID-AJMG30>3.0.CO;2-L; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55499	55505		10.1074/jbc.M407128200	http://dx.doi.org/10.1074/jbc.M407128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489508	hybrid			2022-12-27	WOS:000225960800065
J	Mano, N; Kasuga, K; Kobayashi, N; Goto, J				Mano, N; Kasuga, K; Kobayashi, N; Goto, J			A nonenzymatic modification of the amino-terminal domain of histone H3 by bile acid acyl adenylate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; LITHOCHOLIC ACID; LYSINE RESIDUES; GENE-EXPRESSION; CORE HISTONES; SWISS-MODEL; PROTEIN; COLON; ACETYLATION	Although it has been proposed that the secondary bile acids, deoxycholic acid and lithocholic acid, increase the number of aberrant crypt foci in the colon and may act as colon tumor promoters, there is little evidence detailing their mechanism of action. Histones play an important role in controlling gene expression, and the posttranslational modification of histones plays a role in regulation of intracellular signal transduction. In particular, the amino-terminal tail domain of histone H3 is sensitive to several posttranslational modifications, and acetylation of this domain changes its electrostatic environment and results in the loss of native folding. Therefore, we studied the modification of epsilon-amino groups on human histone H3 by deoxycholyl adenylate, which is an active intermediate in deoxycholyl thioester biosynthesis. After incubation of recombinant human histone H3 with a smaller amount of acyl adenylate, followed by enzymatic digestion, the peptide fragment mixtures were analyzed by matrix-assisted laser desorption ionization mass spectrometry. These data showed the formation of only one adduct fragment, which corresponded to amino acids 3-8 with a deoxycholate adduct, suggesting that the epsilon-amino group of Lys(4) had the highest reactivity. This novel modification, formation of a bile acid adduct on the histone H3 amino-terminal tail domain through an active acyl adenylate, may relate to the carcinogenesis-promoting effects of secondary bile acids.	Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Kobe Pharmaceut Univ, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Tohoku University; Tohoku University; Kobe Pharmaceutical University	Goto, J (corresponding author), Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	jun-goto@mail.pharm.tohoku.ac.jp	Mano, Nariyasu/AAS-9994-2020; Kasuga, Kie/D-2308-2013	Kasuga, Kie/0000-0003-0489-194X; Mano, Nariyasu/0000-0003-1679-9024				Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; BERG P, 1956, J BIOL CHEM, V222, P991; BIEMANN K, 1989, BIOCHEM SOC T, V17, P237, DOI 10.1042/bst0170237; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Fabrizi L, 2003, CHEM RES TOXICOL, V16, P266, DOI 10.1021/tx025565i; Falany CN, 2002, J LIPID RES, V43, P2062, DOI 10.1194/jlr.M200260-JLR200; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gassler N, 2003, HUM PATHOL, V34, P1048, DOI 10.1053/S0046-8177(03)00431-3; Goto J, 2001, RAPID COMMUN MASS SP, V15, P104, DOI 10.1002/1097-0231(20010130)15:2<104::AID-RCM198>3.3.CO;2-E; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Ikegawa S, 1999, ANAL BIOCHEM, V266, P125, DOI 10.1006/abio.1998.2944; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson-Saliba M, 2000, FEBS LETT, V467, P169, DOI 10.1016/S0014-5793(00)01142-X; Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014-5793(98)00752-2; Kobayashi N, 2000, ANAL SCI, V16, P1133, DOI 10.2116/analsci.16.1133; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Mano N, 2004, BIOCHEMISTRY-US, V43, P2041, DOI 10.1021/bi035855d; Martinez JD, 1998, NUTR CANCER, V31, P111, DOI 10.1080/01635589809514689; Milovic V, 2000, INT J COLORECTAL DIS, V15, P264; NAIR PP, 1994, STEROIDS, V59, P212, DOI 10.1016/0039-128X(94)90030-2; NAIR PP, 1978, LIPIDS, V13, P966, DOI 10.1007/BF02533857; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; REDDY BS, 1976, J NATL CANCER I, V56, P441, DOI 10.1093/jnci/56.2.441; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUTHERLAND LAM, 1994, CANCER LETT, V76, P101, DOI 10.1016/0304-3835(94)90384-0; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; TALASZ H, 1993, BIOCHEMISTRY-US, V32, P1188, DOI 10.1021/bi00055a025; TURJMAN N, 1981, CANCER RES, V41, P3761; Wiekowski M, 1997, J CELL SCI, V110, P1147	40	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55034	55041		10.1074/jbc.M409205200	http://dx.doi.org/10.1074/jbc.M409205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15465822	hybrid			2022-12-27	WOS:000225960800008
J	Huang, JN; Huang, Q; Zhou, XL; Shen, MM; Yen, A; Yu, SX; Dong, GQ; Qu, KB; Huang, PY; Anderson, EM; Daniel-Issakani, S; Buller, RML; Payan, DG; Lu, HH				Huang, JN; Huang, Q; Zhou, XL; Shen, MM; Yen, A; Yu, SX; Dong, GQ; Qu, KB; Huang, PY; Anderson, EM; Daniel-Issakani, S; Buller, RML; Payan, DG; Lu, HH			The poxvirus p28 virulence factor is an E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; ECTROMELIA VIRUS; CAUSATIVE AGENT; COMPLEX; PROTEASOME; SYSTEM; CHAIN; RECOGNITION; DESTRUCTION; EXPRESSION	A majority of the orthopoxviruses, including the variola virus that causes the dreaded smallpox disease, encode a highly conserved 28-kDa protein with a classic RING finger sequence motif (C3HC4) at their carboxyl-terminal domains. The RING domain of p28 has been shown to be a critical determinant of viral virulence for the ectromelia virus ( mousepox virus) in a murine infection model (Senkevich, T. G., Koonin, E. V., and Buller, R. M. (1994) Virology 198, 118-128). Here, we demonstrate that the p28 proteins encoded by the ectromelia virus and the variola virus possess E3 ubiquitin ligase activity in biochemical assays as well as in cultured mammalian cells. Point mutations disrupting the RING finger domain of p28 completely abolish its E3 ligase activity. In addition, p28 functions cooperatively with Ubc4 and UbcH5c, the E2 conjugating enzymes involved in 26 S proteasome degradation of protein targets. Moreover, p28 catalyzes the formation of Lys-63-linked polyubiquitin chains in the presence of Ubc13/Uev1A, a heterodimeric E2 conjugating enzyme, indicating that p28 may regulate the biological activity of its cognate viral and/or host cell target(s) by Lys-63-linked ubiquitin multimers. We thus conclude that the poxvirus p28 virulence factor is a new member of the RING finger E3 ubiquitin ligase family and has a unique polyubiquitylation activity. We propose that the E3 ligase activity of the p28 virulence factor may be targeted for therapeutic intervention against infections by the variola virus and other poxviruses.	Rigel Pharmaceut Inc, San Francisco, CA 94080 USA; St Louis Univ, Hlth Sci Ctr, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University	Payan, DG (corresponding author), Rigel Pharmaceut Inc, 1180 Vet Blvd, San Francisco, CA 94080 USA.	dgpayan@rigel.com; hlu@rigel.com						Banks L, 2003, TRENDS BIOCHEM SCI, V28, P452, DOI 10.1016/S0968-0004(03)00141-5; Brick DJ, 1998, VIROLOGY, V249, P42, DOI 10.1006/viro.1998.9304; Brick DJ, 2000, J GEN VIROL, V81, P1087, DOI 10.1099/0022-1317-81-4-1087; Chen NH, 2003, VIROLOGY, V317, P165, DOI 10.1016/S0042-6822(03)00520-8; Chen NH, 2000, VIRUS RES, V66, P155, DOI 10.1016/S0168-1702(99)00135-5; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gray TA, 2000, GENOMICS, V66, P76, DOI 10.1006/geno.2000.6199; Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0; Guerin JL, 2002, J VIROL, V76, P2912, DOI 10.1128/JVI.76.6.2912-2923.2002; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kentsis A, 2001, J MOL BIOL, V312, P609, DOI 10.1006/jmbi.2001.5003; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Moss B, 2001, FIELDS VIROLOGY, P2849; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Pickart CM, 2000, NAT STRUCT BIOL, V7, P999, DOI 10.1038/81018; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; SENKEVICH TG, 1994, VIROLOGY, V198, P118, DOI 10.1006/viro.1994.1014; SENKEVICH TG, 1995, J VIROL, V69, P4103, DOI 10.1128/JVI.69.7.4103-4111.1995; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wong BR, 2003, DRUG DISCOV TODAY, V8, P746, DOI 10.1016/S1359-6446(03)02780-6; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	33	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54110	54116		10.1074/jbc.M410583200	http://dx.doi.org/10.1074/jbc.M410583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496420	hybrid			2022-12-27	WOS:000225793600029
J	Kataoka, K; Yamaguchi, K; Kobayashi, M; Mori, T; Bokui, N; Suzuki, S				Kataoka, K; Yamaguchi, K; Kobayashi, M; Mori, T; Bokui, N; Suzuki, S			Structure-based engineering of Alcaligenes xylosoxidans copper-containing nitrite reductase enhances intermolecular electron transfer reaction with pseudoazurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTION; ACHROMOBACTER-CYCLOCLASTES; ELECTROCHEMICAL PROPERTIES; FAECALIS; SITE; BLUE; COMPLEX; MUTANT; AZURINS; BINDING	The intermolecular electron transfer from Achromobacter cycloclastes pseudoazurin (AcPAZ) to wildtype and mutant Alcaligenes xylosoxidans nitrite reductases (AxNIRs) was investigated using steady-state kinetics and electrochemical methods. The affinity and the electron transfer reaction constant (k(ET)) are considerably lower between AcPAZ and AxNIR (K-m = 1.34 mM and k(ET) = 0.87 x 10(5) M-1 s(-1)) than between AcPAZ and its cognate nitrite reductase (AcNIR) (K-m = 20 muM and k(ET) = 7.3 x 10(5) M-1 s(-1)). A negatively charged hydrophobic patch, comprising seven acidic residues around the type 1 copper site in AcNIR, is the site of protein-protein interaction with a positively charged hydrophobic patch on AcPAZ. In AxNIR, four of the negatively charged residues (Glu-112, Glu-133, Glu-195, and Asp-199) are conserved at the corresponding positions of AcNIR, whereas the other three residues are not acidic amino acids but neutral amino acids (Ala-83, Ala-191, and Gly-198). Seven mutant AxNIRs with additional negatively charged residues surrounding the hydrophobic patch of AxNIR (A83D, A191E, G198E, A83D/A191E, A93D/G198E, A191E/G198E, and A83D/A191E/G198E) were prepared to enhance the specificity of the electron transport reaction between AcPAZ and AxNIR. The kET values of these mutants become progressively larger as the number of mutated residues increases. The Km and k(ET) values of A83D/A191E/G198E (K-m = 88 muM and k(ET) = 4.1 x 10(5) M-1 s(-1)) are 15-fold smaller and 4.7-fold larger than those of wild-type AxNIR, respectively. These results suggest that the introduction of negatively charged residues into the docking surface of AxNIR facilitates both the formation of electron transport complex and the electron transfer reaction.	Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Sci Mat, Kanazawa, Ishikawa 9201192, Japan	Osaka University; Kanazawa University	Suzuki, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan.	bic@ch.wani.osaka-u.ac.jp	KATAOKA, Kunishige/J-8457-2015					ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Bendall DS., 1996, PROTEIN ELECT TRANSF; CLARKE MJ, 1991, LONG RANGE ELECT TRA, V75; DeLano W.L, PYMOL MOL GRAPHICS S; Deligeer, 2002, J INORG BIOCHEM, V91, P132, DOI 10.1016/S0162-0134(02)00442-7; Deligeer, 2000, B CHEM SOC JPN, V73, P1839, DOI 10.1246/bcsj.73.1839; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; Dodd FE, 1998, J MOL BIOL, V282, P369, DOI 10.1006/jmbi.1998.2007; DODD FE, 1995, BIOCHEMISTRY-US, V34, P10180, DOI 10.1021/bi00032a011; Higuchi R., 1989, PCR TECHNOLOGY, P61; Impagliazzo A, 2004, J AM CHEM SOC, V126, P5658, DOI 10.1021/ja049619h; Inoue T, 1998, J BIOCHEM, V124, P876, DOI 10.1093/oxfordjournals.jbchem.a022201; Jansson H, 2003, BBA-BIOENERGETICS, V1607, P203, DOI 10.1016/j.bbabio.2003.09.011; Kataoka K, 2003, BIOCHEM BIOPH RES CO, V303, P519, DOI 10.1016/S0006-291X(03)00381-4; Kataoka K, 2000, J INORG BIOCHEM, V82, P79, DOI 10.1016/S0162-0134(00)00146-X; Kataoka K, 2000, J BIOCHEM-TOKYO, V127, P345, DOI 10.1093/oxfordjournals.jbchem.a022613; KOHZUMA T, 1993, CHEM LETT, P149, DOI 10.1246/cl.1993.149; Kukimoto M, 1996, J BIOL CHEM, V271, P13680, DOI 10.1074/jbc.271.23.13680; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; Kukimoto M, 1996, FEBS LETT, V394, P87, DOI 10.1016/0014-5793(96)00934-9; Murphy LM, 2002, J MOL BIOL, V315, P859, DOI 10.1006/jmbi.2001.5253; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; MURPHY MEP, 1998, NATO SCI SERIES, P115; NICHOLSON RS, 1964, ANAL CHEM, V36, P706, DOI 10.1021/ac60210a007; SIGEL H, 1991, ELECT TRANSFER REACT, V27; Suzuki S, 1999, COORDIN CHEM REV, V190, P245, DOI 10.1016/S0010-8545(99)00069-7; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; Suzuki S, 1999, J BIOL INORG CHEM, V4, P749, DOI 10.1007/s007750050347; Suzuki S, 2000, ACCOUNTS CHEM RES, V33, P728, DOI 10.1021/ar9900257; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; Yamaguchi K, 2003, BIOCHEM BIOPH RES CO, V300, P36, DOI 10.1016/S0006-291X(02)02764-X; ZUMFT WG, 1987, EUR J BIOCHEM, V168, P301, DOI 10.1111/j.1432-1033.1987.tb13421.x; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	34	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53374	53378		10.1074/jbc.M410198200	http://dx.doi.org/10.1074/jbc.M410198200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475344	hybrid			2022-12-27	WOS:000225680600070
J	Kramer, W; Girbig, F; Corsiero, D; Pfenninger, A; Frick, W; Jahne, G; Rhein, M; Wendler, W; Lottspeich, F; Hochleitner, EO; Orso, E; Schmitz, G				Kramer, W; Girbig, F; Corsiero, D; Pfenninger, A; Frick, W; Jahne, G; Rhein, M; Wendler, W; Lottspeich, F; Hochleitner, EO; Orso, E; Schmitz, G			Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETARY-CHOLESTEROL; BINDING-PROTEINS; SMALL-INTESTINE; RECEPTOR; IDENTIFICATION; CORONAVIRUS; SITOSTEROL; METABOLISM; MICRODOMAINS; COMPLEX	Intestinal cholesterol absorption is an important regulator of serum cholesterol levels. Ezetimibe is a specific inhibitor of intestinal cholesterol absorption recently introduced into medical practice; its mechanism of action, however, is still unknown. Ezetimibe neither influences the release of cholesterol from mixed micelles in the gut lumen nor the transfer of cholesterol to the enterocyte brush border membrane. With membrane-impermeable Ezetimibe analogues we could demonstrate that binding of cholesterol absorption inhibitors to the brush border membrane of small intestinal enterocytes from the gut lumen is sufficient for inhibition of cholesterol absorption. A 145-kDa integral membrane protein was identified as the molecular target for cholesterol absorption inhibitors in the enterocyte brush border membrane by photoaffinity labeling with photoreactive Ezetimibe analogues (Kramer, W., Glombik, H., Petry, S., Heuer, H., Schafer, H. L., Wendler, W., Corsiero, D., Girbig, F., and Weyland, C. (2000) FEBS Lett. 487, 293-297). The 145-kDa Ezetimibe-binding protein was purified by three different methods and sequencing revealed its identity with the membrane-bound ectoenzyme aminopeptidase N (( alanyl)aminopeptidase; EC 3.4.11.2; APN; leukemia antigen CD13). The enzymatic activity of APN was not influenced by Ezetimibe ( analogues). The uptake of cholesterol delivered by mixed micelles by confluent CaCo-2 cells was partially inhibited by Ezetimibe and nonabsorbable Ezetimibe analogues. Preincubation of confluent CaCo-2 cells with Ezetimibe led to a strong decrease of fluorescent APN staining with a monoclonal antibody in the plasma membrane. Independent on its enzymatic activity, aminopeptidase N is involved in endocytotic processes like the uptake of viruses. Our findings suggest that binding of Ezetimibe to APN from the lumen of the small intestine blocks endocytosis of cholesterol-rich membrane microdomains, thereby limiting intestinal cholesterol absorption.	Aventis Pharma Deutschland GmbH, Dis Grp Metab Dis, D-65926 Frankfurt, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany	Sanofi-Aventis; Max Planck Society; University of Regensburg	Kramer, W (corresponding author), Aventis Pharma Deutschland GmbH, Dis Grp Metab Dis, Ind Pk Hochst,Bldg G 879, D-65926 Frankfurt, Germany.	Werner.Kramer@aventis.com						Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Arion WJ, 1998, ARCH BIOCHEM BIOPHYS, V351, P279, DOI 10.1006/abbi.1997.0563; Benbacer L, 1997, J VIROL, V71, P734, DOI 10.1128/JVI.71.1.734-737.1997; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BURNETT DA, 1994, J MED CHEM, V37, P1733, DOI 10.1021/jm00038a001; BYERS SO, 1953, AM J PHYSIOL, V175, P375, DOI 10.1152/ajplegacy.1953.175.3.375; Cai TQ, 2002, BBA-MOL CELL BIOL L, V1581, P100, DOI 10.1016/S1388-1981(02)00128-2; Clader JW, 1996, J MED CHEM, V39, P3684, DOI 10.1021/jm960405n; Compassi S, 1997, BIOCHEMISTRY-US, V36, P6643, DOI 10.1021/bi9620666; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; Danielsen EM, 2003, BBA-BIOMEMBRANES, V1617, P1, DOI 10.1016/j.bbamem.2003.09.005; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; FELDMAN EB, 1969, BIOCHIM BIOPHYS ACTA, V193, P221, DOI 10.1016/0005-2736(69)90077-7; Field FJ, 1998, J LIPID RES, V39, P1938; Frick W, 2003, BIOORGAN MED CHEM, V11, P1639, DOI 10.1016/S0968-0896(03)00047-6; GLOMBIK H, 2002, Patent No. 2002050027; GRUNDY SM, 1983, ANNU REV NUTR, V3, P71, DOI 10.1146/annurev.nu.03.070183.000443; Hansen GH, 2003, GUT, V52, P1424, DOI 10.1136/gut.52.10.1424; Hansen GH, 2003, BIOCHEM J, V373, P125, DOI 10.1042/BJ20030235; Hansen GH, 1998, J VIROL, V72, P527, DOI 10.1128/JVI.72.1.527-534.1998; HARWOOD HJ, 1993, J LIPID RES, V34, P377; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Huggins KW, 2003, J BIOL CHEM, V278, P42899, DOI 10.1074/jbc.M303422200; Jardinaud F, 2004, BIOCHIMIE, V86, P105, DOI 10.1016/j.biochi.2003.12.004; Klett EL, 2004, SCIENCE, V303, P1149, DOI 10.1126/science.1095519; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Kramer W, 2003, BBA-MOL CELL BIOL L, V1633, P13, DOI 10.1016/S1388-1981(03)00068-4; Kramer W, 2000, FEBS LETT, V487, P293, DOI 10.1016/S0014-5793(00)02372-3; Kramer W, 2001, J BIOL CHEM, V276, P36020, DOI 10.1074/jbc.M104665200; KRAMER W, 2000, Patent No. 0218432; KRAMER W, 2002, BILE ACIDS GENOMICS, P147; KUNZ J, 1994, J NEUROCHEM, V62, P2375; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; MCINTYRE N, 1973, AM J CLIN NUTR, V26, P647; MOOSEKER MS, 1976, J CELL BIOL, V71, P417, DOI 10.1083/jcb.71.2.417; MULLER G, 1994, BIOCHEMISTRY-US, V33, P12149; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; SALEN G, 1970, J CLIN INVEST, V49, P952, DOI 10.1172/JCI106315; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Santos AN, 2000, ADV EXP MED BIOL, V477, P43; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; SODERBERG C, 1993, J VIROL, V67, P6576; Sparrow CP, 1999, J LIPID RES, V40, P1747; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tresnan DB, 1996, J VIROL, V70, P8669, DOI 10.1128/JVI.70.12.8669-8674.1996; van Heek M, 2000, BRIT J PHARMACOL, V129, P1748, DOI 10.1038/sj.bjp.0703235; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON MD, 1994, J LIPID RES, V35, P943; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465	57	93	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1306	1320		10.1074/jbc.M406309200	http://dx.doi.org/10.1074/jbc.M406309200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15494415	hybrid			2022-12-27	WOS:000226195200056
J	Akimova, OA; Bagrov, AY; Lopina, OD; Kamernitsky, AV; Tremblay, J; Hamet, P; Orlov, SN				Akimova, OA; Bagrov, AY; Lopina, OD; Kamernitsky, AV; Tremblay, J; Hamet, P; Orlov, SN			Cardiotonic steroids differentially affect intracellular Na+ and [Na+](i)/[K+](i)-independent signaling in C7-MDCK cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-GLYCOSIDES; OUABAIN; ATPASE; APOPTOSIS; PUMP; MARINOBUFAGENIN; NA+,K+-ATPASE; LIGAND; INHIBITION; ACTIVATION	Recently, we reported that ouabain kills renal epithelial and vascular endothelial cells independently of elevation of the [Na+](i)/[K+](i) ratio. These observations raised the possibility of finding cardiotonic steroids (CTS) that inhibit the Na+, K+ pump without attenuating cell survival and vice versa. To test this hypothesis, we compared CTS action on Na+, K+ pump, [Na+](i) content, and survival of Madin-Darby canine kidney cells. At a concentration of 1 muM, ouabain and other tested cardenolides, as well as bufadienolides such as bufalin, cinobufagin, cinobufotalin, and telobufotoxin, led to similar to10-fold inhibition of the Na+, K+ pump, a 2-3-fold decrease in staining with dimethylthiazol-diphenyltetrazolium (MTT), and massive death indicated by detachment of similar to80% of cells and caspase-3 activation. In contrast, Na+, K+ pump inhibition and elevation of [Na+](i) seen in the presence of 3 muM marinobufagenin (MBG) and marinobufotoxin did not affect MTT staining and cell survival. Inhibition of the Na+, Rb+ pump in K+-free medium was not accompanied by a decline of MTT staining and cell detachment but increased sensitivity to CTS. In K+-free medium, half-maximal inhibition of Rb-86 influx was observed in the presence of 0.04 muM ouabain and 0.1 muM MBG, whereas half-maximal detachment and decline of MTT staining were detected at 0.03 and 0.004 muM of ouabain versus 10 and 3 muM of MBG, respectively. Both ouabain binding and ouabain-induced [Na+](i),[K+](i)-independent signaling were suppressed in the presence of MBG. Thus, our results show that CTS exhibit distinctly different potency in Na+, K+ pump inhibition and triggering of [Na+](i)/[K+](i)-independent signaling, including cell death.	CHUM Hotel Dieu, Ctr Rech, Montreal, PQ H2W 1T7, Canada; Moscow MV Lomonosov State Univ, Fac Biol, Moscow 119899, Russia; NIA, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Russian Acad Sci, Zelinsky Inst Organ Chem, Moscow 119840, Russia	Universite de Montreal; Lomonosov Moscow State University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Russian Academy of Sciences; Zelinsky Institute of Organic Chemistry	Orlov, SN (corresponding author), CHUM Hotel Dieu, Ctr Rech, 3850 Rue St Urbain, Montreal, PQ H2W 1T7, Canada.	sergei.n.orlov@umontreal.ca	Akimova, Olga/I-2669-2014; Cossette, Suzanne/I-8008-2016; Bagrov, Alexei/AAM-6509-2020; Lopina, Olga/ABE-6918-2021; Tremblay, Johanne/E-2154-2013; ORLOV, SERGEI/I-4071-2013	Lopina, Olga/0000-0001-9608-0196; Bagrov, Alexei/0000-0002-2903-8673	NATIONAL INSTITUTE ON AGING [Z01AG000609, ZIAAG000609] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKERA T, 1985, EUR J PHARMACOL, V111, P147, DOI 10.1016/0014-2999(85)90751-4; BAGROV AY, 1995, EUR J PHARMACOL, V274, P151, DOI 10.1016/0014-2999(94)00735-P; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Chueh SC, 2001, J UROLOGY, V166, P347, DOI 10.1016/S0022-5347(05)66157-5; Contreras RG, 1999, J CELL SCI, V112, P4223; Daniel D, 2003, INT IMMUNOPHARMACOL, V3, P1791, DOI 10.1016/j.intimp.2003.08.004; Dmitrieva RI, 2003, J BIOL CHEM, V278, P28160, DOI 10.1074/jbc.M303768200; Dmitrieva RI, 2002, EXP BIOL MED, V227, P561, DOI 10.1177/153537020222700803; Fedorova OV, 2004, J HYPERTENS, V22, P389, DOI 10.1097/00004872-200402000-00025; Fedorova OV, 2003, HYPERTENSION, V41, P505, DOI 10.1161/01.HYP.0000053446.43894.9F; Fedorova OV, 2002, HYPERTENSION, V39, P298, DOI 10.1161/hy0202.104344; Fedorova OV, 2001, HYPERTENSION, V37, P462, DOI 10.1161/01.HYP.37.2.462; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Glitsch HG, 2001, PHYSIOL REV, V81, P1791, DOI 10.1152/physrev.2001.81.4.1791; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Ho CK, 2000, EUR J CELL BIOL, V79, P765, DOI 10.1078/0171-9335-00091; Huang YT, 2004, BIOCHEM PHARMACOL, V67, P727, DOI 10.1016/j.bcp.2003.10.013; Kawamura A, 1999, P NATL ACAD SCI USA, V96, P6654, DOI 10.1073/pnas.96.12.6654; Krenn L, 1998, PHYTOCHEMISTRY, V48, P1, DOI 10.1016/S0031-9422(97)00426-3; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; Liu J, 2000, J BIOL CHEM, V275, P27838; Maixent JM, 1998, CARDIOVASC DRUG THER, V12, P585, DOI 10.1023/A:1007747623749; Mohammadi K, 2003, J CARDIOVASC PHARM, V41, P609, DOI 10.1097/00005344-200304000-00014; Orlov SN, 2004, PFLUG ARCH EUR J PHY, V448, P335, DOI 10.1007/s00424-004-1262-9; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Pchejetski D, 2003, BIOCHEM BIOPH RES CO, V301, P735, DOI 10.1016/S0006-291X(02)03002-4; Saunders R, 2004, EUR J BIOCHEM, V271, P1054, DOI 10.1111/j.1432-1033.2004.04012.x; Schneider R, 1998, J BIOL CHEM, V273, P784, DOI 10.1074/jbc.273.2.784; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; Ward SC, 2002, HYPERTENSION, V39, P536, DOI 10.1161/hy0202.103048	34	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					832	839		10.1074/jbc.M411011200	http://dx.doi.org/10.1074/jbc.M411011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494417	hybrid			2022-12-27	WOS:000226025100097
J	Andreau, K; Castedo, M; Perfettini, JL; Roumier, T; Pichart, E; Souquere, S; Vivet, S; Larochette, N; Kroemer, G				Andreau, K; Castedo, M; Perfettini, JL; Roumier, T; Pichart, E; Souquere, S; Vivet, S; Larochette, N; Kroemer, G			Preapoptotic chromatin condensation upstream of the mitochondrial checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MEMBRANE PERMEABILIZATION; DNA FRAGMENTATION; DISTINCT PATHWAYS; CYCLOPHILIN-A; HISTONE H2AX; APOPTOSIS; CASPASES; AIF; QUANTITATION	When added for a short period (2-4 h) to cells, the kinase inhibitor staurosporine (STS), can trigger double strand breaks, the formation of nuclear foci containing phosphorylated H2AX, Chk2, and p53, a decrease in transcription, and a minor degree of peripheral chromatin condensation. This "preapoptotic chromatin condensation" (PACC) occurs before mitochondrial membrane permeabilization (MMP) and caspase activation become detectable and is not inhibited by Z-VAD-fmk or Bcl-2. PACC is followed by classical apoptosis, when cells are cultured overnight, even when STS is removed from the system. After overnight incubation, STS-pretreated cells manifest mitochondrial cytochrome c release, caspase activation, phosphatidylserine exposure, and apoptotic DNA fragmentation. Caspase or MMP inhibitors did not influence the advent of PACC yet did suppress the evolution of PACC toward apoptosis. Importantly, two unrelated MMP inhibitors (viral mitochondrial inhibitor of apoptosis (vMIA) from cytomegalovirus and mitochondrion-targeted Bcl-2) had a larger range of effects than the pan-caspase inhibitor Z-VAD-fmk. Caspase inhibition simply prevented the transition from PACC to apoptosis yet did not reverse PACC and did not restore transcription. In contrast, Bcl-2 and vMIA allowed for the repair of the DNA lesions, correlating with the reestablishment of active transcription. PACC could also be induced by a gross perturbation of RNA synthesis or primary DNA damage. Again, inhibition of MMP (but not that of caspases) reversed PACC induced by these stimuli. In synthesis, our data reveal the unexpected capacity of STS to induce DNA lesions and suggest qualitative differences in the cytoprotective and DNA repair-inducing potential of different apoptosis inhibitors.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Andre Lwoff, UPR 1983, Lab Replicat ADN & Ultrastruct Noyau, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; PERFETTINI, Jean-Luc/N-4699-2017; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; PERFETTINI, Jean-Luc/0000-0002-2427-2604; LAROCHETTE, Nathanael/0000-0002-7936-678X; Andreau, Karine/0000-0002-9773-0733				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Banath JP, 2003, CANCER RES, V63, P4347; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Castedo M, 1996, J IMMUNOL, V157, P512; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harborth J, 2001, J CELL SCI, V114, P4557; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; McIlroy D, 2000, GENE DEV, V14, P549; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shinzawa K, 2003, J CELL BIOL, V163, P1219, DOI 10.1083/jcb.200306159; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Wang XD, 2001, GENE DEV, V15, P2922; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2000, METHOD ENZYMOL, V322, P208; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	46	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55937	55945		10.1074/jbc.M406411200	http://dx.doi.org/10.1074/jbc.M406411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498771	hybrid			2022-12-27	WOS:000225960800117
J	Barthelmes, HU; Habermeyer, M; Christensen, MO; Mielke, C; Interthal, H; Pouliot, JJ; Boege, F; Marko, D				Barthelmes, HU; Habermeyer, M; Christensen, MO; Mielke, C; Interthal, H; Pouliot, JJ; Boege, F; Marko, D			TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; PHOSPHODIESTERASE TDP1; COVALENT COMPLEXES; SPINOCEREBELLAR ATAXIA; ENZYME; YEAST; CAMPTOTHECIN; MECHANISM; PATHWAYS; PROTEINS	Tyrosyl DNA phosphodiesterase 1 (TDP1) is a repair enzyme that removes adducts, e. g. of topoisomerase I from the 3'-phosphate of DNA breaks. When expressed in human cells as biofluorescent chimera, TDP1 appeared more mobile than topoisomerase I, less accumulated in nucleoli, and not chromosome-bound at early mitosis. Upon exposure to camptothecin both proteins were cleared from nucleoli and rendered less mobile in the nucleoplasm. However, with TDP1 this happened much more slowly reflecting most likely the redistribution of nucleolar structures upon inhibition of rDNA transcription. Thus, a steady association of TDP1 with topoisomerase I seems unlikely, whereas its integration into repair complexes assembled subsequently to the stabilization of DNA.topoisomerase I intermediates is supported. Cells expressing GFP-tagged TDP1 > 100-fold in excess of endogenous TDP1 exhibited a significant reduction of DNA damage induced by the topoisomerase I poison camptothecin and could be selected by that drug. Surprisingly, DNA damage induced by the topoisomerase II poison VP-16 was also diminished to a similar extent, whereas DNA damage independent of topoisomerase I or II was not affected. Overexpression of the inactive mutant GFP-TDP1(H263A) at similar levels did not reduce DNA damage by camptothecin or VP-16. These observations confirm a requirement of active TDP1 for the repair of topoisomerase I-mediated DNA damage. Our data also suggest a role of TDP1 in the repair of DNA damage mediated by topoisomerase II, which is less clear. Since overexpression of TDP1 did not compromise cell proliferation, it could be a pleiotropic resistance mechanism in cancer therapy.	Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany; Univ Kaiserslautern, Dept Chem, Div Food Chem & Environm Technol, D-67663 Kaiserslautern, Germany; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; NIMH, Mol Biol Lab, Bethesda, MD 20894 USA	Heinrich Heine University Dusseldorf; University of Kaiserslautern; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Boege, F (corresponding author), Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, Moorenstr 5, D-40225 Dusseldorf, Germany.	Boege@med.uni-duesseldorf.de	Marko, Doris/B-9354-2014; Boege, Fritz/H-3261-2019	Marko, Doris/0000-0001-6568-2944; 				Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; CALDECOTT K, 1990, CANCER RES, V50, P5778; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Christensen MO, 2004, J BIOL CHEM, V279, P21873, DOI 10.1074/jbc.M400498200; Christensen MO, 2002, J CELL BIOL, V157, P31, DOI 10.1083/jcb.200112023; Christensen MO, 2003, NUCLEIC ACIDS RES, V31, P7255, DOI 10.1093/nar/gkg927; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Christensen MO, 2002, J BIOL CHEM, V277, P35932, DOI 10.1074/jbc.M204738200; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; GEDIK CM, 1992, INT J RADIAT BIOL, V62, P313, DOI 10.1080/09553009214552161; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Liu CY, 2004, DNA REPAIR, V3, P593, DOI 10.1016/j.dnarep.2004.03.030; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mielke C, 2000, GENE, V254, P1, DOI 10.1016/S0378-1119(00)00294-8; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nivens MC, 2004, CANCER CHEMOTH PHARM, V53, P107, DOI 10.1007/s00280-003-0717-6; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	33	108	114	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55618	55625		10.1074/jbc.M405042200	http://dx.doi.org/10.1074/jbc.M405042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494395	hybrid			2022-12-27	WOS:000225960800080
J	Benie, AJ; Blume, A; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T				Benie, AJ; Blume, A; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T			Characterization of ligand binding to the bifunctional key enzyme in the sialic acid biosynthesis by NMR - II. Investigation of the ManNAc kinase functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIRST 2 STEPS; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; STEREOCHEMICAL COURSE; PHOSPHORYL TRANSFER; RAT-LIVER; SPECTROSCOPY; EXPRESSION; CATALYZES; SUBSTRATE; RECEPTOR	N-Acetylmannosamine (ManNAc) is the physiological precursors to all sialic acids that occur in nature. As variations in the sialic acid decoration of cell surfaces can profoundly affect cell-cell, pathogen-cell, or drug-cell interactions, the enzymes that convert ManNAc into sialic acid are attractive targets for the development of drugs that specifically interrupt sialic acid biosynthesis or lead to modified sialic acids on the surface of cells. The first step in the enzymatic conversion of ManNAc into sialic acid is phosphorylation, yielding N-acetylmannosamine-6-phosphate. The enzyme that catalyzes this conversion is the N-acetylmannosamine kinase (ManNAc kinase) as part of the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Here, we employed saturation transfer difference (STD) NMR experiments to study the binding of ManNAc and related ligands to the ManNAc kinase. It is shown that the configuration of C1 and C4 of ManNAc is crucial for binding to the enzyme, whereas the C2 position not only accepts variations in the attached N-acyl side chain but also tolerates inversion of configuration. Our experiments also show that ManNAc kinase maintains its functionality, even in the absence of Mg2+. From the analysis of the STD NMR-derived binding epitopes, it is concluded that the binding mode of the N-acylmannosamines critically depends on the N-acyl side chain. In conjunction with the relative binding affinities of the ligands obtained from STD NMR titrations, it is possible to derive a structure-binding affinity relationship. This provides a cornerstone for the rational design of drugs for novel therapeutic applications by altering the sialic acid decorations of cell walls.	Charite Univ Med Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; Univ Luebeck, Inst Chem, D-23538 Lubeck, Germany; Univ Konstanz, Fachbereich Chem, Fach M 725, D-78457 Constance, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lubeck; University of Konstanz	Peters, T (corresponding author), Charite Univ Med Berlin, Inst Biochem & Mol Biol, Campus Benjamin Franklin,Arnimallee 22, D-14195 Berlin, Germany.	stephan.hinderlich@charite.de; thomas.peters@chemie.uni-luebeck.de	Peters, Thomas/AAE-1509-2022; Peters, Thomas/GQB-3622-2022	Peters, Thomas/0000-0002-7570-8260; Benie, Andrew/0000-0001-8274-0456				Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; Berger M, 2002, EUR J BIOCHEM, V269, P4212, DOI 10.1046/j.1432-1033.2002.03117.x; Blume A, 2004, J BIOL CHEM, V279, P55715, DOI 10.1074/jbc.M410238200; Blume A, 2002, FEBS LETT, V521, P127, DOI 10.1016/S0014-5793(02)02856-9; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Herrmann M, 1997, J VIROL, V71, P5922, DOI 10.1128/JVI.71.8.5922-5931.1997; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Jacobs CL, 2001, BIOCHEMISTRY-US, V40, P12864, DOI 10.1021/bi010862s; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KAYSER H, 1993, EXPERIENTIA, V49, P885, DOI 10.1007/BF01952603; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; LOWE G, 1981, BIOCHEM J, V199, P227, DOI 10.1042/bj1990227; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Oetke C, 2002, J BIOL CHEM, V277, P6688, DOI 10.1074/jbc.M109973200; POLLARDKNIGHT D, 1982, BIOCHEM J, V201, P421, DOI 10.1042/bj2010421; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319	19	20	21	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55722	55727		10.1074/jbc.M410239200	http://dx.doi.org/10.1074/jbc.M410239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498763	hybrid			2022-12-27	WOS:000225960800093
J	Navarro-Lerida, I; Corvi, MM; Barrientos, AA; Gavilanes, F; Berthiaume, LG; Rodriguez-Crespo, I				Navarro-Lerida, I; Corvi, MM; Barrientos, AA; Gavilanes, F; Berthiaume, LG; Rodriguez-Crespo, I			Palmitoylation of inducible nitric-oxide synthase at Cys-3 is required for proper intracellular traffic and nitric oxide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; ESCHERICHIA-COLI; SKELETAL-MUSCLE; TRANSPORT; CAVEOLIN; TETRAHYDROBIOPTERIN; DIMERIZATION; MACROPHAGES; CALMODULIN; EXPRESSION	A number of cell types express inducible nitric-oxide synthase (NOS2) in response to exogenous insults such as bacterial lipopolysaccharide or proinflammatory cytokines. Although it has been known for some time that the N-terminal end of NOS2 suffers a post-translational modification, its exact identification has remained elusive. Using radioactive fatty acids, we show herein that NOS2 becomes thioacylated at Cys-3 with palmitic acid. Site-directed mutagenesis of this single residue results in the absence of the radiolabel incorporation. Acylation of NOS2 is completely indispensable for intracellular sorting and .NO synthesis. In fact, a C3S mutant of NOS2 is completely inactive and accumulates to intracellular membranes that almost totally co-localize with the Golgi marker beta-cop. Likewise, low concentrations of the palmitoylation blocking agents 2-Br-palmitate or 8-Br-palmitate severely affected the .NO synthesis of both NOS2 induced in muscular myotubes and transfected NOS2. However, unlike endothelial NOS, palmitoylation of inducible NOS is not involved in its targeting to caveolae. We have created 16 NOS2-GFP chimeras to inspect the effect of the neighboring residues of Cys-3 on the degree of palmitoylation. In this regard, the hydrophobic residue Pro-4 and the basic residue Lys-6 seem to be indispensable for palmitoylation. In addition, agents that block the endoplasmic reticulum to Golgi transit such as brefeldin A and monensin drastically reduced NOS2 activity leading to its accumulation in perinuclear areas. In summary, palmitoylation of NOS2 at Cys-3 is required for both its activity and proper intracellular localization.	Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Fdn Ctr Nacl Invest Cardiovasc, Madrid 28029, Spain	Complutense University of Madrid; University of Alberta; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Rodriguez-Crespo, I (corresponding author), Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	nacho@bbm1.ucm.es	Gavilanes, Francisco/K-9903-2014; Alvarez-Barrientos, Alberto/L-9299-2014; Rodriguez-Crespo, J. Ignacio/M-1966-2018	Gavilanes, Francisco/0000-0003-1047-2362; Navarro-Lerida, Inmaculada/0000-0001-9994-8069; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Berthiaume, Luc/0000-0003-0926-059X; Corvi, Maria/0000-0002-6192-5029; Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X				BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bredt DS, 2003, J CELL SCI, V116, P9, DOI 10.1242/jcs.00183; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; Felley-Bosco E, 2002, BIOL RES, V35, P169, DOI 10.4067/S0716-97602002000200007; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Navarro-Lerida I, 2004, J CELL SCI, V117, P1687, DOI 10.1242/jcs.01002; Navarro-Lerida I, 2002, J CELL SCI, V115, P3119; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; RINGHEIM GE, 1995, BIOCHEM BIOPH RES CO, V210, P711, DOI 10.1006/bbrc.1995.1717; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tisdale EJ, 2003, J BIOL CHEM, V278, P38015, DOI 10.1074/jbc.M305381200; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783	31	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55682	55689		10.1074/jbc.M406621200	http://dx.doi.org/10.1074/jbc.M406621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485846	hybrid			2022-12-27	WOS:000225960800088
J	Puri, S; Magenheimer, BS; Maser, RL; Ryan, EM; Zien, CA; Walker, DD; Wallace, DP; Hempson, SJ; Calvet, JP				Puri, S; Magenheimer, BS; Maser, RL; Ryan, EM; Zien, CA; Walker, DD; Wallace, DP; Hempson, SJ; Calvet, JP			Polycystin-1 activates the Calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C BETA; N-TERMINAL KINASE; KIDNEY-DISEASE; SYNTHASE KINASE-3-BETA; TARGETED DISRUPTION; MOLECULAR-GENETICS; CYCLOSPORINE-A; RENAL-FAILURE; ALPHA-SUBUNIT; G-PROTEINS	Regulation of intracellular Ca2+ mobilization has been associated with the functions of polycystin-1 (PC1) and polycystin-2 (PC2), the protein products of the PKD1 and PKD2 genes. We have now demonstrated that PC1 can activate the calcineurin/NFAT ( nuclear factor of activated T-cells) signaling pathway through Galpha(q)-mediated activation of phospholipase C ( PLC). Transient transfection of HEK293T cells with an NFAT promoter-luciferase reporter demonstrated that membrane-targeted PC1 constructs containing the membrane proximal region of the C-terminal tail, which includes the heterotrimeric G protein binding and activation domain, can stimulate NFAT luciferase activity. Inhibition of glycogen synthase kinase-3beta by LiCl treatment further increased PC1-mediated NFAT activity. PC1-mediated activation of NFAT was completely inhibited by the calcineurin inhibitor, cyclosporin A. Cotransfection of a construct expressing the Galpha(q) subunit augmented PC1-mediated NFAT activity, whereas the inhibitors of PLC (U73122) and the inositol trisphosphate and ryanodine receptors (xestospongin and 2-aminophenylborate) and a nonspecific Ca2+ channel blocker (gadolinium) diminished PC1-mediated NFAT activity. PC2 was not able to activate NFAT. An NFAT-green fluorescent protein nuclear localization assay demonstrated that PC1 constructs containing the C-tail only or the entire 11-transmembrane spanning region plus C-tail induced NFAT-green fluorescent protein nuclear translocation. NFAT expression was demonstrated in the M-1 mouse cortical collecting duct cell line and in embryonic and adult mouse kidneys by reverse transcriptase-PCR and immunolocalization. These data suggest a model in which PC1 signaling leads to a sustained elevation of intracellular Ca2+ mediated by PC1 activation of Galpha(q) followed by PLC activation, release of Ca2+ from intracellular stores, and activation of store-operated Ca2+ entry, thus activating calcineurin and NFAT.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA; Panjab Univ, Dept Biochem, Chandigarh 160014, India	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Panjab University	Calvet, JP (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3030,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	jcalvet@kumc.edu		Puri, Sanjeev/0000-0002-3967-987X; Puri, Sanjeev/0000-0002-4314-9871; Wallace, Darren/0000-0003-4616-7669	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053763, P50DK057301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53763, DK 57301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Arnaout MA, 2000, KIDNEY INT, V58, P2599, DOI 10.1046/j.1523-1755.2000.00446.x; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Clapham DE, 2002, J GEN PHYSIOL, V120, P217, DOI 10.1085/jgp.20028618; COWLEY BD, 1993, KIDNEY INT, V43, P522, DOI 10.1038/ki.1993.79; Cuozzo FP, 2002, BBA-MOL BASIS DIS, V1587, P99, DOI 10.1016/S0925-4439(02)00072-8; Dare E, 1998, J MOL ENDOCRINOL, V21, P7, DOI 10.1677/jme.0.0210007; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; Fellner SK, 2002, KIDNEY INT, V61, P2132, DOI 10.1046/j.1523-1755.2002.00383.x; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Gieteling EW, 2003, J NEUROL, V250, P418, DOI 10.1007/s00415-003-0997-0; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; GRANTHAM JJ, 1995, NEW ENGL J MED, V333, P56, DOI 10.1056/NEJM199507063330113; Grantham JJ, 2003, KIDNEY INT, V64, P1157, DOI 10.1046/j.1523-1755.2003.00242.x; Gregory RB, 2003, BIOCHEM J, V370, P695, DOI 10.1042/BJ20021671; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Harris PC, 2002, CURR OPIN NEPHROL HY, V11, P309, DOI 10.1097/00041552-200205000-00007; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Kim SJ, 2003, J BIOL CHEM, V278, P15550, DOI 10.1074/jbc.M210210200; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lanoix J, 1996, ONCOGENE, V13, P1153; Le NH, 2004, J BIOL CHEM, V279, P27472, DOI 10.1074/jbc.M312183200; LEE CH, 1992, J BIOL CHEM, V267, P16044; Liu Bo, 2003, V237, P99; Lohning C, 1997, MAMM GENOME, V8, P307, DOI 10.1007/s003359900429; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maser RL, 2003, METH MOLEC MED, V86, P205; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Munaron L, 2002, INT J MOL MED, V10, P671; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nims N, 2003, BIOCHEMISTRY-US, V42, P13035, DOI 10.1021/bi035074c; Oka T, 2002, BRIT J PHARMACOL, V135, P1959, DOI 10.1038/sj.bjp.0704662; Ong ACM, 2000, EXP NEPHROL, V8, P208; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Peters DJM, 2001, LANCET, V358, P1439, DOI 10.1016/S0140-6736(01)06531-X; Pirson Y, 2002, J AM SOC NEPHROL, V13, P269, DOI 10.1681/ASN.V131269; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Qian Q, 2001, KIDNEY INT, V59, P2005, DOI 10.1046/j.1523-1755.2001.00716.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rubera I, 2000, AM J PHYSIOL-RENAL, V279, pF102, DOI 10.1152/ajprenal.2000.279.1.F102; Rundle DR, 2004, J BIOL CHEM, V279, P29728, DOI 10.1074/jbc.M400544200; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; SCHEFF RT, 1980, ANN INTERN MED, V92, P202, DOI 10.7326/0003-4819-92-2-202; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; van Adelsberg JS, 1999, PEDIATR NEPHROL, V13, P454, DOI 10.1007/s004670050639; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Weston BS, 2003, FEBS LETT, V538, P8, DOI 10.1016/S0014-5793(03)00130-3; Wildman SS, 2003, AM J PHYSIOL-RENAL, V285, pF1168, DOI 10.1152/ajprenal.00171.2003; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; WU DQ, 1992, J BIOL CHEM, V267, P1811; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; YULE DI, 1992, J BIOL CHEM, V267, P13830	97	76	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55455	55464		10.1074/jbc.M402905200	http://dx.doi.org/10.1074/jbc.M402905200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15466861	hybrid			2022-12-27	WOS:000225960800060
J	Streb, JW; Kitchen, CM; Gelman, IH; Miano, JM				Streb, JW; Kitchen, CM; Gelman, IH; Miano, JM			Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PROTEIN-KINASE; SSECKS GENE; SRC; CELLS; SERUM	A Kinase Anchoring Protein 12 (AKAP12; also known as src-suppressed C kinase substrate (SSeCKS) and Gravin) is a multivalent anchoring protein with tumor suppressor activity. Although expression of AKAP12 has been examined in a number of contexts, its expression control remains to be elucidated. Herein, we characterize the genomic organization of the AKAP12 locus, its regulatory regions, and the spatial distribution of the proteins encoded by the AKAP12 gene. Using comparative genomics and various wet-lab assays, we show that the AKAP12 locus is organized as three separate transcription units that are governed by non-redundant promoters coordinating distinct tissue expression profiles. The proteins encoded by the three AKAP12 isoforms (designated alpha, beta, and gamma) share >95% amino acid sequence identity but differ at their N termini. Analysis of the targeting of each isoform reveals distinct spatial distribution profiles. An N-terminal myristoylation motif present in AKAP12alpha is shown to be necessary and sufficient for targeted expression of this AKAP12 isoform to the endoplasmic reticulum, a novel subcellular compartment for AKAP12. Our results demonstrate heretofore unrecognized complexity within the AKAP12 locus and suggest a mechanism for genetic control of signaling specificity through distinct regulation of alternately targeted anchoring protein isoforms.	Univ Rochester, Sch Med & Dent, Ctr Cardiovasc Res, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Rochester; Roswell Park Cancer Institute	Miano, JM (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Cardiovasc Res, Aab Inst Biomed Sci, 601 Elmwood Ave, Rochester, NY 14642 USA.	j.m.miano@rochester.edu	Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207; Ramirez, Christina/0000-0002-8435-0416	NCI NIH HHS [R01 CA094108, R01 CA 94108, R55 CA094108] Funding Source: Medline; NHLBI NIH HHS [R01 HL 70077, T32 HL 07949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA094108, R01CA094108] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070077, T32HL007949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Camus A, 2001, MECH DEVELOP, V105, P79, DOI 10.1016/S0925-4773(01)00384-7; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; Chen JY, 2001, BIOCHEM BIOPH RES CO, V281, P475, DOI 10.1006/bbrc.2001.4362; Coats SR, 2002, BIOCHEM BIOPH RES CO, V297, P1112, DOI 10.1016/S0006-291X(02)02275-1; Coats SR, 2000, J MOL CELL CARDIOL, V32, P2207, DOI 10.1006/jmcc.2000.1246; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Nelson PJ, 1997, MOL CELL BIOCHEM, V175, P233, DOI 10.1023/A:1006836003758; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Scott JD, 1997, SOC GEN PHY, V52, P227; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319	31	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56014	56023		10.1074/jbc.M408828200	http://dx.doi.org/10.1074/jbc.M408828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496411	hybrid			2022-12-27	WOS:000225960800125
J	Nelson, EA; Walker, SR; Alvarez, JV; Frank, DA				Nelson, EA; Walker, SR; Alvarez, JV; Frank, DA			Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1 PROMOTER; BCL-X GENE; BINDING-SITES; GENOMIC SITES; EXPRESSION; TRANSCRIPTION; PROTEINS; GROWTH; CELLS; CIS	STAT5a and STAT5b are two highly related transcription factors that control essential cellular functions. Several STAT5 targets are known, although it is likely that most remain uncharacterized. To identify a more complete set of STAT5-regulated genes, we used a modification of the chromatin immunoprecipitation procedure, which does not presuppose any information regarding these targets. Employing Ba/f3 cells in which STAT5 is activated by interleukin-3, we have identified novel STAT5 binding sites that may be regulatory regions for nearby genes. These sites are typically found far from transcription start sites, and most do not contain CpG islands, indicating that they are not in traditional promoter regions. Nonetheless, when the expression of genes near these STAT5 binding sites was examined, all were expressed in Ba/f3 cells, and most were modulated by interleukin-3. Furthermore, genes identified by this strategy show unique expression patterns in acute leukemias, tumors characterized by activated STAT5. Whereas both STAT5 isoforms bound to all promoters tested, STAT5a and STAT5b bound with different kinetics, suggesting that at least some of the differences between the functions of these two proteins are mediated by their DNA binding activity. Therefore, this method of transcription factor target identification represents an effective strategy to isolate transcription factor targets in an unbiased fashion, and it has revealed many novel STAT5-dependent regulatory regions outside of traditional promoters.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Rm M552B,44 Binney St, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA079547] Funding Source: NIH RePORTER; NCI NIH HHS [CA79547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chavany C, 1998, MOL MED TODAY, V4, P158, DOI 10.1016/S1357-4310(98)01227-1; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Euskirchen G, 2004, MOL CELL BIOL, V24, P3804, DOI 10.1128/MCB.24.9.3804-3814.2004; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Frank David A, 2003, Cancer Treat Res, V115, P267; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jolivet G, 1996, FEBS LETT, V389, P257, DOI 10.1016/0014-5793(96)00598-4; Kubota T, 1998, PATHOL INT, V48, P22, DOI 10.1111/j.1440-1827.1998.tb03823.x; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood-2003-06-1992; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Myerowitz R, 1997, HUM MUTAT, V9, P195, DOI 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Pestina TI, 2003, EXP HEMATOL, V31, P1198, DOI 10.1016/j.exphem.2003.09.002; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rascle A, 2003, NUCLEIC ACIDS RES, V31, P6882, DOI 10.1093/nar/gkg907; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264	41	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54724	54730		10.1074/jbc.M408464200	http://dx.doi.org/10.1074/jbc.M408464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498775	hybrid			2022-12-27	WOS:000225793600100
J	Varela-Gomez, M; Moreno-Sanchez, R; Pardo, JP; Perez-Montfort, R				Varela-Gomez, M; Moreno-Sanchez, R; Pardo, JP; Perez-Montfort, R			Kinetic mechanism and metabolic role of pyruvate phosphate dikinase from Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHOPHOSPHATE DIKINASE; GIARDIA-INTESTINALIS; ESCHERICHIA-COLI; STEADY-STATE; ENZYME; EXPRESSION; CATALYSIS; KINASE; PHOTOSYNTHESIS; PATHWAY	The kinetic mechanism and the metabolic role of pyruvate phosphate dikinase from Entamoeba histolytica were investigated. The initial velocity patterns in double reciprocal plots were parallel for the phosphoenolpyruvate/AMP and phosphoenolpyruvate/pyrophosphate substrate pairs and intersecting for the AMP/pyrophosphate pair. This suggests a kinetic mechanism with two independent reactions. The rate of ATP synthesis at saturating and equimolar concentrations of phosphoenolpyruvate, AMP, and pyrophosphate was inhibited by phosphate, which is consistent with an ordered steady-state mechanism. Enzyme phosphorylation by [P-32(i)] pyrophosphate depends on the formation of a ternary complex between AMP, pyrophosphate, and pyruvate phosphate dikinase. In consequence, the reaction that involves the AMP/pyrophosphate pair follows a sequential steady-state mechanism. The product inhibition patterns of ATP and phosphate versus phosphoenolpyruvate were noncompetitive and uncompetitive, respectively, suggesting that these products were released in an ordered process (phosphate before ATP). The ordered release of phosphate and ATP and the noncompetitive inhibition patterns of pyruvate versus AMP and versus pyrophosphate also supported the sequential kinetic mechanism between AMP and pyrophosphate. Taken together, our data provide evidence for a uni uni bi bi ping-pong mechanism for recombinant pyruvate phosphate dikinase from E. histolytica. The DeltaG value for the reaction catalyzed by pyruvate phosphate dikinase (+2.7 kcal/mol) determined under near physiological conditions indicates that the synthesis of ATP is not thermodynamically favorable in trophozoites of E. histolytica.	Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Inst Nacl Cardiol, Dept Bioquim, Mexico City 14080, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; National Institute of Cardiology - Mexico	Perez-Montfort, R (corresponding author), Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Apartado Postal 70242, Mexico City 04510, DF, Mexico.	ruy@ifc.unam.mx	Moreno-Sanchez, Rafael/A-3158-2011	Moreno-Sanchez, Rafael/0000-0002-9587-7184; Perez-Montfort, Ruy/0000-0003-0810-1159				Agarie S, 1997, PLANT MOL BIOL, V34, P363, DOI 10.1023/A:1005897118660; BERGMEYER HU, 1986, METHOD ENZYMAT AN, V6, P118; BERGMEYER HU, 1986, METHOD ENZYMAT AN, V7, P118; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; EDWARDS GE, 1985, ANNU REV PLANT PHYS, V36, P255, DOI 10.1146/annurev.pp.36.060185.001351; Eisaki N, 1999, BBA-PROTEIN STRUCT M, V1431, P363, DOI 10.1016/S0167-4838(99)00057-6; EVANS HJ, 1968, P NATL ACAD SCI USA, V61, P1448, DOI 10.1073/pnas.61.4.1448; Ghosh SK, 1997, INFECT IMMUN, V65, P4243, DOI 10.1128/IAI.65.10.4243-4249.1997; Ginsburg A, 2002, ARCH BIOCHEM BIOPHYS, V397, P273, DOI 10.1006/abbi.2001.2603; HATCH MD, 1968, BIOCHEM J, V106, P141, DOI 10.1042/bj1060141; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Herzberg O, 2002, BIOCHEMISTRY-US, V41, P780, DOI 10.1021/bi011799+; HRDY I, 1993, EXP PARASITOL, V76, P438, DOI 10.1006/expr.1993.1052; KUKKOKALSKE E, 1985, INT J BIOCHEM, V17, P575, DOI 10.1016/0020-711X(85)90288-5; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MCLAUGHLIN J, 1978, ARCH INVEST MED, V9, P141; MEHL A, 1994, BIOCHEMISTRY-US, V33, P1093, DOI 10.1021/bi00171a007; MILNER Y, 1976, J BIOL CHEM, V251, P7920; Moons A, 1998, PLANT J, V15, P89, DOI 10.1046/j.1365-313X.1998.00185.x; Northrop DB, 1997, ARCH BIOCHEM BIOPHYS, V342, P317, DOI 10.1006/abbi.1997.0131; Osteras M, 1997, MICROBIOL-SGM, V143, P1639, DOI 10.1099/00221287-143-5-1639; Park JH, 1997, EXP PARASITOL, V87, P153, DOI 10.1006/expr.1997.4206; REEVES RE, 1974, ARCH INVEST MED, V5, P331; REEVES RE, 1968, J BIOL CHEM, V243, P5486; REEVES RE, 1968, J BIOL CHEM, V243, P3202; Saavedra E, 2004, EXP PARASITOL, V106, P11, DOI 10.1016/j.exppara.2004.01.009; Saavedra-Lira E, 1998, BBA-PROTEIN STRUCT M, V1382, P47, DOI 10.1016/S0167-4838(97)00139-8; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Scorneaux B, 1999, J VET PHARMACOL THER, V22, P6, DOI 10.1046/j.1365-2885.1999.00185.x; Segel I. H., 1975, ENZYME KINETICS, P560; THRALL SH, 1993, BIOCHEMISTRY-US, V32, P1803, DOI 10.1021/bi00058a014; Varon R, 1997, COMPUT APPL BIOSCI, V13, P159; WANG HC, 1988, BIOCHEMISTRY-US, V27, P625, DOI 10.1021/bi00402a020; Wei M, 2000, J BIOL CHEM, V275, P41156, DOI 10.1074/jbc.M006149200; XU Y, 1995, BIOCHEMISTRY-US, V34, P2195, DOI 10.1021/bi00007a013; YI Y, 1994, MOL BIOCHEM PARASIT, V66, P165, DOI 10.1016/0166-6851(94)90050-7	36	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54124	54130		10.1074/jbc.M401697200	http://dx.doi.org/10.1074/jbc.M401697200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485834	hybrid			2022-12-27	WOS:000225793600031
J	Vazquez-Prado, J; Miyazaki, H; Castellone, MD; Teramoto, H; Gutkind, JS				Vazquez-Prado, J; Miyazaki, H; Castellone, MD; Teramoto, H; Gutkind, JS			Chimeric G alpha(i2)/G alpha(13) proteins reveal the structural requirements for the binding and activation of the RGS-like (RGL)-containing Rho guanine nucleotide exchange factors (GEFs) by G alpha(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-ASSOCIATED RHO; HETEROTRIMERIC G-PROTEINS; PDZ-RHOGEF; TRANSITION-STATE; RGRGS DOMAIN; P115 RHOGEF; LARG; RECEPTOR; LOCALIZATION; MECHANISM	The alpha-subunit of G proteins of the G(12/13) family stimulate Rho by their direct binding to the RGS-like (RGL) domain of a family of Rho guanine nucleotide exchange factors (RGL-RhoGEFs) that includes PDZ-RhoGEF (PRG), p115RhoGEF, and LARG, thereby regulating cellular functions as diverse as shape and movement, gene expression, and normal and aberrant cell growth. The structural features determining the ability of Galpha(12/13) to bind RGL domains and the mechanism by which this association results in the activation of RGL-RhoGEFs are still poorly understood. Here, we explored the structural requirements for the functional interaction between Galpha(13) and RGL-RhoGEFs based on the structure of RGL domains and their similarity with the area by which RGS4 binds the switch region of Galpha(i) proteins. Using Galpha(i2), which does not bind RGL domains, as the backbone in which Galpha(13) sequences were swapped or mutated, we observed that the switch region of Galpha(13) is strictly necessary to bind PRG, and specific residues were identified that are critical for this association, likely by contributing to the binding surface. Surprisingly, the switch region of Galpha(13) was not sufficient to bind RGL domains, but instead most of its GTPase domain is required. Furthermore, membrane localization of Galpha(13) and chimeric Galpha(i2) proteins was also necessary for Rho activation. These findings revealed the structural features by which Galpha(13) interacts with RGL domains and suggest that molecular interactions occurring at the level of the plasma membrane are required for the functional activation of the RGL-containing family of RhoGEFs.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Inst Politecn Nacl, CINVESTAV, Dept Pharmacol, Mexico City 07000, DF, Mexico	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Rm 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	VAZQUEZ-PRADO, JOSE/C-1630-2017; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	FIC NIH HHS [D43 TW06664] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Barac A, 2004, J BIOL CHEM, V279, P6182, DOI 10.1074/jbc.M309579200; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	39	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54283	54290		10.1074/jbc.M410594200	http://dx.doi.org/10.1074/jbc.M410594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485891	hybrid			2022-12-27	WOS:000225793600049
J	Bostrom, K; Zebboudj, AF; Yao, YC; Lin, TS; Torres, A				Bostrom, K; Zebboudj, AF; Yao, YC; Lin, TS; Torres, A			Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta 1 activity in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEIN-2; GENE-EXPRESSION; KEUTEL SYNDROME; MICROARRAY ANALYSIS; MESSENGER-RNA; CALCIFICATION; TRANSCRIPTION; ANGIOGENESIS; MGP	Matrix GLA protein (MGP) is expressed in endothelial cells (EC), and MGP deficiency results in developmental defects suggesting involvement in EC function. To determine the role of MGP in EC, we cultured bovine aortic EC with increasing concentrations of human MGP (hMGP) for 24 h. The results showed increased proliferation, migration, tube formation, and increased release of vascular endothelial growth factor-A (VEGF-A) and basic fibroblast growth factor (bFGF). HMGP, added endogenously or transiently expressed, increased VEGF gene expression dose-dependently as determined by real-time PCR. To determine the mechanism by which hMGP increased VEGF expression, we studied the effect of MGP on the activity of transforming growth factor (TGF)-beta1 compared with that of bone morphogenetic protein (BMP)-2 using transfection assays with TGF-beta and BMP-response element reporter genes. Our results showed a strong enhancement of TGF-beta1 activity by hMGP, which was paralleled by increased VEGF expression. BMP-2 activity, on the other hand, was inhibited by hMGP. Neutralizing antibodies to TGF-beta blocked the effect of MGP on VEGF expression. The enhanced TGF-beta1 activity specifically activated the Smad1/5 pathway indicating that the TGF-beta receptor activin-like kinase 1 (ALK1) had been stimulated. It occurred without changes in expression of TGF-beta1 or ALK1 and was mimicked by transfection of constitutively active ALK1, which increased VEGF expression. Expression of VEGF and MGP was induced by TGF-beta1, but the induction of MGP preceded that of VEGF, consistent with a promoting effect on VEGF expression. Together, the results suggest that MGP plays a role in EC function, altering the response to TGF-beta superfamily growth factors.	Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Bostrom, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Box 951679,Rm 47-123 CHS, Los Angeles, CA 90095 USA.	kbostrom@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004270, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04270, HL030568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Azhar M, 2003, CYTOKINE GROWTH F R, V14, P391, DOI 10.1016/S1359-6101(03)00044-3; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Benckert C, 2003, CANCER RES, V63, P1083; Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CORMODE EJ, 1986, AM J MED GENET, V24, P289, DOI 10.1002/ajmg.1320240209; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; deMello DE, 2000, PEDIATR DEVEL PATHOL, V3, P439, DOI 10.1007/s100240010090; Engelse MA, 2001, CARDIOVASC RES, V52, P281, DOI 10.1016/S0008-6363(01)00375-3; Fan CW, 2001, CANCER LETT, V165, P63, DOI 10.1016/S0304-3835(01)00416-5; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Gilbert KA, 2004, AM J PHYSIOL-LUNG C, V286, pL1179, DOI 10.1152/ajplung.00188.2003; Gilbert KA, 2003, AM J PHYSIOL-LUNG C, V285, pL569, DOI 10.1152/ajplung.00426.2002; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Grainger DJ, 2000, J CELL SCI, V113, P2355; Gray PC, 2001, MOL CELL ENDOCRINOL, V180, P47, DOI 10.1016/S0303-7207(01)00515-9; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Hirschi KK, 2002, ANN NY ACAD SCI, V961, P223, DOI 10.1111/j.1749-6632.2002.tb03090.x; Hough CD, 2001, CANCER RES, V61, P3869; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; Lum RM, 2000, INT J MOL MED, V5, P635; LUO GB, 1995, J BONE MINER RES, V10, P325; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Meier M, 2001, EUR RESPIR J, V17, P566, DOI 10.1183/09031936.01.17305660; Molin DGM, 2003, DEV DYNAM, V227, P431, DOI 10.1002/dvdy.10314; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; Newman B, 2001, J CELL BIOL, V154, P659, DOI 10.1083/jcb.200106040; *PE APPL BIOS, 1997, US B PE APPL BIOS, V2; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Renner U, 2002, ENDOCRINOLOGY, V143, P3759, DOI 10.1210/en.2002-220283; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shin V, 2004, J VASC RES, V41, P193, DOI 10.1159/000077394; Simes DC, 2003, J BONE MINER RES, V18, P244, DOI 10.1359/jbmr.2003.18.2.244; Sugi Y, 2004, DEV BIOL, V269, P505, DOI 10.1016/j.ydbio.2004.01.045; Sweatt A, 2003, J THROMB HAEMOST, V1, P178, DOI 10.1046/j.1538-7836.2003.00023.x; Teebi AS, 1998, AM J MED GENET, V78, P182, DOI 10.1002/(SICI)1096-8628(19980630)78:2<182::AID-AJMG18>3.3.CO;2-K; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Vargesson N, 2003, J ANAT, V202, P93, DOI 10.1046/j.1469-7580.2003.00133.x; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wallin R, 2000, THROMB HAEMOSTASIS, V84, P1039; Warburton D, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-5; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Weston GC, 2002, MOL HUM REPROD, V8, P855, DOI 10.1093/molehr/8.9.855; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zebboudj AF, 2003, J CELL BIOCHEM, V90, P756, DOI 10.1002/jcb.10669; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhao JS, 1999, EUR J CELL BIOL, V78, P715, DOI 10.1016/S0171-9335(99)80040-5; Zhao JS, 1997, AM J PHYSIOL-LUNG C, V273, pL282, DOI 10.1152/ajplung.1997.273.1.L282; ZHOU H, 1993, J CELL PHYSIOL, V155, P112, DOI 10.1002/jcp.1041550115; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301; ZIEREISEN F, 1993, PEDIATR RADIOL, V23, P314, DOI 10.1007/BF02010925	65	92	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52904	52913		10.1074/jbc.M406868200	http://dx.doi.org/10.1074/jbc.M406868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456771	hybrid			2022-12-27	WOS:000225680600014
J	Kurz, EU; Douglas, P; Lees-Miller, SP				Kurz, EU; Douglas, P; Lees-Miller, SP			Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; CATALYTIC SUBUNIT; HISTONE H2AX; P53	The requirement for the serine/threonine protein kinase ATM in coordinating the cellular response to DNA damage induced by ionizing radiation has been studied extensively. Many of the anti-tumor chemotherapeutics in clinical use today cause DNA double strand breaks; however, few have been evaluated for their ability to modulate ATM-mediated pathways. We have investigated the requirement for ATM in the cellular response to doxorubicin, a topoisomerase II-stabilizing drug. Using several ATM-proficient and ATM-deficient cell lines, we have observed ATM-dependent nuclear accumulation of p53 and ATM-dependent phosphorylation of p53 on seven serine residues. This was accompanied by an increased binding of p53 to its cognate binding site, suggesting transcriptional competency of p53 to activate its downstream effectors. Treatment of cells with doxorubicin led to the phosphorylation of histone H2AX on serine 139 with dependence on ATM for the initial response. Doxorubicin treatment also stimulated ATM autophosphorylation on serine 1981 and the ATM-dependent phosphorylation of numerous effectors in the ATM-signaling pathway, including Nbs1 (Ser(343)), SMC1 (Ser(957)), Chk1 (Ser(317) and Ser(345)), and Chk2 (Ser(33/35) and Thr(68)). Although generally classified as a topoisomerase II-stabilizing drug that induces DNA double strand breaks, doxorubicin can intercalate DNA and generate reactive oxygen species. Pretreatment of cells with the superoxide scavenger ascorbic acid had no effect on the doxorubicin-induced phosphorylation and accumulation of p53. In contrast, preincubation of cells with the hydroxyl radical scavenger, N-acetylcysteine, significantly attenuated the doxorubicin-mediated phosphorylation and accumulation of p53, p53-DNA binding, and the phosphorylation of H2AX, Nbs1, SMC1, Chk1, and Chk2, suggesting that hydroxyl radicals contribute to the doxorubicin-induced activation of ATM-dependent pathways.	Univ Calgary, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Kurz, EU (corresponding author), Univ Calgary, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kurz@ucalgary.ca		Lees-Miller, Susan/0000-0001-5809-2516				Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Ahn JY, 2000, CANCER RES, V60, P5934; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9; Chabner B.A, 1996, GOODMAN GILMANS PHAR; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Goodarzi Aaron A, 2003, Prog Cell Cycle Res, V5, P393; Ha N, 2003, J BIOL CHEM, V278, P17885, DOI 10.1074/jbc.M210560200; Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MEREDITH MJ, 1987, CANCER RES, V47, P4576; OLSON RD, 1980, J PHARMACOL EXP THER, V215, P450; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pernin D, 1999, EUR J CANCER, V35, P1130, DOI 10.1016/S0959-8049(99)00059-3; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Siu WY, 2004, MOL CANCER THER, V3, P621; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stern N, 2002, J BIOL CHEM, V277, P602, DOI 10.1074/jbc.M106798200; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Watters DJ, 2003, REDOX REP, V8, P23, DOI 10.1179/135100003125001206; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Ye RQ, 2004, DNA REPAIR, V3, P235, DOI 10.1016/j.dnarep.2003.10.014; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yih LH, 2000, CANCER RES, V60, P6346; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	56	206	209	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53272	53281		10.1074/jbc.M406879200	http://dx.doi.org/10.1074/jbc.M406879200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15489221	hybrid			2022-12-27	WOS:000225680600058
J	Liu, XKK; Lin, X; Gaffen, SL				Liu, XKK; Lin, X; Gaffen, SL			Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTORS; ANTIGEN RECEPTOR; IN-VITRO; IL-17; FAMILY; CYTOKINE; EXPRESSION; KINASE	The biological activities of the inflammatory cytokine interleukin (IL)-17 have been widely studied. However, comparatively little is known about how IL-17 expression is controlled. Here, we examined the basis for transcriptional regulation of the human IL-17 gene. IL-17 secretion was induced in peripheral blood mononuclear cells following anti-CD3 cross-linking to activate the T cell receptor (TCR), and costimulatory signaling through CD28 strongly enhanced CD3-induced IL-17 production. To define cis-acting elements important for IL-17 gene regulation, we cloned 1.25 kb of genomic sequence upstream of the transcriptional start site. This putative promoter was active in Jurkat T cells following CD3 and CD28 cross-linking, and its activity was inhibited by cyclosporin A and MAPK inhibitors. The promoter was also active in Hut102 T cells, which we have shown to secrete IL-17 constitutively. Overexpression of nuclear factor of activated T cells (NFAT) or Ras enhanced IL-17 promoter activity, and studies in Jurkat lines deficient in specific TCR signaling pathways provided supporting evidence for a role for NFAT. To delineate the IL-17 minimal promoter, we created a series of 5' truncations and identified a region between -232 and -159 that was sufficient for inducible promoter activity. Interestingly, two NFAT sites were located within this region, which bound to NFATc1 and NFATc2 in nuclear extracts from Hut102 and Jurkat cells. Moreover, mutations of these sites dramatically reduced both specific DNA binding and reporter gene activity, and chromatin immunoprecipitation assays showed occupancy of NFAT at this region in vivo. Together, these data show that NFAT is the crucial sensor of TCR signaling in the IL-17 promoter.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gaffen, SL (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 36 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329, R01AI050848] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49329, AI50848] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aarvak T, 1999, J IMMUNOL, V162, P1246; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gaffen Sarah L., 1998, P73; Gaffen SL, 2004, CYTOKINE, V28, P109, DOI 10.1016/j.cyto.2004.06.010; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Ghilardi N, 2004, J IMMUNOL, V172, P2827, DOI 10.4049/jimmunol.172.5.2827; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang SH, 2004, ALLERGY ASTHMA PROC, V25, P17; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Johnson RB, 2004, J PERIODONTOL, V75, P37, DOI 10.1902/jop.2004.75.1.37; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Linden A, 2002, ALLERGY, V57, P769, DOI 10.1034/j.1398-9995.2002.02164.x; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luzza F, 2000, J IMMUNOL, V165, P5332, DOI 10.4049/jimmunol.165.9.5332; Mao C, 1996, ONCOGENE, V12, P863; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Oda T, 2003, ORAL MICROBIOL IMMUN, V18, P30, DOI 10.1034/j.1399-302X.2003.180105.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; SCHWARZENBERGER P, 2002, MOD ASPECTS IMMUNOBI, V2, P176; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Shin HCK, 1998, CYTOKINE, V10, P841, DOI 10.1006/cyto.1998.0375; Shin HCK, 1999, CYTOKINE, V11, P257, DOI 10.1006/cyto.1998.0433; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200; Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832	52	128	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52762	52771		10.1074/jbc.M405764200	http://dx.doi.org/10.1074/jbc.M405764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459204	hybrid			2022-12-27	WOS:000225493400123
J	Suresh, MV; Singh, SK; Agrawal, A				Suresh, MV; Singh, SK; Agrawal, A			Interaction of calcium-bound c-reactive protein with fibronectin is controlled by pH - In vivo implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE INFECTION; PHOSPHOCHOLINE-BINDING SITE; IMMUNOHISTOCHEMICAL EXPRESSION; 3-DIMENSIONAL STRUCTURE; COMPLEMENT ACTIVATION; INFLAMMATORY LESIONS; DIRECTED MUTAGENESIS; APOPTOTIC CELLS; MICE; PHOSPHORYLCHOLINE	C-reactive protein (CRP) binds with high affinity to fibronectin (Fn), a major component of the extracellular matrix (ECM), but at physiological pH the binding is inhibited by calcium ions (Ca2+). Because CRP circulates in the blood in Ca2+-bound form, the occurrence of CRP-Fn interactions in vivo has been doubtful. To define the basis of inhibition of CRP-Fn interaction by Ca2+ at pH 7.0, we hypothesized that Fn-binding site on CRP consisted of amino acids co-ordinating Ca2+. Site-directed mutagenesis of amino acids co-ordinating Ca2+ drastically decreased the binding of CRP to Fn, indicating that the Ca2+-binding site indeed formed the Fn-binding site. To determine the requirements for possible interaction between Ca2+-bound CRP and Fn, we investigated inhibition of CRP-Fn interaction by Ca2+ as a function of pH. Ca2+ did not inhibit binding of CRP to Fn at pH 6.5 and lower. The contrasting Fn binding properties of CRP at physiological and mildly acidic pH indicated that the interaction of Ca2+-bound CRP with Fn was controlled by pH. We conclude that the inhibition of binding of CRP to Fn by Ca2+ at pH 7.0 is a mechanism to prevent CRP-Fn interactions under normal conditions. CRP, in its Ca2+-bound state, is capable of binding Fn but only at the inflammatory sites and tumors with low pH. CRP, Fn, and the ECM all have been implicated in cancer. Taken together our data raise the possibility that CRP-Fn interactions may change the architecture of ECM to modify the development of tumors.	E Tennessee State Univ, James H Quillen Coll Med, Dept Pharm, Johnson City, TN 37614 USA	East Tennessee State University	Agrawal, A (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Pharm, POB 70577, Johnson City, TN 37614 USA.	agrawal@etsu.edu	madathilparambil, suresh/L-6791-2019		NHLBI NIH HHS [HL071233, R01 HL071233] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071233] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal A, 2002, J IMMUNOL, V169, P3217, DOI 10.4049/jimmunol.169.6.3217; AGRAWAL A, 1992, J BIOL CHEM, V267, P25352; Agrawal A, 1997, J IMMUNOL, V158, P345; BARNA BP, 1993, CANCER IMMUNOL IMMUN, V36, P171, DOI 10.1007/BF01741088; BERMAN MA, 1988, HUM PATHOL, V19, P784, DOI 10.1016/S0046-8177(88)80261-2; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; Black S, 2003, MOL IMMUNOL, V39, P1045, DOI 10.1016/S0161-5890(03)00031-2; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; DAVID L, 1994, CANCER, V73, P518, DOI 10.1002/1097-0142(19940201)73:3<518::AID-CNCR2820730305>3.0.CO;2-T; DEODHAR SD, 1982, CANCER RES, V42, P5084; DICAMELLI R, 1980, J IMMUNOL, V125, P1933; DUCLOS TW, 1981, CLIN EXP IMMUNOL, V43, P565; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; Hack CE, 1997, IMMUNOL TODAY, V18, P111, DOI 10.1016/S0167-5699(97)01002-5; Hirschfield GM, 2003, QJM-INT J MED, V96, P793, DOI 10.1093/qjmed/hcg134; HURLIMANN J, 1991, AM J SURG PATHOL, V15, P280, DOI 10.1097/00000478-199103000-00008; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; Kresl JJ, 1999, TUMOR BIOL, V20, P72, DOI 10.1159/000030050; KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Lee RT, 2002, J BIOL CHEM, V277, P225, DOI 10.1074/jbc.M106039200; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MIYAZAWA K, 1990, J IMMUNOL, V145, P650; Mold C, 2002, J IMMUNOL, V168, P6375, DOI 10.4049/jimmunol.168.12.6375; MORTENSEN RF, 1975, J EXP MED, V141, P821; MULLENIX MC, 1994, MOL IMMUNOL, V31, P615, DOI 10.1016/0161-5890(94)90169-4; Nozoe T, 2003, CANCER LETT, V192, P89, DOI 10.1016/S0304-3835(02)00630-4; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; POTEMPA LA, 1981, J IMMUNOL, V127, P1509; Ramadan MAM, 2002, ACTA CRYSTALLOGR D, V58, P992, DOI 10.1107/S0907444902005693; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SALONEN EM, 1984, J BIOL CHEM, V259, P1496; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Szalai AJ, 2003, ARTHRITIS RHEUM-US, V48, P1602, DOI 10.1002/art.11026; Tan MH, 2004, BLOOD, V104, P11, DOI 10.1182/blood-2003-09-3363; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; TSENG J, 1988, MOL IMMUNOL, V25, P679, DOI 10.1016/0161-5890(88)90103-4; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Wagner C, 2000, J MOL MED-JMM, V78, P337, DOI 10.1007/s001090000107; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; WOO P, 1985, J BIOL CHEM, V260, P3384; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; YOTHER J, 1982, J IMMUNOL, V128, P2374	48	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52552	52557		10.1074/jbc.M409054200	http://dx.doi.org/10.1074/jbc.M409054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456743	Green Accepted, hybrid			2022-12-27	WOS:000225493400101
J	Tai, SL; Boer, VM; Daran-Lapujade, P; Walsh, MC; de Winde, JH; Daran, JM; Pronk, JT				Tai, SL; Boer, VM; Daran-Lapujade, P; Walsh, MC; de Winde, JH; Daran, JM; Pronk, JT			Two-dimensional transcriptome analysis in chemostat cultures - Combinatorial effects of oxygen availability and macronutrient limitation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; HYPOXIC GENES; YEAST; GROWTH; CARBON; MICROARRAYS; GLUCOSE; FAMILY; ACID	Genome-wide analysis of transcriptional regulation is generally studied by determining sets of "signature transcripts" that are up- or down-regulated relative to a reference situation when a single culture parameter or genetic modification is changed. This approach is especially relevant for defining small subsets of transcripts for use in high throughput, cost-effective diagnostic analyses. However, this approach may overlook the simultaneous control of transcription by more than one environmental parameter. This study represents the first quantitative assessment of the impact of transcriptional cross-regulation by different environmental parameters. As a model, we compared the response of aerobic as well as anaerobic chemostat cultures of the yeast Saccharomyces cerevisiae to growth limitation by four different macronutrients ( carbon, nitrogen, phosphorus, and sulfur). The identity of the growth-limiting nutrient was shown to have a strong impact on the sets of transcripts that responded to oxygen availability and vice versa. We concluded that identification of reliable signature transcripts for specific environmental parameters can be obtained only by combining transcriptome data sets obtained under several sets of reference conditions. Furthermore, the two-dimensional approach to transcriptome analysis is a valuable new tool to study the interaction of different transcriptional regulation systems.	Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands; Heineken Tech Serv, Res & Dev, NL-2380 BB Zoeterwoude, Netherlands; DSM Life Sci, Div Bakery Ingredients, Technol Cluster, NL-2600 MA Delft, Netherlands	Delft University of Technology; Heineken; DSM NV	Daran, JM (corresponding author), Delft Univ Technol, Kluyver Lab Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.	j.m.daran@tnw.tudelft.nl	Tai, Siew L/E-6476-2016; de Winde, J.H./AAC-5520-2021; Daran, Jean-Marc/X-8787-2019	Tai, Siew L/0000-0002-2148-3115; de Winde, J.H./0000-0002-7999-9317; Daran, Jean-Marc/0000-0003-3136-8193; Daran-Lapujade, Pascale/0000-0002-4097-7831; Pronk, Jack/0000-0002-5617-4611				Abramova N, 2001, J BACTERIOL, V183, P2881, DOI 10.1128/JB.183.9.2881-2887.2001; Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; ANDREASEN AA, 1954, J CELL COMPAR PHYSL, V43, P271, DOI 10.1002/jcp.1030430303; ANDREASEN AA, 1953, J CELL COMPAR PHYSL, V41, P23, DOI 10.1002/jcp.1030410103; Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Boles E, 1997, J BACTERIOL, V179, P2987, DOI 10.1128/jb.179.9.2987-2993.1997; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cohen BD, 2001, NUCLEIC ACIDS RES, V29, P799, DOI 10.1093/nar/29.3.799; Daran-Lapujade P, 2004, J BIOL CHEM, V279, P9125, DOI 10.1074/jbc.M309578200; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dwight SS, 2004, BRIEF BIOINFORM, V5, P9, DOI 10.1093/bib/5.1.9; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Flick JS, 1998, GENETICS, V148, P33; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Higgins VJ, 2003, APPL ENVIRON MICROB, V69, P7535, DOI 10.1128/AEM.69.12.7535-7540.2003; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Homma T, 2003, CRYOBIOLOGY, V46, P230, DOI 10.1016/S0011-2240(03)00028-2; Jansen MLA, 2004, APPL ENVIRON MICROB, V70, P1956, DOI 10.1128/AEM.70.4.1956-1963.2004; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; LARSSON C, 1993, J BACTERIOL, V175, P4809, DOI 10.1128/JB.175.15.4809-4816.1993; Lau WTW, 2000, P NATL ACAD SCI USA, V97, P1107, DOI 10.1073/pnas.97.3.1107; Lelandais G, 2004, NUCLEIC ACIDS RES, V32, pD323, DOI 10.1093/nar/gkh135; Lodi T, 1999, MOL GEN GENET, V262, P623, DOI 10.1007/s004380051125; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Mewes HW, 2004, NUCLEIC ACIDS RES, V32, pD41, DOI 10.1093/nar/gkh092; MEYHACK B, 1982, EMBO J, V1, P675, DOI 10.1002/j.1460-2075.1982.tb01229.x; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Persson BL, 1998, BBA-BIOENERGETICS, V1365, P23, DOI 10.1016/S0005-2728(98)00037-1; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P3214, DOI 10.1128/AEM.55.12.3214-3220.1989; Quackenbush J, 2003, SCIENCE, V302, P240, DOI 10.1126/science.1090887; Regnacq M, 2001, MOL MICROBIOL, V40, P1085, DOI 10.1046/j.1365-2958.2001.02450.x; Rosenfeld E, 2003, YEAST, V20, P1115, DOI 10.1002/yea.1026; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Sandager L, 2000, BIOCHEM SOC T, V28, P700; Schmidt U, 2003, INT J BIOCHEM CELL B, V35, P119, DOI 10.1016/S1357-2725(02)00124-3; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; VENTER U, 1989, NUCLEIC ACIDS RES, V17, P1353, DOI 10.1093/nar/17.4.1353; VERDUYN C, 1990, J GEN MICROBIOL, V136, P395, DOI 10.1099/00221287-136-3-395; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; VISSER W, 1990, APPL ENVIRON MICROB, V56, P3785, DOI 10.1128/AEM.56.12.3785-3792.1990; Wilcox LJ, 2002, J BIOL CHEM, V277, P32466, DOI 10.1074/jbc.M204707200; Wu J, 2004, P NATL ACAD SCI USA, V101, P3148, DOI 10.1073/pnas.0308321100; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	69	110	113	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					437	447		10.1074/jbc.M410573200	http://dx.doi.org/10.1074/jbc.M410573200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15496405	hybrid, Green Published			2022-12-27	WOS:000226025100053
J	Sandler, B; Webb, P; Apriletti, JW; Huber, BR; Togashi, M; Lima, STC; Juric, S; Nilsson, S; Wagner, R; Fletterick, RJ; Baxter, JD				Sandler, B; Webb, P; Apriletti, JW; Huber, BR; Togashi, M; Lima, STC; Juric, S; Nilsson, S; Wagner, R; Fletterick, RJ; Baxter, JD			Thyroxine-thyroid hormone receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND BINDING DOMAIN; RETINOID-X-RECEPTOR; NUCLEAR RECEPTORS; L-TRIIODOTHYRONINE; MOLECULAR-BASIS; AFFINITY; ANALOGS; DESIGN; KIDNEY; ASSOCIATION	Thyroid hormone (TH) actions are mediated by nuclear receptors (TRs alpha and beta) that bind triiodothyronine (T-3, 3,5,3'-triiodo-L-thyronine) with high affinity, and its precursor thyroxine (T-4, 3,5,3',5'-tetraiodo-L-thyronine) with lower affinity. T-4 contains a bulky 5' iodine group absent from T-3. Because T-3 is buried in the core of the ligand binding domain (LBD), we have predicted that TH analogues with 5' substituents should fit poorly into the ligand binding pocket and perhaps behave as antagonists. We therefore examined how T-4 affects TR activity and conformation. We obtained several lines of evidence (ligand dissociation kinetics, migration on hydrophobic interaction columns, and non-denaturing gels) that TR-T-4 complexes adopt a conformation that differs from TR-T-3 complexes in solution. Nonetheless, T-4 behaves as an agonist in vitro (in effects on coregulator and DNA binding) and in cells, when conversion to T-3 does not contribute to agonist activity. We determined x-ray crystal structures of the TRbetaLBD in complex with T-3 and T-4 at 2.5-Angstrom and 3.1-Angstrom resolution. Comparison of the structures reveals that TRbeta accommodates T-4 through subtle alterations in the loop connecting helices 11 and 12 and amino acid side chains in the pocket, which, together, enlarge a niche that permits helix 12 to pack over the 5' iodine and complete the coactivator binding surface. While T-3 is the major active TH, our results suggest that T-4 could activate nuclear TRs at appropriate concentrations. The ability of TR to adapt to the 5' extension should be considered in TR ligand design.	Univ Calif San Francisco, Sch Med, Metab Res Unit, San Francisco, CA 94122 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94122 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94122 USA; KaroBio AB, Novum, S-14157 Huddinge, Sweden	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Karolinska Institutet	Baxter, JD (corresponding author), Univ Calif San Francisco, Sch Med, Metab Res Unit, HSW1210,513 Parnassus Ave, San Francisco, CA 94122 USA.	Jbaxter918@aol.com	Togashi, Marie/L-3092-2018	Togashi, Marie/0000-0002-0886-8766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064148, P01DK058390, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58390, DK 64148, DK 41842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1981, J BIOL CHEM, V256, P2094; APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; Baxter JD, 2002, ENDOCRINOLOGY, V143, P517, DOI 10.1210/en.143.2.517; Borngraeber S, 2003, P NATL ACAD SCI USA, V100, P15358, DOI 10.1073/pnas.2136689100; BRAVERMAN LE, 2000, WERNERS INGBARS THYR; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chiellini G, 2002, BIOORGAN MED CHEM, V10, P333, DOI 10.1016/S0968-0896(01)00284-X; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Davis PJ, 2002, J ENDOCRINOL INVEST, V25, P377, DOI 10.1007/BF03344022; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Glass CK, 2000, GENE DEV, V14, P121; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; ICHIKAWA K, 1986, METABOLISM, V35, P861, DOI 10.1016/0026-0495(86)90229-5; Kohrle J, 1999, MOL CELL ENDOCRINOL, V151, P103, DOI 10.1016/S0303-7207(99)00040-4; Nguyen NH, 2002, J MED CHEM, V45, P3310, DOI 10.1021/jm0201013; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; SAMUELS HH, 1979, J CLIN INVEST, V63, P1229, DOI 10.1172/JCI109418; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SILVA JE, 1978, J CLIN INVEST, V61, P1247, DOI 10.1172/JCI109041; SURKS MI, 1977, J CLIN INVEST, V60, P555, DOI 10.1172/JCI108807; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; Watkins RE, 2003, BIOCHEMISTRY-US, V42, P1430, DOI 10.1021/bi0268753; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Webb P, 2002, J STEROID BIOCHEM, V83, P59, DOI 10.1016/S0960-0760(02)00270-4; Ye L, 2003, J MED CHEM, V46, P1580, DOI 10.1021/jm021080f; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	38	94	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55801	55808		10.1074/jbc.M410124200	http://dx.doi.org/10.1074/jbc.M410124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15466465	Green Published, hybrid			2022-12-27	WOS:000225960800102
J	Gorbea, C; Goellner, GM; Teter, K; Holmes, RK; Rechsteiner, M				Gorbea, C; Goellner, GM; Teter, K; Holmes, RK; Rechsteiner, M			Characterization of mammalian ecm29, a 26 S proteasome-associated protein that localizes to the nucleus and membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; CHO-CELLS RESISTANT; VHS DOMAIN; INTRACELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; DENDRITIC CELLS; CHOLERA-TOXIN; UBIQUITIN; ENDOCYTOSIS; RECEPTOR	In addition to its thirty or so core subunits, a number of accessory proteins associate with the 26 S proteasome presumably to assist in substrate degradation or to localize the enzyme within cells. Among these proteins is ecm29p, a 200-kDa yeast protein that contains numerous HEAT repeats as well as a putative VHS domain. Higher eukaryotes possess a well conserved homolog of yeast ecm29p, and we produced antibodies to three peptides in the human Ecm29 sequence. The antibodies show that Ecm29 is present exclusively on 26 S proteasomes in HeLa cells and that Ecm29 levels vary markedly among mouse organs. Confocal immunofluorescence microscopy localizes Ecm29 to the centrosome and a subset of secretory compartments including endosomes, the ER and the ERGIC. Ecm29 is up-regulated 2-3-fold in toxin-resistant mutant CHO cells exhibiting increased rates of ER-associated degradation. Based on these results we propose that Ecm29 serves to couple the 26 S proteasome to secretory compartments engaged in quality control and to other sites of enhanced proteolysis.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Utah System of Higher Education; University of Utah; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Rechsteiner, M (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	marty@biochem.utah.edu	Gorbea, Carlos/L-4406-2019	Teter, Ken/0000-0003-4176-9361	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM039007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043022] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39007] Funding Source: Medline; NINDS NIH HHS [F32NS43022-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Benmerah A, 2004, CURR BIOL, V14, pR314, DOI 10.1016/j.cub.2004.03.053; Benmerah A, 2003, TRAFFIC, V4, P503, DOI 10.1034/j.1600-0854.2003.00102.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Dong JB, 2004, J BIOL CHEM, V279, P21334, DOI 10.1074/jbc.M401022200; Ehlers MD, 2003, SCIENCE, V302, P800, DOI 10.1126/science.1092546; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glickman MH, 2004, PLOS BIOL, V2, P25, DOI 10.1371/journal.pbio.0020013; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hauri HP, 2002, BIOCHEM SOC SYMP, V69, P73; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Kajava AV, 2004, J STRUCT BIOL, V146, P425, DOI 10.1016/j.jsb.2004.01.013; Kobe B, 1999, STRUCTURE, V7, pR91, DOI 10.1016/S0969-2126(99)80060-4; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lohi O, 2002, FEBS LETT, V513, P19, DOI 10.1016/S0014-5793(01)03287-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MAKAROW M, 1985, EMBO J, V4, P1861, DOI 10.1002/j.1460-2075.1985.tb03861.x; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Moron VG, 2003, J IMMUNOL, V171, P2242, DOI 10.4049/jimmunol.171.5.2242; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Patrick GN, 2003, CURR BIOL, V13, P2073, DOI 10.1016/j.cub.2003.10.028; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; PRESCOTT DM, 1972, EXP CELL RES, V71, P480, DOI 10.1016/0014-4827(72)90322-9; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; RECHSTEINER M, 1974, J CELL PHYSIOL, V84, P409, DOI 10.1002/jcp.1040840309; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Tarlac V, 2003, J NEUROSCI RES, V74, P406, DOI 10.1002/jnr.10746; Teter K, 2003, TRAFFIC, V4, P232, DOI 10.1034/j.1600-0854.2003.00070.x; Teter K, 2002, INFECT IMMUN, V70, P6172, DOI 10.1128/IAI.70.11.6172-6179.2002; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Ulrich HD, 2002, CURR TOP MICROBIOL, V268, P137; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev; You JX, 2003, J BIOL CHEM, V278, P23369, DOI 10.1074/jbc.M212887200; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	76	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54849	54861		10.1074/jbc.M410444200	http://dx.doi.org/10.1074/jbc.M410444200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496406	hybrid			2022-12-27	WOS:000225793600114
J	Lee, YN; Malbon, CC; Wang, HY				Lee, YN; Malbon, CC; Wang, HY			G alpha 13 signals via p115RhoGEF cascades regulating JNK1 and primitive endoderm formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; EMBRYONAL CARCINOMA-CELLS; HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; GTPASE-ACTIVATING PROTEIN; FAMILY TYROSINE KINASE; RETINOIC ACID; RHO-GTPASES; G-ALPHA; EXCHANGE FACTORS	The heterotrimeric G-protein G(13) mediates the formation of primitive endoderm from mouse P19 embryonal carcinoma cells in response to retinoic acid, signaling to the level of activation of c-Jun N-terminal kinase. The signal linkage map from MEKK1/MEKK4 to MEK1/MKK4 to JNK is obligate in this Galpha(13)-mediated pathway, whereas that between Galpha(13) and MEKKs is not known. The overall pathway to primitive endoderm formation was shown to be inhibited by treatment with Clostridium botulinum C3 exotoxin, a specific inactivator of RhoA family members. Constitutively active Galpha(13) was found to activate RhoA as well as Cdc42 and Rac1 in these cells. Although constitutively active Cdc42, Rac1, and RhoA all can activate JNK1, only the RhoA mutant was able to promote formation of primitive endoderm, mimicking expression of the constitutively activated Galpha(13). Expression of the constitutively active mutant form of p115RhoGEF ( guanine nucleotide exchange factor) was found to activate RhoA and JNK1 activities. Expression of the dominant negative p115RhoGEF was able to inhibit activation of both RhoA and JNK1 in response to either retinoic acid or the expression of a constitutively activated mutant of Galpha(13). Expression of the dominant negative mutants of RhoA as well as those of either Cdc42 or Rac1, but not Ras, attenuated Galpha(13)-stimulated as well as retinoic acid-stimulated activation of all three of these small molecular weight GTPases, suggesting complex interrelationships among the three GTPases in this pathway. The formation of primitive endoderm in response to retinoic acid also could be blocked by expression of dominant negative mutants of RhoA, Cdc42, or Rac1. Thus, the signal propagated from Galpha(13) to JNK requires activation of p115RhoGEF cascades, including p115RhoGEF itself, RhoA, Cdc42, and Rac1. In a concerted effort, RhoA in tandem with Cdc42 and Rac1 activates the MEKK1/4, MEK1/MKK4, and JNK cascade, thereby stimulating formation of primitive endoderm.	SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA.	wangh@pharm.sunysb.edu	malbon, craig/ABF-3604-2020					Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Cadigan Ken M., 2002, Trends in Genetics, V18, P340, DOI 10.1016/S0168-9525(02)02707-5; Christerson LB, 2002, J CELL PHYSIOL, V192, P200, DOI 10.1002/jcp.10125; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gallagher ED, 2004, J BIOL CHEM, V279, P1872, DOI 10.1074/jbc.M309525200; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KANUNGO J, 2000, J BIOL CHEM; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Le Page SL, 2003, AM J PHYSIOL-CELL PH, V285, pC1197, DOI 10.1152/ajpcell.00083.2003; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Malbon CC, 1997, BIOCHEM PHARMACOL, V53, P1, DOI 10.1016/S0006-2952(96)00662-4; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; McGrew L, 2002, MOL PHARMACOL, V62, P1339, DOI 10.1124/mol.62.6.1339; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Rattan S, 2003, EXP BIOL MED, V228, P972, DOI 10.1177/153537020322800814; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sayas CL, 2002, J NEUROSCI, V22, P6863; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; van Triest Miranda, 2004, Methods Mol Biol, V250, P97; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	62	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54896	54904		10.1074/jbc.M407581200	http://dx.doi.org/10.1074/jbc.M407581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492006	hybrid			2022-12-27	WOS:000225793600119
J	Mahrus, S; Kisiel, W; Craik, CS				Mahrus, S; Kisiel, W; Craik, CS			Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENDED SUBSTRATE-SPECIFICITY; SERINE-PROTEASE; MEDIATED CYTOTOXICITY; PROTEINASE-INHIBITORS; CLONING; PURIFICATION; EXPRESSION; SUPERFAMILY; LYMPHOCYTES; MET-ASE-1	Granzyme M is a trypsin-fold serine protease that is specifically found in the granules of natural killer cells. This enzyme has been implicated recently in the induction of target cell death by cytotoxic lymphocytes, but unlike granzymes A and B, the molecular mechanism of action of granzyme M is unknown. We have characterized the extended substrate specificity of human granzyme M by using purified recombinant enzyme, several positional scanning libraries of coumarin substrates, and a panel of individual p-nitroanilide and coumarin substrates. In contrast to previous studies conducted using thiobenzyl ester substrates (Smyth, M. J., O'Connor, M. D., Trapani, J. A., Kershaw, M. H., and Brinkworth, R. I. ( 1996) J. Immunol. 156, 4174-4181), a strong preference for leucine at P1 over methionine was demonstrated. The extended substrate specificity was determined to be lysine = norleucine at P4, broad at P3, proline > alanine at P2, and leucine > norleucine > methionine at P1. The enzyme activity was found to be highly dependent on the length and sequence of substrates, indicative of a regulatory function for human granzyme M. Finally, the interaction between granzyme M and the serpins alpha(1)-antichymotrypsin, alpha(1)-proteinase inhibitor, and proteinase inhibitor 9 was characterized by using a candidate-based approach to identify potential endogenous inhibitors. Proteinase inhibitor 9 was effectively hydrolyzed and inactivated by human granzyme M, raising the possibility that this orphan granzyme bypasses proteinase inhibitor 9 inhibition of granzyme B.	Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of New Mexico; University of New Mexico's Health Sciences Center; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA.	craik@cgl.ucsf.edu			NCI NIH HHS [CA 72006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Dahlen JR, 1999, BBA-MOL CELL RES, V1451, P233, DOI 10.1016/S0167-4889(99)00095-6; Dauber DS, 2002, J VIROL, V76, P1359, DOI 10.1128/JVI.76.3.1359-1368.2002; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Kelly JM, 2004, J BIOL CHEM, V279, P22236, DOI 10.1074/jbc.M401670200; Kelly JM, 1996, IMMUNOGENETICS, V44, P340, DOI 10.1007/BF02602778; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; POE M, 1991, J BIOL CHEM, V266, P98; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sayers TJ, 2001, J IMMUNOL, V166, P765, DOI 10.4049/jimmunol.166.2.765; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; Smyth MJ, 1996, J IMMUNOL, V156, P4174; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; Sun J, 2001, J BIOL CHEM, V276, P15177, DOI 10.1074/jbc.M006645200; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Volanakis JE, 1996, PROTEIN SCI, V5, P553; Wilharm E, 1999, J BIOL CHEM, V274, P27331, DOI 10.1074/jbc.274.38.27331; WOODARD SL, 1994, J IMMUNOL, V153, P5016	34	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54275	54282		10.1074/jbc.M411482200	http://dx.doi.org/10.1074/jbc.M411482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494398	hybrid			2022-12-27	WOS:000225793600048
J	Shepherd, EG; Zhao, Q; Welty, SE; Hansen, TN; Smith, CV; Liu, YS				Shepherd, EG; Zhao, Q; Welty, SE; Hansen, TN; Smith, CV; Liu, YS			The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; SIGNAL-TRANSDUCTION PATHWAY; B STREPTOCOCCAL DISEASE; AU-RICH ELEMENTS; LIPOTEICHOIC ACID; MAP KINASE; FACTOR-ALPHA; CYTOKINE BIOSYNTHESIS; INNATE IMMUNITY	Mitogen- activated protein (MAP) kinases play a pivotal role in the macrophages in the production of proinflammatory cytokines triggered by lipopolysaccharides. However, their function in the responses of macrophages to Gram-positive bacteria is poorly understood. Even less is known about the attenuation of MAP kinase signaling in macrophages exposed to Gram-positive bacteria. In the present study, we have investigated the regulation of MAP kinases and the role of MAP kinase phosphatase (MKP)-1 in the production of proinflammatory cytokines using murine RAW264.7 and primary peritoneal macrophages after peptidoglycan stimulation. Treatment of macrophages with peptidoglycan resulted in a transient activation of JNK, p38, and extracellular signal-regulated kinase. Most interestingly, MKP-1 expression was potently induced by peptidoglycan, and this induction was concurrent with MAP kinase dephosphorylation. Triptolide, a diterpenoid triepoxide, potently blocked the induction of MKP-1 by peptidoglycan and prolonged the activation of JNK and p38. Overexpression of MKP-1 substantially attenuated the production of tumor necrosis factor (TNF)-alpha induced by peptidoglycan, whereas knockdown of MKP-1 by small interfering RNA substantially increased the production of both TNF-alpha and interleukin-1beta. Finally, we found that in primary murine peritoneal macrophages, MKP-1 induction following peptidoglycan stimulation also coincided with inactivation of JNK and p38. Blockade of MKP-1 induction resulted in a sustained activation of both JNK and p38 in primary macrophages. Our results reveal that MKP-1 critically regulates the expression of TNF-alpha and interleukin-1beta in RAW264.7 cells and further suggest a central role for this phosphatase in controlling the inflammatory responses of primary macrophages to Gram-positive bacterial infection.	Ohio State Univ, Childrens Hosp, Ctr Dev Pharmacol & Toxicol, Childrens Res Inst,Dept Pediat, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	Liu, YS (corresponding author), Ohio State Univ, Childrens Hosp, Ctr Dev Pharmacol & Toxicol, Childrens Res Inst,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	liuy@pediatrics.ohio-state.edu	Shepherd, Edward/E-4080-2011; Welty, Stephen/AAZ-4307-2021; Welty, Stephen/AGS-7454-2022; Liu, Yusen/E-3527-2011	Welty, Stephen/0000-0002-6321-8440; Liu, Yusen/0000-0002-0994-0109	NIAID NIH HHS [AI57798] Funding Source: Medline; NICHD NIH HHS [HD43003] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057798, R21AI057798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1995, J CARDIOVASC PHAR S2, V25, P1; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canton R, 2003, CURR OPIN INFECT DIS, V16, P315, DOI 10.1097/00001432-200308000-00003; Carl VS, 2002, J BIOL CHEM, V277, P17448, DOI 10.1074/jbc.M111847200; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; Chen PL, 2002, PROTEIN EXPRES PURIF, V24, P481, DOI 10.1006/prep.2001.1599; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DINARELLO CA, 1997, CHEST S, V112, P321, DOI DOI 10.1378/CHEST.112.6_SUPPLEMENT.321S; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; FOSTER KD, 1992, AM J PHYSIOL, V262, P211; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gao JJ, 2001, INFECT IMMUN, V69, P751, DOI 10.1128/IAI.69.2.751-757.2001; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; Handel-Fernandez ME, 2000, MACROPHAGES PRACTICA, P1; Hoffman JA, 2003, PEDIATRICS, V112, P1095, DOI 10.1542/peds.112.5.1095; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Hutter D, 2000, J GERONTOL A-BIOL, V55, pB125, DOI 10.1093/gerona/55.3.B125; Kengatharan KM, 1998, J EXP MED, V188, P305, DOI 10.1084/jem.188.2.305; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Nagahira A, 2001, BIOCHEM BIOPH RES CO, V281, P1030, DOI 10.1006/bbrc.2001.4476; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pearlman M, 2003, OBSTET GYNECOL, V102, P414, DOI 10.1016/S0029-7844(03)00583-0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Vieillard-Baron A, 2003, AM J RESP CRIT CARE, V168, P1270, DOI 10.1164/rccm.200306-816CC; Wang JE, 2004, CRIT CARE MED, V32, P546, DOI 10.1097/01.CCM.0000109775.22138.8F; Wang JE, 2000, INFECT IMMUN, V68, P3965, DOI 10.1128/IAI.68.7.3965-3970.2000; Weber SM, 2002, J IMMUNOL, V168, P5303, DOI 10.4049/jimmunol.168.10.5303	68	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54023	54031		10.1074/jbc.M408444200	http://dx.doi.org/10.1074/jbc.M408444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485842	hybrid			2022-12-27	WOS:000225793600018
J	Bannai, H; Fukatsu, K; Mizutani, A; Natsume, T; Iemura, S; Ikegami, T; Inouie, T; Mikoshiba, K				Bannai, H; Fukatsu, K; Mizutani, A; Natsume, T; Iemura, S; Ikegami, T; Inouie, T; Mikoshiba, K			An RNA-interacting protein, SYNCRIP (heterogeneous nuclear ribonuclear protein Q1/NSAP1) is a component of mRNA granule transported with inositol 1,4,5-trisphosphate receptor type 1 mRNA in neuronal dendrites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SOMATODENDRITIC DOMAIN; SYNAPTIC PLASTICITY; FLUORESCENT PROTEIN; LOCALIZATION; STAUFEN; INSULIN; IDENTIFICATION; TRANSLATION; ASSOCIATION	mRNA transport and local translation in the neuronal dendrite is implicated in the induction of synaptic plasticity. Recently, we cloned an RNA-interacting protein, SYNCRIP ( heterogeneous nuclear ribonuclear protein Q1/NSAP1), that is suggested to be important for the stabilization of mRNA. We report here that SYNCRIP is a component of mRNA granules in rat hippocampal neurons. SYNCRIP was mainly found at cell bodies, but punctate expression patterns in the proximal dendrite were also seen. Time-lapse analysis in living neurons revealed that the granules labeled with fluorescent protein-tagged SYNCRIP were transported bi-directionally within the dendrite at similar to0.05 mum/s. Treatment of neurons with nocodazole significantly inhibited the movement of green fluorescent protein-SYNCRIP-positive granules, indicating that the transport of SYNCRIP-containing granules is dependent on microtubules. The distribution of SYN-CRIP-containing granules overlapped with that of dendritic RNAs and elongation factor 1alpha. SYNCRIP was also found to be co-transported with green fluorescent protein-tagged human staufen1 and the 3'-untranslated region of inositol 1,4,5-trisphosphate receptor type 1 mRNA. These results suggest that SYNCRIP is transported within the dendrite as a component of mRNA granules and raise the possibility that mRNA turnover in mRNA granules and the regulation of local protein synthesis in neuronal dendrites may involve SYNCRIP.	RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Neural Signal Informat,NTT IMSUT, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan	RIKEN; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST)	Inouie, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tinoue@ims.u-tokyo.ac.jp	Bannai, Hiroko/I-7130-2014; Natsume, Tohru/M-7627-2018; Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Mizutani, Akihiro/GPS-4809-2022	Bannai, Hiroko/0000-0002-0951-488X; Natsume, Tohru/0000-0002-1510-2582; Inoue, Takafumi/0000-0002-2728-0060; Mizutani, Akihiro/0000-0003-4155-802X				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; Bagni C, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0004.2000; Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Duchaine TF, 2002, J CELL SCI, V115, P3285; Feng Y, 1997, J NEUROSCI, V17, P1539; Fujii S, 2000, LEARN MEMORY, V7, P312, DOI 10.1101/lm.34100; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Harris CE, 1999, J VIROL, V73, P72, DOI 10.1128/JVI.73.1.72-80.1999; Higgins D., 1998, CULTURING NERVE CELL, P37; HILL JM, 1986, NEUROSCIENCE, V17, P1127, DOI 10.1016/0306-4522(86)90082-5; Hinsby AM, 2003, MOL CELL PROTEOMICS, V2, P29, DOI 10.1074/mcp.M200075-MCP200; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; Hresko RC, 2002, J BIOL CHEM, V277, P25233, DOI 10.1074/jbc.M202556200; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Job C, 2001, P NATL ACAD SCI USA, V98, P13037, DOI 10.1073/pnas.231485698; Kacharmina JE, 2000, P NATL ACAD SCI USA, V97, P11545, DOI 10.1073/pnas.97.21.11545; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Kuhl D, 1998, CURR OPIN NEUROBIOL, V8, P600, DOI 10.1016/S0959-4388(98)80087-1; Lin SD, 1998, J BIOMED SCI, V5, P111, DOI 10.1159/000025320; Mallardo M, 2003, P NATL ACAD SCI USA, V100, P2100, DOI 10.1073/pnas.0334355100; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Racca C, 1997, J NEUROSCI, V17, P1691; Rook MS, 2000, J NEUROSCI, V20, P6385, DOI 10.1523/JNEUROSCI.20-17-06385.2000; Severt WL, 1999, J CELL SCI, V112, P3691; Shan JG, 2003, J NEUROSCI, V23, P8859; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Tiedge H, 1999, SCIENCE, V283, P186, DOI 10.1126/science.283.5399.186; Tiedge H, 1996, J NEUROSCI, V16, P7171; Tiruchinapalli DM, 2003, J NEUROSCI, V23, P3251; Torre ER, 1996, J NEUROSCI, V16, P5967; Wanner I, 1997, HISTOCHEM CELL BIOL, V108, P345, DOI 10.1007/s004180050175; WOZNIAK M, 1993, NEUROCHEM INT, V22, P1, DOI 10.1016/0197-0186(93)90062-A; Yanagida M, 2004, J BIOL CHEM, V279, P1607, DOI 10.1074/jbc.M305604200; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	56	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53427	53434		10.1074/jbc.M409732200	http://dx.doi.org/10.1074/jbc.M409732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475564	hybrid			2022-12-27	WOS:000225680600076
J	Martin-Clemente, B; Alvarez-Castelao, B; Mayo, I; Sierra, AB; Diaz, V; Milan, M; Farinas, I; Gomez-Isla, T; Ferrer, I; Castano, JG				Martin-Clemente, B; Alvarez-Castelao, B; Mayo, I; Sierra, AB; Diaz, V; Milan, M; Farinas, I; Gomez-Isla, T; Ferrer, I; Castano, JG			alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; LEWY BODIES; MULTICATALYTIC PROTEINASE; SUBSTANTIA-NIGRA; MUTANT; INHIBITION; INCLUSIONS; DEMENTIA; SYSTEM; ACCUMULATION	alpha-Synuclein (alpha-syn) is a small protein of unknown function that is found aggregated in Lewy bodies, the histopathological hallmark of sporadic Parkinson disease and other synucleinopathies. Mutations in the alpha-syn gene and a triplication of its gene locus have been identified in early onset familial Parkinson disease. alpha-Syn turnover can be mediated by the proteasome pathway. A survey of published data may lead to the suggestion that overexpression of alpha-syn wild type, and/or their variants (A53T and A30P), may produce a decrease in proteasome activity and function, contributing to alpha-syn aggregation. To investigate the relationship between synuclein expression and proteasome function we have studied proteasome peptidase activities and proteasome subunit expression (alpha, beta-constitutive, and inducible) in mice either lacking alpha-syn (knockout mice) or transgenic for human alpha-syn A30P (under control of PrP promoter, at a time when no clear gliosis can be observed). Similar studies are presented in PC12 cells overexpressing enhanced yellow fluorescent protein fusion constructs of human wild type, A30P, and A53T alpha-syn. In these cell lines we have also analyzed the assembly of 20 S proteasome complex and the degradation rate of a well known substrate of the proteasome pathway, Ikappabalpha. Overall the data obtained led us to the conclusion that alpha-synuclein expression levels by themselves have no significant effect on proteasome peptidase activity, subunit expression, and proteasome complex assembly and function. These results strengthen the suggestion that other mechanisms resulting in synuclein aggregation ( not simply expression levels) may be the key to understand the possible effect of aggregated synuclein on proteasome function.	Univ Autonoma Madrid, Consejo Super Invest Cient, Fac Med UAM, Dept Bioquim, Madrid 28029, Spain; Univ Autonoma Madrid, Consejo Super Invest Cient, Fac Med UAM, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Valencia, Fac Biol, Dept Biol Celular, Valencia 46100, Spain; Univ Navarra Clin, Dept Neurociencias, Pamplona 31008, Spain; Hosp Univ Bellvitge, Serv Anat Patol, Inst Neuropatol, Lhospitalet De Llobregat 08907, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Valencia; University of Navarra; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital	Castano, JG (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Fac Med UAM, Dept Bioquim, Madrid 28029, Spain.	joseg.castano@uam.es	alvarez-castelao, beatriz/W-1707-2018; Mayo, Isabel Cantón/AAB-2429-2019; Alvarez-castelao, Beatriz/ABG-8826-2021; Farinas, Isabel/L-7118-2014	alvarez-castelao, beatriz/0000-0001-7505-1855; Mayo, Isabel Cantón/0000-0002-9757-8233; Farinas, Isabel/0000-0003-2903-4960; G. Castano, Jose/0000-0002-6579-8442				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIBAS J, 1994, J BIOL CHEM, V269, P12858; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dawson VL, 2000, SCIENCE, V288, P631, DOI 10.1126/science.288.5466.631; Foltynie T, 2002, J NEUROL, V249, P138, DOI 10.1007/PL00007856; Gomez-Isla T, 2003, NEUROBIOL AGING, V24, P245, DOI 10.1016/S0197-4580(02)00091-X; Gomez-Tortosa E, 2000, ANN NY ACAD SCI, V920, P9; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Kingsbury AE, 2004, MOVEMENT DISORD, V19, P162, DOI 10.1002/mds.10683; Lehmensiek V, 2002, NEUROREPORT, V13, P1279, DOI 10.1097/00001756-200207190-00013; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rodriguez-Vilarino S, 2000, J BIOL CHEM, V275, P6592, DOI 10.1074/jbc.275.9.6592; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Takeda A, 1998, AM J PATHOL, V152, P367; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	40	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52984	52990		10.1074/jbc.M409028200	http://dx.doi.org/10.1074/jbc.M409028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466467	Green Published, hybrid			2022-12-27	WOS:000225680600023
J	Petrosillo, G; Ruggiero, FM; Pistolese, M; Paradies, G				Petrosillo, G; Ruggiero, FM; Pistolese, M; Paradies, G			Ca2+-induced reactive oxygen species production promotes cytochrome c release from rat liver mitochondria via mitochondrial permeability transition (MPT)-dependent and MPT-independent mechanisms - Role of cardiolipin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART SUBMITOCHONDRIAL PARTICLES; CELL-DEATH; OXIDATIVE STRESS; BRAIN MITOCHONDRIA; RESPIRATORY-CHAIN; HYDROGEN-PEROXIDE; APOPTOSIS; CALCIUM; MEMBRANE; PORE	Release of cytochrome c from mitochondria is considered a critical, early event in the induction of an apoptosis cascade that ultimately leads to programmed cell death. Mitochondrial Ca2+ loading is a trigger for the release of cytochrome c, although the molecular mechanism underlying this effect is not fully clarified. This study tested the hypothesis that distinct Ca2+ thresholds may induce cytochrome c release from rat liver mitochondria by membrane permeability transition (MPT)-dependent and independent mechanisms. The involvement of reactive oxygen species (ROS) and cardiolipin in the Ca2+-induced cytochrome c release was also investigated. Cytochrome c was quantitated by a new, very sensitive, and rapid reverse-phase high performance liquid chromatography method with a detection limit of 0.1 pmol/sample. We found that a low extramitochondrial Ca2+ level (2 muM) promoted the release of similar to13% of the total alamethicin releasable pool of cytochrome c from mitochondria. This release was not depending of MPT; it was mediated by Ca2+-induced ROS production and cardiolipin peroxidation and appears to involve the voltage-dependent anion channel. High extramitochondrial Ca2+ level (20 muM) promoted similar to45% of the total releasable pool of cytochrome c. This process was MPT-dependent and was also mediated by ROS and cardiolipin. It is suggested that distinct Ca2+ levels may determine the mode and the amount of cytochrome c release from rat liver mitochondria. The data may help to clarify the molecular mechanism underlying the Ca2+-induced release of cytochrome c from rat liver mitochondria and the role played by ROS and cardiolipin in this process.	Univ Bari, Dept Biochem & Mol Biol, I-70126 Bari, Italy; Univ Bari, CNR, Inst Biomembranes & Bioenerget, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Via E Orabona 4, I-70126 Bari, Italy.	g.paradies@biologia.uniba.it		PETROSILLO, GIUSEPPE/0000-0001-8035-8368				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buege J A, 1978, Methods Enzymol, V52, P302; Colell A, 2004, FEBS LETT, V560, P63, DOI 10.1016/S0014-5793(04)00071-7; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crouser ED, 2003, ANAL BIOCHEM, V317, P67, DOI 10.1016/S0003-2697(03)00044-7; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Esposti MD, 2004, BIOCHEM SOC T, V32, P493; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; FLEURY C, 2003, FBIOCHIMIE PARIS, V84, P131; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kanno T, 2004, FREE RADICAL RES, V38, P27, DOI 10.1080/10715760310001626266; KAUPPINEN RA, 1984, AM J PHYSIOL, V247, pH508, DOI 10.1152/ajpheart.1984.247.4.H508; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MCMILLIN JB, 2002, BIOCHIM BIOPHYS ACTA, V158, P97; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Picklo MJ, 1999, ANAL BIOCHEM, V276, P166, DOI 10.1006/abio.1999.4349; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Schild L, 2001, FASEB J, V15, P565; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; THOMAS WE, 1987, BIOCHEM J, V247, P315, DOI 10.1042/bj2470315; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200	55	134	142	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53103	53108		10.1074/jbc.M407500200	http://dx.doi.org/10.1074/jbc.M407500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475362	hybrid			2022-12-27	WOS:000225680600038
J	Roebroek, AJM; Taylor, NA; Louagie, E; Pauli, I; Smeijers, L; Snellinx, A; Lauwers, A; Van de Ven, WJM; Hartmann, D; Creemers, JWM				Roebroek, AJM; Taylor, NA; Louagie, E; Pauli, I; Smeijers, L; Snellinx, A; Lauwers, A; Van de Ven, WJM; Hartmann, D; Creemers, JWM			Limited redundancy of the proprotein convertase furin in mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; IN-VIVO; PROHORMONE CONVERTASES; INSULIN-RECEPTOR; PROCESSING SITE; MICE DEFICIENT; CELL STRAIN; PRECURSOR; CLEAVAGE; EXPRESSION	Furin is an endoprotease of the family of mammalian proprotein convertases and is involved in the activation of a large variety of regulatory proteins by cleavage at basic motifs. A large number of substrates have been attributed to furin on the basis of in vitro and ex vivo data. However, no physiological substrates have been confirmed directly in a mammalian model system, and early embryonic lethality of a furin knock-out mouse model has precluded in vivo verification of most candidate substrates. Here, we report the generation and characterization of an interferon inducible Mx-Cre/loxP furin knock-out mouse model. Induction resulted in near-complete ablation of the floxed fur exon in liver. In sharp contrast with the general furin knock-out mouse model, no obvious adverse effects were observed in the transgenic mice after induction. Histological analysis of the liver did not reveal any overt deviations from normal morphology. Analysis of candidate substrates in liver revealed complete redundancy for the processing of the insulin receptor. Variable degrees of redundancy were observed for the processing of albumin, alpha(5) integrin, lipoprotein receptor-related protein, vitronectin and alpha(1)-microglobulin/bikunin. None of the tested substrates displayed a complete block of processing. The absence of a severe phenotype raises the possibility of using furin as a local therapeutic target in the treatment of pathologies like cancer and viral infections, although the observed redundancy may require combination therapy or the development of a more broad spectrum convertase inhibitor.	Katholieke Univ Leuven VIB, Dept Human Genet, Mol Cell Biol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Neuronal Cell Biol, Dept Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Mol Oncol Lab, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven	Creemers, JWM (corresponding author), Katholieke Univ Leuven VIB, Dept Human Genet, Mol Cell Biol Lab, Gasthuisberg O-N 6,Box 602,Herestr 49, B-3000 Louvain, Belgium.	john.creemers@med.kuleuven.ac.be						Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; BRATT T, 1994, FEBS LETT, V354, P57, DOI 10.1016/0014-5793(94)01087-0; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNAN SO, 1989, MOL BIOL MED, V6, P87; BRENNAN SO, 1994, FEBS LETT, V338, P147, DOI 10.1016/0014-5793(94)80353-6; Constam DB, 2000, GENE DEV, V14, P1146; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Holyoak T, 2004, BIOCHEMISTRY-US, V43, P2412, DOI 10.1021/bi035849h; Jackson RS, 2003, J CLIN INVEST, V112, P1550, DOI 10.1172/JCI18784; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Ko KWS, 1998, J BIOL CHEM, V273, P27779, DOI 10.1074/jbc.273.43.27779; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; Li M, 1999, NEUROENDOCRINOLOGY, V69, P217, DOI 10.1159/000054422; Li M, 2000, ENDOCRINOLOGY, V141, P3723, DOI 10.1210/en.141.10.3723; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; Mori K, 1999, J BIOCHEM-TOKYO, V125, P627, DOI 10.1093/oxfordjournals.jbchem.a022329; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Sarac MS, 2004, INFECT IMMUN, V72, P602, DOI 10.1128/IAI.72.1.602-605.2004; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Seger D, 2000, FEBS LETT, V480, P169, DOI 10.1016/S0014-5793(00)01917-7; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Sucic JF, 1999, BIOCHEM J, V339, P639, DOI 10.1042/0264-6021:3390639; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Torres RM, 1997, LAB PROTOCOLS CONDIT; Umans L, 1999, NEUROSCIENCE, V94, P315, DOI 10.1016/S0306-4522(99)00242-0; Villeneuve P, 2002, J NEUROCHEM, V82, P783, DOI 10.1046/j.1471-4159.2002.00988.x; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Wouters S, 1998, BIOCHEM J, V336, P311, DOI 10.1042/bj3360311; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	45	95	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53442	53450		10.1074/jbc.M407152200	http://dx.doi.org/10.1074/jbc.M407152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471862	hybrid			2022-12-27	WOS:000225680600078
J	Shcherbik, N; Kee, Y; Lyon, N; Huibregtse, J; Haines, DS				Shcherbik, N; Kee, Y; Lyon, N; Huibregtse, J; Haines, DS			A single PXY motif located within the carboxyl terminus of Spt23p and Mga2p mediates a physical and functional interaction with ubiquitin ligase Rsp5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NF-KAPPA-B1 PRECURSOR PROTEIN; REL HOMOLOGY DOMAIN; GLYCINE-RICH REGION; RSP5P-DEPENDENT UBIQUITINATION; TRANSCRIPTION FACTOR; NUCLEAR EXPORT; MESSENGER-RNA; P105; DEGRADATION	Proteasome-dependent processing of the endoplasmic reticulum localized transcription factor Spt23p of Saccharomyces cerevisiae generates its transcriptionally competent form and requires the WW domain containing Rsp5p ubiquitin ligase. Although previous studies documented an Rsp5p-Spt23p association in cells, very little is known about the nature of this interaction. We report here the identification of an imperfect type I WW domain-binding site (LPKY) within the carboxyl-terminal region of Spt23p that is required for Rsp5p binding in vitro and in vivo. Deletion of this motif abrogates Rsp5p-induced ubiquitination of Spt23p in vitro and reduces ubiquitination of the Spt23p precursor in yeast. In addition, the Spt23pDeltaLPKY mutant is inefficiently processed and is defective at up-regulating target gene (OLE1) expression in cells. Deletion of the corresponding LPKY site within Mga2p, an Spt23p homologue, also abrogates Rsp5p binding and Rsp5p-dependent ubiquitination in vitro as well as Rsp5p binding and Mga2p polyubiquitination in cells. However, the Mga2pDeltaLPKY mutant undergoes efficient proteasome-dependent processing. These experiments indicate that the LPKY motif of Spt23p is required for Rsp5p binding, Rsp5-induced ubiquitination, proteasome-dependent processing, and its OLE1 inducing function. They also suggest that the LPKY motif of Mga2p is required for Rsp5p binding and ubiquitination, and Rsp5p regulates Mga2p function by a mechanism that is independent of providing the partial degradation signal.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Texas System; University of Texas Austin	Haines, DS (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	dhaines@temple.edu	Kee, Younghoon/J-4107-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; Kaminska J, 2002, MOL CELL BIOL, V22, P6946, DOI 10.1128/MCB.22.20.6946-6958.2002; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 2003, J BIOL CHEM, V278, P31479, DOI 10.1074/jbc.M304140200; Neumann S, 2003, EMBO REP, V4, P1156, DOI 10.1038/sj.embor.7400026; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Rodriguez MS, 2003, TRAFFIC, V4, P566, DOI 10.1034/j.1600-0854.2003.00115.x; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Shcherbik N, 2003, CURR BIOL, V13, P1227, DOI 10.1016/S0960-9822(03)00457-3; Shcherbik N, 2002, J CELL SCI, V115, P1041; Zhang SR, 1999, GENETICS, V151, P473	31	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53892	53898		10.1074/jbc.M410325200	http://dx.doi.org/10.1074/jbc.M410325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466864	hybrid			2022-12-27	WOS:000225680600128
J	Wang, Y; Kedei, N; Wang, M; Wang, QJ; Huppler, AR; Toth, A; Tran, R; Blumberg, PM				Wang, Y; Kedei, N; Wang, M; Wang, QJ; Huppler, AR; Toth, A; Tran, R; Blumberg, PM			Interaction between protein kinase C mu and the vanilloid receptor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION LOOP SER(744); DIRECT PHOSPHORYLATION; D PKD; EPSILON; CELLS; VR1; IDENTIFICATION; EXPRESSION; SUBSTRATE; NEURONS	The capsaicin receptor VR1 is a polymodal nociceptor activated by multiple stimuli. It has been reported that protein kinase C plays a role in the sensitization of VR1. Protein kinase D/PKCmu is a member of the protein kinase D serine/threonine kinase family that exhibits structural, enzymological, and regulatory features distinct from those of the PKCs, with which they are related. As part of our effort to optimize conditions for evaluating VR1 pharmacology, we found that treatment of Chinese hamster ovary (CHO) cells heterologously expressing rat VR1 (CHO/rVR1) with butyrate enhanced rVR1 expression and activity. The expression of PKCmu and PKCbeta1, but not of other PKC isoforms, was also enhanced by butyrate treatment, suggesting the possibility that these two isoforms might contribute to the enhanced activity of rVR1. In support of this hypothesis, we found the following. 1) Overexpression of PKCmu enhanced the response of rVR1 to capsaicin and low pH, and expression of a dominant negative variant of PKCmu reduced the response of rVR1. 2) Reduction of endogenous PKCmu using antisense oligonucleotides decreased the response of exogenous rVR1 expressed in CHO cells as well as of endogenous rVR1 in dorsal root ganglion neurons. 3) PKCmu localized to the plasma membrane when overexpressed in CHO/rVR1 cells. 4) PKCmu directly bound to rVR1 expressed in CHO cells as well as to endogenous rVR1 in dorsal root ganglia or to an N-terminal fragment of rVR1, indicating a direct interaction between PKCmu and rVR1. 5) PKCmu directly phosphorylated rVR1 or a longer N-terminal fragment ( amino acids 1-118) of rVR1 but not a shorter one (amino acids 1-99). 6) Mutation of S116A in rVR1 blocked both the phosphorylation of rVR1 by PKCmu and the enhancement by PKCmu of the rVR1 response to capsaicin. We conclude that PKCmu functions as a direct modulator of rVR1.	Peking Univ, Dept Neurobiol, Neurosci Res Inst, Beijing 100083, Peoples R China; NCI, NIH, Bethesda, MD 20892 USA	Peking University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, Y (corresponding author), Peking Univ, Dept Neurobiol, Neurosci Res Inst, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	wangy66@bjmu.edu.cn; blumberp@dc37a.nci.nih.gov	Huppler, Anna R/F-1842-2018; Wang, Qiming Jane/B-6064-2012; Tóth, Attila/F-4859-2010	Huppler, Anna R/0000-0003-1263-6623; Wang, Qiming Jane/0000-0002-9502-4851; Tóth, Attila/0000-0001-6503-3653	NATIONAL CANCER INSTITUTE [Z01BC005270, ZIABC005270] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Chandrasekher G, 1998, EXP EYE RES, V67, P603, DOI 10.1006/exer.1998.0555; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	23	56	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53674	53682		10.1074/jbc.M410331200	http://dx.doi.org/10.1074/jbc.M410331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471852	hybrid			2022-12-27	WOS:000225680600104
J	Zhang, JH; Kew, RR				Zhang, JH; Kew, RR			Identification of a region in the vitamin D-binding protein that mediates its C5a chemotactic cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GC-GLOBULIN; DES ARG; STRUCTURAL BASIS; STEROL-BINDING; ACTIN-BINDING; PLASMA; NEUTROPHILS; COCHEMOTAXIN; RECEPTOR; LIGANDS	The vitamin D-binding protein (DBP), also known as group-specific component or Gc-globulin, is a multifunctional plasma protein that can significantly enhance the leukocyte chemotactic activity to C5a and C5a des-Arg. DBP is a member of the albumin gene family and has a triple domain modular structure with extensive disulfide bonding that is characteristic of this protein family. The goal of this study was to identify a region in DBP that mediates the chemotactic cofactor function for C5a. Full-length and truncated versions of DBP (Gc-2 allele) were expressed in Escherichia coli using a glutathione S-transferase fusion protein expression system. The structure of the expressed proteins was confirmed by SDS-PAGE and immunoblotting, whereas protein function was verified by quantitating the binding of [H-3] vitamin D. Dibutyryl cAMP-differentiated HL-60 cells were utilized to test purified natural DBP and recombinant expressed DBP (reDBP) for their ability to enhance chemotaxis and intracellular Ca2+ flux to C5a. Natural and full-length reDBP ( 458 amino acid residues) as well as truncated reDBPs that contained the N-terminal domain I ( domains I and II, residues 1 - 378; domain I, residues 1 - 191) significantly enhanced both cell movement and intracellular Ca2+ concentrations in response to C5a. Progressive truncation of DBP domain I localized the chemotactic enhancing region between residues 126 - 175. Overlapping peptides corresponding to this region were synthesized, and results indicate that a 20-amino- acid sequence (residues 130 - 149, 5'-EAFRKDP-KEYANQFMWEYST-3') in domain I of DBP is essential for its C5a chemotactic cofactor function.	SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kew, RR (corresponding author), SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA.	rkew@notes.cc.sunysbedu			NIGMS NIH HHS [GM 63769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063769, R56GM063769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Binder R, 1999, MOL IMMUNOL, V36, P885, DOI 10.1016/S0161-5890(99)00110-8; COOKE NE, 1986, J BIOL CHEM, V261, P3441; DiMartino SJ, 1999, J IMMUNOL, V163, P2135; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gomme PT, 2004, TRENDS BIOTECHNOL, V22, P340, DOI 10.1016/j.tibtech.2004.05.001; HADDAD JG, 1992, BIOCHEMISTRY-US, V31, P7174, DOI 10.1021/bi00146a021; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; HIRSCHFELD JAN, 1959, ACTA PATHOL ET MICROBIOL SCAND, V47, P160; Kanda S, 2002, JNCI-J NATL CANCER I, V94, P1311; KEW RR, 1988, J CLIN INVEST, V82, P364, DOI 10.1172/JCI113596; KEW RR, 1995, J LEUKOCYTE BIOL, V58, P55, DOI 10.1002/jlb.58.1.55; KEW RR, 1995, J IMMUNOL, V155, P5369; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; METCALF JP, 1991, AM REV RESPIR DIS, V143, P844, DOI 10.1164/ajrccm/143.4_Pt_1.844; Mizwicki MT, 2003, J BONE MINER RES, V18, P795, DOI 10.1359/jbmr.2003.18.5.795; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; OSAWA M, 1994, BIOCHEM MOL BIOL INT, V34, P1003; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; PEREZ HD, 1988, J CLIN INVEST, V82, P360, DOI 10.1172/JCI113595; PETRINI M, 1991, J ENDOCRINOL INVEST, V14, P405, DOI 10.1007/BF03349090; PIQUETTE CA, 1994, J LEUKOCYTE BIOL, V55, P349, DOI 10.1002/jlb.55.3.349; SENIOR RM, 1988, J IMMUNOL, V141, P3570; Swamy N, 1997, BIOCHEMISTRY-US, V36, P7432, DOI 10.1021/bi962730i; Swamy N, 2002, ARCH BIOCHEM BIOPHYS, V402, P14, DOI 10.1016/S0003-9861(02)00033-4; Swamy N, 1997, PROTEIN EXPRES PURIF, V10, P115, DOI 10.1006/prep.1996.0720; Trujillo G, 2004, J IMMUNOL, V173, P4130, DOI 10.4049/jimmunol.173.6.4130; Verboven C, 2002, NAT STRUCT BIOL, V9, P131, DOI 10.1038/nsb754; White P, 2000, TRENDS ENDOCRIN MET, V11, P320, DOI 10.1016/S1043-2760(00)00317-9; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZWAHLEN RD, 1990, INFLAMMATION, V14, P109, DOI 10.1007/BF00914034	34	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53282	53287		10.1074/jbc.M411462200	http://dx.doi.org/10.1074/jbc.M411462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485893	hybrid			2022-12-27	WOS:000225680600059
J	Mazina, OM; Mazin, AV				Mazina, OM; Mazin, AV			Human Rad54 protein stimulates DNA strand exchange activity of hRad51 protein in the presence of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; INTRACELLULAR CA2+; REPAIR PROTEIN; RECA PROTEIN; REPLICATION; CHROMATIN; CALCIUM; BINDING; TRANSLOCATION; IRRADIATION	Rad51 and Rad54 proteins play a key role in homologous recombination in eukaryotes. Recently, we reported that Ca2+ is required in vitro for human Rad51 protein to form an active nucleoprotein filament that is important for the search of homologous DNA and for DNA strand exchange, two critical steps of homologous recombination. Here we find that Ca2+ is also required for hRad54 protein to effectively stimulate DNA strand exchange activity of hRad51 protein. This finding identifies Ca2+ as a universal cofactor of DNA strand exchange promoted by mammalian homologous recombination proteins in vitro. We further investigated the hRad54-dependent stimulation of DNA strand exchange. The mechanism of stimulation appeared to include specific interaction of hRad54 protein with the hRad51 nucleoprotein filament. Our results show that hRad54 protein significantly stimulates homology-independent coaggregation of dsDNA with the filament, which represents an essential step of the search for homologous DNA. The results obtained indicate that hRad54 protein serves as a dsDNA gateway for the hRad51-ssDNA filament, promoting binding and an ATP hydrolysis-dependent translocation of dsDNA during the search for homologous sequences.	Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19102 USA	Drexel University	Mazin, AV (corresponding author), Drexel Univ, Coll Med, Dept Biochem, 245 N 15th St,MS 497,NCB,Rm 10103, Philadelphia, PA 19102 USA.	avmazin@drexel.edu			NCI NIH HHS [CA100839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100839, R56CA100839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adzuma K, 1998, J BIOL CHEM, V273, P31565, DOI 10.1074/jbc.273.47.31565; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bugreev DV, 2004, P NATL ACAD SCI USA, V101, P9988, DOI 10.1073/pnas.0402105101; CARROLL J, 1994, DEVELOPMENT, V120, P3507; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Gafter U, 1997, J LAB CLIN MED, V130, P33, DOI 10.1016/S0022-2143(97)90056-1; Game JC, 2000, MUTAT RES-FUND MOL M, V451, P277, DOI 10.1016/S0027-5107(00)00055-5; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; NEGRESALVAYRE A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P207, DOI 10.1016/0005-2760(92)90113-A; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RADDING CM, 1993, CURR BIOL, V3, P358, DOI 10.1016/0960-9822(93)90200-8; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; SAKAI H, 1994, BBA-GEN SUBJECTS, V1201, P259, DOI 10.1016/0304-4165(94)90049-3; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; SIGURDSSON S, 2002, J BIOL CHEM; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; SPIELBERG H, 1991, EXP HEMATOL, V19, P742; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; Wyman C, 2004, DNA REPAIR, V3, P827, DOI 10.1016/j.dnarep.2004.03.037; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	55	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52042	52051		10.1074/jbc.M410244200	http://dx.doi.org/10.1074/jbc.M410244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466868	hybrid			2022-12-27	WOS:000225493400041
J	Enoksson, M; Robertson, JD; Gogvadze, V; Bu, PL; Kropotov, A; Zhivotovsky, B; Orrenius, S				Enoksson, M; Robertson, JD; Gogvadze, V; Bu, PL; Kropotov, A; Zhivotovsky, B; Orrenius, S			Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; INDUCED APOPTOSIS; CARDIOLIPIN; RELEASE; BAX; ACTIVATION; PROTEIN; ETOPOSIDE; ENCODES; COMPLEX	Caspases are cysteine proteases that play a central role in the execution of apoptosis. Recent evidence indicates that caspase-2 is activated early in response to genotoxic stress and can function as an upstream modulator of the mitochondrial apoptotic pathway. In particular, we have shown previously that fully processed caspase-2 can permeabilize the outer mitochondrial membrane and cause cytochrome c and Smac/DIABLO release from these organelles. Using permeabilized cells, isolated mitochondria, and protein-free liposomes, we now report that this effect is direct and depends neither on the presence or cleavage of other proteins nor on a specific phospholipid composition of the liposomal membrane. Interestingly, caspase-2 was also shown to disrupt the interaction of cytochrome c with anionic phospholipids, notably cardiolipin, and thereby enhance the release of the hemoprotein caused by treatment of mitochondria with digitonin or the proapoptotic protein Bax. Combined, our data suggest that caspase-2 possesses an unparalleled ability to engage the mitochondrial apoptotic pathway by permeabilizing the outer mitochondrial membrane and/or by breaching the association of cytochrome c with the inner mitochondrial membrane.	Karolinska Inst, Inst Environm Med, Div Toxicol, S-17177 Stockholm, Sweden; Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA	Karolinska Institutet; University of Kansas; University of Kansas Medical Center	Orrenius, S (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden.	Sten.Orrenius@imm.ki.se	Kropotov, Andrey/AAE-9324-2021; Bu, Pengli/J-3575-2019; Gogvadze, Vladimir/A-4392-2014; Zhivotovsky, Boris/A-4346-2014	Bu, Pengli/0000-0003-2576-0607; Zhivotovsky, Boris/0000-0002-2238-3482; Kropotov, Andrey/0000-0002-1865-4008	NIEHS NIH HHS [K22 ES11647] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011647] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALIGA BC, 2004, CELL DEATH DIFFER; Buser CA, 1998, METH MOL B, V84, P267; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	23	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49575	49578		10.1074/jbc.C400374200	http://dx.doi.org/10.1074/jbc.C400374200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15475367	hybrid			2022-12-27	WOS:000225229500006
J	Gu, F; Nguyen, DT; Stuible, M; Dube, N; Tremblay, ML; Chevet, E				Gu, F; Nguyen, DT; Stuible, M; Dube, N; Tremblay, ML; Chevet, E			Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ER STRESS; INSULIN SENSITIVITY; CELL-DEATH; KINASE; ATF6; GENE; DEPHOSPHORYLATION; TRANSCRIPTION; ACTIVATION	Protein-tyrosine phosphatase 1B (PTP-1B) is the prototypic tyrosine phosphatase whose function in insulin signaling and metabolism is well established. Although the role of PTP-1B in dephosphorylating various cell surface receptor tyrosine kinases is clear, the mechanisms by which it modulates receptor function from the endoplasmic reticulum (ER) remains an enigma. Here, we provide evidence that PTP-1B has an essential function in regulating the unfolded protein response in the ER compartment. The absence of PTP-1B caused impaired ER stress-induced IRE1 signaling. More specifically, JNK activation, XBP-1 splicing, and EDEM (ER degradation-enhancing alpha-mannosidase-like protein) gene induction, as well as ER stress-induced apoptosis, were attenuated in PTP-1B knock-out mouse embryonic fibroblasts in response to two ER stressors, tunicamycin and azetidine-2 carboxylic acid. We demonstrate that PTP-1B is not just a passive resident of the ER but on the contrary has an essential role in potentiating IRE1-mediated ER stress signaling pathways.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Royal Victoria Hosp, Dept Surg, Organelle Signaling Lab, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; Royal Victoria Hospital	Tremblay, ML (corresponding author), McGill Univ, Ctr Canc, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	Michel.Tremblay@mcgill.ca; Eric.Chevet@mcgill.ca	Longo, Kenneth A/A-5631-2010; chevet, eric/E-4992-2016	chevet, eric/0000-0001-5855-4522				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	29	163	172	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49689	49693		10.1074/jbc.C400261200	http://dx.doi.org/10.1074/jbc.C400261200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15465829	hybrid			2022-12-27	WOS:000225229500019
J	Hughey, RP; Bruns, JB; Kinlough, CL; Kleyman, TR				Hughey, RP; Bruns, JB; Kinlough, CL; Kleyman, TR			Distinct pools of epithelial sodium channels are expressed at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; NA+ CHANNEL; SUBUNIT STOICHIOMETRY; SERINE PROTEASES; XENOPUS-OOCYTES; GAMMA-SUBUNIT; A6 CELLS; ENAC; ACTIVATION; FURIN	The epithelial Na+ channel ( ENaC) is assembled in the endoplasmic reticulum from three structurally related subunits (alpha, beta, and gamma). Channel maturation within the biosynthetic pathway involves cleavage of the alpha and gamma subunits by furin and processing of N-linked glycans on alpha, beta, and gamma to complex type. Both mature and immature subunits have been observed at the surface of stably transfected Madin-Darby canine kidney cells. We have examined whether channel maturation is an all-or-none event or whether heterogeneous processing of channel subunits occurs within an individual channel complex. Using an immobilized lectin to isolate proteins with complex type N-glycans, we found that individual channel complexes with mature subunits lack immature subunits. Furthermore, terminal processing of N-glycans on ENaC subunits was not dependent on cleavage of ENaC subunits, and proteolysis of channel subunits was not dependent on prior processing of N-glycans. Our results suggest that processing of subunits within an individual channel complex is an all-or-none event such that channels present on the cell surface contain either all mature or all immature subunits. The presence of immature channel complexes at the plasma membrane provides epithelial cells with a reserve of poorly functional channels that can be activated by proteases in post-Golgi compartments.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054787, R01DK054354, R01DK065161, R56DK065161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK65161, DK54354, DK54787] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Bonnon C, 2003, J BIOL CHEM, V278, P48339, DOI 10.1074/jbc.M309120200; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kobata A, 2000, GLYCOCONJUGATE J, V17, P443, DOI 10.1023/A:1011006122704; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rossier Bernard C, 2004, Proc Am Thorac Soc, V1, P4, DOI 10.1513/pats.2306007; Shah N, 2003, BIOCHEMISTRY-US, V42, P13812, DOI 10.1021/bi034742r; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Weisz OA, 2003, AM J PHYSIOL-RENAL, V285, pF833, DOI 10.1152/ajprenal.00088.2003; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	34	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48491	48494		10.1074/jbc.C400460200	http://dx.doi.org/10.1074/jbc.C400460200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15466477	hybrid			2022-12-27	WOS:000225098100003
J	Baev, D; Rivetta, A; Vylkova, S; Sun, JNN; Zeng, GF; Slayman, CL; Edgerton, M				Baev, D; Rivetta, A; Vylkova, S; Sun, JNN; Zeng, GF; Slayman, CL; Edgerton, M			The TRK1 potassium transporter is the critical effector for killing of Candida albicans by the cationic protein, Histatin 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SALIVARY HISTATIN-5; 2 PORE DOMAINS; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; K+-UPTAKE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; FUNGICIDAL ACTIVITY; ELECTROGENIC PUMP; PROTON SYMPORT; CARRIER TRK2P	The principal feature of killing of Candida albicans and other pathogenic fungi by the catonic protein Histatin 5 (Hst 5) is loss of cytoplasmic small molecules and ions, including ATP and K+, which can be blocked by the anion channel inhibitor 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid. We constructed C. albicans strains expressing one, two, or three copies of the TRK1 gene in order to investigate possible roles of Trk1p (the organism's principal K+ transporter) in the actions of Hst 5. All measured parameters (Hst 5 killing, Hst 5-stimulated ATP efflux, normal Trk1p-mediated K+ (Rb-86(+)) influx, and Trk1p-mediated chloride conductance) were similarly reduced (5-7-fold) by removal of a single copy of the TRK1 gene from this diploid organism and were fully restored by complementation of the missing allele. A TRK1 overexpression strain of C. albicans, constructed by integrating an additional TRK1 gene into wild-type cells, demonstrated cytoplasmic sequestration of Trk1 protein, along with somewhat diminished toxicity of Hst 5. These results could be produced either by depletion of intracellular free Hst 5 due to sequestered binding, or to cooperativity in Hst 5-protein interactions at the plasma membrane. Furthermore, Trk1p-mediated chloride conductance was blocked by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid in all of the tested strains, strongly suggesting that the TRK1 protein provides the essential pathway for ATP loss and is the critical effector for Hst 5 toxicity in C. albicans.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Dent Med, Dept Restorat Dent, Buffalo, NY 14214 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Yale University	Edgerton, M (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 310 Foster Hall,Main St Campus,3435 Main St, Buffalo, NY 14214 USA.	edgerto@buffalo.edu		Slayman, Clifford/0000-0002-3029-2054	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060696] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 10641, R01 DE010641-10A1, DE 00406, R01 DE010641] Funding Source: Medline; NIGMS NIH HHS [GM 60696] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal AK, 2003, J BIOL CHEM, V278, P34998, DOI 10.1074/jbc.M306291200; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Baev D, 2002, INFECT IMMUN, V70, P4777, DOI 10.1128/IAI.70.9.4777-4784.2002; Baev D, 2003, INFECT IMMUN, V71, P3251, DOI 10.1128/IAI.71.6.3251-3260.2003; Baev D, 2001, MICROBIOL-SGM, V147, P3323, DOI 10.1099/00221287-147-12-3323; BERTL A, 1993, J MEMBRANE BIOL, V132, P183; Bertl A, 1998, PFLUG ARCH EUR J PHY, V436, P999, DOI 10.1007/s004240050735; Bihler H, 1998, FEBS LETT, V432, P59, DOI 10.1016/S0014-5793(98)00832-1; Bihler H, 2002, BBA-BIOMEMBRANES, V1558, P109, DOI 10.1016/S0005-2736(01)00414-X; Bihler H, 1999, FEBS LETT, V447, P115, DOI 10.1016/S0014-5793(99)00281-1; BLATT MR, 1983, J MEMBRANE BIOL, V72, P223, DOI 10.1007/BF01870589; BLATT MR, 1987, J MEMBRANE BIOL, V98, P169, DOI 10.1007/BF01872129; Bobek LA, 2003, ANTIMICROB AGENTS CH, V47, P643, DOI 10.1128/AAC.47.2.643-652.2003; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Cognetti D, 2002, YEAST, V19, P55, DOI 10.1002/yea.804; Dong J, 2003, J DENT RES, V82, P748, DOI 10.1177/154405910308200917; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Edgerton M, 2000, Adv Dent Res, V14, P16; FONZI WA, 1993, GENETICS, V134, P717; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; Gyurko C, 2000, ANTIMICROB AGENTS CH, V44, P348, DOI 10.1128/AAC.44.2.348-354.2000; GYURKO C, 2001, A LEEUWENHOEK, V79, P279; Harms C, 2001, MICROBIOL-SGM, V147, P2991, DOI 10.1099/00221287-147-11-2991; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Helmerhorst EJ, 2001, J BIOL CHEM, V276, P5643, DOI 10.1074/jbc.M008229200; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Koshlukova SE, 1999, J BIOL CHEM, V274, P18872, DOI 10.1074/jbc.274.27.18872; Koshlukova SE, 2000, INFECT IMMUN, V68, P6848, DOI 10.1128/IAI.68.12.6848-6856.2000; Kuroda T, 2004, J MEMBRANE BIOL, V198, P177, DOI 10.1007/s00232-004-0671-1; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; Lesage F, 1996, J BIOL CHEM, V271, P4183; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Li XWS, 2003, J BIOL CHEM, V278, P28553, DOI 10.1074/jbc.M300680200; LOSBERGER C, 1989, CURR GENET, V16, P153, DOI 10.1007/BF00391471; LUBIN M, 1964, CELLULAR FUNCTIONS M, P193; Madrid R, 1998, J BIOL CHEM, V273, P14838, DOI 10.1074/jbc.273.24.14838; RAJ PA, 1990, J BIOL CHEM, V265, P3898; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; Roberts SK, 1999, J BACTERIOL, V181, P291, DOI 10.1128/JB.181.1.291-297.1999; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Ruissen ALA, 2001, BIOCHEM J, V356, P361, DOI 10.1042/0264-6021:3560361; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; SLAYMAN CL, 1973, J MEMBRANE BIOL, V14, P305, DOI 10.1007/BF01868083; SLAYMAN CL, 1989, BIOCH CELL WALLS MEM, P295; TROXLER RF, 1990, J DENT RES, V69, P2, DOI 10.1177/00220345900690010101; Tsai H, 1997, ANTIMICROB AGENTS CH, V41, P2224, DOI 10.1128/AAC.41.10.2224; Tsai HY, 1997, BBA-GEN SUBJECTS, V1336, P367, DOI 10.1016/S0304-4165(97)00076-7; Uhl MA, 2003, EMBO J, V22, P2668, DOI 10.1093/emboj/cdg256; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Xu YY, 1999, ANTIMICROB AGENTS CH, V43, P2256, DOI 10.1128/AAC.43.9.2256; Zeng GF, 2004, J BIOL CHEM, V279, P3003, DOI 10.1074/jbc.M309760200; [No title captured]	60	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55060	55072		10.1074/jbc.M411031200	http://dx.doi.org/10.1074/jbc.M411031200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485849	hybrid			2022-12-27	WOS:000225960800011
J	Jiang, HM; Weyrich, AS; Zimmerman, GA; McIntyre, TM				Jiang, HM; Weyrich, AS; Zimmerman, GA; McIntyre, TM			Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E-2 production that modulate motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALKYL PHOSPHOLIPIDS; ACTIVATED RECEPTOR-GAMMA; WOUND-INDUCED CA2+; PROSTACYCLIN SYNTHESIS; EXPRESSION; ANGIOGENESIS; CANCER; INFLAMMATION; MIGRATION; SYNTHASE	Endothelial cells line the vasculature and, after mechanical denudation during invasive procedures or cellular loss from natural causes, migrate to reestablish a confluent monolayer. We find confluent monolayers of human umbilical vein endothelial cells were quiescent and expressed low levels of cyclooxygenase-2, but expressed cyclooxygenase-2 at levels comparable with cytokine-stimulated cells when present in a subconfluent culture. Mechanically wounding endothelial cell monolayers stimulated rapid cyclooxygenase-2 expression that increased with the level of wounding. Cyclooxygenase-2 re-expression occurred throughout the culture, suggesting signaling from cells proximal to the wound to distal cells. Media from wounded monolayers stimulated cyclooxygenase-2 expression in confluent monolayers, which correlated with the level of wounding of the donor monolayer. Wounded monolayers and cells in subconfluent cultures secreted enhanced levels of prostaglandin (PG)E-2 that depended on cyclooxygenase-2 activity, and PGE(2) stimulated cyclooxygenase-2 expression in confluent endothelial cell monolayers. Cells from subconfluent monolayers migrated through filters more readily than those from confluent monolayers, and the cyclooxygenase-2-selective inhibitor NS-398 suppressed migration. Adding PGE(2) to NS-398-treated cells augmented migration. Endothelial cells also migrated into mechanically denuded areas of confluent monolayers, and this too was suppressed by NS-398. We conclude that endothelial cells not in contact with neighboring cells express cyclooxygenase-2 that results in enhanced release of PGE(2), and that this autocrine and paracrine loop enhances endothelial cell migration to cover denuded areas of the endothelium.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, NC-10, Cleveland, OH 44195 USA.	mcintyt@ccf.org		Weyrich, Andrew/0000-0001-9622-4647	NHLBI NIH HHS [HL 44513, HL 44525] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R37HL044525, R01HL044513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Bradbury DA, 2003, J BIOL CHEM, V278, P49954, DOI 10.1074/jbc.M307964200; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; Gilroy DW, 2001, FASEB J, V15, P288; Griffioen AW, 2000, PHARMACOL REV, V52, P237; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Ibuki T, 2003, J NEUROCHEM, V86, P318, DOI 10.1046/j.1471-4159.2003.01848.x; INGERMANWOJENSKI CM, 1988, PROSTAGLANDINS, V36, P127, DOI 10.1016/0090-6980(88)90300-0; Janowiak MA, 1998, ENDOCRINOLOGY, V139, P765, DOI 10.1210/en.139.2.765; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Laulederkind SJF, 2000, EXP CELL RES, V258, P409, DOI 10.1006/excr.2000.4961; Majima M, 1997, JPN J PHARMACOL, V75, P105, DOI 10.1254/jjp.75.105; Maldve RE, 2000, J LIPID RES, V41, P873; Mark KS, 2001, J PHARMACOL EXP THER, V297, P1051; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Ozaki-Okayama Y, 2004, CRIT CARE MED, V32, P795, DOI 10.1097/01.CCM.0000114576.60077.FC; PETERSON HI, 1986, ANTICANCER RES, V6, P251; POMERANTZ KB, 1984, T ASSOC AM PHYSICIAN, V97, P275; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; SHOLLEY MM, 1977, LAB INVEST, V36, P18; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Tran POT, 1999, EXP CELL RES, V246, P319, DOI 10.1006/excr.1998.4239; Tran POT, 1998, CELL PROLIFERAT, V31, P155; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520; Zweifel BS, 2002, CANCER RES, V62, P6706	42	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55905	55913		10.1074/jbc.M406094200	http://dx.doi.org/10.1074/jbc.M406094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485847	hybrid			2022-12-27	WOS:000225960800114
J	Shan, WS; Yagita, Y; Wang, ZH; Koch, A; Svenningsen, AF; Gruzglin, E; Pedraza, L; Colman, DR				Shan, WS; Yagita, Y; Wang, ZH; Koch, A; Svenningsen, AF; Gruzglin, E; Pedraza, L; Colman, DR			The minimal essential unit for cadherin-mediated intercellular adhesion comprises extracellular domains 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; UVOMORULIN-CATENIN COMPLEX; N-CADHERIN; CYTOPLASMIC DOMAIN; NEURITE OUTGROWTH; C-CADHERIN; HOMOPHILIC ADHESION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; BINDING	N-cadherin comprises five homologous extracellular domains, a transmembrane, and a cytoplasmic domain. The extracellular domains of N-cadherin play important roles in homophilic cell adhesion, but the contribution of each domain to this phenomenon has not been fully evaluated. In particular, the following questions remain unanswered: what is the minimal domain combination that can generate cell adhesion, how is domain organization related to adhesive strength, and does the cytoplasmic domain serve to facilitate extracellular domain interaction? To address these issues, we made serial constructs of the extracellular domains of N-cadherin and produced various cell lines to examine adhesion properties. We show that the first domain of N-cadherin alone on the cell surface fails to generate adhesive activity and that the first two domains of N-cadherin form the "minimal essential unit" to mediate cell adhesion. Cell lines expressing longer extracellular domains or N-cadherin wild type cells formed larger cellular aggregates than those expressing shorter aggregates. However, adhesion strength, as measured by a shearing test, did not reveal any differences among these aggregative cell lines, suggesting that the first two domains of N-cadherin cells generate the same strength of adhesive activity as longer extracellular domain cells. Furthermore, truncations of the first two domains of N-cadherin are also sufficient to form cis-dimerization at an adhesive junction. Our findings suggest that the extracellular domains of N-cadherin have distinct roles in cell adhesion, i.e. the first two domains are responsible for homophilic adhesion activity, and the other domains promote adhesion efficiency most likely by positioning essential domains relatively far out from the cell surface.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; NYU, Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10023 USA	McGill University; Icahn School of Medicine at Mount Sinai; New York University; New York University	Shan, WS (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	weisong.shan@mcgill.ca; david.colman@mcgill.ca	Svenningsen, Åsa Fex/H-5443-2015; Yagita, Yoshiki/S-6954-2016	Svenningsen, Åsa Fex/0000-0002-5651-265X; 	NINDS NIH HHS [NS 20147] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020147] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DOYLE JP, 1995, J CELL BIOL, V131, P465, DOI 10.1083/jcb.131.2.465; He WZ, 2003, SCIENCE, V302, P109, DOI 10.1126/science.1086957; Horikawa K, 2001, J CELL BIOL, V155, P1297, DOI 10.1083/jcb.200108156; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Leckband D, 2002, STRUCTURE, V10, P739, DOI 10.1016/S0969-2126(02)00783-9; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; Lustig M, 1999, DEV BIOL, V209, P340, DOI 10.1006/dbio.1999.9250; Matsunami H, 1995, DEV BIOL, V172, P466, DOI 10.1006/dbio.1995.8029; MATSUNAMI H, 1993, J CELL SCI, V106, P401; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Sakurai T, 1998, BIOTECHNIQUES, V25, P382, DOI 10.2144/98253bm09; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yoshida M, 2001, NEUROCHEM RES, V26, P703, DOI 10.1023/A:1010999622760	49	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55914	55923		10.1074/jbc.M407827200	http://dx.doi.org/10.1074/jbc.M407827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485826	hybrid			2022-12-27	WOS:000225960800115
J	Acharjee, S; Do-Rego, JL; Oh, DY; Ahn, RS; Choe, H; Vaudry, H; Kim, K; Seong, JY; Kwon, HB				Acharjee, S; Do-Rego, JL; Oh, DY; Ahn, RS; Choe, H; Vaudry, H; Kim, K; Seong, JY; Kwon, HB			Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin - Insights into molecular coevolution of V1a type receptors and their ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG ADRENAL-GLAND; PHARMACOLOGICAL CHARACTERIZATION; SIGNAL-TRANSDUCTION; BINDING DOMAINS; AGONIST; CLONING; ANTAGONIST; ACTIVATION; EXPRESSION; PEPTIDE	Arginine vasotocin (VT) is the ortholog in all nonmammalian vertebrates of arginine vasopressin (AVP) in mammals. We have previously cloned an amphibian V1a-type vasotocin receptor (VT1R) that exhibited higher sensitivity for VT than AVP, while the mammalian V1a type receptor (V1aR) responded better to AVP than VT. In the present study, we identified the amino acid residues that confer differential ligand selectivity for AVP and VT between rat V1aR and bullfrog VT1R (bfVT1R). A chimeric rat V1aR having transmembrane domain (TMD) VI to the carboxyl-terminal tail (C-tail) of bfVT1R showed a reverse ligand preference for AVP and VT, whereas a chimeric VT1R with TMD VI to the C-tail of rat V1aR showed a great increase in sensitivity for AVP. A single mutation (Ile(315(6.53)) to Thr) in TMD VI of V1aR increased the sensitivity for VT, while a single mutation (Phe(313(6.51)) to Tyr or Pro(334(7.33)) to Thr) reduced sensitivity toward AVP. Interestingly the triple mutation (Phe(313(6.51)) to Tyr, Ile(6.53) to Thr, and Pro(7.33) to Thr) of V1aR increased sensitivity to VT but greatly reduced sensitivity to AVP, behaving like bfVT1R. Further, like V1aR, a double mutant (Tyr(306(6.51)) to Phe and Thr(327(7.33)) to Pro) of bfVT1R showed an increased sensitivity to AVP. These results suggest that Phe/Tyr(6.51), Ile/Thr(6.53), and Pro/Thr(7.33) are responsible for the differential ligand selectivity between rat V1aR and bfVT1R. This information regarding the molecular interaction of VT/AVP with their receptors may have important implications for the development of novel AVP analogs.	Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea; Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, INSERM,U413, F-76821 Mont St Aignan, France; Univ Ulsan, Coll Med, Dept Physiol, Seoul 138736, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Chonnam National University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; University of Ulsan; Seoul National University (SNU)	Seong, JY (corresponding author), Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea.	jyseong@jnu.ac.kr; kwonhb@jnu.ac.kr	Ahn, Ryun S./D-1218-2011; Seong, Jae Young/A-5794-2012; choe, han/A-5679-2010	Seong, Jae Young/0000-0002-3312-6924; choe, han/0000-0003-4604-647X				Acharjee S, 2004, J MOL ENDOCRINOL, V33, P293, DOI 10.1677/jme.0.0330293; Alescio-Lautier B, 1998, PROG BRAIN RES, V119, P501; Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223; Burbach JPH, 1995, CELL MOL NEUROBIOL, V15, P573, DOI 10.1007/BF02071318; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chen SH, 1999, J BIOL CHEM, V274, P16320, DOI 10.1074/jbc.274.23.16320; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; Dahia PLM, 1996, J CLIN ENDOCR METAB, V81, P1768, DOI 10.1210/jc.81.5.1768; deKeyzer Y, 1996, J CLIN INVEST, V97, P1311, DOI 10.1172/JCI118547; DEWIED D, 1993, FRONT NEUROENDOCRIN, V14, P251, DOI 10.1006/frne.1993.1009; ELALOUF JM, 1986, P NATL ACAD SCI USA, V83, P2276, DOI 10.1073/pnas.83.7.2276; Eugenin EA, 1998, AM J PHYSIOL-GASTR L, V274, pG1109, DOI 10.1152/ajpgi.1998.274.6.G1109; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; GILLIES GE, 1982, NATURE, V299, P355, DOI 10.1038/299355a0; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; GONZALEZ A, 1992, J COMP NEUROL, V315, P53, DOI 10.1002/cne.903150105; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JOHNSTON CI, 1985, J HYPERTENS, V3, P557, DOI 10.1097/00004872-198512000-00001; Kenakin T, 1996, TRENDS PHARMACOL SCI, V17, P190, DOI 10.1016/0165-6147(96)20026-4; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; LARCHER A, 1989, ENDOCRINOLOGY, V125, P2691, DOI 10.1210/endo-125-5-2691; LARCHER A, 1992, ENDOCRINOLOGY, V130, P475, DOI 10.1210/en.130.1.475; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; Moore FL, 2000, GEN COMP ENDOCR, V117, P281, DOI 10.1006/gcen.1999.7424; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; Oh DY, 2003, MOL CELL ENDOCRINOL, V205, P89, DOI 10.1016/S0303-7207(03)00204-1; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; PANG PKT, 1978, AM J PHYSIOL, V235, pF151, DOI 10.1152/ajprenal.1978.235.2.F151; Phalipou S, 1999, J BIOL CHEM, V274, P23316, DOI 10.1074/jbc.274.33.23316; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Rose JD, 2002, FRONT NEUROENDOCRIN, V23, P317, DOI 10.1016/S0091-3022(02)00004-3; RUGGLES BT, 1985, J CLIN ENDOCR METAB, V60, P914, DOI 10.1210/jcem-60-5-914; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Seong JY, 2003, ENDOCRINOLOGY, V144, P454, DOI 10.1210/en.2002-220683; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; Tan FI, 2000, BIOL REPROD, V62, P8, DOI 10.1095/biolreprod62.1.8; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang CB, 2004, MOL ENDOCRINOL, V18, P105, DOI 10.1210/me.2003-0101; WARBURG MR, 1995, ZOOL SCI, V12, P1, DOI 10.2108/zsj.12.1	48	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54445	54453		10.1074/jbc.M408909200	http://dx.doi.org/10.1074/jbc.M408909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475353	hybrid			2022-12-27	WOS:000225793600067
J	Amcheslavsky, A; Zou, W; Bar-Shavit, Z				Amcheslavsky, A; Zou, W; Bar-Shavit, Z			Toll-like receptor 9 regulates tumor necrosis factor-alpha expression by different mechanisms - Implications for osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INBRED MOUSE STRAINS; TOLL-LIKE RECEPTORS; TRYPANOSOMA-CONGOLENSE INFECTIONS; TNF-ALPHA; BONE-RESORPTION; CPG MOTIFS; RHEUMATOID-ARTHRITIS; GENE POLYMORPHISMS; BACTERIAL-DNA	CpG oligodeoxynucleotides (CpG-ODNs), mimicking bacterial DNA, stimulate osteoclastogenesis via Toll-like receptor 9 (TLR9) in receptor activator of NF-kappaB ligand (RANKL)-primed osteoclast precursors. This activity is mediated via tumor necrosis factor (TNF)-alpha induction by CpG-ODN. To further reveal the role of the cytokine in TLR9-mediated osteoclastogenesis, we compared the ability of CpG-ODN to induce osteoclastogenesis in two murine strains, BALB/c and C57BL/6, expressing different TNF-alpha alleles. The induction of osteoclastogenesis and TNF-alpha release by CpG-ODN was by far more noticeable in BALB/c-derived than in C57BL/6-derived osteoclast precursors. Unexpectedly, as revealed by Northern analysis, CpG-ODN induction of TNF-alpha mRNA increase was more efficient in C57BL/6-derived cells. The cytokine transcript abundance was increased due to both increased message stability and rate of transcription. The difference between the two cell types was the result of a higher transcription rate in CpG-ODN-induced C57BL/6-derived cells caused by a single nucleotide polymorphism in kappaB2a site within the TNF-alpha promoter sequence. CpG-ODN enhanced the rate of the cytokine translation in BALB/c-derived cells. Thus, CpG-ODN modulated both transcription and translation of TNF-alpha. The induction of transcription was more evident in C57BL/6-derived cells, while the induction of translation took place only in BALB/c-derived osteoclast precursors. Altogether the cytokine was induced to a larger extent in BALB/c-derived osteoclast precursors, consistent with the increased CpG-ODN osteoclastogenic effect in these cells.	Hebrew Univ Jerusalem, Fac Med, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Shavit, Z (corresponding author), Hebrew Univ Jerusalem, Fac Med, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel.	barsha@cc.huji.ac.il		Zou, Wei/0000-0001-8081-268X				AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson P, 2004, J LEUKOCYTE BIOL, V76, P42, DOI 10.1189/jlb.1103536; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; Bi YM, 2001, J BONE MINER RES, V16, P2082, DOI 10.1359/jbmr.2001.16.11.2082; BIRKEDALHANSEN H, 1993, J PERIODONTAL RES, V28, P500, DOI 10.1111/j.1600-0765.1993.tb02113.x; Brinkman BMN, 1997, BRIT J RHEUMATOL, V36, P516; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Craandijk J, 2002, J CLIN PERIODONTOL, V29, P28, DOI 10.1034/j.1600-051x.2002.290105.x; Crawford EK, 1997, J BIOL CHEM, V272, P21120, DOI 10.1074/jbc.272.34.21120; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dittmer U, 2003, CURR OPIN MICROBIOL, V6, P472, DOI 10.1016/j.mib.2003.09.007; Fabris M, 2002, J RHEUMATOL, V29, P29; Furuta I, 2004, CALCIFIED TISSUE INT, V74, P509, DOI 10.1007/s00223-003-0105-6; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Hajeer AH, 2001, HUM IMMUNOL, V62, P1191, DOI 10.1016/S0198-8859(01)00322-6; Hajeer AH, 2000, MICROSC RES TECHNIQ, V50, P216, DOI 10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Iraqi F, 1997, IMMUNOGENETICS, V45, P459, DOI 10.1007/s002510050233; Iraqi F, 1999, IMMUNOGENETICS, V49, P242, DOI 10.1007/s002510050487; Ito HO, 1996, ARCH ORAL BIOL, V41, P439, DOI 10.1016/0003-9969(96)00002-7; Karupiah G, 1998, VET IMMUNOL IMMUNOP, V63, P105, DOI 10.1016/S0165-2427(98)00086-5; Kaushik RS, 1999, EXP PARASITOL, V92, P131, DOI 10.1006/expr.1999.4408; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Krieg Arthur M, 2004, Curr Oncol Rep, V6, P88, DOI 10.1007/s11912-004-0019-0; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Kurihara N, 1998, EXP HEMATOL, V26, P1080; Kwon HJ, 2003, BIOCHEM BIOPH RES CO, V311, P129, DOI 10.1016/j.bbrc.2003.09.168; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; LINDEMANN RA, 1988, J DENT RES, V67, P1131, DOI 10.1177/00220345880670081401; Liu T, 2002, INFECT IMMUN, V70, P6638, DOI 10.1128/IAI.70.12.6638-6645.2002; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MILLAR SJ, 1986, INFECT IMMUN, V51, P302, DOI 10.1128/IAI.51.1.302-306.1986; Mohagheghpour N, 2000, CELL IMMUNOL, V199, P25, DOI 10.1006/cimm.1999.1599; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391; Paludan SR, 2001, J IMMUNOL, V167, P2202, DOI 10.4049/jimmunol.167.4.2202; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Saito K, 2001, ARTHRITIS RHEUM-US, V44, P2879, DOI 10.1002/1529-0131(200112)44:12<2879::AID-ART476>3.0.CO;2-4; Sapru K, 1999, CLIN EXP IMMUNOL, V115, P103; Shapira L, 2001, J PERIODONTAL RES, V36, P183, DOI 10.1034/j.1600-0765.2001.360307.x; STASHENKO P, 1987, J IMMUNOL, V138, P1464; TAKAO S, 1993, IMMUNOGENETICS, V37, P199, DOI 10.1007/BF00191885; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Tam YK, 2003, J HEMATOTH STEM CELL, V12, P467, DOI 10.1089/152581603322448178; THOMSON BM, 1987, J IMMUNOL, V138, P775; Ulett GC, 2000, INFECT IMMUN, V68, P2034, DOI 10.1128/IAI.68.4.2034-2042.2000; Uzonna JE, 1999, PARASITE IMMUNOL, V21, P57, DOI 10.1046/j.1365-3024.1999.00202.x; van Heel DA, 2002, HUM MOL GENET, V11, P1281, DOI 10.1093/hmg/11.11.1281; Waldron-Lynch F, 1999, J MED GENET, V36, P214; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Zeggini E, 2002, ARTHRITIS RHEUM-US, V46, P3304, DOI 10.1002/art.10698; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; Zou W, 2003, J BIOL CHEM, V278, P16732, DOI 10.1074/jbc.M212473200; Zou W, 2002, FASEB J, V16, P274, DOI 10.1096/fj.01-0586com; Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211	68	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54039	54045		10.1074/jbc.M409138200	http://dx.doi.org/10.1074/jbc.M409138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485822	hybrid			2022-12-27	WOS:000225793600020
J	Beharry, S; Zhong, M; Molday, RS				Beharry, S; Zhong, M; Molday, RS			N-retinylidene-phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-specific ABC transporter ABCA4 (ABCR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; STARGARDT MACULAR DYSTROPHY; DISEASE GENE ABCR; P-GLYCOPROTEIN; RIM PROTEIN; LIPOFUSCIN FLUOROPHORE; DEGENERATION; HYDROLYSIS; MICE; PHOSPHATIDYLCHOLINE	ABCA4, a member of the family of ATP binding cassette (ABC) proteins found in rod and cone photoreceptors, has been implicated in the transport of retinoid compounds across the outer segment disk membrane following the photoactivation of rhodopsin. Mutations in the ABCA4 gene are responsible for Stargardt macular dystrophy and related retinal degenerative diseases that cause a loss in vision. To identify the retinoid substrate that interacts with ABCA4, we have isolated ABCA4 from rod outer segment disk membranes on an immunoaffinity matrix and analyzed retinoid compounds that bind to ABCA4 using high performance liquid chromatography and radiolabeling methods. When all-trans-retinal was added to ABCA4 in the presence of phosphatidylethanolamine, similar to0.9 mol of N-retinylidene-phosphatidylethanolamine and 0.3 mol of all-trans-retinal were bound per mol of ABCA4 with an apparent K-d of 2-5 muM. ATP and GTP released these retinoids from ABCA4, whereas ADP, GDP, and nonhydrolyzable derivatives, adenosine 5'-(beta,gamma-imido) triphosphate and guanosine 5'-(beta,gamma-imido) triphosphate, were ineffective. One mole of N-retinyl-phosphatidylethanolamine, the reduced form of N-retinylidene-phosphatidylethanolamine, bound per mol of ABCA4, whereas 0.3 mol of all-trans-retinal were bound in the absence of phosphatidylethanolamine. No binding of all-trans-retinol to ABCA4 was observed. Our results indicate that ABCA4 preferentially binds N-retinylidene-phosphatidylethanolamine with high affinity in the absence of ATP. Our studies further suggest that ATP binding and hydrolysis induces a protein conformational change that causes N-retinylidene-phosphatidylethanolamine to dissociate from ABCA4.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol & Visual Sci, Ctr Macular Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca			NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn J, 2000, METHOD ENZYMOL, V315, P864; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Ahn JH, 2003, J BIOL CHEM, V278, P39600, DOI 10.1074/jbc.M304236200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; ROBINSON WE, 1979, NATURE, V280, P398, DOI 10.1038/280398a0; Rozet JM, 1999, MOL GENET METAB, V68, P310, DOI 10.1006/mgme.1999.2925; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Surya A, 1998, EXP EYE RES, V66, P599, DOI 10.1006/exer.1997.0453; TOMASZEK TA, 1986, J BIOL CHEM, V261, P2264; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	39	123	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53972	53979		10.1074/jbc.M405216200	http://dx.doi.org/10.1074/jbc.M405216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471866	hybrid			2022-12-27	WOS:000225793600011
J	Bercovich, Z; Kahana, C				Bercovich, Z; Kahana, C			Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LYSATE; INTRACELLULAR DEGRADATION; REQUIRES INTERACTION; POLYAMINES; CELLS; TARGET; GROWTH; ACCUMULATION; MUTAGENESIS; REPRESSION	Ornithine decarboxylase(ODC) is the most notable example of a protein degraded by the 26 S proteasome without ubiquitination. Instead, ODC is targeted to degradation by direct binding to a polyamine-induced protein termed antizyme (Az). Antizyme inhibitor (AzI) is an ODC-related protein that does not retain enzymatic activity yet binds Az with higher affinity than ODC. We show here that like ODC, AzI is also a short-lived protein that undergoes proteasomal degradation. However, in contrast to ODC degradation, the degradation of AzI is ubiquitin-dependent and does not require interaction with Az. Moreover, Az binding actually stabilizes AzI by inhibiting its ubiquitination. Substituting the C terminus of AzI with that of ODC, which together with Az constitutes the complete degradation signal of ODC, does not subvert AzI degradation from the ubiquitin-dependent mode to the Az-dependent mode, suggesting dominance of the ubiquitination signal. Our results suggest opposing roles of Az in regulating the degradation of AzI and ODC.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kahana, C (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	chaim.kahana@weizmann.ac.il						BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; COFFINO P, 1991, J CELL BIOCHEM, V45, P54, DOI 10.1002/jcb.240450112; FUJITA K, 1982, BIOCHEM J, V204, P647, DOI 10.1042/bj2040647; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; Gandre S, 2002, BIOCHEM BIOPH RES CO, V293, P139, DOI 10.1016/S0006-291X(02)00194-8; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Koguchi K, 1997, BBA-GENE STRUCT EXPR, V1353, P209, DOI 10.1016/S0167-4781(97)00106-1; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1995, J CELL BIOCHEM, P132; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	36	58	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54097	54102		10.1074/jbc.M410234200	http://dx.doi.org/10.1074/jbc.M410234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491992	hybrid			2022-12-27	WOS:000225793600027
J	Finley, NL; Rosevear, PR				Finley, NL; Rosevear, PR			Introduction of negative charge mimicking protein kinase C phosphorylation of cardiac troponin I - Effects on cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; N-TERMINAL DOMAIN; MUTATION; SITES; EXCHANGE; AFFINITY; BOVINE; RABBIT; MUSCLE; REGION	Protein kinase C phosphorylation of cardiac troponin, the Ca2+-sensing switch in muscle contraction, is capable of modulating the response of cardiac muscle to a Ca2+ ion concentration. The N-domain of cardiac troponin I contains two protein kinase C phosphorylation sites. Although the physiological consequences of phosphorylation at Ser(43)/Ser(45) are known, the molecular mechanisms responsible for these functional changes have yet to be established. In this work, NMR was used to identify conformational and dynamic changes in cardiac troponin C upon binding a phosphomimetic troponin I, having Ser(43)/Ser(45) mutated to Asp. Chemical shift perturbation mapping indicated that residues in helix G were most affected. Smaller chemical shift changes were observed in residues located in the Ca2+/Mg2+-binding loops. Amide hydrogen/deuterium exchange rates in the C-lobe of troponin C were compared in complexes containing either the wild-type or phosphomimetic N-domain of troponin I. In the presence of a phosphomimetic domain, exchange rates in helix G increased, whereas a decrease in exchange rates for residues mapping to Ca2+/Mg2+-binding loops III and IV was observed. Increased exchange rates are consistent with destabilization of the Thr(129) - Asp(132) helix capping box previously characterized in helix G. The perturbation of helix G and metal binding loops III and IV suggests that phosphorylation alters metal ion affinity and inter-subunit interactions. Our studies support a novel mechanism for protein kinase C signal transduction, emphasizing the importance of C-lobe Ca2+/Mg2+-dependent troponin interactions.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Cincinnati	Rosevear, PR (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	rosevear@proto.med.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline; NIAMS NIH HHS [AR44324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott MB, 2000, J BIOL CHEM, V275, P20610, DOI 10.1074/jbc.M909252199; Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; BRITO RMM, 1993, J BIOL CHEM, V268, P20966; Burkart EM, 2003, J MOL CELL CARDIOL, V35, P1285, DOI 10.1016/S0022-2828(03)00240-2; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Calvert MJ, 2000, J BIOL CHEM, V275, P32508, DOI 10.1074/jbc.M005764200; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Finley N, 2000, J MOL CELL CARDIOL, V32, P1439, DOI 10.1006/jmcc.2000.1174; Finley NL, 2004, BIOCHEMISTRY-US, V43, P11371, DOI 10.1021/bi049672i; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; Huang L, 2001, AM J PHYSIOL-CELL PH, V280, pC1114, DOI 10.1152/ajpcell.2001.280.5.C1114; Kapp GT, 2004, BIOCHEMISTRY-US, V43, P3814, DOI 10.1021/bi035683k; Kobayashi T, 2004, BIOCHEMISTRY-US, V43, P5996, DOI 10.1021/bi036073n; Leblanc L, 2000, ARCH BIOCHEM BIOPHYS, V384, P296, DOI 10.1006/abbi.2000.2103; Li MX, 2003, BIOCHEMISTRY-US, V42, P14460, DOI 10.1021/bi035408y; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; Montgomery DE, 2002, AM J PHYSIOL-HEART C, V282, pH2397, DOI 10.1152/ajpheart.00714.2001; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Smart JL, 1999, BIOPOLYMERS, V49, P225, DOI 10.1002/(SICI)1097-0282(199903)49:3<225::AID-BIP4>3.0.CO;2-B; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Sumandea MP, 2004, ANN NY ACAD SCI, V1015, P39, DOI 10.1196/annals.1302.004; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TRIGOGONZALEZ G, 1993, BIOCHEMISTRY-US, V32, P9826, DOI 10.1021/bi00088a038; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Ward DG, 2004, BIOCHEMISTRY-US, V43, P5772, DOI 10.1021/bi036310m; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	30	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54833	54840		10.1074/jbc.M408304200	http://dx.doi.org/10.1074/jbc.M408304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485824	hybrid			2022-12-27	WOS:000225793600112
J	Jonas, BA; Privalsky, ML				Jonas, BA; Privalsky, ML			SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR SUPERFAMILY; THYROID-HORMONE RECEPTORS; RETINOIC-ACID; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; KAPPA-B; HISTONE ACETYLATION; SILENCING MEDIATOR; PROTEIN; PHOSPHORYLATION	N-CoR and SMRT are corepressor paralogs that partner with and mediate transcriptional repression by a wide variety of metazoan transcription factors, including nuclear hormone receptors. Although encoded by distinct genetic loci, N-CoR and SMRT share substantial sequence interrelatedness, form analogous assemblies with histone deacetylases and auxiliary factors, can interact with overlapping sets of transcription factor partners, and exert overlapping functions in cells. SMRT is subject to negative regulation by MAPK signaling pathways operating downstream of growth factor and stress signaling pathways. We report here that whereas activation of MEKK1 leads to phosphorylation of SMRT, its dissociation from its transcription factor partners in vivo and in vitro, and its redistribution from the cell nucleus to a cytoplasmic compartment, N-CoR is refractory to all these forms of regulation. In contrast to this MAPK cascade, other signal transduction pathways operating downstream of growth factor/cytokine receptors appear able to affect both corepressor paralogs. Our results indicate that SMRT and N-CoR are embedded in distinct regulatory networks and that the two corepressors interpret growth factor, cytokine, differentiation, and prosurvival signals differently.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Jonas, Brian/AAS-3639-2020	Jonas, Brian/0000-0002-4921-5809	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007377] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK053528-02, DK53528, R01 DK053528] Funding Source: Medline; NIGMS NIH HHS [T32 GM007377, T32 GM007377-22, T32GM07377] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Berger SL, 2001, SCIENCE, V292, P64; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Farboud B, 2003, MOL CELL BIOL, V23, P2844, DOI 10.1128/MCB.23.8.2844-2858.2003; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Glass CK, 2000, GENE DEV, V14, P121; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guenther MG, 2000, GENE DEV, V14, P1048; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Hauksdottir H, 2003, MOL ENDOCRINOL, V17, P373, DOI 10.1210/me.2002-0340; Hermanson O, 2002, NATURE, V419, P934, DOI 10.1038/nature01156; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Tsuda L, 2002, CELL, V110, P625, DOI 10.1016/S0092-8674(02)00875-9; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	80	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54676	54686		10.1074/jbc.M410128200	http://dx.doi.org/10.1074/jbc.M410128200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491994	Green Accepted, hybrid			2022-12-27	WOS:000225793600094
J	Richard, D; Leprohon, P; Drummelsmith, J; Ouellette, M				Richard, D; Leprohon, P; Drummelsmith, J; Ouellette, M			Growth phase regulation of the main folate transporter of Leishmania infantum and its role in methotrexate resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; SYNTHETASE-DIHYDROFOLATE REDUCTASE; VISCERAL LEISHMANIASIS; MEMBRANE-PROTEIN; GENE; AMPLIFICATION; METABOLISM; BIOPTERIN; PURIFICATION; MILTEFOSINE	The protozoan parasite Leishmania relies on the uptake of folate and pterin from the environment to meet its nutritional requirements. We show here that a novel gene ( folate transporter 1 (FT1)) deleted in a Leishmania infantum methotrexate-resistant mutant corresponds to the main folate transporter (K-m, 410 nM). FT1 was established as the main folate transporter by both gene transfection and by targeted gene deletion. Modulation of the expression of FT1 by these manipulations altered the susceptibility of Leishmania cells to methotrexate. Folate transport was stage-regulated with higher activity in the logarithmic phase and less in the stationary phase. FT1 fused to green fluorescent protein led to the observation that FT1 was located in the plasma membrane in the logarithmic phase but was re-targeted to an intracellular organelle followed by a degradation of the protein in stationary phase. Leishmania has several folate transporters with different characteristics, and the growth stage-related activity of at least one transporter is regulated post-translationally.	Univ Laval, Ctr Hosp, Ctr Rech, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Div Microbiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Ouellette, M (corresponding author), CHUQ, Ctr Rech Infectiol, Pavillon CHUL,2705 Boul Laurier, Ste Foy, PQ G1V 4G2, Canada.	Marc.Ouellette@crchul.ulaval.ca	Leprohon, Philippe/U-5474-2019; Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646				CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; Dodge MA, 2004, MOL MICROBIOL, V51, P1563, DOI 10.1111/j.1365-2958.2003.03927.x; El Fadili A, 2004, J BIOL CHEM, V279, P18575, DOI 10.1074/jbc.M400652200; El Fadili A, 2002, MOL BIOCHEM PARASIT, V124, P63, DOI 10.1016/S0166-6851(02)00163-9; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P10053; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; Gilbert IH, 2002, BBA-MOL BASIS DIS, V1587, P249, DOI 10.1016/S0925-4439(02)00088-1; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; HARLOW E, 1988, ANTIBODIES LAB MANUA, P377; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; KAUR K, 1988, J BIOL CHEM, V263, P7020; KUMAR HP, 1987, J BIOL CHEM, V262, P7171; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; LEGARE D, 1994, MOL BIOCHEM PARASIT, V68, P81, DOI 10.1016/0166-6851(94)00156-1; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; LO RS, 1991, P ROY SOC B-BIOL SCI, V246, P161, DOI 10.1098/rspb.1991.0139; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; NARE B, 1997, PARASITOLOGY, V114, P101; Ouellette M, 2002, INT J PARASITOL, V32, P385, DOI 10.1016/S0020-7519(01)00346-0; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; Perez-Victoria FJ, 2003, J BIOL CHEM, V278, P49965, DOI 10.1074/jbc.M308352200; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Roy G, 2001, EXP PARASITOL, V97, P161, DOI 10.1006/expr.2001.4595; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; SHANE B, 1975, J BIOL CHEM, V250, P2243; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946	40	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54494	54501		10.1074/jbc.M409264200	http://dx.doi.org/10.1074/jbc.M409264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15466466	hybrid			2022-12-27	WOS:000225793600073
J	Silberg, JJ; Tapley, TL; Hoff, KG; Vickery, LE				Silberg, JJ; Tapley, TL; Hoff, KG; Vickery, LE			Regulation of the HscA ATPase reaction cycle by the co-chaperone HscB and the iron-sulfur cluster assembly protein IscU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 MOLECULAR CHAPERONE; ESCHERICHIA-COLI; SUBSTRATE-BINDING; J-DOMAIN; SACCHAROMYCES-CEREVISIAE; KINETIC CHARACTERIZATION; NMR STRUCTURE; RICH REGION; DNAK; BIOGENESIS	The ATPase activity of HscA, a specialized hsp70 molecular chaperone from Escherichia coli, is regulated by the iron-sulfur cluster assembly protein IscU and the J-type co-chaperone HscB. IscU behaves as a substrate for HscA, and HscB enhances the binding of IscU to HscA. To better understand the mechanism by which HscB and IscU regulate HscA, we examined binding of HscB to the different conformational states of HscA and the effects of HscB and IscU on the kinetics of the individual steps of the HscA ATPase reaction cycle. Affinity sensor studies revealed that whereas IscU binds both ADP (R-state) and ATP (T-state) HscA complexes, HscB interacts only with an ATP-bound state. Studies of ATPase activity under single-turnover and rapid mixing conditions showed that both IscU and HscB interact with the low peptide affinity T-state of HscA (HscA(double dagger).ATP) and that both modestly accelerate (3-10-fold) the rate-determining steps in the HscA reaction cycle, k(hyd) and k(T-->R). When present together, IscU and HscB synergistically stimulate both k(hyd) (congruent to500-fold) and k(T-->R) (congruent to60-fold), leading to enhanced formation of the HscA.ADP-IscU complex (substrate capture). Following ADP/ATP exchange, IscU also stimulates k(R-->T) (congruent to50-fold) and thereby accelerates the rate at which the low peptide affinity HscA(double dagger).ATP T-state is regenerated. Because HscA nucleotide exchange is fast, the overall rate of the chaperone cycle in vivo will be determined by the availability of the IscU-HscB substrate-co-chaperone complex.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	lvickery@uci.edu	Silberg, Jonathan J/A-3817-2010		NCI NIH HHS [T532CA09054] Funding Source: Medline; NIGMS NIH HHS [GM07311, F32 GM64949-01, GM54264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Cupp-Vickery JR, 2000, J MOL BIOL, V304, P835, DOI 10.1006/jmbi.2000.4252; CUPPVICKERY J, 2004, IN PRESS J MOL BIOL; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2001, P NATL ACAD SCI USA, V98, P14751, DOI 10.1073/pnas.011579098; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Goffin L, 1998, MOL MICROBIOL, V30, P329, DOI 10.1046/j.1365-2958.1998.01067.x; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Mally A, 2001, NAT STRUCT BIOL, V8, P254, DOI 10.1038/85002; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Tapley TL, 2004, J BIOL CHEM, V279, P28435, DOI 10.1074/jbc.M400803200; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WALL D, 1994, J BIOL CHEM, V269, P5446; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wittung-Stafshede P, 2003, BIOCHEMISTRY-US, V42, P4937, DOI 10.1021/bi027333o; Yan W, 1999, MOL CELL BIOL, V19, P7751; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	56	71	73	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53924	53931		10.1074/jbc.M410117200	http://dx.doi.org/10.1074/jbc.M410117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485839	hybrid			2022-12-27	WOS:000225793600005
J	Wang, HM; Hu, XY; Ding, X; Dou, Z; Yang, ZH; Shaw, AW; Teng, MK; Cleveland, DW; Goldberg, ML; Niu, LW; Yao, XB				Wang, HM; Hu, XY; Ding, X; Dou, Z; Yang, ZH; Shaw, AW; Teng, MK; Cleveland, DW; Goldberg, ML; Niu, LW; Yao, XB			Human Zwint-1 specifies localization of zeste white 10 to kinetochores and is essential for mitotic checkpoint signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH-DEAL; CENP-E; SPINDLE MICROTUBULES; HUMAN CANCERS; ZW10; DROSOPHILA; COMPONENT; MITOSIS; CELLS; MAD2	Chromosome segregation in mitosis is orchestrated by dynamic interaction between spindle microtubules and the kinetochore, a multiprotein complex assembled onto centromeric DNA of the chromosome. Here we show that Zwint-1 is required and is sufficient for kinetochore localization of Zeste White 10 (ZW10) in HeLa cells. Zwint-1 specifies the kinetochore association of ZW10 by interacting with its N-terminal domain. Suppression of synthesis of Zwint-1 by small interfering RNA abolishes the localization of ZW10 to the kinetochore, demonstrating the requirement of Zwint-1 for ZW10 kinetochore localization. In addition, depletion of Zwint-1 affects no mitotic arrest but causes aberrant premature chromosome segregation. These Zwint-1-suppressed cells display chromosome bridge phenotype with sister chromatids inter-connected. Moreover, Zwint-1 is required for stable association of CENP-F and dynamitin but not BUB1 with the kinetochore. Finally, our studies show that Zwint-1 is a new component of the mitotic checkpoint, as cells lacking Zwint-1 fail to arrest in mitosis when exposed to microtubule inhibitors, yielding interphase cells with multinuclei. As ZW10 and Zwint-1 are absent from yeast, we reasoned that metazoans evolved an elaborate spindle checkpoint machinery to ensure faithful chromosome segregation in mitosis.	CAS Key Lab Struct Biol, Hefei 230027, Peoples R China; Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Proteom Res Lab, Beijing 100086, Peoples R China; Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Morehouse School of Medicine; Ludwig Institute for Cancer Research; Cornell University	Yao, XB (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China.	yaox6@ustc.edu.cn	Cleveland, Don/AAN-9783-2021; Yao, Xuebiao/P-5771-2014; DOU, ZHEN/N-2022-2013; Hu, Xiaoyu/M-2786-2015	DOU, ZHEN/0000-0003-3303-9393; Cleveland, Don/0000-0002-1934-3682; Wang, Hongmei/0000-0002-5881-2488				Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Scaerou F, 2001, J CELL SCI, V114, P3103; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Starr DA, 2000, J CELL SCI, V113, P1939; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435	27	93	101	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54590	54598		10.1074/jbc.M407588200	http://dx.doi.org/10.1074/jbc.M407588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485811	hybrid			2022-12-27	WOS:000225793600085
J	del Re, E; Sidis, Y; Fabrizio, DA; Lin, HY; Schneyer, A				del Re, E; Sidis, Y; Fabrizio, DA; Lin, HY; Schneyer, A			Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; EXPRESSION CLONING; SIGNALING PATHWAY; SERINE KINASE; III RECEPTOR; BINDING; BETA; GROWTH; FOLLISTATIN; PROTEIN	Activins and inhibins compose a heterogeneous subfamily within the transforming growth factor-beta (TGF-beta) superfamily of growth and differentiation factors with critical biological activities in embryos and adults. They signal through a heteromeric complex of type II, type I, and for inhibin, type III receptors. To characterize the affinity, specificity, and activity of these receptors (alone and in combination) for the inhibin/ activin subfamily, we developed a cell-free assay system using soluble receptor-Fc fusion proteins. The soluble activin type II receptor (sActRII)-Fc fusion protein had a 7-fold higher affinity for activin A compared with sActRIIB-Fc, whereas both receptors had a marked preference for activin A over activin B. Although inhibin A and B binding was 20-fold lower compared with activin binding to either type II receptor alone, the mixture of either type II receptor with soluble TGF-beta type III receptor (TbetaRIII; betaglycan)-Fc reconstituted a soluble high affinity inhibin receptor. In contrast, mixing either soluble activin type II receptor with soluble activin type I receptors did not substantially enhance activin binding. Our results support a cooperative model of binding for the inhibin receptor (ActRII.sTbetaRIII complex) but not for activin receptors (type II + type I) and demonstrate that a complex composed of activin type II receptors and TbetaRIII is both necessary and sufficient for high affinity inhibin binding. This study also illustrates the utility of this cell-free system for investigating hypotheses of receptor complex mechanisms resulting from crystal structure analyses.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Reprod Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Renal Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Schneyer, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Reprod Endocrine Unit, BHX-5,55 Fruit St, Boston, MA 02114 USA.	schneyer.alan@mgh.harvard.edu	del Re, Elisabetta C./AAW-8913-2020	del Re, Elisabetta C./0000-0002-9645-4845				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Brown CW, 2000, NAT GENET, V25, P453, DOI 10.1038/78140; Brown CW, 2003, MOL ENDOCRINOL, V17, P2404, DOI 10.1210/me.2003-0051; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; De Crescenzo G, 2004, J BIOL CHEM, V279, P26013, DOI 10.1074/jbc.M400655200; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Donaldson CJ, 1999, ENDOCRINOLOGY, V140, P1760, DOI 10.1210/en.140.4.1760; DONALDSON CJ, 1995, BIOCHEM BIOPH RES CO, V184, P310; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; HILDEN K, 1994, BLOOD, V83, P2163; Leal AMO, 2002, ENDOCRINOLOGY, V143, P964, DOI 10.1210/en.143.3.964; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; MATHEWS LS, 1993, RECEPTOR, V3, P173; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Rodbard D, 1975, RADIOIMMUNOASSAY REL, V1, P469; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; Schneyer A, 2003, ENDOCRINOLOGY, V144, P1671, DOI 10.1210/en.2002-0203; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sidis Y, 2002, ENDOCRINOLOGY, V143, P1613, DOI 10.1210/en.143.5.1613; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; Wada W, 2004, AM J PHYSIOL-ENDOC M, V287, pE247, DOI 10.1152/ajpendo.00390.2003; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196	43	26	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53126	53135		10.1074/jbc.M408090200	http://dx.doi.org/10.1074/jbc.M408090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475360	hybrid			2022-12-27	WOS:000225680600041
J	Guo, DL; Hu, K; Lei, Y; Wang, YC; Ma, TL; He, DC				Guo, DL; Hu, K; Lei, Y; Wang, YC; Ma, TL; He, DC			Identification and characterization of a novel cytoplasm protein ICF45 that is involved in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONING; SCLERODERMA; SEQUENCE; LOCALIZATION; AUTOANTIBODY; ANTINUCLEAR; CENTROSOME; EXPRESSION; ANTIBODIES; CANCER	A novel cytoplasm protein, interphase cytoplasm foci protein 45 kDa (ICF45), was identified by screening the cDNA expression library for HeLa cells with serum from an autoimmune patient. The complete cDNA sequence of ICF45 was determined to be 1.32 kb and to encode 298 amino acids with an apparent molecular mass of 45 kDa. The ICF45 transcripts were detected in different tissues and were relatively rich in human liver and lung tissues but scarce in brain tissue. Immunofluorescence with anti-ICF45-specific antibodies demonstrated that ICF45 is strongly expressed in interphase and cannot be seen in mitosis. The subcellular localization of ICF45 and fusion proteins GFP-ICF45, ICF45-GFP, and HA-ICF45 showed ICF45 centralized into 1 - 2 dots in the cytoplasm and always near the nuclear membrane. The staining foci of ICF45 appeared to be slightly larger than centrosomes and in some cases were found to colocalize with centrosomes. After effectively silencing the ICF45 by RNAi, the growth and proliferation of the cells were significantly inhibited, and p53 was detected to be up-regulated. The silencing of ICF45 also resulted in an appearance of polycentrosome and multinuclear cells, which finally went to apoptosis. Our results suggest that ICF45 is a highly conserved novel protein, which is expressed in a cell cycle-dependent manner and seemed to be involved in cell cycle progression and cell proliferation.	Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Beijing Normal University; Fox Chase Cancer Center	He, DC (corresponding author), Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China.	dhe@bnu.edu.cn	Guo, Deliang/I-3735-2014	Guo, Deliang/0000-0002-8359-390X				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; CHAN EKL, 1992, RHEUM DIS CLIN N AM, V18, P551; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Ditzel HJ, 2000, IMMUNOL RES, V21, P185, DOI 10.1385/IR:21:2-3:185; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; He DC, 1998, CHROMOSOMA, V107, P189, DOI 10.1007/s004120050296; KIPNIS RJ, 1990, ARTHRITIS RHEUM, V33, P1431, DOI 10.1002/art.1780330917; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; POLLARD KM, 1989, CLIN EXP RHEUMATOL, V7, pS57; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHEETS M, 1992, NUCLEIC ACIDS RES, V18, P5799; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Watson M, 1996, ARTHRITIS RHEUM, V39, P341, DOI 10.1002/art.1780390226; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314	25	21	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53498	53505		10.1074/jbc.M406737200	http://dx.doi.org/10.1074/jbc.M406737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459185	hybrid			2022-12-27	WOS:000225680600085
J	Munroe, ME; Bishop, GA				Munroe, ME; Bishop, GA			Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOTOXIN BETA-RECEPTOR; JUN KINASE ACTIVATION; MONOCLONAL-ANTIBODIES; LATENT MEMBRANE-PROTEIN-1; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; NF-KAPPA-B2 P100; GENE-EXPRESSION; CELL-ACTIVATION	Members of the tumor necrosis factor receptor (TNFR) family play a variety of roles in the regulation of lymphocyte activation. An important TNFR family member for B cell activation is CD40. CD40 signals stimulate B cell TNF-alpha secretion, which subsequently signals via TNFR2 (CD120b) to enhance B cell activation. Although the function of the pro-apoptotic and pro-inflammatory receptor TNFR1 (CD120a) has been the subject of much research, less is understood about the distinct contributions of CD120b to cell activation and how it stimulates downstream events. Members of the tumor necrosis factor receptor family bind various members of the cytoplasmic adapter protein family, the tumor necrosis factor receptor-associated factors (TRAFs), during signaling. Both CD40 and CD120b bind TNF receptor-associated factor 2 (TRAF2) upon ligand stimulation. Wild type and TRAF2-deficient B cells expressing CD40 or the hybrid molecule ( human) CD40 (mouse)-CD120b were examined. CD40- and CD120b-mediated IgM secretion were partly TRAF2-dependent, but only CD40 required TRAF2 for c-Jun N-terminal kinase activation. CD40 and CD120b used primarily divergent mechanisms to activate NF-kappaB, exemplifying how TNFR family members can use diverse mechanisms to mediate similar downstream events.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Bishop, GA (corresponding author), Univ Iowa, Dept Microbiol, 2193B MERF, Iowa City, IA 52242 USA.	gail-bishop@uiowa.edu		Bishop, Gail/0000-0002-1291-5078; Munroe, Melissa/0000-0002-6933-9745	NATIONAL CANCER INSTITUTE [R01CA099997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028847, T32AI007260, R01AI049993, R01AI028847, R56AI028847, R56AI049993] Funding Source: NIH RePORTER; NCI NIH HHS [CA099997] Funding Source: Medline; NIAID NIH HHS [AI49993, AI07343, AI07260, AI28847] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bhushan A, 2001, IMMUNOL RES, V24, P311, DOI 10.1385/IR:24:3:311; Bishop GA, 2002, J LEUKOCYTE BIOL, V72, P19; BISHOP GA, 1995, EUR J IMMUNOL, V25, P1230, DOI 10.1002/eji.1830250515; BISHOP GA, 1991, J IMMUNOL, V147, P1107; Bishop GA, 2001, IMMUNOL RES, V24, P97, DOI 10.1385/IR:24:2:097; Bishop GA, 2001, ARCH IMMUNOL THER EX, V49, P129; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Craxton A, 1998, J IMMUNOL, V161, P3225; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; HAMANO T, 1982, J IMMUNOL, V129, P1403; Haridas V, 1998, J IMMUNOL, V160, P3152; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Hostager BS, 1999, J IMMUNOL, V162, P6307; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hsing Y, 1999, J IMMUNOL, V162, P2804; Hsing Y, 1997, J IMMUNOL, V159, P4898; Kaneko Y, 1996, EUR J IMMUNOL, V26, P3061, DOI 10.1002/eji.1830261236; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kollias G, 2002, CYTOKINE GROWTH F R, V13, P315, DOI 10.1016/S1359-6101(02)00019-9; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lesley R, 2004, IMMUNITY, V20, P441, DOI 10.1016/S1074-7613(04)00079-2; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; MERCOLINO TJ, 1986, J EXP MED, V163, P155, DOI 10.1084/jem.163.1.155; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Renvoize C, 1998, CELL BIOL TOXICOL, V14, P111, DOI 10.1023/A:1007429904664; Rieckmann P, 1997, METHODS, V11, P128, DOI 10.1006/meth.1996.0396; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schonbeck U, 2000, INT J BIOCHEM CELL B, V32, P687, DOI 10.1016/S1357-2725(00)00016-9; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; WARREN WD, 1995, J IMMUNOL, V155, P5637; Wilkinson N, 2003, ARCH DIS CHILD, V88, P186, DOI 10.1136/adc.88.3.186; Xie P, 2004, J EXP MED, V199, P661, DOI 10.1084/jem.20031255; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101; Zeggini E, 2002, ARTHRITIS RHEUM-US, V46, P3304, DOI 10.1002/art.10698	58	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53222	53231		10.1074/jbc.M410539200	http://dx.doi.org/10.1074/jbc.M410539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485859	hybrid			2022-12-27	WOS:000225680600052
J	Zhang, YM; Frank, MW; Virga, KG; Lee, RE; Rock, CO; Jackowski, S				Zhang, YM; Frank, MW; Virga, KG; Lee, RE; Rock, CO; Jackowski, S			Acyl carrier protein is a cellular target for the antibacterial action of the pantothenamide class of pantothenate antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CONTENT; ESCHERICHIA-COLI; BIOSYNTHESIS; KINASE; ACID; GENE; ADENYLYLTRANSFERASE; PHOSPHODIESTERASE; IDENTIFICATION; PURIFICATION	Pantothenate is the precursor of the essential cofactor coenzyme A (CoA). Pantothenate kinase (CoaA) catalyzes the first and regulatory step in the CoA biosynthetic pathway. The pantothenate analogs N-pentylpantothenamide and N-heptylpantothenamide possess antibiotic activity against Escherichia coli. Both compounds are substrates for E. coli CoaA and competitively inhibit the phosphorylation of pantothenate. The phosphorylated pantothenamides are further converted to CoA analogs, which were previously predicted to act as inhibitors of CoA-dependent enzymes. Here we show that the mechanism for the toxicity of the pantothenamides is due to the inhibition of fatty acid biosynthesis through the formation and accumulation of the inactive acyl carrier protein (ACP), which was easily observed as a faster migrating protein using conformationally sensitive gel electrophoresis. E. coli treated with the pantothenamides lost the ability to incorporate [1-C-14] acetate to its membrane lipids, indicative of the inhibition of fatty acid synthesis. Cellular CoA was maintained at the level sufficient for bacterial protein synthesis. Electrospray ionization time-of-flight mass spectrometry confirmed that the inactive ACP was the product of the transfer of the inactive phosphopantothenamide moiety of the CoA analog to apo-ACP, forming the ACP analog that lacks the sulfhydryl group for the attachment of acyl chains for fatty acid synthesis. Inactive ACP accumulated in pantothenamide-treated cells because of the active hydrolysis of regular ACP and the slow turnover of the inactive prosthetic group. Thus, the pantothenamides are pro-antibiotics that inhibit fatty acid synthesis and bacterial growth because of the covalent modification of ACP.	St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Zhang, YM (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, 332 N Lauderdale St, Memphis, TN 38105 USA.	yongmei.zhang@stjude.org	Lee, Richard/J-4997-2013; Lee, Richard/AAX-3996-2021; Jackowski, Suzanne/N-8168-2018	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443; Jackowski, Suzanne/0000-0002-6855-1429; Frank, Matthew/0000-0002-4914-1440	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 62896, GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM062896, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Ivey RA, 2004, J BIOL CHEM, V279, P35622, DOI 10.1074/jbc.M403152200; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JACKOWSKI S, 1984, J BIOL CHEM, V259, P1891; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Keating DH, 1996, J BACTERIOL, V178, P2662, DOI 10.1128/jb.178.9.2662-2667.1996; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; POWELL GL, 1969, J BIOL CHEM, V211, P5610; ROCK CO, 1981, J BIOL CHEM, V256, P2669; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1985, J BACTERIOL, V164, P136, DOI 10.1128/JB.164.1.136-142.1985; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988	33	71	74	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50969	50975		10.1074/jbc.M409607200	http://dx.doi.org/10.1074/jbc.M409607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459190	hybrid			2022-12-27	WOS:000225355800041
J	Buss, H; Dorrie, A; Schmitz, ML; Frank, R; Livingstone, M; Resch, K; Kracht, M				Buss, H; Dorrie, A; Schmitz, ML; Frank, R; Livingstone, M; Resch, K; Kracht, M			Phosphorylation of serine 468 by GSK-3 beta negatively regulates basal p65 NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SPOT-SYNTHESIS; ZETA-PKC; ACTIVATION; TRANSCRIPTION; ALPHA; INHIBITORS; APOPTOSIS; SURVIVAL; SUBUNIT	The activity of NF-kappaB is controlled at several levels including the phosphorylation of the strongly transactivating p65 (RelA) subunit. However, the overall number of phosphorylation sites, the signaling pathways and protein kinases that target p65 NF-kappaB and the functional role of these phosphorylations are still being uncovered. Using a combination of peptide arrays with in vitro kinase assays we identify serine 468 as a novel phosphorylation site of p65 NF-kappaB. Serine 468 lies within a GSK-3beta consensus site, and recombinant GSK-3beta specifically phosphorylates a GST-p65-(354-551) fusion protein at Ser(468) in vitro. In intact cells, phosphorylation of endogenous Ser(468) of p65 is induced by the PP1/PP2A phosphatase inhibitor calyculin A and this effect is inhibited by the GSK-3beta inhibitor LiCl. Reconstitution of p65-deficient cells with a p65 protein where serine 468 was mutated to alanine revealed a negative regulatory role of serine 468 for NF-kappaB activation. Collectively our results suggest that a GSK-3beta-PP1-dependent mechanism regulates phosphorylation of p65 NF-kappaB at Ser(468) in unstimulated cells and thereby controls the basal activity of NF-kappaB.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; German Res Ctr Biotechnol, Dept Biol Chem, D-38124 Braunschweig, Germany; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Hannover Medical School; University of Bern; Helmholtz Association; Helmholtz-Center for Infection Research	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	kracht.michael@MH-hannover.de	Schmitz, M. Lienhard/D-9328-2017; Livingstone, Mark/H-1709-2011	Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X; Livingstone, Mark/0000-0002-2757-7008				Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 2004, IN PRESS BLOOD; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	37	201	211	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49571	49574		10.1074/jbc.C400442200	http://dx.doi.org/10.1074/jbc.C400442200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15465828	hybrid			2022-12-27	WOS:000225229500005
J	Cole, AR; Knebel, A; Morrice, NA; Robertson, LA; Irving, AJ; Connolly, CN; Sutherland, C				Cole, AR; Knebel, A; Morrice, NA; Robertson, LA; Irving, AJ; Connolly, CN; Sutherland, C			GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; HIPPOCAMPAL-NEURONS; RAT-BRAIN; TRANSGENIC MICE; BETA-CATENIN; TAU; GROWTH; CRMP-2; INACTIVATION; EXPRESSION	Elevated glycogen synthase kinase-3 (GSK-3) activity is associated with Alzheimer disease. We have found that collapsin response mediator proteins (CRMP) 2 and 4 are physiological substrates of GSK-3. The amino acids targeted by GSK-3 comprise a hyperphosphorylated epitope first identified in plaques isolated from Alzheimer brain. Expression of wild type CRMP2 in primary hippocampal neurons or SH-SY5Y neuroblastoma cells promotes axon elongation. However, a GSK-3-insensitive CRMP2 mutant has dramatically reduced ability to promote axon elongation, a similar effect to pharmacological inhibition of GSK-3. Hence, we propose that phosphorylation of CRMP proteins by GSK-3 regulates axon elongation. This work provides a direct connection between hyperphosphorylation of these residues and elevated GSK-3 activity, both of which are observed in Alzheimer brain.	Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Lab 4 21, Kinasource, Dundee DD1 4HN, Scotland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Dundee; University of Dundee; University of Dundee	Sutherland, C (corresponding author), Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	c.d.sutherland@dundee.ac.uk	Cole, Adam/B-9785-2011	Knebel, Axel/0000-0002-9197-6054; Sutherland, Calum/0000-0003-4398-7434; Connolly, Christopher/0000-0002-0445-8874	Biotechnology and Biological Sciences Research Council [C18727] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Campbell David G, 2002, J Biomol Tech, V13, P119; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jamsa A, 2004, BIOCHEM BIOPH RES CO, V319, P993, DOI 10.1016/j.bbrc.2004.05.075; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Owen R, 2003, MOL CELL NEUROSCI, V23, P626, DOI 10.1016/S1044-7431(03)00095-2; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rae MG, 2000, J NEUROSCI, V20, P8628; Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takahashi M, 2000, BRAIN RES, V857, P193, DOI 10.1016/S0006-8993(99)02424-5; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yao HB, 2002, J CHEM NEUROANAT, V23, P291, DOI 10.1016/S0891-0618(02)00014-5; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	31	205	215	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50176	50180		10.1074/jbc.C400412200	http://dx.doi.org/10.1074/jbc.C400412200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15466863	Green Accepted, hybrid			2022-12-27	WOS:000225229500077
J	Breustedt, DA; Korndorfer, IP; Redl, B; Skerra, A				Breustedt, DA; Korndorfer, IP; Redl, B; Skerra, A			The 1.8-angstrom crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EBNERS GLAND PROTEIN; DIRECTED TRYPTOPHAN FLUORESCENCE; BINDING INHIBITOR; COMPLEX; CYSTATIN; GENE; PREALBUMIN; REFINEMENT; EXPRESSION; SEQUENCES	In contrast with earlier assumptions, which classified human tear lipocalin (Tlc) as an outlier member of the lipocalin protein family, the 1.8-Angstrom resolution crystal structure of the recombinant apoprotein confirms the typical eight-stranded antiparallel beta-barrel architecture with an alpha-helix attached to it. The fold of Tlc most closely resembles the bovine dander allergen Bos d 2, a well characterized prototypic lipocalin, but also reveals similarity with beta-lactoglobulin. However, compared with other lipocalin structures Tlc exhibits an extremely wide ligand pocket, whose entrance is formed by four partially disordered loops. The cavity deeply extends into the beta-barrel structure, where it ends in two distinct lobes. This unusual structural feature explains the known promiscuity of Tlc for various ligands, with chemical structures ranging from lipids and retinoids to the macrocyclic antibiotic rifampin and even to microbial siderophores. Notably, earlier findings of biological activity as a thiol protease inhibitor have no correspondence in the three-dimensional structure of Tlc, rather it appears that its proteolytic fragments could be responsible for this phenomenon. Hence, the present structural analysis sheds new light on the ligand binding activity of this functionally obscure but abundant human lipocalin.	Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany; Med Univ Innsbruck, Inst Mol Biol, A-6020 Innsbruck, Austria	Technical University of Munich; Medical University of Innsbruck	Skerra, A (corresponding author), Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany.	skerra@wzw.tum.de	Skerra, Arne/A-2269-2013	Skerra, Arne/0000-0002-5717-498X				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BONAVIDA B, 1969, NATURE, V221, P375, DOI 10.1038/221375a0; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Filipek R, 2003, J BIOL CHEM, V278, P40959, DOI 10.1074/jbc.M302926200; Flower DR, 1996, BIOCHEM J, V318, P1; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Fluckinger M, 2004, ANTIMICROB AGENTS CH, V48, P3367, DOI 10.1128/AAC.48.9.3367-3372.2004; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; GASSNER NC, 1998, THESIS U OREGON; Gasymov OK, 2004, BBA-MOL BASIS DIS, V1688, P102, DOI 10.1016/j.bbadis.2003.11.006; Gasymov OK, 1998, BBA-PROTEIN STRUCT M, V1386, P145, DOI 10.1016/S0167-4838(98)00092-2; Gasymov OK, 2000, PROTEIN SCI, V9, P325; Gasymov OK, 2001, BIOCHEMISTRY-US, V40, P14754, DOI 10.1021/bi0110342; Gasymov OK, 1999, BBA-PROTEIN STRUCT M, V1433, P307, DOI 10.1016/S0167-4838(99)00133-8; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GLASGOW BJ, 1995, CURR EYE RES, V14, P363, DOI 10.3109/02713689508999934; Glasgow BJ, 1998, BIOCHEMISTRY-US, V37, P2215, DOI 10.1021/bi9720888; Goetz DH, 2000, BIOCHEMISTRY-US, V39, P1935, DOI 10.1021/bi992215v; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1995, PROTEIN DATA BANK NE, V71, P6; Holzfeind P, 1996, FEBS LETT, V395, P95, DOI 10.1016/0014-5793(96)01008-3; HOLZFEIND P, 1994, GENE, V139, P177, DOI 10.1016/0378-1119(94)90752-8; Jenko S, 2003, J MOL BIOL, V326, P875, DOI 10.1016/S0022-2836(02)01432-8; JOSEPHSON AS, 1964, J IMMUNOL, V93, P532; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacazette E, 2000, HUM MOL GENET, V9, P289, DOI 10.1093/hmg/9.2.289; LALMANACH G, 1993, J PROTEIN CHEM, V12, P23, DOI 10.1007/BF01024910; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oldfield TJ, 2001, ACTA CRYSTALLOGR D, V57, P82, DOI 10.1107/S0907444900014098; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REDL B, 1992, J BIOL CHEM, V267, P20282; Redl B, 2000, BBA-PROTEIN STRUCT M, V1482, P241, DOI 10.1016/S0167-4838(00)00142-4; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Sack RA, 2004, EXP EYE RES, V78, P371, DOI 10.1016/S0014-4835(03)00198-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scalfari F, 1997, COMP BIOCHEM PHYS B, V118, P819, DOI 10.1016/S0305-0491(97)00218-6; Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X; SKERRA A, 1992, NUCLEIC ACIDS RES, V20, P3551, DOI 10.1093/nar/20.14.3551; Skerra A, 2000, METHOD ENZYMOL, V326, P271; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; vantHof W, 1997, J BIOL CHEM, V272, P1837; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wojnar P, 2002, J HISTOCHEM CYTOCHEM, V50, P433, DOI 10.1177/002215540205000314; Wojnar P, 2001, BIOL CHEM, V382, P1515, DOI 10.1515/BC.2001.186; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yusifov TN, 2000, BIOCHEM J, V347, P815, DOI 10.1042/0264-6021:3470815	66	96	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					484	493		10.1074/jbc.M410466200	http://dx.doi.org/10.1074/jbc.M410466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15489503	hybrid, Green Published			2022-12-27	WOS:000226025100058
J	Redeker, V; Levilliers, N; Vinolo, E; Rossier, J; Jaillard, D; Burnette, D; Gaertig, J; Bre, MH				Redeker, V; Levilliers, N; Vinolo, E; Rossier, J; Jaillard, D; Burnette, D; Gaertig, J; Bre, MH			Mutations of tubulin glycylation sites reveal cross-talk between the C termini of alpha- and beta-tubulin and affect the ciliary matrix in Tetrahymena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; POSTTRANSLATIONAL MODIFICATIONS; INTRAFLAGELLAR TRANSPORT; GLUTAMYLATED TUBULIN; AXONEMAL TUBULIN; DIFFERENTIAL DISTRIBUTION; FLAGELLAR MICROTUBULES; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DYNEIN; MASS-SPECTROMETRY	Two types of polymeric post-translational modifications of alpha/beta-tubulin, glycylation and glutamylation, occur widely in cilia and flagella. Their respective cellular functions are poorly understood. Mass spectrometry and immunoblotting showed that two closely related species, the ciliates Tetrahymena and Paramecium, have dramatically different compositions of tubulin post-translational modifications in structurally identical axonemes. Whereas the axonemal tubulin of Paramecium is highly glycylated and has a very low glutamylation content, the axonemal tubulin of Tetrahymena is glycylated and extensively glutamylated. In addition, only the alpha-tubulin of Tetrahymena undergoes detyrosination. Mutations of the known glycylation sites in Tetrahymena tubulin affected the level of each polymeric modification type in both the mutated and nonmutated subunits, revealing cross-talk between alpha- and beta-tubulin. Ultrastructural analyses of glycylation site mutants uncovered defects in the doublet B-subfiber of axonemes and revealed an accumulation of dense material in the ciliary matrix, reminiscent of intraflagellar transport particles seen by others in Chlamydomonas. We propose that polyglycylation and/or polyglutamylation stabilize the B-subfiber of outer doublets and regulate the intraflagellar transport.	Univ Paris 11, Lab Biol Cellulaire 4, CNRS, UMR 8080, F-91405 Orsay, France; Ecole Super Phys & Chim Ind Ville Paris, Neurobiol Lab, CNRS, UMR 7637, F-75005 Paris, France; Univ Paris 11, Ctr Commun Microscopie Elect, F-91405 Orsay, France; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; Universite Paris Saclay; University System of Georgia; University of Georgia	Bre, MH (corresponding author), Univ Paris 11, Lab Biol Cellulaire 4, CNRS, UMR 8080, F-91405 Orsay, France.	Marie-Helene.Bre@ibaic.u-psud.fr	Redeker, Virginie/L-8929-2018; Gaertig, Jacek/F-1553-2010	Redeker, Virginie/0000-0003-2694-8388; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOUTTE A, 1991, BIOL CELL, V71, P227, DOI 10.1016/0248-4900(91)90069-Y; AREVALO MA, 1990, J MOL BIOL, V214, P105, DOI 10.1016/0022-2836(90)90150-K; Bane BC, 2002, CELL TISSUE RES, V307, P57, DOI 10.1007/s00441-001-0483-x; BAROINTOURANCHEAU, 1992, P NATL ACAD SCI USA, V89, P9764; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BRE MH, 1994, CELL MOTIL CYTOSKEL, V27, P337, DOI 10.1002/cm.970270406; Bre MH, 1996, J CELL SCI, V109, P727; Bre MH, 1998, MOL BIOL CELL, V9, P2655, DOI 10.1091/mbc.9.9.2655; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; Brown JM, 1999, MOL BIOL CELL, V10, P3081, DOI 10.1091/mbc.10.10.3081; CALLEN AM, 1994, BIOL CELL, V81, P95, DOI 10.1016/S0248-4900(94)80002-2; Cohen J., 1988, P363; DUPUIS P, 1992, EMBO J, V11, P3713, DOI 10.1002/j.1460-2075.1992.tb05456.x; DupuisWilliams P, 1996, BIOL CELL, V87, P83, DOI 10.1016/S0248-4900(97)89840-1; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FLEURY A, 1995, PROTOPLASMA, V189, P37, DOI 10.1007/BF01280290; FLEURY A, 1992, DEV GENET, V13, P247, DOI 10.1002/dvg.1020130312; Fouquet JP, 1996, MOL REPROD DEV, V43, P358, DOI 10.1002/(SICI)1098-2795(199603)43:3&lt;358::AID-MRD10&gt;3.0.CO;2-Y; Fouquet JP, 1997, TISSUE CELL, V29, P573, DOI 10.1016/S0040-8166(97)80057-2; GAERTIG J, 1992, PROTOPLASMA, V167, P74, DOI 10.1007/BF01353583; GAERTIG J, 1995, J CELL BIOL, V129, P1301, DOI 10.1083/jcb.129.5.1301; Gaertig J, 2000, J EUKARYOT MICROBIOL, V47, P185, DOI 10.1111/j.1550-7408.2000.tb00037.x; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Gagnon C, 1996, J CELL SCI, V109, P1545; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; Huitorel P, 2002, MOL REPROD DEV, V62, P139, DOI 10.1002/mrd.10086; Iftode F, 2000, BIOL CELL, V92, P615, DOI 10.1016/S0248-4900(00)01107-2; Kann ML, 1998, CELL MOTIL CYTOSKEL, V41, P341; KANN ML, 1995, TISSUE CELL, V27, P323, DOI 10.1016/S0040-8166(95)80053-0; Klotz A, 1999, CELL MOTIL CYTOSKEL, V44, P263, DOI 10.1002/(SICI)1097-0169(199912)44:4<263::AID-CM4>3.0.CO;2-V; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; Lechtreck KF, 2000, CELL MOTIL CYTOSKEL, V47, P219, DOI 10.1002/1097-0169(200011)47:3<219::AID-CM5>3.0.CO;2-Q; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena RF, 1998, INT REV CYTOL, V178, P207; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Marshall WF, 2001, J CELL BIOL, V155, P405, DOI 10.1083/jcb.200106141; Mary J, 1996, J BIOL CHEM, V271, P9928, DOI 10.1074/jbc.271.17.9928; MCGRATH KE, 1994, CELL MOTIL CYTOSKEL, V27, P272, DOI 10.1002/cm.970270308; Million K, 1999, J CELL SCI, V112, P4357; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; Multigner L, 1996, BIOCHEMISTRY-US, V35, P10862, DOI 10.1021/bi961057u; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; NOJIMA D, 1995, CURR BIOL, V5, P158, DOI 10.1016/S0960-9822(95)00037-6; Norrander Jan M., 1994, V13, P201; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Pechart I, 1999, BIOL CELL, V91, P685, DOI 10.1016/S0248-4900(00)88532-9; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Plessmann U, 1997, J PROTEIN CHEM, V16, P385, DOI 10.1023/A:1026332621215; Porter ME, 1999, MOL BIOL CELL, V10, P693, DOI 10.1091/mbc.10.3.693; Redeker V, 1998, BIOCHEMISTRY-US, V37, P14838, DOI 10.1021/bi981335k; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Regnard C, 1998, BIOCHEMISTRY-US, V37, P8395, DOI 10.1021/bi9804131; Rosenbaum J, 2000, CURR BIOL, V10, pR801, DOI 10.1016/S0960-9822(00)00767-3; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sackett D L, 1995, Subcell Biochem, V24, P255; Schneider A, 1997, J CELL SCI, V110, P431; Schneider A, 1998, FEBS LETT, V429, P399, DOI 10.1016/S0014-5793(98)00644-9; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; Skiniotis G, 2004, EMBO J, V23, P989, DOI 10.1038/sj.emboj.7600118; Snell WJ, 2004, CELL, V117, P693, DOI 10.1016/j.cell.2004.05.019; Song L, 2001, J BIOL CHEM, V276, P29754, DOI 10.1074/jbc.M103184200; SUPRENANT KA, 1985, P NATL ACAD SCI USA, V82, P6908, DOI 10.1073/pnas.82.20.6908; Thazhath R, 2004, MOL BIOL CELL, V15, P4136, DOI 10.1091/mbc.E04-03-0247; Thazhath R, 2002, NAT CELL BIOL, V4, P256, DOI 10.1038/ncb764; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Tucker C, 1997, J BIOL CHEM, V272, P9481; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; Weber K, 1997, FEBS LETT, V419, P87, DOI 10.1016/S0014-5793(97)01436-1; WEHLAND J, 1987, J CELL BIOL, V104, P1059, DOI 10.1083/jcb.104.4.1059; WEHLAND J, 1987, J CELL SCI, V88, P185; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; Xia L, 2000, J CELL BIOL, V149, P1097, DOI 10.1083/jcb.149.5.1097	83	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					596	606		10.1074/jbc.M408324200	http://dx.doi.org/10.1074/jbc.M408324200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15492004	hybrid			2022-12-27	WOS:000226025100071
J	Ferrari, S; Simmen, KC; Dusserre, Y; Muller, K; Fourel, G; Gilson, E; Mermod, N				Ferrari, S; Simmen, KC; Dusserre, Y; Muller, K; Fourel, G; Gilson, E; Mermod, N			Chromatin domain boundaries delimited by a histone-binding protein in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; TELOMERIC HETEROCHROMATIN; DNA-REPLICATION; SUBTELOMERIC REGIONS; SIR2/SIR4 COMPLEX; SILENT CHROMATIN; SIR3	When located next to chromosomal elements such as telomeres, genes can be subjected to epigenetic silencing. In yeast, this is mediated by the propagation of the SIR proteins from telomeres toward more centromeric regions. Particular transcription factors can protect downstream genes from silencing when tethered between the gene and the telomere, and they may thus act as chromatin domain boundaries. Here we have studied one such transcription factor, CTF-1, that binds directly histone H3. A deletion mutagenesis localized the barrier activity to the CTF-1 histone-binding domain. A saturating point mutagenesis of this domain identified several amino acid substitutions that similarly inhibited the boundary and histone binding activities. Chromatin immunoprecipitation experiments indicated that the barrier protein efficiently prevents the spreading of SIR proteins, and that it separates domains of hypoacetylated and hyperacetylated histones. Together, these results suggest a mechanism by which proteins such as CTF-1 may interact directly with histone H3 to prevent the propagation of a silent chromatin structure, thereby defining boundaries of permissive and silent chromatin domains.	Univ Lausanne, EPFL, UNIL,Ctr Biotechnol, Inst Biotechnol,ISP,FSB,Lab Mol Biotechnol, CH-1015 Lausanne, Switzerland; Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR5665, F-69364 Lyon 07, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Mermod, N (corresponding author), Univ Lausanne, EPFL, UNIL,Ctr Biotechnol, Inst Biotechnol,ISP,FSB,Lab Mol Biotechnol, CH-1015 Lausanne, Switzerland.	Nicolas.Mermod@unil.ch						Adams A, 1997, METHODS YEAST GENETI; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; Arnold BA, 1998, BIOTECHNIQUES, V25, P98, DOI 10.2144/98251st06; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; Bi X, 2001, CURR OPIN GENET DEV, V11, P199, DOI 10.1016/S0959-437X(00)00179-9; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRAUNSTEIN M, 1997, NUCL ORG CHROMATIN S, P250; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Chiu YH, 2003, GENETICS, V165, P115; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Defossez PA, 2002, NUCLEIC ACIDS RES, V30, P5136, DOI 10.1093/nar/gkf629; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Donze D, 2002, BIOESSAYS, V24, P344, DOI 10.1002/bies.10072; Erkine AM, 2003, J BIOL CHEM, V278, P7755, DOI 10.1074/jbc.M211703200; Fourel G, 2002, BIOESSAYS, V24, P828, DOI 10.1002/bies.10139; Fourel G, 2001, EMBO REP, V2, P124, DOI 10.1093/embo-reports/kve024; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; Kristjuhan A, 2003, P NATL ACAD SCI USA, V100, P7551, DOI 10.1073/pnas.1332299100; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lebrun E, 2001, GENETICS, V158, P167; Li R, 1999, J BIOL CHEM, V274, P30310, DOI 10.1074/jbc.274.42.30310; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Memedula S, 2003, CURR BIOL, V13, P241, DOI 10.1016/S0960-9822(03)00048-4; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Muller K, 2000, J BIOL CHEM, V275, P1645, DOI 10.1074/jbc.275.3.1645; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Oki M, 2004, MOL CELL BIOL, V24, P1956, DOI 10.1128/MCB.24.5.1956-1967.2004; PANKIEWICZ R, 2004, IN PRESS J GENE MED, V6; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; van Leeuwen F, 2002, CURR OPIN CELL BIOL, V14, P756, DOI 10.1016/S0955-0674(02)00393-9; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	69	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55520	55530		10.1074/jbc.M410346200	http://dx.doi.org/10.1074/jbc.M410346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15471882	Green Published, hybrid			2022-12-27	WOS:000225960800068
J	Beischlag, TV; Taylor, RT; Rose, DW; Yoon, D; Chen, YM; Lee, WH; Rosenfeld, MG; Hankinson, O				Beischlag, TV; Taylor, RT; Rose, DW; Yoon, D; Chen, YM; Lee, WH; Rosenfeld, MG; Hankinson, O			Recruitment of thyroid hormone receptor/retinoblastoma-interacting protein 230 by the aryl hydrocarbon receptor nuclear translocator is required for the transcriptional response to both dioxin and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; INDUCIBLE FACTOR-ALPHA; HIPPEL-LINDAU PROTEIN; AH RECEPTOR; TRANSACTIVATION DOMAIN; DIRECT BINDING; HIF-ALPHA; COACTIVATOR; COMPLEX; ACTIVATION	The aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor (ARNT/HIF-1beta) mediates an organism's response to various environmental cues, including those to chemical carcinogens, such as 2,3,7,8-tetrachlorodibenzo-rho-dioxin (TCDD or dioxin), via its formation of a functional transcription factor with the ligand activated aryl hydrocarbon receptor (AHR). Similarly, tissue responses to hypoxia are largely mediated through the HIF-1 heterodimeric transcription factor, comprising hypoxia-inducible factor-1alpha (HIF-1alpha) and ARNT. The latter response is essential for a metabolic switch from oxidative phosphorylation to glycolytic anaerobic metabolism as well as for angiogenesis and has been implicated as necessary for growth in many solid tumors. In this report, we demonstrate that the thyroid hormone receptor/retinoblastoma-interacting protein 230 (TRIP230) interacts directly with ARNT and is essential for both hypoxic and TCDD-mediated transcriptional responses. We initially identified TRIP230 as an ARNT-interacting protein in a yeast two-hybrid assay screen. This interaction was confirmed in mammalian cell systems using co-immunoprecipitation and in mammalian two-hybrid assays. Furthermore, TRIP230 could be recorded at sites of activated transcription of either TCDD- or hypoxia-inducible genes in a stimulus-dependent fashion by chromatin immunoprecipitation analysis. Finally, using single-cell microinjection and RNA interference assays, we demonstrate that TRIP230 is indispensable for TCDD- and hypoxia-dependent gene transcription.	Univ Calif Los Angeles, Med Ctr, Ctr Hlth Sci,Mol Biol Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif San Diego, Dept Mol Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Hankinson, O (corresponding author), Univ Calif Los Angeles, Med Ctr, Ctr Hlth Sci,Mol Biol Inst, Dept Pathol & Lab Med, Box 951732, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu			NCI NIH HHS [CA28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen YM, 1999, P NATL ACAD SCI USA, V96, P4443, DOI 10.1073/pnas.96.8.4443; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Glass CK, 2000, GENE DEV, V14, P121; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Ma Q, 1997, J BIOL CHEM, V272, P8878; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200	52	59	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54620	54628		10.1074/jbc.M410456200	http://dx.doi.org/10.1074/jbc.M410456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485806	hybrid			2022-12-27	WOS:000225793600088
J	Curran, SP; Leverich, EP; Koehler, CM; Larsen, PL				Curran, SP; Leverich, EP; Koehler, CM; Larsen, PL			Defective mitochondrial protein translocation precludes normal Caenorhabditis elegans development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAFNESS DYSTONIA SYNDROME; DISTAL TIP CELLS; INTERMEMBRANE SPACE; DAUER DIAPAUSE; IMPORT; BIOGENESIS; COMPLEX; MEMBRANE; GENETICS; RECEPTOR	We demonstrate biochemically that the genes identified by sequence similarity as orthologs of the mitochondrial import machinery are functionally conserved in Caenorhabditis elegans. Specifically, tin-9.1 and tin-10 RNA interference (RNAi) treatment of nematodes impairs import of the ADP/ATP carrier into isolated mitochondria. Developmental phenotypes are associated with gene knock-down of the mitochondrial import components. RNAi of tomm-7 and ddp-1 resulted in mitochondria with an interconnected morphology in vivo, presumably due to defects in the assembly of outer membrane fission/fusion components. RNAi of the small Tim proteins TIN-9.1, TIN-9.2, and TIN-10 resulted in a small body size, reduced number of progeny produced, and partial embryonic lethality. An additional phenotype of the tin-9.2(RNAi) animals is defective formation of the somatic gonad. The biochemical demonstration that the protein import activity is reduced, under the same conditions that yield the defects in specific tissues and lethality in a later generation, suggests that the developmental abnormalities observed are a consequence of defects in mitochondrial inner membrane biogenesis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles	Larsen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	larsenp@uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM070415, R01GM061721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, GM070415, 1R01GM61721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Antebi A, 2000, GENE DEV, V14, P1512; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2002, INT REV NEUROBIOL, V53, P57; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BRENNER S, 1974, GENETICS, V77, P71; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Curran SP, 2004, TOP CURR GENET, V8, P59; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gerisch B, 2004, DEVELOPMENT, V131, P1765, DOI 10.1242/dev.01068; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Kaldi K, 1998, BIOFACTORS, V8, P221, DOI 10.1002/biof.5520080308; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nishiwaki K, 1999, GENETICS, V152, P985; OKIMOTO R, 1992, GENETICS, V130, P471; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rospert S, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P277; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Snow MI, 2000, BBA-GENE STRUCT EXPR, V1494, P104, DOI 10.1016/S0167-4781(00)00224-4; Su MW, 2000, DEVELOPMENT, V127, P585; SULSTON JE, 1988, CELL LINEAGE, P123; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Tsang WY, 2003, BBA-MOL BASIS DIS, V1638, P91, DOI 10.1016/S0925-4439(03)00079-6; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Wiedemann N, 2003, J MOL BIOL, V327, P465, DOI 10.1016/S0022-2836(03)00118-9	62	20	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54655	54662		10.1074/jbc.M409618200	http://dx.doi.org/10.1074/jbc.M409618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485840	hybrid			2022-12-27	WOS:000225793600092
J	Dostanic, I; Schultz, JE; Lorenz, JN; Lingrel, JB				Dostanic, I; Schultz, JE; Lorenz, JN; Lingrel, JB			The alpha 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; SITE-DIRECTED MUTAGENESIS; SODIUM-PUMP ISOFORM; FAILING HUMAN HEART; DEVELOPMENTAL REGULATION; INOTROPIC RESPONSE; BETA-SUBUNIT; EXPRESSION; OUABAIN; MOUSE	The primary objective of this study was to examine the functional role of the Na,K-ATPase alpha1 isoform in the regulation of cardiac contractility. Previous studies using knock-out mice showed that the hearts of animals lacking one copy of the alpha1 or alpha2 isoform gene exhibit opposite phenotypes. Hearts from alpha2(+/-) animals are hypercontractile, whereas those of the alpha1(+/-) animals are hypocontractile. The cardiac phenotype of the alpha1(+/-) animals was unexpected as other studies suggest that inhibition of either isoform increases contraction. To help resolve this difference, we have used genetically engineered knock-in mice expressing a ouabain-sensitive alpha1 isoform and a ouabain-resistant alpha2 isoform of the Na,K-ATPase, and we analyzed cardiac contractility following selective inhibition of the alpha1 isoform by ouabain. Administration of ouabain to these animals and to isolated heart preparations selectively inhibits only the activity of the alpha1 isoform without affecting the activity of the alpha2 isoform. Low concentrations of ouabain resulted in positive cardiac inotropy in both isolated hearts and intact animals expressing the modified alpha1 and alpha2 isoforms. Pretreatment with 10 muM KB-R7943, which inhibits the reverse mode of the Na/Ca exchanger, abolished the cardiotonic effects of ouabain in isolated wild type and knock-in hearts. Immunoprecipitation analysis demonstrated co-localization of the alpha1 isoform and the Na/Ca exchanger in cardiac sarcolemma. The alpha1 isoform coimmunoprecipitated with the Na/Ca exchanger and vice versa. These results demonstrate that the alpha1 isoform regulates cardiac contractility, and that both the alpha1 and alpha2 isoforms are functionally and physically coupled with the Na/Ca exchanger in heart.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066062, R01HL028573] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66062, R01 HL28573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Dostanic I, 2003, J BIOL CHEM, V278, P53026, DOI 10.1074/jbc.M308547200; Golovina VA, 2003, AM J PHYSIOL-CELL PH, V284, pC475, DOI 10.1152/ajpcell.00383.2002; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Jewell EA, 1992, ACTA PHYSL SCAND S, V607, P161; Kang WK, 2002, J PHARMACOL EXP THER, V302, P577, DOI 10.1124/jpet.302.2.577; KENT RB, 1987, P NATL ACAD SCI USA, V84, P5369, DOI 10.1073/pnas.84.15.5369; Kometiani P, 2001, AM J PHYSIOL-HEART C, V280, pH1415, DOI 10.1152/ajpheart.2001.280.3.H1415; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; McDonough AA, 1996, AM J PHYSIOL-CELL PH, V270, pC1221, DOI 10.1152/ajpcell.1996.270.4.C1221; Muller-Ehmsen J, 2001, CELL MOL BIOL, V47, P373; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; Pieske B, 2003, CARDIOVASC RES, V57, P874, DOI 10.1016/S0008-6363(02)00841-6; Pieske B, 2003, CARDIOVASC RES, V57, P871, DOI 10.1016/S0008-6363(02)00849-0; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; Radzyukevich TL, 2004, AM J PHYSIOL-CELL PH, V287, pC1300, DOI 10.1152/ajpcell.00231.2004; Reuter H, 2002, CIRC RES, V90, P305, DOI 10.1161/hh0302.104562; Schwartz A, 2001, CARDIOVASC RES, V51, P9, DOI 10.1016/S0008-6363(01)00336-4; Schwinger RHG, 1999, CIRCULATION, V99, P2105, DOI 10.1161/01.CIR.99.16.2105; SHAMRAJ OI, 1993, CARDIOVASC RES, V27, P2229, DOI 10.1093/cvr/27.12.2229; SHAMRAJ OI, 1991, BIOCHEM BIOPH RES CO, V179, P1434, DOI 10.1016/0006-291X(91)91733-S; Shelly DA, 2004, AM J PHYSIOL-CELL PH, V286, pC813, DOI 10.1152/ajpcell.00389.2003; SWEADNER KJ, 1987, P NATL ACAD SCI USA, V84, P8404, DOI 10.1073/pnas.84.23.8404; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Wang JN, 2001, AM J PHYSIOL-CELL PH, V281, pC1336, DOI 10.1152/ajpcell.2001.281.4.C1336; Zahler R, 1996, AM J PHYSIOL-CELL PH, V270, pC361, DOI 10.1152/ajpcell.1996.270.1.C361; Zahler R, 1996, BASIC RES CARDIOL, V91, P256, DOI 10.1007/BF00788912	33	123	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54053	54061		10.1074/jbc.M410737200	http://dx.doi.org/10.1074/jbc.M410737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485817	hybrid			2022-12-27	WOS:000225793600022
J	Ikari, A; Hirai, N; Shiroma, M; Harada, H; Sakai, H; Hayashi, H; Suzuki, Y; Degawa, M; Takagi, K				Ikari, A; Hirai, N; Shiroma, M; Harada, H; Sakai, H; Hayashi, H; Suzuki, Y; Degawa, M; Takagi, K			Association of paracellin-1 with ZO-1 augments the reabsorption of divalent cations in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSEPITHELIAL ELECTRICAL-RESISTANCE; TIGHT JUNCTION STRANDS; THICK ASCENDING LIMB; CANINE KIDNEY-CELLS; CALCIUM REABSORPTION; MAGNESIUM TRANSPORT; SELECTIVE CHANNELS; DIRECT BINDING; HUMAN HOMOLOG; MDCK CELLS	Paracellin-1 (PCLN-1) belongs to the claudin family of tight junction proteins and possibly plays a critical role in the reabsorption of magnesium and calcium. So far, the physiological properties of PCLN-1 have not been clarified. In the present study, we investigated whether PCLN-1 is associated with ZO-1. We also investigated whether Ca-45(2+) transport across the paracellular barrier is affected by this association. In vitro binding analysis using glutathione S-transferase fusion protein showed that the C-terminal TRV sequence, especially Thr and Val residues, of PCLN-1 interacts with ZO-1. Next, PCLN-1 was stably expressed in Madin-Darby canine kidney cells using a FLAG tagging vector. ZO-1 was co-immunoprecipitated with the wild-type PCLN-1 and the alanine substitution (TAV) mutant. However, mutants of the deletion (DeltaTRV) and the alanine substitution (ARV and TRA) inhibited the association of PCLN-1 with ZO-1. Confocal immunofluorescence demonstrated that the wild-type PCLN-1 and the TAV mutant localized in the tight junction along with ZO-1, but the DeltaTRV, ARV, and TRA mutants were widely distributed in the lateral membrane including the tight junction area. Interestingly, monolayers of cells expressing the wild-type PCLN-1 and the TAV mutant showed higher activities of Ca-45(2+) transport from apical to basal compartments, compared with those expressing the DeltaTRV, ARV, and TRA mutants and the mock cells. Ca-45(2+) transport was inhibited by increased magnesium concentration suggesting that magnesium and calcium were competitively transported by PCLN-1. It was noted that a positive electrical potential gradient enhanced Ca-45(2+) transport from apical to basal compartments without affecting the opposite direction of transport. Thus, PCLN-1 localizes to the tight junction followed by association with ZO-1, and the PCLN-1 . ZO-1 complex may play an essential role in the reabsorption of divalent cations in renal epithelial cells.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Mol Toxicol, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Pharmaceut Sci, 21st Century COE Program, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Food & Nutr Sci, Physiol Lab, Shizuoka 4228526, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Pharmaceut Physiol, Toyama 9300194, Japan	University of Shizuoka; University of Shizuoka; University of Shizuoka; University of Shizuoka; University of Toyama	Ikari, A (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, 52-1 Yada, Shizuoka 4228526, Japan.	ikari@u-shizuoka-ken.ac.jp	Hayashi, Hisayoshi/K-5883-2013; Degawa, Masakuni/F-5702-2010					Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Blanchard A, 2001, KIDNEY INT, V59, P2206, DOI 10.1046/j.1523-1755.2001.00736.x; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GIULIANO AR, 1991, AM J PHYSIOL, V260, pG207, DOI 10.1152/ajpgi.1991.260.2.G207; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hasegawa H, 1999, J BIOL CHEM, V274, P20982, DOI 10.1074/jbc.274.30.20982; Ikari A, 2002, J BIOL CHEM, V277, P33338, DOI 10.1074/jbc.M200310200; Ikari A, 2001, BIOCHEM BIOPH RES CO, V287, P671, DOI 10.1006/bbrc.2001.5644; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kobayashi J, 2002, HISTOCHEM CELL BIOL, V117, P29, DOI 10.1007/s00418-001-0359-x; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; McCarthy KM, 2000, J CELL SCI, V113, P3387; Monnens L, 2000, NEPHROL DIAL TRANSPL, V15, P568, DOI 10.1093/ndt/15.5.568; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Muller D, 2003, AM J HUM GENET, V73, P1293, DOI 10.1086/380418; Olsen O, 2003, J BIOL CHEM, V278, P6873, DOI 10.1074/jbc.M210165200; Quamme GA, 2000, FRONT BIOSCI-LANDMRK, V5, pD694, DOI 10.2741/Quamme; QUAMME GA, 1989, AM J PHYSIOL, V256, pF197, DOI 10.1152/ajprenal.1989.256.2.F197; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Weber S, 2001, J AM SOC NEPHROL, V12, P1872, DOI 10.1681/ASN.V1291872; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	29	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54826	54832		10.1074/jbc.M406331200	http://dx.doi.org/10.1074/jbc.M406331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496416	hybrid			2022-12-27	WOS:000225793600111
J	Palm-Leis, A; Singh, US; Herbelin, BS; Olsovsky, GD; Baker, KM; Pan, J				Palm-Leis, A; Singh, US; Herbelin, BS; Olsovsky, GD; Baker, KM; Pan, J			Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-trans retinoic acid on the hypertrophic growth of cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; MYOCARDIAL-CELL HYPERTROPHY; CONGESTIVE-HEART-FAILURE; N-TERMINAL KINASE; MAP KINASE; GENE-EXPRESSION; ANGIOTENSIN-II; X-RECEPTOR	All-trans retinoic acid ( RA) has been implicated in mediation of cardiac growth inhibition in neonatal cardiomyocytes. However, the associated signaling mechanisms remain unclear. Utilizing neonatal cardiomyocytes, we demonstrated that RA suppressed the hypertrophic features induced by cyclic stretch or angiotensin II (Ang II). Cyclic stretch- or Ang II-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAP kinase) was dose- and time-dependently inhibited by RA. Significant inhibition was observed by 5 muM RA, from 8 to 24 h of pretreatment. This inhibitory effect was not mediated at the level of mitogen-activated protein kinase kinases (MKKs), because RA had no effect on stretch- or Ang II-induced phosphorylation of MEK1/2, MKK4, and MKK3/6. However, the phosphatase inhibitor vanadate reversed the inhibitory effect of RA on MAP kinases and protein synthesis. RA up-regulated the expression level of MAP kinase phosphatase-1 (MKP-1) and MKP-2, and the time course was correlated with the inhibitory effect of RA on activation of MAP kinases. Overexpression of wild-type MKP-1 inhibited the phosphorylation of JNK and p38 in cardiomyocytes. These data indicated that MKPs were involved in the inhibitory effect of RA on MAP kinases. Using specific RAR and RXR antagonists, we demonstrated that both RARs and RXRs were involved in regulating stretch- or Ang II-induced activation of MAP kinases. Our findings provide the first evidence that the anti-hypertrophic effect of RA is mediated by up-regulation of MKPs and inhibition of MAP kinase signaling pathways.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Cardiovasc Res Inst, Div Mol Cardiol, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Dept Internal Med, Div Mol Cardiol, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Pan, J (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Cardiovasc Res Inst, Div Mol Cardiol, 1901 S 1st St,Bldg 205, Temple, TX 76504 USA.	jpan@medicine.tamu.edu						Aboseif SR, 1997, PROSTATE, V31, P161; Aikawa R, 2000, MOL CELL BIOCHEM, V212, P177, DOI 10.1023/A:1007185711745; Akazawa H, 2003, CIRC RES, V92, P1079, DOI 10.1161/01.RES.0000072977.86706.23; ALESSI DR, 1993, ONCOGENE, V8, P2015; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Clabby ML, 2003, J BIOL CHEM, V278, P5760, DOI 10.1074/jbc.M208173200; Clerk A, 1999, AM J CARDIOL, V83, p64H; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Davies EL, 1997, BIOCHEM SOC T, V25, pS223, DOI 10.1042/bst025223s; DE LUCA LM, 1991, FASEB J, V5, P2924; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Fischer TA, 2001, HYPERTENSION, V37, P1222, DOI 10.1161/01.HYP.37.5.1222; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fuller SJ, 1997, BIOCHEM J, V323, P313, DOI 10.1042/bj3230313; Georgiades P, 1998, CELL BIOL INT, V22, P457, DOI 10.1006/cbir.1998.0282; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Hiroi Y, 2001, HYPERTENS RES, V24, P385, DOI 10.1291/hypres.24.385; Hofken T, 2000, BIOCHEM BIOPH RES CO, V276, P680, DOI 10.1006/bbrc.2000.3530; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Kagechika H, 2002, CURR MED CHEM, V9, P591, DOI 10.2174/0929867024606975; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kim L, 1999, AM J PHYSIOL-HEART C, V277, pH1808, DOI 10.1152/ajpheart.1999.277.5.H1808; Kodama H, 1997, CIRC RES, V81, P656; Kodama H, 1998, CIRC RES, V82, P244; KOMURO I, 1990, JPN CIRC J, V54, P526, DOI 10.1253/jcj.54.526; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200; Kosaka C, 2001, HYPERTENS RES, V24, P579, DOI 10.1291/hypres.24.579; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Molkentin JD, 1997, CIRCULATION, V96, P3833; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Samarel AM, 2001, J MOL CELL CARDIOL, V33, P1637, DOI 10.1006/jmcc.2001.1427; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; Ueyama T, 2000, J MOL CELL CARDIOL, V32, P947, DOI 10.1006/jmcc.2000.1135; Wang HJ, 2002, J APPL PHYSIOL, V92, P2162, DOI 10.1152/japplphysiol.01192.2001; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; YAMAZAKI T, 1995, J MOL CELL CARDIOL, V27, P133, DOI 10.1016/S0022-2828(08)80013-2; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	76	58	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54905	54917		10.1074/jbc.M407383200	http://dx.doi.org/10.1074/jbc.M407383200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494319	Green Published, hybrid			2022-12-27	WOS:000225793600120
J	Tomita, T; Mizumachi, Y; Chong, K; Ogawa, K; Konishi, N; Sugawara-Tomita, N; Dohmae, N; Hashimoto, Y; Takio, K				Tomita, T; Mizumachi, Y; Chong, K; Ogawa, K; Konishi, N; Sugawara-Tomita, N; Dohmae, N; Hashimoto, Y; Takio, K			Protein sequence analysis, cloning, and expression of flammutoxin, a pore-forming cytolysin from Flammulina velutipes - Maturation of dimeric precursor to monomeric active form by carboxyl-terminal truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; PLEUROTUS-OSTREATUS; TOXIN AEROLYSIN; MUSHROOM; ACTIVATION; PURIFICATION	Flammutoxin (FTX), a 31-kDa pore-forming cytolysin from Flammulina velutipes, is specifically expressed during the fruiting body formation. We cloned and expressed the cDNA encoding a 272-residue protein with an identical N-terminal sequence with that of FTX but failed to obtain hemolytically active protein. This, together with the presence of multiple FTX family proteins in the mushroom, prompted us to determine the complete primary structure of FTX by protein sequence analysis. The N-terminal 72 and C-terminal 107 residues were sequenced by Edman degradation of the fragments generated from the alkylated FTX by enzymatic digestions with Achromobacter protease I or Staphylococcus aureus V8 protease and by chemical cleavages with CNBr, hydroxylamine, or 1% formic acid. The central part of FTX was sequenced with a surface-adhesive 7-kDa fragment, which was generated by a tryptic digestion of FTX and recovered by rinsing the wall of a test tube with 6 M guanidine HCl. The 7-kDa peptide was cleaved with 12 M HCl, thermolysin, or S. aureus V8 protease to produce smaller peptides for sequence analysis. As a result, FTX consisted of 251 residues, and protein and nucleotide sequences were in accord except for the lack of the initial Met and the C-terminal 20 residues in protein. Recombinant FTX (rFTX) with or without the C-terminal 20 residues (rFTX271 or rFTX251, respectively) was prepared to study the maturation process of FTX. Like natural FTX, rFTX251 existed as a monomer in solution and assembled into an SDS-stable, ring-shaped pore complex on human erythrocytes, causing hemolysis. In contrast, rFTX271, existing as a dimer in solution, bound to the cells but failed to form pore complex. The dimeric rFTX271 was converted to hemolytically active monomers upon the cleavage between Lys(251) and Met(252) by trypsin.	Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan; Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, Saitama 3388570, Japan; RIKEN, Div Biomol Characterizat, Wako, Saitama 3510198, Japan	Tohoku University; Saitama University; RIKEN	Tomita, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan.	tomita@biochem.tohoku.ac.jp	Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410				BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Berne S, 2002, BBA-GEN SUBJECTS, V1570, P153, DOI 10.1016/S0304-4165(02)00190-3; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BERNHEIMER AW, 1987, TOXICON, V25, P1145, DOI 10.1016/0041-0101(87)90132-2; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Bittencourt SET, 2003, FEBS LETT, V549, P47, DOI 10.1016/S0014-5793(03)00763-4; Bornstein P, 1977, Methods Enzymol, V47, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Espinar MTF, 1997, CURR GENET, V32, P420, DOI 10.1007/s002940050297; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; FAULSTICH H, 1983, BIOCHEMISTRY-US, V22, P4574, DOI 10.1021/bi00288a035; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gros E., 1967, METHOD ENZYMOL, V11, P238; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landon, 1977, Methods Enzymol, V47, P145; LIN JY, 1974, NATURE, V252, P235, DOI 10.1038/252235a0; Menestrina G, 2003, FEBS LETT, V552, P54, DOI 10.1016/S0014-5793(03)00850-0; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Nonaka T, 1997, J BIOL CHEM, V272, P30032, DOI 10.1074/jbc.272.48.30032; Ohnishi M, 1998, J BIOL CHEM, V273, P453, DOI 10.1074/jbc.273.1.453; Parker MW, 2003, TOXICON, V42, P1, DOI 10.1016/S0041-0101(03)00106-5; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Sakamoto Yuichi, 2000, Mycoscience, V41, P279, DOI 10.1007/BF02489684; Sugawara-Tomita N, 2002, J BACTERIOL, V184, P4747, DOI 10.1128/JB.184.17.4747-4756.2002; Tadjibaeva G, 2000, BBA-BIOMEMBRANES, V1467, P431, DOI 10.1016/S0005-2736(00)00240-6; TITANI K, 1964, J BIOCHEM-TOKYO, V56, P241, DOI 10.1093/oxfordjournals.jbchem.a127986; Tomita T, 2004, J BIOL CHEM, V279, P26975, DOI 10.1074/jbc.M402676200; Tomita T, 1998, BIOCHEM J, V333, P129, DOI 10.1042/bj3330129; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; Watanabe H, 1999, EUR J BIOCHEM, V262, P850, DOI 10.1046/j.1432-1327.1999.00440.x; WILMSEN HU, 1985, EUR BIOPHYS J BIOPHY, V12, P199	33	11	17	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54161	54172		10.1074/jbc.M408783200	http://dx.doi.org/10.1074/jbc.M408783200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489231	hybrid			2022-12-27	WOS:000225793600035
J	Loretz, CA; Pollina, C; Hyodo, S; Takei, Y; Chang, WH; Shoback, D				Loretz, CA; Pollina, C; Hyodo, S; Takei, Y; Chang, WH; Shoback, D			CDNA cloning and functional expression of a Ca2+-sensing receptor with truncated C-terminal tail from the Mozambique tilapia (Oreochromis mossambicus)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; HUMAN CA2+ RECEPTOR; IDENTIFICATION; PROTEIN; KIDNEY; LOCALIZATION; FILAMIN; DOMAIN; ACTIVATION; PHOSPHATE	The complete cDNA sequence of the tilapia extracellular Ca2+-sensing receptor (CaR) was determined. The transcript length of tilapia CaR (tCaR) is 3.4 kbp and encodes a 940-amino acid, 7-transmembrane domain protein that is consistent in its structural features with known mammalian and piscine CaRs. The tCaR extracellular domain includes a characteristic hydrophobic segment, conserved cysteine residues that are implicated in receptor dimerization (Cys(129) and Cys(131)) and in coupling to the transmembrane domain ( nine conserved cysteine residues), and conserved serine residues (Ser(147) and Ser(169 - 171)) that are linked to receptor binding of Ca2+ and L-amino acid-mediated potentiation of function. mRNA expression of tCaR was strong in kidney, brain, and gill. Weaker expression was observed in pituitary, stomach, intestine, urinary bladder, and heart. This distribution is consistent with possible physiological roles in endocrine cells, excitable tissues, and ion-transporting barrier epithelia. Expression of tCaR mRNA in kidney and intestine was salinity-dependent, suggesting a role for the receptor in iono-/osmoregulation in this euryhaline teleost species. Human embryonic kidney-293 cells transiently transfected with tCaR cDNA demonstrated dose-dependent phospholipase C activation in response to elevations in the extracellular Ca2+ concentration ([Ca2+](o)). Functional activation of the mitogen-activated protein kinase cascade by high [Ca2+](o) was also confirmed in these cells despite the naturally occurring truncation of the receptor's intracellular tail, which removes segments variably linked in mammalian CaRs to filamin-coupled activation of mitogen-activated protein kinase cascades. Sensitivity of phospholipase C activation to [Ca2+](o) was dependent on the ionic strength of the bathing medium, supporting a role in salinity sensing.	Amer Embassy, Natl Sci Fdn Tokyo Reg Off, Minato Ku, Tokyo 1078420, Japan; Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan; Univ Calif San Francisco, Dept Med, Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA	University of Tokyo; University of California System; University of California San Francisco	Loretz, CA (corresponding author), Amer Embassy, Natl Sci Fdn Tokyo Reg Off, Minato Ku, 1-10-5 Akasaka, Tokyo 1078420, Japan.	cloretz@nsf.gov	; Takei, Yoshio/R-2368-2017	Hyodo, Susumu/0000-0001-8146-2386; Takei, Yoshio/0000-0003-3004-8905	NIA NIH HHS [R01 AG21353] Funding Source: Medline; NIDDK NIH HHS [R01 DK55846] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021353] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Ba JM, 2004, CELL CALCIUM, V35, P229, DOI 10.1016/j.ceca.2003.10.016; Ba JM, 2003, AM J PHYSIOL-RENAL, V285, pF1233, DOI 10.1152/ajprenal.00249.2003; Bai M, 2004, CELL CALCIUM, V35, P197, DOI 10.1016/j.ceca.2003.10.018; Bieter RN, 1935, J PHARMACOL EXP THER, V53, P347; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brown Edward M., 1996, American Journal of the Medical Sciences, V312, P99; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chang WH, 2001, J BIOL CHEM, V276, P44129, DOI 10.1074/jbc.M104834200; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Chen RA, 2004, AM J PHYSIOL-RENAL, V286, pF1005, DOI 10.1152/ajprenal.00013.2004; Cheng SX, 2002, AM J PHYSIOL-GASTR L, V283, pG240, DOI 10.1152/ajpgi.00500.2001; Cima RR, 1997, AM J PHYSIOL-GASTR L, V273, pG1051, DOI 10.1152/ajpgi.1997.273.5.G1051; Fellner SK, 2002, J EXP BIOL, V205, P1889; Flanagan JA, 2002, GEN COMP ENDOCR, V127, P117, DOI 10.1016/S0016-6480(02)00035-7; Flik Gert, 1995, V14, P317; Gama L, 1997, AM J PHYSIOL-CELL PH, V273, pC1168, DOI 10.1152/ajpcell.1997.273.4.C1168; Hebert SC, 1997, J EXP BIOL, V200, P295; Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015; Hentschel H, 2003, AM J PHYSIOL-RENAL, V285, pF430, DOI 10.1152/ajprenal.00081.2002; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Hubbard PC, 2000, J EXP BIOL, V203, P3821; Hyodo S, 2004, GEN COMP ENDOCR, V138, P97, DOI 10.1016/j.ygcen.2004.05.009; Ingleton PM, 2002, J ANAT, V200, P487, DOI 10.1046/j.1469-7580.2002.00036.x; Loretz C.A., 1995, CELLULAR MOL APPROAC, P25, DOI [10.1016/s1546-5098(08)60241-1, DOI 10.1016/S1546-5098(08)60241-1]; LORETZ CA, 1981, GEN COMP ENDOCR, V43, P325, DOI 10.1016/0016-6480(81)90291-4; LORETZ CA, 1981, NEUROSECRETION MOL C, P319; Lund O., 2002, CASP5 C, pA102; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002-220240; Radman DP, 2002, MOL CELL ENDOCRINOL, V186, P111, DOI 10.1016/S0303-7207(01)00643-8; RAMNEEK G, 2002, EUR C COMP BIOL 2002; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rutten MJ, 1999, AM J PHYSIOL-GASTR L, V277, pG662, DOI 10.1152/ajpgi.1999.277.3.G662; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; Sasayama Y, 1999, ZOOL SCI, V16, P857, DOI 10.2108/zsj.16.857; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Uchida K, 2002, CAN J ZOOL, V80, P1100, DOI 10.1139/Z02-090; Wagner Graham F., 1994, P273; Yano S, 2004, CELL CALCIUM, V35, P257, DOI 10.1016/j.ceca.2003.10.008; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	54	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53288	53297		10.1074/jbc.M410098200	http://dx.doi.org/10.1074/jbc.M410098200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456780	hybrid			2022-12-27	WOS:000225680600060
J	Namekata, K; Enokido, Y; Ishii, I; Nagai, Y; Harada, T; Kimura, H				Namekata, K; Enokido, Y; Ishii, I; Nagai, Y; Harada, T; Kimura, H			Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM STRESS; SITE-DIRECTED MUTAGENESIS; ENDOTHELIAL DYSFUNCTION; RAT-LIVER; A-I; PLASMA-LIPOPROTEINS; APOLIPOPROTEIN-E; HOMOCYSTEINE	Hyperhomocysteinemia (HHCY) is a consequence of impaired methionine/cysteine metabolism and is caused by deficiency of vitamins and/or enzymes such as cystathionine beta-synthase (CBS). Although HHCY is an important and independent risk factor for cardiovascular diseases that are commonly associated with hepatic steatosis, the mechanism by which homocysteine promotes the development of fatty liver is poorly understood. CBS-deficient (CBS-/-) mice were previously generated by targeted deletion of the Cbs gene and exhibit pathological features similar to HHCY patients, including endothelial dysfunction and hepatic steatosis. Here we show abnormal lipid metabolism in CBS-/- mice. Triglyceride and nonesterified fatty acid levels were markedly elevated in CBS-/- mouse liver and serum. The activity of thiolase, a key enzyme in beta-oxidation of fatty acids, was significantly impaired in CBS-/- mouse liver. Hepatic apolipoprotein B100 levels were decreased, whereas serum apolipoprotein B100 and very low density lipoprotein levels were elevated in CBS-/- mice. Serum levels of cholesterol/phospholipid in high density lipoprotein fractions but not of total cholesterol/phospholipid were decreased, and the activity of lecithin-cholesterol acyltransferase was severely impaired in CBS-/- mice. Abnormal high density lipoprotein particles with higher mobility in polyacrylamide gel electrophoresis were observed in serum obtained from CBS-/- mice. Moreover, serum cholesterol/triglyceride distribution in lipoprotein fractions was altered in CBS-/- mice. These results suggest that hepatic steatosis in CBS-/- mice is caused by or associated with abnormal lipid metabolism.	Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Tokyo 1878551, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Tokyo 1838526, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Kimura, H (corresponding author), Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Ogawahigashi 4-1-1, Tokyo 1878551, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; Enokido, Yasushi/0000-0003-3252-504X; Ishii, Isao/0000-0002-5367-205X				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOMHOFF JP, 1978, SCAND J CLIN LAB INV, V38, P177, DOI 10.3109/00365517809104922; CHEUNG MC, 1986, J LIPID RES, V27, P1135; Conde-Knape K, 2002, J LIPID RES, V43, P2136, DOI 10.1194/jlr.M200210-JLR200; Cravo ML, 1996, AM J CLIN NUTR, V63, P220, DOI 10.1093/ajcn/63.2.220; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; FRAUSCHER G, 1995, LIFE SCI, V57, P813, DOI 10.1016/0024-3205(95)02009-8; GAULL G, 1974, J PEDIATR-US, V84, P381, DOI 10.1016/S0022-3476(74)80721-3; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; Herrmann Wolfgang, 2002, Clin Lab, V48, P471; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; JONES BG, 1994, ATHEROSCLEROSIS, V105, P165, DOI 10.1016/0021-9150(94)90046-9; Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; Magoori K, 2003, J BIOL CHEM, V278, P11331, DOI 10.1074/jbc.M211987200; MARINETTI GV, 1958, BIOCHIM BIOPHYS ACTA, V30, P642, DOI 10.1016/0006-3002(58)90117-3; Mathieu M, 1997, J MOL BIOL, V273, P714, DOI 10.1006/jmbi.1997.1331; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; Ng DS, 2004, J BIOL CHEM, V279, P7636, DOI 10.1074/jbc.M309439200; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; OSUMI T, 1979, BIOCHIM BIOPHYS ACTA, V574, P258; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; QU SJ, 1993, BIOCHEMISTRY-US, V32, P8732, DOI 10.1021/bi00085a002; Sakai N, 1997, J BIOL CHEM, V272, P7506, DOI 10.1074/jbc.272.11.7506; Stead LM, 2000, BIOCHEM J, V350, P685, DOI 10.1042/0264-6021:3500685; Usui S, 2002, J LIPID RES, V43, P805; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Wang MH, 2004, CHEM REV, V104, P119, DOI 10.1021/cr020466v; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1989, J BIOL CHEM, V264, P11373	41	126	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52961	52969		10.1074/jbc.M406820200	http://dx.doi.org/10.1074/jbc.M406820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466479	hybrid			2022-12-27	WOS:000225680600020
J	Storch, S; Pohl, S; Braulke, T				Storch, S; Pohl, S; Braulke, T			A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the Batten disease-related CLN3 protein are required for efficient lysosomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TYROSINE-BASED SIGNAL; SORTING SIGNALS; MEDIUM CHAINS; DI-LEUCINE; MEMBRANE-GLYCOPROTEINS; INVARIANT CHAIN; AP-3 ADAPTER; HIV-1 NEF; LIMP-II	The juvenile form of ceroid lipofuscinosis ( Batten disease) is a neurodegenerative lysosomal storage disorder caused by mutations in the CLN3 gene. CLN3 encodes a multimembrane-spanning protein of unknown function, which is mainly localized in lysosomes in non-neuronal cells and in endosomes in neuronal cells. For this study we constructed chimeric proteins of three CLN3 cytoplasmic domains fused to the lumenal and transmembrane domains of the reporter proteins LAMP-1 and lysosomal acid phosphatase to identify lysosomal targeting motifs and to determine the intracellular transport and subcellular localization of the chimera in transfected cell lines. We report that a novel type of dileucine-based sorting motif, EEEX8LI, present in the second cytoplasmic domain of CLN3, is sufficient for proper targeting to lysosomes. The first cytoplasmic domain of CLN3 and the mutation of the dileucine motif resulted in a partial mis-sorting of chimeric proteins to the plasma membrane. At equilibrium, 4-13% of the different chimera are present at the cell surface. Analysis of lysosome-specific proteolytic processing revealed that lysosomal acid phosphatase chimera containing the second cytoplasmic domain of CLN3 showed the highest rate of lysosomal delivery, whereas the C terminus of CLN3 was found to be less efficient in lysosomal targeting. However, none of these cytosolic CLN3 domains was able to interact with AP-1, AP-3, or GGA3 adaptor complexes. These data revealed that lysosomal sorting motifs located in an intramolecular cytoplasmic domain of a multimembrane-spanning protein have different structural requirements for adaptor binding than sorting signals found in the C-terminal cytoplasmic domains of single- or dual-spanning lysosomal membrane proteins.	Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Braulke, T (corresponding author), Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, Martinistr 52,Bldg W 23, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Pohl, Sandra/AAF-1943-2020; Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532; Pohl, Sandra/0000-0001-7409-7042; Storch, Stephan/0000-0002-8807-5917				Blumstein J, 2001, J NEUROSCI, V21, P8034, DOI 10.1523/JNEUROSCI.21-20-08034.2001; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Cherqui S, 2001, J BIOL CHEM, V276, P13314, DOI 10.1074/jbc.M010562200; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Ezaki J, 2003, J NEUROCHEM, V87, P1296, DOI 10.1046/j.1471-4159.2003.02132.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Geyer M, 2002, MOL BIOL CELL, V13, P2045, DOI 10.1091/mbc.02-02-0026; GOEBEL HH, 1999, NEURONAL CEROID LIPO, V33; Golabek AA, 2000, MOL GENET METAB, V70, P203, DOI 10.1006/mgme.2000.3006; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; Janes RW, 1996, FEBS LETT, V399, P75, DOI 10.1016/S0014-5793(96)01290-2; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jarvela I, 1998, HUM MOL GENET, V7, P85, DOI 10.1093/hmg/7.1.85; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; Kida E, 1999, MOL GENET METAB, V66, P265, DOI 10.1006/mgme.1999.2837; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; Kyttala A, 2004, MOL BIOL CELL, V15, P1313, DOI 10.1091/mbc.E03-02-0120; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Le Borgne R, 2001, J CELL SCI, V114, P2831; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Luiro K, 2001, HUM MOL GENET, V10, P2123, DOI 10.1093/hmg/10.19.2123; Mao QW, 2003, FEBS LETT, V555, P351, DOI 10.1016/S0014-5793(03)01274-2; Mao QW, 2003, FEBS LETT, V541, P40, DOI 10.1016/S0014-5793(03)00284-9; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Obermuller S, 2002, J CELL SCI, V115, P185; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Persaud-Sawin DANW, 2002, HUM MOL GENET, V11, P2129, DOI 10.1093/hmg/11.18.2129; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodionov DG, 2002, J BIOL CHEM, V277, P47436, DOI 10.1074/jbc.M207149200; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Salazar G, 2004, J BIOL CHEM, V279, P25430, DOI 10.1074/jbc.M402331200; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Simmen T, 1999, J CELL SCI, V112, P45; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; Storch S, 2001, J BIOL CHEM, V276, P4298, DOI 10.1074/jbc.M005548200; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Taschner PEM, 1997, NEUROPEDIATRICS, V28, P18, DOI 10.1055/s-2007-973658; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	62	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53625	53634		10.1074/jbc.M410930200	http://dx.doi.org/10.1074/jbc.M410930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469932	hybrid			2022-12-27	WOS:000225680600099
J	Ellis, MA; Miedel, MT; Guerriero, CJ; Weisz, OA				Ellis, MA; Miedel, MT; Guerriero, CJ; Weisz, OA			ADP-ribosylation factor 1-independent protein sorting and export from the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLARIZED MDCK CELLS; CLATHRIN-MEDIATED ENDOCYTOSIS; INFLUENZA-VIRUS HEMAGGLUTININ; VESICULAR STOMATITIS-VIRUS; GTP-GAMMA-S; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; EPITHELIAL-CELLS; APICAL MEMBRANE	Polarized epithelial cells efficiently sort newly synthesized apical and basolateral proteins into distinct transport carriers that emerge from the trans-Golgi network (TGN), and this sorting is recapitulated in nonpolarized cells. While the targeting signals of basolaterally destined proteins are generally cytoplasmically disposed, apical sorting signals are not typically accessible to the cytosol, and the transport machinery required for segregation and export of apical cargo remains largely unknown. Here we investigated the molecular requirements for TGN export of the apical marker influenza hemagglutinin (HA) in HeLa cells using an in vitro reconstitution assay. HA was released from the TGN in intact membrane-bound compartments, and export was dependent on addition of an ATP-regenerating system and exogenous cytosol. HA release was inhibited by guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) as well as under conditions known to negatively regulate apical transport in vivo, including expression of the acid-activated proton channel influenza M2. Interestingly, release of HA was unaffected by depletion of ADP-ribosylation factor 1, a small GTPase that has been implicated in the recruitment of all known adaptors and coat proteins to the Golgi complex. Furthermore, regulation of HA release by GTPgammaS or M2 expression was unaffected by cytosolic depletion of ADP-ribosylation factor 1, suggesting that HA sorting remains functionally intact in the absence of the small GTPase. These data suggest that TGN sorting and export of influenza HA does not require classical adaptors involved in the formation of other classes of exocytic carriers and thus appears to proceed via a novel mechanism.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu		Guerriero, Christopher/0000-0002-1046-2300; Miedel, Mark/0000-0002-0132-6032	NIDDK NIH HHS [R01 DK54407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Altschuler Y, 2003, CURR OPIN CELL BIOL, V15, P423, DOI 10.1016/S0955-0674(03)00084-X; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; Banting G, 1998, J CELL SCI, V111, P3451; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Chen JL, 2004, FEBS LETT, V566, P281, DOI 10.1016/j.febslet.2004.04.061; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; CIAMPOR F, 1992, VIROLOGY, V188, P14, DOI 10.1016/0042-6822(92)90730-D; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Gleeson PA, 1996, J CELL SCI, V109, P2811; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Happe S, 1998, J CELL BIOL, V140, P511, DOI 10.1083/jcb.140.3.511; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495; Henkel JR, 1998, J BIOL CHEM, V273, P6518, DOI 10.1074/jbc.273.11.6518; Hu JS, 1997, BIOCHEMISTRY-US, V36, P5045, DOI 10.1021/bi963010e; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Jacob R, 2004, J BIOL CHEM, V279, P3680, DOI 10.1074/jbc.C300503200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Ling WLW, 1998, METHODS, V16, P141, DOI 10.1006/meth.1998.0661; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McLauchlan HJ, 2001, CELL BIOL INT, V25, P705, DOI 10.1006/cbir.2001.0717; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Pauloin A, 1999, J CELL SCI, V112, P4089; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Potter BA, 2004, MOL BIOL CELL, V15, P1407, DOI 10.1091/mbc.E03-08-0550; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; REAVES B, 1994, FEBS LETT, V345, P61, DOI 10.1016/0014-5793(94)00437-4; Reaves BJ, 1998, MOL BIOL CELL, V9, P1107, DOI 10.1091/mbc.9.5.1107; Rodriguez-Boulan E, 2004, CURR OPIN CELL BIOL, V16, P436, DOI 10.1016/j.ceb.2004.06.013; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Rustom A, 2002, TRAFFIC, V3, P279, DOI 10.1034/j.1600-0854.2002.030405.x; Scheiffele P, 2000, ESSAYS BIOCHEM, V36, P27, DOI 10.1042/bse0360027; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Simon JP, 1998, P NATL ACAD SCI USA, V95, P1073, DOI 10.1073/pnas.95.3.1073; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; Stumber M, 2002, EUR J BIOCHEM, V269, P3270, DOI 10.1046/j.1432-1033.2002.03003.x; Takeda T, 2003, AM J PHYSIOL-CELL PH, V284, pC1105, DOI 10.1152/ajpcell.00514.2002; Tall RD, 2003, TRAFFIC, V4, P838, DOI 10.1046/j.1398-9219.2003.0138.x; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WAGNER M, 1994, J CELL SCI, V107, P933; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Wylie FG, 2003, TRAFFIC, V4, P175, DOI 10.1034/j.1600-0854.2003.00106.x; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	70	7	7	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52735	52743		10.1074/jbc.M410533200	http://dx.doi.org/10.1074/jbc.M410533200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459187	hybrid			2022-12-27	WOS:000225493400120
J	Ripaud, L; Maillet, L; Immel-Torterotot, F; Durand, F; Cullin, C				Ripaud, L; Maillet, L; Immel-Torterotot, F; Durand, F; Cullin, C			The [URE3] yeast prion results from protein aggregates that differ from amyloid filaments formed in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; STRUCTURAL-CHARACTERIZATION; MAMMALIAN PRIONS; SCRAPIE; DOMAIN; CELLS; DETERMINANT; PROPAGATION; PRODUCTS; FIBERS	The [URE3] yeast prion is a self-propagating inactive form of the Ure2 protein. Ure2p is composed of two domains, residues 1 - 93, the prion-forming domain, and the remaining C-terminal part of the protein, which forms the functional domain involved in nitrogen catabolite repression. In vitro, Ure2p forms amyloid filaments that have been proposed to be the aggregated prion form found in vivo. Here we showed that the biochemical characteristics of these two species differ. Protease digestions of Ure2p filaments and soluble Ure2p are comparable when analyzed by Coomassie staining as by Western blot. However, this finding does not explain the pattern specifically observed in [ URE3] strains. Antibodies raised against the C-terminal part of Ure2p revealed the existence of proteolysis sites efficiently cleaved when [ URE3], but not wild-type crude extracts, were submitted to limited proteolysis. The same antibodies lead to an equivalent digestion pattern when recombinant Ure2p ( either soluble or amyloid) was analyzed in the same way. These results strongly suggest that aggregated Ure2p in [ URE3] yeast cells is different from the amyloid filaments generated in vitro.	Univ Bordeaux 2, CNRSI, UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Cullin, C (corresponding author), Univ Bordeaux 2, CNRSI, UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	Christophe.Cullin@ibgc.u-bordeaux2.fr	MAILLET, Laurent/K-7959-2015; cullin, christophe/AAM-2179-2020; Immel, Françoise/GNP-4167-2022; Immel, Françoise/N-7079-2019	MAILLET, Laurent/0000-0002-8169-060X; cullin, christophe/0000-0003-4110-4677; Immel, Françoise/0000-0002-2028-902X; 				AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; Bach S, 2003, NAT BIOTECHNOL, V21, P1075, DOI 10.1038/nbt855; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Fernandez-Bellot E, 2000, EMBO J, V19, P3215, DOI 10.1093/emboj/19.13.3215; Fernandez-Bellot E, 2002, EMBO REP, V3, P76, DOI 10.1093/embo-reports/kvf011; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Ripaud L, 2003, EMBO J, V22, P5251, DOI 10.1093/emboj/cdg488; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Schlumpberger M, 2001, MOL CELL BIOL, V21, P7035, DOI 10.1128/MCB.21.20.7035-7046.2001; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; TUROSCY V, 1987, J BACTERIOL, V169, P2598, DOI 10.1128/jb.169.6.2598-2600.1987; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50962	50968		10.1074/jbc.M408792200	http://dx.doi.org/10.1074/jbc.M408792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456789	Green Published, hybrid			2022-12-27	WOS:000225355800040
J	Rosenberg, MF; Callaghan, R; Modok, S; Higgins, CF; Ford, RC				Rosenberg, MF; Callaghan, R; Modok, S; Higgins, CF; Ford, RC			Three-dimensional structure of P-glycoprotein - The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ABC TRANSPORTER; CONFORMATIONAL-CHANGES; ATP-BINDING; CLOSED CONFORMATION; ELECTRON-MICROSCOPY; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DOMAINS	Multidrug resistance of cancer cells and pathogens is a serious clinical problem. A major factor contributing to drug resistance in cancer is the over-expression of P-glycoprotein, a plasma membrane ATP-binding cassette (ABC) drug efflux pump. Three-dimensional structural data with a resolution limit of similar to8 Angstrom have been obtained from two-dimensional crystals of P-glycoprotein trapped in the nucleotide-bound state. Each of the two transmembrane domains of P-glycoprotein consists of six long a-helical segments. Five of the a-helices from each transmembrane domain are related by a pseudo-2-fold symmetry, whereas the sixth breaks the symmetry. The two a-helices positioned closest to the (pseudo-) symmetry axis at the center of the molecule appear to be kinked. A large loop of density at the extracellular surface of the transporter is likely to correspond to the glycosylated first extracellular loop, whereas two globular densities at the cytoplasmic side correspond to the hydrophilic, nucleotide-binding domains. This is the first three-dimensional structure for an intact eukaryotic ABC transporter. Comparison with the structures of two prokaryotic ABC transporters suggests significant differences in the packing of the transmembrane a-helices within this protein family.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Oxford, John Radcliffe Hosp, Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, London W12 0NN, England	University of Manchester; University of Oxford; Imperial College London	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	r.ford@umist.ac.uk	Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Ford, Robert/0000-0002-0958-1505				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; Gabriel MP, 2003, BIOCHEMISTRY-US, V42, P7780, DOI 10.1021/bi0341049; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GLAESER RM, 1992, ULTRAMICROSCOPY, V47, P256, DOI 10.1016/0304-3991(92)90201-T; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P39706, DOI 10.1074/jbc.M308559200; Loo TW, 2004, J BIOL CHEM, V279, P18232, DOI 10.1074/jbc.M400229200; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2004, J BIOL CHEM, V279, P39051, DOI 10.1074/jbc.M407434200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Rothnie A, 2004, J BIOL CHEM, V279, P34913, DOI 10.1074/jbc.M405336200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897	39	149	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2857	2862		10.1074/jbc.M410296200	http://dx.doi.org/10.1074/jbc.M410296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15485807	hybrid			2022-12-27	WOS:000226449100060
J	Del Vecchio, RL; Tonks, NK				Del Vecchio, RL; Tonks, NK			The conserved immunoglobulin domain controls the subcellular localization of the homophilic adhesion receptor protein-tyrosine phosphatase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; PTP-MU; IN-VIVO; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; RPTP-MU; EXPRESSION; INHIBITION; BINDING; ALPHA	The receptor protein-tyrosine phosphatase mu (PTPmu) is a homophilic adhesion protein thought to regulate cell-cell adhesion in the vascular endothelium through dephosphorylation of cell junction proteins. In subconfluent cell cultures, PTPmu resides in an intracellular membrane pool; however, as culture density increases and cell contacts form, the phosphatase localizes to sites of cell-cell contact, and its expression level increases. These characteristics of PTPmu, which are consistent with a role in cell-cell adhesion, suggest that control of subcellular localization is an important mechanism to regulate the function of this phosphatase. To gain a better understanding of how PTPmu is regulated, we examined the importance of the conserved immunoglobulin domain, containing the homophilic binding site, in control of the localization of the enzyme. Deletion of the immunoglobulin domain impaired localization of PTPmu to the cell-cell contacts in endothelial and epithelial cells. In addition, deletion of the immunoglobulin domain affected the distribution of PTPmu in subconfluent endothelial cells when homophilic binding to another PTPmu molecule on an apposing cell was not possible, resulting in an accumulation of the mutant phosphatase at the cell surface with a concentration at the cell periphery in the region occupied by focal adhesions. This aberrant localization correlated with reduced survival and alterations in normal focal adhesion and cytoskeleton morphology. This study therefore illustrates the critical role of the immunoglobulin domain in regulation of the localization of PTPmu and the importance of such control for the maintenance of normal cell physiology.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Beltran PJ, 2003, FRONT BIOSCI, V8, pD87, DOI 10.2741/941; Bianchi C, 1999, EXP CELL RES, V248, P329, DOI 10.1006/excr.1999.4428; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Chang C, 2004, SCIENCE, V305, P103, DOI 10.1126/science.1096983; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Haspel J, 2003, FRONT BIOSCI-LANDMRK, V8, pS1210, DOI 10.2741/1108; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Krueger NX, 2003, MOL CELL BIOL, V23, P6909, DOI 10.1128/MCB.23.19.6909-6921.2003; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Symons JR, 2002, BIOCHEM J, V365, P513, DOI 10.1042/BJ20020381; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Wang J, 1999, MOL CELL NEUROSCI, V14, P370, DOI 10.1006/mcne.1999.0789; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Zamir E, 2001, J CELL SCI, V114, P3583; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1603	1612		10.1074/jbc.M410181200	http://dx.doi.org/10.1074/jbc.M410181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15491993	hybrid			2022-12-27	WOS:000226195200091
J	Shang, LJL; Dudley, SC				Shang, LJL; Dudley, SC			Tandem promoters and developmentally regulated 5 '- and 3 '-mRNA untranslated regions of the mouse Scn5a cardiac sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; BRUGADA-SYNDROME; GENE-EXPRESSION; MESSENGER-RNA; HUMAN BRAIN; TRANSLATIONAL REGULATION; FUNCTIONAL EXPRESSION; ATRIAL-FIBRILLATION; DOG-MODEL; MUTATION	The SCN5A gene encodes a voltage-sensitive sodium channel expressed in cardiac and skeletal muscle. Coding region mutations cause cardiac sudden death syndromes and conduction system failure. Polymorphisms in the 5'-sequence adjacent to the SCN5A gene have been linked to cardiac arrhythmias. We identified three alternative 5'-splice variants (1A, 1B, and 1C) of the untranslated exon 1 and two 3'-variants in the murine Scn5a mRNA. Two of the exon 1 isoforms ( 1B and 1C) were novel when compared with the published human and rat SCN5A sequences. Quantitative real time PCR results showed that the abundance of the isoforms varied during cardiac development. The 1A, 1B, and 1C mRNA splice variants increased 7.8 +/- 1.7-fold (E1A), 6.0 +/- 1.0-fold (E1B), and 20.6 +/- 3.7-fold (E1C) from fetal to adult heart, respectively. Promoter deletion and luciferase reporter gene analysis using cardiac and skeletal muscle cell lines demonstrated a pattern of distinct cardiac-specific enhancer elements associated with exons 1A and 1C. In the case of exon 1C, the enhancer element appeared to be within the exon. A 5'-repressor preceded each cardiac enhancer element. We concluded that the murine Na+ channel has both 5'- and 3'-untranslated region mRNA variants that are developmentally regulated and that the promoter region contains two distinct cardiac-specific enhancer regions. The presence of homologous human splicing suggests that that these regions may be fruitful new areas of study in understanding cardiac sodium channel regulation and the genetic susceptibility to sudden death.	Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Decatur, GA 30322 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Dudley, SC (corresponding author), Emory Univ, VAMC, Div Cardiol, 1670 Clairmont Rd 111B, Decatur, GA 30033 USA.	sdudley@emory.edu	Dudley, Samuel C/A-7085-2009; Dudley, Samuel/AAR-7950-2021	Dudley, Samuel/0000-0001-5843-5961	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antzelevitch C, 2002, CIRC RES, V91, P1114, DOI 10.1161/01.RES.0000046046.53721.90; Baroudi G, 1999, CIRCULATION, V100, P278; Baroudi G, 2000, FEBS LETT, V467, P12, DOI 10.1016/S0014-5793(00)01099-1; Baroudi G, 2002, CIRC RES, V90, pE11, DOI 10.1161/hh0102.102977; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bezzina CR, 2001, CARDIOVASC RES, V49, P257, DOI 10.1016/S0008-6363(00)00272-8; Bremner HR, 2002, AM J PHYSIOL-LUNG C, V282, pL124, DOI 10.1152/ajplung.2002.282.1.L124; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Donahue LM, 2000, BRAIN RES, V887, P335, DOI 10.1016/S0006-8993(00)03033-X; Gaspo R, 1997, CIRC RES, V81, P1045; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Gollob MH, 2002, CURR OPIN CARDIOL, V17, P229, DOI 10.1097/00001573-200205000-00004; Hake LE, 1997, BBA-REV CANCER, V1332, pM31, DOI 10.1016/S0304-419X(96)00039-X; Herfst LJ, 2004, J MOL CELL CARDIOL, V36, P185, DOI 10.1016/j.yjmcc.2003.11.014; Herfst LJ, 2003, J MOL CELL CARDIOL, V35, P549, DOI 10.1016/S0022-2828(03)00078-6; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Kang JX, 1997, P NATL ACAD SCI USA, V94, P2724, DOI 10.1073/pnas.94.6.2724; Lu CM, 1998, J MOL NEUROSCI, V11, P179, DOI 10.1385/JMN:11:3:179; Ou Y, 2002, NEUROGASTROENT MOTIL, V14, P477, DOI 10.1046/j.1365-2982.2002.00348.x; Probst V, 2000, CIRCULATION, V102, P281; Schade SD, 2000, MOL BRAIN RES, V81, P187, DOI 10.1016/S0169-328X(00)00145-5; Shang LJ, 2004, BIOPHYS J, V86, p424A; SHENG ZH, 1994, DNA CELL BIOL, V13, P9, DOI 10.1089/dna.1994.13.9; Stennard FA, 2003, DEV BIOL, V262, P206, DOI 10.1016/S0012-1606(03)00385-3; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Watson J, 2000, J MED GENET, V37, pS82; Yang P, 2004, CARDIOVASC RES, V61, P56, DOI 10.1016/j.cardiores.2003.09.030; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; Yue LX, 1999, CIRC RES, V84, P776; Zhang H, 1999, GENE EXPRESSION, V8, P85; Zogopoulos G, 1999, J MOL ENDOCRINOL, V23, P67, DOI 10.1677/jme.0.0230067	33	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					933	940		10.1074/jbc.M409977200	http://dx.doi.org/10.1074/jbc.M409977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15485820	hybrid			2022-12-27	WOS:000226195200012
J	van Lith, M; Hartigan, N; Hatch, J; Benham, AM				van Lith, M; Hartigan, N; Hatch, J; Benham, AM			PDILT, a divergent testis-specific protein disulfide isomerase with a non-classical SXXC motif that engages in disulfide-dependent interactions in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; FOLDING CATALYST; QUALITY-CONTROL; REDOX STATE; FAMILY; DOMAINS; BONDS; YEAST	Protein disulfide isomerase (PDI) is the archetypal enzyme involved in the formation and reshuffling of disulfide bonds in the endoplasmic reticulum (ER). PDI achieves its redox function through two highly conserved thioredoxin domains, and PDI can also operate as an ER chaperone. The substrate specificities and the exact functions of most other PDI family proteins remain important unsolved questions in biology. Here, we characterize a new and striking member of the PDI family, which we have named protein disulfide isomerase-like protein of the testis (PDILT). PDILT is the first eukaryotic SXXC protein to be characterized in the ER. Our experiments have unveiled a novel, glycosylated PDI-like protein whose tissue-specific expression and unusual motifs have implications for the evolution, catalytic function, and substrate selection of thioredoxin family proteins. We show that PDILT is an ER resident glycoprotein that liaises with partner proteins in disulfide-dependent complexes within the testis. PDILT interacts with the oxidoreductase Ero1alpha, demonstrating that the N-terminal cysteine of the CXXC sequence is not required for binding of PDI family proteins to ER oxidoreductases. The expression of PDILT, in addition to PDI in the testis, suggests that PDILT performs a specialized chaperone function in testicular cells. PDILT is an unusual PDI relative that highlights the adaptability of chaperone and redox function in enzymes of the endoplasmic reticulum.	Univ Durham, Dept Biol Sci, Durham DH1 3LE, England	Durham University	Benham, AM (corresponding author), Univ Durham, Dept Biol Sci, South Rd, Durham DH1 3LE, England.	Adam.benham@durham.ac.uk	Benham, Adam/AAC-6606-2019	Van Lith, Marcel/0000-0003-0225-5501; Benham, Adam/0000-0002-0919-7431				Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Benayoun B, 2001, J BIOL CHEM, V276, P13830, DOI 10.1074/jbc.M010933200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Clissold PM, 2003, BIOESSAYS, V25, P603, DOI 10.1002/bies.10287; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Haebel PW, 2002, EMBO J, V21, P4774, DOI 10.1093/emboj/cdf489; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; Marcus N, 1996, BBA-GENE STRUCT EXPR, V1309, P253, DOI 10.1016/S0167-4781(96)00133-9; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Miranda-Vizuete A, 2004, ANTIOXID REDOX SIGN, V6, P25, DOI 10.1089/152308604771978327; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Norgaard P, 2001, BIOCHEM J, V358, P269, DOI 10.1042/0264-6021:3580269; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Solovyov A, 2004, PROTEIN SCI, V13, P1902, DOI 10.1110/ps.04716104; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WATANABE D, 1994, J BIOL CHEM, V269, P7744; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200	40	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1376	1383		10.1074/jbc.M408651200	http://dx.doi.org/10.1074/jbc.M408651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15475357	hybrid			2022-12-27	WOS:000226195200064
J	Shiina, T; Konno, A; Oonuma, T; Kitamura, H; Imaoka, K; Takeda, N; Todokoro, K; Morimatsu, M				Shiina, T; Konno, A; Oonuma, T; Kitamura, H; Imaoka, K; Takeda, N; Todokoro, K; Morimatsu, M			Targeted disruption of MAIL, a nuclear I kappa B protein, leads to severe atopic dermatitis-like disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; NC/NGA MICE; SKIN; ALPHA; FIBROBLASTS; ACTIVATION; GAMMA	MAIL (molecule-possessing ankyrin repeats induced by lipopolysaccharide) is a nuclear IkappaB protein that is also termed interleukin-1-inducible nuclear ankyrin repeat protein or inhibitor of nuclear factor kappaB (IkappaB) zeta. In this study, we generated Mail(-/-) mice to investigate the roles of MAIL in whole organisms. Mail(-/-) mice grew normally until 4-8 weeks after birth, when they began to develop lesions in the skin of the periocular region, face, and neck. MAIL mRNA and protein were constitutively expressed in the skin of wild type controls, especially in the keratinocytes. Serum IgE was higher in Mail(-/-) mice than in normal. Histopathological analysis indicated that the Mail(-/-) skin lesions appeared to be atopic dermatitis ( AD) eczema with inflammatory cell infiltration. In addition, markedly elevated expression of some chemokines such as thymus and activation-regulated chemokine was detected in the Mail(-/-) skin lesions, similar to that observed in the skin of patients with AD. In Mail(-/-) mice, MAIL-deficient keratinocytes might be activated to produce chemokines and induce intraepidermal filtration of inflammatory cells, resulting in the onset of the AD-like disease. These findings suggest that MAIL is an essential molecule for homeostatic regulation of skin immunity. The Mail(-/-) mouse is a valuable new animal model for research on AD.	Hokkaido Univ, Lab Cytol & Histol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; Iwate Univ, Fac Agr, Dept Vet Physiol, Morioka, Iwate 0208550, Japan; Gifu Univ, Dept Vet Med, Fac Appl Biol Sci, Gifu 5011193, Japan; Hokkaido Univ, Lab Anat, Dept Biomed Sci, Grad Sch Vet Med, Sapporo, Hokkaido 0600818, Japan; Gifu Univ, United Grad Sch Vet Sci, Gifu 5011193, Japan; Inst Phys & Chem Res, Immunogenet Lab, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; Natl Inst Infect Dis, Dept Vet Sci, Tokyo 1628640, Japan; Kumamoto Univ, Dept Morphogenesis, Kumamoto 8600811, Japan; Inst Phys & Chem Res, Cell Fate Signaling Res Unit, Discovery Res Inst, Wako, Saitama 3510198, Japan; Hokkaido Univ, Lab Cytol & Histol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Iwate University; Gifu University; Hokkaido University; Gifu University; RIKEN; National Institute of Infectious Diseases (NIID); Kumamoto University; RIKEN; Hokkaido University	Morimatsu, M (corresponding author), Hokkaido Univ, Lab Cytol & Histol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan.	mmorimat@med.hokudai.ac.jp	Morimatsu, Masami/A-6698-2012	Morimatsu, Masami/0000-0003-0740-0157				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560; BURSTONE MS, 1958, J NATL CANCER I, V21, P523; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Heishi M, 2003, INT ARCH ALLERGY IMM, V132, P355, DOI 10.1159/000074903; Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200; Ito T, 2004, GENE, V342, P137, DOI 10.1016/j.gene.2004.07.032; Kitamura H, 2003, ARCH HISTOL CYTOL, V66, P53, DOI 10.1679/aohc.66.53; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Konno A, 2003, AUTOIMMUNITY, V36, P247, DOI 10.1080/0891693031000141077; KOYAMA Y-I, 1990, Journal of Dermatology (Tokyo), V17, P211; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Noso N, 1996, J IMMUNOL, V156, P1946; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schon MP, 2003, J INVEST DERMATOL, V121, P951, DOI 10.1046/j.1523-1747.2003.12563.x; Shiina T, 2001, IMMUNOGENETICS, V53, P649, DOI 10.1007/s00251-001-0376-x; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Villagomez MT, 2004, BRIT J DERMATOL, V150, P910, DOI 10.1111/j.1365-2133.2004.05937.x; Weih F, 1997, J IMMUNOL, V158, P5211; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200	32	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55493	55498		10.1074/jbc.M409770200	http://dx.doi.org/10.1074/jbc.M409770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15491998	hybrid			2022-12-27	WOS:000225960800064
J	Tran, AX; Karbarz, MJ; Wang, XY; Raetz, CRH; McGrath, SC; Cotter, RJ; Trent, MS				Tran, AX; Karbarz, MJ; Wang, XY; Raetz, CRH; McGrath, SC; Cotter, RJ; Trent, MS			Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT SALMONELLA-TYPHIMURIUM; MEMBRANE-BOUND PHOSPHATASES; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; STRUCTURAL-CHARACTERIZATION; OUTER-MEMBRANE; INNER MEMBRANE; IMMUNOBIOLOGICAL ACTIVITIES; POLYMYXIN RESISTANCE; EXPRESSION CLONING	Pathogenic bacteria modify the lipid A portion of their lipopolysaccharide to help evade the host innate immune response. Modification of the negatively charged phosphate groups of lipid A aids in resistance to cationic antimicrobial peptides targeting the bacterial cell surface. The lipid A of Helicobacter pylori contains a phosphoethanolamine (pEtN) unit directly linked to the 1-position of the disaccharide backbone. This is in contrast to the pEtN units found in other pathogenic Gram-negative bacteria, which are attached to the lipid A phosphate group to form a pyrophosphate linkage. This study describes two enzymes involved in the periplasmic modification of the 1-phosphate group of H. pylori lipid A. By using an in vitro assay system, we demonstrate the presence of lipid A 1-phosphatase activity in membranes of H. pylori. In an attempt to identify genes encoding possible lipid A phosphatases, we cloned four putative orthologs of Escherichia coli pgpB, the phosphatidylglycerol-phosphate phosphatase, from H. pylori 26695. One of these orthologs, Hp0021, is the structural gene for the lipid A 1-phosphatase and is required for removal of the 1-phosphate group from mature lipid A in an in vitro assay system. Heterologous expression of Hp0021 in E. coli resulted in the highly selective removal of the 1-phosphate group from E. coli lipid A, as demonstrated by mass spectrometry. We also identified the structural gene for the H. pylori lipid A pEtN transferase (Hp0022). Mass spectrometric analysis of the lipid A isolated from E. coli expressing Hp0021 and Hp0022 shows the addition of a single pEtN group at the 1-position, confirming that Hp0022 is responsible for the addition of a pEtN unit at the 1-position in H. pylori lipid A. In summary, we demonstrate that modification of the 1-phosphate group of H. pylori lipid A requires two enzymatic steps.	E Tennessee State Univ, James H Quillen Coll Med, Dept Microbiol, Johnson City, TN 37614 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	East Tennessee State University; Duke University; Johns Hopkins University	Trent, MS (corresponding author), Box 70579, Johnson City, TN 37614 USA.	trentms@mail.etsu.edu			NIAID NIH HHS [K22 AI 53645, K22 AI053645] Funding Source: Medline; NIGMS NIH HHS [R37 GM 51796, R37 GM051796, R37 GM051796-08, R01 GM 6440] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI053645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Appelmelk BJ, 2000, GUT, V47, P10, DOI 10.1136/gut.47.1.10; Appelmelk BJ, 1997, TRENDS MICROBIOL, V5, P70, DOI 10.1016/S0966-842X(96)10084-6; Appelmelk BJ, 2000, TRENDS MICROBIOL, V8, P565, DOI 10.1016/S0966-842X(00)01875-8; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Cox AD, 2003, J BACTERIOL, V185, P3270, DOI 10.1128/JB.185.11.3270-3277.2003; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; Gunn JS, 1998, MICROB PATHOGENESIS, V25, P77, DOI 10.1006/mpat.1998.0217; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hoshino K, 1999, J IMMUNOL, V162, P3749; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; JOHNSON AG, 1994, CLIN MICROBIOL REV, V7, P277, DOI 10.1128/CMR.7.3.277-289.1994; JOHNSON AG, 1987, REV INFECT DIS, V9, P512; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Mitaku S, 1999, BIOPHYS CHEM, V82, P165, DOI 10.1016/S0301-4622(99)00116-7; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Ogawa T, 2003, FEMS IMMUNOL MED MIC, V36, P1, DOI 10.1016/S0928-8244(03)00093-2; Ogawa T, 1997, VACCINE, V15, P1598, DOI 10.1016/S0264-410X(97)00102-3; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, CELLULAR MOL BIOL, P1035; Schmitt L, 2002, CHEMBIOCHEM, V3, P161, DOI 10.1002/1439-7633(20020301)3:2/3<161::AID-CBIC161>3.0.CO;2-F; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1998, J IMMUNOL, V161, P5464; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stukey J, 1997, PROTEIN SCI, V6, P469; Suda Y, 2001, J ENDOTOXIN RES, V7, P95, DOI 10.1179/096805101101532594; Suda Y, 1997, J BIOCHEM-TOKYO, V121, P1129; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; TOMAI MA, 1987, J BIOL RESP MODIF, V6, P99; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2004, BIOCHEM CELL BIOL, V82, P71, DOI 10.1139/o03-070; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	77	76	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55780	55791		10.1074/jbc.M406480200	http://dx.doi.org/10.1074/jbc.M406480200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489235	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000225960800100
J	Chaisson, ML; Branstetter, DG; Derry, JM; Armstrong, AP; Tometsko, ME; Takeda, K; Akira, S; Dougall, WC				Chaisson, ML; Branstetter, DG; Derry, JM; Armstrong, AP; Tometsko, ME; Takeda, K; Akira, S; Dougall, WC			Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; IKK-ALPHA; LIVER DEGENERATION; RECEPTOR ACTIVATOR; NF-KAPPA-B2 P100; KEY REGULATOR; RANK; LIGAND; GROWTH; OSTEOPETROSIS	Signaling through the receptor activator of nuclear factor kappaB (RANK) is required for both osteoclast differentiation and mammary gland development, yet the extent to which RANK utilizes similar signaling pathways in these tissues remains unclear. Mice expressing a kinase-inactive form of the inhibitor of kappaB kinase alpha(IKKalpha) have mammary gland defects similar to those of RANK-null mice yet have apparently normal osteoclast function. Because mice that completely lack IKKalpha have severe skin and skeletal defects that are not associated with IKKalpha-kinase activity, we wished to directly examine osteoclastogenesis in IKKalpha(-/-) mice. We found that unlike RANK-null mice, which completely lack osteoclasts, IKKalpha(-/-) mice did possess normal numbers of TRAP(+) osteoclasts. However, only 32% of these cells were multinucleated compared with 57% in wild-type littermates. A more profound defect in osteoclastogenesis was observed in vitro using IKKalpha(-/-) hematopoietic cells treated with colony-stimulating factor 1 and RANK ligand ( RANKL), as the cells failed to form large, multinucleated osteoclasts. Additionally, overall RANKL-induced global gene expression was significantly blunted in IKKalpha(-/-) cells, including osteoclast-specific genes such as TRAP, MMP-9, and c-Src. IKKalpha was not required for RANKL-mediated IkappaBalpha degradation or phosphorylation of mitogen-activated protein kinases but was required for RANKL-induced p100 processing. Treatment of IKKalpha(-/-) cells with tumor necrosis factor alpha (TNFalpha) in combination with RANKL led to partial rescue of osteoclastogenesis despite a lack of p100 processing. However, the ability of TNFalpha alone or in combination with transforming growth factor beta to induce osteoclast differentiation was dependent on IKKalpha, suggesting that synergy between RANKL and TNFalpha can overcome p100 processing defects in IKKalpha(-/-) cells.	Amgen Inc, Dept Canc Biol, Seattle, WA 98119 USA; Amgen Inc, Dept Pathol, Seattle, WA 98119 USA; Amgen Inc, Dept Med Sci, Seattle, WA 98119 USA; Kyushu Univ, Fukuoka 8128582, Japan; Osaka Univ, Suita, Osaka 5650871, Japan	Amgen; Amgen; Amgen; Kyushu University; Osaka University	Chaisson, ML (corresponding author), 1201 Amgen Ct W, Seattle, WA 98119 USA.	chaissom@amgen.com	Akira, Shizuo/C-3134-2009; Takeda, Kiyoshi/C-9331-2009	Takeda, Kiyoshi/0000-0002-1778-6332; Dougall, William/0000-0001-9487-251X				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; DAI S, 2004, J BIOL CHEM; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008; Jimi E, 1999, J IMMUNOL, V163, P434; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Menaa C, 2000, BIOCHEM BIOPH RES CO, V267, P943, DOI 10.1006/bbrc.1999.2042; Nishimura T, 2000, AM J REPROD IMMUNOL, V43, P351, DOI 10.1111/j.8755-8920.2000.430604.x; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Ohazama A, 2004, DEV CELL, V6, P219, DOI 10.1016/S1534-5807(04)00024-3; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; Rudolph D, 2000, GENE DEV, V14, P854; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004	39	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54841	54848		10.1074/jbc.M406392200	http://dx.doi.org/10.1074/jbc.M406392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485831	hybrid			2022-12-27	WOS:000225793600113
J	Chu, JJH; Ng, ML				Chu, JJH; Ng, ML			Interaction of West Nile virus with alpha(v)beta(3) integrin mediates virus entry into cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN DENDRITIC CELLS; ENVELOPE PROTEIN; DOMAIN-III; ENCEPHALITIS-VIRUS; JAPANESE ENCEPHALITIS; VIRAL ENTRY; INFECTION; BINDING; GLYCOPROTEIN	The functional receptor for the flavivirus West Nile (WNV) infection has been characterized in this study with a combination of biochemical and molecular approaches. A 105-kDa protease-sensitive glycoprotein that binds WNV was isolated from the plasma membrane of cells permissive to WNV infection. The protein was subjected to peptide sequencing, and this glycoprotein was identified as a member of the integrin superfamily. Infection of WNV was shown to be markedly inhibited in Vero cells pretreated with blocking antibodies against alpha(v)beta(3) integrin and its subunits by receptor competition assay. It was also noted that cells pretreated with antibodies against alpha(v)beta(3) integrin can effectively inhibit flavivirus Japanese encephalitis but to a lesser extent flavivirus dengue infections. West Nile virus entry is independent of divalent cations and is not highly blocked by arginine-glycine-aspartic acid (RGD) peptides, suggesting that the interaction between the virus and alpha(v)beta(3) integrin is not highly dependent on the classical RGD binding motif. In addition, gene silencing of the beta(3) integrin subunit in cells has resulted in cells largely resistant to WNV infection. In contrast, expression of recombinant human beta(3) integrin substantially increased the permissiveness of CS-1 melanoma cells for WNV infection. Soluble alpha(v)beta(3) integrin can also effectively block WNV infection in a dose-dependent manner. Furthermore, WNV infection also triggered the outside-in signaling pathway via the activation of integrin-associated focal adhesion kinase. The identification of alpha(v)beta(3) integrin as a receptor for WNV provides insight into virus-receptor interaction, hence creating opportunities in the development of anti-viral strategies against WNV infection.	Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, Singapore 117597, Singapore	National University of Singapore	Ng, ML (corresponding author), Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, 5 Sci Dr 2, Singapore 117597, Singapore.	micngml@nus.edu.sg	Chu, Justin Jang Hann/ABA-8297-2021; Ng, Mei Li/Q-3704-2016	Chu, Justin Jang Hann/0000-0002-1673-6819; Ng, Mei Li/0000-0001-9917-4534				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Aplin JD, 1996, MOL HUM REPROD, V2, P527, DOI 10.1093/molehr/2.7.527; BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Brinton MA, 2001, ANN NY ACAD SCI, V951, P207; Burke RD, 1999, INT REV CYTOL, V191, P257, DOI 10.1016/S0074-7696(08)60161-8; CASTLE E, 1987, ARCH VIROL, V92, P309, DOI 10.1007/BF01317487; Chu JJH, 2004, J VIROL, V78, P10543, DOI 10.1128/JVI.78.19.10543-10555.2004; Chu JJH, 2003, VIROLOGY, V312, P458, DOI 10.1016/S0042-6822(03)00261-7; Chu JJH, 2002, J GEN VIROL, V83, P2427, DOI 10.1099/0022-1317-83-10-2427; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; Filardo EJ, 1996, J CELL SCI, V109, P1615; Gavrilovskaya IN, 1998, P NATL ACAD SCI USA, V95, P7074, DOI 10.1073/pnas.95.12.7074; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; HEINZ FX, 1994, ARCH VIROL, V9, P339; Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004; Hurrelbrink RJ, 2001, J VIROL, V75, P7692, DOI 10.1128/JVI.75.16.7692-7702.2001; Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x; Joki-Korpela P, 2001, J VIROL, V75, P1958, DOI 10.1128/JVI.75.4.1958-1967.2001; KIMURA T, 1994, ARCH VIROL, V139, P239, DOI 10.1007/BF01310788; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Ni HL, 2000, J VIROL, V74, P2903, DOI 10.1128/JVI.74.6.2903-2906.2000; O'Leary DR, 2004, VECTOR-BORNE ZOONOT, V4, P61, DOI 10.1089/153036604773083004; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RICE CM, 1996, VIROLOGY, P931; RIEDER E, 1994, J VIROL, V68, P5296, DOI 10.1128/JVI.68.8.5296-5299.1994; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; Ruoslahti E, 1997, KIDNEY INT, V51, P1413, DOI 10.1038/ki.1997.193; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Solomon T, 2002, CURR TOP MICROBIOL, V267, P171; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Thullier P, 2001, J GEN VIROL, V82, P1885, DOI 10.1099/0022-1317-82-8-1885; van der Most RG, 1999, VIROLOGY, V265, P83, DOI 10.1006/viro.1999.0026; Volk DE, 2004, J BIOL CHEM, V279, P38755, DOI 10.1074/jbc.M402385200	39	167	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54533	54541		10.1074/jbc.M410208200	http://dx.doi.org/10.1074/jbc.M410208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475343	hybrid			2022-12-27	WOS:000225793600078
J	Lim, KP; Hong, WJ				Lim, KP; Hong, WJ			Human nischarin/imidazoline receptor antisera-selected protein is targeted to the endosomes by a combined action of a PX domain and a coiled-coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORTING NEXIN; FYVE DOMAIN; BINDING; FAMILY; IDENTIFICATION; INTERACTS; NISCHARIN; SMART; IRAS	Around 50 mammalian and 15 yeast proteins are known to contain the phox (PX) domain, the majority ( about 30) of which is classified as sorting nexins (SNXs). The PX domain, a hallmark of these proteins, is a conserved stretch of about 120 amino acids and is recently shown to mediate phosphoinositide binding. A few PX domain proteins (including some SNXs) have been shown to participate in diverse cellular processes such as protein sorting, signal transduction, and vesicle fusion. In this report, we present our results supporting a role of human IRAS to act as a SNX. The mouse homologue, previously identified as Nischarin, has been shown to interact with the alpha(5) subunit of integrin and inhibit cell migration (Alahari, S. K., Lee J. W., and Juliano R. L. (2000) J. Cell Biol. 51, 1141-1154). Its human homologue (imidazoline receptor antisera-selected ( IRAS)), on the other hand, contains an NH2-terminal extension and is a larger protein of 1504 amino acids consisting of an NH2-terminal PX domain, 5 putative leucine-rich repeats, a predicted coiled-coil domain, and a long COOH-terminal region. We show that it has the ability to homo-oligomerize via its coiled-coil region. The PX domain of IRAS is essential for association with phosphatidylinositol 3-phosphate-enriched endosomal membranes. However, the PX domain of IRAS alone is insufficient for its localization to endosomes, unless the coiled-coil domain was included or it is artificially dimerized by glutathione S-transferase. Interaction of human IRAS with alpha(5) integrin is not affected by the NH2-terminal extension, and overexpression of IRAS could cause a redistribution of surface alpha(5) integrin to intracellular endosomal structures.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, Proteos Bldg,Rm 5-21B,61 Biopolis Dr, Singapore 138673, Singapore.	mcbhwj@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Alahari SK, 2004, BIOCHEM J, V377, P449, DOI 10.1042/BJ20030411; Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BUCK CA, 1987, J CELL SCI, P231; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Dontenwill M, 2003, CELL DEATH DIFFER, V10, P933, DOI 10.1038/sj.cdd.4401275; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hanson BJ, 2003, J BIOL CHEM, V278, P34617, DOI 10.1074/jbc.M300143200; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lowe SL, 1996, J CELL SCI, V109, P209; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Patterson CE, 2000, MOL BIOL CELL, V11, P3925, DOI 10.1091/mbc.11.11.3925; Pierini LM, 2000, BLOOD, V95, P2471; Piletz JE, 2000, DNA CELL BIOL, V19, P319, DOI 10.1089/10445490050043290; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Raiborg C, 2001, J CELL SCI, V114, P2255; Sano H, 2002, J BIOL CHEM, V277, P19439, DOI 10.1074/jbc.M111838200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; XU Y, 2001, BIOCHEM J, V15, P513; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	39	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54770	54782		10.1074/jbc.M411315200	http://dx.doi.org/10.1074/jbc.M411315200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475348	hybrid			2022-12-27	WOS:000225793600105
J	Wower, IK; Zwieb, C; Wower, J				Wower, IK; Zwieb, C; Wower, J			Contributions of pseudoknots and protein SmpB to the structure and function of tmRNA in trans-translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TMRNA; ELONGATION-FACTOR TU; TRANSFER-RNA; 10SA RNA; STALLED RIBOSOME; MESSENGER-RNA; BINDING; SEQUENCE; L27; S1	Bacteria contain transfer-messenger RNA ( tmRNA), a molecule that during trans-translation tags incompletely translated proteins with a small peptide to signal the proteolytic destruction of defective polypeptides. TmRNA is composed of tRNA- and mRNA-like domains connected by several pseudoknots. Using truncated ribosomal protein L27 as a reporter for tagging in vitro and in vivo, we have developed exceptionally sensitive assays to study the role of Escherichia coli tmRNA in trans-translation. Site-directed mutagenesis experiments showed that pseudoknot 2 and the abutting helix 5 were particularly important for the binding of ribosomal protein S1 to tmRNA. Pseudoknot 4 not only facilitated tmRNA maturation but also promoted tagging. In addition, the three pseudoknots (pk2 to pk4) were shown to play a significant role in the proper folding of the tRNA- like domain. Protein SmpB enhanced tmRNA processing, suggesting a new role for SmpB in trans-translation. Taken together, these results provide unanticipated insights into the functions of the pseudoknots and protein SmpB during tmRNA folding, maturation, and protein synthesis.	Auburn Univ, Dept Anim Sci, Auburn, AL 36849 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Biol, Tyler, TX 75708 USA	Auburn University System; Auburn University; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Wower, J (corresponding author), Auburn Univ, Dept Anim Sci, 210 Upchurch Hall, Auburn, AL 36849 USA.	iwower@acesag.auburn.edu			NIGMS NIH HHS [GM58267] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058267] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barends S, 2000, BIOCHEMISTRY-US, V39, P2652, DOI 10.1021/bi992439d; Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bordeau V, 2002, BIOCHIMIE, V84, P723, DOI 10.1016/S0300-9084(02)01442-6; Chen GJ, 2000, BIOTECHNIQUES, V28, P498, DOI 10.2144/00283st08; Felden B, 1997, RNA, V3, P89; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; Giedroc DP, 2000, J MOL BIOL, V298, P167, DOI 10.1006/jmbi.2000.3668; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; Maguire BA, 2001, J BACTERIOL, V183, P6565, DOI 10.1128/JB.183.22.6565-6572.2001; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; Nameki N, 1999, NUCLEIC ACIDS RES, V27, P3667, DOI 10.1093/nar/27.18.3667; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nameki N, 1999, J MOL BIOL, V286, P733, DOI 10.1006/jmbi.1998.2487; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; Tadaki T, 1996, FEBS LETT, V399, P223, DOI 10.1016/S0014-5793(96)01330-0; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1996, RNA, V2, P1306; WOWER I, 1992, J BACTERIOL, V174, P1213, DOI 10.1128/jb.174.4.1213-1221.1992; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063; ZWIEB C, 1999, NUCL ACIDS RES S, V41, P200	35	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54202	54209		10.1074/jbc.M410488200	http://dx.doi.org/10.1074/jbc.M410488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494393	hybrid			2022-12-27	WOS:000225793600039
J	Deneke, J; Burgin, AB; Wilson, SL; Chaconas, G				Deneke, J; Burgin, AB; Wilson, SL; Chaconas, G			Catalytic residues of the telomere resolvase ResT - A pattern similar to, but distinct from, tyrosine recombinases and type IB topoisomerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR PLASMID PROPHAGE; LYME-DISEASE SPIROCHETE; DNA TOPOISOMERASE; ACTIVE-SITE; INTEGRASE FAMILY; BIDIRECTIONAL REPLICATION; RESOLUTION; RECOGNITION; MECHANISM; SEQUENCE	ResT is a member of the telomere resolvases, a newly discovered class of DNA breakage and reunion enzymes. These enzymes are involved in the formation of covalently closed hairpin DNA ends that are found in linear prokaryotic chromosomes and plasmids. The hairpins are generated by telomere resolution, where the replicated linear DNA ends are processed by DNA breakage followed by joining of DNA free ends to the complementary strand of the same molecule. Previous studies have shown that ResT catalyzes hairpin formation through a two-step transesterification similar to tyrosine recombinases and type IB topoisomerases. In the present study we have probed the reaction mechanism of ResT. The enzyme was found to efficiently utilize a substrate with a 5'-bridging phosphorothiolate at each cleavage site, similar to tyrosine recombinases/type IB topoisomerases. Using such a substrate to trap the covalent protein-DNA intermediate, coupled with affinity purification and mass spectroscopy, we report a new, non-radioactive approach to directly determine the position of the amino acid in the protein, which is linked to the DNA. We report that tyrosine 335 is the active site nucleophile in ResT, strengthening the link between ResT and tyrosine recombinases/type IB topoisomerases. However, a distinct pattern of catalytic residues with similarities, but distinct differences from the above enzymes was suggested. The differences include the apparent absence of a general acid catalyst, as well as the dispensability of the final histidine in the RKHRHY hexad. Finally, two signature motifs (GRR(2X)E(6X)F and LGH(4-6X)T(3X)Y) near the catalytic residues of aligned telomere resolvases are noted.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 1N4, Canada; deCode BioStruct, Bainbridge Isl, WA 98110 USA	University of Calgary; University of Calgary	Chaconas, G (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada.	chaconas@ucalgary.ca						Bankhead T, 2004, P NATL ACAD SCI USA, V101, P13768, DOI 10.1073/pnas.0405762101; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Burgin AB, 2000, METH MOL B, V95, P119; Byram R, 2004, J BACTERIOL, V186, P3561, DOI 10.1128/JB.186.11.3561-3569.2004; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Chaconas G, 2001, EMBO J, V20, P3229, DOI 10.1093/emboj/20.12.3229; Chaconas George, 2005, P525; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Deneke J, 2002, J BIOL CHEM, V277, P10410, DOI 10.1074/jbc.M111769200; Deneke J, 2000, P NATL ACAD SCI USA, V97, P7721, DOI 10.1073/pnas.97.14.7721; DENEKE J, 2002, THESIS FACHBEREICH C; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; Hertwig S, 2003, MOL MICROBIOL, V48, P989, DOI 10.1046/j.1365-2958.2003.03458.x; HINNEBUSCH J, 1993, MOL MICROBIOL, V10, P917, DOI 10.1111/j.1365-2958.1993.tb00963.x; Huang WM, 2004, J MOL BIOL, V337, P77, DOI 10.1016/j.jmb.2004.01.012; Kobryn K, 2002, MOL CELL, V9, P195, DOI 10.1016/S1097-2765(01)00433-6; Kobryn K, 2001, CURR OPIN MICROBIOL, V4, P558, DOI 10.1016/S1369-5274(00)00251-4; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; KROGH BO, 2001, J BIOL CHEM, V5, P5; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Picardeau M, 1999, MOL MICROBIOL, V32, P437, DOI 10.1046/j.1365-2958.1999.01368.x; Ravin NV, 2003, NUCLEIC ACIDS RES, V31, P6552, DOI 10.1093/nar/gkg856; Ravin NV, 2003, FEMS MICROBIOL LETT, V221, P1, DOI 10.1016/S0378-1097(03)00125-3; Rybchin VN, 1999, MOL MICROBIOL, V33, P895, DOI 10.1046/j.1365-2958.1999.01533.x; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; Stewart P, 2004, PLASMID BIOLOGY, P291; SVARCHEVSKY AN, 1986, THESIS LENINGRAD STA; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tourand Y, 2003, MOL MICROBIOL, V48, P901, DOI 10.1046/j.1365-2958.2003.03485.x; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x	42	34	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53699	53706		10.1074/jbc.M409001200	http://dx.doi.org/10.1074/jbc.M409001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471873	hybrid			2022-12-27	WOS:000225680600107
J	Ring, G; Eichler, J				Ring, G; Eichler, J			In the archaea Haloferax volcanii, membrane protein biogenesis and protein synthesis rates are affected by decreased ribosomal binding to the translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM; BOUND RIBOSOMES; IN-VIVO; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FUSION PROTEINS; SRP RNA; COMPONENTS; BACTERIOOPSIN	In the haloarchaea Haloferax volcanii, ribosomes are found in the cytoplasm and membrane-bound at similar levels. Transformation of H. volcanii to express chimeras of the translocon components SecY and SecE fused to a cellulose-binding domain substantially decreased ribosomal membrane binding, relative to non-transformed cells, likely due to steric hindrance by the cellulose-binding domain. Treatment of cells with the polypeptide synthesis terminator puromycin, with or without low salt washes previously shown to prevent in vitro ribosomal membrane binding in halophilic archaea, did not lead to release of translocon-bound ribosomes, indicating that ribosome release is not directly related to the translation status of a given ribosome. Release was, however, achieved during cell starvation or stationary growth, pointing at a regulated manner of ribosomal release in H. volcanii. Decreased ribosomal binding selectively affected membrane protein levels, suggesting that membrane insertion occurs co-translationally in Archaea. In the presence of chimera-incorporating sterically hindered translocons, the reduced ability of ribosomes to bind in the transformed cells modulated protein synthesis rates over time, suggesting that these cells manage to compensate for the reduction in ribosome binding. Possible strategies for this compensation, such as a shift to a post-translational mode of membrane protein insertion or maintained ribosomal membrane-binding, are discussed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Eichler, J (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	jeichler@bgumail.bgu.ac.il	EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bardy SL, 2003, PROTEIN SCI, V12, P1833, DOI 10.1110/ps.03148703; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; Bhuiyan SH, 2000, NUCLEIC ACIDS RES, V28, P1365, DOI 10.1093/nar/28.6.1365; CHANT J, 1986, SYST APPL MICROBIOL, V7, P106, DOI 10.1016/S0723-2020(86)80132-1; CHRISTIAN JHB, 1962, BIOCHIM BIOPHYS ACTA, V65, P506, DOI 10.1016/0006-3002(62)90453-5; Dale H, 2000, P NATL ACAD SCI USA, V97, P7847, DOI 10.1073/pnas.140216497; Dale H, 1999, J BIOL CHEM, V274, P22693, DOI 10.1074/jbc.274.32.22693; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; DYALLSMITH M, 2004, HALOHANDBOOK PROTOCO; Eichler J, 2001, TRENDS MICROBIOL, V9, P130, DOI 10.1016/S0966-842X(01)01954-0; Eichler J, 2000, ARCH MICROBIOL, V173, P445, DOI 10.1007/s002030000152; GINZBURG M, 1970, Journal of General Physiology, V55, P187, DOI 10.1085/jgp.55.2.187; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; Hainzl T, 2002, NATURE, V417, P767, DOI 10.1038/nature00768; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Herskovits AA, 2000, P NATL ACAD SCI USA, V97, P4621, DOI 10.1073/pnas.080077197; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Irihimovitch V, 2003, J BIOL CHEM, V278, P12881, DOI 10.1074/jbc.M210762200; Irihimovitch V, 2003, EXTREMOPHILES, V7, P71, DOI 10.1007/s00792-002-0297-0; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; Lichi T, 2004, EUR J BIOCHEM, V271, P1382, DOI 10.1111/j.1432-1033.2004.04050.x; Maeshima H, 2001, FEBS LETT, V507, P336, DOI 10.1016/S0014-5793(01)02996-9; Moll RG, 2004, J BIOENERG BIOMEMBR, V36, P47, DOI 10.1023/B:JOBB.0000019597.36170.5f; Moll RG, 2003, BIOCHEM J, V374, P247, DOI 10.1042/BJ20030475; MUECKLER MM, 1981, J CELL BIOL, V90, P495, DOI 10.1083/jcb.90.2.495; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Ortenberg R, 2000, J BIOL CHEM, V275, P22839, DOI 10.1074/jbc.M908916199; Oubridge C, 2002, MOL CELL, V9, P1251, DOI 10.1016/S1097-2765(02)00530-0; Pohlschroder M, 2004, FEMS MICROBIOL REV, V28, P3, DOI 10.1016/j.femsre.2003.07.004; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; RANDALL LL, 1977, EUR J BIOCHEM, V75, P43, DOI 10.1111/j.1432-1033.1977.tb11502.x; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; Ring G, 2004, J BIOENERG BIOMEMBR, V36, P35, DOI 10.1023/B:JOBB.0000019596.76554.7a; Ring G, 2004, J MOL BIOL, V336, P997, DOI 10.1016/j.jmb.2004.01.008; Rose RW, 2002, J BACTERIOL, V184, P3260, DOI 10.1128/JB.184.12.3260-3267.2002; Rosendal KR, 2003, P NATL ACAD SCI USA, V100, P14701, DOI 10.1073/pnas.2436132100; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; Tozik I, 2002, NUCLEIC ACIDS RES, V30, P4166, DOI 10.1093/nar/gkf548; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Zaigler A, 2003, MOL MICROBIOL, V48, P1089, DOI 10.1046/j.1365-2958.2003.03497.x; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200; Zwieb Christian, 2002, Archaea, V1, P27, DOI 10.1155/2002/729649	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53160	53166		10.1074/jbc.M410590200	http://dx.doi.org/10.1074/jbc.M410590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475349	hybrid, Green Published			2022-12-27	WOS:000225680600045
J	Hirata, T; Furukawa, Y; Yang, BG; Hieshima, K; Fukuda, M; Kannagi, R; Yoshie, O; Miyasaka, M				Hirata, T; Furukawa, Y; Yang, BG; Hieshima, K; Fukuda, M; Kannagi, R; Yoshie, O; Miyasaka, M			Human P-selectin glycoprotein ligand-1 (PSGL-1) interacts with the skin-associated chemokine CCL27 via sulfated tyrosines at the PSGL-1 amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; HIGH-AFFINITY BINDING; HUMAN LYMPH-NODES; MEMORY T-CELLS; SIALYL-LEWIS-X; MOLECULAR-BASIS; CUTTING EDGE; HIV-1 ENTRY; O-GLYCANS; IN-VIVO	P-selectin glycoprotein ligand-1 (PSGL-1), a sialomucin expressed on leukocytes, is a major ligand for P-selectin and mediates leukocyte rolling on the endothelium. Here we show that human PSGL-1 interacts with CCL27 (CTACK/ILC/ESkine), a skin-associated chemokine that attracts skin-homing T lymphocytes. A recombinant soluble form of PSGL-1 (rPSGL-Ig) preferentially bound CCL27 among several chemokines tested. This interaction was abrogated by arylsulfatase treatment of rPSGL-Ig, suggesting that sulfated tyrosines play a critical role. In contrast, removal of either N-glycans or O-glycans by glycosidase treatment of rPSGL-Ig did not affect the interaction. The binding of CCL27 to a recombinant PSGL-1 synthesized in the presence of a sulfation inhibitor was lower than that produced in normal medium. Moreover, mutation of the tyrosines at the amino terminus of PSGL-1 to phenylalanine abolished the binding, further supporting the role of sulfated tyrosines in the CCL27-PSGL-1 interaction. Functionally, rPSGL-Ig reduced the chemotaxis of L1.2 cells expressing CCR10, the receptor for CCL27. In addition, the expression of human PSGL-1 on CCR10-expressing L1.2 cells resulted in reduced chemotaxis to CCL27. These findings suggest a role for PSGL-1 in regulating chemokine-mediated responses, in addition to its role as a selectin ligand.	Osaka Univ, Grad Sch Med C8, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Aichi 4648681, Japan; Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Osaka University; Aichi Cancer Center; Sanford Burnham Prebys Medical Discovery Institute; Kindai University (Kinki University); Osaka University	Hirata, T (corresponding author), Osaka Univ, Grad Sch Med C8, Lab Mol & Cellular Recognit, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	thirata@orgctl.med.osaka-u.ac.jp	Hieshima, Kunio/AAF-7040-2019; Kannagi, Reiji/Q-6459-2018	Hieshima, Kunio/0000-0002-7786-4646; Kannagi, Reiji/0000-0003-4202-2921; Yang, Bo-Gie/0000-0002-1538-8488; Yoshie, Osamu/0000-0003-4353-5809; Hirata, Takako/0000-0002-1740-6168	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; Dulkanchainun TS, 1998, ANN SURG, V227, P832, DOI 10.1097/00000658-199806000-00006; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Hayward R, 1999, CARDIOVASC RES, V41, P65, DOI 10.1016/S0008-6363(98)00266-1; Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Jarmin DI, 2000, J IMMUNOL, V164, P3460, DOI 10.4049/jimmunol.164.7.3460; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; MCEVER RP, 1997, J CLIN INVEST, V100, P97; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA M, 1993, BIOCHEM BIOPH RES CO, V193, P337, DOI 10.1006/bbrc.1993.1629; Scalia R, 1999, CIRC RES, V84, P93; Scalia R, 1999, J EXP MED, V189, P931, DOI 10.1084/jem.189.6.931; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2003, J EXP MED, V197, P1355, DOI 10.1084/jem.20021854; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yanaba K, 2004, ANN RHEUM DIS, V63, P583, DOI 10.1136/ard.2003.011122; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	48	30	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51775	51782		10.1074/jbc.M409868200	http://dx.doi.org/10.1074/jbc.M409868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466853	hybrid			2022-12-27	WOS:000225493400010
J	Morimoto, A; Irie, K; Murakami, K; Masuda, Y; Ohigashi, H; Nagao, M; Fukuda, H; Shimizu, T; Shirasawa, T				Morimoto, A; Irie, K; Murakami, K; Masuda, Y; Ohigashi, H; Nagao, M; Fukuda, H; Shimizu, T; Shirasawa, T			Analysis of the secondary structure of beta-amyloid (A beta 42) fibrils by systematic proline replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; PHORBOL ESTER-BINDING; ALZHEIMERS-DISEASE; SENILE PLAQUES; DUTCH-TYPE; PEPTIDE; PROTEIN; NEUROTOXICITY; AGGREGATION; CONSTRAINTS	Amyloid fibrils in Alzheimer's disease mainly consist of 40- and 42-mer beta-amyloid peptides (Abeta40 and Abeta42) that exhibit aggregative ability and neurotoxicity. Although the aggregates of Abeta peptides are rich in intermolecular beta-sheet, the precise secondary structure of Abeta in the aggregates remains unclear. To identify the amino acid residues involved in the beta-sheet formation, 34 proline-substituted mutants of Abeta42 were synthesized and their aggregative ability and neurotoxicity on PC12 cells were examined. Prolines are rarely present in beta-sheet, whereas they are easily accommodated in beta-turn as a Pro-X corner. Among the mutants at positions 15-32, only E22P-Abeta42 extensively aggregated with stronger neurotoxicity than wild-type Abeta42, suggesting that the residues at positions 15-21 and 24-32 are involved in the beta-sheet and that the turn at positions 22 and 23 plays a crucial role in the aggregation and neurotoxicity of Abeta42. The C-terminal proline mutants (A42P-, I41P-, and V40P-Abeta42) hardly aggregated with extremely weak cytotoxicity, whereas the C-terminal threonine mutants (A42T- and I41T-Abeta42) aggregated potently with significant cytotoxicity. These results indicate that the hydrophobicity of the C-terminal two residues of Abeta42 is not related to its aggregative ability and neurotoxicity, rather the C-terminal three residues adopt the beta-sheet. These results demonstrate well the large difference in aggregative ability and neurotoxicity between Abeta42 and Abeta40. In contrast, the proline mutants at the N-terminal 13 residues showed potent aggregative ability and neurotoxicity similar to those of wild-type Abeta42. The identification of the beta-sheet region of Abeta42 is a basis for designing new aggregation inhibitors of Abeta peptides.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan; Univ Tokyo, Inst Med Sci, Tokyo 1088539, Japan; Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Tokyo 1730015, Japan	Kyoto University; Kyoto University; University of Tokyo; Tokyo Metropolitan Institute of Gerontology	Irie, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.	irie@kais.kyoto-u.ac.jp	Irie, Kazuhiro/A-6121-2014; Murakami, Kazuma/GQA-7062-2022	Irie, Kazuhiro/0000-0001-7109-8568; Murakami, Kazuma/0000-0003-3152-1784; Masuda, Yuichi/0000-0002-8067-5897				Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; BURDICK D, 1992, J BIOL CHEM, V267, P546; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Fukuda H, 1999, BIOORG MED CHEM LETT, V9, P953, DOI 10.1016/S0960-894X(99)00121-3; Fukuda H, 1999, BIOORGAN MED CHEM, V7, P1213, DOI 10.1016/S0968-0896(99)00037-1; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KANSKI J, 2001, BIOCHIM BIOPHYS ACTA, V1586, P190; Lakdawala AS, 2002, J AM CHEM SOC, V124, P15150, DOI 10.1021/ja0273290; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Morimoto A, 2002, BIOCHEM BIOPH RES CO, V295, P306, DOI 10.1016/S0006-291X(02)00670-8; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shimizu T, 2002, J NEUROSCI RES, V70, P451, DOI 10.1002/jnr.10350; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2003, BIOCHEMISTRY-US, V42, P3151, DOI 10.1021/bi027378p; WEINREB PH, 1994, J AM CHEM SOC, V116, P10835, DOI 10.1021/ja00102a079; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003	29	151	154	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52781	52788		10.1074/jbc.M406262200	http://dx.doi.org/10.1074/jbc.M406262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459202	hybrid			2022-12-27	WOS:000225493400125
J	Nguyen, TA; Takemoto, LJ; Takemoto, DJ				Nguyen, TA; Takemoto, LJ; Takemoto, DJ			Inhibition of gap junction activity through the release of the C1B domain of protein kinase c gamma (PKC gamma) from 14-3-3 - Identification of PKC gamma-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; ACTIVATION; 14-3-3-PROTEINS; RECEPTOR; BRAIN; MECHANISMS; ISOFORMS; AFFINITY; CELLS; LEDGF	We have shown previously that insulin-like growth factor-I or lens epithelium-derived growth factor increases the translocation of protein kinase Cgamma (PKCgamma) to the membrane and the phosphorylation of Cx43 by PKCgamma and causes a subsequent decrease of gap junction activity (Nguyen, T. A., Boyle, D. L., Wagner, L. M., Shinohara, T., and Takemoto, D. J. (2003) Exp. Eye Res. 76, 565-572; Lin, D., Boyle, D. L., and Takemoto, D. J. ( 2003) Investig. Ophthalmol. Vis. Sci. 44, 1160-1168). Gap junction activity in lens epithelial cells is regulated by PKCgamma-mediated phosphorylation of Cx43. PKCgamma activity is stimulated by growth factor-regulated increases in the synthesis of diacylglycerol but is inhibited by cytosolic docking proteins such as 14-3-3. Here we have identified two sites on the PKCgamma-C1B domain that are responsible for its interaction with 14-3-3epsilon. Two sites, C1B1 (residues 101-112) and C1B5 (residues 141-151), are located within the C1 domain of PKCgamma. C1B1 and/or C1B5 synthetic peptides can directly compete for the binding of 14-3-3epsilon, resulting in the release of endogenous cellular PKCgamma from 14-3-3epsilon, in vivo or in vitro, in activation of PKCgamma enzyme activity, phosphorylation of PKCgamma, in the subsequent translocation of PKCgamma to the membrane, and in inhibition of gap junction activity. Gap junction activity was decreased by at least 5-fold in cells treated with C1B1 or C1B5 peptides when compared with a control. 100 muM of C1B1 or C1B5 peptides also caused a 10- or 4-fold decrease of Cx43 plaque formation compared with control cells. The uptake of these synthetic peptides into cells was verified by using high pressure liquid chromatography and matrix-assisted laser desorption ionization time-of-flight-mass spectrometry. We have demonstrated that the activity and localization of PKCgamma are regulated by its binding to 14-3-3epsilon at the C1B domain of PKCgamma. Synthetic peptides corresponding to these regions of PKCgamma successfully competed for the binding of 14-3-3epsilon to endogenous PKCepsilon, resulting in inhibition of gap junction activity. This demonstrates that synthetic peptides can be used to exogenously regulate gap junctions.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University; Kansas State University	Takemoto, DJ (corresponding author), Kansas State Univ, Dept Biochem, 103 Willard Hall, Manhattan, KS 66506 USA.	dtak@ksu.edu			NATIONAL EYE INSTITUTE [R01EY002932, R01EY013421] Funding Source: NIH RePORTER; NEI NIH HHS [EY13421, EY02932] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Aronowski J, 2000, J CEREBR BLOOD F MET, V20, P343, DOI 10.1097/00004647-200002000-00016; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Beyer EC, 2002, CURR DRUG TARGETS, V3, P409, DOI 10.2174/1389450023347245; Bowers BJ, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-21-j0004.2001; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 2000, ANN REV PHARM TOXICO, V40, P619; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 1997, PROTEIN SCI, V6, P477; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Irie K, 1997, BIOORGAN MED CHEM, V5, P1725, DOI 10.1016/S0968-0896(97)00116-8; Kowara R, 1999, ACTA BIOCHIM POL, V46, P405, DOI 10.18388/abp.1999_4173; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Le ACN, 1998, DEV BIOL, V204, P80, DOI 10.1006/dbio.1998.9030; Lin D, 2004, MOL VIS, V10, P688; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P1160, DOI 10.1167/iovs.02-0737; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P1168; Narita M, 2001, J BIOL CHEM, V276, P15409, DOI 10.1074/jbc.M009716200; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nguyen TA, 2003, EXP EYE RES, V76, P565, DOI 10.1016/S0014-4835(03)00049-6; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Saltman AE, 2002, J THORAC CARDIOV SUR, V124, P371, DOI 10.1067/mtc.2002.124239; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wagner LM, 2002, MOL VIS, V8, P59; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	48	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52714	52725		10.1074/jbc.M403040200	http://dx.doi.org/10.1074/jbc.M403040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459208	hybrid			2022-12-27	WOS:000225493400118
J	Rajkovic, M; Middendorff, R; Wetzel, MG; Frkovic, D; Damerow, S; Seitz, HJ; Weitzel, JM				Rajkovic, M; Middendorff, R; Wetzel, MG; Frkovic, D; Damerow, S; Seitz, HJ; Weitzel, JM			Germ cell nuclear factor relieves cAMP-response element modulator tau-mediated activation of the testis-specific promoter of human mitochondrial glycerol-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MULTIPLE PROMOTERS; ORPHAN RECEPTOR; DIFFERENTIAL EXPRESSION; MICE LACKING; DNA-BINDING; GENE; CREM; TISSUE; TARGETS	Mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH) is an essential component of the glycerol phosphate shuttle that transfers reduction equivalents from the cytosol into the mitochondrion. Within the testis, immunohistological analysis localized human mGPDH to late spermatids and to the midpiece of spermatozoa. The expression of human mGPDH is regulated by two somatic promoters, and here, we describe a third testis-specific promoter of human mGPDH. The usage of this testis-specific promoter correlates with the expression of a shortened mGPDH transcript of similar to2.4 kb in length, which is solely detectable from testicular RNA. Within the testis-specific promoter, we detected a cAMP-response element (CRE) site at -51, which binds the testis-specific transcriptional activator CRE modulator tau (CREMtau) in electrophoretic mobility shift assays. This recognition site overlaps with a nuclear receptor binding half-site at - 49, which binds the testis-specific transcriptional repressor germ cell nuclear factor ( GCNF). Both factors compete for binding to the same DNA response element. Ectopic expression of CREMtau in HepG2 cells activated a promoter-driven luciferase construct in transient transfection experiments. Additional cotransfection of GCNF relieved this activity, suggesting a down-regulation of CREMtau-mediated activation by GCNF. This effect was preserved by introducing the CRE/nuclear receptor-binding element into a heterologous promoter context. Our data suggest a down-regulation of CREMtau-mediated gene expression by GCNF, which might be a general regulation mechanism for several postmeiotically expressed genes with a temporal expression peak during early spermatid development.	Univ Hamburg, Klinikum Eppendorf, Inst Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Inst Anat, Zentrum Expt Med, D-20246 Hamburg, Germany; Fac Med Belgrade, Inst Biochem, YU-11000 Belgrade, Serbia; Univ Giessen, Inst Anat & Zellbiol, D-35385 Giessen, Germany	University of Hamburg; University of Hamburg; University of Belgrade; Justus Liebig University Giessen	Weitzel, JM (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Biochem & Mol Biol, Martinistr 52, D-20246 Hamburg, Germany.	weitzel@uke.uni-hamburg.de		Weitzel, Joachim/0000-0002-4073-6691				Behr R, 2001, INT J ANDROL, V24, P126, DOI 10.1046/j.1365-2605.2001.00277.x; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Brown LJ, 2002, J BIOL CHEM, V277, P32892, DOI 10.1074/jbc.M202408200; BUCHER T, 1958, ANGEW CHEM INT EDIT, V70, P552, DOI 10.1002/ange.19580701707; Chung ACK, 2001, MOL CELL BIOL, V21, P663, DOI 10.1128/MCB.21.2.663-677.2001; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6; DAWSON AG, 1979, TRENDS BIOCHEM SCI, V4, P171, DOI 10.1016/0968-0004(79)90417-1; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; Don J, 2002, MOL CELL ENDOCRINOL, V187, P115, DOI 10.1016/S0303-7207(01)00696-7; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Ferrer J, 1996, DIABETES, V45, P262, DOI 10.2337/diabetes.45.2.262; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Gong DW, 1998, DNA CELL BIOL, V17, P301, DOI 10.1089/dna.1998.17.301; Gong QM, 2000, J BIOL CHEM, V275, P38012, DOI 10.1074/jbc.M004078200; Ha H, 1997, J CELL BIOCHEM, V64, P94, DOI 10.1002/(SICI)1097-4644(199701)64:1<94::AID-JCB12>3.3.CO;2-H; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; Ivell R, 2004, MOL CELL ENDOCRINOL, V216, P65, DOI 10.1016/j.mce.2003.10.079; Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; Lan ZJ, 2003, BIOL REPROD, V68, P282, DOI 10.1095/biolreprod.102.008151; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Russell L. D., 1990, HISTOLOGICAL HISTOPA; San Agustin JT, 2001, BIOL REPROD, V65, P151, DOI 10.1095/biolreprod65.1.151; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; SIBONY M, 1994, BIOL REPROD, V50, P1015, DOI 10.1095/biolreprod50.5.1015; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; Urcelay E, 2000, EUR J BIOCHEM, V267, P7209, DOI 10.1046/j.1432-1327.2000.01832.x; Weitzel JM, 2000, BIOL CHEM, V381, P611, DOI 10.1515/BC.2000.078; Weitzel JM, 2003, BIOL REPROD, V68, P699, DOI 10.1095/biolreprod.102.008540; Weitzel JM, 2001, NUCLEIC ACIDS RES, V29, P5148, DOI 10.1093/nar/29.24.5148; Weitzel JM, 2001, EUR J BIOCHEM, V268, P4095, DOI 10.1046/j.1432-1327.2001.02332.x; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yan ZJ, 2000, J BIOL CHEM, V275, P35077, DOI 10.1074/jbc.M005566200; Yang GY, 2003, BIOL REPROD, V68, P1620, DOI 10.1095/biolreprod.102.012013; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	39	20	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52493	52499		10.1074/jbc.M404467200	http://dx.doi.org/10.1074/jbc.M404467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456763	hybrid			2022-12-27	WOS:000225493400095
J	Dorovkov, MV; Ryazanov, AG				Dorovkov, MV; Ryazanov, AG			Phosphorylation of annexin I by TRPM7 channel-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-2 KINASE; HEAVY-CHAIN KINASE; PROTEIN-KINASE; ION-CHANNEL; CATALYTIC DOMAIN; TERMINAL DOMAIN; ALPHA-KINASES; BINDING; RECEPTOR; IDENTIFICATION	TRPM7 is an unusual bifunctional molecule consisting of a TRP ion channel fused to a protein kinase domain. It has been shown that TRPM7 plays a key role in the regulation of intracellular magnesium homeostasis as well as in anoxic neuronal death. TRPM7 channel has been characterized using electrophysiological techniques; however, the function of the kinase domain is not known and endogenous substrates for the kinase have not been reported previously. Here we have identified annexin 1 as a substrate for TRPM7 kinase. Phosphorylation of annexin 1 by TRPM7 kinase is stimulated by Ca2+ and is dramatically increased in extracts from cells overexpressing TRPM7. Phosphorylation of annexin 1 by TRPM7 kinase occurs at a conserved serine residue (Ser(5)) located within the N-terminal amphipathic alpha-helix of annexin 1. The N-terminal region plays a crucial role in interaction of annexin 1 with other proteins and membranes, and therefore, phosphorylation of annexin 1 at Ser(5) by TRPM7 kinase may modulate function of annexin 1.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Ryazanov, AG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	ryazanag@umdnj.edu	ryazanov, alexey/J-8081-2017		NATIONAL CANCER INSTITUTE [R01CA081102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057300] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81102] Funding Source: Medline; NIGMS NIH HHS [R01 GM57300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; ANDO Y, 1989, J BIOL CHEM, V264, P6948; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dempsey AC, 2003, STRUCTURE, V11, P887, DOI 10.1016/S0969-2126(03)00126-6; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hanano T, 2004, J PHARMACOL SCI, V95, P403, DOI 10.1254/jphs.FP0040273; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Perretti M, 2003, TRENDS PHARMACOL SCI, V24, P574, DOI 10.1016/j.tips.2003.09.010; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rosengarth A, 2003, J MOL BIOL, V326, P1317, DOI 10.1016/S0022-2836(03)00027-5; Rosengarth A, 2001, J MOL BIOL, V306, P489, DOI 10.1006/jmbi.2000.4423; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Ryazanova L. V., 2001, Molekulyarnaya Biologiya (Moscow), V35, P321; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; WANG W, 1994, BIOCHEMISTRY-US, V33, P275, DOI 10.1021/bi00167a036; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; Yoon MK, 2000, FEBS LETT, V484, P241, DOI 10.1016/S0014-5793(00)02160-8	37	159	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50643	50646		10.1074/jbc.C400441200	http://dx.doi.org/10.1074/jbc.C400441200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485879	hybrid			2022-12-27	WOS:000225355800002
J	Hansson, CA; Frykman, S; Farmery, MR; Tjernberg, LO; Nilsberth, C; Pursglove, SE; Ito, A; Winblad, B; Cowburn, RF; Thyberg, J; Ankarcrona, M				Hansson, CA; Frykman, S; Farmery, MR; Tjernberg, LO; Nilsberth, C; Pursglove, SE; Ito, A; Winblad, B; Cowburn, RF; Thyberg, J; Ankarcrona, M			Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-APP; APOPTOSIS; TRAFFICKING; MATURATION; INHIBITORS; SIGNAL; BRAIN	Mitochondria are central in the regulation of cell death. Apart from providing the cell with ATP, mitochondria also harbor several death factors that are released upon apoptotic stimuli. Alterations in mitochondrial functions, increased oxidative stress, and neurons dying by apoptosis have been detected in Alzheimer's disease patients. These findings suggest that mitochondria may trigger the abnormal onset of neuronal cell death in Alzheimer's disease. We previously reported that presenilin 1 (PS1), which is often mutated in familial forms of Alzheimer's disease, is located in mitochondria and hypothesized that presenilin mutations may sensitize cells to apoptotic stimuli at the mitochondrial level. Presenilin forms an active gamma-secretase complex together with Nicastrin (NCT), APH-1, and PEN-2, which among other substrates cleaves the beta-amyloid precursor protein (beta-APP) generating the amyloid beta-peptide and the beta-APP intracellular domain. Here we have identified dual targeting sequences ( for endoplasmic reticulum and mitochondria) in NCT and showed expression of NCT in mitochondria by immunoelectron microscopy. We also showed that NCT together with APH-1, PEN-2, and PS1 form a high molecular weight complex located in mitochondria. gamma-Secretase activity in isolated mitochondria was demonstrated using C83 ( alpha-secretase-cleaved C-terminal 83-residue beta-APP fragment from BD8 cells lacking presenilin and thus gamma-secretase activity) or recombinant C100-Flag (C-terminal 100-residue beta-APP fragment) as substrates. Both systems generated an APP intracellular domain, and the activity was inhibited by the gamma-secretase inhibitors L-685,458 or Compound E. This novel localization of NCT, PS1, APH-1, and PEN-2 expands the role and importance of gamma-secretase activity to mitochondria.	Huddinge Hosp, Karolinska Inst, KASPAC, SE-14157 Huddinge, Sweden; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Sumitomo Pharmaceut Co Ltd, Osaka 5418510, Japan; Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, SE-17177 Stockholm, Sweden	Karolinska Institutet; University of Sydney; Karolinska Institutet	Ankarcrona, M (corresponding author), Huddinge Hosp, Karolinska Inst, KASPAC, 5th Floor, SE-14157 Huddinge, Sweden.	ankarcrona@neurotec.ki.se		Ankarcrona, Maria/0000-0002-7022-3694				Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Ankarcrona M, 2002, BIOCHEM BIOPH RES CO, V295, P766, DOI 10.1016/S0006-291X(02)00735-0; Bagshaw RD, 2003, BIOCHEM BIOPH RES CO, V300, P615, DOI 10.1016/S0006-291X(02)02865-6; Brookes PS, 2002, PROTEOMICS, V2, P969, DOI 10.1002/1615-9861(200208)2:8<969::AID-PROT969>3.0.CO;2-3; Butterfield DA, 2003, CNS DRUGS, V17, P641, DOI 10.2165/00023210-200317090-00004; Chen FS, 2003, J BIOL CHEM, V278, P19974, DOI 10.1074/jbc.M210049200; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Keller JN, 1998, J NEUROSCI, V18, P4439; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Mecocci P, 2002, ARCH NEUROL-CHICAGO, V59, P794, DOI 10.1001/archneur.59.5.794; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; REICHMANN H, 1993, J NEUROL, V240, P377, DOI 10.1007/BF00839971; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Siman R, 2003, J NEUROCHEM, V84, P1143, DOI 10.1046/j.1471-4159.2003.01616.x; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	41	202	218	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51654	51660		10.1074/jbc.M404500200	http://dx.doi.org/10.1074/jbc.M404500200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456764	hybrid			2022-12-27	WOS:000225355800121
J	Ma, CL; Kotaria, R; Mayor, JA; Remani, S; Walters, DE; Kaplan, RS				Ma, CL; Kotaria, R; Mayor, JA; Remani, S; Walters, DE; Kaplan, RS			The yeast mitochondrial citrate transport protein - Characterization of transmembrane domain III residue involvement in substrate translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; FATTY-ACID SYNTHESIS; STRUCTURE/FUNCTION RELATIONSHIPS; OXALOBACTER-FORMIGENES; TRICARBOXYLATE CARRIER; REENTRANT LOOP; PATHWAY; PURIFICATION; IDENTIFICATION; PERMEATION	Previous examination of the accessibility of a panel of single-Cys mutants in transmembrane domain III (TM-DIII) of the yeast mitochondrial citrate transport protein to hydrophilic, cysteine-specific methanethiosulfonate reagents, enabled identification of the water-accessible surface of this domain and suggested its potential participation in the formation of a portion of the substrate translocation pathway. To evaluate this idea, we conducted a detailed characterization of the functional properties of 20 TMDIII single-Cys substitution mutants. Kinetic studies indicate that the A118C, S123C, and K134C mutants displayed a 3- to 7-fold increase in K-m. Moreover, the A118C mutation caused a doubling of the V-max value, whereas the S123C, E131C, and K134C mutations caused Vmax to dramatically decrease, resulting in a reduction of the catalytic efficiencies of these three mutants by > 97%. Examination of the ability of citrate to protect against the inhibition mediated by sodium (2-sulfonatoethyl) methanethiosulfonate (MTSES) indicated that citrate conferred significant protection of cysteines substituted at eight water-accessible locations (i.e. Gly-115, Leu-116, Gly-117, Leu-121, Ser-123, Val-127, Glu-131, and Thr-135), but not at other sites. Importantly, similar levels of protection were observed at both 4 degreesC and 20 degreesC. The temperature independence of the protection indicates that substrate binding and/or occupancy of the transport pathway sterically blocks the access of MTSES to these sites, thereby providing direct protection, without involvement of a major protein conformational change. The significance of these extensive functional investigations is discussed in terms of the three-dimensional CTP homology model that we previously developed and a new model of the dimer interface.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Kaplan, RS (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	Ronald.Kaplan@rosalindfranklin.edu	Mayor, June/AAP-1544-2021; Walters, D. Eric/C-9626-2010	Walters, D. Eric/0000-0002-1513-3522	NIGMS NIH HHS [GM-054642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Friedman M. A., 1986, PRINCIPLES MODELS BI, p[45, 105, 154, 346]; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KOARIA R, 1999, J BIOENERG BIOMEMBR, V31, P543; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; Ma CL, 2004, J BIOL CHEM, V279, P1533, DOI 10.1074/jbc.M310866200; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; Walters DE, 2004, BIOPHYS J, V87, P907, DOI 10.1529/biophysj.104.042127; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Xu Y, 2000, J BIOL CHEM, V275, P7117, DOI 10.1074/jbc.275.10.7117; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255; Ye LW, 2002, J BIOL CHEM, V277, P20372, DOI 10.1074/jbc.M111140200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	25	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2331	2340		10.1074/jbc.M411474200	http://dx.doi.org/10.1074/jbc.M411474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15498760	hybrid			2022-12-27	WOS:000226341700070
J	Martowicz, ML; Grass, JA; Boyer, ME; Guend, H; Bresnick, EH				Martowicz, ML; Grass, JA; Boyer, ME; Guend, H; Bresnick, EH			Dynamic GATA factor interplay at a multicomponent regulatory region of the GATA-2 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; BETA-GLOBIN LOCUS; RNA-POLYMERASE-II; HYPERSENSITIVE SITES; HISTONE ACETYLATION; CHROMATIN DOMAIN; ERYTHROID-DIFFERENTIATION; MAMMALIAN-CELLS; BINDING PROTEIN; NUCLEOSOMAL DNA	Given the simplicity of the DNA sequence that mediates binding of GATA transcription factors, GATA motifs reside throughout chromosomal DNA. However, chromatin immunoprecipitation analysis has revealed that GATA-1 discriminates exquisitely among these sites. GATA-2 selectively occupies the -2.8-kilobase (kb) region of the GATA-2 locus in the active state despite there being numerous GATA motifs throughout the locus. The GATA-1-mediated displacement of GATA-2 is tightly coupled to repression of GATA-2 transcription. We have used high resolution chromatin immunoprecipitation to show that GATA-1 and GATA-2 occupy two additional regions, -3.9 and -1.8 kb of the GATA-2 locus. GATA-1 and GATA-2 had distinct preferences for occupancy at these regions, with GATA-1 and GATA-2 occupancy highest at the -3.9- and -1.8- kb regions, respectively. Activation of an estrogen receptor fusion to GATA-1 (ER-GATA-1) induced similar kinetics of ER-GATA-1 occupancy and GATA-2 displacement at the sites. In the transcriptionally active state, DNase I hypersensitive sites (HSs) were detected at the -3.9- and -1.8-kb regions, with a weak HS at the -2.8-kb region. Whereas ER-GATA-1-instigated repression abolished the -1.8-kb HS, the -3.9-kb HS persisted in the repressed state. Transient transfection analysis provided evidence that the -3.9-kb region functions distinctly from the -2.8- and -1.8-kb regions. We propose that GATA-2 transcription is regulated via the collective actions of complexes assembled at the -2.8- and -1.8-kb regions, which share similar properties, and through a qualitatively distinct activity of the -3.9-kb complex.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave,383 Med Sci Ctr, Madison, WI 53706 USA.	ehbresni@wisc.edu			NIDDK NIH HHS [DK67633, DK50107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050107, R21DK067633] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender MA, 2000, BLOOD, V95, P3600, DOI 10.1182/blood.V95.11.3600.011k42_3600_3604; Bender MA, 2001, BLOOD, V98, P2022, DOI 10.1182/blood.V98.7.2022; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Im Hogune, 2004, Methods Mol Biol, V284, P129; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kiekhaefer CM, 2004, J BIOL CHEM, V279, P7456, DOI 10.1074/jbc.M309750200; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Minegishi N, 2003, BLOOD, V102, P896, DOI 10.1182/blood-2002-12-3809; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; Molete JM, 2001, MOL CELL BIOL, V21, P2969, DOI 10.1128/MCB.21.9.2969-2980.2001; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; Pal S, 2004, J BIOL CHEM, V279, P31348, DOI 10.1074/jbc.M403475200; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Peterson KR, 1998, ANN NY ACAD SCI, V850, P28, DOI 10.1111/j.1749-6632.1998.tb10459.x; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642	51	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1724	1732		10.1074/jbc.M406038200	http://dx.doi.org/10.1074/jbc.M406038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15494394	hybrid			2022-12-27	WOS:000226341700004
J	Gardian, G; Browne, SE; Choi, DK; Klivenyi, P; Gregorio, J; Kubilus, JK; Ryu, H; Langley, B; Ratan, RR; Ferrante, RJ; Beal, MF				Gardian, G; Browne, SE; Choi, DK; Klivenyi, P; Gregorio, J; Kubilus, JK; Ryu, H; Langley, B; Ratan, RR; Ferrante, RJ; Beal, MF			Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; ORAL SODIUM PHENYLBUTYRATE; CREB-BINDING PROTEIN; LONG-TERM TREATMENT; EXPANDED POLYGLUTAMINE; DEPENDENT NEURODEGENERATION; TRANSCRIPTIONAL REPRESSION; MEDIATED TRANSCRIPTION; ALTERED TRANSCRIPTION	Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding the huntingtin protein (Htt), however, the means by which neurodegeneration occurs remains obscure. There is evidence that mutant Htt interacts with transcription factors leading to reduced histone acetylation. We report that administration of the histone deacetylase inhibitor phenylbutyrate after onset of symptoms in a transgenic mouse model of HD significantly extends survival and attenuates both gross brain and neuronal atrophy. Administration of phenylbutyrate increased brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots. Phenylbutyrate increased mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum. These results show that administration of phenylbutyrate, at doses that are well tolerated in man, exerts significant neuroprotective effects in a transgenic mouse model of HD, and therefore represents a very promising therapeutic approach for HD.	Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA; Bedford Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Cornell Univ, Coll Med, Burke Med Res Inst, White Plains, NY 10605 USA	Cornell University; NewYork-Presbyterian Hospital; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Cornell University	Beal, MF (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,Rm F610, New York, NY 10021 USA.	fbeal@med.cornell.edu	Langley, Brett C/P-7207-2017	Langley, Brett C/0000-0003-4009-2109; Klivenyi, Peter/0000-0002-5389-3266; Ryu, Hoon/0000-0001-6544-3732; Choi, Dong-Kug/0000-0001-7041-1524	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035255, P01NS045242] Funding Source: NIH RePORTER; NINDS NIH HHS [NS045242, NS32958, NS35255] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreassen OA, 2001, NEUROBIOL DIS, V8, P479, DOI 10.1006/nbdi.2001.0406; Andreassen OA, 2001, ANN NEUROL, V50, P112, DOI 10.1002/ana.1085; AUSUBEL FM, 2000, CURRENT PROTOCOLS MO, P61; Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x; Burlina AB, 2001, MOL GENET METAB, V72, P351, DOI 10.1006/mgme.2001.3156; Carducci MA, 2001, CLIN CANCER RES, V7, P3047; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; Dedeoglu A, 2003, J NEUROCHEM, V85, P1359, DOI 10.1046/j.1471-4159.2003.01706.x; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; DOVER GJ, 1994, BLOOD, V84, P339; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hoppe C, 1999, AM J HEMATOL, V62, P221, DOI 10.1002/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R; Hughes RE, 2001, P NATL ACAD SCI USA, V98, P13201, DOI 10.1073/pnas.191498198; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; JENKINS BG, 2004, IN PRESS J NEUROCHEM; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kiechle T, 2002, NEUROMOL MED, V1, P183; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Maestri NE, 1996, NEW ENGL J MED, V335, P855, DOI 10.1056/NEJM199609193351204; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Obrietan K, 2004, J NEUROSCI, V24, P791, DOI 10.1523/JNEUROSCI.3493-03.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Perez-Severiano F, 2000, BRAIN RES, V862, P234, DOI 10.1016/S0006-8993(00)02082-5; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Schilling G, 2001, NEUROSCI LETT, V315, P149, DOI 10.1016/S0304-3940(01)02326-6; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Schilling G, 2001, NEUROBIOL DIS, V8, P405, DOI 10.1006/nbdi.2001.0385; Sekimata M, 2001, J BIOL CHEM, V276, P42632, DOI 10.1074/jbc.M107048200; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Taylor JP, 2003, GENE DEV, V17, P1463, DOI 10.1101/gad.1087503; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Yu ZX, 2003, J NEUROSCI, V23, P2193; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	51	351	366	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					556	563		10.1074/jbc.M410210200	http://dx.doi.org/10.1074/jbc.M410210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494404	hybrid			2022-12-27	WOS:000226025100066
J	Chung, MC; Kawamoto, S				Chung, MC; Kawamoto, S			IRF-2 is involved in up-regulation of nonmuscle myosin heavy chain II-A gene expression during phorbol ester-induced promyelocytic HL-60 differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-2; IN-VITRO; FACTOR-2; CELLS; ACTIVATION; IDENTIFICATION; REQUIRES; FECHTNER; MUTATION; MUSCLE	Transcription of the nonmuscle myosin heavy chain II-A (NMHC-A) gene is regulated by various factors, including cell type, proliferation and differentiation stage, and extracellular stimuli. We have identified an intronic region (designated 32kb-150), which is located 32 kb downstream of the transcription start sites in the human NMHC-A gene, as a transcriptional regulatory region. 32kb-150 contains an interferon-stimulated response element (ISRE). By using HeLa and NIH3T3 cells, in which NMHC-A is constitutively expressed, interferon regulatory factor (IRF)-2 was found to be the only major protein, among the IRF family proteins, that bound to the ISRE in 32kb-150 both in vitro and in intact cells. IRF-2, which is known to either repress or activate target gene expression, acts as a transcriptional activator in the context of the 32kb-150 reporter gene. The carboxyl-terminal basic region of IRF-2 serves as an activation domain in this context. This is in contrast to its acting as a repressor domain in the context of the synthetic core ISRE. Furthermore, after treatment of promyelocytic HL-60 cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), which triggers differentiation into macrophages, both NMHC-A expression and IRF-2 expression were found to be up-regulated with a similar time course. TPA treatment leads to recruitment of IRF-2 to 32kb-150 of the endogenous NMHC-A gene and acetylation of the core histones surrounding this region. In addition, the ISRE in the 32kb-150 reporter gene recruits IRF-2 and mediates TPA-induced activation of a reporter gene in HL-60 cells. Together, these results indicate that IRF-2 contributes to transcriptional activation of the NMHC-A gene via 32kb-150 during TPA-induced differentiation of HL-60 cells.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kawamoto, S (corresponding author), Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	kawamots@mail.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004236, Z01HL004236] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araki N, 2003, J CELL SCI, V116, P247, DOI 10.1242/jcs.00235; Beohar N, 1998, J BIOL CHEM, V273, P9168, DOI 10.1074/jbc.273.15.9168; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Childs KS, 2003, NUCLEIC ACIDS RES, V31, P3016, DOI 10.1093/nar/gkg431; Chung MC, 2001, BIOCHEMISTRY-US, V40, P8887, DOI 10.1021/bi002847d; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; Lalwani AK, 2000, AM J HUM GENET, V67, P1121, DOI 10.1016/S0002-9297(07)62942-5; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Ma XF, 2004, MOL BIOL CELL, V15, P2568, DOI 10.1091/mbc.E03-11-0836; Madsen CS, 1998, CIRC RES, V82, P908; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Manabe I, 2001, J BIOL CHEM, V276, P39076, DOI 10.1074/jbc.M105402200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Seri M, 2000, NAT GENET, V26, P103; Seri M, 2003, MEDICINE, V82, P203, DOI 10.1097/00005792-200305000-00006; Staal A, 2000, J CELL PHYSIOL, V185, P269, DOI 10.1002/1097-4652(200011)185:2<269::AID-JCP12>3.0.CO;2-L; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TOOTHAKER LE, 1991, BLOOD, V78, P1826; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613; Xie RL, 2003, J BIOL CHEM, V278, P26589, DOI 10.1074/jbc.M301491200; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	49	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56042	56052		10.1074/jbc.M404791200	http://dx.doi.org/10.1074/jbc.M404791200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496418	hybrid			2022-12-27	WOS:000225960800128
J	Wong, DS; Zhang, JY; Awasthi, Y; Sharma, A; Rogers, L; Matlock, EF; Van Lint, C; Karpova, T; McNally, J; Harrod, R				Wong, DS; Zhang, JY; Awasthi, Y; Sharma, A; Rogers, L; Matlock, EF; Van Lint, C; Karpova, T; McNally, J; Harrod, R			Nerve growth factor receptor signaling induces histone acetyltransferase domain-dependent nuclear translocation of p300/CREB-binding protein-associated factor and hGCN5 acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-INHIBITOR P21(WAF1/CIP1); TRANSCRIPTION FACTOR CREB; LONG-TERM FACILITATION; VIRUS TYPE-1 TAX; SYMPATHETIC NEURONS; PC12 CELLS; BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL-NEURONS	The transcriptional coactivators, p300/CREB-binding protein-associated factor (PCAF) and hGCN5, are recruited to chromatin-remodeling complexes on enhancers of various gene promoters in response to growth factor stimulation. However, the molecular mechanisms by which surface receptor signals modulate the assembly of nuclear transcription complexes are not fully understood. Here we report that nerve growth factor receptor signaling induces nuclear translocation of PCAF and hGCN5 dependent upon the phosphorylation of Ser and Thr residues within their histone acetyltransferase domains, which requires activation of PI3K, Rsk2(pp90), and MSK-1. Neurotrophin stimulation induces p53(K320) acetylation by PCAF and transcriptionally activates p53-responsive enhancer elements within the p21(WAF/CIP1) promoter associated with G(1)/S arrest during neuronal differentiation. Most importantly, these findings represent the first evidence for signal-dependent nuclear translocation of PCAF and hGCN5 acetyltransferases and allude to a novel mechanism for ligand/receptor modulation of nuclear chromatin-remodeling complexes in neurons.	So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; NCI, Lab Receptor Biol & Gene Express, Fluorescence Imaging Facil, Ctr Canc Res ,NIH, Bethesda, MD 20892 USA	Southern Methodist University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harrod, R (corresponding author), So Methodist Univ, Dept Biol Sci, Mol Virol Lab, 334-DLS,6501 Airline Dr, Dallas, TX 75275 USA.	rharrod@mail.smu.edu		Mauldin, Kasuen/0000-0001-9220-8033; Karpova, Tatiana/0000-0001-6025-2128	NATIONAL CANCER INSTITUTE [Z01BC010571, ZICBC010571] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Billon N, 1996, ONCOGENE, V13, P2047; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Li XC, 2000, P NATL ACAD SCI USA, V97, P8584, DOI 10.1073/pnas.140222497; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Liu L, 1999, MOL CELL BIOL, V19, P1202; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nagano T, 2003, MOL CELL NEUROSCI, V24, P340, DOI 10.1016/S1044-7431(03)00172-6; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Parker D, 1996, MOL CELL BIOL, V16, P694; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Pierchala BA, 2004, J BIOL CHEM, V279, P27986, DOI 10.1074/jbc.M312237200; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schinder AF, 2000, NEURON, V25, P151, DOI 10.1016/S0896-6273(00)80879-X; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SUNGHOE C, 1999, P NATL ACAD SCI USA, V96, P4095; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vaghefi H, 2004, J BIOL CHEM, V279, P15604, DOI 10.1074/jbc.M311500200; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang B, 2002, NAT NEUROSCI, V5, P539, DOI 10.1038/nn853; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	61	36	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55667	55674		10.1074/jbc.M408174200	http://dx.doi.org/10.1074/jbc.M408174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496412	hybrid			2022-12-27	WOS:000225960800086
J	Massaad, CA; Portier, BP; Taglialatela, G				Massaad, CA; Portier, BP; Taglialatela, G			Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL OUTER-MEMBRANE; ANTI-APOPTOTIC FUNCTION; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; BH4 DOMAIN; SIGNALING PATHWAYS; OXIDATIVE-STRESS; FAMILY PROTEINS	Using a reporter gene assay in PC12, HEK293, HeLa, and NIH-3T3 cells, we show that the anti-apoptotic protein Bcl-2 significantly inhibits transcriptional activation of various transcription factors, including NFkappaB, AP1, CRE, and NFAT. A Bcl-2 mutant lacking its BH4 domain (DeltaBH4) also inhibited transcription, whereas a Bcl-2 mutant lacking its transmembrane domain (DeltaTM) was ineffective. Furthermore, Bcl-2 chimeric proteins containing transmembrane domains from the mitochondrial protein monoamine oxidase B ( MaoB) or the endoplasmic reticulum protein cytochrome b(5) showed no effect on transcription factor activity. Subcellular localization studies showed that under conditions of transient transfection, the active Bcl-2 forms ( wild type and DeltaBH4) were predominantly found in the nuclear fraction, whereas the non-active forms (DeltaTM, MaoB, and cytochrome b(5)) were in the non-nuclear fraction. Additionally, stably expressed Bcl-2 loses its ability to inhibit transcriptional activation and localizes predominantly to the non-nuclear fraction. Expression of FKBP38 ( a chaperone that shuttles Bcl-2 to the mitochondria) removes co-expressed Bcl-2 from the nuclear fraction and reverses its effect on transcription factor activity. Finally, using an inducible gene expression system, we show that nuclear compartment-associated Bcl-2 prevents entry of NFkappaB subunits to the nucleus without affecting NFkappaB release from its cytosolic inhibitory subunit IkappaBalpha. These results suggest that (a) Bcl-2 suppresses transcriptional activity of multiple transcription factors; (b) Bcl-2 does not interfere with NFkappaB activation but prevents entrance of its active subunits to the nucleus; ( c) membrane anchoring is required for this function of Bcl-2; and (d) association of Bcl-2 with the nuclear compartment is also necessary. We speculate that nuclear compartment-associated Bcl-2 may affect nuclear trafficking of multiple factors necessary for transcriptional activity.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Taglialatela, G (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	gtaglial@utmb.edu						Abidi P, 2004, J NUTR BIOCHEM, V15, P210, DOI 10.1016/j.jnutbio.2003.11.007; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Frasca D, 2004, MECH AGEING DEV, V125, P111, DOI 10.1016/j.mad.2003.11.004; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Giardina C, 2002, CELL STRESS CHAPERON, V7, P207, DOI 10.1379/1466-1268(2002)007<0207:GOWNFB>2.0.CO;2; Gosselin K, 2003, EXP GERONTOL, V38, P1271, DOI 10.1016/j.exger.2003.09.007; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jang JH, 2003, BIOCHEM PHARMACOL, V66, P1371, DOI 10.1016/S0006-2952(03)00487-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Kaufmann JA, 2003, J NEUROCHEM, V87, P981, DOI 10.1046/j.1471-4159.2003.02092.x; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kaufmann JA, 2002, NEUROREPORT, V13, P1917, DOI 10.1097/00001756-200210280-00017; Kirshenbaum LA, 2000, CLIN INVEST MED, V23, P322; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Massaad CA, 2003, NEUROREPORT, V14, P1167, DOI 10.1097/00001756-200306110-00013; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Sheikh MS, 2004, VITAM HORM, V67, P169; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Sorenson CM, 2004, J BIOL CHEM, V279, P11368, DOI 10.1074/jbc.M310079200; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200	55	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54470	54478		10.1074/jbc.M407659200	http://dx.doi.org/10.1074/jbc.M407659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471874	hybrid			2022-12-27	WOS:000225793600070
J	Rancour, DM; Park, S; Knight, SD; Bednarek, SY				Rancour, DM; Park, S; Knight, SD; Bednarek, SY			Plant UBX domain-containing protein 1, PUX1, regulates the oligomeric structure and activity of Arabidopsis CDC48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; MULTIPLE SEQUENCE ALIGNMENT; P97 AAA ATPASE; CELL-CYCLE; MEMBRANE-FUSION; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; ADAPTER PROTEIN; UBIQUITIN	p97/CDC48 is a highly abundant hexameric AAA-ATPase that functions as a molecular chaperone in numerous diverse cellular activities. We have identified an Arabidopsis UBX domain-containing protein, PUX1, which functions to regulate the oligomeric structure of the Arabidopsis homolog of p97/CDC48, AtCDC48, as well as mammalian p97. PUX1 is a soluble protein that co-fractionates with non-hexameric AtCDC48 and physically interacts with AtCDC48 in vivo. Binding of PUX1 to AtCDC48 is mediated through the UBX-containing C-terminal domain. However, disassembly of the chaperone is dependent upon the N-terminal domain of PUX1. These findings provide evidence that the assembly and disassembly of the hexameric p97/CDC48 complex is a dynamic process. This new unexpected level of regulation for p97/CDC48 was demonstrated to be critical in vivo as pux1 loss-of-function mutants display accelerated growth relative to wild-type plants. These results suggest a role for AtCDC48 and PUX1 in regulating plant growth.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bednarek, SY (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	bednarek@biochem.wisc.edu		Rancour, David/0000-0002-3624-5750				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BarPeled M, 1997, PLANT PHYSIOL, V114, P315, DOI 10.1104/pp.114.1.315; Beemster GTS, 1998, PLANT PHYSIOL, V116, P1515, DOI 10.1104/pp.116.4.1515; Beemster GTS, 2003, TRENDS PLANT SCI, V8, P154, DOI 10.1016/S1360-1385(03)00046-3; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Chook YM, 2002, BIOCHEMISTRY-US, V41, P6955, DOI 10.1021/bi012122p; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Decottignies A, 2004, YEAST, V21, P127, DOI 10.1002/yea.1071; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; EGERTON M, 1994, J BIOL CHEM, V269, P11435; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Huyton T, 2003, J STRUCT BIOL, V144, P337, DOI 10.1016/j.jsb.2003.10.007; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Kang BH, 2001, PLANT PHYSIOL, V126, P47, DOI 10.1104/pp.126.1.47; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Partridge JJ, 2003, MOL BIOL CELL, V14, P4221, DOI 10.1091/mbc.E03-02-0111; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rancour DM, 2002, PLANT PHYSIOL, V130, P1241, DOI 10.1104/pp.011742; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Riou-Khamlichi C, 2000, MOL CELL BIOL, V20, P4513, DOI 10.1128/MCB.20.13.4513-4521.2000; Rockel B, 2002, J MOL BIOL, V317, P673, DOI 10.1006/jmbi.2002.5448; Roggy JL, 1999, MOL BIOCHEM PARASIT, V98, P1, DOI 10.1016/S0166-6851(98)00114-5; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Rowlands MG, 2004, ANAL BIOCHEM, V327, P176, DOI 10.1016/j.ab.2003.10.038; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Sugita S, 2000, BIOCHEMISTRY-US, V39, P2940, DOI 10.1021/bi9920984; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchiyama K, 2003, J CELL BIOL, V161, P1067, DOI 10.1083/jcb.200303048; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Yamada T, 2000, FEBS LETT, V466, P287, DOI 10.1016/S0014-5793(99)01673-7; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yuan XM, 2004, J BIOMOL NMR, V28, P309, DOI 10.1023/B:JNMR.0000013689.02494.07; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	76	79	89	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54264	54274		10.1074/jbc.M405498200	http://dx.doi.org/10.1074/jbc.M405498200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498773	hybrid			2022-12-27	WOS:000225793600047
J	Izumikawa, T; Kitagawa, H; Mizuguchi, S; Nomura, KH; Nomura, K; Tamura, J; Gengyo-Ando, K; Mitani, S; Sugahara, K				Izumikawa, T; Kitagawa, H; Mizuguchi, S; Nomura, KH; Nomura, K; Tamura, J; Gengyo-Ando, K; Mitani, S; Sugahara, K			Nematode chondroitin polymerizing factor showing cell-/organ-specific expression is indispensable for chondroitin synthesis and embryonic cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; HEPARAN-SULFATE; N-ACETYLGALACTOSAMINYLTRANSFERASE; TUMOR SUPPRESSORS; GENETIC INTERFERENCE; BIOSYNTHESIS; ELONGATION; INITIATION	Chondroitin polymerization was first demonstrated in vitro when human chondroitin synthase (ChSy) was coexpressed with human chondroitin polymerizing factor (ChPF), which is homologous to ChSy but has little glycosyltransferase activity. To analyze the biological function of chondroitin, the Caenorhabditis elegans ortholog of human ChSy (sqv-5) was recently cloned, and the expression of its product was depleted by RNA-mediated interference (RNAi) and deletion mutagenesis. Blocking of chondroitin synthesis resulted in defects of cytokinesis in early embryogenesis, and eventually, cell division stopped. Here, we cloned the ortholog of human ChPF in C. elegans, PAR2.4. Despite little glycosyltransferase activity of the gene product, chondroitin polymerization was demonstrated as in the case of mammals when PAR2.4 was coexpressed with cChSy in vitro. The worm phenotypes including the reversion of cytokinesis, observed after the depletion of PAR2.4 by RNAi, were very similar to the cChSy (sqv-5)-RNAi phenotypes. Thus, PAR2.4 in addition to cChSy is indispensable for the biosynthesis of chondroitin in C. elegans, and the two cooperate to synthesize chondroitin in vivo. The expression of the PAR2.4 protein was observed in seam cells, which can act as neural stem cells in early embryonic lineages. The expression was also detected in vulva and distal tip cells of the growing gonad arms from L3 through to the young adult stage. These findings are consistent with the notion that chondroitin is involved in the organogenesis of the vulva and maturation of the gonad and also indicative of an involvement in distal tip cell migration and neural development.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyushu Univ, Grad Sch, Fac Sci, Dept Biol Sci, Fukuoka 8128581, Japan; JST, CREST, Kawaguchi, Saitama 3320012, Japan; Tottori Univ, Fac Reg Sci, Dept Reg Environm, Tottori 6808551, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan	Kobe Pharmaceutical University; Kyushu University; Japan Science & Technology Agency (JST); Tottori University; Tokyo Women's Medical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020; Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; 				Borovkov AY, 1997, BIOTECHNIQUES, V22, P812, DOI 10.2144/97225bm04; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Koh K, 2001, DEVELOPMENT, V128, P2867; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Tamura J, 1999, J CARBOHYD CHEM, V18, P1, DOI 10.1080/07328309908543974; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	34	48	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53755	53761		10.1074/jbc.M409615200	http://dx.doi.org/10.1074/jbc.M409615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485872	hybrid			2022-12-27	WOS:000225680600113
J	Komori, K; Hidaka, M; Horiuchi, T; Fujikane, R; Shinagawa, H; Ishino, Y				Komori, K; Hidaka, M; Horiuchi, T; Fujikane, R; Shinagawa, H; Ishino, Y			Cooperation of the N-terminal helicase and C-terminal endonuclease activities of archaeal Hef protein in processing stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION RESOLVASE; DNA-REPLICATION; PYROCOCCUS-FURIOSUS; BRANCH MIGRATION; RECQ HELICASES; REPAIR; MUS81-EME1; RESOLUTION; GENOME; DOMAIN	Blockage of replication fork progression often occurs during DNA replication, and repairing and restarting stalled replication forks are essential events in all organisms for the maintenance of genome integrity. The repair system employs processing enzymes to restore the stalled fork. In Archaea Hef is a well conserved protein that specifically cleaves nicked, flapped, and fork-structured DNAs. This enzyme contains two distinct domains that are similar to the DEAH helicase family and XPF nuclease superfamily proteins. Analyses of truncated mutant proteins consisting of each domain revealed that the C-terminal nuclease domain independently recognized and incised fork-structured DNA. The N-terminal helicase domain also specifically unwound fork-structured DNA and Holliday junction DNA in the presence of ATP. Moreover, the endonuclease activity of the whole Hef protein was clearly stimulated by ATP hydrolysis catalyzed by the N-terminal domain. These enzymatic properties suggest that Hef efficiently resolves stalled replication forks by two steps, which are branch point transfer to the 5'-end of the nascent lagging strand by the N-terminal helicase followed by template strand incision for leading strand synthesis by the C-terminal endonuclease.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Higashi Ku, Fukuoka 8128581, Japan; Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Microbiol, Osaka 5650871, Japan	Kyushu University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka University	Ishino, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	ishino@agr.kyushu-u.ac.jp		Fujikane, Ryosuke/0000-0002-6621-3848; Ishino, Yoshizumi/0000-0001-9419-0826				Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Briggs GS, 2004, PHILOS T R SOC B, V359, P49, DOI 10.1098/rstb.2003.1364; Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Ciccia A, 2003, J BIOL CHEM, V278, P25172, DOI 10.1074/jbc.M302882200; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; DiRuggiero J, 1998, NEW DEVELOPMENTS IN MARINE BIOTECHNOLOGY, P193; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Gaillard PHL, 2003, MOL CELL, V12, P747, DOI 10.1016/S1097-2765(03)00342-3; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; Heyer WD, 2003, TRENDS BIOCHEM SCI, V28, P548, DOI 10.1016/j.tibs.2003.08.011; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Hochegger H, 2004, BIOESSAYS, V26, P151, DOI 10.1002/bies.10403; Hollingsworth NM, 2004, GENE DEV, V18, P117, DOI 10.1101/gad.1165904; HORIUCHI T, 1995, J BACTERIOL, V177, P783, DOI 10.1128/jb.177.3.783-791.1995; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Jansen JG, 2003, DNA REPAIR, V2, P1075, DOI 10.1016/S1568-7864(03)00119-8; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Komori K, 2002, GENES GENET SYST, V77, P227, DOI 10.1266/ggs.77.227; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Komori K, 2000, J BIOL CHEM, V275, P40385, DOI 10.1074/jbc.M006294200; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lehmann AR, 2003, CELL CYCLE, V2, P300, DOI 10.4161/cc.2.4.407; Maniantis T., 1989, MOL CLONING LAB MANU, P382; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nishino T, 2003, STRUCTURE, V11, P445, DOI 10.1016/S0969-2126(03)00046-7; Nishino T, 2001, STRUCTURE, V9, P197, DOI 10.1016/S0969-2126(01)00576-7; Ogrunc M, 2003, J BIOL CHEM, V278, P21715, DOI 10.1074/jbc.M302484200; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; PRAKASH L, 1977, GENETICS, V86, P33; Roberts JA, 2003, MOL MICROBIOL, V48, P361, DOI 10.1046/j.1365-2958.2003.03444.x; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Scheller J, 2000, GENETICS, V155, P1069; Sgouros J, 1999, TRENDS BIOCHEM SCI, V24, P95, DOI 10.1016/S0968-0004(99)01355-9; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Whitby MC, 2003, J BIOL CHEM, V278, P6928, DOI 10.1074/jbc.M210006200; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Xiao W, 1998, MOL GEN GENET, V257, P614, DOI 10.1007/s004380050689; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9	63	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53175	53185		10.1074/jbc.M409243200	http://dx.doi.org/10.1074/jbc.M409243200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485882	hybrid			2022-12-27	WOS:000225680600047
J	Pauw, B; Hilliou, FAO; Martin, VS; Chatel, G; de Wolf, CJF; Champion, A; Pre, M; van Duijn, B; Kijne, JW; van der Fits, L; Memelink, J				Pauw, B; Hilliou, FAO; Martin, VS; Chatel, G; de Wolf, CJF; Champion, A; Pre, M; van Duijn, B; Kijne, JW; van der Fits, L; Memelink, J			Zinc finger proteins act as transcriptional repressors of alkaloid biosynthesis genes in Catharanthus roseus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET-SEQUENCE RECOGNITION; SIGNALING PATHWAYS; INDUCED EXPRESSION; SUPERMAN PROTEIN; DNA RECOGNITION; JASMONATE; ELICITOR; PROMOTER; CELL; CULTURES	In Catharanthus roseus cell suspensions, the expression of several terpenoid indole alkaloid biosynthetic genes, including two genes encoding strictosidine synthase (STR) and tryptophan decarboxylase (TDC), is coordinately induced by fungal elicitors such as yeast extract. To identify molecular mechanisms regulating the expression of these genes, a yeast one-hybrid screening was performed with an elicitor-responsive part of the TDC promoter. This screening identified three members of the Cys(2)/His(2)-type (transcription factor IIIA-type) zinc finger protein family from C. roseus, ZCT1, ZCT2, and ZCT3. These proteins bind in a sequence-specific manner to the TDC and STR promoters in vitro and repress the activity of these promoters in trans-activation assays. In addition, the ZCT proteins can repress the activating activity of APETALA2/ethylene response-factor domain transcription factors, the ORCAs, on the STR promoter. The expression of the ZCT genes is rapidly induced by yeast extract and methyljasmonate. These results suggest that the ZCT proteins act as repressors in the regulation of elicitor-induced secondary metabolism in C. roseus.	Leiden Univ, Clusius Lab, Inst Biol, NL-2333 AL Leiden, Netherlands; Netherlands Org Appl Sci Res, Dept Appl Plant Sci, NL-2333 CK Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Netherlands Organization Applied Science Research	Memelink, J (corresponding author), Leiden Univ, Clusius Lab, Inst Biol, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	memelink@rulbim.leidenuniv.nl	Hilliou, Frédérique/T-5714-2019; Champion, Antony/E-4148-2015; Sandonís, Virginia/K-2884-2014	Champion, Antony/0000-0002-3731-1510; Sandonís, Virginia/0000-0001-5762-7531; hilliou, frederique/0000-0002-3020-2987; Memelink, Johan/0000-0002-4767-506X				Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Dathan N, 2002, NUCLEIC ACIDS RES, V30, P4945, DOI 10.1093/nar/gkf613; Gantet P, 2002, TRENDS PHARMACOL SCI, V23, P563, DOI 10.1016/S0165-6147(02)02098-9; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARPER JW, 1993, CELL, V75, P805; Hiratsu K, 2003, PLANT J, V34, P733, DOI 10.1046/j.1365-313X.2003.01759.x; Hiratsu K, 2002, FEBS LETT, V514, P351, DOI 10.1016/S0014-5793(02)02435-3; Kazuoka T, 2000, PLANT J, V24, P191, DOI 10.1046/j.1365-313x.2000.00864.x; Kim JC, 2001, PLANT J, V25, P247, DOI 10.1046/j.1365-313x.2001.00947.x; Kubo K, 1998, NUCLEIC ACIDS RES, V26, P608, DOI 10.1093/nar/26.2.608; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Meijer AH, 1998, YEAST, V14, P1407, DOI 10.1002/(SICI)1097-0061(199811)14:15<1407::AID-YEA325>3.0.CO;2-M; Meissner R, 1997, PLANT MOL BIOL, V33, P615, DOI 10.1023/A:1005746803089; Memelink J, 2001, TRENDS PLANT SCI, V6, P212, DOI 10.1016/S1360-1385(01)01924-0; Menke FLH, 1999, EMBO J, V18, P4455, DOI 10.1093/emboj/18.16.4455; Menke FLH, 1999, PLANT PHYSIOL, V119, P1289, DOI 10.1104/pp.119.4.1289; MORENO PRH, 1995, PLANT CELL TISS ORG, V42, P1, DOI 10.1007/BF00037677; Nimchuk Z, 2003, ANNU REV GENET, V37, P579, DOI 10.1146/annurev.genet.37.110801.142628; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; Ouwerkerk PBF, 1999, MOL GEN GENET, V261, P610, DOI 10.1007/s004380050003; Ouwerkerk PBF, 1999, PLANT MOL BIOL, V39, P129, DOI 10.1023/A:1006138601744; PASQUALI G, 1992, PLANT MOL BIOL, V18, P1121, DOI 10.1007/BF00047715; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Roberts SGE, 2000, CELL MOL LIFE SCI, V57, P1149, DOI 10.1007/PL00000755; ROEWER IA, 1992, PLANT CELL REP, V11, P86, DOI 10.1007/BF00235259; Sakamoto H, 2000, GENE, V248, P23, DOI 10.1016/S0378-1119(00)00133-5; Siberil Y, 2001, PLANT MOL BIOL, V45, P477, DOI 10.1023/A:1010650906695; SILVA ODE, 1993, PLANT J, V4, P125, DOI 10.1046/j.1365-313X.1993.04010125.x; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; Sugano S, 2003, PLANT J, V36, P830, DOI 10.1046/j.1365-313X.2003.01924.x; Takatsuji H, 1999, PLANT MOL BIOL, V39, P1073, DOI 10.1023/A:1006184519697; Takatsuji H, 1996, J BIOL CHEM, V271, P23368, DOI 10.1074/jbc.271.38.23368; Tiwari SB, 2004, PLANT CELL, V16, P533, DOI 10.1105/tpc.017384; van der Fits L, 2000, PLANT MOL BIOL, V44, P675, DOI 10.1023/A:1026526522555; van der Fits L, 2000, SCIENCE, V289, P295, DOI 10.1126/science.289.5477.295; van der Fits L, 2001, PLANT J, V25, P43, DOI 10.1046/j.1365-313x.2001.00932.x; van der Krol AR, 1999, PLANT PHYSIOL, V121, P1153, DOI 10.1104/pp.121.4.1153; vanderFits L, 1997, PLANT MOL BIOL, V33, P943, DOI 10.1023/A:1005763605355; Yoshioka K, 2001, J BIOL CHEM, V276, P35802, DOI 10.1074/jbc.M104079200	43	126	141	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52940	52948		10.1074/jbc.M404391200	http://dx.doi.org/10.1074/jbc.M404391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465826	Green Published, hybrid			2022-12-27	WOS:000225680600018
J	Lecut, C; Arocas, V; Ulrichts, H; Elbaz, A; Villeval, JL; Lacapere, JJ; Deckmyn, H; Jandrot-Perrus, M				Lecut, C; Arocas, V; Ulrichts, H; Elbaz, A; Villeval, JL; Lacapere, JJ; Deckmyn, H; Jandrot-Perrus, M			Identification of residues within human glycoprotein VI involved in the binding to collagen - Evidence for the existence of distinct binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; INTEGRIN ALPHA(2)BETA(1); IMMUNOGLOBULIN SUPERFAMILY; TYROSINE PHOSPHORYLATION; PLATELET ACTIVATION; CRYSTAL-STRUCTURE; LIGAND-BINDING; RECEPTOR; CONVULXIN; ADHESION	Glycoprotein VI (GPVI) has a crucial role in platelet responses to collagen. Still, little is known about its interaction with its ligands. In binding assays using soluble or cell-expressed human GPVI, we observed that (i) collagen, and the GPVI-specific ligands collagen-related peptides (CRP) and convulxin, competed with one another for the binding to GPVI and (ii) monoclonal antibodies directed against the extracellular part of the human receptor displayed selective inhibitory properties on GPVI interaction with its ligands. Monoclonal antibody 9E18 strongly reduced the binding of GPVI to collagen/CRP, 3F8 inhibited its interaction with convulxin, whereas 9O12 prevented all three interactions. These observations suggest that ligand-binding sites are distinct, exhibiting specific features but at the same time also sharing some common residues participating in the recognition of these ligands. The epitope of 9O12 was mapped by phage display, along with molecular modeling of human GPVI, which allowed the identification of residues within GPVI potentially involved in ligand recognition. Site-directed mutagenesis revealed that valine 34 and leucine 36 are critical for GPVI interaction with collagen and CRP. The loop might thus be part of a collagen/CRP-binding site.	Univ Paris 07, INSERM, E348, F-75870 Paris 18, France; Univ Paris 07, INSERM, U410, F-75870 Paris 18, France; Katholieke Univ Leuven, Interdisciplinary Res Ctr, Lab Thrombosis Res, B-8500 Kortrijk, Belgium; Millennium Pharmaceut Inc, Cambridge, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; KU Leuven; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Jandrot-Perrus, M (corresponding author), Univ Paris 07, INSERM, E348, BP416,16 Rue Henri Huchard, F-75870 Paris 18, France.	mjandrot@bichat.inserm.fr	Arocas, Veronique/M-7075-2017; Deckmyn, Hans/N-8932-2019; Jandrot-Perrus, Martine/GZM-1526-2022; Deckmyn, Hans/L-9434-2015	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; JANDROT-PERRUS, Martine/0000-0002-8450-9247; Arocas, Veronique/0000-0002-2872-8058; Villeval, Jean-Luc/0000-0002-0562-925X				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Fan QR, 2001, NAT IMMUNOL, V2, P452, DOI 10.1038/87766; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Kehrel B, 1998, BLOOD, V91, P491; Lagrue-Lak-Hal AH, 2001, J BIOL CHEM, V276, P15316, DOI 10.1074/jbc.M009117200; Lecut C, 2003, J THROMB HAEMOST, V1, P2653, DOI 10.1111/j.1538-7836.2003.00495.x; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; SILJANDER PR, 2003, BLOOD; SMETHURST PA, 2003, BLOOD; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ulrichts H, 2001, THROMB HAEMOSTASIS, V86, P630, DOI 10.1055/s-0037-1616097; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781	28	49	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52293	52299		10.1074/jbc.M406342200	http://dx.doi.org/10.1074/jbc.M406342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466473	Green Published, hybrid			2022-12-27	WOS:000225493400070
J	Kawakatsu, T; Ogita, H; Fukuhara, T; Fukuyama, T; Minami, Y; Shimizu, K; Takai, Y				Kawakatsu, T; Ogita, H; Fukuhara, T; Fukuyama, T; Minami, Y; Shimizu, K; Takai, Y			Vav2 as a Rac-GDP/GTP exchange factor responsible for the nectin-induced, c-Src- and Cdc42-mediated activation of Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; SMALL G-PROTEIN; ADHERENS JUNCTIONS; TYROSINE PHOSPHORYLATION; CADHERIN SUPERFAMILY; TRANS-INTERACTIONS; KINASE ACTIVATION; FAMILY PROTEINS; HOMOLOGY DOMAIN; CDC42	Nectins are Ca2+ -independent immunoglobulin-like cell-cell adhesion molecules that form homo. and hetero-trans-dimers (trans-interactions). Nectins first form cell-cell contact and then recruit cadherins to the nectin-based cell-cell contact sites to form adherens junctions cooperatively with cadherins. In addition, the trans-interactions of nectins induce the activation of Cdc42 and Rac small G proteins, which enhances the formation of adherens junctions by forming filopodia and lamellipodia, respectively. The trans-interactions of nectins first recruit and activate c-Src at the nectinbased cell-cell contact sites. c-Src then phosphorylates and activates FRG, a Cdc42-GDP/GTP exchange factor (GEF) for Cdc42. The activation of both c-Src and Cdc42 by FRG is necessary for the activation of Rac, but the Rac-GEF responsible for this activation of Rac remains unknown. We showed here that the nectin-induced activation of Rac was inhibited by a dominant negative mutant of Vav2, a Rac-GEF. Nectins recruited and tyrosine-phosphorylated Vav2 through c-Src at the nectinbased cell-cell contact sites, whereas Cdc42 was not necessary for the nectin-induced recruitment of Vav2 or the nectin-induced, c-Src-mediated tyrosine phosphorylation of Vav2. Cdc42 activated through c-Src then enhanced the GEF activity of tyrosine-phosphorylated Vav2 on Rac1. These results indicate that Vav2 is a GEF responsible for the nectin-induced, c-Src-, and Cdc42-mediated activation of Rac.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Ogita, Hisakazu/0000-0001-6750-1668				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; FUKUYAMA T, 2004, J BIOL CHEM; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Pearce AC, 2002, BLOOD, V100, P3561, DOI 10.1182/blood.V100.10.3561; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takeichi M, 2000, PHILOS T ROY SOC B, V355, P885, DOI 10.1098/rstb.2000.0624; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takenawa T, 2001, J CELL SCI, V114, P1801; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Yagi T, 2000, GENE DEV, V14, P1169; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YONEMURA S, 1995, J CELL SCI, V108, P127	53	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4940	4947		10.1074/jbc.M408710200	http://dx.doi.org/10.1074/jbc.M408710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15485841	hybrid			2022-12-27	WOS:000227096600115
J	Grote, K; Bavendiek, U; Grothusen, C; Flach, I; Hilfiker-Kleiner, D; Drexler, H; Schieffer, B				Grote, K; Bavendiek, U; Grothusen, C; Flach, I; Hilfiker-Kleiner, D; Drexler, H; Schieffer, B			Stretch-inducible expression of the angiogenic factor CCN1 in vascular smooth muscle cells is mediated by Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; MULTIPLE SIGNALING PATHWAYS; MESSENGER-RNA EXPRESSION; HUMAN ENDOTHELIAL-CELLS; GROWTH-FACTOR; MECHANICAL STRETCH; ANGIOTENSIN-II; CYR61; INDUCTION; STRAIN	CCN1 is an angiogenic factor that promotes cell adhesion, proliferation, and differentiation. CCN1-deficient mice suffer embryonic death because of vascular defects, demonstrating that CCN1 is required for vessel development. Because mechanical stretch may act as a trigger for vessel development, we investigated the impact of mechanical stretch on the regulatory mechanism of CCN1 expression. Mechanical stretch rapidly enhances CCN1 expression and release in vascular smooth muscle cells (VSMC) in vitro and CCN1 expression in murine aortic segments in vivo. Transfection experiments of VSMC with deletion constructs of the CCN1 promoter revealed the regulatory region responsible for the stretch-induced CCN1 expression in the similar to200-bp promoter region upstream of the TATA-box containing potential binding sites for early growth response-1 (Egr1), nuclear factor of activated T-cells and cAMP response element binding protein. Decoy oligonucleotides to Egr-1, but not to nuclear factor of activated T-cells or cAMP response element binding protein, abolished the stretch-induced transcription of CCN1. In addition, mutagenesis of the Egr-1 binding site within the CCN1 promoter completely blunted the stretch-induced activation of the promoter. Furthermore, mechanical stretch induced the expression and DNA-binding activity of Egr-1 in VSMC as demonstrated by Western blot and electromobility shift assay. Moreover, a pressure over-load-dependent de novo synthesis of Egr-1 was observed after aortic banding. These findings indicate that mechanical stretch leads to enhanced expression of CCN1 via the mechanosensitive transcription factor Egr-1, suggesting a central role for mechanical stretch in the regulation of CCN1-dependent pro-angiogenic potency.	Hannover Med Sch, Abt Kardiol & Angiol, Dept Cardiol & Angiol, D-30625 Hannover, Germany	Hannover Medical School	Grote, K (corresponding author), Hannover Med Sch, Abt Kardiol & Angiol, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	grote.karsten@mh-hannover.de		Grote, Karsten/0000-0001-7914-3159				Akuzawa N, 2000, ARTERIOSCL THROM VAS, V20, P377, DOI 10.1161/01.ATV.20.2.377; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bavendiek U, 2002, J BIOL CHEM, V277, P25032, DOI 10.1074/jbc.M204003200; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; Brading AF, 1997, SCAND J UROL NEPHROL, V31, P51; Chaqour B, 2002, AM J PHYSIOL-ENDOC M, V283, pE765, DOI 10.1152/ajpendo.00131.2002; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Dzau V J, 1993, Curr Opin Nephrol Hypertens, V2, P27, DOI 10.1097/00041552-199301000-00004; Fuchs M, 2003, FASEB J, V17, P2118, DOI 10.1096/fj.03-0331fje; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Han JS, 2003, EUR J BIOCHEM, V270, P3408, DOI 10.1046/j.1432-1033.2003.03723.x; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Morawietz H, 1999, CIRC RES, V84, P678, DOI 10.1161/01.RES.84.6.678; Naftilan A J, 1994, Curr Opin Nephrol Hypertens, V3, P218, DOI 10.1097/00041552-199403000-00014; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Schunkert H, 1995, J CLIN INVEST, V96, P2768, DOI 10.1172/JCI118346; Smith JD, 2001, ENDOTHELIUM-J ENDOTH, V8, P41, DOI 10.3109/10623320109063156; Stula M, 2000, MOL CELL BIOCHEM, V210, P101, DOI 10.1023/A:1007126218740; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Tamura I, 2001, AM J PHYSIOL-CELL PH, V281, pC1524, DOI 10.1152/ajpcell.2001.281.5.C1524; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wu KJ, 2000, INT J MOL MED, V6, P433; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X; Yamaguchi S, 2002, LAB INVEST, V82, P949, DOI 10.1097/01.LAB.0000020408.77307.E9	33	43	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55675	55681		10.1074/jbc.M406532200	http://dx.doi.org/10.1074/jbc.M406532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492009	hybrid			2022-12-27	WOS:000225960800087
J	Ran, QT; Liang, HY; Gu, MJ; Qi, WB; Walter, CA; Roberts, LJ; Herman, B; Richardson, A; Van Remmen, H				Ran, QT; Liang, HY; Gu, MJ; Qi, WB; Walter, CA; Roberts, LJ; Herman, B; Richardson, A; Van Remmen, H			Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; LIPID-PEROXIDATION; OXIDANT STRESS; CYTOCHROME-C; DAMAGE; CELLS; INJURY; GENE; DIQUAT; PHGPX	Glutathione peroxidase 4 (Gpx4) is uniquely involved in the detoxification of oxidative damage to membrane lipids. Our previous studies showed that Gpx4 is essential for mouse survival and that Gpx4 deficiency makes cells vulnerable to oxidative injury. In the present study, we generated two lines of transgenic mice overexpressing Gpx4 (Tg(GPX4) mice) using a genomic clone containing the human GPX4 gene. Both lines of Tg(GPX4) mice, Tg5 and Tg6, had elevated levels of Gpx4 (mRNA and protein) in all tissues investigated, and overexpression of Gpx4 did not cause alterations in activities of glutathione peroxidase 1, catalase, Cu/Zn superoxide dismutase, and manganese superoxide dismutase. The human GPX4 transgene rescued the lethal phenotype of null mutation of the mouse Gpx4 gene, indicating that the transgene can replace the essential role of mouse Gpx4 in mouse development. Cell death induced by t-butylhydroperoxide and diquat was significantly less in murine embryonic fibroblasts from Tg(GPX4) mice compared with wild type mice. Liver damage and lipid peroxidation induced by diquat were reduced significantly in Tg(GPX4) mice. In addition, diquat-induced apoptosis was decreased in Tg(GPX4) mice, as evidenced by attenuated caspase-3 activation and reduced cytochrome c release from mitochondria. These data demonstrate that Gpx4 plays a role in vivo in the mechanism of apoptosis induced by oxidative stress that most likely occurs through oxidative damage to mitochondrial phospholipids such as cardiolipin.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, San Antonio Canc Inst, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Vanderbilt University; Vanderbilt University	Van Remmen, H (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, GRECC 182, 7400 Merton Mintor Blvd, San Antonio, TX 78284 USA.	vanremmen@uthscsa.edu	Liang, Hanyu/A-1066-2010		NIA NIH HHS [P01 AG 19316, K01 AG 22014, 1P30 AG 13319] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013319, K01AG022014, P01AG019316] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANTUNES F, 1995, FREE RADICAL BIO MED, V19, P669, DOI 10.1016/0891-5849(95)00040-5; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; AWAD JA, 1994, J PHARMACOL EXP THER, V270, P858; Barriere G, 2004, ANTICANCER RES, V24, P1387; Brigelius-Flohe R, 2000, ATHEROSCLEROSIS, V152, P307, DOI 10.1016/S0021-9150(99)00486-4; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chen CJ, 2000, PROSTAG LEUKOTR ESS, V62, P261, DOI 10.1103/PhysRevD.62.094026; Chen XL, 2003, MECH AGEING DEV, V124, P219, DOI 10.1016/S0047-6374(02)00161-6; DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Esworthy RS, 2000, AM J PHYSIOL-GASTR L, V279, pG426, DOI 10.1152/ajpgi.2000.279.2.G426; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Fu YX, 1999, FREE RADICAL BIO MED, V27, P605, DOI 10.1016/S0891-5849(99)00104-5; Girotti AW, 1998, J LIPID RES, V39, P1529; Guo ZM, 1998, MUTAT RES-DNA REPAIR, V409, P37, DOI 10.1016/S0921-8777(98)00041-X; Guo ZM, 2001, MECH AGEING DEV, V122, P1771, DOI 10.1016/S0047-6374(01)00298-6; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hurst R, 2001, FREE RADICAL BIO MED, V31, P1051, DOI 10.1016/S0891-5849(01)00685-2; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 2001, BIOL REPROD, V64, P674, DOI 10.1095/biolreprod64.2.674; Jones GM, 2000, J TOXICOL-CLIN TOXIC, V38, P123, DOI 10.1081/CLT-100100926; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Mylonas C, 1999, IN VIVO, V13, P295; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Ran QT, 2003, FREE RADICAL BIO MED, V35, P1101, DOI 10.1016/S0891-5849(03)00466-0; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; ROHN TT, 1993, BIOCHIM BIOPHYS ACTA, V1153, P67, DOI 10.1016/0005-2736(93)90277-7; Sakamoto H, 2002, J BIOL CHEM, V277, P50431, DOI 10.1074/jbc.M204190200; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; SMITH CV, 1985, J PHARMACOL EXP THER, V235, P172; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; van Kuijk F J, 1985, J Free Radic Biol Med, V1, P421, DOI 10.1016/0748-5514(85)90156-4; Wang HP, 2001, FREE RADICAL BIO MED, V30, P825, DOI 10.1016/S0891-5849(01)00469-5; Yagi K, 1996, BIOCHEM BIOPH RES CO, V219, P486, DOI 10.1006/bbrc.1996.0260; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x	45	184	190	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55137	55146		10.1074/jbc.M410387200	http://dx.doi.org/10.1074/jbc.M410387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496407	hybrid			2022-12-27	WOS:000225960800020
J	Arniges, M; Vazquez, E; Fernandez-Fernandez, JM; Valverde, MA				Arniges, M; Vazquez, E; Fernandez-Fernandez, JM; Valverde, MA			Swelling-activated Ca2+ entry via TRPV4 channel is defective in cystic fibrosis airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; ARACHIDONIC-ACID RELEASE; HEAT-EVOKED ACTIVATION; PRIMARY CULTURES; CATION CHANNEL; PHORBOL ESTER; CL-CURRENTS; VR-OAC; CELLS; CFTR	The vertebrate transient receptor potential cationic channel TRPV4 has been proposed as an osmo- and mechanosensor channel. Studies using knock-out animal models have further emphasized the relevance of the TRPV4 channel in the maintenance of the internal osmotic equilibrium and mechanosensation. However, at the cellular level, there is still one important question to answer: does the TRPV4 channel generate the Ca2+ signal in those cells undergoing a Ca2+-dependent regulatory volume decrease (RVD) response? RVD in human airway epithelia requires the generation of a Ca2+ signal to activate Ca2+-dependent K+ channels. The RVD response is lost in airway epithelia affected with cystic fibrosis (CF), a disease caused by mutations in the cystic fibrosis transmembrane conductance regulator channel. We have previously shown that the defective RVD in CF epithelia is linked to the lack of swelling-dependent activation of Ca2+-dependent K+ channels. In the present study, we show the expression of TRPV4 in normal human airway epithelia, where it functions as the Ca2+ entry pathway that triggers the RVD response after hypotonic stress, as demonstrated by TRPV4 antisense experiments. However, cell swelling failed to trigger Ca2+ entry via TRPV4 channels in CF airway epithelia, although the channel's response to a specific synthetic activator, 4alpha-phorbol 12,13-didecanoate, was maintained. Furthermore, RVD was recovered in CF airway epithelia treated with 4alpha-phorbol 12,13-didecanoate. Together, these results suggest that defective RVD in CF airway epithelia might be caused by the absence of a TRPV4-mediated Ca2+ signal and the subsequent activation of Ca2+-dependent K+ channels.	Univ Pompeu Fabra, Lab Fisiol Mol, Unitat Senyalitzacio Cellular, Barcelona 08003, Spain	Pompeu Fabra University	Valverde, MA (corresponding author), Univ Pompeu Fabra, Lab Fisiol Mol, Unitat Senyalitzacio Cellular, C Dr Aiguader 80, Barcelona 08003, Spain.	miguel.valverde@upf.edu	Fernández-Fernández, José Manuel M/M-8157-2015	Fernández-Fernández, José Manuel M/0000-0003-2330-8449; Valverde, Miguel A./0000-0002-6961-3361; Vazquez, Esther/0000-0003-1052-0424				Barriere H, 2003, AM J PHYSIOL-RENAL, V284, pF796, DOI 10.1152/ajprenal.00237.2002; Basavappa S, 1998, J NEUROPHYSIOL, V79, P1441, DOI 10.1152/jn.1998.79.3.1441; Belfodil R, 2003, AM J PHYSIOL-RENAL, V284, pF812, DOI 10.1152/ajprenal.00238.2002; Berguerand M, 1997, AM J RESP CELL MOL, V17, P481, DOI 10.1165/ajrcmb.17.4.2734; Bond TD, 1998, J PHYSIOL-LONDON, V511, P45, DOI 10.1111/j.1469-7793.1998.045bi.x; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; CARLSTEDTDUKE J, 1986, P NATL ACAD SCI USA, V83, P9202, DOI 10.1073/pnas.83.23.9202; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 1998, J GEN PHYSIOL, V111, P623, DOI 10.1085/jgp.111.5.623; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; FELIPE A, 1993, AM J PHYSIOL, V265, pC1230, DOI 10.1152/ajpcell.1993.265.5.C1230; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; GRAHAM A, 1992, J PHYSIOL-LONDON, V453, P475, DOI 10.1113/jphysiol.1992.sp019240; Guler AD, 2002, J NEUROSCI, V22, P6408; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Lock H, 2000, J BIOL CHEM, V275, P34849, DOI 10.1074/jbc.C000633200; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Niemeyer MI, 2001, J BIOL CHEM, V276, P43166, DOI 10.1074/jbc.M107192200; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Porcelli AM, 1999, CELL MOL LIFE SCI, V56, P167, DOI 10.1007/s000180050015; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1985, J BIOL CHEM, V260, P1596; Sardini A, 2003, BBA-BIOMEMBRANES, V1618, P153, DOI 10.1016/j.bbamem.2003.10.008; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; VALVERDE MA, 1995, P NATL ACAD SCI USA, V92, P9038, DOI 10.1073/pnas.92.20.9038; Valverde MA, 2000, CELL PHYSIOL BIOCHEM, V10, P321, DOI 10.1159/000016365; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	48	128	141	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54062	54068		10.1074/jbc.M409708200	http://dx.doi.org/10.1074/jbc.M409708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489228	hybrid			2022-12-27	WOS:000225793600023
J	Bilodeau, PS; Winistorfer, SC; Allaman, MM; Surendhran, K; Kearney, WR; Robertson, AD; Piper, RC				Bilodeau, PS; Winistorfer, SC; Allaman, MM; Surendhran, K; Kearney, WR; Robertson, AD; Piper, RC			The GAT domains of clathrin-associated GGA proteins have two ubiquitin binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOWN-REGULATION; AMINO-ACID PERMEASE; COMPLEX; YEAST; TRANSPORT; TOM1; ARF; UBIQUITYLATION; ENDOCYTOSIS; ENDOSOMES	Ubiquitin (Ub) attachment to membrane proteins can serve as a sorting signal for lysosomal delivery. Recognition of Ub as a sorting signal can occur at the trans-Golgi network and is mediated in part by the clathrin-associated Golgi-localizing, gamma-adaptin ear domain homology, ARF-binding proteins (GGA). GGA proteins bind Ub via a three-helix bundle subdomain in their GAT ( GGA target of Myb1 protein) domain, which is also present in the Ub binding domain of target of Myb1 protein. Ubiquitin binding by yeast Ggas is required to direct sorting of ubiquitinated proteins such as general amino acid permease (Gap1) from the trans-Golgi network to endosomes. Using affinity chromatography and nuclear magnetic resonance spectroscopy, we have found that the human GGA3 GAT domain contains two Ub binding motifs that bind to the same surface of ubiquitin. These motifs are found within different helices within the three-helix GAT subdomain. When functionally analyzed in yeast, each motif was sufficient to mediate trans-Golgi network to endosomal sorting of Gap1, and mutation of both motifs resulted in defective Gap1 sorting without defects in other GGA-dependent processes.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, NMR Facil, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Piper, RC (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	robert-piper@uiowa.edu	Allaman, Margaret/GNO-9854-2022	Allaman, Margaret M./0000-0002-2803-1365; Piper, Robert/0000-0001-9995-5699	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058202, R01GM046869] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058202, R01 GM058202-07, GM58202, R01 GM046869] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Blondel MO, 2004, MOL BIOL CELL, V15, P883, DOI 10.1091/mbc.E03-04-0202; Boman AL, 2002, MOL BIOL CELL, V13, P3078, DOI 10.1091/mbc.E02-02-0078; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Katoh Y, 2004, J BIOL CHEM, V279, P24435, DOI 10.1074/jbc.M400059200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P31409, DOI 10.1074/jbc.M402183200; Pizzirusso M, 2004, MOL BIOL CELL, V15, P2401, DOI 10.1091/mbc.E03-10-0727; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; SCHNEIDER DM, 1992, BIOCHEMISTRY-US, V31, P3645, DOI 10.1021/bi00129a013; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sivaraman T, 2001, NAT STRUCT BIOL, V8, P331, DOI 10.1038/86208; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Sundd M, 2002, BIOCHEMISTRY-US, V41, P7586, DOI 10.1021/bi025571d; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Wakasugi M, 2003, BIOCHEM BIOPH RES CO, V306, P687, DOI 10.1016/S0006-291X(03)01032-5; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200	35	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54808	54816		10.1074/jbc.M406654200	http://dx.doi.org/10.1074/jbc.M406654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494413	hybrid, Green Accepted			2022-12-27	WOS:000225793600109
J	Morton, HC; Pleass, RJ; Woof, JM; Brandtzaeg, P				Morton, HC; Pleass, RJ; Woof, JM; Brandtzaeg, P			Characterization of the ligand binding site of the bovine IgA Fc receptor (bFc alpha R)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; MOLECULAR-BASIS; IDENTIFICATION; RESIDUES; CD89; INSIGHTS; 19Q13.4; COMPLEX; CLUSTER; CLONING	Recently, we identified a bovine IgA Fc receptor (bFcalphaR), which shows high homology to the human myeloid FcalphaR, CD89. IgA binding has previously been shown to depend on several specific residues located in the B-C and F-G loops of the membrane-distal extracellular domain 1 of CD89. To compare the ligand binding properties of these two FcalphaRs, we have mapped the IgA binding site of bFcalphaR. We show that, in common with CD89, Tyr-35 in the B-C loop is essential for IgA binding. However, in contrast to earlier observations on CD89, mutation of residues in the F-G loop did not significantly inhibit IgA binding.	Univ Oslo, Rikshosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Univ Dundee, Sch Med, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland	University of Oslo; National Hospital Norway; University of Dundee	Morton, HC (corresponding author), Univ Oslo, Rikshosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway.	h.c.morton@medisin.uio.no	Pleass, Richard/N-7831-2019; Pleass, Richard J/L-4148-2015; Morton, H. Craig/H-8600-2012	Pleass, Richard/0000-0001-7438-8296; Pleass, Richard J/0000-0001-7438-8296; Morton, H. Craig/0000-0002-9440-5759	Medical Research Council [G0300145] Funding Source: Medline; MRC [G0300145] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Claypool SM, 2002, J BIOL CHEM, V277, P28038, DOI 10.1074/jbc.M202367200; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Ding Y, 2003, J BIOL CHEM, V278, P27966, DOI 10.1074/jbc.C300223200; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; Klungland H, 1997, MAMM GENOME, V8, P300, DOI 10.1007/s003359900425; KREMER EJ, 1992, HUM GENET, V89, P107, DOI 10.1007/BF00207054; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; McQueen KL, 2002, EUR J IMMUNOL, V32, P810, DOI 10.1002/1521-4141(200203)32:3<810::AID-IMMU810>3.0.CO;2-P; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Morton HC, 2004, IMMUNOLOGY, V111, P204, DOI 10.1111/j.0019-2805.2003.01808.x; Morton HC, 2001, J BIOL CHEM, V276, P47794, DOI 10.1074/jbc.M104066200; Morton HC, 1999, J EXP MED, V189, P1715; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Radaev S, 2002, MOL IMMUNOL, V38, P1073, DOI 10.1016/S0161-5890(02)00036-6; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Storset AK, 2003, EUR J IMMUNOL, V33, P980, DOI 10.1002/eji.200323710; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Woof JM, 2004, NAT REV IMMUNOL, V4, P89, DOI 10.1038/nri1266; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4; ZHANG GP, 1995, J IMMUNOL, V155, P1534	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54018	54022		10.1074/jbc.M407807200	http://dx.doi.org/10.1074/jbc.M407807200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485844	hybrid, Green Published			2022-12-27	WOS:000225793600017
J	Zhu, L; Jang, GF; Jastrzebska, B; Filipek, S; Pearce-Kelling, SE; Aguirre, GD; Stenkamp, RE; Acland, GM; Palczewski, K				Zhu, L; Jang, GF; Jastrzebska, B; Filipek, S; Pearce-Kelling, SE; Aguirre, GD; Stenkamp, RE; Acland, GM; Palczewski, K			A naturally occurring mutation of the opsin gene (T4R) in dogs affects glycosylation and stability of the G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; VITAMIN-A SUPPLEMENTATION; RHODOPSIN GENE; TRANSDUCIN ACTIVATION; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; MOUSE MODEL; MUTANTS; DEGENERATION; PHOTOTRANSDUCTION	Rho ( rhodopsin; opsin plus 11-cis-retinal) is a prototypical G protein-coupled receptor responsible for the capture of a photon in retinal photoreceptor cells. A large number of mutations in the opsin gene associated with autosomal dominant retinitis pigmentosa have been identified. The naturally occurring T4R opsin mutation in the English mastiff dog leads to a progressive retinal degeneration that closely resembles human retinitis pigmentosa caused by the T4K mutation in the opsin gene. Using genetic approaches and biochemical assays, we explored the properties of the T4R mutant protein. Employing immunoaffinity-purified Rho from affected RHOT4R/T4R dog retina, we found that the mutation abolished glycosylation at Asn(2), whereas glycosylation at Asn(15) was unaffected, and the mutant opsin localized normally to the rod outer segments. Moreover, we found that T4R Rho* lost its chromophore faster as measured by the decay of meta-rhodopsin II and that it was less resistant to heat denaturation. Detergent-solubilized T4R opsin regenerated poorly and interacted abnormally with the G protein transducin (G(t)). Structurally, the mutation affected mainly the "plug" at the intradiscal (extracellular) side of Rho, which is possibly responsible for protecting the chromophore from the access of bulk water. The T4R mutation may represent a novel molecular mechanism of degeneration where the unliganded form of the mutant opsin exerts a detrimental effect by losing its structural integrity.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA; Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Cornell University; University of Pennsylvania	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, 1957 NE Pacific St,POB 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY013385, R29EY008061, U01EY006855, P30EY001730, U10EY013729, R01EY013132, R01EY008061, R01EY006855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdulaev NG, 2003, TRENDS BIOCHEM SCI, V28, P399, DOI 10.1016/S0968-0004(03)00164-6; ACLAND GM, 1987, EXP EYE RES, V44, P491, DOI 10.1016/S0014-4835(87)80160-4; Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Aguirre G D, 1998, Mol Vis, V4, P23; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FLIESLER SJ, 1985, J CELL BIOL, V100, P574, DOI 10.1083/jcb.100.2.574; FLIESLER SJ, 1984, NATURE, V311, P575, DOI 10.1038/311575a0; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUJIKI K, 1995, JPN J HUM GENET, V40, P271, DOI 10.1007/BF01876186; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2009, DOI 10.1021/bi020613j; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2002, DOI 10.1021/bi020612r; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Janz JM, 2003, VISION RES, V43, P2991, DOI 10.1016/j.visres.2003.08.010; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Jin SN, 2003, NAT NEUROSCI, V6, P731, DOI 10.1038/nn1070; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kijas JW, 2003, J HERED, V94, P27, DOI 10.1093/jhered/esg007; Kijas JW, 2002, P NATL ACAD SCI USA, V99, P6328, DOI 10.1073/pnas.082714499; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PLANTNER JJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P527, DOI 10.1016/0003-9861(80)90541-X; PRASAD AVK, 1992, EXP EYE RES, V54, P913, DOI 10.1016/0014-4835(92)90155-L; Ramon E, 2003, J BIOL CHEM, V278, P6427, DOI 10.1074/jbc.M210929200; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; ROOF DJ, 1994, INVEST OPHTH VIS SCI, V35, P4049; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Saliba RS, 2002, J CELL SCI, V115, P2907; SULLIVAN LJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1512, DOI 10.1001/archopht.1993.01090110078029; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1994, J NEUROSCI, V14, P5818; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Teller DC, 2003, FEBS LETT, V555, P151, DOI 10.1016/S0014-5793(03)01152-9; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; VANDENBORN LI, 1994, OPHTHALMIC GENET, V15, P51, DOI 10.3109/13816819409098864; Yang T, 1997, P NATL ACAD SCI USA, V94, P13559, DOI 10.1073/pnas.94.25.13559; Yoshii M, 1998, OPHTHALMIC RES, V30, P1	72	53	60	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53828	53839		10.1074/jbc.M408472200	http://dx.doi.org/10.1074/jbc.M408472200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459196	hybrid, Green Submitted, Green Accepted			2022-12-27	WOS:000225680600121
J	Bruey, JM; Bruey-Sedano, N; Newman, R; Chandler, S; Stehlik, C; Reed, JC				Bruey, JM; Bruey-Sedano, N; Newman, R; Chandler, S; Stehlik, C; Reed, JC			PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappa B and caspase-1 activation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR; CONTAINING APAF1-LIKE PROTEIN; DEATH-DOMAIN-FOLD; PYRIN DOMAIN; CUTTING EDGE; RECRUITMENT DOMAIN; APOPTOSIS; ASC; CANCER; FAMILY	Genes encoding proteins with PYRIN/PAAD/DAPIN domains, a nucleotide binding fold (NACHT), and leucine rich repeats have recently been recognized as important mediators in autoimmune inflammatory disorders. Here we characterize the expression and function of a member of the PYRIN and NACHT domain (PAN) family, PAN1 (also known as NALP2 and PYPAF2). PAN1 protein expression is regulated by lipopolysaccharide (LPS) and interferons (IFNbeta and IFNgamma) in THP-1 macrophage cells. In gene transfection studies PAN1 manifests an inhibitory influence on NF-kappaB activation induced by various pro-inflammatory stimuli, including tumor necrosis factor TNFalpha and interleukin1beta (IL-1beta). Gene transfer-mediated elevations in PAN1 protein also suppressed activation of IkappaB kinases induced by inflammatory cytokines. Conversely, reducing endogenous levels of PAN1 using small interfering RNA enhanced LPS-induced production of ICAM-1 (intercellular adhesion molecule 1), an NF-kappaB-dependent gene. We also show here that PAN1 binds via its PYRIN domain to ASC, an adapter protein involved in caspase-1 activation. This binding is disrupted by mutation of the alpha1 helix of ASC. In gene transfer experiments PAN1 enhances caspase-1 activation and IL-1beta secretion in collaboration with ASC. Conversely, reducing endogenous levels of PAN1 using small interfering RNA significantly reduced LPS-induced secretion of IL-1beta in monocytes. We propose that PAN1 functions as a modulator of the activation of NF-kappaB and procaspase-1 in macrophages.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Stehlik, Christian/AAG-2132-2021	Stehlik, Christian/0000-0002-3782-2484	NIAID NIH HHS [R01 AI-56324] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; Hiller S, 2003, STRUCTURE, V11, P1199, DOI 10.1016/j.str.2003.08.009; Hoshino K, 1999, J IMMUNOL, V162, P3749; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2003, BIOCHEM J, V373, P101, DOI 10.1042/BJ20030304; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027	45	123	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51897	51907		10.1074/jbc.M406741200	http://dx.doi.org/10.1074/jbc.M406741200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456791	hybrid			2022-12-27	WOS:000225493400023
J	Fukuda, M; Kanno, E; Satoh, M; Saegusa, C; Yamamoto, A				Fukuda, M; Kanno, E; Satoh, M; Saegusa, C; Yamamoto, A			Synaptotagmin VII is targeted to dense-core vesicles and regulates their Ca2+-dependent exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT OLIGOMERIZATION; CONSERVED WHXL MOTIF; TANDEM C2 DOMAINS; NEUROTRANSMITTER RELEASE; INSULIN EXOCYTOSIS; BETA-CELLS; ANTIBODY INJECTION; MOLECULAR-CLONING; RNA INTERFERENCE; DISTINCT CA2+	It has recently been proposed that synaptotagmin (Syt) VII functions as a plasma membrane Ca2+ sensor for dense-core vesicle exocytosis in PC12 cells based on the results of transient overexpression studies using green fluorescent protein (GFP)-tagged Syt VII; however, the precise subcellular localization of Syt VII is still a matter of controversy ( plasma membrane versus secretory granules). In this study we established a PC12 cell line "stably expressing" the Syt VII-GFP molecule and demonstrated by immunocytochemical and immunoelectron microscopic analyses that the Syt VII-GFP protein is localized on dense-core vesicles as well as in other intracellular membranous structures, such as the trans-Golgi network and lysosomes. Syt VII-GFP forms a complex with endogenous Syts I and IX, but not with Syt IV, and it colocalize well with Syts I and IX in the cellular processes (where dense-core vesicles are accumulated) in the PC12 cell line. We further demonstrated by an N-terminal antibody-uptake experiment that Syt VII-GFP-containing dense-core vesicles undergo Ca2+-dependent exocytosis, the same as endogenous Syt IX-containing vesicles. Moreover, silencing of Syt VII-GFP with specific small interfering RNA dramatically reduced high KCl-dependent neuropeptide Y secretion from the stable PC12 cell line (similar to60% of the control cells), whereas the same small interfering RNA had little effect on neuropeptide Y secretion from the wild-type PC12 cells (similar to85-90% of the control cells), indicating that the level of endogenous expression of Syt VII molecules must be low. Our results indicate that the targeting of Syt VII-GFP molecules to specific membrane compartment(s) is affected by the transfection method ( transient expression versus stable expression) and suggested that Syt VII molecule on dense-core vesicles functions as a vesicular Ca2+ sensor for exocytosis in endocrine cells.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Nagahama Inst Biosci & Technol, Shiga 5260829, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Adolfsen B, 2001, CELL MOL LIFE SCI, V58, P393, DOI 10.1007/PL00000865; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chieregatti E, 2004, MOL BIOL CELL, V15, P1918, DOI 10.1091/mbc.E03-09-0684; Craxton M, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-43; Dasgupta S, 2003, J CELL SCI, V116, P1327, DOI 10.1242/jcs.00290; Eaton BA, 2000, J NEUROSCI, V20, P7334; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2000, NEUROSCI LETT, V295, P33, DOI 10.1016/S0304-3940(00)01585-8; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2004, J BIOCHEM, V136, P245, DOI 10.1093/jb/mvh116; Fukuda M, 2004, BIOCHEM J, V380, P875, DOI 10.1042/BJ20040096; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2003, BIOCHEM BIOPH RES CO, V306, P64, DOI 10.1016/S0006-291X(03)00911-2; Fukuda M, 2003, J BIOCHEM, V133, P641, DOI 10.1093/jb/mvg082; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2003, J BIOL CHEM, V278, P3220, DOI 10.1074/jbc.M208323200; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gut A, 2001, J CELL SCI, V114, P1709; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Iezzi M, 2004, J CELL SCI, V117, P3119, DOI 10.1242/jcs.01179; Kreft M, 2003, AM J PHYSIOL-CELL PH, V284, pC547, DOI 10.1152/ajpcell.00333.2002; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; Moss EG, 2001, CURR BIOL, V11, pR772, DOI 10.1016/S0960-9822(01)00467-5; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Rao SK, 2004, J BIOL CHEM, V279, P20471, DOI 10.1074/jbc.M400798200; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rickman C, 2004, BIOCHEM J, V378, P681, DOI 10.1042/BJ20031407; Roy D, 2004, SCIENCE, V304, P1515, DOI 10.1126/science.1098371; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Zhang Q, 2004, P NATL ACAD SCI USA, V101, P9441, DOI 10.1073/pnas.0401960101; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	67	69	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52677	52684		10.1074/jbc.M409241200	http://dx.doi.org/10.1074/jbc.M409241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456748	hybrid			2022-12-27	WOS:000225493400114
J	Ozbek, S; Pokidysheva, E; Schwager, M; Schulthess, T; Tariq, N; Barth, D; Milbradt, AG; Moroder, L; Engel, J; Holstein, TW				Ozbek, S; Pokidysheva, E; Schwager, M; Schulthess, T; Tariq, N; Barth, D; Milbradt, AG; Moroder, L; Engel, J; Holstein, TW			The glycoprotein NOWA and minicollagens are part of a disulfide-linked polymer that forms the cnidarian nematocyst wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDRA NEMATOCYSTS; MINI-COLLAGENS; PROTEIN; DISCHARGE; CAPSULES; LINKAGE; SWITCH; RICH	The nematocyst is a unique extrusive organelle involved in the defense and capture of prey in cnidarians. Minicollagens and the glycoprotein NOWA are major components of the nematocyst capsule wall, which resists osmotic pressure of 15 MPa. Here we present the recombinant expression of NOWA, which spontaneously assembles to globular macromolecular particles that are sensitive to reduction as the native wall structure. Ultrastructural analysis showed that the Hydra nematocyst wall is composed of several layers of globular particles, which are interconnected via radiating rodlike protrusions. Evidence is presented that native wall particles contain NOWA and minicollagen, supposed to be linked via disulfide bonds between their homologous cysteine-rich domains. Our data suggest a continuous suprastructure of the nematocyst wall, assembled from wall proteins that share a common oligomerization motif.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany	University of Basel; Max Planck Society; Technical University of Darmstadt	Ozbek, S (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Suat.Oezbek@unibas.ch	Özbek, Suat/D-3701-2014	Moroder, Luis/0000-0001-9570-5713; Ozbek, Suat/0000-0003-2569-3942; Holstein, Thomas/0000-0003-0480-4674				BLANQUET R, 1966, SCIENCE, V154, P152, DOI 10.1126/science.154.3745.152; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Engel U, 2002, J CELL SCI, V115, P3923, DOI 10.1242/jcs.00084; Engel U, 2001, EMBO J, V20, P3063, DOI 10.1093/emboj/20.12.3063; HOLSTEIN T, 1984, SCIENCE, V223, P830, DOI 10.1126/science.6695186; HOLSTEIN T, 1981, J ULTRA MOL STRUCT R, V75, P276, DOI 10.1016/S0022-5320(81)80085-8; HOLSTEIN TW, 1994, SCIENCE, V265, P402, DOI 10.1126/science.265.5170.402; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; LENHOFF HM, 1957, BIOCHIM BIOPHYS ACTA, V26, P204, DOI 10.1016/0006-3002(57)90074-4; MARISCAL RN, 1969, EXPERIENTIA, V25, P330, DOI 10.1007/BF02034427; Mascarenhas JB, 2003, EMBO J, V22, P529, DOI 10.1093/emboj/cdg041; Ozbek S, 2002, J BIOL CHEM, V277, P49200, DOI 10.1074/jbc.M209401200; Ozbek S, 2002, J STRUCT BIOL, V137, P11, DOI 10.1006/jsbi.2002.4436; POKIDYSHEVA E, 2004, J BIOL CHEM; SLAUTTERBACK DB, 1963, J CELL BIOL, V18, P367, DOI 10.1083/jcb.18.2.367; WATSON GM, 1985, TISSUE CELL, V17, P199, DOI 10.1016/0040-8166(85)90089-8; WEBER J, 1990, J BIOL CHEM, V265, P9664; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626	18	28	31	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52016	52023		10.1074/jbc.M407613200	http://dx.doi.org/10.1074/jbc.M407613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466471	hybrid			2022-12-27	WOS:000225493400038
J	Parent, M; Yung, TMC; Rancourt, A; Ho, ELY; Vispe, S; Suzuki-Matsuda, F; Uehara, A; Wada, T; Handa, H; Satoh, MS				Parent, M; Yung, TMC; Rancourt, A; Ho, ELY; Vispe, S; Suzuki-Matsuda, F; Uehara, A; Wada, T; Handa, H; Satoh, MS			Poly(ADP-ribose) polymerase-1 is a negative regulator of HIV-1 transcription through competitive binding to TAR RNA with Tat center dot Positive transcription elongation factor b (p-TEFb) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NF-KAPPA-B; DNA TOPOISOMERASES; GENE-EXPRESSION; PROTEIN-KINASE; II ELONGATION; CYCLIN T1; IN-VITRO; ACTIVATION; DSIF	Human immunodeficiency virus, type 1 (HIV-1) transcription is regulated by a virus-encoded protein, Tat, which forms a complex with a host cellular factor, positive transcription elongation factor b (P-TEFb). When this complex binds to TAR RNA synthesized from the HIV-1 long terminal repeat promoter element, transcription is trans-activated. In this study we showed that, in host cells, HIV-1 transcription is negatively regulated by competition of poly(ADP-ribose) polymerase-1 (PARP-1) with Tat.P-TEFb for binding to TAR RNA. PARP-1, which has a high affinity for TAR RNA (K-D = 1.35 x 10(-10) (M)), binds to the loop region of TAR RNA and displaces Tat or Tat.P-TEFb from the RNA. In vitro transcription assays showed that this displacement leads to suppression of Tat-mediated trans-activation of transcription. Furthermore in vivo expression of luciferase or destabilized enhanced green fluorescent protein genes under the control of the HIV-1 long terminal repeat promoter was suppressed by PARP-1. Thus, these results suggest that PARP-1 acts as a negative regulator of HIV-1 transcription through competitive binding with Tat or the Tat.P-TEFb complex to TAR RNA.	Univ Laval, Med Ctr, Div Hlth & Environm Res, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Anat & Physiol, Ste Foy, PQ G1V 4G2, Canada; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Laval University; Laval University; Tokyo Institute of Technology	Satoh, MS (corresponding author), Univ Laval, Med Ctr, Div Hlth & Environm Res, 2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Masahiko.sato@crchul.ulaval.ca						ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gwack Y, 2003, MOL CELL BIOL, V23, P8282, DOI 10.1128/MCB.23.22.8282-8294.2003; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; Siva AC, 2002, J VIROL, V76, P11904, DOI 10.1128/JVI.76.23.11904-11910.2002; TERWILLIGER E, 1988, J ACQ IMMUN DEF SYND, V1, P317; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200; Yung TMC, 2004, J BIOL CHEM, V279, P11992, DOI 10.1074/jbc.M312459200; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; ZEICHNER SL, 1992, J VIROL, V66, P2268, DOI 10.1128/JVI.66.4.2268-2273.1992; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1	49	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					448	457		10.1074/jbc.M408435200	http://dx.doi.org/10.1074/jbc.M408435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498776	hybrid			2022-12-27	WOS:000226025100054
J	Blume, A; Benie, AJ; Stolz, F; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T				Blume, A; Benie, AJ; Stolz, F; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T			Characterization of ligand binding to the bifunctional key enzyme in the sialic acid biosynthesis by NMR - I. Investigation of the UDP-GlcNAc 2-epimerase functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE 2-EPIMERASE; TRANSFER DIFFERENCE NMR; 1ST 2 STEPS; RAT-LIVER; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; ESCHERICHIA-COLI; D-GLUCOSAMINE; PURIFICATION; RECOGNITION; EXPRESSION	The bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase is the key enzyme for the biosynthesis of sialic acids. As terminal components of glycoconjugates, sialic acids are associated with a variety of pathological processes such as inflammation and cancer. For the first time, this study reveals characteristics of the interaction of the epimerase site of the enzyme with its natural substrate, UDP-N-acetylglucosamine (UDP-GlcNAc) and derivatives thereof at atomic resolution. Saturation transfer difference NMR experiments were crucial in obtaining ligand binding epitopes and to rank ligands according to their binding affinities. Employing a fragment based approach, it was possible to assign the major component of substrate recognition to the UDP moiety. In particular, the binding epitopes of the uridine moieties of UMP, UDP, UDP-GalNAc, and UDP-GlcNAc are rather similar, suggesting that the binding mode of the UDP moiety is the same in all cases. In contrast, the hexopyranose units of UDP-GlcNAc and UDP-GalNAc display small differences reflecting the inability of the enzyme to process UDP-GalNAc. Surprisingly, saturation transfer difference NMR titrations show that UDP has the largest binding affinity to the epimerase site and that at least one phosphate group is required for binding. Consequently, this study provides important new data for rational drug design.	Charite Univ Med Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; Univ Lubeck, Inst Chem, D-23538 Lubeck, Germany; Univ Konstanz, Fachbereich Chem, Fach M 725, D-78457 Constance, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lubeck; University of Konstanz	Hinderlich, S (corresponding author), Charite Univ Med Berlin, Inst Biochem & Mol Biol, Campus Benjamin Franklin,Arnimallee 22, D-14195 Berlin, Germany.	stephan.hinderlich@charite.de; thomas.peters@chemie.uni-luebeck.de	Peters, Thomas/AAE-1509-2022; Peters, Thomas/GQB-3622-2022	Peters, Thomas/0000-0002-7570-8260; Benie, Andrew/0000-0001-8274-0456				Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Benie AJ, 2003, J AM CHEM SOC, V125, P14, DOI 10.1021/ja027691e; Benie AJ, 2004, J BIOL CHEM, V279, P55722, DOI 10.1074/jbc.M410239200; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; Biet T, 2001, ANGEW CHEM INT EDIT, V40, P4189, DOI 10.1002/1521-3773(20011119)40:22<4189::AID-ANIE4189>3.0.CO;2-A; Blume A, 2004, PROTEIN EXPRES PURIF, V35, P387, DOI 10.1016/j.pep.2004.02.013; Blume A, 2002, FEBS LETT, V521, P127, DOI 10.1016/S0014-5793(02)02856-9; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Chen H, 2002, GLYCOBIOLOGY, V12, P65, DOI 10.1093/glycob/12.2.65; Chou WK, 2003, J AM CHEM SOC, V125, P2455, DOI 10.1021/ja021309g; CORFIELD AP, 1982, OCCURRENCE SIALIC AC, P5; DENNIS JW, 1985, CANCER RES, V45, P6034; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x; Jayalakshmi V, 2004, J AM CHEM SOC, V126, P8610, DOI 10.1021/ja048703u; Jayalakshmi V, 2002, J MAGN RESON, V155, P106, DOI 10.1006/jmre.2001.2499; KAMERLING JP, 1979, BIOCHIM BIOPHYS ACTA, V583, P403, DOI 10.1016/0304-4165(79)90465-3; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KEPPLER DOR, 1970, EUR J BIOCHEM, V17, P246, DOI 10.1111/j.1432-1033.1970.tb01160.x; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meinecke R, 2001, J MED CHEM, V44, P3059, DOI 10.1021/jm0109154; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; PRAVDIC N, 1975, CARBOHYD RES, V45, P302, DOI 10.1016/S0008-6215(00)85889-9; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V268, P590, DOI 10.1016/0005-2744(72)90356-7; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Stolz F, 2004, J ORG CHEM, V69, P665, DOI 10.1021/jo0353029; Stolz F, 2004, EUR J ORG CHEM, V2004, P3304, DOI 10.1002/ejoc.200400197; Suzuki Y, 2000, J VIROL, V74, P11825, DOI 10.1128/JVI.74.24.11825-11831.2000; Vann WF, 2004, J BACTERIOL, V186, P706, DOI 10.1128/JB.186.3.706-712.2004; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Vogtherr M, 2000, J AM CHEM SOC, V122, P6093, DOI 10.1021/ja0001916; WATSON DR, 1966, J BIOL CHEM, V241, P5627	43	19	19	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55715	55721		10.1074/jbc.M410238200	http://dx.doi.org/10.1074/jbc.M410238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498764	hybrid			2022-12-27	WOS:000225960800092
J	Baetz, A; Frey, M; Heeg, K; Dalpke, AH				Baetz, A; Frey, M; Heeg, K; Dalpke, AH			Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT INHIBITOR-1 (SSI-1)/SUPPRESSOR; ADAPTER MOLECULE; INTERFERON-BETA; IFN-GAMMA; GENE-EXPRESSION; MACROPHAGES; LIPOPOLYSACCHARIDE; INDUCTION; ACTIVATION; PATHWAY	Suppressor of cytokine signaling ( SOCS) proteins constitute a class of negative regulators for Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways. These intracellular proteins are induced by cytokine signaling, but they can also be induced by stimulation of Toll-like receptors (TLR). It has even been suggested that SOCS proteins are important negative regulators of TLR signaling. Here we have elucidated the nature of the regulatory role of SOCS in TLR signaling. Induction of SOCS-3 and cytokine-inducible Src homology 2-containing protein (CIS) by TLR stimulation was strictly dependent on MyD88 but showed differing needs in case of SOCS-1. However, induction of SOCS proteins by TLR ligands was independent of type I interferon. In macrophages overexpressing SOCS, we were not able to observe an inhibitory effect of SOCS-1, SOCS-2, SOCS-3, or CIS on prototypical TLR target genes such as tumor necrosis factor-alpha. However, we found that TLR-2, TLR-3, TLR-4, and TLR-9 stimulation induced interferon-beta (IFN-beta), which is able to exert auto- and paracrine signaling, leading to the activation of secondary genes like IP-10. SOCS- 1 and, to a lesser extent, SOCS- 3 and CIS were able to inhibit this indirect signaling pathway following TLR stimulation, whereas neither MAP kinase nor NFkappaB signaling were affected. However, STAT-1 tyrosine phosphorylation following TLR triggering was severely impaired by SOCS- 1 overexpression. Thus, our data suggest that SOCS proteins induced by TLR stimulation limit the extent of TLR signaling by inhibiting type I IFN signaling but not the main NFkappaB pathway.	Univ Marburg, Inst Med Microbiol & Hyg, D-35037 Marburg, Germany; Heidelberg Univ, Dept Hyg & Med Microbiol, D-69120 Heidelberg, Germany	Philipps University Marburg; Ruprecht Karls University Heidelberg	Dalpke, AH (corresponding author), Univ Marburg, Inst Med Microbiol & Hyg, D-35037 Marburg, Germany.	dalpke@mailer.uni-marburg.de						Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Crespo A, 2002, EUR J IMMUNOL, V32, P710, DOI 10.1002/1521-4141(200203)32:3<710::AID-IMMU710>3.0.CO;2-T; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dalpke AH, 2003, EUR J IMMUNOL, V33, P1776, DOI 10.1002/eji.200323621; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; De Sepulveda P, 1999, EMBO J, V18, P904; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Hattori Y, 1996, BIOCHEM MOL BIOL INT, V40, P889; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Park SH, 2003, DNA CELL BIOL, V22, P131, DOI 10.1089/104454903321515931; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Stoiber D, 1999, J IMMUNOL, V163, P2640; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	47	225	244	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54708	54715		10.1074/jbc.M410992200	http://dx.doi.org/10.1074/jbc.M410992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491991	hybrid			2022-12-27	WOS:000225793600098
J	Rotmann, A; Stand, D; Martine, U; Closs, EI				Rotmann, A; Stand, D; Martine, U; Closs, EI			Protein kinase C activation promotes the internalization of the human cationic amino acid transporter hCAT-1 - A new regulatory mechanism for hCAT-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; HUMAN DOPAMINE TRANSPORTER; L-ARGININE TRANSPORT; MURINE RETROVIRUSES; ENDOTHELIAL-CELLS; EXPRESSION; GENE; TRAFFICKING; MACROPHAGES; MEMBRANE	The human cationic amino acid transporter hCAT-1 is almost ubiquitously expressed and probably the most important entity for supplying cells with extracellular arginine, lysine, and ornithine. We have previously shown that hCAT-1-mediated transport is decreased after protein kinase C (PKC) activation by phorbol 12-myristate 13-acetate (PMA) (Graf, P., Forstermann, U., and Closs, E. I. ( 2001) Br. J. Pharmacol. 132, 1193-1200). In the present study, we examined the mechanism of this down-regulation. In both Xenopus laevis oocytes and U373MG glioblastoma cells, PMA treatment promoted the internalization of hCAT-1 ( fused to the enhanced green fluorescence protein (EGFP)) as visualized by fluorescence microscopy. Biotinylation of cell surface proteins and subsequent Western blot analyses confirmed that the cell surface expression of hCAT-1.EGFP was significantly reduced upon PMA treatment. Pretreatment with the PKC inhibitor bisindolylmaleimide I prevented the reduction by PMA of both hCAT-1.EGFP-induced arginine transport and the internalization of the transporter. Similar results were obtained with hCAT-1 expressed endogenously in DLD-1 colon carcinoma cells. Inhibition of protein synthesis did not augment the PMA effect. In addition, the PMA effect was reverted in washout experiments without changing the hCAT-1 protein expression, suggesting that the PMA effect is reversible in these cells. PKC did not phosphorylate hCAT-1 directly as evidenced by in vivo phosphorylation experiments and mutational analysis, indicating an indirect action of PKC on hCAT-1.	Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Closs, EI (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pharmacol, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.	Closs@mail.uni-mainz.de	Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Bauman AL, 2000, J NEUROSCI, V20, P7571; Closs EI, 2004, J NUTR, V134, p2752S, DOI 10.1093/jn/134.10.2752S; Closs EI, 2002, CURR OPIN NEPHROL HY, V11, P99, DOI 10.1097/00041552-200201000-00015; Closs EI, 1997, BIOCHEMISTRY-US, V36, P6462, DOI 10.1021/bi962829p; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Durante W, 2001, CIRCULATION, V103, P1121, DOI 10.1161/01.CIR.103.8.1121; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Graf P, 2001, BRIT J PHARMACOL, V132, P1193, DOI 10.1038/sj.bjp.0703921; Grusovin J, 2003, FRONT BIOSCI-LANDMRK, V8, pD620, DOI 10.2741/1052; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Krotova KY, 2003, AM J PHYSIOL-LUNG C, V284, pL1037, DOI 10.1152/ajplung.00308.2002; Lee KH, 2004, NEUROCHEM RES, V29, P1405, DOI 10.1023/B:NERE.0000026404.08779.43; Lee SY, 1999, J VIROL, V73, P5994, DOI 10.1128/JVI.73.7.5994-6005.1999; Lopez-Corcuera B, 2001, BIOCHEM SOC T, V29, P742, DOI 10.1042/0300-5127:0290742; Manner CK, 2003, J NEUROCHEM, V85, P476, DOI 10.1046/j.1471-4159.2003.01695.x; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; PAN M, 1995, ANN SURG, V221, P590, DOI 10.1097/00000658-199505000-00017; Pan M, 2002, J GASTROINTEST SURG, V6, P876, DOI 10.1016/S1091-255X(02)00052-5; PAN M, 1995, BIOCHIM BIOPHYS ACTA, V4, P27; Pastor CM, 1995, AM J PHYSIOL-GASTR L, V269, pG861, DOI 10.1152/ajpgi.1995.269.6.G861; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; Peters KW, 2001, PFLUG ARCH EUR J PHY, V443, pS65, DOI 10.1007/s004240100647; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Racke K, 1998, J PHYSIOL-LONDON, V511, P813, DOI 10.1111/j.1469-7793.1998.813bg.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Simon A, 2003, CIRC RES, V93, P813, DOI 10.1161/01.RES.0000097761.19223.0D; Vekony N, 2001, BIOCHEMISTRY-US, V40, P12387, DOI 10.1021/bi011345c; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Wolf S, 2002, BIOCHEM J, V364, P767, DOI 10.1042/BJ20020084; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	35	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54185	54192		10.1074/jbc.M409556200	http://dx.doi.org/10.1074/jbc.M409556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491978	hybrid			2022-12-27	WOS:000225793600037
J	Zhang, J; Hellwig, P; Osborne, JP; Gennis, RB				Zhang, J; Hellwig, P; Osborne, JP; Gennis, RB			Arginine 391 in subunit I of the cytochrome bd quinol oxidase from Escherichia coli stabilizes the reduced form of the hemes and is essential for quinol oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; AEROBIC RESPIRATORY-CHAIN; UBIQUINOL OXIDASE; ELECTRON-TRANSFER; D COMPLEX; SPECTROSCOPIC EVIDENCE; CONFORMATIONAL-CHANGES; B(558) COMPONENT; AXIAL LIGANDS; SITE	The cytochrome bd quinol oxidase is one of two respiratory oxidases in Escherichia coli. It oxidizes dihydroubiquinol or dihydromenaquinol while reducing dioxygen to water. The bd-type oxidases have only been found in prokaryotes and have been implicated in the survival of some bacteria, including pathogens, under conditions of low aeration. With a high affinity for dioxygen, cytochrome bd not only couples respiration to the generation of a proton motive force but also scavenges O-2. In the current work, the role of a highly conserved arginine residue is explored by site-directed mutagenesis. Four mutations were made: R391A, R391K, R391M, and R391Q. All of the mutations except R391K result in enzyme lacking ubiquinol oxidase activity. Oxidase activity using the artificial reductant N,N,N',N'-tetramethyl-p-phenylenediamine in place of ubiquinol was, however, unimpaired by the mutations, indicating that the catalytic center where O-2 is reduced is intact. UV-visible spectra of each of the mutant oxidases show no perturbations to any of the three heme components (heme b(558), heme b(595), and heme d). However, spectroelectrochemical titrations of the R391A mutant reveal that the midpoint potentials of all of the heme components are substantially lower compared with the wild type enzyme. Since Arg(391) is close to Met(393), one of the axial ligands to heme b(558), it is to be expected that the R391A mutation might destabilize the reduced form of heme b(558). The fact that the midpoint potentials of heme d and heme b(595) are also significantly lowered in the R391A mutant is consistent with these hemes being physically close together on the periplasmic side of the membrane.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Frankfurt, Inst Biophys, D-65690 Frankfurt, Germany	University of Illinois System; University of Illinois Urbana-Champaign; Goethe University Frankfurt	Gennis, RB (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews St, Urbana, IL 61801 USA.	r-gennis@uiuc.edu		hellwig, petra/0000-0001-6294-5163				Baughn AD, 2004, NATURE, V427, P441, DOI 10.1038/nature02285; DUEWEKE TJ, 1990, J BIOL CHEM, V265, P4273; DUEWEKE TJ, 1991, BIOCHEMISTRY-US, V30, P3401, DOI 10.1021/bi00228a007; Endley S, 2001, J BACTERIOL, V183, P2454, DOI 10.1128/JB.183.8.2454-2462.2001; FANG H, 1989, J BIOL CHEM, V264, P8026; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; Hellwig P, 1998, BBA-BIOENERGETICS, V1409, P107, DOI 10.1016/S0005-2728(98)00151-0; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; HILL S, 1990, J BACTERIOL, V172, P2071, DOI 10.1128/jb.172.4.2071-2078.1990; Hirota S, 1995, BIOSPECTROSCOPY, V1, P305, DOI 10.1002/bspy.350010502; Junemann S, 1997, BIOCHEMISTRY-US, V36, P9323, DOI 10.1021/bi970055m; JUNEMANN S, 1994, FEBS LETT, V345, P198, DOI 10.1016/0014-5793(94)00372-6; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; Juty NS, 1997, MICROBIOL-SGM, V143, P2673, DOI 10.1099/00221287-143-8-2673; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P445, DOI 10.1021/bi00298a008; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; LORENCE RM, 1984, BIOCHIM BIOPHYS ACTA, V790, P148, DOI 10.1016/0167-4838(84)90218-8; LORENCE RM, 1988, J BIOL CHEM, V11, P5271; MILLER MJ, 1985, J BIOL CHEM, V260, P4003; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Osborne JP, 1999, BBA-BIOENERGETICS, V1410, P32, DOI 10.1016/S0005-2728(98)00171-6; PROVENCHER SW, 1976, BIOPHYS J, V16, P27, DOI 10.1016/S0006-3495(76)85660-3; SPINNER F, 1995, BIOCHEM J, V308, P641, DOI 10.1042/bj3080641; Sun J, 1996, BIOCHEMISTRY-US, V35, P2403, DOI 10.1021/bi9518252; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Way SS, 1999, J BACTERIOL, V181, P1229, DOI 10.1128/JB.181.4.1229-1237.1999; Zhang J, 2004, FEBS LETT, V561, P58, DOI 10.1016/S0014-5793(04)00125-5; Zhang J, 2001, BIOCHEMISTRY-US, V40, P8548, DOI 10.1021/bi010469m; Zhang J, 2002, BIOCHEMISTRY-US, V41, P4612, DOI 10.1021/bi011784b	33	17	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53980	53987		10.1074/jbc.M408626200	http://dx.doi.org/10.1074/jbc.M408626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475358	hybrid			2022-12-27	WOS:000225793600012
J	Sdek, P; Ying, HQ; Zheng, HW; Margulis, A; Tang, XR; Tian, K; Xiao, ZXJ				Sdek, P; Ying, HQ; Zheng, HW; Margulis, A; Tang, XR; Tian, K; Xiao, ZXJ			The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ONCOPROTEIN MDM2; TUMOR-SUPPRESSOR; GENE-PRODUCT; RING FINGER; UBIQUITIN LIGASE; BINDING DOMAIN; P53; PROTEIN; RB	Retinoblastoma (Rb) protein is a paradigm of tumor suppressors. Inactivation of Rb plays a critical role in the development of human malignancies. MDM2, an oncogene frequently found amplified and overexpressed in a variety of human tumors and cancers, directly interacts and inhibits the p53 tumor suppressor protein. In addition, MDM2 has been shown to stimulate E2F transactivation activity and promote S-phase entry independent of p53, yet the mechanism of which is still not fully understood. In this study, we demonstrate that MDM2 specifically binds to Rb C-pocket and that the central acidic domain of MDM2 is essential for Rb interaction. In addition, we show that overexpression of MDM2 reduces Rb-E2F complexes in vivo. Moreover, the ectopic expression of the wild type MDM2, but not mutant MDM2 defective in Rb interaction, stimulates E2F transactivation activity and inhibits Rb growth suppression function. Taken together, these results suggest that MDM2-mediated inhibition of Rb likely contributes to MDM2 oncogenic activity.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	jxiao@bu.edu	Ying, Haoqiang/AAK-4325-2020; Sdek, Patima/A-5340-2010	Tang, Xiaoren/0000-0002-2402-3659; Zheng, Hongwu/0000-0002-5823-4913	NCI NIH HHS [R01CA79804] Funding Source: Medline; NIGMS NIH HHS [R01GM70017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu L, 2003, FEBS LETT, V544, P218, DOI 10.1016/S0014-5793(03)00502-7; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumura T, 1996, ONCOLOGY, V53, P308; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; WATANABE T, 1994, BLOOD, V84, P3158; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	41	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53317	53322		10.1074/jbc.M406062200	http://dx.doi.org/10.1074/jbc.M406062200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485814	hybrid			2022-12-27	WOS:000225680600063
J	Correia, IJ; Paquete, CM; Coelho, A; Almeida, CC; Catarino, T; Louro, RO; Frazao, C; Saraiva, LM; Carrondo, MA; Turner, DL; Xavier, AV				Correia, IJ; Paquete, CM; Coelho, A; Almeida, CC; Catarino, T; Louro, RO; Frazao, C; Saraiva, LM; Carrondo, MA; Turner, DL; Xavier, AV			Proton-assisted two-electron transfer in natural variants of tetraheme cytochromes from Desulfomicrobium Sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; ENERGY TRANSDUCTION; ELECTRON-TRANSFER; DESULFURICANS NORWAY; REDOX POTENTIALS; STRUCTURAL BASIS; 4 HEMES; C(3); COOPERATIVITY; ANGSTROM	The tetraheme cytochrome c(3) isolated from Desulfomicrobium baculatum (DSM 1743) (Dsmb) was cloned, and the sequence analysis showed that this cytochrome differs in just three amino acid residues from the cytochrome c(3) isolated from Desulfomicrobium norvegicum (Dsmn): (DsmnXXDsmb) Thr-37 --> Ser, Val-45 --> Ala, and Phe-88 --> Tyr. X-ray crystallography was used to determine the structure of cytochrome c(3) from Dsmb, showing that it is very similar to the published structure of cytochrome c(3) from Dsmn. A detailed thermodynamic and kinetic characterization of these two tetraheme cytochromes c(3) was performed by using NMR and visible spectroscopy. The results obtained show that the network of cooperativities between the redox and protonic centers is consistent with a synergetic process to stimulate the hydrogen uptake activity of hydrogenase. This is achieved by increasing the affinity of the cytochrome for protons through binding electrons and, reciprocally, by favoring a concerted two-electron transfer assisted by the binding of proton(s). The data were analyzed within the framework of the differences in the primary and tertiary structures of the two proteins, showing that residue 88, close to heme I, is the main cause for the differences in the microscopic thermodynamic parameters obtained for these two cytochromes c(3). This comparison reveals how replacement of a single amino acid can tune the functional properties of energy-transducing proteins, so that they can be optimized to suit the bioenergetic constraints of specific habitats.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Beira Interior, Fac Ciencias Saude, Ctr Invest Ciencias Saude, P-6201001 Covilha, Portugal; Univ Evora, Dept Quim, P-7000 Evora, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, P-2829516 Caparica, Portugal; Univ Southampton, Sch Chem, Southampton SO17 1BJ, Hants, England	Universidade Nova de Lisboa; Universidade da Beira Interior; University of Evora; Universidade Nova de Lisboa; University of Southampton	Xavier, AV (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.	xavier@itqb.unl.pt	Correia, Ilidio/S-8295-2016; Saraiva, Ligia M/H-8537-2012; Catarino, Teresa/A-9267-2012; Louro, Ricardo O./AAB-4601-2020; Correia, I. J./AAE-2400-2020; Coelho, Ana V/H-8885-2012; Turner, David/B-8267-2009; Coelho, Ana V Varela/O-3977-2014; Turner, David L/B-9061-2011; Paquete, Catarina M./A-6615-2016; DE ALMEIDA, CARLOS CAETANO/K-4265-2016; Frazao, Carlos/C-1965-2008	Correia, Ilidio/0000-0003-1613-9675; Saraiva, Ligia M/0000-0002-0675-129X; Catarino, Teresa/0000-0003-3782-4014; Louro, Ricardo O./0000-0002-2392-6450; Correia, I. J./0000-0003-1613-9675; Coelho, Ana V/0000-0002-6143-4203; Coelho, Ana V Varela/0000-0002-6143-4203; Turner, David L/0000-0002-3754-6459; Paquete, Catarina M./0000-0002-1511-3732; DE ALMEIDA, CARLOS CAETANO/0000-0002-3215-5731; Carrondo, Maria Armenia/0000-0002-1261-1162; Frazao, Carlos/0000-0002-7725-1671				Aubert C, 2000, BBA-PROTEIN STRUCT M, V1476, P85, DOI 10.1016/S0167-4838(99)00221-6; Ausubel F., 1999, CURRENT PROTOCOLS MO; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brennan L, 2000, J MOL BIOL, V298, P61, DOI 10.1006/jmbi.2000.3652; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR SYSTEM PROTEIN; CAPEILLEREBLANDIN C, 1986, BIOCHIM BIOPHYS ACTA, V848, P279, DOI 10.1016/0005-2728(86)90202-1; Catarino T, 2001, CHEMBIOCHEM, V2, P416, DOI 10.1002/1439-7633(20010601)2:6<416::AID-CBIC416>3.3.CO;2-Q; CATARINO T, 1998, THESIS U NOVA LISBOA; CHRISTENSEN HEM, 1994, J PHOTOCH PHOTOBIO A, V82, P103, DOI 10.1016/1010-6030(94)87009-8; COLETTA M, 1991, EUR J BIOCHEM, V202, P1101, DOI 10.1111/j.1432-1033.1991.tb16476.x; Correia IJ, 2002, EUR J BIOCHEM, V269, P5722, DOI 10.1046/j.1432-1033.2002.03286.x; COUTINHO IB, 1995, EUR J BIOCHEM, V230, P1007, DOI 10.1111/j.1432-1033.1995.tb20649.x; COUTINHO IB, 1993, BIOCHEM J, V294, P899, DOI 10.1042/bj2940899; COUTINHO IB, 1994, METHOD ENZYMOL, V243, P119; Cruickshank D.W.J, 1996, P CCP4 STUD WEEK, P11; CZJZEK M, 1994, J MOL BIOL, V243, P653, DOI 10.1016/0022-2836(94)90039-6; DELGADO R, 1991, ANAL CHIM ACTA, V245, P271, DOI 10.1016/S0003-2670(00)80232-9; DIXON M, 1971, BIOCHIM BIOPHYS ACTA, V226, P241, DOI 10.1016/0005-2728(71)90092-2; Dutton P L, 1978, Methods Enzymol, V54, P411; FREY M, 1976, J MOL BIOL, V104, P741, DOI 10.1016/0022-2836(76)90134-0; GAYDA JP, 1988, EUR J BIOCHEM, V177, P199, DOI 10.1111/j.1432-1033.1988.tb14362.x; Genthner BRS, 1997, INT J SYST BACTERIOL, V47, P889; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Louro RO, 1998, BIOCHEMISTRY-US, V37, P15808, DOI 10.1021/bi981505t; Louro RO, 1998, J AM CHEM SOC, V120, P13240, DOI 10.1021/ja983102m; Louro RO, 2004, FEBS LETT, V576, P77, DOI 10.1016/j.febslet.2004.08.066; Louro RO, 1997, J BIOL INORG CHEM, V2, P488, DOI 10.1007/s007750050160; Louro RO, 2001, J BIOL CHEM, V276, P44044, DOI 10.1074/jbc.M107136200; Louro RO, 2001, CHEMBIOCHEM, V2, P831, DOI 10.1002/1439-7633(20011105)2:11<831::AID-CBIC831>3.0.CO;2-W; Louro RO, 1996, J BIOL INORG CHEM, V1, P34, DOI 10.1007/s007750050020; LOURO RO, 1998, THESIS U NOVA LISBOA; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATIAS PM, 1993, J MOL BIOL, V234, P680, DOI 10.1006/jmbi.1993.1620; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; MCKENNA CE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P109, DOI 10.1016/0304-4165(91)90082-R; Messias AC, 1998, J MOL BIOL, V281, P719, DOI 10.1006/jmbi.1998.1974; MILLER JDA, 1964, J GEN MICROBIOL, V37, P419, DOI 10.1099/00221287-37-3-419; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MOURA I, 1988, EUR J BIOCHEM, V176, P365, DOI 10.1111/j.1432-1033.1988.tb14290.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NETA P, 1987, J PHYS CHEM-US, V91, P1606, DOI 10.1021/j100290a063; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P71; Park JS, 1996, BBA-PROTEIN STRUCT M, V1293, P45, DOI 10.1016/0167-4838(95)00239-1; PFENNIG N, 1976, ARCH MICROBIOL, V110, P3, DOI 10.1007/BF00416962; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, pC66; Salgueiro CA, 2001, BIOCHEMISTRY-US, V40, P9709, DOI 10.1021/bi010330b; Salgueiro CA, 1997, EUR J BIOCHEM, V244, P721, DOI 10.1111/j.1432-1033.1997.00721.x; SALGUEIRO CA, 1992, FEBS LETT, V314, P155, DOI 10.1016/0014-5793(92)80963-H; SANTOS H, 1984, EUR J BIOCHEM, V141, P283, DOI 10.1111/j.1432-1033.1984.tb08190.x; Saraiva LM, 1996, J BIOL INORG CHEM, V1, P542, DOI 10.1007/s007750050090; Saraiva LM, 1998, BIOCHEMISTRY-US, V37, P12160, DOI 10.1021/bi981001v; SHAPOSHNIKOV VV, 1960, NATURE, V187, P167, DOI 10.1038/187167a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P547, DOI 10.1107/S0907444997013875; TURNER DL, 1994, BBA-BIOENERGETICS, V1187, P232, DOI 10.1016/0005-2728(94)90117-1; Turner DL, 1998, EUR BIOPHYS J BIOPHY, V27, P367, DOI 10.1007/s002490050144; Turner DL, 1996, EUR J BIOCHEM, V241, P723, DOI 10.1111/j.1432-1033.1996.00723.x; Valente FMA, 2001, CHEMBIOCHEM, V2, P895, DOI 10.1002/1439-7633(20011203)2:12<895::AID-CBIC895>3.0.CO;2-V; Xavier AV, 2004, BBA-BIOENERGETICS, V1658, P23, DOI 10.1016/j.bbabio.2004.03.017; XAVIER AV, 1986, J INORG BIOCHEM, V28, P239, DOI 10.1016/0162-0134(86)80087-3; Xavier AV, 2002, FEBS LETT, V532, P261, DOI 10.1016/S0014-5793(02)03692-X; YAGI T, 1968, BIOCHIM BIOPHYS ACTA, V153, P699, DOI 10.1016/0005-2728(68)90197-7	65	22	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52227	52237		10.1074/jbc.M408763200	http://dx.doi.org/10.1074/jbc.M408763200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456779	hybrid			2022-12-27	WOS:000225493400063
J	Pekkala, M; Hieta, R; Bergmann, U; Kivirikko, KI; Wierenga, RK; Myllyharju, J				Pekkala, M; Hieta, R; Bergmann, U; Kivirikko, KI; Wierenga, RK; Myllyharju, J			The peptide-substrate-binding domain of collagen prolyl 4-hydroxylases is a tetratricopeptide repeat domain with functional aromatic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; PROLINE; ENZYMES; IDENTIFICATION; RECOGNITION; MECHANISM; COMPLEX; DESIGN	Collagen prolyl 4-hydroxylases catalyze the formation of 4-hydroxyproline in -X-Pro-Gly- sequences and have an essential role in collagen synthesis. The vertebrate enzymes are alpha(2)beta(2) tetramers in which the catalytic alpha-subunits contain separate peptide-substrate-binding and catalytic domains. We report on the crystal structure of the peptide-substrate-binding domain of the human type I enzyme refined at 2.3 resolution. It was found to belong to a family of tetratricopeptide repeat domains that are involved in many protein-protein interactions and consist of five alpha-helices forming two tetratricopeptide repeat motifs plus the solvating helix. A prominent feature of its concave surface is a deep groove lined by tyrosines, a putative binding site for proline-rich peptides. Solvent-exposed side chains of three of the tyrosines have a repeat distance similar to that of a poly-L-proline type II helix. The aromatic surface ends at one of the tyrosines, where the groove curves almost 90 away from the linear arrangement of the three tyrosine side chains, possibly inducing a bent conformation in the bound peptide. This finding is consistent with previous suggestions by others that a minimal structural requirement for proline 4-hydroxylation may be a sequence in the poly-L-proline type II conformation followed by a beta-turn in the Pro-Gly segment. Site-directed mutagenesis indicated that none of the tyrosines was critical for tetramer assembly, whereas most of them were critical for the binding of a peptide substrate and inhibitor both to the domain and the alpha(2)beta(2) enzyme tetramer.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi		Hieta, Reija/0000-0001-5724-6253				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Dijkstra K, 1999, J BIOMOL NMR, V14, P195, DOI 10.1023/A:1008331225208; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freund C, 2002, EMBO J, V21, P5985, DOI 10.1093/emboj/cdf602; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Nodelman IM, 1999, J MOL BIOL, V294, P1271, DOI 10.1006/jmbi.1999.3318; Pekkala M, 2003, ACTA CRYSTALLOGR D, V59, P940, DOI 10.1107/S0907444903005420; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Rucker AL, 2003, PROTEINS, V53, P68, DOI 10.1002/prot.10477; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; ZARRINPAR A, 2003, SCI STKE	50	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52255	52261		10.1074/jbc.M410007200	http://dx.doi.org/10.1074/jbc.M410007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456751	hybrid			2022-12-27	WOS:000225493400066
J	Smith, AMO; Ratcliffe, RG; Sweetlove, LJ				Smith, AMO; Ratcliffe, RG; Sweetlove, LJ			Activation and function of mitochondrial uncoupling protein in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE; MATRIX; METABOLISM; GLYCOLYSIS; HOMOLOGS; STRESS	Plant mitochondrial uncoupling protein (UCP) is activated by superoxide suggesting that it may function to minimize mitochondrial reactive oxygen species (ROS) formation. However, the precise mechanism of superoxide activation and the exact function of UCP in plants are not known. We demonstrate that 4-hydroxy-2-nonenal (HNE), a product of lipid peroxidation, and a structurally related compound, trans-retinal, stimulate a proton conductance in potato mitochondria that is inhibitable by GTP ( a characteristic of UCP). Proof that the effects of HNE and trans-retinal are mediated by UCP is provided by examination of proton conductance in transgenic plants overexpressing UCP. These experiments demonstrate that the mechanism of activation of UCP is conserved between animals and plants and imply a conservation of function. Mitochondria from transgenic plants overexpressing UCP were further studied to provide insight into function. Experimental conditions were designed to mimic a bioenergetic state that might be found in vivo ( mitochondria were supplied with pyruvate as well as tricarboxylic cycle acids at in vivo cytosolic concentrations and an exogenous ATP sink was established). Under such conditions, an increase in UCP protein content resulted in a modest but significant decrease in the rate of superoxide production. In addition, C-13-labeling experiments revealed an increase in the conversion of pyruvate to citrate as a result of increased UCP protein content. These results demonstrate that under simulated in vivo conditions, UCP is active and suggest that UCP may influence not only mitochondrial ROS production but also tricarboxylic acid cycle flux.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Sweetlove, LJ (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	lee.sweetlove@plants.ox.ac.uk		Ratcliffe, R. George/0000-0001-8394-1575	Biotechnology and Biological Sciences Research Council [JF16984] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aubert S, 2001, J EXP BOT, V52, P37, DOI 10.1093/jexbot/52.354.37; Brand M. D., 1995, BIOENERGETICS, V154, P62; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Brandalise M, 2003, PLANT SCI, V165, P329, DOI 10.1016/S0168-9452(03)00159-6; Brandalise M, 2003, J BIOENERG BIOMEMBR, V35, P203, DOI 10.1023/A:1024603530043; Calegario FF, 2003, J BIOENERG BIOMEMBR, V35, P211, DOI 10.1023/A:1024655514113; Considine MJ, 2003, J BIOL CHEM, V278, P22298, DOI 10.1074/jbc.M301075200; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Fernie AR, 2004, CURR OPIN PLANT BIOL, V7, P254, DOI 10.1016/j.pbi.2004.03.007; FOX GG, 1989, J MAGN RESON, V82, P360, DOI 10.1016/0022-2364(89)90039-5; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Heazlewood JL, 2003, PLANT PHYSIOL, V132, P230, DOI 10.1104/pp.102.018986; Hourton-Cabassa U, 2004, PLANT PHYSIOL BIOCH, V42, P283, DOI 10.1016/j.plaphy.2004.01.007; Jenner HL, 2001, PLANT PHYSIOL, V126, P1139, DOI 10.1104/pp.126.3.1139; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Picault N, 2004, TRENDS PLANT SCI, V9, P138, DOI 10.1016/j.tplants.2004.01.007; Rasmusson AG, 2004, ANNU REV PLANT BIOL, V55, P23, DOI 10.1146/annurev.arplant.55.031903.141720; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Schwender J, 2003, J BIOL CHEM, V278, P29442, DOI 10.1074/jbc.M303432200; Sluse FE, 2002, FEBS LETT, V510, P117, DOI 10.1016/S0014-5793(01)03229-X; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Thimm O, 2004, PLANT J, V37, P914, DOI 10.1111/j.1365-313X.2004.02016.x; Trono D, 2004, PLANT CELL ENVIRON, V27, P437, DOI 10.1111/j.1365-3040.2003.01162.x; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643	31	121	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51944	51952		10.1074/jbc.M408920200	http://dx.doi.org/10.1074/jbc.M408920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456782	hybrid			2022-12-27	WOS:000225493400029
J	Yu, WF; Liang, XQ; Ensenauer, RE; Vockley, J; Sweetman, L; Schulz, H				Yu, WF; Liang, XQ; Ensenauer, RE; Vockley, J; Sweetman, L; Schulz, H			Leaky beta-oxidation of a trans-fatty acid - Incomplete beta-oxidation of elaidic acid is due to the accumulation of 5-trans-tetradecenoyl-CoA and its hydrolysis and conversion to 5-trans-tetradecenoylcarnitine in the matrix of rat mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; HEART-MITOCHONDRIA; LIVER MITOCHONDRIA; METABOLISM; PURIFICATION; ACYLATION; FAMILY; ENZYME; ESTERS	The degradation of elaidic acid (9-trans-octadecenoic acid), oleic acid, and stearic acid by rat mitochondria was studied to determine whether the presence of a trans double bond in place of a cis double bond or no double bond affects beta-oxidation. Rat mitochondria from liver or heart effectively degraded the coenzyme A derivatives of all three fatty acids. However, with elaidoyl-CoA as a substrate, a major metabolite accumulated in the mitochondrial matrix. This metabolite was isolated and identified as 5-trans-tetradecenoyl-CoA. In contrast, little or none of the corresponding metabolites were detected with oleoyl-CoA or stearoyl-CoA as substrates. A kinetic study of long-chain acyl-CoA dehydrogenase (LCAD) and very long-chain acyl-CoA dehydrogenase revealed that 5-trans-tetradecenoyl-CoA is a poorer substrate of LCAD than is 5-cis-tetradecenoyl-CoA, while both unsaturated acyl-CoAs are poor substrates of very long-chain acyl-CoA dehydrogenase when compared with myristoyl-CoA. Tetradecenoic acid and tetradecenoylcarnitine were detected by gas chromatography/ mass spectrometry and tandem mass spectrometry, respectively, when rat liver mitochondria were incubated with elaidoyl-CoA but not when oleoyl-CoA was the substrate. These observations support the conclusion that 5-trans-tetradecenoyl-CoA accumulates in the mitochondrial matrix, because it is less efficiently dehydrogenated by LCAD than is its cis isomer and that the accumulation of this beta-oxidation intermediate facilitates its hydrolysis and conversion to 5-trans-tetradecenoylcarnitine thereby permitting a partially degraded fatty acid to escape from mitochondria. Analysis of this compromised but functional process provides insight into the operation of beta-oxidation in intact mitochondria.	CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Ctr, New York, NY 10031 USA; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX 75226 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System; Mayo Clinic; Baylor University; Baylor University Medical Center	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.	hoschu@sci.ccny.cuny.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1998, T FATTY ACIDS HUMAN, P235; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIGSCHMIDT MC, 1998, T FATTY ACIDS HUMAN, P59; DAVIDSON B, 1982, ARCH BIOCHEM BIOPHYS, V213, P155, DOI 10.1016/0003-9861(82)90450-7; DeMar JC, 1999, PROG LIPID RES, V38, P49, DOI 10.1016/S0163-7827(98)00020-4; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; IZAI K, 1992, J BIOL CHEM, V267, P1027; KLER RS, 1991, J BIOL CHEM, V266, P22932; LAWSON LD, 1979, LIPIDS, V14, P501, DOI 10.1007/BF02533469; Le WP, 2000, BBA-MOL CELL BIOL L, V1485, P121, DOI 10.1016/S1388-1981(00)00034-2; Liang X, 2001, BIOCHEM SOC T, V29, P279, DOI 10.1042/BST0290279; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Lindwasser OW, 2002, P NATL ACAD SCI USA, V99, P13037, DOI 10.1073/pnas.212409999; LINESTEAD RP, 1931, J CHEM SOC, P740; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOORE KH, 1982, J MOL CELL CARDIOL, V14, P451, DOI 10.1016/0022-2828(82)90151-1; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; NEDERGAARD MM, 1979, METHOD ENZYMOL, V69, P390; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Rashed MS, 1997, CLIN CHEM, V43, P1129; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; THORPE C, 1986, ANAL BIOCHEM, V155, P391, DOI 10.1016/0003-2697(86)90452-5; Ventura FV, 1998, EUR J BIOCHEM, V253, P614, DOI 10.1046/j.1432-1327.1998.2530614.x; WILLEBRA.AF, 1966, BIOCHIM BIOPHYS ACTA, V116, P583, DOI 10.1016/0005-2760(66)90130-5; Zhang DY, 2001, J BIOL CHEM, V276, P13622, DOI 10.1074/jbc.M011315200	30	23	25	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52160	52167		10.1074/jbc.M409640200	http://dx.doi.org/10.1074/jbc.M409640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466478	hybrid			2022-12-27	WOS:000225493400055
J	Zzaman, S; Reddy, JM; Bastia, D				Zzaman, S; Reddy, JM; Bastia, D			The DnaK-DnaJ-GrpE chaperone system activates inert wild type pi initiator protein of R6K into a form active in replication initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PLASMID R6K; MOLECULAR CHAPERONE; IN-VITRO; SPECIFICITY COMPONENT; NUCLEOTIDE-SEQUENCE; NEGATIVE CONTROL; BINDING-SITES; ORIGIN-GAMMA	The plasmid R6K is an interesting model system for investigating initiation of DNA replication, not only near the primary binding sites of the initiator protein pi but also at a distance, caused by pi-mediated DNA looping. An important milestone in the mechanistic analysis of this replicon was the development of a reconstituted replication system consisting of 22 different highly purified proteins (Abhyankar, M. A., Zzaman, S., and Bastia, D. ( 2003) J. Biol. Chem. 278, 45476 - 45484). Although the in vitro reconstituted system promotes ori gamma-specific initiation of replication by a mutant form of the initiator called pi*, the wild type (WT) pi is functionally inert in this system. Here we show that the chaperone DnaK along with its co-chaperone DnaJ and the nucleotide exchange factor GrpE were needed to activate WTpi and caused it to initiate replication in vitro at the correct origin. We show further that the reaction was relatively chaperone-specific and that other chaperones, such as ClpB and ClpX, were incapable of activating WTpi. The molecular mechanism of activation appeared to be a chaperone-catalyzed facilitation of dimeric inert WT pi into iteron-bound monomers. Protein-protein interaction analysis by enzyme-linked immunosorbent assay revealed that, in the absence of ATP, DnaJ directly interacted with pi but its binary interactions with DnaK and GrpE and with ClpB and ClpX were at background levels, suggesting that pi is recruited by protein-protein interaction with DnaJ and then fed into the DnaK chaperone machine to promote initiator activation.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	bastia@musc.edu						Abhyankar MM, 2004, J BIOL CHEM, V279, P6711, DOI 10.1074/jbc.M312052200; Abhyankar MM, 2003, J BIOL CHEM, V278, P45476, DOI 10.1074/jbc.M308516200; ALFANO C, 1989, J BIOL CHEM, V264, P10709; BASTIA D, 1981, GENE, V14, P81, DOI 10.1016/0378-1119(81)90150-5; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chattoraj D K, 1995, Genet Eng (N Y), V17, P81; Chattoraj DK, 1996, GENES CELLS, V1, P189, DOI 10.1046/j.1365-2443.1996.d01-235.x; Chattoraj DK, 1997, PROG NUCLEIC ACID RE, V57, P145, DOI 10.1016/S0079-6603(08)60280-9; CROSA JH, 1978, J MOL BIOL, V124, P443, DOI 10.1016/0022-2836(78)90181-X; CROSA JH, 1980, J BIOL CHEM, V255, P1075; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; Dibbens JA, 1997, MOL MICROBIOL, V26, P185, DOI 10.1046/j.1365-2958.1997.5691920.x; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; HUPP TR, 1993, J BIOL CHEM, V268, P13143; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KAWASAKI Y, 1992, J BIOL CHEM, V267, P11520; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KELLEY WL, 1992, NEW BIOL, V4, P569; KELLEY WL, 1992, P NATL ACAD SCI USA, V89, P5078, DOI 10.1073/pnas.89.11.5078; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; Konieczny I, 1999, GENET ENG P, V21, P95; LOVETT MA, 1975, P NATL ACAD SCI USA, V72, P2905, DOI 10.1073/pnas.72.8.2905; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; Park K, 2001, EMBO J, V20, P7323, DOI 10.1093/emboj/20.24.7323; PARK SK, 1993, J BIOL CHEM, V268, P20170; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SHON M, 1982, J BIOL CHEM, V257, P13823; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; Zylicz M, 2001, IUBMB LIFE, V51, P283; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; Zzaman S, 2004, J BIOL CHEM, V279, P17404, DOI 10.1074/jbc.M400021200	64	19	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50886	50894		10.1074/jbc.M407531200	http://dx.doi.org/10.1074/jbc.M407531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485812	hybrid			2022-12-27	WOS:000225355800031
J	Yin, L				Yin, L			Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY PROTEIN 1-ALPHA; MULTIPLE-MYELOMA; BONE DESTRUCTION; NOTCH; FRINGE; ACTIVATION; MODEL; GLYCOSYLTRANSFERASE; MICROENVIRONMENT; PROTEOGLYCANS	There is a symbiotic relationship between continued growth and proliferation of myeloma cells and the bone destructive process. It has been shown in animal models that blocking bone destruction can result in decreased myeloma tumor burden. Osteoclasts are bone destroying cells found in the bone marrow, and their significance in myeloma is supported by recent findings that osteoclasts alone can support sustained survival and proliferation of purified primary myeloma cells in ex vivo co-cultures. However, molecular mechanisms associated with interactions between myeloma cells and osteoclasts remain unclear. Here, we show that when myeloma plasma cells are co-cultured with osteoclasts, chondroitin synthase 1 (CHSY1) is the most significantly altered soluble, secreted protein present in the conditioned medium. RNA interference experiments with CHSY1 small interfering RNA ( siRNA) reduced the amount of CHSY1 in the co-culture conditioned medium, and this was associated with a 6.25-fold increase in apoptotic myeloma cells over control co-cultures. CHSY1 contains a Fringe domain, and Fringe is well known for its regulation of Notch signaling via its DDD motif. And interestingly, Fringe domain in CHSY1 has this DDD motif. Shortly after co-culture with osteoclasts, we found that the Notch2 receptor was activated in myeloma cells but Notch1 was not. Activation of Notch2 was down-regulated by CHSY1 siRNA treatment. Modulating Notch signaling by CHSY1 via its DDD motif provides new insight into mechanisms of the interactions between myeloma cells and their bone marrow microenvironment. Targeting this interaction could shed light on treatment of myeloma, which is currently incurable.	Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Yin, L (corresponding author), 1 Canton Rd,Mailbox 035, Quincy, MA 02171 USA.	larryyin888@yahoo.com						Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593; Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116; Choi SJ, 2000, BLOOD, V96, P671; Dhodapkar MV, 1998, BRIT J HAEMATOL, V103, P530, DOI 10.1046/j.1365-2141.1998.00976.x; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Grigorieva I, 1998, EXP HEMATOL, V26, P597; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; HARDIN J, 1994, BLOOD, V84, P3063; Hussein MA, 2002, CURR OPIN ONCOL, V14, P31, DOI 10.1097/00001622-200201000-00006; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Koch U, 2003, SEMIN IMMUNOL, V15, P99, DOI 10.1016/S1044-5323(03)00006-X; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood-2003-06-1992; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Mustonen T, 2002, DEV BIOL, V248, P281, DOI 10.1006/dbio.2002.0734; Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood-2003-07-2340; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood-2002-12-3905; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365-2141.2002.03257.x; Yaccoby S, 1999, BLOOD, V94, P3576, DOI 10.1182/blood.V94.10.3576.422k01_3576_3582; Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008-5472.CAN-03-1131; Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913	37	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15666	15672		10.1074/jbc.M409877200	http://dx.doi.org/10.1074/jbc.M409877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15485809	hybrid			2022-12-27	WOS:000228444800027
J	Soboleva, TA; Jans, DA; Johnson-Saliba, M; Baker, RT				Soboleva, TA; Jans, DA; Johnson-Saliba, M; Baker, RT			Nuclear-cytoplasmic shuttling of the oncogenic mouse UNP/USP4 deubiquitylating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-SPECIFIC PROTEASE; FUNCTIONAL-CHARACTERIZATION; LOCALIZATION SEQUENCE; UNP; EXPORT; EXPRESSION; ENCODES; BINDING; IMPORT; CELLS	The oncogenic deubiquitylating enzyme (DUB) Unp/Usp4, which binds to the retinoblastoma family of tumor suppressor proteins, was originally described as a nuclear protein. However, more recent studies have shown it to be cytoplasmic. In addition, analysis of its subcellular localization has been complicated by the existence of the paralog Usp15. In this study, we resolved this controversy by investigating the localization of exogenously expressed Usp4 ( using red fluorescent protein-Usp4) and of endogenous Usp4 (using highly specific antibodies that can distinguish Usp4 from Usp15). We found that by inhibiting nuclear export with leptomycin B, both exogenous and endogenous Usp4 accumulate in the nucleus. Further, using a Rev-green fluorescent protein-based export assay, we confirmed the existence of a nuclear export signal ((VEVYLLELKL142)-V-133) in Usp4. In addition, a functional nuclear import signal ((766)QPQKKKK(772)) was also identified, which was specifically recognized by importin alpha/beta. Finally, we show that the equilibrium of Usp4 subcellular localization varies between different cell types. Usp4 is thus the first DUB reported to have nucleocytoplasmic shuttling properties. The implications of this shuttling for its function as a DUB are discussed.	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Nucl Signalling Lab, Canberra, ACT 0200, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Australian National University; John Curtin School of Medical Research; Monash University	Baker, RT (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Nucl Signalling Lab, Canberra, ACT 0200, Australia.	Rohan.Baker@anu.edu.au	; Soboleva, Tatiana A/O-3110-2018	Jans, David/0000-0001-5115-4745; Soboleva, Tatiana A/0000-0003-0391-8530				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Angelats C, 2003, MAMM GENOME, V14, P31, DOI 10.1007/s00335-002-3035-0; Baker RT, 2000, MOL B INT U, V12, P236; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Blanchette P, 2001, ONCOGENE, V20, P5533, DOI 10.1038/sj.onc.1204823; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gilchrist CA, 2000, BBA-PROTEIN STRUCT M, V1481, P297, DOI 10.1016/S0167-4838(00)00134-5; Gilchrist CA, 1997, J BIOL CHEM, V272, P32280, DOI 10.1074/jbc.272.51.32280; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jiang H, 2000, ONCOGENE, V19, P3878, DOI 10.1038/sj.onc.1203722; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NISHI K, 1994, J BIOL CHEM, V269, P6320; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Park KC, 2000, BIOCHEM J, V349, P443, DOI 10.1042/0264-6021:3490443; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soboleva TA, 2004, CURR PROTEIN PEPT SC, V5, P191, DOI 10.2174/1389203043379765; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Zhu YA, 1997, J BIOL CHEM, V272, P51	46	37	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					745	752		10.1074/jbc.M401394200	http://dx.doi.org/10.1074/jbc.M401394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494318	hybrid			2022-12-27	WOS:000226025100088
J	de Melker, AA; van der Horst, G; Borst, J				de Melker, AA; van der Horst, G; Borst, J			Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTORS; ENDOCYTIC PATHWAY; TYROSINE KINASES; PLASMA-MEMBRANE; RING FINGER; MEDIATED ENDOCYTOSIS; INTERACTING MOTIF; DOWN-REGULATION; BINDING DOMAIN; CELL BIOLOGY	We have demonstrated previously that c-Cbl requires the presence of a functional ubiquitin interacting motif (UIM) in Eps15 to mediate epidermal growth factor receptor ( EGFR) endocytosis. Both the ubiquitin ligase activity of c-Cbl and the UIM of Eps15 were necessary for plasma membrane recruitment of Eps15 and entry of ligand-bound EGFR into coated pits and vesicles containing Eps15. This is consistent with a scenario in which ubiquitin moieties appended to activated EGFR complexes act as docking sites for Eps15 and thereby recruit receptors into clathrin coated pits. Here, we have investigated which additional structural features of c-Cbl are required for this process. We find that c-Cbl can guide ligand-bound EGFR into the Eps15 internalization route by two distinct mechanisms. These are either dependent on the phosphotyrosine binding domain of c-Cbl that directly binds to the EGFR or on the region C-terminal of the Ring finger, which allows for indirect binding to an alternative site on the receptor. No strict requirement exists for either ubiquitin modified EGFR or the Cbl binding ubiquitination substrate CIN85 as docking site for the UIM of Eps15. Only in the phosphotyrosine binding-dependent pathway, the EGFR is ubiquitinated and may serve as a site of recruitment for Eps15. Only in this pathway, Eps15 is tyrosine-phosphorylated, but this appears unrelated to its capacity to participate in EGFR internalization.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Borst, Jan Willem/B-1259-2011					Belleudi F, 2003, FEBS LETT, V553, P262, DOI 10.1016/S0014-5793(03)01020-2; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; BLAKE TJ, 1991, ONCOGENE, V6, P653; Carbone R, 1997, CANCER RES, V57, P5498; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; de Melker AA, 2004, J CELL SCI, V117, P5001, DOI 10.1242/jcs.01354; de Melker AA, 2001, J CELL SCI, V114, P2167; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Morgan JR, 2003, J BIOL CHEM, V278, P33583, DOI 10.1074/jbc.M304346200; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Riezman H, 2002, NATURE, V416, P381, DOI 10.1038/416381a; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sorkina T, 1999, J CELL SCI, V112, P317; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	63	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55465	55473		10.1074/jbc.M409765200	http://dx.doi.org/10.1074/jbc.M409765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15465819	hybrid			2022-12-27	WOS:000225960800061
J	Pathak, SK; Bhattacharyya, A; Pathak, S; Basak, C; Mandal, D; Kundu, M; Basu, J				Pathak, SK; Bhattacharyya, A; Pathak, S; Basak, C; Mandal, D; Kundu, M; Basu, J			Toll-like receptor 2 and mitogen- and stress-activated kinase 1 are effectors of mycobacterium avium-induced cyclooxygenase-2 expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-FACTOR; GENE-EXPRESSION; SYNTHASE-2 GENE; PHORBOL ESTER; C/EBP-DELTA; MAP KINASE; LIPOPOLYSACCHARIDE	Understanding how pathogenic mycobacteria subvert the protective immune response is crucial to the development of strategies aimed at controlling mycobacterial infections. Prostaglandin E-2 exerts an immunosuppressive function in the context of mycobacterial infection. Because cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in prostaglandin biosynthesis, there is a need to delineate the mechanisms through which pathogenic mycobacteria regulate COX-2 expression in macrophages. Our studies demonstrate that the NF-kappaB and CRE elements of the COX-2 promoter are critical to Mycobacterium avium-induced COX-2 gene expression. M. avium-triggered signaling originates at the Toll-like receptor 2 (TLR2). Ras associates with TLR2 and activates the mitogen-activated protein kinase ( MAPK) extracellular signal-regulated kinase (ERK), whereas tumor necrosis factor receptor-associated factor 6 (TRAF6)/transforming growth factor beta-activated kinase 1 (TAK1)-dependent signaling activates p38 MAPK. Both ERK and p38 MAPK activation converge to regulate the activation of mitogen- and stress-activated kinase 1 (MSK1). MSK1 mediates the phosphorylation of the transcription factor CREB accounting for its stimulatory effect on CRE-dependent gene expression. M. avium-triggered cytoplasmic NF-kappaB activation following IkappaB phosphorylation is necessary but not sufficient for COX-2 promoter-driven gene expression. MSK1 activation is also essential for M. avium-triggered NF-kappaB-dependent gene expression, presumably mediating nucleosomal modifications. These studies demonstrate that the nuclear kinase MSK1 is necessary in regulating the pathogen-driven expression of a gene by controlling two transcription factors. The attenuation of MSK1 may therefore have potential benefit in restricting survival of pathogenic mycobacteria in macrophages.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Kundu, M (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.	manikuntala@vsnl.net; joyoti@vsnl.com	mandal, debabrata/AAF-6690-2019; PATHAK, SHRESH/I-6938-2012	PATHAK, SHRESH/0000-0001-5275-1816; Bhattacharyya, Asima/0000-0001-7292-6644				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Basu J, 2004, CURR SCI INDIA, V86, P103; Bhattacharyya A, 2002, FEMS IMMUNOL MED MIC, V34, P73, DOI 10.1111/j.1574-695X.2002.tb00605.x; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Chen CC, 1999, MOL PHARMACOL, V55, P481; Chen G, 1999, LIFE SCI, V64, P1231, DOI 10.1016/S0024-3205(99)00055-7; CHEN JD, 1997, MOL PHARM, V59, P493; CHOUAIB S, 1985, J IMMUNOL, V135, P1172; DAVIE JR, 2003, SCI STKE; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giri DK, 1998, J IMMUNOL, V161, P4834; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; HASLER F, 1983, J IMMUNOL, V131, P768; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moreno JM, 2002, IMMUNOLOGY, V106, P257, DOI 10.1046/j.1365-2567.2002.01403.x; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; RIDGWAY D, 1991, J CLIN IMMUNOL, V11, P357, DOI 10.1007/BF00918801; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tse HM, 2002, J IMMUNOL, V168, P825, DOI 10.4049/jimmunol.168.2.825; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wittinghofer F, 1998, NATURE, V394, P317, DOI 10.1038/28492; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	41	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55127	55136		10.1074/jbc.M409885200	http://dx.doi.org/10.1074/jbc.M409885200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496409	hybrid			2022-12-27	WOS:000225960800019
J	Ridsdale, R; Tseu, I; Roth-Kleiner, M; Wang, JX; Post, M				Ridsdale, R; Tseu, I; Roth-Kleiner, M; Wang, JX; Post, M			Increased phosphatidylcholine production but disrupted glycogen metabolism in fetal type II cells of mice that overexpress CTP : Phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; LUNG SURFACTANT; SP-B; PULMONARY SURFACTANT; GENE-EXPRESSION; MOUSE LUNG; IDENTIFICATION; PROTEIN; PHOSPHORYLATION; DOMAIN	CTP:phosphocholine cytidylyltransferase (CCT) is a rate-determining enzyme in the de novo synthesis of phosphatidylcholine (PtdCho). Alveolar type II cells synthesize large quantities of disaturated PtdCho, the surface-active agent of pulmonary surfactant, particularly at late gestation when the lung prepares itself for postnatal air breathing. To clarify the role of CCTalpha in lung surfactant maturation, we overexpressed CCTalpha(1-367) using the surfactant protein-C promoter. Lungs of transgenic mice were analyzed at day 18 of gestation (term=19 days). Overexpression of CCTalpha(1-367) increased the synthesis and content of PtdCho in fetal type II cells isolated from the transgenic mice. Also, PtdCho content of fetal lung fluid was increased. No changes in surfactant protein content were detected. Interestingly, fetal type II cells of transgenic mice contained more glycogen than control cells. Incorporation studies with [U-C-14] glucose demonstrated that overexpression of CCTalpha(1-367) in fetal type II cells increased glycogen synthesis without affecting glycogen breakdown. To determine which domain contributes to this glycogen phenotype, two additional transgenes were created overexpressing either CCTalpha(1-239) or CCTalpha(239-367). Glycogen synthesis and content were increased in fetal type II cells expressing CCTalpha(239-367) but not CCTalpha(1-239). We conclude that overexpression of CCTalpha increases surfactant PtdCho synthesis without affecting surfactant protein levels but that it disrupts glycogen metabolism in differentiating type II cells via its regulatory domain.	Univ Toronto, Hosp Sick Children, Res Inst, Canadian Inst Hlth Res Grp Lung Dev,Div Lung Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Post, M (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst, Canadian Inst Hlth Res Grp Lung Dev,Div Lung Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	martin.post@sickkids.ca						Bernhard W, 2001, AM J RESP CELL MOL, V25, P725, DOI 10.1165/ajrcmb.25.6.4616; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURBON JR, 1982, BIOCHIM BIOPHYS ACTA, V712, P382, DOI 10.1016/0005-2760(82)90356-3; BREHIER A, 1981, EXP LUNG RES, V2, P273, DOI 10.3109/01902148109052323; Buettner R, 2004, AM J PHYSIOL-ENDOC M, V286, pE828, DOI 10.1152/ajpendo.00453.2003; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; CARLSON KS, 1987, PEDIATR RES, V22, P79, DOI 10.1203/00006450-198707000-00018; Clement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643, DOI 10.1006/bbrc.1999.0512; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; FARRELL PM, 1986, BIOCHIM BIOPHYS ACTA, V878, P159, DOI 10.1016/0005-2760(86)90142-6; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; Helmink BA, 2003, BIOCHEMISTRY-US, V42, P5043, DOI 10.1021/bi027431+; Hogan B, 1994, MANIPULATING MOUSE E; HOGAN M, 1994, AM J PHYSIOL, V267, pL25, DOI 10.1152/ajplung.1994.267.1.L25; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Ikegami M, 2000, J APPL PHYSIOL, V89, P644, DOI 10.1152/jappl.2000.89.2.644; Ikegami M, 1997, AM J PHYSIOL-LUNG C, V272, pL479, DOI 10.1152/ajplung.1997.272.3.L479; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Li JL, 2002, AM J RESP CELL MOL, V26, P709, DOI 10.1165/ajrcmb.26.6.4720; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Melton KR, 2003, AM J PHYSIOL-LUNG C, V285, pL543, DOI 10.1152/ajplung.00011.2003; POST M, 1980, BIOCHIM BIOPHYS ACTA, V618, P308, DOI 10.1016/0005-2760(80)90037-5; Post M, 1992, PULMONARY SURFACTANT, P379; Postle AD, 2001, COMP BIOCHEM PHYS A, V129, P65, DOI 10.1016/S1095-6433(01)00306-3; Ridsdale R, 2004, AM J PHYSIOL-LUNG C, V287, pL743, DOI 10.1152/ajplung.00146.2004; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; RINAUDO MT, 1981, INT J BIOCHEM, V13, P511; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; SEIFTER S, 1950, ARCH BIOCHEM, V25, P191; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; ZIMMERMANN LJ, 1993, AM J PHYSIOL, V264, pL575, DOI 10.1152/ajplung.1993.264.6.L575	49	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55946	55957		10.1074/jbc.M407670200	http://dx.doi.org/10.1074/jbc.M407670200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498769	hybrid			2022-12-27	WOS:000225960800118
J	Yamauchi, K; Nishimura, Y; Shigematsu, S; Takeuchi, Y; Nakamura, J; Aizawa, T; Hashizume, K				Yamauchi, K; Nishimura, Y; Shigematsu, S; Takeuchi, Y; Nakamura, J; Aizawa, T; Hashizume, K			Vascular endothelial cell growth factor attenuates actions of transforming growth factor-beta in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS IN-VITRO; SIGNAL-TRANSDUCTION; ACTIVATION; FAMILY; SMAD3; PHOSPHORYLATION; COMPLICATIONS; PROMOTER; MEDIATOR; RECEPTOR	Because vascular endothelial cell growth factor (VEGF) and transforming growth factor-alpha (TGF-beta) are both involved in cellular growth and differentiation, we examined whether VEGF modifies TGF-beta signaling cascade in human umbilical cord vein endothelial cells (HUVEC). Production of plasminogen activator inhibitor-1 (PAI-1), which is under the specific control of TGF-beta, was strongly enhanced (3.5-fold) by TGF-beta treatment. Remarkably, physiological concentration of VEGF (30 nM) profoundly (by 60%) attenuated the TGF-beta stimulation of PAI-1 production without an effect on the basal PAI-1 production. In HUVECs transiently transfected with an expression construct containing a PAI-1 promoter fused to luciferase reporter gene, TGF-beta-stimulation of transcription of PAI-1 was clearly (by 60%) inhibited by VEGF. TGF-beta phosphorylation of Smad2/3, an obligatory step of intracellular TGF-beta signaling, was also suppressed by VEGF. VEGF attenuation of TGF-beta action was also demonstrated in two other endothelial cell lines. In conclusion, VEGF attenuates TGF-beta action in the human endothelial cell, specifically at the level of transcription of PAI-1 gene and Smad2/3 phosphorylation.	Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, Matsumoto, Nagano 3908621, Japan	Shinshu University	Yamauchi, K (corresponding author), Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	keishi@hsp.md.shinshu-u.ac.jp						Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Chiarelli F, 2000, HORM RES, V53, P53, DOI 10.1159/000023515; Cohen AW, 1999, AM J PHYSIOL-HEART C, V277, pH2038, DOI 10.1152/ajpheart.1999.277.5.H2038; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Gambaro G, 1998, CRIT REV CL LAB SCI, V35, P117, DOI 10.1080/10408369891234174; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; KLASSEN KJ, 1993, CORONARY ARTERY DIS, V4, P713, DOI 10.1097/00019501-199308000-00007; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; MIKHAIL N, 1993, J CARDIOVASC PHARM, V22, pS64; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Pfeiffer A, 1997, DIABETES, V46, pS26, DOI 10.2337/diab.46.2.S26; PFEIFFER A, 1995, EXP CLIN ENDOCR DIAB, V103, P7, DOI 10.1055/s-0029-1211323; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zochodne DW, 1996, SEMIN NEUROL, V16, P153, DOI 10.1055/s-2008-1040971	29	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55104	55108		10.1074/jbc.M407423200	http://dx.doi.org/10.1074/jbc.M407423200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494412	hybrid			2022-12-27	WOS:000225960800016
J	Yang, YZ; Cao, JS; Shi, YG				Yang, YZ; Cao, JS; Shi, YG			Identification and characterization of a gene encoding human LPGAT1, an endoplasmic reticulum-associated lysophosphatidylglycerol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BARTH-SYNDROME; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; ANTIPHOSPHOLIPID SYNDROME; CARDIOLIPIN BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; SPECIES PATTERN; LUNG SURFACTANT; II CELLS; MUTANT	Phosphatidylglycerol (PG) is an important membrane polyglycerolphospholipid required for the activity of a variety of enzymes and is a precursor for synthesis of cardiolipin and bis(monoacylglycerol) phosphate. PG is subjected to remodeling subsequent to its de novo biosynthesis to incorporate appropriate acyl content for its biological functions and to prevent the harmful effect of lysophosphatidylglycerol (LPG) accumulation. The enzymes involved in the remodeling process have not yet been identified. We report here the identification and characterization of a human gene encoding an acyl-CoA: lysophosphatidylglycerol acyltransferase (LPGAT1). Expression of the LPGAT1 cDNA in Sf9 insect and COS-7 cells led to a significant increase in LPG acyltransferase activity. In contrast, no significant acyltransferase activities were detected against glycerol 3-phosphate or a variety of lysophospholipids, including lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylinositol, and lysophosphatidylserine. The recombinant human LPGAT1 enzyme recognized various acyl-CoAs and LPGs as substrates but demonstrated clear preference to long chain saturated fatty acyl-CoAs and oleoyl-CoA as acyl donors, which is consistent with the lipid composition of endogenous PGs identified from different tissues. Kinetic analyses of LPGAT1 expressed in COS-7 cells showed that oleoyl-LPG was preferred over palmitoyl-LPG as an acyl receptor, whereas oleoyl-CoA was preferred over lauroyl-CoA as an acyl donor. Consistent with its proposed microsomal origin, LPGAT1 was localized to the endoplasmic reticulum by subcellular fractionation and immunohistochemical analyses. Northern blot analysis indicated that the human LPGAT1 was widely distributed, suggesting a dynamic functional role of the enzyme in different tissues.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, DC 0545, Indianapolis, IN 46285 USA.	shi_yuguang@lilly.com						AKESSON B, 1970, BIOCHIM BIOPHYS ACTA, V218, P57, DOI 10.1016/0005-2760(70)90092-5; AMIDON B, 1995, BIOCHEMISTRY-US, V34, P5554, DOI 10.1021/bi00016a029; Berger A, 1993, Adv Food Nutr Res, V37, P259, DOI 10.1016/S1043-4526(08)60118-7; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Cheng P, 1996, BBA-LIPID LIPID MET, V1302, P61, DOI 10.1016/0005-2760(96)00012-4; Choy PC, 1997, BBA-LIPID LIPID MET, V1348, P124, DOI 10.1016/S0005-2760(97)00114-8; CHOY PC, 1992, METHOD ENZYMOL, V209, P80; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; FUNKHOUSER JD, 1981, BIOCHIM BIOPHYS ACTA, V666, P1, DOI 10.1016/0005-2760(81)90084-9; GREENFIELD D, 2001, NETW MAG, V16, P18; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HALLMAN M, 1975, BIOCHIM BIOPHYS ACTA, V409, P172, DOI 10.1016/0005-2760(75)90152-6; HALLMAN M, 1976, AM J OBSTET GYNECOL, V125, P613, DOI 10.1016/0002-9378(76)90782-1; HATCH GM, 1995, BIOCHEM J, V306, P759, DOI 10.1042/bj3060759; Heravi J, 1999, BBA-MOL CELL BIOL L, V1437, P277, DOI 10.1016/S1388-1981(99)00021-9; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Ma BJ, 1999, J LIPID RES, V40, P1837; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; MAN RYK, 1983, LIFE SCI, V32, P1325, DOI 10.1016/0024-3205(83)90806-8; MASON RJ, 1980, J BIOL CHEM, V255, P5101; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; OKANO G, 1979, LIPIDS, V14, P541, DOI 10.1007/BF02533529; Rand JH, 2003, ANNU REV MED, V54, P409, DOI 10.1146/annurev.med.54.101601.152412; ROONEY SA, 1975, J LIPID RES, V16, P418; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; SANDERS RL, 1975, BIOCHEMISTRY-US, V14, P835, DOI 10.1021/bi00675a030; SANFORD GL, 1983, BIOCHEM BIOPH RES CO, V116, P23, DOI 10.1016/0006-291X(83)90375-3; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015; SCHLAME M, 1986, BIOCHEM J, V240, P247, DOI 10.1042/bj2400247; SCHLAME M, 1988, BIOCHEM J, V253, P209, DOI 10.1042/bj2530209; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; Taylor WA, 2003, J BIOL CHEM, V278, P12716, DOI 10.1074/jbc.M210329200; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; THORNBURG T, 1991, J BIOL CHEM, V266, P6834; Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174; VANCURA A, 1994, J BIOL CHEM, V269, P27209; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; WITTELS B, 1973, J BIOL CHEM, V248, P2906; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	52	73	77	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55866	55874		10.1074/jbc.M406710200	http://dx.doi.org/10.1074/jbc.M406710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485873	hybrid			2022-12-27	WOS:000225960800110
J	Ananthanarayanan, M; Li, SD; Balasubramaniyan, N; Suchy, FJ; Walsh, MJ				Ananthanarayanan, M; Li, SD; Balasubramaniyan, N; Suchy, FJ; Walsh, MJ			Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; PROTEIN METHYLTRANSFERASE; COACTIVATOR; CHROMATIN; GENE; ACID; ENHANCEMENT; ACETYLATION; REQUIREMENT; MODULATION	In this study we demonstrate that the class II nuclear hormone receptor, farnesoid X-receptor (FXR), incorporates histone methyltransferase activity within the gene locus for bile salt export pump (BSEP), a well established FXR target gene that functions as an ATP-dependent canalicular bile acid transporter. This methyltransferase activity is directed specifically to arginine 17 of histone H3. We demonstrate that FXR is directly associated with (c) under baro-activator- (a) under bar ssociated (a) under bar rginine (m) under bar ethyltransferase 1 (CARM1) activity. Furthermore, we show by chromatin immunoprecipitation that the ligand-dependent activation of the human BSEP locus is associated with a simultaneous increase of FXR and CARM1 occupation. The increased occupation of the BSEP locus by CARM1 also corresponds with the increased deposition of Arg-17 methylation and Lys-9 acetylation of histone H3 within the FXR DNA-binding element of BSEP. Consistent with these findings, CARM1 led to increased BSEP promoter activity with an intact FXR regulatory element, whereas CARM1 failed to transactivate the BSEP promoter with a mutated FXRE. Induction of endogenous BSEP mRNA and Arg-17 methylation by FXR regulatory element ligand, CDCA, requires CARM1 activity. Therefore, histone methylation at Arg-17 by CARM1 is a downstream target of signaling through ligand-mediated activation of FXR. Our studies provide evidence that FXR directly recruits specific chromatin modifying activity of CARM1 necessary for full potentiation of the BSEP locus in vivo.	Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Pediat, New York, NY 10027 USA	Icahn School of Medicine at Mount Sinai	Ananthanarayanan, M (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Pediat, Box 1664,1 Gustave L Levy Pl, New York, NY 10027 USA.	meena.ananth@mssm.edu; martin.walsh@mssm.edu			NHLBI NIH HHS [HL67099] Funding Source: Medline; NICHD NIH HHS [HD20632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Grant PA, 2001, GENOME BIOL, V2; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; Redinger RN, 2003, AM J SURG, V185, P168, DOI 10.1016/S0002-9610(02)01212-6; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Sedkov Y, 2003, NATURE, V426, P78, DOI 10.1038/nature02080; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Wagner M, 2003, GASTROENTEROLOGY, V125, P825, DOI 10.1016/S0016-5085(03)01068-0; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang LH, 2004, NAT MED, V10, P40, DOI 10.1038/nm969; Xu W, 2003, METHOD ENZYMOL, V364, P205; Zollner G, 2003, J HEPATOL, V39, P480, DOI 10.1016/S0168-8278(03)00228-9	37	57	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54348	54357		10.1074/jbc.M410021200	http://dx.doi.org/10.1074/jbc.M410021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471871	hybrid			2022-12-27	WOS:000225793600057
J	Culina, S; Lauvau, G; Gubler, B; van Endert, PM				Culina, S; Lauvau, G; Gubler, B; van Endert, PM			Calreticulin promotes folding of functional human leukocyte antigen class I molecules in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CYTOTOXIC T-LYMPHOCYTES; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; QUALITY-CONTROL; HEAVY-CHAINS; LOADING COMPLEX; CELL-LINE; CALNEXIN	The assembly of MHC class I molecules with beta(2)-microglobulin and peptides is assisted by the housekeeping chaperones calnexin, calreticulin, and Erp57 and the dedicated accessory protein, tapasin. Tapasin and calreticulin are essential for efficient MHC class I assembly, but their precise action during class I assembly remains to be elucidated. Previous in vitro studies have demonstrated that the lectin calreticulin interacts with monoglucosylated MHC class I heavy chains, whatever their state of assembly with light chains and peptide, and inhibits their aggregation above physiological temperature. We used a soluble single chain HLA-A2/beta(2)-microglobulin molecule, A2SC, to study the effect of calreticulin on the peptide binding capacity of HLA class I molecules. Calreticulin inhibited the formation of A2SC aggregates both when co-expressed in insect cells and during incubations at elevated temperature. Calreticulin dramatically enhanced acquisition of peptide binding capacity when added to denatured A2SC molecules during refolding at 4degreesC. However, it had no effect on the rapid loss of A2SC peptide binding capacity at physiological temperature. We conclude that calreticulin promotes the folding of HLA class I molecules to a state in which, at low temperature, they spontaneously acquire peptide binding capacity. However, it does not induce or maintain a peptide-receptive state of the class I-binding site, which is likely to be promoted by one or several other components of the class I loading complexes. By being amenable to complementation with additional proteins, the described system should be useful for identification of these components.	Univ Paris 05, INSERM, U580, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	van Endert, PM (corresponding author), Univ Paris 05, INSERM, U580, 161 Rue Sevres, F-75015 Paris, France.	vanendert@necker.fr	van Endert, Peter/R-4606-2017; Gubler, Brigitte/D-9479-2018	van Endert, Peter/0000-0003-3782-0750; Culina, Slobodan/0000-0001-6461-6953				AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; Harris MR, 1998, J IMMUNOL, V160, P5404; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; Lauvau G, 1999, J BIOL CHEM, V274, P31349, DOI 10.1074/jbc.274.44.31349; Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200; Lee L, 1996, HUM IMMUNOL, V49, P28, DOI 10.1016/0198-8859(96)00056-0; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P11193, DOI 10.1021/bi010948l; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Lone YC, 1998, J IMMUNOTHER, V21, P283, DOI 10.1097/00002371-199807000-00006; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SCOTT JE, 1995, J IMMUNOL, V155, P143; SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1; Solheim JC, 1997, J IMMUNOL, V158, P2236; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Toshitani K, 1996, P NATL ACAD SCI USA, V93, P236, DOI 10.1073/pnas.93.1.236; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wearsch PA, 2004, J BIOL CHEM, V279, P25112, DOI 10.1074/jbc.M401721200; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8	41	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54210	54215		10.1074/jbc.M410841200	http://dx.doi.org/10.1074/jbc.M410841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494401	hybrid			2022-12-27	WOS:000225793600040
J	Harrell, JM; Murphy, PJM; Morishima, Y; Chen, HF; Mansfield, JF; Galigniana, MD; Pratt, WB				Harrell, JM; Murphy, PJM; Morishima, Y; Chen, HF; Mansfield, JF; Galigniana, MD; Pratt, WB			Evidence for glucocorticoid receptor transport on microtubules by dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; CYTOPLASMIC DYNEIN; IN-VIVO; HSP90-BINDING IMMUNOPHILINS; HSP90; BINDING; ASSOCIATION; MECHANISM; COMPLEX; FKBP52	Rapid, ligand-dependent movement of glucocorticoid receptors (GR) from cytoplasm to the nucleus is hsp90-dependent, and much of the movement system has been defined. GR.hsp90 heterocomplexes isolated from cells contain one of several hsp90-binding immunophilins that link the complex to cytoplasmic dynein, a molecular motor that processes along microtubular tracks to the nucleus. The immunophilins link to dynein indirectly via the dynamitin component of the dynein-associated dynactin complex (Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004) J. Biol. Chem. 279, 22483-22489). Although it is known that rapid, hsp90-dependent GR movement requires intact microtubules, it has not been shown that the movement is dynein-dependent. Here, we show that overexpression of dynamitin, which blocks movement by dissociating the dynein motor from its cargo, inhibits ligand-dependent movement of the GR to the nucleus. We show that native GR.hsp90.immnunophilin complexes contain dynamitin as well as dynein and that GR heterocomplexes isolated from cytosol containing paclitaxel and GTP to stabilize microtubules also contain tubulin. The complete movement system, including the dynein motor complex and tubulin, can be assembled under cell-free conditions by incubating GR immune pellets with paclitaxel/GTP-stabilized cytosol prepared from GR(-) L cells. This is the first evidence that the movement of a steroid receptor is dynein-dependent, and it is the first isolation of a steroid receptor bound to the entire system that determines its retrograde movement.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Engn, Univ Michigan N Campus Electron Microbeam Anal La, Ann Arbor, MI 48109 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol,Programa Regulac Hormonal & Metab, Consejo Nacl Invest Cient & Techn Argentina, Buenos Aires, DF, Argentina	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Harrell, JM (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3, Ann Arbor, MI 48109 USA.	harrellj@umich.edu	Chen, Haifeng/H-8438-2014	GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, P60DK020572, R37DK031573] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [P60DK-20572, DK31573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; BARSONY J, 1992, J BIOL CHEM, V267, P24457; Betley TA, 2001, LANGMUIR, V17, P2768, DOI 10.1021/la001297h; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 2004, MOL BRAIN RES, V123, P27, DOI 10.1016/j.molbrainres.2003.12.015; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P10879, DOI 10.1021/bi00159a031; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; Yang J, 1996, MOL ENDOCRINOL, V10, P3, DOI 10.1210/me.10.1.3; Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0	34	93	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54647	54654		10.1074/jbc.M406863200	http://dx.doi.org/10.1074/jbc.M406863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485845	Green Published, hybrid			2022-12-27	WOS:000225793600091
J	Hu, YM; Leo, C; Yu, S; Huang, BCB; Wang, H; Shen, M; Luo, Y; Daniel-Issakani, S; Payan, DG; Xu, X				Hu, YM; Leo, C; Yu, S; Huang, BCB; Wang, H; Shen, M; Luo, Y; Daniel-Issakani, S; Payan, DG; Xu, X			Identification and functional characterization of a novel human Misshapen/Nck interacting kinase-related kinase, hMINK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; MOLECULAR-CLONING; CELL-SURFACE; PATHWAY; NCK; ADAPTER; RECEPTOR; FAMILY	Misshapen/NIKs-related kinase (MINK) is a member of the germinal center family of kinases that are homologous to the yeast sterile 20 (Ste20) kinases and regulate a wide variety of cellular processes, including cell morphology, cytoskeletal rearrangement, and survival. Here, we present the cloning and functional characterization of a novel human Misshapen/NIKs-related kinase beta (hMINKbeta) that encodes a polypeptide of 1312 amino acids. hMINKbeta is ubiquitously expressed in most tissues with at least five alternatively spliced isoforms. Similar to Nck interacting kinase (NIK) and Traf2 and Nck-interacting kinase (TNIK), hMINKbeta moderately activates c-Jun N-terminal kinase (JNK) and associates with Nck via the intermediate domain in the yeast two-hybrid system and in a glutathione S-transferase (GST) pull-down assay. Interestingly, overexpression of the kinase domain deleted and kinase-inactive mutants of hMINKbeta in human fibrosarcoma HT1080 cells enhanced cell spreading, actin stress fiber formation, and adhesion to extracellular matrix, as well as decreased cell motility and cell invasion. Furthermore, these mutants also promoted cell-cell adhesion in human breast carcinoma MCF7 cells, evidenced with cell growth in clusters and increased membrane localization of beta-catenin, a multifunctional protein involved in E-cadherin-mediated cell adhesion. Finally, hMINKbeta protein was found to colocalize with the Golgi apparatus, implicating that hMINKbeta might exert its functions, at least in part, through the modulation of intracellular protein transport. Taken together, these results suggest that hMINKbeta plays an important role in cytoskeleton reorganization, cell adhesion, and cell motility.	Rigel Pharmaceut Inc, San Francisco, CA 94080 USA		Xu, X (corresponding author), Rigel Pharmaceut Inc, San Francisco, CA 94080 USA.	xxu@rigel.com						Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; Caplan S, 2001, J CELL BIOL, V154, P109, DOI 10.1083/jcb.200102142; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLIGAN JE, 1999, CURR PROTOCOLS IMM S, V31; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GRENZ H, 1993, J CELL SCI, V105, P739; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Machida N, 2004, J BIOL CHEM, V279, P15711, DOI 10.1074/jbc.C300542200; Paricio N, 1999, EMBO J, V18, P4669, DOI 10.1093/emboj/18.17.4669; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Poinat P, 2002, CURR BIOL, V12, P622, DOI 10.1016/S0960-9822(02)00764-9; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Qu KB, 2004, CURR MED CHEM, V11, P569, DOI 10.2174/0929867043455873; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Rivera GM, 2004, CURR BIOL, V14, P11, DOI 10.1016/j.cub.2003.12.033; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; Shi CS, 1999, J IMMUNOL, V163, P3279; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Su YC, 2000, MOL CELL BIOL, V20, P4736, DOI 10.1128/MCB.20.13.4736-4744.2000; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Xue YZ, 2001, DEVELOPMENT, V128, P1559; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	42	46	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54387	54397		10.1074/jbc.M404497200	http://dx.doi.org/10.1074/jbc.M404497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15469942	hybrid			2022-12-27	WOS:000225793600061
J	Jiang, HB; Jiang, Q; Feng, J				Jiang, HB; Jiang, Q; Feng, J			Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; INDUCED APOPTOSIS; DISEASE; DEGRADATION; AGGRESOMES; STRESS; GLYCOSYLATION; INHIBITION; MUTATIONS; BINDING	Mutations of parkin, a protein-ubiquitin E3 ligase, are linked to Parkinson's disease (PD). Although a variety of parkin substrates have been identified, none of these is selectively expressed in dopaminergic neurons, whose degeneration plays a critical role in PD. Here we show that parkin significantly increased dopamine uptake in the human dopaminergic neuroblastoma cell line SH-SY5Y. This effect was accompanied by increased V-max of dopamine uptake and unchanged K-m. Consistent with this, increased binding sites for dopamine transporter (DAT) ligand were observed in SH-SY5Y cells overexpressing parkin. The results were confirmed when parkin was transfected in HEK293 cells stably expressing DAT. In these cells, parkin enhanced the ubiquitination and degradation of DAT, increased its cell surface expression, and augmented dopamine uptake. The effects of parkin were significantly abrogated by its PD-causing mutations. Because the cell surface expression of functional DAT requires its oligomerization, misfolded DAT, induced either by the protein glycosylation inhibitor tunicamycin or by its C-terminal truncation, significantly attenuated cell surface expression of native DAT and reduced dopamine uptake. Expression of parkin, but not its T240R mutant, significantly alleviated these detrimental effects of misfolded DAT. Thus, our studies suggest that parkin increases dopamine uptake by enhancing the ubiquitination and degradation of misfolded DAT, so as to prevent it from interfering with the oligomerization and cell surface expression of native DAT. This function of parkin would enhance the precision of dopaminergic transmission, increase the efficiency of dopamine utilization, and reduce dopamine toxicity on neighboring cells.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu			AHRQ HHS [HS41722] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; Feng Jian, 2003, Current Neuropharmacology, V1, P301, DOI 10.2174/1570159033477053; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hersch SM, 1997, J COMP NEUROL, V388, P211; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; JENNER P, 1996, NEUROLOGY S3, V47, P161; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Muqit MMK, 2004, HUM MOL GENET, V13, P117, DOI 10.1093/hmg/ddh012; PATEL A, 1993, J NEUROCHEM, V61, P496; Ren Y, 2003, J NEUROSCI, V23, P3316; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	35	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54380	54386		10.1074/jbc.M409282200	http://dx.doi.org/10.1074/jbc.M409282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492001	hybrid			2022-12-27	WOS:000225793600060
J	Pearce, AC; Senis, YA; Billadeau, DD; Turner, M; Watson, SP; Vigorito, E				Pearce, AC; Senis, YA; Billadeau, DD; Turner, M; Watson, SP; Vigorito, E			Vav1 and Vav3 have critical but redundant roles in mediating platelet activation by collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; EXCHANGE FACTOR VAV; TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; DIFFERENTIAL REQUIREMENT; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; GLYCOPROTEIN-VI; DEFICIENT MICE; FAMILY	Vav family proteins are guanine nucleotide exchange factors for the Rho/Rac family of small GTP-binding proteins. In addition, they have domains that mediate protein-protein interactions, including one Src homology 2 (SH2) and two Src homology 3 (SH3) domains. Vav1, Vav2, and Vav3 play a crucial role in the regulation of phospholipase Cgamma (PLCgamma) isoforms by immuno-tyrosine-based activation motif (ITAM)-coupled receptors, including the T- and B-cell antigen receptors. We have reported in platelets, however, that Vav1 and Vav2 are not required for activation of PLCgamma2 in response to stimulation of the ITAM-coupled collagen receptor glycoprotein VI (GPVI). Here we report that Vav3 is tyrosine-phosphorylated upon activation of GPVI but that Vav3-deficient platelets also exhibit a normal response upon activation of the ITAM receptor. In sharp contrast, platelets deficient in both Vav1 and Vav3 show a marked inhibition of aggregation and spreading upon activation of GPVI, which is associated with a reduction in tyrosine phosphorylation of PLCgamma2. The phenotype of Vav1/2/3 triple-deficient platelets is similar to that of Vav1/3 double-deficient cells. These results demonstrate that Vav3 and Vav1 play crucial but redundant roles in the activation of PLCgamma2 by GPVI. This is the first time that absolute redundancy between two protein isoforms has been observed with respect to the regulation of PLCgamma2 in platelets.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Babraham Inst, Lab Lymphocyte Signalling & Dev, Mol Immunol Programme, Cambridge CB2 4AT, England; Mayo Clin, Dept Immunol, Mayo Grad Sch, Rochester, MN 55905 USA; Univ Birmingham, Ctr Cardiovasc Studies, Inst Biomed Res, Div Med Sci, Birmingham B15 2TT, W Midlands, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Mayo Clinic; University of Birmingham	Pearce, AC (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	a.c.pearce@bham.ac.uk	Senis, Yotis/AAD-7183-2021; Watson, Stephen P/Q-6292-2016; Turner, Martin/N-9976-2014	Watson, Stephen P/0000-0002-7846-7423; Turner, Martin/0000-0002-3801-9896; Senis, Yotis/0000-0002-0947-9957	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000M050] Funding Source: Medline; Medical Research Council [G117/424] Funding Source: Medline; MRC [G117/424] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; Atkinson BT, 2003, BLOOD, V102, P3592, DOI 10.1182/blood-2003-04-1142; Best D, 2003, BLOOD, V102, P2811, DOI 10.1182/blood-2003-01-0231; Billadeau DD, 2000, J EXP MED, V192, P381, DOI 10.1084/jem.192.3.381; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Judd BA, 2001, ONCOGENE, V20, P6291, DOI 10.1038/sj.onc.1204772; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Mangin P, 2003, FEBS LETT, V542, P53, DOI 10.1016/S0014-5793(03)00337-5; Movilla N, 1999, MOL CELL BIOL, V19, P7870; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Pearce AC, 2003, BLOOD, V102, p208A; Pearce AC, 2002, BLOOD, V100, P3561, DOI 10.1182/blood.V100.10.3561; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 2000, BLOOD, V96, P4246; Reynolds LF, 2004, J BIOL CHEM, V279, P18239, DOI 10.1074/jbc.M400257200; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Suzuki-Inoue K, 2003, BLOOD, V102, P1367, DOI 10.1182/blood-2003-01-0029; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WENG WK, 1994, J BIOL CHEM, V269, P32514	40	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53955	53962		10.1074/jbc.M410355200	http://dx.doi.org/10.1074/jbc.M410355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15456756	hybrid			2022-12-27	WOS:000225793600009
J	Carter, S; Urbe, S; Clague, MJ				Carter, S; Urbe, S; Clague, MJ			The Met receptor degradation pathway - Requirement for Lys(48)-linked polyubiquitin independent of proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; UBIQUITIN-BINDING; HUMAN CANCER; DYNAMICS; PROTEINS; MUTATION; ENDOCYTOSIS; EXPRESSION; TRANSPORT	Acute stimulation of the receptor for the hepatocyte growth factor/scatter factor Met leads to receptor ubiquitination and down-regulation through the lysosomal degradation pathway. We have determined that the Met receptor undergoes multiple monoubiquitination as opposed to the appendage of polyubiquitin chains. Nevertheless, overexpression of ubiquitin in HEK293T cells enhances the rate of Met receptor degradation, in contrast to a point mutant of ubiquitin (K48R) that cannot form Lys(48)-linked polyubiquitin chains. Furthermore, an enhancement of Met degradation is also seen under conditions where the proteasome is inhibited by lactacystin. We propose that this reflects polyubiquitin-dependent sorting of Met, as the overexpression of ubiquitin but not K48R ubiquitin also restores hepatocyte growth factor-dependent phosphorylation of the endosomal coat protein Hrs from inhibition by lactacystin. Our data indicate a requirement for K48-R-linked polyubiquitin for Met endosomal trafficking independent of its canonical function of targeting for proteasomal degradation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Clague, MJ (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	clague@liv.ac.uk	Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; Urbe, Sylvie/0000-0003-4735-9814				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; HAAS AL, 1987, J BIOL CHEM, V262, P345; Haddad R, 2001, ANTICANCER RES, V21, P4243; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2004, CURR TOP MICROBIOL, V286, P21; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; POLO S, 2003, SCI STKE; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Tsirigotis M, 2001, J BIOL CHEM, V276, P46073, DOI 10.1074/jbc.M109023200; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169	31	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52835	52839		10.1074/jbc.M407769200	http://dx.doi.org/10.1074/jbc.M407769200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466866	hybrid			2022-12-27	WOS:000225680600007
J	Gu, LB; Zhu, NX; Findley, HW; Woods, WG; Xhou, MX				Gu, LB; Zhu, NX; Findley, HW; Woods, WG; Xhou, MX			Identification and characterization of the IKK alpha promoter - Positive and negative regulation by ETS-1 and p53, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; ACUTE LYMPHOBLASTIC-LEUKEMIA; INDUCED APOPTOSIS; GENE-EXPRESSION; DNA-BINDING; KINASE-ALPHA; TRANSCRIPTIONAL REPRESSION	IKKalpha, a subunit of IkBalpha kinase (IKK) complex, has an important role in the activation of nuclear factor-kB (NF-kB), a key regulator of normal and tumor cell proliferation, apoptosis, and response to chemotherapy. However, little is known about the transcriptional regulation of the IKKalpha gene itself. The present study revealed that the transcriptional induction of the IKKalpha gene is positively regulated by binding ETS-1, the protein product of the ETS-1 proto-oncogene. Furthermore, ETS-1 mediated activation of IKKalpha is negatively regulated by p53 binding to ETS-1. By analyzing the genomic DNA sequence, we identified the putative IKKalpha promoter sequence in the 5'-flanking untranslated region of the IKKalpha gene. Transfection of EU-4, an acute lymphoblastic leukemia (ALL) cell line, with plasmids containing the IKKalpha 5'-untranslated region sequence upstream of the luciferase reporter showed that this region possessed major promoter activity. Induction or enforced overexpression of p53 represses IKKalpha mRNA and protein expression as well as IKKalpha promoter activity. Deletion and mutation analyses as well as chromatin immunoprecipitation and electrophoretic mobility shift assay indicated that ETS-1 binds to the core IKKalpha promoter and strongly induces its activity. Although p53 does not directly bind to the IKKalpha promoter, it physically interacts with ETS-1 and specifically inhibits ETS-1-induced IKKalpha promoter activity. These results suggest that the proximal 5'-flanking region of the IKKalpha gene contains a functional promoter reciprocally regulated by p53 and ETS-1. Furthermore, loss of p53-mediated control over ETS-1-dependent transactivation of IKKalpha may represent a novel pathway for the constitutive activation of NF-kB-mediated gene expression and therapy resistance in cancer.	Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, Atlanta, GA 30322 USA	Emory University	Xhou, MX (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	mzhou@emory.edu			NCI NIH HHS [R01 CA82323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FISHER RJ, 1991, ONCOGENE, V6, P2249; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Post A, 1998, J NEUROSCI, V18, P8236; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	52	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52141	52149		10.1074/jbc.M407915200	http://dx.doi.org/10.1074/jbc.M407915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469934	hybrid			2022-12-27	WOS:000225493400053
J	Lee, CY; Bai, HB; Houle, R; Wilson, GM; Lu, AL				Lee, CY; Bai, HB; Houle, R; Wilson, GM; Lu, AL			An Escherichia coli MutY mutant without the six-helix barrel domain is a dimer in solution and assembles cooperatively into multisubunit complexes with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; MISMATCH REPAIR; STRUCTURAL BASIS; DAMAGED BASE; GLYCOSYLASE; ADENINE; 8-OXOGUANINE; RECOGNITION; SPECIFICITY; MUTAGENESIS	Escherichia coli MutY is an adenine and weak guanine DNA glycosylase involved in reducing the mutagenic effects of 7,8-dihydro-8-oxoguanine (GO). MutY contains three structural domains: an iron-sulfur module, a six-helix barrel module with the helix-hairpin-helix motif, and a C-terminal domain. Here, we demonstrate that the mutant MutY(Delta26-134), which lacks the six-helix barrel domain, cannot complement the mutator phenotype of a mutY mutant in vivo. However, the mutant can still bind DNA and has weak catalytic activity at high enzyme concentrations. The mutant is a dimer in solution and assembled into two and multiple (up to five) complexes with 20- and 44-bp DNA fragments, respectively, in a concentration-dependent manner. Higher order complexes with DNA substrates containing A/GO mismatches were formed at lower protein concentrations than with the A/G mismatch and homoduplex DNA. Measurement of equilibrium binding using fluorescence anisotropy showed that the mutant protein retains some specificity for A/GO-containing DNA substrates and that the binding event is highly cooperative. This is consistent with the MutY structure determined, which indicates that GO specificity is contributed by both the six-helix barrel and C-terminal domains. The nonspecific binding of MutY(Delta26-134) to DNA suggests a model in which the specific binding of mismatched DNA by MutY involves sequential interactions, in which one MutY molecule scans the DNA and enhances binding of another MutY molecule to the A/GO mismatch.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Combined PhD Program Biochem, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluorescence Sepct, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	aluchang@umaryland.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [CA102428] Funding Source: Medline; NCRR NIH HHS [P41 RR 08119] Funding Source: Medline; NIGMS NIH HHS [GM35132] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102428, R56CA102428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuer W, 2001, ANAL BIOCHEM, V299, P194, DOI 10.1006/abio.2001.5378; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Dandliker W B, 1981, Methods Enzymol, V74 Pt C, P3; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Li L, 2003, NUCLEIC ACIDS RES, V31, P3038, DOI 10.1093/nar/gkg434; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Lu AL, 2003, BIOCHEMISTRY-US, V42, P3742, DOI 10.1021/bi0269198; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; Lu AL, 2000, METH MOL B, V152, P3; Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL, P216; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Wong I, 2003, J BIOL CHEM, V278, P2411, DOI 10.1074/jbc.M209802200; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669; Zhao JY, 2000, J BACTERIOL, V182, P5025, DOI 10.1128/JB.182.17.5025-5028.2000; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 2000, BIOCHEMISTRY-US, V39, P14768, DOI 10.1021/bi001538k	53	13	14	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52653	52663		10.1074/jbc.M405271200	http://dx.doi.org/10.1074/jbc.M405271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456766	hybrid			2022-12-27	WOS:000225493400112
J	Ouhammouch, M; Werner, F; Weinzierl, ROJ; Geiduschek, EP				Ouhammouch, M; Werner, F; Weinzierl, ROJ; Geiduschek, EP			A fully recombinant system for activator-dependent archaeal transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TFIIE-ALPHA; INITIATION; SUBUNIT; DOMAIN; RECOGNITION; PROTEIN	The core components of the archaeal transcription apparatus closely resemble those of eukaryotic RNA polymerase II, while the DNA-binding transcriptional regulators are predominantly of bacterial type. Here we report the construction of an entirely recombinant system for positively regulated archaeal transcription. By omitting individual subunits, or sets of subunits, from the in vitro assembly of the 12-subunit RNA polymerase from the hyperthermophile Methanocaldococcus jannaschii, we describe a functional dissection of this RNA polymerase II-like enzyme, and its interactions with the general transcription factor TFE, as well as with the transcriptional activator Ptr2.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	University of California System; University of California San Diego; University of California System; University of California San Diego; Imperial College London	Ouhammouch, M (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	mouham@biomail.ucsd.edu		Werner, Finn/0000-0002-3930-3821				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Ouhammouch M, 2004, CURR OPIN GENET DEV, V14, P133, DOI 10.1016/j.gde.2004.01.002; Ouhammouch M, 2003, P NATL ACAD SCI USA, V100, P5097, DOI 10.1073/pnas.0837150100; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9	19	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51719	51721		10.1074/jbc.C400446200	http://dx.doi.org/10.1074/jbc.C400446200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15485836	hybrid			2022-12-27	WOS:000225493400002
J	Pacheco-Alvarez, D; Solorzano-Vargas, RS; Gravel, RA; Cervantes-Roldan, R; Velazquez, A; Leon-Del-Rio, A				Pacheco-Alvarez, D; Solorzano-Vargas, RS; Gravel, RA; Cervantes-Roldan, R; Velazquez, A; Leon-Del-Rio, A			Paradoxical regulation of biotin utilization in brain and liver and implications for inherited multiple carboxylase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; HOLOCARBOXYLASE SYNTHETASE; PYRUVATE-CARBOXYLASE; MESSENGER-RNA; FUNCTIONAL EXPRESSION; GUANYLATE-CYCLASE; RAT-LIVER; BIOTINYLATION; CELLS; GLUCOKINASE	Holocarboxylase synthetase (HCS) catalyzes the biotinylation of five carboxylases in human cells, and mutations of HCS cause multiple carboxylase deficiency (MCD). Although HCS also participates in the regulation of its own mRNA levels, the relevance of this mechanism to normal metabolism or to the MCD phenotype is not known. In this study, we show that mRNA levels of enzymes involved in biotin utilization, including HCS, are down-regulated during biotin deficiency in liver while remaining constitutively expressed in brain. We propose that this mechanism of regulation is aimed at sparing the essential function of biotin in the brain at the expense of organs such as liver and kidney during biotin deprivation. In MCD, it is possible that some of the manifestations of the disease may be associated with down-regulation of biotin utilization in liver because of the impaired activity of HCS and that high dose biotin therapy may in part be important to overcoming the adverse regulatory impact in such organs.	Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Mexico City 04510, DF, Mexico; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Unidad Genet Nutr, Mexico City 04530, DF, Mexico	Universidad Nacional Autonoma de Mexico; University of Calgary; Universidad Nacional Autonoma de Mexico	Leon-Del-Rio, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Mexico City 04510, DF, Mexico.	leon@biomedicas.unam.mx	Solorzano-Vargas, R Sergio/D-4869-2016; Leon-Del-Rio, Alfonso/L-5932-2019	Leon-Del-Rio, Alfonso/0000-0001-7683-5109; Pacheco-Alvarez, Diana/0000-0001-5454-9267				Balamurugan K, 2003, AM J PHYSIOL-GASTR L, V285, pG73, DOI 10.1152/ajpgi.00059.2003; BHAGAVAN HN, 1970, J NEUROCHEM, V17, P289, DOI 10.1111/j.1471-4159.1970.tb02213.x; Borboni P, 1996, ACTA DIABETOL, V33, P154; BOWERSKOMRO DM, 1984, NUTR REV, V42, P360; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CHIANG GS, 1974, P SOC EXP BIOL MED, V146, P21, DOI 10.3181/00379727-146-38035; COLLINS JC, 1988, J BIOL CHEM, V263, P11280; DAKSHINAMURTI K, 1970, CAN J BIOCHEM CELL B, V48, P493, DOI 10.1139/o70-079; Das UG, 1999, AM J PHYSIOL-REG I, V276, pR809, DOI 10.1152/ajpregu.1999.276.3.R809; De la Vega LA, 2000, AM J PHYSIOL-CELL PH, V279, pC2037, DOI 10.1152/ajpcell.2000.279.6.C2037; DEODHAR AD, 1970, LIFE SCI 2-BIOCH GEN, V9, P581, DOI 10.1016/0024-3205(70)90166-9; Dupuis L, 1999, MOL GENET METAB, V66, P80, DOI 10.1006/mgme.1998.2785; Hassel B, 2000, MOL NEUROBIOL, V22, P21, DOI 10.1385/MN:22:1-3:021; HYMES J, 1995, BIOCHEM MOL MED, V56, P76, DOI 10.1006/bmme.1995.1059; Hymes J, 1996, CLIN CHIM ACTA, V255, P1, DOI 10.1016/0009-8981(96)06396-6; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LO W, 1991, J NUTR SCI VITAMINOL, V37, P567, DOI 10.3177/jnsv.37.567; Maeda Y, 1996, J NUTR, V126, P61, DOI 10.1093/jn/126.1.61; Morita J, 1998, MOL GENET METAB, V64, P250, DOI 10.1006/mgme.1998.2700; NARANG MA, 2003, HUM MOL GENET; Pacheco-Alvarez D, 2002, ARCH MED RES, V33, P439, DOI 10.1016/S0188-4409(02)00399-5; PETRELLI F, 1978, MOL BIOL REP, V4, P87, DOI 10.1007/BF00775966; Prasad PD, 1999, ARCH BIOCHEM BIOPHYS, V366, P95, DOI 10.1006/abbi.1999.1213; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; Rodriguez-Melendez R, 2001, J NUTR, V131, P1909, DOI 10.1093/jn/131.7.1909; Rodriguez-Melendez R, 1999, MOL GENET METAB, V66, P16, DOI 10.1006/mgme.1998.2777; RODRIGUEZPOMBO P, 1992, J NEUROCHEM, V58, P1460, DOI 10.1111/j.1471-4159.1992.tb11364.x; Salto R, 1999, MOL CELL BIOCHEM, V200, P111, DOI 10.1023/A:1007091116952; SANDER JE, 1982, NEUROLOGY, V32, P878, DOI 10.1212/WNL.32.8.878; SINGH IN, 1988, MOL CELL BIOCHEM, V79, P47, DOI 10.1007/BF00229397; Solorzano-Vargas RS, 2002, P NATL ACAD SCI USA, V99, P5325, DOI 10.1073/pnas.082097699; SPENCE JT, 1984, J BIOL CHEM, V259, P6393; Stanley JS, 2001, EUR J BIOCHEM, V268, P5424, DOI 10.1046/j.0014-2956.2001.02481.x; Suormala T, 2002, INT J VITAM NUTR RES, V72, P278, DOI 10.1024/0300-9831.72.4.278; VESELY DL, 1982, SCIENCE, V216, P1329, DOI 10.1126/science.6123152; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; WEINER D, 1991, BIOCHEM MED METAB B, V46, P344, DOI 10.1016/0885-4505(91)90083-W; WOLF B, 1985, J INHERIT METAB DIS, V8, P53, DOI 10.1007/BF01800660; Wolf B., 2001, METABOLIC MOL BASES, V3935, P3962, DOI DOI 10.1097/MAO.0000000000002044; Zempleni J, 1999, ARCH BIOCHEM BIOPHYS, V371, P83, DOI 10.1006/abbi.1999.1431	43	33	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52312	52318		10.1074/jbc.M407056200	http://dx.doi.org/10.1074/jbc.M407056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456772	hybrid			2022-12-27	WOS:000225493400072
J	Peng, JM; Liang, SM; Liang, CM				Peng, JM; Liang, SM; Liang, CM			VP1 of foot-and-mouth disease virus induces apoptosis via the Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MUSCLE-CELLS; ACTIVATION; RECEPTOR; CANCER; ATTACHMENT; INHIBITION	Foot-and-mouth disease virus (FMDV) binds to cellular integrins through an RGD motif in its capsid protein, VP1. It is unclear, however, what kind of cellular event(s) are triggered after the binding of VP1 to the cells. In this study, we show that aqueous soluble recombinant DNA-derived VP1 (rVP1) of FMDV induced apoptosis of BHK-21 cells after binding to integrins. In addition, treatment of BHK-21 cells with rVP1 resulted in deactivation of Akt and enhancement of several proapoptotic responses such as dephosphorylation of glycogen synthase kinase-3beta and cleavage of procaspase-3, -7, and -9. Additional studies revealed that the rVP1 treatment caused apoptosis of cancer cells, including MCF-7 (a breast carcinoma cell line with a functional deletion of the caspase-3 gene) and PC-3 (a sphingosine 1-phosphate receptor subtype 3-deficient androgen-independent prostate cancer cell line). These results suggest that rVP1 of FMDV may be used selectively as a potent apoptotic agent for human cancer by modulating the Akt signaling pathway and that its effect is not primarily dependent on either activation of procaspase-3 or deactivation of sphingosine 1-phosphate receptor subtype 3.	Acad Sinica, Inst Bioagr Sci, Taipei 11529, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan	Liang, SM (corresponding author), Acad Sinica, Inst Bioagr Sci, No 128,Acad Rd,Sect 2, Taipei 11529, Taiwan.	smyang@gate.sinica.edu.tw; cmliang@gate.sinica.edu.tw		Liang, Shu-Mei/0000-0001-8926-4747				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje; BAXT B, 1984, J VIROL, V51, P298, DOI 10.1128/JVI.51.2.298-305.1984; Bayry J, 1999, MICROBIOL IMMUNOL, V43, P765, DOI 10.1111/j.1348-0421.1999.tb02468.x; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BELSHAM GJ, 1993, PROG BIOPHYS MOL BIO, V60, P241, DOI 10.1016/0079-6107(93)90016-D; Benetti L, 2003, J VIROL, V77, P6567, DOI 10.1128/JVI.77.11.6567-6573.2003; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson T, 2000, J GEN VIROL, V81, P1383, DOI 10.1099/0022-1317-81-5-1383; Jackson T, 2002, J VIROL, V76, P935, DOI 10.1128/JVI.76.3.935-941.2002; Jackson T, 2000, J VIROL, V74, P4949, DOI 10.1128/JVI.74.11.4949-4956.2000; Kiaris H, 1999, P SOC EXP BIOL MED, V221, P87, DOI 10.1046/j.1525-1373.1999.d01-59.x; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; Nishida K, 2004, J HISTOCHEM CYTOCHEM, V52, P843, DOI 10.1369/jhc.4C6315.2004; Patil PK, 2002, VACCINE, V20, P1163, DOI 10.1016/S0264-410X(01)00431-5; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Ruoslahti E, 2003, MATRIX BIOL, V22, P459, DOI 10.1016/S0945-053X(03)00083-0; SaCarvalho D, 1997, J VIROL, V71, P5115, DOI 10.1128/JVI.71.7.5115-5123.1997; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shieh JJ, 2001, VACCINE, V19, P4002, DOI 10.1016/S0264-410X(01)00114-1; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; Stoeltzing O, 2003, INT J CANCER, V104, P496, DOI 10.1002/ijc.10958; SUROVOI AY, 1988, SOVIET J BIOORG CHEM, V14, P965; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; Wang JH, 2003, VACCINE, V21, P3721, DOI 10.1016/S0264-410X(03)00363-3; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Woolhouse M, 2001, NATURE, V411, P258, DOI 10.1038/35077149; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; Zhang HFM, 2003, J BIOL CHEM, V278, P33011, DOI 10.1074/jbc.M305352200	56	43	55	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52168	52174		10.1074/jbc.M403686200	http://dx.doi.org/10.1074/jbc.M403686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466859	hybrid			2022-12-27	WOS:000225493400056
J	Trosky, JE; Mukherjee, S; Burdette, DL; Roberts, M; McCarter, L; Siegel, RM; Orth, K				Trosky, JE; Mukherjee, S; Burdette, DL; Roberts, M; McCarter, L; Siegel, RM; Orth, K			Inhibition of MAPK signaling pathways by VopA from Vibrio parahaemolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YERSINIA EFFECTOR YOPJ	During infection, bacterial pathogens utilize a type III secretion system to inject effectors into the cytoplasm of a target cell where they disrupt the defense system of the host cell. Vibrio parahaemolyticus, a causative agent of gastroenteritis endemic in Southeast Asia, has a type III secretion system that encodes a novel member of the YopJ-like protein effector family, VopA ( Vibrio outer protein A). Our studies revealed that Vibrio VopA encodes an evolutionarily conserved activity that is extremely potent and requires an intact catalytic site to abrogate signaling pathways in a manner distinct from that of other YopJ-like effectors. We observed that VopA efficiently inhibits the MAPK signaling pathways but not the NFkappaB pathway in mammalian cells. When expressed in yeast, VopA induces a growth arrest phenotype and also blocks yeast MAPK signaling pathways. Our observations provide insight into the immense diversity of targets utilized by YopJ-like effectors to manipulate eukaryotic signaling machineries that are important for the response and survival of the host cell during infection and/or symbiosis.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; NIAMS, Immunoregulat Unit, Autoimmun Branch, NIH, Bethesda, MD 20892 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Iowa	Orth, K (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd,Room NA5-320, Dallas, TX 75390 USA.	kimorth@hamon.swmed.edu	Dinalo, Jennifer/AAN-8708-2020; Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Dinalo, Jennifer/0000-0001-5174-5756	NIAID NIH HHS [Y2-AI-3739, AI056404] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akeda Y, 2002, INFECT IMMUN, V70, P970, DOI 10.1128/IAI.70.2.970-973.2002; BEG AA, 1996, SCIENCE, V274, P784; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; Hotson A, 2003, MOL MICROBIOL, V50, P377, DOI 10.1046/j.1365-2958.2003.03730.x; Makino K, 2003, LANCET, V361, P743, DOI 10.1016/S0140-6736(03)12659-1; McCarter Linda, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P51; NISHIBUCHI M, 1995, INFECT IMMUN, V63, P2093, DOI 10.1128/IAI.63.6.2093-2099.1995; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Prager R, 2003, J CLIN MICROBIOL, V41, P4270, DOI 10.1128/JCM.41.9.4270-4278.2003; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Sun J, 2004, AM J PHYSIOL-GASTR L, V287, pG220, DOI 10.1152/ajpgi.00498.2003; VAN AD, 1996, SCIENCE, V274, P787; Yoon S, 2003, J BIOL CHEM, V278, P2131, DOI 10.1074/jbc.M209905200	16	96	100	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51953	51957		10.1074/jbc.M407001200	http://dx.doi.org/10.1074/jbc.M407001200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459200	hybrid			2022-12-27	WOS:000225493400030
J	Choi, YB; Ko, JK; Shin, J				Choi, YB; Ko, JK; Shin, J			The transcriptional corepressor, PELP1, recruits HDAC2 and masks Histones using two separate domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; INTERACTING PROTEIN; CHROMATIN-STRUCTURE; ACETYLATION; DEACETYLASE; ACTIVATION; COMPLEXES; PHOSPHORYLATION; COOPERATION; REPRESSION	PELP1 (proline-, glutamic acid-, and leucine-rich protein 1) has been recognized as a coactivator of estrogen receptor (ER)-recruiting p300/CREB-binding protein histone acetyltransferase to the target chromosome. The present study shows that PELP1 does indeed coactivate ER-mediated transcription but also serves as a corepressor of other nuclear hormone receptors (NR)- and non-NR sequence-specific transcription factors tested, including GR, Nur77, AP1, NF-kappaB, and TCF/SRF. PELP1 expression also retarded the proliferation of mouse fibroblast cell lines in which there was no detectable ER. This was due, at least in part, to the suppressed activation of serum-response genes such as c-fos that in turn resulted from the blocked histone hyperacetylation of nucleosomes containing the c-fos promoter region. The N-terminal leucine-abundant region of PELP1 was observed to interact with HDAC2 and exhibited repressive activity when tethered to the chromatin. In addition, the C-terminal glutamic acid- abundant region bound to the hypoacetylated histones H3 and H4 and prevented them from becoming substrates of histone acetyltransferase. Thus PELP1 promotes and maintains the hypoacetylated state of histones at the target genomic site, and ER binding reverses its role to hyperacetylate histones through an as yet unidentified mechanism.	Sungkyunkwan Univ, Sch Med, Suwon 440746, Kyonggi Do, South Korea; Samsung Biomed Res Inst, Suwon 440746, Kyonggi Do, South Korea	Sungkyunkwan University (SKKU)	Shin, J (corresponding author), Sungkyunkwan Univ, Sch Med, Suwon 440746, Kyonggi Do, South Korea.	jkshin@med.skku.ac.kr	Choi, Young Bong/J-4317-2019	Choi, Young Bong/0000-0002-2523-1441				Ahmad A, 2003, BIOCHEM BIOPH RES CO, V312, P1266, DOI 10.1016/j.bbrc.2003.11.073; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Flores-Saaib RD, 2000, NUCLEIC ACIDS RES, V28, P4189, DOI 10.1093/nar/28.21.4189; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Sambrook J., 2001, MOL CLONING LAB MANU; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326	43	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50930	50941		10.1074/jbc.M406831200	http://dx.doi.org/10.1074/jbc.M406831200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456770	hybrid			2022-12-27	WOS:000225355800036
J	Vidali, M; Hidestrand, M; Eliasson, E; Mottaran, E; Reale, E; Rolla, R; Occhino, G; Albano, E; Ingelman-Sundberg, M				Vidali, M; Hidestrand, M; Eliasson, E; Mottaran, E; Reale, E; Rolla, R; Occhino, G; Albano, E; Ingelman-Sundberg, M			Use of molecular simulation for mapping conformational CYP2E1 epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM AUTOANTIBODIES; INDUCED AUTOIMMUNE HEPATITIS; HUMAN CYTOCHROME-P450 2E1; HALOTHANE HEPATITIS; ANTI-LIVER; ESCHERICHIA-COLI; ADDISONS-DISEASE; PLASMA-MEMBRANE; RAT HEPATOCYTES; ANTIBODIES	The identification of the epitopes recognized by autoantibodies against cytochrome P450s (CYPs) associated with drug-induced hepatotoxicity is difficult because of their conformational nature. In the present investigation, we used a novel approach based on the analysis of the whole molecule antigenic capacity following single amino acid substitutions to identify the conformational epitopes on CYP2E1. A molecular model of CYP2E1 was generated based on the CYP2C5 crystal structure, and potential motifs for amino acid exchanges were selected by computer simulation in the surface of alpha helices and beta sheets. Fourteen modified, apparently correctly folded CYP2E1 variants were produced in Escherichia coli and evaluated in immunoprecipitation experiments using sera with anti-CYP2E1 autoreactivity from 10 patients with halothane hepatitis and 12 patients with alcoholic liver disease. Ala substitution of Glu-248 and Lys-251 as well as of Lys-324, Lys-342, Lys-420, and Phe-421 severely decreased or abolished CYP2E1 recognition by the majority of both the halothane hepatitis and alcoholic liver disease sera, whereas the other substitutions had only minor effects. Based on the structural model, these substitutions identified two distinct epitopes on the CYP2E1 surface corresponding to the G-helix and an area formed by juxtaposition of the J' and K" helices, respectively. The combined use of molecular modeling and single amino acid mutagenesis is thus a useful approach for the characterization of conformational epitopes recognized by autoantibodies.	Univ Amedeo Avogadro E Piedmont, Dept Med Sci, I-28100 Novara, Italy; IRCAD, I-28100 Novara, Italy; Karolinska Inst, Inst Environm Med, Div Mol Toxicol, SE-17177 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Lab Sci, Div Clin Pharmacol, SE-14186 Huddinge, Sweden	University of Eastern Piedmont Amedeo Avogadro; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Albano, E (corresponding author), Univ Amedeo Avogadro E Piedmont, Dept Med Sci, Via Solaroli 17, I-28100 Novara, Italy.	albano@med.unipmn.it	Ingelman-Sundberg, Magnus/ABD-9302-2021; Roberta, Rolla/ABH-5361-2020; Albano, Emanuele/K-2580-2016; Vidali, Matteo/T-2621-2019	Roberta, Rolla/0000-0003-0805-8285; Albano, Emanuele/0000-0003-4738-7049; Vidali, Matteo/0000-0001-9991-7502; Eliasson, Erik/0000-0002-4707-4256				Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; Belloc C, 1997, PHARMACOGENETICS, V7, P181, DOI 10.1097/00008571-199706000-00002; Bourdi M, 1996, CHEM RES TOXICOL, V9, P1159, DOI 10.1021/tx960083q; BOURDI M, 1990, J CLIN INVEST, V85, P1967, DOI 10.1172/JCI114660; Clot P, 1997, GASTROENTEROLOGY, V113, P265, DOI 10.1016/S0016-5085(97)70104-5; DUCLOSVALLEE JC, 1995, GASTROENTEROLOGY, V108, P470, DOI 10.1016/0016-5085(95)90076-4; Eliasson E, 1996, MOL PHARMACOL, V50, P573; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KENNA JG, 1988, HEPATOLOGY, V8, P1635, DOI 10.1002/hep.1840080627; Kerkar N, 2003, J IMMUNOL, V170, P1481, DOI 10.4049/jimmunol.170.3.1481; Lecoeur S, 1996, MOL PHARMACOL, V50, P326; LEEDER JS, 1992, J PHARMACOL EXP THER, V263, P360; Leeder JS, 1996, MOL PHARMACOL, V49, P234; Lewis DFV, 2003, TOXICOL IN VITRO, V17, P93, DOI 10.1016/S0887-2333(02)00098-X; Lytton SD, 1999, MOL PHARMACOL, V55, P223, DOI 10.1124/mol.55.2.223; Lytton SD, 2002, CLIN EXP IMMUNOL, V127, P293, DOI 10.1046/j.1365-2249.2002.01754.x; Ma Y, 2002, J IMMUNOL, V169, P277, DOI 10.4049/jimmunol.169.1.277; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; Manns MP, 1997, HEPATOLOGY, V26, P1054; Neve EPA, 2003, BIOCHEMISTRY-US, V42, P14566, DOI 10.1021/bi035193s; Njorku DB, 2002, ANESTH ANALG, V94, P243; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ronis MJJ, 1996, CYTOCHROMES P450 MET, P211; SCHWEDE T, NUCL ACIDS RES, V31, P3381; SMITH GCM, 1993, LANCET, V342, P963, DOI 10.1016/0140-6736(93)92005-E; Stewart SF, 2004, J HEPATOL, V40, P176, DOI 10.1016/S0168-8278(04)90602-2; UIBO R, 1994, J CLIN ENDOCR METAB, V78, P323, DOI 10.1210/jc.78.2.323; Vidali M, 2003, HEPATOLOGY, V37, P410, DOI 10.1053/jhep.2003.50049; Williams D, 2000, PERFORM RES, V5, P131; WINQVIST O, 1993, J CLIN INVEST, V92, P2377, DOI 10.1172/JCI116843; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; YAMAMOTO AM, 1993, GASTROENTEROLOGY, V104, P1762, DOI 10.1016/0016-5085(93)90657-X	34	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50949	50955		10.1074/jbc.M407329200	http://dx.doi.org/10.1074/jbc.M407329200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456790	hybrid			2022-12-27	WOS:000225355800038
J	Wojciechowska, M; Bacolla, A; Larson, JE; Wells, RD				Wojciechowska, M; Bacolla, A; Larson, JE; Wells, RD			The myotonic dystrophy type 1 triplet repeat sequence induces gross deletions and qInversions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAK; ORIENTATION-DEPENDENT MANNER; TRANSCRIPTION-COUPLED REPAIR; REPLICATION IN-VIVO; B DNA CONFORMATIONS; ESCHERICHIA-COLI; HUMAN-DISEASE; STICKY DNA	The capacity of (CTG . CAG)(n) and (GAA . TTC)(n) repeat tracts in plasmids to induce mutations in DNA flanking regions was evaluated in Escherichia coli. Long repeats of these sequences are involved in the etiology of myotonic dystrophy type 1 and Friedreich's ataxia, respectively. Long (CTG . CAG)(n) (where n = 98 and 175) caused the deletion of most, or all, of the repeats and the flanking GFP gene. Deletions of 0.6 - 1.8 kbp were found as well as inversions. Shorter repeat tracts ( where n = 0 or 17) were essentially inert, as observed for the (GAA . TTC)(176)-containing plasmid. The orientation of the triplet repeat sequence (TRS) relative to the unidirectional origin of replication had a pronounced effect, signaling the participation of replication and/or repair systems. Also, when the TRS was transcribed, the level of deletions was greatly elevated. Under certain conditions, 30 - 50% of the products contained gross deletions. DNA sequence analyses of the breakpoint junctions in 47 deletions revealed the presence of 1-8-bp direct or inverted homologies in all cases. Also, the presence of non-B folded conformations (i.e. slipped structures, cruciforms, or triplexes) at or near the breakpoints was predicted in all cases. This genetic behavior, which was previously unrecognized for a TRS, may provide the basis for a new type of instability of the myotonic dystrophy protein kinase (DMPK) gene in patients with a full mutation.	Texas A&M Univ Syst Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	wojciechowska, marzena/H-4900-2014; Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NIEHS NIH HHS [ES11347] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Beletskii A, 2000, J MOL BIOL, V300, P1057, DOI 10.1006/jmbi.2000.3944; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Epstein HF, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P147; Feschenko VV, 2003, P NATL ACAD SCI USA, V100, P1134, DOI 10.1073/pnas.0233122100; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GACY AM, 1995, CELL, V81, P533; Gellibolian R, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P561; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hartenstine MJ, 2002, J BIOL CHEM, V277, P41379, DOI 10.1074/jbc.M207013200; Hebert ML, 2004, J MOL BIOL, V336, P655, DOI 10.1016/j.jmb.2003.12.038; HO C, 1993, J BACTERIOL, V175, P5411, DOI 10.1128/JB.175.17.5411-5419.1993; Iyer RR, 2000, J BIOL CHEM, V275, P2174, DOI 10.1074/jbc.275.3.2174; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 2000, IUBMB LIFE, V50, P355, DOI 10.1080/152165400300089358; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Krasilnikova MM, 1998, EMBO J, V17, P5095, DOI 10.1093/emboj/17.17.5095; Lahiri M, 2004, MOL CELL, V15, P287, DOI 10.1016/j.molcel.2004.06.034; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Liu L, 2002, MOL CELL BIOL, V22, P3852, DOI 10.1128/MCB.22.11.3852-3863.2002; Marcadier JL, 2003, J BIOL CHEM, V278, P33848, DOI 10.1074/jbc.M304284200; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Pluciennik A, 2000, J BIOL CHEM, V275, P28386, DOI 10.1074/jbc.M000154200; Rangarajan S, 1997, P NATL ACAD SCI USA, V94, P946, DOI 10.1073/pnas.94.3.946; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schumacher S, 2001, J MOL BIOL, V307, P39, DOI 10.1006/jmbi.2000.4489; SELBY CP, 1993, J BACTERIOL, V175, P7509, DOI 10.1128/JB.175.23.7509-7514.1993; Siianova E Iu, 2001, Mol Biol (Mosk), V35, P208; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden RR, 1998, ADV GENOM B, V5, P1; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; Trigueros S, 2001, J BIOL CHEM, V276, P2243, DOI 10.1074/jbc.M008930200; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vetcher AA, 2004, J BIOL CHEM, V279, P6434, DOI 10.1074/jbc.M309595200; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vilette D, 1996, MOL GEN GENET, V252, P398, DOI 10.1007/BF02173004; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; ZHONG N, 1995, AM J HUM GENET, V57, P351	76	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					941	952		10.1074/jbc.M410427200	http://dx.doi.org/10.1074/jbc.M410427200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15489504	hybrid			2022-12-27	WOS:000226195200013
J	Jin, TG; Kurakin, A; Benhaga, N; Abe, K; Mohseni, M; Sandra, F; Song, K; Kay, BK; Khosravi-Far, R				Jin, TG; Kurakin, A; Benhaga, N; Abe, K; Mohseni, M; Sandra, F; Song, K; Kay, BK; Khosravi-Far, R			Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FLICE-INHIBITORY PROTEINS; PROGRAMMED CELL-DEATH; LIGAND TRAIL; MOLECULAR-CLONING; INDUCED APOPTOSIS; TNF-FAMILY; FADD; CASPASE-8; ACTIVATION	Here we show a novel mechanism by which FLICE-like inhibitory protein (c-FLIP) regulates apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand ( TRAIL) and one of its receptors, DR5. c-FLIP is a critical regulator of the TNF family of cytokine receptor signaling. c-FLIP has been postulated to prevent formation of the competent death-inducing signaling complex ( DISC) in a ligand-dependent manner, through its interaction with FADD and/or caspase-8. In order to identify regulators of TRAIL function, we used the intracellular death domain ( DD) of DR5 as a target to screen a phage-displayed combinatorial peptide library. The DD of DR5 selected from the library a peptide that showed sequence similarity to a stretch of amino acids in the C terminus of c-FLIPL. The phage-displayed peptide selectively interacted with the DD of DR5 in in vitro binding assays. Similarly, full-length c-FLIP (c-FLIPL) and the C-terminal p12 domain of c-FLIP interacted with DR5 both in in vitro pull-down assays and in mammalian cells. This interaction was independent of TRAIL. To the contrary, TRAIL treatment released c-FLIPL from DR5, permitting the recruitment of FADD to the active DR5 signaling complex. By employing FADD-deficient Jurkat cells, we demonstrate that DR5 and c-FLIPL interact in a FADD-independent manner. Moreover, we show that a cellular membrane permeable version of the peptide corresponding to the DR5 binding domain of c-FLIP induces apoptosis in mammalian cells. Taken together, these findings indicate that c-FLIPL interacts with the DD of DR5, thus preventing death signaling by DR5 prior to the formation of an active DISC. Because TRAIL and DR5 are ubiquitously expressed, the interaction of c-FLIPL and DR5 indicates a mechanism by which tumor selective apoptosis can be achieved through protecting normal cells from undergoing death receptor-induced apoptosis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Buck Inst Age Res, Novato, CA 94945 USA; Argonne Natl Lab, Argonne, IL 60439 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Buck Institute for Research on Aging; United States Department of Energy (DOE); Argonne National Laboratory	Khosravi-Far, R (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 99 Brookline Ave,RN 270F, Boston, MA 02215 USA.	rkhosrav@bidmc.harvard.edu	Sandra, Ferry/AAN-9713-2020; Sandra, Ferry/M-9414-2015; Khosravi-Far, Roya/C-3789-2008	Sandra, Ferry/0000-0002-5852-1074; Sandra, Ferry/0000-0002-5852-1074; 	NATIONAL CANCER INSTITUTE [R55CA087675] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080192] Funding Source: NIH RePORTER; NCI NIH HHS [1R55 CA 87675, R55 CA087675-01A1] Funding Source: Medline; NHLBI NIH HHS [R01 HL080192-07, HL 080192, R01 HL080192] Funding Source: Medline; PHS HHS [T32 H 07893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe K, 2000, ANN NY ACAD SCI, V926, P52; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; ESPOSTI MD, 1999, J LEUKOCYTE BIOL, V65, P535; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Futaki S, 2003, CURR PROTEIN PEPT SC, V4, P87, DOI 10.2174/1389203033487261; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guo F, 2002, CANCER BIOL THER, V1, P528, DOI 10.4161/cbt.1.5.170; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kay BK, 2000, FEBS LETT, V480, P55, DOI 10.1016/S0014-5793(00)01778-6; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kurakin A, 1998, J PEPT RES, V52, P331; Leverkus M, 2000, CANCER RES, V60, P553; MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Meier P, 2003, NAT CELL BIOL, V5, P1035, DOI 10.1038/ncb1203-1035; Micheau O, 2003, EXPERT OPIN THER TAR, V7, P559, DOI 10.1517/eott.7.4.559.22500; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 2004, CURR CANCER DRUG TAR, V4, P97, DOI 10.2174/1568009043481597; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; SPARKS AB, 1995, METHOD ENZYMOL, V255, P498; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takada H, 2003, MOL CELL BIOL, V23, P4026, DOI 10.1128/MCB.23.11.4026-4033.2003; Takenobu T, 2002, MOL CANCER THER, V1, P1043; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yang XL, 2002, CANCER BIOL THER, V1, P407, DOI 10.4161/cbt.1.4.16; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	72	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55594	55601		10.1074/jbc.M401056200	http://dx.doi.org/10.1074/jbc.M401056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485835	Green Accepted, hybrid			2022-12-27	WOS:000225960800077
J	Lusetti, SL; Drees, JC; Stohl, EA; Seifert, HS; Cox, MM				Lusetti, SL; Drees, JC; Stohl, EA; Seifert, HS; Cox, MM			The DinI and RecX proteins are competing modulators of RecA function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; FILAMENTS; COMPLEXES; EXCHANGE; REPAIR; SSDNA; GENE; RECOMBINATION	The DinI and RecX proteins of Escherichia coli both modulate the function of RecA protein, but have very different effects. DinI protein stabilizes RecA filaments, preventing disassembly but permitting assembly. RecX protein blocks RecA filament extension, which can lead to net filament disassembly. We demonstrate that both proteins can interact with the RecA filament, and propose that each can replace the other. The DinI/RecX displacement reactions are slow, requiring multiple minutes even when a large excess of the challenging protein is present. The effects of RecX protein on RecA filaments are manifest at lower modulator concentrations than the effects of DinI protein. Together, the DinI and RecX proteins constitute a new regulatory network. The two proteins compete directly as mainly positive (DinI) and negative (RecX) modulators of RecA function.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Feinberg School of Medicine	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 44239, R01 AI044239] Funding Source: Medline; NIGMS NIH HHS [R01 GM 52725] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; DREES JC, 2004, J BIOL CHEM; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Pages V, 2003, DNA REPAIR, V2, P273, DOI 10.1016/S1568-7864(02)00217-3; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, J MOL BIOL, V333, P345, DOI 10.1016/j.jmb.2003.08.053; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Walker GC, 2000, BACTERIAL STRESS RESPONSES, P131; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; WEISEMANN JM, 1985, J BACTERIOL, V163, P748, DOI 10.1128/JB.163.2.748-755.1985; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256	33	51	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55073	55079		10.1074/jbc.M410371200	http://dx.doi.org/10.1074/jbc.M410371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489505	hybrid			2022-12-27	WOS:000225960800012
J	Paulhe, F; Imhof, BA; Wehrle-Haller, B				Paulhe, F; Imhof, BA; Wehrle-Haller, B			A specific endoplasmic reticulum export signal drives transport of stem cell factor (Kitl) to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-GOLGI TRANSPORT; COPII-DEPENDENT TRANSPORT; EARLY SECRETORY PATHWAY; VIRUS G-PROTEIN; GROWTH-FACTOR; PROTGF-ALPHA; C-KIT; MELANOCYTE PRECURSORS; MEMBRANE-PROTEINS; SELECTIVE EXPORT	Stem cell factor, also known as Kit ligand (Kitl), belongs to the family of dimeric transmembrane growth factors. Efficient cell surface presentation of Kitl is essential for the migration, proliferation, and survival of melanocytes, germ cells, hemopoietic stem cells, and mastocytes. Here we demonstrate that intracellular transport of Kitl to the cell surface is driven by a motif in the cytoplasmic tail that acts independently of the previously described basolateral sorting signal. Transport of Kitl to the cell surface is controlled at the level of the endoplasmic reticulum ( ER) and requires a C-terminal valine residue positioned at a distance of 19-36 amino acids from the border between the transmembrane and cytoplasmic domains. Deletion or substitution of the valine with other hydrophobic amino acids results in ER accumulation and reduced cell surface transport of Kitl at physiological expression levels. When these mutant proteins are overexpressed in the ER, they are transported by bulk flow to the cell surface albeit at lower efficiency. A fusion construct between Kitl and the green fluorescent protein-labeled extracellular domain of a temperature-sensitive mutant of vesicular stomatitis virus G protein revealed the valine-dependent recruitment into coat protein complex II-coated ER exit sites and vesicular ER to Golgi transport in living cells. Thus the C-terminal valine defines a specific ER export signal in Kitl. It is responsible for the capture of Kitl at coat protein complex II-coated ER exit sites, leading to subsequent cell surface transport under physiological conditions.	Ctr Med Univ Geneva, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland	University of Geneva	Wehrle-Haller, B (corresponding author), Ctr Med Univ Geneva, Dept Pathol & Immunol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Bernhard.Wehrle-Haller@medecine.unige.ch						Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Chalfie M, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, pVII; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Coleman R Edward, 1998, Clin Positron Imaging, V1, P15, DOI 10.1016/S1095-0397(97)00004-6; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; NOURRY C, 2003, SCI STKE; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Powers J, 2002, MOL BIOL CELL, V13, P880, DOI 10.1091/mbc.01-10-0499; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Stephens DJ, 2000, J CELL SCI, V113, P2177; Tajima Y, 1998, J EXP MED, V187, P1451, DOI 10.1084/jem.187.9.1451; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; Urena JM, 1999, J CELL SCI, V112, P773; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Wehrle-Haller B, 1999, DEV BIOL, V210, P71, DOI 10.1006/dbio.1999.9260; Wehrle-Haller B, 2003, PIGM CELL RES, V16, P287, DOI 10.1034/j.1600-0749.2003.00055.x; Wehrle-Haller B, 2001, J BIOL CHEM, V276, P12667, DOI 10.1074/jbc.M008357200; WehrleHaller B, 1996, DEV BIOL, V177, P463, DOI 10.1006/dbio.1996.0178; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	61	20	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55545	55555		10.1074/jbc.M407813200	http://dx.doi.org/10.1074/jbc.M407813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475566	hybrid			2022-12-27	WOS:000225960800071
J	Tran, POT; Parker, SM; LeRoy, E; Franklin, CC; Kavanagh, TJ; Zhang, T; Zhou, HR; Vliet, P; Oseid, E; Harmon, JS; Robertson, RP				Tran, POT; Parker, SM; LeRoy, E; Franklin, CC; Kavanagh, TJ; Zhang, T; Zhou, HR; Vliet, P; Oseid, E; Harmon, JS; Robertson, RP			Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE SYNTHESIS; DIABETES-MELLITUS; GLUCOSE TOXICITY; GENE-EXPRESSION; BETA-CELLS; SYNTHETASE; INTERLEUKIN-1-BETA; INHIBITION; DEFENSE; ENZYMES	The catalytic subunit of glutamylcysteine ligase (GCLC) primarily regulates de novo synthesis of glutathione (GSH) in mammalian cells and is central to the antioxidant capacity of the cell. However, GCLC expression in pancreatic islets has not been previously examined. We designed experiments to ascertain whether GCLC is normally expressed in islets and whether it is up-regulated by interleukin-1beta (IL-1beta). GCLC expression levels were intermediate compared with other metabolic tissues (kidney, liver, muscle, fat, and lung). IL-1beta up-regulated GCLC expression (10 ng/ml IL-1beta, 3.76+/-0.86; 100 ng/ml IL-1beta, 4.22+/-0.68-fold control) via the p38 form of mitogen-activated protein kinase and NFkappaB and also increased reactive oxygen species levels (10 ng/ml IL-1beta, 5.41+/-1.8-fold control). This was accompanied by an increase in intraislet GSH/GSSG ratio (control, 7.1+/-0.1; 10 ng/ml IL-1beta, 8.0+/-0.5; 100 ng/ml IL-1beta, 8.2+/-0.5-fold control; p<0.05). To determine whether overexpression of GCLC increases the antioxidant capacity of the islet and prevents the adverse effects of IL-1 beta on glucose-induced insulin secretion, islets were infected with an adenovirus encoding GCLC. IL-1 beta significantly decreased glucose-stimulated insulin secretion (control, 123.8 +/- 17.7; IL-1 beta, 40.2 +/- 3.9 microunits/ml insulin/islet). GCLC overexpression increased intraislet GSH levels and partially prevented the decrease in glucose-stimulated insulin secretion caused by IL-1 beta. These data provide the first report of GCLC expression in the islet and demonstrate that adenoviral overexpression of GCLC increases intracellular GSH levels and protects the beta cell from the adverse effects of IL-1 beta.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, NIEHS, Ctr Ecogenet & Environm Hlth, NIH,Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	rpr@pnri.org	Roberston, R Paul/AAX-5613-2021		NCI NIH HHS [CA90473] Funding Source: Medline; NIDDK NIH HHS [R01 DK38325] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038325] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Catherwood MA, 2002, KIDNEY INT, V61, P599, DOI 10.1046/j.1523-1755.2002.00168.x; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Lu SC, 1999, INVEST OPHTH VIS SCI, V40, P1776; MAEDLER K, J CLIN INVESTIG, V110, pHI851; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURAKAMI K, 1989, METABOLISM, V38, P753, DOI 10.1016/0026-0495(89)90061-9; REED DJ, CURRENT PROTOCOLS TO; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Sharma A, 2000, METABOLISM, V49, P160, DOI 10.1016/S0026-0495(00)91117-X; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; YOSHIDA K, 1995, DIABETOLOGIA, V38, P201, DOI 10.1007/s001250050271	21	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53988	53993		10.1074/jbc.M404809200	http://dx.doi.org/10.1074/jbc.M404809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485876	hybrid			2022-12-27	WOS:000225793600013
J	Behm-Ansmant, I; Grosjean, H; Massenet, S; Motorin, Y; Branlant, C				Behm-Ansmant, I; Grosjean, H; Massenet, S; Motorin, Y; Branlant, C			Pseudouridylation at position 32 of mitochondrial and cytoplasmic tRNAs requires two distinct enzymes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; ESCHERICHIA-COLI; U2 SNRNA; GENETIC CLASSIFICATION; CRYSTAL-STRUCTURE; NORMAL GROWTH; SYNTHASE; YEAST; PROTEIN; PURIFICATION	Cytoplasmic and mitochondrial tRNAs contain several pseudouridylation sites, and the tRNA:Psi-synthase acting at position 32 had not been identified in Saccharomyces cerevisiae. By combining genetic and biochemical analyses, we demonstrate that two enzymes, Rib2/Pus8p and Pus9p, are required for Psi32 formation in cytoplasmic and mitochondrial tRNAs, respectively. Pus9p acts mostly in mitochondria, and Rib2/Pus8p is strictly cytoplasmic. This is the first case reported so far of two distinct tRNA modification enzymes acting at the same position but present in two different compartments. This peculiarity may be the consequence of a gene fusion that occurred during yeast evolution. Indeed, Rib2/Pus8p displays two distinct catalytic activities involved in completely unrelated metabolism: its C-terminal domain has a DRAP-deaminase activity required for riboflavin biogenesis in the cytoplasm, whereas its N-terminal domain carries the tRNA:Psi32-synthase activity. Pus9p has only a tRNA:Psi32-synthase activity and contains a characteristic mitochondrial targeting sequence at its N terminus. These results are discussed in terms of RNA:Psi-synthase evolution.	UHP Nancy 1, Fac Sci, UMR 7567 CNRS, Lab Maturat Acides Ribonucle, F-54506 Vandoeuvre Les Nancy, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Motorin, Y (corresponding author), UHP Nancy 1, Fac Sci, UMR 7567 CNRS, Lab Maturat Acides Ribonucle, BP 239, F-54506 Vandoeuvre Les Nancy, France.	Yuri.Motorin@maem.uhp-nancy.fr	MOTORIN, Yuri/E-2499-2011; MOTORIN, Yuri/AAQ-9527-2020; BEHM-ANSMANT, Isabelle/B-1406-2012	MOTORIN, Yuri/0000-0002-8018-334X; Branlant, Christiane/0000-0003-4728-5499; Severine, Massenet/0000-0001-5187-8356; Motorin, Alexandr/0000-0001-9622-4591; Behm-Ansmant, Isabelle/0000-0001-8909-0660				Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941; Ansmant I, 2001, J BIOL CHEM, V276, P34934, DOI 10.1074/jbc.M103131200; ARNEZ JG, 1994, BIOCHEMISTRY-US, V33, P7560, DOI 10.1021/bi00190a008; Auffinger P, 1997, J MOL BIOL, V269, P326, DOI 10.1006/jmbi.1997.1022; Bacher A, 2001, VITAM HORM, V61, P1; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Bonnerot C, 2003, MOL CELL, V12, P1309, DOI 10.1016/S1097-2765(03)00435-0; Conrad J, 1999, RNA, V5, P751, DOI 10.1017/S1355838299990167; Conrad J, 1998, J BIOL CHEM, V273, P18562, DOI 10.1074/jbc.273.29.18562; Del Campo M, 2004, RNA, V10, P231, DOI 10.1261/rna.5187404; Del Campo M, 2001, RNA, V7, P1603; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; LUE PF, 1969, BIOCHEM BIOPH RES CO, V34, P426, DOI 10.1016/0006-291X(69)90399-4; Ma XJ, 2003, EMBO J, V22, P1889, DOI 10.1093/emboj/cdg191; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NISHIMURA H, 1979, TRNASFER RNA STRUCTU, P547; NOSAKA K, 1994, J BIOL CHEM, V269, P30510; NURSE K, 1995, RNA, V1, P102; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; ROSE AM, 1995, BIOCHIMIE, V77, P45, DOI 10.1016/0300-9084(96)88103-X; Schaub M, 2002, BIOCHIMIE, V84, P791, DOI 10.1016/S0300-9084(02)01446-3; SHAVLOVSKII G M, 1982, Mikrobiologiya, V51, P96; SHAVLOVSKY GM, 1979, GENETIKA+, V15, P1561; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Urban A, 2003, J CHROMATOGR B, V786, P187, DOI 10.1016/S1570-0232(02)00742-0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437	45	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52998	53006		10.1074/jbc.M409581200	http://dx.doi.org/10.1074/jbc.M409581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466869	Green Published, hybrid			2022-12-27	WOS:000225680600025
J	Edqvist, J; Ronnberg, E; Rosenquist, S; Blomqvist, K; Viitanen, L; Salminen, TA; Nylund, M; Tuuf, J; Mattjus, P				Edqvist, J; Ronnberg, E; Rosenquist, S; Blomqvist, K; Viitanen, L; Salminen, TA; Nylund, M; Tuuf, J; Mattjus, P			Plants express a lipid transfer protein with high similarity to mammalian sterol carrier protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; GLYCOLIPID TRANSFER; COMPLETE GENOME; DEHYDROGENASE FAMILY; GENE; SEQUENCE; LOCALIZATION; REVEALS; CLONING; CATABOLISM	This is the first report describing the cloning and characterization of sterol carrier protein-2 (SCP-2) from plants. Arabidopsis thaliana SCP-2 (AtSCP-2) consists of 123 amino acids with a molecular mass of 13.6 kDa. AtSCP-2 shows 35% identity and 56% similarity to the human SCP-2-like domain present in the human D-bifunctional protein (DBP) and 30% identity and 54% similarity to the human SCP-2 encoded by SCP-X. The presented structural models of apo-AtSCP-2 and the ligand-bound conformation of AtSCP-2 reveal remarkable similarity with two of the structurally known SCP-2s, the SCP-2-like domain of human DBP and the rabbit SCP-2, correspondingly. The AtSCP-2 models in both forms have a similar hydrophobic ligand-binding tunnel, which is extremely suitable for lipid binding. AtSCP-2 showed in vitro transfer activity of BODIPY-phosphatidylcholine (BODIPY-PC) from donor membranes to acceptor membranes. The transfer of BODIPY-PC was almost completely inhibited after addition of 1-palmitoyl 2-oleoyl phosphatidylcholine or ergosterol. Dimyristoyl phosphatidic acid, stigmasterol, steryl glucoside, and cholesterol showed a moderate to marginal ability to lower the BODIPY-PC transfer rate, and the single chain palmitic acid and stearoyl-coenzyme A did not affect transfer at all. Expression analysis showed that AtSCP-2 mRNA is accumulating in most plant tissues. Plasmids carrying fusion genes between green fluorescent protein and AtSCP-2 were transformed with particle bombardment to onion epidermal cells. The results from analyzing the transformants indicate that AtSCP-2 is localized to peroxisomes.	Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, S-75007 Uppsala, Sweden; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland	Swedish University of Agricultural Sciences; Abo Akademi University	Edqvist, J (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, Box 7080, S-75007 Uppsala, Sweden.	Johan.Edqvist@vbsg.slu.se	Mattjus, Peter/AAQ-7531-2021; Salminen, Tiina A./AAM-5443-2021; Nylund, Matts/I-5604-2013; Edqvist, Johan/H-7803-2019; Ronnberg, Elin/ABA-8898-2020; Salminen, Tiina A/G-7492-2019; Mattjus, Peter/ABE-3596-2021	Salminen, Tiina A./0000-0002-4135-8020; Ronnberg, Elin/0000-0002-4628-9968; Salminen, Tiina A/0000-0002-4135-8020; Mattjus, Peter/0000-0001-8991-5933; Edqvist, Johan/0000-0002-8174-4540; Rosenquist, Sara/0000-0001-7648-9103; Blomqvist, Kristina/0000-0003-1364-5337				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Barnes TM, 1996, J NEUROCHEM, V67, P46; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; Dansen TB, 1999, BIOCHEM J, V339, P193, DOI 10.1042/0264-6021:3390193; David S., 1996, WEEDS WORLD, V3, P43; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dyer DH, 2003, J BIOL CHEM, V278, P39085, DOI 10.1074/jbc.M306214200; Edqvist J, 2002, PLANTA, V215, P41, DOI 10.1007/s00425-001-0717-x; Eklund DM, 2003, PLANT PHYSIOL, V132, P1249, DOI 10.1104/pp.103.020875; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Garcia FL, 2000, J MOL BIOL, V295, P595, DOI 10.1006/jmbi.1999.3355; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Haapalainen AM, 2001, J MOL BIOL, V313, P1127, DOI 10.1006/jmbi.2001.5084; HWANG CW, 1991, GENE, V106, P61, DOI 10.1016/0378-1119(91)90566-T; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; Johnson MS, 2000, BIOINFORMATICS; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LEENDERS F, 1994, MOL CELL ENDOCRINOL, V104, P127, DOI 10.1016/0303-7207(94)90114-7; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; LEHTONEN JV, 2004, IN PRESS J COMPUTER; Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104; Matile P, 1999, ANNU REV PLANT PHYS, V50, P67, DOI 10.1146/annurev.arplant.50.1.67; Matsuoka S, 2003, EUKARYOT CELL, V2, P638, DOI 10.1128/EC.2.3.638-645.2003; Mattjus P, 2003, BIOCHEMISTRY-US, V42, P535, DOI 10.1021/bi026896x; Mattjus P, 2002, BIOCHEMISTRY-US, V41, P266, DOI 10.1021/bi015718l; Mattjus P, 1999, ANAL BIOCHEM, V268, P297, DOI 10.1006/abio.1998.3065; Mattjus P, 2000, BIOCHEMISTRY-US, V39, P1067, DOI 10.1021/bi991810u; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Requena N, 1999, MOL PLANT MICROBE IN, V12, P934, DOI 10.1094/MPMI.1999.12.10.934; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scott A, 1999, BIOTECHNIQUES, V26, P1125, DOI 10.2144/99266st04; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Seidel G, 1998, GENE, V225, P23, DOI 10.1016/S0378-1119(98)00532-0; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; TAN H, 1994, YEAST, V10, P1065, DOI 10.1002/yea.320100808; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Wu SH, 2001, PLANT PHYSIOL BIOCH, V39, P917, DOI 10.1016/S0981-9428(01)01322-5; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	53	26	32	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53544	53553		10.1074/jbc.M405099200	http://dx.doi.org/10.1074/jbc.M405099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456765	hybrid			2022-12-27	WOS:000225680600090
J	He, YY; Huang, JL; Chignell, CF				He, YY; Huang, JL; Chignell, CF			Delayed and sustained activation of extracellular signal-regulated kinase in human keratinocytes by UVA - Implications in carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; DOWN-REGULATION; SINGLET OXYGEN; ERK; APOPTOSIS; RAS; JNK; PHOSPHORYLATION; P38; ULTRAVIOLET	Exposure to the sun's UV radiation appears to be the most important environmental factor involved in the development of skin cancer. UVA is the major portion of UV radiation in sunlight and is considered to be a human carcinogen. In this study, we have investigated the delayed and sustained activation of ERK MAPK by UVA exposure. In parallel, a delayed Ras activation with a similar time course was observed after UVA exposure. The activated Ras was found to be localized in endomembranes such as the Golgi apparatus instead of plasma membranes. Expression of dominant negative Ras (N17Ras) abolished ERK activation by UVA. The presence of AG1478, an epidermal growth factor (EGF) receptor ( EGFR) kinase inhibitor, had no effect on ERK or Ras activation, indicating that EGFR kinase activity is not involved in ERK activation by UVA. In contrast, protein kinase C (PKC) depletion by chronic 12-O-tetradecanoylphorbol-13-acetate treatment nearly abolished UVA-induced ERK and Ras activation. The presence of the Ca2+-dependent-PKC inhibitor Go6976 had a similar effect. These findings suggest that ERK activation by UVA is mediated by PKC in a Ras-dependent pathway. In addition, a gradual increase in intracellular calcium level after UVA exposure was detected by flow cytometry. The presence of the PLC inhibitor U73122 or the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N, N, N',N'-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM) blocked both ERK and Ras activation, suggesting that both PLC and calcium are required for ERK activation. Our findings demonstrated that, different from UVC and UVB, UVA-induced delayed and sustained ERK activation is EGFR kinase activity-independent, but PLC/calcium/PKC-mediated. The delayed and sustained ERK activation provides a survival signal to human HaCaT keratinocytes, which may serve as an important mechanism for cell transformation and potential skin carcinogenesis in vivo caused by UVA exposure.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, FO-06,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050046, Z01ES050046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COFFER PJ, 1995, ONCOGENE, V11, P561; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; JONES GA, 1993, J BIOL CHEM, V268, P20845; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pourzand C, 1999, PHOTOCHEM PHOTOBIOL, V70, P380, DOI 10.1111/j.1751-1097.1999.tb08239.x; Princen K, 2003, CYTOM PART A, V51A, P35, DOI 10.1002/cyto.a.10008; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Stadheim TA, 2001, CANCER RES, V61, P1533; Tong ZM, 2002, CANCER RES, V62, P5528; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	32	71	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53867	53874		10.1074/jbc.M405781200	http://dx.doi.org/10.1074/jbc.M405781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471881	hybrid			2022-12-27	WOS:000225680600125
J	Koeppel, MA; McCarthy, CC; Moertl, E; Jakobi, R				Koeppel, MA; McCarthy, CC; Moertl, E; Jakobi, R			Identification and characterization of PS-GAP as a novel regulator of caspase-activated PAK-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GAMMA-PAK; ANCHORAGE-INDEPENDENT GROWTH; P21-ACTIVATED KINASE; MOLECULAR-CLONING; PROTEIN-KINASES; ADAPTER PROTEIN; CLEAVAGE; DOMAIN; CELLS; CDC42	p21-activated protein kinase (PAK)-2 is a member of the PAK family of serine/threonine kinases. PAKs are activated by the p21 G-proteins Rac and Cdc42 in response to a variety of extracellular signals and act in pathways controlling cell growth, shape, motility, survival, and death. PAK-2 is unique among the PAK family members because it is also activated through proteolytic cleavage by caspase-3 or similar proteases to generate the constitutively active PAK-2p34 fragment. Activation of full-length PAK-2 by Rac or Cdc42 stimulates cell survival and protects cells from cell death, whereas caspase-activated PAK-2p34 induces a cell death response. Caspase-activated PAK-2p34 is rapidly degraded by the 26 S proteasome, but full-length PAK-2 is not. Stabilization of PAK-2p34 by preventing its polyubiquitination and degradation results in a dramatic stimulation of cell death. Although many proteins have been shown to interact with and regulate full-length PAK-2, little is known about the regulation of caspase-activated PAK-2p34. Here, we identify PS-GAP as a regulator of caspase-activated PAK-2p34. PS-GAP is a GTPase-activating protein for Cdc42 and RhoA that was originally identified by its interaction with the tyrosine kinase PYK-2. PS-GAP interacts specifically with caspase-activated PAK-2p34, but not active or inactive full-length PAK-2, through a region between the GAP and SH3 domains. The interaction with PS-GAP inhibits the protein kinase activity of PAK-2p34 and changes the localization of PAK-2p34 from the nucleus to the perinuclear region. Furthermore, PS-GAP decreases the stimulation of cell death induced by stabilization of PAK-2p34.	Kansas City Univ Med & Biosci, Dept Biochem, Kansas City, MO 64106 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Kansas City University of Medicine & Biosciences; Medical College of Wisconsin	Jakobi, R (corresponding author), Kansas City Univ Med & Biosci, Dept Biochem, 1750 Independence Ave, Kansas City, MO 64106 USA.	rjakobi@kcumb.edu						Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Hashimoto S, 2001, J BIOL CHEM, V276, P6037, DOI 10.1074/jbc.M005854200; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; Jakobi R, 2004, DRUG RESIST UPDATE, V7, P11, DOI 10.1016/j.drup.2004.01.001; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2002, BIOTECHNIQUES, V33, P1218, DOI 10.2144/02336bm07; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; James P, 1996, GENETICS, V144, P1425; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KREBS EG, 1994, TRENDS BIOCHEM SCI, V19, P439, DOI 10.1016/0968-0004(94)90125-2; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tu H, 1999, MOL CELL BIOL, V19, P602; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	55	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53653	53664		10.1074/jbc.M410530200	http://dx.doi.org/10.1074/jbc.M410530200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471851	hybrid			2022-12-27	WOS:000225680600102
J	Kuai, J; Wooters, J; Hall, JP; Rao, VR; Nickbarg, E; Chatterjee-Kishore, M; Qiu, YC; Lin, LL				Kuai, J; Wooters, J; Hall, JP; Rao, VR; Nickbarg, E; Chatterjee-Kishore, M; Qiu, YC; Lin, LL			NAK is recruited to the TNFR1 complex in a TNF alpha-dependent manner and mediates the production of RANTES - Identification of endogenous TNFR-interacting proteins by a proteomic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; LYMPHOTOXIN BETA-RECEPTOR; SEVERE LIVER DEGENERATION; DEATH DOMAIN; INTRACELLULAR DOMAIN; EMBRYONIC LETHALITY; SIGNAL-TRANSDUCTION; DEFICIENT MICE; KINASE IKK	Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine with pleiotropic immunological and biological activities. TNFalpha signaling is triggered by the engagement of soluble TNFalpha to two types of cell surface receptors, TNFR1 and TNFR2. This recruits cytosolic proteins to the intracellular domains of the receptors and initiates signaling to downstream effectors. In this study, we used a proteomic approach to identify these cytosolic proteins from affinity-purified, endogenous TNFalpha.TNFR complexes in human myelomonocytic U937 cells. Seven proteins were identified, including TRADD, TRAP2, and TRAF2, which are three proteins known to be recruited to TNFalpha receptors. NAK, RasGAP3, TRCP1, and TRCP2 were also identified. We further showed that NAK is recruited to TNFR1 in a temporally regulated and TNFalpha-dependent manner and that it mediates the TNFalpha-induced production of the chemokine RANTES ( regulated on activation normal T cell expressed and secreted). These data demonstrate that NAK is a component of the TNFalpha.TNFR1 signaling complex and confirm the physiological role of NAK in the TNFalpha-mediated response.	Wyeth Res, Inflammat Signaling, Dept Inflammat, Cambridge, MA 02140 USA; Wyeth Res, Dept Prot Chem & Proteom, Cambridge, MA 02140 USA; Wyeth Res, Dept Genom, Cambridge, MA 02140 USA	Pfizer; Pfizer; Pfizer	Lin, LL (corresponding author), Wyeth Res, Inflammat Signaling, Dept Inflammat, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	llin@wyeth.com						Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dunbar JD, 1997, J IMMUNOL, V158, P4252; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hornung F, 2000, J IMMUNOL, V164, P6180, DOI 10.4049/jimmunol.164.12.6180; Houthaeve T, 1997, J PROTEIN CHEM, V16, P343, DOI 10.1023/A:1026372302560; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rudolph D, 2000, GENE DEV, V14, P854; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331	34	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53266	53271		10.1074/jbc.M411037200	http://dx.doi.org/10.1074/jbc.M411037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485837	hybrid			2022-12-27	WOS:000225680600057
J	Pirih, FQ; Tang, A; Ozkurt, IC; Nervina, JM; Tetradis, S				Pirih, FQ; Tang, A; Ozkurt, IC; Nervina, JM; Tetradis, S			Nuclear orphan receptor Nurr1 directly transactivates the osteocalcin gene in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER GENE; INDUCED BONE-RESORPTION; PROTEIN-KINASE-A; PARATHYROID-HORMONE; TYROSINE KINASE; MICE LACKING; NGFI-B; RET PROTOONCOGENE; DEFICIENT MICE; EXPRESSION	Nurr1, an NGFI-B nuclear orphan receptor, which transactivates promoters through an NGFI-B response element (NBRE), is strongly induced by parathyroid hormone through the cAMP-protein kinase A signaling pathway in osteoblasts. Here, we demonstrate that multiple agents activating diverse signaling pathways in osteoblasts induce Nurr1. The strongest Nurr1 inducers were activators of cAMP-protein kinase A-coupled signaling, followed by protein kinase C- and calcium-coupled signaling activators. Receptor tyrosine kinase activators had minimal effect, whereas serine/threonine kinase activators had no effect on basal Nurr1 mRNA levels. Computer analysis of osteoblastic promoters indicated two potential NBREs in the rat osteocalcin (Ocn) promoter. Intriguingly, the proximal site maps to the cAMP-responsive cis-element. We tested whether Nurr1 induces Ocn expression through the NBRE-like site. Recombinant and endogenous Nurr1 protein from primary mouse osteoblasts bound to a consensus NBRE in EMSAs. Nurr1 induced a consensus 3xNBRE-luciferase reporter construct in mouse osteoblasts. Recombinant and endogenous Nurr1 protein bound to the proximal NBRE-like site in the Ocn promoter in EMSAs. Endogenous Nurr1 protein bound to this site as a monomer, because neither retinoid X receptor alpha nor retinoid X receptor beta antibody supershifted the protein-DNA complex. Ocn promoter-luciferase constructs lacking or containing a mutated proximal NBRE-like site had markedly blunted responses to Nurr1 overexpression. Finally, adenovirally expressed Nurr1 protein bound to the proximal NBRE-like site in chromatin immunoprecipitation assays and induced Ocn mRNA in primary rat osteoblasts. We conclude that Ocn is a Nurr1 target gene, which positions Nurr1 in the core of transcriptional factors regulating osteoblastic gene expression.	Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Sect Orthodont, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Tetradis, S (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Rm 53-068 CHS, Los Angeles, CA 90095 USA.	sotirist@dent.ucla.edu			NIDCR NIH HHS [R01-DE13316, T32 DE007296] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013316, T32DE007296] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756-3282(99)00232-X; Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999; Bosse R, 1997, NEURON, V19, P127, DOI 10.1016/S0896-6273(00)80353-0; Brosenitsch TA, 2001, J NEUROSCI, V21, P2571, DOI 10.1523/JNEUROSCI.21-08-02571.2001; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ihara H, 2001, J BIOL CHEM, V276, P13065, DOI 10.1074/jbc.M010938200; Iida-Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Iwawaki T, 2000, BIOCHEM BIOPH RES CO, V274, P590, DOI 10.1006/bbrc.2000.3204; Jiang D, 2004, J BIOL CHEM, V279, P5329, DOI 10.1074/jbc.M311547200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JY, 2003, J NEUROCHEM, V85, P1443, DOI 10.1046/j.1471-4159.2003.01780.x; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191; Lee HT, 2004, J AM SOC NEPHROL, V15, P102, DOI 10.1097/01.ASN.0000102474.68613.AE; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Liu F, 2003, J CELL SCI, V116, P1787, DOI 10.1242/jcs.00376; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; NODA M, 1988, J BIOL CHEM, V263, P18574; Ozkurt IC, 2003, J BIOL CHEM, V278, P26803, DOI 10.1074/jbc.M212652200; Park JI, 2003, MOL CELL ENDOCRINOL, V202, P25, DOI 10.1016/S0303-7207(03)00057-1; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Sacchetti P, 2002, J BIOL CHEM, V277, P35088, DOI 10.1074/jbc.M205816200; Sacchetti P, 1999, MOL BRAIN RES, V74, P167, DOI 10.1016/S0169-328X(99)00275-2; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; Wallen-Mackenzie A, 2003, GENE DEV, V17, P3036, DOI 10.1101/gad.276003; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	53	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53167	53174		10.1074/jbc.M405677200	http://dx.doi.org/10.1074/jbc.M405677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485875	hybrid			2022-12-27	WOS:000225680600046
J	Xu, LJ; Deng, XM				Xu, LJ; Deng, XM			Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY NEUROENDOCRINE CELLS; GREEN FLUORESCENT PROTEIN; LUNG-CARCINOMA CELLS; CANCER INVASION; TUMOR-CELLS; KINASE-C; METASTASIS; MOTILITY; ACTIVATION; TRANSFORMATION	Mounting evidence indicates that cigarette smoking not only promotes tumorigenesis but also may increase the spread of cancer cells in the body. However, the intracellular mechanism(s) by which cigarette smoking promotes metastasis of human lung cancer remains enigmatic. Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is an important component in cigarette smoke and is formed by nitrosation of nicotine. mu- and m-calpain (calpain I and calpain II) are major members of the calpain family, which are ubiquitously expressed in both small cell lung cancer and non-small cell lung cancer cells. Our findings indicated that NNK potently induces phosphorylation of both mu- and m-calpain in association with their activation and increased migration as well as invasion of lung cancer cells. Treatment of cells with PD98059 blocked phosphorylation of m- and mu-calpain and resulted in suppression of NNK-induced cell migration and invasion. p44 MAPK/extracellular signal-regulated kinase 1 (ERK1) and p42 MAPK/ERK2 were activated by NNK, co-localized with mu- and m-calpain in cytoplasm, and directly phosphorylated mu- and m-calpain in vitro. These findings suggest a role for the ERK1/2 kinases as NNK-activated physiological calpain kinases. Specific knock-down of mu- and/or m- calpain expression by RNA interference blocked NNK-stimulated migration and invasion, suggesting that mu- and m-calpain may act as required targets in a NNK-induced metastatic signaling pathway. Furthermore, NNK promotes secretion of active mu- and m-calpain from lung cancer cells through vesicles, which may have the potential to cleave substrates in the extracellular matrix. Thus, NNK-induced cell migration and invasion may occur, at least in part, through a novel mechanism involving phosphorylation of calpains that leads to their activation and secretion, which may contribute to metastasis and/or progression of lung cancer.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu						ALBINI A, 1987, CANCER RES, V47, P3239; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Condeelis JS, 2000, EUR J CANCER, V36, P1671, DOI 10.1016/S0959-8049(00)00155-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Farina KL, 1998, CANCER RES, V58, P2528; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gomez DE, 1999, ONCOL REP, V6, P1363; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; Heino J, 2002, CELL INVASION MED IN, P1; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mamoune A, 2003, CANCER RES, V63, P4632; Murin S, 2001, CHEST, V119, P1635, DOI 10.1378/chest.119.6.1635; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Palecek SP, 1998, J CELL SCI, V111, P929; REPESH LA, 1989, INVAS METAST, V9, P192; SAMET JM, 1994, EPIDEMIOLOGY LUNG CA, P437; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Wells A, 2000, ADV CANCER RES, V78, P31; Wyckoff JB, 2000, CANCER RES, V60, P2504	39	74	79	5	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53683	53690		10.1074/jbc.M409889200	http://dx.doi.org/10.1074/jbc.M409889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471877	hybrid			2022-12-27	WOS:000225680600105
J	Yarovinsky, F; Andersen, JF; King, LR; Caspar, P; Aliberti, J; Golding, H; Sher, A				Yarovinsky, F; Andersen, JF; King, LR; Caspar, P; Aliberti, J; Golding, H; Sher, A			Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLOPHILIN-A; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CELL LINE; INFECTION; RECEPTOR; BINDING; ENTRY; INHIBITION	The protozoan parasite Toxoplasma gondii possesses a protein, cyclophilin-18 (C-18), which binds to the chemokine receptor CCR5, induces interleukin-12 production from murine dendritic cells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-receptor antagonism. Site-directed mutagenesis was employed to identify the domains in C-18 responsible for its CCR5 binding and antiviral functions. To do so we focused on amino acid differences with Plasmodium falciparum cyclophilin, which, although 53% identical with C-18, has minimal binding activity for CCR5, and we generated 22 mutants with substitutions in the regions of non-homology located on the putative surface of the molecule. Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity. In contrast, four mutations in C-18 specifically designed to abolish the peptidylprolyl cis-trans-isomerase activity of the protein failed to inactivate its CCR5 binding and HIV inhibitory activities. Interleukin-12 induction by C-18, on the other hand, was abrogated by mutations effecting either the CCR5 binding or enzymatic function of the molecule. These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent.	NIAID, Parasit Dis Lab, Immunobiol Sect, NIH, Bethesda, MD 20892 USA; NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)	Sher, A (corresponding author), NIAID, Parasit Dis Lab, Immunobiol Sect, NIH, Bethesda, MD 20892 USA.	asher@mail.nih.gov	Aliberti, Julio/I-7354-2013; Aliberti, Julio/G-4565-2012	Aliberti, Julio/0000-0003-3420-8478; Yarovinsky, Felix/0000-0001-5825-8002	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000579, Z01AI000579] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti J, 2003, NAT IMMUNOL, V4, P485, DOI 10.1038/ni915; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bondue A, 2002, BIOCHEMISTRY-US, V41, P13548, DOI 10.1021/bi026087d; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cooley LA, 2003, J CLIN VIROL, V26, P121, DOI 10.1016/S1386-6532(02)00111-7; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Davis CW, 2004, J EXP MED, V199, P1037, DOI 10.1084/jem.20040426; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Golding H, 2003, BLOOD, V102, P3280, DOI 10.1182/blood-2003-04-1096; HIGH KP, 1994, J BIOL CHEM, V269, P9105; HILLMAN K, 1990, J IMMUNOL, V144, P2131; Holst PJ, 2003, MICROBES INFECT, V5, P179, DOI 10.1016/S1286-4579(02)00081-3; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Minder D, 2002, ARCH VIROL, V147, P1531, DOI 10.1007/s00705-002-0826-2; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Peterson MR, 2000, J MOL BIOL, V298, P123, DOI 10.1006/jmbi.2000.3633; Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Sher A, 2003, IMMUNOL RES, V27, P521, DOI 10.1385/IR:27:2-3:521; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Trkola A, 1999, J VIROL, V73, P8966, DOI 10.1128/JVI.73.11.8966-8974.1999; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200; Zhang YJ, 1998, J VIROL, V72, P9337, DOI 10.1128/JVI.72.11.9337-9344.1998; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	36	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53635	53642		10.1074/jbc.M410550200	http://dx.doi.org/10.1074/jbc.M410550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469936	hybrid			2022-12-27	WOS:000225680600100
J	Gabrielsen, M; Bond, CS; Hallyburton, I; Hecht, S; Bacher, A; Eisenreich, W; Rohdich, F; Hunter, WN				Gabrielsen, M; Bond, CS; Hallyburton, I; Hecht, S; Bacher, A; Eisenreich, W; Rohdich, F; Hunter, WN			Hexameric assembly of the bifunctional methylerythritol 2,4-cyclodiphosphate synthase and protein-protein associations in the deoxy-xylulose-dependent pathway of isoprenoid precursor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYXYLULOSE PHOSPHATE-PATHWAY; NON-MEVALONATE PATHWAY; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; 2-C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE; NONMEVALONATE PATHWAY; ESSENTIAL ENZYME; 4-PHOSPHATE; TERPENOIDS; MAPS	The bifunctional methylerythritol 4-phosphate cytidylyltransferase methylerythritol 2,4-cyclodiphosphate synthase (IspDF) is unusual in that it catalyzes nonconsecutive reactions in the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway of isoprenoid precursor biosynthesis. The crystal structure of IspDF from the bacterial pathogen Campylobacter jejuni reveals an elongated hexamer with D-3 symmetry compatible with the dimeric 2C-methyl-D-erythritol-4-phosphate cytidylyltransferase and trimeric 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase monofunctional enzymes. Complex formation of IspDF with 4-diphosphocytidyl-2C-methyl-D-erythritol kinase (IspE), the intervening enzyme activity in the pathway, has been observed in solution for the enzymes from C. jejuni and Agrobacterium tumefaciens. The monofunctional enzymes (2C-methyl-D-erythritol-4-phosphate cytidylyltransferase, IspE, and 2C-methyl-D-erythritol2,4-cyclodiphosphate synthase) involved in the DOXP biosynthetic pathway of Escherichia coli also show physical associations. We propose that complex formation of the three enzymes at the core of the DOXP pathway can produce an assembly localizing 18 catalytic centers for the early stages of isoprenoid biosynthesis.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	University of Dundee; Technical University of Munich	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dow St, Dundee DD1 5EH, Scotland.	w.n.hunter@dundee.ac.uk	Eisenreich, Wolfgang/A-1258-2013; Bond, Charles/AAF-9608-2020; Hunter, William/AAE-3947-2019; Bond, Charles S/B-4094-2011	Eisenreich, Wolfgang/0000-0002-9832-8279; Bond, Charles/0000-0002-9584-6783; Bond, Charles S/0000-0002-9584-6783; Gabrielsen, Mads/0000-0002-9848-2276; Hallyburton, Irene/0000-0003-4883-5560				Adam P, 2002, P NATL ACAD SCI USA, V99, P12108, DOI 10.1073/pnas.182412599; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; Boucher Y, 2000, MOL MICROBIOL, V37, P703, DOI 10.1046/j.1365-2958.2000.02004.x; Campos N, 2001, BIOCHEM J, V353, P59, DOI 10.1042/bj3530059; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Enright AJ, 2001, GENOME BIOL, V2; Freiberg C, 2001, J MOL MICROB BIOTECH, V3, P483; GABRIELSEN M, 2004, EUR J BIOCHEM, V271, P1; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Herz S, 2000, P NATL ACAD SCI USA, V97, P2486, DOI 10.1073/pnas.040554697; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemp LE, 2003, ACTA CRYSTALLOGR D, V59, P607, DOI 10.1107/S090744490202365X; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; Kemp LE, 2001, ACTA CRYSTALLOGR D, V57, P1189, DOI 10.1107/S0907444901010137; Kishida H, 2003, ACTA CRYSTALLOGR D, V59, P23, DOI 10.1107/S0907444902017705; Kollas AK, 2002, FEBS LETT, V532, P432, DOI 10.1016/S0014-5793(02)03725-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzuyama T, 2003, NAT PROD REP, V20, P171, DOI 10.1039/b109860h; Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200; Kuzuyama T, 2000, TETRAHEDRON LETT, V41, P703, DOI 10.1016/S0040-4039(99)02143-7; Lange BM, 2000, P NATL ACAD SCI USA, V97, P13172, DOI 10.1073/pnas.240454797; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miallau L, 2003, P NATL ACAD SCI USA, V100, P9173, DOI 10.1073/pnas.1533425100; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; Richard SB, 2002, J BIOL CHEM, V277, P8667, DOI 10.1074/jbc.C100739200; Richard SB, 2001, NAT STRUCT BIOL, V8, P641, DOI 10.1038/89691; Rodriguez-Concepcion M, 2002, PLANT PHYSIOL, V130, P1079, DOI 10.1104/pp.007138; Rohdich F, 2003, PURE APPL CHEM, V75, P393, DOI 10.1351/pac200375020393; Rohdich F, 2003, P NATL ACAD SCI USA, V100, P1586, DOI 10.1073/pnas.0337742100; Rohdich F, 2001, EUR J BIOCHEM, V268, P3190, DOI 10.1046/j.1432-1327.2001.02204.x; Rohdich F, 1999, P NATL ACAD SCI USA, V96, P11758, DOI 10.1073/pnas.96.21.11758; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Steinbacher S, 2002, J MOL BIOL, V316, P79, DOI 10.1006/jmbi.2001.5341; Takagi M, 2000, TETRAHEDRON LETT, V41, P3395, DOI 10.1016/S0040-4039(00)00375-0; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wolff M, 2003, FEBS LETT, V541, P115, DOI 10.1016/S0014-5793(03)00317-X	56	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52753	52761		10.1074/jbc.M408895200	http://dx.doi.org/10.1074/jbc.M408895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466439	hybrid			2022-12-27	WOS:000225493400122
J	Molina, MM; Belli, G; de la Torre, MA; Rodriguez-Manzaneque, MT; Herrero, E				Molina, MM; Belli, G; de la Torre, MA; Rodriguez-Manzaneque, MT; Herrero, E			Nuclear monothiol glutaredoxins of Saccharomyces cerevisiae can function as mitochondrial glutaredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OXIDATIVE STRESS; THIOLTRANSFERASE GLUTAREDOXIN; ESCHERICHIA-COLI; PROTEIN-KINASE; REDOX STATE; THIOREDOXIN; GLUTATHIONE; EXPRESSION; DISULFIDE	Glutaredoxins are thiol oxidoreductases that regulate protein redox state. In Saccharomyces cerevisiae, Grx1 and Grx2 are cytosolic dithiol glutaredoxins, whereas Grx3, Grx4, and Grx5 are monothiol glutaredoxins. Grx5 locates at the mitochondrial matrix and is needed for iron/sulfur cluster biogenesis. Its absence causes phenotypes such as inactivation of iron/sulfur enzymes and sensitivity to oxidative stress. Whereas Grx5 contains a single glutaredoxin domain, in Grx3 and Grx4 a thioredoxin-like domain is fused to the glutaredoxin domain. Here we have shown that Grx3 locates at the nucleus and that the thioredoxin-like domain is required for such location. We have addressed the functional divergence among glutaredoxins by targeting Grx2/3/4 molecules to the mitochondrial matrix using the Grx5 targeting sequence. The mitochondrial forms of Grx3 and Grx4 partially rescue the defects of a grx5 null mutant. On the contrary, mitochondrially targeted Grx2 does not suppress the mutant phenotype. Both the thioredoxin-like and glutaredoxin domains are needed for the mitochondrial activity of Grx3, although none of the cysteine residues at the thioredoxin-like domain is required for rescue of the grx5 phenotypes. We have concluded that dithiol glutaredoxins are functionally divergent from monothiol ones, but the latter can interchange their biological activities when compartment barriers are surpassed.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25008, Spain	Universitat de Lleida	Herrero, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Montserrat Roig 2, Lleida 25008, Spain.	enric.herrero@cmb.udl.es	de la Torre, M Angeles/A-7357-2010; Rodriguez-Manzaneque Martinez, Maria Teresa/C-6449-2011; belli, gemma/A-7424-2011; Bellí, Gemma/AAD-5325-2019; Herrero, Enrique/B-5592-2009	de la Torre, M Angeles/0000-0002-6111-1359; belli, gemma/0000-0002-4161-3204; Bellí, Gemma/0000-0002-4161-3204; Herrero, Enrique/0000-0002-6763-111X; , Micaela/0000-0002-2103-0351				Arino J, 2003, METHOD ENZYMOL, V366, P347; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Babichev Y, 2001, ADV EXP MED BIOL, V495, P41; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Cha MK, 2004, J BIOL CHEM, V279, P11035, DOI 10.1074/jbc.M312657200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gerber J, 2004, MOL CELL BIOL, V24, P4848, DOI 10.1128/MCB.24.11.4848-4857.2004; Gietz RD., 1988, GENE, V74, P3065; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Greene NDE, 2002, J BIOL CHEM, V277, P41645, DOI 10.1074/jbc.M203607200; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hughes AL, 2003, GENOME RES, V13, P1258; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Kenchappa RS, 2002, J NEUROSCI, V22, P8402; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Llorente B, 2000, FEBS LETT, V487, P122, DOI 10.1016/S0014-5793(00)02291-2; Lopreiato R, 2004, BIOCHEM J, V377, P395, DOI 10.1042/BJ20030638; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Outten CE, 2004, J BIOL CHEM, V279, P7785, DOI 10.1074/jbc.M312421200; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; Porras P, 2002, BIOCHEM BIOPH RES CO, V295, P1046, DOI 10.1016/S0006-291X(02)00771-4; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rouhier N, 2002, ANN NY ACAD SCI, V973, P520, DOI 10.1111/j.1749-6632.2002.tb04693.x; Sadek CM, 2003, J BIOL CHEM, V278, P13133, DOI 10.1074/jbc.M300369200; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Tatchell K, 2002, METHOD ENZYMOL, V351, P661; Toledano MB, 2003, TOP CURR GENET, V1, P241; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Vilella F, 2004, COMP FUNCT GENOM, V5, P328, DOI 10.1002/cfg.406; Weiner Michael P., 1995, P613; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wheeler GL, 2004, PHYSIOL PLANTARUM, V120, P12, DOI 10.1111/j.0031-9317.2004.0193.x; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200	62	77	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51923	51930		10.1074/jbc.M410219200	http://dx.doi.org/10.1074/jbc.M410219200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456753	Green Published, hybrid			2022-12-27	WOS:000225493400026
J	Miller, AL; Suntharalingam, M; Johnson, SL; Audhya, A; Emr, SD; Wente, SR				Miller, AL; Suntharalingam, M; Johnson, SL; Audhya, A; Emr, SD; Wente, SR			Cytoplasmic inositol hexakisphosphate production is sufficient for mediating the Gle1-mRNA export pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; YEAST NUCLEOPORIN; NUCLEOCYTOPLASMIC TRANSPORT; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; CONDITIONAL ALLELE; PROTEOMIC ANALYSIS; BINDING-PROTEINS	Production of inositol hexakisphosphate (IP6) by Ipk1, the inositol-1,3,4,5,6-pentakisphosphate 2-kinase, is required for Gle1-mediated mRNA export in Saccharomyces cerevisiae cells. To examine the network of interactions that require IP6 production, an analysis of fitness defects was conducted in mutants harboring both an ipk1 null allele and a mutant allele in genes encoding nucleoporins or transport factors. Enhanced lethality was observed with a specific subset of mutants, including nup42, nup116, nup159, dbp5, and gle2, all of which had been previously connected to Gle1 function. Complementation of the nup116Deltaipk1Delta and nup42Deltaipk1Delta double mutants did not require the Phe-Gly repeat domains in the respective nucleoporins, suggesting that IP6 was acting subsequent to heterogeneous nuclear ribonucleoprotein targeting to the nuclear pore complex. With Nup42 and Nup159 localized exclusively to the nuclear pore complex cytoplasmic side, we speculated that IP6 may regulate a cytoplasmic step in mRNA export. To test this prediction, the spatial requirements for the production of IP6 were investigated. Restriction of Ipk1 to the cytoplasm did not block IP6 production. Moreover, coincident sequestering of both Ipk1 and Mss4 ( an enzyme required for phosphatidylinositol 4,5-bisphosphate production) to the cytoplasm also did not block IP6 production. Given that the kinase required for inositol 1,3,4,5,6-pentakisphosphate production (Ipk2) is localized in the nucleus, these results indicated that soluble inositides were diffusing between the nucleus and the cytoplasm. Additionally, the cytoplasmic production of IP6 by plasma membrane-anchored Ipk1 rescued a gle1-2 ipk1-4 synthetic lethal mutant. Thus, cytoplasmic IP6 production is sufficient for mediating the Gle1-mRNA export pathway.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Vanderbilt University; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Wente, SR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, 3120 MRBIII,465 21st Ave S, Nashville, TN 37232 USA.	susan.wente@vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051219, R01GM051219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Bai C, 1997, METHOD ENZYMOL, V283, P141; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; BERCY J, 1987, GENE, V55, P277, DOI 10.1016/0378-1119(87)90287-3; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Divecha N, 2000, CELL MOL LIFE SCI, V57, P379, DOI 10.1007/PL00000700; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Feldherr CM, 1997, J CELL SCI, V110, P3065; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Goldstein AL, 1996, MOL BIOL CELL, V7, P917, DOI 10.1091/mbc.7.6.917; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hood JK, 2000, J CELL SCI, V113, P1471; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; Izaurralde E, 2002, EUR J CELL BIOL, V81, P577, DOI 10.1078/0171-9335-00273; James P, 1996, GENETICS, V144, P1425; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Maraldi NM, 1999, J CELL PHYSIOL, V181, P203, DOI 10.1002/(SICI)1097-4652(199911)181:2<203::AID-JCP3>3.0.CO;2-O; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Rayala HJ, 2004, MOL CELL PROTEOMICS, V3, P145, DOI 10.1074/mcp.M300106-MCP200; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; SIKORSKI RS, 1989, GENETICS, V122, P19; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Suntharalingam M, 2004, J BIOL CHEM, V279, P35384, DOI 10.1074/jbc.M402044200; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002	92	42	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51022	51032		10.1074/jbc.M409394200	http://dx.doi.org/10.1074/jbc.M409394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459192	hybrid			2022-12-27	WOS:000225355800047
J	Skorvaga, M; DellaVecchia, MJ; Croteau, DL; Theis, K; Truglio, JJ; Mandavilli, BS; Kisker, C; Van Houten, B				Skorvaga, M; DellaVecchia, MJ; Croteau, DL; Theis, K; Truglio, JJ; Mandavilli, BS; Kisker, C; Van Houten, B			Identification of residues within UvrB that are important for efficient DNA binding and damage processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CRYSTAL-STRUCTURE; THERMUS-THERMOPHILUS; PROTEIN COMPLEX; RECOGNITION; HELICASE; ENZYME	The UvrB protein is the central recognition protein in bacterial nucleotide excision repair. We have shown previously that the highly conserved beta-hairpin motif in Bacillus caldotenax UvrB is essential for DNA binding, damage recognition, and UvrC-mediated incision, as deletion of the upper part of the beta-hairpin ( residues 97 112) results in the inability of UvrB to be loaded onto damaged DNA, defective incision, and the lack of strand-destabilizing activity. In this work, we have further examined the role of the beta-hairpin motif of UvrB by a mutational analysis of 13 amino acids within or in the vicinity of the beta-hairpin. These amino acids are predicted to be important for the interaction of UvrB with both damaged and non-damaged DNA strands as well as the formation of salt bridges between the beta-hairpin and domain 1b of UvrB. The resulting mutants were characterized by standard functional assays such as oligonucleotide incision, electrophoretic mobility shift, strand-destabilizing, and ATPase assays. Our data indicated a direct role of Tyr(96), Glu(99), and Arg(123) in damage-specific DNA binding. In addition, Tyr(93) plays an important but less essential role in DNA binding by UvrB. Finally, the formation of salt bridges between the beta-hairpin and domain 1b, involving amino acids Lys(111) bound to Glu(307) and Glu(99) bound to Arg(367) or Arg(289), are important but not essential for the function of UvrB.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Slovak Acad Sci, Canc Res Inst, Dept Mol Genet, Bratislava 83391, Slovakia; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Slovak Academy of Sciences; University of Massachusetts System; University of Massachusetts Amherst	Kisker, C (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	kisker@pharm.sunysb.edu; vanhout1@niehs.nih.gov	Skorvaga, Milan/AAO-2360-2021; Kisker, Caroline/T-1724-2019; Van Houten, Bennett/K-2284-2019; Croteau, Deb/AAP-5933-2020	Kisker, Caroline/0000-0002-0216-6026; Theis, Karsten/0000-0003-2697-6143; Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061060] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DellaVecchia MJ, 2004, J BIOL CHEM, V279, P45245, DOI 10.1074/jbc.M408659200; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; Nakagawa N, 1999, J BIOCHEM, V126, P986, DOI 10.1093/oxfordjournals.jbchem.a022566; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; Zou Y, 2004, BIOCHEMISTRY-US, V43, P4196, DOI 10.1021/bi035992a	14	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51574	51580		10.1074/jbc.M409266200	http://dx.doi.org/10.1074/jbc.M409266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456749	hybrid			2022-12-27	WOS:000225355800113
J	Rubin, BB; Downey, GP; Koh, A; Degousee, N; Ghomashchi, F; Nallan, L; Stefanski, E; Harkin, DW; Sun, CX; Smart, BP; Lindsay, TF; Cherepanov, V; Vachon, E; Kelvin, D; Sadilek, M; Brown, GE; Yaffe, MB; Plumb, J; Grinstein, S; Glogauer, M; Gelbe, MH				Rubin, BB; Downey, GP; Koh, A; Degousee, N; Ghomashchi, F; Nallan, L; Stefanski, E; Harkin, DW; Sun, CX; Smart, BP; Lindsay, TF; Cherepanov, V; Vachon, E; Kelvin, D; Sadilek, M; Brown, GE; Yaffe, MB; Plumb, J; Grinstein, S; Glogauer, M; Gelbe, MH			Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection - Cpla2-alpha does not regulate neutrophil NADPH oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; GRAM-NEGATIVE BACTERIAL; GROUP-X; RESPIRATORY BURST; DEFICIENT MICE; PIVOTAL ROLE; LUNG INJURY; GROUP-V; A(2); PHAGOCYTOSIS	The role of a cytosolic phospholipase A(2)-alpha( cPLA(2)-alpha) in neutrophil arachidonic acid release, platelet-activating factor ( PAF) biosynthesis, NADPH oxidase activation, and bacterial killing in vitro, and the innate immune response to bacterial infection in vivo was examined. cPLA(2)-alpha activity was blocked with the specific cPLA(2)-alpha inhibitor, Pyrrolidine-1 ( human cells), or by cPLA(2)-alpha gene disruption ( mice). cPLA(2)-alpha inhibition or gene disruption led to complete suppression of neutrophil arachidonate release and PAF biosynthesis but had no effect on neutrophil NADPH oxidase activation, FcgammaII/III or CD11b surface expression, primary or secondary granule secretion, or phagocytosis of Escherichia coli in vitro. In contrast, cPLA(2)-alpha inhibition or gene disruption diminished neutrophil-mediated E. coli killing in vitro, which was partially rescued by exogenous arachidonic acid or PAF but not leukotriene B-4. Following intratracheal inoculation with live E. coli in vivo, pulmonary PAF biosynthesis, inflammatory cell infiltration, and clearance of E. coli were attenuated in cPLA(2)-alpha(-I-) mice compared with wild type littermates. These studies identify a novel role for cPLA(2)-alpha in the regulation of neutrophil-mediated bacterial killing and the innate immune response to bacterial infection.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Toronto, Hlth Network, Div Vasc Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hlth Network, Dept Med, Div Resp, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hlth Network, Toride Kyodo Gen Hosp, Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Toronto Gen Hosp, Toronto Gen Res Inst,Hlth Network, Div Expt Therapeut, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Toronto Gen Res Inst,Hlth Network, Dept Immunol, Toronto, ON M5G 2C4, Canada; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Dent, Toronto, ON M5S 3E2, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Gelbe, MH (corresponding author), Univ Washington, Dept Chem, Campus Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Glogauer, Michael/D-2504-2011	gelb, michael/0000-0001-7000-5219; Downey, Gregory P/0000-0003-3253-5862; Harkin, Denis/0000-0002-4701-8350; Glogauer, Michael/0000-0002-6248-5977	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050040-10, HL50040, R01 HL036235-21, HL36236, R01 HL036235, R01 HL050040] Funding Source: Medline; NIGMS NIH HHS [R01 GM059281, GM59281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen LAH, 2002, CURR BIOL, V12, P1762, DOI 10.1016/S0960-9822(02)01216-2; Bailie MB, 1996, J IMMUNOL, V157, P5221; Baker PRS, 2002, BBA-MOL CELL RES, V1592, P175, DOI 10.1016/S0167-4889(02)00314-2; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Baughman RP, 1999, RESPIRATION, V66, P95, DOI 10.1159/000029349; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Blackwood RA, 1996, J LEUKOCYTE BIOL, V59, P663, DOI 10.1002/jlb.59.5.663; BLIGH EG, 1959, CAN J MED SCI, V37, P911, DOI DOI 10.1139/O59-099; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Daniels I, 1998, CLIN DIAGN LAB IMMUN, V5, P683, DOI 10.1128/CDLI.5.5.683-689.1998; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; ELY EW, 1995, BBA-LIPID LIPID MET, V1258, P135; Fonteh AN, 2002, EUR J BIOCHEM, V269, P3760, DOI 10.1046/j.1432-1033.2002.03070.x; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; Hegen M, 2003, J EXP MED, V197, P1297, DOI 10.1084/jem.20030016; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; Lee WL, 2003, MICROBES INFECT, V5, P1299, DOI 10.1016/j.micinf.2003.09.014; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lie WJ, 2003, CLIN EXP ALLERGY, V33, P1125, DOI 10.1046/j.1365-2222.2003.01726.x; Mancuso P, 1998, INFECT IMMUN, V66, P5140, DOI 10.1128/IAI.66.11.5140-5146.1998; Marshall J, 2000, J IMMUNOL, V164, P2084, DOI 10.4049/jimmunol.164.4.2084; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015; Morgan E, 2004, CLIN IMMUNOL, V110, P252, DOI 10.1016/j.clim.2003.11.017; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Sajjan U, 2001, INFECT IMMUN, V69, P5138, DOI 10.1128/IAI.69.8.5138-5150.2001; SAKATA A, 1987, J IMMUNOL, V138, P4353; Shmelzer Z, 2003, J CELL BIOL, V162, P683, DOI 10.1083/jcb.200211056; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; Souza DG, 2003, BRIT J PHARMACOL, V139, P733, DOI 10.1038/sj.bjp.0705296; Stroncek DF, 1998, TRANSFUSION, V38, P663, DOI 10.1046/j.1537-2995.1998.38798346635.x; TAVARES DL, 1998, EUR J PHARMACOL, V358, P69; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; Yaffe MB, 1999, SURGERY, V126, P248, DOI 10.1016/S0039-6060(99)70162-5; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601; Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	59	85	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7519	7529		10.1074/jbc.M407438200	http://dx.doi.org/10.1074/jbc.M407438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15475363	hybrid, Green Accepted			2022-12-27	WOS:000227395700014
J	Bowen, WS; Van Dyke, N; Murgola, EJ; Lodmell, JS; Hill, WE				Bowen, WS; Van Dyke, N; Murgola, EJ; Lodmell, JS; Hill, WE			Interaction of thiostrepton and elongation factor-G with the ribosomal protein L11-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; FACTOR EF-G; 23S RNA; TRANSLATION TERMINATION; CONFORMATIONAL-CHANGE; GTPASE CENTER; 70S RIBOSOME; BINDING; SUBUNIT; COMPLEX	Ribosomal protein L11 and the L11 binding region of ribosomal RNA constitute an important domain involved in active functions of the ribosome during translation. We studied the effects of L11 knock-out and truncation mutations on the structure of the rRNA in this region and on its interactions with a translation elongation factor and the antibiotic thiostrepton. The results indicated that the structure of the L11-binding rRNA becomes conformationally flexible when ribosomes lack the entire L11 protein, but not when the C-terminal domain is present on ribosomes. Probing wild type and mutant ribosomes in the presence of the antibiotic thiostrepton and elongation factor-G (EF-G) rigorously localized the binding cleft of thiostrepton and suggested a role for the rRNA in the L11-binding domain in modulating factor binding. Our results also provide evidence that the structure of the rRNA stabilized by the C-terminal domain of L11 is necessary to stabilize EF-G binding in the post-translocation state, and thiostrepton may modulate this structure in a manner that interferes with the ribosome-EF-G interaction. The implications for recent models of thiostrepton activity and factor interactions are discussed.	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Montana System; University of Montana; University of Texas System; UTMD Anderson Cancer Center	Hill, WE (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	bi_weh@selway.umt.edu			NIGMS NIH HHS [GM21499, GM35717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035717, R01GM021499] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Arkov AL, 2000, BIOCHIMIE, V82, P671, DOI 10.1016/S0300-9084(00)01162-7; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Batey RT, 1996, J MOL BIOL, V261, P550, DOI 10.1006/jmbi.1996.0482; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BODLEY JW, 1970, J BIOL CHEM, V245, P5656; Bowen WS, 2001, METHODS, V25, P344, DOI 10.1006/meth.2001.1246; BROT N, 1974, P NATL ACAD SCI USA, V71, P89, DOI 10.1073/pnas.71.1.89; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-15; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; CUNDLIFFE E, 1979, J MOL BIOL, V132, P235, DOI 10.1016/0022-2836(79)90393-0; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717; DRAPER DE, 1995, J MOL BIOL, V249, P231, DOI 10.1006/jmbi.1995.0291; ECKSTEIN F, 1971, BIOCHEM BIOPH RES CO, V45, P1151, DOI 10.1016/0006-291X(71)90139-2; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; ENDO Y, 1982, J BIOL CHEM, V257, P9054; Gale EF, 1981, MOL BASIS ANTIBIOTIC, P402; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HIGHLAND JH, 1975, J BIOL CHEM, V250, P1141; JUCKER FM, 1995, RNA, V1, P219; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; Lentzen G, 2003, CHEM BIOL, V10, P769, DOI 10.1016/S1074-5521(03)00173-X; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Muth GW, 1999, NUCLEIC ACIDS RES, V27, P1906, DOI 10.1093/nar/27.8.1906; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; STERN S, 1988, METHOD ENZYMOL, V164, P481; STOFFLER G, 1980, J BIOL CHEM, V255, P517; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TAM MF, 1981, J BIOL CHEM, V256, P6430; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; Van Dyke N, 2003, J MOL BIOL, V330, P9, DOI 10.1016/S0022-2836(03)00537-0; Van Dyke N, 2002, J MOL BIOL, V319, P329, DOI 10.1016/S0022-2836(02)00304-2; Wilson KS, 2004, J MOL BIOL, V337, P15, DOI 10.1016/j.jmb.2004.01.013; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	49	34	34	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2934	2943		10.1074/jbc.M407008200	http://dx.doi.org/10.1074/jbc.M407008200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15492007	hybrid			2022-12-27	WOS:000226449100069
J	Hryciw, DH; Ekberg, J; Lee, A; Lensink, IL; Kumar, S; Guggino, WB; Cook, DI; Pollock, CA; Poronnik, P				Hryciw, DH; Ekberg, J; Lee, A; Lensink, IL; Kumar, S; Guggino, WB; Cook, DI; Pollock, CA; Poronnik, P			Nedd4-2 functionally interacts with ClC-5 - Involvement in constitutive albumin endocytosis in proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; UBIQUITIN LIGASE NEDD4-2; CHLORIDE CHANNEL; DENTS-DISEASE; IMPAIRS ENDOCYTOSIS; RENAL-FAILURE; PROTEIN; RECEPTOR; SERUM; DEGRADATION	Constitutive albumin uptake by the proximal tubule is achieved by a receptor-mediated process in which the Cl- channel, ClC-5, plays an obligate role. Here we investigated the functional interaction between ClC-5 and ubiquitin ligases Nedd4 and Nedd4-2 and their role in albumin uptake in opossum kidney proximal tubule (OK) cells. In vivo immunoprecipitation using an anti-HECT antibody demonstrated that ClC-5 bound to ubiquitin ligases, whereas glutathione S-transferase pull-downs confirmed that the C terminus of ClC-5 bound both Nedd4 and Nedd4-2. Nedd4-2 alone was able to alter ClC-5 currents in Xenopus oocytes by decreasing cell surface expression of ClC-5. In OK cells, a physiological concentration of albumin (10 mug/ml) rapidly increased cell surface expression of ClC-5, which was also accompanied by the ubiquitination of ClC-5. Albumin uptake was reduced by inhibiting either the lysosome or proteasome. Total levels of Nedd4-2 and proteasome activity also increased rapidly in response to albumin. Overexpression of ligase defective Nedd4-2 or knockdown of endogenous Nedd4-2 with small interfering RNA resulted in significant decreases in albumin uptake. In contrast, pathophysiological concentrations of albumin (100 and 1000 mug/ml) reduced the levels of ClC-5 and Nedd4-2 and the activity of the proteasome to the levels seen in the absence of albumin. These data demonstrate that normal constitutive uptake of albumin by the proximal tubule requires Nedd4-2, which may act via ubiquitination to shunt ClC-5 into the endocytic pathway.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Univ Sydney, Royal N Shore Hosp, Kolling Inst, Sydney, NSW 2065, Australia	University of Queensland; Hanson Institute; Institute Medical & Veterinary Science Australia; Johns Hopkins University; University of Sydney; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Poronnik, P (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	p.poronnik@uq.edu.au	Kumar, Sharad/AAX-7787-2020; Hryciw, Deanne/P-2642-2019; Ekberg, Jenny/AAV-2006-2020	Kumar, Sharad/0000-0001-7126-9814; Hryciw, Deanne/0000-0003-1697-8890; Poronnik, Philip/0000-0002-6246-528X; Ekberg, Jenny/0000-0001-5151-4966	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 32753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Drumm K, 2003, CELL PHYSIOL BIOCHEM, V13, P199, DOI 10.1159/000072422; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Gekle M, 2001, J PHYSIOL-LONDON, V531, P619, DOI 10.1111/j.1469-7793.2001.0619h.x; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Hegde AN, 2004, PROG NEUROBIOL, V73, P311, DOI 10.1016/j.pneurobio.2004.05.005; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hryciw DH, 2003, J BIOL CHEM, V278, P40169, DOI 10.1074/jbc.M307890200; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kirkpatrick DS, 2003, TOXICOL APPL PHARM, V186, P101, DOI 10.1016/S0041-008X(02)00019-4; Klisic J, 2003, J AM SOC NEPHROL, V14, P3008, DOI 10.1097/01.ASN.0000098700.70804.D3; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee EM, 2003, AM J PHYSIOL-RENAL, V285, pF748, DOI 10.1152/ajprenal.00442.2002; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lou XJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134918; Maack T, 2000, KIDNEY PHYSL PATHOPH, P3005; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Melman L, 2002, MOL BIOL CELL, V13, P3325, DOI 10.1091/mbc.E02-03-0152; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Moulin P, 2003, KIDNEY INT, V63, P1285, DOI 10.1046/j.1523-1755.2003.00851.x; Norden AGW, 2001, KIDNEY INT, V60, P1885, DOI 10.1046/j.1523-1755.2001.00016.x; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Palmada M, 2004, AM J PHYSIOL-GASTR L, V287, pG143, DOI 10.1152/ajpgi.00121.2003; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Portero-Otin M, 1999, DIABETES, V48, P2215, DOI 10.2337/diabetes.48.11.2215; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Russo LM, 2002, AM J KIDNEY DIS, V39, P899, DOI 10.1053/ajkd.2002.32764; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; Shankland SJ, 2000, AM J PHYSIOL-RENAL, V278, pF515, DOI 10.1152/ajprenal.2000.278.4.F515; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; WRONG OM, 1994, Q J MED, V87, P473; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	60	77	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					54996	55007		10.1074/jbc.M411491200	http://dx.doi.org/10.1074/jbc.M411491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489223	hybrid			2022-12-27	WOS:000225960800004
J	Reiley, W; Zhang, MY; Sun, SC				Reiley, W; Zhang, MY; Sun, SC			Negative regulation of JNK signaling by the tumor suppressor CYLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; JUN NH2-TERMINAL KINASE; NECROSIS-FACTOR; TERMINAL KINASE; UBIQUITIN LIGASE; CELL-DEATH; ACTIVATION; APOPTOSIS; EXPRESSION; INDUCTION	CYLD is a tumor suppressor that is mutated in familial cylindromatosis, an autosomal dominant predisposition to multiple tumors of the skin appendages. Recent studies suggest that transfected CYLD has deubiquitinating enzyme activity and inhibits the activation of transcription factor NF-kappaB. However, the role of endogenous CYLD in regulating cell signaling remains poorly defined. Here we report a critical role for CYLD in negatively regulating the c-Jun NH2-terminal kinase (JNK). CYLD knockdown by RNA interference results in hyperactivation of JNK by diverse immune stimuli, including tumor necrosis factor-alpha, interleukin-1, lipopolysaccharide, and an agonistic anti-CD40 antibody. The JNK-inhibitory function of CYLD appears to be specific for immune receptors because the CYLD knockdown has no significant effect on stress-induced JNK activation. Consistently, CYLD negatively regulates the activation of MKK7, an upstream kinase known to mediate JNK activation by immune stimuli. We further demonstrate that CYLD also negatively regulates IkappaB kinase, although this function of CYLD is seen in a receptor-dependent manner. These findings identify the JNK signaling pathway as a major downstream target of CYLD and suggest a receptor-dependent role of CYLD in regulating the IkappaB kinase pathway.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA094922, T32CA060395] Funding Source: NIH RePORTER; NCI NIH HHS [CA 094922, 5T32 CA 60395-09] Funding Source: Medline; NIAID NIH HHS [AI 45045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brooke HG, 1892, BRIT J DERMATOL, V4, P269; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HIMENO T, 1990, CANCER RES, V50, P4941; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jensen LE, 2003, FEBS LETT, V553, P190, DOI 10.1016/S0014-5793(03)00998-0; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Liu ZG, 2003, MOL CELL, V12, P795, DOI 10.1016/S1097-2765(03)00399-X; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Spiegler E., 1899, ARCH DERMATOL SYPHIL, V50, P163; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsuiki H, 2003, CANCER RES, V63, P250; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xu X, 1996, ONCOGENE, V13, P135; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	56	125	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55161	55167		10.1074/jbc.M411049200	http://dx.doi.org/10.1074/jbc.M411049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496400	hybrid			2022-12-27	WOS:000225960800023
J	Kimball, SR; Siegfried, BA; Jefferson, LS				Kimball, SR; Siegfried, BA; Jefferson, LS			Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-METABOLISM; TRANSLATION INITIATION; TUMOR-SUPPRESSOR; SKELETAL-MUSCLE; TUBEROUS-SCLEROSIS; S6 KINASE; HELICASE ACTIVITY; CELLULAR-ENERGY; PHOSPHORYLATION; MTOR	The opposing actions of glucagon and insulin on glucose metabolism within the liver are essential mechanisms for maintaining plasma glucose concentrations within narrow limits. Less well studied are the counter-regulatory actions of glucagon on protein metabolism. In the present study, the effect of glucagon on amino acid-induced signaling through the mammalian target of rapamycin ( mTOR), an important controller of the mRNA binding step in translation initiation, was examined using the perfused rat liver as an experimental model. The results show that amino acids enhance signaling through mTOR resulting in phosphorylation of eukaryotic initiation factor 4E-binding protein (4E-BP)1, the 70-kDa ribosomal protein (rp)S6 kinase, S6K1, and rpS6. In contrast, glucagon repressed both basal and amino acid-induced signaling through mTOR, as assessed by changes in the phosphorylation of 4E-BP1 and S6K1. The repression was associated with the activation of protein kinase A and enhanced phosphorylation of LKB1 and the AMP-activated protein kinase (AMPK). Surprisingly, the phosphorylation of two S6K1 substrates, rpS6 and eukaryotic initiation factor 4B, was not repressed but instead was increased by glucagon treatment, regardless of the amino acid concentration. The latter finding could be explained by the glucagon-induced phosphorylation of the ERK1 and the 90-kDa rpS6 kinase p90(rsk). Thus, glucagon represses phosphorylation of 4E-BP1 and S6K1 through the activation of a protein kinase A-LKB-AMPK-mTOR signaling pathway, while simultaneously enhancing phosphorylation of other downstream effectors of mTOR through the activation of the extracellular signal-regulated protein kinase 1-p90(rsk) signaling pathway. Amino acids also enhance AMPK phosphorylation, although to a lesser extent than glucagon and amino acids combined.	Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kimball, SR (corresponding author), Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	skimball@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK013499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13499] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthony JC, 2000, J NUTR, V130, P2413; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Charlton MR, 1996, J CLIN INVEST, V98, P90, DOI 10.1172/JCI118782; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; COUET C, 1990, AM J PHYSIOL, V258, pE78, DOI 10.1152/ajpendo.1990.258.1.E78; Dalle S, 2004, J BIOL CHEM, V279, P20345, DOI 10.1074/jbc.M312483200; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Exton J H, 1975, Methods Enzymol, V39, P25; FELDHOFF RC, 1977, J BIOL CHEM, V252, P3611; FLAKOLL PJ, 1994, METABOLISM, V43, P1509, DOI 10.1016/0026-0495(94)90009-4; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JEFFERIES HBJ, 1996, COLD SPRING HARBOR M, V30, P389; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; Kimball SR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1080, DOI 10.1152/ajpendo.2000.279.5.E1080; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200; NAIR KS, 1995, J CLIN INVEST, V95, P2926, DOI 10.1172/JCI118000; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sampson JR, 2003, BIOCHEM SOC T, V31, P592, DOI 10.1042/BST0310592; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; TOLMAN EL, 1973, J BIOL CHEM, V248, P4552; WOODSIDE KH, 1974, J BIOL CHEM, V249, P5458; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Yoshizawa F, 1998, AM J PHYSIOL-ENDOC M, V275, pE814, DOI 10.1152/ajpendo.1998.275.5.E814	53	107	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54103	54109		10.1074/jbc.M410755200	http://dx.doi.org/10.1074/jbc.M410755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494402	hybrid			2022-12-27	WOS:000225793600028
J	Kojma, Y; Hirata, K; Ishida, T; Shimokawa, Y; Inoue, N; Kawashima, S; Quertermous, T; Yokoyama, M				Kojma, Y; Hirata, K; Ishida, T; Shimokawa, Y; Inoue, N; Kawashima, S; Quertermous, T; Yokoyama, M			Endothelial lipase modulates monocyte adhesion to the vessel wall - A potential role in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CELL-DERIVED LIPASE; SERUM-LIPOPROTEINS; ENHANCES BINDING; HEPARAN-SULFATE; MESSENGER-RNA; ATHEROSCLEROSIS; GENE; EXPRESSION; ENDOTOXIN	Endothelial lipase (EL), a new member of the lipoprotein lipase gene family, plays a central role in high density lipoprotein metabolism. Previous studies indicated that EL is expressed in endothelial cells, macrophages, and smooth muscle cells in atherosclerotic lesions in human coronary arteries. However, the functional role of EL in the local vessel wall remains obscure. In this study, we evaluated the ability of EL to modulate monocyte adhesion to the endothelial cell surface. EL mRNA and protein levels were markedly increased in tissues of the mouse model of inflammation induced by lipopolysaccharide injection. Adhesion assays in vitro revealed that overexpression of EL in COS7 or Pro5 cells enhanced monocyte bindings to the EL-expression cells. Heparin or heparinase treatment inhibited EL-mediated increases of monocyte adhesion in a dose-dependent manner. Moreover, ex vivo adhesion assays revealed that the number of adherent monocytes on aortic strips was significantly increased in EL transgenic mice and decreased in EL knock-out mice as compared with wildtype mice. These results suggest that EL on the endothelial cell surface can promote monocyte adhesion to the vascular endothelium through the interaction with heparan sulfate proteoglycans. Thus, the up-regulation of EL by inflammatory stimuli may be involved in the progression of inflammation.	Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Stanford Univ, Donald W Reynolds Cardiovasc Clin Res Ctr, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA	Kobe University; Stanford University	Hirata, K (corresponding author), Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	hiratak@med.kobe-u.ac.jp		Quertermous, Thomas/0000-0002-7645-9067				AVIRAM M, 1988, J BIOL CHEM, V263, P15416; Azumi H, 2003, CARDIOVASC RES, V58, P647, DOI 10.1016/S0008-6363(03)00287-6; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; DICHEK HL, 1993, J LIPID RES, V34, P1393; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; Feingold KR, 1999, ATHEROSCLEROSIS, V142, P379, DOI 10.1016/S0021-9150(98)00265-2; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; HILL MR, 1995, INFECT IMMUN, V63, P858, DOI 10.1128/IAI.63.3.858-864.1995; Hirata K, 2000, BIOCHEM BIOPH RES CO, V272, P90, DOI 10.1006/bbrc.2000.2747; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Ishida T, 2004, J BIOL CHEM, V279, P45085, DOI 10.1074/jbc.M406360200; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Ishida T, 2004, GENOMICS, V83, P24, DOI 10.1016/S0888-7543(03)00181-2; Ishida T, 1999, CARDIOVASC RES, V41, P267, DOI 10.1016/S0008-6363(98)00162-X; JACKSON RL, 1983, ENZYMES, V16, P141; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2003, CIRC RES, V92, P644, DOI 10.1161/01.RES.0000064502.47539.6D; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; Mamputu JC, 1997, J LIPID RES, V38, P1722; McCoy MG, 2002, J LIPID RES, V43, P921; NAVAB M, 1994, CORONARY ARTERY DIS, V5, P198, DOI 10.1097/00019501-199403000-00003; Obunike JC, 1997, ARTERIOSCL THROM VAS, V17, P1414, DOI 10.1161/01.ATV.17.7.1414; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSSNER S, 1978, ATHEROSCLEROSIS, V31, P93, DOI 10.1016/0021-9150(78)90041-2; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Rutledge JC, 1997, CIRC RES, V80, P819; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; Santamarina-Fojo S, 2000, INT J TISSUE REACT, V22, P39; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; Wang GP, 2002, ARTERIOSCL THROM VAS, V22, P1777, DOI 10.1161/01.ATV.0000035404.18281.37; WEI YZ, 1995, STEM CELLS, V13, P541, DOI 10.1002/stem.5530130512; Yamashita T, 2000, CIRCULATION, V101, P931, DOI 10.1161/01.CIR.101.8.931; Yu KCW, 2004, J LIPID RES, V45, P1614, DOI 10.1194/jlr.M400069-JLR200; Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407	42	40	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54032	54038		10.1074/jbc.M411112200	http://dx.doi.org/10.1074/jbc.M411112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485805	hybrid			2022-12-27	WOS:000225793600019
J	Wang, B; Liu, K; Lin, FT; Lin, WC				Wang, B; Liu, K; Lin, FT; Lin, WC			A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA FAMILY PROTEINS; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; PHOSPHORYLATION; P53; DEGRADATION; ASSOCIATION; STABILITY; ACCUMULATION; SPECIFICITY	Genotoxic stress triggers apoptosis through multiple signaling pathways. Recent studies have demonstrated a specific induction of E2F1 accumulation and a role for E2F1 in apoptosis upon DNA damage. Induction of E2F1 is mediated by phosphorylation events that are dependent on DNA damage-responsive protein kinases, such as ATM. How ATM phosphorylation leads to E2F1 stabilization is unknown. We now show that 14-3-3tau, a phosphoserine-binding protein, mediates E2F1 stabilization. 14-3-3tau interacts with ATM-phosphorylated E2F1 during DNA damage and inhibits E2F1 ubiquitination. Depletion of 14-3-3tau or E2F1, but not E2F2 or E2F3, blocks adriamycin-induced apoptosis. 14-3-3tau is also required for expression and induction of E2F1 apoptotic targets, such as p73, Apaf-1, and caspases, during DNA damage. Together, these data demonstrate a novel function for 14-3-3tau in the regulation of E2F1 protein stability and apoptosis during DNA damage.	Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lin, WC (corresponding author), 520A Wallace Tumor Inst, 1530 3rd Ave S, Birmingham, AL 35294 USA.	wclin@uab.edu			NCI NIH HHS [CA100848, CA100857, R01 CA100848, R01 CA100857] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100848, R01CA100857] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Meng RD, 1999, INT J ONCOL, V14, P5; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohta T, 2001, CANCER RES, V61, P1347; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003	42	76	77	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54140	54152		10.1074/jbc.M410493200	http://dx.doi.org/10.1074/jbc.M410493200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494392	Green Accepted, hybrid			2022-12-27	WOS:000225793600033
J	Avkin, S; Goldsmith, M; Velasco-Miguel, S; Geacintov, N; Friedberg, EC; Livneh, Z				Avkin, S; Goldsmith, M; Velasco-Miguel, S; Geacintov, N; Friedberg, EC; Livneh, Z			Quantitative analysis of translesion DNA synthesis across a benzo[a] pyrene-guanine adduct in mammalian cells - The role of DNA polymerase kappa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM VARIANT; BENZO<A>PYRENE DIOL EPOXIDE; PRONE LESION BYPASS; ESCHERICHIA-COLI; SEQUENCE CONTEXT; ERROR-FREE; HUMAN HOMOLOG; Y-FAMILY; IN-VITRO; POL-V	Replication across unrepaired DNA lesions in mammalian cells is effected primarily by specialized, low fidelity DNA polymerases. We studied translesion DNA synthesis (TLS) across a benzo[ a] pyrene-guanine (BP-G) adduct, a major mutagenic DNA lesion generated by tobacco smoke. This was done using a quantitative assay that measures TLS indirectly, by measuring the recovery of gapped plasmids transfected into cultured mammalian cells. Analysis of PolK(+/+) mouse embryo fibroblasts (MEFs) showed that TLS across the BP-G adduct occurred with an efficiency of 48 +/- 4%, which is an order of magnitude higher than in Escherichia coli. In PolK(-/-) MEFs, bypass was 16 +/- 1%, suggesting that at least two-thirds of the BP-G adducts in MEFs were bypassed exclusively by polymerase kappa (polkappa). In contrast, poleta was not required for bypass across BP-G in a human XP-V cell line. Analysis of misinsertion specificity across BP-G revealed that bypass was more error-prone in MEFs lacking polkappa. Expression of polkappa from a plasmid introduced into PolK(-/-) MEFs restored both the extent and fidelity of bypass across BP-G. Polkappa was not required for bypass of a synthetic abasic site. In vitro analysis demonstrated efficient bypass across BP-G by both polkappa and poleta, suggesting that the biological role of polkappa in TLS across BP-G is due to regulation of TLS and not due to an exclusive ability to bypass this lesion. These results indicate that BP-G is bypassed in mammalian cells with relatively high efficiency and that polkappa bypasses BP-G in vivo with higher efficiency and higher accuracy than other DNA polymerases.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA; NYU, Dept Chem, New York, NY 10003 USA	Weizmann Institute of Science; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	zvi.livneh@weizmann.ac.il			NATIONAL CANCER INSTITUTE [R01CA099194] Funding Source: NIH RePORTER; NCI NIH HHS [CA099194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Arghavani MB, 1998, BIOCHEMISTRY-US, V37, P8575, DOI 10.1021/bi980237w; Avkin S, 2002, P NATL ACAD SCI USA, V99, P3764, DOI 10.1073/pnas.062038699; Avkin S, 2002, MUTAT RES-FUND MOL M, V510, P81, DOI 10.1016/S0027-5107(02)00254-3; Berdichevsky A, 2002, MOL CELL, V10, P917, DOI 10.1016/S1097-2765(02)00679-2; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Cleaver JE, 1999, CANCER RES, V59, P1102; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Goodwin BK, 2000, J AGR RESOUR ECON, V25, P195; Hanrahan CJ, 1997, CHEM RES TOXICOL, V10, P369, DOI 10.1021/tx9601925; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; MAO B, 1995, CARCINOGENESIS, V16, P357, DOI 10.1093/carcin/16.2.357; Maor-Shoshani A, 2003, P NATL ACAD SCI USA, V100, P14760, DOI 10.1073/pnas.2433503100; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Schenten D, 2002, EUR J IMMUNOL, V32, P3152, DOI 10.1002/1521-4141(200211)32:11<3152::AID-IMMU3152>3.0.CO;2-2; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Shukla R, 1997, BIOCHEMISTRY-US, V36, P10256, DOI 10.1021/bi970541+; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Washington MT, 2001, P NATL ACAD SCI USA, V98, P8355, DOI 10.1073/pnas.121007298; YANG JL, 1987, MOL CELL BIOL, V7, P1267, DOI 10.1128/MCB.7.3.1267; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1	55	149	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53298	53305		10.1074/jbc.M409155200	http://dx.doi.org/10.1074/jbc.M409155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475561	hybrid			2022-12-27	WOS:000225680600061
J	Ma, BY; Nussinov, R				Ma, BY; Nussinov, R			Release factors eRF1 and RF2 - A universal mechanism controls the large conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME RECYCLING FACTOR; TRANSFER-RNA HYDROLYSIS; POLYPEPTIDE RELEASE; CRYSTAL-STRUCTURE; TRANSLATION TERMINATION; HISTIDINE PROTONATION; STRUCTURALLY DISTINCT; ANGSTROM RESOLUTION; STOP CODONS; FACTOR RRF	Class I release factors 1 and 2 (RF1 and RF2) terminate protein synthesis by recognizing stop codons on the mRNA via their conserved amino acid motifs (NIKS in eRF1 and SPF in RF2) and by the conserved tripeptide (GGQ) interactions with the ribosomal peptidyltransferase center. Crystal structures of eRF1 and RF2 do not fit their ribosomal binding pocket (similar to73 Angstrom). Cryoelectron microscopy indicates large conformational changes in the ribosome-bound RF2. Here, we investigate the conformational dynamics of the eRF1 and RF2 using molecular dynamics simulation, structural alignment, and electrostatic analysis of domain interactions. We show that relaxed eRF1 has a shape remarkably similar to the ribosome-bound RF2 observed by cryoelectron microscopy. The similarity between the two release factors is as good as between elongation factor G and elongation factor Tuguanosine-5'(beta,gamma-imido)triphosphate-tRNA. Further, the conformational transitions and dynamics of eRF1 and RF2 between the free and ribosome-bound states are most likely controlled by protonation of conserved histidines. For eRF1, the distance between the NIKS and GGQ motifs shrinks from 97.5 Angstromin the crystal to 70-80 Angstrom. For RF2, the separation between SPF and GGQ elongates from 32 Angstrom in the crystal to 50 Angstrom. Coulombic interaction strongly favors the open conformation of eRF1; however, solvation and histidine protonation modulate the domain interactions, making the closed conformation of eRF1 more accessible. Thus, RF1 and RF2 function like molecular machines, most likely fueled by histidine protonation. The unified conformational control and the shapes of eRF1 and RF2 support the proposition that the termination of protein synthesis involves similar mechanisms across species.	NCI, Basic Res Program, SAIC Frederick Inc, Lab Expt & Computat Biol,NIH, Frederick, MD 21702 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine	Ma, BY (corresponding author), NCI, Basic Res Program, SAIC Frederick Inc, Lab Expt & Computat Biol,NIH, Frederick, MD 21702 USA.	mab@ncifcrf.gov; ruthn@ncifcrf.gov	Ma, Buyong/F-9491-2011	Ma, Buyong/0000-0002-7383-719X; Nussinov, Ruth/0000-0002-8115-6415	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ankerst M, 1999, Proc Int Conf Intell Syst Mol Biol, P34; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Brodersen DE, 2003, NAT STRUCT BIOL, V10, P78, DOI 10.1038/nsb0203-78; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carneiro FA, 2003, J BIOL CHEM, V278, P13789, DOI 10.1074/jbc.M210615200; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Inagaki Y, 2002, NUCLEIC ACIDS RES, V30, P532, DOI 10.1093/nar/30.2.532; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Kjeldgaard M, 2003, MOL CELL, V11, P8, DOI 10.1016/S1097-2765(03)00015-7; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Kong CG, 2004, MOL CELL, V14, P233, DOI 10.1016/S1097-2765(04)00206-0; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Lee MS, 2003, J COMPUT CHEM, V24, P1348, DOI 10.1002/jcc.10272; Lundback T, 2000, BIOCHEMISTRY-US, V39, P8909, DOI 10.1021/bi000231i; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nakamura Y, 2003, TRENDS BIOCHEM SCI, V28, P99, DOI 10.1016/S0968-0004(03)00006-9; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Park C, 2001, BIOCHEMISTRY-US, V40, P4949, DOI 10.1021/bi0100182; Pavlov MY, 1998, J MOL BIOL, V284, P579, DOI 10.1006/jmbi.1998.2220; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Pichon C, 2001, ADV DRUG DELIVER REV, V53, P75, DOI 10.1016/S0169-409X(01)00221-6; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Uno M, 2002, P NATL ACAD SCI USA, V99, P1819, DOI 10.1073/pnas.032457599; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; Wolfson AD, 2001, COLD SPRING HARB SYM, V66, P185, DOI 10.1101/sqb.2001.66.185; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	35	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53875	53885		10.1074/jbc.M407412200	http://dx.doi.org/10.1074/jbc.M407412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475364	hybrid			2022-12-27	WOS:000225680600126
J	Patnaik, D; Chin, HG; Esteve, PO; Benner, J; Jacobsen, SE; Pradhan, S				Patnaik, D; Chin, HG; Esteve, PO; Benner, J; Jacobsen, SE; Pradhan, S			Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; LYSINE-9 METHYLATION; CATALYTIC MECHANISM; CPG METHYLATION; SUPPRESSOR GENE; STEADY-STATE; HETEROCHROMATIN; CHROMATIN; PROTEIN; ARABIDOPSIS	Lysine-specific murine histone H3 methyltransferase, G9a, was expressed and purified in a baculovirus expression system. The primary structure of the recombinant enzyme is identical to the native enzyme. Enzymatic activity was favorable at alkaline conditions (> pH 8) and low salt concentration and virtually unchanged between 25 and 42 degreesC. Purified G9a was used for substrate specificity and steady-state kinetic analysis with peptides representing un- or dimethylated lysine 9 histone H3 tails with native lysine 4 or with lysine 4 changed to alanine (K4AK9). In vitro methylation of the H3 tail peptide resulted in trimethylation of Lys-9 and the reaction is processive. The turnover number (k(cat)) for methylation was 88 and 32 h(-1) on the wild type and K4AK9 histone H3 tail, respectively. The Michaelis constants for wild type and K4AK9 (K-m(pep)) were 0.9 and 1.0 muM and for S-adenosyl-L-methionine (K-m(AdoMet)) were 1.8 and 0.6 muM, respectively. Comparable kinetic constants were obtained for recombinant histone H3. The conversion of K4AK9 di- to trimethyl-lysine was 7-fold slower than methyl group addition to unmethylated peptide. Preincubation studies showed that G9a-AdoMet and G9a-peptide complexes are catalytically active. Initial velocity data with peptide and S-adenosyl-L-methionine (AdoMet) and product inhibition studies with S-adenosyl-L-homocysteine were performed to assess the kinetic mechanism of the reaction. Double reciprocal plots and preincubation studies revealed S- adenosyl- L-homocysteine as a competitive inhibitor to AdoMet and mixed inhibitor to peptide. Trimethylated peptides acted as a competitive inhibitor to substrate peptide and mixed inhibitor to AdoMet suggesting a random mechanism in a Bi Bi reaction for recombinant G9a where either substrate can bind first to the enzyme, and either product can release first.	New England Biolabs Inc, Beverly, MA 01915 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Pradhan, S (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	pradhan@neb.com	Patnaik, Debasis/K-8779-2019; Patnaik, Debasis/A-9752-2016	Patnaik, Debasis/0000-0002-9829-3352; Patnaik, Debasis/0000-0002-9829-3352	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM060398, R01GM060398] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60398] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; BORUN TW, 1972, J BIOL CHEM, V247, P4288; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CRANKSHAW MW, 1993, PROTEIN SEQUENCE ANA, P1; Eskeland R, 2004, BIOCHEMISTRY-US, V43, P3740, DOI 10.1021/bi035964s; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Malygin EG, 2003, J BIOL CHEM, V278, P15713, DOI 10.1074/jbc.M213213200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; SEGAL IH, 1975, ENZYME KINETICS BEHA; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WAITEREES PA, 1991, J BACTERIOL, V173, P5207, DOI 10.1128/jb.173.16.5207-5219.1991; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7	38	115	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53248	53258		10.1074/jbc.M409604200	http://dx.doi.org/10.1074/jbc.M409604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485804	hybrid			2022-12-27	WOS:000225680600055
J	Sivendran, S; Patterson, D; Spiegel, E; McGown, I; Cowley, D; Colman, RF				Sivendran, S; Patterson, D; Spiegel, E; McGown, I; Cowley, D; Colman, RF			Two novel mutant human adenylosuccinate Lyases (ASLs) associated with autism and characterization of the equivalent mutant Bacillus subtilis ASL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INBORN ERROR; ACTIVE-SITE; DEFICIENCY; ENZYME; IDENTIFICATION; PURIFICATION; CATALYSIS; MUTATION; HIS(141); DISEASE	An Australian patient with autism was found to be heterozygous for two mutations in the gene encoding adenylosuccinate lyase (ASL), resulting in the protein mutations E80D and D87E. The patient's mother carried only the E80D mutation. The equivalent positions are 62 and 69 in Bacillus subtilis ASL. Although both human and B. subtilis enzymes normally have Asp at position 87 (or 69), the B. subtilis ASL has Ile and Asp at 62 and 65, respectively, whereas human ASL has Glu and Arg at the equivalent positions. We have constructed, expressed, and purified the double mutant I62E/D65R as a "humanized" normal B. subtilis enzyme to compare with enzymes with a single mutation at position 62 (I62D/D65R), at position 69 (I62E/D65R/D69E), or at both positions (I62D/D65R/D69E). V-max for conversion of adenylosuccinate to AMP and fumarate is 0.57 mumol/min/mg for I62E/D65R, 0.064 mumol/min/mg for I62D/D65R, 0.27 mumol/min/mg for I62E/D65R/D69E, and 0.069 mumol/min/mg for I62D/D65R/D69E. The K-m for adenylosuccinate is elevated in the X62D mutants, and I62D/D65R is the least stable of these ASLs at 37 degreesC. The CD spectra of mutant and wild type enzymes are similar; thus, there are no appreciable structural changes. Clearly the Asp(62) causes the most drastic effect on ASL function, whereas the Glu(69) mutation produces only modest change. These results emphasize the importance of expanding tests for ASL deficiency to individuals with developmental delay of any severity, including individuals with autistic spectrum disorder. This study further demonstrates the usefulness of the B. subtilis ASL as a model to mimic the defective enzyme in ASL deficiency.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Denver, Eleanor Roosevelt Inst, Denver, CO 80206 USA; Mater Misericordiae Univ Hosp, Brisbane, Australia	University of Delaware; University of Denver; University College Dublin	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu	Cowley, David M/M-9674-2013	Cowley, David M/0000-0002-4153-934X	NIDDK NIH HHS [R01-DK60504] Funding Source: Medline; NIMH NIH HHS [R01-MH65431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosius JL, 2000, BIOCHEMISTRY-US, V39, P13336, DOI 10.1021/bi001488j; Brosius JL, 2002, BIOCHEMISTRY-US, V41, P2217, DOI 10.1021/bi011998t; Castro M, 2002, NEUROPEDIATRICS, V33, P186, DOI 10.1055/s-2002-34493; JAEKEN J, 1988, EUR J PEDIATR, V148, P126, DOI 10.1007/BF00445919; JAEKEN J, 1984, LANCET, V2, P1058; Kmoch S, 2000, HUM MOL GENET, V9, P1501, DOI 10.1093/hmg/9.10.1501; Kohler M, 1999, Eur J Paediatr Neurol, V3, P3, DOI 10.1053/ejpn.1999.0172; LAIKIND PK, 1986, ANAL BIOCHEM, V156, P81, DOI 10.1016/0003-2697(86)90158-2; Lee TT, 1999, BIOCHEMISTRY-US, V38, P22, DOI 10.1021/bi982299s; Lee TT, 1998, BIOCHEMISTRY-US, V37, P8481, DOI 10.1021/bi9805339; Lee TT, 1997, J BIOL CHEM, V272, P458; Marie S, 2002, AM J HUM GENET, V71, P14, DOI 10.1086/341036; Marie S, 2004, AM J HUM GENET, V74, P1276, DOI 10.1086/421475; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Palenchar JB, 2003, PROTEIN SCI, V12, P1694, DOI 10.1110/ps.0303903; Palenchar JB, 2003, BIOCHEMISTRY-US, V42, P1831, DOI 10.1021/bi020640+; Race V, 2000, HUM MOL GENET, V9, P2159, DOI 10.1093/hmg/9.14.2159; Ratner S, 1972, ENZYMES, P167; Redinbo MR, 1996, PROTEIN SCI, V5, P786; Segall ML, 2004, BIOCHEMISTRY-US, V43, P7391, DOI 10.1021/bi0494774; Sivendran S, 2004, FASEB J, V18, pC241; Stathis SL, 2000, J AM ACAD CHILD PSY, V39, P274, DOI 10.1097/00004583-200003000-00007; STONE RL, 1993, J BIOL CHEM, V268, P19710; TORNHEIM K, 1972, J BIOL CHEM, V247, P162; Toth EA, 2000, STRUCT FOLD DES, V8, P163, DOI 10.1016/S0969-2126(00)00092-7; VANDENBERGH F, 1993, J INHERIT METAB DIS, V16, P415, DOI 10.1007/BF00710291; VANDENBERGHE G, 2001, METABOLIC MOL BASIS, V2, P2653; Vitkup D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r72; WOODWARD DO, 1966, J BIOL CHEM, V241, P580; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	32	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53789	53797		10.1074/jbc.M409974200	http://dx.doi.org/10.1074/jbc.M409974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471876	hybrid			2022-12-27	WOS:000225680600117
J	Spiegel, PC; Murphy, P; Stoddard, BL				Spiegel, PC; Murphy, P; Stoddard, BL			Surface-exposed hemophilic mutations across the factor VIIIC2 domain have variable effects on stability and binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COAGULATION-FACTOR-VIII; LINEAR EXTRAPOLATION METHOD; C2 DOMAIN; BLOOD-COAGULATION; MEMBRANE-BINDING; FACTOR-V; MONOCLONAL-ANTIBODY; MISSENSE MUTATIONS; CRYSTAL-STRUCTURE	Factor VIII (fVIII) is a plasma glycoprotein that functions as an essential cofactor in blood coagulation. Its carboxyl-terminal "C2" domain is responsible for binding to both activated platelet surfaces and von Willebrand factor. We characterized the effect of 20 hemophilia-associated missense mutations across this domain ( that all occur in patients in vivo) on its stability and its binding activities. At least six of these mutations were severely destabilizing, and another four caused moderate destabilization and corresponding reductions in both binding functions. One mutant (A2201P) displayed a significant reduction in its membrane binding activity but normal von Willebrand factor binding, while two others (P2300S and R2304H) caused the opposite effect. Several mutations (including L2210P, V2223M, M2238V, and R2304C) displayed near wild-type stabilities and binding activities and may instead affect mRNA splicing or alternative properties or functions of the protein. This study demonstrated that von Willebrand factor and membrane binding activities can be uncoupled and uniquely disrupted by different mutations and that either effect can lead to similar reductions in clotting activity. It also illustrated how a heterogeneous genetic disorder causes diverse molecular phenotypes that result in similar disease states.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Grad Program Biomol Struct & Design, Seattle, WA 98195 USA; Univ Washington, Med Sci Training Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Mailstop A3-025,1100 Fairview Ave N, Seattle, WA 98109 USA.	bstoddar@fhcrc.org						Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; d'Oiron R, 2004, BLOOD, V103, P155, DOI 10.1182/blood-2003-04-1321; Dantas G, 2003, J MOL BIOL, V332, P449, DOI 10.1016/S0022-2836(03)00888-X; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; KANE WH, 1988, BLOOD, V71, P539; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; Lewis DA, 2001, THROMB HAEMOSTASIS, V85, P260, DOI 10.1055/s-0037-1615697; Liu ML, 2000, BLOOD, V96, P979, DOI 10.1182/blood.V96.3.979.015k42a_979_987; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; Nogami K, 2000, J BIOL CHEM, V275, P25774, DOI 10.1074/jbc.M002007200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 1996, J BIOL CHEM, V271, P25671, DOI 10.1074/jbc.271.41.25671; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Saenko E, 1999, J CHROMATOGR A, V852, P59, DOI 10.1016/S0021-9673(99)00491-4; Saenko E, 2001, J CHROMATOGR A, V921, P49, DOI 10.1016/S0021-9673(01)00601-X; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; Saenko EL, 2002, BRIT J HAEMATOL, V119, P323, DOI 10.1046/j.1365-2141.2002.03793.x; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; Schatz SM, 2004, BRIT J HAEMATOL, V125, P629, DOI 10.1111/j.1365-2141.2004.04959.x; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; Spiegel PC, 2004, CHEM BIOL, V11, P1413, DOI 10.1016/j.chembiol.2004.08.006; Spiegel PC, 2001, BLOOD, V98, P13, DOI 10.1182/blood.V98.1.13; Spiegel PC, 2002, BRIT J HAEMATOL, V119, P310, DOI 10.1046/j.1365-2141.2002.03845.x; Takeshima K, 2003, THROMB HAEMOSTASIS, V89, P788, DOI 10.1055/s-0037-1613463; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; Tuddenham E G, 1994, Nucleic Acids Res, V22, P4851, DOI 10.1093/nar/22.22.4851; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wilson WW, 2003, J STRUCT BIOL, V142, P56, DOI 10.1016/S1047-8477(03)00038-8; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53691	53698		10.1074/jbc.M409389200	http://dx.doi.org/10.1074/jbc.M409389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471879	hybrid			2022-12-27	WOS:000225680600106
J	Westlake, CJ; Payen, L; Gao, M; Cole, SPC; Deeley, RG				Westlake, CJ; Payen, L; Gao, M; Cole, SPC; Deeley, RG			Identification and characterization of functionally important elements in the multidrug resistance protein 1 COOH-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAINS; CONJUGATE EXPORT PUMP; ABC-TRANSPORTER; ATP-BINDING; MEMBRANE TOPOLOGY; LEUKOTRIENE C-4; MRP GENE; CONGENITAL HYPERINSULINISM; VINCRISTINE TRANSPORT	The ATP binding cassette (ABC) transporter, multidrug resistance protein 1 (MRP1/ABCC1), transports a broad spectrum of conjugated and unconjugated compounds, including natural product chemotherapeutic agents. In this study, we have investigated the importance of the COOH-terminal region of MRP1 for transport activity and basolateral plasma membrane trafficking. The COOH-terminal regions of some ABCC proteins have been implicated in protein trafficking, but the function of this region of MRP1 has not been defined. In contrast to results obtained with other ABCC proteins, we found that the COOH-proximal 30 amino acids of MRP1 can be removed without affecting trafficking to basolateral membranes. However, the truncated protein is inactive. Furthermore, removal of as few as 4 COOH-terminal amino acids profoundly decreases transport activity. Although amino acid sequence conservation of the COOH-terminal regions of ABC proteins is low, secondary structure predictions indicate that they consist of a broadly conserved helix-sheet-sheet-helix-helix structure. Consistent with a conservation of secondary and tertiary structure, MRP1 hybrids containing the COOH-terminal regions of either the homologous MRP2 or the distantly related P-glycoprotein were fully active and trafficked normally. Using mutated proteins, we have identified structural elements containing five conserved hydrophobic amino acids that are required for activity. We show that these are important for binding and hydrolysis of ATP by nucleotide binding domain 2. Based on crystal structures of several ABC proteins, we suggest that the conserved amino acids may stabilize a helical bundle formed by the COOH-terminal three helices and may contribute to interactions between the COOH-terminal region and the protein's two nucleotide binding domains.	Queens Univ, Canc Res Inst, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; McMaster University; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Inst, Botterell Hall, Kingston, ON K7L 3N6, Canada.	deeleyr@post.queensu.ca	Cole, Susan P.C./I-6389-2017; Westlake, Christopher/AAG-1150-2019; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Westlake, Christopher/0000-0001-7476-2014; 				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BATES SE, 2003, ABC PROTEINS BACTERI, P359; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Campbell JD, 2003, EMBO REP, V4, P1038, DOI 10.1038/sj.embor.7400003; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Deeley RG, 2003, ABC PROTEINS BACTERI, P393; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fernandez SBM, 2002, J BIOL CHEM, V277, P31048, DOI 10.1074/jbc.M204267200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FLENS MJ, 1994, CANCER RES, V54, P4557; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gentzsch M, 2002, BIOCHEM J, V366, P541, DOI 10.1042/BJ20020511; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Huopio H, 2002, J CLIN ENDOCR METAB, V87, P4502, DOI 10.1210/jc.2002-020378; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Matsushita K, 2002, CIRC RES, V90, P554, DOI 10.1161/01.RES.0000012666.42782.30; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x; Norman BH, 2002, BIOORG MED CHEM LETT, V12, P883, DOI 10.1016/S0960-894X(02)00051-3; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qian YM, 2002, J BIOL CHEM, V277, P35225, DOI 10.1074/jbc.M206058200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Reimann F, 2003, DIABETOLOGIA, V46, P241, DOI 10.1007/s00125-002-1014-3; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Schmitt L, 2003, J MOL BIOL, V330, P333, DOI 10.1016/S0022-2836(03)00592-8; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Westlake CJ, 2003, BIOCHEMISTRY-US, V42, P14099, DOI 10.1021/bi035333y; Yabuuchi H, 2002, BIOCHEM BIOPH RES CO, V299, P410, DOI 10.1016/S0006-291X(02)02658-X; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200	60	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53571	53583		10.1074/jbc.M402528200	http://dx.doi.org/10.1074/jbc.M402528200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459206	hybrid			2022-12-27	WOS:000225680600093
J	Siligardi, G; Hu, B; Panaretou, B; Piper, PW; Pearl, LH; Prodromou, C				Siligardi, G; Hu, B; Panaretou, B; Piper, PW; Pearl, LH; Prodromou, C			Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN 90; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; STRUCTURAL BASIS; CLIENT PROTEIN; BINDING-SITE; DIMERIZATION; P50(CDC37); COMPLEX	ATP hydrolysis by the Hsp90 molecular chaperone requires a connected set of conformational switches triggered by ATP binding to the N-terminal domain in the Hsp90 dimer. Central to this is a segment of the structure, which closes like a "lid" over bound ATP, promoting N-terminal dimerization and assembly of a competent active site. Hsp90 mutants that influence these conformational switches have strong effects on ATPase activity. ATPase activity is specifically regulated by Hsp90 co-chaperones, which directly influence the conformational switches. Here we have analyzed the effect of Hsp90 mutations on binding ( using isothermal titration calorimetry and difference circular dichroism) and ATPase regulation by the co-chaperones Aha1, Sti1 (Hop), and Sba1 (p23). The ability of Sti1 to bind Hsp90 and arrest its ATPase activity was not affected by any of the mutants screened. Sba1 bound in the presence of AMPPNP to wild-type and ATPase hyperactive mutants with similar affinity but only very weakly to hypoactive mutants despite their wild-type ATP affinity. Unexpectedly, in all cases Sba1 bound to Hsp90 with a 1: 2 molar stoichiometry. Aha1 binding to mutants was similar to wild-type, but the - fold activation of their ATPase varied substantially between mutants. Analysis of complex formation with co-chaperone mixtures showed Aha1 and p50(cdc37) able to bind Hsp90 simultaneously but without direct interaction. Sba1 and p50cdc37 bound independently to Hsp90-AMPPNP but not together. These data indicated that Sba1 and Aha1 regulate Hsp90 by influencing the conformational state of the "ATP lid" and consequent N-terminal dimerization, whereas Sti1 does not.	Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England; Kings Coll London, Pharmaceut Opt Spect Ctr, London SE1 9NN, England; Kings Coll London, Div Life Sci, Dept Pharm, London SE1 9NN, England; Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2UH, S Yorkshire, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; University of London; King's College London; University of Sheffield	Prodromou, C (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	chris.prodromou@icr.ac.uk	Hu, Bin/GWZ-8912-2022; Prodromou, Chrisostomos/ABA-9133-2021; Siligardi, Giuliano/AAO-7024-2020	Hu, Bin/0000-0001-6316-2830; Prodromou, Chrisostomos/0000-0003-4320-1147; Pearl, Laurence/0000-0002-6910-1809; Piper, Peter William/0000-0003-4019-2329				Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; Meyer P, 2004, EMBO J, V23, P511, DOI 10.1038/sj.emboj.7600060; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100	33	152	158	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51989	51998		10.1074/jbc.M410562200	http://dx.doi.org/10.1074/jbc.M410562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466438	hybrid			2022-12-27	WOS:000225493400035
J	Treiber, C; Simons, A; Strauss, M; Hafner, M; Cappai, R; Bayer, TA; Multhaup, G				Treiber, C; Simons, A; Strauss, M; Hafner, M; Cappai, R; Bayer, TA; Multhaup, G			Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; A-BETA; TRANSGENIC MICE; TRACE-ELEMENT; DOMAIN; BINDING; VITAMIN-B12; METABOLISM; EXPRESSION; REDUCTION	The key protein in Alzheimer's disease, the amyloid precursor protein (APP), is a ubiquitously expressed copper-binding glycoprotein that gives rise to the Abeta amyloid peptide. Whereas overexpression of APP results in significantly reduced brain copper levels in three different lines of transgenic mice, knock-out animals revealed increased copper levels. A provoked rise in peripheral levels of copper reduced concentrations of soluble amyloid peptides and resulted in fewer pathogenic Abeta plaques. Contradictory evidence has been provided by the efficacy of copper chelation treatment with the drug clioquinol. Using a yeast model system, we show that adding clioquinol to the yeast culture medium drastically increased the intracellular copper concentration but there was no significant effect observed on zinc levels. This finding suggests that clioquinol can act therapeutically by changing the distribution of copper or facilitating copper uptake rather than by decreasing copper levels. The overexpression of the human APP or APLP2 extracellular domains but not the extracellular domain of APLP1 decreased intracellular copper levels. The expression of a mutant APP deficient for copper binding increased intracellular copper levels several-fold. These data uncover a novel biological function for APP and APLP2 in copper efflux and provide a new conceptual framework for the formerly diverging theories of copper supplementation and chelation in the treatment of Alzheimer's disease.	Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; ZMBH, Ctr Mol Biol, D-69120 Heidelberg, Germany; Hochschule Tech & Gestaltung, Fachhochschule Mannheim, D-68163 Mannheim, Germany; Univ Melbourne, Dept Pathol, Ctr Neurosci, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3052, Australia; Univ Saarland, Med Ctr, Dept Psychiat, Div Neurobiol, D-66421 Homburg, Germany	Free University of Berlin; Ruprecht Karls University Heidelberg; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Saarland University	Multhaup, G (corresponding author), Free Univ Berlin, Inst Chem Biochem, Thielallee 63, D-14195 Berlin, Germany.	multhaup@chemie.fu-berlin.de	Cappai, Roberto/B-3347-2010	Cappai, Roberto/0000-0002-9505-8496				Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Dulubova I, 2004, BIOCHEMISTRY-US, V43, P9583, DOI 10.1021/bi049041o; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Loonen AJM, 2003, INT J GERIATR PSYCH, V18, P540, DOI 10.1002/gps.882; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SAMUDRALWAR DL, 1995, J NEUROL SCI, V130, P139, DOI 10.1016/0022-510X(95)00018-W; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shim H, 2003, J NUTR, V133, p1527S, DOI 10.1093/jn/133.5.1527S; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; Squitti R, 2002, NEUROLOGY, V59, P1153, DOI 10.1212/WNL.59.8.1153; SUGAWARA N, 1991, RES COMMUN CHEM PATH, V72, P97; Thiele DJ, 2003, J NUTR, V133, p1579S, DOI 10.1093/jn/133.5.1579S; THOMPSON CM, 1988, NEUROTOXICOLOGY, V9, P1; VANTIGGELEN CJM, 1984, AM J PSYCHIAT, V141, P136; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 1998, J NEUROSCI, V18, P6207; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Yassin MS, 2000, J NEUROL SCI, V173, P40, DOI 10.1016/S0022-510X(99)00297-X	35	120	127	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51958	51964		10.1074/jbc.M407410200	http://dx.doi.org/10.1074/jbc.M407410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465814	hybrid			2022-12-27	WOS:000225493400031
J	Jogl, G; Hsiao, YS; Tong, L				Jogl, G; Hsiao, YS; Tong, L			Crystal structure of mouse carnitine octanoyltransferase and molecular determinants of substrate selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ANOMALOUS DIFFRACTION; LIVER PEROXISOMES; ACETYLTRANSFERASE; PALMITOYLTRANSFERASE; SYSTEM; ACYLTRANSFERASES; MITOCHONDRIA; SPECIFICITY; TRANSPORT	Carnitine acyltransferases have crucial functions in fatty acid metabolism. Members of this enzyme family show distinctive substrate preferences for short-, medium- or long-chain fatty acids. The molecular mechanism for this substrate selectivity is not clear as so far only the structure of carnitine acetyltransferase has been determined. To further our understanding of these important enzymes, we report here the crystal structures at up to 2.0-resolution of mouse carnitine octanoyltransferase alone and in complex with the substrate octanoylcarnitine. The structures reveal significant differences in the acyl group binding pocket between carnitine octanoyltransferase and carnitine acetyltransferase. Amino acid substitutions and structural changes produce a larger hydrophobic pocket that binds the octanoyl group in an extended conformation. Mutation of a single residue (Gly-553) in this pocket can change the substrate preference between short- and medium- chain acyl groups. The side chains of Cys-323 and Met-335 at the bottom of this pocket assume dual conformations in the substrate complex, and mutagenesis studies suggest that the Met-335 residue is important for catalysis.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	tong@como.bio.columbia.edu	Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315; Tong, Liang/0000-0002-0563-6468	NIDDK NIH HHS [DK67238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai YY, 2004, EMBO J, V23, P2047, DOI 10.1038/sj.emboj.7600221; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Cordente AG, 2004, J BIOL CHEM, V279, P33899, DOI 10.1074/jbc.M402685200; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; DeLano W, 2002, PYMOL 0 99; FARRELL SO, 1983, ARCH BIOCHEM BIOPHYS, V222, P123, DOI 10.1016/0003-9861(83)90509-X; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; Ferdinandusse S, 1999, BIOCHEM BIOPH RES CO, V263, P213, DOI 10.1006/bbrc.1999.1340; Giannessi F, 2001, J MED CHEM, V44, P2383, DOI 10.1021/jm010889+; Govindasamy L, 2004, J STRUCT BIOL, V146, P416, DOI 10.1016/j.jsb.2004.01.011; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramsay RR, 1999, AM J MED SCI, V318, P28, DOI 10.1097/00000441-199907000-00005; Ramsay RR, 2003, TRENDS BIOCHEM SCI, V28, P343, DOI 10.1016/S0968-0004(03)00137-3; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; RAMSAY RR, 1987, BIOCHEM J, V244, P271, DOI 10.1042/bj2440271; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Sigauke E, 2003, LAB INVEST, V83, P1543, DOI 10.1097/01.LAB.0000098428.51765.83; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Wagman AS, 2001, CURR PHARM DESIGN, V7, P417, DOI 10.2174/1381612013397915; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	36	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					738	744		10.1074/jbc.M409894200	http://dx.doi.org/10.1074/jbc.M409894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15492013	hybrid			2022-12-27	WOS:000226025100087
J	Helmlinger, D; Bonnet, J; Mandel, JL; Trottier, Y; Devys, D				Helmlinger, D; Bonnet, J; Mandel, JL; Trottier, Y; Devys, D			Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; INHIBITS HUNTINGTIN AGGREGATION; TRUNCATED ANDROGEN RECEPTOR; BULBAR MUSCULAR-ATROPHY; HEAT-SHOCK PROTEINS; POLYGLUTAMINE DISEASE; MOLECULAR CHAPERONES; MOUSE MODEL; MEDIATED NEURODEGENERATION; CELLULAR TOXICITY	Nine neurodegenerative diseases, including spinocerebellar ataxia type 7 (SCA7), are caused by the expansion of polyglutamine stretches in the respective disease-causing proteins. A hallmark of these diseases is the aggregation of expanded polyglutamine-containing proteins in nuclear inclusions that also accumulate molecular chaperones and components of the ubiquitin-proteasome system. Manipulation of HSP70 and HSP40 chaperone levels has been shown to suppress aggregates in cellular models, prevent neuronal death in Drosophila, and improve to some extent neurological symptoms in mouse models. An important issue in mammals is the relative expression levels of toxic and putative rescuing proteins. Furthermore, overexpression of both HSP70 and its co-factor HSP40/HDJ2 has never been investigated in mice. We decided to address this question in a SCA7 transgenic mouse model that progressively develops retinopathy, similar to SCA7 patients. To co-express HSP70 and HDJ2 with the polyglutamine protein, in the same cell type, at comparable levels and with the same time course, we generated transgenic mice that express the heat shock proteins specifically in rod photoreceptors. While co-expression of HSP70 with its co-factor HDJ2 efficiently suppressed mutant ataxin-7 aggregation in transfected cells, they did not prevent either neuronal toxicity or aggregate formation in SCA7 mice. Furthermore, nuclear inclusions in SCA7 mice were composed of a cleaved mutant ataxin-7 fragment, whereas they contained the full-length protein in transfected cells. We propose that differences in the aggregation process might account for the different effects of chaperone overexpression in cellular and animal models of polyglutamine diseases.	Coll France, CNRS,INSERM ULP, Inst Genet & Biol Mol & Cellulaire, Dept Mol Pathol, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Devys, D (corresponding author), Coll France, CNRS,INSERM ULP, Inst Genet & Biol Mol & Cellulaire, Dept Mol Pathol, BP 10142, F-67404 Illkirch Graffenstaden, France.	devys@igbmc.u-strasbg.fr	Helmlinger, Dom/T-4419-2019; Trottier, Yvon/H-8852-2016; Mandel, Jean Louis/Q-2668-2016	Trottier, Yvon/0000-0001-7230-4810; Mandel, Jean Louis/0000-0002-0535-6589; Helmlinger, Dom/0000-0003-1501-0423; Devys, Didier/0000-0001-9655-3512				Adachi H, 2003, J NEUROSCI, V23, P2203; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chuang JZ, 2002, J BIOL CHEM, V277, P19831, DOI 10.1074/jbc.M109613200; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Ghosh S, 2004, HUM MOL GENET, V13, P2011, DOI 10.1093/hmg/ddh214; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Helmlinger D, 2004, J NEUROSCI, V24, P1881, DOI 10.1523/JNEUROSCI.4407-03.2004; Helmlinger D, 2002, HUM MOL GENET, V11, P3351, DOI 10.1093/hmg/11.26.3351; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Mauger C, 1999, MOL BRAIN RES, V74, P35, DOI 10.1016/S0169-328X(99)00256-9; Michalik A, 2004, EUR J HUM GENET, V12, P2, DOI 10.1038/sj.ejhg.5201108; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Mitsui K, 2002, J NEUROSCI, V22, P9267; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Opal P, 2002, TRENDS MOL MED, V8, P232, DOI 10.1016/S1471-4914(02)02310-9; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Takahashi J, 2002, BRAIN, V125, P1534, DOI 10.1093/brain/awf154; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Yvert G, 2000, HUM MOL GENET, V9, P2491, DOI 10.1093/hmg/9.17.2491; Yvert G, 2001, HUM MOL GENET, V10, P1679, DOI 10.1093/hmg/10.16.1679; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	60	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55969	55977		10.1074/jbc.M409062200	http://dx.doi.org/10.1074/jbc.M409062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494410	hybrid, Green Published			2022-12-27	WOS:000225960800120
J	Wong, EY; Lin, J; Forget, BG; Bodine, DM; Gallagher, PG				Wong, EY; Lin, J; Forget, BG; Bodine, DM; Gallagher, PG			Sequences downstream of the erythroid promoter are required for high level expression of the human alpha-spectrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; MEMBRANE SKELETAL PROTEINS; DIMER-DIMER ASSOCIATION; BETA-GLOBIN PROMOTER; HEREDITARY PYROPOIKILOCYTOSIS; CHROMATIN STRUCTURE; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; TRANSGENIC MICE; GAMMA-GLOBIN	alpha-Spectrin is a membrane protein critical for the flexibility and stability of the erythrocyte. We are attempting to identify and characterize the molecular mechanisms controlling the erythroid-specific expression of the alpha-spectrin gene. Previously, we demonstrated that the core promoter of the human alpha-spectrin gene directed low levels of erythroid-specific expression only in the early stages of erythroid differentiation. We have now identified a region 3' of the core promoter that contains a DNase I hypersensitive site and directs high level, erythroid-specific expression in reporter gene/transfection assays. In vitro DNase I footprinting and electrophoretic mobility shift assays identified two functional GATA-1 sites in this region. Both GATA-1 sites were required for full activity, suggesting that elements binding to each site interact in a combinatorial manner. This region did not demonstrate enhancer activity in any orientation or position relative to either the alpha-spectrin core promoter or the thymidine kinase promoter in reporter gene assays. In vivo studies using chromatin immunoprecipitation assays demonstrated hyperacetylation of this region and occupancy by GATA-1 and CBP (cAMP-response element-binding protein (CREB)-binding protein). These results demonstrate that a region 3' of the alpha-spectrin core promoter contains a GATA-1-dependent positive regulatory element that is required in its proper genomic orientation. This is an excellent candidate region for mutations associated with decreased alpha-spectrin gene expression in patients with hereditary spherocytosis and hereditary pyropoikilocytosis.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; NHGRI, Hematopoiesis Sect, NIH, Bethesda, MD 20892 USA	Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.	patrick.gallagher@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065448] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1982, NEW ENGL J MED, V306, P1155, DOI 10.1056/NEJM198205133061906; AGRE P, 1986, NEW ENGL J MED, V315, P1579, DOI 10.1056/NEJM198612183152504; AGRE P, 1985, NATURE, V314, P380, DOI 10.1038/314380a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bieker J J, 1998, Curr Opin Hematol, V5, P145; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; Boulanger L, 2002, J BIOL CHEM, V277, P41563, DOI 10.1074/jbc.M208184200; CALLAGHER PG, 1997, HEMATOLOGY INFANCY C, V1, P544; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; COETZER T, 1990, BLOOD, V75, P2235; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Frazar TF, 2003, MOL CELL BIOL, V23, P4753, DOI 10.1128/MCB.23.14.4753-4763.2003; Gallagher PG, 2000, BLOOD, V96, P1136, DOI 10.1182/blood.V96.3.1136.015k48_1136_1143; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GALLAGHER PG, 1991, T ASSOC AM PHYSICIAN, V104, P32; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; HANSPAL M, 1993, BLOOD, V82, P1652; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1992, BLOOD, V80, P530; Harju S, 2002, EXP BIOL MED, V227, P683, DOI 10.1177/153537020222700902; Hural JA, 2000, J IMMUNOL, V165, P3239, DOI 10.4049/jimmunol.165.6.3239; Hwang ES, 2002, J IMMUNOL, V169, P248, DOI 10.4049/jimmunol.169.1.248; Im H, 2003, J BIOL CHEM, V278, P18346, DOI 10.1074/jbc.M300890200; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; KOURY MJ, 1987, J CELL PHYSIOL, V133, P438, DOI 10.1002/jcp.1041330304; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; LIN HJ, 1987, J CLIN INVEST, V80, P374, DOI 10.1172/JCI113082; LIU SC, 1981, J CLIN INVEST, V68, P597, DOI 10.1172/JCI110293; LIU SC, 1982, P NATL ACAD SCI-BIOL, V79, P2072, DOI 10.1073/pnas.79.6.2072; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MORROW JS, 1997, HDB PHYSIOL 14, P485; Nemeth MJ, 2001, BLOOD CELL MOL DIS, V27, P767, DOI 10.1006/bcmd.2001.0448; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; Ronchi Antonella, 1997, Genes and Function, V1, P245; Sabatino DE, 2000, J BIOL CHEM, V275, P28549, DOI 10.1074/jbc.M004043200; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAHR KE, 1989, J CLIN INVEST, V84, P1243, DOI 10.1172/JCI114291; Sahr KE, 1996, BLOOD, V88, P4500, DOI 10.1182/blood.V88.12.4500.bloodjournal88124500; Seshasayee D, 2000, J BIOL CHEM, V275, P22969, DOI 10.1074/jbc.M002931200; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; WALENSKY LD, 2003, BLOOD PRINCIPLES PRA, P1709; Wandersee N J, 2000, Hematol J, V1, P235, DOI 10.1038/sj.thj.6200030; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	62	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55024	55033		10.1074/jbc.M408886200	http://dx.doi.org/10.1074/jbc.M408886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15456760	hybrid			2022-12-27	WOS:000225960800007
J	van Waardenburg, RCAM; de Jong, LA; van Eijndhovan, MAJ; Verseyden, C; Pluim, D; Jansen, LET; Bjornsti, MA; Schellens, JHM				van Waardenburg, RCAM; de Jong, LA; van Eijndhovan, MAJ; Verseyden, C; Pluim, D; Jansen, LET; Bjornsti, MA; Schellens, JHM			Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRASTRAND CROSS-LINK; ANTICANCER AGENTS; MAJOR ADDUCT; SYNERGISTIC CYTOTOXICITY; CELLULAR PHARMACOLOGY; PHASE-I; ARA-C; TOPOTECAN; CISPLATIN; COMBINATION	Camptothecins constitute a novel class of chemotherapeutics that selectively target DNA topoisomerase I (Top1) by reversibly stabilizing a covalent enzyme-DNA intermediate. This cytotoxic mechanism contrasts with that of platinum drugs, such as cisplatin, which induce inter- and intrastrand DNA adducts. In vitro combination studies using platinum drugs combined with Top1 poisons, such as topotecan, showed a schedule-dependent synergistic activity, with promising results in the clinic. However, whereas the molecular mechanism of these single agents may be relatively well understood, the mode of action of these chemotherapeutic agents in combination necessitates a more complete understanding. Indeed, we recently reported that a functional homologous recombination pathway is required for cisplatin and topotecan synergy yet represses the synergistic toxicity of 1-beta-D-arabinofuranosyl cytidine in combination with topotecan ( van Waardenburg, R. C., de Jong, L. A., van Delft, F., van Eijndhoven, M. A., Bohlander, M., Bjornsti, M. A., Brouwer, J., and Schellens, J. H. ( 2004) Mol. Cancer Ther. 3, 393-402). Here we provide direct evidence for Pt-1,3-d(GTG) poisoning of Top1 in vitro and demonstrate that persistent Pt-DNA adducts correlate with increased covalent Top1-DNA complexes in vivo. This contrasts with a lack of persistent lesions induced by the alkylating agent bis[chloroethyl]nitrosourea, which exhibits only additive activity with topotecan in a range of cell lines. In human IGROV-1 ovarian cancer cells, the synergistic activity of cisplatin with topotecan requires processive DNA polymerization, whereas overexpression of Top1 enhances yeast cell sensitivity to cisplatin. These results indicate that the cytotoxic activity of cisplatin is due, in part, to poisoning of Top1, which is exacerbated in the presence of topotecan.	Netherlands Canc Inst, Dept Expt Therapy, Div Med Oncol, NL-1066 CX Amsterdam, Netherlands; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Leiden Univ, Leiden Inst Chem, MGC Dept Mol Genet, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Fac Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands	Netherlands Cancer Institute; St Jude Children's Research Hospital; Leiden University; Leiden University - Excl LUMC; Utrecht University	Schellens, JHM (corresponding author), Netherlands Canc Inst, Dept Expt Therapy, Div Med Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jhm@nki.nl		Jansen, Lars/0000-0002-2158-0345	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099, R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA23099, CA58755, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOMMAERT FA, 1995, BIOCHEMISTRY-US, V34, P8474, DOI 10.1021/bi00026a031; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2000, METH MOL B, V95, P81; Chen AY, 1999, ONCOLOGY-NY, V13, P39; CHENG MF, 1994, ONCOL RES, V6, P269; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Coleman RL, 2002, ONCOLOGIST, V7, P46; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Fiorica JV, 2002, ONCOLOGIST, V7, P36; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; Goldwasser F, 1996, CLIN CANCER RES, V2, P687; Goldwasser F, 1999, ANTI-CANCER DRUG, V10, P195, DOI 10.1097/00001813-199902000-00008; Gross-Goupil M, 2002, EUR J CANCER, V38, P1888, DOI 10.1016/S0959-8049(02)00232-0; Ho YP, 2003, MED RES REV, V23, P633, DOI 10.1002/med.10038; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KANO Y, 1992, INT J CANCER, V50, P604, DOI 10.1002/ijc.2910500420; Kaufmann SH, 1996, J NATL CANCER I, V88, P734, DOI 10.1093/jnci/88.11.734; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Ma JG, 1998, CANCER CHEMOTH PHARM, V41, P307, DOI 10.1007/s002800050744; Peters GJ, 2000, PHARMACOL THERAPEUT, V87, P227, DOI 10.1016/S0163-7258(00)00086-3; Pluim D, 1999, ANAL BIOCHEM, V275, P30, DOI 10.1006/abio.1999.4302; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reedijk J, 2003, P NATL ACAD SCI USA, V100, P3611, DOI 10.1073/pnas.0737293100; Rixe O, 1996, BIOCHEM PHARMACOL, V52, P1855, DOI 10.1016/S0006-2952(97)81490-6; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Rowinsky EK, 1996, J CLIN ONCOL, V14, P3074, DOI 10.1200/JCO.1996.14.12.3074; ROWINSKY EK, 1997, SEMIN ONCOL, V24; Sabourin M, 2000, NUCLEIC ACIDS RES, V28, P1947, DOI 10.1093/nar/28.9.1947; Sandler AB, 2003, SEMIN ONCOL, V30, P9, DOI 10.1053/sonc.2003.50012; Shivji MKK, 1999, METH MOL B, V113, P373; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Subramanian D, 2000, METH MOL B, V95, P137; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Teuben JM, 1999, BIOCHEMISTRY-US, V38, P12305, DOI 10.1021/bi9904757; van Waardenburg RCA, 2004, MOL CANCER THER, V3, P393; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; Wall ME, 1998, MED RES REV, V18, P299; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wilke HJ, 2003, ANN ONCOL, V14, P49, DOI 10.1093/annonc/mdg730; Wilstermann AM, 2003, CURR TOP MED CHEM, V3, P321, DOI 10.2174/1568026033452519; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Zeghari-Squalli N, 1999, CLIN CANCER RES, V5, P1189	50	33	34	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54502	54509		10.1074/jbc.M410103200	http://dx.doi.org/10.1074/jbc.M410103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471886	hybrid			2022-12-27	WOS:000225793600074
J	Voehringer, D; Rosen, DB; Lanier, LL; Locksley, RM				Voehringer, D; Rosen, DB; Lanier, LL; Locksley, RM			CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELL; IMMUNOGLOBULIN-LIKE RECEPTORS; FC-GAMMA-RIIB; MYELOID CELLS; MACROPHAGE ACTIVATION; CUTTING EDGE; MICE; RECOGNITION; DAP12; CYTOMEGALOVIRUS	Modulation by balancing activating and inhibitory receptors constitutes an important mechanism for regulating lymphocyte and myeloid cell effector responses. Using a microarray screen during parasitic helminth infection, we identified CD200 receptor-like 3 as a transcript highly expressed in basophils. Novel splice variants were present that generated proteins that differed in surface expression. The second immunoglobulin-like domain, encoded by exon 4, was required for cell surface expression and recruitment of DAP12 to the cell surface. Splice variants also generated unique cytoplasmic domains, which contributed to efficient pairing with DAP12. Despite expression on basophils and mast cells, which are integral components of allergic immunity, the absence of DAP12 did not alter effector cell recruitment or the host response elicited by helminth infection with Nippostrongylus brasiliensis.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Locksley, RM (corresponding author), Univ Calif San Francisco, Dept Med, Box 0654,C-443,521 Parnassus Ave, San Francisco, CA 94143 USA.	locksley@medicine.ucsf.edu	Lanier, Lewis L/E-2139-2014; Voehringer, David/K-2776-2019	Lanier, Lewis L/0000-0003-1308-3952; 	NHLBI NIH HHS [HL56385] Funding Source: Medline; PHS HHS [R01 30663] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056385, P50HL056385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arase H, 2004, REV MED VIROL, V14, P83, DOI 10.1002/rmv.422; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Bakker ABH, 2000, IMMUNITY, V13, P345, DOI 10.1016/S1074-7613(00)00034-0; Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Chung YH, 2002, J VIROL, V76, P4688, DOI 10.1128/JVI.76.10.4688-4698.2002; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Foster-Cuevas M, 2004, J VIROL, V78, P7667, DOI 10.1128/JVI.78.14.7667-7676.2004; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Gorczynski R, 2004, J IMMUNOL, V172, P7744, DOI 10.4049/jimmunol.172.12.7744; Gorczynski RM, 2001, CLIN IMMUNOL, V101, P328, DOI 10.1006/clim.2001.5117; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Kumagai H, 2003, BIOCHEM BIOPH RES CO, V307, P719, DOI 10.1016/S0006-291X(03)01245-2; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lucas M, 2002, EUR J IMMUNOL, V32, P2653, DOI 10.1002/1521-4141(200209)32:9<2653::AID-IMMU2653>3.0.CO;2-V; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Onishi M, 1996, EXP HEMATOL, V24, P324; Rosen DB, 2004, J IMMUNOL, V173, P2470, DOI 10.4049/jimmunol.173.4.2470; Sjolin H, 2002, J EXP MED, V195, P825, DOI 10.1084/jem.20011427; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Tomasello E, 2000, IMMUNITY, V13, P355, DOI 10.1016/S1074-7613(00)00035-2; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Yotsumoto K, 2003, J EXP MED, V198, P223, DOI 10.1084/jem.20021825	31	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54117	54123		10.1074/jbc.M406997200	http://dx.doi.org/10.1074/jbc.M406997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471863	hybrid			2022-12-27	WOS:000225793600030
J	Zang, MX; Li, Y; Wang, H; Wang, JB; Jia, HT				Zang, MX; Li, Y; Wang, H; Wang, JB; Jia, HT			Cooperative interaction between the basic helix-loop-helix transcription factor dHAND and myocyte enhancer factor 2C regulates myocardial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; MEF2; PROTEIN; PROMOTER; BINDING; ROLES; HAND2; TBX5; MYOD	Cardiac-restricted transcription factors dHAND and myocyte enhancer factor 2C are expressed in the developing heart and activate several cardiac promoters. However, their regulatory mechanisms are still to be understood. To elucidate their exact regulatory functions, we have developed an RNA interference strategy to specifically inhibit dHAND and myocyte enhancer factor 2C protein production in H9c2 cells, which are derived from rat embryonic heart. Expression of endogenous cardiac genes atrial natriuretic peptide and alpha-myosin heavy chain was down-regulated in H9c2 cells lacking both dHAND and myocyte enhancer factor 2C, indicating that these factors are required for the maintenance of the cardiac genetic program. Consistent with these, expression of atrial natriuretic peptide and alpha-myosin heavy chain was up-regulated in H9c2 cells, which overexpressed dHAND and myocyte enhancer factor 2C. In addition, dHAND and myocyte enhancer factor 2C interact to synergistically activate atrial natriuretic peptide and alpha-myosin heavy chain transcription. Furthermore, chromatin immunoprecipitation analysis in H9c2 cells treated with phenylephrine showed that dHAND and myocyte enhancer factor 2C protein complex bind to the A/T sequence on atrial natriuretic peptide promoter. Taken together, these results not only suggest that the complex cis-trans interaction of dHAND, myocyte enhancer factor 2C, and the target gene may fine-tune gene expression in cardiac myocytes but also provide a molecular paradigm to elucidate the mechanisms of action of dHAND and myocyte enhancer factor 2C in the developing heart.	Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Nutr & Food Hyg,Lab Dev Mol Biol, Beijing 100083, Peoples R China; Clin Res Inst Montreal, Lab Cardiac Growth & Differentiat, Montreal, PQ H2W 1R7, Canada; Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Peking University	Li, Y (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Nutr & Food Hyg,Lab Dev Mol Biol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	liyong@bjmu.edu.cn		Wang, Hao/0000-0003-1537-661X				Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Finn SG, 2001, BIOCHEM J, V358, P489, DOI 10.1042/0264-6021:3580489; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MCDONOUGH PM, 1993, AM J PHYSIOL, V264, pH625, DOI 10.1152/ajpheart.1993.264.2.H625; Miano JM, 2002, J MOL CELL CARDIOL, V34, P1287, DOI 10.1006/jmcc.2002.2101; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thattaliyath BD, 2002, J MOL CELL CARDIOL, V34, P1335, DOI 10.1006/jmcc.2002.2085; Thomas T, 1998, DEVELOPMENT, V125, P3005; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Zang MX, 2004, J CELL BIOCHEM, V93, P1255, DOI 10.1002/jcb.20225	25	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54258	54263		10.1074/jbc.M408502200	http://dx.doi.org/10.1074/jbc.M408502200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485823	hybrid			2022-12-27	WOS:000225793600046
J	Zhang, Y; Ma, K; Song, SL; Elam, MB; Cook, GA; Park, EA				Zhang, Y; Ma, K; Song, SL; Elam, MB; Cook, GA; Park, EA			Peroxisomal proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; MESSENGER-RNA ABUNDANCE; HEPATIC GLUCONEOGENESIS; TRANSCRIPTIONAL COACTIVATOR; MITOCHONDRIAL BIOGENESIS; NUCLEAR RECEPTORS; BINDING PROTEIN; 1ST INTRON; RAT-LIVER; PGC-1	Carnitine palmitoyltransferase I (CPT-I) catalyzes the rate-controlling step in the pathway of mitochondrial fatty acid oxidation. Thyroid hormone will stimulate the expression of the liver isoform of CPT-I (CPT-Ialpha). This induction of CPT-Ialpha gene expression requires the thyroid hormone response element in the promoter and sequences within the first intron. The peroxisomal proliferator-activated receptor-gamma coactivator-1alpha(PGC-1alpha) is a coactivator that promotes mitochondrial biogenesis, mitochondrial fatty acid oxidation, and hepatic gluconeogenesis. In addition, PGC-1alpha will stimulate the expression of CPT-Ialpha in primary rat hepatocytes. Here we report that thyroid hormone will increase PGC-1alpha mRNA and protein levels in rat hepatocytes. In addition, overexpression of PGC-1alpha will enhance the thyroid hormone induction of CPT-Ialpha indicating that PGC-1alpha is a coactivator for thyroid hormone. By using chromatin immunoprecipitation assays, we show that PGC-1alpha is associated with both the thyroid hormone response element in the CPT-Ialpha gene promoter and the first intron of the CPT-Ialpha gene. Our data demonstrate that PGC-1alpha participates in the stimulation of CPT-Ialpha gene expression by thyroid hormone and suggest that PGC-1alpha is a coactivator for thyroid hormone.	Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Park, EA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu			NHLBI NIH HHS [HL-66924] Funding Source: Medline; NIDDK NIH HHS [DK-059368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrero MJ, 2000, BIOCHEM BIOPH RES CO, V279, P81, DOI 10.1006/bbrc.2000.3893; Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; Cook GA, 1999, AM J MED SCI, V318, P43, DOI 10.1097/00000441-199907000-00007; Cook GA, 2001, J MOL CELL CARDIOL, V33, P317, DOI 10.1006/jmcc.2000.1304; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Jackson-Hayes L, 2003, J BIOL CHEM, V278, P7964, DOI 10.1074/jbc.M211062200; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Lavrentyev EN, 2004, BIOCHEM BIOPH RES CO, V315, P174, DOI 10.1016/j.bbrc.2004.01.040; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MYNATT RL, 1994, BIOCHEM BIOPH RES CO, V201, P932, DOI 10.1006/bbrc.1994.1791; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; Park EA, 1998, BIOCHEM J, V330, P217; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Song SL, 2004, BBA-GENE STRUCT EXPR, V1679, P164, DOI 10.1016/j.bbaexp.2004.06.006; Sorensen Annette, 2002, Brain Res Gene Expr Patterns, V1, P167; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Weitzel JM, 2003, J MOL ENDOCRINOL, V31, P291, DOI 10.1677/jme.0.0310291; Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506; Weitzel JM, 2001, NUCLEIC ACIDS RES, V29, P5148, DOI 10.1093/nar/29.24.5148; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	39	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53963	53971		10.1074/jbc.M406028200	http://dx.doi.org/10.1074/jbc.M406028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15469941	hybrid			2022-12-27	WOS:000225793600010
J	Chou, CJ; Wisedchaisri, G; Monfeli, RR; Oram, DM; Holmes, RK; Hol, WGJ; Beeson, C				Chou, CJ; Wisedchaisri, G; Monfeli, RR; Oram, DM; Holmes, RK; Hol, WGJ; Beeson, C			Functional studies of the Mycobacterium tuberculosis iron-dependent regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN REPRESSOR; METAL ION-ACTIVATION; DNA COMPLEX REVEALS; CRYSTAL-STRUCTURE; 3RD DOMAIN; BINDING; IDER; DTXR; IDENTIFICATION; VIRULENCE	The iron-dependent regulator (IdeR) protein in Mycobacterium tuberculosis, and its better characterized homologue, the diphtheria toxin repressor (DtxR) from Corynebacterium diphtheriae, are iron-dependent regulatory proteins that control gene expression in response to iron availability in bacteria. IdeR regulates several genes required for iron uptake and storage including those involved in the synthesis of transition metal chelators called siderophores that are linked to the M. tuberculosis virulence. In this study, the metal ion and binding affinities for IdeR binding to an fxbA operator duplex DNA were estimated using fluorescence assays. The Fe2+, Co2+, and Ni2+ affinities of the two metal ion binding sites in IdeR that are involved in the activation of the regulator DNA binding process in vitro were independently estimated. Binding to the two metal ion binding sites is apparently cooperative and the two affinities differ significantly. Occupation of the first metal ion binding site causes dimerization of IdeR, and the metal ion affinity is about 4 muM for Ni2+ and much less for Fe2+ and Co2+. Binding of the second metal ion fully activates IdeR for binding to the fxbA operator. The equilibrium metal ion dissociation constants for IdeR-fxbA operator binding are similar to9 muM for Fe2+, 13 muM for Ni2+, and 23 muM for Co2+. Interestingly, the natural IdeR cofactor, Fe2+, shows high affinities toward both binding sites. These results provide insight into the possible roles for each metal binding site in IdeR activation.	Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem & Biomol Struct, Seattle, WA 98195 USA; Univ Washington, Biomol Struct & Design Grad Program, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Medical University of South Carolina; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Beeson, C (corresponding author), Med Univ S Carolina, Dept Pharmaceut Sci, 280 Calhoun St,Box 250140, Charleston, SC 29425 USA.	beesonc@musc.edu	Chou, C. James/I-6563-2012	Oram, Diana/0000-0001-8546-6800; Wisedchaisri, Goragot/0000-0002-6967-5925	NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014107, R22AI014107, R01AI014107] Funding Source: NIH RePORTER; NCI NIH HHS [CA65656] Funding Source: Medline; NIAID NIH HHS [AI14107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; Chen CSY, 2000, BIOCHEMISTRY-US, V39, P10397, DOI 10.1021/bi0009284; Dhople AM, 1996, MICROBIOS, V87, P77; Ding X, 1996, NAT STRUCT BIOL, V3, P382, DOI 10.1038/nsb0496-382; Dussurget O, 1999, J BACTERIOL, V181, P3402, DOI 10.1128/JB.181.11.3402-3408.1999; Feese MD, 2001, J BIOL CHEM, V276, P5959, DOI 10.1074/jbc.M007531200; FISS EH, 1994, MOL MICROBIOL, V14, P557, DOI 10.1111/j.1365-2958.1994.tb02189.x; Goranson-Siekierke J, 1999, INFECT IMMUN, V67, P1806; Horsburgh MJ, 2002, MOL MICROBIOL, V44, P1269, DOI 10.1046/j.1365-2958.2002.02944.x; Jobling MG, 2000, P NATL ACAD SCI USA, V97, P14662, DOI 10.1073/pnas.011442598; Kochan I, 1973, Curr Top Microbiol Immunol, V60, P1; Love JF, 2004, P NATL ACAD SCI USA, V101, P2506, DOI 10.1073/pnas.0303794101; MACHAM LP, 1975, J GEN MICROBIOL, V89, P379, DOI 10.1099/00221287-89-2-379; Manabe YC, 1999, P NATL ACAD SCI USA, V96, P12844, DOI 10.1073/pnas.96.22.12844; Pan J, 1999, P NATL ACAD SCI USA, V96, P6149, DOI 10.1073/pnas.96.11.6149; PAYNE SM, 1989, MOL MICROBIOL, V3, P1301, DOI 10.1111/j.1365-2958.1989.tb00281.x; Pohl E, 1998, J BIOL CHEM, V273, P22420, DOI 10.1074/jbc.273.35.22420; Pohl E, 1999, J MOL BIOL, V285, P1145, DOI 10.1006/jmbi.1998.2339; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; Pohl E, 1997, PROTEIN SCI, V6, P1114, DOI 10.1002/pro.5560060519; Qiu XY, 1996, BIOCHEMISTRY-US, V35, P12292, DOI 10.1021/bi960861d; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAGHU B, 1993, BIOCHEM MOL BIOL INT, V31, P341; Rodriguez G. Marcela, 1999, Tubercle and Lung Disease, V79, P287; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; SCHMITT MP, 1995, INFECT IMMUN, V63, P4284, DOI 10.1128/IAI.63.11.4284-4289.1995; SCHMITT MP, 1992, P NATL ACAD SCI USA, V89, P7576, DOI 10.1073/pnas.89.16.7576; Spiering MM, 2003, P NATL ACAD SCI USA, V100, P3808, DOI 10.1073/pnas.0737977100; Sritharan M, 2000, WORLD J MICROB BIOT, V16, P769, DOI 10.1023/A:1008995313232; TAO X, 1995, P NATL ACAD SCI USA, V92, P6803, DOI 10.1073/pnas.92.15.6803; TAO X, 1992, P NATL ACAD SCI USA, V89, P5897, DOI 10.1073/pnas.89.13.5897; Twigg PD, 2001, P NATL ACAD SCI USA, V98, P11259, DOI 10.1073/pnas.191354798; Wang G, 1999, P NATL ACAD SCI USA, V96, P6119, DOI 10.1073/pnas.96.11.6119; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wisedchaisri G, 2004, J MOL BIOL, V342, P1155, DOI 10.1016/j.jmb.2004.07.083; XU T, 1992, J BIOL CHEM, V267, P21761	38	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53554	53561		10.1074/jbc.M407385200	http://dx.doi.org/10.1074/jbc.M407385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456786	hybrid			2022-12-27	WOS:000225680600091
J	Day, PW; Tesmer, JJG; Sterne-Marr, R; Freeman, LC; Benovic, JL; Wedegaertner, PB				Day, PW; Tesmer, JJG; Sterne-Marr, R; Freeman, LC; Benovic, JL; Wedegaertner, PB			Characterization of the GRK2 binding site of G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SIGNALING PROTEINS; GTPASE-ACTIVATING PROTEINS; COUPLED RECEPTOR KINASE; BETA(2)-ADRENERGIC RECEPTOR; SELECTIVE REGULATION; POINT MUTATION; BETA-ARRESTIN; RGS; REGULATOR; DOMAIN	Heterotrimeric guanine nucleotide-binding proteins (G proteins) transmit signals from membrane bound G protein-coupled receptors (GPCRs) to intracellular effector proteins. The G(q) subfamily of Galpha subunits couples GPCR activation to the enzymatic activity of phospholipase C-beta (PLC-beta). Regulators of G protein signaling (RGS) proteins bind to activated Galpha subunits, including Galpha(q), and regulate Galpha signaling by acting as GTPase activating proteins (GAPs), increasing the rate of the intrinsic GTPase activity, or by acting as effector antagonists for Galpha subunits. GPCR kinases (GRKs) phosphorylate agonist-bound receptors in the first step of receptor desensitization. The amino termini of all GRKs contain an RGS homology ( RH) domain, and binding of the GRK2 RH domain to Galpha(q) attenuates PLC-beta activity. The RH domain of GRK2 interacts with Galpha(q/11) through a novel Galpha binding surface termed the "C" site. Here, molecular modeling of the Galpha(q).GRK2 complex and site-directed mutagenesis of Galpha(q) were used to identify residues in Galpha(q) that interact with GRK2. The model identifies Pro(185) in Switch I of Galpha(q) as being at the crux of the interface, and mutation of this residue to lysine disrupts Galpha(q) binding to the GRK2-RH domain. Switch III also appears to play a role in GRK2 binding because the mutations Galpha(q)-V240A, Galpha(q)-D243A, both residues within Switch III, and Galpha(q)-Q152A, a residue that structurally supports Switch III, are defective in binding GRK2. Furthermore, GRK2-mediated inhibition of Galpha(q)-Q152A-R183C-stimulated inositol phosphate release is reduced in comparison to Galpha(q)-R183C. Interestingly, the model also predicts that residues in the helical domain of Galpha(q) interact with GRK2. In fact, the mutants Galpha(q)-K77A, Galpha(q)-L78D, Galpha(q)-Q81A, and Galpha(q)-R92A have reduced binding to the GRK2-RH domain. Finally, although the mutant Galpha(q)-T187K has greatly reduced binding to RGS2 and RGS4, it has little to no effect on binding to GRK2. Thus the RH domain A and C sites for Galpha(q) interaction rely on contacts with distinct regions and different Switch I residues in Galpha(q).	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Siena Coll, Dept Biol, Loudonville, NY 12211 USA	Jefferson University; University of Texas System; University of Texas Austin	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St,839 Blumle Life Sci Bldg, Philadelphia, PA 19107 USA.	P_Wedegaertner@mail.jci.tju.edu		Tesmer, John/0000-0003-1125-3727	NIGMS NIH HHS [GM62884, R01 GM062884, GM44944, R01 GM044944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R01GM062884] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Day PW, 2003, BIOCHEMISTRY-US, V42, P9176, DOI 10.1021/bi034442+; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Usui K, 2000, INT J MOL MED, V5, P335; Vajda S, 2004, TRENDS BIOTECHNOL, V22, P110, DOI 10.1016/j.tibtech.2004.01.006; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wodak SJ, 2004, CURR OPIN STRUC BIOL, V14, P242, DOI 10.1016/j.sbi.2004.02.003; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	36	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53643	53652		10.1074/jbc.M401438200	http://dx.doi.org/10.1074/jbc.M401438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471870	Green Accepted, hybrid			2022-12-27	WOS:000225680600101
J	Fabbretti, E; Sokolova, E; Masten, L; D'Arco, M; Fabbro, A; Nistri, A; Giniatullin, R				Fabbretti, E; Sokolova, E; Masten, L; D'Arco, M; Fabbro, A; Nistri, A; Giniatullin, R			Identification of negative residues in the P2X(3) ATP receptor ectodomain as structural determinants for desensitization and the Ca2+-sensing modulatory sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR PHYSIOLOGY; DRG NEURONS; DEPENDENCE; RECOVERY; CALCIUM; DOMAIN; MOTIF	On nociceptive neurons, one important mechanism to generate pain signals is the activation of P2X(3) receptors, which are membrane proteins gated by extracellular ATP. In the presence of the agonist, P2X(3) receptors rapidly desensitize and then recover slowly. One unique property of P2X(3) receptors is the recovery acceleration by extracellular Ca2+ that can play the role of the gain-setter of receptor function only when P2X(3) receptors are desensitized. To study negatively charged sites potentially responsible for this action of Ca2+, we mutated 15 non-conserved aspartate or glutamate residues in the P2X3 receptor ectodomain with alanine and expressed such mutated receptors in human embryonic kidney cells studied with patch clamping. Unlike most mutants, D266A (P2X(3) receptor numbering) desensitized very slowly, indicating that this residue is important for generating desensitization. Recovery appeared structurally distinct from desensitization because E111A and D266A had a much faster recovery and D220A and D289A had a much slower one despite their standard desensitization. Furthermore, E161A, E187A, or E270A mutants showed lessened sensitivity to the action of extracellular Ca2+, suggesting that these determinants were important for the effect of this cation on desensitization recovery. This study is the first report identifying several negative residues in the P2X(3) receptor ectodomain differentially contributing to the general process of receptor desensitization. At least one residue was important to enable the development of rapid desensitization, whereas others controlled recovery from it or the facilitating action of Ca2+. Thus, these findings outline diverse potential molecular targets to modulate P2X(3) receptor function in relation to its functional state.	SISSA, Neurobiol Sector, I-34014 Trieste, Italy	International School for Advanced Studies (SISSA)	Nistri, A (corresponding author), SISSA, Neurobiol Sector, Via Beirut 4, I-34014 Trieste, Italy.	nistri@sissa.it	Giniatullin, Rashid/Y-9687-2018	Giniatullin, Rashid/0000-0002-1580-6280	Telethon [GGP04037] Funding Source: Medline	Telethon(Fondazione Telethon)		Borst JGG, 1999, J PHYSIOL-LONDON, V521, P123, DOI 10.1111/j.1469-7793.1999.00123.x; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Cook SP, 1998, J NEUROSCI, V18, P9238; Ding SH, 2000, J PHYSIOL-LONDON, V522, P199, DOI 10.1111/j.1469-7793.2000.t01-1-00199.x; Egan TM, 2004, CURR TOP MED CHEM, V4, P821, DOI 10.2174/1568026043451005; Fischer W, 2003, J NEUROCHEM, V85, P779, DOI 10.1046/j.1471-4159.2003.01716.x; Giniatullin R, 2003, NEUROPHARMACOLOGY, V44, P132, DOI 10.1016/S0028-3908(02)00338-6; Haines WR, 1999, MOL PHARMACOL, V56, P720; He ML, 2003, J BIOL CHEM, V278, P10182, DOI 10.1074/jbc.M209094200; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Koshimizu T, 2002, J BIOL CHEM, V277, P46891, DOI 10.1074/jbc.M205274200; Li ZY, 2004, J NEUROSCI, V24, P7378, DOI 10.1523/JNEUROSCI.1423-04.2004; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North R Alan, 2003, Curr Opin Investig Drugs, V4, P833; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Rettinger J, 2004, J BIOL CHEM, V279, P6426, DOI 10.1074/jbc.M306987200; Sokolova E, 2004, BRIT J PHARMACOL, V141, P1048, DOI 10.1038/sj.bjp.0705701; Virginio C, 1998, J PHYSIOL-LONDON, V510, P27, DOI 10.1111/j.1469-7793.1998.027bz.x; Vulchanova L, 1998, EUR J NEUROSCI, V10, P3470, DOI 10.1046/j.1460-9568.1998.00355.x; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Xiong KM, 2004, NEUROSCI LETT, V365, P195, DOI 10.1016/j.neulet.2004.04.078; Zemkova H, 2004, J NEUROSCI, V24, P6968, DOI 10.1523/JNEUROSCI.1471-04.2004	26	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53109	53115		10.1074/jbc.M409772200	http://dx.doi.org/10.1074/jbc.M409772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475563	hybrid			2022-12-27	WOS:000225680600039
J	Kinlough, CL; Poland, PA; Bruns, JB; Harkleroad, KL; Hughey, RP				Kinlough, CL; Poland, PA; Bruns, JB; Harkleroad, KL; Hughey, RP			MUC1 membrane trafficking is modulated by multiple interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; CARCINOMA-ASSOCIATED ANTIGEN; BREAST-CANCER; CYTOPLASMIC TAIL; BETA-CATENIN; LIPID RAFTS; CELL-ADHESION; EGF RECEPTORS; RING FINGER	MUC1 is a mucin-like transmembrane protein found on the apical surface of many epithelia. Because aberrant intracellular localization of MUC1 in tumor cells correlates with an aggressive tumor and a poor prognosis for the patient, experiments were designed to characterize the features that modulate MUC1 membrane trafficking. By following [S-35]Met/Cys-labeled MUC1 in glycosylation-defective Chinese hamster ovary cells, we found previously that truncation of O-glycans on MUC1 inhibited its surface expression and stimulated its internalization by clathrin-mediated endocytosis. To identify signals for MUC1 internalization that are independent of its glycosylation state, the ectodomain of MUC1 was replaced with that of Tac, and chimera endocytosis was measured by the same protocol. Endocytosis of the chimera was significantly faster than for MUC1, indicating that features of the highly extended ectodomain inhibit MUC1 internalization. Analysis of truncation mutants and tyrosine mutants showed that Tyr(20) and Tyr(60) were both required for efficient endocytosis. Mutation of Tyr(20) significantly blocked coimmunoprecipitation of the chimera with AP-2, indicating that (YHPM)-H-20 is recognized as a YXXphi motif by the mu2 subunit. The tyrosine-phosphorylated (YTNP)-T-60 was previously identified as an SH2 site for Grb2 binding, and we found that mutation of Tyr(60) blocked coimmunoprecipitation of the chimera with Grb2. This is the first indication that Grb2 plays a significant role in the endocytosis of MUC1.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughey, RP (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, 930 Scaife Hall, Pittsburgh, PA 15261 USA.	hughey@msx.dept-med.pitt.edu			NCI NIH HHS [P50-CA9044] Funding Source: Medline; NIDDK NIH HHS [P50-DK56490, DK54787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490, R01DK054787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Arcasoy SM, 1997, AM J RESP CELL MOL, V17, P422, DOI 10.1165/ajrcmb.17.4.2714; ARCASOY SM, 1998, AM J RESP CRIT CARE, V157, pA582; Bieche I, 1997, THYROID, V7, P725, DOI 10.1089/thy.1997.7.725; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Chu JS, 1999, CANCER LETT, V142, P121, DOI 10.1016/S0304-3835(99)00161-5; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; FONTENOT JD, 1995, J BIOMOL STRUCT DYN, V13, P245, DOI 10.1080/07391102.1995.10508837; FONTENOT JD, 1993, CANCER RES, V53, P5386; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Fujita K, 1999, BRIT J CANCER, V80, P301, DOI 10.1038/sj.bjc.6690355; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Guddo F, 1998, ANTICANCER RES, V18, P1915; Guddo F, 1998, J CLIN PATHOL, V51, P667, DOI 10.1136/jcp.51.9.667; Handa K, 2001, BIOCHEM BIOPH RES CO, V285, P788, DOI 10.1006/bbrc.2001.5225; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Hudson MJH, 1996, AM J PATHOL, V148, P951; Hull S R, 1989, Cancer Commun, V1, P261; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Julian J, 2002, BIOCHEM BIOPH RES CO, V293, P1183, DOI 10.1016/S0006-291X(02)00352-2; Kam JL, 1998, CANCER RES, V58, P5577; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Lillehoj EP, 2002, AM J PHYSIOL-LUNG C, V282, pL751, DOI 10.1152/ajplung.00383.2001; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Muller S, 2002, J BIOL CHEM, V277, P26103, DOI 10.1074/jbc.M202921200; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PANDEY P, 1995, CANCER RES, V55, P4000; Poland PA, 1997, GLYCOCONJUGATE J, V14, P89, DOI 10.1023/A:1018569100438; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Xu XZ, 2000, ONCOGENE, V19, P3172, DOI 10.1038/sj.onc.1203645; Zhang K, 1996, J CELL BIOCHEM, V60, P538, DOI 10.1002/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.3.CO;2-A	78	46	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53071	53077		10.1074/jbc.M409360200	http://dx.doi.org/10.1074/jbc.M409360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471854	hybrid			2022-12-27	WOS:000225680600034
J	Morais-de-Sa, E; Pereira, PJB; Saraiva, MJ; Damas, AM				Morais-de-Sa, E; Pereira, PJB; Saraiva, MJ; Damas, AM			The crystal structure of transthyretin in complex with diethylstilbestrol - A promising template for the design of amyloid inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-BINDING; 2.5 ANGSTROM RESOLUTION; RAT TRANSTHYRETIN; THYROXINE-BINDING; NATIVE-STATE; PROTEIN; DISEASE; PREALBUMIN; REVEALS; VARIANT	Transthyretin ( TTR) is a homotetrameric plasma protein that, in conditions not yet completely understood, may aggregate, forming the fibrillar material associated with TTR amyloidosis. A number of reported experiments indicate that dissociation of the TTR tetramer occurs prior to fibril formation, and therefore, studies aiming at the discovery of compounds that stabilize the protein quaternary structure, thereby acting as amyloid inhibitors, are being performed. The ability of diethylstilbestrol ( DES) to act as a competitive inhibitor for the thyroid hormone binding to TTR indicated a possible stabilizing effect of DES upon binding. Here we report the crystallographic study of DES binding to TTR. The structural data reveal two different binding modes, both located in the thyroxine binding channel. In both cases, DES binds deeply in the channel and establishes interactions with the equivalent molecule present in the adjacent binding site. The most remarkable features of DES interaction with TTR are its hydrophobic interactions within the protein halogen binding pockets, where its ethyl groups are snugly fitted, and the hydrogen bonds established at the center of the tetramer with Ser-117. Experiments concerning amyloid formation in vitro suggest that DES is effectively an amyloid inhibitor in acid-mediated fibrillogenesis and may be used for the design of more powerful drugs. The present study gave us further insight in the molecular mechanism by which DES competes with thyroid hormone binding to TTR and highlights key interactions between DES and TTR that oppose amyloid formation.	Univ Porto, Inst Biol Mol & Celular, P-4150 Oporto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Damas, AM (corresponding author), Univ Porto, Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150 Oporto, Portugal.	amdamas@ibmc.up.pt	Saraiva, Maria João/K-3907-2013; Pereira, Pedro/F-8972-2011; Morais-de-Sá, Eurico/I-2157-2013	Saraiva, Maria João/0000-0002-3360-6899; Pereira, Pedro/0000-0003-0969-5438; Morais-de-Sá, Eurico/0000-0003-3525-8231				Adamski-Werner SL, 2004, J MED CHEM, V47, P355, DOI 10.1021/jm030347n; Almeida MR, 2004, BIOCHEM J, V381, P351, DOI 10.1042/BJ20040011; Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Alves IL, 1997, HUM MUTAT, V9, P226, DOI 10.1002/(SICI)1098-1004(1997)9:3<226::AID-HUMU3>3.3.CO;2-W; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAVALIERI RR, 1981, PHARMACOL REV, V33, P55; CHENG SY, 1977, BIOCHEMISTRY-US, V16, P3707, DOI 10.1021/bi00635a031; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; Damas AM, 1996, ACTA CRYSTALLOGR D, V52, P966, DOI 10.1107/S0907444996003307; Green NS, 2003, J AM CHEM SOC, V125, P13404, DOI 10.1021/ja030294z; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Hammarstrom P, 2001, BIOCHEMISTRY-US, V40, P11453, DOI 10.1021/bi010673+; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hornberg A, 2004, BBA-PROTEINS PROTEOM, V1700, P93, DOI 10.1016/j.bbapap.2004.04.004; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; Ishihara A, 2003, MOL CELL ENDOCRINOL, V199, P105, DOI 10.1016/S0303-7207(02)00302-7; Jury HH, 2000, J STEROID BIOCHEM, V75, P167, DOI 10.1016/S0960-0760(00)00168-0; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CRYSTALLOGRAPHIC COM, V5; Miller SR, 2004, LAB INVEST, V84, P545, DOI 10.1038/labinvest.3700059; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Muziol T, 2001, ACTA BIOCHIM POL, V48, P885; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NILSSON SF, 1975, J BIOL CHEM, V250, P8554; PAZ PDL, 1992, DESIGN DRUGS MACROMO; Quintas A, 1999, J BIOL CHEM, V274, P32943, DOI 10.1074/jbc.274.46.32943; Redondo C, 2000, BIOCHEM J, V348, P167, DOI 10.1042/0264-6021:3480167; REID DG, 1989, J BIOL CHEM, V264, P2013; ROUSSEL A, 1989, TURBOFRODO SILICON G; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Sebastiao MP, 2001, J MOL BIOL, V306, P733, DOI 10.1006/jmbi.2000.4415; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sousa MM, 2001, AM J PATHOL, V159, P1993; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046; Wojtczak A, 1997, ACTA BIOCHIM POL, V44, P505, DOI 10.18388/abp.1997_4400; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P1061, DOI 10.1107/S0907444901007235; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P957, DOI 10.1107/S0907444901006047	52	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53483	53490		10.1074/jbc.M408053200	http://dx.doi.org/10.1074/jbc.M408053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469931	hybrid			2022-12-27	WOS:000225680600083
J	Obach, M; Navarro-Sabate, A; Caro, J; Kong, XG; Duran, J; Gomez, M; Perales, JC; Ventura, F; Rosa, JL; Bartrons, R				Obach, M; Navarro-Sabate, A; Caro, J; Kong, XG; Duran, J; Gomez, M; Perales, JC; Ventura, F; Rosa, JL; Bartrons, R			6-phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; FRUCTOSE 2,6-BISPHOSPHATASE; ERYTHROPOIETIN GENE; PROTEIN-KINASE; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; EXPRESSION; GLYCOLYSIS; CELLS; PATHWAY; FAMILY	The up-regulation of glycolysis to enhance the production of energy under reduced pO(2) is a hallmark of the hypoxic response. A key regulator of glycolytic flux is fructose-2,6-bisphosphate, and its steady state concentration is regulated by the action of different isozymes product of four genes (pfkfb1-4). pfkfb3 has been found in proliferating cells and tumors, being induced by hypoxia. To understand the organization of cis-acting sequences that are responsible for the oxygen-regulated pfkfb3 gene, we have studied its 5'-flanking region. Extensive analysis of the 5' pfkfb3 promoter sequence revealed the presence of putative consensus binding sites for various transcription factors that could play an important role in pfkfb3 gene regulation. These DNA consensus sequences included estrogen receptor, hypoxia response element (HRE), early growth response, and specific protein 1 putative binding sites. Promoter deletion analysis as well as putative HREs sequences ( wild type and mutated) fused to a c-fos minimal promoter unit constructs demonstrate that the sequence located from -1269 to -1297 relative to the start site is required for hypoxia-inducible factor 1 (HIF-1) induction. The effective binding of HIF-1 transcription factor to the HREs at -1279 and -1288 was corroborated by electrophoretic mobility shift assay and biotinylated oligonucleotide pull-down. In addition, HIF-1alpha null mouse embryo fibroblasts transfected with a full-length pfkfb3 promoter-luciferase reporter construct further demonstrated that HIF-1 protein was critically involved for hypoxia transactivation of this gene. Altogether, these results demonstrate that pfkfb3 is a hypoxia-inducible gene that is stimulated through HIF interaction with the consensus HRE site in its promoter region.	Univ Barcelona, Dept Ciencies Fisiol 2, Unitat Bioquim & Biol Mol, E-08907 Pavello De Govern, Lhospitalet, Spain; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA	University of Barcelona; Jefferson University	Bartrons, R (corresponding author), Univ Barcelona, Dept Ciencies Fisiol 2, Unitat Bioquim & Biol Mol, Campus Bellvitge,Feixa Llarga S-N, E-08907 Pavello De Govern, Lhospitalet, Spain.	rbartrons@ub.edu	Ventura, Francesc/ABG-2285-2020; Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/K-9700-2014; PERALES, JOSE C. C/D-5586-2012; Navarro-Sabaté, Aurea/K-6329-2018; PERALES, JOSE C./AAC-3156-2019; PERALES, JOSE C/J-7457-2017	Ventura, Francesc/0000-0001-9673-9405; Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; PERALES, JOSE C. C/0000-0001-7363-2226; Navarro-Sabaté, Aurea/0000-0002-8286-9732; PERALES, JOSE C./0000-0001-7363-2226; PERALES, JOSE C/0000-0001-7363-2226; Bartrons, Ramon/0000-0001-9349-5847; Obach, Merce/0000-0002-2756-6181				Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Atsumi T, 2002, CANCER RES, V62, P5881; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Ebert BL, 1999, BLOOD, V94, P1864; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Goren N, 2000, MOL BRAIN RES, V75, P138, DOI 10.1016/S0169-328X(99)00319-8; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; Hirata T, 1998, BIOCHEM BIOPH RES CO, V242, P680, DOI 10.1006/bbrc.1997.8024; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HUE L, 1993, ADV ENZYME REGUL, V33, P97; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Krebs H A, 1972, Essays Biochem, V8, P1; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; Navarro-Sabate A, 2001, GENE, V264, P131, DOI 10.1016/S0378-1119(00)00591-6; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Perez JX, 2000, AM J PHYSIOL-CELL PH, V279, pC1359, DOI 10.1152/ajpcell.2000.279.5.C1359; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; Riera L, 2002, BBA-MOL CELL RES, V1589, P89, DOI 10.1016/S0167-4889(02)00169-6; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VENTURA F, 1991, BIOCHEM J, V276, P455, DOI 10.1042/bj2760455; WANG GL, 1993, BLOOD, V82, P3610; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe F, 1997, J NEUROCHEM, V69, P1	38	180	187	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53562	53570		10.1074/jbc.M406096200	http://dx.doi.org/10.1074/jbc.M406096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466858	Green Published, hybrid			2022-12-27	WOS:000225680600092
J	Peng, HM; Morishima, Y; Jenkins, GJ; Dunbar, AY; Lau, M; Patterson, C; Pratt, WB; Osawa, Y				Peng, HM; Morishima, Y; Jenkins, GJ; Dunbar, AY; Lau, M; Patterson, C; Pratt, WB; Osawa, Y			Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a chaperone-dependent E3 ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; IN-VITRO; PROTEIN; IDENTIFICATION; TRAFFICKING; DEGRADATION; SYSTEM; TARGET; HSP90; HSC70	It is established that neuronal nitric-oxide synthase (nNOS) is ubiquitylated and proteasomally degraded. The proteasomal degradation of nNOS is enhanced by suicide inactivation of nNOS or by the inhibition of hsp90, which is a chaperone found in a native complex with nNOS. In the current study, we have examined whether CHIP, a chaperone-dependent E3 ubiquitin-protein isopeptide ligase that is known to ubiquitylate other hsp90-chaperoned proteins, could act as an ubiquitin ligase for nNOS. We found with the use of HEK293T or COS-7 cells and transient transfection methods that CHIP overexpression causes a decrease in immunodetectable levels of nNOS. The extent of the loss of nNOS is dependent on the amount of CHIP cDNA used for transfection. Lactacystin (10 muM), a selective proteasome inhibitor, attenuates the loss of nNOS in part by causing the nNOS to be found in a detergent-insoluble form. Immunoprecipitation of the nNOS and subsequent Western blotting with an anti-ubiquitin IgG shows an increase in nNOS-ubiquitin conjugates because of CHIP. Moreover, incubation of nNOS with a purified system containing an E1 ubiquitin-activating enzyme, an E2 ubiquitin carrier protein conjugating enzyme (UbcH5a), CHIP, glutathione S-transferase-tagged ubiquitin, and an ATP-generating system leads to the ubiquitylation of nNOS. The addition of purified hsp70 and hsp40 to this in vitro system greatly enhances the amount of nNOS-ubiquitin conjugates, suggesting that CHIP is an E3 ligase for nNOS whose action is facilitated by (and possibly requires) its interaction with nNOS-bound hsp70.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	osawa@umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065619, R37HL065619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65619] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM61728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Billecke SS, 2004, J BIOL CHEM, V279, P30252, DOI 10.1074/jbc.M403864200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; Osawa Y, 2003, J PHARMACOL EXP THER, V304, P493, DOI 10.1124/jpet.102.035055; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200	23	61	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52970	52977		10.1074/jbc.M406926200	http://dx.doi.org/10.1074/jbc.M406926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466472	Green Published, hybrid			2022-12-27	WOS:000225680600021
J	Sebulsky, MT; Speziali, CD; Shilton, BH; Edgell, DR; Heinrichs, DE				Sebulsky, MT; Speziali, CD; Shilton, BH; Edgell, DR; Heinrichs, DE			FhuD1, a ferric hydroxamate-binding lipoprotein in Staphylococcus aureus - A case of gene duplication and lateral transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREPONEMA-PALLIDUM TROA; IRON TRANSPORT; STREPTOCOCCUS-PNEUMONIAE; OLIGOPEPTIDE TRANSPORT; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MALTOSE-BINDING; ABC TRANSPORTER; PROTEIN; IDENTIFICATION	Staphylococcus aureus can utilize ferric hydroxamates as a source of iron under iron-restricted growth conditions. Proteins involved in this transport process are: FhuCBG, which encodes a traffic ATPase; FhuD2, a post-translationally modified lipoprotein that acts as a high affinity receptor at the cytoplasmic membrane for the efficient capture of ferric hydroxamates; and FhuD1, a protein with similarity to FhuD2. Gene duplication likely gave rise to fhuD1 and fhuD2. While the genomic locations of fhuCBG and fhuD2 in S. aureus strains are conserved, both the presence and the location of fhuD1 are variable. The apparent redundancy of FhuD1 led us to examine the role of this protein. We demonstrate that FhuD1 is expressed only under conditions of iron limitation through the regulatory activity of Fur. FhuD1 fractions with the cell membrane and binds hydroxamate siderophores but with lower affinity than FhuD2. Using small angle x-ray scattering, the solution structure of FhuD1 resembles that of FhuD2, and only a small conformational change is associated with ferrichrome binding. FhuD1, therefore, appears to be a receptor for ferric hydroxamates, like FhuD2. Our data to date suggest, however, that FhuD1 is redundant to FhuD2 and plays a minor role in hydroxamate transport. However, given the very real possibility that we have not yet identified the proper conditions where FhuD1 does provide an advantage over FhuD2, we anticipate that FhuD1 serves an enhanced role in the transport of untested hydroxamate siderophores and that it may play a prominent role during the growth of S. aureus in its natural environments.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Heinrichs, DE (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.	david.heinrichs@fmd.uwo.ca	Heinrichs, David/ABD-5702-2021; Edgell, David/AAJ-1971-2020; Shilton, Brian H/A-6667-2011	Speziali, Craig/0000-0002-6401-0174; Heinrichs, David/0000-0002-7217-2456				ALLOING G, 1994, J MOL BIOL, V241, P44, DOI 10.1006/jmbi.1994.1472; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Byers BR, 1998, MET IONS BIOL SYST, V35, P37; Cockayne A, 1998, INFECT IMMUN, V66, P3767, DOI 10.1128/IAI.66.8.3767-3774.1998; Courcol RJ, 1997, INFECT IMMUN, V65, P1944, DOI 10.1128/IAI.65.5.1944-1948.1997; Dale SE, 2004, INFECT IMMUN, V72, P29, DOI 10.1128/IAI.72.1.29-37.2004; DRECHSEL H, 1993, BIOMETALS, V6, P185; Garault P, 2002, J BIOL CHEM, V277, P32, DOI 10.1074/jbc.M107002200; Guinier A., 1955, SMALL ANGLE SCATTERI; Hammersley A. P., 1997, ESRF97HA02T; HAMMERSLEY AP, 1998, ESRF97HA02T; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; KONETSCHNYRAPP S, 1990, EUR J BIOCHEM, V191, P65, DOI 10.1111/j.1432-1033.1990.tb19094.x; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lindsay JA, 2004, TRENDS MICROBIOL, V12, P378, DOI 10.1016/j.tim.2004.06.004; Meyer JM, 1997, MICROBIOL-UK, V143, P35, DOI 10.1099/00221287-143-1-35; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER R, 1993, MOL MICROBIOL, V8, P111, DOI 10.1111/j.1365-2958.1993.tb01208.x; Sebulsky MT, 2000, J BACTERIOL, V182, P4394, DOI 10.1128/JB.182.16.4394-4400.2000; Sebulsky MT, 2003, J BIOL CHEM, V278, P49890, DOI 10.1074/jbc.M305073200; Sebulsky MT, 2001, J BACTERIOL, V183, P4994, DOI 10.1128/JB.183.17.4994-5000.2001; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Sutcliffe IC, 2002, MICROBIOL-SGM, V148, P2065, DOI 10.1099/00221287-148-7-2065; Tai SS, 2003, FEMS MICROBIOL LETT, V220, P303, DOI 10.1016/S0378-1097(03)00135-6; Weinberg ED, 1997, PERSPECT BIOL MED, V40, P578	38	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53152	53159		10.1074/jbc.M409793200	http://dx.doi.org/10.1074/jbc.M409793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475351	hybrid			2022-12-27	WOS:000225680600044
J	Thompson, T; Tovar, C; Yang, H; Carvajal, D; Vu, BT; Xu, QL; Wahl, GM; Heimbrook, DC; Vassilev, LT				Thompson, T; Tovar, C; Yang, H; Carvajal, D; Vu, BT; Xu, QL; Wahl, GM; Heimbrook, DC; Vassilev, LT			Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR PROTEIN P53; PROLYL ISOMERASE PIN1; DNA-DAMAGE; IN-VIVO; P53-DEPENDENT APOPTOSIS; MDM2; GROWTH; PATHWAY; SITES; ACETYLATION	The p53 tumor suppressor is a key mediator of the cellular response to stress. Phosphorylation induced by multiple stress-activated kinases has been proposed to be essential for p53 stabilization, interaction with transcriptional co-activators, and activation of p53 target genes. However, genetic studies suggest that stress-activated phosphorylation may not be essential for p53 activation. We therefore investigated the role of p53 phosphorylation on six key serine residues (Ser(6), Ser(15), Ser(20), Ser(37), Ser(46), and Ser(392)) for p53 activation using nutlin-3, a recently developed small molecule MDM2 antagonist. We show here that nutlin does not induce the phosphorylation of p53. Comparison of the activity of unphosphorylated and phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide in HCT116 and RKO cells revealed no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes and to induce p53-dependent apoptosis. We conclude that p53 phosphorylation on six major serine sites is not required for activation of p53 target genes or biological responses in vivo.	Hoffmann La Roche Inc, Roche Res Ctr, Discovery Oncol, Nutley, NJ 07110 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Roche Holding; Salk Institute	Vassilev, LT (corresponding author), Hoffmann La Roche Inc, Roche Res Ctr, Discovery Oncol, 340 Kingsland St, Nutley, NJ 07110 USA.	lyubomir.vassilev@roche.com						Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Perego P, 2001, CURR MED CHEM, V8, P31, DOI 10.2174/0929867013373994; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schmitt CA, 2002, J MOL MED-JMM, V80, P137, DOI 10.1007/s00109-001-0293-3; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Steensma David P, 2003, Methods Mol Med, V85, P323, DOI 10.1385/1-59259-380-1:323; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yang H, 2003, MOL CANCER THER, V2, P1023; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	43	201	206	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53015	53022		10.1074/jbc.M410233200	http://dx.doi.org/10.1074/jbc.M410233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471885	hybrid			2022-12-27	WOS:000225680600027
J	Wilson, SJ; Roche, AM; Kostetskaia, E; Smyth, EM				Wilson, SJ; Roche, AM; Kostetskaia, E; Smyth, EM			Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS NEOINTIMAL FORMATION; A(2) RECEPTOR; PROTEIN-KINASE; HUMAN PLATELETS; LIGAND-BINDING; DEFICIENT MICE; BETA ISOFORMS; IN-VIVO; PHOSPHORYLATION; PROSTAGLANDIN	Prostacyclin (PGI(2)) and thromboxane (TxA(2)) are biological opposites; PGI(2), a vasodilator and inhibitor of platelet aggregation, limits the deleterious actions of TxA(2), a vasoconstrictor and platelet activator. The molecular mechanisms involved in the counterregulation of PGI(2)/TxA(2) signaling are unclear. We examined the interaction of the receptors for PGI(2) (IP) and TxA(2) (TPalpha). IP-induced cAMP and TP-induced inositol phosphate generation were unaltered when the receptors were co-expressed in HEK 293 cells (IP/TPalpha-HEK). TP-cAMP generation, in response to TP agonists or a TP-dependent isoprostane, iPE(2)III, was evident in IP/TPalpha-HEK and in aortic smooth muscle cells, but not in cells expressing either receptor alone, or in IP-deficient aortic smooth muscle cells. Augmentation of TP-induced cAMP generation, with the IP agonist cicaprost, was ablated in IP-deficient cells and was independent of direct IP signaling. IP/TPalpha heterodimers were formed constitutively when the receptors were co-expressed, with no overt changes in ligand binding to the individual receptor sites. However, despite inefficient binding of iPE(2)III to either the IP or TPalpha, expressed alone or in combination, robust cAMP generation was evident in IP/TPalpha-HEK, suggesting the formation of an alternative receptor site. Thus, IP/TPalpha dimerization was coincident with TP-cAMP generation, promoting a "PGI(2)-like" cellular response to TP activation. This represents a previously unknown mechanism by which IP may limit the cellular effects of TP.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	Smyth, EM (corresponding author), Univ Penn, Ctr Expt Therapeut, 808 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	emer@spirit.gcrc.upenn.edu						AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Audoly LP, 2000, CIRCULATION, V101, P2833, DOI 10.1161/01.CIR.101.24.2833; Belton OA, 2003, CIRCULATION, V108, P3017, DOI 10.1161/01.CIR.0000104565.78013.AD; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Chiang N, 1998, ARCH BIOCHEM BIOPHYS, V352, P207, DOI 10.1006/abbi.1998.0620; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; DORN GW, 1987, CIRC RES, V60, P952, DOI 10.1161/01.RES.60.6.952; EGAN KM, 2004, IN PRESS SCIENCE; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Giguere V, 2004, EUR J PHARMACOL, V494, P11, DOI 10.1016/j.ejphar.2004.04.041; GRIMALDI M, 1994, J NEUROCHEM, V63, P344; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Harada M, 1999, CARDIOVASC RES, V43, P481, DOI 10.1016/S0008-6363(99)00107-8; Hirata M, 1993, Nihon Rinsho, V51, P1586; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; MONCADA S, 1981, CLIN SCI, V61, P369, DOI 10.1042/cs0610369; MURRAY R, 1990, J BIOL CHEM, V265, P21670; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Numaguchi Y, 1999, ARTERIOSCL THROM VAS, V19, P727, DOI 10.1161/01.ATV.19.3.727; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; Pakala R, 1997, CIRCULATION, V96, P2280; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Ropero AB, 1999, J PHYSIOL-LONDON, V521, P397, DOI 10.1111/j.1469-7793.1999.00397.x; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; Vane J. R., 1995, AM J CARDIOL, V75, p3A; Walsh MT, 2000, BBA-MOL CELL RES, V1496, P164, DOI 10.1016/S0167-4889(00)00031-8; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	51	74	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53036	53047		10.1074/jbc.M405002200	http://dx.doi.org/10.1074/jbc.M405002200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471868	hybrid			2022-12-27	WOS:000225680600030
J	Labrecque, L; Nyalendo, C; Langlois, S; Durocher, Y; Roghi, C; Murphy, G; Gingras, D; Beliveau, R				Labrecque, L; Nyalendo, C; Langlois, S; Durocher, Y; Roghi, C; Murphy, G; Gingras, D; Beliveau, R			Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; 1-MATRIX METALLOPROTEINASE; IN-VIVO; C-SRC; TRANSIENT TRANSFECTION; SIGNAL-TRANSDUCTION; CELL MIGRATION; UP-REGULATION; MT1-MMP; ACTIVATION	We have recently shown that stimulation of endothelial cells with vascular endothelial growth factor ( VEGF) induces dissociation of caveolin-1 from the VEGFR-2 receptor, followed by Src family kinase-dependent tyrosine phosphorylation of the protein (Labrecque, L., Royal, I., Surprenant, D. S., Patterson, C., Gingras, D., and Beliveau, R. (2003) Mol. Biol. Cell 14, 334 - 347). In this study, we provide evidence that the VEGF-dependent tyrosine phosphorylation of caveolin-1 induces interaction of the protein with the membrane-type 1 matrix metalloproteinase ( MT1-MMP). This interaction requires the phosphorylation of caveolin-1 on tyrosine 14 by members of the Src family of protein kinases, such as Src and Fyn, because it is completely abolished by expression of a catalytically inactive Src mutant or by site-directed mutagenesis of tyrosine 14 of caveolin-1. Most interestingly, the association of MT1-MMP with phosphorylated caveolin-1 induced the recruitment of Src and a concomitant inhibition of the kinase activity of the enzyme, suggesting that this complex may be involved in the negative regulation of Src activity. The association of MT1-MMP with phosphorylated caveolin-1 occurs in caveolae membranes and involves the cytoplasmic domain of MT1-MMP because it was markedly reduced by mutation of Cys(574) and Val(582) residues of the cytoplasmic tail of the enzyme. Most interestingly, the reduction of the interaction between MT1-MMP and caveolin-1 by using these mutants also decreases MT1-MMP-dependent cell locomotion. Overall these results indicate that MT1-MMP associates with tyrosine-phosphorylated caveolin-1 and that this complex may play an important role in MT1-MMP regulation and function.	Univ Montreal, Hop St Justine, Mol Med Lab, Ctr Canc Charles Bruneau, Montreal, PQ H3T 1C5, Canada; Anim Cell Technol Grp, Montreal, PQ H4P 2R2, Canada; Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England	Universite de Montreal; University of Cambridge	Beliveau, R (corresponding author), Univ Montreal, Hop St Justine, Mol Med Lab, Ctr Canc Charles Bruneau, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	molmed@justine.umontreal.ca	Durocher, Yves/K-8709-2019; Roghi, Christian/F-3228-2012	Roghi, Christian/0000-0002-4109-6382				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Deryugina EI, 2002, CANCER RES, V62, P580; Duan LJ, 2004, BLOOD, V103, P1370, DOI 10.1182/blood-2003-05-1701; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; Fielding PE, 2004, BIOCHEMISTRY-US, V43, P2578, DOI 10.1021/bi035442c; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gingras D, 2000, BBA-MOL CELL RES, V1497, P341, DOI 10.1016/S0167-4889(00)00071-9; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Jeong J W, 1999, Angiogenesis, V3, P167, DOI 10.1023/A:1009065709676; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kadono Y, 1998, CANCER RES, V58, P2240; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; Koike T, 2002, J CELL BIOCHEM, V86, P748, DOI 10.1002/jcb.10257; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Pham PL, 2003, BIOTECHNOL BIOENG, V84, P332, DOI 10.1002/bit.10774; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Urena JM, 1999, J CELL SCI, V112, P773; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yamamoto M, 1999, EXP CELL RES, V247, P380, DOI 10.1006/excr.1998.4379; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	53	132	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52132	52140		10.1074/jbc.M409617200	http://dx.doi.org/10.1074/jbc.M409617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466865	hybrid			2022-12-27	WOS:000225493400052
J	Nonami, A; Kato, R; Taniguchi, K; Yoshiga, D; Taketomi, T; Fukuyama, S; Harada, M; Sasaki, A; Yoshimura, A				Nonami, A; Kato, R; Taniguchi, K; Yoshiga, D; Taketomi, T; Fukuyama, S; Harada, M; Sasaki, A; Yoshimura, A			Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; INDUCED PROLIFERATION; SPROUTY; RAS; ERYTHROPOIETIN; SUPPRESSES; PATHWAY; ANTAGONIST; RECEPTOR	Sprouty/Spred family proteins have been identified as negative regulators of growth factor-induced ERK/mitogen-activated protein (MAP) kinase activation. However, it has not been clarified whether these proteins regulate cytokine-induced ERK activity. We found that Spred-1 is highly expressed in interleukin-3 (IL-3)-dependent hematopoietic cell lines and bone marrow-derived mast cells. To investigate the roles of Spred-1 in hematopoiesis, we expressed wild-type Spred-1 and a dominant negative form of Spred-1, DeltaC-Spred, in IL-3- and stem cell factor (SCF)-dependent cell lines as well as hematopoietic progenitor cells from mouse bone marrow by retrovirus gene transfer. In IL-3- dependent Ba/F3 cells expressing c-kit, forced expression of Spred-1 resulted in a reduced proliferation rate and ERK activation in response to not only SCF but also IL-3. In contrast, DeltaC-Spred augmented IL-3- induced cell proliferation and ERK activation. Wild-type Spred-1 inhibited colony formation of bone marrow cells in the presence of cytokines, whereas DeltaC-Spred-1 expression enhanced colony formation. Augmentation of ERK activation and proliferation in response to IL-3 was also observed in Spred-1-deficient bone marrow-derived mast cells. These data suggest that Spred-1 negatively regulates hematopoiesis by suppressing not only SCF-induced but also IL-3- induced ERK activation.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med, Dept Internal Med 1, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013; YOSHIGA, Daigo/GZM-9352-2022	YOSHIGA, Daigo/0000-0001-9603-3138; Sasaki, Atsuo/0000-0003-2963-4501				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Kerkhoff E, 2001, ADV ENZYME REGUL, V41, P261, DOI 10.1016/S0065-2571(00)00023-6; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; METCALF D, 1977, HEMOPOIETIC COLONIES, P12; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Nobuhisa I, 2004, J EXP MED, V199, P737, DOI 10.1084/jem.20030830; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; OKUDA K, 1992, BLOOD, V79, P2880; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Reich A, 1999, DEVELOPMENT, V126, P4139; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rojnuckarin P, 2001, J BIOL CHEM, V276, P41014, DOI 10.1074/jbc.M106508200; Sakamoto H, 2000, J BIOL CHEM, V275, P35857, DOI 10.1074/jbc.M006317200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Secchiero P, 2004, BLOOD, V103, P517, DOI 10.1182/blood-2003-06-2137; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	47	70	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52543	52551		10.1074/jbc.M405189200	http://dx.doi.org/10.1074/jbc.M405189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465815	hybrid			2022-12-27	WOS:000225493400100
J	Wang, JL; Julin, DA				Wang, JL; Julin, DA			DNA helicase activity of the RecD protein from Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T4 DDA HELICASE; ESCHERICHIA-COLI; RECBCD ENZYME; CHLAMYDIA-TRACHOMATIS; IONIZING-RADIATION; SACCHAROMYCES-CEREVISIAE; GENOME SEQUENCE; BINDING-PROTEIN; IN-VITRO	The bacterium Deinococcus radiodurans is extremely resistant to high levels of DNA-damaging agents, including gamma rays and ultraviolet light that can lead to double-stranded DNA breaks. Surprisingly, the organism does not appear to have a RecBCD enzyme, an enzyme that is critical for double-strand break repair in many other bacteria. The D. radiodurans genome does encode a protein whose closest characterized homologues are RecD subunits of RecBCD enzymes in other bacteria. We have purified this novel D. radiodurans RecD protein and characterized its biochemical activities. The D. radiodurans RecD protein is a DNA helicase that unwinds short ( 20 base pairs) DNA duplexes with either a 5'-single-stranded tail or a forked end, but not blunt-ended or 3'-tailed duplexes. Duplexes with 10 - 12 nucleotide (nt) 5'-tails are good unwinding substrates and are bound tightly, while DNA with shorter tails ( 4 - 8 nt) are poor unwinding substrates and are bound much less tightly. The RecD protein is much less efficient at unwinding slightly longer substrates ( 52 or 76 base pairs, with 12 nt 5'-tails). Unwinding of the longer substrates is stimulated somewhat ( 4 - 5-fold) by the single-stranded DNA-binding protein from D. radiodurans. These results show that the D. radiodurans RecD protein is a DNA helicase with 5'-3' polarity and low processivity.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Julin, DA (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	dj13@umail.umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039777, R01GM039777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AltMorbe J, 1996, J BACTERIOL, V178, P4248, DOI 10.1128/jb.178.14.4248-4257.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; Bessler JB, 2001, TRENDS CELL BIOL, V11, P60, DOI 10.1016/S0962-8924(00)01877-8; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Byrd DR, 1997, MOL MICROBIOL, V25, P1011, DOI 10.1046/j.1365-2958.1997.5241885.x; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; Chedin F, 2002, MOL MICROBIOL, V43, P823, DOI 10.1046/j.1365-2958.2002.02785.x; Chen HW, 1997, J BIOL CHEM, V272, P10072; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; Courcelle J, 2001, GENETICS, V158, P41; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Edwards JS, 2003, TRENDS BIOTECHNOL, V21, P381, DOI 10.1016/S0167-7799(03)00196-3; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUTMAN PD, 1994, GENE, V141, P31, DOI 10.1016/0378-1119(94)90124-4; Haft DH, 2003, NUCLEIC ACIDS RES, V31, P371, DOI 10.1093/nar/gkg128; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Ivessa AS, 2003, MOL CELL, V12, P1525, DOI 10.1016/S1097-2765(03)00456-8; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kim JI, 2002, J BACTERIOL, V184, P1649, DOI 10.1128/JB.184.6.1649-1660.2002; KORANGY F, 1992, J BIOL CHEM, V267, P3088; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAHAYE A, 1993, J BIOL CHEM, V268, P26155; LENNON E, 1990, J BACTERIOL, V172, P2955, DOI 10.1128/jb.172.6.2955-2961.1990; Lipton MS, 2002, P NATL ACAD SCI USA, V99, P11049, DOI 10.1073/pnas.172170199; Liu YQ, 2003, P NATL ACAD SCI USA, V100, P4191, DOI 10.1073/pnas.0630387100; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Nanduri B, 2001, NUCLEIC ACIDS RES, V29, P2829, DOI 10.1093/nar/29.13.2829; Noirot-Gros MF, 2002, MOL GENET GENOMICS, V267, P391, DOI 10.1007/s00438-002-0670-9; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Sambrook J, 1989, MOL CLONING LAB MANU, V2; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tada S, 2001, NUCLEIC ACIDS RES, V29, P3835, DOI 10.1093/nar/29.18.3835; Taneja P, 2002, J BIOL CHEM, V277, P40853, DOI 10.1074/jbc.M208067200; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	64	34	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52024	52032		10.1074/jbc.M408645200	http://dx.doi.org/10.1074/jbc.M408645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466873	hybrid			2022-12-27	WOS:000225493400039
J	Morton, DB				Morton, DB			Atypical soluble guanylyl cyclases in Drosophila can function as molecular oxygen sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SUBUNIT; HEME; MECHANISMS	Conventional soluble guanylyl cyclases are heterodimeric enzymes that synthesize cGMP and are activated by nitric oxide. Recently, a separate class of soluble guanylyl cyclases has been identified that are only slightly activated by or are insensitive to nitric oxide. These atypical guanylyl cyclases include the vertebrate beta2 subunit and examples from the invertebrates Manduca sexta, Caenorhabditis elegans, and Drosophila melanogaster. A member of this family, GCY-35 in C. elegans, was recently shown to be required for a behavioral response to low oxygen levels and may be directly regulated by oxygen (Gray, J. M., Karow, D. S., Lu, H., Chang, A. J., Chang, J. S., Ellis, R. E., Marletta, M. A., and Bargmann, C. I. ( 2004) Nature 430, 317 - 322). Drosophila contains three genes that code for atypical soluble guanylyl cyclases: Gyc-88E, Gyc-89Da, and Gyc-89Db. COS-7 cells co-transfected with Gyc-88E and Gyc-89Da or Gyc-89Db accumulate low levels of cGMP under normal atmospheric oxygen concentrations and are potently activated under anoxic conditions. The increase in activity is graded over oxygen concentrations of 0 - 21%, can be detected within 1 min of exposure to anoxic conditions and is blocked by the soluble guanylyl cyclase inhibitor, 1H-[1,2,4] oxadiazolo[ 4,3-a] quinoxaline-1-one (ODQ). Gyc-88E and Gyc-89Db are co-expressed in a subset of sensory neurons where they would be ideally situated to act as oxygen sensors. This is the first demonstration of a soluble guanylyl cyclase that is activated in response to changing oxygen concentrations.	Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97239 USA	Oregon Health & Science University	Morton, DB (corresponding author), Oregon Hlth & Sci Univ, Dept Integrat Biosci, SD,611 SW Campus Dr, Portland, OR 97239 USA.	mortonda@ohsu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029740, R29NS029740] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29740] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Gray JM, 2004, NATURE, V430, P317, DOI 10.1038/nature02714; Kingan TG, 1997, J EXP BIOL, V200, P3245; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Langlais KK, 2004, J EXP BIOL, V207, P2323, DOI 10.1242/jeb.01025; Lawson DM, 2003, BIOCHEM SOC T, V31, P553, DOI 10.1042/BST0310553; Lucas KA, 2000, PHARMACOL REV, V52, P375; Morton DB, 2004, MOL NEUROBIOL, V29, P97, DOI 10.1385/MN:29:2:097; Peers C, 2001, RESP RES, V2, P145, DOI 10.1186/rr51; Prabhakar NR, 2000, RESP PHYSIOL, V122, P209, DOI 10.1016/S0034-5687(00)00160-2; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; SHAH S, 1995, J BIOL CHEM, V270, P15368, DOI 10.1074/jbc.270.25.15368; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296	15	48	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50651	50653		10.1074/jbc.C400461200	http://dx.doi.org/10.1074/jbc.C400461200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485853	hybrid			2022-12-27	WOS:000225355800004
J	Vila-Perello, M; Sanchez-Vallet, A; Garcia-Olmedo, F; Molina, A; Andreu, D				Vila-Perello, M; Sanchez-Vallet, A; Garcia-Olmedo, F; Molina, A; Andreu, D			Structural dissection of a highly knotted peptide reveals minimal motif with antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PROTEIN; RESISTANCE; THIONIN; MODE; SUSCEPTIBILITY; PUROTHIONIN; MECHANISMS; ANALOGS; DESIGN	The increasing occurrence of bacterial resistance to antibiotics is driving a renewed interest on antimicrobial peptides, in the hope that understanding the structural features responsible for their activity will provide leads into new anti-infective drug candidates. Most chemical studies in this field have focused on linear peptides of various eukaryotic origins, rather than on structures with complex folding patterns found also in nature. We have undertaken the structural dissection of a highly knotted, cysteine-rich plant thionin, with the aim of defining a minimal, synthetically accessible, structure that preserves the bioactive properties of the parent peptide. Using efficient strategies for directed disulfide bond formation, we have prepared a substantially simplified (45% size reduction) version with undiminished antimicrobial activity against a representative panel of pathogens. Analysis by circular dichroism shows that the downsized peptide preserves the central double alpha-helix of the parent form as an essential bioactive motif. Membrane permeability and surface plasmon resonance studies confirm that the mechanism of action remains unchanged.	Pompeu Fabra Univ, Dept Expt & Hlth Sci, E-08003 Barcelona, Spain; Univ Politecn Madrid, ETSIA, Dept Biotechnol, Biochem Lab, E-28040 Madrid, Spain	Pompeu Fabra University; Universidad Politecnica de Madrid	Andreu, D (corresponding author), Pompeu Fabra Univ, Dept Expt & Hlth Sci, Dr Aiguader 80, E-08003 Barcelona, Spain.	david.andreu@upf.edu	Molina, Antonio/G-9789-2015; Sánchez-vallet, Andrea/B-6128-2019; Andreu, David/I-4359-2014	Molina, Antonio/0000-0003-3137-7938; Sánchez-vallet, Andrea/0000-0002-3668-9503; Andreu, David/0000-0002-6317-6666				Andreu D, 1994, Methods Mol Biol, V35, P91; ANDREU D, 1983, P NATL ACAD SCI-BIOL, V80, P6475, DOI 10.1073/pnas.80.21.6475; Andreu D, 2000, SOLID-PHASE SYNTHESIS, P365; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Annis I, 1997, METHOD ENZYMOL, V289, P198; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; Berrocal-Lobo M, 2002, PLANT PHYSIOL, V128, P951, DOI 10.1104/pp.010685; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Caaveiro JMM, 1997, FEBS LETT, V410, P338, DOI 10.1016/S0014-5793(97)00613-3; CARMONA MJ, 1993, PLANT J, V3, P457, DOI 10.1046/j.1365-313X.1993.t01-24-00999.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; DECALEYA RF, 1972, APPL MICROBIOL, V23, P998, DOI 10.1128/AEM.23.5.998-1000.1972; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRACKI WS, 1992, TOXICON, V30, P1427, DOI 10.1016/0041-0101(92)90518-A; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Garcia-Olmedo F., 1992, Genes involved in plant defense., P283; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hackeng TM, 1998, BIOPOLYMERS, V46, P53, DOI 10.1002/(SICI)1097-0282(199808)46:2<53::AID-BIP1>3.0.CO;2-W; Hughes P, 2000, J BIOL CHEM, V275, P823, DOI 10.1074/jbc.275.2.823; LEE FS, 1993, J COMPUT CHEM, V14, P161, DOI 10.1002/jcc.540140205; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Mangoni ML, 2003, BIOCHEMISTRY-US, V42, P14023, DOI 10.1021/bi034521l; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; Mozsolits H, 2002, BIOPOLYMERS, V66, P3, DOI 10.1002/bip.10200; Osusky M, 2000, NAT BIOTECHNOL, V18, P1162, DOI 10.1038/81145; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; Romestand B, 2003, EUR J BIOCHEM, V270, P2805, DOI 10.1046/j.1432-1033.2003.03657.x; Roth BL, 1997, APPL ENVIRON MICROB, V63, P2421, DOI 10.1128/AEM.63.6.2421-2431.1997; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Sitaram N, 2002, ANTIMICROB AGENTS CH, V46, P2279, DOI 10.1128/AAC.46.7.2279-2283.2002; Vila-Perello M, 2003, FEBS LETT, V536, P215, DOI 10.1016/S0014-5793(03)00053-X; WADA K, 1982, J BIOCHEM-TOKYO, V91, P257, DOI 10.1093/oxfordjournals.jbchem.a133683; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yount NY, 2004, P NATL ACAD SCI USA, V101, P7363, DOI 10.1073/pnas.0401567101; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	32	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1661	1668		10.1074/jbc.M410577200	http://dx.doi.org/10.1074/jbc.M410577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15494403	hybrid, Green Accepted			2022-12-27	WOS:000226195200097
J	Zheng, L; Settle, M; Brubaker, G; Schmitt, D; Hazen, SL; Smith, JD; Kinter, M				Zheng, L; Settle, M; Brubaker, G; Schmitt, D; Hazen, SL; Smith, JD; Kinter, M			Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC INTIMA; HUMAN NEUTROPHILS EMPLOY; ACUTE CORONARY SYNDROMES; CARDIOVASCULAR-DISEASE; LIPID-PEROXIDATION; PROTEIN NITRATION; MASS-SPECTROMETRY; DEFICIENT MICE; VIVO	We recently reported that apolipoprotein A-I (apoA-I), the major protein component of high density lipoprotein, is a selective target for myeloperoxidase (MPO)catalyzed nitration and chlorination in both and serum of subjects with cardiovascular disease. We further showed that the extent of both apoA-I nitration and chlorination correlated with functional impairment in reverse cholesterol transport activity of the isolated lipoprotein. Herein we used tandem mass spectrometry to map the sites of MPO-mediated apoA-I nitration and chlorination in vitro and in vivo and to relate the degree of site-specific modifications to loss of apoA-I lipid binding and cholesterol efflux functions. Of the seven tyrosine residues in apoA-I, Tyr-192, Tyr-166, Tyr-236, and Tyr-29 were nitrated and chlorinated in MPO-mediated reactions. Site-specific liquid chromatography-mass spectrometry quantitative analyses demonstrated that the favored modification site following exposure to MPO-generated oxidants is Tyr-192. MPO-dependent nitration and chlorination both proceed with Tyr-166 as a secondary site and with Tyr-236 and Tyr-29 modified only minimally. Parallel functional studies demonstrated dose-dependent losses of ABCA1-dependent cholesterol acceptor and lipid binding activities with apoA-I modification by MPO. Finally tandem mass spectrometry analyses showed that apoA-I in human atherosclerotic tissue is nitrated at the MPO-preferred sites, Tyr-192 and Tyr-166. The present studies suggest that site-specific modifications of apoA-I by MPO are associated with impaired lipid binding and ABCA1-dependent cholesterol acceptor functions, providing a molecular mechanism that likely contributes to the clinical link between MPO levels and cardiovascular disease risk.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Kinter, M (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kinterm@ccf.org	Hazen, Stanley L/ABD-5845-2021; Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X; Kinter, Michael/0000-0001-7409-8918	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016794, M01RR018390, S10RR015794] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066082, P01HL076491, R01HL070621, R01HL077692] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15794, RR16794, RR018390] Funding Source: Medline; NHLBI NIH HHS [HL70621, HL66082, P01 HL076491, HL077692] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bergt C, 1999, FEBS LETT, V452, P295, DOI 10.1016/S0014-5793(99)00677-8; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2001, EUR J BIOCHEM, V268, P3523, DOI 10.1046/j.1432-1327.2001.02253.x; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Heinecke JW, 2003, AM J CARDIOL, V91, p12A; Ji YB, 2003, MOL PHARMACOL, V63, P136, DOI 10.1124/mol.63.1.136; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Koeck T, 2004, MOL CELL PROTEOMICS, V3, P548, DOI 10.1074/mcp.M300141-MCP200; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; Macdonald DL, 2003, ARTERIOSCL THROM VAS, V23, P1583, DOI 10.1161/01.ATV.0000085840.67498.00; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; Navab M, 2002, CURR OPIN LIPIDOL, V13, P363, DOI 10.1097/00041433-200208000-00003; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Orton KJP, 1927, J CHEM SOC, P986, DOI 10.1039/jr9270000986; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruse CI, 2002, ANAL CHEM, V74, P1658, DOI 10.1021/ac0157122; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Vadseth C, 2004, J BIOL CHEM, V279, P8820, DOI 10.1074/jbc.M306101200; Vita JA, 2004, CIRCULATION, V110, P1134, DOI 10.1161/01.CIR.0000140262.20831.8F; Wang WQ, 1998, J BIOL CHEM, V273, P17391, DOI 10.1074/jbc.273.28.17391; Willard BB, 2003, ANAL CHEM, V75, P2370, DOI 10.1021/ac034033j; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	53	174	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					38	47		10.1074/jbc.M407019200	http://dx.doi.org/10.1074/jbc.M407019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498770	hybrid			2022-12-27	WOS:000226025100006
J	Spence, E; Bailey, S; Nenninger, A; Moller, SG; Robinson, C				Spence, E; Bailey, S; Nenninger, A; Moller, SG; Robinson, C			A homolog of Albino3/OxaI is essential for thylakoid biogenesis in the cyanobacterium Synechocystis sp PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; MEMBRANE-PROTEIN INSERTION; HETEROTROPHIC GROWTH; PATHWAYS; MITOCHONDRIAL; CHLOROPLASTS; TRANSPORT; IMPORT; BACTERIAL; SEQUENCE	YidC/OxaI play essential roles in the insertion of a wide range of membrane proteins in Eschericha coli and mitochondria, respectively. In contrast, the chloroplast thylakoid homolog Albino3 (Alb3) facilitates the insertion of only a specialized subset of proteins, and the vast majority insert into thylakoids by a pathway that is so far unique to chloroplasts. In this study, we have analyzed the role of Alb3 in the cyanobacterium Synechocystis sp. PCC6803, which contains internal thylakoids that are similar in some respects to those of chloroplasts. The single alb3 gene (slr1471) was disrupted by the introduction of an antibiotic cassette, and photoautotrophic growth resulted in the generation of a merodiploid species (but not full segregation), indicating an essential role for Alb3 in maintaining the photosynthetic apparatus. Thylakoid organization is lost under these conditions, and the levels of photosynthetic pigments fall to similar to40% of wild-type levels. Photosynthetic electron transport and oxygen evolution are reduced by a similar extent. Growth on glucose relieves the selective pressure to maintain photosynthetic competence, and under these conditions, the cells become completely bleached, again indicating that Alb3 is essential for thylakoid biogenesis. Full segregation could not be achieved under any growth regime, strongly suggesting that the slr1471 open reading frame is essential for cell viability.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Leicester, Fac Med & Biol Sci, Dept Biol, Leicester LE1 7RT, Leics, England	University of Warwick; University of Leicester	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk		Moller, Simon/0000-0002-0460-3592				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Bellafiore S, 2002, PLANT CELL, V14, P2303, DOI 10.1105/tpc.003442; Campbell D, 1998, MICROBIOL MOL BIOL R, V62, P667, DOI 10.1128/MMBR.62.3.667-683.1998; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DOUCE R, 1996, ADV PHOTOSYNTH, V4, P69; Fulgosi H, 2002, P NATL ACAD SCI USA, V99, P11501, DOI 10.1073/pnas.172032599; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; MANNAN RM, 1993, PLANT PHYSIOL, V103, P971, DOI 10.1104/pp.103.3.971; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; MURATA N, 1989, J BIOENERG BIOMEMBR, V21, P61, DOI 10.1007/BF00762212; MYERS J, 1980, PLANT PHYSIOL, V66, P1144, DOI 10.1104/pp.66.6.1144; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Robinson C, 2001, TRAFFIC, V2, P245, DOI 10.1034/j.1600-0854.2001.1r010.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	33	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55792	55800		10.1074/jbc.M411041200	http://dx.doi.org/10.1074/jbc.M411041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498761	hybrid			2022-12-27	WOS:000225960800101
J	Kathiriya, IS; King, IN; Murakami, M; Nakagawa, M; Astle, JM; Gardner, KA; Gerard, RD; Olson, EN; Srivastava, D; Nakagawa, O				Kathiriya, IS; King, IN; Murakami, M; Nakagawa, M; Astle, JM; Gardner, KA; Gerard, RD; Olson, EN; Srivastava, D; Nakagawa, O			Hairy-related transcription factors inhibit GATA-dependent cardiac gene expression through a signal-responsive mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HEART-DEFECTS; HEAVY-CHAIN GENE; PROTEIN-KINASE; IN-VIVO; VENTRAL MORPHOGENESIS; TRANSGENIC MICE; TUBE FORMATION; HYPERTROPHY; ENHANCER; PATHWAY	Combinatorial actions of transcription factors in multiprotein complexes dictate gene expression profiles in cardiac development and disease. The Hairy-related transcription factor (HRT) family of basic helix-loop-helix proteins is composed of transcriptional repressors highly expressed in the cardiovascular system. However, it has remained unclear whether HRT proteins modulate gene expression driven by cardiac transcriptional activators. Here, we have shown that HRT proteins inhibit cardiac gene transcription by interfering with GATA transcription factors that are implicated in cardiac development and hypertrophy. HRT proteins inhibited GATA-dependent transcriptional activation of cardiac gene promoters such as the atrial natriuretic factor (ANF) promoter. Adenovirus-mediated expression of Hrt2 suppressed mRNA expression of ANF and other cardiac-specific genes in cultured cardiomyocytes. Among various signaling molecules implicated in cardiomyocyte growth, constitutively active Akt1/protein kinase Balpha relieved Hrt2-mediated inhibition of GATA-dependent transcription. HRT proteins physically interacted with GATA proteins, and the basic domain of HRT was critical for physical association as well as transcriptional inhibition. These results suggest that HRT proteins may regulate specific sets of cardiac genes by modulating the function of GATA proteins and other cardiac transcriptional activators in a signal-dependent manner.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nakagawa, O (corresponding author), 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Osamu.Nakagawa@UTSouthwestern.edu			NHLBI NIH HHS [L40 HL078465, L40 HL078465-02] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akazawa H, 2003, CIRC RES, V92, P1079, DOI 10.1161/01.RES.0000072977.86706.23; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; Hasegawa K, 1997, CIRCULATION, V96, P3943; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lien CL, 1999, DEVELOPMENT, V126, P75; McFadden DG, 2000, DEVELOPMENT, V127, P5331; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Sakata Y, 2002, P NATL ACAD SCI USA, V99, P16197, DOI 10.1073/pnas.252648999; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Tremblay JJ, 2003, J BIOL CHEM, V278, P22128, DOI 10.1074/jbc.M213149200; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	60	55	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54937	54943		10.1074/jbc.M409879200	http://dx.doi.org/10.1074/jbc.M409879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485867	hybrid			2022-12-27	WOS:000225793600123
J	Jaburek, M; Miyamoto, S; Di Mascio, P; Garlid, KD; Jezek, P				Jaburek, M; Miyamoto, S; Di Mascio, P; Garlid, KD; Jezek, P			Hydroperoxy fatty acid cycling mediated by mitochondrial uncoupling protein UCP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; RESPIRATORY-CHAIN; PROTON TRANSPORT; OXIDATIVE STRESS; FREE-RADICALS; MECHANISM; SUPEROXIDE; GENERATION; ACTIVATION; LIVER	Functional activation of mitochondrial uncoupling protein-2 (UCP2) is proposed to decrease reactive oxygen species production. Skulachev and Goglia (Skulachev, V. P., and Goglia, F. (2003) FASEB J. 17, 1585-1591) hypothesized that hydroperoxy fatty acid anions are translocated by UCPs but cannot flip-flop across the membrane. We found that the second aspect is otherwise; the addition of synthesized linoleic acid hydroperoxides (LAOOH, a mix of four isomers) caused a fast flip-flop-dependent acidification of liposomes, comparable with the linoleic acid (LA)-dependent acidification. Using Escherichia coli-expressed UCP2 reconstituted into liposomes we found that LAOOH induced purine nucleotide-sensitive H+ uniport in UCP2-proteoliposomes with higher affinity than LA (K-m values 97 muM for LAOOH and 275 muM for LA). In UCP2-proteoliposomes LAOOH also induced purine nucleotide-sensitive K+ influx balanced by anionic charge transfer, indicating that LAOOH was also transported as an anion with higher affinity than linoleate anion, the Km values being 90 and 350 muM, respectively. These data suggest that hydroperoxy fatty acids are transported via UCP2 by a fatty acid cycling mechanism. This may alternatively explain the observed activation of UCP2 by the externally generated superoxide. The ability of LAOOH to induce UCP2-mediated H+ uniport points to the essential role of superoxide reaction products, such as hydroperoxyl radical, hydroxyl radical, or peroxynitrite, initiating lipoperoxidation, the released products of which support the UCP2-mediated uncoupling and promote the feedback down-regulation of mitochondrial reactive oxygen species production.	Acad Sci Czech Republ, Inst Physiol, Dept Membrane Transport Biophys, CR-14220 Prague, Czech Republic; Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05513970 Sao Paulo, Brazil; Portland State Univ, Dept Biol, Portland, OR 97207 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Universidade de Sao Paulo; Portland State University	Jezek, P (corresponding author), Acad Sci Czech Republ, Inst Physiol, Dept 75, Videnska 1083, CR-14220 Prague 4, Czech Republic.	jezek@biomed.cas.cz	Miyamoto, Sayuri/A-2144-2008; Di Mascio, Paolo/D-1264-2014; Jaburek, Martin/B-9652-2012; Jezek, Petr/B-9264-2012; Jabůrek, Martin/H-1114-2019	Miyamoto, Sayuri/0000-0002-5714-8984; Di Mascio, Paolo/0000-0003-4125-8350; Jezek, Petr/0000-0002-2720-9395; Jabůrek, Martin/0000-0002-4357-1116; Garlid, Keith/0000-0002-6777-1235	FIC NIH HHS [TW01487] Funding Source: Medline; NIDDK NIH HHS [DK 56273] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056273] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKENS J, 1991, J BIOL CHEM, V266, P15091; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bernardi P, 2002, VITAM HORM, V65, P97, DOI 10.1016/S0083-6729(02)65061-7; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; Deiana M, 2001, TOXICOL LETT, V123, P125, DOI 10.1016/S0378-4274(01)00372-1; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duval C, 2002, BIOCHEM CELL BIOL, V80, P757, DOI 10.1139/O02-158; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Garlid KD, 2001, BIOCHEM SOC T, V29, P803, DOI 10.1042/BST0290803; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Girotti AW, 1998, J LIPID RES, V39, P1529; GNAIGER E, 2003, HYPOXIA LIFECYCLE, P1; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Guidarelli A, 2002, BIOCHEM J, V366, P307, DOI 10.1042/BJ20020284; HALLIWELL B, 2002, FREE RADICAL BIO MED, P936; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Lima ES, 2002, BIOCHEMISTRY-US, V41, P10717, DOI 10.1021/bi025504j; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; Madesh M, 1997, ARCH BIOCHEM BIOPHYS, V346, P187, DOI 10.1006/abbi.1997.0288; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; MELOV S, 2002, ANN NY ACAD SCI, V959, P219; Miyamoto S, 2003, LIPIDS, V38, P641, DOI 10.1007/s11745-003-1109-6; Miyamoto S, 2003, J AM CHEM SOC, V125, P6172, DOI 10.1021/ja029115o; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Spiteller G, 2002, ANN NY ACAD SCI, V959, P30, DOI 10.1111/j.1749-6632.2002.tb02080.x; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Urbankova E, 2003, J BIOL CHEM, V278, P32497, DOI 10.1074/jbc.M303721200; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200	58	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53097	53102		10.1074/jbc.M405339200	http://dx.doi.org/10.1074/jbc.M405339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475368	hybrid			2022-12-27	WOS:000225680600037
J	Kaido, T; Yebra, M; Cirulli, V; Montgomery, AM				Kaido, T; Yebra, M; Cirulli, V; Montgomery, AM			Regulation of human beta-cell adhesion, motility, and insulin secretion by collagen IV and its receptor alpha(1)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; ALPHA(2)BETA(1) INTEGRINS; RAT; EXPRESSION; ISLETS; PANCREAS; ADULT; MIGRATION; PORCINE	Collagens have been shown to influence the survival and function of cultured beta-cells; however, the utilization and function of individual collagen receptors in beta-cells is largely unknown. The integrin superfamily contains up to five collagen receptors, but we have determined that alpha(1)beta(1) is the primary receptor utilized by both fetal and adult beta-cells. Cultured beta-cells adhered to and migrated on collagen type IV (Col-IV), and these responses were mediated almost exclusively by alpha(1)beta(1). The migration of cultured beta-cells to Col-IV significantly exceeded that to other matrix components suggesting that this substrate is of unique importance for beta-cell motility. The interaction of alpha(1)beta(1) with Col-IV also resulted in significant insulin secretion at basal glucose concentrations. A subset of beta-cells in developing islets was confirmed to express alpha(1)beta(1), and this expression co-localized with Col-IV in the basal membranes of juxtaposed endothelial cells. Our findings indicate that alpha(1)beta(1) and Col-IV contribute to beta-cell functions known to be important for islet morphogenesis and glucose homeostasis.	Univ Calif San Diego, Whittier Inst Diabet, Islet Res Lab, Dept Pediat, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Montgomery, AM (corresponding author), Univ Calif San Diego, Whittier Inst Diabet, Islet Res Lab, Dept Pediat, 9894 Genesee Ave, La Jolla, CA 92037 USA.	ammontgo@ucsd.edu						Barg S, 2003, PHARMACOL TOXICOL, V92, P3, DOI 10.1034/j.1600-0773.2003.920102.x; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; Beattie GM, 1997, J CLIN ENDOCR METAB, V82, P1852, DOI 10.1210/jc.82.6.1852; Bernard-Kargar C, 2001, DIABETES, V50, pS125, DOI 10.2337/diabetes.50.2007.S125; BONNERWEIR S, 1988, DIABETES, V37, P616, DOI 10.2337/diabetes.37.5.616; Bosco D, 2001, DIABETES, V50, P1039, DOI 10.2337/diabetes.50.5.1039; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; Chao S H, 1992, Cell Transplant, V1, P51; Cirulli V, 2000, J CELL BIOL, V150, P1445, DOI 10.1083/jcb.150.6.1445; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Edamura K, 2003, CELL TRANSPLANT, V12, P439, DOI 10.3727/000000003108746867; Gogal RM, 2000, CYTOMETRY, V39, P310, DOI 10.1002/(SICI)1097-0320(20000401)39:4<310::AID-CYTO10>3.0.CO;2-V; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; HALL PA, 1991, J PATHOL, V165, P33, DOI 10.1002/path.1711650107; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; Kadono G, 2004, PANCREAS, V29, P61, DOI 10.1097/00006676-200407000-00057; Kaido T, 2004, J BIOL CHEM, V279, P17731, DOI 10.1074/jbc.M308425200; Kantengwa S, 1997, EXP CELL RES, V237, P394, DOI 10.1006/excr.1997.3803; KerrConte J, 1996, DIABETES, V45, P1108, DOI 10.2337/diabetes.45.8.1108; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; LIKE AA, 1978, LAB INVEST, V38, P470; LUCASCLERC C, 1993, MOL CELL ENDOCRINOL, V94, P9, DOI 10.1016/0303-7207(93)90046-M; Mercurio AM, 2002, AM J PATHOL, V161, P3, DOI 10.1016/S0002-9440(10)64149-1; METRAKOS P, 1994, TRANSPLANT P, V26, P3349; Moulin V, 2002, BRIT J DERMATOL, V147, P886, DOI 10.1046/j.1365-2133.2002.04975.x; Nagata N, 2002, J BIOMAT SCI-POLYM E, V13, P579, DOI 10.1163/15685620260178418; Nagata N, 2001, CELL TRANSPLANT, V10, P447; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Rooprai HK, 1999, NEUROSCI LETT, V263, P214, DOI 10.1016/S0304-3940(99)00125-1; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; VANDEIJNEN JHM, 1994, CELL TISSUE RES, V277, P115, DOI 10.1007/BF00303087; Vogel WF, 2001, EUR J DERMATOL, V11, P506; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Wang RN, 1999, J HISTOCHEM CYTOCHEM, V47, P499, DOI 10.1177/002215549904700408; WEINEL RJ, 1992, INT J CANCER, V52, P827, DOI 10.1002/ijc.2910520526; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; White SA, 1999, J MOL MED-JMM, V77, P79, DOI 10.1007/s001090050306; Yuan S, 1995, TRANSPLANT P, V27, P3364; Yuan SY, 1996, DIFFERENTIATION, V61, P67, DOI 10.1046/j.1432-0436.1996.6110067.x	51	145	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53762	53769		10.1074/jbc.M411202200	http://dx.doi.org/10.1074/jbc.M411202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485856	hybrid			2022-12-27	WOS:000225680600114
J	Liu, AMF; Wong, YH				Liu, AMF; Wong, YH			G(16)-mediated activation of nuclear factor kappa B by the adenosine A(1) receptor involves c-Src, protein kinase C, and ERK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; FMET-LEU-PHE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; COUPLED RECEPTORS; ALPHA; G-ALPHA(16); EXPRESSION; NECROSIS; PATHWAYS	The G(i)-linked adenosine A1 receptor has been shown to mediate anti-inflammatory actions, possibly via modulation of the transcription factor nuclear factor-kappaB (NFkappaB). Here we demonstrate that an adenosine A1 agonist, N-6-cyclohexyladenosine (CHA), activated IKKalpha/beta phosphorylation through PTX-insensitive G proteins in human lymphoblastoma Reh cells. To delineate the mechanism of action, different PTX-insensitive G proteins were expressed in human embryonic kidney 293 cells. Only Galpha(16) supported the CHA-induced IKK phosphorylation and NFkappaB-driven luciferase activity in time-dependent, dose-dependent, and PTX-insensitive manners. Gbetagamma subunits also modulated IKK/NFkappaB, as indicated by the stimulatory actions of G(beta1gamma2) and the abrogation of CHA-induced response by transducin. The participation of phospholipase Cbeta, protein kinase C, and calmodulin-dependent kinase II in CHA-induced IKK/NFkappaB activation were demonstrated by employing specific inhibitors and dominant-negative mutants. Inhibition of c-Src and numerous intermediates along the extracellular signal-regulated (ERK) kinase cascade including Ras, Raf-1 kinase, and MEK1/2 abolished the CHA-induced IKK/NFkappaB activation. Although c-Jun N-terminal kinase and p38 MAPK were also activated by CHA, they were not required for the IKK/NFkappaB regulation. Similar results were obtained using Reh cells. These data suggest that the G(16)-mediated activation of IKK/NFkappaB by CHA required a complex signaling network composed of multiple intermediates.	Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	boyung@ust.hk		Wong, Yung Hou/0000-0002-0123-7697				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chan JSC, 2000, MOL PHARMACOL, V57, P700, DOI 10.1124/mol.57.4.700; Crespo Piero, 2004, Methods Mol Biol, V250, P203; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; Druey KM, 2003, EXPERT OPIN THER TAR, V7, P475, DOI 10.1517/14728222.7.4.475; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fredholm BB, 2003, DRUG NEWS PERSPECT, V16, P283, DOI 10.1358/dnp.2003.16.5.829316; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hill KJ, 2003, BRIT J PHARMACOL, V139, P721, DOI 10.1038/sj.bjp.0705294; Ho MKC, 2002, NEUROSIGNALS, V11, P115, DOI 10.1159/000058548; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Lee HT, 2004, J AM SOC NEPHROL, V15, P102, DOI 10.1097/01.ASN.0000102474.68613.AE; Lee HT, 2002, AM J PHYSIOL-RENAL, V282, pF844, DOI 10.1152/ajprenal.00195.2001; Lee JWM, 1998, J NEUROCHEM, V70, P2203; Liu AMF, 2003, J BIOMOL SCREEN, V8, P39, DOI 10.1177/1087057102239665; Liu J, 2002, J BIOL CHEM, V277, P20927, DOI 10.1074/jbc.M110712200; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; MAPARA MY, 1995, BLOOD, V85, P1836, DOI 10.1182/blood.V85.7.1836.bloodjournal8571836; Marty C, 2003, MOL CELL BIOL, V23, P3847, DOI 10.1128/MCB.23.11.3847-3858.2003; Mody SM, 2000, MOL PHARMACOL, V57, P13; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang Y, 2003, J AM SOC NEPHROL, V14, P28, DOI 10.1097/01.ASN.0000043180.18456.47; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang M, 2003, MOL PHARMACOL, V64, P447, DOI 10.1124/mol.64.2.447; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhen XC, 2001, MOL PHARMACOL, V60, P857	49	60	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53196	53204		10.1074/jbc.M410196200	http://dx.doi.org/10.1074/jbc.M410196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485865	Green Published, hybrid			2022-12-27	WOS:000225680600049
J	Yan, XL; Forbes, BE; McNeil, KA; Baxter, RC; Firth, SM				Yan, XL; Forbes, BE; McNeil, KA; Baxter, RC; Firth, SM			Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEIN; CELL-SURFACE BINDING; ACID-LABILE SUBUNIT; FACTOR-I; AMINO-ACIDS; STRUCTURAL DETERMINANTS; HIGH-AFFINITY; FRAGMENTS; DOMAIN; SUBSTITUTIONS	Insulin-like growth factor-binding protein-3 (IGFBP-3), the major IGFBP in the circulation, sequesters IGF in a stable ternary complex with the acid-labile subunit. The high affinity IGF-binding site is proposed to reside within an N-terminal hydrophobic domain in IGFBP-3, but C-terminal residues have also been implicated in the homologous protein IGFBP-5. We have mutated in various combinations Leu(77), Leu(80), and Leu(81) in the N terminus and Gly(217) and Gln(223) in the C terminus of IGFBP-3. All mutants retained immunoreactivity toward a polyclonal IGFBP-3 antibody, whereas IGF ligand blotting showed that all of the mutants had reduced binding to IGFs. Both solution IGF binding assays and BIAcore analysis indicated that mutations to the N-terminal region caused greater reduction in IGF binding activity than C-terminal mutations. The combined N- and C-terminal mutants showed undetectable binding to IGF-I but retained <10% IGF-II binding activity. Reduced ternary complex formation was seen only in mutants that had considerably reduced IGF-I binding, consistent with previous studies indicating that the binary IGF.IGFBP-3 complex is required for acid-labile subunit binding. Decreased IGF binding was also reflected in the inability of the mutants to inhibit IGF-I signaling in IGF receptor overexpressing cells. However, when present in excess, IGFBP-3 analogs defined as non-IGF-binding by biochemical assays could still inhibit IGF signaling. This suggests that residual binding activity of IGFBP-3 mutants may still be sufficient to inhibit IGF biological activity and questions the use of such analogs to study IGF-independent effects of IGFBP-3.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Adelaide	Firth, SM (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	sfirth@med.usyd.edu.au	Baxter, Robert C/F-3927-2012; Forbes, Briony/R-1838-2019	Baxter, Robert C/0000-0001-5061-2142; Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Carrick FE, 2001, J BIOL CHEM, V276, P27120, DOI 10.1074/jbc.M101317200; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; Devi GR, 2000, ENDOCRINOLOGY, V141, P4171, DOI 10.1210/en.141.11.4171; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FIELDER PJ, 1994, GROWTH REGULAT, V4, P164; Firth SM, 1999, PROTEIN EXPRES PURIF, V16, P202, DOI 10.1006/prep.1999.1075; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; GARGOSKY SE, 1991, J ENDOCRINOL, V131, P491, DOI 10.1677/joe.0.1310491; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Hwa V, 1999, ACTA PAEDIATR, V88, P37, DOI 10.1111/j.1651-2227.1999.tb14349.x; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1994, CURR OPIN ENDOCRINOL, V1, P16; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1998, BIOPHYS J, V75, P583, DOI 10.1016/S0006-3495(98)77549-6; OH YM, 1993, J BIOL CHEM, V268, P14964; Payet LD, 2003, ENDOCRINOLOGY, V144, P2797, DOI 10.1210/en.2003-0102; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; Standker L, 1998, FEBS LETT, V441, P281, DOI 10.1016/S0014-5793(98)01497-5; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; Standker L, 2003, BIOCHEM BIOPH RES CO, V304, P708, DOI 10.1016/S0006-291X(03)00658-2; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; Twigg SM, 1998, J BIOL CHEM, V273, P28791, DOI 10.1074/jbc.273.44.28791; WALSH G, 1995, BIO-TECHNOL, V13, P1167, DOI 10.1038/nbt1195-1167; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	48	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53232	53240		10.1074/jbc.M409345200	http://dx.doi.org/10.1074/jbc.M409345200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485880	hybrid			2022-12-27	WOS:000225680600053
J	Isnardi, I; Lesourne, R; Bruhns, P; Fridman, WH; Cambier, JC; Daeron, M				Isnardi, I; Lesourne, R; Bruhns, P; Fridman, WH; Cambier, JC; Daeron, M			Two distinct tyrosine-based motifs enable the inhibitory receptor Fc gamma RIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; B-CELLS; NEGATIVE REGULATION; ANTIGEN RECEPTOR; DEFICIENT MICE; CYTOPLASMIC DOMAIN; PROTEIN; IGG; SHC	FcgammaRIIB are low-affinity receptors for IgG that contain an immunoreceptor tyrosine-based inhibition motif (ITIM) and inhibit immunoreceptor tyrosine-based activation motif (ITAM)-dependent cell activation. When co-aggregated with ITAM-bearing receptors, FcgammaRIIB become tyrosyl-phosphorylated and recruit the Src homology 2 (SH2) domain-containing inositol 5'-phosphatases SHIP1 and SHIP2, which mediate inhibition. The FcgammaRIIB ITIM was proposed to be necessary and sufficient for recruiting SHIP1/2. We show here that a second tyrosine-containing motif in the intracytoplasmic domain of FcgammaRIIB is required for SHIP1/2 to be coprecipitated with the receptor. This motif functions as a docking site for the SH2 domain-containing adapters Grb2 and Grap. These adapters interact via their C-terminal SH3 domain with SHIP1/2 to form a stable receptor-phosphatase-adapter trimolecular complex. Both Grb2 and Grap are required for an optimal coprecipitation of SHIP with FcgammaRIIB, but one adapter is sufficient for the phosphatase to coprecipitate in a detectable manner with the receptors. In addition to facilitating the recruitment of SHIPs, the second tyrosine-based motif may confer upon FcgammaRIIB the properties of scaffold proteins capable of altering the composition and stability of the signaling complexes generated following receptor engagement.	Inst Pasteur, Dept Immunol, Unite Allergol Mol & Cellulaire, F-75015 Paris, France; Inst Rech Biomed Cordeliers, Lab Immunol Cellulaire & Clin, INSERM, U255, F-75006 Paris, France; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Denver, CO 80262 USA; Inst Pasteur, Unite Allergol Mol & Cellulaire, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Daeron, M (corresponding author), Inst Pasteur, Dept Immunol, Unite Allergol Mol & Cellulaire, 25 Rue Dr Roux, F-75015 Paris, France.	daeron@pasteur.fr	Lesourne, Renaud/M-1855-2014; Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; fridman, wolf herman/0000-0002-1332-0973; Cambier, John/0000-0002-7803-242X; Lesourne, Renaud/0000-0003-3816-7087				Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Brauweiler A, 2001, J IMMUNOL, V167, P204, DOI 10.4049/jimmunol.167.1.204; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Bruhns P, 1999, J IMMUNOL, V162, P3168; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; Burshtyn DN, 1999, J IMMUNOL, V162, P897; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 2001, J BIOL CHEM, V276, P30381, DOI 10.1074/jbc.M011094200; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Shen R, 2002, MOL CELL BIOL, V22, P3230, DOI 10.1128/MCB.22.10.3230-3236.2002; SINCLAIR NRS, 1971, ADV EXP MED BIOL, V12, P609; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Wernersson S, 1999, J IMMUNOL, V163, P618; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yamasaki S, 2003, MOL CELL BIOL, V23, P2515, DOI 10.1128/MCB.23.7.2515-2529.2003; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187	47	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51931	51938		10.1074/jbc.M410261200	http://dx.doi.org/10.1074/jbc.M410261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456754	hybrid, Green Submitted			2022-12-27	WOS:000225493400027
J	Rohloff, P; Montalvetti, A; Docampo, R				Rohloff, P; Montalvetti, A; Docampo, R			Acidocalcisomes and the contractile vacuole complex are involved in osmoregulation in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-PUMPING PYROPHOSPHATASE; MICROTUBULE-ASSOCIATED PROTEIN-2; DICTYOSTELIUM-DISCOIDEUM; PLASMA-MEMBRANE; ION CHANNELS; CYCLIC-AMP; CYTOSKELETON; TRAFFICKING; PHOSPHORYLATION; IDENTIFICATION	Trypanosoma cruzi, the etiologic agent of Chagas disease, resists extreme fluctuations in osmolarity during its life cycle. T. cruzi possesses a robust regulatory volume decrease mechanism that completely reverses cell swelling when submitted to hypo-osmotic stress. The efflux of amino acids and K+ release could account for only part for this volume reversal. In this work we demonstrate that swelling of acidocalcisomes mediated by an aquaporin and microtubule- and cyclic AMP-mediated fusion of acidocalcisomes to the contractile vacuole complex with translocation of this aquaporin and the resulting water movement are responsible for the volume reversal not accounted for by efflux of osmolytes. Contractile vacuole bladders were isolated by subcellular fractionation in iodixanol gradients, showed a high concentration of basic amino acids and inorganic phosphate, and were able to transport protons in the presence of ATP or pyrophosphate. Taken together, these results strongly support a role for acidocalcisomes and the contractile vacuole complex in osmoregulation and identify a functional role for aquaporin in protozoal osmoregulation.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Rohloff, Peter/P-8722-2017	Rohloff, Peter/0000-0001-7274-8315	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen RD, 2000, BIOESSAYS, V22, P1035; Allen RD, 2002, INT REV CYTOL, V215, P351; Boassa D, 2002, TRENDS PHARMACOL SCI, V23, P558, DOI 10.1016/S0165-6147(02)02112-0; BONE G, 1969, NATURE, V178, P308; BOWERS B, 1973, J CELL BIOL, V59, P784, DOI 10.1083/jcb.59.3.784; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; CRONKITE DL, 1991, J PROTOZOOL, V38, P565, DOI 10.1111/j.1550-7408.1991.tb06081.x; Diviani D, 2001, J CELL SCI, V114, P1431; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; FOK AK, 1995, J CELL SCI, V108, P3163; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; Gustafson CE, 1998, HISTOCHEM CELL BIOL, V110, P377, DOI 10.1007/s004180050298; Hansen M, 2002, J BIOL CHEM, V277, P4874, DOI 10.1074/jbc.M110683200; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kollien AH, 2000, PARASITOL TODAY, V16, P381, DOI 10.1016/S0169-4758(00)01724-5; Kollien AH, 2001, J INSECT PHYSIOL, V47, P739, DOI 10.1016/S0022-1910(00)00170-0; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; Levi V, 2003, BIOCHEM SOC T, V31, P997; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; MCKANNA JA, 1973, SCIENCE, V179, P88, DOI 10.1126/science.179.4068.88; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Merzendorfer H, 1997, J EXP BIOL, V200, P225; MILLS I, 1990, BIOCHEM BIOPH RES CO, V171, P143, DOI 10.1016/0006-291X(90)91368-3; Montalvetti A, 2004, J BIOL CHEM, V279, P38673, DOI 10.1074/jbc.M406304200; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; QUIVIGER B, 1978, J ULTRA MOL STRUCT R, V62, P228, DOI 10.1016/S0022-5320(78)80020-3; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RICHTERLANDSBERG C, 1985, J NEUROCHEM, V45, P1218, DOI 10.1111/j.1471-4159.1985.tb05545.x; Rohloff P, 2003, MOL BIOCHEM PARASIT, V126, P219, DOI 10.1016/S0166-6851(02)00277-3; ROHLOFF P, 2003, THESIS U ILLINOIS UR; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Schekman R, 1998, NATURE, V396, P514, DOI 10.1038/24986; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Seufferheld M, 2003, J BIOL CHEM, V278, P29971, DOI 10.1074/jbc.M304548200; Steck TL, 1997, J EUKARYOT MICROBIOL, V44, P503, DOI 10.1111/j.1550-7408.1997.tb05731.x; Taylor MC, 1999, MOL BIOCHEM PARASIT, V104, P205, DOI 10.1016/S0166-6851(99)00154-1; Temesvari LA, 1996, J CELL SCI, V109, P1479; Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001; VANROSSUM GDV, 1987, CURR TOP MEMBR TRANS, V30, P45; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	57	91	93	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52270	52281		10.1074/jbc.M410372200	http://dx.doi.org/10.1074/jbc.M410372200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466463	hybrid			2022-12-27	WOS:000225493400068
J	Toro, R; Saadi, I; Kuburas, A; Nemer, M; Russo, AF				Toro, R; Saadi, I; Kuburas, A; Nemer, M; Russo, AF			Cell-specific activation of the atrial natriuretic factor promoter by PITX2 and MEF2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; TRANSCRIPTION FACTOR MEF2C; RIEGER-SYNDROME; GENE-EXPRESSION; HOMEODOMAIN PROTEIN; SIGNALING PATHWAY; NONMUSCLE CELLS; PEPTIDE SYSTEM; MUSCLE; ISOFORMS	The PITX2 homeodomain protein is mutated in patients with Axenfeld-Rieger syndrome and is involved in the development of multiple organ systems, including the heart. We have examined the interaction of PITX2 isoforms with myocyte-enhancing factor 2A (MEF2A), which is a known regulator of cardiac development. A direct interaction between PITX2a and MEF2A was demonstrated using yeast two-hybrid and GST pull-down assays. To study the functional significance of this interaction, we used the atrial natriuretic factor (ANF) promoter. Coexpression of MEF2A and PITX2a or Pitx2c resulted in a strong synergistic activation of the ANF promoter in LS8 oral epithelial cells but not in other cell lines (NIH/3T3, Chinese hamster ovary, or C2C12). The synergism was dependent on promoter context, because it required MEF2 binding sites and was not seen with two other PITX2 target promoters. DNA binding by MEF2A was required but not sufficient for synergism. Upstream activators of p38 MAP kinases, MKK3 and MKK6, increased PITX2a and Pitx2c activity to yield up to 90-fold activation of the ANF promoter in LS8 cells. Because Axenfeld-Rieger syndrome is autosomal dominant and affects development of the oral epithelium, we tested one of the known PITX2 mutants. The PITX2a-K88E mutant protein suppressed wild type PITX2a synergism with MEF2A. These results demonstrate a promoter- and cell-specific functional interaction between PITX2 and MEF2A and suggest the possibility of coordinate control by these factors in the oral epithelium.	Univ Iowa, Genet Program, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada	University of Iowa; University of Iowa; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Russo, AF (corresponding author), Univ Iowa, Genet Program, Iowa City, IA 52242 USA.	andrew-russo@uiowa.edu	Saadi, Irfan/I-5989-2019	Saadi, Irfan/0000-0002-6250-6651; Russo, Andrew/0000-0002-8156-5649	PHS HHS [E13076] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; Amendt BA, 2000, CELL MOL LIFE SCI, V57, P1652, DOI 10.1007/PL00000647; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Cho ES, 2000, EXP EYE RES, V71, P333, DOI 10.1006/exer.2000.0885; Cox CJ, 2002, J BIOL CHEM, V277, P25001, DOI 10.1074/jbc.M201737200; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Gage PJ, 1999, MAMM GENOME, V10, P197, DOI 10.1007/s003359900970; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Ganga M, 2003, J BIOL CHEM, V278, P22437, DOI 10.1074/jbc.M210163200; Green PD, 2001, GENE EXPRESSION, V9, P265, DOI 10.3727/000000001783992515; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Harris AN, 1997, J MOL CELL CARDIOL, V29, P515, DOI 10.1006/jmcc.1996.0295; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Jankowski M, 1996, REGUL PEPTIDES, V62, P53, DOI 10.1016/0167-0115(96)00004-3; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lines MA, 2002, HUM MOL GENET, V11, P1177, DOI 10.1093/hmg/11.10.1177; LIU ML, 1994, J BIOL CHEM, V269, P28514; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Melo LG, 2000, PHYSIOL GENOMICS, V3, P45, DOI 10.1152/physiolgenomics.2000.3.1.45; MIKAMI Y, 1995, CURR EYE RES, V14, P391, DOI 10.3109/02713689508999937; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Park BK, 1998, ARCH ORAL BIOL, V43, P611, DOI 10.1016/S0003-9969(98)00039-9; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Saadi I, 2003, MOL CELL BIOL, V23, P1968, DOI 10.1128/MCB.23.6.1968-1982.2003; Saadi I, 2001, J BIOL CHEM, V276, P23034, DOI 10.1074/jbc.M008592200; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; St Amand TR, 2000, DEV BIOL, V217, P323, DOI 10.1006/dbio.1999.9547; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; Tremblay JJ, 2000, NEUROENDOCRINOLOGY, V71, P277, DOI 10.1159/000054547; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; VOLLMAR AM, 1991, ANAT EMBRYOL, V184, P331, DOI 10.1007/BF00957894; Westmoreland JJ, 2001, J NEUROSCI, V21, P6810, DOI 10.1523/JNEUROSCI.21-17-06810.2001; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YU Y, 1992, GENE DEV, V9, P1783	51	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52087	52094		10.1074/jbc.M404802200	http://dx.doi.org/10.1074/jbc.M404802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466416	hybrid			2022-12-27	WOS:000225493400047
J	Michlig, S; Mercier, A; Doucet, A; Schild, L; Horisberger, JD; Rossier, BC; Firsov, D				Michlig, S; Mercier, A; Doucet, A; Schild, L; Horisberger, JD; Rossier, BC; Firsov, D			ERK1/2 controls Na,K-ATPase activity and transepithelial sodium transport in the principal cell of the cortical collecting duct of the mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL ALPHA-SUBUNIT; EPITHELIAL-CELLS; GLUCOCORTICOID HORMONE; SURFACE EXPRESSION; KINASE INHIBITORS; RAT-KIDNEY; ACTIVATION; PHOSPHORYLATION; ALDOSTERONE; PATHWAYS	The collecting duct of normal kidney exhibits significant activity of the MEK1/2-ERK1/2 pathway as shown in vivo by immunostaining of phosphorylated active ERK1/2 (pERK1/2). The MEK1/2-ERK1/2 pathway controls many different ion transports both in proximal and distal nephron, raising the question of whether this pathway is involved in the basal and/or hormone-dependent transepithelial sodium reabsorption in the principal cell of the cortical collecting duct (CCD), a process mediated by the apical epithelial sodium channel and the basolateral sodium pump (Na, K-ATPase). To answer this question we used ex vivo microdissected CCDs from normal mouse kidney or in vitro cultured mpkCCD(cl4) principal cells. Significant basal levels of pERK1/2 were observed ex vivo and in vitro. Aldosterone and vasopressin, known to up-regulate sodium reabsorption in CCDs, did not change ERK1/2 activity either ex vivo or in vitro. Basal and aldosterone- or vasopressin-stimulated sodium transport was down-regulated by the MEK1/2 inhibitor PD98059, in parallel with a decrease in pERK1/2 in vitro. The activity of Na, K-ATPase but not that of epithelial sodium channel was inhibited by MEK1/2 inhibitors in both unstimulated and aldosteroneor vasopressin-stimulated CCDs in vitro. Cell surface biotinylation showed that intrinsic activity rather than cell surface expression of Na, K-ATPase was controlled by pERK1/2. PD98059 also significantly inhibited the activity of Na, K-ATPase ex vivo. Our data demonstrate that the ERK1/2 pathway controls Na, K-ATPase activity and transepithelial sodium transport in the principal cell and indicate that basal constitutive activity of the ERK1/2 pathway is a critical component of this control.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Paris 06, Inst Cordeliers, CNRS, UMR 7134,Lab Physiol & Genom Cellules Renales, F-75270 Paris, France	University of Lausanne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Firsov, D (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	dmitri.firsov@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009					Al-Khalili L, 2004, J BIOL CHEM, V279, P25211, DOI 10.1074/jbc.M402152200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andreucci M, 2003, KIDNEY INT, V64, P1189, DOI 10.1046/j.1523-1755.2003.00204.x; Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; Bacic D, 2003, PFLUG ARCH EUR J PHY, V446, P52, DOI 10.1007/s00424-002-0969-8; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Campean V, 2003, AM J PHYSIOL-RENAL, V285, pF19, DOI 10.1152/ajprenal.00443.2002; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dechenes G, 2000, J AM SOC NEPHROL, V11, P604, DOI 10.1681/ASN.V114604; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; Feranchak AP, 2001, J CLIN INVEST, V108, P1495, DOI 10.1172/JCI200112190; Fujita H, 2004, AM J PHYSIOL-RENAL, V286, pF120, DOI 10.1152/ajprenal.00351.2002; Geering K, 1997, CURR OPIN NEPHROL HY, V6, P434, DOI 10.1097/00041552-199709000-00005; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; Hu HJ, 2003, J NEUROPHYSIOL, V90, P1671, DOI 10.1152/jn.00340.2003; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Khundmiri SJ, 2004, J BIOL CHEM, V279, P17418, DOI 10.1074/jbc.M311715200; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Laroche-Joubert N, 2003, AM J PHYSIOL-RENAL, V284, pF948, DOI 10.1152/ajprenal.00394.2002; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; Masaki T, 2003, KIDNEY INT, V63, P1256, DOI 10.1046/j.1523-1755.2003.00874.x; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; Nicod M, 2002, EMBO J, V21, P5109, DOI 10.1093/emboj/cdf509; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Shen JP, 2003, AM J PHYSIOL-RENAL, V284, pF57, DOI 10.1152/ajprenal.00028.2002; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; SILVER RB, 1993, AM J PHYSIOL, V264, pF557, DOI 10.1152/ajprenal.1993.264.3.F557; Summa V, 2001, J BIOL CHEM, V276, P47087, DOI 10.1074/jbc.M107165200; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Watanabe S, 2002, P NATL ACAD SCI USA, V99, P8366, DOI 10.1073/pnas.122210599; Watts BA, 2002, AM J PHYSIOL-RENAL, V282, pF1056, DOI 10.1152/ajprenal.00133.2001; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	40	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51002	51012		10.1074/jbc.M405674200	http://dx.doi.org/10.1074/jbc.M405674200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456767	hybrid			2022-12-27	WOS:000225355800045
J	Heeren, J; Grewal, T; Laatsch, A; Becker, N; Rinninger, F; Rye, KA; Beisiegel, U				Heeren, J; Grewal, T; Laatsch, A; Becker, N; Rinninger, F; Rye, KA; Beisiegel, U			Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; MONOCYTE-DERIVED MACROPHAGES; LIPID EFFLUX; IN-VIVO; CELLULAR CHOLESTEROL; ALZHEIMERS-DISEASE; MOUSE HEPATOCYTES; E POLYMORPHISM	After internalization of triglyceride-rich lipoproteins (TRL) in hepatoma cells, TRL particles are immediately disintegrated in the early endosomal compartment. This involves the targeting of lipids and apoprotein B along the degradative pathway and the recycling of TRL-derived apoE through recycling endosomes. Re-secretion of apoE is accompanied by the concomitant association of apoE and cellular cholesterol with high-density lipoproteins (HDL). Since epidemiological data showed that apoE3 and apoE4 have differential effects on HDL metabolism, we investigated whether the intracellular processing of TRL-derived apoE4 differs from apoE3-TRL. In this study, we demonstrated by radioactive and immunofluorescence uptake experiments that cell-surface binding and internalization of TRL-derived apoE4 are increased compared with apoE3 in hepatoma cells. Pulse-chase experiments revealed that HDL-induced recycling, but not disintegration and degradation, of apoE4-enriched TRL is strongly reduced in these cells. Furthermore, impaired HDL-induced apoE4 recycling is associated with reduced cholesterol efflux. Studies performed in Tangier fibroblasts showed that apoE recycling does not depend on ATP-binding cassette transporter A1 activity. These studies provide initial evidence that impaired recycling of apoE4 could interfere with intracellular cholesterol transport and contribute to the pathophysiological lipoprotein profile observed in apoE4 homozygotes.	Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol Mol Cell Biol 2, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany; Univ New S Wales, Ctr Immunol, St Vincents Hosp, Darlinghurst, NSW 2010, Australia; Heart Res Inst, Camperdown, NSW 2050, Australia	University of Hamburg; University of Hamburg; St Vincents Hospital Sydney; University of New South Wales Sydney; University of Sydney; Heart Research Institute	Heeren, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol Mol Cell Biol 2, Martinistr 52, D-20246 Hamburg, Germany.	heeren@uke.uni-hamburg.de		Becker, Nils/0000-0002-4732-0138; Grewal, Thomas/0000-0002-7937-8887				BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Bohnet K, 1996, J LIPID RES, V37, P1316; Costet P, 2000, J BIOL CHEM, V275, P28240; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Farkas MH, 2004, J LIPID RES, V45, P1546, DOI 10.1194/jlr.M400104-JLR200; Farkas MH, 2003, J BIOL CHEM, V278, P9412, DOI 10.1074/jbc.M208026200; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Heeren J, 1999, J CELL SCI, V112, P349; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; Heeren J, 2002, J MOL MED-JMM, V80, P576, DOI 10.1007/s00109-002-0351-5; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; Hopkins PCR, 2002, J LIPID RES, V43, P1881, DOI 10.1194/jlr.M200172-JLR200; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Krimbou L, 2004, J LIPID RES, V45, P839, DOI 10.1194/jlr.M300418-JLR200; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Laatsch A, 2004, EUR J CELL BIOL, V83, P113, DOI 10.1078/0171-9335-00364; Lin CY, 1999, J LIPID RES, V40, P1618; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Malloy SI, 2004, ARTERIOSCL THROM VAS, V24, P91, DOI 10.1161/01.ATV.0000094963.07902.FB; Mamotte CDS, 1999, AM J PHYSIOL-ENDOC M, V276, pE553, DOI 10.1152/ajpendo.1999.276.3.E553; Mann WA, 1999, ATHEROSCLEROSIS, V145, P61, DOI 10.1016/S0021-9150(99)00015-5; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; SCHNEIDER WJ, 1981, J CLIN INVEST, V68, P1075, DOI 10.1172/JCI110330; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	55	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55483	55492		10.1074/jbc.M409324200	http://dx.doi.org/10.1074/jbc.M409324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485881	hybrid			2022-12-27	WOS:000225960800063
J	Hertel, J; Struthers, H; Horj, CB; Hruz, PW				Hertel, J; Struthers, H; Horj, CB; Hruz, PW			A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER ISOFORM GLUT4; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; DIFFERENTIATION; HYPERLIPIDEMIA; INFECTION; MEMBRANE; BINDING; EPITOPE; CELLS	Human immunodeficiency virus (HIV) protease inhibitors (PIs) act as reversible noncompetitive inhibitors of GLUT4 with binding affinities in the low micromolar range and are known to contribute to alterations in glucose homeostasis during treatment of HIV infection. As aspartyl protease inhibitors, these compounds all possess a core peptidomimetic structure together with flanking hydrophobic moieties. To determine the molecular basis for GLUT4 inhibition, a family of related oligopeptides containing structural elements found in PIs was screened for their ability to inhibit 2-deoxyglucose transport in primary rat adipocytes. The peptide oxybenzylcarbonyl-His-Phe-Phe-O-ethyl ester (zHFFe) was identified as a potent inhibitor of zero-trans glucose flux with a K-i of 26 muM. Similar to PIs, transport inhibition by this peptide was acute, noncompetitive, and reversible. Within a Xenopus oocyte expression system, zHFFe acutely and reversibly inhibited GLUT4-mediated glucose uptake, whereas GLUT1 activity was unaffected at concentrations as high as 1 mM. The related photoactivatable peptide zHFF-p-benzoylphenylalanine-[I-125] Tyr-O-ethyl ester selectively labeled GLUT4 in rat adipocytes and indinavir effectively protected against photolabeling. Furthermore, GLUT4 bound to a peptide affinity column containing the zHFF sequence and was eluted by indinavir. These data establish a structural basis for PI effects on GLUT4 activity and support the direct binding of PIs to the transport protein as the mechanism for acute inhibition of insulin-stimulated glucose uptake.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hruz, PW (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	hruz_p@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	NIAID NIH HHS [AI 48747, K08 AI049747] Funding Source: Medline; NIDDK NIH HHS [DK 064572, R01 DK064572] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048747, K08AI049747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064572] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1986, BIOCHEMISTRY-US, V25, P3944, DOI 10.1021/bi00361a031; Cammalleri C, 2003, J LIPID RES, V44, P103, DOI 10.1194/jlr.M200245-JLR200; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; Hruz PW, 2002, DIABETES, V51, P937, DOI 10.2337/diabetes.51.4.937; INOUYE K, 1966, BIOCHEMISTRY-US, V5, P2473, DOI 10.1021/bi00871a044; KELLER K, 1989, J BIOL CHEM, V264, P18884; Koster JC, 2003, DIABETES, V52, P1695, DOI 10.2337/diabetes.52.7.1695; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; MURPHY R, 2003, P 10 C RETR OPP INF; NOOR M, 2000, ANTIVIR THER S, V5, P8; Noordam JC, 2002, J CHEMOMETR, V16, P1, DOI 10.1002/cem.656; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Schutt M, 2000, DIABETOLOGIA, V43, P1145, DOI 10.1007/s001250051505; Schwarcz SK, 2000, AM J EPIDEMIOL, V152, P178, DOI 10.1093/aje/152.2.178; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; Wang S, 2002, ANTIVIR THER, V7, pL6; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Woerle IJ, 2003, DIABETES, V52, P918, DOI 10.2337/diabetes.52.4.918; Xu AM, 2004, ENDOCRINOLOGY, V145, P487, DOI 10.1210/en.2003-1140	23	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55147	55152		10.1074/jbc.M410826200	http://dx.doi.org/10.1074/jbc.M410826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496402	Green Accepted, hybrid			2022-12-27	WOS:000225960800021
J	Emonard, H; Bellon, G; Troeberg, L; Berton, A; Robinet, A; Henriet, P; Marbaix, E; Kirkegaard, K; Patthy, L; Eeckhout, Y; Nagase, H; Hornebeck, W; Courtoy, PJ				Emonard, H; Bellon, G; Troeberg, L; Berton, A; Robinet, A; Henriet, P; Marbaix, E; Kirkegaard, K; Patthy, L; Eeckhout, Y; Nagase, H; Hornebeck, W; Courtoy, PJ			Low density lipoprotein receptor-related protein mediates endocytic clearance of Pro-MMP-2 center dot TIMP-2 complex through a thrombospondin-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE MT1-MMP; ENDOMETRIAL STROMAL CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; TISSUE INHIBITOR; IV COLLAGENASE; GELATINASE-A; EXTRACELLULAR-MATRIX; HIGH-AFFINITY; TYROSINE PHOSPHORYLATION; CELLULAR INTERNALIZATION	The low density lipoprotein receptor-related protein (LRP) mediates the endocytic clearance of various proteinases and proteinase . inhibitor complexes, including thrombospondin (TSP)-dependent endocytosis of matrix metalloproteinase (MMP)-2 ( or gelatinase A), a key effector of extracellular matrix remodeling and cancer progression. However, the zymogen of MMP-2 (pro-MMP-2) mostly occurs in tissues as a complex with the tissue inhibitor of MMPs (TIMP-2). Here we show that clearance of the pro-MMP-2 . TIMP-2 complex is also mediated by LRP, because addition of receptor-associated protein ( RAP), a natural LRP ligand antagonist, inhibited endocytosis and lysosomal degradation of I-125-pro-MMP-2 . TIMP-2. Both TIMP-2 and the pro-MMP-2 collagen-binding domain independently competed for endocytosis of I-125-pro-MMP-2 . TIMP-2 complex. Surface plasmon resonance studies indicated that pro-MMP-2, TIMP-2, and pro-MMP-2 . TIMP- 2 directly interact with LRP in the absence of TSP. LRP-mediated endocytic clearance of I-125-pro-MMP-2 was inhibited by anti-TSP antibodies and accelerated upon complexing with TSP-1, but these treatments had no effect on I-125-pro-MMP-2 . TIMP- 2 uptake. This implies that mechanisms of clearance by LRP of pro-MMP-2 and pro-MMP-2 . TIMP- 2 complex are different. Interestingly, RAP did not inhibit binding of I-125-pro-MMP-2 . TIMP- 2 to the cell surface. We conclude that clearance of pro-MMP-2 . TIMP- 2 complex is a TSP-independent two-step process, involving (i) initial binding to the cell membrane in a RAP-insensitive manner and (ii) subsequent LRP-dependent (RAP-sensitive) internalization and degradation.	Fac Med, IFR Biomol 53, CNRS, UMR 6198, F-51100 Reims, France; Christian de Duve Inst Cellular Pathol, Cell Biol Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England; Univ Aarhus, Inst Med Biochem, Aarhus, Denmark; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Universite Catholique Louvain; Imperial College London; University of Oxford; Aarhus University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Courtoy, PJ (corresponding author), UCL ICP 7541, CELL Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.	courtoy@cell.ucl.ac.be	Emonard, Hervé/AAD-5432-2019; Patthy, Laszlo/Q-6058-2019; Emonard, Herve/R-9718-2019; Patthy, Laszlo/A-2353-2013	/0000-0003-0939-4651; Kirkegaard, Kirstine/0000-0001-8267-9042; Henriet, Patrick/0000-0003-4602-8888				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Berton A, 2001, J BIOL CHEM, V276, P20458, DOI 10.1074/jbc.M011664200; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; CASSLEN B, 1995, J CLIN ENDOCR METAB, V80, P2776, DOI 10.1210/jc.80.9.2776; Casslen B, 1998, MOL HUM REPROD, V4, P585, DOI 10.1093/molehr/4.6.585; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Chen H, 1996, J BIOL CHEM, V271, P15993, DOI 10.1074/jbc.271.27.15993; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; deVries TJ, 1996, CANCER RES, V56, P1432; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Foca C, 2000, MOL HUM REPROD, V6, P921, DOI 10.1093/molehr/6.10.921; Fridman R, 2003, CURR TOP DEV BIOL, V54, P75, DOI 10.1016/S0070-2153(03)54005-4; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh T, 1998, CANCER RES, V58, P1048; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; KANCHA RK, 1994, ONCOL RES, V6, P365; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LIMET JN, 1985, EUR J BIOCHEM, V146, P539, DOI 10.1111/j.1432-1033.1985.tb08685.x; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Nagase H, 1997, BIOL CHEM, V378, P151; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Tyteca D, 2002, EXP CELL RES, V281, P86, DOI 10.1006/excr.2002.5613; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	69	86	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54944	54951		10.1074/jbc.M406792200	http://dx.doi.org/10.1074/jbc.M406792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489233	hybrid			2022-12-27	WOS:000225793600124
J	Rametti, A; Esclaire, F; Yardin, C; Terro, F				Rametti, A; Esclaire, F; Yardin, C; Terro, F			Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL FILAMENT-TAU; CEREBELLAR GRANULE CELLS; ICE-LIKE PROTEASES; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MICROTUBULE-BINDING; SERUM DEPRIVATION; PC12 CELLS; PROTEIN; DEPHOSPHORYLATION	Neurofibrillary tangles (NFTs) are classic lesions of Alzheimer's disease. NFTs are bundles of abnormally phosphorylated tau, the paired helical filaments. The initiating mechanisms of NFTs and their role in neuronal loss are still unknown. Accumulating evidence supports a role for the activation of proteolytic enzymes, caspases, in neuronal death observed in brains of patients with Alzheimer's disease. Alterations in tau phosphorylation and tau cleavage by caspases have been previously reported in neuronal apoptosis. However, the links between the alterations in tau phosphorylation and its proteolytic cleavage have not yet been documented. Here, we show that, during staurosporine-induced neuronal apoptosis, tau first undergoes transient hyperphosphorylation, which is followed by dephosphorylation and cleavage. This cleavage generated a 10-kDa fragment in addition to the 17- and 50-kDa tau fragments previously reported. Prior tau dephosphorylation by a glycogen synthase kinase-3beta inhibitor, lithium, enhanced tau cleavage and sensitized neurons to staurosporine-induced apoptosis. Caspase inhibition prevented tau cleavage without reversing changes in tau phosphorylation linked to apoptosis. Furthermore, the microtubule depolymerizing agent, colchicine, induced tau dephosphorylation and caspase-independent tau cleavage and degradation. Both phenomena were blocked by inhibiting protein phosphatase 2A (PP2A) by okadaic acid. These experiments indicate that tau dephosphorylation precedes and is required for its cleavage and degradation. We propose that the absence of cleavage and degradation of hyperphosphorylated tau ( due to PP2A inhibition) may lead to its accumulation in degenerating neurons. This mechanism may contribute to the aggregation of hyperphosphorylated tau into paired helical filaments in Alzheimer's disease where reduced PP2A activity has been reported.	Fac Med Limoges, Dept Histol & Cell Biol, EA 3842, F-87025 Limoges, France		Terro, F (corresponding author), Fac Med Limoges, Dept Histol & Cell Biol, EA 3842, 2 Rue Dr Marcland, F-87025 Limoges, France.	faraj.terro@unilim.fr	TERRO, FARAJ/O-8423-2016	TERRO, FARAJ/0000-0002-3655-3964				Arendt T, 2003, J NEUROSCI, V23, P6972, DOI 10.1523/JNEUROSCI.23-18-06972.2003; BAUM L, 1995, MOL BRAIN RES, V34, P1, DOI 10.1016/0169-328X(95)00111-5; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; BONFOCO E, 1995, EXP CELL RES, V218, P189, DOI 10.1006/excr.1995.1147; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BUEESCHERRER V, 1995, AM J PATHOL, V146, P924; Canu N, 1998, J NEUROSCI, V18, P7061; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; Davis PK, 1999, J BIOL CHEM, V274, P35686, DOI 10.1074/jbc.274.50.35686; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hall Garth F., 1999, J Alzheimers Dis, V1, P379; JAMESON L, 1980, BIOCHEMISTRY-US, V19, P2472, DOI 10.1021/bi00552a027; JENKINS SM, 2000, BIOCHEM J, V275, P263; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lesort M, 1997, MOL BRAIN RES, V45, P127, DOI 10.1016/S0169-328X(96)00284-7; Levee MG, 1996, AM J PHYSIOL-CELL PH, V271, pC1981, DOI 10.1152/ajpcell.1996.271.6.C1981; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martinou JC, 1996, CURR OPIN NEUROBIOL, V6, P609, DOI 10.1016/S0959-4388(96)80092-4; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; McCarthy MJ, 1997, J CELL SCI, V110, P2165; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; Mills JC, 1998, J CELL SCI, V111, P625; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sergeant N, 1997, J NEUROCHEM, V69, P834; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Terro F, 2000, NEUROSCI LETT, V278, P149, DOI 10.1016/S0304-3940(99)00911-8; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; YEN SH, 1995, NEUROBIOL AGING, V16, P381, DOI 10.1016/0197-4580(95)00022-7; Zhang JW, 2000, J NEUROCHEM, V75, P2346, DOI 10.1046/j.1471-4159.2000.0752346.x	38	51	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54518	54528		10.1074/jbc.M408186200	http://dx.doi.org/10.1074/jbc.M408186200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475565	hybrid			2022-12-27	WOS:000225793600076
J	Rees, EM; Lee, J; Thiele, DJ				Rees, EM; Lee, J; Thiele, DJ			Mobilization of intracellular copper stores by the Ctr2 vacuolar copper transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; METAL TRANSPORTERS; SECRETORY PATHWAY; IRON TRANSPORT; CA2+ ATPASES; YEAST	Copper plays an essential role in processes including signaling to the transcription and protein trafficking machinery, oxidative phosphorylation, iron mobilization, neuropeptide maturation, and normal development. Whereas much is known about intracellular mobilization of ions such as calcium, little information is available on how eukaryotic cells mobilize intracellular copper stores. We describe a mechanism by which the Saccharomyces cerevisiae Ctr2 protein provides bio-available copper via mobilization of intracellular copper stores. Whereas Ctr2 exhibits structural similarity to the Ctr1 plasma membrane copper importer, microscopic and biochemical fractionation studies localize Ctr2 to the vacuole membrane. We demonstrate that Ctr2 mobilizes vacuolar copper stores in a manner dependent on amino acid residues conserved between the Ctr1 and Ctr2 copper transport family and that ctr2Delta mutants hyper-accumulate vacuolar copper. Furthermore, a Ctr2 mutant that is mislocalized to the plasma membrane stimulates extracellular copper uptake, supporting a direct role for Ctr2 in copper transport across membranes. These studies identify a novel mechanism for copper mobilization and suggest that organisms cope with copper deprivation via the use of intracellular vesicular stores.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	Duke University; Duke University; University of Nebraska System; University of Nebraska Lincoln	Thiele, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	dennis.thiele@duke.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR-17675] Funding Source: Medline; NIGMS NIH HHS [GM41840] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bellemare DR, 2002, J BIOL CHEM, V277, P46676, DOI 10.1074/jbc.M206444200; BODE HP, 1995, EUR J BIOCHEM, V228, P337; Cherqui S, 2001, J BIOL CHEM, V276, P13314, DOI 10.1074/jbc.M010562200; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; EILAM Y, 1985, MICROBIOS, V44, P51; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Hartley AD, 1996, MOL GEN GENET, V251, P556; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; IIDA H, 1990, J BIOL CHEM, V265, P21216; Kalatzis V, 2001, EMBO J, V20, P5940, DOI 10.1093/emboj/20.21.5940; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Kellermayer R, 2003, J CELL SCI, V116, P1637, DOI 10.1242/jcs.00372; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mori IC, 1998, BIOSCI BIOTECH BIOCH, V62, P986, DOI 10.1271/bbb.62.986; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; RAMSAY LM, 1997, FEMS MICROBIOL LETT, V152, P292; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Tokes-Fuzesi M, 2002, MOL MICROBIOL, V44, P1299, DOI 10.1046/j.1365-2958.2002.02956.x; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2003, J BIOL CHEM, V278, P48210, DOI 10.1074/jbc.M309820200; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	56	156	161	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54221	54229		10.1074/jbc.M411669200	http://dx.doi.org/10.1074/jbc.M411669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494390	Green Published, hybrid			2022-12-27	WOS:000225793600042
J	Henderson, NS; So, SSK; Martin, C; Kulkarni, R; Thanassi, DG				Henderson, NS; So, SSK; Martin, C; Kulkarni, R; Thanassi, DG			Topology of the outer membrane usher PapC determined by site-directed fluorescence labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; CELL-SURFACE LOCALIZATION; GENERAL SECRETORY PATHWAY; DRIVES FIBER FORMATION; X-RAY-STRUCTURE; PILUS BIOGENESIS; OXALOBACTER-FORMIGENES; SUBUNIT COMPLEXES; CRYSTAL-STRUCTURE; STRUCTURAL BASIS	In contrast to typical membrane proteins that span the lipid bilayer via transmembrane alpha-helices, bacterial outer membrane proteins adopt a beta-barrel architecture composed of antiparallel transmembrane beta-strands. The topology of outer membrane proteins is difficult to predict accurately using computer algorithms, and topology mapping protocols commonly used for alpha-helical membrane proteins do not work for beta-barrel proteins. We present here the topology of the PapC usher, an outer membrane protein required for assembly and secretion of P pili by the chaperone/usher pathway in uropathogenic Escherichia coli. An initial attempt to map PapC topology by insertion of protease cleavage sites was largely unsuccessful due to lack of cleavage at most sites and the requirement to disrupt the outer membrane to identify periplasmic sites. We therefore adapted a site-directed fluorescence labeling technique to permit topology mapping of outer membrane proteins using small molecule probes in intact bacteria. Using this method, we demonstrated that PapC has the potential to encode up to 32 transmembrane beta-strands. Based on experimental evidence, we propose that the usher consists of an N-terminal beta-barrel domain comprised of 26 beta-strands and that a distinct C-terminal domain is not inserted into the membrane but is located instead within the lumen of the N-terminal beta-barrel similar to the plug domains encoded by the outer membrane iron-siderophore uptake proteins.	SUNY Stony Brook, Ctr Infect Dis 242, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Thanassi, DG (corresponding author), SUNY Stony Brook, Ctr Infect Dis 242, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	David.Thanassi@stonybrook.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagos PG, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-29; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; Barnhart MM, 2000, P NATL ACAD SCI USA, V97, P7709, DOI 10.1073/pnas.130183897; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; BOCK K, 1985, J BIOL CHEM, V260, P8545; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Guedin S, 2000, J BIOL CHEM, V275, P30202, DOI 10.1074/jbc.M005515200; Harms Nellie, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P319; KLEMM P, 1990, MOL GEN GENET, V220, P334; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; Newton SMC, 1996, J BACTERIOL, V178, P3447, DOI 10.1128/jb.178.12.3447-3456.1996; Ng TW, 2004, J BACTERIOL, V186, P5321, DOI 10.1128/JB.186.16.5321-5331.2004; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nishlyama M, 2003, J MOL BIOL, V330, P513, DOI 10.1016/S0022-2836(03)00591-6; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Saulino ET, 1998, EMBO J, V17, P2177, DOI 10.1093/emboj/17.8.2177; SCHIFFERLI DM, 1994, J BACTERIOL, V176, P1099, DOI 10.1128/JB.176.4.1099-1110.1994; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; Seal RP, 1998, METHOD ENZYMOL, V296, P318; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Tamm LK, 2001, J BIOL CHEM, V276, P32399, DOI 10.1074/jbc.R100021200; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Thanassi DG, 2002, J BACTERIOL, V184, P6260, DOI 10.1128/JB.184.22.6260-6269.2002; VALENT QA, 1995, MOL MICROBIOL, V16, P1243, DOI 10.1111/j.1365-2958.1995.tb02346.x; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Ye LW, 2001, J BACTERIOL, V183, P2490, DOI 10.1128/JB.183.8.2490-2496.2001; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	49	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53747	53754		10.1074/jbc.M409192200	http://dx.doi.org/10.1074/jbc.M409192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485883	hybrid			2022-12-27	WOS:000225680600112
J	Kumar, S; Gupta, L; Han, YS; Barillas-Mury, C				Kumar, S; Gupta, L; Han, YS; Barillas-Mury, C			Inducible Peroxidases mediate nitration of Anopheles midgut cells undergoing apoptosis in response to Plasmodium invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; IN-VITRO; NITROTYROSINE FORMATION; EOSINOPHIL PEROXIDASE; OOKINETE INVASION; MYELOPEROXIDASE; PEROXYNITRITE; TYROSINE; MECHANISM; GAMBIAE	Plasmodium berghei invasion of Anopheles stephensi midgut cells causes severe damage, induces expression of nitric-oxide synthase, and leads to apoptosis. The present study indicates that invasion results in tyrosine nitration, catalyzed as a two-step reaction in which nitric-oxide synthase induction is followed by increased peroxidase activity. Ookinete invasion induced localized expression of peroxidase enzymes, which catalyzed protein nitration in vitro in the presence of nitrite and H2O2. Histochemical stainings revealed that when a parasite migrates laterally and invades more than one cell, the pattern of induced peroxidase activity is similar to that observed for tyrosine nitration. In Anopheles gambiae, ookinete invasion elicited similar responses; it induced expression of 5 of the 16 peroxidase genes predicted by the genome sequence and decreased mRNA levels of one of them. One of these inducible peroxidases has a C-terminal oxidase domain homologous to the catalytic moiety of phagocyte NADPH oxidase and could provide high local levels of superoxide anion (O-2(radical anion)), that when dismutated would generate the local increase in H2O2 required for nitration. Chemically induced apoptosis of midgut cells also activated expression of four ookinete-induced peroxidase genes, suggesting their involvement in general apoptotic responses. The two-step nitration reaction provides a mechanism to precisely localize and circumscribe the toxic products generated by defense reactions involving nitration. The present study furthers our understanding of the biochemistry of midgut defense reactions to parasite invasion and how these may influence the efficiency of malaria transmission by anopheline mosquitoes.	NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University	Barillas-Mury, C (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 12735 Twinbrook Pkwy, Rockville, MD 20852 USA.	cbarillas@niaid.nih.gov	Gupta, Lalita/R-1111-2019	Kumar, Sanjeev/0000-0003-3866-4593; GUPTA, LALITA/0000-0002-0712-8512	NIAID NIH HHS [R01AI45573] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045573, Z01AI000947] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGERMULLER S, 1981, HISTOCHEMISTRY, V71, P33, DOI 10.1007/BF00592568; Billker O, 1997, PARASITOLOGY, V115, P1, DOI 10.1017/S0031182097008895; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Danielli A, 2005, CELL MICROBIOL, V7, P181, DOI 10.1111/j.1462-5822.2004.00445.x; Danielli A, 2003, J BIOL CHEM, V278, P4184, DOI 10.1074/jbc.M208187200; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Ferret Pierre-Jacques, 2002, BMC Immunol, V3, P3; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Gorren ACF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P734; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Han YS, 2002, INSECT BIOCHEM MOLEC, V32, P1311, DOI 10.1016/S0965-1748(02)00093-0; Jiao KS, 2001, ANAL BIOCHEM, V293, P43, DOI 10.1006/abio.2001.5118; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; McElhinney B, 2003, J LEUKOCYTE BIOL, V74, P897, DOI 10.1189/jlb.0103028; Monzani E, 2004, EUR J BIOCHEM, V271, P895, DOI 10.1111/j.1432-1033.2004.03992.x; Moulian N, 2001, BLOOD, V97, P3521, DOI 10.1182/blood.V97.11.3521; Myzak MC, 2002, REDOX REP, V7, P47, DOI 10.1179/135100002125000181; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Ribeiro JMC, 1999, J EXP BIOL, V202, P809; RIBEIRO JMC, 1993, J EXP BIOL, V179, P273; SALAZAR CE, 1993, NUCLEIC ACIDS RES, V21, P4147, DOI 10.1093/nar/21.17.4147; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Tsurubuchi T, 2001, J LEUKOCYTE BIOL, V70, P52; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Vlachou D, 2004, CELL MICROBIOL, V6, P671, DOI 10.1111/j.1462-5822.2004.00394.x; Zieler H, 2000, P NATL ACAD SCI USA, V97, P11516, DOI 10.1073/pnas.97.21.11516	33	98	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53475	53482		10.1074/jbc.M409905200	http://dx.doi.org/10.1074/jbc.M409905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456781	hybrid			2022-12-27	WOS:000225680600082
J	Uchida, T; Mogi, T; Nakamura, H; Kitagawa, T				Uchida, T; Mogi, T; Nakamura, H; Kitagawa, T			Role of Tyr-288 at the dioxygen reduction site of cytochrome bo studied by stable isotope labeling and resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX METAL CENTERS; COPPER BINUCLEAR CENTER; ELECTRON PARAMAGNETIC RESONANCE; AMINO-ACID-RESIDUES; SUBUNIT-I PERTURB; C-OXIDASE; ESCHERICHIA-COLI; UBIQUINOL OXIDASE; HYDROGEN-PEROXIDE; ACTIVE-SITE	To explore the role of a cross-link between side chains of Tyr-288 and His-284 at the heme-copper binuclear center, we prepared cytochrome bo where d(4)-Tyr, 1-[C-13]Tyr, or 4-[C-13]Tyr has been biosynthetically incorporated. Unexpectedly, the d(4)-Tyr-labeled enzyme showed a large decrease in the ubiquinol-1 oxidase and CO binding activities. Optical absorption and resonance Raman spectra identified the defect in the distal side of the heme-copper binuclear center. In the CO-bound d(4)-Tyr-labeled enzyme, a large fraction of the nu((Fe-C)) mode was shifted from the normal 520-cm(-1) band to a broad band centered around 491 cm(-1), as found for the Y288F mutant. Our results suggested that the substitution of ring hydrogens of Tyr-288 with deuteriums slows down the formation of the His-Tyr cross-link essential for dioxygen reduction at the binuclear center.	Natl Inst Nat Sci, Okazuki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Org, ATP Syst Project, Exploratory Res Adv Technol, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagasuta 4259, Japan; RIKEN, Harima Inst, Mikazuki, Hyogo 6795148, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; RIKEN; Yokohama City University	Mogi, T (corresponding author), Natl Inst Nat Sci, Okazuki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	tmogi@res.titech.ac.jp; teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Aki M, 2002, J PHYS CHEM A, V106, P3436, DOI 10.1021/jp012492n; Blomberg MRA, 2000, J INORG BIOCHEM, V80, P261, DOI 10.1016/S0162-0134(00)00080-5; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Cappuccio JA, 2002, J AM CHEM SOC, V124, P1750, DOI 10.1021/ja011852h; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Das TK, 1998, BIOCHEMISTRY-US, V37, P14471, DOI 10.1021/bi981500w; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; Fabian M, 1999, P NATL ACAD SCI USA, V96, P13114, DOI 10.1073/pnas.96.23.13114; Fabian M, 1999, BIOCHEMISTRY-US, V38, P6270, DOI 10.1021/bi982541v; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HIROTA S, 1994, FEBS LETT, V352, P67, DOI 10.1016/0014-5793(94)00919-8; HOFFMAN BM, 1979, P NATL ACAD SCI USA, V76, P6132, DOI 10.1073/pnas.76.12.6132; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; HOSLER JP, 1994, J AM CHEM SOC, V116, P5515, DOI 10.1021/ja00091a084; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Iwaki M, 2003, BIOCHEMISTRY-US, V42, P8809, DOI 10.1021/bi034522d; KAINOSHO M, 1982, BIOCHEMISTRY-US, V21, P6273, DOI 10.1021/bi00267a036; Kannt A, 1998, J BIOENERG BIOMEMBR, V30, P81, DOI 10.1023/A:1020563629032; Kawasaki M, 1997, J BIOCHEM, V122, P422; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; Matsuura K, 2004, BIOCHEMISTRY-US, V43, P2288, DOI 10.1021/bi0355490; McCauley KM, 2000, J AM CHEM SOC, V122, P2403, DOI 10.1021/ja993774s; Mogi T, 1998, BIOCHEMISTRY-US, V37, P1632, DOI 10.1021/bi971978k; MOGI T, 1995, FEBS LETT, V370, P259; Mogi T, 1999, FEBS LETT, V457, P61, DOI 10.1016/S0014-5793(99)01007-8; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Ogura T, 2004, BBA-BIOENERGETICS, V1655, P290, DOI 10.1016/j.bbabio.2003.10.013; Ogura T, 1996, J AM CHEM SOC, V118, P5443, DOI 10.1021/ja951922i; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P5356, DOI 10.1021/bi9727592; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Sucheta A, 1998, BIOCHEMISTRY-US, V37, P17905, DOI 10.1021/bi981092w; THOMAS JW, 1994, BIOCHEMISTRY-US, V33, P13013, DOI 10.1021/bi00248a010; Tomson F, 2002, BIOCHEMISTRY-US, V41, P14383, DOI 10.1021/bi026370c; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1994, J BIOL CHEM, V269, P30861; Uchida T, 2000, BIOCHEMISTRY-US, V39, P6669, DOI 10.1021/bi992538r; UNO T, 1994, J BIOL CHEM, V269, P11912; VAROTSIS CA, 1995, J AM CHEM SOC, V117, P11260, DOI 10.1021/ja00150a025; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, BIOCHEMISTRY-US, V34, P15504, DOI 10.1021/bi00047a016; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WATMOUGH NJ, 1994, BIOCHEM J, V300, P469, DOI 10.1042/bj3000469; Whittaker MM, 2003, J BIOL CHEM, V278, P22090, DOI 10.1074/jbc.M300112200; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; WITTENBERG BA, 1968, J BIOL CHEM, V243, P1863; Yamazaki Y, 1999, J BIOCHEM-TOKYO, V125, P1131, DOI 10.1093/oxfordjournals.jbchem.a022395; YONETANI T, 1966, J BIOL CHEM, V241, P3240; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	71	21	21	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53613	53620		10.1074/jbc.M409719200	http://dx.doi.org/10.1074/jbc.M409719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465820	hybrid			2022-12-27	WOS:000225680600097
J	Wu, Q; Burghardt, R; Safe, S				Wu, Q; Burghardt, R; Safe, S			Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen receptor alpha (ER alpha) involves multiple domains of both proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; TRANSCRIPTIONAL REGULATION; BREAST-CANCER; DEPENDENT TRANSCRIPTION; RESPONSIVE PROMOTERS; MAMMALIAN MEDIATOR; HORMONE-RECEPTORS; IN-VIVO; COMPLEX; ACTIVATION	Vitamin D-interacting protein 205 (DRIP205) is a mediator complex protein that anchors the complex to the estrogen receptor ( ER) and other nuclear receptors (NRs). In ZR-75 breast cancer cells treated with 17beta-estradiol (E2) and transfected with a construct containing three tandem estrogen responsive elements (pERE(3)), DRIP205 coactivates ERalpha-mediated transactivation. DRIP205Delta587-636 is a DRIP205 mutant in which both NR boxes within amino acids 587-636 have been deleted and, in parallel transfection studies, DRIP205Delta587-636 also coactivates ERalpha. Moreover, both wild-type and variant DRIP205 also colocalize with ERalpha in the nuclei of transfected cells. Extensive deletion analysis of DRIP205 shows that multiple domains of this protein play a role in coactivation of ERalpha and in interactions with ERalpha. Coactivation of ERalpha by DRIP205 does not require NR boxes, and variants with deletion of N-terminal (amino acids 1-639) and C-terminal (amino acids 576-1566) significantly coactivate ERalpha. DRIP205 resembles p160 coactivators that also interact with multiple regions of ERalpha; however, unlike p160 coactivators, DRIP205 coactivation of ERalpha does not require NR boxes.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU,Vet Res Bldg 409, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444				Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2; Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Edwards DP, 1999, VITAM HORM, V55, P165; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heimann R, 1996, JNCI-J NATL CANCER I, V88, P1764, DOI 10.1093/jnci/88.23.1764; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Klinge CM, 1999, MOL CELL ENDOCRINOL, V157, P105, DOI 10.1016/S0303-7207(99)00165-3; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; ONATE SA, 1995, SCIENCE, V270, P1354; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Yang W, 1999, J BIOL CHEM, V274, P16838, DOI 10.1074/jbc.274.24.16838; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	50	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53602	53612		10.1074/jbc.M409778200	http://dx.doi.org/10.1074/jbc.M409778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471764	hybrid			2022-12-27	WOS:000225680600096
J	Hannah, BLA; Misenheimer, TM; Pranghofer, MM; Mosher, DF				Hannah, BLA; Misenheimer, TM; Pranghofer, MM; Mosher, DF			A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; C-TERMINAL REGION; MYOCARDIAL-INFARCTION; TYPE-3 REPEATS; PSEUDOACHONDROPLASIA; CALCIUM; MUTATIONS; GLYCOPROTEIN; PLATELETS	A single nucleotide polymorphism that results in substitution at residue 700 of a serine (Ser-700) for an asparagine (Asn-700) in thrombospondin-1 is associated with familial premature coronary artery disease. The polymorphism is located in the first of 13 Ca2+-binding motifs, within a consensus sequence in which Asn-700 likely coordinates Ca2+. Equilibrium dialysis of constructs comprised of the adjoining epidermal growth factor-like module and the Ca2+-binding region (E3Ca) demonstrated that E3Ca Ser-700 binds significantly less Ca2+ than E3Ca Asn-700 at low [Ca2+]. The hypothesis that this difference is due to loss of a binding site in Ser-700 protein was tested with truncations of E3Ca containing four (Tr4), three (Tr3), two (Tr2), or one (Tr1) N-terminal Ca2+-binding motifs. The Ser-700 truncation constructs bound 1 fewer Ca2+ than matching Asn-700 constructs and exhibited decreased binding affinities. Intrinsic fluorescence of a tryptophan at residue 698 (Trp-698) in the most N-terminal motif was cooperatively quenched by the addition of Ca2+ to Asn-700 Tr2, Tr3, and Tr4 constructs. In Ser-700 constructs, quenching of Trp-698 was incomplete in the Tr2 and Tr3 constructs and complete only in the Tr4 construct. Ca2+-induced quenching of Ser-700 constructs required higher [Ca2+] and was slower as shown in stopped-flow experiments than quenching of Asn-700 constructs. Such differences were not found with Tb3+, which quenched the fluorescence of Asn-700 and Ser-700 constructs equivalently. Thus, the Ser-700 polymorphism alters a rapidly filled, high affinity Ca2+-binding site in the first Ca2+-binding motif. Slower Ca2+ binding to adjoining motifs partly compensates for the change.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Med Sci Training Programs, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Rm 4285 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462] Funding Source: Medline; NIGMS NIH HHS [T32 GM08688] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2003, J MOL BIOL, V328, P479, DOI 10.1016/S0022-2836(03)00248-1; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adolph KW, 2002, DNA SEQUENCE, V13, P277, DOI 10.1080/1042517021000019278; Adolph KW, 2001, GENE, V269, P177, DOI 10.1016/S0378-1119(01)00441-3; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; Boekholdt SM, 2002, ARTERIOSCL THROM VAS, V22, pE24, DOI 10.1161/01.ATV.0000046235.22451.66; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Demaurex N, 2003, CELL CALCIUM, V34, P109, DOI 10.1016/S0143-4160(03)00081-2; ELIN RJ, 1996, CECIL TXB MED, P2224; Groves P, 2001, ACTA BIOCHIM POL, V48, P113; Hannah BLA, 2003, J BIOL CHEM, V278, P8929, DOI 10.1074/jbc.M211185200; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Kleerekoper Q, 2002, J BIOL CHEM, V277, P10581, DOI 10.1074/jbc.M109944200; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; Mabuchi A, 2004, AM J MED GENET A, V129A, P35, DOI 10.1002/ajmg.a.30164; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; Misenheimer TM, 2003, BIOCHEMISTRY-US, V42, P5125, DOI 10.1021/bi026983p; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; Narizhneva NV, 2004, J BIOL CHEM, V279, P21651, DOI 10.1074/jbc.M311090200; Pimanda JE, 2002, BLOOD, V100, P2832, DOI 10.1182/blood-2002-03-0770; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; YAMANO K, 2004, BIOL REPROD	34	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51915	51922		10.1074/jbc.M409632200	http://dx.doi.org/10.1074/jbc.M409632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456750	hybrid			2022-12-27	WOS:000225493400025
J	Kweon, GR; Marks, JD; Krencik, R; Leung, EH; Schumacker, PT; Hyland, K; Kang, UJ				Kweon, GR; Marks, JD; Krencik, R; Leung, EH; Schumacker, PT; Hyland, K; Kang, UJ			Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-INDUCED ATP LOSS; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; MITOCHONDRIAL RESPIRATION; GLUTATHIONE-PEROXIDASE; TYROSINE-HYDROXYLASE; SUPEROXIDE-DISMUTASE; BRAIN MITOCHONDRIA; SUBSTANTIA-NIGRA; NEURONS	Chronic mitochondrial dysfunction, in particular of complex I, has been strongly implicated in the dopaminergic neurodegeneration in Parkinson's disease. To elucidate the mechanisms of chronic complex I disruption-induced neurodegeneration, we induced differentiation of immortalized midbrain dopaminergic (MN9D) and non-dopaminergic (MN9X) neuronal cells, to maintain them in culture without significant cell proliferation and compared their survivals following chronic exposure to nanomolar rotenone, an irreversible complex I inhibitor. Rotenone killed more dopaminergic MN9D cells than non-dopaminergic MN9X cells. Oxidative stress played an important role in rotenone-induced neurodegeneration of MN9X cells, but not MN9D cells: rotenone oxidatively modified proteins more in MN9X cells than in MN9D cells and antioxidants decreased rotenone toxicity only in MN9X cells. MN9X cells were also more sensitive to exogenous oxidants than MN9D cells. In contrast, disruption of bioenergetics played a more important role in MN9D cells: rotenone decreased mitochondrial membrane protential and ATP levels in MN9D cells more than in MN9X cells. Supplementation of cellular energy with a ketone body, D-beta-hydroxybutyrate, decreased rotenone toxicity in MN9D cells, but not in MN9X cells. MN9D cells were also more susceptible to disruption of oxidative phosphorylation or glycolysis than MN9X cells. These findings indicate that, during chronic rotenone exposure, MN9D cells die primarily through mitochondrial energy disruption, whereas MN9X cells die primarily via oxidative stress. Thus, intrinsic properties of individual cell types play important roles in determining the predominant mechanism of complex I inhibition-induced neurodegeneration.	Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Physiol & Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX 75226 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; Baylor University; Baylor University Medical Center	Kang, UJ (corresponding author), Univ Chicago, Dept Neurol, MC2030, Chicago, IL 60637 USA.	unkang@uchicago.edu	Marks, Jeremy/W-2087-2019; Kang, Un/AAV-2858-2020	Marks, Jeremy/0000-0002-2644-5257; Kang, Un/0000-0002-5970-6839; Schumacker, Paul T/0000-0001-9591-2034; Krencik, Robert/0000-0002-2968-3162	NHLBI NIH HHS [HL66315] Funding Source: Medline; NIGMS NIH HHS [T32 GM07281] Funding Source: Medline; NINDS NIH HHS [R01 NS038547-03, NS38547, R01 NS038547-04, R01 NS038547, NS32080, R01 NS038547-02, R01 NS43286, R01 NS038547-01A1, R01 NS038547-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043286, R29NS032080, R01NS032080, R01NS038547] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BATES TE, 1994, J NEUROCHEM, V63, P640; Beal MF, 2003, ANN NEUROL, V53, pS39, DOI 10.1002/ana.10479; Bencsics C, 1996, J NEUROSCI, V16, P4449; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; CHAN P, 1993, J NEUROCHEM, V61, P610; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; DIMONTE D, 1986, BIOCHEM BIOPH RES CO, V137, P310, DOI 10.1016/0006-291X(86)91211-8; Ferrante RJ, 1997, BRAIN RES, V753, P157, DOI 10.1016/S0006-8993(97)00008-5; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Han BS, 2003, J NEUROSCI, V23, P5069; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; HEIKKILA RE, 1985, NEUROSCI LETT, V58, P133, DOI 10.1016/0304-3940(85)90342-8; Hoglinger GU, 2003, J NEUROCHEM, V84, P491, DOI 10.1046/j.1471-4159.2003.01533.x; HOWELLS DW, 1987, CLIN CHIM ACTA, V167, P23, DOI 10.1016/0009-8981(87)90081-7; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; Mazzio E, 2003, NEUROTOXICOLOGY, V24, P137, DOI 10.1016/S0161-813X(02)00110-9; Menegon A, 1998, LANCET, V352, P1344, DOI 10.1016/S0140-6736(98)03453-9; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; Nakamura K, 2000, J NEUROCHEM, V74, P2305, DOI 10.1046/j.1471-4159.2000.0742305.x; Nakamura K, 2000, MOL PHARMACOL, V58, P271, DOI 10.1124/mol.58.2.271; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perier C, 2003, TRENDS NEUROSCI, V26, P345, DOI 10.1016/S0166-2236(03)00144-9; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PRZEDBORSKI S, 1992, J NEUROCHEM, V58, P1760, DOI 10.1111/j.1471-4159.1992.tb10051.x; Royland JE, 1999, BRAIN RES, V839, P41, DOI 10.1016/S0006-8993(99)01689-3; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2002, J NEUROSCI, V22, P7006; Storch A, 2000, BRAIN RES, V855, P67, DOI 10.1016/S0006-8993(99)02272-6; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862	42	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51783	51792		10.1074/jbc.M407336200	http://dx.doi.org/10.1074/jbc.M407336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469939	hybrid			2022-12-27	WOS:000225493400011
J	Lazzell, DR; Belizaire, R; Thakur, P; Sherry, DM; Janz, R				Lazzell, DR; Belizaire, R; Thakur, P; Sherry, DM; Janz, R			SV2B regulates synaptotagmin 1 by direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; MOUSE RETINA; T-SNARE; NEUROTRANSMITTER RELEASE; BINDING; EXOCYTOSIS; ENDOCYTOSIS; SYNTAXIN; CYCLE; IDENTIFICATION	SV2 proteins are abundant synaptic vesicle proteins expressed in two major (SV2A and SV2B) and one minor (SV2C) isoform. SV2A and SV2B have been shown to be involved in the regulation of synaptic vesicle exocytosis. Previous studies found that SV2A, but not SV2B, can interact with the cytoplasmic domain of synaptotagmin 1, a Ca2+ sensor for synaptic vesicle exocytosis. To determine whether SV2B can interact with full-length synaptotagmin 1, we performed immunoprecipitations from brain protein extracts and found that SV2B interacts strongly with synaptotagmin 1 in a detergent-resistant, Ca2+-independent manner. In contrast, an interaction between native SV2A and synaptotagmin 1 was not detectable under these conditions. The SV2B-synaptotagmin 1 complex also contained the synaptic t-SNARE proteins, syntaxin 1 and SNAP-25, suggesting that SV2B may participate in exocytosis by modulating the interaction of synaptotagmin 1 with t-SNARE proteins. Analysis of retinae in SV2B knock-out mice revealed a strong reduction in the level of synaptotagmin 1 in rod photoreceptor synapses, which are unique in that they express only the SV2B isoform. In contrast, other synaptic vesicle proteins were not affected by SV2B knock out, indicating a specific role for SV2B in the regulation of synaptotagmin 1 levels at certain synapses. These experiments suggest that the SV2B-synaptotagmin 1 complex is involved in the regulation of synaptotagmin 1 stability and/or trafficking. This study has demonstrated a new role of SV2B as a regulator of synaptotagmin 1 that is likely mediated by direct interaction of these two synaptic proteins.	Univ Texas, WM Keck Ctr Learning & Memory, Dept Neurobiol & Anat, Sch Med, Houston, TX 77030 USA; Univ Houston, Coll Optometry, Houston, TX 77204 USA	University of Texas System; University of Houston System; University of Houston	Janz, R (corresponding author), Univ Texas, WM Keck Ctr Learning & Memory, Dept Neurobiol & Anat, Sch Med, Houston, TX 77030 USA.	Roger.Janz@uth.tmc.edu		Janz, Roger/0000-0002-9872-0596; Belizaire, Roger/0000-0001-8496-287X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007467] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY07751] Funding Source: Medline; NINDS NIH HHS [5-T32-NS07467] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aravanis AM, 2003, NEUROPHARMACOLOGY, V45, P797, DOI 10.1016/S0028-3908(03)00310-1; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; Belizaire R, 2004, J COMP NEUROL, V470, P266, DOI 10.1002/cne.20008; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; FEANY MB, 1993, J CELL BIOL, V123, P575, DOI 10.1083/jcb.123.3.575; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; Fergestad T, 2001, J NEUROSCI, V21, P1218; Fergestad T, 1999, J NEUROSCI, V19, P5847, DOI 10.1523/JNEUROSCI.19-14-05847.1999; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Janz R, 1999, NEUROSCIENCE, V94, P1279, DOI 10.1016/S0306-4522(99)00370-X; Janz R, 1998, J NEUROSCI, V18, P9269; Janz R, 1999, NEURON, V24, P1003, DOI 10.1016/S0896-6273(00)81046-6; Jarousse N, 2001, J CELL BIOL, V154, P857, DOI 10.1083/jcb.200103040; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Kee Y, 1996, J NEUROSCI, V16, P1975; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Paillart C, 2003, J NEUROSCI, V23, P4092; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Rea R, 2004, NEURON, V41, P755, DOI 10.1016/S0896-6273(04)00088-1; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Rieke F, 1996, J PHYSIOL-LONDON, V493, P1; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Sudhof TC, 2000, NEURON, V28, P317, DOI 10.1016/S0896-6273(00)00109-4; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tokuoka H, 2003, NEURON, V38, P521, DOI 10.1016/S0896-6273(03)00290-3; Verona M, 2000, J NEUROCHEM, V74, P209, DOI 10.1046/j.1471-4159.2000.0740209.x; Wang MM, 2003, J COMP NEUROL, V460, P106, DOI 10.1002/cne.10636; Xu T, 2001, NAT CELL BIOL, V3, P691, DOI 10.1038/35087000; Yoshihara M, 2003, CURR OPIN NEUROBIOL, V13, P315, DOI 10.1016/S0959-4388(03)00063-1; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	46	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52124	52131		10.1074/jbc.M407502200	http://dx.doi.org/10.1074/jbc.M407502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466855	hybrid			2022-12-27	WOS:000225493400051
J	Mashhoon, N; Carroll, M; Pruss, C; Eberhard, J; Ishikawa, S; Estabrook, RA; Reich, N				Mashhoon, N; Carroll, M; Pruss, C; Eberhard, J; Ishikawa, S; Estabrook, RA; Reich, N			Functional characterization of Escherichia coli DNA adenine methyltransferase, a novel target for antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE; KINETIC MECHANISM; DAM METHYLASE; CYTOSINE-C-5 METHYLTRANSFERASE; FACILITATED DIFFUSION; CATALYTIC PROPERTIES; SECONDARY STRUCTURE; GATC SITES; ENZYME; BINDING	We have characterized Escherichia coli DNA adenine methyltransferase, a critical regulator of bacterial virulence. Steady-state kinetics, product inhibition, and isotope exchange studies are consistent with a kinetic mechanism in which the cofactor S-adenosylmethionine binds first, followed by sequence-specific DNA binding and catalysis. The enzyme has a fast methyl transfer step followed by slower product release steps, and we directly demonstrate the competence of the enzyme cofactor complex. Methylation of adjacent GATC sites is distributive with DNA derived from a genetic element that controls the transcription of the adjacent genes. This indicates that the first methylation event is followed by enzyme release. The affinity of the enzyme for both DNA and S-adenosylmethionine was determined. Our studies provide a basis for further structural and functional analysis of this important enzyme and for the identification of inhibitors for potential therapeutic applications.	EpiGenX Pharmaceut, Pacific Technol Ctr, Santa Barbara, CA 93111 USA; Univ Kiel, Dept Operat Dent & Periodontol, Kiel, Germany; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of Kiel; University of California System; University of California Santa Barbara	Reich, N (corresponding author), EpiGenX Pharmaceut, Pacific Technol Ctr, Santa Barbara, CA 93111 USA.	reich@chem.ucsb.edu	Eberhard, Joerg/AAY-9034-2020; Eberhard, Jörg/G-1103-2012; Pruss, Cynthia/P-2552-2019; Pruss, Cynthia/A-7945-2013	Eberhard, Joerg/0000-0001-8060-2893; Pruss, Cynthia/0000-0002-3841-8336; Pruss, Cynthia/0000-0002-3841-8336	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI048377] Funding Source: NIH RePORTER; NIAID NIH HHS [2 R43 AI48377-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; BARRAS F, 1988, NUCLEIC ACIDS RES, V16, P9821, DOI 10.1093/nar/16.20.9821; Berdis AJ, 1998, P NATL ACAD SCI USA, V95, P2874, DOI 10.1073/pnas.95.6.2874; BERGERAT A, 1990, NUCLEIC ACIDS RES, V18, P4369, DOI 10.1093/nar/18.15.4369; BERGERAT A, 1991, P NATL ACAD SCI USA, V88, P6394, DOI 10.1073/pnas.88.15.6394; BERGERAT A, 1989, J BIOL CHEM, V264, P4064; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; HALE WB, 1994, J BACTERIOL, V176, P3438, DOI 10.1128/jb.176.11.3438-3441.1994; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; Hernday A, 2002, P NATL ACAD SCI USA, V99, P16470, DOI 10.1073/pnas.182427199; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kossykh VG, 2004, J BACTERIOL, V186, P2061, DOI 10.1128/JB.186.7.2061-2067.2004; KRIEBARDIS A, 1987, FEBS LETT, V213, P297, DOI 10.1016/0014-5793(87)81509-0; Liebert K, 2004, J MOL BIOL, V341, P443, DOI 10.1016/j.jmb.2004.05.033; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; MARINUS MG, 1983, MOL GEN GENET, V192, P288, DOI 10.1007/BF00327681; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; Reisenauer A, 1999, J BACTERIOL, V181, P5135, DOI 10.1128/JB.181.17.5135-5139.1999; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; SZILAK L, 1993, EUR J BIOCHEM, V218, P727, DOI 10.1111/j.1432-1033.1993.tb18427.x; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; Wahnon DC, 2001, J AM CHEM SOC, V123, P976, DOI 10.1021/ja003285o; WU JC, 1987, J BIOL CHEM, V262, P4778	35	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52075	52081		10.1074/jbc.M408182200	http://dx.doi.org/10.1074/jbc.M408182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456775	hybrid			2022-12-27	WOS:000225493400045
J	Wu, YY; Chang, YC; Hsu, TL; Hsieh, SL; Lai, MZ				Wu, YY; Chang, YC; Hsu, TL; Hsieh, SL; Lai, MZ			Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR SUPERFAMILY; LIGAND-INDUCED APOPTOSIS; DEATH RECEPTORS; CANCER-CELLS; CYTOCHROME-C; FAS LIGAND; IN-VIVO; T-CELL; MEDIATED APOPTOSIS; LEUKEMIA-CELLS	Decoy receptor 3 (DcR3)/TR6/M68 is a soluble receptor that binds to the Fas ligand LIGHT and TL1A. Elevated levels of DcR3 expression have been found in many tumors. We report an unexpected effect of DcR3 by sensitizing Jurkat and U937 cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cell death triggered by anti-Fas and tumor necrosis factor was unaffected by DcR3. DcR3 by itself did not stimulate apoptosis. The ability to augment TRAIL-initiated cell death was not observed with soluble lymphotoxin beta receptor or soluble death receptor 3, indicating that binding to LIGHT or TL1A alone is insufficient to trigger TRAIL sensitivity. Incubation with DcR3 did not increase the surface expression of TRAIL receptor, and the level of Fas-associated death domain protein and cellular FLICE-like inhibitory protein was not altered. Instead, in the presence of DcR3, TRAIL engagement resulted in an increased activation of caspase-8, an elevated cleavage of Bid, and enhanced release of Smac and cytochrome c from mitochondria to cytosol compared with TRAIL alone. This led to increased activation of caspase-9 and caspase-3. The unusual ability of DcR3 to promote TRAIL-triggered death may be used to potentiate TRAIL efficacy during treatment tumors overexpressing DcR3.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11529, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Taiwan Univ, Inst Immunol, Taipei 11529, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Hsu, Tsui-Ling/H-6704-2015; Hsu, Tsui-Ling/AAE-8821-2019; Lai, Ming-Zong/AAA-4408-2021; Hsieh, Shie-Liang Edmond/ABA-9184-2021	Hsu, Tsui-Ling/0000-0002-2912-3261; Lai, Ming-Zong/0000-0002-3237-4803				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chang YC, 2004, J LEUKOCYTE BIOL, V75, P486, DOI 10.1189/jlb.0903448; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hsu MJ, 2004, EXP CELL RES, V292, P241, DOI 10.1016/j.yexcr.2003.09.019; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hsu TL, 2002, J IMMUNOL, V168, P4846, DOI 10.4049/jimmunol.168.10.4846; Keane MM, 1999, CANCER RES, V59, P734; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Nimmanapalli R, 2001, CANCER RES, V61, P759; Ohshima K, 2000, CANCER LETT, V160, P89, DOI 10.1016/S0304-3835(00)00567-X; Otsuki T, 2000, CLIN EXP IMMUNOL, V119, P323; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Roth W, 2001, CANCER RES, V61, P2759; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shi GX, 2003, J IMMUNOL, V171, P3407, DOI 10.4049/jimmunol.171.7.3407; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Takahama Yasushi, 2002, Gastric Cancer, V5, P61, DOI 10.1007/s101200200011; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wan XC, 2003, J CELL BIOCHEM, V89, P603, DOI 10.1002/jcb.10523; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang CR, 2004, CANCER RES, V64, P1122, DOI 10.1158/0008-5472.CAN-03-0609; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhang J, 2001, J CLIN INVEST, V107, P1459, DOI 10.1172/JCI12159; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427	51	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44211	44218		10.1074/jbc.408842200	http://dx.doi.org/10.1074/jbc.408842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15475369	Bronze			2022-12-27	WOS:000224383100100
J	Wada, S; Tanabe, K; Yamazaki, A; Niimi, M; Uehara, Y; Niimi, K; Lamping, E; Cannon, RD; Monk, BC				Wada, S; Tanabe, K; Yamazaki, A; Niimi, M; Uehara, Y; Niimi, K; Lamping, E; Cannon, RD; Monk, BC			Phosphorylation of Candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE; YEAST; GENE; EPIDEMIOLOGY; KINASES	Fungal ATP-binding cassette transporter regulation was investigated using Candida glabrata Cdr1p and Pdh1p expressed in Saccharomyces cerevisiae. Rephosphorylation of Pdh1p and Cdr1p was protein kinase A inhibitor-sensitive but responded differentially to Tpk isoforms, stressors, and glucose concentration. Cdr1p Ser(307), which borders the nucleotide binding domain 1 ABC signature motif, and Ser(484), near the membrane, were dephosphorylated on glucose depletion and independently rephosphorylated during glucose exposure or under stress. The S484A enzyme retained half the wild type ATPase activity without affecting azole resistance, but the S307A enzyme was unstable to plasma membrane isolation. Studies of pump function suggested conformational interaction between Ser(484) and Ser(307). An S307A/S484A double mutant, which failed to efflux the Cdr1p substrate rhodamine 6G, had a fluconazole susceptibility 4-fold greater than the Cdr1p expressing strain, twice that of the S307A mutant, but 64-fold less than the control null strain. Stable intragenic suppressors indicative of homodimer nucleotide binding domain 1-nucleotide binding domain 1 interactions partially restored rhodamine 6G pumping and increased fluconazole and rhodamine 6G resistance in the S307A/S484A mutant. Nucleotide binding domain 1 of Cdr1p is a sensor of important physiological stimuli.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Otago, Dept Oral Sci, Dunedin, New Zealand	National Institute of Infectious Diseases (NIID); University of Otago	Niimi, M (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	niimi@nih.go.jp	Lamping, Erwin/C-5104-2009	Cannon, Richard/0000-0002-5398-2066; Monk, Brian/0000-0003-2264-3480; Lamping, Erwin/0000-0002-4942-4782				Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; Diekema DJ, 2002, J CLIN MICROBIOL, V40, P1298, DOI 10.1128/JCM.40.4.1298-1302.2002; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; Fidel PL, 1999, CLIN MICROBIOL REV, V12, P80, DOI 10.1128/CMR.12.1.80; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Izumikawa K, 2003, YEAST, V20, P249, DOI 10.1002/yea.962; Jha S, 2003, BIOCHEM BIOPH RES CO, V310, P869, DOI 10.1016/j.bbrc.2003.09.094; Kolling R, 2002, FEBS LETT, V531, P548, DOI 10.1016/S0014-5793(02)03621-9; Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3; Miyazaki H, 1998, ANTIMICROB AGENTS CH, V42, P1695, DOI 10.1128/AAC.42.7.1695; Nanduri J, 2001, MOL BIOL CELL, V12, P1835, DOI 10.1091/mbc.12.6.1835; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Robertson LS, 2000, P NATL ACAD SCI USA, V97, P5984, DOI 10.1073/pnas.100113397; Sanglard D, 1999, ANTIMICROB AGENTS CH, V43, P2753, DOI 10.1128/AAC.43.11.2753; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Taglicht D, 1998, METHOD ENZYMOL, V292, P130; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC370, DOI 10.1152/ajpcell.1999.276.2.C370; Wada S, 2002, J BIOL CHEM, V277, P46809, DOI 10.1074/jbc.M207817200	27	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					94	103		10.1074/jbc.M408252200	http://dx.doi.org/10.1074/jbc.M408252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498768				2022-12-27	WOS:000226025100013
J	Ge, L; Shenoy, SK; Lefkowitz, RJ; DeFea, K				Ge, L; Shenoy, SK; Lefkowitz, RJ; DeFea, K			Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; ALPHA-1-ANTITRYPSIN DEFICIENCY; REPLACEMENT THERAPY; FACTOR VIIA; RECEPTOR 2; PSEUDOPODIA; CHEMOTAXIS; INVASION; SCAFFOLD; DESENSITIZATION	Protease-activated receptor-2 (PAR-2) is activated by trypsin-like serine proteases and can promote cell migration through an ERK1/2-dependent pathway, involving formation of a scaffolding complex at the leading edge of the cell. Previous studies also showed that expression of a dominant negative fragment of beta-arrestin-1 reduces PAR-2-stimulated internalization, ERK1/2 activation, and cell migration; however, this reagent may block association of many proteins, including beta-arrestin-2 with clathrin-coated pits. Here we investigate the role of PAR-2 in the constitutive migration of a metastatic breast cancer cell line, MDA MB-231, and use small interfering RNA to determine the contribution of each beta-arrestin to this process. We demonstrate that a trypsin-like protease secreted from MDA MB-231 cells can promote cell migration through autocrine activation of PAR-2 and this correlates with constitutive localization of PAR-2, beta-arrestin-2, and activated ERK1/2 to pseudopodia. Addition of MEK-1 inhibitors, trypsin inhibitors, a scrambled PAR-2 peptide, and silencing of beta-arrestins with small interfering RNA also reduce base-line migration of MDA MB-231 cells. In contrast, a less metastatic PAR-2 expressing breast cancer cell line does not exhibit constitutive migration, pseudopodia formation, or trypsin secretion; in these cells PAR-2 is more uniformly distributed around the cell periphery. These data demonstrate a requirement for both beta-arrestins in PAR-2-mediated motility and suggest that autocrine activation of PAR-2 by secreted proteases may contribute to the migration of metastatic tumor cells through beta-arrestin-dependent ERK1/2 activation.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Biochem & Mol Biol Program, Riverside, CA 92521 USA; Univ Calif Riverside, Cellular Mol & Dev Biol Program, Riverside, CA 92521 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	DeFea, K (corresponding author), Univ Calif Riverside, Div Biomed Sci, B605 Stat Rd, Riverside, CA 92521 USA.	katie.defea@ucr.edu	Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663; DeFea, Kathryn/0000-0001-6056-907X	NHLBI NIH HHS [R01 HL 016037] Funding Source: Medline; NIGMS NIH HHS [R01 GM066151-02, R01 GM 066151, R01 GM066151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Al-Ani B, 2002, J PHARMACOL EXP THER, V300, P702, DOI 10.1124/jpet.300.2.702; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; COURTNEY M, 1985, NATURE, V313, P149, DOI 10.1038/313149a0; D'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ducroc R, 2002, LIFE SCI, V70, P1359, DOI 10.1016/S0024-3205(01)01519-3; Eden E, 2003, CHEST, V123, P765, DOI 10.1378/chest.123.3.765; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; GADEK JE, 1981, J CLIN INVEST, V68, P1158, DOI 10.1172/JCI110360; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Greenberg DL, 2003, BIOCHEMISTRY-US, V42, P702, DOI 10.1021/bi027100x; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Kamath L, 2001, CANCER RES, V61, P5933; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McGuire JJ, 2004, J PHARMACOL EXP THER, V309, P1124, DOI 10.1124/jpet.103.064584; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; ZHANG RD, 1991, INVAS METAST, V11, P204	32	140	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55419	55424		10.1074/jbc.M410312200	http://dx.doi.org/10.1074/jbc.M410312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489220	hybrid			2022-12-27	WOS:000225960800056
J	Ganesan, LP; Wei, G; Pengal, RA; Moldovan, L; Moldovan, N; Ostrowski, MC; Tridandapani, S				Ganesan, LP; Wei, G; Pengal, RA; Moldovan, L; Moldovan, N; Ostrowski, MC; Tridandapani, S			The serine/threonine kinase Akt promotes Fc gamma receptor-mediated phagocytosis in murine macrophages through the activation of p70S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTEGRIN-LINKED KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; S6 KINASE; CELLULAR-SURVIVAL; HUMAN MONOCYTES; PKB; PHOSPHORYLATION; IDENTIFICATION	Fcgamma receptor (FcgammaR) clustering by immune complexes activates multiple signaling pathways leading to phagocytosis. We and others have previously reported that Akt is phosphorylated in response to FcgammaR clustering. However, the functional consequence of Akt activation by FcgammaR is not known. Using Raw 264.7 macrophage cells transfected to overexpress either constitutively active myristoylated (Myr)-Akt or a dominant-negative CAAX-Akt and bone marrow macrophages (BMMs) from wild-type and transgenic mice expressing macrophage-specific Myr-Akt, we analyzed the function of Akt in phagocytosis. We report that overexpression of Myr-Akt resulted in significant increase in phagocytic efficiency, whereas CAAX-Akt down-regulated phagocytosis in Raw 264.7 cells. Likewise BMMs expressing Myr-Akt displayed enhanced phagocytic ability. Analyzing the downstream effectors of Akt, we demonstrate that p70S6 kinase is constitutively phosphorylated in Myr-Akt-expressing BMMs. p70S6 kinase is reported to influence actin cytoskeleton and cell migration, suggesting that Akt may influence phagocytosis through the activation of p70S6 kinase. Consistent with this, overexpression of either wild-type or constitutively active but not a kinase-inactive p70S6 kinase in Raw 264.7 cells significantly enhanced phagocytosis. Likewise suppression of p70S6 kinase with rapamycin down-regulated phagocytic efficiency conferred by the expression of constitutively active Akt. These findings demonstrate a novel role for Akt in phagocytosis through the activation of p70S6 kinase.	Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Tridandapani, S (corresponding author), Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, 473 W 12th Ave, Columbus, OH 43210 USA.	tridandapani.2@osu.edu	Tridandapani, Susheela/E-4209-2011; Ostrowski, Michael/H-3108-2011	Moldovan, Leni/0000-0003-1967-2408; Ostrowski, Michael/0000-0003-2948-6297	NCI NIH HHS [P01 CA095426, P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095426, P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Johanson SO, 1999, EXP CELL RES, V248, P223, DOI 10.1006/excr.1999.4405; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Nakamura K, 2002, BLOOD, V100, P3374, DOI 10.1182/blood-2002-03-0787; Ozes ON, 1999, NATURE, V401, P82; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Pengal RA, 2003, J BIOL CHEM, V278, P22657, DOI 10.1074/jbc.M302907200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pricop L, 2001, J IMMUNOL, V166, P531, DOI 10.4049/jimmunol.166.1.531; Ptak W, 1998, SCAND J IMMUNOL, V47, P136; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Strzelecka-Kiliszek A, 2002, J IMMUNOL, V169, P6787, DOI 10.4049/jimmunol.169.12.6787; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tridandapani S, 2003, J IMMUNOL, V170, P4572, DOI 10.4049/jimmunol.170.9.4572; Tridandapani S, 2002, J BIOL CHEM, V277, P5082, DOI 10.1074/jbc.M110277200; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150	47	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54416	54425		10.1074/jbc.M408188200	http://dx.doi.org/10.1074/jbc.M408188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485887	hybrid			2022-12-27	WOS:000225793600064
J	Kunjilwar, K; Strang, C; DeRubeis, D; Pfaffinger, PJ				Kunjilwar, K; Strang, C; DeRubeis, D; Pfaffinger, PJ			KChIP3 rescues the functional expression of Shal channel tetramerization mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED-STATE INACTIVATION; POTASSIUM CHANNELS; K+ CHANNEL; TERMINAL DOMAINS; KV4 CHANNELS; T1 DOMAIN; I-TO; MODULATION; PROTEIN; BINDING	KChIP proteins regulate Shal, Kv4.x, channel expression by binding to a conserved sequence at the N terminus of the subunit. The binding of KChIP facilitates a redistribution of Kv4 protein to the cell surface, producing a large increase in current along with significant changes in channel gating kinetics. Recently we have shown that mutants of Kv4.2 lacking the ability to bind an intersubunit Zn2+ between their T1 domains fail to form functional channels because they are unable to assemble to tetramers and remain trapped in the endoplasmic reticulum. Here we find that KChIPs are capable of rescuing the function of Zn2+ site mutants by driving the mutant subunits to assemble to tetramers. Thus, in addition to known trafficking effects, KChIPs play a direct role in subunit assembly by binding to monomeric subunits within the endoplasmic reticulum and promoting tetrameric channel assembly. Zn2+-less Kv4.2 channels expressed with KChIP3 demonstrate several distinct kinetic changes in channel gating, including a reduced time to peak and faster entry into the inactivated state as well as extending the time to recover from inactivation by 3-4 fold.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Pfaffinger, PJ (corresponding author), Baylor Coll Med, Div Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	paulp@bcm.tmc.edu			NICHD NIH HHS [HD24064] Funding Source: Medline; NINDS NIH HHS [P01NS37444, R01NS31583] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031583, P01NS037444] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bahring R, 2001, J PHYSIOL-LONDON, V535, P65, DOI 10.1111/j.1469-7793.2001.00065.x; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Beck EJ, 2001, BIOPHYS J, V81, P867, DOI 10.1016/S0006-3495(01)75747-5; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Gebauer M, 2004, BIOPHYS J, V86, P210, DOI 10.1016/S0006-3495(04)74097-7; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Jahng AW, 2002, J BIOL CHEM, V277, P47885, DOI 10.1074/jbc.M208416200; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Kim LA, 2004, NEURON, V41, P513, DOI 10.1016/S0896-6273(04)00050-9; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lilliehook C, 2003, J NEUROSCI, V23, P9097; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nanao MH, 2003, P NATL ACAD SCI USA, V100, P8670, DOI 10.1073/pnas.1432840100; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; SHEN NV, 1993, NEURON, V11, P67; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5	27	37	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54542	54551		10.1074/jbc.M409721200	http://dx.doi.org/10.1074/jbc.M409721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485870	hybrid			2022-12-27	WOS:000225793600079
J	Ostrowski, J; Klimek-Tomczak, K; Wyrwicz, LS; Mikula, M; Schullery, DS; Bomsztyk, K				Ostrowski, J; Klimek-Tomczak, K; Wyrwicz, LS; Mikula, M; Schullery, DS; Bomsztyk, K			Heterogeneous nuclear ribonucleoprotein K enhances insulin-induced expression of mitochondrial UCP2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; UNCOUPLING PROTEIN-2; HNRNP-K; COMMON POLYMORPHISM; GENE-EXPRESSION; OXIDATIVE-PHOSPHORYLATION; BINDING; YEAST; DNA; IDENTIFICATION	The uncoupling protein 2, UCP2, is a member of a family of inner mitochondrial membrane ion carriers involved in a host of metabolic processes. UCP2 protein is encoded by nuclear genome, but the protein is found exclusively in the mitochondria. The heterogeneous nuclear ribonucleoprotein K (hnRNPK) is an RNA-binding protein involved in many processes that compose gene expression, including mRNA processing and translation. The yeast three-hybrid screen revealed K protein bound to ucp2 mRNA through sites located in the 3'-untranslated region of the transcript. ucp2 mRNA-K protein complexes were associated with polysome-coated mitochondria. Expression of exogenous K protein augmented the insulin-induced mitochondrial level of UCP2 protein that was not accompanied by a corresponding increase in ucp2 mRNA. These results suggest the insulin stimulates translation of ucp2 mRNA in a process that involves K protein.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Med Ctr Postgrad Educ, Dept Gastroenterol, PL-02781 Warsaw, Poland; Maria Sklodowska Curie Mem Canc Ctr, PL-02781 Warsaw, Poland; Inst Oncol, PL-02781 Warsaw, Poland; BioInfoBank Inst, PL-60744 Poznan, Poland	University of Washington; University of Washington Seattle; Centre of Postgraduate Medical Education - Poland; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Box 356523, Seattle, WA 98195 USA.	karolb@u.washington.edu	Mikula, Michal/G-8276-2011; Wyrwicz, Lucjan/ABD-6558-2021	Mikula, Michal/0000-0003-3447-7328; Wyrwicz, Lucjan/0000-0003-0808-6892; Ostrowski, Jerzy/0000-0003-1363-3766				Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Boirie Y, 2003, TRENDS ENDOCRIN MET, V14, P393, DOI 10.1016/j.tem.2003.09.002; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; Daneholt B, 2001, P NATL ACAD SCI USA, V98, P7012, DOI 10.1073/pnas.111145498; de Bilbao F, 2004, J NEUROCHEM, V89, P1283, DOI 10.1111/j.1471-4159.2004.02432.x; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Erlanson-Albertsson C, 2003, ACTA PHYSIOL SCAND, V178, P405, DOI 10.1046/j.1365-201X.2003.01159.x; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0; GERMANYUK YL, 1978, ENDOCRINOL EXP, V12, P233; Goffart S, 2003, EXP PHYSIOL, V88, P33, DOI 10.1113/eph8802500; HAAPARANTA T, 1983, ARCH BIOCHEM BIOPHYS, V223, P458, DOI 10.1016/0003-9861(83)90610-0; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Horimoto M, 2004, HEPATOLOGY, V39, P386, DOI 10.1002/hep.20047; Huang X, 1999, DIABETES, V48, P1508, DOI 10.2337/diabetes.48.8.1508; Ji QH, 2004, J HYPERTENS, V22, P97, DOI 10.1097/00004872-200401000-00018; Kabat AR, 2003, COMP BIOCHEM PHYS B, V134, P71, DOI 10.1016/S1096-4959(02)00189-6; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Karlberg EOL, 2003, NAT REV GENET, V4, P391, DOI 10.1038/nrg1063; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Klimek-Tomczak K, 2004, J MOL BIOL, V342, P1131, DOI 10.1016/j.jmb.2004.07.099; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; Lightowlers RN, 1996, BIOCHEM SOC T, V24, P527, DOI 10.1042/bst0240527; Lipshitz HD, 2000, CURR OPIN GENET DEV, V10, P476, DOI 10.1016/S0959-437X(00)00116-7; MacManus JP, 2004, J CEREBR BLOOD F MET, V24, P657, DOI 10.1097/01.WCB.0000123141.67811.91; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; Meinhardt A, 1999, HUM REPROD UPDATE, V5, P108, DOI 10.1093/humupd/5.2.108; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Mihara Motohiro, 2003, Methods Mol Biol, V234, P203; Mikula M, 2003, J MICROBIOL METH, V55, P351, DOI 10.1016/S0167-7012(03)00166-0; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ostrowski J, 2003, BRIT J CANCER, V89, P1493, DOI 10.1038/sj.bjc.6601250; Ostrowski J, 2002, J BIOL CHEM, V277, P6303, DOI 10.1074/jbc.M110267200; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Pedersen SB, 2001, BIOCHEM BIOPH RES CO, V283, P19, DOI 10.1006/bbrc.2001.4736; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; Rousset S, 2004, DIABETES, V53, pS130, DOI 10.2337/diabetes.53.2007.S130; Saleh MC, 2002, DIABETOLOGIA, V45, P174, DOI 10.1007/s00125-001-0737-x; Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280; Suzuki H, 1998, AM J PHYSIOL-RENAL, V275, pF518, DOI 10.1152/ajprenal.1998.275.4.F518; Swanson MS, 1999, METH MOL B, V118, P299; Sylvestre J, 2003, MOL BIOL CELL, V14, P3848, DOI 10.1091/mbc.E03-02-0074; Sylvestre J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r44; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	71	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54599	54609		10.1074/jbc.M406753200	http://dx.doi.org/10.1074/jbc.M406753200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485813	hybrid			2022-12-27	WOS:000225793600086
J	Abajian, C; Yatsunyk, LA; Ramirez, BE; Rosenzweig, AC				Abajian, C; Yatsunyk, LA; Ramirez, BE; Rosenzweig, AC			Yeast Cox17 solution structure and copper(I) binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SUPEROXIDE-DISMUTASE; CRYSTAL-STRUCTURE; METALLOCHAPERONE COX17; CU(I)-BINDING PROTEIN; UNSTRUCTURED PROTEINS; ATX1 METALLOCHAPERONE; BACILLUS-SUBTILIS; TERMINAL DOMAIN; NMR STRUCTURE	Cox17 is a 69-residue cysteine-rich, copper-binding protein that has been implicated in the delivery of copper to the Cu-A and Cu-B centers of cytochrome c oxidase via the copper-binding proteins Sco1 and Cox11, respectively. According to isothermal titration calorimetry experiments, fully reduced Cox17 binds one Cu(I) ion with a Ka of (6.15 +/- 5.83) x 10(6) M-1. The solution structures of both apo and Cu(I)-loaded Cox17 reveal two alpha helices preceded by an extensive, unstructured N-terminal region. This region is reminiscent of intrinsically unfolded proteins. The two structures are very similar overall with residues in the copper-binding region becoming more ordered in Cu(I)-loaded Cox17. Based on the NMR data, the Cu(I) ion has been modeled as two-coordinate with ligation by conserved residues Cys(23) and Cys(26). This site is similar to those observed for the Atx1 family of copper chaperones and is consistent with reported mutagenesis studies. A number of conserved, positively charged residues may interact with complementary surfaces on Sco1 and Cox11, facilitating docking and copper transfer. Taken together, these data suggest that Cox17 is not only well suited to a copper chaperone function but is specifically designed to interact with two different target proteins.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Struct Biol NMR Facil, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58518] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Banci L, 2004, J BIOL CHEM, V279, P34833, DOI 10.1074/jbc.M403655200; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Banci L, 2003, BIOCHEMISTRY-US, V42, P13422, DOI 10.1021/bi0353326; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Brown K, 2000, J BIOL CHEM, V275, P41133, DOI 10.1074/jbc.M008617200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Cobine PA, 2004, J BIOL CHEM, V279, P14447, DOI 10.1074/jbc.M312693200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Elam JS, 2002, ADV PROTEIN CHEM, V60, P151; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Hamza I, 2002, J BIOENERG BIOMEMBR, V34, P381, DOI 10.1023/A:1021254104012; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krezel A, 2001, J INORG BIOCHEM, V84, P77, DOI 10.1016/S0162-0134(00)00212-9; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Palumaa P, 2004, BIOCHEM J, V382, P307, DOI 10.1042/BJ20040360; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ralle M, 2003, J BIOL CHEM, V278, P23163, DOI 10.1074/jbc.M303474200; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350	58	90	92	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53584	53592		10.1074/jbc.M408099200	http://dx.doi.org/10.1074/jbc.M408099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465825	hybrid			2022-12-27	WOS:000225680600094
J	Habelhah, H; Laine, A; Erdjument-Bromage, H; Tempst, P; Gershwin, ME; Bowtell, DDL; Ronai, Z				Habelhah, H; Laine, A; Erdjument-Bromage, H; Tempst, P; Gershwin, ME; Bowtell, DDL; Ronai, Z			Regulation of 2-oxoglutarate (alpha-ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; PROTEASOME PATHWAY; PROTEIN; HOMOLOGS; STRESS; SINA; EPITHELIUM; RESPONSES; HYPOXIA; DISEASE	The 2-oxoglutarate dehydrogenase complex (OGHDC) (also known as the alpha-ketoglutarate dehydrogenase complex) is a rate-limiting enzyme in the mitochondrial Krebs cycle. Here we report that the RING finger ubiquitin-protein isopeptide ligase Siah2 binds to and targets OGDHC-E2 for ubiquitination-dependent degradation. OGDHC-E2 expression and activity are elevated in Siah2(-/-) cells compared with Siah2(-/-) cells. Deletion of the mitochondrial targeting sequence of OGDHC-E2 results in its cytoplasmic localization and rapid proteasome-dependent degradation in Siah2(-/-) but not in Siah2(-/-) cells. Significantly, because of its overexpression or disruption of the mitochondrial membrane potential, the release of OGDHC-E2 from mitochondria to the cytoplasm also results in its concomitant degradation. The role of the Siah family of ligases in the regulation of OGDHC-E2 stability is expected to take place under pathological conditions in which the levels of OGDHC-E2 are altered.	CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; University of California System; University of California Davis; Peter Maccallum Cancer Center	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525; RONAI, ZEEV/0000-0002-3859-0400; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Habelhah, Hasem/0000-0003-4097-1007	NCI NIH HHS [CA78419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gershwin ME, 2000, IMMUNOL REV, V174, P210, DOI 10.1034/j.1600-0528.2002.017402.x; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Harada K, 1999, HEPATOLOGY, V30, P36, DOI 10.1002/hep.510300145; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; JOPLIN RE, 1994, HEPATOLOGY, V19, P1375, DOI 10.1002/hep.1840190610; Lai JCK, 2003, NEUROCHEM RES, V28, P933, DOI 10.1023/A:1023235712524; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Migliaccio C, 1998, J IMMUNOL, V161, P5157; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Sourisseau T, 2001, J CELL SCI, V114, P1409; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tretter L, 1999, ANN NY ACAD SCI, V893, P412, DOI 10.1111/j.1749-6632.1999.tb07867.x; TSUNEYAMA K, 1995, HEPATOLOGY, V21, P1031, DOI 10.1016/0270-9139(95)90251-1; VandeWater J, 1996, HEPATOLOGY, V24, P1079; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	29	46	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53782	53788		10.1074/jbc.M410315200	http://dx.doi.org/10.1074/jbc.M410315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466852	hybrid			2022-12-27	WOS:000225680600116
J	Argyrou, A; Vetting, MW; Blanchard, JS				Argyrou, A; Vetting, MW; Blanchard, JS			Characterization of a new member of the flavoprotein disulfide reductase family of enzymes from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE; ESCHERICHIA-COLI LACKING; REDOX-ACTIVE DISULFIDE; ELECTRON-DENSITY MAPS; X-RAY-STRUCTURE; LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; STAPHYLOCOCCUS-AUREUS; TRYPANOTHIONE REDUCTASE; AZOTOBACTER-VINELANDII	The lpdA (Rv3303c) gene from Mycobacterium tuberculosis encoding a new member of the flavoprotein disulfide reductases was expressed in Escherichia coli, and the recombinant LpdA protein was purified to homogeneity. LpdA is a homotetramer and co-purifies with one molecule of tightly but noncovalently bound FAD and NADP(+) per monomer. Although annotated as a probable lipoamide dehydrogenase in M. tuberculosis, LpdA cannot catalyze reduction of lipoyl substrates, because it lacks one of two cysteine residues involved in dithiol-disulfide interchange with lipoyl substrates and a His-Glu pair involved in general acid catalysis. The crystal structure of LpdA was solved by multiple isomorphous replacement with anomalous scattering, which confirmed the absence of these catalytic residues from the active site. Although LpdA cannot catalyze reduction of disulfide-bonded substrates, it catalyzes the NAD(P) H-dependent reduction of alternative electron acceptors such as 2,6-dimethyl-1,4-benzoquinone and 5-hydroxy-1,4-naphthaquinone. Significant primary deuterium kinetic isotope effects were observed with [4S-H-2]NADH establishing that the enzyme promotes transfer of the C-4-proS hydride of NADH. The absence of an isotope effect with [4S-H-2]NADPH, the low K-m value of 0.5 muM for NADPH, and the potent inhibition of the NADH-dependent reduction of 2,6-dimethyl-1,4-benzoquinone by NADP(+) (K-i similar to 6 nM) and 2'-phospho-ADP-ribose (K-i similar to 800 nM), demonstrate the high affinity of LpdA for 2'-phosphorylated nucleotides and that the physiological substrate/product pair is NADPH/NADP(+) rather than NADH/NAD(+). Modeling of NADP(+) in the active site revealed that LpdA achieves the high specificity for NADP(+) through interactions involving the 2'-phosphate of NADP(+) and amino acid residues that are different from those in glutathione reductase.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Argyrou, A (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	aargyrou@medusa.bioc.aecom.yu.edu; vetting@aecom.yu.edu	Argyrou, Argyrides/AAC-4156-2020	Argyrou, Argyrides/0000-0003-3141-9122	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033449] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33696] Funding Source: Medline; NIGMS NIH HHS [GM33449] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argyrou A, 2004, PROG NUCLEIC ACID RE, V78, P89, DOI 10.1016/S0079-6603(04)78003-4; Argyrou A, 2003, BIOCHEMISTRY-US, V42, P2218, DOI 10.1021/bi020654f; Argyrou A, 2002, BIOCHEMISTRY-US, V41, P14580, DOI 10.1021/bi020376k; Argyrou A, 2001, BIOCHEMISTRY-US, V40, P11353, DOI 10.1021/bi010575o; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; Boonstra B, 1999, J BACTERIOL, V181, P1030, DOI 10.1128/JB.181.3.1030-1034.1999; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; CENAS NK, 1989, BIOCHIM BIOPHYS ACTA, V973, P399, DOI 10.1016/S0005-2728(89)80381-0; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOK PF, 1991, ENZYME MECH ISOTOPE, P207; Corran HS, 1939, BIOCHEM J, V33, P793, DOI 10.1042/bj0330793; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; DIXON M, 1979, ENZYMES, P53; Duax WL, 2003, PROTEINS, V53, P931, DOI 10.1002/prot.10512; French CE, 1997, J BACTERIOL, V179, P2761, DOI 10.1128/jb.179.8.2761-2765.1997; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11757, DOI 10.1021/bi00037a013; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11766, DOI 10.1021/bi00037a014; HORECKER BL, 1948, J BIOL CHEM, V175, P385; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; Macheroux P, 1999, METH MOL B, V131, P1; MASSEY V, 1958, BIOCHIM BIOPHYS ACTA, V30, P205, DOI 10.1016/0006-3002(58)90270-1; MASSEY V, 1960, BIOCHIM BIOPHYS ACTA, V37, P314, DOI 10.1016/0006-3002(60)90239-0; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; OTTOLINA G, 1989, BIOCHIM BIOPHYS ACTA, V998, P173, DOI 10.1016/0167-4838(89)90270-7; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAR; Patel MP, 1999, BIOCHEMISTRY-US, V38, P11827, DOI 10.1021/bi991025h; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; RydstroM J., 1976, ENZYME, V13, P51; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SEGEL IH, 1975, ENZYME KINETICS, P143; SIEGEL JM, 1959, ARCH BIOCHEM BIOPHYS, V82, P288, DOI 10.1016/0003-9861(59)90124-9; STEHLE T, 1990, FEBS LETT, V267, P186, DOI 10.1016/0014-5793(90)80921-5; STEIN AM, 1963, BIOCHEMISTRY-US, V338, P1015; Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1092, DOI 10.1107/S0907444902006510; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; VEEGER C., 1960, BIOCHIM ET BIOPHYS ACTA, V37, P181, DOI 10.1016/0006-3002(60)90108-6; VIENOZINSKIS J, 1990, BIOCHEM J, V269, P101, DOI 10.1042/bj2690101; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	51	11	14	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52694	52702		10.1074/jbc.M410704200	http://dx.doi.org/10.1074/jbc.M410704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456792	hybrid			2022-12-27	WOS:000225493400116
J	Karlsson, C; Korayem, AM; Scherfer, C; Loseva, O; Dushay, MS; Theopold, U				Karlsson, C; Korayem, AM; Scherfer, C; Loseva, O; Dushay, MS; Theopold, U			Proteomic analysis of the Drosophila larval hemolymph clot	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; IMMUNE-RESPONSE; CROSS-LINKING; PROTEINS; IDENTIFICATION; MELANOGASTER; GELSOLIN; PHAGOCYTOSIS; COAGULATION; ACTIVATION	Components of the insect clot, an extremely rapid forming and critical part of insect immunity, are just beginning to be identified ( 1). Here we present a proteomic comparison of larval hemolymph before and after clotting to learn more about this process. This approach was supplemented by the identification of substrates for the enzyme transglutaminase, which plays a role in both vertebrate blood clotting ( as factor XIIIa) and hemolymph coagulation in arthropods. Hemolymph proteins present in lower amounts after clotting include CG8502 ( a protein with a mucin-type domain and a domain with similarity to cuticular components), CG11313 ( a protein with similarity to prophenoloxidase-activating proteases), and two phenoloxidases, lipophorin, a secreted gelsolin, and CG15825, which had previously been isolated from clots ( 2). Proteins whose levels increase after clotting include a ferritin-subunit and two members of the immunoglobulin family with a high similarity to the small immunoglobulin-like molecules involved in mammalian innate immunity. Our results correlate with findings from another study of coagulation ( 2) that involved a different experimental approach. Proteomics allows the isolation of novel candidate clotting factors, leading to a more complete picture of clotting. In addition, our two-dimensional protein map of cell-free Drosophila hemolymph includes many additional proteins that were not found in studies performed on whole hemolymph.	Univ Stockholm, Dept Mol Biol & Funct Genom, S-10691 Stockholm, Sweden; Assiut Univ, Fac Sci, Dept Zool, Assiut 71516, Egypt; Dept Nat Sci, S-14189 Huddinge, Sweden	Stockholm University; Egyptian Knowledge Bank (EKB); Assiut University	Theopold, U (corresponding author), Univ Stockholm, Dept Mol Biol & Funct Genom, S-10691 Stockholm, Sweden.	uli@molbio.su.se	Dushay, Mitchell/B-1029-2009; Theopold, Ulrich/P-7205-2015	Theopold, Ulrich/0000-0002-1009-8254				Andersen SO, 1998, INSECT BIOCHEM MOLEC, V28, P421, DOI 10.1016/S0965-1748(98)00028-9; ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; Asha H, 2003, GENETICS, V163, P203; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Engstrom Y, 2004, TRENDS BIOTECHNOL, V22, P600, DOI 10.1016/j.tibtech.2004.09.002; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Guedes SD, 2003, BIOCHEM BIOPH RES CO, V312, P545, DOI 10.1016/j.bbrc.2003.10.156; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HEINTZELMAN MB, 1993, J MOL BIOL, V230, P709, DOI 10.1006/jmbi.1993.1191; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Ikura K, 1998, ARCH BIOCHEM BIOPHYS, V356, P280, DOI 10.1006/abbi.1998.0775; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Korayem AM, 2004, INSECT BIOCHEM MOLEC, V34, P1297, DOI 10.1016/j.ibmb.2004.09.001; Levy F, 2004, MOL CELL PROTEOMICS, V3, P156, DOI 10.1074/mcp.M300114-MCP200; Li D, 2002, INSECT BIOCHEM MOLEC, V32, P919, DOI 10.1016/S0965-1748(02)00030-9; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Loseva O, 2004, MOL CELL PROTEOMICS, V3, P796, DOI 10.1074/mcp.M400028-MCP200; Naitza S, 2004, MOL IMMUNOL, V40, P887, DOI 10.1016/j.molimm.2003.10.008; Osaki T, 2002, J BIOL CHEM, V277, P40084, DOI 10.1074/jbc.M206773200; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Scherfer C, 2004, CURR BIOL, V14, P625, DOI 10.1016/j.cub.2004.03.030; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Theopold U, 1996, J BIOL CHEM, V271, P12708, DOI 10.1074/jbc.271.22.12708; Theopold U, 2004, TRENDS IMMUNOL, V25, P289, DOI 10.1016/j.it.2004.03.004; Vierstraete E, 2004, BIOCHEM BIOPH RES CO, V317, P1052, DOI 10.1016/j.bbrc.2004.03.150; Vierstraete E, 2004, P NATL ACAD SCI USA, V101, P470, DOI 10.1073/pnas.0304567101; Vierstraete E, 2003, BIOCHEM BIOPH RES CO, V304, P831, DOI 10.1016/S0006-291X(03)00683-1; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6	39	122	130	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52033	52041		10.1074/jbc.M408220200	http://dx.doi.org/10.1074/jbc.M408220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466469	hybrid			2022-12-27	WOS:000225493400040
J	Korporaal, SJA; Relou, IAM; van Eck, M; Strasser, V; Bezemer, M; Gorter, G; van Berkel, TJC; Nimpf, J; Akkerman, JWN; Lenting, PJ				Korporaal, SJA; Relou, IAM; van Eck, M; Strasser, V; Bezemer, M; Gorter, G; van Berkel, TJC; Nimpf, J; Akkerman, JWN; Lenting, PJ			Binding of low density lipoprotein to platelet apolipoprotein E receptor 2 ' results in phosphorylation of p38(MAPK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); KNOCKOUT MICE; RECEPTOR; IDENTIFICATION; REELIN; SITES; LDL; ACTIVATION; FIBRINOGEN; SECRETION	Binding of low density lipoprotein (LDL) to platelets enhances platelet responsiveness to various aggregation-inducing agents. However, the identity of the platelet surface receptor for LDL is unknown. We have previously reported that binding of the LDL component apolipoprotein B100 to platelets induces rapid phosphorylation of p38 mitogen-activated protein kinase (p38(MAPK)). Here, we show that LDL-dependent activation of this kinase is inhibited by receptor-associated protein ( RAP), an inhibitor of members of the LDL receptor family. Confocal microscopy revealed a high degree of co-localization of LDL and a splice variant of the LDL receptor family member apolipoprotein E receptor-2 (apoER2') at the platelet surface, suggesting that apoER2' may contribute to LDL-induced platelet signaling. Indeed, LDL was unable to induce p38(MAPK) activation in platelets of apoER2-deficient mice. Furthermore, LDL bound efficiently to soluble apoER2', and the transient LDL-induced activation of p38(MAPK) was mimicked by an anti-apoER2 antibody. Association of LDL to platelets resulted in tyrosine phosphorylation of apoER2', a process that was inhibited in the presence of PP1, an inhibitor of Src-like tyrosine kinases. Moreover, phosphorylated but not native apoER2' co-precipitated with the Src family member Fgr. This suggests that exposure of platelets to LDL induces association of apoER2' to Fgr, a kinase that is able to activate p38(MAPK). In conclusion, our data indicate that apoER2' contributes to LDL-dependent sensitization of platelets.	Univ Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, Univ Med Ctr Utrecht, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands; Leiden Univ, Gorlaeus Labs, Div Biopharmaceut, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands; Univ Vienna, A-1030 Vienna, Austria; Bioctr, Div Mol Genet, Dept Med Biochem, A-1030 Vienna, Austria	Utrecht University; Utrecht University Medical Center; Utrecht University; Leiden University; Leiden University - Excl LUMC; University of Vienna	Lenting, PJ (corresponding author), Univ Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, Univ Med Ctr Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	p.j.lenting@lab.azu.nl	Lenting, Peter/F-8269-2013; Van Berkel, Theo/ABD-7677-2021; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Nimpf, Johannes/0000-0002-9273-3492; van Eck, Miranda/0000-0003-3936-3194				Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Hackeng CM, 1999, ARTERIOSCL THROM VAS, V19, P239, DOI 10.1161/01.ATV.19.2.239; Hackeng CM, 2000, BIOCHEM J, V349, P231, DOI 10.1042/0264-6021:3490231; Hackeng CM, 1999, THROMB HAEMOSTASIS, V82, P1749, DOI 10.1055/s-0037-1614909; HASSALL DG, 1983, ARTERIOSCLEROSIS, V3, P332, DOI 10.1161/01.ATV.3.4.332; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Hussain MM, 2001, FRONT BIOSCI, V6, pD417, DOI 10.2741/Hussain1; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kamada N, 2001, J Atheroscler Thromb, V8, P1; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; KOLLER E, 1989, J BIOL CHEM, V264, P12412; Korschineck I, 2001, J BIOL CHEM, V276, P13192, DOI 10.1074/jbc.M011795200; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Lutters BCH, 2003, J BIOL CHEM, V278, P33831, DOI 10.1074/jbc.M212655200; Ma SL, 2002, NEUROSCI LETT, V332, P216, DOI 10.1016/S0304-3940(02)00942-4; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Nofer JR, 1997, CIRCULATION, V95, P1370; PEDRENO J, 1992, ARTERIOSCLER THROMB, V12, P1353, DOI 10.1161/01.ATV.12.11.1353; Pedreno J, 1997, ARTERIOSCL THROM VAS, V17, P156, DOI 10.1161/01.ATV.17.1.156; Relou IAM, 2003, J BIOL CHEM, V278, P32638, DOI 10.1074/jbc.M212675200; Relou IAM, 2003, BIOCHEM J, V369, P407, DOI 10.1042/BJ20020410; Relou IAM, 2002, THROMB HAEMOSTASIS, V87, P880; Rice DS, 1998, DEVELOPMENT, V125, P3719; Riddell DR, 1998, BIOCHEM SOC T, V26, pS244, DOI 10.1042/bst026s244; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; SURYA II, 1992, BIOCHIM BIOPHYS ACTA, V1165, P19, DOI 10.1016/0005-2760(92)90070-C; Terpstra V, 2000, ARTERIOSCL THROM VAS, V20, P1860, DOI 10.1161/01.ATV.20.8.1860; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; van der Geer P, 2002, TRENDS CARDIOVAS MED, V12, P160, DOI 10.1016/S1050-1738(02)00154-8; VANWILLIGEN G, 1994, ARTERIOSCLER THROMB, V14, P41, DOI 10.1161/01.ATV.14.1.41; Volf I, 1997, AM J PHYSIOL-CELL PH, V273, pC118, DOI 10.1152/ajpcell.1997.273.1.C118	45	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52526	52534		10.1074/jbc.M407407200	http://dx.doi.org/10.1074/jbc.M407407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459198	hybrid, Green Published			2022-12-27	WOS:000225493400098
J	McEwen, DP; Isom, LL				McEwen, DP; Isom, LL			Heterophilic interactions of sodium channel beta 1 subunits with axonal and glial cell adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; RAT-BRAIN; MYELINATED AXONS; ANKYRIN-G; STRUCTURAL REQUIREMENTS; FUNCTIONAL EXPRESSION; AUXILIARY SUBUNIT; RANVIER FORMATION; INITIAL SEGMENTS; ALPHA-SUBUNITS	Voltage-gated sodium channels localize at high density in axon initial segments and nodes of Ranvier in myelinated axons. Sodium channels consist of a pore-forming alpha subunit and at least one beta subunit. beta1 is a member of the immunoglobulin superfamily of cell adhesion molecules and interacts homophilically and heterophilically with contactin and Nf186. In this study, we characterized beta1 interactions with contactin and Nf186 in greater detail and investigated interactions of beta1 with NrCAM, Nf155, and sodium channel beta2 and beta3 subunits. Using Fc fusion proteins and immunocytochemical techniques, we show that beta1 interacts with the fibronectin-like domains of contactin. beta1 also interacts with NrCAM, Nf155, sodium channel beta2, and Nf186 but not with sodium channel beta3. The interaction of the extracellular domains of beta1 and beta2 requires the region (169)TEEEGKTDGEGNA(181) located in the intracellular domain of beta2. Interaction of beta1 with Nf186 results in increased Na(v)1.2 cell surface density over alpha alone, similar to that shown previously for contactin and beta2. We propose that beta1 is the critical communication link between sodium channels, nodal cell adhesion molecules, and ankyrin(G).	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1150 W Med Ctr Dr,1301 MSRB 3, Ann Arbor, MI 48109 USA.	lisom@umich.edu		Isom, Lori/0000-0002-9479-6729	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS043067, R01NS017965] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH59980] Funding Source: Medline; NINDS NIH HHS [R01NS17965-17, NS43067] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arroyo EJ, 1999, J NEUROCYTOL, V28, P333, DOI 10.1023/A:1007009613484; BERGLUND EO, 1994, GENOMICS, V21, P571, DOI 10.1006/geno.1994.1316; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; Custer AW, 2003, J NEUROSCI, V23, P10032; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; Dupree JL, 1999, J CELL BIOL, V147, P1145, DOI 10.1083/jcb.147.6.1145; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; Gollan L, 2003, J CELL BIOL, V163, P1213, DOI 10.1083/jcb.200309147; Gollan L, 2002, J CELL BIOL, V157, P1247, DOI 10.1083/jcb.200203050; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Isom LL, 2002, FRONT BIOSCI, V7, P12; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jenkins SM, 2002, P NATL ACAD SCI USA, V99, P2303, DOI 10.1073/pnas.042601799; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Lambert S, 1997, J NEUROSCI, V17, P7025; Lustig M, 2001, CURR BIOL, V11, P1864, DOI 10.1016/S0960-9822(01)00586-3; Lustig M, 2001, J COMP NEUROL, V434, P13, DOI 10.1002/cne.1161; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; McEwen DP, 2004, J BIOL CHEM, V279, P16044, DOI 10.1074/jbc.M400856200; Meadows L, 2001, J NEUROCHEM, V76, P1871, DOI 10.1046/j.1471-4159.2001.00192.x; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Rios JC, 2003, J NEUROSCI, V23, P7001, DOI 10.1523/JNEUROSCI.23-18-07001.2003; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Salzer JL, 2003, NEURON, V40, P297, DOI 10.1016/S0896-6273(03)00628-7; Scherer SS, 1999, ANN NY ACAD SCI, V883, P131, DOI 10.1111/j.1749-6632.1999.tb08576.x; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; Simmons DL, 1999, METH MOL B, V96, P39; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; Vabnick I, 1996, J NEUROSCI, V16, P4914; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	53	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52744	52752		10.1074/jbc.M405990200	http://dx.doi.org/10.1074/jbc.M405990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466474	hybrid			2022-12-27	WOS:000225493400121
J	Saerens, D; Kinne, J; Bosmans, E; Wernery, U; Muyldermans, S; Conrath, K				Saerens, D; Kinne, J; Bosmans, E; Wernery, U; Muyldermans, S; Conrath, K			Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ANTIBODIES; RIBOSOME DISPLAY; IN-VITRO; FRAGMENTS; COMPLEX; PROTEIN; IDENTIFICATION; INHIBITION; GENERATION; STABILITY	The importance of the lymphocyte source to generate hybridomas or to construct antibody gene libraries from which to identify potent monoclonal antibodies is understudied. However, the few comparative studies that exist seem to favor the lymph node tissue as a B-cell source. Here the peripheral blood and lymph node lymphocytes of a dromedary immunized with prostate-specific antigen (PSA) have been employed to clone two independent gene banks of the variable domains of heavy-chain antibodies (i.e. the VHHs). Several PSA-specific VHHs were retrieved after panning of these phage-displayed VHH libraries. Some of them were derived from the same B-cell lineage, possibly reflecting the restricted primary repertoire of heavy-chain antibodies. Other binders originated from different B-cell lineages and apparently converged toward a striking homologous amino acid sequence motif in their CDR3. This illustrates the strong somatic hypermutation and stringent antigen-driven selection ongoing in these animals. Although the various antigen binders exhibit a broad range of kinetic rate constants for their interaction with the PSA, leading to equilibrium constants from 70 pM to 100 nM, no significant difference existed between the binders from the two B-cell sources. The VHHs of both libraries were categorized in three groups based on non-overlapping epitopes. Some of these VHHs could inhibit and others could enhance the proteolytic activity of the antigen. Remarkably, VHHs seem to sense or induce conformational changes on different PSA isoforms, a feature that might be exploited to study the PSA conformational flexibility and to discriminate the stages of prostate cancer.	Free Univ Brussels VIB, Cellular Immunol Lab, Dept Cellular & Mol Interact, B-1050 Brussels, Belgium; Cent Vet Res Lab, Dubai, U Arab Emirates; DiaMed Eurogen NV, B-2300 Turnhout, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Saerens, D (corresponding author), Free Univ Brussels VIB, Cellular Immunol Lab, Dept Cellular & Mol Interact, Pleinlaan 2, B-1050 Brussels, Belgium.	dsaerens@vub.ac.be	Saerens, Dirk/B-9162-2008; Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575; Saerens, Dirk/0000-0001-8894-8039				Basalp A, 2003, HYBRIDOMA HYBRIDOM, V22, P329, DOI 10.1089/153685903322538863; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Carvalho AL, 2002, J MOL BIOL, V322, P325, DOI 10.1016/S0022-2836(02)00705-2; Conrath KE, 2003, DEV COMP IMMUNOL, V27, P87, DOI 10.1016/S0145-305X(02)00071-X; Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Ledeboer AM, 2002, J DAIRY SCI, V85, P1376, DOI 10.3168/jds.S0022-0302(02)74204-5; Linton HJ, 2003, CLIN CHEM, V49, P253, DOI 10.1373/49.2.253; Lipovsek D, 2004, J IMMUNOL METHODS, V290, P51, DOI 10.1016/j.jim.2004.04.008; Michel S, 1999, CLIN CHEM, V45, P638; Mikolajczyk SD, 2004, CLIN BIOCHEM, V37, P519, DOI 10.1016/j.clinbiochem.2004.05.016; Mikolajczyk SD, 2002, UROLOGY, V59, P797, DOI 10.1016/S0090-4295(01)01605-3; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Pleschberger M, 2004, BIOCONJUGATE CHEM, V15, P664, DOI 10.1021/bc049964w; Sambrook J., 2001, MOL CLONING LAB MANU; Sieber V, 1998, NAT BIOTECHNOL, V16, P955, DOI 10.1038/nbt1098-955; Sinkora M, 2000, MOL IMMUNOL, V37, P1025, DOI 10.1016/S0161-5890(01)00022-0; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200; Thomassen YE, 2002, ENZYME MICROB TECH, V30, P273, DOI 10.1016/S0141-0229(01)00497-5; Wan XS, 2003, PROSTATE, V56, P131, DOI 10.1002/pros.10247; Wu P, 2000, EUR J BIOCHEM, V267, P6212, DOI 10.1046/j.1432-1327.2000.01696.x; Yau KYF, 2003, J IMMUNOL METHODS, V281, P161, DOI 10.1016/j.jim.2003.07.011; Yip YL, 1997, IMMUNOTECHNOLOGY, V3, P195, DOI 10.1016/S1380-2933(97)00013-4; Zhang JB, 2004, J MOL BIOL, V335, P49, DOI 10.1016/j.jmb.2003.09.034	36	113	141	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51965	51972		10.1074/jbc.M409292200	http://dx.doi.org/10.1074/jbc.M409292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459193	hybrid			2022-12-27	WOS:000225493400032
J	Ueda, T; Kato, A; Ogawa, Y; Torizawa, T; Kuramitsu, S; Iwai, S; Terasawa, H; Shimada, I				Ueda, T; Kato, A; Ogawa, Y; Torizawa, T; Kuramitsu, S; Iwai, S; Terasawa, H; Shimada, I			NMR study of repair mechanism of DNA photolyase by FAD-induced paramagnetic relaxation enhancement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SUBSTRATE COMPLEX; BLUE-LIGHT PHOTORECEPTOR; ABSOLUTE ACTION SPECTRUM; LONG-RANGE STRUCTURE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; RECOGNITION MECHANISM; ANACYSTIS-NIDULANS; DENATURED STATE	Cyclobutane pyrimidine dimer (CPD) photolyases, which contain FAD as a cofactor, use light to repair CPDs. We performed structural analyses of the catalytic site of the Thermus thermophilus CPD photolyase-DNA complex, using FAD-induced paramagnetic relaxation enhancement (PRE). The distances between the tryptophan residues and the FAD calculated from the PRE agree well with those observed in the x-ray structure ( with an error of <3 angstrom). Subsequently, a single-stranded DNA containing C-13-labeled CPD was prepared, and the FAD-induced PRE of the NMR resonances from the CPD lesion in complex with the CPD photolyase was investigated. The distance between the FAD and the CPD calculated from the PRE is 16 +/- 3 angstrom. The FAD-induced PRE was also observed in the CPD photolyase-double-stranded DNA complex. Based on these results, a model of the CPD photolyase-DNA complex was constructed, and the roles of Arg-201, Lys-240, Trp-247, and Trp-353 in the CPD-repair reaction are discussed.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp						AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Antony J, 2000, J AM CHEM SOC, V122, P1057, DOI 10.1021/ja993784t; Battiste JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/bi000060h; Carell T, 1997, ANGEW CHEM INT EDIT, V36, P1461, DOI 10.1002/anie.199714611; Carell T, 1998, EUR J ORG CHEM, V1998, P1245; Christine KS, 2002, J BIOL CHEM, V277, P38339, DOI 10.1074/jbc.M206531200; Gillespie JR, 1997, J MOL BIOL, V268, P158, DOI 10.1006/jmbi.1997.0954; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; HARM H, 1970, MUTAT RES, V10, P307, DOI 10.1016/0027-5107(70)90045-X; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Iwahara J, 2004, J AM CHEM SOC, V126, P5879, DOI 10.1021/ja031580d; Iwahara J, 2003, J AM CHEM SOC, V125, P6634, DOI 10.1021/ja034488q; Johnson PE, 1999, J MOL BIOL, V287, P609, DOI 10.1006/jmbi.1999.2627; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; KAVARNOS GJ, 1993, FUNDAMENTALS PHOTOIN, P185; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; KIM ST, 1994, J AM CHEM SOC, V116, P3115, DOI 10.1021/ja00086a048; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Langenbacher T, 1997, J AM CHEM SOC, V119, P10532, DOI 10.1021/ja9721024; Lietzow MA, 2002, J MOL BIOL, V322, P655, DOI 10.1016/S0022-2836(02)00847-1; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MacFarlane AW, 2001, BIOCHEMISTRY-US, V40, P15203, DOI 10.1021/bi0114224; Mal TK, 2002, J AM CHEM SOC, V124, P14002, DOI 10.1021/ja028109p; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 1987, J BIOL CHEM, V262, P478; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Schelvis JPM, 2003, J PHYS CHEM B, V107, P12352, DOI 10.1021/jp034209l; SOLOMON I, 1956, J CHEM PHYS, V25, P261, DOI 10.1063/1.1742867; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; Torizawa T, 2004, J BIOL CHEM, V279, P32950, DOI 10.1074/jbc.M404536200; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m	46	17	17	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52574	52579		10.1074/jbc.M409942200	http://dx.doi.org/10.1074/jbc.M409942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465818	hybrid			2022-12-27	WOS:000225493400104
J	Ling, JH; Ainol, L; Zhang, L; Yu, XP; Pi, WH; Tuan, D				Ling, JH; Ainol, L; Zhang, L; Yu, XP; Pi, WH; Tuan, D			HS2 enhancer function is blocked by a transcriptional terminator inserted between the enhancer and the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; RNA-POLYMERASE-II; BETA-GLOBIN GENE; HYPERSENSITIVE SITES; INTERGENIC TRANSCRIPTION; LAC OPERATOR; REPRESSOR; ACTIVATION; DISTANCE; EXPRESSION	The HS2 enhancer in the beta-globin locus control region regulates transcription of the globin genes 10 - 50 kb away. How the HS2 enhancer acts over this distance is not clearly understood. Earlier studies show that in erythroid cells the HS2 enhancer initiates synthesis of intergenic RNAs from sites within and downstream of the enhancer, and the enhancer-initiated RNAs are transcribed through the intervening DNA into the cis-linked promoter and gene. To investigate the functional significance of the enhancer-initiated transcription, here we inserted the lac operator sequence in the intervening DNA between the HS2 enhancer and the epsilon-globin promoter in reporter plasmids and integrated the plasmids into erythroid K562 cells expressing the lac repressor protein. We found that the interposed lac operator/repressor complex blocked the elongation of enhancer-initiated transcription through the intervening DNA and drastically reduced HS2 enhancer function as measured by the level of mRNA synthesized from the epsilon-globin promoter. The results indicate that the tracking and transcription mechanism of the HS2 enhancer-assembled transcriptional machinery from the enhancer through the intervening DNA into the cis-linked promoter can mediate enhancer-promoter interaction over a long distance.	Med Coll Georgia, Dept Biochem & Mol Biol, Sch Med, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Tuan, D (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Sch Med, Augusta, GA 30912 USA.	dtuanlo@mail.mcg.edu		Yu, Xiuping/0000-0003-2844-7026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062308, R01HL039948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62308, HL39948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN M, 1983, CELL, V35, P187; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1999, MOL CELL BIOL, V19, P3062; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CHAO MV, 1980, BIOCHEMISTRY-US, V19, P3260, DOI 10.1021/bi00555a025; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; Drewell RA, 2002, P NATL ACAD SCI USA, V99, P16853, DOI 10.1073/pnas.222671199; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Gilbert W, 1972, Ciba Found Symp, V7, P245; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; Hogga I, 2002, DEVELOPMENT, V129, P4915; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; Kong SM, 1997, MOL CELL BIOL, V17, P3955, DOI 10.1128/MCB.17.7.3955; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; Ling JH, 2003, NUCLEIC ACIDS RES, V31, P4582, DOI 10.1093/nar/gkg646; Ling JH, 2002, J VIROL, V76, P2410, DOI 10.1128/JVI.76.5.2410-2423.2002; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; Plant KE, 2001, MOL CELL BIOL, V21, P6507, DOI 10.1128/MCB.21.19.6507-6514.2001; *PROM, 1989, B PROM, V80; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ramchandran R, 2000, AM J HEMATOL, V65, P14, DOI 10.1002/1096-8652(200009)65:1<14::AID-AJH3>3.0.CO;2-F; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1992, P NATL ACAD SCI USA, V89, P11219, DOI 10.1073/pnas.89.23.11219; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554	39	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51704	51713		10.1074/jbc.M404039200	http://dx.doi.org/10.1074/jbc.M404039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15465832	hybrid			2022-12-27	WOS:000225355800127
J	Liu, SY; Yu, SX; Hasegawa, Y; LaPushin, R; Xu, HJ; Woodgett, JR; Mills, GB; Fang, XJ				Liu, SY; Yu, SX; Hasegawa, Y; LaPushin, R; Xu, HJ; Woodgett, JR; Mills, GB; Fang, XJ			Glycogen synthase kinase 3 beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; BETA-CATENIN; LYSOPHOSPHATIDIC ACID; CELL-LINES; DIFFERENTIAL REGULATION; XENOPUS EMBRYOS; AXIS FORMATION; MAP KINASES; PHOSPHORYLATION	The c-Jun N-terminal kinase (JNK)/stress activated protein kinase is preferentially activated by stress stimuli. Growth factors, particularly ligands for G protein-coupled receptors, usually induce only modest JNK activation, although they may trigger marked activation of the related extracellular signal-regulated kinase. In the present study, we demonstrated that homozygous disruption of glycogen synthase kinase 3beta (GSK-3beta) dramatically sensitized mouse embryonic fibroblasts (MEFs) to JNK activation induced by lysophosphatidic acid (LPA) and sphingosine-1-phosphate, two prototype ligands for G protein-coupled receptors. To a lesser degree, a lack of GSK-3beta also potentiated JNK activation in response to epidermal growth factor. In contrast, the absence of GSK-3beta decreased UV light-induced JNK activation. The increased JNK activation induced by LPA in GSK-3beta null MEFs was insufficient to trigger apoptotic cell death or growth inhibition. Instead, the increased JNK activation observed in GSK-3beta-/- MEFs was associated with an increased proliferative response to LPA, which was reduced by the inhibition of JNK. Ectopic expression of GSK-3beta in GSK-3beta-negative MEFs restrained LPA-triggered JNK phosphorylation and induced a concomitant decrease in the mitogenic response to LPA compatible with GSK-3beta through the inhibition of JNK activation, thus limiting LPA-induced cell proliferation. Mutation analysis indicated that GSK-3beta kinase activity was required for GSK-3beta to optimally inhibit LPA-stimulated JNK activation. Thus GSK-3beta serves as a physiological switch to specifically repress JNK activation in response to LPA, sphingosine-1-phosphate, or the epidermal growth factor. These results reveal a novel role for GSK-3beta in signal transduction and cellular responses to growth factors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Liu, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, POB 0814,1515 Holcombe Blvd, Houston, TX 77030 USA.	sliu@mail.mdanderson.org	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NATIONAL CANCER INSTITUTE [R01CA082716, P30CA016672, P01CA064602] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [12043] Funding Source: Medline; NCI NIH HHS [CA82716, P01 CA064602, P30 CA016672, R01 CA082716, CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bost F, 1999, MOL CELL BIOL, V19, P1938; Castillo SS, 2003, J NUTR, V133, P3343, DOI 10.1093/jn/133.11.3343; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; GOODE N, 1992, J BIOL CHEM, V267, P16878; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Jacobs-Helber SM, 2004, BLOOD, V104, P696, DOI 10.1182/blood-2003-05-1754; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pear Warren S., 1997, P41; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Sasaki T, 1998, J BIOCHEM, V124, P934, DOI 10.1093/oxfordjournals.jbchem.a022210; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shin SY, 2002, EXP MOL MED, V34, P444, DOI 10.1038/emm.2002.62; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200	48	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51075	51081		10.1074/jbc.M408607200	http://dx.doi.org/10.1074/jbc.M408607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15466414	Green Accepted, hybrid			2022-12-27	WOS:000225355800053
J	Buss, H; Dorrie, A; Schmitz, ML; Hoffmann, E; Resch, K; Kracht, M				Buss, H; Dorrie, A; Schmitz, ML; Hoffmann, E; Resch, K; Kracht, M			Constitutive and interleukin-1-inducible phosphorylation of p65 NF-kappa B at serine 536 is mediated by multiple protein kinases including I kappa B kinase (IKK)-alpha, IKK beta, IKK epsilon, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LIVER DEGENERATION; RELA/P65 SUBUNIT; MICE LACKING; ZETA-PKC; ACTIVATION; P53; DEGRADATION; DISRUPTION; INDUCTION	Phosphorylation of NF-kappaB p65(RelA) serine 536 is physiologically induced in response to a variety of proinflammatory stimuli, but the responsible pathways have not been conclusively unraveled, and the function of this phosphorylation is largely elusive. In contrast to previous studies, we found no evidence for a role of c-Jun N-terminal kinase, p38 kinase, extracellular signal-regulated kinase, or phosphatidylinositol 3-kinase in interleukin-1- or tumor necrosis factor-induced Ser-536 phosphorylation, as revealed by pharmacological inhibitors. We were not able to suppress Ser-536 phosphorylation by either RNA interference directed at IkappaB kinase (IKK)-alpha/beta (the best characterized Ser-536 kinases so far) or the IKKbeta inhibitor SC-514 or dominant negative mutants of either IKK. A green fluorescent protein p65 fusion protein was phosphorylated at Ser-536 in the absence of IKK activation, suggesting the existence of IKKalpha/beta-independent Ser-536 kinases. Chromatographic fractionation of cell extracts allowed the identification of two distinct enzymatic activities phosphorylating Ser-536. Peak 1 represents an unknown kinase, whereas peak 2 contained IKKalpha, IKKbeta, IKKepsilon, and TBK1. Overexpressed IKKepsilon and TBK1 phosphorylate Ser-536 in vivo and in vitro. Reconstitution of mutant p65 proteins in p65-deficient fibroblasts that either mimicked phosphorylation (S536D) or preserved a predicted hydrogen bond between Ser-536 and Asp-533 (S536N) revealed that phosphorylation of Ser-536 favors interleukin-8 transcription mediated by TATA-binding protein-associated factor II31, a component of TFIID. In the absence of phosphorylation, the hydrogen bond favors binding of the corepressor amino-terminal enhancer of split to the p65 terminal transactivation domain. Collectively, our results provide evidence for at least five kinases that converge on Ser-536 of p65 and a novel function for this phosphorylation site in the recruitment of components of the basal transcriptional machinery to the interleukin-8 promoter.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	Hannover Medical School; University of Bern	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X; Hoffmann-Lucke, Elke/0000-0002-2437-0140				Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; KRACHT M, 1994, BIOCHEM J, V302, P897, DOI 10.1042/bj3020897; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	56	296	305	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55633	55643		10.1074/jbc.M409825200	http://dx.doi.org/10.1074/jbc.M409825200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489227	hybrid			2022-12-27	WOS:000225960800082
J	Matsuda, N; Kobayashi, H; Katoh, H; Ogawa, T; Futatsugi, L; Nakamura, T; Bakker, EP; Uozumi, N				Matsuda, N; Kobayashi, H; Katoh, H; Ogawa, T; Futatsugi, L; Nakamura, T; Bakker, EP; Uozumi, N			Na+-dependent K+ uptake ktr system from the cyanobacterium Synechocystis sp PCC 6803 and its role in the early phases of cell adaptation to hyperosmotic shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POTASSIUM UPTAKE; HKT TRANSPORTERS; PHOSPHATE SYNTHASE; OSMOTIC ADJUSTMENT; STRUCTURAL MODELS; BACILLUS-SUBTILIS; GENE-CLUSTER; SODIUM; EXPRESSION	Transmembrane ion transport processes play a key role in the adaptation of cells to hyperosmotic conditions. Previous work has shown that the disruption of a ktrB/ntpJ-like putative Na+/K+ transporter gene in the cyanobacterium Synechocystis sp. PCC 6803 confers increased Na+ sensitivity, and inhibits HCO3- uptake. Here, we report on the mechanistic basis of this effect. Heterologous expression experiments in Escherichia coli show that three Synechocystis genes are required for K+ transport activity. They encode an NAD(+)-binding peripheral membrane protein ( ktrA; sll0493), an integral membrane protein, belonging to a superfamily of K+ transporters ( ktrB; formerly ntpJ; slr1509), and a novel type of ktr gene product, not previously found in Ktr systems (ktrE; slr1508). In E. coli, Synechocystis KtrABE-mediated K+ uptake occurred with a moderately high affinity (K-m of about 60 muM), and depended on both Na+ and a high membrane potential, but not on ATP. KtrABE neither mediated Na+ uptake nor Na+ efflux. In Synechocystis sp. PCC 6803, KtrB-mediated K+ uptake required Na+ and was inhibited by protonophore. A DeltaktrB strain was sensitive to long term hyperosmotic stress elicited by either NaCl or sorbitol. Hyperosmotic shock led initially to loss of net K+ from the cells. The DeltaktrB cells shocked with sorbitol failed to reaccumulate K+ up to its original level. These data indicate that in strain PCC 6803 K+ uptake via KtrABE plays a crucial role in the early phase of cell turgor regulation after hyperosmotic shock.	Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Niigata Univ Pharm & Appl Life Sci, Fac Pharm, Niigata 9502081, Japan; Univ Osnabruck, Abt Mikrobiol, D-49076 Osnabruck, Germany	Nagoya University; Chiba University; Niigata University; University Osnabruck	Uozumi, N (corresponding author), Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan.	uozumi@agr.nagoya-u.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019	Uozumi, Nobuyuki/0000-0003-4268-1126				BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BAKKER EP, 1990, FEMS MICROBIOL LETT, V75, P319, DOI 10.1111/j.1574-6968.1990.tb04105.x; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; Berry S, 2003, FEBS LETT, V548, P53, DOI 10.1016/S0014-5793(03)00729-4; Berthomieu P, 2003, EMBO J, V22, P2004, DOI 10.1093/emboj/cdg207; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Fairbairn DJ, 2000, PLANT MOL BIOL, V43, P515, DOI 10.1023/A:1006496402463; Ferjani A, 2003, PLANT PHYSIOL, V131, P1628, DOI 10.1104/pp.102.017277; Garciadeblas B, 2003, PLANT J, V34, P788, DOI 10.1046/j.1365-313X.2003.01764.x; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; GOHMANN S, 1994, MICROB PATHOGENESIS, V16, P53, DOI 10.1006/mpat.1994.1005; Harms C, 2001, MICROBIOL-SGM, V147, P2991, DOI 10.1099/00221287-147-11-2991; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Holtmann G, 2003, J BACTERIOL, V185, P1289, DOI 10.1128/JB.185.4.1289-1298.2003; Horie T, 2001, PLANT J, V27, P129, DOI 10.1046/j.1365-313x.2001.01077.x; Inaba M, 2001, J BACTERIOL, V183, P1376, DOI 10.1128/JB.183.4.1376-1384.2001; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; Kawano M, 1999, FEMS MICROBIOL LETT, V176, P449; Kawano M, 2000, J BACTERIOL, V182, P2507, DOI 10.1128/JB.182.9.2507-2512.2000; Lee SJ, 2004, MOL CELL, V14, P153, DOI 10.1016/S1097-2765(04)00202-3; Liu WH, 2001, PLANT PHYSIOL, V127, P283, DOI 10.1104/pp.127.1.283; Marin K, 2002, J BACTERIOL, V184, P2870, DOI 10.1128/JB.184.11.2870-2877.2002; Marin K, 1998, J BACTERIOL, V180, P4843, DOI 10.1128/JB.180.18.4843-4849.1998; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; Nakamura T, 1998, J BACTERIOL, V180, P3491, DOI 10.1128/JB.180.13.3491-3494.1998; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; OHYAMA T, 1994, J BACTERIOL, V176, P4311, DOI 10.1128/jb.176.14.4311-4315.1994; Oren A, 1999, MICROBIOL MOL BIOL R, V63, P334, DOI 10.1128/MMBR.63.2.334-348.1999; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; REED RH, 1985, MAR BIOL, V88, P1, DOI 10.1007/BF00393037; REED RH, 1985, FEMS MICROBIOL LETT, V28, P225, DOI 10.1016/0378-1097(85)90086-2; RHOADS DB, 1977, J BIOL CHEM, V252, P1394; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Rus A, 2001, P NATL ACAD SCI USA, V98, P14150, DOI 10.1073/pnas.241501798; Sakuma T, 1998, BBA-BIOENERGETICS, V1363, P231, DOI 10.1016/S0005-2728(97)00102-3; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Shibata M, 2002, J BIOL CHEM, V277, P18658, DOI 10.1074/jbc.M112468200; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; STUMPE S, 1996, HDB BIOL PHYS, P473; Su H, 2003, PLANT MOL BIOL, V52, P967, DOI 10.1023/A:1025445612244; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tchernov D, 2001, J BIOL CHEM, V276, P23450, DOI 10.1074/jbc.M101973200; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; Uozumi N, 2001, AM J PHYSIOL-CELL PH, V281, pC733, DOI 10.1152/ajpcell.2001.281.3.C733; Walderhaug M.O., 1987, ION TRANSPORT PROKAR, P85; Wang L, 2002, J BACTERIOL, V184, P2620, DOI 10.1128/JB.184.10.2620-2625.2002; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2521, DOI 10.1099/00221287-136-12-2521; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527	65	72	76	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54952	54962		10.1074/jbc.M407268200	http://dx.doi.org/10.1074/jbc.M407268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15459199	hybrid			2022-12-27	WOS:000225793600125
J	Rosales, JL; Ernst, JD; Hallows, J; Lee, KY				Rosales, JL; Ernst, JD; Hallows, J; Lee, KY			GTP-dependent secretion from neutrophils is regulated by Cdk5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-5 CDK5; BOVINE BRAIN; PROTEIN; PHOSPHORYLATION; EXOCYTOSIS; MEMBRANE; P35; ACTIVATION; EXPRESSION; RECEPTOR	We have previously shown evidence for the existence of a calcium-independent, GTP-regulated mechanism of secretion from neutrophils, but this secretory mechanism remains to be fully elucidated. Cyclin-dependent kinase 5 (Cdk5), the various substrates of which include Munc18 and synapsin 1, has been implicated in neuronal secretion. Although the Cdk5 activator, p35, and Cdk5p35 activity are primarily associated with neurons, we report here that p35 also exists in neutrophils and that an active Cdk5-p35 complex is present in these cells. Cdk5-p35 activity in human neutrophils is mostly localized in secretory granules, which show an increase in Cdk5-p35 level and activity upon GTP stimulation. The potent Cdk5 inhibitor, roscovitine, completely blocks GTP-stimulated granule Cdk5 activity, which accompanies lactoferrin secretion from neutrophil-specific granules. Roscovitine also inhibits GTP-induced lactoferrin secretion and surface localization of the secretion markers, CD63 and CD66b, to a certain extent. Furthermore, neutrophils from wild-type mice treated with roscovitine and neutrophils from p35(-/-) mice exhibit comparable surface expression levels of both CD63 and CD66b upon GTP stimulation. Although our data suggest that other molecules control GTP-induced secretion from neutrophils, it is clear that Cdk5-p35 is required to elicit the maximum GTP-induced secretory response. Our observation that multiple proteins in neutrophil granules serve as specific substrates of Cdk5 further supports the premise that the kinase is a key component of the GTP-regulated secretory apparatus in neutrophils.	Univ Calgary, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	University of Calgary; University of Washington; University of Washington Seattle; New York University	Rosales, JL (corresponding author), Univ Calgary, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada.	rosales@ucalgary.ca		Ernst, Joel/0000-0001-9951-6207; Rosales, Jesusa/0000-0002-2543-3801				Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X; DEHAAS M, 1994, BLOOD, V84, P3885, DOI 10.1182/blood.V84.11.3885.bloodjournal84113885; Downey GP, 1998, J IMMUNOL, V160, P434; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Gao CY, 1997, DEV GENET, V20, P267; Hallows JL, 2003, J NEUROSCI, V23, P10633; Kaldi K, 2002, J LEUKOCYTE BIOL, V71, P695; KUIJPERS TW, 1991, BLOOD, V78, P1105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lard LR, 1999, J LEUKOCYTE BIOL, V66, P411, DOI 10.1002/jlb.66.3.411; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Meshki J, 2004, AM J PHYSIOL-CELL PH, V286, pC264, DOI 10.1152/ajpcell.00287.2003; NIESSEN HWM, 1992, CELL SIGNAL, V4, P501, DOI 10.1016/0898-6568(92)90019-5; Qi RZ, 2004, FEBS LETT, V561, P177, DOI 10.1016/S0014-5793(04)00174-7; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Rosales JL, 1997, J IMMUNOL, V159, P6195; Rosales JL, 2000, J CELL BIOCHEM, V80, P37; Sahlgren CM, 2003, MOL CELL BIOL, V23, P5090, DOI 10.1128/MCB.23.14.5090-5106.2003; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Smith D, 2003, NEUROSIGNALS, V12, P239, DOI 10.1159/000074626; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tapper H, 1997, J IMMUNOL, V159, P409; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Xin XN, 2004, J CELL SCI, V117, P4739, DOI 10.1242/jcs.01333	33	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53932	53936		10.1074/jbc.M408467200	http://dx.doi.org/10.1074/jbc.M408467200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492003	hybrid			2022-12-27	WOS:000225793600006
J	Fessenden, JD; Feng, W; Pessah, IN; Allen, PD				Fessenden, JD; Feng, W; Pessah, IN; Allen, PD			Mutational analysis of putative calcium binding motifs within the skeletal ryanodine receptor isoform, RyR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SITES; IDENTIFICATION; ACTIVATION; PROTEIN; LOCALIZATION; INACTIVATION; SENSITIVITY; EXPRESSION; CAFFEINE	The functional relevance of putative Ca2+ binding motifs previously identified with Ca2+ overlay binding analysis within the skeletal muscle ryanodine receptor isoform (RyR1) was examined using mutational analysis. EF hands between amino acid positions 4081 and 4092 (EF1) and 4116 and 4127 (EF2) were scrambled singly or in combination within the full-length rabbit RyR1 cDNA. These cDNAs were expressed in 1B5 RyR-deficient myotubes and channel function assessed using Ca2+-imaging techniques, [H-3]ryanodine binding measurements, and single channel experiments. In intact myotubes, these mutations did not affect functional responses to either depolarization or RyR agonists (caffeine, 4-chloro-m-cresol) compared with wtRyR1. However, in [H-3]ryanodine binding measurements, both Ca2+ activation and inhibition of the EF1 mutant was significantly altered compared with wtRyR1. No high affinity [H-3]ryanodine binding was observed in membranes expressing the EF2 mutation, although in single channel measurements, the EF2-disrupted channel could be activated by micromolar Ca2+ concentrations. In addition, micromolar levels of ryanodine placed these channels into the classical half-conductance state, thus indicating that occupancy of high affinity ryanodine binding sites is not required for ryanodine-induced subconductance states in RyR1. Disruption of three additional putative RyR1 calcium binding motifs located between amino acid positions 4254 and 4265 (EF3), 4407 and 4418 (EF4), or 4490 and 4502 (EF5) either singly or in combination (EF3-5) did not affect functional responses in 1B5 myotubes except that the EC50 for caffeine activation for the EF3 construct was significantly increased compared with wtRyR1. However, in [H-3]ryanodine binding experiments, the Ca2+-dependent activation and inactivation of mutated RyRs containing EF3, EF4, or EF5 was unaffected when compared with wtRyR1.	Brigham & Womens Hosp, Dept Anesthesia Res, Boston, MA 02115 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis	Fessenden, JD (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	fessenden@bbri.org	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Feng W, 1999, MOL PHARMACOL, V55, P821; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Fessenden JD, 2003, J BIOL CHEM, V278, P28727, DOI 10.1074/jbc.M303821200; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; HADAD N, 1994, J BIOL CHEM, V269, P24864; Hamada T, 2002, J MOL BIOL, V324, P123, DOI 10.1016/S0022-2836(02)01032-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tu HP, 2003, BIOPHYS J, V85, P290, DOI 10.1016/S0006-3495(03)74474-9; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Xiong H, 1998, BIOCHEMISTRY-US, V37, P4804, DOI 10.1021/bi971198b; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	30	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53028	53035		10.1074/jbc.M411136200	http://dx.doi.org/10.1074/jbc.M411136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469935	hybrid			2022-12-27	WOS:000225680600029
J	Paithoonrangsarid, K; Shumskaya, MA; Kanesaki, Y; Satoh, S; Tabata, S; Los, DA; Zinchenko, VV; Hayashi, H; Tanticharoen, M; Suzuki, I; Murata, N				Paithoonrangsarid, K; Shumskaya, MA; Kanesaki, Y; Satoh, S; Tabata, S; Los, DA; Zinchenko, VV; Hayashi, H; Tanticharoen, M; Suzuki, I; Murata, N			Five histidine kinases perceive osmotic stress and regulate distinct sets of genes in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; SP PCC-6803; ESCHERICHIA-COLI; SALT STRESS; EXPRESSION; PROTEINS; PERCEPTION; PATHWAY; HIK33	Microorganisms respond to hyperosmotic stress via changes in the levels of expression of large numbers of genes. Such responses are essential for acclimation to a new osmotic environment. To identify factors involved in the perception and transduction of signals caused by hyperosmotic stress, we examined the response of Synechocystis sp. PCC 6803, which has proven to be a particularly useful microorganism in similar analyses. We screened knockout libraries of histidine kinases (Hiks) and response regulators (Rres) in Synechocystis by DNA microarray and slot-blot hybridization analyses, and we identified several two-component systems, which we designated Hik-Rre systems, namely, Hik33-Rre31, Hik34-Rre1, and Hik10-Rre3, as well as Hik16-Hik41-Rre17, as the transducers of hyperosmotic stress. We also identified Hik2-Rre1 as a putative additional two-component system. Each individual two-component system regulated the transcription of a specific group of genes that were responsive to hyperosmotic stress.	Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan; Natl Ctr Genet Engn & Biotechnol, Bangkok 12120, Thailand; Russian Acad Sci, Inst Plant Physiol, Moscow 127276, Russia; Ehime Univ, Satellite Venture Business Lab, Matsuyama, Ehime 7908577, Japan; Kazusa DNA Res Inst, Dept Plant Gene Res, Chiba 2920818, Japan; Moscow MV Lomonosov State Univ, Dept Genet, Moscow 119899, Russia; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Russian Academy of Sciences; Timiryazev Institute of Plant Physiology; Ehime University; Kazusa DNA Research Institute; Lomonosov Moscow State University; Graduate University for Advanced Studies - Japan	Murata, N (corresponding author), Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	Shumskaya, Maria/P-5972-2017; Kanesaki, Yu/J-3817-2017; Murata, Norio/E-6569-2010; Zinchenko, Vladislav V/K-3363-2017; Murata, Norio/O-7945-2019; LOS, Dmitry A./C-6608-2013	Shumskaya, Maria/0000-0001-7916-462X; Kanesaki, Yu/0000-0003-3537-9789; Zinchenko, Vladislav V/0000-0003-1931-2509; Murata, Norio/0000-0002-6605-5800; LOS, Dmitry A./0000-0002-0142-7853; , Kalyanee/0000-0001-9121-3295				COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Glockner G, 2000, J MOL EVOL, V51, P382; Inaba M, 2003, J BIOL CHEM, V278, P12191, DOI 10.1074/jbc.M212204200; Jiang M, 2000, MOL MICROBIOL, V38, P535, DOI 10.1046/j.1365-2958.2000.02148.x; Kaneko T, 2003, DNA RES, V10, P221, DOI 10.1093/dnares/10.5.221; Kaneko T, 1996, DNA Res, V3, P109; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Koretke KK, 2000, MOL BIOL EVOL, V17, P1956, DOI 10.1093/oxfordjournals.molbev.a026297; Los D A, 2000, Sci STKE, V2000, ppe1, DOI 10.1126/stke.2000.62.pe1; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; Marin K, 2003, P NATL ACAD SCI USA, V100, P9061, DOI 10.1073/pnas.1532302100; Marin K, 1998, J BACTERIOL, V180, P4843, DOI 10.1128/JB.180.18.4843-4849.1998; Mary I, 2003, FEMS MICROBIOL LETT, V226, P135, DOI 10.1016/S0378-1097(03)00587-1; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Poolman B, 2002, MOL MICROBIOL, V44, P889, DOI 10.1046/j.1365-2958.2002.02894.x; Postier BL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-23; Raffa RG, 2002, MOL MICROBIOL, V45, P1599, DOI 10.1046/j.1365-2958.2002.03112.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	26	101	110	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53078	53086		10.1074/jbc.M410162200	http://dx.doi.org/10.1074/jbc.M410162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471853	Green Published, hybrid			2022-12-27	WOS:000225680600035
J	Toleman, C; Paterson, AJ; Whisenhunt, TR; Kudlow, JE				Toleman, C; Paterson, AJ; Whisenhunt, TR; Kudlow, JE			Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; BETA-D-GLUCOSAMINIDASE; TRANSCRIPTIONAL REPRESSION; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; CYTOSOLIC PROTEINS; GLYCOSYLATION; NUCLEAR; ACETYLGLUCOSAMINIDASE; STREPTOZOTOCIN	Histones and transcription factors are regulated by a number of post-translational modifications that in turn regulate the transcriptional activity of genes. These modifications occur in large, multisubunit complexes. We have reported previously that mSin3A can recruit O-GlcNAc transferase (OGT) along with histone deacetylase into such a corepressor complex. This physical association allows OGT to act cooperatively with histone deacetylation in gene repression by catalyzing the O-GlcNAc modification on specific transcription factors to inhibit their activity. For rapid, reversible gene regulation, the enzymes responsible for the converse reactions must be present. Here, we report that O-GlcNAcase, which is responsible for the removal of O-GlcNAc additions on nuclear and cytosolic proteins, possesses intrinsic histone acetyltransferase (HAT) activity in vitro. Free as well as reconstituted nucleosomal histones are substrates of this bifunctional enzyme. This protein, now termed NCOAT (nuclear cytoplasmic O-GlcNAcase and acetyltransferase) has a typical HAT domain that has both active and inactive states. This finding demonstrates that NCOAT may be regulated to reduce the state of glycosylation of transcriptional activators while increasing the acetylation of histones to allow for the concerted activation of eukaryotic gene transcription.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.	kudlow@uab.edu						Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; AUSUBEL J, 1990, CURRENT PROTOCOLS MO, V1; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Comtesse N, 2001, BIOCHEM BIOPH RES CO, V283, P634, DOI 10.1006/bbrc.2001.4815; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanaka Y, 2004, METHODS, V33, P3, DOI 10.1016/j.ymeth.2003.10.024; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TURK J, 1993, BIOCHEM BIOPH RES CO, V197, P1458, DOI 10.1006/bbrc.1993.2641; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; WOLFFE A, 1992, CHROMATIN STRUCTURE; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	49	163	187	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53665	53673		10.1074/jbc.M410406200	http://dx.doi.org/10.1074/jbc.M410406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485860	hybrid			2022-12-27	WOS:000225680600103
J	Jirawatnotai, S; Aziyu, A; Osmundson, EC; Moons, DS; Zou, XH; Kineman, RD; Kiyokawa, H				Jirawatnotai, S; Aziyu, A; Osmundson, EC; Moons, DS; Zou, XH; Kineman, RD; Kiyokawa, H			Cdk4 is indispensable for postnatal proliferation of the anterior pituitary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELEASING-HORMONE; CYCLIN-DEPENDENT KINASE-4; GROWTH-HORMONE; CELL-PROLIFERATION; TRANSGENIC MICE; EXPRESSION; DEFICIENT; GLAND; TUMORIGENESIS; HYPERPLASIA	For proper development and tissue homeostasis, cell cycle progression is controlled by multilayered mechanisms. Recent studies using knock-out mice have shown that animals can develop relatively normally with deficiency for each of the G(1)/S-regulatory proteins, D-type and E-type cyclins, cyclin-dependent kinase 4 (Cdk4), and Cdk2. Although Cdk4-null mice show no embryonic lethality, they exhibit specific endocrine phenotypes, i.e. dwarfism, infertility, and diabetes. Here we have demonstrated that Cdk4 plays an essential non-redundant role in postnatal proliferation of the anterior pituitary. Pituitaries from wild-type and Cdk4-null embryos at embryonic day 17.5 are morphologically indistinguishable with similar numbers of cells expressing a proliferating marker, Ki67, and cells expressing a differentiation marker, growth hormone. In contrast, anterior pituitaries of Cdk4-null mice at postnatal 8 weeks are extremely hypoplastic with markedly decreased numbers of Ki67(+) cells, suggesting impaired cell proliferation. Pituitary hyperplasia induced by transgenic expression of human growth hormone-releasing hormone (GHRH) is significantly diminished in the Cdk4+/- genetic background and completely abrogated in the Cdk4-/- background. Small interfering RNA ( siRNA)mediated knockdown of Cdk4 inhibits GHRH-induced proliferation of GH3 somato/lactotroph cells with restored expression of GHRH receptors. Cdk4 siRNA also inhibits estrogen-dependent cell proliferation in GH3 cells and closely related GH4 cells. In contrast, Cdk6 siRNA does not diminish proliferation of these cells. Furthermore, Cdk4 siRNA does not affect GHRH-induced proliferation of mouse embryonic fibroblasts or estrogen-dependent proliferation of mammary carcinoma MCF-7 cells. Taken together, Cdk4 is dispensable for prenatal development of the pituitary or proliferation of other nonendocrine tissues but indispensable specifically for postnatal proliferation of somato/lactotrophs.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kiyokawa, H (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	kiyokawa@uic.edu	Kineman, Rhonda D/H-2221-2011; zou, Xianghong/E-4374-2011	Kineman, Rhonda D/0000-0001-7322-1152; Kiyokawa, Hiroaki/0000-0002-7942-6455	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085, U54HD040093] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100204] Funding Source: NIH RePORTER; NCI NIH HHS [CA100204] Funding Source: Medline; NICHD NIH HHS [HD38085, U54 HD40093] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard-Kargar C, 2001, DIABETES, V50, pS30, DOI 10.2337/diabetes.50.2007.S30; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; BRAR AK, 1989, ENDOCRINOLOGY, V125, P801, DOI 10.1210/endo-125-2-801; Burgess R, 2002, CURR OPIN GENET DEV, V12, P534, DOI 10.1016/S0959-437X(02)00337-4; Canavese G, 2001, HUM PATHOL, V32, P1094, DOI 10.1053/hupa.2001.28234; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Cohen LE, 2000, ENDOCRINE, V12, P99, DOI 10.1385/ENDO:12:2:99; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Frohman LA, 2002, TRENDS ENDOCRIN MET, V13, P299, DOI 10.1016/S1043-2760(02)00613-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HU NP, 1994, ONCOGENE, V9, P1021; JANSSON JO, 1987, ENDOCRINOLOGY, V120, P525, DOI 10.1210/endo-120-2-525; Kiaris H, 2002, P NATL ACAD SCI USA, V99, P196, DOI 10.1073/pnas.012590999; Lee EJ, 2001, ENDOCRINOLOGY, V142, P414, DOI 10.1210/en.142.1.414; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Martin J, 2003, ONCOGENE, V22, P5261, DOI 10.1038/sj.onc.1206506; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; Teixeira LT, 2000, ONCOGENE, V19, P1875, DOI 10.1038/sj.onc.1203490; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; ZEYTIN FN, 1984, ENDOCRINOLOGY, V114, P2054, DOI 10.1210/endo-114-6-2054	39	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51100	51106		10.1074/jbc.M409080200	http://dx.doi.org/10.1074/jbc.M409080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456744	hybrid			2022-12-27	WOS:000225355800056
J	Futami, T; Miyagishi, M; Taira, K				Futami, T; Miyagishi, M; Taira, K			Identification of a network involved in thapsigargin-induced apoptosis using a library of small interfering RNA expression vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; GENE-EXPRESSION; HAIRPIN RNAS; SEQUENCE; NEURONS	We describe here the construction of a library of small interfering RNA expression vectors targeted to a few hundred apoptosis-related genes and the application of this library to an investigation of thapsigargin (TG)-induced apoptosis. Thapsigargin triggers endoplasmic reticulum stress, with subsequent apoptosis, but the molecular mechanisms underlying this process are incompletely understood. Using our library, we identified three anti-apoptotic genes, namely, NOXA, E2F1, and MAPK1, in addition to already characterized genes in the apoptotic pathway. In contrast to proposals by others, our data revealed (i) that TG-induced apoptosis is associated with Apaf1 in a caspase-3- and caspase-9-independent manner; (ii) that the E2F1-PUMA pathway might be involved; and (iii) that the ERK pathway, via MAP3K8 (mitogen-activated protein kinase kinase 8), is required for the induction by TG of apoptosis. Our study demonstrates clearly that unexpected and novel genes can be identified effectively by our method, and it provides evidence for the efficacy and utility of the comprehensive analysis of signaling networks and pathways using a library of small interfering RNA expression vectors.	Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Taira, K (corresponding author), Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Tokyo 1138656, Japan.	taira@chembio.t.u-tokyo.ac.jp	Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Futami T, 2003, ANTISENSE NUCLEIC A, V13, P9, DOI 10.1089/108729003764097304; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Ho AT, 2004, EMBO J, V23, P460, DOI 10.1038/sj.emboj.7600039; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyagishi M, 2003, OLIGONUCLEOTIDES, V13, P325, DOI 10.1089/154545703322617005; MIYAGISHI M, 2005, IN PRESS RNA INTERFE; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	32	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					826	831		10.1074/jbc.M409948200	http://dx.doi.org/10.1074/jbc.M409948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15485892	hybrid			2022-12-27	WOS:000226025100096
J	Held, MA; Tan, L; Kamyab, A; Hare, M; Shpak, E; Kieliszewski, MJ				Held, MA; Tan, L; Kamyab, A; Hare, M; Shpak, E; Kieliszewski, MJ			Di-isodityrosine is the intermolecular cross-link of isodityrosine-rich extensin analogs cross-linked in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL GLYCOPROTEIN; CONTIGUOUS HYDROXYPROLINE RESIDUES; O-GLYCOSYLATION CODES; TOMATO EXTENSIN; ARABINOGALACTAN-PROTEINS; SUSPENSION CULTURES; PURIFICATION; PEROXIDASE; PRECURSORS; ROOT	Extensins are cell wall hydroxyproline-rich glycoproteins that form covalent networks putatively involving tyrosyl and lysyl residues in cross-links catalyzed by one or more extensin peroxidases. The precise cross-links remain to be chemically identified both as network components in muro and as enzymic products generated in vitro with native extensin monomers as substrates. However, some extensin monomers contain variations within their putative cross-linking motifs that complicate cross-link identification. Other simpler extensins are recalcitrant to isolation including the ubiquitous P3-type extensin whose major repetitive motif, Ser(Hyp)(4)-Ser-Hyp-Ser-(Hyp)(4)-Tyr-Tyr-Tyr-Lys, is of particular interest, not least because its Tyr-Tyr-Tyr intramolecular isodityrosine cross-link motifs are also putative candidates for further intermolecular cross-linking to form di-isodityrosine. Therefore, we designed a set of extensin analogs encoding tandem repeats of the P3 motif, including Tyr --> Phe and Lys --> Leu variations. Expression of these P3 analogs in Nicotiana tabacum cells yielded glycoproteins with virtually all Pro residues hydroxylated and subsequently arabinosylated and with likely galactosylated Ser residues. This was consistent with earlier analyses of P3 glycopeptides isolated from cell wall digests and the predictions of the Hyp contiguity hypothesis. The tyrosine-rich P3 analogs also contained isodityrosine, formed in vivo. Significantly, these isodityrosine-containing analogs were further crosslinked in vitro by an extensin peroxidase to form the tetra-tyrosine intermolecular cross-link amino acid di-isodityrosine. This is the first identification of an intermolecular cross-link amino acid in an extensin module and corroborates earlier suggestions that di-isodityrosine represents one mechanism for cross-linking extensins in muro.	Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Washington, Dept Biol, Seattle, WA 98125 USA	University System of Ohio; Ohio University; Oregon State University; University of Washington; University of Washington Seattle	Kieliszewski, MJ (corresponding author), Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA.	kielisze@helios.phy.ohiou.edu		Held, Michael/0000-0003-2604-8048	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 00210] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; An G., 1989, PLANT MOL BIOL MANUA, P1, DOI [DOI 10.1007/978-94-009-0951-9, 10.1007/978-94-017-5294-7_3]; Bergman T., 1986, ADV METHODS PROTEIN, P45; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Brady JD, 1996, BIOCHEM J, V315, P323, DOI 10.1042/bj3150323; Brady JD, 1998, PHYTOCHEMISTRY, V47, P349, DOI 10.1016/S0031-9422(97)00592-X; BROWNLEADER MD, 1995, PLANT PHYSIOL, V109, P1115, DOI 10.1104/pp.109.3.1115; CASSAB GI, 1986, PLANTA, V168, P441, DOI 10.1007/BF00392262; DELOOSE M, 1991, GENE, V99, P95, DOI 10.1016/0378-1119(91)90038-D; EPSTEIN L, 1984, PHYTOCHEMISTRY, V23, P1241, DOI 10.1016/S0031-9422(00)80433-1; ESQUERRETUGAYE MT, 1979, PLANT PHYSIOL, V64, P314, DOI 10.1104/pp.64.2.314; EVERDEEN DS, 1988, PLANT PHYSIOL, V87, P616, DOI 10.1104/pp.87.3.616; FRANSSEN HJ, 1987, P NATL ACAD SCI USA, V84, P4495, DOI 10.1073/pnas.84.13.4495; Frueauf JB, 2000, PHYTOCHEMISTRY, V55, P429, DOI 10.1016/S0031-9422(00)00336-8; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GOODENOUGH UW, 1986, J CELL BIOL, V103, P405, DOI 10.1083/jcb.103.2.405; Hall Q, 2002, PLANT CELL, V14, P1161, DOI 10.1105/tpc.010477; KIELISZEWSKI MJ, 1995, J BIOL CHEM, V270, P2541, DOI 10.1074/jbc.270.6.2541; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; KIELISZEWSKI MJ, 1988, SELF ASSEMBLING ARCH, V46, P61; Lamport D. T. A., 1977, RECENT ADV PHYTOCHEM, V11, P79; LAMPORT DTA, 1967, NATURE, V216, P1322, DOI 10.1038/2161322a0; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LAMPORT DTA, 1971, PLANT PHYSIOL, V48, P454, DOI 10.1104/pp.48.4.454; LAMPORT DTA, 1963, J BIOL CHEM, V238, P1438; LAMPORT DTA, 1969, BIOCHEMISTRY-US, V8, P1155, DOI 10.1021/bi00831a049; LAMPORT DTA, 1983, CURRENT TOPICS PLANT, V2, P73; LAMPORT DTA, 1973, 1 INT PROT C, P27; Lewis RV, 1996, PROTEIN EXPRES PURIF, V7, P400, DOI 10.1006/prep.1996.0060; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; MCGRATH KP, 1990, BIOTECHNOL PROGR, V6, P186; NAKAJIMA R, 1979, J BIOL CHEM, V254, P872; Price NJ, 2003, J BIOL CHEM, V278, P41389, DOI 10.1074/jbc.M304519200; ROBERTS K, 1974, PHILOS T R SOC B, V268, P129, DOI 10.1098/rstb.1974.0021; SANGER MP, 1983, ANAL BIOCHEM, V128, P66, DOI 10.1016/0003-2697(83)90345-7; Schnabelrauch LS, 1996, PLANT J, V9, P477, DOI 10.1046/j.1365-313X.1996.09040477.x; Shirsat AH, 1996, PLANTA, V199, P618, DOI 10.1007/BF00195195; SHOWALTER AM, 1991, PLANT MOL BIOL, V16, P547, DOI 10.1007/BF00023421; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Shpak E, 1999, P NATL ACAD SCI USA, V96, P14736, DOI 10.1073/pnas.96.26.14736; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; SMITH JJ, 1984, PHYTOCHEMISTRY, V23, P1233, DOI 10.1016/S0031-9422(00)80432-X; SMITH JJ, 1986, PHYTOCHEMISTRY, V25, P1021, DOI 10.1016/S0031-9422(00)81547-2; Tan L, 2003, PLANT PHYSIOL, V132, P1362, DOI 10.1104/pp.103.021766; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Zhang SG, 2002, BIOTECHNOL ADV, V20, P321, DOI 10.1016/S0734-9750(02)00026-5; Zhao ZD, 2002, PLANT J, V31, P431, DOI 10.1046/j.1365-313X.2002.01365.x; ZHOU J, 1992, PLANT MOL BIOL, V20, P5, DOI 10.1007/BF00029144	49	85	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55474	55482		10.1074/jbc.M408396200	http://dx.doi.org/10.1074/jbc.M408396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15465824	hybrid			2022-12-27	WOS:000225960800062
J	Nijhout, HF; Reed, MC; Budu, P; Ulrich, CM				Nijhout, HF; Reed, MC; Budu, P; Ulrich, CM			A mathematical model of the folate cycle - New insights into folate homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; SERINE HYDROXYMETHYLTRANSFERASE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHASE; FOLIC-ACID; METHYLENETETRAHYDROFOLATE REDUCTASE; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; POLYGLUTAMATE SPECIFICITY; BINDING-PROTEINS; RAT-LIVER	A mathematical model is developed for the folate cycle based on standard biochemical kinetics. We use the model to provide new insights into several different mechanisms of folate homeostasis. The model reproduces the known pool sizes of folate substrates and the fluxes through each of the loops of the folate cycle and has the qualitative behavior observed in a variety of experimental studies. Vitamin B-12 deficiency, modeled as a reduction in the V-max of the methionine synthase reaction, results in a secondary folate deficiency via the accumulation of folate as 5-methyltetrahydrofolate (the "methyl trap"). One form of homeostasis is revealed by the fact that a 100-fold up-regulation of thymidylate synthase and dihydrofolate reductase (known to occur at the G(1)/S transition) dramatically increases pyrimidine production without affecting the other reactions of the folate cycle. The model also predicts that an almost total inhibition of dihydrofolate reductase is required to significantly inhibit the thymidylate synthase reaction, consistent with experimental and clinical studies on the effects of methotrexate. Sensitivity to variation in enzymatic parameters tends to be local in the cycle and inversely proportional to the number of reactions that interconvert two folate substrates. Another form of homeostasis is a consequence of the nonenzymatic binding of folate substrates to folate enzymes. Without folate binding, the velocities of the reactions decrease approximately linearly as total folate is decreased. In the presence of folate binding and allosteric inhibition, the velocities show a remarkable constancy as total folate is decreased.	Duke Univ, Dept Biol, Durham, NC 27708 USA; Duke Univ, Dept Math, Durham, NC 27708 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA	Duke University; Duke University; Fred Hutchinson Cancer Center	Nijhout, HF (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	hfn@duke.edu			NATIONAL CANCER INSTITUTE [R01CA105437, R01CA059045] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59045, CA 105437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; BAGGO JE, 2000, AM J CLIN NUTR, V74, P701; Bailey L. B., 1995, FOLATE HLTH DIS, P123; Bailey L. B., 1995, FOLATE HLTH DIS; BARAM J, 1988, J BIOL CHEM, V263, P7105; Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1; Blakley R L, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P23; BRODIE JD, 1971, BIOCHEMISTRY-US, V10, P3079; CAPERELLI CA, 1985, BIOCHEMISTRY-US, V24, P1316, DOI 10.1021/bi00327a008; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; Carmel R., 2001, HOMOCYSTEINE HLTH DI; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Chen J, 2003, CANCER EPIDEM BIOMAR, V12, P958; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; CIESLA J, 1995, BBA-PROTEIN STRUCT M, V1249, P127, DOI 10.1016/0167-4838(95)00032-P; Cleland W. W, 1970, ENZYMES, V2, P1; CONWAY JG, 1983, J BIOL CHEM, V258, P3825; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; COOK RJ, 1986, METHOD ENZYMOL, V122, P255; Cook RJ, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P113; Cook RJ, 2000, AM J CLIN NUTR, V72, P1419; DAUBNER SC, 1982, J BIOL CHEM, V257, P140; De Bree A, 2002, PHARMACOL REV, V54, P599, DOI 10.1124/pr.54.4.599; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; Fukushima M, 2003, INT J MOL MED, V12, P839; Giovannucci E, 2002, J NUTR, V132, p2350S, DOI 10.1093/jn/132.8.2350S; GREEN JM, 1988, BIOCHEMISTRY-US, V27, P8014, DOI 10.1021/bi00421a007; Gregory J F 3rd, 1996, Adv Food Nutr Res, V40, P81, DOI 10.1016/S1043-4526(08)60021-2; Gregory JF, 2002, ANNU REV NUTR, V22, P199, DOI 10.1146/annurev.nutr.22.120701.083554; Gregory JF, 2001, AM J CLIN NUTR, V74, P702; Gregory JF, 2000, AM J CLIN NUTR, V72, P1535; Haldane JBS, 1930, ENZYMES; HERBERT V, 1962, J CLIN INVEST, V41, P1263, DOI 10.1172/JCI104589; *I MED, 1998, DIET REF INT THAM RI, P203; Jackman A L, 1999, ANTIFOLATE DRUGS CAN; JACKSON RC, 1980, INT J BIOMED COMPUT, V11, P197, DOI 10.1016/0020-7101(80)90045-8; JACKSON RC, 1983, BIOCHEM PHARMACOL, V32, P3783, DOI 10.1016/0006-2952(83)90150-8; JACKSON RC, 1995, TOXICOLOGY, V102, P197, DOI 10.1016/0300-483X(95)03048-K; JACKSON RC, 1979, PHARMACOL THERAPEUT, V4, P245, DOI 10.1016/0163-7258(79)90138-4; Jackson RC, 1999, CANC DRUG DISC DEV, P1; JACKSON RC, 1973, ARCH BIOCHEM BIOPHYS, V158, P827, DOI 10.1016/0003-9861(73)90579-1; Kim DW, 1997, ANAL BIOCHEM, V253, P201, DOI 10.1006/abio.1997.2388; Kim DW, 1996, BIOCHEMISTRY-US, V35, P15772, DOI 10.1021/bi9619684; LU YZ, 1984, BIOCHEMISTRY-US, V23, P6870, DOI 10.1021/bi00321a091; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; MASUDA T, 1987, J BIOCHEM, V101, P643, DOI 10.1093/jb/101.3.643; MATTHEWS RG, 1986, METHOD ENZYMOL, V122, P372; MATTHEWS RG, 1982, BIOCHEMISTRY-US, V21, P1230, DOI 10.1021/bi00535a019; MATTHEWS RG, 1982, ADV ENZYME REGUL, V20, P123, DOI 10.1016/0065-2571(82)90012-7; MATTHEWS RG, 1982, BIOCHEMISTRY-US, V19, P2040; McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Morris MS, 2003, LANCET NEUROL, V2, P425, DOI 10.1016/S1474-4422(03)00438-1; MORRISON PF, 1989, J BIOL CHEM, V264, P10552; Obama K, 2002, INT J ONCOL, V21, P309; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Reed MC, 2004, J THEOR BIOL, V226, P33, DOI 10.1016/j.jtbi.2003.08.001; Refsum H, 2001, BRIT J NUTR, V85, pS109, DOI 10.1079/BJN2000302; Robien K, 2003, AM J EPIDEMIOL, V157, P571, DOI 10.1093/aje/kwg024; ROSS J, 1984, BIOCHEMISTRY-US, V23, P1796, DOI 10.1021/bi00303a033; ROWE PB, 1973, BIOCHEMISTRY-US, V12, P1962, DOI 10.1021/bi00734a020; Ryan BM, 2001, J LAB CLIN MED, V138, P164, DOI 10.1067/mlc.2001.117161; SANTI DV, 1972, P NATL ACAD SCI USA, V69, P1855, DOI 10.1073/pnas.69.7.1855; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; Schirch V, 1997, METHOD ENZYMOL, V281, P146; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHULZ AR, 1994, ENZYME KINETICS DIS, P38; SEGEL IH, 1975, ENZYME KINETICS, P275; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SHANE B, 1985, ANNU REV NUTR, V5, P115, DOI 10.1146/annurev.nu.05.070185.000555; Shane B., 1995, FOLATE HLTH DIS, V2, P1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPEARS CP, 1982, CANCER RES, V42, P450; Stites TE, 1997, AM J CLIN NUTR, V65, P53, DOI 10.1093/ajcn/65.1.53; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; STRONG WB, 1990, J BIOL CHEM, V265, P12149; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; VORONTSOV I N, 1980, Biokhimiya, V45, P83; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; Wagner C, 1996, J NUTR, V126, pS1228, DOI 10.1093/jn/126.suppl_4.1228S; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; WAGNER C, 1995, ARCH BIOCHEM BIOPHYS, V316, P141, DOI 10.1006/abbi.1995.1021; Wagner C, 1995, FOLATE HLTH DIS, P23; WHITE JC, 1981, J BIOL CHEM, V256, P5722; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; ZAMIEROWSKI M, 1974, BIOCHEM BIOPH RES CO, V60, P81, DOI 10.1016/0006-291X(74)90175-2; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933	90	138	148	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55008	55016		10.1074/jbc.M410818200	http://dx.doi.org/10.1074/jbc.M410818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496403	hybrid			2022-12-27	WOS:000225960800005
J	Carland, JE; Moorhouse, AJ; Barry, PH; Johnston, GAR; Chebib, M				Carland, JE; Moorhouse, AJ; Barry, PH; Johnston, GAR; Chebib, M			Charged residues at the 2 ' position of human GABA(c) rho 1 receptors invert ion selectivity and influence open state probability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; M2 DOMAIN; CHANNEL CONDUCTANCE; XENOPUS-OOCYTES; AMINO-ACID; SUBUNIT; MUTATIONS; CLONING; PICROTOXIN; AGONIST	The ability of members of the nicotinicoid superfamily of ligand-gated ion channels to selectively conduct anions or cations is critical to their function within the central nervous system. Recent work has demonstrated that residues at the intracellular end of the second transmembrane domain, between the -3' and 2' positions, form the ion selectivity filter of these receptors. In this study, the proline residue at the 2' position (Pro-2') at the intracellular end of the second transmembrane domain of the gamma-aminobutyric acid type C rho1 subunit was mutated to glutamate (rho1P2'E) and arginine (rho1P2'R). Dilution potential experiments indicated that the charge selectivity of the rho1P2'E receptor channels had been inverted, with the channels now becoming predominantly cation selective, indicating the ability of negatively charged residues at this 2' position to control charge selectivity. The mutation was also seen to have significantly decreased agonist potency and intrinsic efficacy. In contrast, the rho1P2'R receptor channels were anion-selective but were now found to be constitutively open with high holding currents (inhibited by low gamma-aminobutyric acid doses and the competitive antagonist, 1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid alone) and increased agonist activity. Hill coefficients of both mutants were decreased, but competitive antagonist studies indicated that their binding sites were not significantly affected.	Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Univ New S Wales, Dept Physiol & Pharmacol, Sydney, NSW 2052, Australia	University of Sydney; University of Sydney; University of New South Wales Sydney	Chebib, M (corresponding author), Univ Sydney, Fac Pharm, A15, Sydney, NSW 2006, Australia.	maryc@pharm.usyd.edu.au	Moorhouse, Andrew J/B-8526-2011; Johnston, Graham AR/B-9827-2009; Johnston, Graham/AAJ-9569-2021	Moorhouse, Andrew J/0000-0001-7957-2498; Johnston, Graham/0000-0001-8872-4078; Carland, Jane/0000-0002-1456-876X				Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Carland JE, 2004, NEUROPHARMACOLOGY, V46, P770, DOI 10.1016/j.neuropharm.2003.11.027; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Chebib M, 1998, EUR J PHARMACOL, V357, P227, DOI 10.1016/S0014-2999(98)00552-4; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DANI JA, 1986, BIOPHYS J, V49, P607, DOI 10.1016/S0006-3495(86)83688-8; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Duke RK, 2000, J NEUROCHEM, V75, P2602, DOI 10.1046/j.1471-4159.2000.0752602.x; ENZ R, 1995, NEUROREPORT, V6, P1569, DOI 10.1097/00001756-199507310-00026; Filippova N, 2004, J BIOL CHEM, V279, P20906, DOI 10.1074/jbc.M401012200; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HANRAHAN JR, 2001, J CHEM SOC P1, V19, P2389; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moorhouse AJ, 2002, J GEN PHYSIOL, V119, P411, DOI 10.1085/jgp.20028553; Ogurusu T, 1996, BBA-GENE STRUCT EXPR, V1305, P15, DOI 10.1016/0167-4781(95)00205-7; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; ROBINSON RA, 1965, ACTIVITY COEFFICIENT; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; WOLF AV, 1980, CRC HDB CHEM PHYSICS, pD261; WOTRIN VE, 2003, J PHYSL, P527; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P109; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756	47	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54153	54160		10.1074/jbc.M410625200	http://dx.doi.org/10.1074/jbc.M410625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485818	hybrid			2022-12-27	WOS:000225793600034
J	Chang, Q; Gyftogianni, E; van de Graaf, SFJ; Hoefs, S; Weidema, FA; Bindels, RJM; Hoenderop, JGJ				Chang, Q; Gyftogianni, E; van de Graaf, SFJ; Hoefs, S; Weidema, FA; Bindels, RJM; Hoenderop, JGJ			Molecular determinants in TRPV5 channel assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CALCIUM-CHANNEL; D-3-1-ALPHA-HYDROXYLASE KNOCKOUT MICE; NEPHROGENIC DIABETES-INSIPIDUS; SHAKER POTASSIUM CHANNEL; CA2+ CHANNEL; CONFORMATIONAL-CHANGES; FUNCTIONAL EXPRESSION; GENE STRUCTURE; DIETARY CA2+; K+ CHANNELS	The epithelial Ca2+ channels TRPV5 and TRPV6 mediate the Ca2+ influx in 1,25-dihydroxyvitamin D-3-responsive epithelia and are therefore essential in the maintenance of the body Ca2+ balance. These Ca2+ channels assemble in (hetero) tetrameric channel complexes with different functional characteristics regarding Ca2+-dependent inactivation, ion selectivity, and pharmacological block. Glutathione S-transferase pull-downs and co-immunoprecipitations demonstrated an essential role of the intracellular N- and C-tails in TRPV5 channel assembly by physical interactions between N-N tails, C-C tails, and N-C-tails. Patch clamp analysis in human embryonic kidney (HEK293) cells and Ca-45(2+) uptake experiments in Xenopus laevis oocytes co-expressing TRPV5 wild-type and truncated proteins indicated that TRPV5DeltaN (deleted N-tail) and TRPV5DeltaC (deleted C-tail) decreased channel activity of wild-type TRPV5 in a dominant-negative manner, whereas TRPV5DeltaNDeltaC (deleted N-tail/C-tail) did not affect TRPV5 activity. Oocytes co-expressing wild-type TRPV5 and TRPV5DeltaN or TRPV5DeltaC showed virtually no wild-type TRPV5 expression on the plasma membrane, whereas co-expression of wild-type TRPV5 and TRPV5DeltaNDeltaC displayed normal channel surface expression. This indicates that TRPV5 trafficking toward the plasma membrane was disturbed by assembly with TRPV5DeltaN or TRPV5DeltaC but not with TRPV5DeltaNDeltaC. TRPV5 channel assembly signals were refined between amino acid positions 64-77 and 596-601 in the N- tail and C-tail, respectively. Pull-down assays and co-immunoprecipitations demonstrated that N- or C-tail mutants lacking these critical assembly domains were unable to interact with tails of TRPV5. In conclusion, two domains in the N- tail (residues 64-77) and C-tail (residues 596-601) of TRPV5 are important for channel subunit assembly, subsequent trafficking of the TRPV5 channel complex to the plasma membrane, and channel activity.	Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Hoenderop, JGJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.Hoenderop@ncmls.ru.nl	Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013	Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; van de Graaf, Stan/0000-0003-4238-4359				Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Hoenderop JGJ, 2004, KIDNEY INT, V65, P531, DOI 10.1111/j.1523-1755.2004.00402.x; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Mulders SM, 1997, AM J PHYSIOL-RENAL, V273, pF451, DOI 10.1152/ajprenal.1997.273.3.F451; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; Muller D, 2000, BIOCHEM BIOPH RES CO, V275, P47, DOI 10.1006/bbrc.2000.3227; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; van Abel M, 2003, AM J PHYSIOL-GASTR L, V285, pG78, DOI 10.1152/ajpgi.00036.2003; Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121	40	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54304	54311		10.1074/jbc.M406222200	http://dx.doi.org/10.1074/jbc.M406222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489237	Green Published, hybrid			2022-12-27	WOS:000225793600051
J	Omara-Opyene, AL; Moura, PA; Sulsona, CR; Bonilla, JA; Yowell, CA; Fujioka, H; Fidock, DA; Dame, JB				Omara-Opyene, AL; Moura, PA; Sulsona, CR; Bonilla, JA; Yowell, CA; Fujioka, H; Fidock, DA; Dame, JB			Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROFOLATE-REDUCTASE; HUMAN MALARIA PARASITES; CYSTEINE PROTEASE; HEMOGLOBIN DEGRADATION; ASPARTIC PROTEINASE; FOOD VACUOLE; II INHIBITORS; INFECTING MAN; CATHEPSIN-D; IDENTIFICATION	The digestive vacuole plasmepsins PfPM1, PfPM2, PfPM4, and PfHAP (a histoaspartic proteinase) are 4 aspartic proteinases among 10 encoded in the Plasmodium falciparum malarial genome. These have been hypothesized to initiate and contribute significantly to hemoglobin degradation, a catabolic function essential to the survival of this intraerythrocytic parasite. Because of their perceived significance, these plasmepsins have been proposed as potential targets for antimalarial drug development. To test their essentiality, knockout constructs were prepared for each corresponding gene such that homologous recombination would result in two partial, nonfunctional gene copies. Disruption of each gene was achieved, as confirmed by PCR, Southern, and Northern blot analyses. Western and two-dimensional gel analyses revealed the absence of mature or even truncated plasmepsins corresponding to the disrupted gene. Reduced growth rates were observed with PfPM1 and PfPM4 knockouts, indicating that although these plasmepsins are not essential, they are important for parasite development. Abnormal mitochondrial morphology also appeared to accompany loss of PfPM2, and an abundant accumulation of electron-dense vesicles in the digestive vacuole was observed upon disruption of PfPM4; however, those phenotypes only manifested in about a third of the disrupted cells. The ability to compensate for loss of individual plasmepsin function may be explained by close similarity in the structure and active site of these four vacuolar enzymes. Our data imply that drug discovery efforts focused on vacuolar plasmepsins must incorporate measures to develop compounds that can inhibit two or more of this enzyme family.	Univ Florida, Dept Pathobiol, Gainesville, FL 32611 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University	Dame, JB (corresponding author), Univ Florida, Dept Pathobiol, Gainesville, FL 32611 USA.	damej@mail.vetmed.ufl.edu		Dame, John B./0000-0002-5772-5454; Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [AI39211] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039211] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6; BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bernstein NK, 2003, J MOL BIOL, V329, P505, DOI 10.1016/S0022-2836(03)00444-3; Bernstein NK, 1999, NAT STRUCT BIOL, V6, P32, DOI 10.1038/4905; Berry C, 1999, FEBS LETT, V447, P149, DOI 10.1016/S0014-5793(99)00276-8; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Carroll CD, 1998, BIOORG MED CHEM LETT, V8, P3203, DOI 10.1016/S0960-894X(98)00554-X; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; Dame JB, 2003, MOL BIOCHEM PARASIT, V130, P1, DOI 10.1016/S0166-6851(03)00137-3; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Ersmark K, 2004, J MED CHEM, V47, P110, DOI 10.1021/jm030933g; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GAMBOADE DN, 1996, BLOOD, V87, P4448; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Goodyer ID, 1997, EXP PARASITOL, V86, P158, DOI 10.1006/expr.1997.4156; Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t; HAYNES JD, 1976, NATURE, V263, P767, DOI 10.1038/263767a0; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lew VL, 2004, BLOOD CELL MOL DIS, V32, P353, DOI 10.1016/j.bcmd.2004.01.006; Li T, 2004, MOL BIOCHEM PARASIT, V135, P101, DOI 10.1016/j.molbiopara.2004.01.010; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Murata CE, 2003, MOL BIOCHEM PARASIT, V129, P123, DOI 10.1016/S0166-6851(03)00098-7; Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z; Nezami A, 2002, BIOCHEMISTRY-US, V41, P2273, DOI 10.1021/bi0117549; Noteberg D, 2003, J MED CHEM, V46, P734, DOI 10.1021/jm020951i; OConnell KL, 1997, ELECTROPHORESIS, V18, P349, DOI 10.1002/elps.1150180309; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; Omara-Opyene AL, 1997, MOL BIOCHEM PARASIT, V90, P247, DOI 10.1016/S0166-6851(97)00158-8; Oscarsson K, 2003, BIOORGAN MED CHEM, V11, P1235, DOI 10.1016/S0968-0896(02)00643-0; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; ROSENTHAL PJ, 1995, EXP PARASITOL, V80, P272, DOI 10.1006/expr.1995.1033; Rosenthal PJ, 1998, EMERG INFECT DIS, V4, P49, DOI 10.3201/eid0401.980107; Sabnis YA, 2003, PROTEIN SCI, V12, P501, DOI 10.1110/ps.0228103; Saliba KJ, 1998, BIOCHEM PHARMACOL, V56, P313, DOI 10.1016/S0006-2952(98)00140-3; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Silva AM, 1998, ADV EXP MED BIOL, V436, P363; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Wyatt DM, 2002, FEBS LETT, V513, P159, DOI 10.1016/S0014-5793(02)02241-X	59	101	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54088	54096		10.1074/jbc.M409605200	http://dx.doi.org/10.1074/jbc.M409605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491999	hybrid			2022-12-27	WOS:000225793600026
J	Tisdale, EJ; Kelly, C; Artalejo, CR				Tisdale, EJ; Kelly, C; Artalejo, CR			Glyceraldehyde-3-phosphate dehydrogenase interacts with Rab2 and plays an essential role in endoplasmic reticulum to Golgi transport exclusive of its glycolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; VESICULAR TRANSPORT; VESICLE FORMATION; PROTEIN; NEUROLEUKIN; MEMBRANE; CELLS; COMPLEX; BINDING; RECRUITMENT	Rab2 requires atypical protein kinase C iota/lambda (aPKCiota/lambda) to promote vesicle formation from (v) under bar esicular (t) under bar ubular (c) under bar lusters (VTCs). The Rab2-generated vesicles are enriched in recycling proteins suggesting that the carriers are retrograde-directed and retrieve transport machinery back to the endoplasmic reticulum. These vesicles also contained the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We have previously established that GAPDH is required for membrane transport between the endoplasmic reticulum and the Golgi complex. Moreover, GAPDH is phosphorylated by aPKCiota/lambda and binds to the aPKCiota/lambda regulatory domain. In this study, we employed a combination of in vivo and in vitro assays and determined that GAPDH also interacts with Rab2. The site of GAPDH interaction was mapped to Rab2 residues 20-50. In addition to its glycolytic function, GAPDH has multiple intracellular roles. However, the function of GAPDH in the early secretory pathway is unknown. One possibility is that GAPDH ultimately provides energy in the form of ATP. To determine whether GAPDH catalytic activity was critical for transport in the early secretory pathway, a conservative substitution was made at Cys-149 located at the active site, and the mutant was biochemically characterized in a battery of assays. Although GAPDH (C149G) has no catalytic activity, Rab2 recruited the mutant protein to membranes in a quantitative binding assay. GAPDH ( C149G) is phosphorylated by aPKCiota/lambda and binds directly to Rab2 when evaluated in an overlay binding assay. Importantly, VSV-G transport between the ER and Golgi complex is restored when an in vitro trafficking assay is performed with GAPDH-depleted cytosol and GAPDH (C149G). These data suggest that GAPDH imparts a unique function necessary for membrane trafficking from VTCs that does not require GAPDH glycolytic activity.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave,6374 Scott Hall, Detroit, MI 48201 USA.	etisdale@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH047181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58921, R01 DK058921] Funding Source: Medline; NIMH NIH HHS [MH47181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; GURNEY ME, 1986, SCIENCE, V234, P566, DOI 10.1126/science.3764429; Harrison J., 1976, P1; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; Paduch M, 2001, ACTA BIOCHIM POL, V48, P829; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Steck T L, 1974, Methods Enzymol, V31, P172; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 2003, J BIOL CHEM, V278, P52524, DOI 10.1074/jbc.M309343200; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; VINALS AEL, 1987, BIOCHEM BIOPH RES CO, V143, P403, DOI 10.1016/0006-291X(87)90680-2; WATANABE K, 1996, CANCER RES, V56, P2954; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yun M, 2000, BIOCHEMISTRY-US, V39, P10702, DOI 10.1021/bi9927080; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	36	80	88	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54046	54052		10.1074/jbc.M409472200	http://dx.doi.org/10.1074/jbc.M409472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485821	hybrid			2022-12-27	WOS:000225793600021
J	Hogan, A; Yakubchyk, Y; Chabot, J; Obagi, C; Daher, E; Maekawa, K; Gee, SH				Hogan, A; Yakubchyk, Y; Chabot, J; Obagi, C; Daher, E; Maekawa, K; Gee, SH			The phosphoinositol 3,4-bisphosphate-binding protein TAPP1 interacts with syntrophins and regulates actin cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; DIACYLGLYCEROL KINASE-ZETA; PDZ DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE-PHOSPHATASE; ANTIGEN RECEPTOR; SODIUM-CHANNELS; ADAPTER PROTEIN; SKELETAL-MUSCLE; BINDING DOMAIN	Syntrophins are scaffold proteins of the dystrophin glycoprotein complex (DGC), which target ion channels, receptors, and signaling proteins to specialized subcellular domains. A yeast two-hybrid screen of a human brain cDNA library with the PSD-95, Discs-large, ZO-1 (PDZ) domain of gamma1-syntrophin yielded overlapping clones encoding the C terminus of TAPP1, a pleckstrin homology (PH) domain-containing adapter protein that interacts specifically with phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-2). In biochemical assays, the C terminus of TAPP1 bound specifically to the PDZ domains of gamma1-, alpha1-, and beta2-syntrophin and was required for syntrophin binding and for the correct subcellular localization of TAPP1. TAPP1 is recruited to the plasma membrane of cells stimulated with platelet-derived growth factor ( PDGF), a motogen that produces PI(3,4)P-2. Cell migration in response to PDGF stimulation is characterized by a rapid reorganization of the actin cytoskeleton, which gives rise to plasma membrane specializations including peripheral and dorsal circular ruffles. Both TAPP1 and syntrophins were localized to PDGF-induced circular membrane ruffles in NIH-3T3 cells. Ectopic expression of TAPP1 potently blocked PDGF-induced formation of dorsal circular ruffles, but did not affect peripheral ruffling. Interestingly, coexpression of alpha1- or gamma1-syntrophin with TAPP1 prevented the blockade of circular ruffling. In addition to syntrophins, several other proteins of the DGC were enriched in circular ruffles. Collectively, our results suggest syntrophins regulate the localization of TAPP1, which may be important for remodeling the actin cytoskeleton in response to growth factor stimulation.	Univ Ottawa, Ctr Neuromuscular Dis, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Shionogi Inst Med Sci, Osaka 5660022, Japan	University of Ottawa; Shionogi & Company Limited	Gee, SH (corresponding author), Univ Ottawa, Ctr Neuromuscular Dis, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	stevegee@uottawa.ca						Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Gee SH, 1998, J NEUROSCI, V18, P128; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Janmey PA, 2004, NAT REV MOL CELL BIO, V5, P658, DOI 10.1038/nrm1434; Kimber WA, 2003, BIOCHEM J, V376, P525, DOI 10.1042/BJ20031154; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; Marshall AJ, 2002, MOL CELL BIOL, V22, P5479, DOI 10.1128/MCB.22.15.5479-5491.2002; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piluso G, 2000, J BIOL CHEM, V275, P15851, DOI 10.1074/jbc.M000439200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rohrschneider LR, 2000, GENE DEV, V14, P505; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Watt SA, 2004, BIOCHEM J, V377, P653, DOI 10.1042/BJ20031397; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517	45	45	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53717	53724		10.1074/jbc.M410654200	http://dx.doi.org/10.1074/jbc.M410654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485858	hybrid			2022-12-27	WOS:000225680600109
J	Jiang, F; Bao, JY; Li, PF; Nicosia, SV; Bai, WL				Jiang, F; Bao, JY; Li, PF; Nicosia, SV; Bai, WL			Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D-3 through the down-regulation of telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; CATALYTIC SUBUNIT; VITAMIN-D; C-MYC; PROSTATE-CANCER; EXPRESSION; INHIBITION; GROWTH; RECEPTOR; ACID	The maintenance of telomere length is required for continued cell proliferation, and similar to85-90% of human cancers, including ovarian epithelial cancers (OCa), show high activity of telomerase. In the present study we report that 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)VD3) induces OCa cell apoptosis by down-regulating telomerase. Quantitative reverse transcription-PCR analysis shows that 1,25(OH)(2)VD3 decreases the level of human telomerase reverse transcriptase ( hTERT) mRNA, the catalytic subunit of telomerase. The decrease is not due to transcriptional repression through the putative vitamin D response element present in the 5' regulatory region of hTERT gene. Instead, 1,25(OH)(2)VD3 decreases the stability of the hTERT mRNA. Stable expression of hTERT in OCa cells decreases their response to 1,25(OH)(2)VD3-induced growth suppression. Although the cell cycle progression of these clones stably expressing hTERT is inhibited by 1,25(OH)(2)VD3 to a similar degree as that of the parental cells, these clones are more resistant to apoptosis induced by 1,25(OH)(2)VD3. In contrast to parental cells, which lose proliferation potential after the 1,25(OH)(2)VD3 treatment, hTERT-expressing clones resume rapid growth after withdrawal of 1,25(OH)(2)VD3. Overall, the study suggests that the down-regulation of telomerase activity by 1,25(OH)(2)VD3 and the resulting cell death are important components of the response of OCa cells to 1,25(OH)(2)VD3-induced growth suppression.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Program Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Program Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Biroccio A, 2003, J BIOL CHEM, V278, P35693, DOI 10.1074/jbc.M304597200; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Braunstein I, 2001, CANCER RES, V61, P5529; Cech TR, 2004, CELL, V116, P273, DOI 10.1016/S0092-8674(04)00038-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Feldman D, 1995, Adv Exp Med Biol, V375, P53; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Ikeda N, 2003, MOL CANCER THER, V2, P739; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kyo S, 1999, INT J CANCER, V80, P804; Kyo S, 1999, CANCER RES, V59, P5917; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li PF, 2004, J BIOL CHEM, V279, P25260, DOI 10.1074/jbc.M311052200; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Newbold RF, 2002, MUTAGENESIS, V17, P539, DOI 10.1093/mutage/17.6.539; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Saretzki G, 2003, CANCER LETT, V194, P209, DOI 10.1016/S0304-3835(02)00708-5; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; Takahashi T, 1997, LEUKEMIA LYMPHOMA, V27, P25, DOI 10.3109/10428199709068268; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Villa R, 2000, INT J ONCOL, V16, P995; WELSH J, 1994, BIOCHEM CELL BIOL, V72, P537, DOI 10.1139/o94-072; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	33	117	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53213	53221		10.1074/jbc.M410395200	http://dx.doi.org/10.1074/jbc.M410395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485861	hybrid			2022-12-27	WOS:000225680600051
J	Nevo, Y; Nelson, N				Nevo, Y; Nelson, N			The mutation F227I increases the coupling of metal ion transport in DCT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE; IRON UPTAKE; MEMBRANE; PROTEIN; NRAMP2; FAMILY; EXPRESSION; RESISTANCE; MECHANISM; BINDING	Metal ion transport by DCT1, a member of the natural resistance-associated macrophage protein family, is driven by protons. The stoichiometry of the proton to metal ion is variable, and under optimal transport conditions, more than 10 protons are co-transported with a single metal ion. To understand this phenomenon better, we used site-directed mutagenesis of DCT1 and analyzed the mutants by complementation of yeast suppressor of mitochondria import function-null mutants and electrophysiology with Xenopus oocytes. The mutation F227I resulted in an increase of up to 14-fold in the ratio between metal ions to protons transported. This observation suggests that low metal ion to proton transport of DCT1 resulting from a proton slippage is not a necessity of the transport mechanism in which positively charged protons are driving two positive charges of the metal ion in the same direction. It supports the idea that the proton slippage has a physiological advantage, and the proton slip was positively selected during the evolution of DCT1.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	nelson@post.tau.ac.il		Nelson, Nathan/0000-0003-3588-7265				Bers DM, 2002, ANN NY ACAD SCI, V976, P500; Blair DF, 2003, FEBS LETT, V545, P86, DOI 10.1016/S0014-5793(03)00397-1; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Cohen A, 2003, P NATL ACAD SCI USA, V100, P10694, DOI 10.1073/pnas.1934572100; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Goswami T, 2002, BIOCHEM CELL BIOL, V80, P679, DOI 10.1139/O02-159; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Inoue K, 2004, BIOCHEM J, V378, P949, DOI 10.1042/BJ20031261; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Lam-Yuk-Tseung S, 2003, BLOOD, V101, P3699, DOI 10.1182/blood-2002-07-2108; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Marciani P, 2004, J MEMBRANE BIOL, V197, P91, DOI 10.1007/s00232-003-0644-9; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Nelson N, 2002, NAT REV MOL CELL BIO, V3, P876, DOI 10.1038/nrm955; Nelson N, 1998, J NEUROCHEM, V71, P1785; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sacher A, 2001, J EXP BIOL, V204, P1053; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Weinglass AB, 2003, EMBO J, V22, P1467, DOI 10.1093/emboj/cdg145; WRIGHT EM, 1994, J EXP BIOL, V196, P197	42	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53056	53061		10.1074/jbc.M408398200	http://dx.doi.org/10.1074/jbc.M408398200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475345	hybrid, Green Submitted			2022-12-27	WOS:000225680600032
J	Wang, K; Yamamoto, H; Chin, JR; Werb, Z; Vu, TH				Wang, K; Yamamoto, H; Chin, JR; Werb, Z; Vu, TH			Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; METALLOPROTEINASE MT1-MMP; TARGETED DISRUPTION; FACTOR-ALPHA; LONG BONES; EXPRESSION; MORPHOGENESIS; CARTILAGE	The epidermal growth factor receptor (EGFR) and its ligands function in diverse cellular functions including cell proliferation, differentiation, motility, and survival. EGFR signaling is important for the development of many tissues, including skin, lungs, intestines, and the craniofacial skeleton. We have now determined the role of EGFR signaling in endochondral ossification. We analyzed long bone development in EGFR-deficient mice. EGFR deficiency caused delayed primary ossification of the cartilage anlage and delayed osteoclast and osteoblast recruitment. Ossification of the growth plates was also abnormal resulting in an expanded area of growth plate hypertrophic cartilage and few bony trabeculae. The delayed osteoclast recruitment was not because of inadequate expression of matrix metalloproteinases, including matrix metalloproteinase-9, which have previously been shown to be important for osteoclast recruitment. EGFR was expressed by osteoclasts, suggesting that EGFR ligands may act directly to affect the formation and/or function of these cells. EGFR signaling regulated osteoclast formation. Inhibition of EGFR tyrosine kinase activity decreased the generation of osteoclasts from cultured bone marrow cells.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vu, TH (corresponding author), Univ Calif San Francisco, Dept Med, Box 2911, San Francisco, CA 94143 USA.	thiennu@itsa.ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046238] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR046238-06A2, R01 AR046238, AR46238] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albrecht U, 1997, MOL CELLULAR METHODS, P23; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; BLAVIER L, 1995, J CELL SCI, V108, P3649; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; CANOUN C, 1993, J SURG RES, V54, P638, DOI 10.1006/jsre.1993.1098; CAPLAN AI, 1988, CIBA F SYMP, V136, P3021; Chan SY, 2000, J BIOL CHEM, V275, P38693, DOI 10.1074/jbc.M004189200; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; Davideau JL, 1995, CONNECT TISSUE RES, V32, P47, DOI 10.3109/03008209509013705; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Fuller K, 2000, J CELL SCI, V113, P2445; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Irie K, 2001, TISSUE CELL, V33, P478; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kheradmand F, 2002, J CELL SCI, V115, P839; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOZA J, 1995, BONE, V16, pS341; MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275; MARTINEAUDOIZE B, 1988, ENDOCRINOLOGY, V123, P841, DOI 10.1210/endo-123-2-841; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Miettinen PJ, 1999, NAT GENET, V22, P69, DOI 10.1038/8773; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PARTANEN AM, 1985, DEV BIOL, V111, P84, DOI 10.1016/0012-1606(85)90437-3; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Sasano Y, 2002, J HISTOCHEM CYTOCHEM, V50, P325, DOI 10.1177/002215540205000304; Sato T, 1997, J CELL SCI, V110, P589; SHUM L, 1993, DEVELOPMENT, V118, P903; Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; STEIN GS, 1989, CONNECT TISSUE RES, V20, P3, DOI 10.3109/03008208909049996; STERN PH, 1985, J CLIN INVEST, V76, P2016, DOI 10.1172/JCI112202; TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; Wilson SE, 1999, EXP EYE RES, V68, P377, DOI 10.1006/exer.1998.0603	46	92	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53848	53856		10.1074/jbc.M403114200	http://dx.doi.org/10.1074/jbc.M403114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456762	hybrid, Green Accepted			2022-12-27	WOS:000225680600123
J	Huang, ZH; Zhou, B; Zhong, YZ				Huang, ZH; Zhou, B; Zhong, YZ			Molecular determinants of substrate recognition in hematopoietic protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; MAP-KINASE; CATALYTIC ACTIVATION; ENZYMATIC-ACTIVITY; INTERACTION MOTIF; TRAPPING MUTANTS; STRUCTURAL BASIS; DOCKING SITE; IN-VIVO; PTP-SL	The extracellular signal-regulated protein kinase 2 (ERK2) plays a central role in cellular proliferation and differentiation. Full activation of ERK2 requires dual phosphorylation of Thr(183) and Tyr(185) in the activation loop. Tyr(185) dephosphorylation by the hematopoietic protein-tyrosine phosphatase (HePTP) represents an important mechanism for down-regulating ERK2 activity. The bisphosphorylated ERK2 is a highly efficient substrate for HePTP with a k(cat)/K-m of 2.6 x 10(6) M-1 s(-1). In contrast, the k(cat)/K-m values for the HePTP-catalyzed hydrolysis of Tyr(P) peptides are 3 orders of magnitude lower. To gain insight into the molecular basis for HePTP substrate specificity, we analyzed the effects of altering structural features unique to HePTP on the HePTP-catalyzed hydrolysis of p-nitrophenyl phosphate, Tyr( P) peptides, and its physiological substrate ERK2. Our results suggest that substrate specificity is conferred upon HePTP by both negative and positive selections. To avoid nonspecific tyrosine dephosphorylation, HePTP employs Thr(106) in the substrate recognition loop as a key negative determinant to restrain its protein-tyrosine phosphatase activity. The extremely high efficiency and fidelity of ERK2 dephosphorylation by HePTP is achieved by a bipartite protein-protein interaction mechanism, in which docking interactions between the kinase interaction motif in HePTP and the common docking site in ERK2 promote the HePTP-catalyzed ERK2 dephosphorylation (similar to20-fold increase in k(cat)/K-m) by increasing the local substrate concentration, and second site interactions between the HePTP catalytic site and the ERK2 substrate-binding region enhance catalysis (similar to20-fold increase in k(cat)/K-m) by organizing the catalytic residues with respect to Tyr(P)(185) for optimal phosphoryl transfer.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhong, YZ (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Oh-hora M, 1999, J IMMUNOL, V163, P1282; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pedersen AK, 2004, BIOCHEM J, V378, P421, DOI 10.1042/BJ20030565; Pettiford SM, 2000, ONCOGENE, V19, P858, DOI 10.1038/sj.onc.1203408; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Szedlacsek SE, 2001, J MOL BIOL, V311, P557, DOI 10.1006/jmbi.2001.4890; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	53	25	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52150	52159		10.1074/jbc.M407820200	http://dx.doi.org/10.1074/jbc.M407820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466470	hybrid			2022-12-27	WOS:000225493400054
J	Jaramillo, M; Godbout, M; Naccache, PH; Olivier, M				Jaramillo, M; Godbout, M; Naccache, PH; Olivier, M			Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; INDUCED NEUTROPHIL ACTIVATION; INDUCED ACUTE-INFLAMMATION; NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; MESSENGER-RNA; INDUCED ARTHRITIS; ALVEOLAR MACROPHAGES	Chemokine production has been associated with leukocyte infiltration into the joint during gouty arthritis, and monosodium urate (MSU) crystals, the causative agent of this arthropathy, have been shown to modulate their expression. In the present study, we investigated the transductional mechanisms underlying this cellular regulation in the murine macrophage cell line B10R. We report that MSU crystals rapidly and transiently increase mRNA levels of various chemokines in a concentration-dependent manner. Examination of second messenger activation revealed that macrophage exposure to MSU crystals led to MEK1/2, ERK1/2, and inhibitory protein kappaBalpha phosphorylation as well as to NF-kappaB and AP-1 nuclear translocation. Of interest, specific blockage of the ERK1/2 pathway drastically reduced up-modulation of MSU crystal-mediated chemokine production and activation of nuclear factors. Similarly, selective inhibition of NF-kappaB suppressed NF-kappaB DNA binding activity and the induction of all chemokine transcripts. These findings indicate that ERK1/2-dependent signals seem to be required for AP-1 and NF-kappaB activation and subsequent mRNA expression of the various macrophage chemokines. In addition, transcription and stability assays performed in presence of actinomycin D showed that MSU crystal-mediated MIP-1alpha mRNA up-regulation resulted solely from transcriptional control, whereas that of MIP-1alpha, MIP-2, and MCP-1 was due to both gene transcription activation and mRNA posttranscriptional stabilization. Overall, the results of this study help to define the molecular events that govern macrophage chemokine regulation in response to MSU crystals, which is of paramount importance to better understand, and eventually to tame, the inflammatory response during acute gout.	McGill Univ, Dept Med, Ctr Study Host Resistance, McGill Univ Hlth Ctr,Res Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3A 2B4, Canada; Univ Laval, Fac Med, Dept Med Biol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med, Ste Foy, PQ G1V 4G2, Canada; Ctr Hosp Univ Quebec, Ctr Rech Rhumatol & Immunol, Quebec City, PQ, Canada	McGill University; McGill University; McGill University; Laval University; Laval University; Laval University	Olivier, M (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St,duff Med Bldg,Rm 600, Montreal, PQ H3A 2B4, Canada.	martin.olivier@staff.mcgill.ca	Jaramillo, Maritza/T-7467-2019	Jaramillo, Maritza/0000-0002-1910-5684				ABRAMSON S, 1982, ARTHRITIS RHEUM, V25, P174, DOI 10.1002/art.1780250210; Agudelo CA, 2001, CURR OPIN RHEUMATOL, V13, P234, DOI 10.1097/00002281-200105000-00015; Bhat NR, 1998, J NEUROSCI, V18, P1633; Blanchette J, 2003, IMMUNOLOGY, V108, P513, DOI 10.1046/j.1365-2567.2003.01620.x; BOMALASKI JS, 1990, J IMMUNOL, V145, P3391; Chan ED, 2001, INFECT IMMUN, V69, P2001, DOI 10.1128/IAI.69.4.2001-2010.2001; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen XL, 1998, CIRC RES, V83, P952; DIGIOVINE FS, 1991, J CLIN INVEST, V87, P1375, DOI 10.1172/JCI115142; DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213; Fujiwara K, 2002, LAB INVEST, V82, P1297, DOI 10.1097/01.LAB.0000029206.27080.D2; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GUERNE PA, 1989, ARTHRITIS RHEUM-US, V32, P1443, DOI 10.1002/anr.1780321114; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153; Jaramillo M, 2004, J IMMUNOL, V172, P5734, DOI 10.4049/jimmunol.172.9.5734; Jaramillo M, 2002, J IMMUNOL, V169, P7026, DOI 10.4049/jimmunol.169.12.7026; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; Kan H, 1999, AM J PHYSIOL-HEART C, V277, pH1641, DOI 10.1152/ajpheart.1999.277.4.H1641; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARSHALL NJ, 1995, GROWTH REGULAT, V5, P69; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Matsukawa A, 1998, LAB INVEST, V78, P973; Matsukawa A, 1998, LAB INVEST, V78, P559; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murakami Y, 2003, ARTHRITIS RHEUM, V48, P2931, DOI 10.1002/art.11271; Murakami Y, 2002, ARTHRITIS RHEUM, V46, P2504, DOI 10.1002/art.10468; NACCACHE PH, 1993, ARTHRITIS RHEUM, V36, P117, DOI 10.1002/art.1780360119; Nishimura A, 1997, J LEUKOCYTE BIOL, V62, P444, DOI 10.1002/jlb.62.4.444; PALIT J, 1986, BR J RHEUMATOL S1, V25, pA21; PASCUAL E, 1995, BRIT J RHEUMATOL, V34, P724; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poon M, 1999, MOL CELL BIOL, V19, P6471; Punzi L, 2002, CRIT REV CL LAB SCI, V39, P63, DOI 10.1080/10408360290795448; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; ROBERGE CJ, 1994, J IMMUNOL, V152, P5485; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rouleau P, 2003, CLIN IMMUNOL, V107, P46, DOI 10.1016/S1521-6616(02)00043-8; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Ryckman C, 2003, ARTHRITIS RHEUM-US, V48, P2310, DOI 10.1002/art.11079; SHI MM, 1995, BIOCHEM BIOPH RES CO, V211, P289, DOI 10.1006/bbrc.1995.1809; Shi MM, 1996, J BIOL CHEM, V271, P5878, DOI 10.1074/jbc.271.10.5878; Shi MM, 1999, IMMUNOLOGY, V97, P309; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; TERKELTAUB R, 1996, ARTHRITIS ALLIED CON, P2085; TERKELTAUB RA, 1990, J IMMUNOL, V144, P2719; WIDMER U, 1993, J IMMUNOL, V150, P4996; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7	56	47	54	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52797	52805		10.1074/jbc.M403823200	http://dx.doi.org/10.1074/jbc.M403823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471869	hybrid			2022-12-27	WOS:000225493400127
J	Kim, SH; Yin, YI; Li, YM; Sisodia, SS				Kim, SH; Yin, YI; Li, YM; Sisodia, SS			Evidence that assembly of an active gamma-secretase complex occurs in the early compartments of the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; BETA-APP; PRESENILIN-1; APH-1; NICASTRIN; NOTCH; PEN-2; RECONSTITUTION; SUBCOMPLEX; CLEAVAGE	The gamma-secretase complex, consisting of presenilins (PS), nicastrin (NCT), APH-1, and PEN-2, catalyzes the intramembranous proteolysis of truncated beta-amyloid precursor protein (APP) and Notch derivatives to generate the APP intracellular domain ( AICD) and Notch intracellular domain (NICD), respectively. To examine the intracellular sites in which active gamma-secretase resides, we expressed NCT variants harboring either an endoplasmic reticulum (ER) retention signal (NCT-ER) or a trans-Golgi network (TGN) targeting motif (NCT-TGN) along with PS1, APH-1, and PEN-2 and examined gamma-secretase activity in these settings. In cells expressing NCT- ER and the other components, PS1 fragments hyperaccumulated, but AICD levels were not elevated. On the other hand, upon coexpression of an ER-retained APP variant or a constitutionally active Notch mutant, NDeltaE, we observed enhanced production of AICD or NICD, respectively, in cells expressing NCT- ER. Moreover, we show that membranes from cells expressing NCT- ER, NCT- TGN, or NCT-WT contain identical levels of PS1 derivatives that can be photoaffinity cross-linked to a biotinylated, benzophenone-derivatized gamma-secretase inhibitor. Finally, our cell-free gamma-secretase assays revealed nearly equivalent gamma-secretase activities in cells expressing PS1, APH-1, PEN-2, and either NCT-WT or NCT-ER. Taken together, we interpret these findings as suggesting that active gamma-secretase complex is generated in the early compartments of the secretory pathway but that these complexes are transported to late compartments in which substrates are encountered and subsequently processed within respective transmembrane segments.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA	University of Chicago; Memorial Sloan Kettering Cancer Center	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	ssisodia@bsd.uchicago.edu			NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER; NIA NIH HHS [AG021494] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; Peraus GC, 1997, J NEUROSCI, V17, P7714; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	26	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48615	48619		10.1074/jbc.C400396200	http://dx.doi.org/10.1074/jbc.C400396200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15456788	hybrid			2022-12-27	WOS:000225098100017
J	Solovjov, DA; Pluskota, E; Plow, EF				Solovjov, DA; Pluskota, E; Plow, EF			Distinct roles for the alpha and beta subunits in the functions of integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; I-DOMAIN; A-DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; EXTRACELLULAR SEGMENT; RECOGNITION SITE; GAMMA-CHAIN; MAC-1; ADHESION	Integrin alpha(M)beta(2) (Mac-1, CD11b/CD18) is a noncovalently linked heterodimer of alpha(M) and beta(2) subunits on the surface of leukocytes, where it plays a pivotal role in the adhesion and migration of these cells. Using HEK293 cells expressing alpha(M)beta(2) or the individual constituent chains on their surface, we analyzed the contributions of the alpha(M) or beta(2) subunits to functional responses mediated by the integrin. In cells expressing only alpha(M) or beta(2), the individual subunits were not associated with the endogenous integrins of the cells, and other partners for the subunits were not detected by surface labeling and immunoprecipitation under a variety of conditions. The alpha(M) cells mediated adhesion and spreading on a series of alpha(M)beta(2) ligands (fibrinogen, Factor X, iC3b, ICAM-1 (intercellular adhesion molecule-1), and denatured ovalbumin) but could not support cell migration to any of these. The spreading of the alpha(M) cells suggested an unanticipated linkage of this subunit to the cytoskeleton. The beta(2) cells supported migration and attachment but not spreading on a subset of the alpha(M)beta(2) ligands. The heterodimeric receptor and its individual subunits were purified from the cells by affinity chromatography and recapitulated the ligand binding properties of the corresponding cell lines. These data indicate that each subunit of alpha(M)beta(2) contributes distinct properties to alpha(M)beta(2) and that, in most but not all cases, the response of the integrin is a composite of the functions of its individual subunits.	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Plow, EF (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB-50,9500 Euclid Ave, Cleveland, OH 44195 USA.	plowe@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1986, J CLIN INVEST, V78, P968, DOI 10.1172/JCI112687; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Dabrosin C, 2002, AM J PATHOL, V161, P909, DOI 10.1016/S0002-9440(10)64251-4; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Ding ZM, 1999, J IMMUNOL, V163, P5029; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Drbal K, 2001, IMMUNOBIOLOGY, V203, P687, DOI 10.1016/S0171-2985(01)80017-6; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Forsyth CB, 2001, J EXP MED, V193, P1123, DOI 10.1084/jem.193.10.1123; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 2000, MOL BIOL CELL, V11, P677, DOI 10.1091/mbc.11.2.677; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Leitinger B, 1999, BIOCHEM SOC T, V27, P826, DOI 10.1042/bst0270826; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liu SC, 2000, J CELL SCI, V113, P3563; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILLER LJ, 1987, J IMMUNOL, V138, P2381; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Pluskota E, 2001, BLOOD, V98, p700A; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Seow KT, 2002, BIOCHEM PHARMACOL, V64, P805, DOI 10.1016/S0006-2952(02)01142-5; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; Ustinov VA, 2002, J BIOL CHEM, V277, P18769, DOI 10.1074/jbc.M110242200; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Yalamanchili P, 2000, J BIOL CHEM, V275, P21877, DOI 10.1074/jbc.M908868199; Yan SR, 1997, J IMMUNOL, V158, P1902; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	64	200	201	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1336	1345		10.1074/jbc.M406968200	http://dx.doi.org/10.1074/jbc.M406968200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15485828	hybrid			2022-12-27	WOS:000226195200059
J	Kardos, J; Yamamoto, K; Hasegawa, K; Naiki, H; Goto, Y				Kardos, J; Yamamoto, K; Hasegawa, K; Naiki, H; Goto, Y			Direct measurement of the thermodynamic parameters of amyloid formation by isothermal titration calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; FIBRIL FORMATION; IN-VITRO; PROTEIN AGGREGATION; SELF-ASSOCIATION; HEAT-CAPACITY; BETA(2)-MICROGLOBULIN; BINDING; VARIANTS; STATE	Amyloid fibril deposition is associated with over 20 degenerative diseases, including Alzheimer's, Parkinson's, and prion diseases. Although research over the last few years has revealed the morphology and structural features of the amyloid form, knowledge about the thermodynamics of amyloid formation is limited. Here, we report for the first time a direct thermodynamic study of amyloid formation using isothermal titration calorimetry. beta(2)-Microglobulin, a protein responsible for dialysis-related amyloidosis, was used for extending amyloid fibrils in a seed-controlled reaction in the cell of the calorimeter. We investigated the enthalpy and heat capacity changes of the reaction, where the monomeric, acid-denatured molecules adopt an ordered, cross-beta-sheet structure in the rigid amyloid fibrils. Despite the dramatic difference in morphology, beta(2)-microglobulin exhibited a similar heat capacity change upon amyloid formation to that of the folding to the native globular state, whereas the enthalpy change of the reaction proved to be markedly lower. In comparison with the native state, the results outline the important structural features of the amyloid fibrils: a similar extent of surface burial even with the supramolecular architecture of amyloid fibrils, a lower level of internal packing, and the possible presence of unfavorable side chain contributions.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; Univ Fukui, Fac Med Sci, Fukui 9101193, Japan; Japan Sci & Technol Agcy, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); Eotvos Lorand University; University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Kardos, József/J-1035-2017; Naiki, Hironobu/G-5599-2014	Kardos, József/0000-0002-2135-2932; 				Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P879, DOI 10.1110/ps.42401; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Ferrao-Gonzales AD, 2003, J MOL BIOL, V328, P963, DOI 10.1016/S0022-2836(03)00368-1; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Freire E, 1995, Methods Mol Biol, V40, P191; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; Hilser VJ, 1996, PROTEINS, V26, P123, DOI 10.1002/(SICI)1097-0134(199610)26:2<123::AID-PROT2>3.0.CO;2-H; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Kinoshita M, 2004, CHEM PHYS LETT, V387, P54, DOI 10.1016/j.cplett.2004.01.112; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Litvinovich SV, 1998, J MOL BIOL, V280, P245, DOI 10.1006/jmbi.1998.1863; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Martsev SP, 2002, BIOCHEMISTRY-US, V41, P3389, DOI 10.1021/bi015894u; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Schuler B, 1999, J BIOL CHEM, V274, P18589, DOI 10.1074/jbc.274.26.18589; Shnyrov VL, 2000, BIOPHYS CHEM, V88, P61, DOI 10.1016/S0301-4622(00)00199-X; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Souillac PO, 2002, J BIOL CHEM, V277, P12657, DOI 10.1074/jbc.M109230200; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 2001, J BIOL CHEM, V276, P37149, DOI 10.1074/jbc.M105720200; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Yutani K, 2000, BIOCHEMISTRY-US, V39, P2769, DOI 10.1021/bi991406v	45	104	105	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55308	55314		10.1074/jbc.M409677200	http://dx.doi.org/10.1074/jbc.M409677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494406	Green Published, hybrid			2022-12-27	WOS:000225960800042
J	Bender, V; Ali, M; Amon, M; Diefenbach, E; Manolios, N				Bender, V; Ali, M; Amon, M; Diefenbach, E; Manolios, N			T cell antigen receptor peptide-lipid membrane interactions using surface plasmon resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE HELICAL INTERACTIONS; SPECTROSCOPY; MECHANISM; INSERTION; ZETA	This study examines the binding properties of a new class of immunomodulating peptides derived from the transmembrane region of the T cell antigen receptor, on model membranes using surface plasmon resonance. The di-basic "core" peptide was found to bind to both zwitterionic and anionic model membranes as well as to a T cell membrane preparation. By contrast, switching one or both of the basic residues to acidic residues led to a complete loss of binding to model membranes. In addition, the position of the charged amino acids in the sequence, the number of hydrophobic amino acids between the charged residues, and substitution of one or both basic to neutral amino acids were found to effect binding. These results when compared with in vitro T cell stimulation assays and in vivo adjuvant-induced arthritis models, showed very close correlation and confirmed the findings that amino acid charge and location may have a role in peptide activity. These initial biophysical peptide-membrane interactions are critically important and correlate well with the subsequent cellular expression and biological effect of these hydrophobic peptides. Targeting and understanding the biophysical interactions between peptides and membranes at their site of action is paramount to the description of cell function and drug design.	Westmead Hosp, Dept Rheumatol, Westmead, NSW 2145, Australia; Westmead Millenium Inst, Westmead, NSW 2145, Australia	University of Sydney; University of Sydney; Westmead Institute for Medical Research	Manolios, N (corresponding author), Westmead Hosp, Dept Rheumatol, Westmead, NSW 2145, Australia.	nickm@westgate.wh.usyd.edu.au		Manolios, Nicholas/0000-0002-6525-7830; Ali, Marina/0000-0001-8546-9948				Aivazian D, 2000, NAT STRUCT BIOL, V7, P1023; Ali M, 2001, LETT PEPT SCI, V8, P227; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Engelman DM, 1996, SCIENCE, V274, P1850, DOI 10.1126/science.274.5294.1850; Gollner GP, 2000, GENE THER, V7, P1000, DOI 10.1038/sj.gt.3301183; Hayes SM, 2003, IMMUNOL REV, V191, P28, DOI 10.1034/j.1600-065X.2003.00011.x; Mahnke K, 2003, NAT BIOTECHNOL, V21, P903, DOI 10.1038/nbt842; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; Manolios Nicholas, 2002, Australas J Dermatol, V43, P226; MAY GL, 1986, J BIOL CHEM, V261, P3048; Mozsolits H, 2002, BIOCHEMISTRY-US, V41, P7830, DOI 10.1021/bi0121813; Mozsolits H, 2003, J PEPT SCI, V9, P77, DOI 10.1002/psc.439; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2001, PEPTIDES, V22, P1629, DOI 10.1016/S0196-9781(01)00498-3; Wang W, 1998, J BIOL CHEM, V273, P27438, DOI 10.1074/jbc.273.42.27438; Wang XM, 2002, CLIN IMMUNOL, V105, P199, DOI 10.1006/clim.2002.5270; Wang XM, 2002, CELL IMMUNOL, V215, P12, DOI 10.1016/S0008-8749(02)00002-3	24	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54002	54007		10.1074/jbc.M403909200	http://dx.doi.org/10.1074/jbc.M403909200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485851	hybrid			2022-12-27	WOS:000225793600015
J	Doucette, PA; Whitson, LJ; Cao, XH; Schirf, V; Demeler, B; Valentine, JS; Hansen, JC; Hart, PJ				Doucette, PA; Whitson, LJ; Cao, XH; Schirf, V; Demeler, B; Valentine, JS; Hansen, JC; Hart, PJ			Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant - Insights into the molecular basis for dimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN-SUPEROXIDE DISMUTASE; SUBUNIT STRUCTURE; ESCHERICHIA-COLI; WILD-TYPE; ANALYTICAL ULTRACENTRIFUGATION; ELECTROSTATIC RECOGNITION; QUATERNARY STRUCTURE; WHEAT-GERM; MUTANT	The dissociation of apo- and metal-bound human copper-zinc superoxide dismutase (SOD1) dimers induced by the chaotrope guanidine hydrochloride (GdnHCl) or the reductant Tris(2-carboxyethyl) phosphine ( TCEP) has been analyzed using analytical ultracentrifugation. Global fitting of sedimentation equilibrium data under native solution conditions ( without GdnHCl or TCEP) demonstrate that both the apo- and metal-bound forms of SOD1 are stable dimers. Sedimentation velocity experiments show that apo- SOD1 dimers dissociate cooperatively over the range 0.5-1.0 M GdnHCl. In contrast, metal-bound SOD1 dimers possess a more compact shape and dissociate at significantly higher GdnHCl concentrations (2.0-3.0 M). Reduction of the intrasubunit disulfide bond within each SOD1 subunit by 5-10 mM TCEP promotes dissociation of apo- SOD1 dimers, whereas the metal-bound enzyme remains a stable dimer under these conditions. The Cys-57 --> Ser mutant of SOD1, a protein incapable of forming the intrasubunit disulfide bond, sediments as a monomer in the absence of metal ions and as a dimer when metals are bound. Taken together, these data indicate that the stability imparted to the human SOD1 dimer by metal binding and the formation of the intrasubunit disulfide bond are mediated by independent molecular mechanisms. By combining the sedimentation data with previous crystallographic results, a molecular explanation is provided for the existence of different SOD1 macromolecular shapes and multiple SOD1 dimeric species with different stabilities.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; Colorado State University	Valentine, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jsv@chem.ucla.edu; pjhart@biochem.uthscsa.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Demeler, Borries/0000-0002-2414-9518	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [R01 NS039112, NS39112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1995, EUR J BIOCHEM, V234, P855, DOI 10.1111/j.1432-1033.1995.855_a.x; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; BANNISTER JV, 1978, BIOCHEM BIOPH RES CO, V81, P469, DOI 10.1016/0006-291X(78)91557-7; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; BATTISTONI A, 1995, FEBS LETT, V374, P199, DOI 10.1016/0014-5793(95)01106-O; BEAUCHAMP CO, 1973, BIOCHIM BIOPHYS ACTA, V317, P50, DOI 10.1016/0005-2795(73)90198-0; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CARRICO RJ, 1970, J BIOL CHEM, V245, P723; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Cole J L, 1999, J Biomol Tech, V10, P163; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; DEMELER B, 2004, ULTRASCAND SOFTWARE; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Djinovic Carugo K, 1996, Acta Crystallogr D Biol Crystallogr, V52, P176, DOI 10.1107/S0907444995007608; Doucette P, 2004, THESIS U CALIFORNIA; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FEE JA, 1973, J BIOL CHEM, V248, P4229; Ferraroni M, 1999, J MOL BIOL, V288, P413, DOI 10.1006/jmbi.1999.2681; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1972, J BIOL CHEM, V247, P6960; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GOSCIN SA, 1972, ARCH BIOCHEM BIOPHYS, V153, P778, DOI 10.1016/0003-9861(72)90398-0; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HART PJ, 2004, INPRESS MED INORGANI; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; INOUYE K, 1994, J BIOCHEM-TOKYO, V115, P507, DOI 10.1093/oxfordjournals.jbchem.a124367; KITAGAWA Y, 1991, J BIOCHEM-TOKYO, V109, P477, DOI 10.1093/oxfordjournals.jbchem.a123407; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; MARMOCCHI F, 1974, FEBS LETT, V44, P337, DOI 10.1016/0014-5793(74)81172-5; MARMOCCHI F, 1978, FEBS LETT, V94, P109, DOI 10.1016/0014-5793(78)80917-X; MARMOCCHI F, 1975, PHYSIOL CHEM PHYS M, V7, P465; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; Paciaroni A, 1999, EUR BIOPHYS J BIOPHY, V28, P447, DOI 10.1007/s002490050227; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; RIGO A, 1978, BIOCHEMISTRY-US, V17, P534, DOI 10.1021/bi00596a025; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Russell TR, 2004, BIOCHEMISTRY-US, V43, P1580, DOI 10.1021/bi035578a; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; SILVA N, 1993, BIOPHYS CHEM, V48, P171, DOI 10.1016/0301-4622(93)85008-6; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Valentine J. S., 1981, METAL IONS BIOL, P291; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515	76	136	139	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54558	54566		10.1074/jbc.M409744200	http://dx.doi.org/10.1074/jbc.M409744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485869	hybrid			2022-12-27	WOS:000225793600081
J	Grass, I; Thiel, S; Honing, S; Haucke, V				Grass, I; Thiel, S; Honing, S; Haucke, V			Recognition of a basic AP-2 binding motif within the C2B domain of synaptotagmin is dependent on multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; ENDOCYTOSIS; RECEPTOR; SITE; AP2; MECHANISM; INTERACTS; MUTANTS; PROTEIN; CLUSTER	Synaptotagmin is a multifunctional membrane protein that may regulate exo-endocytic cycling of synaptic vesicles at the presynaptic plasmalemma. Its C2B domain has been postulated to interact with a variety of effector molecules including acidic phospholipids, phosphoinositides, SNAREs ( soluble N-ethylmaleimide- sensitive factor attachment protein receptors), calcium channels, and the clathrin adaptor complex AP-2. Here we report that a basic motif within the C2B domain is required and sufficient for binding to AP-2 via its mu2 subunit and that this interaction is dependent on multimerization of the AP-2 binding site. Moreover, we show that upon fusion to a plasma membrane reporter protein this sequence is sufficient to target the chimeric molecule for internalization. We hypothesize that basic motifs within multimeric membrane proteins may represent a novel type of clathrin/AP-2-dependent endocytosis signal.	Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Free University of Berlin; University of Gottingen	Haucke, V (corresponding author), Free Univ Berlin, Inst Chem Biochem, Takustr 6, D-14195 Berlin, Germany.	vhaucke@chemie.fu-berlin.de		Haucke, Volker/0000-0003-3119-6993				Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Fache MP, 2004, J CELL BIOL, V166, P571, DOI 10.1083/jcb.200312155; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Jarousse N, 2003, TRAFFIC, V4, P468, DOI 10.1034/j.1600-0854.2003.00101.x; Jarousse N, 2001, J CELL BIOL, V154, P857, DOI 10.1083/jcb.200103040; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Poskanzer KE, 2003, NATURE, V426, P559, DOI 10.1038/nature02184; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	37	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54872	54880		10.1074/jbc.M409995200	http://dx.doi.org/10.1074/jbc.M409995200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491995	hybrid			2022-12-27	WOS:000225793600116
J	Meng, GY; Zhao, YT; Nag, A; Zeng, MS; Dimri, G; Gao, GS; Wazer, DE; Kumar, R; Band, H; Band, V				Meng, GY; Zhao, YT; Nag, A; Zeng, MS; Dimri, G; Gao, GS; Wazer, DE; Kumar, R; Band, H; Band, V			Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; NUCLEAR HORMONE-RECEPTORS; MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; PROTEIN COACTIVATOR; E6 ONCOPROTEIN; COMPLEXES; ALPHA; DOMAIN	We have recently identified the hADA3 protein, the human homologue of yeast transcriptional coactivator yADA3, as a novel HPV16 E6 target. Using ectopic expression approaches, we further demonstrated that hADA3 directly binds to the 9-cis retinoic acid receptors alpha and beta, and functions as a coactivator for retinoid receptor-mediated transcriptional activation. Here, we examined the role of endogenous hADA3 as a coactivator for estrogen receptor ( ER), an important member of the nuclear hormone receptor superfamily. We show that ADA3 directly interacts with ERalpha and ERbeta. Using the chromatin immunoprecipitation assay, we also show that hADA3 is a component of the activator complexes bound to the native ER response element within the promoter of the estrogen-responsive gene pS2. Furthermore, using an ER response element-luciferase reporter, we show that overexpression of ADA3 enhances the ERalpha- and ERbeta-mediated sequence-specific transactivation. Reverse transcription-PCR analysis showed an ADA3-mediated increase in estrogen-induced expression of the endogenous pS2 gene. More importantly, using RNA interference against hADA3, we demonstrate that inhibition of endogenous hADA3 inhibited ER-mediated transactivation and the estrogen-induced increase in the expression of pS2, cathepsin D, and progesterone receptor, three widely known ER-responsive genes. The HPV E6 protein, by targeting hADA3 for degradation, inhibited the ERalpha-mediated transactivation and the protein expression of ER target genes. Thus, our results demonstrate that ADA3 directly binds to human estrogen receptor and enhances the transcription of ER-responsive genes, suggesting a broader role of mammalian hADA3 as a coactivator of nuclear hormone receptors and the potential role of these pathways in HPV oncogenesis.	Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Dept Med,Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Dept Med,Div Mol Oncol, Evanston, IL 60201 USA; Tufts Univ, Sch Med, New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Tufts Medical Center; Tufts University; University of Texas System; UTMD Anderson Cancer Center	Band, V (corresponding author), Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Dept Med,Div Canc Biol, 1001 Univ Pl, Evanston, IL 60201 USA.	v-band@northwestern.edu		zeng, musheng/0000-0003-3509-5591	NATIONAL CANCER INSTITUTE [R01CA096986, R01CA096844, R01CA095221, R01CA099163, R01CA087986, R01CA081076, R01CA076118, R01CA094143, R01CA099900] Funding Source: NIH RePORTER; NCI NIH HHS [CA76118, CA99163, CA94143, R01 CA095221-01A1, R01 CA095221-03, R01 CA096986-01A1, R01 CA096986-02, R01 CA096986-05, R01 CA095221-05, CA81076, R01 CA096986-04, CA96844, R01 CA096986-03, CA99900, R01 CA095221-02, CA87986, R01 CA095221-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; An WJ, 2003, J BIOL CHEM, V278, P1504, DOI 10.1074/jbc.M209355200; AUBORN KJ, 1991, INT J CANCER, V49, P867, DOI 10.1002/ijc.2910490611; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Band Vimla, 2003, Methods Mol Biol, V223, P237; Barnes CJ, 2004, CELL MOL LIFE SCI, V61, P281, DOI 10.1007/s00018-003-3222-5; Benecke A, 2002, NUCLEIC ACIDS RES, V30, P2508, DOI 10.1093/nar/30.11.2508; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Campos SM, 2003, ONCOLOGY-BASEL, V64, P289, DOI 10.1159/000070284; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; de Villiers EM, 2003, INT J CANCER, V103, P705, DOI 10.1002/ijc.10868; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dimri GP, 2002, CANCER RES, V62, P4736; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Edwards DP, 2000, J MAMMARY GLAND BIOL, V5, P307, DOI 10.1023/A:1009503029176; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Jaber BM, 2004, J MOL ENDOCRINOL, V32, P307, DOI 10.1677/jme.0.0320307; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MITRANIROSENBAUM S, 1989, J GEN VIROL, V70, P2227, DOI 10.1099/0022-1317-70-8-2227; Moodley J, 2004, CURR OPIN OBSTET GYN, V16, P27, DOI 10.1097/00001703-200402000-00006; Newfield L, 1998, P SOC EXP BIOL MED, V217, P322; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; SPYRATOS F, 1994, BRIT J CANCER, V69, P394, DOI 10.1038/bjc.1994.73; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wang WM, 2003, BIOCHEM BIOPH RES CO, V303, P932, DOI 10.1016/S0006-291X(03)00444-3; Yuan LWC, 2002, ONCOGENE, V21, P2253, DOI 10.1038/sj.onc.1205283; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	46	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54230	54240		10.1074/jbc.M404482200	http://dx.doi.org/10.1074/jbc.M404482200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496419	hybrid			2022-12-27	WOS:000225793600043
J	Ray, A; Kumar, D; Ray, P; Ray, BK				Ray, A; Kumar, D; Ray, P; Ray, BK			Transcriptional activity of serum amyloid A-activating factor-1 is regulated by distinct functional modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NUCLEAR-LOCALIZATION SIGNALS; ADENOVIRUS E1A PROTEIN; DNA-BINDING DOMAINS; ALZ-50 CLONE 1; GENE-EXPRESSION; CRYSTAL-STRUCTURE; KINASE-A; SP1; PROMOTER	Serum amyloid A-activating transcription factor-1 (SAF-1) plays a major role in regulating transcription of several inflammation-responsive genes, including SAA and matrix metalloproteinase-1, that are implicated in the pathogenesis of reactive secondary amyloidosis, atherosclerosis, and arthritis. SAF-1 is a 477-amino acid protein with six zinc fingers. Its activation during inflammatory condition by a phosphorylation event that leads to an altered structure suggested possible structural modification of this protein as a leading cause of higher activity. However, no information is available regarding structural features that might regulate its activity. Here, we have characterized its functional domains, delineating activation and repression modules, DNA binding, and nuclear localization activities. Using GAL4AD chimeras and a DNA-binding assay with proteins prepared from various deletion constructs, the core DNA-binding domain of SAF-1 is mapped between amino acids 282 and 361, which contain second, third, and fourth zinc fingers. Results from several deletion and point mutants using green fluorescent protein reporter show that SAF-1 contains two independent nuclear localization signals; one is composed of a stretch of basic amino acids, and the other is a bipartite signal located within the core DNA-binding domain. SAF-1 contains several negative and positively functioning transactivation modules clustered at the two ends of this protein. Removal of any one of the terminal negative modules renders the SAF-1 protein functionally very active. These findings suggest that the terminal repression modules act in conjunction to regulate the functional activity of this protein.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.	rayb@missouri.edu			NIDDK NIH HHS [DK49205] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205, R56DK049205] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EKKER SC, 1991, EMBO J, V10, P179; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Jordan-Sciutto KL, 1999, J BIOL CHEM, V274, P35262, DOI 10.1074/jbc.274.49.35262; Jordan-Sciutto KL, 2000, BIOCHEMISTRY-US, V39, P3206, DOI 10.1021/bi992211q; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2003, ARTHRITIS RHEUM, V48, P134, DOI 10.1002/art.10706; Ray A, 2003, J BIOL CHEM, V278, P22586, DOI 10.1074/jbc.M300705200; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200; Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637; Ray BK, 2001, J IMMUNOL, V167, P2343, DOI 10.4049/jimmunol.167.4.2343; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Ugai H, 2001, BIOCHEM BIOPH RES CO, V286, P1087, DOI 10.1006/bbrc.2001.5469; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646	42	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54637	54646		10.1074/jbc.M411830200	http://dx.doi.org/10.1074/jbc.M411830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498774	hybrid			2022-12-27	WOS:000225793600090
J	Drees, JC; Lusetti, SL; Cox, MM				Drees, JC; Lusetti, SL; Cox, MM			Inhibition of RecA protein by the Escherichia coli RecX protein - Modulation by the RecA C terminus and filament functional state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; STALLED REPLICATION FORKS; BINDING-PROTEIN; RECOMBINATIONAL REPAIR; GENETIC-RECOMBINATION; ATP HYDROLYSIS; EXCHANGE; COMPLEXES; DINI; EXPRESSION	The RecX protein is a potent inhibitor of RecA activities. We identified several factors that affect RecX-RecA interaction. The interaction is enhanced by the RecA C terminus and by significant concentrations of free Mg2+ ion. The interaction is also enhanced by an N-terminal His(6) tag on the RecX protein. We conclude that RecX protein interacts most effectively with a RecA functional state designated A(o) and that the RecA C terminus has a role in modulating the interaction. We further identified a C-terminal point mutation in RecA protein (E343K) that significantly alters the interaction between RecA and RecX proteins.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NIGMS NIH HHS [GM 52725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DEMOT R, 1994, NUCLEIC ACIDS RES, V22, P1313, DOI 10.1093/nar/22.7.1313; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; Haruta N, 2003, J BIOL CHEM, V278, P52710, DOI 10.1074/jbc.M308563200; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Pages V, 2003, DNA REPAIR, V2, P273, DOI 10.1016/S1568-7864(02)00217-3; Papavinasasundaram KG, 1998, MOL MICROBIOL, V30, P525, DOI 10.1046/j.1365-2958.1998.01083.x; Papavinasasundaram KG, 1997, MOL MICROBIOL, V24, P141, DOI 10.1046/j.1365-2958.1997.3441697.x; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; SANO Y, 1993, J BACTERIOL, V175, P2451, DOI 10.1128/JB.175.8.2451-2454.1993; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; Stohl EA, 2001, MOL MICROBIOL, V40, P1301, DOI 10.1046/j.1365-2958.2001.02463.x; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sukchawalit R, 2001, FEMS MICROBIOL LETT, V205, P83, DOI 10.1111/j.1574-6968.2001.tb10929.x; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, J MOL BIOL, V333, P345, DOI 10.1016/j.jmb.2003.08.053; Venkatesh R, 2002, P NATL ACAD SCI USA, V99, P12091, DOI 10.1073/pnas.192178999; Vierling S, 2000, J BACTERIOL, V182, P4005, DOI 10.1128/JB.182.14.4005-4011.2000; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Yang MK, 2001, CURR MICROBIOL, V42, P257, DOI 10.1007/s002840010214; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256; Yu VPCC, 2000, GENE DEV, V14, P1400	47	52	54	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52991	52997		10.1074/jbc.M409050200	http://dx.doi.org/10.1074/jbc.M409050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466870	hybrid			2022-12-27	WOS:000225680600024
J	Han, GS; Gable, K; Yan, LY; Natarajan, M; Krishnamurthy, J; Gupta, SD; Borovitskaya, A; Harmon, JM; Dunn, TM				Han, GS; Gable, K; Yan, LY; Natarajan, M; Krishnamurthy, J; Gupta, SD; Borovitskaya, A; Harmon, JM; Dunn, TM			The topology of the Lcb1p subunit of yeast serine palmitoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY SENSORY NEUROPATHY; MEMBRANE-PROTEIN STRUCTURE; PREDICTION; MUTATIONS; ENZYME; LOCALIZATION; COMPONENT; MUTANTS; SPTLC1	The structural organization and topology of the Lcb1p subunit of yeast and mammalian serine palmitoyltransferases (SPT) were investigated. In the yeast protein, three membrane-spanning domains were identified by insertion of glycosylation and factor Xa cleavage sites at various positions. The first domain of the yeast protein, located between residues 50 and 84, was not required for the stability, membrane association, interaction with Lcb2p, or enzymatic activity. Deletion of the comparable domain of the mammalian protein SPTLC1 also had little effect on its function, demonstrating that this region is not required for membrane localization or heterodimerization with SPTLC2. The second and third membrane-spanning domains of yeast Lcb1p, located between residues 342 and 371 and residues 425 and 457, respectively, create a luminal loop of similar to60 residues. In contrast to the first membrane-spanning domain, the second and third membrane-spanning domains were both required for Lcb1p stability. In addition, mutations in the luminal loop destabilized the SPT heterodimer indicating that this region of the protein is important for SPT structure and function. Mutations in the extreme carboxyl-terminal region of Lcb1p also disrupted heterodimer formation. Taken together, these data suggest that in contrast to other members of the alpha-oxoamine synthases that are soluble homodimers, the Lcb1p and Lcb2p subunits of the SPT heterodimer may interact in the cytosol, as well as within the membrane and/or the lumen of the endoplasmic reticulum.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	tdunn@usuhs.mil		Natarajan, Mukil/0000-0001-8908-7306; Harmon, Jeffrey/0000-0001-7833-931X	NINDS NIH HHS [NS47717] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047717] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Dunn TM, 2000, METHOD ENZYMOL, V312, P317; El Bawab S, 2002, J LIPID RES, V43, P141; Gable K, 2002, J BIOL CHEM, V277, P10194, DOI 10.1074/jbc.M107873200; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Sherman F., 1986, METHODS YEAST GENETI; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Uhlinger DJ, 2001, THROMB HAEMOSTASIS, V86, P1320; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200	30	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53707	53716		10.1074/jbc.M410014200	http://dx.doi.org/10.1074/jbc.M410014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485854	hybrid			2022-12-27	WOS:000225680600108
J	O'Leary, JM; Hamilton, JM; Deane, CM; Valeyev, NV; Sandell, LJ; Downing, AK				O'Leary, JM; Hamilton, JM; Deane, CM; Valeyev, NV; Sandell, LJ; Downing, AK			Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand factor type c module) from collagen IIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; EARLY MOUSE DEVELOPMENT; GROWTH-FACTOR BINDING; AMINO-PROPEPTIDE; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; EXTRACELLULAR-MATRIX; STRUCTURE PREDICTION; COUPLING-CONSTANTS; CHEMICAL-EXCHANGE	Chordin-like cysteine-rich (CR) repeats ( also referred to as von Willebrand factor type C (VWC) modules) have been identified in similar to200 extracellular matrix proteins. These repeats, named on the basis of amino acid conservation of 10 cysteine residues, have been shown to bind members of the transforming growth factor-beta (TGF-beta) superfamily and are proposed to regulate growth factor signaling. Here we describe the intramolecular disulfide bonding, solution structure, and dynamics of a prototypical chordin-like CR repeat from procollagen IIA (CRColIIA), which has been previously shown to bind TGF-beta1 and bone morphogenetic protein-2. The CRColIIA structure manifests a two sub-domain architecture tethered by a flexible linkage. Initial structures were calculated using RosettaNMR, a de novo prediction method, and final structure calculations were performed using CANDID within CYANA. The N-terminal region contains mainly beta-sheet and the C-terminal region is more irregular with the fold constrained by disulfide bonds. Mobility between the N- and C-terminal sub-domains on a fast time-scale was confirmed using NMR relaxation measurements. We speculate that the mobility between the two sub-domains may decrease upon ligand binding. Structure and sequence comparisons have revealed an evolutionary relationship between the N- terminal sub-domain of the CR module and the fibronectin type 1 domain, suggesting that these domains share a common ancestry. Based on the previously reported mapping of fibronectin binding sites for vascular endothelial growth factor to regions containing fibronectin type 1 domains, we discuss the possibility that this structural homology might also have functional relevance.	Univ Oxford, Dept Biochem, Div Struct Biol, Oxford OX1 3QU, England; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA	University of Oxford; University of Oxford; Washington University (WUSTL)	Downing, AK (corresponding author), Univ Oxford, Dept Biochem, Div Struct Biol, South Pks Rd, Oxford OX1 3QU, England.	kristy.downing@bioch.ox.ac.uk		Deane, Charlotte/0000-0003-1388-2252				Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Aigner T, 1999, ARTHRITIS RHEUM, V42, P1443, DOI 10.1002/1529-0131(199907)42:7<1443::AID-ANR18>3.0.CO;2-A; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Bachiller D, 2000, NATURE, V403, P658, DOI 10.1038/35001072; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BISHOP PN, 1994, BIOCHEM BIOPH RES CO, V203, P289, DOI 10.1006/bbrc.1994.2180; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; Chivian D, 2003, PROTEINS, V53, P524, DOI 10.1002/prot.10529; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; Diao JS, 1997, ACTA CRYSTALLOGR D, V53, P507, DOI 10.1107/S0907444997004034; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Foley SF, 2003, EUR J BIOCHEM, V270, P3610, DOI 10.1046/j.1432-1033.2003.03749.x; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Innis CA, 2000, PROTEIN ENG, V13, P839, DOI 10.1093/protein/13.12.839; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Larrain J, 2000, DEVELOPMENT, V127, P821; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUI VCH, 1995, DEV DYNAM, V203, P198, DOI 10.1002/aja.1002030208; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Meissner A, 1997, J BIOMOL NMR, V10, P89, DOI 10.1023/A:1018331001961; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; OLEARY JM, 2004, IN PRESS PROTEIN EXP; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Reardon A, 2000, MATRIX BIOL, V19, P169, DOI 10.1016/S0945-053X(00)00058-5; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SATTLER M, 1995, J BIOMOL NMR, V5, P97, DOI 10.1007/BF00227475; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Shakhnovich BE, 2003, J MOL BIOL, V326, P1, DOI 10.1016/S0022-2836(02)01362-1; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; SWIDERSKI RE, 1994, DEV DYNAM, V200, P294, DOI 10.1002/aja.1002000404; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; WILLIAMS RW, 1984, BIOCHEMISTRY-US, V23, P6796, DOI 10.1021/bi00321a080; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	77	70	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53857	53866		10.1074/jbc.M409225200	http://dx.doi.org/10.1074/jbc.M409225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466413	hybrid			2022-12-27	WOS:000225680600124
J	Pandey, RR; Ceribelli, M; Singh, PB; Ericsson, J; Mantovani, R; Kanduri, C				Pandey, RR; Ceribelli, M; Singh, PB; Ericsson, J; Mantovani, R; Kanduri, C			NF-Y regulates the antisense promoter, bidirectional silencing, and differential epigenetic marks of the Kcnq1 imprinting control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; DE-NOVO METHYLATION; BINDING PROTEINS; RNA; DNA; TRANSCRIPTION; COMPONENTS; MOUSE; H19	Antisense transcription has been shown to be one of the hierarchies that control gene expression in eukaryotes. Recently, we have documented that the mouse Kcnq1 imprinting control region (ICR) harbors bidirectional silencing property, and this feature is linked to an antisense RNA, Kcnq1ot1. In this investigation, using genomic footprinting, we have identified three NF-Y transcription factor binding sites appearing in a methylation-sensitive manner in the Kcnq1ot1 promoter. By employing a dominant negative mutant to the NF-Y transcription factor, we have shown that the NF-Y transcription factor positively regulates antisense transcription. Selective mutation of the conserved nucleotides in the NF-Y binding sites resulted in the loss of antisense transcription. The loss of antisense transcription from the Kcnq1ot1 promoter coincides with an enrichment in the levels of deacetylation and methylation at the lysine 9 residue of histone H3 and DNA methylation at the CpG residues, implying a crucial role for the NF-Y transcription factor in organizing the parent of origin-specific chromatin conformation in the Kcnq1 ICR. Parallel to the loss of antisense transcription, the loss of silencing of the flanking reporter genes was observed, suggesting that NF-Y-mediated Kcnq1ot1 transcription is critical in the bidirectional silencing process of the Kcnq1 ICR. These data highlight the NF-Y transcription factor as a crucial regulator of antisense promoter-mediated bidirectional silencing and the parent of origin-specific epigenetic marks at the Kcnq1 ICR. More importantly, for the first time, we document that NF-Y is involved in maintaining the antisense promoter activity against strong silencing conditions.	Uppsala Univ, Evolutionary Biol Centrum, Dept Genet & Dev, SE-75236 Uppsala, Sweden; Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland; Ludwig Inst Canc Res, Ctr Biomed, Gene Express Lab, S-75124 Uppsala, Sweden	Uppsala University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Ludwig Institute for Cancer Research	Kanduri, C (corresponding author), Uppsala Univ, Evolutionary Biol Centrum, Dept Genet & Dev, Norbyvagen 18A, SE-75236 Uppsala, Sweden.	kanduri.chandrasekhar@ebc.uu.se	Ericsson, Johan/AAA-6664-2020; Pandey, Radha Raman/AAQ-8593-2020; Singh, Prim/G-1088-2014	Ericsson, Johan/0000-0003-1186-6574; Pandey, Radha Raman/0000-0002-4439-8386; Singh, Prim/0000-0002-9571-0974; Kanduri, Chandrasekhar/0000-0001-6271-9078				Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chandrasekhar K, 1997, MOL REPROD DEV, V48, P421; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Du MJ, 2004, GENOMICS, V84, P288, DOI 10.1016/j.ygeno.2004.03.008; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Grange T, 1997, METHODS, V11, P151, DOI 10.1006/meth.1996.0401; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; Jeffery L, 2004, J BIOL CHEM, V279, P49479, DOI 10.1074/jbc.M409070200; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Kanduri C, 2002, CANCER RES, V62, P4545; Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Thakur N, 2004, MOL CELL BIOL, V24, P7855, DOI 10.1128/MCB.24.18.7855-7862.2004; Thakur N, 2003, J BIOL CHEM, V278, P9514, DOI 10.1074/jbc.M212203200; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	23	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52685	52693		10.1074/jbc.M408084200	http://dx.doi.org/10.1074/jbc.M408084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459184	hybrid			2022-12-27	WOS:000225493400115
J	Torban, E; Wang, HJ; Groulx, N; Gros, P				Torban, E; Wang, HJ; Groulx, N; Gros, P			Independent mutations in mouse Vangl2 that cause neural tube defects in looptail mice impair interaction with members of the Dishevelled family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR CELL-POLARITY; DROSOPHILA TISSUE POLARITY; PDZ DOMAINS; CONVERGENT EXTENSION; SIGNALING PATHWAYS; NATURAL-RESISTANCE; GENE; STRABISMUS; PROTEIN; GASTRULATION	Mammalian Vangl1 and Vangl2 are highly conserved membrane proteins that have evolved from a single ancestral protein Strabismus/Van Gogh found in Drosophila. Mutations in the Vangl2 gene cause a neural tube defect (craniorachischisis) characteristic of the looptail (Lp) mouse. Studies in model organisms indicate that Vangl proteins play a key developmental role in establishing planar cell polarity (PCP) and in regulating convergent extension (CE) movements during embryogenesis. The role of Vangl1 in these processes is virtually unknown, and the molecular function of Vangl1 and Vangl2 in PCP and CE is poorly understood. Using a yeast two-hybrid system, glutathione S-transferase pull-down and co-immunoprecipitation assays, we show that both mouse Vangl1 and Vangl2 physically interact with the three members of the cytoplasmic Dishevelled (Dvl) protein family. This interaction is shown to require both the predicted cytoplasmic C-terminal half of Vangl1/2 and a portion of the Dvl protein containing PDZ and DIX domains. In addition, we show that the two known Vangl2 loss-of-function mutations identified in two independent Lp alleles associated with neural tube defects impair binding to Dvl1, Dvl2, and Dvl3. These findings suggest a molecular mechanism for the neural tube defect seen in Lp mice. Our observations indicate that Vangl1 biochemical properties parallel those of Vangl2 and that Vangl1 might, therefore, participate in PCP and CE either in concert with Vangl2 or independently of Vangl2 in discrete cell types.	McGill Univ, Dept Biochem, Ctr Host Resistance, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, Ctr Host Resistance, 3655 Drummond St,Rm 907, Montreal, PQ H3G 1Y6, Canada.	philippe.gros@mcgill.ca						Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Carreira-Barbosa F, 2003, DEVELOPMENT, V130, P4037, DOI 10.1242/dev.00567; Chae J, 1999, DEVELOPMENT, V126, P5421; Copp AJ, 2003, NAT REV GENET, V4, P784, DOI 10.1038/nrg1181; Courville P, 2004, J BIOL CHEM, V279, P3318, DOI 10.1074/jbc.M309913200; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Frey L, 2003, EPILEPSIA, V44, P4, DOI 10.1046/j.1528-1157.44.s3.2.x; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Gubb D, 1999, GENE DEV, V13, P2315, DOI 10.1101/gad.13.17.2315; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; Jenny A, 2003, EMBO J, V22, P4409, DOI 10.1093/emboj/cdg424; Jessen JR, 2004, GENE EXPR PATTERNS, V4, P339, DOI 10.1016/j.modgep.2003.09.012; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Katoh M, 2002, INT J MOL MED, V10, P11; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kibar Z, 2003, GENOMICS, V82, P397, DOI 10.1016/S0888-7543(03)00113-7; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kibar Z, 2001, GENOMICS, V72, P331, DOI 10.1006/geno.2000.6493; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Penton A, 2002, GENETICS, V161, P747; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Takeuchi M, 2003, CURR BIOL, V13, P674, DOI 10.1016/S0960-9822(03)00245-8; Taylor J, 1998, GENETICS, V150, P199; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vidal SM, 1996, J IMMUNOL, V157, P3559; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wolff T, 1998, DEVELOPMENT, V125, P1149	50	131	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52703	52713		10.1074/jbc.M408675200	http://dx.doi.org/10.1074/jbc.M408675200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456783	hybrid			2022-12-27	WOS:000225493400117
J	Firlej, V; Bocquet, B; Desbiens, X; de Launoit, Y; Chotteau-Lelievre, A				Firlej, V; Bocquet, B; Desbiens, X; de Launoit, Y; Chotteau-Lelievre, A			Pea3 transcription factor cooperates with USF-1 in regulation of the murine bax transcription without binding to an Ets-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND DEVELOPMENT; DUCT-LIKE STRUCTURES; ONCOGENE FAMILY; MOLECULAR-CLONING; EPITHELIAL-CELLS; BREAST-CANCER; DNA-BINDING; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; PROTEIN-PROTEIN	The Pea3 transcription factor (which belongs to the PEA3 group) from the Ets family has been shown to be involved in mammary embryogenesis and oncogenesis. However, except for proteinases, only few of its target genes have been reported. In the present report, we identified bax as a Pea3 up-regulated gene. We provide evidence of this regulation by using Pea3 overexpression and Pea3 silencing in a mammary cell line. Both Pea3 and Erm, another member of the PEA3 group, are able to transactivate bax promoter fragments. Although the minimal Pea3-regulated bax promoter does not contain an Ets-binding site, two functional upstream stimulatory factor-regulated E boxes are present. We further demonstrate the ability of Pea3 and USF-1 to cooperate for the transactivation of the bax promoter, mutation of the E boxes dramatically reducing the Pea3 transactivation potential. Although Pea3 did not directly bind to the minimal bax promoter, we provide evidence that USF-1 could form a ternary complex with Pea3 and DNA. Taken together, our results suggest that Pea3 may regulate bax transcription via the interaction with USF-1 but without binding to DNA.	Univ Sci & Technol Lille, Lab Biol Dev UPRES EA1033, F-59655 Villeneuve Dascq, France; Inst Pasteur, Inst Biol Lille, USTL, CNRS,UMR 8117, F-59021 Lille, France; ULB, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite Libre de Bruxelles	Chotteau-Lelievre, A (corresponding author), Univ Sci & Technol Lille, Lab Biol Dev UPRES EA1033, F-59655 Villeneuve Dascq, France.	anne.chotteau@ibl.fr	Bocquet, Beatrice/AAY-8447-2020; Firlej, Virginie/AFQ-6362-2022; Firlej, Virginie/R-2065-2018	Bocquet, Beatrice/0000-0002-6369-4818; Firlej, Virginie/0000-0003-4132-0695; 				Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bieche I, 2004, CARCINOGENESIS, V25, P405, DOI 10.1093/carcin/bgh024; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Chotteau-Lelievre A, 2004, CLIN CANCER RES, V10, P7297, DOI 10.1158/1078-0432.CCR-04-0593; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; COGNET M, 1991, J BIOL CHEM, V266, P7368; Coletta RD, 2004, J MAMMARY GLAND BIOL, V9, P39, DOI 10.1023/B:JOMG.0000023587.40966.f6; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Drevet JR, 1998, MOL REPROD DEV, V49, P131, DOI 10.1002/(SICI)1098-2795(199802)49:2<131::AID-MRD4>3.0.CO;2-Q; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; Laget MP, 1996, ONCOGENE, V12, P1325; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Liu YM, 2004, J BIOL CHEM, V279, P18694, DOI 10.1074/jbc.M308136200; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Lynch CC, 2004, INT J ONCOL, V24, P1565; MIYASHITA T, 1995, CELL, V80, P293; MONTE D, 1994, ONCOGENE, V9, P1397; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Perez A, 2003, J BIOL CHEM, V278, P36942, DOI 10.1074/jbc.M300264200; Roehl H, 2001, CURR BIOL, V11, P503, DOI 10.1016/S0960-9822(01)00143-9; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Soriano JV, 1996, BIOCHEM BIOPH RES CO, V220, P879, DOI 10.1006/bbrc.1996.0499; SORIANO JV, 1995, J CELL SCI, V108, P413; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wick W, 2001, J NEUROSCI, V21, P3360, DOI 10.1523/JNEUROSCI.21-10-03360.2001; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yan SQ, 2003, BIOL CHEM, V384, P1421, DOI 10.1515/BC.2003.157	66	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					887	898		10.1074/jbc.M408017200	http://dx.doi.org/10.1074/jbc.M408017200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15466854	hybrid			2022-12-27	WOS:000226195200007
J	Li, DX; Hirsila, M; Koivunen, P; Brenner, MC; Xu, L; Yang, C; Kivirikko, KI; Myllyharju, J				Li, DX; Hirsila, M; Koivunen, P; Brenner, MC; Xu, L; Yang, C; Kivirikko, KI; Myllyharju, J			Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1 alpha-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases - Substitution of 3,4-dehydroproline or azetidine-2-carboxylic acid for the proline leads to a high rate of uncoupled 2-oxoglutarate decarboxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN; PROTEIN; ALPHA; HYDROXYPROLINE; RECOGNITION; DESTRUCTION; SUBUNIT; REVEALS; COMPLEX; ENZYMES	Three human prolyl 4-hydroxylases (P4Hs) regulate the hypoxia-inducible transcription factors (HIFs) by hydroxylating a Leu-Xaa-Xaa-Leu-Ala-Pro motif. We report here that the two leucines in the Leu-Glu-Met-Leu-Ala-Pro core motif of a 20-residue peptide corresponding to the sequence around Pro(564) in HIF-1alpha can be replaced by many residues with no or only a modest decrease in its substrate properties or in some cases even a slight increase. The glutamate and methionine could be substituted by almost any residue, eight amino acids in the former position and four in the latter being even better for HIF-P4H-3 than the wild-type residues. Alanine was by far the strictest requirement, because no residue could fully substitute for it in the case of HIF-P4H-1, and only serine or isoleucine, valine, and serine did this in the cases of HIF-P4Hs 2 and 3. Peptides with more than one substitution, having the core sequences Trp-Glu-Met-Val-Ala-Pro, Tyr-Glu-Met-Ile-Ala-Pro, Ile-Glu-Met-Ile-Ala-Pro, Trp-Glu-Met-Val-Ser-Pro, and Trp-Glu-Ala-Val-Ser-Pro were in most cases equally as good or almost as good substrates as the wild-type peptide. The acidic residues present in the 20-residue peptide also played a distinct role, but alanine substitution for any six of them, and in some combinations even three of them, had no negative effects. Substitution of the proline by 3,4-dehydroproline or L-azetidine-2-carboxylic acid, but not any other residue, led to a high rate of uncoupled 2-oxoglutarate decarboxylation with no hydroxylation. The data obtained for the three HIF-P4Hs in various experiments were in most cases similar, but in some cases HIF-P4H-3 showed distinctly different properties.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; DEJONG L, 1984, BIOCHIM BIOPHYS ACTA, V787, P105; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Wu M, 2000, BIOORG MED CHEM LETT, V10, P1511, DOI 10.1016/S0960-894X(00)00224-9; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	32	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55051	55059		10.1074/jbc.M410287200	http://dx.doi.org/10.1074/jbc.M410287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485863	hybrid			2022-12-27	WOS:000225960800010
J	Liu, J; Ernst, SA; Gladycheva, SE; Lee, YYF; Lentz, SI; Ho, CS; Li, QW; Stuenkel, EL				Liu, J; Ernst, SA; Gladycheva, SE; Lee, YYF; Lentz, SI; Ho, CS; Li, QW; Stuenkel, EL			Fluorescence resonance energy transfer reports properties of syntaxin1A interaction with Munc18-1 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; SYNAPTIC VESICLE DOCKING; PROTEIN-PROTEIN INTERACTIONS; N-TERMINAL DOMAIN; NEUROTRANSMITTER RELEASE; CALCIUM-CHANNELS; 3-DIMENSIONAL STRUCTURE; TRANSMITTER RELEASE; MEMBRANE-FUSION; RAT-BRAIN	Syntaxin1A, a neural-specific N-ethylmaleimide-sensitive factor attachment protein receptor protein essential to neurotransmitter release, in isolation forms a closed conformation with an N-terminal alpha-helix bundle folded upon the SNARE motif (H3 domain), thereby limiting interaction of the H3 domain with cognate SNAREs. Munc18-1, a neural-specific member of the Sec1/Munc18 protein family, binds to syntaxin1A, stabilizing this closed conformation. We used fluorescence resonance energy transfer (FRET) to characterize the Munc18-1/syntaxin1A interaction in intact cells. Enhanced cyan fluorescent protein-Munc18-1 and a citrine variant of enhanced yellow fluorescent protein-syntaxin1A, or mutants of these proteins, were expressed as donor and acceptor pairs in human embryonic kidney HEK293-S3 and adrenal chromaffin cells. Apparent FRET efficiency was measured using two independent approaches with complementary results that unambiguously verified FRET and provided a spatial map of FRET efficiency. In addition, enhanced cyan fluorescent protein-Munc18-1 and a citrine variant of enhanced yellow fluorescent protein-syntaxin1A colocalized with a Golgi marker and exhibited FRET at early expression times, whereas a strong plasma membrane colocalization, with similar FRET values, was apparent at later times. Trafficking of syntaxin1A to the plasma membrane was dependent on the presence of Munc18-1. Both syntaxin1A(L165A/E166A), a constitutively open conformation mutant, and syntaxin1A(I233A), an H3 domain point mutant, demonstrated apparent FRET efficiency that was reduced similar to70% from control. In contrast, the H3 domain mutant syntaxin1A(I209A) had no effect. By using phosphomimetic mutants of Munc18-1, we also established that Ser-313, a Munc18-1 protein kinase C phosphorylation site, and Thr-574, a cyclin-dependent kinase 5 phosphorylation site, regulate Munc18-1/syntaxin1A interaction in HEK293-S3 and chromaffin cells. We conclude that FRET imaging in living cells may allow correlated regulation of Munc18-1/syntaxin1A interactions to Ca2+-regulated secretory events.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Michigan Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Stuenkel, EL (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 7807 Med Sci II Bldg, Ann Arbor, MI 48109 USA.	esterm@umich.edu		Stuenkel, Edward/0000-0001-8225-5725; Lentz, Stephen/0000-0003-1686-7998	NINDS NIH HHS [NS 39914] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039914] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Betz A, 1997, J BIOL CHEM, V272, P2520; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Degtiar VE, 2000, J NEUROSCI, V20, P4355, DOI 10.1523/JNEUROSCI.20-12-04355.2000; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fisher RJ, 1999, PFLUG ARCH EUR J PHY, V437, P754, DOI 10.1007/s004240050842; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Gladycheva SE, 2004, J PHYSIOL-LONDON, V558, P857, DOI 10.1113/jphysiol.2004.067249; Graham ME, 2004, J BIOL CHEM, V279, P32751, DOI 10.1074/jbc.M400827200; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Li QW, 2003, J PHYSIOL-LONDON, V550, P431, DOI 10.1113/jphysiol.2003.039073; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Marsal J, 1997, P NATL ACAD SCI USA, V94, P14871, DOI 10.1073/pnas.94.26.14871; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Phillips GN, 1997, CURR OPIN STRUC BIOL, V7, P821, DOI 10.1016/S0959-440X(97)80153-4; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; Rowe J, 2001, J CELL SCI, V114, P3323; Rowe J, 1999, J CELL SCI, V112, P1865; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SNYDER B, 1982, BIOPHYS J, V40, P137, DOI 10.1016/S0006-3495(82)84468-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Stanley EF, 2003, EUR J NEUROSCI, V18, P2403, DOI 10.1046/j.1460-9568.2003.02948.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; Toonen RFG, 2003, BIOCHEM SOC T, V31, P848, DOI 10.1042/BST0310848; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Wu MN, 2001, EUR J CELL BIOL, V80, P196, DOI 10.1078/0171-9335-00143; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	71	41	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55924	55936		10.1074/jbc.M410024200	http://dx.doi.org/10.1074/jbc.M410024200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489225	hybrid			2022-12-27	WOS:000225960800116
J	Nakata, S; Matsumura, I; Tanaka, H; Ezoe, S; Satoh, Y; Ishikawa, J; Era, T; Kanakura, Y				Nakata, S; Matsumura, I; Tanaka, H; Ezoe, S; Satoh, Y; Ishikawa, J; Era, T; Kanakura, Y			NF-kappa B family proteins participate in multiple steps of hematopoiesis through elimination of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE-DEPENDENT GROWTH; TRANSCRIPTION FACTORS; MICE LACKING; SPLENIC MICROARCHITECTURE; TARGETED DISRUPTION; IMMUNE-RESPONSES; EXHIBIT DEFECTS; CELL LINE; EXPRESSION; APOPTOSIS	examine the roles for NF-kappaB family proteins in hematopoiesis, we first expressed dominant negative Rel/NF-kappaB (IkappaBSR) in a factor-dependent cell line, Ba/F3. Although IkappaBSR neither affected thrombopoietindependent nor gp130-mediated growth, it suppressed interleukin-3- and erythropoietin-dependent growth at low concentrations. In addition, IkappaBSR enhanced factor-deprived apoptosis through the accumulation of reactive oxygen species (ROS). When expressed in normal hematopoietic stem/progenitor cells, IkappaBSR induced apoptosis even in the presence of appropriate cytokines by accumulating ROS. We also expressed IkappaBSR in an inducible fashion at various stages of hematopoiesis using the OP9 system, in which hematopoietic cells are induced to develop from embryonic stem cells. When IkappaBSR was expressed at the stage of Flk-1(+) cells (putative hemangioblasts), IkappaBSR inhibited the development of primitive hematopoietic progenitor cells by inducing apoptosis through the ROS accumulation. Furthermore, when IkappaBSR was expressed after the development of hematopoietic progenitor cells, it inhibited their terminal differentiation toward erythrocytes, megakaryocytes, and granulocytes by inducing apoptosis through the ROS accumulation. These results indicate that NF-kappaB is required for preventing apoptosis at multiple steps of hematopoiesis by eliminating ROS.	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; RIKEN Ctr Dev Biol, Stem Cell Biol Grp, Tyuo Ku, Kobe, Hyogo 6500047, Japan	Osaka University; RIKEN	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	matumura@bldon.med.osaka-u.ac.jp						Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Kataoka Y, 2003, J BIOL CHEM, V278, P44178, DOI 10.1074/jbc.M304884200; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MATSUMURA I, 1995, BLOOD, V86, P703, DOI 10.1182/blood.V86.2.703.bloodjournal862703; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pyatt DW, 1999, BLOOD, V93, P3302, DOI 10.1182/blood.V93.10.3302.410a38_3302_3308; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	43	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55578	55586		10.1074/jbc.M408238200	http://dx.doi.org/10.1074/jbc.M408238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485843	hybrid			2022-12-27	WOS:000225960800075
J	Orcutt, SJ; Krishnaswamy, S				Orcutt, SJ; Krishnaswamy, S			Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XA; MACROMOLECULAR SUBSTRATE; FACTOR-VA; CATALYZED ACTIVATION; BOVINE TRYPSINOGEN; REACTION-MECHANISM; CRYSTAL-STRUCTURE; EXOSITE BINDING; COMPLEX; MEIZOTHROMBIN	Thrombin formation results from cleavage of prothrombin following Arg(271) and Arg(320). Both bonds are accessible for cleavage, yet the sequential action of prothrombinase on Arg(320) followed by Arg(271) is implied by the intermediate observed during prothrombin activation. We have studied the individual cleavage reactions catalyzed by prothrombinase by using a series of recombinant derivatives: wild type prothrombin (IIWT) contained both cleavage sites; IIQ271 contained a single cleavable site at Arg(320); IIQ320 and IIA320 contained a single cleavable site at Arg(271); and IIQQ was resistant to cleavage. Cleavage at Arg(320) in IIQ271 could account for the initial cleavage reaction leading to the consumption of either plasma prothrombin or IIWT, whereas cleavage at Arg(271) in either IIQ320 or IIA320 was found to be similar to30-fold slower. Equivalent kinetic constants were obtained for three of the four possible half-reactions. Slow cleavage at Arg(271) in intact prothrombin resulted from an similar to 30-fold reduction in V-max. Thus, the observed pathway of bond cleavage by prothrombinase can be explained by the kinetic constants for the four possible individual cleavage reactions. IIQ320 was a competitive inhibitor of IIQ271 cleavage, and IIQQ was a competitive inhibitor for each reaction with K-i approximate to K-m. The data are inconsistent with previous proposals and suggest a model in which substrates for each of the four possible half-reactions bind in a mutually exclusive manner and with equal affinity to prothrombinase in a cleavage site-independent way. Despite equivalent exosite binding interactions between all four possible substrates and the enzyme, we propose that ordered bond cleavage results from the constraints associated with the binding of substrates in one of two conformations to a single form of prothrombinase.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310A Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NHLBI NIH HHS [HL-74124, HL-62523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062523, P01HL074124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; BILLY D, 1995, J BIOL CHEM, V270, P26883, DOI 10.1074/jbc.270.45.26883; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Boskovic DS, 2004, J BIOL CHEM, V279, P20786, DOI 10.1074/jbc.M400469200; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; ESMON CT, 1974, J BIOL CHEM, V249, P7782; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; Moore J.W., 1981, KINETICS MECH, V3rd, P284; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; PRICE PA, 1983, METHOD ENZYMOL, V91, P13; ROSING J, 1986, J BIOL CHEM, V261, P4224; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; TANS G, 1991, J BIOL CHEM, V266, P21864; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Weinreb GE, 2003, J BIOL CHEM, V278, P5679, DOI 10.1074/jbc.M208423200; YE J, 1995, BIOCHEMISTRY-US, V34, P6448, DOI 10.1021/bi00019a026	49	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54927	54936		10.1074/jbc.M410866200	http://dx.doi.org/10.1074/jbc.M410866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494418	hybrid			2022-12-27	WOS:000225793600122
J	Yang, JC; Wong, RK; Wang, XJ; Moibi, J; Hessner, MJ; Greene, S; Wu, JM; Sukumvanich, S; Wolf, BA; Gao, ZY				Yang, JC; Wong, RK; Wang, XJ; Moibi, J; Hessner, MJ; Greene, S; Wu, JM; Sukumvanich, S; Wolf, BA; Gao, ZY			Leucine culture reveals that ATP synthase functions as a fuel sensor in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; HUMAN SKELETAL-MUSCLE; UNCOUPLING PROTEIN-2; ADENINE-NUCLEOTIDES; SIGNALING PATHWAY; RAT ISLETS; B-CELLS; GLUCOSE; GLUCOKINASE; RELEASE	Our goal was to investigate whether leucine culture affects beta-cell glucose sensing. One-day culture of rat islets with 10 mM leucine had no effect on glucose-induced insulin secretion. One-week leucine culture decreased the threshold for glucose-induced insulin secretion and increased maximal insulin secretion at 30 mM glucose. Glucose-induced cytosolic free Ca2+ was increased at 1 week but not at 1 day of leucine culture. Without glucose, ATP content was not different with or without leucine culture for 1 week. With 20 mM glucose, ATP content was higher by 1.5-fold in islets cultured for 1 week with leucine than those without leucine. Microarray experiments indicated that culture of RINm5F cells with leucine increased expression of ATP synthase beta subunit 3.2-fold, which was confirmed by real time reverse transcription-PCR analysis (3.0-+/-0.4-fold) in rat islets at 1 week but not after 1 day with leucine culture. Down-regulation of ATP synthase beta subunit by siRNA decreased INS1 cell ATP content and insulin secretion with 20 mM glucose. Overexpression of ATP synthase beta subunit in INS1 cell increased insulin secretion in the presence of 5 and 20 mM glucose. In conclusion, one-week leucine culture of rat islets up-regulated ATP synthase and increased ATP content, which resulted in elevated [Ca2+] levels and more insulin exocytosis by glucose. Depletion of ATP synthase beta subunit with siRNA produced opposite effects. These data reveal the fuel-sensing role of mitochondrial ATP synthase in the control of ATP production from glucose and the control of glucose-induced insulin secretion.	Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Medical College of Wisconsin	Gao, ZY (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, 803 Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	gao@email.chop.edu						Anello M, 2001, AM J PHYSIOL-ENDOC M, V281, pE1082, DOI 10.1152/ajpendo.2001.281.5.E1082; Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Brownlee M, 2003, J CLIN INVEST, V112, P1788, DOI 10.1172/JCI200320501; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Fitzhugh DJ, 2000, J IMMUNOL, V165, P6677, DOI 10.4049/jimmunol.165.12.6677; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; He J, 2001, DIABETES, V50, P817, DOI 10.2337/diabetes.50.4.817; Hojlund K, 2003, J BIOL CHEM, V278, P10436, DOI 10.1074/jbc.M212881200; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Kutlu B, 2003, DIABETES, V52, P348, DOI 10.2337/diabetes.52.2.348; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lee SH, 2003, J HISTOCHEM CYTOCHEM, V51, P1005, DOI 10.1177/002215540305100804; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Lin X, 2003, J VIROL, V77, P8227, DOI 10.1128/JVI.77.15.8227-8236.2003; Liu YJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE380, DOI 10.1152/ajpendo.00008.2003; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Massa O, 2001, DIABETOLOGIA, V44, P898; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Patti Mary-Elizabeth, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P89; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Weinhaus AJ, 2003, J CLIN ENDOCR METAB, V88, P2753, DOI 10.1210/jc.2002-021542; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; Zhang DD, 2001, MT RES DEV, V21, P61, DOI 10.1659/0276-4741(2001)021[0061:TCFLOT]2.0.CO;2	41	28	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53915	53923		10.1074/jbc.M405309200	http://dx.doi.org/10.1074/jbc.M405309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489222	hybrid			2022-12-27	WOS:000225793600004
J	Barney, BM; Igarashi, RY; Dos Santos, PC; Dean, DR; Seefeldt, LC				Barney, BM; Igarashi, RY; Dos Santos, PC; Dean, DR; Seefeldt, LC			Substrate interaction at an iron-sulfur face of the FeMo-cofactor during nitrogenase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MOFE-PROTEIN; CLOSTRIDIUM-PASTEURIANUM; ACETYLENE-REDUCTION; MOLYBDENUM; DINITROGEN; BINDING; INTERMEDIATE; LOCALIZATION; CHROOCOCCUM	Nitrogenase catalyzes biological dinitrogen fixation, the reduction of N-2 to 2NH(3). Recently, the binding site for a non-physiological alkyne substrate (propargyl alcohol, HCequivalent toC-CH2OH) was localized to a specific Fe-S face of the FeMo-cofactor approached by the MoFe protein amino acid alpha-70(Val). Here we provide evidence to indicate that the smaller alkyne substrate acetylene (HCequivalent toCH), the physiological substrate dinitrogen, and its semi-reduced form hydrazine (H2N-NH2) interact with the same Fe-S face of the FeMo-cofactor. Hydrazine is a relatively poor substrate for the wild-type (alpha-70(Val)) MoFe protein. Substitution of the alpha-70(Val) residue by an amino acid having a smaller side chain (alanine) dramatically enhanced hydrazine reduction activity. Conversely, substitution of alpha-70(Val) by an amino acid having a larger side chain (isoleucine) significantly lowered the capacity of the MoFe protein to reduce dinitrogen, hydrazine, or acetylene.	Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Virginia Polytechnic Institute & State University; Utah System of Higher Education; Utah State University	Dean, DR (corresponding author), Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA.	deandr@vt.edu; seefeldt@cc.usu.edu	Barney, Brett M/A-6125-2013	Barney, Brett M/0000-0002-5976-5492; Seefeldt, Lance/0000-0002-6457-9504; Dos Santos, Patricia/0000-0002-3364-0931	NIGMS NIH HHS [GM-59087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benton PMC, 2003, BIOCHEMISTRY-US, V42, P9102, DOI 10.1021/bi034595x; Benton PMC, 2001, J AM CHEM SOC, V123, P1822, DOI 10.1021/ja003662x; Benton PMC, 2001, BIOCHEMISTRY-US, V40, P13816, DOI 10.1021/bi011571m; Betley TA, 2003, J AM CHEM SOC, V125, P10782, DOI 10.1021/ja036687f; Chan JM, 1999, BIOCHEMISTRY-US, V38, P5779, DOI 10.1021/bi982866b; Christiansen J, 2000, PROKARYOTIC NITROGEN FIXATION, P101; Christiansen J, 2000, J BIOL CHEM, V275, P36104, DOI 10.1074/jbc.M004889200; Christiansen J, 2000, J BIOL CHEM, V275, P11459, DOI 10.1074/jbc.275.15.11459; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Cui Z, 2003, INORG CHEM, V42, P6252, DOI 10.1021/ic030108q; Dance I, 2003, CHEM COMMUN, P324, DOI 10.1039/b211036a; DAVIS LC, 1980, ARCH BIOCHEM BIOPHYS, V204, P270, DOI 10.1016/0003-9861(80)90033-8; DILWORTH MJ, 1991, BIOCHEM J, V277, P465, DOI 10.1042/bj2770465; DILWORTH MJ, 1966, BIOCHIM BIOPHYS ACTA, V127, P285, DOI 10.1016/0304-4165(66)90383-7; DILWORTH MJ, 1993, BIOCHEM J, V289, P395, DOI 10.1042/bj2890395; Durrant MC, 2002, BIOCHEMISTRY-US, V41, P13934, DOI 10.1021/bi025623z; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Fisher K, 2000, BIOCHEMISTRY-US, V39, P15570, DOI 10.1021/bi0017834; HWANG JC, 1973, BIOCHIM BIOPHYS ACTA, V292, P256, DOI 10.1016/0005-2728(73)90270-3; Igarashi RY, 2004, J BIOL CHEM, V279, P34770, DOI 10.1074/jbc.M403194200; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Lee HI, 2004, J AM CHEM SOC, V126, P9563, DOI 10.1021/ja048714n; Mayer SM, 2002, J CHEM SOC DALTON, P802, DOI 10.1039/b107336b; RIVERAORTIZ JM, 1975, J BACTERIOL, V123, P537, DOI 10.1128/JB.123.2.537-545.1975; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; Smith JM, 2001, J AM CHEM SOC, V123, P9222, DOI 10.1021/ja016094+; THORNELEY RNF, 1978, NATURE, V272, P557, DOI 10.1038/272557a0; Vela J, 2004, J AM CHEM SOC, V126, P4522, DOI 10.1021/ja049417l; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326	33	114	115	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53621	53624		10.1074/jbc.M410247200	http://dx.doi.org/10.1074/jbc.M410247200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465817	hybrid			2022-12-27	WOS:000225680600098
J	Chien, WW; Kumagai, T; Miller, CW; Desmond, JC; Frank, JM; Said, JW; Koeffler, HP				Chien, WW; Kumagai, T; Miller, CW; Desmond, JC; Frank, JM; Said, JW; Koeffler, HP			Cyr61 suppresses growth of human endometrial cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CCN FAMILY; BREAST-CANCER; LUNG-CANCER; C-MYC; ENDOTHELIAL-CELLS; BCL-2 FAMILY; APOPTOSIS; DEATH; EXPRESSION	Cyr61 (CCN1) is a member of the CCN protein family; these secreted proteins are involved in diverse biological processes such as cell adhesion, angiogenesis, apoptosis, and either growth arrest or growth stimulation depending on the cellular context. We studied the role of Cyr61 in endometrial tumorigenesis. Levels of Cyr61 were decreased in endometrial tumors compared with normal endometrium. Knockdown of Cyr61 expression by RNA interference in a well differentiated endometrial adenocarcinoma cell line (Ishikawa) stimulated its cellular growth. Conversely, overexpression of the protein in the undifferentiated AN3CA endometrial cancer cell line decreased their growth concurrently with increased apoptosis in liquid culture. These same cells had decreased clonogenic capacity and a nearly complete loss of tumorigenicity in vivo. Furthermore, partially purified Cyr61 suppressed growth of endometrial cancer cells. The increased apoptosis in these endometrial cancer cells with forced overexpression of Cyr61 was associated with elevated expression of the pro-apoptotic proteins Bax, Bad, and TRAIL (tumor necrosis factor receptor-associated ligand). Cyr61-induced caspase-3 activation and depolarization of mitochondrial membrane. In summary, endometrial cancer cells have decreased expression of Cyr61 compared with normal endometrium, and this lowered expression may provide the transformed cells a growth advantage over their normal counterpart.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chien, WW (corresponding author), Cedars Sinai Med Ctr, Dept Hematol Oncol, 110 George Burns Rd,D5065, Los Angeles, CA 90048 USA.	chienw@ucla.edu						Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Brunelle JK, 2004, J BIOL CHEM, V279, P4305, DOI 10.1074/jbc.M312241200; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Genini M, 1996, INT J CANCER, V66, P571; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hishikawa K, 2000, EUR J PHARMACOL, V392, P19, DOI 10.1016/S0014-2999(00)00115-1; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; KIHANA T, 1995, CANCER, V76, P72, DOI 10.1002/1097-0142(19950701)76:1<72::AID-CNCR2820760110>3.0.CO;2-3; Kim KH, 2003, J BIOL CHEM, V278, P13847, DOI 10.1074/jbc.M210128200; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lea RG, 1999, AM J REPROD IMMUNOL, V42, P100; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; McLaren J, 1997, HUM REPROD, V12, P146, DOI 10.1093/humrep/12.1.146; Muramatsu Y, 2002, KIDNEY INT, V62, P1601, DOI 10.1046/j.1523-1755.2002.00633.x; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Pilarsky CP, 1998, PROSTATE, V36, P85; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; Sasaki T, 2003, CANCER RES, V63, P801; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; Sheets EE, 1997, ANN MED, V29, P121, DOI 10.3109/07853899709113697; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Spencer S J, 1996, Obstet Gynecol Surv, V51, P314, DOI 10.1097/00006254-199605000-00023; Tao XJ, 1997, J CLIN ENDOCR METAB, V82, P2738, DOI 10.1210/jc.82.8.2738; Tong XJ, 2004, ONCOGENE, V23, P4847, DOI 10.1038/sj.onc.1207628; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Xu LF, 2000, GENE DEV, V14, P585; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	47	83	98	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53087	53096		10.1074/jbc.M410254200	http://dx.doi.org/10.1074/jbc.M410254200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471875	hybrid			2022-12-27	WOS:000225680600036
J	Jun, Y; Fratti, RA; Wickner, W				Jun, Y; Fratti, RA; Wickner, W			Diacylglycerol and its formation by phospholipase C regulate Rab- and SNARE-dependent yeast vacuole fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-COMPLEX FORMATION; ETHER LIPID ANALOGS; SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; SELECTIVE-INHIBITION; VESICLE FUSION; GTPASE YPT7P; ALPHA-SNAP; PROTEIN; DOCKING	Although diacylglycerol (DAG) can trigger liposome fusion, biological membrane fusion requires Rab and SNARE proteins. We have investigated whether DAG and phosphoinositide-specific phospholipase C (PLC) have a role in the Rab- and SNARE-dependent homotypic vacuole fusion in Saccharomyces cerevisiae. Vacuole fusion was blocked when DAG was sequestered by a recombinant C1b domain. DAG underwent ATP-dependent turnover during vacuole fusion, but was replenished by the hydrolysis of phosphatidylinositol 4,5-bisphosphate to DAG by PLC. The PLC inhibitors 3-nitrocoumarin and U73122 blocked vacuole fusion in vitro, whereas their inactive homologues did not. Plc1p is the only known PLC in yeast. Yeast cells lacking the PLC1 gene have many small vacuoles, indicating defects in protein trafficking to the vacuole or vacuole fusion, and purified Plc1p stimulates vacuole fusion. Docking-dependent Ca2+ efflux is absent in plc1Delta vacuoles and was restored only upon the addition of both Plc1p and the Vam7p SNARE. However, vacuoles purified from plc1Delta strains still retain PLC activity and significant 3-nitrocoumarin- and U73122-sensitive fusion, suggesting that there is another PLC in S. cerevisiae with an important role in vacuole fusion.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@dartmouth.edu	Jun, Youngsoo/Q-3624-2018	Jun, Youngsoo/0000-0002-2387-032X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023377, R01GM023377] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23377] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHKONG QF, 1973, BIOCHEM J, V136, P147, DOI 10.1042/bj1360147; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ANGUS WW, 1975, J BIOL CHEM, V250, P22; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; BELDE PJM, 1993, FEBS LETT, V323, P113, DOI 10.1016/0014-5793(93)81460-H; BERGGREN MI, 1993, CANCER RES, V53, P4297; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Kahana JA, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P139; Kato M, 2001, EMBO J, V20, P4035, DOI 10.1093/emboj/20.15.4035; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; MIZUNOKAMIYA M, 1995, J BIOCHEM-TOKYO, V118, P693, DOI 10.1093/oxfordjournals.jbchem.a124967; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; POWIS G, 1992, CANCER RES, V52, P2835; SANCHEZMIGALLON MP, 1995, BIOPHYS J, V68, P558, DOI 10.1016/S0006-3495(95)80217-1; SANCHEZMIGALLON MP, 1994, ARCH BIOCHEM BIOPHYS, V314, P205, DOI 10.1006/abbi.1994.1431; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; SIKORSKI RS, 1989, GENETICS, V122, P19; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Taylor GS, 2001, ANAL BIOCHEM, V295, P122, DOI 10.1006/abio.2001.5179; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Tisi R, 2001, CELL BIOCHEM FUNCT, V19, P229, DOI 10.1002/cbf.918; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; Villar AV, 2000, BIOCHEMISTRY-US, V39, P14012, DOI 10.1021/bi992515c; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wang YX, 2001, J BIOL CHEM, V276, P35133, DOI 10.1074/jbc.M103937200; Ward PD, 2002, J BIOL CHEM, V277, P35760, DOI 10.1074/jbc.M203134200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644	61	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53186	53195		10.1074/jbc.M411363200	http://dx.doi.org/10.1074/jbc.M411363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485855	hybrid			2022-12-27	WOS:000225680600048
J	Wachter, T; Sprick, M; Hausmann, D; Kerstan, A; McPherson, K; Stassi, G; Brocker, EB; Walczak, H; Leverkus, M				Wachter, T; Sprick, M; Hausmann, D; Kerstan, A; McPherson, K; Stassi, G; Brocker, EB; Walczak, H; Leverkus, M			cFLIP(L) inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappa B activation at the death-inducing signaling complex in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN KINASE RIP; TNF RECEPTOR; CASPASE-8 ACTIVATION; GENE INDUCTION; CD95 LIGAND; C-FLIP; TRAIL; PROTEIN; FAS; EXPRESSION	Human keratinocytes undergo apoptosis following treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via surface-expressed TRAIL receptors 1 and 2. In addition, TRAIL triggers nonapoptotic signaling pathways including activation of the transcription factor NF-kappaB, in particular when TRAIL-induced apoptosis is blocked. The intracellular protein cFLIP(L) interferes with TRAIL-induced apoptosis at the death-inducing signaling complex (DISC) in many cell types. To study the role of cFLIP(L) in TRAIL signaling, we established stable HaCaT keratinocyte cell lines expressing varying levels of cFLIP(L). Functional analysis revealed that relative cFLIP(L) levels correlated with apoptosis resistance to TRAIL. Surprisingly, cFLIP(L) specifically blocked TRAIL-induced NF-kappaB activation and TRAIL-dependent induction of the proinflammatory target gene interleukin-8. Biochemical characterization of the signaling pathways involved showed that apoptosis signaling was inhibited at the DISC in cFLIP(L)-overexpressing keratinocytes, although cFLIP(L) did not significantly impair enzymatic activity of the receptor complex. In contrast, recruitment and modification of receptor-interacting protein was blocked in cFLIP(L)-overexpressing cells. Taken together, our data demonstrate that cFLIP(L) is not only a central antiapoptotic modulator of TRAIL-mediated apoptosis but also an inhibitor of TRAIL-induced NF-kappaB activation and subsequent proinflammatory target gene expression. Hence, cFLIP(L) modulation in keratinocytes may not only influence apoptosis sensitivity but may also lead to altered death receptor-dependent skin inflammation.	Univ Wurzburg, Sch Med, Dept Dermatol, D-97080 Wurzburg, Germany; Deutsch Krebsforschungszentrum, Dept Apoptosis Regulat D040, D-69120 Heidelberg, Germany; Univ Palermo, Lab Cellular & Mol Pathophysiol, Dept Surg & Oncol Sci, I-90127 Palermo, Italy	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Palermo	Leverkus, M (corresponding author), Univ Wurzburg, Sch Med, Dept Dermatol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	leverkus_m@klinik.uni-wuerzburg.de	Stassi, Giorgio/AAC-1175-2022; Walczak, Henning/AAV-2214-2020; McPherson, Kirsty G/E-6331-2017; Sprick, Martin R./I-7995-2019; Sprick, Martin R./A-8611-2008	Walczak, Henning/0000-0002-6312-4591; McPherson, Kirsty G/0000-0003-3083-6303; Sprick, Martin R./0000-0001-9691-7574; Sprick, Martin R./0000-0001-9691-7574				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bachmann F, 2001, J INVEST DERMATOL, V117, P59, DOI 10.1046/j.0022-202x.2001.01380.x; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Fang LW, 2004, J BIOL CHEM, V279, P13, DOI 10.1074/jbc.M303860200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannetti L, 2004, ONCOL REP, V11, P401; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grignani F, 1998, CANCER RES, V58, P14; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Lee SH, 2003, APMIS, V111, P309, DOI 10.1034/j.1600-0463.2003.1110203.x; Leverkus M, 2000, BLOOD, V96, P2628; Leverkus M, 2000, CANCER RES, V60, P553; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Qin JZ, 2002, EXP DERMATOL, V11, P573, DOI 10.1034/j.1600-0625.2002.110610.x; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wajant H, 2004, VITAM HORM, V67, P101; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Weisfelner Michelle Emily, 2003, J Drugs Dermatol, V2, P385; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	71	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52824	52834		10.1074/jbc.M409554200	http://dx.doi.org/10.1074/jbc.M409554200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459191	hybrid			2022-12-27	WOS:000225680600006
J	Yu, Q; Chen, D; Konig, R; Mariani, R; Unutmaz, D; Landau, NR				Yu, Q; Chen, D; Konig, R; Mariani, R; Unutmaz, D; Landau, NR			APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRION INFECTIVITY FACTOR; ANTIVIRAL ACTIVITY; VIF PROTEIN; HIV-1 VIF; CYTIDINE DEAMINASE; ENZYME APOBEC3G; IN-VIVO; DNA; HYPERMUTATION; DETERMINANT	In the human genome the apolipoprotein B mRNA-editing enzyme catalytic polypeptide ( APOBEC) 3 gene has expanded into a tandem array of genes termed APOBEC3A-G. Two members of this family, APOBEC3G and APOBEC3F, have been found to have potent activity against virion infectivity factor deficient (Deltavif) human immunodeficiency virus 1 (HIV-1). These enzymes become encapsidated in Deltavif HIV-1 virions and in the next round of infection deaminate the newly synthesized reverse transcripts. The lentiviral Vif protein prevents the deamination by inducing the degradation of APOBEC3G and APOBEC3F. We report here that two additional APOBEC3 family members, APOBEC3B and APOBEC3C, have potent antiviral activity against simian immunodeficiency virus (SIV), but not HIV-1. Both enzymes were encapsidated in HIV-1 and SIV virions and were active against Deltavif SIVmac and SIVagm. SIV Vif neutralized the antiviral activity of APOBEC3C, but not that of APOBEC3B. APOBEC3B induced abundant G --> A mutations in both wild-type and Deltavif SIV reverse transcripts. APOBEC3C induced substantially fewer mutations. APOBEC3F was found to be active against SIV and sensitive to SIVmac Vif. These findings raise the possibility that the different APOBEC3 family members function to neutralize specific lentiviruses.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA	Salk Institute; Vanderbilt University	Landau, NR (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Landau@salk.edu	König, Renate/AAB-8918-2019	König, Renate/0000-0003-4882-9179	NIAID NIH HHS [AI49131, AI58864] Funding Source: Medline; NIDA NIH HHS [DA14494] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058864, R01AI049131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014494] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Li JL, 2004, J CELL BIOCHEM, V92, P560, DOI 10.1002/jcb.20082; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Navarro F, 2004, CURR OPIN IMMUNOL, V16, P477, DOI 10.1016/j.coi.2004.05.006; Onishi M, 1996, EXP HEMATOL, V24, P324; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; Schrofelbauer B, 2004, AIDS REV, V6, P34; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Sundrud MS, 2003, J IMMUNOL, V171, P3542, DOI 10.4049/jimmunol.171.7.3542; Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang JZ, 2004, HUM MOL GENET, V13, P1785, DOI 10.1093/hmg/ddh183; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	36	247	259	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53379	53386		10.1074/jbc.M408802200	http://dx.doi.org/10.1074/jbc.M408802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466872	hybrid			2022-12-27	WOS:000225680600071
J	Zhao, H; Russell, P				Zhao, H; Russell, P			DNA binding domain in the replication checkpoint protein Mrc1 of Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; FISSION YEAST; KINASES CDS1; IN-VITRO; DAMAGE; PHOSPHORYLATION; CLASPIN; ACTIVATION; REPAIR; CHK1	The replication checkpoint is activated when replication forks are obstructed by DNA lesions or protein complexes bound to DNA or when DNA synthesis is restrained by the limited availability of deoxyribonucleotides. This checkpoint preserves genome integrity by stabilizing stalled forks and delaying the onset of mitosis. In the fission yeast Schizosaccharomyces pombe, Mrc1 is a replication checkpoint adaptor protein that allows the sensor kinase Rad3-Rad26 to activate the effector kinase Cds1. In Saccharomyces cerevisiae, Mrc1 associates with replication forks and co-precipitates with the DNA replication protein Cdc45. Whether or not Mrc1 interacts directly with DNA is unknown. Here we define a similar to150 amino acid DNA binding domain (DBD) in the N-terminal region of S. pombe Mrc1. The DBD interacts preferentially with branched DNA structures in vitro. Deletion of the DBD or point mutations that diminish its DNA binding activity render cells sensitive to the replication inhibitor hydroxyurea. These mutations also impair the replication checkpoint arrest. The DBD has a helix-loop-helix motif that is predicted to bind DNA. This motif is conserved in the recently identified N-terminal DBD of human Claspin, a presumptive homolog of yeast Mrc1 proteins.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	prussell@scripps.edu			NIGMS NIH HHS [GM59477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Heyer WD, 2004, CURR BIOL, V14, pR56, DOI 10.1016/j.cub.2003.12.043; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Murakami H, 2002, NAT CELL BIOL, V4, P384, DOI 10.1038/ncb789; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Rhind N, 2000, J CELL SCI, V113, P3889; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Tanaka K, 2004, J BIOL CHEM, V279, P32079, DOI 10.1074/jbc.M404834200; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Xu H, 2004, MOL CELL BIOL, V24, P7082, DOI 10.1128/MCB.24.16.7082-7090.2004; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003	34	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53023	53027		10.1074/jbc.M410449200	http://dx.doi.org/10.1074/jbc.M410449200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471884	hybrid			2022-12-27	WOS:000225680600028
J	Li, Q; Ching, AKK; Chan, BCL; Chow, SKY; Lim, PL; Ho, TCY; Ip, WK; Wong, CK; Lam, CWK; Lee, KKH; Chan, JYH; Chui, YL				Li, Q; Ching, AKK; Chan, BCL; Chow, SKY; Lim, PL; Ho, TCY; Ip, WK; Wong, CK; Lam, CWK; Lee, KKH; Chan, JYH; Chui, YL			A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; STRESS-MODULATING GENE; PROGRAMMED CELL-DEATH; MEDIATED APOPTOSIS; SIGNALING PATHWAYS; CD95 FAS/APO-1; BHRF1 PROTEIN; VIRUS ENCODES	BRE, brain and reproductive organ-expressed protein, was found previously to bind the intracellular juxtamembrane domain of a ubiquitous death receptor, tumor necrosis factor receptor 1 (TNF-R1), and to downregulate TNF-alpha-induced activation of NF-kappaB. Here we show that BRE also binds to another death receptor, Fas, and upon overexpression conferred resistance to apoptosis induced by TNF-alpha, anti-Fas agonist antibody, cycloheximide, and a variety of stress-related stimuli. However, down-regulation of the endogenous BRE by small interfering RNA increased apoptosis to TNF-alpha, but nottoetoposide, indicating that the physiological antiapoptotic role of this protein is specific to death receptor-mediated apoptosis. We further demonstrate that BRE mediates antiapoptosis by inhibiting the mitochondrial apoptotic machinery but without translocation to the mitochondria or nucleus or down-regulation of the cellular level of truncated Bid. Dissociation of BRE rapidly from TNF-R1, but not from Fas, upon receptor ligation suggests that this protein interacts with the death inducing signaling complex during apoptotic induction. Increased association of BRE with phosphorylated, sumoylated, and ubiquitinated proteins after death receptor stimulation was also detected. We conclude that in contrast to the truncated Bid that integrates mitochondrial apoptosis to death receptor-triggered apoptotic cascade, BRE inhibits the integration. We propose that BRE inhibits, by ubiquitination-like activity, components in or proximal to the death-inducing signaling complexes that are necessary for activation of the mitochondria.	Chinese Univ Hong Kong, Clin Immunol Unit, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Chem Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Texas System; UTMD Anderson Cancer Center	Chui, YL (corresponding author), Chinese Univ Hong Kong, Clin Immunol Unit, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	yiuloonchui@cuhk.edu.hk	Wong, CK/H-3256-2016; Lee, Kenneth Ka Ho/H-6698-2013	Wong, CK/0000-0002-5637-8331; Lee, Kenneth Ka Ho/0000-0002-6520-304X; Chui, Yiu-Loon/0000-0002-3441-9729				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baier A, 2003, CURR OPIN RHEUMATOL, V15, P274, DOI 10.1097/00002281-200305000-00015; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Ching AKK, 2003, DNA CELL BIOL, V22, P497, DOI 10.1089/10445490360708900; Ching AKK, 2001, BIOCHEM BIOPH RES CO, V288, P535; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYAN AM, 1995, CELL, V81, P512; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dive C, 1992, Semin Cancer Biol, V3, P417; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Everett H, 2000, J EXP MED, V191, P1487, DOI 10.1084/jem.191.9.1487; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu CH, 1998, FASEB J, V12, P1101, DOI 10.1096/fasebj.12.12.1101; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kawanishi M, 1997, J VIROL, V71, P3319, DOI 10.1128/JVI.71.4.3319-3322.1997; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee JC, 2003, IMMUNOL REV, V193, P39, DOI 10.1034/j.1600-065X.2003.00043.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marshall WL, 1999, J VIROL, V73, P5181, DOI 10.1128/JVI.73.6.5181-5185.1999; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Miao J, 2001, J HISTOCHEM CYTOCHEM, V49, P491, DOI 10.1177/002215540104900409; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Okura T, 1996, J IMMUNOL, V157, P4277; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shchepina LA, 2002, ONCOGENE, V21, P8149, DOI 10.1038/sj.onc.1206053; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Wasilenko ST, 2003, P NATL ACAD SCI USA, V100, P14345, DOI 10.1073/pnas.2235583100; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	65	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52106	52116		10.1074/jbc.M408678200	http://dx.doi.org/10.1074/jbc.M408678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465831	hybrid			2022-12-27	WOS:000225493400049
J	Wang, G; Conover, RC; Benoit, S; Olczak, AA; Olson, JW; Johnson, MK; Maier, RJ				Wang, G; Conover, RC; Benoit, S; Olczak, AA; Olson, JW; Johnson, MK; Maier, RJ			Role of a bacterial organic hydroperoxide detoxification system in preventing catalase inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI CATALASE; OXIDATIVE-STRESS RESISTANCE; UNSATURATED FATTY-ACIDS; NEUTROPHIL-ACTIVATING PROTEIN; THIOL-SPECIFIC ANTIOXIDANT; KATA-ASSOCIATED PROTEIN; HYDROGEN-PEROXIDE; HOST COLONIZATION; PSEUDOMONAS-AERUGINOSA; OXYGEN RADICALS	In the gastric pathogen Helicobacter pylori, catalase (KatA) and alkyl hydroperoxide reductase (AhpC) are two highly abundant enzymes that are crucial for oxidative stress resistance and survival of the bacterium in the host. Here we report a connection unidentified previously between the two stress resistance enzymes. We observed that the catalase in ahpC mutant cells in comparison with the parent strain is inactivated partially ( approximately 50%). The decrease of catalase activity is well correlated with the perturbation of the heme environment in catalase, as detected by electron paramagnetic resonance spectroscopy. To understand the reason for this catalase inactivation, we examined the inhibitory effects of hydroperoxides on H. pylori catalase ( either present in cell extracts or added to the purified enzyme) by monitoring the enzyme activity and the EPR signal of catalase. H. pylori catalase is highly resistant to its own substrate, without the loss of enzyme activity by treatment with a molar ratio of 1:3000 H2O2. However, it is inactivated by lower concentrations of organic hydroperoxides (the substrate of AhpC). Treatment with a molar ratio of 1:400 t-butyl hydroperoxide resulted in an inactivation of catalase by approximately 50%. UV-visible absorption spectra indicated that the catalase inactivation by organic hydroperoxides is caused by the formation of a catalytically incompetent compound II species. To further support the idea that organic hydroperoxides, which accumulate in the ahpC mutant cells, are responsible for the inactivation of catalase, we compared the level of lipid peroxidation found in ahpC mutant cells with that found in wild type cells. The results showed that the total amount of extractable lipid hydroperoxides in the ahpC mutant cells is approximately three times that in the wild type cells. Our findings reveal a novel role of the organic hydroperoxide detoxification system in preventing catalase inactivation.	Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Maier, RJ (corresponding author), Univ Georgia, Dept Microbiol, 805 Biol Sci Bldg, Athens, GA 30602 USA.	rmaier@uga.edu		Benoit, Stephane/0000-0002-9314-8586	NIDDK NIH HHS [1-R01-DK30061] Funding Source: Medline; NIGMS NIH HHS [GM62545] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; Bagchi D, 1996, FREE RADICAL RES, V24, P439, DOI 10.3109/10715769609088043; Baillon MLA, 1999, J BACTERIOL, V181, P4798, DOI 10.1128/JB.181.16.4798-4804.1999; Baker LMS, 2001, J BACTERIOL, V183, P1961, DOI 10.1128/JB.183.6.1961-1973.2001; Bereswill S, 1998, MICROBIOL-SGM, V144, P2505, DOI 10.1099/00221287-144-9-2505; BICOUT DJ, 1995, BBA-PROTEIN STRUCT M, V1252, P172, DOI 10.1016/0167-4838(95)00123-C; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Cooksley C, 2003, J MED MICROBIOL, V52, P461, DOI 10.1099/jmm.0.05070-0; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Harris AG, 2003, FEMS MICROBIOL LETT, V229, P283, DOI 10.1016/S0378-1097(03)00850-4; Harris AG, 2003, MICROBIOL-SGM, V149, P665, DOI 10.1099/mic.0.26012-0; Harris AG, 2002, MICROBIOL-SGM, V148, P3813, DOI 10.1099/00221287-148-12-3813; HAZELL SL, 1991, J GEN MICROBIOL, V137, P57, DOI 10.1099/00221287-137-1-57; HAZELL SL, 1990, J CLIN MICROBIOL, V28, P1060, DOI 10.1128/JCM.28.5.1060-1061.1990; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Jungblut PR, 2000, MOL MICROBIOL, V36, P710, DOI 10.1046/j.1365-2958.2000.01896.x; KHULUSI S, 1995, J MED MICROBIOL, V42, P276, DOI 10.1099/00222615-42-4-276; Loewen PC, 2004, BIOCHEMISTRY-US, V43, P3089, DOI 10.1021/bi035663i; LOWEN P, 1997, OXIDATIVE STRESS MOL, P273; Lundstrom AM, 2000, MICROB PATHOGENESIS, V29, P257, DOI 10.1006/mpat.2000.0388; Ma JF, 1999, J BACTERIOL, V181, P3730, DOI 10.1128/JB.181.12.3730-3742.1999; Maniatis T., 1982, MOL CLONING; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; MOORE GR, 1994, BIOCHEM J, V304, P493, DOI 10.1042/bj3040493; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Odenbreit S, 1996, J BACTERIOL, V178, P6960, DOI 10.1128/jb.178.23.6960-6967.1996; Olczak AA, 2003, INFECT IMMUN, V71, P580, DOI 10.1128/IAI.71.1.580-583.2003; Olczak AA, 2002, J BACTERIOL, V184, P3186, DOI 10.1128/JB.184.12.3186-3193.2002; Radcliff FJ, 1997, INFECT IMMUN, V65, P4668, DOI 10.1128/IAI.65.11.4668-4674.1997; Ramarao N, 2000, MOL MICROBIOL, V38, P103, DOI 10.1046/j.1365-2958.2000.02114.x; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seyler RW, 2001, INFECT IMMUN, V69, P4034, DOI 10.1128/IAI.69.6.4034-4040.2001; Storz G, 2000, BACTERIAL STRESS RESPONSES, P47; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; Wang G, 2004, INFECT IMMUN, V72, P1391, DOI 10.1128/IAI.72.3.1391-1396.2004; Windle HJ, 2000, J BIOL CHEM, V275, P5081, DOI 10.1074/jbc.275.7.5081; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; [No title captured]	43	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51908	51914		10.1074/jbc.M408450200	http://dx.doi.org/10.1074/jbc.M408450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456778	hybrid			2022-12-27	WOS:000225493400024
J	Zelenina, M; Tritto, S; Bondar, AA; Zelenin, S; Aperia, A				Zelenina, M; Tritto, S; Bondar, AA; Zelenin, S; Aperia, A			Copper inhibits the water and glycerol permeability of aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRINKING-WATER; CHANNEL; PROTEIN; ZINC; LOCALIZATION; TRANSPORT; AQP3	Aquaporin-3 (AQP3) is an aquaglyceroporin expressed in erythrocytes and several other tissues. Erythrocytes are, together with kidney and liver, the main targets for copper toxicity. Here we report that both water and glycerol permeability of human AQP3 is inhibited by copper. Inhibition is fast, dose-dependent, and reversible. If copper is dissolved in carbonic acid-bicarbonate buffer, the natural buffer system in our body, doses in the range of those observed in Wilson disease and in copper poisoning caused significant inhibition. AQP7, another aquaglyceroporin, was insensitive to copper. Three extracellular amino acid residues, Trp(128), Ser(152), and His(241), were identified as responsible for the effect of copper on AQP3. We have previously shown that Ser(152) is involved in regulation of AQP3 by pH. The fact that Ser(152) mediates regulation of AQP3 by copper may explain the phenomenon of exquisite sensitivity of human erythrocytes to copper at acidic pH. When AQP3 was co-expressed with another AQP, only glycerol but not water permeability was inhibited by copper. Our results provide a better understanding of processes that occur in severe copper metabolism defects such as Wilson disease and in copper poisoning.	Karolinska Inst, Dept Woman & Child Hlth, S-17177 Stockholm, Sweden; Russian Acad Sci, Inst Cytol & Genet, Lab Physiol Genet, Siberian Branch, Novosibirsk 630090, Russia; Univ Pavia, Dept Expt Med, Sect Human Physiol, I-27100 Pavia, Italy; Russian Acad Sci, Grp Funct Genom, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk 630090, Russia	Karolinska Institutet; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Pavia; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences	Aperia, A (corresponding author), Astrid Lindgren Childrens Hosp, Q2-09, S-17176 Stockholm, Sweden.	anita.aperia@kbh.ki.se	Tritto, Simona/A-5594-2013; Bondar, Alexander/AAA-7087-2020	Tritto, Simona/0000-0001-6629-3553; Bondar, Alexander/0000-0001-9181-0487				ALAM IA, 1989, ENVIRON POLLUT, V57, P167, DOI 10.1016/0269-7491(89)90008-0; Amancio OMS, 2003, EUR J CLIN NUTR, V57, P706, DOI 10.1038/sj.ejcn.1601601; Araya M, 2003, REGUL TOXICOL PHARM, V38, P389, DOI 10.1016/j.yrtph.2003.08.001; BAKER A, 1995, J HEPATOL, V23, P538, DOI 10.1016/0168-8278(95)80059-X; BASHIR NA, 1995, ANN TROP PAEDIATR, V15, P291, DOI 10.1080/02724936.1995.11747786; Bhattacharyya J, 2001, J PHYSIOL PHARMACOL, V52, P145; Bhowmik D, 2001, RENAL FAILURE, V23, P731, DOI 10.1081/JDI-100107371; Bremner I, 1998, AM J CLIN NUTR, V67, p1069S, DOI 10.1093/ajcn/67.5.1069S; CARLSEN A, 1976, ACTA PHYSIOL SCAND, V97, P501, DOI 10.1111/j.1748-1716.1976.tb10290.x; Coddou C, 2002, J NEUROCHEM, V80, P626, DOI 10.1046/j.0022-3042.2001.00732.x; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; Hoveyda N, 2003, J ENVIRON HEALTH, V66, P29; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Kajanachumpol Saowanee, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P877; Kawahara S, 1998, Rinsho Ketsueki, V39, P665; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuwahara M, 1997, BIOCHEMISTRY-US, V36, P13973, DOI 10.1021/bi9711442; Lee Je-Jung, 1998, Journal of Korean Medical Science, V13, P548; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; Liu JT, 2001, J TOXICOL-CLIN TOXIC, V39, P161, DOI 10.1081/CLT-100103832; Matsuzaki T, 1999, J HISTOCHEM CYTOCHEM, V47, P1275, DOI 10.1177/002215549904701007; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Shim H, 2003, J NUTR, V133, p1527S, DOI 10.1093/jn/133.5.1527S; Tanner MS, 1998, AM J CLIN NUTR, V67, p1074S, DOI 10.1093/ajcn/67.5.1074S; Trombley PQ, 1996, J NEUROPHYSIOL, V76, P2536, DOI 10.1152/jn.1996.76.4.2536; Zelenina M, 2000, EUR BIOPHYS J BIOPHY, V29, P165, DOI 10.1007/PL00006645; Zelenina M, 2003, J BIOL CHEM, V278, P30037, DOI 10.1074/jbc.M302206200; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	33	106	113	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51939	51943		10.1074/jbc.M407645200	http://dx.doi.org/10.1074/jbc.M407645200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456785	hybrid			2022-12-27	WOS:000225493400028
J	Ishigaki, S; Hishikawa, N; Niwa, J; Iemura, S; Natsume, T; Hori, S; Kakizuka, A; Tanaka, K; Sobue, G				Ishigaki, S; Hishikawa, N; Niwa, J; Iemura, S; Natsume, T; Hori, S; Kakizuka, A; Tanaka, K; Sobue, G			Physical and functional interaction between Dorfin and Valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; RING-FINGER PROTEIN; ENDOPLASMIC-RETICULUM; ATPASE ACTIVITY; LEWY BODIES; UBIQUITIN; DISEASE; SYSTEM; GENE; VCP	Dorfin, a RING-IBR type ubiquitin ligase (E3), can ubiquitylate mutant superoxide dismutase 1, the causative gene of familial amyotrophic lateral sclerosis (ALS). Dorfin is located in ubiquitylated inclusions ( UBIs) in various neurodegenerative disorders, such as ALS and Parkinson's disease (PD). Here we report that Valosin-containing protein (VCP) directly binds to Dorfin and that VCP ATPase activity profoundly contributes to the E3 activity of Dorfin. High through-put analysis using mass spectrometry identified VCP as a candidate of Dorfin-associated protein. Glycerol gradient centrifugation analysis showed that endogenous Dorfin consisted of a 400 - 600-kDa complex and was co-immunoprecipitated with endogenous VCP. In vitro experiments showed that Dorfin interacted directly with VCP through its C-terminal region. These two proteins were colocalized in aggresomes in HEK293 cells and UBIs in the affected neurons of ALS and PD. VCPK524A, a dominant negative form of VCP, reduced the E3 activity of Dorfin against mutant superoxide dismutase 1, whereas it had no effect on the autoubiquitylation of Parkin. Our results indicate that VCPs functionally regulate Dorfin through direct interaction and that their functional interplay may be related to the process of UBI formation in neurodegenerative disorders, such as ALS or PD.	Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668500, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan; Natl Inst Adv Sci & Technol, Biol Informat Res Ctr, Tokyo 1350064, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Funct Biol, Kyoto 6068502, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Nagoya University; Tokyo Metropolitan Institute of Medical Science; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto University; Japan Science & Technology Agency (JST)	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668500, Japan.	sobueg@med.nagoya-u.ac.jp	ISHIGAKI, Shinsuke/I-7305-2014; Natsume, Tohru/M-7627-2018	Natsume, Tohru/0000-0002-1510-2582; Ishigaki, Shinsuke/0000-0002-9555-0659				Asai T, 2002, JPN J CANCER RES, V93, P296, DOI 10.1111/j.1349-7006.2002.tb02172.x; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Hishikawa N, 2003, AM J PATHOL, V163, P609, DOI 10.1016/S0002-9440(10)63688-7; Ishigaki S, 2002, FEBS LETT, V531, P354, DOI 10.1016/S0014-5793(02)03546-9; Ishigaki S, 2002, J NEUROCHEM, V82, P576, DOI 10.1046/j.1471-4159.2002.00998.x; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Matsuda N, 2001, J CELL SCI, V114, P1949; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; Mayer R J, 1989, Prog Clin Biol Res, V317, P809; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Mizuno Y, 2003, NEUROSCI LETT, V343, P77, DOI 10.1016/S0304-3940(03)00280-5; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	41	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51376	51385		10.1074/jbc.M406683200	http://dx.doi.org/10.1074/jbc.M406683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456787	hybrid			2022-12-27	WOS:000225355800089
J	Wang, XJ; Ikeguchi, Y; McCloskey, DE; Nelson, P; Pegg, AE				Wang, XJ; Ikeguchi, Y; McCloskey, DE; Nelson, P; Pegg, AE			Spermine synthesis is required for normal viability, growth, and fertility in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED HYPOPHOSPHATEMIA; SYNTHASE GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRANSGENIC MICE; CELL-GROWTH; PEX GENE; POLYAMINES; GY; DEFICIENCY	Spermidine is essential for viability in eukaryotes but the importance of the longer polyamine spermine has not been established. Spermine is formed from spermidine by the action of spermine synthase, an aminopropyltransferase, whose gene (SpmS) is located on the X chromosome. Deletion of part of the X chromosome that include SpmS in Gy mice leads to a striking phenotype in affected males that includes altered phosphate metabolism and symptoms of hypophosphatemic rickets, circling behavior, hyperactivity, head shaking, inner ear abnormalities, deafness, sterility, a profound postnatal growth retardation, and a propensity to sudden death. It was not clear to what extent these alterations were due to the loss of spermine synthase activity, since this chromosomal deletion extends well beyond the SpmS gene and includes at least one other gene termed Phex. We have bred the Gy carrier female mice with transgenic mice (CAG/SpmS mice) that express spermine synthase from the ubiquitous CAG promoter. The resulting Gy-CAG/SpmS mice had extremely high levels of spermine synthase and contained spermine in all tissues examined. These mice had a normal life span and fertility and a normal growth rate except for a reduction in body weight due to a loss of bone mass that was consistent with the observation that the derangement in phosphate metabolism is due to the loss of the Phex gene and was not restored. These results show that spermine synthesis is needed for normal growth, viability, and fertility in male mice and that regulation of spermine synthase content is not required.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pegg, AE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	apegg@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM26290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carpinelli MR, 2002, AM J PATHOL, V161, P1925, DOI 10.1016/S0002-9440(10)64468-9; Cason AL, 2003, EUR J HUM GENET, V11, P937, DOI 10.1038/sj.ejhg.5201072; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P2261, DOI 10.1073/pnas.2627990100; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chattopadhyay MK, 2002, P NATL ACAD SCI USA, V99, P10330, DOI 10.1073/pnas.162362899; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; GERNER EW, 1988, CANCER RES, V48, P4881; Grieff M, 1997, GENOMICS, V44, P227, DOI 10.1006/geno.1997.4876; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HAKOVIRTA H, 1993, MOL ENDOCRINOL, V7, P1430, DOI 10.1210/me.7.11.1430; Hamasaki-Katagiri N, 1998, GENE, V210, P195, DOI 10.1016/S0378-1119(98)00027-4; Ikeguchi Y, 2004, BIOCHEM J, V381, P701, DOI 10.1042/BJ20040419; Ikeguchi Y, 2003, BIOCHEM J, V373, P885, DOI 10.1042/BJ20030246; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Kato M, 1999, MOL REPROD DEV, V54, P43, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;43::AID-MRD6&gt;3.0.CO;2-N; Korhonen VP, 2001, MOL PHARMACOL, V59, P231, DOI 10.1124/mol.59.2.231; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; Lopatin AN, 2000, J MOL CELL CARDIOL, V32, P2007, DOI 10.1006/jmcc.2000.1232; Lorenz B, 1998, HUM MOL GENET, V7, P541, DOI 10.1093/hmg/7.3.541; LYON MF, 1986, P NATL ACAD SCI USA, V83, P4899, DOI 10.1073/pnas.83.13.4899; Mackintosh CA, 2000, BIOCHEM J, V351, P439, DOI 10.1042/0264-6021:3510439; MEYER RA, 1995, J ORTHOPAED RES, V13, P30, DOI 10.1002/jor.1100130107; Meyer RA, 1998, GENOMICS, V48, P289, DOI 10.1006/geno.1997.5169; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nilsson J, 2000, BIOCHEM J, V352, P381, DOI 10.1042/0264-6021:3520381; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; Park MH, 1997, BIOL SIGNAL, V6, P115; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1985, BIOCHEM BIOPH RES CO, V133, P82, DOI 10.1016/0006-291X(85)91844-3; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Phillips LR, 2003, J GEN PHYSIOL, V122, P795, DOI 10.1085/jgp.200308953; Rea G, 2004, IUBMB LIFE, V56, P167, DOI 10.1080/15216540410001673996; Sawicki JA, 1998, EXP CELL RES, V244, P367, DOI 10.1006/excr.1998.4175; Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Strom TM, 1997, HUM MOL GENET, V6, P165, DOI 10.1093/hmg/6.2.165; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Tristani-Firouzi M, 2001, AM J MED, V110, P50, DOI 10.1016/S0002-9343(00)00623-9; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wang YL, 2002, BIOCHEM J, V366, P79, DOI 10.1042/bj20020211; Warters RL, 1999, RADIAT RES, V151, P354, DOI 10.2307/3579948; WIEST L, 1997, METHOD MOL BIOL, V79, P51; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200	51	65	69	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51370	51375		10.1074/jbc.M410471200	http://dx.doi.org/10.1074/jbc.M410471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459188	hybrid			2022-12-27	WOS:000225355800088
J	Lee, JH; Cook, JR; Yang, ZH; Mirochnitchenko, O; Gunderson, SI; Felix, AM; Herth, N; Hoffmann, R; Pestka, S				Lee, JH; Cook, JR; Yang, ZH; Mirochnitchenko, O; Gunderson, SI; Felix, AM; Herth, N; Hoffmann, R; Pestka, S			PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM PROTEINS; ASYMMETRIC DIMETHYLARGININE; SUBSTRATE-SPECIFICITY; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; METHYLATION; RESIDUES; COMPLEX; TRANSCRIPTION; HOMOLOG	The cDNA for PRMT7, a recently discovered human protein-arginine methyltransferase, (PRMT), was cloned and expressed in Escherichia coli and mammalian cells. Immunopurified PRMT7 actively methylated histones, myelin basic protein, a fragment of human fibrillarin (GAR) and spliceosomal protein SmB. Amino acid analysis showed that the modifications produced were predominantly monomethylarginine and symmetric dimethylarginine (SDMA). Examination of PRMT7 expressed in E. coli demonstrated that peptides corresponding to sequences contained in histone H4, myelin basic protein, and SmD3 were methylated. Furthermore, analysis of the methylated proteins showed that symmetric dimethylarginine and relatively small amounts of monomethylarginine and asymmetric dimethylarginine were produced. SDMA was also formed when a GRG tripeptide was methylated by PRMT7, indicating that a GRG motif is by itself sufficient for symmetric dimethylation to occur. Symmetric dimethylation is reduced dramatically compared with monomethylation as the concentration of the substrate is increased. The data demonstrate that PRMT7 (like PRMT5) is a Type II methyltransferase capable of producing SDMA modifications in proteins.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Rutgers State Univ, Piscataway, NJ 08854 USA; Ramapo Coll, Mahwah, NJ 07430 USA; Univ Leipzig, Fac Chem & Mineral, Ctr Biotechnol & Biochem, D-04103 Leipzig, Germany; PBL Biomed Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Ramapo College New Jersey (RCNJ); Leipzig University	Pestka, S (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 675 Hoes Ln,Rm 727, Piscataway, NJ 08854 USA.	pestka@waksman.rutgers.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059465, T32AI007403, R01AI043369, R01AI036450] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43369, R01 AI36450, R01 AI059465, 2 T32-AI07403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chie L, 2003, ANN CLIN LAB SCI, V33, P200; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Fleck C, 2003, CLIN CHIM ACTA, V336, P1, DOI 10.1016/S0009-8981(03)00338-3; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gros L, 2003, CANCER RES, V63, P164; Hebert MD, 2002, DEV CELL, V3, P329, DOI 10.1016/S1534-5807(02)00222-8; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Miranda TB, 2004, BIOCHEM BIOPH RES CO, V323, P382, DOI 10.1016/j.bbrc.2004.08.107; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PAQUET A, 1976, CAN J CHEM, V54, P733, DOI 10.1139/v76-106; PESTKA S, 1972, J BIOL CHEM, V247, P4669; Pipkorn R, 2002, J PEPT RES, V59, P105, DOI 10.1034/j.1399-3011.2002.01958.x; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Rajagopalan S, 2003, ARTHRITIS RHEUM-US, V48, P1992, DOI 10.1002/art.11060; Rattazzi M, 2003, J NEPHROL, V16, P11; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIGLER GF, 1983, BIOPOLYMERS, V22, P2157, DOI 10.1002/bip.360221002; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; STOCK A, 1987, J BIOL CHEM, V262, P8011; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Valkonen VP, 2001, LANCET, V358, P2127, DOI 10.1016/S0140-6736(01)07184-7; Yoo JH, 2001, ATHEROSCLEROSIS, V158, P425, DOI 10.1016/S0021-9150(01)00444-0	41	162	164	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3656	3664		10.1074/jbc.M405295200	http://dx.doi.org/10.1074/jbc.M405295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15494416	hybrid			2022-12-27	WOS:000226983900065
J	Cho, JH; Johnson, GVW				Cho, JH; Johnson, GVW			Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; GRANULOVACUOLAR DEGENERATION; NEUROFIBRILLARY TANGLES; MICROTUBULE-BINDING; TRANSGENIC MICE; PROTEIN-TAU; PC12 CELLS; PHOSPHORYLATION; ACTIVATION; APOPTOSIS	Tau is a substrate of caspases, and caspase-cleaved tau has been detected in Alzheimer's disease brain but not in control brain. Furthermore, in vitro studies have revealed that caspase-cleaved tau is more fibrillogenic than full-length tau. Considering these previous findings, the purpose of this study was to determine how the caspase cleavage of tau affected tau function and aggregation in a cell model system. The effects of glycogen synthase kinase 3beta (GSK3beta), a well established tau kinase, on these processes also were examined. Tau or tau that had been truncated at Asp-421 to mimic caspase cleavage (Tau-D421) was transfected into cells with or without GSK3beta, and phosphorylation, microtubule binding, and tau aggregation were examined. Tau-D421 was not as efficiently phosphorylated by GSK3beta as full-length tau. Tau-D421 efficiently bound microtubules, and in contrast to the full-length tau, co-expression with GSK3beta did not result in a reduction in the ability of Tau-D421 to bind microtubules. In the absence of GSK3beta, neither Tau-D421 nor full-length tau formed Sarkosyl-insoluble inclusions. However, in the presence of GSK3beta, Tau-D421, but not full-length tau, was present in the Sarkosyl-insoluble fraction and formed thioflavin-S-positive inclusions in the cell. Nonetheless, co-expression of GSK3beta and Tau-D421 did not result in an enhancement of cell death. These data suggest that a combination of phosphorylation events and caspase activation contribute to the tau oligomerization process in Alzheimer's disease, with GSK3beta-mediated tau phosphorylation preceding caspase cleavage.	Univ Alabama, Sch Med, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Sch Med, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035060] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35060] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Davis PK, 1999, J BIOL CHEM, V274, P35686, DOI 10.1074/jbc.274.50.35686; Davis PK, 1997, J NEUROCHEM, V68, P2338; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Hardy J, 2003, J MOL NEUROSCI, V20, P203, DOI 10.1385/JMN:20:2:203; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Johnson G V, 1999, J Alzheimers Dis, V1, P329; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Johnson GVW, 2002, J ALZHEIMERS DIS, V4, P375, DOI 10.3233/JAD-2002-4505; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Krishnamurthy PK, 2000, J NEUROSCI RES, V61, P515, DOI 10.1002/1097-4547(20000901)61:5<515::AID-JNR6>3.0.CO;2-#; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Marks N, 1999, NEUROCHEM INT, V35, P195, DOI 10.1016/S0197-0186(99)00061-3; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Rossiter JP, 2000, NEUROPATH APPL NEURO, V26, P342, DOI 10.1046/j.1365-2990.2000.00252.x; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Sun AY, 2002, J HISTOCHEM CYTOCHEM, V50, P463, DOI 10.1177/002215540205000403; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; VALLET PG, 1992, ACTA NEUROPATHOL, V83, P170, DOI 10.1007/BF00308476	47	89	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54716	54723		10.1074/jbc.M403364200	http://dx.doi.org/10.1074/jbc.M403364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494420	hybrid			2022-12-27	WOS:000225793600099
J	Hu, YL; Fay, AW; Dos Santos, PC; Naderi, F; Ribbe, MW				Hu, YL; Fay, AW; Dos Santos, PC; Naderi, F; Ribbe, MW			Characterization of Azotobacter vinelandii nifZ deletion strains - Indication of stepwise MoFe protein assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM-COFACTOR; FEMO-COFACTOR; NITROGEN-FIXATION; P-CLUSTERS; BIOSYNTHESIS; COMPLEX; EPR; PURIFICATION; MECHANISM; INSERTION	The nifZ gene product (NifZ) of Azotobacter vinelandii has been implicated in MoFe protein maturation. However, its exact function in this process remains largely unknown. Here, we report a detailed biochemical/biophysical characterization of His-tagged MoFe proteins purified from A. vinelandii nifZ and nifZ/nifB deletion strains DJ1182 and YM6A (DeltanifZ and DeltanifZDeltanifB MoFe proteins, respectively). Our data from EPR, metal, activity, and stability analyses indicate that one alphabeta subunit pair of the DeltanifZ MoFe protein contains a P cluster ([8Fe-7S]) and an iron-molybdenum cofactor (FeMoco) ([Mo-7Fe-9S-X-homocitrate]), whereas the other contains a presumed P cluster precursor, possibly comprising a pair of [4Fe-4S]-like clusters, and a vacant FeMoco site. Likewise, the DeltanifZDeltanifB MoFe protein has the same composition as the DeltanifZ MoFe protein except for the absence of FeMoco, an effect caused by the deletion of the nifB gene. These results suggest that the MoFe protein is likely assembled stepwise, i.e. one alphabeta subunit pair of the tetrameric MoFe protein is assembled prior to the other, and that NifZ might act as a chaperone in the assembly of the second alphabeta subunit pair by facilitating a conformational rearrangement that is required for the formation of the P cluster through the condensation of two [4Fe-4S]-like clusters. The possibility of NifZ exercising its effect through the Fe protein was ruled out because the Fe proteins from nifZ and nifZ/nifB deletion strains are not defective in their normal functions. However, the detailed mechanism of how NifZ carries out its exact function in MoFe protein maturation awaits further investigation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	University of California System; University of California Irvine; Virginia Polytechnic Institute & State University	Ribbe, MW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 2236 McGaugh Hall, Irvine, CA 92697 USA.	mribbe@uci.edu	Naderi, Fereshteh/AAN-9952-2021	Dos Santos, Patricia/0000-0002-3364-0931	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-67626] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Benton PMC, 2003, BIOCHEMISTRY-US, V42, P9102, DOI 10.1021/bi034595x; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; Campbell M., 2004, J BIOL CHEM, V279, P28276; Chen KS, 2002, J BIOL CHEM, V277, P5603, DOI 10.1074/jbc.M108916200; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; Eady RR, 2003, COORDIN CHEM REV, V237, P23, DOI 10.1016/S0010-8545(02)00248-5; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Frazzon J, 2002, MET IONS BIOL SYST, V39, P163; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; Grossmann JG, 2001, J BIOL CHEM, V276, P6582, DOI 10.1074/jbc.M005350200; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Huang JF, 1999, ACTA BOT SIN, V41, P1217; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Jung YS, 2000, J BIOL CHEM, V275, P36974, DOI 10.1074/jbc.M004947200; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; LUDDEN PW, 1993, ACS SYM SER, V535, P196; LUDDEN PW, 1998, BIOL NITROGEN FIXATI, P33; MORNINGSTAR JE, 1987, J AM CHEM SOC, V109, P6854, DOI 10.1021/ja00256a051; MUCHMORE SW, 1996, MECH METALLOCLUSTER, V11, P111; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Ribbe M, 1997, J BIOL CHEM, V272, P26627, DOI 10.1074/jbc.272.42.26627; Ribbe MW, 2002, J BIOL CHEM, V277, P23469, DOI 10.1074/jbc.M202061200; Ribbe MW, 2001, P NATL ACAD SCI USA, V98, P5521, DOI 10.1073/pnas.101119498; Ribbe MW, 2000, J BIOL CHEM, V275, P17631, DOI 10.1074/jbc.275.23.17631; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Rubio L. M., 2002, Nitrogen fixation at the millennium, P101, DOI 10.1016/B978-044450965-9/50004-5; Schmid B, 2002, SCIENCE, V296, P352, DOI 10.1126/science.1070010; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TAL S, 1991, J BIOL CHEM, V266, P10654; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; Wang DY, 1999, ACTA BOT SIN, V41, P71; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685	58	44	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54963	54971		10.1074/jbc.M408983200	http://dx.doi.org/10.1074/jbc.M408983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485884	hybrid			2022-12-27	WOS:000225793600126
J	Li, XC; Zhang, D; Hannink, M; Beamer, LJ				Li, XC; Zhang, D; Hannink, M; Beamer, LJ			Crystal structure of the Kelch domain of human Keap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIANT AXONAL NEUROPATHY; ANTIOXIDANT RESPONSIVE ELEMENTS; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; GENE-EXPRESSION; REPEAT SUPERFAMILY; PROTEIN STRUCTURES; GALACTOSE-OXIDASE; BINDING-PROTEIN; NRF2	Keap1 is a substrate adaptor protein for an ubiquitin ligase complex that targets the Nrf2 transcription factor for degradation. Keap1 binds Nrf2 through its C-terminal Kelch domain, which contains six copies of the evolutionarily conserved kelch repeat sequence motif. The structure of the Kelch domain from human Keap1 has been determined by x-ray crystallography to a resolution of 1.85 Angstrom. The Kelch domain forms a 6-bladed beta-propeller structure, with residues at the C terminus forming the first strand in the first blade. Key structural roles have been identified for the highly conserved glycine, tyrosine, and tryptophan residues that define the kelch repeat sequence motif. In addition, we show that substitution of a single amino acid located within a loop that extends out from the bottom of the beta-propeller structure abolishes binding of Nrf2. The structure of the Kelch domain of Keap1 represents a high quality model for the superfamily of eukaryotic kelch repeat proteins and provides insight into how disease-causing mutations perturb the structural integrity of the Kelch domain.	Univ Missouri, Life Sci Ctr, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Beamer, LJ (corresponding author), Univ Missouri, Life Sci Ctr, Columbia, MO 65211 USA.	Beamerl@missouri.edu	Zhang, Donna/B-1015-2012		NCI NIH HHS [P50 CA103130] Funding Source: Medline; NIGMS NIH HHS [GM59213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA103130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; AMES BN, 1993, OXIDANTS ARE MAJOR C, P1; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Bruno C, 2004, NEUROLOGY, V62, P13, DOI 10.1212/01.WNL.0000101676.41505.A7; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Delano W.L., 2002, DELANO SCI; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kelso RJ, 2002, J CELL BIOL, V156, P703, DOI 10.1083/jcb.200110063; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlenbaumer G, 2002, NEUROLOGY, V58, P1273, DOI 10.1212/WNL.58.8.1273; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemke CT, 2002, ACTA CRYSTALLOGR D, V58, P2096, DOI 10.1107/S0907444902018838; LI X, 2004, IN PRESS ACTA CRYS D; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; *NO 4 C C P, 1994, ACTA CRYSTALLOGR D, V50, P760; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Rao AV, 2002, NUTR NEUROSCI, V5, P291, DOI 10.1080/1028415021000033767; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Takagi J, 2003, NATURE, V424, P969, DOI 10.1038/nature01873; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG DD, 2004, IN PRESS MOL CELL BI	55	167	178	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54750	54758		10.1074/jbc.M410073200	http://dx.doi.org/10.1074/jbc.M410073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475350	hybrid			2022-12-27	WOS:000225793600103
J	Pacifico, F; Mauro, C; Barone, C; Crescenzi, E; Mellone, S; Monaco, M; Chiappetta, G; Terrazzano, G; Liguoro, D; Vito, P; Consiglio, E; Formisano, S; Leonardi, A				Pacifico, F; Mauro, C; Barone, C; Crescenzi, E; Mellone, S; Monaco, M; Chiappetta, G; Terrazzano, G; Liguoro, D; Vito, P; Consiglio, E; Formisano, S; Leonardi, A			Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL CARCINOMA; CYTOCHROME-C; ACTIVATION; EXPRESSION; JNK; FAMILY; TARGET; ALPHA	Thyroid cancer includes three types of carcinomas classified as differentiated thyroid carcinomas (DTC), medullary thyroid carcinomas, and undifferentiated carcinomas (UTC). DTC and medullary thyroid carcinomas generally have a good prognosis, but UTC are usually fatal. Consequently, there is a need for new effective therapeutic modalities to improve the survival of UTC patients. Here we show that NF-kappaB is activated in human thyroid neoplasms, particularly in undifferentiated carcinomas. Thyroid cell lines, reproducing in vitro the different thyroid neoplasias, also show basal NF-kappaB activity and resistance to drug-induced apoptosis, which correlates with the level of NF-kappaB activation. Activation of NF-kappaB in the DTC cell line NPA renders these cells resistant to drug-induced apoptosis. Stable expression of a super-repressor form of IkappaBalpha (IkappaBalphaM) in the UTC cell line FRO results in enhanced sensitivity to drug-induced apoptosis, to the loss of the ability of these cells to form colonies in soft agar, and to induce tumor growth in nude mice. In addition, we show that FRO cells display a very low JNK activity that is restored in FRO-IkappaBalphaM clones. Moreover, inhibition of JNK activity renders FRO-IkappaBalphaM clones resistant to apoptosis induced by chemotherapeutic agents. Our results indicate that NF-kappaB plays a pivotal role in thyroid carcinogenesis, being required for tumor growth and for resistance to drug-induced apoptosis, the latter function very likely through the inhibition of JNK activity. Furthermore, the strong constitutive NF-kappaB activity in human anaplastic thyroid carcinomas, besides representing a novel diagnostic tool, makes NF-kappaB a target for the development of novel therapeutic strategies.	Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Ist Nazl Tumori Fdn G Pascale, I-80131 Naples, Italy; Univ Sannio, Fac Sci, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Fondazione Pascale; University of Sannio	Leonardi, A (corresponding author), Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	leonardi@unina.it	vito, pasquale/ABF-5505-2020; Pacifico, Francesco/AAX-3958-2020; leonardi, antonio/A-2887-2009; Mauro, Claudio/AAN-1848-2021	Pacifico, Francesco/0000-0001-9563-3596; leonardi, antonio/0000-0001-8636-9623; Mauro, Claudio/0000-0002-3736-0099; CRESCENZI, ELVIRA/0000-0002-9258-8053; vito, pasquale/0000-0002-5721-7716; TERRAZZANO, Giuseppe/0000-0003-3556-6891				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALL DW, 1996, THYROID, P1166; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duffey DC, 1999, CANCER RES, V59, P3468; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FIGGE J, 1999, THYROID CANC COMPREH, P515; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Hwang JH, 2003, J CLIN ENDOCR METAB, V88, P408, DOI 10.1210/jc.2002-021381; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Ludwig L, 2001, CANCER RES, V61, P4526; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; McIver B, 2001, SURGERY, V130, P1028, DOI 10.1067/msy.2001.118266; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TENNVALL J, 1994, CANCER-AM CANCER SOC, V74, P1348, DOI 10.1002/1097-0142(19940815)74:4<1348::AID-CNCR2820740427>3.0.CO;2-D; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	47	93	103	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54610	54619		10.1074/jbc.M403492200	http://dx.doi.org/10.1074/jbc.M403492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475567	Green Published, hybrid			2022-12-27	WOS:000225793600087
J	Proudfoot, M; Kuznetsova, E; Brown, G; Rao, NN; Kitagawa, M; Mori, H; Savchenko, A; Yakunin, AF				Proudfoot, M; Kuznetsova, E; Brown, G; Rao, NN; Kitagawa, M; Mori, H; Savchenko, A; Yakunin, AF			General enzymatic screens identify three new nucleotidases in Escherichia coli - Biochemical characterization of SurE, YfbR, and YjjG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC 5'-NUCLEOTIDASE I; K-M 5'-NUCLEOTIDASE; ACID-PHOSPHATASE; CRYSTAL-STRUCTURE; CYTOPLASMIC 5'-NUCLEOTIDASE; PHOSPHOSERINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; SOLUBLE 5'-NUCLEOTIDASE; FUNCTIONAL-ANALYSIS; KINETIC-PROPERTIES	To find proteins with nucleotidase activity in Escherichia coli, purified unknown proteins were screened for the presence of phosphatase activity using the general phosphatase substrate p-nitrophenyl phosphate. Proteins exhibiting catalytic activity were then assayed for nucleotidase activity against various nucleotides. These screens identified the presence of nucleotidase activity in three uncharacterized E. coli proteins, SurE, YfbR, and YjjG, that belong to different enzyme superfamilies: SurE-like family, HD domain family ( YfbR), and haloacid dehalogenase (HAD)-like superfamily ( YjjG). The phosphatase activity of these proteins had a neutral pH optimum (pH 7.0-8.0) and was strictly dependent on the presence of divalent metal cations (SurE: Mn2+ > Co2+ > Ni2+ > Mg2+; YfbR: Co2+ > Mn2+ > Cu2+; YjjG: Mg2+ > Mn2+ > Co2+). Further biochemical characterization of SurE revealed that it has a broad substrate specificity and can dephosphorylate various ribo- and deoxyribonucleoside 5'-monophosphates and ribonucleoside 3'-monophosphates with highest affinity to 3'-AMP. SurE also hydrolyzed polyphosphate (exopolyphosphatase activity) with the preference for short-chain-length substrates (P20-25). YfbR was strictly specific to deoxyribonucleoside 5'-monophosphates, whereas YjjG showed narrow specificity to 5'-dTMP, 5'-dUMP, and 5'-UMP. The three enzymes also exhibited different sensitivities to inhibition by various nucleoside di- and triphosphates: YfbR was equally sensitive to both di- and triphosphates, SurE was inhibited only by triphosphates, and YjjG was insensitive to these effectors. The differences in their sensitivities to nucleotides and their varied substrate specificities suggest that these enzymes play unique functions in the intracellular nucleotide metabolism in E. coli.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Takara Bio Inc, Dragon Genom Ctr, Yokaichi, Mie 5121211, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	University of Toronto; Stanford University; Takara Bio Inc.; Nara Institute of Science & Technology	Yakunin, AF (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	a.iakounine@utoronto.ca	Yakunin, Alexander/J-1519-2014	Yakunin, Alexander/0000-0003-0813-6490	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1993, J BIOL CHEM, V268, P633; Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; AN G, 1979, J BACTERIOL, V137, P1100, DOI 10.1128/JB.137.3.1100-1110.1979; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; Gallinaro L, 2002, J BIOL CHEM, V277, P35080, DOI 10.1074/jbc.M203755200; Garvey EP, 1998, BIOCHEMISTRY-US, V37, P9043, DOI 10.1021/bi980209d; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Genschik P, 1997, EMBO J, V16, P2955, DOI 10.1093/emboj/16.10.2955; GLASER L, 1967, J BIOL CHEM, V242, P1944; GUREVITZ M, 1982, EUR J BIOCHEM, V124, P553; HEINEMEYER EA, 1977, FEBS LETT, V84, P357, DOI 10.1016/0014-5793(77)80724-2; Hogg T, 2004, CELL, V117, P57, DOI 10.1016/S0092-8674(04)00260-0; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; KAMINSKA BJ, 1986, J BIOL CHEM, V261, P449; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; Kim YC, 2004, J BIOL CHEM, V279, P517, DOI 10.1074/jbc.M306054200; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; KOHN J, 1963, J BACTERIOL, V86, P713, DOI 10.1128/JB.86.4.713-716.1963; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KOSHLAND DE, 1984, TRENDS BIOCHEM SCI, V9, P155, DOI 10.1016/0968-0004(84)90125-7; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lee JY, 2001, NAT STRUCT BIOL, V8, P789, DOI 10.1038/nsb0901-789; MADRIDMARINA V, 1986, J BIOL CHEM, V261, P444; Mechold U, 1996, J BACTERIOL, V178, P1401, DOI 10.1128/jb.178.5.1401-1411.1996; Mura C, 2003, J MOL BIOL, V326, P1559, DOI 10.1016/S0022-2836(03)00056-1; NEU HC, 1967, J BIOL CHEM, V242, P3896; NEWSHOLME EA, 1984, TRENDS BIOCHEM SCI, V9, P277, DOI 10.1016/0968-0004(84)90165-8; Niedzwiecka J, 1996, BIOCHEM BIOPH RES CO, V221, P471, DOI 10.1006/bbrc.1996.0619; NISHIKAWA S, 1986, BIOCHEM BIOPH RES CO, V138, P789, DOI 10.1016/S0006-291X(86)80566-6; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHANDLEY SF, 1995, FASEB J, V9, pA1299; OKAZAKI R, 1964, J BIOL CHEM, V239, P269; Orford MR, 1996, J NEUROCHEM, V67, P795; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rees DC, 2003, BRIT J HAEMATOL, V120, P375, DOI 10.1046/j.1365-2141.2003.03980.x; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reilly TJ, 2004, PROTEIN EXPRES PURIF, V33, P48, DOI 10.1016/j.pep.2003.08.020; Riehle MM, 2001, P NATL ACAD SCI USA, V98, P525, DOI 10.1073/pnas.021448998; Rinaldo-Matthis A, 2002, NAT STRUCT BIOL, V9, P779, DOI 10.1038/nsb846; Sala-Newby GB, 2001, BBA-GENE STRUCT EXPR, V1521, P12, DOI 10.1016/S0167-4781(01)00278-0; Sala-Newby GB, 2000, J BIOL CHEM, V275, P11666, DOI 10.1074/jbc.275.16.11666; SCHRADER WP, 1978, J BACTERIOL, V133, P576, DOI 10.1128/JB.133.2.576-583.1978; SETO D, 1988, J BIOL CHEM, V263, P1494; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; TRETON BY, 1992, CURR GENET, V22, P345, DOI 10.1007/BF00352435; Valentin-Hansen P, 1978, Methods Enzymol, V51, P308; Visick JE, 1998, FEMS MICROBIOL LETT, V167, P19, DOI 10.1111/j.1574-6968.1998.tb13202.x; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503; Wu J, 2003, J BIOL CHEM, V278, P18117, DOI 10.1074/jbc.M301983200; WURST H, 1994, J BIOL CHEM, V269, P10996; Xu WL, 2003, J BIOL CHEM, V278, P37492, DOI 10.1074/jbc.M307639200; Yakunin AF, 2004, J BIOL CHEM, V279, P36819, DOI 10.1074/jbc.M405120200; Zhang GF, 2004, BIOCHEMISTRY-US, V43, P4990, DOI 10.1021/bi036309n; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	70	77	83	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54687	54694		10.1074/jbc.M411023200	http://dx.doi.org/10.1074/jbc.M411023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489502	hybrid			2022-12-27	WOS:000225793600095
J	Tng, E; Tan, SM; Ranganathan, S; Cheng, M; Law, SKA				Tng, E; Tan, SM; Ranganathan, S; Cheng, M; Law, SKA			The integrin alpha(L)beta(2) hybrid domain serves as a link for the propagation of activation signal from its stalk regions to the I-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; CYSTEINE-RICH REGION; A-DOMAIN; LIGAND-BINDING; CR3-DEPENDENT ADHESION; EXTRACELLULAR SEGMENT; ELECTRON-MICROSCOPY; SURFACE EXPRESSION; AVIDITY REGULATION; MISSENSE MUTATION	Integrin activation involves global conformational changes as demonstrated by various functional and structural analyses. The integrin beta hybrid domain is proposed to be involved in the propagation of this activation signal. Our previous study showed that the integrin beta(2)-specific monoclonal antibody 7E4 abrogates monoclonal antibody KIM185-activated but not Mg2+/EGTA-activated leukocyte function-associated antigen-1 (LFA-1; alpha(L)beta(2))-mediated adhesion to ICAM-1. Here we investigated the allosteric inhibitory property of 7E4. By using human/mouse chimeras and substitution mutations, the epitope of 7E4 was mapped to Val(407), located in the mid-region of the beta(2) hybrid domain. Two sets of constitutively active LFA-1 variants were used to examine the effect of 7E4 on LFA-1/ICAM-1 binding. 7E4 attenuated the binding of variants that have modifications to regions membrane proximal with respect to the beta(2) hybrid domain. In contrast, the inhibitory effect was minimal on variants with alterations in the alpha(L)I- and beta(2) I-like domains preceding the hybrid domain. Furthermore, 7E4 abrogated LFA-1/ICAM-1 adhesion of phorbol 12-myristate 13-acetate-treated MOLT-4 cells. Our data demonstrate that interaction between the hybrid and I-like domain is critical for the regulation of LFA-1-mediated adhesion.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore	University of Oxford; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Law, SKA (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	Alaw@ntu.edu.sg	Law, Alex/A-2212-2011; Tan, Suet/A-2224-2011	Tan, Suet-Mien/0000-0003-2371-8739; Ranganathan, Shoba/0000-0002-8290-813X				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BASIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Douglass WA, 1998, FEBS LETT, V440, P414, DOI 10.1016/S0014-5793(98)01498-7; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kijas JMH, 1999, GENOMICS, V61, P101, DOI 10.1006/geno.1999.5948; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Mathew EC, 2000, CLIN EXP IMMUNOL, V121, P133, DOI 10.1046/j.1365-2249.2000.01277.x; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; NELSON C, 1992, J BIOL CHEM, V267, P3351; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Shaw JM, 2001, CLIN EXP IMMUNOL, V126, P311, DOI 10.1046/j.1365-2249.2001.01661.x; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tan SM, 2001, FEBS LETT, V505, P27, DOI 10.1016/S0014-5793(01)02778-8; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WRIGHT AH, 1995, EUR J IMMUNOL, V25, P717, DOI 10.1002/eji.1830250313; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	44	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54334	54339		10.1074/jbc.M407818200	http://dx.doi.org/10.1074/jbc.M407818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15456774	hybrid			2022-12-27	WOS:000225793600055
J	Hiromura, M; Okada, F; Obata, T; Auguin, D; Shibata, T; Roumestand, C; Noguchi, M				Hiromura, M; Okada, F; Obata, T; Auguin, D; Shibata, T; Roumestand, C; Noguchi, M			Inhibition of Akt kinase activity by a peptide spanning the beta A strand of the proto-oncogene TCL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL-SURVIVAL; HUMAN CANCER; ACTIVATION; BINDING; 3-KINASE	Akt plays a central role in the regulation of cellular anti-apoptosis underlying various human neoplastic diseases. We have demonstrated previously that TCL1 ( a proto-oncogene underlying human T cell prolymphocytic leukemia) interacts with Akt and functions as an Akt kinase co-activator. With the aim to develop an Akt kinase inhibitor, we hypothesized that a peptide, which spans the Akt-binding site, binds to Akt and modulates Akt kinase activity and its downstream biological responses. Indeed, we demonstrated that a peptide, named "Akt-in" (Akt inhibitor, NH2-AVTDHPDRLWAWEKFCOOH, encompassing the betaA strand of human TCL1), interacted with Akt and specifically inhibited its kinase activity. Nuclear magnetic resonance studies suggested that interaction of Akt-in with the pleckstrin homology domain (PH) of Akt caused conformational changes on the variable loop 1 of Akt, the locus mediating phosphoinositide binding. Consistently, interaction of Akt-in with the Akt PH domain prevented phosphoinositide binding and hence inhibited membrane translocation and activation of Akt. Moreover, Akt-in inhibited not only cellular proliferation and anti-apoptosis in vitro but also in vivo tumor growth without any adverse effect. The roles of Akt, which possesses a PH domain, in intracellular signaling were well established. Hence, Akt inhibitors create an attractive target for anticancer therapy. However, no effective inhibitors specific for Akt have been developed. Akt-in, which inhibits association of phosphatidylinositol with Akt, is the first molecule to demonstrate specific Akt kinase inhibition potency. This observation will facilitate the design of specific inhibitors for Akt, a core intracellular survival factor underlying various human neoplastic diseases.	Hokkaido Univ, Inst Med Genet, Div Canc Biol, Sapporo, Hokkaido, Japan; Yamagata Univ, Grad Sch Med, Dept Biomol Funct, Yamagata 990, Japan; Fac Pharm Montpellier, Ctr Biochim Struct, Montpellier, France; Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 770, Japan; Appl Biosyst Japan Ltd, Tokyo, Japan	Hokkaido University; Yamagata University; Universite de Montpellier; Tokushima University; Thermo Fisher Scientific; Applied Biosystems	Noguchi, M (corresponding author), N15,W7,Kita Ku, Sapporo, Hokkaido 0600815, Japan.	m_noguch@igm.hokudai.ac.jp	Auguin, Daniel/Y-2074-2019	Auguin, Daniel/0000-0003-4713-9096; ROUMESTAND, Christian/0000-0002-4082-3293; Okada, Futoshi/0000-0003-4733-1037				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Auguin D, 2004, J BIOL CHEM, V279, P35890, DOI 10.1074/jbc.M400364200; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barr RK, 2004, J BIOL CHEM, V279, P36327, DOI 10.1074/jbc.M402181200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Coffer PJ, 1998, BIOCHEM J, V335, P1; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; Datta K, 2001, CANCER RES, V61, P1768; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Gold MR, 2003, TRENDS IMMUNOL, V24, P104, DOI 10.1016/S1471-4906(03)00022-X; Hoh F, 1998, STRUCTURE, V6, P147, DOI 10.1016/S0969-2126(98)00017-3; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lock RB, 2003, INT J BIOCHEM CELL B, V35, P1614, DOI 10.1016/S1357-2725(03)00146-8; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; OKADA F, 1992, BRIT J CANCER, V66, P635, DOI 10.1038/bjc.1992.329; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Reuveni H, 2000, J CELL BIOL, V151, P1179, DOI 10.1083/jcb.151.6.1179; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	62	75	87	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53407	53418		10.1074/jbc.M403775200	http://dx.doi.org/10.1074/jbc.M403775200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459205	hybrid			2022-12-27	WOS:000225680600074
J	Wang, W; Stock, RE; Gronostajski, RM; Wong, YW; Schachner, M; Kilpatrick, DL				Wang, W; Stock, RE; Gronostajski, RM; Wong, YW; Schachner, M; Kilpatrick, DL			A role for nuclear factor I in the intrinsic control of cerebellar granule neuron gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA 6 SUBUNIT; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; REGULATORY ELEMENT; CELLS; SPECIFICATION; NFI; VITRO; VIVO; DIFFERENTIATION	Nervous system formation requires the elaboration of a complex series of differentiation events in both a spatially and maturation-regulated manner. A fundamental question is how neuronal subtype specification and developmental gene expression are controlled within maturing neurons. The alpha6 subunit of the gamma-aminobutyric acid type A (GABA(A)) receptor (GABRA6) is preferentially expressed in cerebellar granule neurons and is part of an intrinsic program directing their differentiation. We have employed a lentiviral approach to examine the transcriptional mechanisms controlling neuronal subtype-selective expression of this gene. These studies demonstrated that nuclear factor I (NFI) proteins are required for both transgenic GABRA6 promoter activity as well as endogenous expression of this gene in cerebellar granule neurons. Chromatin immunoprecipitation also showed that NFI proteins are bound to the GABRA6 promoter in these cells in vivo. Furthermore, analyses of gene knockout mice revealed that Nfia is specifically required for normal expression of the GABRA6 gene in cerebellar granule neurons. NFI expression and DNA binding activity are highly enriched in granule neurons, implicating this transcription factor family in the neuronal subtype-selective expression of the GABRA6 gene. These studies define a new role for NFI proteins as neuronal subtype-enriched transcriptional regulators that participate in an intrinsic transcriptional program directing the differentiation of cerebellar granule neurons.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Hamburg; University Medical Center Hamburg-Eppendorf; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kilpatrick, DL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, BSB S4-139,55 Lake Ave N, Worcester, MA 01655 USA.	daniel.kilpatrick@umassmed.edu		Gronostajski, Richard/0000-0003-4264-208X; , wei/0000-0002-5138-2892	NATIONAL CANCER INSTITUTE [R01CA079999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058401] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79999] Funding Source: Medline; NIDDK NIH HHS [R01DK58401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; Bahn S, 1999, EUR J NEUROSCI, V11, P2194, DOI 10.1046/j.1460-9568.1999.00662.x; Bahn S, 1997, P NATL ACAD SCI USA, V94, P9417, DOI 10.1073/pnas.94.17.9417; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Carletti B, 2002, J NEUROSCI, V22, P7132; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; CONDIT RC, 2001, PRINCIPLES VIRUS STR, P31; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; GAO B, 1995, DEV BRAIN RES, V88, P1, DOI 10.1016/0165-3806(95)00062-I; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunder A, 2002, MECH DEVELOP, V112, P69, DOI 10.1016/S0925-4773(01)00640-2; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; INOUE T, 1990, J BIOL CHEM, V265, P19065; Jankovski A, 1996, EUR J NEUROSCI, V8, P2308, DOI 10.1111/j.1460-9568.1996.tb01194.x; Jones A, 1996, J NEUROCHEM, V67, P907; KATO K, 1990, J MOL BIOL, V214, P619, DOI 10.1016/0022-2836(90)90276-R; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Lin X, 1996, NEUROSCI LETT, V220, P81, DOI 10.1016/S0304-3940(96)13214-6; Liu F, 1997, J BIOL CHEM, V272, P5056, DOI 10.1074/jbc.272.8.5056; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; McLean PJ, 2000, J NEUROCHEM, V74, P1858, DOI 10.1046/j.1471-4159.2000.0741858.x; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; PUZIANOWSKAKUZNICK, 1996, J BIOL CHEM, V271, P6273; Reiser J, 2000, GENE THER, V7, P910, DOI 10.1038/sj.gt.3301188; Shu TZ, 2003, J NEUROSCI, V23, P203; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; Steele-Perkins G, 2003, MOL CELL BIOL, V23, P1075, DOI 10.1128/MCB.23.3.1075-1084.2003; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; Yacubova E, 2002, J NEUROSCI, V22, P5966; Yamasaki T, 2001, DEVELOPMENT, V128, P3133; ZHENG T, 1993, DEV BRAIN RES, V75, P91, DOI 10.1016/0165-3806(93)90068-L; Zhou HP, 2001, GENE EXPRESSION, V9, P217, DOI 10.3727/000000001783992597; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	42	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53491	53497		10.1074/jbc.M410370200	http://dx.doi.org/10.1074/jbc.M410370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466411	hybrid			2022-12-27	WOS:000225680600084
J	Dinour, D; Chang, MH; Satoh, J; Smith, BL; Angle, N; Knecht, A; Serban, I; Holtzman, EJ; Romero, MF				Dinour, D; Chang, MH; Satoh, J; Smith, BL; Angle, N; Knecht, A; Serban, I; Holtzman, EJ; Romero, MF			A novel missense mutation in the sodium bicarbonate cotransporter (NBCe1/SLC4A4) causes proximal tubular acidosis and glaucoma through ion transport defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROGENIC NA+-HCO3-COTRANSPORTER; CARBONIC-ANHYDRASE-IV; NA/HCO3 COTRANSPORTERS; FUNCTIONAL EXPRESSION; AUTOSOMAL-DOMINANT; CLONING; LOCALIZATION; GENE; IMMUNOLOCALIZATION; DEPENDENCE	In humans and terrestrial vertebrates, the kidney controls systemic pH in part by absorbing filtered bicarbonate in the proximal tubule via an electrogenic Na+/HCO3- cotransporter (NBCe1/SLC4A4). Recently, human genetics revealed that NBCe1 is the major renal contributor to this process. Homozygous point mutations in NBCe1 cause proximal renal tubular acidosis (pRTA), glaucoma, and cataracts (Igarashi, T., Inatomi, J., Sekine, T., Cha, S. H., Kanai, Y., Kunimi, M., Tsukamoto, K., Satoh, H., Shimadzu, M., Tozawa, F., Mori, T., Shiobara, M., Seki, G., and Endou, H. (1999) Nat. Genet. 23, 264-266). We have identified and functionally characterized a novel, homozygous, missense mutation (S427L) in NBCe1, also resulting in pRTA and similar eye defects without mental retardation. To understand the pathophysiology of the syndrome, we expressed wild-type (WT) NBCe1 and S427L-NBCe1 in Xenopus oocytes. Function was evaluated by measuring intracellular pH (HCO3- transport) and membrane currents using micro-electrodes. HCO3--elicited currents for S427L were similar to10% of WT NBCe1, and CO2-induced acidification was similar to4-fold faster. Na+-dependent HCO3- transport (currents and acidification) was also similar to10% of WT. Current-voltage (I-V) analysis reveals that S427L has no reversal potential in HCO3-, indicating that under physiological ion gradient conditions, NaHCO3 could not move out of cells as is needed for renal HCO3- absorption and ocular pressure homeostasis. I-V analysis without Na+ further shows that the S427L-mediated NaHCO3 efflux mode is depressed or absent. These experiments reveal that voltage- and Na+-dependent transport by S427L-hkN-BCe1 is unfavorably altered, thereby causing both insufficient HCO3- absorption by the kidney (proximal RTA) and inappropriate anterior chamber fluid transport (glaucoma).	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Tel Aviv Univ, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Hypertens & Nephrol, IL-52621 Tel Hashomer, Israel	Case Western Reserve University; Case Western Reserve University; Tel Aviv University; Chaim Sheba Medical Center	Romero, MF (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	Michael.romero@case.edu			NIDDK NIH HHS [DK-56218] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056218] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; Alvarez BV, 2003, BIOCHEMISTRY-US, V42, P12321, DOI 10.1021/bi0353124; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Bevensee MO, 2000, AM J PHYSIOL-CELL PH, V278, pC1200, DOI 10.1152/ajpcell.2000.278.6.C1200; Bok D, 2001, AM J PHYSIOL-RENAL, V281, pF920, DOI 10.1152/ajprenal.2001.281.5.F920; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; Chang MH, 2004, FASEB J, V18, pA1269; DINOUR D, 2000, J AM SOC NEPHROL, V11; Douglas RM, 2001, NEUROSCIENCE, V102, P217, DOI 10.1016/S0306-4522(00)00473-5; Grichtchenko I, 2002, FASEB J, V16, pA795; Grichtchenko II, 2000, J GEN PHYSIOL, V115, P533, DOI 10.1085/jgp.115.5.533; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Igarashi T, 1999, NAT GENET, V23, P264, DOI 10.1038/15440; Igarashi T, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025281.70901.30; Igarashi T, 2001, J AM SOC NEPHROL, V12, P713, DOI 10.1681/ASN.V124713; IGARASHI T, 2000, J AM SOC NEPHROL, V11; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; Kakei M, 1996, BBA-GEN SUBJECTS, V1289, P226, DOI 10.1016/0304-4165(95)00145-X; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Luo X, 2001, J BIOL CHEM, V276, P9808, DOI 10.1074/jbc.M008548200; OKUYAMA T, 1993, GENOMICS, V16, P678, DOI 10.1006/geno.1993.1247; Park K, 2002, ARCH ORAL BIOL, V47, P1, DOI 10.1016/S0003-9969(01)00098-X; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 2002, FASEB J, V16, pA52; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Roussa E, 1999, AM J PHYSIOL-GASTR L, V277, pG1288, DOI 10.1152/ajpgi.1999.277.6.G1288; Schmitt BM, 2000, J NEUROSCI, V20, P6839, DOI 10.1523/JNEUROSCI.20-18-06839.2000; Sciortino CM, 2001, AM J PHYSIOL-CELL PH, V281, pC449, DOI 10.1152/ajpcell.2001.281.2.C449; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; Sciortino CM, 2001, THESIS CASE W RESERV; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stehberger PA, 2003, J AM SOC NEPHROL, V14, P3027, DOI 10.1097/01.ASN.0000099375.74789.AB; Stover EH, 2002, J MED GENET, V39, P796, DOI 10.1136/jmg.39.11.796; Tatishchev S, 2003, BIOCHEMISTRY-US, V42, P755, DOI 10.1021/bi026826q; Usui T, 2001, J CLIN INVEST, V108, P107, DOI 10.1172/JCI11869; WINSNES A, 1979, ACTA PAEDIATR SCAND, V68, P861	41	133	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52238	52246		10.1074/jbc.M406591200	http://dx.doi.org/10.1074/jbc.M406591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471865	hybrid			2022-12-27	WOS:000225493400064
J	Nixon, JC; Rajaiya, J; Webb, CF				Nixon, JC; Rajaiya, J; Webb, CF			Mutations in the DNA-binding domain of the transcription factor bright act as dominant negative proteins and interfere with immunoglobulin transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; DEAD RINGER GENE; CELL DIFFERENTIATION; EXPRESSION; FAMILY; SEQUENCE; REGION; LIPOPOLYSACCHARIDE; INTERLEUKIN-5; INDUCTION	Bright, for B cell regulator of immunoglobulin heavy chain transcription, binds A + T-rich sequences in the intronic enhancer regions of the murine heavy chain locus and 5'-flanking sequences of some variable heavy chain promoters. Most resting B cells do not express Bright; however, it is induced after stimulation with antigen or polyclonal mitogens. Bright activation results in up-regulation of mu transcription; however, it is not clear whether Bright function is critical for normal B cell development. To begin to address Bright function during B cell development, seven mutated forms of Bright were produced. Five of the seven mutants revealed little or no DNA binding activity. Furthermore, because Bright binds DNA as a dimer, two of the mutants formed complexes with wild type Bright and acted in a dominant negative fashion. Dominant negative Bright prevented the up-regulation of mu transcription in transfected Chinese hamster ovary cells transfected with wild type Bright. These data identify regions within Bright that are required for the DNA binding activity of Bright and for its function as a transcription factor.	Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Webb, CF (corresponding author), Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, 825 NE 13th St,MS 36, Oklahoma City, OK 73104 USA.	carol-webb@omrf.ouhsc.edu		Rajaiya, Jaya/0000-0002-4559-5613	NIAID NIH HHS [T32 AI007633, AI44215, AI45864] Funding Source: Medline; PHS HHS [T32 07364] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUCHANAN KL, 1995, J IMMUNOL, V155, P4270; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Iwahara J, 1999, EMBO J, V18, P6084, DOI 10.1093/emboj/18.21.6084; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Kaplan MH, 2001, J BIOL CHEM, V276, P21325, DOI 10.1074/jbc.M100836200; KEARNEY JF, 1976, J IMMUNOL, V117, P1567; Kortschak RD, 1998, GENOMICS, V51, P288, DOI 10.1006/geno.1998.5259; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; Nixon JC, 2004, CELL IMMUNOL, V228, P42, DOI 10.1016/j.cellimm.2004.03.004; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shandala T, 1999, DEVELOPMENT, V126, P4341; Shandala T, 2003, DEVELOPMENT, V130, P1505, DOI 10.1242/dev.00377; Shandala T, 2002, INT J DEV BIOL, V46, P423; Suzuki M, 1998, ONCOGENE, V17, P853, DOI 10.1038/sj.onc.1202163; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Webb C, 1999, COLD SPRING HARB SYM, V64, P109, DOI 10.1101/sqb.1999.64.109; Webb CF, 1998, J IMMUNOL, V160, P4747; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WEBB CF, 1991, MOL CELL BIOL, V11, P5197, DOI 10.1128/MCB.11.10.5197; WEBB CF, 1989, J IMMUNOL, V143, P3934; WEBB CF, 1983, EUR J IMMUNOL, V13, P556, DOI 10.1002/eji.1830130708; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95	30	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52465	52472		10.1074/jbc.M403028200	http://dx.doi.org/10.1074/jbc.M403028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456761	hybrid			2022-12-27	WOS:000225493400091
J	Rochais, F; Vandecasteele, G; Lefebvre, F; Lugnier, C; Lum, H; Mazet, JL; Cooper, DMF; Fischmeister, R				Rochais, F; Vandecasteele, G; Lefebvre, F; Lugnier, C; Lum, H; Mazet, JL; Cooper, DMF; Fischmeister, R			Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes - An in vivo study using adenovirus-mediated expression of CNG channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADENYLYL-CYCLASE ACTIVITY; GATED CHANNELS; AMP PHOSPHODIESTERASE; VENTRICULAR MYOCYTES; CALCIUM-CHANNELS; BETA-ARRESTINS; LIVING CELLS; CA2+ CURRENT; ACTIVATION	Intracardiac cAMP levels are modulated by hormones and neuromediators with specific effects on contractility and metabolism. To understand how the same second messenger conveys different information, mutants of the rat olfactory cyclic nucleotide-gated (CNG) channel alpha-subunit CNGA2, encoded into adenoviruses, were used to monitor cAMP in adult rat ventricular myocytes. CNGA2 was not found in native myocytes but was strongly expressed in infected cells. In whole cell patch-clamp experiments, the forskolin analogue L-858051 (L-85) elicited a non-selective, Mg2+-sensitive current observed only in infected cells, which was thus identified as the CNG current (I-CNG). The beta-adrenergic agonist isoprenaline (ISO) also activated I-CNG, although the maximal efficiency was approximate to 5 times lower than with L-85. However, ISO and L-85 exerted a similar maximal increase of the L-type Ca2+ current. The use of a CNGA2 mutant with a higher sensitivity for cAMP indicated that this difference is caused by the activation of a localized fraction of CNG channels by ISO. cAMP-dependent protein kinase (PKA) blockade with H89 or PKI, or phosphodiesterase (PDE) inhibition with IBMX, dramatically potentiated ISO- and L-85-stimulated I-CNG. A similar potentiation of beta-adrenergic stimulation occurred when PDE4 was blocked, whereas PDE3 inhibition had a smaller effect (by 2-fold). ISO and L-85 increased total PDE3 and PDE4 activities in cardiomyocytes, although this effect was insensitive to H89. However, in the presence of IBMX, H89 had no effect on ISO stimulation of I-CNG. This study demonstrates that subsarcolemmal cAMP levels are dynamically regulated by a negative feedback involving PKA stimulation of subsarcolemmal cAMP-PDE.	Univ Paris Sud, INSERM, Fac Pharm, U 446, F-92296 Chatenay Malabry, France; Univ Louis Pasteur Strasbourg 1, Lab Pharmacol & Physicochim Interact Cellulaires, UMR 7034, CNRS,Fac Pharm, F-67401 Illkirch Graffenstaden, France; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Cambridge	Vandecasteele, G (corresponding author), Univ Paris Sud, INSERM, Fac Pharm, U 446, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	gregoire.vandecasteele@cep.u-psud.fr	Rochais, Francesca/ABF-4675-2021; lugnier, claire/AAF-3911-2020; Rochais, Francesca/A-5326-2017; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Rochais, Francesca/0000-0001-9355-8916; Rochais, Francesca/0000-0001-9355-8916; Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171; LEFEBVRE, florence/0000-0003-0133-5825				AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; Bolger GB, 2003, J BIOL CHEM, V278, P49230, DOI 10.1074/jbc.M303772200; BRUNTON LL, 1979, NATURE, V280, P78, DOI 10.1038/280078a0; Bushnik T, 1996, BIOCHEM SOC T, V24, P1014, DOI 10.1042/bst0241014; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cui H, 2003, BIOCHEM BIOPH RES CO, V307, P119, DOI 10.1016/S0006-291X(03)01130-6; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; EcklyMichel A, 1997, BRIT J PHARMACOL, V122, P158, DOI 10.1038/sj.bjp.0701339; ESPINASSE I, 1995, J MOL CELL CARDIOL, V27, P1789, DOI 10.1016/0022-2828(95)90002-0; Fagan KA, 2001, FEBS LETT, V500, P85, DOI 10.1016/S0014-5793(01)02564-9; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Geoffroy V, 1999, EUR J BIOCHEM, V259, P892, DOI 10.1046/j.1432-1327.1999.00123.x; Georget M, 2003, FASEB J, V17, P1380, DOI 10.1096/fj.02-0784com; Goaillard JM, 2001, J PHYSIOL-LONDON, V530, P79, DOI 10.1111/j.1469-7793.2001.0079m.x; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; HUNDAL SP, 1993, BIOCHEM SOC T, V21, P119; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; JUREVICIUS J, J PHYSL, V551, P239; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KERAVIS TM, 1980, BIOCHIM BIOPHYS ACTA, V613, P116, DOI 10.1016/0005-2744(80)90198-9; KIRSTEIN M, 1995, J CLIN INVEST, V95, P794, DOI 10.1172/JCI117729; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGNIER C, 1993, J PHARMACOL EXP THER, V265, P1142; Lum H, 1999, AM J PHYSIOL-CELL PH, V277, pC580, DOI 10.1152/ajpcell.1999.277.3.C580; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; MULLER B, 1990, J CARDIOVASC PHARM, V16, P796, DOI 10.1097/00005344-199011000-00016; MULLER B, 1992, EUR J PHARM-MOLEC PH, V225, P263, DOI 10.1016/0922-4106(92)90028-T; Murthy KS, 2002, AM J PHYSIOL-CELL PH, V282, pC508, DOI 10.1152/ajpcell.00373.2001; OCONNELL TD, 2003, AFCS RES REPORTS, V1; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Petroff MGV, 2001, CIRC RES, V89, P445, DOI 10.1161/hh1701.095716; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; Rich TC, 2002, ANN BIOMED ENG, V30, P1088, DOI 10.1114/1.1511242; Rich TC, 2001, J GEN PHYSIOL, V118, P63, DOI 10.1085/jgp.118.1.63; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Ruiz ML, 1996, J MOL CELL CARDIOL, V28, P1453, DOI 10.1006/jmcc.1996.0136; Saucerman JJ, 2003, J BIOL CHEM, V278, P47997, DOI 10.1074/jbc.M308362200; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAHID M, 1990, N-S ARCH PHARMACOL, V342, P698, DOI 10.1007/BF00175715; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Stoclet J.C., 1995, EXPERT OPIN INV DRUG, V4, P1081; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Verde I, 1999, BRIT J PHARMACOL, V127, P65, DOI 10.1038/sj.bjp.0702506; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Wechsler J, 2002, J BIOL CHEM, V277, P38072, DOI 10.1074/jbc.M203647200; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; YU HJ, 1993, MOL PHARMACOL, V44, P689; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	68	109	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52095	52105		10.1074/jbc.M405697200	http://dx.doi.org/10.1074/jbc.M405697200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466415	Green Published, hybrid			2022-12-27	WOS:000225493400048
J	Chappell, KJ; Nall, TA; Stoermer, MJ; Fang, NX; Tyndall, JDA; Fairlie, DP; Young, PR				Chappell, KJ; Nall, TA; Stoermer, MJ; Fang, NX; Tyndall, JDA; Fairlie, DP; Young, PR			Site-directed mutagenesis and kinetic studies of the West Nile virus NS3 protease identify key enzyme-substrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; RETRACTED ARTICLE. SEE; CRYSTAL-STRUCTURE; SERINE-PROTEASE; CLEAVAGE SITE; HOMOLOGY MODEL; DRUG DESIGN; DENGUE; PROTEINASE; FLAVIVIRUS	The flavivirus West Nile virus (WNV) has spread rapidly throughout the world in recent years causing fever, meningitis, encephalitis, and fatalities. Because the viral protease NS2B/NS3 is essential for replication, it is attracting attention as a potential therapeutic target, although there are currently no antiviral inhibitors for any flavivirus. This paper focuses on elucidating interactions between a hexapeptide substrate (Ae-KPGLKR-p-nitroanilide) and residues at S1 and S2 in the active site of WNV protease by comparing the catalytic activities of selected mutant recombinant proteases in vitro. Homology modeling enabled the predictions of key mutations in VWNV NS3 protease at S1 (V115A/F, D129A/ E/N, S135A, Y150A/F, S160A, and S163A) and S2 (N152A) that might influence substrate recognition and catalytic efficiency. Key conclusions are that the substrate P1 Arg strongly interacts with S1 residues Asp-129, Tyr-150, and Ser-163 and, to a lesser extent, Ser-160, and P2 Lys makes an essential interaction with Asn-152 at S2. The inferred substrate-enzyme interactions provide a basis for rational protease inhibitor design and optimization. High sequence conservation within flavivirus proteases means that this study may also be relevant to design of protease inhibitors for other flavivirus proteases.	Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Otago, Sch Pharm, Dunedin 9015, New Zealand	University of Queensland; University of Queensland; University of Otago	Young, PR (corresponding author), Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia.	p.young@uq.edu.au	Fairlie, David P/F-8865-2014; Young, Paul R/A-6176-2010; Stoermer, Martin J/E-2317-2012; tyndall, joel/C-2803-2008	Fairlie, David P/0000-0002-7856-8566; Young, Paul R/0000-0002-2040-5190; Stoermer, Martin J/0000-0003-3445-2104; tyndall, joel/0000-0003-0783-1635				Abbenante G, 2000, LETT PEPT SCI, V7, P347, DOI 10.1023/A:1013016323676; Amberg SM, 1999, J VIROL, V73, P8083, DOI 10.1128/JVI.73.10.8083-8094.1999; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Brinkworth RI, 1999, J GEN VIROL, V80, P1167, DOI 10.1099/0022-1317-80-5-1167; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Buckley A, 2003, J GEN VIROL, V84, P2807, DOI 10.1099/vir.0.19341-0; *CBBG, XWINNMR VERS 2 6; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; Gussio R, 1996, J MED CHEM, V39, P1645, DOI 10.1021/jm9508088; Hayes CG, 2001, ANN NY ACAD SCI, V951, P25; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hicks RP, 2003, BIOPOLYMERS, V68, P459, DOI 10.1002/bip.10325; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; LIN C, 1993, VIROLOGY, V192, P596, DOI 10.1006/viro.1993.1076; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P6218, DOI 10.1073/pnas.90.13.6218; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; Tesh RB, 2002, EMERG INFECT DIS, V8, P1392, DOI 10.3201/eid0812.020229; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valle RPC, 1998, J VIROL, V72, P624, DOI 10.1128/JVI.72.1.624-632.1998; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; Wuthrich K, 1986, NMR PROTEINS NUCL AC	39	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2896	2903		10.1074/jbc.M409931200	http://dx.doi.org/10.1074/jbc.M409931200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15494419	hybrid			2022-12-27	WOS:000226449100065
J	Fishman, A; Tao, Y; Rui, LY; Wood, TK				Fishman, A; Tao, Y; Rui, LY; Wood, TK			Controlling the regiospecific oxidation of aromatics via active site engineering of toluene para-monooxygenase of Ralstonia pickettii PKO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE METHANE MONOOXYGENASE; PSEUDOMONAS-STUTZERI OX1; METHYLOSINUS-TRICHOSPORIUM OB3B; METHYLOCOCCUS-CAPSULATUS BATH; ENHANCED 1-NAPHTHOL SYNTHESIS; BURKHOLDERIA-CEPACIA G4; O-XYLENE MONOOXYGENASE; DIRECTED EVOLUTION; TRICHLOROETHYLENE DEGRADATION; CHLOROFORM DEGRADATION	A primary goal of protein engineering is to control catalytic activity. Here we show that through mutagenesis of three active site residues, the catalytic activity of a multicomponent monooxygenase is altered so that it hydroxylates all three positions of toluene as well as both positions of naphthalene. Hence, for the first time, an enzyme has been engineered so that its regiospecific oxidation of a substrate can be controlled. Through the A107G mutation in the alpha-subunit of toluene para-monooxygenase, a variant was formed that hydroxylated toluene primarily at the ortho-position while converting naphthalene to 1-naphthol. Conversely, the A107T variant produced >98% p-cresol and p-nitrophenol from toluene and nitrobenzene, respectively, as well as produced 2-naphthol from naphthalene. The mutation I100S/G103S produced a toluene para-monooxygenase variant that formed 75% m-cresol from toluene and 100% m-nitrophenol from nitrobenzene; thus, for the first time a true meta-hydroxylating toluene monooxygenase was created.	Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut; University of Connecticut	Wood, TK (corresponding author), Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.	twood@engr.uconn.edu	Wood, Thomas/GWZ-2481-2022; Fishman, Ayelet/A-6293-2018	Wood, Thomas/0000-0001-8962-8571; Fishman, Ayelet/0000-0002-1644-9377; Wood, Thomas/0000-0002-6258-529X				Bertoni G, 1998, APPL ENVIRON MICROB, V64, P3626; Branden C, 1999, INTRO PROTEIN STRUCT, P14; Brazeau BJ, 2003, BIOCHEMISTRY-US, V42, P5618, DOI 10.1021/bi027429i; Burton SG, 2003, TRENDS BIOTECHNOL, V21, P543, DOI 10.1016/j.tibtech.2003.10.006; Bylina EJ, 2000, ASM NEWS, V66, P211; BYRNE AM, 1995, GENE, V154, P65, DOI 10.1016/0378-1119(94)00844-I; Byrne AM, 1996, J BACTERIOL, V178, P6327, DOI 10.1128/jb.178.21.6327-6337.1996; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; Dolfing Jan, 1993, Biodegradation, V4, P261, DOI 10.1007/BF00695974; EATON RW, 1995, J BACTERIOL, V177, P6983, DOI 10.1128/jb.177.23.6983-6988.1995; Fishman A, 2004, BIOTECHNOL BIOENG, V87, P779, DOI 10.1002/bit.20185; Fishman A, 2004, J BACTERIOL, V186, P3117, DOI 10.1128/JB.186.10.3117-3123.2004; FISHMAN A, 2004, IN PRESS BIOCATAL BI; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAIGLER BE, 1991, APPL ENVIRON MICROB, V57, P3156, DOI 10.1128/AEM.57.11.3156-3162.1991; HOWEGRANT M, 1991, KIRKOTHMER ENCY CHEM, V16, P994; Jahng D, 1996, BIOTECHNOL BIOENG, V51, P349, DOI 10.1002/(SICI)1097-0290(19960805)51:3&lt;349::AID-BIT10&gt;3.0.CO;2-H; JAHNG DJ, 1994, APPL ENVIRON MICROB, V60, P2473, DOI 10.1128/AEM.60.7.2473-2482.1994; Kahng HY, 2000, J BACTERIOL, V182, P1232, DOI 10.1128/JB.182.5.1232-1242.2000; Kirk O, 2002, CURR OPIN BIOTECH, V13, P345, DOI 10.1016/S0958-1669(02)00328-2; Leahy JG, 2003, FEMS MICROBIOL REV, V27, P449, DOI 10.1016/S0168-6445(03)00023-8; Leahy JG, 1996, APPL ENVIRON MICROB, V62, P825, DOI 10.1128/AEM.62.3.825-833.1996; Li Z, 2002, CURR OPIN CHEM BIOL, V6, P136, DOI 10.1016/S1367-5931(02)00296-X; Liebeton K, 2000, CHEM BIOL, V7, P709, DOI 10.1016/S1074-5521(00)00015-6; Luu PP, 1995, APPL MICROBIOL BIOT, V44, P259, DOI 10.1007/BF00164512; May O, 2000, NAT BIOTECHNOL, V18, P317, DOI 10.1038/73773; MCMURRY J, 2004, ORGANIC CHEM, P528; Mitchell KH, 2003, P NATL ACAD SCI USA, V100, P3784, DOI 10.1073/pnas.0636619100; Mitchell KH, 2002, BIOCHEMISTRY-US, V41, P3176, DOI 10.1021/bi012036p; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; OLSEN RH, 1994, J BACTERIOL, V176, P3749, DOI 10.1128/JB.176.12.3749-3756.1994; Park J, 2002, APPL ENVIRON MICROB, V68, P5231, DOI 10.1128/AEM.68.11.5231-5240.2002; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Perry R. H, 1973, CHEM ENG HDB; Pikus JD, 2000, BIOCHEMISTRY-US, V39, P791, DOI 10.1021/bi992187g; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; Reetz MT, 1997, ANGEW CHEM INT EDIT, V36, P2830, DOI 10.1002/anie.199728301; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Rui LY, 2005, APPL MICROBIOL BIOT, V66, P422, DOI 10.1007/s00253-004-1698-z; Rui LY, 2004, APPL ENVIRON MICROB, V70, P3246, DOI 10.1128/AEM.70.6.3246-3252.2004; Sakamoto T, 2001, APPL ENVIRON MICROB, V67, P3882, DOI 10.1128/AEM.67.9.3882-3887.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sazinsky MH, 2004, J BIOL CHEM, V279, P30600, DOI 10.1074/jbc.M400710200; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Schoemaker HE, 2003, SCIENCE, V299, P1694, DOI 10.1126/science.1079237; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shim H, 2001, APPL MICROBIOL BIOT, V56, P265, DOI 10.1007/s002530100650; Smith CA, 2003, APPL ENVIRON MICROB, V69, P7385, DOI 10.1128/AEM.69.12.7385-7394.2003; Straathof AJJ, 2002, CURR OPIN BIOTECH, V13, P548, DOI 10.1016/S0958-1669(02)00360-9; Tao Y, 2004, APPL ENVIRON MICROB, V70, P3814, DOI 10.1128/AEM.70.7.3814-3820.2004; Tao Y, 2004, J BACTERIOL, V186, P4705, DOI 10.1128/JB.186.14.4705-4713.2004; van Beilen JB, 2003, TRENDS BIOTECHNOL, V21, P170, DOI 10.1016/S0167-7799(03)00032-5; Vardar G, 2004, APPL ENVIRON MICROB, V70, P3253, DOI 10.1128/AEM.70.6.3253-3262.2004; Vardar G, 2005, J BIOTECHNOL, V115, P145, DOI 10.1016/j.jbiotec.2004.08.008; Zhou NY, 1998, FEBS LETT, V430, P181, DOI 10.1016/S0014-5793(98)00653-X	58	56	63	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					506	514		10.1074/jbc.M410320200	http://dx.doi.org/10.1074/jbc.M410320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498762	hybrid			2022-12-27	WOS:000226025100060
J	Jowsey, PA; Doherty, AJ; Rouse, J				Jowsey, PA; Doherty, AJ; Rouse, J			Human PTIP facilitates ATM-mediated activation of p53 and promotes cellular resistance to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; BRCT DOMAIN; PROTEIN; 53BP1; CHECKPOINT; PHOSPHORYLATION; REPAIR; PATHWAY; ARREST; CHK1	Mus musculus Pax2 transactivation domain-interacting protein (Ptip) is an essential gene required for the maintenance of genome stability, although its precise molecular role is unclear. Human PTIP (hPTIP) was recently isolated in a screen for proteins, translated from cDNA pools, capable of interacting with peptides phosphorylated by the ATM (ataxia telangiectasia-mutated)/ATR (ataxia telangiectasia-related) protein kinases. hPTIP was described as a 757-amino acid protein bearing four BRCT domains. Here we report that instead full-length endogenous hPTIP contains 1069 amino acids and six BRCT domains. hPTIP shows increased association with 53BP1 in response to ionizing radiation (IR) but not in response to other DNA-damaging agents. Whereas translocation of both 53BP1 and hPTIP to sites of IR-induced DNA damage occurs independently of ATM, IR-induced association of PTIP and 53BP1 requires ATM. Deletion analysis identified the domains of 53BP1 and hPTIP required for protein-protein interaction and focus formation. Data characterizing the cellular roles of hPTIP are also presented. Small interfering RNA was used to show that hPTIP is required for ATM-mediated phosphorylation of p53 at Ser(15) and for IR-induced up-regulation of the cyclin-dependent kinase inhibitor p21. Lowering hPTIP levels also increased cellular sensitivity to IR, suggesting that this protein plays a critical role in maintaining genome stability.	Univ Dundee, Wellcome Trust Bioctr, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Dundee; University of Sussex	Rouse, J (corresponding author), Univ Dundee, Wellcome Trust Bioctr, MRC, Prot Phosphorylat Unit, Med Sci Inst Complex,Dow St, Dundee DD1 5EH, Scotland.	j.rouse@dundee.ac.uk		Doherty, Aidan/0000-0002-6370-1109; Jowsey, Paul/0000-0003-2867-6857				Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cho EA, 2003, MOL CELL BIOL, V23, P1666, DOI 10.1128/MCB.23.5.1666-1673.2003; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mochan TA, 2003, CANCER RES, V63, P8586; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Rouse J, 2004, EMBO J, V23, P1188, DOI 10.1038/sj.emboj.7600129; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimizu K, 2001, MOL CELL BIOL, V21, P3901, DOI 10.1128/MCB.21.12.3901-3912.2001; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	23	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55562	55569		10.1074/jbc.M411021200	http://dx.doi.org/10.1074/jbc.M411021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15456759	hybrid			2022-12-27	WOS:000225960800073
J	Schneider, A; Araujo, GW; Trajkovic, K; Herrmann, MM; Merkler, D; Mandelkow, EM; Weissert, R; Simons, M				Schneider, A; Araujo, GW; Trajkovic, K; Herrmann, MM; Merkler, D; Mandelkow, EM; Weissert, R; Simons, M			Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; MULTIPLE-SCLEROSIS; AXONAL DAMAGE; ACTIVATOR P35; PHOSPHORYLATION; CDK5; BRAIN; KINASE; P25	Axonal damage is a major morphological correlate and cause of permanent neurological deficits in patients with multiple sclerosis (MS), a multifocal, inflammatory and demyelinating disease of the central nervous system. Hyperphosphorylation and pathological aggregation of microtubule-associated protein tau is a common feature of many neurodegenerative diseases with axonal degeneration including Alzheimer's disease. We have therefore analyzed tau phosphorylation, solubility and distribution in the brainstem of rats with experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Tau was hyperphosphorylated at several sites also phosphorylated in Alzheimer's disease and became partially detergent-insoluble in EAE brains. Morphological examination demonstrated accumulation of amorphous deposits of abnormally phosphorylated tau in the cell body and axons of neurons within demyelinating plaques. Hyperphosphorylation of tau was accompanied by up-regulation of p25, an activator of cyclin-dependent kinase 5. Phosphorylation of tau, activation of cdk5, and axonal pathology were significantly reduced when diseased rats were treated with prednisolone, a standard therapy of acute relapses in MS. Hyperphosphorylation of tau was not observed in a genetic or nutritional model of axonal degeneration or demyelination, suggesting that inflammation as detected in the brains of rats with EAE is the specific trigger of tau pathology. In summary, our data provide evidence that axonal damage in EAE and possibly MS is linked to tau pathology.	Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol, D-72076 Tubingen, Germany; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37075 Gottingen, Germany; Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; Univ Gottingen, Dept Neuropathol, D-37099 Gottingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Gottingen; Max Planck Society; University of Gottingen	Weissert, R (corresponding author), Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	robert.weissert@uni-tuebingen.de; msimons@gwdg.de	Weissert, Robert/B-2585-2009; Trajkovic, Katarina/AAJ-4219-2021; Weissert, Robert/AAA-4791-2019; Schneider, Anja/F-5293-2010; Merkler, Doron/N-9157-2016	Weissert, Robert/0000-0002-1295-1271; Trajkovic, Katarina/0000-0002-2716-1491; Merkler, Doron/0000-0002-0247-2007; Simons, Mikael/0000-0001-5329-192X; Schneider, Anja/0000-0001-9540-8700				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Friedhoff P, 2000, BBA-MOL BASIS DIS, V1502, P122, DOI 10.1016/S0925-4439(00)00038-7; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hamdane M, 2003, J BIOL CHEM, V278, P34026, DOI 10.1074/jbc.M302872200; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kins S, 2001, J BIOL CHEM, V276, P38193; Kornek B, 1999, BRAIN PATHOL, V9, P651; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Matthews PM, 1998, SEMIN NEUROL, V18, P327, DOI 10.1055/s-2008-1040884; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shields DC, 1999, J NEUROSCI RES, V55, P533, DOI 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8; Shin T, 2003, J NEUROIMMUNOL, V140, P118, DOI 10.1016/S0165-5728(03)00174-7; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Weissert R, 1998, J CLIN INVEST, V102, P1265, DOI 10.1172/JCI3022; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382	51	47	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55833	55839		10.1074/jbc.M409954200	http://dx.doi.org/10.1074/jbc.M409954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494405	hybrid			2022-12-27	WOS:000225960800106
J	Tan, W; Kim, S; Boyer, TG				Tan, W; Kim, S; Boyer, TG			Tetrameric oligomerization mediates transcriptional repression by the BRCA1-dependent Kruppel-associated box-zinc finger protein ZBRK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; KRAB; CELLS; SUBFAMILY; DOMAINS; FAMILY; BRCA1; KS1	The Kruppel-associated box (KRAB)-zinc finger protein ZBRK1 has been implicated in the transcriptional regulation of DNA damage-response genes that function in cell growth control and survival. Recently, we described a novel BRCA1-dependent C-terminal transcriptional repression domain (CTRD) within ZBRK1, the mode of repression of which is functionally distinguishable from that of the N-terminal KRAB repression domain within ZBRK1. The identification of BRCA1 binding-competent but repression-defective CTRD mutants further revealed that BRCA1 binding is necessary, but not sufficient, for ZBRK1 CTRD function. During an unbiased search for possible co-regulators of the CTRD, we identified ZBRK1 itself, suggesting that ZBRK1 can oligomerize through its CTRD. Herein we explore the physical and functional requirements for ZBRK1 oligomerization in ZBRK1-directed transcriptional repression. Protein interaction analyses confirmed that ZBRK1 can homo-oligomerize both in vitro and in vivo and further mapped the ZBRK1 oligomerization domain to the CTRD C terminus. Biochemical analyses, including protein cross-linking and gel filtration chromatography, revealed that ZBRK1 homo-oligomers exist as tetramers in solution. Functionally, ZBRK1 oligomerization facilitates ZBRK1-directed transcriptional repression through ZBRK1 response elements; requirements for oligomerization-dependent repression include the ZBRK1 CTRD and KRAB repression domains but not the DNA binding activity of ZBRK1. These observations suggest that higher order oligomers of ZBRK1 may assemble on target ZBRK1 response elements through both protein-DNA and CTRD-dependent protein-protein interactions. These findings thus reveal an unanticipated dual function for ZBRK1 in both DNA binding-dependent and -independent modes of transcriptional repression and further establish the CTRD as a novel protein interaction surface responsible for directing homotypic and heterotypic interactions necessary for ZBRK1-directed transcriptional repression.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Boyer, TG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	boyer@uthscsa.edu			NATIONAL CANCER INSTITUTE [R01CA098301] Funding Source: NIH RePORTER; NCI NIH HHS [CA 098301-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; Krebs CJ, 2003, GENE DEV, V17, P2664, DOI 10.1101/gad.1135703; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Ran QT, 2001, EXP CELL RES, V263, P156, DOI 10.1006/excr.2000.5068; Schumacher C, 2000, J BIOL CHEM, V275, P17173, DOI 10.1074/jbc.M000119200; Shannon M, 2003, GENOME RES, V13, P1097, DOI 10.1101/gr.963903; Shannon M, 1996, GENOMICS, V33, P112, DOI 10.1006/geno.1996.0166; Shannon M, 1998, DNA SEQUENCE, V8, P303, DOI 10.3109/10425179809034075; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Tan W, 2004, J BIOL CHEM, V279, P6576, DOI 10.1074/jbc.M312270200; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	26	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55153	55160		10.1074/jbc.M410926200	http://dx.doi.org/10.1074/jbc.M410926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496401	hybrid			2022-12-27	WOS:000225960800022
J	Turnbull, CI; Looi, K; Mangum, JE; Meyer, M; Sayer, RJ; Hubbard, MJ				Turnbull, CI; Looi, K; Mangum, JE; Meyer, M; Sayer, RJ; Hubbard, MJ			Calbindin independence of calcium transport in developing teeth contradicts the calcium ferry dogma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTAL ENAMEL CELLS; VITAMIN-D-RECEPTOR; ENDOPLASMIC-RETICULUM; RENAL CALBINDIN-D28K; PURKINJE-CELLS; KNOCKOUT MICE; CA2+; PROTEIN; ABSORPTION; EXPRESSION	Cytosolic calcium-binding proteins termed calbindins are widely regarded as a key component of the machinery used to transport calcium safely across cells. Acting as mobile buffers, calbindins are thought to ferry calcium in bulk and simultaneously protect against its potentially cytotoxic effects. Here, we contradict this dogma by showing that teeth and bones were produced normally in null mutant mice lacking calbindin(28kDa). Structural analysis of dental enamel, the development of which depends critically on active calcium transport, showed that mineralization was unaffected in calbindin(28kDa)-null mutants. An unchanged rate of calcium transport was verified by measurements of Ca-45 incorporation into developing teeth in vivo. In enamel-forming cells, the absence of calbindin(28kDa) was not compensated by other cytosolic calcium-binding proteins as detectable by Ca-45 overlay, two-dimensional gel, and equilibrium binding analyses. Despite a 33% decrease in cytosolic buffer capacity, cytotoxicity was not evident in either the null mutant enamel or its formative cells. This is the first definitive evidence that calbindins are not required for active calcium transport, either as ferries or as facilitative buffers. Moreover, in challenging the broader notion of a cytosolic route for calcium, the findings support an alternative paradigm involving passage via calcium-tolerant organelles.	Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Sch Dent Sci, Parkville, Vic 3052, Australia; Univ Otago, Dept Biochem, Dunedin 9001, New Zealand; Univ Otago, Dept Physiol, Dunedin 9001, New Zealand; Univ Munich, Inst Physiol, D-80336 Munich, Germany	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Otago; University of Otago; University of Munich	Hubbard, MJ (corresponding author), Royal Childrens Hosp, Dept Paediat, Flemington Rd, Parkville, Vic 3052, Australia.	mike.hubbard@unimelb.edu.au	Hubbard, Mike (Michael) J/AAE-6573-2022	Hubbard, Mike (Michael) J/0000-0002-5432-9421				Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Barski JJ, 2003, J NEUROSCI, V23, P3469; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; BERDAL A, 1993, DEV BIOL, V155, P172, DOI 10.1006/dbio.1993.1016; Berdal A, 1996, J BONE MINER RES, V11, P768; Bronner F, 2003, J CELL BIOCHEM, V88, P387, DOI 10.1002/jcb.10330; Christakos S, 2004, J STEROID BIOCHEM, V89-90, P401, DOI 10.1016/j.jsbmb.2004.03.007; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; Franklin IK, 2001, BIOCHEM J, V358, P217, DOI 10.1042/0264-6021:3580217; HEMMINGSEN C, 1995, CALCIFIED TISSUE INT, V56, P372, DOI 10.1007/BF00301605; Hemmingsen C, 1997, KIDNEY BLOOD PRESS R, V20, P247, DOI 10.1159/000174153; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; HUBBARD MJ, 1982, J DENT RES, V61, P14, DOI 10.1177/00220345820610010201; Hubbard MJ, 1998, CONNECT TISSUE RES, V38, P17, DOI 10.3109/03008209809017013; Hubbard MJ, 1996, EUR J BIOCHEM, V239, P611, DOI 10.1111/j.1432-1033.1996.0611u.x; Hubbard MJ, 2000, EUR J BIOCHEM, V267, P1945, DOI 10.1046/j.1432-1327.2000.01193.x; HUBBARD MJ, 1995, EUR J BIOCHEM, V230, P68, DOI 10.1111/j.1432-1033.1995.0068i.x; Hubbard MJ, 2000, CRIT REV ORAL BIOL M, V11, P437, DOI 10.1177/10454411000110040401; Larsson Dennis, 2002, Journal of Biomedicine & Biotechnology, V2, P117, DOI 10.1155/S1110724302205045; Lee CT, 2002, KIDNEY INT, V62, P2055, DOI 10.1046/j.1523-1755.2002.00670.x; LIMEBACK H, 1992, J DENT RES, V71, P346, DOI 10.1177/00220345920710020101; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Nijenhuis T, 2004, J AM SOC NEPHROL, V15, P549, DOI 10.1097/01.ASN.0000113318.56023.B6; Nijenhuis T, 2003, KIDNEY INT, V64, P555, DOI 10.1046/j.1523-1755.2003.00128.x; Peng JB, 2003, NEWS PHYSIOL SCI, V18, P158, DOI 10.1152/nips.01440.2003; REISNER PD, 1992, FEBS LETT, V297, P127, DOI 10.1016/0014-5793(92)80342-E; Sayer RJ, 2000, CELL TISSUE RES, V302, P171, DOI 10.1007/s004410000285; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Shnyder SD, 2002, J HISTOCHEM CYTOCHEM, V50, P557, DOI 10.1177/002215540205000413; Song YR, 2003, J NUTR, V133, P374, DOI 10.1093/jn/133.2.374; Sooy K, 2000, CURR OPIN NEPHROL HY, V9, P341, DOI 10.1097/00041552-200007000-00004; Sooy K, 1999, J BIOL CHEM, V274, P34343, DOI 10.1074/jbc.274.48.34343; Takano Y, 1995, Connect Tissue Res, V33, P127, DOI 10.3109/03008209509016992; TIMMERMANS JAH, 1995, J NUTR, V125, pS1981, DOI 10.1093/jn/125.suppl_7.1981S; WASSERMAN RH, 1995, J NUTR, V125, pS1971, DOI 10.1093/jn/125.suppl_7.1971S; WOOD JD, 2004, J ASS RES OTOLARYNGO	37	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55850	55854		10.1074/jbc.M409299200	http://dx.doi.org/10.1074/jbc.M409299200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494408	hybrid			2022-12-27	WOS:000225960800108
J	Colley, WC; van der Merwe, M; Vance, JR; Burgin, AB; Bjornsti, MA				Colley, WC; van der Merwe, M; Vance, JR; Burgin, AB; Bjornsti, MA			Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPTOTHECIN; YEAST; MECHANISMS; COVALENT; CELLS; RESISTANCE; SENSITIVITY; COMPLEXES; MUTANTS; REPAIR	Eukaryotic DNA topoisomerase I (Top1p) catalyzes the relaxation of supercoiled DNA and constitutes the cellular target of camptothecin (CPT). Mutation of conserved residues in close proximity to the active site tyrosine (Tyr(727) of yeast Top1p) alters the DNA cleavage religation equilibrium, inducing drug-independent cell lethality. Previous studies indicates that yeast Top1T722Ap and Top1N726Hp cytotoxicity results from elevated levels of covalent enzyme-DNA intermediates. Here we show that Top1T722Ap acts as a CPT mimetic by exhibiting reduced rates of DNA religation, whereas increased Top1N726Hp.DNA complexes result from elevated DNA binding and cleavage. We also report that the combination of the T722A and N726H mutations in a single protein potentiates the cytotoxic action of the enzyme beyond that induced by co-expression of the single mutants. Moreover, the addition of CPT to cells expressing the double top1T722A/N726H mutant did not enhance cell lethality. Thus, independent alterations in DNA cleavage and religation contribute to the lethal phenotype. The formation of distinct cytotoxic lesions was also evidenced by the different responses induced by low levels of these self-poisoning enzymes in isogenic strains defective for the Rad9 DNA damage checkpoint, processive DNA replication, or ubiquitin-mediated proteolysis. Substitution of Asn(726) with Phe or Tyr also produces self-poisoning enzymes, implicating stacking interactions in the increased kinetics of DNA cleavage by Top1N726Hp and Top1N726Fp. In contrast, replacing the amide side chain of Asn(726) with Gln renders Top1N726Qp resistant to CPT, suggesting that the orientation of the amide within the active site is critical for effective CPT binding.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; deCODE Genet Inc, Biostruct Grp, Bainbridge Isl, WA 98110 USA	St Jude Children's Research Hospital	Bjornsti, MA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale, Memphis, TN 38105 USA.	mary-ann.bjornsti@stjude.org			NCI NIH HHS [CA21765, CA58755] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA058755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Bjornsti MA, 2002, CANCER CELL, V2, P267, DOI 10.1016/S1535-6108(02)00160-5; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2000, ANN NY ACAD SCI, V922, P56; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2004, J BIOL CHEM, V279, P21271, DOI 10.1074/jbc.M312338200; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; KAISER C, 1994, METHODS YEAST GENETI, P133; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Simon JA, 2000, CANCER RES, V60, P328; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Zhang H, 2003, MUTAT RES-FUND MOL M, V527, P37, DOI 10.1016/S0027-5107(03)00074-5	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54069	54078		10.1074/jbc.M409764200	http://dx.doi.org/10.1074/jbc.M409764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489506	hybrid			2022-12-27	WOS:000225793600024
J	Gingras, S; Parganas, E; de Pauw, A; Ihle, JN; Murray, PJ				Gingras, S; Parganas, E; de Pauw, A; Ihle, JN; Murray, PJ			Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING-1; GENE-EXPRESSION; IFN-GAMMA; NEGATIVE REGULATION; IN-VIVO; SUPPRESSOR; MACROPHAGES; MICE; LIPOPOLYSACCHARIDE; INHIBITION	Suppressor of cytokine signaling 1 (SOCS1) is an obligate negative regulator of cytokine signaling and most importantly in vivo, signaling via the interferon-gamma (IFN-gamma) receptor. SOCS1, via its Src homology 2 domain, binds to phosphotyrosine residues in its targets, reducing the amplitude of signaling from cytokine receptors. SOCS1 is also implicated in blocking Toll-like receptor (TLR) signaling in macrophages activated by TLR agonists such as lipopolysaccharide (LPS), thus regulating multiple steps in the activation of innate immune responses. To rigorously test this, we isolated macrophages from Socs1-/- mice on multiple genetic backgrounds. We found no evidence that SOCS1 blocked TLR-activated pathways, endotoxin tolerance, or nitric oxide production. However, Socs1-/-; IFN-gamma-/- mice were extremely susceptible to LPS challenge, confirming previous findings. Because LPS induces IFN-beta production from macrophages, we tested whether SOCS1 regulates IFN-alpha/beta receptor signaling. We find that SOCS1 is required to inhibit IFN-alpha/beta receptor signaling in vitro. Furthermore, the absence of a single allele encoding TYK2, a JAK ( Janus kinase) family member essential IFN-alpha/beta receptor signaling, rescued Socs1-/- mice from early lethality, even in the presence of IFN-gamma. We conclude that previous reports linking SOCS1 to TLR signaling are most likely due to effects on IFN-alpha/beta receptor signaling.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital	Murray, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.murray@stjude.org	Murray, Peter J/K-4725-2018	Murray, Peter J/0000-0001-6329-9802	NIAID NIH HHS [AI53478-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI053478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chong MMW, 2003, IMMUNITY, V18, P475, DOI 10.1016/S1074-7613(03)00078-5; Cornish AL, 2003, J BIOL CHEM, V278, P22755, DOI 10.1074/jbc.M303021200; Cornish AL, 2003, J IMMUNOL, V170, P878, DOI 10.4049/jimmunol.170.2.878; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Kamezaki K, 2004, INT IMMUNOL, V16, P1173, DOI 10.1093/intimm/dxh118; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Lang R, 2002, J IMMUNOL, V168, P3402, DOI 10.4049/jimmunol.168.7.3402; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Metcalf D, 2000, P NATL ACAD SCI USA, V97, P9174, DOI 10.1073/pnas.160255197; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Shimoda K, 2002, BLOOD, V99, P2094, DOI 10.1182/blood.V99.6.2094; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774	29	108	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54702	54707		10.1074/jbc.M411043200	http://dx.doi.org/10.1074/jbc.M411043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491990	hybrid			2022-12-27	WOS:000225793600097
J	Li, Z; David, G; Hung, KW; DePinho, RA; Fu, AKY; Ip, NY				Li, Z; David, G; Hung, KW; DePinho, RA; Fu, AKY; Ip, NY			Cdk5/p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; HISTONE DEACETYLASE ACTIVITY; COREPRESSOR COMPLEX; NEURONAL MIGRATION; INTEGRAL COMPONENT; GENE-TRANSCRIPTION; INDUCED APOPTOSIS; NERVOUS-SYSTEM; PROTEIN-KINASE; BOVINE BRAIN	Cyclin-dependent kinase 5 (Cdk5), a serine/threonine kinase that displays kinase activity predominantly in neurons, is activated by two non-cyclin activators, p35 or p39. Here, we report a physical and functional interaction between the Cdk5/p35 complex and mouse Sds3 (mSds3), an essential component of mSin3-histone deacetylase ( HDAC) co-repressor complex. mSds3 binds to p35 both in vitro and in vivo, enabling active Cdk5 to phosphorylate mSds3 at serine 228. A mSds3 S228A mutant retained mSin3 binding activity, but its dimerization was not greatly enhanced by p35 when compared with wild type. Notably, p35 overexpression augmented mSds3-mediated transcriptional repression in vitro. Interestingly, mutational studies revealed that the ability of exogenous mSds3 to rescue cell growth and viability in mSds3 null cells correlates with its ability to be phosphorylated by Cdk5. The identification of mSds3 as a substrate of the Cdk5/p35 complex reveals a new regulatory mechanism in controlling the mSin3-HDAC transcriptional repressor activity and provides a new potential therapeutic means to inhibit specific HDAC activities in disease.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China; Dana Farber Canc Inst, Dept Med Oncol Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Peoples R China.	BOIP@UST.HK		DePinho, Ronald/0000-0002-5625-577X; Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Fu, Kit Yu/0000-0003-4085-6201; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Cheng K, 2003, NEUROSIGNALS, V12, P180, DOI 10.1159/000074619; Cheng K, 2002, J BIOL CHEM, V277, P31988, DOI 10.1074/jbc.M201161200; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Fu AKY, 1999, MOL CELL NEUROSCI, V14, P241, DOI 10.1006/mcne.1999.0784; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Fu WY, 2002, NEUROREPORT, V13, P243, DOI 10.1097/00001756-200202110-00014; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Ip FCF, 2000, MOL CELL NEUROSCI, V16, P661, DOI 10.1006/mcne.2000.0892; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lee KY, 1997, J BIOL CHEM, V272, P5622, DOI 10.1074/jbc.272.9.5622; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; Lin H, 2004, J BIOL CHEM, V279, P29302, DOI 10.1074/jbc.M403664200; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Mattson MP, 2003, AGEING RES REV, V2, P329, DOI 10.1016/S1568-1637(03)00013-8; Morabito MA, 2004, J NEUROSCI, V24, P865, DOI 10.1523/JNEUROSCI.4582-03.2004; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Qi RZ, 2004, FEBS LETT, V561, P177, DOI 10.1016/S0014-5793(04)00174-7; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Xie ZG, 2004, CELL CYCLE, V3, P108; Zhang JW, 2002, J NEUROCHEM, V81, P307, DOI 10.1046/j.1471-4159.2002.00824.x; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	40	28	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54438	54444		10.1074/jbc.M411002200	http://dx.doi.org/10.1074/jbc.M411002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489224	hybrid, Green Published			2022-12-27	WOS:000225793600066
J	Rodolfo, C; Mormone, E; Matarrese, P; Ciccosanti, F; Farrace, MG; Garofano, E; Piredda, L; Fimia, GM; Malorni, W; Piacentini, M				Rodolfo, C; Mormone, E; Matarrese, P; Ciccosanti, F; Farrace, MG; Garofano, E; Piredda, L; Fimia, GM; Malorni, W; Piacentini, M			Tissue transglutaminase is a multifunctional BH3-only protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN NEUROBLASTOMA-CELLS; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; GTP-BINDING PROTEIN; RETINOIC ACID; ANTENNAPEDIA HOMEODOMAIN; PERMEABILITY TRANSITION; MITOCHONDRIAL-MEMBRANE; BH3 DOMAIN	Tissue transglutaminase (TG2) protein accumulates to high levels in cells during early stages of apoptosis both in vivo and in vitro. The analysis of the TG2 primary sequence showed the presence of an eight amino acid domain, sharing 70% identity with the Bcl-2 family BH3 domain. Cell-permeable peptides, mimicking the domain sequence, were able to induce Bax conformational change and translocation to mitochondria, mitochondrial depolarization, release of cytochrome c, and cell death. Moreover, we found that the TG2-BH3 peptides as well as TG2 itself were able to interact with the pro-apoptotic Bcl-2 family member Bax, but not with anti-apoptotic members Bcl-2 and Bcl-XL. Mutants in the TG2-BH3 domain failed to sensitize cells toward apoptosis. In TG2-overexpressing cells about half of the protein is localized on the outer mitochondrial membrane where, upon cell death induction, it cross-links many protein substrates including Bax. TG2 is the first member of a new subgroup of multifunctional BH3-only proteins showing a large mass size (80 kDa) and enzymatic activity.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, I-00161 Rome, Italy; IRCCS Lazzaro Spallanzani, INMI, Cell Biol Lab, I-00149 Rome, Italy; IRCCS Lazzaro Spallanzani, INMI, EM, I-00149 Rome, Italy	University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); IRCCS Lazzaro Spallanzani; IRCCS Lazzaro Spallanzani	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	mauro.piacentini@uniroma2.it	Rodolfo, Carlo/H-8953-2019; Ciccosanti, Fabiola/B-5284-2017; Mormone, Elisabetta/AAB-1736-2021; Matarrese, Paola/A-4369-2014; Piacentini, Mauro/I-2411-2016; Malorni, Walter/G-5874-2016; Fimia, Gian Maria/K-3232-2016	Rodolfo, Carlo/0000-0001-7087-545X; Ciccosanti, Fabiola/0000-0003-0481-6878; Piacentini, Mauro/0000-0003-2919-1296; Fimia, Gian Maria/0000-0003-4438-3325; malorni, walter/0000-0002-1223-7000				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Bernassola F, 1999, ANN NY ACAD SCI, V887, P83, DOI 10.1111/j.1749-6632.1999.tb07924.x; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; COSSARIZZA A, 1995, BIOCHEM BIOPH RES CO, V214, P503, DOI 10.1006/bbrc.1995.2315; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Ikura K, 1998, ARCH BIOCHEM BIOPHYS, V356, P280, DOI 10.1006/abbi.1998.0775; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nardacci R, 2003, CELL DEATH DIFFER, V10, pS79, DOI 10.1038/sj.cdd.4401112; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Piacentini M, 1999, IMMUNOL TODAY, V20, P130, DOI 10.1016/S0167-5699(98)01416-9; Piacentini M, 1994, Prog Clin Biol Res, V385, P123; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; Szegezdi E, 2000, CELL DEATH DIFFER, V7, P1225, DOI 10.1038/sj.cdd.4400751; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2001, METHOD CELL BIOL, V65, P147, DOI 10.1016/S0091-679X(01)65009-X	51	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54783	54792		10.1074/jbc.M410938200	http://dx.doi.org/10.1074/jbc.M410938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485857	hybrid, Green Published			2022-12-27	WOS:000225793600106
J	Srisodsai, A; Kurotani, R; Chiba, Y; Sheikh, F; Young, HA; Donnelly, RP; Kimura, S				Srisodsai, A; Kurotani, R; Chiba, Y; Sheikh, F; Young, HA; Donnelly, RP; Kimura, S			Interleukin-10 induces uteroglobin-related protein (UGRP) 1 gene expression in lung epithelial cells through homeodomain transcription factor T/EBP/NKX2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; FACTOR-I; CYTOKINE PRODUCTION; HOMEOBOX GENE; DNA-BINDING; B GENE; A GENE; IL-10; PROMOTER; RECEPTOR	UGRP1 is a downstream target gene for homeodomain transcription factor T/EBP/NKX2.1, which is predominantly expressed in lung epithelial cells, and may play an anti-inflammatory role in lung inflammation. To understand the role of UGRP1 in inflammation, its expression was investigated in relation to cytokine signaling. In vivo experiments using mouse embryonic lung organ culture and intranasal administration of interleukin (IL) 10 revealed that constitutive expression of Ugrp1 mRNA is enhanced by IL-10. Increase of protein levels was also demonstrated by immunohistochemistry using embryonic lungs. This IL-10 induction of Ugrp1 gene expression occurs at the transcriptional level when examined using mouse embryonic lung primary cultures. In human lung NCI-H441 cells that in contrast to mouse lung cells, do not exhibit constitutive expression of the gene, expression of the UGRP1 gene was induced in a rapid and stable fashion. Two T/EBP, but not STAT3, binding sites located in the human UGRP1 gene promoter are responsible for IL-10 induction of the UGRP1 gene as judged by transfection, gel shift, and chromatin immunoprecipitation analyses. The IL-10 receptor chains, IL-10R1 and IL-10R2, are expressed in H441 cells, however, STAT3 was only weakly activated upon IL-10 treatment. In contrast, STAT3 was strongly activated when the cells were treated with other cytokines such as IL-22 and interferon-beta but UGRP1 expression was not increased. Together these results demonstrate that IL-10 induces UGRP1 gene expression in lung epithelial cells through a T/EBP/NKX2.1-dependent pathway. The results further suggest that UGRP1 might be a target for IL-10 anti-inflammatory activities in the lung.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; US FDA, Div Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NCI, Expt Immunol Lab, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kimura, S (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 3112B,9000 Rockville Pike, Bethesda, MD 20892 USA.	shioko@helix.nih.gov	Donnelly, Raymond P./AFT-8600-2022; Young, Howard/A-6350-2008	Donnelly, Raymond P./0000-0002-0695-5276; Young, Howard/0000-0002-3118-5111	NATIONAL CANCER INSTITUTE [Z01BC010449, ZIABC010449] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Aurisicchio L, 1998, J BIOL CHEM, V273, P1477, DOI 10.1074/jbc.273.3.1477; Bin LH, 2003, J IMMUNOL, V171, P924, DOI 10.4049/jimmunol.171.2.924; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; Denning TL, 2000, INT IMMUNOL, V12, P133, DOI 10.1093/intimm/12.2.133; Donnelly RP, 2004, J LEUKOCYTE BIOL, V76, P314, DOI 10.1189/jlb.0204117; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Endo T, 1997, MOL ENDOCRINOL, V11, P1747, DOI 10.1210/me.11.11.1747; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KIKKAWA F, 1990, MOL CELL BIOL, V10, P6216, DOI 10.1128/MCB.10.12.6216; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Lejeune D, 2002, J BIOL CHEM, V277, P33676, DOI 10.1074/jbc.M204204200; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Liu Y, 1997, J IMMUNOL, V158, P604; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Niimi T, 2002, CYTOGENET GENOME RES, V97, P120, DOI 10.1159/000064067; Niimi T, 2002, AM J HUM GENET, V70, P718, DOI 10.1086/339272; Niimi T, 2001, MOL ENDOCRINOL, V15, P2021, DOI 10.1210/me.15.11.2021; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Rolfe FG, 1997, AM J RESP CELL MOL, V17, P243, DOI 10.1165/ajrcmb.17.2.2819; Ruan SB, 2002, INFECT IMMUN, V70, P6107, DOI 10.1128/IAI.70.11.6107-6113.2002; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; Wang M, 2003, BRIT J CANCER, V88, P1605, DOI 10.1038/sj.bjc.6600855; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yuan BB, 2000, DEV DYNAM, V217, P180, DOI 10.1002/(SICI)1097-0177(200002)217:2<180::AID-DVDY5>3.0.CO;2-3; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	46	21	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54358	54368		10.1074/jbc.M405331200	http://dx.doi.org/10.1074/jbc.M405331200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485815	hybrid			2022-12-27	WOS:000225793600058
J	Zhou, SX; Schmelz, A; Seufferlein, T; Li, YP; Zhao, JS; Bachem, MG				Zhou, SX; Schmelz, A; Seufferlein, T; Li, YP; Zhao, JS; Bachem, MG			Molecular mechanisms of low intensity pulsed ultrasound in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ACTIN STRESS FIBERS; BINDING PROTEIN RHO; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; THERAPEUTIC ULTRASOUND; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; ADHESION; REQUIRES	Soluble factors such as polypeptide growth factors, mitogenic lipids, inflammatory cytokines, and hormones are known regulators of cell proliferation. However, the effect of mechanical stimuli on cell proliferation is less well understood. Here we examined the effect of low intensity pulsed ultrasound ( US), which is used to promote wound healing, on the proliferation of primary human foreskin fibroblasts and the underlying signaling mechanisms. We show that a single 6-11-min US stimulation increases bromodeoxyuridine incorporation. In addition, an increase in the total cell number is observed after sequential US stimulation. US induced stress fiber and focal adhesion formation via activation of Rho. We further observed that US selectively induced activation of extracellular signal-regulated kinase (ERK) 1/2. Inhibition of Rho-associated coiled-coil-containing protein kinase ( ROCK) prevented US-induced ERK1/2 activation, demonstrating that the Rho/ROCK pathway is an upstream regulator of ERK activation in response to US. Consequently, activation of ROCK and MEK-1 was required for US-induced DNA synthesis. Finally, an integrin beta(1) blocking antibody as well as a RGD peptide prevented US-induced DNA synthesis. In addition, US slightly increased phosphorylation of Src at Tyr(416), and Src activity was found to be required for ERK1/2 activation in response to US. In conclusion, our data demonstrate for the first time that US promotes cell proliferation via activation of integrin receptors and a Rho/ROCK/Src/ERK signaling pathway.	Univ Ulm, Dept Clin Chem, D-89081 Ulm, Germany; Univ Ulm, Dept Traumatol, D-89070 Ulm, Germany; Med Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; SE Univ, Sch Publ Hlth, Nanjing 210009, Peoples R China	Ulm University; Ulm University; Ulm University; Southeast University - China	Bachem, MG (corresponding author), Univ Klin Ulm, Zent Einrichtung Klin Chem, Robert Koch Str 8, D-89081 Ulm, Germany.	max.bachem@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018					Aplin AE, 1998, PHARMACOL REV, V50, P197; Armulik A, 2004, MOL BIOL CELL, V15, P2558, DOI 10.1091/mbc.E03-09-0700; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014-5793(03)01157-8; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLARK RAF, 1985, J AM ACAD DERMATOL, V13, P701, DOI 10.1016/S0190-9622(85)70213-7; CORREAMEYER E, 2002, AM J PHYSIOL, V82, pL883; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HASHIMOTO D, 2001, ALLERGOL INT, V50, P63; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ingber DE, 2003, P NATL ACAD SCI USA, V100, P1472, DOI 10.1073/pnas.0530201100; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Iwasaki H, 2000, AM J PHYSIOL-HEART C, V278, pH521, DOI 10.1152/ajpheart.2000.278.2.H521; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kippenberger S, 2000, J INVEST DERMATOL, V114, P408, DOI 10.1046/j.1523-1747.2000.00915.x; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Leung KS, 2004, CLIN ORTHOP RELAT R, P253; Luttenberger T, 2000, LAB INVEST, V80, P47, DOI 10.1038/labinvest.3780007; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360; Numaguchi K, 1999, CIRC RES, V85, P5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Parvizi J, 1999, J ORTHOPAED RES, V17, P488, DOI 10.1002/jor.1100170405; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Reher P, 1998, EUR J CANCER, V34, P1962, DOI 10.1016/S0959-8049(98)00238-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623-200102000-00015; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278; Zhang ZJ, 2003, ULTRASOUND MED BIOL, V29, P1645, DOI 10.1016/j.ultrasmedbio.2003.08.011; Zhao ZY, 2003, DEV DYNAM, V226, P24, DOI 10.1002/dvdy.10212	46	172	191	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54463	54469		10.1074/jbc.M404786200	http://dx.doi.org/10.1074/jbc.M404786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485877	Green Published, hybrid			2022-12-27	WOS:000225793600069
J	Blumenstein, L; Ahmadian, MR				Blumenstein, L; Ahmadian, MR			Models of the cooperative mechanism for Rho effector recognition - Implications for RhoA-mediated effector activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SERINE-THREONINE KINASE; GTP-BINDING PROTEINS; CELLULAR-TRANSFORMATION; PUTATIVE TARGET; INSERT REGION; CITRON-KINASE; SERINE/THREONINE KINASE; ACTIN CYTOSKELETON; CATALYTIC-ACTIVITY	Activated GTPases of the Rho family regulate a spectrum of functionally diverse downstream effectors, initiating a network of signal transduction pathways by interaction and activation of effector proteins. Although effectors are defined as proteins that selectively bind the GTP-bound state of the small GTPases, there have been also several indications for a nucleotide-independent binding mode. By characterizing the molecular mechanism of RhoA interaction with its effectors, we have determined the equilibrium dissociation constants of several Rho-binding domains of three different effector proteins ( Rhotekin, ROCKI/ROKbeta/p160ROCK, PRK1/ PKNalpha where ROK is RhoA-binding kinase) for both RhoA . GDP and RhoA . GTP using fluorescence spectroscopy. In addition, we have identified two novel Rho-interacting domains in ROCKI, which bind RhoA with high affinity but not Cdc42 or Rac1. Our results, together with recent structural data, support the notion of multiple effector-binding sites in RhoA and strongly indicate a cooperative binding mechanism for PRK1 and ROCKI that may be the molecular basis of Rho-mediated effector activation.	Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany	Max Planck Society	Ahmadian, MR (corresponding author), Max Planck Inst Mol Physiol, Dept Biol Struct, Otto Hahn Str 11, D-44227 Dortmund, Germany.	reza.ahmadian@mpi-dortmund.mpg.de						Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Di Cunto F, 2002, J CELL SCI, V115, P4819, DOI 10.1242/jcs.00163; Doran JD, 2004, BIOCHEM J, V384, P255, DOI 10.1042/BJ20040344; Dvorsky R, 2004, J BIOL CHEM, V279, P7098, DOI 10.1074/jbc.M311911200; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Eda M, 2001, J CELL SCI, V114, P3273; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Fujita A, 2000, J CELL SCI, V113, P103; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1997, FASEB J, V11, pA994; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Liu HF, 2003, J BIOL CHEM, V278, P2541, DOI 10.1074/jbc.M210391200; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Madaule P, 2000, MICROSC RES TECHNIQ, V49, P123, DOI 10.1002/(SICI)1097-0029(20000415)49:2<123::AID-JEMT3>3.0.CO;2-R; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mircescu H, 2002, EUR J BIOCHEM, V269, P6241, DOI 10.1046/j.1432-1033.2002.03343.x; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Nomanbhoy T, 1999, BIOCHEMISTRY-US, V38, P15878, DOI 10.1021/bi9916832; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Peck JW, 2002, J BIOL CHEM, V277, P43924, DOI 10.1074/jbc.M203569200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Scheffzek K, 2001, STRUCTURE, V9, P1043, DOI 10.1016/S0969-2126(01)00674-8; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Walker SJ, 2002, J BIOL CHEM, V277, P26260, DOI 10.1074/jbc.M201811200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551; Zong H, 2001, MOL CELL BIOL, V21, P5287, DOI 10.1128/MCB.21.16.5287-5298.2001	74	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53419	53426		10.1074/jbc.M409551200	http://dx.doi.org/10.1074/jbc.M409551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475352	hybrid			2022-12-27	WOS:000225680600075
J	Granja, AG; Nogal, ML; Hurtado, C; Vila, V; Carrascosa, AL; Salas, ML; Fresno, M; Revilla, Y				Granja, AG; Nogal, ML; Hurtado, C; Vila, V; Carrascosa, AL; Salas, ML; Fresno, M; Revilla, Y			The viral protein A238L inhibits cyclooxygenase-2 expression through a nuclear factor of activated T cell-dependent transactivation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWINE-FEVER-VIRUS; NF-KAPPA-B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; TRANSCRIPTION FACTOR NFAT1; MESSENGER-RNA STABILITY; C-JUN; PHOSPHATASE CALCINEURIN; SIGNALING CASCADE; G/H SYNTHASE; TNF-ALPHA	Cyclooxygenase-2 is transiently induced upon cell activation or viral infections, resulting in inflammation and modulation of the immune response. Here we report that A238L, an African swine fever virus protein, efficiently inhibits cyclooxygenase-2 gene expression in Jurkat T cells and in virus-infected Vero cells. Transfection of Jurkat cells stably expressing A238L with cyclooxygenase-2 promoter-luciferase constructs containing 5'-terminal deletions or mutations in distal or proximal nuclear factor of activated T cell ( NFAT) response elements revealed that these sequences are involved in the inhibition induced by A238L. Overexpression of a constitutively active version of the calcium-dependent phosphatase calcineurin or NFAT reversed the inhibition mediated by A238L on cyclooxygenase-2 promoter activation, whereas overexpression of p65 NFkappaB had no effect. A238L does not modify the nuclear localization of NFAT after phorbol 12-myristate 13-acetate/calcium ionophore stimulation. Moreover, we show that the mechanism by which the viral protein down-regulates cyclooxygenase-2 activity does not involve inhibition of the binding between NFAT and its specific DNA sequences into the cyclooxygenase-2 promoter. Strikingly, A238L dramatically inhibited the transactivation mediated by a GAL4-NFAT fusion protein containing the N-terminal transactivation domain of NFAT1. Taken together, these data indicate that A238L down-regulates cyclooxygenase-2 transcription through the NFAT response elements, being NFAT-dependent transactivation implicated in this down-regulation.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Revilla, Y (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	yrevilla@cbm.uam.es	Granja, Aitor/K-8102-2014; Carrascosa, Angel L/K-4439-2014; Hurtado-Marcos, Carolina/AAH-3586-2020	Hurtado-Marcos, Carolina/0000-0003-0364-7742; Vila-del Sol, Virginia/0000-0002-5606-2767; Yolanda, Revilla/0000-0001-6555-6331; Fresno Escudero, Manuel/0000-0002-9223-5477				APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bergqvist A, 2001, J VIROL, V75, P772, DOI 10.1128/JVI.75.2.772-781.2001; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, J BIOL CHEM, V266, P12508; GARCIA R, 1995, J BIOTECHNOL, V40, P121, DOI 10.1016/0168-1656(95)00037-Q; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang ZF, 2000, BIOCHEM PHARMACOL, V59, P187, DOI 10.1016/S0006-2952(99)00312-3; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Janelle ME, 2002, J BIOL CHEM, V277, P30665, DOI 10.1074/jbc.M203041200; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Luo C, 1996, MOL CELL BIOL, V16, P3955; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Moriuchi M, 2001, J VIROL, V75, P192, DOI 10.1128/JVI.75.1.192-198.2001; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Nogal ML, 2001, J VIROL, V75, P2535, DOI 10.1128/JVI.75.6.2535-2543.2001; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Parry RV, 2003, NAT IMMUNOL, V4, P821, DOI 10.1038/ni0903-821; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; Rodriguez CI, 2002, J VIROL, V76, P3936, DOI 10.1128/JVI.76.8.3936-3942.2002; San-Antonio B, 2002, J BIOL CHEM, V277, P27073, DOI 10.1074/jbc.M106983200; Savard M, 2000, J IMMUNOL, V164, P6467, DOI 10.4049/jimmunol.164.12.6467; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Scott ES, 2001, J VIROL, V75, P9955, DOI 10.1128/JVI.75.20.9955-9965.2001; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Steer SA, 2003, J IMMUNOL, V170, P1070, DOI 10.4049/jimmunol.170.2.1070; STILLMAN DJ, 1984, J BIOL CHEM, V259, P7955; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; YOCUM DE, 1989, CELL IMMUNOL, V122, P131, DOI 10.1016/0008-8749(89)90154-8	62	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53736	53746		10.1074/jbc.M406620200	http://dx.doi.org/10.1074/jbc.M406620200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471864	hybrid, Green Published			2022-12-27	WOS:000225680600111
J	Im, YJ; Na, Y; Kang, GB; Rho, SH; Kim, MK; Lee, JH; Chung, CH; Eom, SH				Im, YJ; Na, Y; Kang, GB; Rho, SH; Kim, MK; Lee, JH; Chung, CH; Eom, SH			The active site of a Lon protease from Methanococcus jannaschii distinctly differs from the canonical catalytic dyad of Lon proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SIGNAL PEPTIDASE; ATP-DEPENDENT PROTEASE; SER-LYS DYAD; MITOCHONDRIAL LON; CRYSTAL-STRUCTURE; 20S PROTEASOME; QUALITY; PROTEOLYSIS; PROTEINS; BINDING	ATP-dependent Lon proteases catalyze the degradation of various regulatory proteins and abnormal proteins within cells. Methanococcus jannaschii Lon (Mj-Lon) is a homologue of Escherichia coli Lon (Ec-Lon) but has two transmembrane helices within its N-terminal ATPase domain. We solved the crystal structure of the proteolytic domain of Mj-Lon using multiwavelength anomalous dispersion, refining it to 1.9-Angstrom resolution. The structure displays an overall fold conserved in the proteolytic domain of Ec-Lon; however, the active site shows uniquely configured catalytic Ser-Lys-Asp residues that are not seen in Ec-Lon, which contains a catalytic dyad. In Mj-Lon, the C-terminal half of the beta4-alpha2 segment is an alpha-helix, whereas it is a beta-strand in Ec-Lon. Consequently, the configurations of the active sites differ due to the formation of a salt bridge between Asp-547 and Lys-593 in Mj-Lon. Moreover, unlike Ec-Lon, Mj-Lon has a buried cavity in the region of the active site containing three water molecules, one of which is hydrogen-bonded to catalytic Ser-550. The geometry and environment of the active site residues in Mj-Lon suggest that the charged Lys-593 assists in lowering the pK(a) of the Ser-550 hydroxyl group via its electrostatic potential, and the water in the cavity acts as a proton acceptor during catalysis. Extensive sequence alignment and comparison of the structures of the proteolytic domains clearly indicate that Lon proteases can be classified into two groups depending on active site configuration and the presence of DGPSA or (D/E) GDSA consensus sequences, as represented by Ec-Lon and Mj-Lon.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Seoul Natl Univ, Sch Biol Sci, Natl Res Lab Prot Biochem, Seoul 151742, South Korea	Gwangju Institute of Science & Technology (GIST); Seoul National University (SNU)	Eom, SH (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	eom@gist.ac.kr		Rho, Seong-Hwan/0000-0002-8650-8205				Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V60, P760; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Fersht A. R., 1999, STRUCTURE MECH PROTE, P472; Fu GK, 1997, J BIOL CHEM, V272, P534; Fukui T, 2002, J BACTERIOL, V184, P3689, DOI 10.1128/JB.184.13.3689-3698.2002; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; Gottesman S, 1999, CURR OPIN MICROBIOL, V2, P142, DOI 10.1016/S1369-5274(99)80025-3; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LEE AY, 2004, J BIOL CHEM; Lee AYL, 2004, EUR J BIOCHEM, V271, P834, DOI 10.1111/j.1432-1033.2004.03988.x; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; SWAMY KHS, 1981, NATURE, V292, P652, DOI 10.1038/292652a0; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; Ward Donald E., 2002, Archaea, V1, P63, DOI 10.1155/2002/503191; WATABE S, 1985, J BIOL CHEM, V260, P4498; Watanabe S, 1999, EUR J BIOCHEM, V266, P811, DOI 10.1046/j.1432-1327.1999.00907.x; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yoo SJ, 1997, FEBS LETT, V412, P57, DOI 10.1016/S0014-5793(97)00742-4	35	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53451	53457		10.1074/jbc.M410437200	http://dx.doi.org/10.1074/jbc.M410437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456757	hybrid			2022-12-27	WOS:000225680600079
J	Kobayashi, Y; Kobayashi, K; Umehara, K; Dohra, H; Murata, T; Usui, T; Kawagishi, H				Kobayashi, Y; Kobayashi, K; Umehara, K; Dohra, H; Murata, T; Usui, T; Kawagishi, H			Purification, characterization, and sugar binding specificity of an N-glycolylneuraminic acid-specific lectin from the mushroom Chlorophyllum molybdites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANGANUTZIU-DEICHER ANTIGEN; ASPARAGINE-LINKED OLIGOSACCHARIDES; GAS-LIQUID-CHROMATOGRAPHY; HUMAN-COLON CANCER; MASS-SPECTROMETRY; FRUITING BODIES; SIALIC-ACID; STRUCTURAL DETERMINANTS; AFFINITY-CHROMATOGRAPHY; POLYPORUS-SQUAMOSUS	A carbohydrate-binding protein was isolated from the carpophores of the mushrooms and designated the Chlorophyllum molybdites lectin (CML) based on its origin. The molecular mass of CML was 32 kDa, and it was composed of two 16-kDa monomers with no disulfide bonds. Monosaccharide analysis indicated that 12% of the mass of CML was carbohydrate and consisted of GlcNAc:GalNAc:Gal:Man:L-Fuc in a molar ratio of 1.5:1.9:4.4:4.8:1.0. In the hemagglutination inhibition assay, CML exhibited the strongest binding specificity toward N-glycolylneuraminic acid (NeuGc) among the monosaccharides tested, whereas NeuAc did not inhibit the hemagglutination at all. GalNAc and Mealpha-GalNAc were also inhibitory at much higher concentrations than NeuGc. Among the glycoproteins, asialobovine submaxillary mucin (BSM) and porcine stomach mucin (PSM) showed strong inhibitory effects. In surface plasmon resonance analysis, asialo-BSM and PSM exhibited the strongest binding affinity. After co-injection of CML and NeuGc or GalNAc onto the asialo-BSM- or PSM-immobilized chip, the dissociation of CML from the immobilized PSM was accelerated by NeuGc and GalNAc, but the dissociation of CML from the immobilized asialo-BSM was only promoted by GalNAc. These results and the other surface plasmon resonance experiments allowed us to conclude that the binding of asialo-BSM to CML was because of an interaction between the lectin and the GalNAc residues of asialo-BSM, and both the NeuGc and GalNAc residues were responsible for the binding of PSM to CML. The results also suggested that CML had two different carbohydrate binding domains, one specific for NeuGc and the other for GalNAc.	Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, Shizuoka 4228529, Japan; Gifu Univ, United Grad Sch, Gifu 5011193, Japan; Shizuoka Univ, Inst Genet Res & Biotechnol, Shizuoka 4228529, Japan	Shizuoka University; Gifu University; Shizuoka University	Kawagishi, H (corresponding author), Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, 836 Ohya, Shizuoka 4228529, Japan.	achkawa@agr.shizuoka.ac.jp		Dohra, Hideo/0000-0002-3919-3538				[Anonymous], INT J MED MUSH; BLAYNEY D, 1980, WESTERN J MED, V132, P74; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCHER HP, 1974, EUR J BIOCHEM, V50, P71, DOI 10.1111/j.1432-1033.1974.tb03873.x; CASALSSTENZEL J, 1975, ANAL BIOCHEM, V65, P507, DOI 10.1016/0003-2697(75)90536-9; CHAI WG, 1992, EUR J BIOCHEM, V203, P257, DOI 10.1111/j.1432-1033.1992.tb19855.x; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DAM TK, 1993, BIOCHEM BIOPH RES CO, V196, P422, DOI 10.1006/bbrc.1993.2266; DEICHER H., 1926, ZEITSCHR HYG U INFEKTIONSKR, V106, P561, DOI 10.1007/BF02176298; DEVINE PL, 1991, CANCER RES, V51, P5826; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Hanganutziu M, 1924, CR SOC BIOL, V91, P1457; HIGASHI H, 1985, CANCER RES, V45, P3796; HIGASHI H, 1988, JPN J CANCER RES, V79, P952, DOI 10.1111/j.1349-7006.1988.tb00060.x; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P614; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P251; Hodge JE, 1962, METHODS CARBOHYDRATE, V1, P338; KAWACHI S, 1988, INT ARCH ALLER A IMM, V85, P381, DOI 10.1159/000234536; KAWAGISHI H, 1994, J BIOL CHEM, V269, P1375; KAWAGISHI H, 1988, FEBS LETT, V227, P99, DOI 10.1016/0014-5793(88)80876-7; Kawagishi H, 2001, BIOSCI BIOTECH BIOCH, V65, P2437, DOI 10.1271/bbb.65.2437; Kawagishi H, 2001, PHYTOCHEMISTRY, V56, P53, DOI 10.1016/S0031-9422(00)00351-4; KAWAGISHI H, 1990, BIOCHIM BIOPHYS ACTA, V1034, P247, DOI 10.1016/0304-4165(90)90045-X; Kawagishi H, 2000, BBA-GEN SUBJECTS, V1474, P299, DOI 10.1016/S0304-4165(00)00027-1; Kawagishi H, 1997, PHYTOCHEMISTRY, V44, P7, DOI 10.1016/S0031-9422(96)00492-X; KAWAGISHI H, 1988, CARBOHYD RES, V183, P150, DOI 10.1016/0008-6215(88)80057-0; KAWAGISHI H, 1994, FEBS LETT, V340, P56, DOI 10.1016/0014-5793(94)80172-X; KAWAGISHI H, 2001, J APPL GLYCOSCI, V48, P99; KAWAI T, 1991, CANCER RES, V51, P1242; KAWANO T, 1995, J BIOL CHEM, V270, P16458, DOI 10.1074/jbc.270.27.16458; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Kobayashi K, 1997, MACROMOLECULES, V30, P2016, DOI 10.1021/ma961681e; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT RD, 1977, J BIOL CHEM, V252, P2961; LEHMANN PF, 1992, MYCOPATHOLOGIA, V118, P3, DOI 10.1007/BF00472564; LEVITAN D, 1981, TOXICON, V19, P179, DOI 10.1016/0041-0101(81)90130-6; Malykh Yanina N., 2001, BIOCHIMIE PARIS, V83, P623; Marquina G, 1996, CANCER RES, V56, P5165; MERCY PD, 1993, EUR J BIOCHEM, V215, P697, DOI 10.1111/j.1432-1033.1993.tb18081.x; MERCY SPD, 1992, EXPERIENTIA, V48, P498, DOI 10.1007/BF01928173; MIYAKE M, 1990, CANCER, V65, P499, DOI 10.1002/1097-0142(19900201)65:3<499::AID-CNCR2820650321>3.0.CO;2-P; MIYOSHI I, 1986, MOL IMMUNOL, V23, P631, DOI 10.1016/0161-5890(86)90100-8; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; MOORE S, 1963, J BIOL CHEM, V238, P235; Ratanapo S, 2001, PLANT SCI, V160, P739, DOI 10.1016/S0168-9452(00)00454-4; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARRIS AH, 1979, J BIOL CHEM, V254, P6724; SMITH CW, 1980, HAWAII MED J, V39, P13; STENKLYFT PH, 1990, J TOXICOL-CLIN TOXIC, V28, P159, DOI 10.3109/15563659008993488; SWARNAKAR S, 1991, BIOCHEM BIOPH RES CO, V178, P85, DOI 10.1016/0006-291X(91)91783-9; Tsuchida A, 1998, J BIOCHEM, V123, P715; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; Yasuno S, 1997, BIOSCI BIOTECH BIOCH, V61, P1944, DOI 10.1271/bbb.61.1944; Zeng XX, 1998, CARBOHYD RES, V312, P209, DOI 10.1016/S0008-6215(98)00259-6; Zhang BY, 2001, GLYCOBIOLOGY, V11, P141, DOI 10.1093/glycob/11.2.141	58	34	34	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53048	53055		10.1074/jbc.M407997200	http://dx.doi.org/10.1074/jbc.M407997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471858	hybrid			2022-12-27	WOS:000225680600031
J	Malone, MH; Wang, ZQ; Distelhorst, CW				Malone, MH; Wang, ZQ; Distelhorst, CW			The glucocorticoid-induced gene tdag8 encodes a pro-apoptotic G protein-coupled receptor whose activation promotes glucocorticoid-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED THYMOCYTE APOPTOSIS; ABC-TRANSPORTER TAP; CELL-DEATH; LYMPHOMA-CELLS; MOLECULAR-MECHANISMS; IN-VITRO; RESISTANCE; EXPRESSION; BIM; BAX	The apoptotic action of glucocorticoids on lymphocytes makes them effective therapeutics for many lymphoid malignancies. Although it is clear that glucocorticoid-induced apoptosis requires transcription, the gene products that induce apoptosis remain unknown. Using gene expression profiles of lymphoma cell lines and primary thymocytes treated with the synthetic glucocorticoid dexamethasone, we discovered that induction of tdag8 (T-cell death-associated gene 8) was a common event in each model system investigated. Activation of TDAG8 by its agonist psychosine markedly enhanced dexamethasone-induced apoptosis in a TDAG8-dependent manner. Expression of a TDAG8-GFP fusion protein was sufficient to induce apoptosis, and repression of endogenous TDAG8 using RNA interference partially inhibited dexamethasone-induced apoptosis. Together, these data suggest that TDAG8 is a regulator of glucocorticoid-induced apoptosis and that agonists of TDAG8 may be promising agents to improve the efficacy of glucocorticoids for the treatment of leukemia and lymphoma.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, WRB 3-133,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@po.cwru.edu			NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA042755] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703, T32 CA059366-10, R01 CA042755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos CL, 1998, CYTOKINE, V10, P662, DOI 10.1006/cyto.1998.0351; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; Briehl MM, 1997, ONCOL RES, V9, P281; Cancedda C, 2002, ANN NY ACAD SCI, V966, P49, DOI 10.1111/j.1749-6632.2002.tb04201.x; COHEN JJ, 1984, J IMMUNOL, V132, P38; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; DOUGHERTY TF, 1943, P SOC EXP BIOL MED, V53; FLOMERFELT FA, 1993, J CELL PHYSIOL, V154, P573, DOI 10.1002/jcp.1041540316; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; HEILMAN RR, 1944, ENDOCRINOLOGY, V34, P416; Hillmann AG, 2000, CANCER RES, V60, P2056; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; Izquierdo MA, 1996, BRIT J CANCER, V74, P1961, DOI 10.1038/bjc.1996.660; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Lage H, 2001, FEBS LETT, V503, P179, DOI 10.1016/S0014-5793(01)02722-3; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MIGLIORATI G, 1992, PHARMACOL RES, V25, P15, DOI 10.1016/1043-6618(92)90518-G; MIGLIORATI G, 1993, BLOOD, V81, P1352; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P619; PANAYIOTIDIS P, 1994, BRIT J HAEMATOL, V86, P169, DOI 10.1111/j.1365-2141.1994.tb03269.x; PEARSON OH, 1949, CANCER, V2, P943, DOI 10.1002/1097-0142(194911)2:6<943::AID-CNCR2820020602>3.0.CO;2-P; Raggers RJ, 1999, J CELL SCI, V112, P415; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; ROBERTSON AMG, 1978, J PATHOL, V126, P181, DOI 10.1002/path.1711260307; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; SIBLEY CH, 1974, CELL, V2, P221, DOI 10.1016/0092-8674(74)90014-2; Tome ME, 2001, CANCER RES, V61, P2766; Tonomura N, 2003, J IMMUNOL, V170, P2469, DOI 10.4049/jimmunol.170.5.2469; Tosa N, 2003, INT IMMUNOL, V15, P741, DOI 10.1093/intimm/dxg070; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield PD, 2001, J LIPID RES, V42, P2092; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; YAMAMOTO KR, 1974, P NATL ACAD SCI USA, V71, P3901, DOI 10.1073/pnas.71.10.3901; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	58	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52850	52859		10.1074/jbc.M408040200	http://dx.doi.org/10.1074/jbc.M408040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485889	hybrid			2022-12-27	WOS:000225680600009
J	Price, MP; Thompson, RJ; Eshcol, JO; Wemmie, JA; Benson, CJ				Price, MP; Thompson, RJ; Eshcol, JO; Wemmie, JA; Benson, CJ			Stomatin modulates gating of acid-sensing ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; CENTRAL-NERVOUS-SYSTEM; BRAIN NA+ CHANNEL; CAENORHABDITIS-ELEGANS; SENSORY NEURONS; HEREDITARY STOMATOCYTOSIS; MECHANOSENSORY TERMINALS; HIPPOCAMPAL-NEURONS; ACTIVATED CURRENTS; DEG/ENAC CHANNELS	Acid-sensing ion channels (ASICs) are H+-gated members of the degenerin/epithelial Na+ channel (DEG/ENaC) family in vertebrate neurons. Several ASICs are expressed in sensory neurons, where they play a role in responses to nociceptive, taste, and mechanical stimuli; others are expressed in central neurons, where they participate in synaptic plasticity and some forms of learning. Stomatin is an integral membrane protein found in lipid/protein-rich microdomains, and it is believed to regulate the function of ion channels and transporters. In Caenorhabditis elegans, stomatin homologs interact with DEG/ENaC channels, which together are necessary for normal mechanosensation in the worm. Therefore, we asked whether stomatin interacts with and modulates the function of ASICs. We found that stomatin co-immunoprecipitated and co-localized with ASIC proteins in heterologous cells. Moreover, stomatin altered the function of ASIC channels. Stomatin potently reduced acid-evoked currents generated by ASIC3 without changing steady state protein levels or the amount of ASIC3 expressed at the cell surface. In contrast, stomatin accelerated the desensitization rate of ASIC2 and heteromeric ASICs, whereas current amplitude was unaffected. These data suggest that stomatin binds to and alters the gating of ASICs. Our findings indicate that modulation of DEG/ENaC channels by stomatin-like proteins is evolutionarily conserved and may have important implications for mammalian nociception and mechanosensation.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Benson, CJ (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 200 Hawkins Dr,E314-1 GH, Iowa City, IA 52242 USA.	chris-benson@uiowa.edu		Eshcol, Jayasheel/0000-0002-1784-8513; Wemmie, John/0000-0001-7531-9065; Benson, Christopher/0000-0001-6600-8193	NHLBI NIH HHS [HL04349] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004349] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; Chalfie M, 1997, BIOL BULL, V192, P125, DOI 10.2307/1542584; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; EBER SW, 1989, BRIT J HAEMATOL, V72, P452, DOI 10.1111/j.1365-2141.1989.tb07731.x; Fricke B, 2003, BLOOD, V102, P2268, DOI 10.1182/blood-2002-06-1705; Fricke B, 2000, CELL TISSUE RES, V299, P327; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Gu GQ, 1996, P NATL ACAD SCI USA, V93, P6577, DOI 10.1073/pnas.93.13.6577; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; Hille B, 2001, ION CHANNELS EXCITAB, P61; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Mamet J, 2002, J NEUROSCI, V22, P10662; Mannsfeldt AG, 1999, MOL CELL NEUROSCI, V13, P391, DOI 10.1006/mcne.1999.0761; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Sedensky MM, 2004, AM J PHYSIOL-CELL PH, V287, pC468, DOI 10.1152/ajpcell.00182.2003; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Zhang JZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1277, DOI 10.1152/ajpcell.2001.280.5.C1277; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	66	97	105	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53886	53891		10.1074/jbc.M407708200	http://dx.doi.org/10.1074/jbc.M407708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471860	hybrid			2022-12-27	WOS:000225680600127
J	Santos, SG; Powis, SJ; Arosa, FA				Santos, SG; Powis, SJ; Arosa, FA			Misfolding of major histocompatibility complex class I molecules in activated T cells allows cis-interactions with receptors and signaling molecules and is associated with tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HEAVY-CHAINS; MONOCLONAL-ANTIBODY; CYTOPLASMIC DOMAIN; ALPHA-3 DOMAIN; HLA MOLECULES; SURFACE; LYMPHOCYTES; ANTIGEN; HLA-B27	Knowledge of the origin and biochemical status of beta(2)-microglobulin-free or misfolded major histocompatibility complex (MHC)-I molecules is essential for understanding their pleiotropic properties. Here we show that in normal human T cells, misfolding of MHC-I molecules is turned on upon activation and cell division and is proportional to the level of proliferation. Immunoprecipitation showed that a number of proteins are associated with MHC-I heavy chains at the surface of activated T cells, including the CD8alphabeta receptor and the chaperone tandem calreticulin/ERp57, associations that rely upon the existence of a pool of HC-10-reactive molecules. Biochemical analysis showed that misfolded MHC-I molecules present at the cell surface are fully glycosylated mature molecules. Importantly, misfolded MHC-I molecules are tyrosine phosphorylated and are associated with kinase activity. In vitro kinase assays followed by reprecipitation indicated that tyrosine phosphorylation of the class I heavy chain is probably mediated by a Src tyrosine kinase because Lck was found associated with HC-10 immunocomplexes. Finally, we show that inhibition of tyrosine phosphorylation by using the Src-family tyrosine kinase inhibitor PP2 resulted in enhanced release of MHC-I heavy chains from the cell surface of activated T cells and a slight down-regulation of cell surface W6/32-reactive molecules. This study provides new insights into the biology of MHC-I molecules and suggests that tyrosine phosphorylation may be involved in the regulation of MHC-I misfolding and expression.	Inst Mol & Cell Biol, Div Human Genet & Genet Disorders, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	Universidade do Porto; Universidade do Porto; University of Dundee	Arosa, FA (corresponding author), Inst Mol & Cell Biol, Div Human Genet & Genet Disorders, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	farosa@ibmc.up.pt	Santos, Susana G/L-9351-2013; Arosa, Fernando A./E-5640-2010	Santos, Susana G/0000-0002-8604-2978; Arosa, Fernando A./0000-0002-7209-4507; Powis, Simon/0000-0003-4218-2984				Allen RL, 1999, J IMMUNOL, V162, P5045; Antoniou AN, 2004, J BIOL CHEM, V279, P8895, DOI 10.1074/jbc.M311757200; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Bird LA, 2003, EUR J IMMUNOL, V33, P748, DOI 10.1002/eji.200323678; BLUE ML, 1988, CELL, V54, P413, DOI 10.1016/0092-8674(88)90204-8; Bodnar A, 2003, INT IMMUNOL, V15, P331, DOI 10.1093/intimm/dxg042; Bregenholt S, 1996, J IMMUNOL, V157, P993; BUSHKIN Y, 1986, J EXP MED, V164, P458, DOI 10.1084/jem.164.2.458; BUSHKIN Y, 1988, P NATL ACAD SCI USA, V85, P3985, DOI 10.1073/pnas.85.11.3985; CAPPS GG, 1993, J IMMUNOL, V151, P159; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CARRENO BM, 1994, EUR J IMMUNOL, V24, P1285, DOI 10.1002/eji.1830240607; Chang AH, 2001, EUR J IMMUNOL, V31, P2382, DOI 10.1002/1521-4141(200108)31:8<2382::AID-IMMU2382>3.0.CO;2-K; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293; Damjanovich S, 2002, IMMUNOL LETT, V82, P93, DOI 10.1016/S0165-2478(02)00024-X; DASGUPTA JD, 1987, P NATL ACAD SCI USA, V84, P1094, DOI 10.1073/pnas.84.4.1094; DEFELICE M, 1987, J IMMUNOL, V139, P2683; DEMARIA S, 1993, INT J CLIN LAB RES, V23, P61, DOI 10.1007/BF02592285; DEMARIA S, 1992, CELL IMMUNOL, V142, P103, DOI 10.1016/0008-8749(92)90272-Q; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Fonseca AM, 2003, CELL IMMUNOL, V224, P17, DOI 10.1016/S0008-8749(03)00170-9; GEPPERT TD, 1988, J IMMUNOL, V140, P2155; GILLILAND LK, 1989, HUM IMMUNOL, V25, P269, DOI 10.1016/0198-8859(89)90089-X; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; GUILD BC, 1984, J BIOL CHEM, V259, P3504; Gur H, 1997, MOL IMMUNOL, V34, P125, DOI 10.1016/S0161-5890(97)00007-2; GUR H, 1990, J EXP MED, V172, P1267, DOI 10.1084/jem.172.4.1267; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Jelonek MT, 1998, J IMMUNOL, V160, P2809; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Le Gall S, 2000, J VIROL, V74, P9256, DOI 10.1128/JVI.74.19.9256-9266.2000; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lizee G, 2003, NAT IMMUNOL, V4, P1065, DOI 10.1038/ni989; MADRIGAL JA, 1991, J EXP MED, V174, P1085, DOI 10.1084/jem.174.5.1085; MATKO J, 1994, J IMMUNOL, V152, P3353; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARHAM P, 1979, J IMMUNOL, V123, P342; Pickl WF, 1996, IMMUNOLOGY, V88, P104, DOI 10.1046/j.1365-2567.1996.d01-644.x; Puppo F, 2000, INT IMMUNOL, V12, P195, DOI 10.1093/intimm/12.2.195; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SAMBHARA SR, 1991, SCIENCE, V252, P1424; Sanders CR, 2000, CURR OPIN STRUC BIOL, V10, P438, DOI 10.1016/S0959-440X(00)00112-3; SCHNABL E, 1990, J EXP MED, V171, P1431, DOI 10.1084/jem.171.5.1431; SHARON M, 1988, J IMMUNOL, V141, P3512; SKOV S, 1995, J IMMUNOL, V154, P1167; Skov S, 1997, J IMMUNOL, V158, P3189; SMITH DM, 1994, J IMMUNOL, V153, P1054; Solheim JC, 1999, IMMUNOL REV, V172, P11, DOI 10.1111/j.1600-065X.1999.tb01352.x; Spaggiari GM, 2002, BLOOD, V100, P4098, DOI 10.1182/blood-2002-04-1284; STAM NJ, 1986, J IMMUNOL, V137, P2299; TAYLOR DS, 1986, P NATL ACAD SCI USA, V83, P4446, DOI 10.1073/pnas.83.12.4446; THOR G, 1993, J IMMUNOL, V151, P211; WACHOLTZ MC, 1989, J IMMUNOL, V142, P4201; Wearsch PA, 2004, J BIOL CHEM, V279, P25112, DOI 10.1074/jbc.M401721200	56	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53062	53070		10.1074/jbc.M408794200	http://dx.doi.org/10.1074/jbc.M408794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471856	hybrid			2022-12-27	WOS:000225680600033
J	Martindale, JJ; Wall, JA; Martinez-Longoria, DM; Aryal, P; Rockman, HA; Guo, YR; Bolli, R; Glembotski, CC				Martindale, JJ; Wall, JA; Martinez-Longoria, DM; Aryal, P; Rockman, HA; Guo, YR; Bolli, R; Glembotski, CC			Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; NF-KAPPA-B; P38-ALPHA MAP KINASE; P38 MAPK; CARDIAC-HYPERTROPHY; REPERFUSION INJURY; CELL-SURVIVAL; LATE-PHASE; APOPTOSIS; EXPRESSION	The mitogen-activated protein kinases ( MAPK) have been the subject of many studies to identify signaling pathways that promote cell survival or death. In cultured cardiac myocytes, p38 MAPK promotes cell survival or death depending on whether it is activated by mitogen-activated protein kinase kinase 6 (MKK6) or MKK3, respectively. The objectives of the current study were to examine the effects of MKK6-mediated p38 activation in the heart in vivo. Accordingly, we generated transgenic (TG) mice that overexpress wild type MKK6 in a cardiac-restricted manner. Although p38 was about 17-fold more active in TG than non-transgenic (NTG) mouse hearts, TG mouse hearts were morphologically and functionally similar to those of NTG littermates. However, upon transient ischemia followed by reperfusion, the MKK6 TG mouse hearts exhibited significantly better functional recovery and less injury than NTG mouse hearts. Because MKK6 increases levels of the protective small heat shock protein, alphaB-crystallin (alphaBC), in cultured cardiac myocytes, we examined alphaBC levels in the mouse hearts. The level of alphaBC was 2-fold higher in MKK6 TG than NTG mouse hearts. Moreover, ischemia followed by reperfusion induced a 6.4-fold increase in alphaBC levels in the mitochondrial fractions of TG mouse hearts but no increase in alphaBC levels in any of the other fractions analyzed. These alterations in alphaBC expression and localization suggest possible mechanisms of cardio-protection in MKK6 TG mouse hearts.	San Diego State Univ, SDSU Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Duke Univ, Med Ctr, Dept Med & Genet, Durham, NC 27710 USA; Univ Louisville, Inst Mol Cardiol, Louisville, KY 40292 USA	California State University System; San Diego State University; California State University System; San Diego State University; Duke University; University of Louisville	Glembotski, CC (corresponding author), San Diego State Univ, SDSU Heart Inst, San Diego, CA 92182 USA.	cglembotski@sciences.sdsu.edu	Guo, Yiru/L-2618-2015	Guo, Yiru/0000-0002-0614-9899	NHLBI NIH HHS [HL-68088, R01 HL055757, R01 HL063975, HL-75573, P01 HL046345, R01 HL070897, HL-55757, R01 HL068088, HL-70897, HL-63975, R37 HL055757, R01 HL075573, HL-46345] Funding Source: Medline; NINDS NIH HHS [R01 NS025037, NS/HL-25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055757, R01HL068088, R01HL070897, R01HL055757, R01HL075573, R01HL063975, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 2000, CIRC RES, V86, P607, DOI 10.1161/01.RES.86.6.607; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Degousee N, 2003, CIRC RES, V92, P757, DOI 10.1161/01.RES.0000067929.01404.03; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Esposito G, 2000, AM J PHYSIOL-HEART C, V279, pH3101, DOI 10.1152/ajpheart.2000.279.6.H3101; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Guo YR, 1998, AM J PHYSIOL-HEART C, V275, pH1375; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jones W Keith, 2003, Cardiovasc Toxicol, V3, P229, DOI 10.1385/CT:3:3:229; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kajstura J, 1996, LAB INVEST, V74, P86; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Lemke LE, 2001, J MOL CELL CARDIOL, V33, P1527, DOI 10.1006/jmcc.2001.1415; Li SP, 2003, CANCER RES, V63, P3473; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Marais E, 2001, J MOL CELL CARDIOL, V33, P769, DOI 10.1006/jmcc.2001.1347; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mocanu MM, 2000, BASIC RES CARDIOL, V95, P472, DOI 10.1007/s003950070023; Morrison LE, 2004, AM J PHYSIOL-HEART C, V286, pH847, DOI 10.1152/ajpheart.00715.2003; Morrison LE, 2003, CIRC RES, V92, P203, DOI 10.1161/01.RES.0000052989.83995.A5; Nakagawa M, 2001, EXP CELL RES, V271, P161, DOI 10.1006/excr.2001.5362; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Otsu K, 2003, BIOCHEM BIOPH RES CO, V302, P56, DOI 10.1016/S0006-291X(03)00096-2; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Ping PP, 2000, CIRC RES, V86, P921, DOI 10.1161/01.RES.86.9.921; Ravingerova T, 2003, MOL CELL BIOCHEM, V247, P127, DOI 10.1023/A:1024119224033; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; Sato M, 2000, AM J PHYSIOL-HEART C, V279, pH901, DOI 10.1152/ajpheart.2000.279.3.H901; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	51	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					669	676		10.1074/jbc.M406690200	http://dx.doi.org/10.1074/jbc.M406690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15492008	hybrid, Green Accepted			2022-12-27	WOS:000226025100079
J	Chavakis, T; Keiper, T; Matz-Westphal, R; Hersemeyer, K; Sachs, UJ; Nawroth, PP; Preissner, KT; Santoso, S				Chavakis, T; Keiper, T; Matz-Westphal, R; Hersemeyer, K; Sachs, UJ; Nawroth, PP; Preissner, KT; Santoso, S			The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; UROKINASE RECEPTOR; PECAM-1; COUNTERRECEPTOR; INTERACTS; LIGAND; JAMS; GLYCOPROTEIN; ENDOTHELIUM; MONOCYTES	The third member of the family of junctional adhesion molecules (JAMs), JAM-3, also called JAM-C, was recently shown to be a novel counter-receptor on platelets for the leukocyte beta(2)-integrin Mac-1 (alphaMbeta(2), CD11b/CD18). Here, new functional aspects of the role of endothelial cell JAM-C were investigated. Endothelial cells express JAM-C, which is predominantly localized within junctions at interendothelial contacts, since it codistributes with a tight junction component, zonula occludens-1. Whereas JAM-C does not participate in neutrophil adhesion to endothelial cells, it mediates neutrophil transmigration in a Mac-1-dependent manner. In particular, inhibition of JAM-C significantly reduced neutrophil transendothelial migration, and the combination of JAM-C and platelet/endothelial cell adhesion molecule-1 blockade almost completely abolished neutrophil transendothelial migration in vitro. In vivo, inhibition of JAM-C with soluble mouse JAM-C resulted in a 50% reduction of neutrophil emigration in the mouse model of acute thioglycollate-induced peritonitis. Thus, JAM-C participates in neutrophil transmigration and thereby provides a novel molecular target for antagonizing interactions between vascular cells that promote inflammatory vascular pathologies.	Heidelberg Univ, Dept Internal Med 1, D-69120 Heidelberg, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany	Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Justus Liebig University Giessen	Chavakis, T (corresponding author), Heidelberg Univ, Dept Internal Med 1, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	triantafyllos.chavakis@med.uni-heidelberg.de	Chavakis, Triantafyllos/ABE-8845-2020; Sachs, Ulrich/GSI-7824-2022	MATZ, Rachel/0000-0001-5832-7063	NATIONAL CANCER INSTITUTE [ZIABC010663, Z01BC010663] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ager Ann, 1994, Trends in Cell Biology, V4, P326, DOI 10.1016/0962-8924(94)90234-8; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kroll H, 2000, BLOOD, V96, P1409, DOI 10.1182/blood.V96.4.1409.h8001409_1409_1414; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Liu Y, 2000, J CELL SCI, V113, P2363; Mamdouh Z, 2003, NATURE, V421, P748, DOI 10.1038/nature01300; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rohnelt RK, 1997, INT IMMUNOL, V9, P435, DOI 10.1093/intimm/9.3.435; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Santoso S, 1999, BLOOD, V94, P4103, DOI 10.1182/blood.V94.12.4103.424k27_4103_4111; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	40	153	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55602	55608		10.1074/jbc.M404676200	http://dx.doi.org/10.1074/jbc.M404676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485832	hybrid			2022-12-27	WOS:000225960800078
J	Honda, Y; Kitaoka, M				Honda, Y; Kitaoka, M			A family 8 glycoside hydrolase from bacillus halodurans C-125 (BH2105) is a reducing end xylose-releasing exo-oligoxylanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.8 ANGSTROM RESOLUTION; AMINO-ACID-SEQUENCE; ACTIVE-SITE; CELLOBIOSE PHOSPHORYLASE; CELLVIBRIO-GILVUS; ESCHERICHIA-COLI; D-GLUCOSE; LOW PH; XYLANASE; SUBSTRATE	The gene encoding family 8 glycoside hydrolases from Bacillus halodurans C-125 (BH2105), an alkalophilic bacterium with a known genomic sequence, was expressed in Escherichia coli. The protein was expressed with the intact N-terminal sequence, suggesting that it did not possess a signal peptide and that it was an intracellular enzyme. The recombinant enzyme showed no hydrolytic activity on xylan, whereas it had been annotated as xylanase Y. It hydrolyzed xylooligosaccharide whose degree of polymerization is greater than or equal to 3 in an exosplitting manner with anomeric inversion, releasing the xylose unit at the reducing end. Judging from its substrate specificity and reaction mechanism, we named the enzyme reducing end xylose-releasing exo-oligoxylanase (Rex). Rex was found to utilize only the beta-anomer of the substrate to form beta-xylose and alpha-xylooligosaccharide. The optimum pH of the enzymatic reaction (6.2-7.3) was found in the neutral range, a range beneficial for intracellular enzymes. The genomic sequence suggests that B. halodurans secretes two endoxylanases and possesses two alpha-arabinofuranosidases, one alpha-glucuronidase, and three beta-xylosidases intracellularly in addition to Rex. The extracellular enzymes supposedly hydrolyze xylan into arabino/glucurono-xylooligosaccharides that are then transported into the cells. Rex may play a role as a key enzyme in intracellular xylan metabolism in B. halodurans by cleaving xylooligosaccharides that were produced by the action of other intracellular enzymes from the arabino/glucurono-xylooligosaccharides.	Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Kitaoka, M (corresponding author), Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	mkitaoka@nfri.affrc.go.jp	Kitaoka, Motomitsu/R-1536-2019	Kitaoka, Motomitsu/0000-0002-0083-1838				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Canals A, 2003, ACTA CRYSTALLOGR D, V59, P1447, DOI 10.1107/S0907444903012629; Collins T, 2002, J BIOL CHEM, V277, P35133, DOI 10.1074/jbc.M204517200; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; Dupont C, 1998, BIOCHEM J, V330, P41, DOI 10.1042/bj3300041; FLETCHER HG, 1963, METHODS CARBOHYDR CH, P197; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Fushinobu S, 1998, PROTEIN ENG, V11, P1121, DOI 10.1093/protein/11.12.1121; Gruber K, 1998, BIOCHEMISTRY-US, V37, P13475, DOI 10.1021/bi980864l; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Hakulinen N, 2003, EUR J BIOCHEM, V270, P1399, DOI 10.1046/j.1432-1033.2003.03496.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONDA H, 1985, J BACTERIOL, V161, P784, DOI 10.1128/JB.161.2.784-785.1985; Honda Y, 2002, J BIOSCI BIOENG, V93, P313, DOI 10.1016/S1389-1723(02)80034-2; Horikoshi K, 1999, MICROBIOL MOL BIOL R, V63, P735, DOI 10.1128/MMBR.63.4.735-750.1999; KITAOKA M, 1993, BIOSCI BIOTECH BIOCH, V57, P1987, DOI 10.1271/bbb.57.1987; KITAOKA M, 1993, CARBOHYD RES, V247, P355, DOI 10.1016/0008-6215(93)84271-7; Koga D, 1998, BIOSCI BIOTECH BIOCH, V62, P1643, DOI 10.1271/bbb.62.1643; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 2002, BIOCHEM BIOPH RES CO, V295, P818, DOI 10.1016/S0006-291X(02)00748-9; McCarthy AA, 2000, ACTA CRYSTALLOGR D, V56, P1367, DOI 10.1107/S0907444900009896; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; Nidetzky B, 2000, BIOCHEM J, V351, P649, DOI 10.1042/0264-6021:3510649; Nishimoto M, 2002, J BIOSCI BIOENG, V93, P428, DOI 10.1263/jbb.93.428; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; REITHEL FJ, 1945, J AM CHEM SOC, V67, P1056, DOI 10.1021/ja01223a006; SAHA BC, 1997, FUELS CHEM BIOMASS, V666, P47; SAHA BC, 1999, UTILIZING NATURES AD, V723, P167; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Shintate K, 2003, CARBOHYD RES, V338, P1981, DOI 10.1016/S0008-6215(03)00314-8; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TAPIO S, 1991, J BIOL CHEM, V266, P19450; TSUMURAYA Y, 1990, ARCH BIOCHEM BIOPHYS, V281, P58, DOI 10.1016/0003-9861(90)90412-R; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; WAFFENSCHMIDT S, 1987, ANAL BIOCHEM, V165, P337, DOI 10.1016/0003-2697(87)90278-8; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Wouters J, 2001, ACTA CRYSTALLOGR D, V57, P1813, DOI 10.1107/S0907444901015153	44	76	78	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55097	55103		10.1074/jbc.M409832200	http://dx.doi.org/10.1074/jbc.M409832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15491996	hybrid			2022-12-27	WOS:000225960800015
J	Peter, JC; Wallukat, G; Tugler, J; Maurice, D; Roegel, JC; Briand, JP; Hoebeke, J				Peter, JC; Wallukat, G; Tugler, J; Maurice, D; Roegel, JC; Briand, JP; Hoebeke, J			Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTORS; INVERSE AGONIST; CHAGAS-DISEASE; PROTEIN-L; BINDING; AUTOANTIBODIES; ANTAGONIST; EPITOPES; SURFACE	Antibodies directed against the second extracellular loop of G protein-coupled receptors are known to have functional activities. From a partial agonist monoclonal antibody directed against the M2 muscarinic receptor, we constructed and produced a single chain variable fragment with high affinity for its target epitope. The fragment is able to recognize its receptor on Chinese hamster ovary cells transfected with the M2 muscarinic acetylcholine receptor to block the effect of carbachol on this receptor and to exert an inverse agonist activity on the basal activity of the receptor. The antibody fragment is also able to increase the basal rhythm of cultured neonatal rat cardiomyocytes and to inhibit in a non-competitive manner the negative chronotropic effect of carbachol. This antibody fragment is able to exert its inverse agonist activity in vivo on mouse heart activity. The immunological strategy presented here could be useful to develop specific allosteric inverse agonist reagents for G protein-coupled receptors.	Inst Biol Mol & Cellulaire, Lab Therapeut Chem & Immunol, CNRS, UPR 9021, F-67084 Strasbourg, France; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Sch Med, Inst Pharmacol, Forenap Therapeut Discovery, F-67000 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; CHU Strasbourg; Universite de Franche-Comte	Hoebeke, J (corresponding author), Inst Biol Mol & Cellulaire, Lab Therapeut Chem & Immunol, CNRS, UPR 9021, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	j.hoebeke@ibmc.u-strasbg.fr	Maurice, Donald/AAE-9332-2019					AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; Aubrey N, 2001, BIOL CHEM, V382, P1621, DOI 10.1515/BC.2001.197; Bes C, 2001, FEBS LETT, V508, P67, DOI 10.1016/S0014-5793(01)03036-8; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; Borda ES, 1996, INT J CARDIOL, V54, P149, DOI 10.1016/0167-5273(96)02592-2; Brodde OE, 1998, J CLIN INVEST, V101, P471, DOI 10.1172/JCI1113; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; Chaves AA, 2003, LIFE SCI, V72, P2401, DOI 10.1016/S0024-3205(03)00137-1; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Daeffler L, 1999, BRIT J PHARMACOL, V126, P1246, DOI 10.1038/sj.bjp.0702407; Daeffler L, 2000, FUND CLIN PHARMACOL, V14, P73, DOI 10.1111/j.1472-8206.2000.tb00395.x; Eftekhari P, 2001, EUR J IMMUNOL, V31, P573, DOI 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9; Elies R, 1996, J IMMUNOL, V157, P4203; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Graille M, 2001, STRUCTURE, V9, P679, DOI 10.1016/S0969-2126(01)00630-X; HALLE W, 1970, AM J CARDIOL, V25, P292, DOI 10.1016/S0002-9149(70)80006-6; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; RichaletSecordel PM, 1997, ANAL BIOCHEM, V249, P165, DOI 10.1006/abio.1997.2183; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; WALLUKAT G, 1995, J MOL CELL CARDIOL, V27, P397, DOI 10.1016/S0022-2828(08)80036-3; WALLUKAT G, 1987, BIOMED BIOCHIM ACTA, V46, P634	32	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55697	55706		10.1074/jbc.M407213200	http://dx.doi.org/10.1074/jbc.M407213200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485827	hybrid			2022-12-27	WOS:000225960800090
J	Rausell, C; Pardo-Lopez, L; Sanchez, J; Munoz-Garay, C; Morera, C; Soberon, M; Bravo, A				Rausell, C; Pardo-Lopez, L; Sanchez, J; Munoz-Garay, C; Morera, C; Soberon, M; Bravo, A			Unfolding events in the water-soluble monomeric Cry1Ab toxin during transition to oligomeric pre-pore and membrane-inserted pore channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECTICIDAL CRYSTAL PROTEINS; STAPHYLOCOCCAL ALPHA-TOXIN; BRUSH-BORDER MEMBRANE; BACILLUS-THURINGIENSIS; DELTA-ENDOTOXIN; MANDUCA-SEXTA; AMINOPEPTIDASE-N; FORMING TOXIN; BINDING; DOMAIN	The insecticidal crystal (Cry) proteins produced by Bacillus thuringiensis undergo several conformational changes from crystal inclusion protoxins to membrane-inserted channels in the midgut epithelial cells of the target insect. Here we analyzed the stability of the different forms of Cry1Ab toxin, monomeric toxin, pre-pore complex, and membrane-inserted channel, after urea and thermal denaturation by monitoring intrinsic tryptophan fluorescence of the protein and 1-anilinonaphthalene-8-sulfonic acid binding to partially unfolded proteins. Our results showed that flexibility of the monomeric toxin was dramatically enhanced upon oligomerization and was even further increased by insertion of the pre-pore into the membrane as shown by the lower concentration of chaotropic agents needed to achieve unfolding of the oligomeric species. The flexibility of the toxin structures is further increased by alkaline pH. We found that the monomer-monomer interaction in the pre-pore is highly stable because urea promotes oligomer denaturation without disassembly. Partial unfolding and limited proteolysis studies demonstrated that domains II and III were less stable and unfold first, followed by unfolding of the most stable domain I, and also that domain I is involved in monomer-monomer interaction. The thermal-induced unfolding and analysis of energy transfer from Trp residues to bound 1-anilinonaphthalene-8-sulfonic acid dye showed that in the membrane-inserted pore domains II and III are particularly sensitive to heat denaturation, in contrast to domain I, suggesting that only domain I may be inserted into the membrane. Finally, the insertion into the membrane of the oligomeric pre-pore structure was not affected by pH. However, a looser conformation of the membrane-inserted domain I induced by neutral or alkaline pH correlates with active channel formation. Our studies suggest for the first time that a more flexible conformation of Cry toxin could be necessary for membrane insertion, and this flexible structure is induced by toxin oligomerization. Finally the alkaline pH found in the midgut lumen of lepidopteran insects could increase the flexibility of membrane-inserted domain I necessary for pore formation.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico	Universidad Nacional Autonoma de Mexico	Bravo, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Apdo Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	bravo@ibt.unam.mx	de la Parra, Maria Alejandra Bravo/R-6740-2017; Rausell, Carolina/ABG-9554-2020	Rausell, Carolina/0000-0002-5849-9102; Bravo, Alejandra/0000-0002-7573-7475; Munoz-Garay, Carlos/0000-0002-7218-4027; Pardo Lopez, Liliana/0000-0002-8927-1733				ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Barry JK, 1999, BIOCHEMISTRY-US, V38, P6520, DOI 10.1021/bi9900727; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P237, DOI 10.1016/0022-2011(92)90004-N; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; Cabiaux V, 1997, INT J BIOL MACROMOL, V21, P285, DOI 10.1016/S0141-8130(97)00078-0; Cabiaux V, 1997, BIOCHEMISTRY-US, V36, P15224, DOI 10.1021/bi971216p; CONVENTS D, 1990, J BIOL CHEM, V265, P1369; CONVENTS D, 1991, EUR J BIOCHEM, V195, P631, DOI 10.1111/j.1432-1033.1991.tb15747.x; Dorsch JA, 2002, INSECT BIOCHEM MOLEC, V32, P1025, DOI 10.1016/S0965-1748(02)00040-1; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P13180, DOI 10.1021/bi960990u; Fang Y, 1997, BIOCHEMISTRY-US, V36, P9518, DOI 10.1021/bi970600j; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Guidry JJ, 2000, PROTEIN SCI, V9, P2109, DOI 10.1110/ps.9.11.2109; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFTE H, 1988, APPL ENVIRON MICROB, V54, P2010; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; Lesieur C, 1999, J BIOL CHEM, V274, P36722, DOI 10.1074/jbc.274.51.36722; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Lorence A, 1997, FEBS LETT, V414, P303, DOI 10.1016/S0014-5793(97)01014-4; Loseva OI, 2001, BIOCHEMISTRY-US, V40, P14143, DOI 10.1021/bi010171w; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; MUGA A, 1993, J BIOL CHEM, V268, P1553; ORT P, 1995, J PROTEIN CHEM, V14, P241, DOI 10.1007/BF01886765; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Rosenberger CM, 2000, CURR BIOL, V10, pR823, DOI 10.1016/S0960-9822(00)00788-0; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Sirangelo I, 2002, PHOTOCHEM PHOTOBIOL, V76, P381, DOI 10.1562/0031-8655(2002)076<0381:ROTAFE>2.0.CO;2; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Vecsey-Semjen B, 1999, BIOCHEMISTRY-US, V38, P4296, DOI 10.1021/bi982472k; VecseySemjen B, 1996, J BIOL CHEM, V271, P8655, DOI 10.1074/jbc.271.15.8655; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WEBER G, 1966, BIOCHEMISTRY-US, V5, P1900, DOI 10.1021/bi00870a017; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	42	42	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55168	55175		10.1074/jbc.M406279200	http://dx.doi.org/10.1074/jbc.M406279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498772	hybrid			2022-12-27	WOS:000225960800024
J	Gline, SE; Cambier, S; Govaerts, C; Nishimura, SL				Gline, SE; Cambier, S; Govaerts, C; Nishimura, SL			A 50-angstrom separation of the integrin alpha(v)beta(3) extracellular domain C termini reveals an intermediate activation state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; LIGAND-BINDING; HIGH-AFFINITY; ALPHA-V-BETA-3; RECEPTOR; COMPLEX; ALPHA-IIB-BETA-3	The integrin alpha(v)beta(3) has been shown to exist in low and high affinity conformations. Activation to the high affinity state is thought to depend on the "switchblade-like" opening, from a low affinity bent conformation with a closed headpiece to an extended form of the integrin with an open headpiece. Activation has been shown to depend on separation of the cytoplasmic domains. How cytoplasmic domain separation is related to separation of the transmembrane domains is unknown, and the distance of separation of the transmembrane domains required for activation has not been defined. A constrained secreted form of alpha(v)beta(3) was engineered that introduced a 50-Angstrom separation of the integrin C-terminal tails of the extracellular domains of the alpha(v) and beta(3) subunits. Receptor binding and recognition by ligand-induced binding state (LIBS) monoclonal antibodies demonstrated that the mutant receptor was locked into a low affinity state that was likely in a partially extended conformation but with a closed headpiece. In the presence of RGD peptide, the constrained receptor was able to fully extend, as determined by full exposure of LIBS epitopes. In the presence of the appropriate LIBS antibody, high affinity ligand binding of the constrained receptor was achieved. The results support the existence of transient intermediate activation states of secreted alpha(v)beta(3). Furthermore, these results with the secreted alpha(v)beta(3) receptor support a model for the full-length membrane-bound form of alpha(v)beta(3), whereby a 50-Angstrom lateral separation of the integrin alpha(v) and beta(3) transmembrane domains would be sufficient to enforce the switchblade-like opening to the extended conformation but insufficient for full receptor activation.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco	Nishimura, SL (corresponding author), San Francisco Gen Hosp, Dept Pathol, Bldg 3,Rm 207,1001 Potrero Ave, San Francisco, CA 94110 USA.	cdog@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL070622, R01HL063993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044155] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70622, HL63993] Funding Source: Medline; NINDS NIH HHS [NS-44155] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; NEWMAN PJ, 1987, BLOOD, V69, P668; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	23	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54567	54572		10.1074/jbc.M406582200	http://dx.doi.org/10.1074/jbc.M406582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475365	hybrid			2022-12-27	WOS:000225793600082
J	Mandal, AK; Yang, Y; Kertesz, TM; Arguello, JM				Mandal, AK; Yang, Y; Kertesz, TM; Arguello, JM			Identification of the transmembrane metal binding site in Cu+-transporting P-IB-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; WILSONS-DISEASE PROTEIN; HIGH-AFFINITY TRANSPORT; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; CALCIUM-PUMP; ARCHAEOGLOBUS-FULGIDUS; CATION-BINDING; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL CONSEQUENCES	P-IB-type ATPases have an essential role maintaining copper homeostasis. Metal transport by these membrane proteins requires the presence of a transmembrane metal occlusion/binding site. Previous studies showed that Cys residues in the H6 transmembrane segment are required for metal transport. In this study, the participation in metal binding of conserved residues located in transmembrane segments H7 and H8 was tested using CopA, a model Cu+-ATPase from Archaeoglobus fulgidus. Four invariant amino acids in the central portion of H7 (Tyr(682) and Asn(683)) and H8 (Met(711) and Ser(715)) were identified as required for Cu+ binding. Replacement of these residues abolished enzyme activity. These proteins did not undergo Cu+-dependent phosphorylation by ATP but were phosphorylated by P-i in the absence of Cu+. Moreover, the presence of Cu+ could not prevent the enzyme phosphorylation by P-i. Other conserved residues in the H7-H8 region were not required for metal binding. Mutation of two invariant Pro residues had little effect on enzyme function. Replacement of residues located close to the cytoplasmic end of H7-H8 led to inactive enzymes. However, these were able to interact with Cu+ and undergo phosphorylation. This suggests that the integrity of this region is necessary for conformational transitions but not for ligand binding. These data support the presence of a unique transmembrane Cu+ binding/translocation site constituted by Tyr-Asn in H7, Met and Ser in H8, and two Cys in H6 of Cu+-ATPases. The likely Cu+ coordination during transport appears distinct from that observed in Cu+ chaperone proteins or catalytic/redox metal binding sites.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA	Worcester Polytechnic Institute	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, 100 Inst Rd, Worcester, MA 01609 USA.	arguello@wpi.edu	Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P254, DOI 10.1006/abbi.1999.1124; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Eitinger T, 1997, J BIOL CHEM, V272, P17139, DOI 10.1074/jbc.272.27.17139; Eren E, 2004, PLANT PHYSIOL, V136, P3712, DOI 10.1104/pp.104.046292; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Fulkerson JF, 1998, J BIOL CHEM, V273, P235, DOI 10.1074/jbc.273.1.235; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; HOMAREDA H, 1993, BIOCHEM CELL BIOL, V71, P410, DOI 10.1139/o93-060; Hsi G, 2004, HUM GENET, V114, P165, DOI 10.1007/s00439-003-1045-y; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lam-Yuk-Tseung S, 2003, BLOOD, V101, P3699, DOI 10.1182/blood-2002-07-2108; Loudianos G, 1999, J MED GENET, V36, P833; Lowe J, 2004, J BIOL CHEM, V279, P25986, DOI 10.1074/jbc.M308736200; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; LUTSENKO S, 1995, P NATL ACAD SCI USA, V87, P4566; Mana-Capelli S, 2003, J BIOL CHEM, V278, P40534, DOI 10.1074/jbc.M306907200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mikhailova L, 2002, BIOCHEMISTRY-US, V41, P8195, DOI 10.1021/bi025721k; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; POST RL, 1972, J BIOL CHEM, V247, P6530; Ralle M, 1999, J INORG BIOCHEM, V74, P271; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsai KJ, 2002, J BIOENERG BIOMEMBR, V34, P147, DOI 10.1023/A:1016085301323; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008	61	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54802	54807		10.1074/jbc.M410854200	http://dx.doi.org/10.1074/jbc.M410854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494391	hybrid			2022-12-27	WOS:000225793600108
J	Mosley, AL; Ozcan, S				Mosley, AL; Ozcan, S			The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-EXPRESSION; TRANSCRIPTION FACTOR PDX-1; MUSCLE DIFFERENTIATION; CELL FUNCTION; PHOSPHORYLATION; PROMOTER; COACTIVATOR; CBP/P300; COMPLEX; BINDING	We have previously demonstrated that high concentrations of glucose stimulate insulin gene expression by causing hyperacetylation of histone H4 at the insulin gene promoter. Furthermore, we have shown that the glucose-mediated hyperacetylation of histone H4 depends on the recruitment of the histone acetyltransferase p300 by the beta cell-specific transcription factor Pdx-1. In this study, we demonstrate that the histone deacetylases Hdac-1 and Hdac-2 are rapidly recruited to the insulin promoter in the mouse insulinoma cell line MIN6 when cells are switched from high to low glucose media. Moreover, we demonstrate that the beta cell-specific homeodomain protein Pdx-1 interacts with histone deacetylases Hdac-1 and Hdac-2 at low levels of glucose. In vitro studies indicate that the interaction between Pdx-1 and Hdac-1 or Hdac-2 is direct and requires the C terminus of Pdx-1. Treatment of MIN6 cells with okadaic acid, which inhibits the activity of protein phosphatases, abolishes the interaction of Pdx-1 with Hdac-1 and Hdac-2 on low levels of glucose, suggesting the requirement of a dephosphorylation event for this interaction to occur. These data indicate that insulin gene expression is decreased on low levels of glucose by recruitment of Hdac-1 and Hdac-2 to the insulin promoter by the transcription factor Pdx-1.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, MN608, Lexington, KY 40536 USA.	sozcan@uky.edu						Asahara H, 1999, MOL CELL BIOL, V19, P8219; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Edlund H, 2001, DIABETOLOGIA, V44, P1071, DOI 10.1007/s001250100623; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; Goodman RH, 2000, GENE DEV, V14, P1553; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heltweg B, 2002, ANAL BIOCHEM, V302, P175, DOI 10.1006/abio.2001.5542; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leibowitz G, 2001, DIABETES, V50, pS138, DOI 10.2337/diabetes.50.2007.S138; Liu AH, 2004, MOL CELL BIOL, V24, P4372, DOI 10.1128/MCB.24.10.4372-4383.2004; Macfarlane WM, 2000, DIABETES, V49, P418, DOI 10.2337/diabetes.49.3.418; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Melloul D, 2004, ANN NY ACAD SCI, V1014, P28, DOI 10.1196/annals.1294.003; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Mosley Amber L, 2003, Methods Mol Med, V83, P73; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	48	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54241	54247		10.1074/jbc.M410379200	http://dx.doi.org/10.1074/jbc.M410379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496408	hybrid			2022-12-27	WOS:000225793600044
J	Sorgen, PL; Duffy, HS; Sahoo, P; Coombs, W; Delmar, M; Spray, DC				Sorgen, PL; Duffy, HS; Sahoo, P; Coombs, W; Delmar, M; Spray, DC			Structural changes in the carboxyl terminus of the gap junction protein connexin43 indicates signaling between binding domains for c-Src and zonula occludens-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; V-SRC; CARDIAC MYOCYTES; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; NULL MUTATION; PH REGULATION; CHANNELS; COMMUNICATION	Regulation of cell-cell communication by the gap junction protein connexin43 can be modulated by a variety of connexin-associating proteins. In particular, c-Src can disrupt the connexin43 (Cx43)-zonula occludens-1 (ZO-1) interaction, leading to down-regulation of gap junction intercellular communication. The binding sites for ZO-1 and c-Src correspond to widely separated Cx43 domains (similar to100 residues apart); however, little is known about the structural modifications that may allow information to be transferred over this distance. Here, we have characterized the structure of the connexin43 carboxyl-terminal domain (Cx43CT) to assess its ability to interact with domains from ZO-1 and c-Src. NMR data indicate that the Cx43CT exists primarily as an elongated random coil, with two regions of alpha-helical structure. NMR titration experiments determined that the ZO-1 PDZ-2 domain affected the last 19 Cx43CT residues, a region larger than that reported to be required for Cx43CT-ZO-1 binding. The c-Src SH3 domain affected Cx43CT residues Lys-264-Lys-287, Ser-306-Glu-316, His-331-Phe-337, Leu-356-Val-359, and Ala-367-Ser-372. Only region Lys-264-Lys-287 contains the residues previously reported to act as an SH3 binding domain. The specificity of these interactions was verified by peptide competition experiments. Finally, we demonstrated that the SH3 domain could partially displace the Cx43CT-PDZ-2 complex. These studies represent the first structural characterization of a connexin domain when integrated in a multimolecular complex. Furthermore, we demonstrate that the structural characteristics of a disordered Cx43CT are advantageous for signaling between different binding partners that may be important in describing the mechanism of channel closure or internalization in response to pathophysiological stimuli.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	University of Nebraska System; University of Nebraska Medical Center; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sorgen, PL (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	psorgen@unmc.edu		Delmar, Mario/0000-0002-2085-5589; Spray, David/0000-0001-8368-5073	NHLBI NIH HHS [HL39707] Funding Source: Medline; NIGMS NIH HHS [GM57691] Funding Source: Medline; NIMH NIH HHS [MH65495] Funding Source: Medline; NINDS NIH HHS [NS41282] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL039707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; ATKINSON MM, 1995, J CELL SCI, V108, P3079; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Brizuela BJ, 2001, DEV BIOL, V230, P217, DOI 10.1006/dbio.2000.0116; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukauskas FF, 2002, J GEN PHYSIOL, V119, P171, DOI 10.1085/jgp.119.2.171; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Calero G, 1998, CIRC RES, V82, P929, DOI 10.1161/01.RES.82.9.929; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dermietzel R, 2000, BRAIN RES REV, V32, P45, DOI 10.1016/S0165-0173(99)00067-3; Duffy HS, 2004, CIRC RES, V94, P215, DOI 10.1161/01.RES.0000113924.06926.11; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; DUNHAM B, 1992, CIRC RES, V70, P1233, DOI 10.1161/01.RES.70.6.1233; Dunker AK, 2001, NAT BIOTECHNOL, V19, P805, DOI 10.1038/nbt0901-805; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; Fujimoto K, 1997, J CELL SCI, V110, P311; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; Herve JC, 2004, BBA-BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022; Homma N, 1998, CIRC RES, V83, P27, DOI 10.1161/01.RES.83.1.27; Iacobas DA, 2004, NEUROCHEM INT, V45, P243, DOI 10.1016/j.neuint.2003.12.008; Iacobas DA, 2003, PHYSIOL GENOMICS, V15, P177, DOI 10.1152/physiolgenomics.00062.2003; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; Liao Y, 2001, P NATL ACAD SCI USA, V98, P9989, DOI 10.1073/pnas.171305298; Lin R, 2001, CELL COMMUN ADHES, V8, P265, DOI 10.3109/15419060109080735; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Morley GE, 1999, J CARDIOVASC ELECTR, V10, P1361, DOI 10.1111/j.1540-8167.1999.tb00192.x; MUNSTER PN, 1993, PFLUG ARCH EUR J PHY, V423, P181, DOI 10.1007/BF00374392; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Saez JC, 1997, J MOL CELL CARDIOL, V29, P2131, DOI 10.1006/jmcc.1997.0447; Scemes E, 2000, J NEUROSCI, V20, P1435; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sohl G, 2004, CARDIOVASC RES, V62, P228, DOI 10.1016/j.cardiores.2003.11.013; Solan JL, 2003, J CELL SCI, V116, P2203, DOI 10.1242/jcs.00428; Sorgen PL, 2004, BIOPHYS J, V87, P574, DOI 10.1529/biophysj.103.039230; Sorgen PL, 2002, J BIOMOL NMR, V23, P245, DOI 10.1023/A:1019892719979; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SPRAY DC, 1991, BRAIN RES, V568, P1, DOI 10.1016/0006-8993(91)91373-9; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; VUISTER GW, 1993, J MAGN RESON, V96, P432; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	79	150	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54695	54701		10.1074/jbc.M409552200	http://dx.doi.org/10.1074/jbc.M409552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492000	hybrid			2022-12-27	WOS:000225793600096
J	Vives, RR; Crublet, E; Andrieu, JP; Gagnon, J; Rousselle, P; Lortat-Jacob, H				Vives, RR; Crublet, E; Andrieu, JP; Gagnon, J; Rousselle, P; Lortat-Jacob, H			A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE OLIGOSACCHARIDES; LAMININ ALPHA-1 CHAIN; PSEUDORABIES VIRUS; BINDING DOMAIN; GLYCOSAMINOGLYCAN BINDING; RECEPTOR-BINDING; RANTES; SITE; CHEMOKINES	The binding of proteins to glycosaminoglycans (GAGs) is the prerequisite for a large number of cellular processes and regulatory events and is associated to many pathologies. However, progress in the understanding of these mechanisms has been hampered by the lack of simple and comprehensive analytical tools for the identification of the structural attributes involved in protein/saccharide interaction. Characterization of GAG binding motifs on proteins has so far relied on site-directed mutagenesis studies, protein sequence mapping using synthetic peptides, molecular modeling, or structural analysis. Here, we report the development of a novel approach for identifying protein residues involved in the binding to heparin, the archetypal member of the GAG family. This method, which uses native proteins, is based on the formation of cross-linked complexes of the protein of interest with heparin beads, the proteolytic digestion of these complexes, and the subsequent identification of the heparin binding containing peptides by N terminus sequencing. Analysis of the CC chemokine regulated on activation, normal T-cell expressed, and secreted (RANTES), the envelope glycoprotein gC from pseudorabies virus and the laminin-5 alpha3LG4/5 domain validated the techniques and provided novel information on the heparin binding motifs present within these proteins. Our results highlighted this method as a fast and valuable alternative to existing approaches. Application of this technique should greatly contribute to facilitate the structural study of protein/GAG interactions and the understanding of their biological functions.	UJF, CEA, CNRS, Inst Biol Struct, F-38027 Grenoble 01, France; Univ Grenoble 1, Fac Med, CNRS, FRE 2685, F-38706 La Tronche, France; Univ Grenoble 1, Fac Pharm, CNRS, FRE 2685, F-38706 La Tronche, France; IFR 128 BioSci Lyon Gerland, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Vives, RR (corresponding author), UJF, CEA, CNRS, Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble 01, France.	vives@ibs.fr	Rousselle, Patricia/J-5290-2019; Rousselle, Patricia/CAF-3915-2022; Gagnon, Jean/C-3136-2008; Vives, Romain/I-9372-2012	Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562; Gagnon, Jean/0000-0002-0177-824X; 				Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Baker SE, 1996, J CELL SCI, V109, P2509; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feizi T, 2003, CURR OPIN STRUC BIOL, V13, P637, DOI 10.1016/j.sbi.2003.09.002; Flynn SJ, 1996, J VIROL, V70, P1355, DOI 10.1128/JVI.70.3.1355-1364.1996; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Karger A, 1996, J VIROL, V70, P2138, DOI 10.1128/JVI.70.4.2138-2145.1996; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LIANG XP, 1993, VIROLOGY, V194, P233, DOI 10.1006/viro.1993.1254; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; METTENLEITER TC, 1990, J VIROL, V64, P278, DOI 10.1128/JVI.64.1.278-286.1990; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Najjam S, 1997, CYTOKINE, V9, P1013, DOI 10.1006/cyto.1997.0246; Nishiyama T, 2000, J DERMATOL SCI, V24, pS51, DOI 10.1016/S0923-1811(00)00142-0; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Okamoto O, 2003, J BIOL CHEM, V278, P44168, DOI 10.1074/jbc.M300726200; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Suzuki N, 2003, BIOCHEMISTRY-US, V42, P12625, DOI 10.1021/bi030014s; Trybala E, 1998, J BIOL CHEM, V273, P5047, DOI 10.1074/jbc.273.9.5047; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Yamashita H, 2004, J MOL BIOL, V335, P1145, DOI 10.1016/j.jmb.2003.11.047; Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003	46	39	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54327	54333		10.1074/jbc.M409760200	http://dx.doi.org/10.1074/jbc.M409760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485868				2022-12-27	WOS:000225793600054
J	Walker, KD; Klettke, K; Akiyama, T; Croteau, R				Walker, KD; Klettke, K; Akiyama, T; Croteau, R			Cloning, heterologous expression, and characterization of a phenylalanine aminomutase involved in Taxol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE AMMONIA-LYASE; 4-METHYLIDENEIMIDAZOLE-5-ONE-CONTAINING TYROSINE AMINOMUTASE; ANTIBIOTIC C-1027 BIOSYNTHESIS; STREPTOMYCES-GRISEUS; PHENYLPROPANOID METABOLISM; LEUCINE 2,3-AMINOMUTASE; CLOSTRIDIUM-STICKLANDII; RADICAL MECHANISMS; STRUCTURAL GENE; BETA-TYROSINE	Biosynthesis of the N-benzoyl phenylisoserinoyl side chain of the anticancer drug Taxol starts with the conversion of 2S-alpha-phenylalanine to 3R-beta-phenylalanine by phenylalanine aminomutase (PAM). A gene cloning approach was based on the assumption that PAM would resemble the well known plant enzyme phenylalanine ammonia lyase. A phenylalanine ammonia lyase-like sequence acquired from a Taxus cuspidata cDNA library was expressed functionally in Escherichia coli and confirmed as the target aminomutase that is virtually identical to the recombinant enzyme and clone from Taxus chinensis, acquired recently by a reverse genetics approach (Bristol-Myers Squibb (August 14, 2003) U.S. Patent WO 03/066871 A2). The full-length cDNA has an open reading frame of 2094 base pairs and encodes a protein of 698 residues with a calculated molecular mass of 76,530 Da. The recombinant mutase has a pH optimum of 8.5, a k(cat) value of 0.015 s(-1), and a K-m of 45+/-8 muM for 2S-alpha-phenylalanine. The stereochemical mechanism of PAM involves the removal and interchange of the pro-3S hydrogen and the amino group, which rebonds at C-3 with retention of configuration. The recombinant enzyme appears to catalyze both the forward and reverse reactions with specificity for both 2S-alpha-phenylalanine and 3S- or 3R-beta-phenylalanine substrates, respectively, whereas the related phenylpropanoids 2S-aminocyclohexanepropanoic acid, 2R-alpha-phenylalanine, and 2S-alpha-tyrosine are not converted to their beta-isomers by the mutase.	Michigan State Univ, Dept Chem & Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Michigan State University; Michigan State University; Washington State University	Walker, KD (corresponding author), Michigan State Univ, Dept Chem, 320 Chem, E Lansing, MI 48824 USA.	walke284@msu.edu		Walker, Kevin/0000-0001-5208-6692	NCI NIH HHS [CA-55254] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055254, R37CA055254] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERHART DJ, 1983, J AM CHEM SOC, V105, P5461, DOI 10.1021/ja00354a046; APPERT C, 1994, EUR J BIOCHEM, V225, P491, DOI 10.1111/j.1432-1033.1994.00491.x; Campbell MM, 1996, PLANT PHYSIOL, V110, P3, DOI 10.1104/pp.110.1.3; Chen HP, 2001, J BIOL CHEM, V276, P44744, DOI 10.1074/jbc.M108365200; Christenson SD, 2003, BIOCHEMISTRY-US, V42, P12708, DOI 10.1021/bi035223r; Christenson SD, 2003, J AM CHEM SOC, V125, P6062, DOI 10.1021/ja034609m; COMMERCON A, 1992, TETRAHEDRON LETT, V33, P5185, DOI 10.1016/S0040-4039(00)79128-3; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; FREER I, 1981, J CHEM SOC CHEM COMM, P80, DOI 10.1039/c39810000080; Frey P. A., 1999, Chemistry and biochemistry of B12., P835; Frey PA, 2000, ARCH BIOCHEM BIOPHYS, V382, P6, DOI 10.1006/abbi.2000.2010; GEORG GI, 1994, EXPERT OPIN THER PAT, V4, P109; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; He LF, 2000, BIOCHEMISTRY-US, V39, P3972, DOI 10.1021/bi992518p; Hefner J, 1998, ARCH BIOCHEM BIOPHYS, V360, P62, DOI 10.1006/abbi.1998.0926; HOCKING MB, 1969, CAN J CHEMISTRY, V47, P4567, DOI 10.1139/v69-757; Holton RA., 1995, TAXOL SCI APPL, P97, DOI DOI 10.1002/CHIN.199552275; Jennewein S, 2004, P NATL ACAD SCI USA, V101, P9149, DOI 10.1073/pnas.0403009101; JORDAN PM, 1994, CURR OPIN STRUC BIOL, V4, P902, DOI 10.1016/0959-440X(94)90273-9; Ketchum REB, 2003, PHYTOCHEMISTRY, V62, P901, DOI 10.1016/S0031-9422(02)00711-2; KURYLOBOROWSKA Z, 1972, BIOCHIM BIOPHYS ACTA, V264, P1, DOI 10.1016/0304-4165(72)90110-9; Kyndt JA, 2002, FEBS LETT, V512, P240, DOI 10.1016/S0014-5793(02)02272-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER M, 1995, ANGEW CHEM INT EDIT, V34, P1464, DOI 10.1002/anie.199514641; MORLEY CGD, 1970, BIOCHEMISTRY-US, V9, P4890, DOI 10.1021/bi00827a010; PARNESS J, 1982, BIOCHEM BIOPH RES CO, V105, P1082, DOI 10.1016/0006-291X(82)91080-4; PARRY RJ, 1980, J AM CHEM SOC, V102, P836, DOI 10.1021/ja00522a065; POSTON JM, 1988, METHOD ENZYMOL, V166, P130; POSTON JM, 1980, J BIOL CHEM, V255, P67; POSTON JM, 1978, PHYTOCHEMISTRY, V17, P401, DOI 10.1016/S0031-9422(00)89324-3; PRABHAKARAN PC, 1988, J AM CHEM SOC, V110, P5785, DOI 10.1021/ja00225a033; RETEY J, 1978, HELV CHIM ACTA, V61, P2989, DOI 10.1002/hlca.19780610824; Rother R, 2001, EUR J BIOCHEM, V268, P6011; SCHUSTER B, 1995, P NATL ACAD SCI USA, V92, P8433, DOI 10.1073/pnas.92.18.8433; Schwede TF, 1999, BIOCHEMISTRY-US, V38, P5355, DOI 10.1021/bi982929q; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; STEELE CL, 2003, Patent No. 2003633941; Walker K, 2002, P NATL ACAD SCI USA, V99, P12715, DOI 10.1073/pnas.192463699; Walker K, 2002, P NATL ACAD SCI USA, V99, P9166, DOI 10.1073/pnas.082115799; WALKER K, 1997, THESIS U WASHINGTON; Walker KD, 1998, J AM CHEM SOC, V120, P5333, DOI 10.1021/ja980457x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU PC, 1992, GENE, V115, P19, DOI 10.1016/0378-1119(92)90535-W; WU PC, 1995, J BACTERIOL, V177, P854, DOI 10.1128/jb.177.3.854-857.1995; WU PC, 1992, J BACTERIOL, V174, P1647, DOI 10.1128/jb.174.5.1647-1655.1992; Zeng G, 1998, BIOTECHNIQUES, V25, P788	46	100	119	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53947	53954		10.1074/jbc.M411215200	http://dx.doi.org/10.1074/jbc.M411215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494399	hybrid			2022-12-27	WOS:000225793600008
J	Zamboni, DS; Campos, MA; Torrecilhas, ACT; Kiss, K; Samuel, JE; Golenbock, DT; Lauw, FN; Roy, CR; Almeida, IC; Gazzinelli, RT				Zamboni, DS; Campos, MA; Torrecilhas, ACT; Kiss, K; Samuel, JE; Golenbock, DT; Lauw, FN; Roy, CR; Almeida, IC; Gazzinelli, RT			Stimulation of Toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; TUMOR-NECROSIS-FACTOR; PHASE-II; Q-FEVER; LIPID-A; CELL ACTIVATION; HUMAN MONOCYTES; IN-VITRO; LIPOPOLYSACCHARIDE; LIPOPROTEINS	Innate and adaptive immune responses are initiated upon recognition of microbial molecules by Toll-like receptors (TLRs). We have investigated the importance of these receptors in the induction of pro-inflammatory cytokines and macrophage resistance to infection with Coxiella burnetii, an obligate intracellular bacterium and the etiological agent of Q fever. By using a Chinese hamster ovary/CD14 cell line expressing either functional TLR2 or TLR4, we determined that C. burnetii phase II activates TLR2 but not TLR4. Macrophages deficient for TLR2, but not TLR4, produced less tumor necrosis factor-alpha and interleukin-12 upon C. burnetii infection. Furthermore, it was found that TLR2 activation interfered with C. burnetii intracellular replication, as macrophages from TLR2-deficient mice were highly permissive for C. burnetii growth compared with macrophages from wild type mice or TLR4-deficient mice. Although LPS modifications distinguish virulent C. burnetii phase I bacteria from avirulent phase II organisms, electrospray ionization-mass spectrometry analysis showed that the lipid A moieties isolated from these two phase variants are identical. Purified lipid A derived from either phase I or phase II LPS failed to activate TLR2 and TLR4. Indeed, the lipid A molecules were able to interfere with TLR4 signaling in response to purified Escherichia coli LPS. These studies indicate that TLR2 is an important host determinant that mediates recognition of C. burnetii and a response that limits growth of this intracellular pathogen.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Oswaldo Cruz Fdn, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil; Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, BR-05508000 Sao Paulo, Brazil; Texas A&M Univ Syst, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, BR-31270901 Belo Horizonte, MG, Brazil	Yale University; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Texas A&M University System; Texas A&M University College Station; University of Massachusetts System; University of Massachusetts Worcester; Universidade Federal de Minas Gerais	Zamboni, DS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, Rm 354,295 Congress Ave, New Haven, CT 06536 USA.	dario.zamboni@yale.edu	Almeida, Igor C./AAF-9409-2019; Torrecilhas, Ana Claudia/AFR-7084-2022; Campos, Marco Antonio/AAU-6229-2021; Zamboni, Dario S/D-3024-2012; /W-6163-2019; Campos, Marco A/C-4000-2013	Almeida, Igor C./0000-0002-2443-8213; Torrecilhas, Ana Claudia/0000-0001-5724-2199; Campos, Marco Antonio/0000-0003-4683-0176; Zamboni, Dario S/0000-0002-7856-7512; Campos, Marco A/0000-0003-4683-0176; Roy, Craig/0000-0003-4490-440X; Gazzinelli, Ricardo/0000-0003-2427-7699	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037744, R01AI049309, R21AI037744, R29AI037744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37744, AI49309, AI448191] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; AMANO KI, 1984, J BACTERIOL, V160, P994, DOI 10.1128/JB.160.3.994-1002.1984; Baca Oswald G., 1994, Trends in Microbiology, V2, P476, DOI 10.1016/0966-842X(94)90651-3; Beron W, 2002, INFECT IMMUN, V70, P5816, DOI 10.1128/IAI.70.10.5816-5821.2002; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; CHAN S, 1994, ANAL BIOCHEM, V218, P63, DOI 10.1006/abio.1994.1141; Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004; Dellacasagrande J, 2000, INFECT IMMUN, V68, P5673, DOI 10.1128/IAI.68.10.5673-5678.2000; Dellacasagrande J, 1999, J IMMUNOL, V162, P2259; Delude RL, 1998, J IMMUNOL, V161, P3001; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; Girard R, 2003, J CELL SCI, V116, P293, DOI 10.1242/jcs.00212; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heinzen RA, 1999, TRENDS MICROBIOL, V7, P149, DOI 10.1016/S0966-842X(99)01475-4; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Honstettre A, 2004, J IMMUNOL, V172, P3695, DOI 10.4049/jimmunol.172.6.3695; Honstettre AL, 2003, J INFECT DIS, V187, P956, DOI 10.1086/368129; Hoover TA, 2002, INFECT IMMUN, V70, P6726, DOI 10.1128/IAI.70.12.6726-2733.2002; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Marrie TJ, 2004, CURR OPIN INFECT DIS, V17, P137, DOI 10.1097/00001432-200404000-00012; MAURIN M, 1992, INFECT IMMUN, V60, P5013, DOI 10.1128/IAI.60.12.5013-5016.1992; Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; Muroi M, 2003, INFECT IMMUN, V71, P3221, DOI 10.1128/IAI.71.6.3221-3226.2003; Norlander L, 2000, MICROBES INFECT, V2, P417, DOI 10.1016/S1286-4579(00)00325-7; Ogawa T, 2002, INT IMMUNOL, V14, P1325, DOI 10.1093/intimm/dxf097; Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAMUEL JE, 1985, INFECT IMMUN, V49, P775, DOI 10.1128/IAI.49.3.775-779.1985; SCHRAMEK S, 1982, INFECT IMMUN, V38, P53, DOI 10.1128/IAI.38.1.53-57.1982; Seshadri R, 2003, P NATL ACAD SCI USA, V100, P5455, DOI 10.1073/pnas.0931379100; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Toman R, 2003, ACTA VIROL, V47, P129; Tomasik P, 2004, C F P F C S, V5, P1; Tujulin E, 1999, VET IMMUNOL IMMUNOP, V68, P159, DOI 10.1016/S0165-2427(99)00023-9; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLIAMS JC, 1991, BIOL COXIELLA BURNET, P175; WILLIAMS JC, 1991, BIOL COXIELLA BURNET, P21; WOLLENWEBER HW, 1985, ARCH MICROBIOL, V142, P6, DOI 10.1007/BF00409228; Zamboni DS, 2004, INFECT IMMUN, V72, P2395, DOI 10.1128/IAI.72.4.2395-2399.2004; Zamboni DS, 2004, INFECT IMMUN, V72, P2075, DOI 10.1128/IAI.72.4.2075-2080.2004; Zamboni DS, 2002, MICROBES INFECT, V4, P591, DOI 10.1016/S1286-4579(02)01577-0; Zamboni DS, 2001, J MICROBIOL METH, V43, P223, DOI 10.1016/S0167-7012(00)00223-2; Zamboni DS, 2003, INFECT IMMUN, V71, P1225, DOI 10.1128/IAI.71.3.1225-1233.2003; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	56	74	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54405	54415		10.1074/jbc.M410340200	http://dx.doi.org/10.1074/jbc.M410340200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485838	hybrid			2022-12-27	WOS:000225793600063
J	Lee, I; Skinner, MA; Guo, HB; Sujan, A; Pierce, M				Lee, I; Skinner, MA; Guo, HB; Sujan, A; Pierce, M			Expression of the vacuolar H+-ATPase 16-kDa subunit results in the Triton X-100-insoluble aggregation of beta(1) integrin and reduction of its cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; GROWTH-FACTOR-BETA; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; PAPILLOMAVIRUS E5; EPITHELIAL-CELLS; N-GLYCOSYLATION; V-ATPASE	Vacuolar H+-ATPase functions as a vacuolar proton pump and is responsible for acidification of intracellular compartments such as the endoplasmic reticulum, Golgi, lysosomes, and endosomes. Previous reports have demonstrated that a 16-kDa subunit (16K) of vacuolar H+-ATPase via one of its transmembrane domains, TMD4, strongly associates with beta(1) integrin, affecting beta(1) integrin N-linked glycosylation and inhibiting its function as a matrix adhesion receptor. Because of this dramatic inhibition of beta(1) integrin-mediated HEK-293 cell motility by 16K expression, we investigated the mechanism by which 16 kDa was having this effect. Using HT1080 cells whose alpha(5)beta(1) integrin-mediated adhesion to fibronectin has been extensively studied, the expression of 16 kDa also resulted in reduced cell spreading on fibronectin-coated substrates. A pulse-chase study of beta(1) integrin biosynthesis indicated that 16K expression down-regulated the level of the 110-kDa biosynthetic form of beta(1) integrin (premature form) and, consequently, the level of the 130-kDa form of beta(1) integrin (mature form). Further experiments showed that the normal levels of association between the premature beta(1) integrin form and calnexin were significantly decreased by the expression of either 16 kDa or TMD4. Expression of 16 kDa also resulted in a Triton X-100-insoluble aggregation of an unusual 87-kDa form of beta(1) integrin. Interestingly, both Western blotting and a pulse-chase experiment showed co-immunoprecipitation of calnexin and 16K. These results indicate that 16K expression inhibits beta(1) integrin surface expression and spreading on matrix by a novel mechanism that results in reduced levels of functional beta(1) integrin.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Guelph	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	hawkeye@uga.edu		Lee, Intaek/0000-0003-1084-674X	NCI NIH HHS [R01CA64462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; ARAI H, 1988, J BIOL CHEM, V263, P8796; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; DELCOMMENNE M, 1995, J BIOL CHEM, V270, P26794, DOI 10.1074/jbc.270.45.26794; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FORGAC M, 1992, ANN NY ACAD SCI, V671, P273, DOI 10.1111/j.1749-6632.1992.tb43802.x; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Gottfried C, 2003, NEUROSCIENCE, V121, P553, DOI 10.1016/S0306-4522(03)00557-8; Guo HB, 2002, CANCER RES, V62, P6837; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HEINO J, 1989, J BIOL CHEM, V264, P380; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; LENTER M, 1994, J BIOL CHEM, V269, P12263; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Milner R, 2002, MOL CELL NEUROSCI, V20, P616, DOI 10.1006/mcne.2002.1151; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; Perlino E, 2000, AM J PATHOL, V157, P1727, DOI 10.1016/S0002-9440(10)64809-2; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Rubinstein E, 1997, EUR J IMMUNOL, V27, P1919, DOI 10.1002/eji.1830270815; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Vihinen P, 2000, MELANOMA RES, V10, P243, DOI 10.1097/00008390-200010030-00006; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	39	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53007	53014		10.1074/jbc.M405717200	http://dx.doi.org/10.1074/jbc.M405717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466867	hybrid			2022-12-27	WOS:000225680600026
J	Allende, ML; Sasaki, T; Kawai, H; Olivera, A; Mi, YD; van Echten-Deckert, G; Hajdu, R; Rosenbach, M; Keohane, CA; Mandala, S; Spiegel, S; Proia, RL				Allende, ML; Sasaki, T; Kawai, H; Olivera, A; Mi, YD; van Echten-Deckert, G; Hajdu, R; Rosenbach, M; Keohane, CA; Mandala, S; Spiegel, S; Proia, RL			Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FUNCTIONAL-CHARACTERIZATION; VASCULAR MATURATION; MOLECULAR-CLONING; IMMUNOSUPPRESSANT FTY720; 1-PHOSPHATE RECEPTOR; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; GROWTH; S1P(1)	Sphingosine-1-phosphate (S1P), a lipid signaling molecule that regulates many cellular functions, is synthesized from sphingosine and ATP by the action of sphingosine kinase. Two such kinases have been identified, SPHK1 and SPHK2. To begin to investigate the physiological functions of sphingosine kinase and S1P signaling, we generated mice deficient in SPHK1. Sphk1 null mice were viable, fertile, and without any obvious abnormalities. Total SPHK activity in most Sphk1-/- tissues was substantially, but not completely, reduced indicating the presence of multiple sphingosine kinases. S1P levels in most tissues from the Sphk1 -/- mice were not markedly decreased. In serum, however, there was a significant decrease in the S1P level. Although S1P signaling regulates lymphocyte trafficking, lymphocyte distribution was unaffected in lymphoid organs of Sphk1 -/- mice. The immunosuppressant FTY720 was phosphorylated and elicited lymphopenia in the Sphk1 null mice showing that SPHK1 is not required for the functional activation of this sphingosine analogue prodrug. The results with these Sphk1 null mice reveal that some key physiologic processes that require S1P receptor signaling, such as vascular development and proper lymphocyte distribution, can occur in the absence of SPHK1.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIAMSD, NIH, Bethesda, MD 20892 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA; Merck & Co Inc, Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Bonn; Virginia Commonwealth University; Merck & Company	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314,10 Ctr Dr,MSC 1821, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Chiba K, 1998, J IMMUNOL, V160, P5037; Clair T, 2003, CANCER RES, V63, P5446; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Herr DR, 2004, J BIOL CHEM, V279, P12685, DOI 10.1074/jbc.M310647200; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Kluk MJ, 2003, FEBS LETT, V533, P25, DOI 10.1016/S0014-5793(02)03742-0; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Krueger LA, 2002, CURRENT PROTOCOLS CY; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li GC, 2001, DEVELOPMENT, V128, P3473; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	47	371	382	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52487	52492		10.1074/jbc.M406512200	http://dx.doi.org/10.1074/jbc.M406512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459201	hybrid			2022-12-27	WOS:000225493400094
J	Raschle, M; Van Komen, S; Chi, P; Ellenberger, T; Sung, P				Raschle, M; Van Komen, S; Chi, P; Ellenberger, T; Sung, P			Multiple interactions with the Rad51 recombinase govern the homologous recombination function of Rad54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; YEAST RAD51; PROTEIN; CHROMATIN; REPAIR; FAMILY	In eukaryotes, Rad51 and Rad54 functionally cooperate to mediate homologous recombination and the repair of damaged chromosomes by recombination. Rad51, the eukaryotic counterpart of the bacterial RecA recombinase, forms filaments on single-stranded DNA that are capable of pairing the bound DNA with a homologous double-stranded donor to yield joint molecules. Rad54 enhances the homologous DNA pairing reaction, and this stimulatory effect involves a physical interaction with Rad51. Correspondingly, the ability of Rad54 to hydrolyze ATP and introduce superhelical tension into covalently closed circular plasmid DNA is stimulated by Rad51. By controlled proteolysis, we show that the amino-terminal region of yeast Rad54 is rather unstructured. Truncation mutations that delete the N-terminal 113 or 129 amino acid residues of Rad54 attenuate or ablate physical and functional interactions with Rad51 under physiological ionic strength, respectively. Surprisingly, under less stringent conditions, the Rad54 Delta129 protein can interact with Rad51 in affinity pull-down and functional assays. These results highlight the functional importance of the N-terminal Rad51 interaction domain of Rad54 and reveal that Rad54 contacts Rad51 through separable epitopes.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Yale University	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu; Patrick.Sung@yale.edu	Chi, Peter/AAI-1580-2019; Huang, Wenchi/F-3981-2010	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460	NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM52504, GM57814] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2004, J BIOL CHEM, V279, P27824, DOI 10.1074/jbc.M402648200; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2004, PHILOS T ROY SOC B, V359, P79, DOI 10.1098/rstb.2003.1367; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9	29	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51973	51980		10.1074/jbc.M410101200	http://dx.doi.org/10.1074/jbc.M410101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465810	hybrid			2022-12-27	WOS:000225493400033
J	Huang, YS; Li, T; Sane, DC; Li, LW				Huang, YS; Li, T; Sane, DC; Li, LW			IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; TOLL-LIKE RECEPTORS; NF-KAPPA-B; PHOSPHORYLATION; ACTIVATION; FAMILY; MEMBER; TRANSCRIPTION; TYROSINE; RESPOND	Being one of the key kinases downstream of Toll-like receptors, IRAK1 has initially thought to be responsible for NFkappaB activation. Yet IRAK1 knock-out mice still exhibit NFkappaB activation upon lipopolysaccharide (LPS) challenge, suggesting that IRAK1 may play other uncharacterized function. In this report, we show that IRAK1 is mainly involved in Stat3 activation and subsequent interleukin-10 (IL-10) gene expression. Splenocytes from IRAK1-deficient mice fail to exhibit LPS-induced Stat3 serine phosphorylation and IL-10 gene expression yet still maintain normal IL-1beta gene expression upon LPS challenge. Mechanistically, we observe that IRAK1 modification upon LPS challenge leads to its modification, nuclear distribution, and interaction with Stat3. IRAK1 can directly use Stat3 as a substrate and cause Stat3 serine 727 phosphorylation. In addition, nuclear IRAK1 binds directly with IL-10 promoter in vivo upon LPS treatment. Atherosclerosis patients usually have elevated serum IL-10 levels. We document here that IRAK1 is constitutively modified and localized in the nucleus in the peripheral blood mononuclear cells from atherosclerosis patients. These observations reveal the mechanism for the novel role of IRAK1 in the complex Toll-like receptor signaling network and indicate that IRAK1 regulation may be intimately linked with the pathogenesis and/or resolution of atherosclerosis.	Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA	Wake Forest University	Li, LW (corresponding author), Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA.	lwli@wfubmc.edu	LI, TAO/AAL-5932-2020	LI, TAO/0000-0001-7343-9688; Li, Liwu/0000-0001-8870-5299	NIAID NIH HHS [AI50089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050089] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2001, CRIT CARE MED, V29, pS16, DOI 10.1097/00003246-200107001-00008; Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bol GF, 2000, FEBS LETT, V477, P73, DOI 10.1016/S0014-5793(00)01759-2; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Feldmann K, 2002, EUR J IMMUNOL, V32, P1393, DOI 10.1002/1521-4141(200205)32:5<1393::AID-IMMU1393>3.0.CO;2-M; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li T, 2004, MOL IMMUNOL, V41, P85, DOI 10.1016/j.molimm.2004.03.009; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611, DOI 10.1161/01.ATV.19.3.611; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Mueller LP, 2001, SHOCK, V16, P430, DOI 10.1097/00024382-200116060-00005; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	34	97	106	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51697	51703		10.1074/jbc.M410369200	http://dx.doi.org/10.1074/jbc.M410369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15465816	hybrid			2022-12-27	WOS:000225355800126
J	Morelli, L; Llovera, E; Mathov, I; Lue, LF; Frangione, B; Ghiso, J; Castano, EM				Morelli, L; Llovera, E; Mathov, I; Lue, LF; Frangione, B; Ghiso, J; Castano, EM			Insulin-degrading enzyme in brain microvessels - Proteolysis of amyloid beta vasculotropic variants and reduced activity in cerebral amyloid angiopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; A-BETA; TRANSGENIC MICE; EXTRACELLULAR LEVELS; APOLIPOPROTEIN-E; CATHEPSIN-D; DUTCH-TYPE; PROTEIN; DEGRADATION; EXPRESSION	The accumulation of amyloid beta (Abeta) in the walls of small vessels in the cerebral cortex is associated with diseases characterized by dementia or stroke. These include Alzheimer's disease, Down syndrome, and sporadic and hereditary cerebral amyloid angiopathies (CAAs) related to mutations within the Abeta sequence. A higher tendency of Abeta to aggregate, a defective clearance to the systemic circulation, and insufficient proteolytic removal have been proposed as mechanisms that lead to Abeta accumulation in the brain. By using immunoprecipitation and mass spectrometry, we show that insulin-degrading enzyme (IDE) from isolated human brain microvessels was capable of degrading I-125-insulin and cleaved Abeta-(1-40) wild type and the genetic variants Abeta A21G (Flemish), Abeta E22Q (Dutch), and Abeta E22K (Italian) at the predicted sites. In microvessels from Alzheimer's disease cases with CAA, IDE protein levels showed a 44% increase as determined by sandwich enzyme-linked immunosorbent assay and Western blot. However, the activity of IDE upon radiolabeled insulin was significantly reduced in CAA as compared with age-matched controls. These results support the notion that a defect in Abeta proteolysis by IDE contributes to the accumulation of this peptide in the cortical microvasculature. Moreover they raise the possibility that IDE inhibition or inactivation is a pathogenic mechanism that may open novel strategies for the treatment of cerebrovascular Abeta amyloidoses.	Consejo Nacl Invest Cient & Tecn, Catedra Quim Biol Patol, Dept Quim Biol,Fac Farm & Bioquim, IQUIFIB, Buenos Aires, DF, Argentina; Sun Hlth Res Inst, Sun City, AZ 85351 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Banner Research; Banner Health; Banner Sun Health Research Institute; New York University; New York University	Castano, EM (corresponding author), Consejo Nacl Invest Cient & Tecn, Catedra Quim Biol Patol, Dept Quim Biol,Fac Farm & Bioquim, IQUIFIB, Junin 956,C1113AAD, Buenos Aires, DF, Argentina.	edcast@ffyb.uba.ar			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010491, R01AG005891, R01AG008721, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05891, AG 10491, AG 08721] Funding Source: Medline; NINDS NIH HHS [NS 38777] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; Bernstein HG, 1999, NEUROSCI LETT, V263, P161, DOI 10.1016/S0304-3940(99)00135-4; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Carpentier M, 2002, J NEUROPATH EXP NEUR, V61, P849, DOI 10.1093/jnen/61.10.849; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; Chalmers K, 2003, NEUROPATH APPL NEURO, V29, P231, DOI 10.1046/j.1365-2990.2003.00457.x; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Davis J, 2003, J BIOL CHEM, V278, P19054, DOI 10.1074/jbc.M301398200; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Deb S, 1996, J NEUROCHEM, V66, P1641; Deng A, 2001, AM J PATHOL, V159, P1061, DOI 10.1016/S0002-9440(10)61781-6; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DUCKWORTH WC, 1981, ENDOCRINOLOGY, V108, P1142, DOI 10.1210/endo-108-4-1142; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jung SS, 2003, J NEUROCHEM, V85, P1208, DOI 10.1046/j.1471-4159.2003.01745.x; KALARIA RN, 1993, AM J PATHOL, V143, P886; KAMINO K, 1992, AM J HUM GENET, V51, P998; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Kuo YM, 2000, MOL MED, V6, P430, DOI 10.1007/BF03401785; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LEMERE CA, 1995, AM J PATHOL, V146, P848; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lue LF, 1996, J NEUROPATH EXP NEUR, V55, P1083, DOI 10.1097/00005072-199655100-00008; Marr RA, 2003, J NEUROSCI, V23, P1992; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MCKENZIE RA, 1984, ARCH BIOCHEM BIOPHYS, V229, P604, DOI 10.1016/0003-9861(84)90193-0; Melchor JP, 2003, J NEUROSCI, V23, P8867; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Monro OR, 2002, NEUROBIOL AGING, V23, P405, DOI 10.1016/S0197-4580(01)00317-7; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Morelli L, 2002, NEUROCHEM RES, V27, P1387, DOI 10.1023/A:1021679817756; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; OGAWA W, 1992, J BIOL CHEM, V267, P1310; PARDRIDGE WM, 1987, J NEUROCHEM, V49, P1394, DOI 10.1111/j.1471-4159.1987.tb01005.x; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; Preston SD, 2003, NEUROPATH APPL NEURO, V29, P106, DOI 10.1046/j.1365-2990.2003.00424.x; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Roher AE, 2003, MOL MED, V9, P112, DOI 10.1007/BF03402043; Saric T, 2003, MOL CELL ENDOCRINOL, V204, P11, DOI 10.1016/S0303-7207(03)00154-0; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Thal DR, 2002, J NEUROPATH EXP NEUR, V61, P282, DOI 10.1093/jnen/61.3.282; Tucker HM, 2000, J NEUROSCI, V20, P3937; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; YONG WH, 1992, ARCH NEUROL-CHICAGO, V49, P51, DOI 10.1001/archneur.1992.00530250055016	66	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56004	56013		10.1074/jbc.M407283200	http://dx.doi.org/10.1074/jbc.M407283200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489232	hybrid			2022-12-27	WOS:000225960800124
J	Regaya, I; Beeton, C; Ferrat, G; Andreotti, N; Darbon, H; De Waard, M; Sabatier, JM				Regaya, I; Beeton, C; Ferrat, G; Andreotti, N; Darbon, H; De Waard, M; Sabatier, JM			Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; DISULFIDE BRIDGE; CHEMICAL-SYNTHESIS; LEIUROTOXIN-I; HIGH-AFFINITY; MAUROTOXIN; MAURUS; SPECTROSCOPY; INHIBITOR; PEPTIDES	Maurotoxin (MTX) and HsTx1 are two scorpion toxins belonging to the alpha-KTx6 structural family. These 34-residue toxins, cross-linked by four disulfide bridges, share 59% sequence identity and fold along the classical alpha/beta scaffold. Despite these structural similarities, they fully differ in their pharmacological profiles. MTX is highly active on small (SK) and intermediate (IK) conductance Ca2+-activated (K+) channels and on voltage-gated Kv1.2 channel, whereas HsTx1 potently blocks voltage-gated Kv1.1 and Kv1.3 channels only. Here, we designed and chemically produced MTX-HsTx1, a chimera of both toxins that contains the N-terminal helical region of MTX (sequence 1-16) and the C-terminal beta-sheet region of HsTx1 (sequence 17-34). The three-dimensional structure of the peptide in solution was solved by H-1 NMR. MTX-HsTx1 displays the activity of MTX on SK channel, whereas it exhibits the pharmacological profile of HsTx1 on Kv1.1, Kv1.2, Kv1.3, and IK channels. These data demonstrate that the helical region of MTX exerts a key role in SK channel recognition, whereas the beta-sheet region of HsTx1 is crucial for activity on all other channel types tested.	CNRS Format Rech Expt 2738, Biochim Lab, F-13916 Marseille 20, France; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; CNRS, Unite Propre Rech 9039, F-13402 Marseille, France; CEA, INSERM,U607, Inst Federatif Rech 27, Dept Rech Dynam Cellulaire Canaux Calc Fonct & Pa, F-38054 Grenoble 09, France; Lab Cellpep SA, F-13015 Marseille, France	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Irvine; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sabatier, JM (corresponding author), CNRS Format Rech Expt 2738, Biochim Lab, Blvd Pierre Dramard, F-13916 Marseille 20, France.	sabatier.jm@jean-roche.univ-mrs.fr	De Waard, Michel/G-7406-2014; Regaya, Imed/L-7899-2018	De Waard, Michel/0000-0002-2782-9615; Regaya, Imed/0000-0001-8671-5186; SABATIER, Jean-Marc/0000-0002-9040-5647; Beeton, Christine/0000-0002-2500-5874				Avdonin V, 2000, BIOPHYS J, V79, P776, DOI 10.1016/S0006-3495(00)76335-1; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Blanc E, 1997, PROTEINS, V29, P321, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;321::AID-PROT6&gt;3.0.CO;2-D; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier E, 2000, J PEPT RES, V55, P419, DOI 10.1034/j.1399-3011.2000.00715.x; Castle NA, 2003, MOL PHARMACOL, V63, P409, DOI 10.1124/mol.63.2.409; Darbon H, 1999, PERSPECT DRUG DISCOV, V16, P41; Fajloun Z, 2000, J BIOL CHEM, V275, P39394, DOI 10.1074/jbc.M006810200; Fajloun Z, 2000, J BIOL CHEM, V275, P13605, DOI 10.1074/jbc.275.18.13605; GRAY EG, 1962, J ANAT, V96, P79; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lebrun B, 1997, BIOCHEM J, V328, P321, DOI 10.1042/bj3280321; M'Barek S, 2003, J BIOL CHEM, V278, P31095, DOI 10.1074/jbc.M304271200; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Mouhat S, 2004, BIOCHEM J, V378, P717, DOI 10.1042/BJ20031860; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Olamendi-Portugal T, 1998, TOXICON, V36, P759, DOI 10.1016/S0041-0101(97)00163-3; OlamendiPortugal T, 1996, BIOCHEM J, V315, P977, DOI 10.1042/bj3150977; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Savarin P, 1999, PROTEIN SCI, V8, P2672; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; [No title captured]	35	48	51	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55690	55696		10.1074/jbc.M410055200	http://dx.doi.org/10.1074/jbc.M410055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498765	hybrid			2022-12-27	WOS:000225960800089
J	Rubi, B; del Arco, A; Bartley, C; Satrustegui, J; Maechler, P				Rubi, B; del Arco, A; Bartley, C; Satrustegui, J; Maechler, P			The malate-aspartate NADH shuttle member Aralar1 determines glucose metabolic fate, mitochondrial activity, and insulin secretion in beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE DEHYDROGENASE; PYRIDINE NUCLEOTIDES; PANCREATIC-ISLETS; RAT-LIVER; EXOCYTOSIS; GLUTAMATE; MODEL; GLYCOLYSIS; OXIDATION; PYRUVATE	The NADH shuttle system, which transports reducing equivalents from the cytosol to the mitochondria, is essential for the coupling of glucose metabolism to insulin secretion in pancreatic beta cells. Aralar1 and citrin are two isoforms of the mitochondrial aspartate/glutamate carrier, one key constituent of the malate-aspartate NADH shuttle. Here, the effects of Aralar1 overexpression in INS-1E beta cells and isolated rat islets were investigated for the first time. We prepared a recombinant adenovirus encoding for human Aralar1 (AdCA-Aralar1), tagged with the small FLAG epitope. Transduction of INS-1E cells and isolated rat islets with AdCA-Aralar1 increased aralar1 protein levels and immunostaining revealed mitochondrial localization. Compared with control INS-1E cells, overexpression of Aralar1 potentiated metabolism secretion coupling stimulated by 15 mM glucose. In particular, there was an increase of NAD(P)H generation, of mitochondrial membrane hyperpolarization, ATP levels, glucose oxidation, and insulin secretion (+45%, p < 0.01). Remarkably, this was accompanied by reduced lactate production. Rat islets overexpressing Aralar1 secreted more insulin at 16.7 mM glucose (+65%, p < 0.05) compared with controls. These results show that aspartate-glutamate carrier capacity limits glucose-stimulated insulin secretion and that Aralar1 overexpression enhances mitochondrial metabolism.	Univ Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain; Fac Ciencias Medio Ambiente, Toledo 45071, Spain	University of Geneva; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Maechler, P (corresponding author), Univ Med Ctr, Dept Cell Physiol & Metab, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Pierre.Maechler@medecine.unige.ch	del Arco, Araceli/R-5653-2019; Satrustegui, Jorgina/R-6732-2019	Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667; Maechler, Pierre/0000-0002-2005-1433; del Arco, Araceli/0000-0002-6839-542X				Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERRY MN, 1994, EUR J BIOCHEM, V225, P557, DOI 10.1111/j.1432-1033.1994.00557.x; Brennan L, 2002, DIABETES, V51, P1714, DOI 10.2337/diabetes.51.6.1714; Broca C, 2003, FEBS LETT, V545, P167, DOI 10.1016/S0014-5793(03)00526-X; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; Collins CL, 1998, BIOTECHNIQUES, V24, P803, DOI 10.2144/98245st04; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 2002, EUR J BIOCHEM, V269, P3313, DOI 10.1046/j.1432-1033.2002.03018.x; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Eto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE262, DOI 10.1152/ajpendo.00542.2002; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Everse J, 1975, Methods Enzymol, V41, P41; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; HANSFORD RG, 1972, BIOCHEM J, V127, P271, DOI 10.1042/bj1270271; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Ishihara H, 1996, DIABETES, V45, P1238, DOI 10.2337/diabetes.45.9.1238; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; MacDonald MJ, 2002, METABOLISM, V51, P318, DOI 10.1053/meta.2002.29960; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacDonald MJ, 2000, ARCH BIOCHEM BIOPHYS, V384, P143, DOI 10.1006/abbi.2000.2107; MACDONALD MJ, 2000, SCIENCE, V287, P931; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 2002, CELL MOL LIFE SCI, V59, P1803, DOI 10.1007/PL00012507; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Noda M, 2002, J BIOL CHEM, V277, P41817, DOI 10.1074/jbc.M207690200; Novelli M, 2001, MOL CELL ENDOCRINOL, V175, P57, DOI 10.1016/S0303-7207(01)00400-2; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Song DK, 2000, METABOLISM, V49, P92, DOI 10.1016/S0026-0495(00)90838-2; SUGANO T, 1990, J BIOL CHEM, V265, P21549; Tan C, 2002, DIABETES, V51, P2989, DOI 10.2337/diabetes.51.10.2989; Varadi A, 2002, J CELL SCI, V115, P4177, DOI 10.1242/jcs.00083; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; WATKINS D, 1971, ENDOCRINOLOGY, V88, P1380, DOI 10.1210/endo-88-6-1380; WATKINS D, 1968, SCIENCE, V162, P283, DOI 10.1126/science.162.3850.283; WATKINS DT, 1972, ENDOCRINOLOGY, V90, P272, DOI 10.1210/endo-90-1-272; WATKINS DT, 1977, ENDOCRINOLOGY, V100, P1461, DOI 10.1210/endo-100-5-1461; Yu W, 2000, DIABETES, V49, P945, DOI 10.2337/diabetes.49.6.945; ZAMMIT VA, 1976, BIOCHEM J, V154, P677, DOI 10.1042/bj1540677	52	89	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55659	55666		10.1074/jbc.M409303200	http://dx.doi.org/10.1074/jbc.M409303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494407	hybrid			2022-12-27	WOS:000225960800085
J	Tomlinson, MG; Heath, VL; Turck, CW; Watson, SP; Weiss, A				Tomlinson, MG; Heath, VL; Turck, CW; Watson, SP; Weiss, A			SHIP family inositol phosphatases interact with and negatively regulate the tec tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; ADAPTER PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; LIPID PHOSPHATASE; SELF-ASSOCIATION; BINDING PROTEIN; SH3 DOMAIN; T-CELLS	The Tec family of protein-tyrosine kinases (PTKs), that includes Tec, Itk, Btk, Bmx, and Txk, plays an essential role in phospholipase Cgamma (PLCgamma) activation following antigen receptor stimulation. This function requires activation of phosphatidylinositol 3-kinase (PI 3-kinase), which promotes Tec membrane localization through phosphatidylinositol 3,4,5-trisphosphate (PtdIns 3,4,5-P-3) generation. The mechanism of negative regulation of Tec family PTKs is poorly understood. In this study, we show that the inositol 5' phosphatases SHIP1 and SHIP2 interact preferentially with Tec, compared with other Tec family members. Four lines of evidence suggest that SHIP phosphatases are negative regulators of Tec. First, SHIP1 and SHIP2 are potent inhibitors of Tec activity. Second, inactivation of the Tec SH3 domain, which is necessary and sufficient for SHIP binding, generates a hyperactive form of Tec. Third, SHIP1 inhibits Tec membrane localization. Finally, constitutively targeting Tec to the membrane relieves SHIP1-mediated inhibition. These data suggest that SHIP phosphatases can interact with and functionally inactivate Tec by de-phosphorylation of local PtdIns 3,4,5-P-3 and inhibition of Tec membrane localization.	Univ Birmingham, Inst Biomed Res, Div Med Sci, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of Birmingham; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tomlinson, MG (corresponding author), Univ Birmingham, Inst Biomed Res, Div Med Sci, Ctr Cardiovasc Sci, Wolfson Dr, Birmingham B15 2TT, W Midlands, England.	m.g.tomlinson@bham.ac.uk	Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Tomlinson, Michael/0000-0002-1189-0091	NCI NIH HHS [CA 72531] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Aoki N, 2004, J BIOL CHEM, V279, P10765, DOI 10.1074/jbc.M310401200; Atkinson BT, 2003, BLOOD, V102, P3592, DOI 10.1182/blood-2003-04-1142; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Damen JE, 2001, BLOOD, V97, P1343, DOI 10.1182/blood.V97.5.1343; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Garcon F, 2004, EUR J IMMUNOL, V34, P1972, DOI 10.1002/eji.200324777; Garcon F, 2004, J IMMUNOL, V173, P770, DOI 10.4049/jimmunol.173.2.770; Gerard A, 2004, ONCOGENE, V23, P1594, DOI 10.1038/sj.onc.1207283; Heath VL, 2004, EUKARYOT CELL, V3, P695, DOI 10.1128/EC.3.3.695-704.2004; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; James P, 1996, GENETICS, V144, P1425; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Labno CM, 2003, CURR BIOL, V13, P1619, DOI 10.1016/j.cub.2003.08.005; Laederach A, 2003, J MOL BIOL, V329, P1011, DOI 10.1016/S0022-2836(03)00531-X; Laederach A, 2002, PROTEIN SCI, V11, P36, DOI 10.1110/ps.ps.26702; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu WM, 2001, NAT IMMUNOL, V2, P939, DOI 10.1038/ni1001-939; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; March ME, 2002, SEMIN IMMUNOL, V14, P37, DOI 10.1006/smim.2001.0340; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Nore BF, 2003, BBA-PROTEINS PROTEOM, V1645, P123, DOI 10.1016/S1570-9639(02)00524-1; Okada H, 1998, J IMMUNOL, V161, P5129; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Pursglove SE, 2002, J BIOL CHEM, V277, P755, DOI 10.1074/jbc.M108318200; Reth M, 2004, NAT REV IMMUNOL, V4, P269, DOI 10.1038/nri1335; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; SWEENEY MJ, 2002, BIOMOLEC TECHN, V13, P43; Takesono A, 2002, J CELL SCI, V115, P3039; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; Yang WC, 2001, J IMMUNOL, V166, P387, DOI 10.4049/jimmunol.166.1.387; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; ZARRINPAR A, 2003, SCI STKE	63	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55089	55096		10.1074/jbc.M408141200	http://dx.doi.org/10.1074/jbc.M408141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492005	hybrid			2022-12-27	WOS:000225960800014
J	Katakami, N; Kaneto, H; Hao, H; Umayahara, Y; Fujitani, Y; Sakamoto, K; Gorogawa, S; Yasuda, T; Kawamori, D; Kajimoto, Y; Matsuhisa, M; Yutani, C; Hori, M; Yamasaki, Y				Katakami, N; Kaneto, H; Hao, H; Umayahara, Y; Fujitani, Y; Sakamoto, K; Gorogawa, S; Yasuda, T; Kawamori, D; Kajimoto, Y; Matsuhisa, M; Yutani, C; Hori, M; Yamasaki, Y			Role of pim-1 in smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; C-MYC; PROTOONCOGENE EXPRESSION; ANTISENSE OLIGODEOXYNUCLEOTIDES; CYCLE PROGRESSION; MESSENGER-RNA; IN-VITRO; ANGIOPLASTY; GENES; ATHEROSCLEROSIS	The proliferation of vascular smooth muscle cells (VSMCs) and alterations of their phenotype are implicated in the pathogenesis of atherosclerosis. Arterial wall injury induces the expression of proto-oncogenes, leading to the proliferation of VSMCs. In particular, c-Myc and c-Myb play a central role in cell cycle progression and are essential for VSMC replication. The protooncogene Pim-1 cooperates with c-Myc and enhances the transcriptional activity of c-Myb in hematopoietic cells, suggesting that Pim-1 is involved in cell cycle regulation. The aim of this study was to examine the possible involvement of Pim-1 in VSMC proliferation. Pim-1 was substantially induced in neointimal VSMCs of balloon-injured rat carotid arteries, and in vivo infection with a dominant negative Pim-1-expressing adenovirus (Ad-DN-Pim-1) markedly suppressed neointima formation and cell cycle progression in the balloon-injured arteries. In cultured VSMCs, treatment with serum or H2O2 induced Pim-1 expression, and H2O2- or serum-stimulated cell cycle progression and DNA synthesis were almost completely inhibited by DN-Pim-1 overexpression. Furthermore, we performed immunohistochemical staining for Pim-1 in human thoracic aortas and coronary arteries obtained from six individuals at autopsy and found that Pim-1-positive cells are observed predominantly in the thickened intima of the aortas and coronary arteries. To the best of our knowledge, this is the first report showing Pim-1 expression in rodent and human arterial walls. To summarize, Pim-1 expression was observed in the neointima of balloon-injured rat carotid arteries and in human thoracic aortas and coronary arteries showing intimal thickening, and the specific inhibition of Pim-1 function markedly suppressed neointima formation after balloon injury and the proliferation of cultured VSMCs, suggesting that Pim-1 plays a role in VSMC proliferation.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Natl Cardiovasc Ctr, Dept Pathol, Osaka 5650873, Japan	Osaka University; National Cerebral & Cardiovascular Center - Japan	Yamasaki, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamasaki@medone.med.osaka-u.ac.jp	Katakami, Naoto/AAM-8822-2021	Katakami, Naoto/0000-0001-9020-8320				Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; BAUTERS C, 1992, EUR HEART J, V13, P556, DOI 10.1093/oxfordjournals.eurheartj.a060213; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; EBBECKE M, 1992, BASIC RES CARDIOL, V87, P585, DOI 10.1007/BF00788668; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; LILLY M, 1992, ONCOGENE, V7, P727; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MIANO JM, 1990, AM J PATHOL, V137, P761; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; Rahman Z, 2001, IMMUNOL LETT, V75, P199, DOI 10.1016/S0165-2478(00)00322-9; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827	30	59	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54742	54749		10.1074/jbc.M409140200	http://dx.doi.org/10.1074/jbc.M409140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471855	hybrid			2022-12-27	WOS:000225793600102
J	Kawamura, K; Takano, K; Suetsugu, S; Kurisu, S; Yamazaki, D; Miki, H; Takenawa, T; Endo, T				Kawamura, K; Takano, K; Suetsugu, S; Kurisu, S; Yamazaki, D; Miki, H; Takenawa, T; Endo, T			N-WASP and WAVE2 acting downstream of phosphatidylinositol 3-kinase are required for myogenic cell migration induced by hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SKELETAL-MUSCLE; ARP2/3 COMPLEX; DEPOLYMERIZING PROTEIN; EPITHELIAL-CELLS; HOMOLOGY DOMAINS; SATELLITE CELLS; NEURAL CREST; STEM-CELLS; ACTIVATION	During skeletal muscle regeneration caused by injury, muscle satellite cells proliferate and migrate toward the site of muscle injury. This migration is mainly induced by hepatocyte growth factor (HGF) secreted by intact myofibers and also released from injured muscle. However, the intracellular machinery for the satellite cell migration has not been elucidated. To examine the mechanisms of satellite cell migration, we utilized satellite cell-derived mouse C2C12 skeletal muscle cells. HGF induced reorganization of actin cytoskeleton to form lamellipodia in C2C12 myoblasts. HGF treatment facilitated both nondirectional migration of the myoblasts in phagokinetic track assay and directional chemotactic migration toward HGF in a three-dimensional migration chamber assay. Endogenous N-WASP and WAVE2 were concentrated in the lamellipodia at the leading edge of the migrating cells. Moreover, exogenous expression of wild-type N-WASP or WAVE2 promoted lamellipodial formation and migration. By contrast, expression of the dominant-negative mutant of N-WASP or WAVE2 and knockdown of N-WASP or WAVE2 expression by the RNA interference prevented the HGF-induced lamellipodial formation and migration. When the cells were treated with LY294002, an inhibitor of phosphatidylinositol 3-kinase, the HGF-induced lamellipodial formation and migration were abrogated. These results imply that both N-WASP and WAVE2, which are activated downstream of phosphatidylinositol 3-kinase, are required for the migration through the lamellipodial formation of C2C12 cells induced by HGF.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Chiba Univ, Grad Sch Sci & Technol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Inst Med Sci, Div Canc Genom, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan	Chiba University; Chiba University; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.	t.endo@faculty.chiba-u.jp	Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020; Kurisu, Shusaku/AAB-1799-2022; Suetsugu, Shiro/B-3300-2010	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Kurisu, Shusaku/0000-0002-4876-4419				Abe T, 2003, J CELL SCI, V116, P155, DOI 10.1242/jcs.00208; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Birchmeier C, 2000, CURR OPIN CELL BIOL, V12, P725, DOI 10.1016/S0955-0674(00)00159-9; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; BISCHOFF R, 1994, MYOGENESIS, V2, P97; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Dahl JP, 2003, J NEUROSCI, V23, P3343; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Gammill LS, 2003, NAT REV NEUROSCI, V4, P795, DOI 10.1038/nrn1219; Grounds MD, 2002, J HISTOCHEM CYTOCHEM, V50, P589, DOI 10.1177/002215540205000501; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lorenz M, 2004, CURR BIOL, V14, P697, DOI 10.1016/j.cub.2004.04.008; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Miller KJ, 2000, AM J PHYSIOL-CELL PH, V278, pC174, DOI 10.1152/ajpcell.2000.278.1.C174; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Sheehan SM, 2000, MUSCLE NERVE, V23, P239, DOI 10.1002/(SICI)1097-4598(200002)23:2<239::AID-MUS15>3.0.CO;2-U; Sheehan SM, 1999, J CELL PHYSIOL, V181, P499, DOI 10.1002/(SICI)1097-4652(199912)181:3<499::AID-JCP14>3.0.CO;2-1; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Takenawa T, 2001, J CELL SCI, V114, P1801; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Villena J, 2004, J CELL PHYSIOL, V198, P169, DOI 10.1002/jcp.10422; Ward ME, 2004, P NATL ACAD SCI USA, V101, P970, DOI 10.1073/pnas.0306258101; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamaguchi H, 2002, CANCER RES, V62, P2503; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	68	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54862	54871		10.1074/jbc.M408057200	http://dx.doi.org/10.1074/jbc.M408057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496413	hybrid			2022-12-27	WOS:000225793600115
J	Song, ES; Juliano, MA; Juliano, L; Fried, MG; Wagner, SL; Hersh, LB				Song, ES; Juliano, MA; Juliano, L; Fried, MG; Wagner, SL; Hersh, LB			ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IN-VIVO; CHROMOSOME-10; CATABOLISM; INSULYSIN; LINKAGE; LOCUS	It has been reported previously that ATP inhibits the insulysin reaction (Camberos, M. C., Perez, A. A., Udrisar, D. P., Wanderley, M. I., and Cresto, J. C. ( 2001) Exp. Biol. Med. 226, 334-341). We report here that with 2-aminobenzoyl-GGFLRKHGQ-ethylenediamine-2,4-dinitrophenyl as substrate, ATP and other nucleotides increase the rate >20-fold in Tris buffer. There is no specificity with respect to the nucleotide; however, ATP is more effective than ADP, which is more effective than AMP. Triphosphate itself was as effective as ATP, indicating it is this moiety that is responsible for activation. The binding of triphosphate was shown to be at a site distinct from the active site, thus acting as a noncompetitive activator. With the physiological substrates insulin and amyloid beta peptide, nucleotides and triphosphate were without effect. However, with small physiological peptides such as bradykinin and dynorphin B-9, ATP and triphosphate increased the rate of hydrolysis similar to10-fold. Triphosphate and ATP shifted the oligomeric state of the enzyme from primarily dimer-tetramers to a monomer. These data suggest the presence of an allosteric regulatory site on insulysin that may shift its specificity toward small peptide substrates.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Escola Paulista Med, Dept Biophys, BR-04023900 Sao Paulo, Brazil; Neurogenet Inc, La Jolla, CA 92037 USA	University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	lhersh@uky.edu	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER; NIA NIH HHS [AG19323] Funding Source: Medline; NIDA NIH HHS [DA02243] Funding Source: Medline; NIDDK NIH HHS [DK54289] Funding Source: Medline; NIGMS NIH HHS [R01 GM070662, R01 GM070662-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Camberos MC, 2001, EXP BIOL MED, V226, P334, DOI 10.1177/153537020122600411; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; HASHIMOTO N, 1987, J BIOL CHEM, V262, P15026; Hersh LB, 2003, CURR PHARM DESIGN, V9, P449, DOI 10.2174/1381612033391676; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; MILLAY RH, 1978, J BIOL CHEM, V253, P1371; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mukherjee A, 2002, J ALZHEIMERS DIS, V4, P341, DOI 10.3233/JAD-2002-4501; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200	15	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54216	54220		10.1074/jbc.M411177200	http://dx.doi.org/10.1074/jbc.M411177200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494400	hybrid			2022-12-27	WOS:000225793600041
J	Okumura, F; Hatakeyama, S; Matsumoto, M; Kamura, T; Nakayama, KI				Okumura, F; Hatakeyama, S; Matsumoto, M; Kamura, T; Nakayama, KI			Functional regulation of FEZ1 by the U-box-type ubiquitin ligase E4B contributes to neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; MULTIUBIQUITIN CHAIN; NEURITE OUTGROWTH; AXONAL OUTGROWTH; PC12H CELLS; PROTEIN; CHAPERONE; DEGRADATION; PATHWAY; FAMILY	E4B ( also known as UFD2a) is a mammalian homolog of Saccharomyces cerevisiae Ufd2, which was originally described as a ubiquitin chain assembly factor (E4). E4B is a U-box-type ubiquitin-protein isopeptide ligase (E3) and likely functions as either an E3 or an E4. With a yeast two-hybrid screen, we have now identified FEZ1 (fasciculation and elongation protein zeta 1) as a protein that interacts with E4B. FEZ1 is implicated in neuritogenesis when phosphorylated by protein kinase Czeta (PKCzeta). Interaction between E4B and FEZ1 in mammalian cells was enhanced by coexpression of constitutively active PKCzeta. E4B mediated the polyubiquitylation of FEZ1 but did not affect its intracellular stability, suggesting that such modification of FEZ1 is not a signal for its proteolysis. Polyubiquitylation of FEZ1 by E4B required Lys(27) of ubiquitin. Expression of a dominant-negative mutant of E4B in rat pheochromocytoma PC12 cells resulted in inhibition of neurite extension induced either by nerve growth factor or by coexpression of FEZ1 and constitutively active PKCzeta. These findings indicate that E4B serves as a ubiquitin ligase for FEZ1 and thereby regulates its function but not its degradation.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979; Matsumoto, Masaki/0000-0002-6987-0288				Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Espinet C, 2000, J NEUROSCI METH, V100, P63, DOI 10.1016/S0165-0270(00)00233-8; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gindhart JG, 2003, MOL BIOL CELL, V14, P3356, DOI 10.1091/mbc.E02-12-0800; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ohtani-Kaneko R, 1998, NEUROCHEM RES, V23, P1435, DOI 10.1023/A:1020763009488; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; TAKADA K, 1994, NEUROCHEM RES, V19, P391, DOI 10.1007/BF00967315; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	47	43	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53533	53543		10.1074/jbc.M402916200	http://dx.doi.org/10.1074/jbc.M402916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466860	hybrid			2022-12-27	WOS:000225680600089
J	Davare, MA; Saneyoshi, T; Guire, ES; Nygaard, SC; Soderling, TR				Davare, MA; Saneyoshi, T; Guire, ES; Nygaard, SC; Soderling, TR			Inhibition of calcium/calmodulin-dependent protein kinase kinase by protein 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; 14-3-3 BINDING; T-CELLS; ACTIVATION; CAMP; BAD; SURVIVAL	Intracellular calcium concentrations regulate diverse cellular events including cytoskeletal dynamics, gene transcription, and synaptic plasticity. The calcium signal is transduced in part by the calcium/calmodulin-dependent protein kinase (CaMK) cascade that is comprised of CaMK kinase (CaMKK) and its primary downstream substrates, CaMKI and CaMKIV. The CaMK cascade also participates in cross-talk with other signaling pathways: CaMKK/CaMKI can activate the mitogen-activated protein kinase pathway and cAMP-dependent protein kinase (PKA) can directly phosphorylate two inhibitory sites (Thr(108) and Ser(458)) in CaMKK. Here we report an additional PKA-dependent regulation of CaMKK through its interaction with protein 14-3-3. CaMKK and 14-3-3 co-immunoprecipitated from co-transfected heterologous cells as well as from rat brain homogenate, and site-directed mutagenesis studies identified phospho-Ser74 in CaMKK as the primary 14-3-3 binding site. In cultured rat hippocampal neurons and acute hippocampal slices this interaction was robustly stimulated by activation of PKA through forskolin treatment and was blocked by inhibition of PKA. Interaction of 14-3-3 with CaMKK had two regulatory consequences in vitro. It directly inhibited CaMKK activity, and it also blocked dephosphorylation of Thr108, an inhibitory PKA phosphorylation site. In human embryonic kidney 293 cells transfected with CaMKK and stimulated with forskolin, co-transfection with 14-3-3 prevented dephosphorylation of Thr108 to the same extent as did inhibition of protein phosphatases with okadaic acid. We conclude that binding of 14-3-3 to CaMKK stabilizes its inhibition by PKA-mediated phosphorylation, which may have important consequences in the regulation of CaMKI, CaMKIV, protein kinase B, and ERK signaling pathways.	Oregon Hlth Sci Univ, Vollum Inst L474, Portland, OR 97239 USA	Oregon Health & Science University	Soderling, TR (corresponding author), Oregon Hlth Sci Univ, Vollum Inst L474, 3181 SW Same Jackson Pk Rd, Portland, OR 97239 USA.	soderlit@ohsu.edu	Saneyoshi, Takeo/AAF-5170-2019	Davare, Monika/0000-0003-1802-7597	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK007680] Funding Source: Medline; NIGMS NIH HHS [R01 GM41292] Funding Source: Medline; NINDS NIH HHS [NS27037] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Baxter HC, 2002, NEUROSCIENCE, V109, P5, DOI 10.1016/S0306-4522(01)00492-4; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Okuno S, 2001, J BIOCHEM, V130, P503, DOI 10.1093/oxfordjournals.jbchem.a003013; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; Qin H, 2003, J BIOL CHEM, V278, P48570, DOI 10.1074/jbc.M308781200; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Takahashi Y, 2003, NEUROCHEM RES, V28, P1265, DOI 10.1023/A:1024296932670; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WATANABE M, 1993, MOL BRAIN RES, V17, P135, DOI 10.1016/0169-328X(93)90082-Z; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	56	50	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52191	52199		10.1074/jbc.M409873200	http://dx.doi.org/10.1074/jbc.M409873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469938	hybrid			2022-12-27	WOS:000225493400059
J	Jackers, P; Szalai, G; Moussa, O; Watson, DK				Jackers, P; Szalai, G; Moussa, O; Watson, DK			Ets-dependent regulation of target gene expression during megakaryopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; GLYCOPROTEIN IX PROMOTER; MURINE LEUKEMIA-VIRUS; RNA-POLYMERASE-II; CELL-LINE CMK; FLI-1 GENE; HISTONE ACETYLATION; BINDING PROTEIN; FAMILY; DIFFERENTIATION	Megakaryopoiesis is the process by which hematopoietic stem cells in the bone marrow differentiate into mature megakaryocytes. The expression of megakaryocytic genes during megakaryopoiesis is controlled by specific transcription factors. Fli-1 and GATA-1 transcription factors are required for development of megakaryocytes and promoter analysis has defined in vitro functional binding sites for these factors in several megakaryocytic genes, including GPIIb, GPIX, and C-MPL. Herein, we utilize chromatin immunoprecipitation to examine the presence of Ets-1, Fli-1, and GATA-1 on these promoters in vivo. Fli-1 and Ets-1 occupy the promoters of GPIIb, GPIX, and C-MPL genes in both Meg-01 and CMK11-5 cells. Whereas GPIIb is expressed in both Meg-01 and CMK11-5 cells, GPIX and C-MPL are only expressed in the more differentiated CMK11-5 cells. Thus, in vivo occupancy by an Ets factor is not sufficient to promote transcription of some megakaryocytic genes. GATA-1 and Fli-1 are both expressed in CMK11-5 cells and co-occupy the GPIX and C-MPL promoters. Transcription of all three megakaryocytic genes is correlated with the presence of acetylated histone H3 and phosphorylated RNA polymerase II on their promoters. We also show that exogenous expression of GATA-1 in Meg-01 cells leads to the expression of endogenous c-mpl and gpIX mRNA. Whereas GPIIb, GPIX, and C-MPL are direct target genes for Fli-1, both Fli-1 and GATA-1 are required for formation of an active transcriptional complex on the C-MPL and GPIX promoters in vivo. In contrast, GPIIb expression appears to be independent of GATA-1 in Meg-01 cells.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave, Charleston, SC 29403 USA.	watsondk@musc.edu	Szalai, Gabor/ABA-4146-2021	Szalai, Gabor/0000-0002-9462-8602	NCI NIH HHS [P01 CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1991, EXP HEMATOL, V19, P923; Alexander WS, 1999, INT J BIOCHEM CELL B, V31, P1027, DOI 10.1016/S1357-2725(99)00079-5; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGERON D, 1993, LEUKEMIA, V7, P954; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Denicourt C, 1999, J VIROL, V73, P4439, DOI 10.1128/JVI.73.5.4439-4442.1999; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Eisbacher M, 2001, CELL GROWTH DIFFER, V12, P435; FONG AM, 1994, J BIOL CHEM, V269, P18441; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Georgiou P, 1996, INT J ONCOL, V9, P9; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; Holmes ML, 2002, J BIOL CHEM, V277, P48333, DOI 10.1074/jbc.M206127200; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; KOMATSU N, 1989, BLOOD, V74, P42; Kubo M, 2003, AM J PATHOL, V163, P571, DOI 10.1016/S0002-9440(10)63685-1; Kwiatkowski BA, 2000, BLOOD CELL MOL DIS, V26, P84, DOI 10.1006/bcmd.2000.0282; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Lu J, 2004, MOL CELL BIOL, V24, P428, DOI 10.1128/MCB.24.1.428-441.2004; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; OGURA M, 1985, BLOOD, V66, P1384; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PHILLIPS DR, 1988, BLOOD, V71, P831; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sakurai T, 2003, INT J ONCOL, V22, P1327; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sato N, 2000, EXP HEMATOL, V28, P802, DOI 10.1016/S0301-472X(00)00176-4; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WATSON DK, 2002, ENCY CANC, V2, P189; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	75	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52183	52190		10.1074/jbc.M407489200	http://dx.doi.org/10.1074/jbc.M407489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466856	hybrid			2022-12-27	WOS:000225493400058
J	Katsafanas, GC; Moss, B				Katsafanas, GC; Moss, B			Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE MESSENGER-RNAS; GENE-EXPRESSION; LATE PROMOTER; ENDORIBONUCLEASE G3BP; IN-VITRO; PURIFICATION; POLYMERASE; IDENTIFICATION; CELLS; SUBUNIT	Transcription of the DNA genome of vaccinia virus occurs in the cytoplasm and is temporally programmed by early, intermediate, and late stage-specific transcription factors in conjunction with a viral multisubunit RNA polymerase. The RNA polymerase, capping enzyme, and three factors (VITF-1, VITF-2, and VITF-3) are sufficient for in vitro transcription of a DNA template containing an intermediate stage promoter. Vaccinia virus intermediate transcription factor (VITF)-1 and -3 are virus-encoded, whereas VITF-2 was partially purified from extracts of uninfected HeLa cells. Using purified and recombinant viral proteins, we showed that the HeLa cell factor was required for transcription of linear or nicked circular templates but not of super coiled DNA. HeLa cell polypeptides of similar to110 and 66 kDa co-purified with VITF-2 activity through multiple chromatographic steps. The polypeptides were separated by SDS-polyacrylamide gel electrophoresis and identified by mass spectrometry as Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and p137, recently named cytoplasmic activation/proliferation-associated protein-1. The co-purification of the two polypeptides with transcription-complementing activity was confirmed with specific antibodies, and their association with each other was demonstrated by affinity chromatography of tagged recombinant forms. Furthermore, recombinant G3BP and p137 expressed individually or together in mammalian or bacterial cells complemented the activity of the viral RNA polymerase and transcription factors. The involvement of cellular proteins in transcription of intermediate stage genes may regulate the transition between early and late phases of vaccinia virus replication.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Ctr Dr,MSC 0445, Bethesda, MD 20892 USA.	bmoss@nih.gov		Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000307, Z01AI000307] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1989, J VIROL, V63, P226, DOI 10.1128/JVI.63.1.226-232.1989; AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; BALDICK CJ, 1993, J VIROL, V67, P3515, DOI 10.1128/JVI.67.6.3515-3527.1993; BERTHOLET C, 1987, CELL, V50, P153, DOI 10.1016/0092-8674(87)90211-X; Broyles SS, 1999, J BIOL CHEM, V274, P35662, DOI 10.1074/jbc.274.50.35662; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; Broyles SS, 2003, J GEN VIROL, V84, P2293, DOI 10.1099/vir.0.18942-0; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; DENG L, 1994, J BIOL CHEM, V269, P14323; EARL PL, 1998, CURRENT PROTOCOLS MO, V2; ELLIS JA, 1995, J BIOL CHEM, V270, P20717, DOI 10.1074/jbc.270.35.20717; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gessler M, 1996, GENOMICS, V32, P169, DOI 10.1006/geno.1996.0099; Grill B, 2004, J IMMUNOL, V172, P2389, DOI 10.4049/jimmunol.172.4.2389; Hubbs AE, 1996, J VIROL, V70, P327, DOI 10.1128/JVI.70.1.327-331.1996; Katsafanas GC, 1999, VIROLOGY, V258, P469, DOI 10.1006/viro.1999.9744; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; KECK JG, 1993, J VIROL, V67, P5749, DOI 10.1128/JVI.67.10.5749-5753.1993; Kovacs GR, 1996, J VIROL, V70, P6796, DOI 10.1128/JVI.70.10.6796-6802.1996; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; Moss B, 2001, FIELDS VIROLOGY, P2849; Parker F, 1996, MOL CELL BIOL, V16, P2561; Passarelli AL, 1996, J VIROL, V70, P4444, DOI 10.1128/JVI.70.7.4444-4450.1996; PATEL DD, 1987, EMBO J, V6, P3787, DOI 10.1002/j.1460-2075.1987.tb02714.x; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; Sanz P, 1999, P NATL ACAD SCI USA, V96, P2692, DOI 10.1073/pnas.96.6.2692; SCHWER B, 1987, CELL, V50, P163, DOI 10.1016/0092-8674(87)90212-1; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; WRIGHT CF, 1993, J VIROL, V67, P7264, DOI 10.1128/JVI.67.12.7264-7270.1993; Wright CF, 2001, J BIOL CHEM, V276, P40680, DOI 10.1074/jbc.M102399200; ZHANG YF, 1992, J VIROL, V66, P6470, DOI 10.1128/JVI.66.11.6470-6479.1992	39	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52210	52217		10.1074/jbc.M411033200	http://dx.doi.org/10.1074/jbc.M411033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471883	hybrid			2022-12-27	WOS:000225493400061
J	Shan, Y; Lambrecht, RW; Ghaziani, T; Donohue, SE; Bonkovsky, HL				Shan, Y; Lambrecht, RW; Ghaziani, T; Donohue, SE; Bonkovsky, HL			Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells - Insights from studies with small interfering RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED INDUCTION; PRIMARY CULTURES; PHENYLARSINE OXIDE; EPITHELIAL-CELLS; HEPATOMA-CELLS; GENE; EXPRESSION; METALLOPORPHYRINS; TRANSCRIPTION; MECHANISM	Heme oxygenase-1 is an antioxidant defense enzyme that converts heme to biliverdin, iron, and carbon monoxide. Bach-1 is a bZip protein that forms heterodimers with small Maf proteins and was reported recently to down-regulate the HO-1 gene in mice. Using small interfering RNAs targeted to human Bach-1 mRNA, we investigated whether modulation of human hepatic Bach-1 expression by small interfering ( si) RNA technology influences heme oxygenase-1 gene expression. We found that Bach-1 siRNAs transfected into Huh-7 cells significantly reduced Bach-1 mRNA and protein levels similar to80%, compared with non siRNA-treated cells. In contrast, transfection with the same amounts of nonspecific control duplexes or LaminB2-duplex did not reduce Bach-1 mRNA or protein levels, confirming the specificity of Bach-1 siRNA. Expression of the heme oxygenase-1 gene in Bach-1 siRNA-transfected cells was up-regulated 7-fold, compared with cells without Bach-1 siRNA. The effect of increasing concentrations of heme to up-regulate levels of heme oxygenase-1 was more pronounced when Bach-1 siRNA was present. Taken together, these results indicated that Bach-1 has a specific and selective ability to repress expression of human hepatic heme oxygenase-1. Silencing of Bach-1 by siRNAs is a useful method for up-regulating HO-1 gene expression. Exogenous heme produces additional up-regulation, beyond that produced by Bach-1 siRNAs, suggesting that heme does not act solely through its effects on Bach-1.	Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Pharmacol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Gen Clin Res Ctr, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	Shan, Y (corresponding author), 263 Farmington Ave,MC-1111, Farmington, CT 06030 USA.	Shan@uchc.edu			NCRR NIH HHS [MO1-RR06192] Funding Source: Medline; NIDDK NIH HHS [R01-DK38825, N0-1 DK 92326, UO-1 DK065193] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038825, U01DK065193, N01DK092326] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1992, J BIOL CHEM, V267, P16379; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; ALAM J, 1989, J BIOL CHEM, V264, P6371; Bonkovsky H. L., 2002, OXIDATIVE STRESS AGI, P690; CABLE E, 1990, BIOCHEM BIOPH RES CO, V168, P176, DOI 10.1016/0006-291X(90)91690-T; Cable EE, 1997, MOL CELL BIOCHEM, V169, P13, DOI 10.1023/A:1006817207166; CABLE JW, 1993, MOL CELL BIOCHEM, V129, P93, DOI 10.1007/BF00926580; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; ELBIRT KK, 1998, ROLE MAP KINASES IND, P102; Gildemeister OS, 2001, MOL CELL BIOCHEM, V226, P17; Hill-Kapturczak N, 2002, DNA CELL BIOL, V21, P307, DOI 10.1089/104454902753759726; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; LAMBRECHT RW, ASCITES RENAL DYSFUN; LINCOLN BC, 1988, BIOCHEM J, V250, P189, DOI 10.1042/bj2500189; Lu TH, 1997, BBA-GENE STRUCT EXPR, V1352, P293, DOI 10.1016/S0167-4781(97)00028-6; Lu TH, 1998, GENE, V207, P177, DOI 10.1016/S0378-1119(97)00623-9; Lu TH, 2000, MOL CELL BIOCHEM, V209, P17, DOI 10.1023/A:1007025505842; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; Nath KA, 2001, KIDNEY INT, V59, P106, DOI 10.1046/j.1523-1755.2001.00471.x; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Shan Y, 1999, HEPATOLOGY, V30, p512A; Shan Y, 2004, HEPATOLOGY, V40, p527A; Shan Y, 2004, BBA-GENE STRUCT EXPR, V1679, P87, DOI 10.1016/j.bbaexp.2004.05.003; Shan Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P159, DOI 10.1006/abbi.2001.2742; Shan Y, 1999, ARCH BIOCHEM BIOPHYS, V372, P224, DOI 10.1006/abbi.1999.1490; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; SRIVASTAVA KK, 1993, EUR J BIOCHEM, V213, P909, DOI 10.1111/j.1432-1033.1993.tb17835.x; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748	39	64	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51769	51774		10.1074/jbc.M409463200	http://dx.doi.org/10.1074/jbc.M409463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465821	hybrid			2022-12-27	WOS:000225493400009
J	Smith, AJ; Sanders, MA; Thompson, BR; Londos, C; Kraemer, FB; Bernlohr, DA				Smith, AJ; Sanders, MA; Thompson, BR; Londos, C; Kraemer, FB; Bernlohr, DA			Physical association between the adipocyte fatty acid-binding protein and hormone-sensitive lipase - A fluorescence resonance energy transfer analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; DIFFERENTIATION-RELATED PROTEIN; A-MEDIATED LIPOLYSIS; INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES; LIPID DROPLETS; ADIPOSE-TISSUE; PERILIPIN-A; KINASE; CELLS	Previous in vitro studies have established that hormone sensitive lipase (HSL) and adipocyte fatty acid-binding protein (AFABP) form a physical complex that presumably positions the FABP to accept a product fatty acid generated during catalysis. To assess AFABP-HSL interaction within a cellular context, we have used lipocytes derived from 293 cells (C8PA cells) and examined physical association using fluorescence resonance energy transfer. Transfection of C8PA cells with cyan fluorescent protein (CFP)-HSL, yellow fluorescent protein (YFP)-adipocyte FABP, or YFP-liver FABP revealed that under basal conditions each protein was cytoplasmic. In the presence of 20 muM forskolin, CFP-HSL translocated to the triacylglycerol droplet, coincident with BODIPY-FA labeled depots. Fluorescence resonance energy transfer analysis demonstrated that CFP-HSL associated with YFP-adipocyte FABP in both basal and forskolin-treated cells. In contrast, little if any fluorescence resonance energy transfer could be detected between CFP-HSL and YFP-liver FABP. These results suggest that a pre-lipolysis complex containing at least AFABP and HSL exists and that the complex translocates to the surface of the lipid droplet.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Imaging Ctr, St Paul, MN 55108 USA; NIDDK, Membrane Regulat Sect, NIH, Bethesda, MD 20892 USA; Stanford Univ, Dept Med, Div Endocrinol, Stanford, CA 94305 USA; Vet Adm Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE, Minneapolis, MN 55455 USA.	bern1001@umn.edu	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807	NIDDK NIH HHS [DK 46942, DK 53189] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053189, R01DK046942] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; CASTLEMAN K. R., 1996, DIGITAL IMAGE PROCES, P207; Chamberlain CE, 2000, METHOD ENZYMOL, V325, P389; Coe NR, 1999, J LIPID RES, V40, P967; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Hatch GM, 2002, J LIPID RES, V43, P1380, DOI 10.1194/jlr.M200130-JLR200; Helledie T, 2000, J LIPID RES, V41, P1740; Hertzel AV, 2002, J LIPID RES, V43, P2105, DOI 10.1194/jlr.M200227-JLR200; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Jenkins-Kruchten AE, 2003, J BIOL CHEM, V278, P47636, DOI 10.1074/jbc.M307680200; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Maeda K, 2003, DIABETES, V52, P300, DOI 10.2337/diabetes.52.2.300; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; TORNQVIST H, 1972, J LIPID RES, V13, P424; XU ZH, 1991, J BIOL CHEM, V266, P14367; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	33	49	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52399	52405		10.1074/jbc.M410301200	http://dx.doi.org/10.1074/jbc.M410301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456755	hybrid			2022-12-27	WOS:000225493400084
J	Bagriantsev, S; Liebman, SW				Bagriantsev, S; Liebman, SW			Specificity of prion assembly in vivo - [PSI+] and [PIN+] form separate structures in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; GUANIDINE-HYDROCHLORIDE; SUP35 PROTEIN; PROPAGATION; HSP104; STRAINS; SCRAPIE; PSI(+); VITRO	The yeast prions [PSI+] and [PIN+] are self-propagating amyloid aggregates of the Gln/Asn-rich proteins Sup35p and Rnq1p, respectively. Like the mammalian PrP prion "strains," [PSI+] and [PIN+] exist in different conformations called variants. Here, [PSI+] and [PIN+] variants were used to model in vivo interactions between co-existing heterologous amyloid aggregates. Two levels of structural organization, like those previously described for [PSI+], were demonstrated for [PIN+]. In cells with both [PSI+] and [PIN+] the two prions formed separate structures at both levels. Also, the destabilization of [PSI+] by certain [PIN+] variants was shown not to involve alterations in the [PSI+] prion size. Finally, when two variants of the same prion that have aggregates with distinct biochemical characteristics were combined in a single cell, only one aggregate type was propagated. These studies demonstrate the intracellular organization of yeast prions and provide insight into the principles of in vivo amyloid assembly.	Univ Illinois, Mol Biol Lab, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Liebman, SW (corresponding author), Univ Illinois, Mol Biol Lab, 900 S Ashland Ave,MC567 Mol Biol Res Bldg,Rm 4068, Chicago, IL 60607 USA.	sueL@uic.edu		Bagriantsev, Sviatoslav/0000-0002-6661-3403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56350, R01 GM056350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balguerie A, 2004, J CELL SCI, V117, P2599, DOI 10.1242/jcs.01116; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Borchsenius AS, 2001, EMBO J, V20, P6683, DOI 10.1093/emboj/20.23.6683; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley ME, 2003, GENETICS, V165, P1675; Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; Bruce ME, 2003, BRIT MED BULL, V66, P99, DOI 10.1093/bmb/66.1.99; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1998, P NATL ACAD SCI USA, V95, P2400, DOI 10.1073/pnas.95.5.2400; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Eaglestone SS, 2000, P NATL ACAD SCI USA, V97, P240, DOI 10.1073/pnas.97.1.240; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Grimminger V, 2004, J BIOL CHEM, V279, P7378, DOI 10.1074/jbc.M312403200; Kim K, 2002, J CELL BIOL, V156, P101, DOI 10.1083/jcb.200107037; Kimura Y, 2003, CELL STRUCT FUNCT, V28, P187; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Ness F, 2002, MOL CELL BIOL, V22, P5593, DOI 10.1128/MCB.22.15.5593-5605.2002; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Silveira JR, 2004, CURR TOP MICROBIOL, V284, P1; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner Reed B., 2004, VVolume 41, P305; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	46	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51042	51048		10.1074/jbc.M410611200	http://dx.doi.org/10.1074/jbc.M410611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15465809	hybrid			2022-12-27	WOS:000225355800049
J	Piboonpocanun, S; Chiba, H; Mitsuzawa, H; Martin, W; Murphy, RC; Harbeck, RJ; Voelker, DR				Piboonpocanun, S; Chiba, H; Mitsuzawa, H; Martin, W; Murphy, RC; Harbeck, RJ; Voelker, DR			Surfactant protein A binds Mycoplasma pneumoniae with high affinity and attenuates its growth by recognition of disaturated phosphatidylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY HOST-DEFENSE; ALVEOLAR MACROPHAGES; PHOSPHOLIPID SECRETION; MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; CANDIDA-ALBICANS; DEFICIENT MICE; IN-VITRO; II CELLS; COLLECTINS	Surfactant Protein A (SP-A) is an abundant, multifunctional lectin that resides within the bronchoalveolar compartment of the lung and plays an important role in the innate immunity of the organ. Mycoplasma pneumoniae is a human pathogen that resides in the same compartment as SP-A, and we examined the interaction between the two. Preparations of human and rat SP-A recognized the mycoplasma with high affinity in the presence of Ca2+, exhibiting apparent K-d values in the nanomolar range. Membranes prepared from the microbe also bound human and rat SP-A with similar characteristics and affinity to the intact cells. The ligand for SP-A was insensitive to proteolysis. Lipid extracts prepared from the mycoplasma, bound SP-A with high affinity when examined by ligand blot analysis. These lipid extracts were also potent competitive inhibitors (IC50=0.2 nM) of human SP-A binding to mycoplasma membranes. The major lipid ligands for the protein identified by mass spectrometry are a group of disaturated phosphatidylglycerols. The addition of SP-A to cultures of M. pneumoniae markedly attenuated the growth of the organism assessed by colony formation, metabolic activity, and DNA replication. The bacteriostatic effects of SP-A were reversed by dipalmitoylphosphatidylglycerol. These findings demonstrate that human SP-A can play a direct role in antibody-independent immunity to M. pneumoniae by interacting with lipid ligands expressed on the surface of the organism and implicate SP-A in the immediate host response to the bacteria.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org	Murphy, Robert/AAO-5349-2020; Piboonpocanun, Surapon/M-7823-2019	Murphy, Robert/0000-0002-9430-6515; , surapon/0000-0003-4374-8003	NHLBI NIH HHS [P01 HL073907, HL45286, P01-HL073907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073907, R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GIL JC, 1993, ANN ALLERGY, V70, P23; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hickman-Davis JM, 2004, AM J RESP CELL MOL, V30, P319, DOI 10.1165/rcmb.2003-0246OC; HickmanDavis JM, 1997, INFECT IMMUN, V65, P2278, DOI 10.1128/IAI.65.6.2278-2282.1997; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996, DOI 10.1152/ajplung.1997.272.5.L996; KUROKI Y, 1985, BIOCHIM BIOPHYS ACTA, V836, P201; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577, DOI 10.1165/ajrcmb.24.5.4315; McCormack FX, 2003, J BIOL CHEM, V278, P36250, DOI 10.1074/jbc.M303086200; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Rosseau S, 1999, J IMMUNOL, V163, P4495; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Sano H, 1999, J IMMUNOL, V163, P387; STAMME C, 2000, AM J RESP CRIT CARE, V161, pA515; Tully X, 1995, MOL DIAGNOSTIC PROCE, P33; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889	32	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					9	17		10.1074/jbc.M411570200	http://dx.doi.org/10.1074/jbc.M411570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498759	hybrid			2022-12-27	WOS:000226025100003
J	Jing, H; Yen, JH; Ganea, D				Jing, H; Yen, JH; Ganea, D			A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; TRANSCRIPTION FACTOR; DENDRITIC CELLS; PROSTANOID RECEPTORS; PHOSPHORYLATION; EPAC; RAP1	In response to pathogen-associated molecular patterns, dendritic cells initiate an innate immune response characterized by expression and release of proinflammatory cytokines and chemokines. The extent of the inflammatory response is limited by various endogenous factors, including lipid mediators such as prostaglandin E-2 (PGE(2)). We described previously the inhibitory effect of PGE(2) on the expression and release of the inflammatory chemokines CCL3 and CCL4 from activated dendritic cells. In this study we describe a novel PGE2 signaling pathway that proceeds through EP-2-->cAMP-->EPAC-->phosphatidylinositol 3-kinase-->protein kinase B-->GSK-3 and results in increased DNA binding of the CCAAT displacement protein (CDP), a potent mammalian transcriptional repressor. The direct link between CDP and CCL3/4 transcription was established in knock-down experiments using CDP small interference RNA.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu		Yen, Jui-Hung Jimmy/0000-0002-7325-9756	NIAID NIH HHS [AI 47325, AI 52306] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI147325, R56AI047325, R01AI047325, R01AI052306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amsterdam A, 2002, BIOCHEM PHARMACOL, V64, P843, DOI 10.1016/S0006-2952(02)01147-4; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Delgado M, 2004, PHARMACOL REV, V56, P249, DOI 10.1124/pr.56.2.7; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujita H, 2004, J INVEST DERMATOL, V122, P1331, DOI 10.1111/j.0022-202X.2004.22534.x; Granucci F, 2004, INT ARCH ALLERGY IMM, V134, P179, DOI 10.1159/000078764; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Jing H, 2003, J LEUKOCYTE BIOL, V74, P868, DOI 10.1189/jlb.0303116; Jozefowski S, 2003, INT IMMUNOPHARMACOL, V3, P865, DOI 10.1016/S1567-5769(03)00072-9; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kalinski P, 1997, ADV EXP MED BIOL, V417, P363; Kalinski P, 2001, BLOOD, V97, P3466, DOI 10.1182/blood.V97.11.3466; KATAMURA K, 1995, J IMMUNOL, V155, P4604; MARTIN CA, 1991, CELL IMMUNOL, V135, P245, DOI 10.1016/0008-8749(91)90269-H; Matsumoto M, 1998, INT IMMUNOL, V10, P1825, DOI 10.1093/intimm/10.12.1825; Mazzoni A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/jlb.1003482; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Nirodi C, 2001, J BIOL CHEM, V276, P26122, DOI 10.1074/jbc.M102872200; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; Okada N, 2001, CANCER RES, V61, P7913; PROFFITT J, 1995, GENE, V152, P173, DOI 10.1016/0378-1119(94)00701-S; RITTER LM, 1995, MOL CELL BIOL, V15, P3110; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Shen ZH, 1997, J IMMUNOL, V158, P2723; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Steinman RM, 2003, PATHOL BIOL, V51, P59, DOI 10.1016/S0369-8114(03)00096-8; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; VANLIESHOUT TW, 2004, IN PRESS ANN RHEUM D; Vassiliou E, 2003, CELL IMMUNOL, V223, P120, DOI 10.1016/S0008-8749(03)00158-8	38	70	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55176	55186		10.1074/jbc.M409816200	http://dx.doi.org/10.1074/jbc.M409816200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498767	hybrid			2022-12-27	WOS:000225960800025
J	Katragadda, M; Morikis, D; Lambris, JD				Katragadda, M; Morikis, D; Lambris, JD			Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; CATALYTIC MECHANISM; COMPLEMENT INHIBITOR; MONOCLONAL-ANTIBODY; WATER-MOLECULES; HEAT-CAPACITY; BINDING-SITE; PROTEIN; PEPTIDE; CYCLOPHILIN	Compstatin is a 13-residue cyclic peptide that inhibits complement activation by binding to complement component, C3. Although the activity of compstatin has been improved severalfold using combinatorial and rational design approaches, the molecular basis for its interaction with C3 is not yet fully understood. In the present study, isothermal titration calorimetry was employed to dissect the molecular forces that govern the interaction of compstatin with C3 using four different compstatin analogs. Our studies indicate that the C3-compstatin interaction is an enthalpy-driven process. Substitution of the valine and histidine residues at positions 4 and 9 with tryptophan and alanine, respectively, resulted in the increase of enthalpy of the interaction, thereby increasing the binding affinity for C3. The data also suggest that the interaction is mediated by water molecules. These interfacial water molecules could be the source for unfavorable entropy and large negative heat capacity changes observed in the interaction. Although part of the negative heat capacity changes could be accounted for by the water molecules, the rest might be resulting from the conformational changes in C3 and/or compstatin up on binding. Finally, we propose based on the pK(a) values determined from the protonation studies that histidine on compstatin participates in protonation changes and contributes to the specificity of the interaction between compstatin and C3. These protonation changes vary significantly between the binding of different compstatin analogs to C3.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA; Univ Calif Riverside, Dept Environm Chem & Engn, Riverside, CA 92521 USA	University of Pennsylvania; University of California System; University of California Riverside	Lambris, JD (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA.	lambris@mail.med.upenn.edu	Morikis, Dimitrios/L-8527-2013; Lambris, John/Q-5633-2018	Morikis, Dimitrios/0000-0003-0083-4665; Lambris, John/0000-0002-9370-5776	NIGMS NIH HHS [GM 069736, GM 62134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062134, R24GM069736] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHOVCHIN WW, 1981, P NATL ACAD SCI-BIOL, V78, P7323, DOI 10.1073/pnas.78.12.7323; Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w; DECRISTOFARO R, 1995, BIOCHEM J, V310, P49, DOI 10.1042/bj3100049; Doyle ML, 1998, METHOD ENZYMOL, V295, P88; Fanghanel J, 2003, BIOPHYS CHEM, V100, P351, DOI 10.1016/S0301-4622(02)00292-2; FINUCANE MD, 1992, BIOCHEM J, V286, P889, DOI 10.1042/bj2860889; Gallo P, 1998, J BIOCHEM-TOKYO, V124, P880, DOI 10.1093/oxfordjournals.jbchem.a022202; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; Gribenko AV, 2002, PROTEIN SCI, V11, P1367, DOI 10.1110/ps.0202202; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; Hernaiz MJ, 2002, EUR J BIOCHEM, V269, P2860, DOI 10.1046/j.1432-1033.2002.02964.x; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; Jacobson T, 2004, ARCH BIOCHEM BIOPHYS, V422, P125, DOI 10.1016/j.abb.2003.12.016; Klepeis JL, 2003, J AM CHEM SOC, V125, P8422, DOI 10.1021/ja034846p; KORNBLATT JA, 1993, BIOPHYS J, V65, P1059, DOI 10.1016/S0006-3495(93)81168-8; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; Makrides SC, 1998, PHARMACOL REV, V50, P59; Mallik B, 2003, PROTEINS, V53, P130, DOI 10.1002/prot.10491; Matulis D, 2001, BIOPHYS CHEM, V93, P53, DOI 10.1016/S0301-4622(01)00208-3; McNemar C, 1997, BIOCHEMISTRY-US, V36, P10006, DOI 10.1021/bi9704360; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311; Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200; Morikis D, 2001, PROTEIN SCI, V10, P2379, DOI 10.1110/ps.17301; Morton CJ, 1996, PROTEIN SCI, V5, P2115, DOI 10.1002/pro.5560051018; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ortiz-Salmeron E, 2003, J BIOL CHEM, V278, P46938, DOI 10.1074/jbc.M305043200; Ottiger M, 1997, J MOL BIOL, V272, P64, DOI 10.1006/jmbi.1997.1220; Patskovsky YV, 1999, BIOCHEMISTRY-US, V38, P1193, DOI 10.1021/bi982164m; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Sundberg EJ, 2000, BIOCHEMISTRY-US, V39, P15375, DOI 10.1021/bi000704l; Swaminathan CP, 1999, J BIOL CHEM, V274, P31272, DOI 10.1074/jbc.274.44.31272; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; Xavier KA, 1997, BIOPHYS J, V73, P2116, DOI 10.1016/S0006-3495(97)78242-0; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; YU LP, 1994, BBA-PROTEIN STRUCT M, V1209, P24, DOI 10.1016/0167-4838(94)90132-5	49	21	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					54987	54995		10.1074/jbc.M409963200	http://dx.doi.org/10.1074/jbc.M409963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489226	hybrid			2022-12-27	WOS:000225960800003
J	Haegebarth, A; Heap, D; Bie, WJ; Derry, JJ; Richard, SP; Tyner, AL				Haegebarth, A; Heap, D; Bie, WJ; Derry, JJ; Richard, SP; Tyner, AL			The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-ASSOCIATED PROTEIN; MAMMARY EPITHELIAL-CELLS; KH-DOMAIN; GASTROINTESTINAL-TRACT; CYCLE PROGRESSION; HIV REPLICATION; REV FUNCTION; GSG DOMAIN; BRK; EXPRESSION	Expression of the intracellular tyrosine kinase BRK/Sik is epithelial-specific and regulated during differentiation. Only a few substrates have been identified for BRK/Sik, including the KH domain containing RNA-binding protein Sam68 and the novel adaptor protein BKS. Although the physiological role of Sam68 is unknown, it has been shown to regulate mRNA transport, pre-mRNA splicing, and polyadenylation. Here we demonstrate that the Sam68-like mammalian proteins SLM-1 and SLM-2 but not the related KH domain containing heterogeneous nuclear ribonucleoprotein K are novel substrates of BRK/Sik. The expression of active BRK/Sik results in increased SLM-1 and SLM-2 phosphorylation and increased retention of BRK/Sik within the nucleus. The phosphorylation of SLM-1 and SLM-2 has functional relevance and leads to inhibition of their RNA-binding abilities. We show that SLM-1, SLM-2, and BRK/Sik have restricted patterns of expression unlike the ubiquitously expressed Sam68. Moreover, BRK/Sik, SLM-1, and Sam68 transcripts were coexpressed in the mouse gastrointestinal tract and skin, suggesting that SLM-1 and Sam68 could be physiologically relevant BRK/Sik targets in vivo. The ability of BRK/Sik to negatively regulate the RNA-binding activities of the KH domain RNA binding proteins SLM-1 and Sam68 may have an impact on the posttranscriptional regulation of epithelial cell gene expression.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res,Dept Oncol, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res,Dept Med, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIDDK NIH HHS [R01 DK044525, R01 DK044525-10, DK07788, DK44525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525, R55DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Cans C, 2000, BIOCHEM PHARMACOL, V60, P1203, DOI 10.1016/S0006-2952(00)00434-2; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hong EM, 2004, J BIOL CHEM, V279, P29700, DOI 10.1074/jbc.M313185200; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; LASKO P, 2003, SCI STKE; Lee JS, 1999, GENE, V240, P133, DOI 10.1016/S0378-1119(99)00421-7; LEE ST, 1993, ONCOGENE, V8, P3403; Li JL, 2002, J VIROL, V76, P4526, DOI 10.1128/JVI.76.9.4526-4535.2002; Li JL, 2002, J VIROL, V76, P8374, DOI 10.1128/JVI.76.16.8374-8382.2002; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mclaren M, 2004, RNA, V10, P1119, DOI 10.1261/rna.5263904; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Petro BJ, 2004, ORAL ONCOL, V40, P1040, DOI 10.1016/j.oraloncology.2004.05.010; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Rafalska I, 2004, HUM MOL GENET, V13, P1535, DOI 10.1093/hmg/ddh167; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Serfas MS, 2003, ONCOL RES, V13, P409; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Stoss O, 2004, MOL CELL NEUROSCI, V27, P8, DOI 10.1016/j.mcn.2004.04.011; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	53	69	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54398	54404		10.1074/jbc.M409579200	http://dx.doi.org/10.1074/jbc.M409579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471878	hybrid			2022-12-27	WOS:000225793600062
J	Moy, LY; Tsai, LH				Moy, LY; Tsai, LH			Cyclin-dependent kinase 5 phosphorylates serine 31 of tyrosine hydroxylase and regulates its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; PARKINSONS-DISEASE; LEWY-BODIES; CDK5; PROTEIN; GENE; P35; NEURODEGENERATION; TETRAHYDROPTERIN; ACTIVATION	Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine biosynthesis, and its activity is regulated by phosphorylation in the N-terminal regulatory domain. The proline-directed serine/threonine kinase cyclin-dependent kinase 5 (cdk5) plays an important role in diverse neuronal processes. In the present study, we identify TH as a novel substrate of cdk5. We show that cdk5 phosphorylates TH at serine 31 and that this phosphorylation is associated with an increase in total TH activity. In transgenic mice with increased cdk5 activity, the immunoreactivity for phosphorylated TH at Ser-31 is enhanced in neurons of the substantia nigra, a brain region enriched with TH-positive neurons. In addition, we demonstrate that co-expression of cdk5 and its regulatory activator p35 with TH increases the stability of TH. Consistent with these findings, TH protein levels are reduced in cdk5 knock-out mice. Importantly, the TH activity and protein turnover of the phosphorylation-defective mutant TH S31A was not altered by cdk5 activity. Taken together, these data suggest that cdk5 phosphorylation of TH is an important regulator of TH activity through stabilization of TH protein levels.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	lily_moy@hms.harvard.edu; li-huei_tsai@hms.harvard.edu			NIA NIH HHS [AG000111-10] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alterio J, 1998, J BIOL CHEM, V273, P10196, DOI 10.1074/jbc.273.17.10196; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BRION JP, 1995, AM J PATHOL, V147, P1465; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; HALLORAN SM, 1994, J BIOL CHEM, V269, P30960; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HORNYKIE.O, 1973, FED PROC, V32, P183; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Kumer SC, 1996, J NEUROCHEM, V67, P443; Ludecke B, 1996, HUM MOL GENET, V5, P1023, DOI 10.1093/hmg/5.7.1023; Nakamura S, 1997, ACTA NEUROPATHOL, V94, P153, DOI 10.1007/s004010050687; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; WU DK, 1994, J NEUROCHEM, V62, P863; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	24	59	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54487	54493		10.1074/jbc.M406636200	http://dx.doi.org/10.1074/jbc.M406636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471880	hybrid			2022-12-27	WOS:000225793600072
J	Yamanaka, M; Shegogue, D; Pei, HP; Bu, SZ; Bielawska, A; Bielawski, J; Pettus, B; Hannun, YA; Obeid, L; Trojanowska, M				Yamanaka, M; Shegogue, D; Pei, HP; Bu, SZ; Bielawska, A; Bielawski, J; Pettus, B; Hannun, YA; Obeid, L; Trojanowska, M			Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMAL FIBROBLASTS; GENE-EXPRESSION; TISSUE INHIBITOR; KINASE-ACTIVITY; ONCOSTATIN-M; PROTEIN; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; INTERACTS; METALLOPROTEINASE-1	Transforming growth factor-beta(TGF-beta) signaling plays a pivotal role in extracellular matrix deposition by stimulating collagen production and other extracellular matrix proteins and by inhibiting matrix degradation. The present study was undertaken to define the role of sphingosine kinase (SphK) in TGF-beta signaling. TGF-beta markedly up-regulated SphK1 mRNA and protein amounts and caused a prolonged increase in SphK activity in dermal fibroblasts. Concomitantly, TGF-beta reduced sphingosine-1-phosphate phosphatase activity. Consistent with the changes in enzyme activity, corresponding changes in sphingolipid levels were observed such that sphingosine 1-phosphate (S1P) was increased (similar to2-fold), whereas sphingosine and ceramide were reduced after 24 h of TGF-beta treatment. Given the relatively early induction of SphK gene expression in response to TGF-beta, we examined whether SphK1 may be involved in the regulation of TGF-beta-inducible genes that exhibit compatible kinetics, e.g. tissue inhibitor of metalloproteinase-1 (TIMP-1). We demonstrate that decreasing SphK1 expression by small interfering RNA (siRNA) blocked TGF-beta-mediated up-regulation of TIMP-1 protein suggesting that up-regulation of SphK1 contributes to the induction of TIMP-1 in response to TGF-beta. The role of SphK1 as a positive regulator of TIMP-1 gene expression was further corroborated by using ectopically expressed SphK1 in the absence of TGF-beta. Adenovirally expressed SphK1 led to a 2-fold increase of endogenous S1P and to increased TIMP-1 mRNA and protein production. In addition, ectopic SphK1 and TGF-beta cooperated in TIMP-1 up-regulation. Mechanistically, experiments utilizing TIMP-1 promoter constructs demonstrated that the action of SphK1 on the TIMP-1 promoter is through the AP1-response element, consistent with the SphK1-mediated up-regulation of phospho-c-Jun levels, a key component of AP1. Together, these experiments demonstrate that SphK/S1P are important components of the TGF-beta signaling pathway involved in up-regulation of the TIMP-1 gene.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Ste 912, Charleston, SC 29425 USA.	trojanme@musc.edu		Trojanowska, Maria/0000-0001-9550-7178; obeid, lina/0000-0002-0734-0847	NIAMS NIH HHS [P60 AR049459] Funding Source: Medline; NIA NIH HHS [AG16538] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR049459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R44AG016538, R43AG016538] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; French KJ, 2003, CANCER RES, V63, P5962; Fujita T, 2004, BIOCHEM J, V382, P717, DOI 10.1042/BJ20040141; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Levy MT, 2000, J HEPATOL, V32, P218, DOI 10.1016/S0168-8278(00)80066-5; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2000, METHOD ENZYMOL, V311, P215; ONEILL L, 1991, CARDIOSCIENCE, V2, P1; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Sohara N, 2002, J HEPATOL, V36, P191, DOI 10.1016/S0168-8278(01)00265-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; SULLARDS MC, 2001, SCI STKE; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xin CY, 2004, J BIOL CHEM, V279, P35255, DOI 10.1074/jbc.M312091200; YAMAKAGE A, 1992, J EXP MED, V175, P1227, DOI 10.1084/jem.175.5.1227; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200	45	112	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53994	54001		10.1074/jbc.M410144200	http://dx.doi.org/10.1074/jbc.M410144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485866	hybrid			2022-12-27	WOS:000225793600014
J	Satake, H; Ogasawara, M; Kawada, T; Masuda, K; Aoyama, M; Minakata, H; Chiba, T; Metoki, H; Satou, Y; Satoh, N				Satake, H; Ogasawara, M; Kawada, T; Masuda, K; Aoyama, M; Minakata, H; Chiba, T; Metoki, H; Satou, Y; Satoh, N			Tachykinin and tachykinin receptor of an ascidian, Ciona intestinalis - Evolutionary origin of the vertebrate tachykinin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P-LIKE; GENE-EXPRESSION; NEUROKININ-A; K RECEPTOR; PROTOCHORDATE; ORGANIZATION; PEPTIDE; BRAIN; MOUSE; IMMUNOREACTIVITY	Tachykinins (TKs) are the most prevalent vertebrate brain/gut peptides. In this study, we originally identified authentic TKs and their receptor from a protochordate, Ciona intestinalis. The Ciona TK (Ci-TK) precursor, like mammalian gamma-preprotachykinin A (gamma-PPTA), encodes two TKs, Ci-TK-I and -II, including the -FXGLM-NH2 vertebrate TK consensus. Mass spectrometry of the neural extract revealed the production of both Ci-TKs. Ci-TK-I contains several Substance P (SP)-typical amino acids, whereas a Thr is exceptionally located at position 4 from the C terminus of Ci-TK-II. The Ci-TK gene encodes both Ci-TKs in the same exon, indicating no alternative generation of Ci-TKs, unlike the PPTA gene. These results suggested that the alternative splicing of the PPTA gene was established during evolution of vertebrates. The only Ci-TK receptor, Ci-TK-R, was equivalently activated by Ci-TK-I, SP, and neurokinin A at physiological concentrations, whereas Ci-TK-II showed 100-fold less potent activity, indicating that the ligand selectivity of Ci-TK-R is distinct from those of vertebrate TK receptors. Ci-TK-I, like SP, also elicited the typical contraction on the guinea pig ileum. The Ci-TK gene was expressed in neurons of the brain ganglion, small cells in the intestine, and the zone 7 in the endostyle, which corresponds to the vertebrate thyroid gland. Furthermore, the Ci-TK-R mRNA was distributed in these three tissues plus the gonad. These results showed that Ci-TKs play major roles in sexual behavior and feeding in protochordates as brain/gut peptides and endocrine/paracrine molecules. Taken together, our data revealed the biochemical and structural origins of vertebrate TKs and their receptors.	Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Kyoto Univ, Grad Sch Sci, Dept Zool, Sakyo Ku, Kyoto, Japan	Suntory Holdings Ltd; Chiba University; Kyoto University	Satake, H (corresponding author), Suntory Inst Bioorgan Res, Wakayamadai 1-1-1, Shimamoto, Osaka 6188503, Japan.	satake@sunbor.or.jp	Metoki, Hirohito/B-3376-2009; Satou, Yutaka/AAJ-2194-2021; Satou, Yutaka/K-7131-2012; Satoh, Nori/C-4123-2009	Metoki, Hirohito/0000-0002-1894-3328; Satou, Yutaka/0000-0001-5193-0708; Satou, Yutaka/0000-0001-5193-0708; Satoh, Nori/0000-0002-4480-3572				Adams BA, 2003, ENDOCRINOLOGY, V144, P1907, DOI 10.1210/en.2002-0216; BOLLNER T, 1992, J COMP NEUROL, V325, P572, DOI 10.1002/cne.903250409; Burighel P, 1997, MICROSCOPICAL ANATOM, V15, P221; CHIWAKATA C, 1991, ENDOCRINOLOGY, V128, P2441, DOI 10.1210/endo-128-5-2441; Corbo JC, 2001, CELL, V106, P535, DOI 10.1016/S0092-8674(01)00481-0; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Di Fiore MM, 2000, P NATL ACAD SCI USA, V97, P2343, DOI 10.1073/pnas.040549097; Evangelista S, 2001, CURR PHARM DESIGN, V7, P19, DOI 10.2174/1381612013398446; FRISTCH HAR, 1982, CELL TISSUE RES, V223, P369; GRUNDITZ T, 1987, ENDOCRINOLOGY, V121, P575, DOI 10.1210/endo-121-2-575; HOLLAND PW, 1994, DEV S, V43, P125; JOHNSEN AH, 1990, J BIOL CHEM, V265, P3054; JONASSEN JA, 1987, ENDOCRINOLOGY, V121, P1555, DOI 10.1210/endo-121-4-1555; Kanda A, 2003, PEPTIDES, V24, P35, DOI 10.1016/S0196-9781(02)00274-7; Kawada T, 1999, BIOCHEM BIOPH RES CO, V263, P848, DOI 10.1006/bbrc.1999.1465; Kawada T, 2002, EUR J BIOCHEM, V269, P4238, DOI 10.1046/j.1432-1033.2002.03106.x; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; KOZAWA H, 1991, BIOCHEM BIOPH RES CO, V177, P588, DOI 10.1016/0006-291X(91)92024-E; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Kurtz MM, 2002, GENE, V296, P205, DOI 10.1016/S0378-1119(02)00861-2; LEMBECK F, 1985, PEPTIDES, V6, P231, DOI 10.1016/0196-9781(85)90379-1; Lin XW, 1997, PEPTIDES, V18, P817, DOI 10.1016/S0196-9781(97)00013-2; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Moss C, 1998, TISSUE CELL, V30, P517, DOI 10.1016/S0040-8166(98)80031-1; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; Ogasawara M, 1999, J EXP ZOOL, V285, P158, DOI 10.1002/(SICI)1097-010X(19990815)285:2<158::AID-JEZ8>3.0.CO;2-0; Ogasawara M, 1998, BIOL BULL-US, V195, P60, DOI 10.2307/1542776; Ogasawara M, 2002, DEV GENES EVOL, V212, P173, DOI 10.1007/s00427-002-0230-7; ONEIL GS, 1987, GEN COMP ENDOCR, V66, P314, DOI 10.1016/0016-6480(87)90240-1; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Page NM, 2003, P NATL ACAD SCI USA, V100, P6245, DOI 10.1073/pnas.0931458100; Patak E, 2003, BRIT J PHARMACOL, V139, P523, DOI 10.1038/sj.bjp.0705279; Pennefather JN, 2004, LIFE SCI, V74, P1445, DOI 10.1016/j.lfs.2003.09.039; Pintado CO, 2003, BIOL REPROD, V69, P940, DOI 10.1095/biolreprod.103.017111; ROTH KA, 1990, J CLIN ENDOCR METAB, V71, P1089, DOI 10.1210/jcem-71-5-1089; Sasakura Y, 2003, P NATL ACAD SCI USA, V100, P7726, DOI 10.1073/pnas.1230736100; Satake H, 2003, ZOOL SCI, V20, P533, DOI 10.2108/zsj.20.533; Satake H, 1999, J BIOL CHEM, V274, P5605, DOI 10.1074/jbc.274.9.5605; Satoh N, 2003, TRENDS GENET, V19, P376, DOI 10.1016/S0168-9525(03)00144-6; Satou Y, 2001, GENESIS, V30, P103, DOI 10.1002/gene.1040; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; Siviter RJ, 2000, J BIOL CHEM, V275, P23273, DOI 10.1074/jbc.M002875200; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; Takeuchi H, 2003, INSECT MOL BIOL, V12, P291, DOI 10.1046/j.1365-2583.2003.00414.x; TORRENS Y, 1989, J NEUROCHEM, V52, P1913, DOI 10.1111/j.1471-4159.1989.tb07276.x; WANG YX, 1992, BIOCHEM J, V287, P827, DOI 10.1042/bj2870827; WAUGH D, 1994, PEPTIDES, V15, P155, DOI 10.1016/0196-9781(94)90185-6; Zhang Y, 2000, NAT IMMUNOL, V1, P392, DOI 10.1038/80826	51	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53798	53805		10.1074/jbc.M408161200	http://dx.doi.org/10.1074/jbc.M408161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485888	hybrid			2022-12-27	WOS:000225680600118
J	Schmeck, B; Zahlten, J; Moog, K; van Laak, V; Huber, S; Hocke, AC; Opitz, B; Hoffmann, E; Kracht, M; Zerrahn, J; Hammerschmidt, S; Rosseau, S; Suttorp, N; Hippenstiel, S				Schmeck, B; Zahlten, J; Moog, K; van Laak, V; Huber, S; Hocke, AC; Opitz, B; Hoffmann, E; Kracht, M; Zerrahn, J; Hammerschmidt, S; Rosseau, S; Suttorp, N; Hippenstiel, S			Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COMMUNITY-ACQUIRED PNEUMONIA; RHO-PROTEIN-INHIBITION; P65 SUBUNIT; C-JUN; KINASE; ACTIVATION; EXPRESSION; CELLS; TRANSFORMATION	Streptococcus pneumoniae is the major cause of community-acquired pneumonia and one of the most common causes of death by infectious disease in industrialized countries. Little is known concerning the mechanisms of target cell activation in this disease. The present study shows that NF-kappaB and p38 MAPK signaling pathways contribute to chemokine synthesis by lung epithelial cells in response to pneumococci. In infected lungs of mice pneumococci stimulate expression of the interleukin (IL)-8 homolog keratinocyte-derived chemokine and granulocyte-macrophage colony-stimulating factor, as well as activate p38 MAPK. Human bronchial epithelium was chosen as a cellular model, because it establishes the first barrier against pathogens, and little is known about its function in innate immunity. Pneumococci infection induces expression of IL-8 and granulocyte-macrophage colony-stimulating factor as well as activation of p38 MAPK in human bronchial epithelial cells (BEAS-2B). Inhibition of p38 MAPK activity by SB202190 and SB203580 blocks pneumococci-induced cytokine release. In mouse lungs in vivo as well as in cultured cells, pneumococci activate NF-kappaB in an IkappaB kinase-dependent manner. Inhibition of p38 MAPK by chemical inhibitors or by RNA interference targeting p38alpha reduces pneumococci-induced NF-kappaB-dependent gene transcription. Blockade of p38 activity did not affect inducible nuclear translocation and recruitment of NF-kappaB/RelA to the IL-8 promotor but did reduce the level of phosphorylated RelA ( serine 536) at IL-8 promotor and inhibited pneumococci-mediated recruitment of RNA polymerase II to IL-8 promotor. Thus, p38 MAPK contributes to pneumococci-induced chemokine transcription by modulating p65 NF-kappaB-mediated transactivation.	Univ Med Berlin, Charite, Dept Internal Med Infect Dis, D-13353 Berlin, Germany; Hannover Med Sch, Inst Pharmacol, D-30623 Hannover, Germany; Max Planck Inst Infect Biol, D-10117 Berlin, Germany; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; Max Planck Society; University of Wurzburg	Hippenstiel, S (corresponding author), Univ Med Berlin, Charite, Dept Internal Med Infect Dis, Augustenburger Pl 1, D-13353 Berlin, Germany.	stefan.hippenstiel@charite.de	Rosseau, Simone/AAO-1201-2020; Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681; Suttorp, Norbert/0000-0002-3958-1151; Hippenstiel, Stefan/0000-0002-5146-1064; Opitz, Bastian/0000-0003-1276-836X; Kracht, Michael/0000-0002-8501-043X; Hoffmann-Lucke, Elke/0000-0002-2437-0140				Austrian R, 1999, J INFECT DIS, V179, pS338, DOI 10.1086/513841; Benton KA, 1997, MICROB PATHOGENESIS, V23, P201, DOI 10.1006/mpat.1997.0150; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Finch R, 2001, CLIN MICROBIOL INFEC, V7, P30, DOI 10.1046/j.1469-0691.2001.00052.x; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hale KK, 1999, J IMMUNOL, V162, P4246; Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399; Hippenstiel S, 2002, BIOCHEM PHARMACOL, V64, P971, DOI 10.1016/S0006-2952(02)01162-0; Hippenstiel S, 2000, BLOOD, V95, P3044; Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Koch A, 2004, AM J RESP CELL MOL, V30, P342, DOI 10.1165/rcmb.2003-0122OC; Koedel U, 2003, J IMMUNOL, V170, P438, DOI 10.4049/jimmunol.170.1.438; Krull M, 1999, J IMMUNOL, V162, P4834; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Nick JA, 2002, J IMMUNOL, V169, P5260, DOI 10.4049/jimmunol.169.9.5260; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; REDDEL RR, 1988, CANCER RES, V48, P1904; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schmeck B, 2003, INFLAMMATION, V27, P89, DOI 10.1023/A:1023278600596; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Strieter RM, 2003, CURR OPIN INFECT DIS, V16, P193, DOI 10.1097/00001432-200306000-00002; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; TIRABY JG, 1973, P NATL ACAD SCI USA, V70, P3541, DOI 10.1073/pnas.70.12.3541; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang EJ, 2001, INFECT IMMUN, V69, P5294, DOI 10.1128/IAI.69.9.5294-5304.2001; Zhou LM, 2003, AM J RESP CELL MOL, V28, P762, DOI 10.1165/rcmb.2002-0261OC; Zysk G, 2001, INFECT IMMUN, V69, P845, DOI 10.1128/IAI.69.2.845-852.2001	36	103	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53241	53247		10.1074/jbc.M313702200	http://dx.doi.org/10.1074/jbc.M313702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485852	hybrid			2022-12-27	WOS:000225680600054
J	Winshell, J; Paulson, BA; Buelow, BD; Champoux, JJ				Winshell, J; Paulson, BA; Buelow, BD; Champoux, JJ			Requirements for DNA unpairing during displacement synthesis by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DOUBLE-STRANDED DNA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; AVIAN RETROVIRUS; TEMPLATE-PRIMER; THERMODYNAMIC PARAMETERS; FUNCTIONAL IMPLICATIONS; NUCLEIC-ACID; INITIATION	DNA displacement synthesis by reverse transcriptase during retroviral replication is required for the production of the linear precursor to integration. The sensitivity of unpaired thymines to KMnO4 oxidation was used to probe for the extent of DNA melting by human immunodeficiency virus, type 1 (HIV-1) reverse transcriptase in front of the primer terminus in model oligonucleotide-based displacement constructs. Unpairing of the two base pairs downstream of the primer (+1 and +2 positions) requires the presence of the next correct dNTP, indicating that DNA melting only occurs after the formation of the ternary complex with the enzyme tightly clamped around the DNA. The amount or extent of DNA melting is not significantly affected by the length of the already-displaced strand or the base composition of the DNA beyond the +2 position. The F61W mutant form of HIV-1 reverse transcriptase, which is partially impaired for displacement synthesis, exhibits a reduction in the amount of melting at the +1 and +2 positions. These results demonstrate the importance of the observed melting to displacement synthesis and suggest that the unpairing reaction is mediated by an intimate association between the fingers region of the enzyme and the DNA in the closed clamp conformation of the protein.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Bommarito S, 2000, NUCLEIC ACIDS RES, V28, P1929, DOI 10.1093/nar/28.9.1929; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; DOKTYCZ MJ, 1990, BIOPOLYMERS, V30, P829, DOI 10.1002/bip.360300718; Fisher TS, 2003, J MOL BIOL, V325, P443, DOI 10.1016/S0022-2836(02)01225-1; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HANSLER U, 1993, J AM CHEM SOC, V115, P8554, DOI 10.1021/ja00072a005; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; Hou EW, 2004, PROTEIN EXPRES PURIF, V34, P75, DOI 10.1016/j.pep.2003.10.018; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; Lanciault C, 2004, J BIOL CHEM, V279, P32252, DOI 10.1074/jbc.M404117200; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Najmudin S, 2000, J MOL BIOL, V296, P613, DOI 10.1006/jmbi.1999.3477; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Ramaiah D, 1998, NUCLEIC ACIDS RES, V26, P3940, DOI 10.1093/nar/26.17.3940; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SENIOR M, 1988, BIOCHEMISTRY-US, V27, P3879, DOI 10.1021/bi00410a053; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Sugimoto N, 1996, NUCLEIC ACIDS RES, V24, P4501, DOI 10.1093/nar/24.22.4501; TAYLOR JM, 1983, J VIROL, V48, P654, DOI 10.1128/JVI.48.3.654-659.1983; VARMUS H, 1989, MOBILE DNA, P53; Whiting SH, 1998, J MOL BIOL, V278, P559, DOI 10.1006/jmbi.1998.1720; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; Winshell J, 2001, J MOL BIOL, V306, P931, DOI 10.1006/jmbi.2001.4439; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	40	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52924	52933		10.1074/jbc.M409134200	http://dx.doi.org/10.1074/jbc.M409134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465813	hybrid			2022-12-27	WOS:000225680600016
J	Bonin, F; Ryan, SD; Migahed, L; Mo, F; Lallier, J; Franks, DJ; Arai, H; Bennett, SAL				Bonin, F; Ryan, SD; Migahed, L; Mo, F; Lallier, J; Franks, DJ; Arai, H; Bennett, SAL			Anti-apoptotic actions of the platelet-activating factor acetylhydrolase I alpha(2) catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PAF-ACETHER; FACTOR RECEPTOR; CELL-DEATH; TRANSBILAYER MOVEMENT; PHOSPHOLIPASE A(2); EXPRESSION; INHIBITION; ANTAGONISTS; METABOLISM; BINDING	Platelet-activating factor (PAF) is an important mediator of cell loss following diverse pathophysiological challenges, but the manner in which PAF transduces death is not clear. Both PAF receptor-dependent and - independent pathways are implicated. In this study, we show that extracellular PAF can be internalized through PAF receptor-independent mechanisms and can initiate caspase-3-dependent apoptosis when cytosolic concentrations are elevated by similar to 15 pM/cell for 60 min. Reducing cytosolic PAF to less than 10 pM/cell terminates apoptotic signaling. By pharmacological inhibition of PAF acetylhydrolase I and II (PAF-AH) activity and down-regulation of PAF-AH I catalytic subunits by RNA interference, we show that the PAF receptor-independent death pathway is regulated by PAF-AH I and, to a lesser extent, by PAF-AH II. Moreover, the anti-apoptotic actions of PAF-AH I are subunit-specific. PAF-AH I alpha(1) regulates intracellular PAF concentrations under normal physiological conditions, but expression is not sufficient to reduce an acute rise in intracellular PAF levels. PAF-AH I alpha(2) expression is induced when cells are deprived of serum or exposed to apoptogenic PAF concentrations limiting the duration of pathological cytosolic PAF accumulation. To block PAF receptor-independent death pathway, we screened a panel of PAF antagonists (CV-3988, CV-6209, BN 52021, and FR 49175). BN 52021 and FR 49175 accelerated PAF hydrolysis and inhibited PAF-mediated caspase 3 activation. Both antagonists act indirectly to promote PAF-AH I alpha(2) homodimer activity by reducing PAF-AH I alpha(1) expression. These findings identify PAF-AH I alpha(2) as a potent antiapoptotic protein and describe a new means of pharmacologically targeting PAF-AH I to inhibit PAF-mediated cell death.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Neural Regenerat Lab, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Pathol, Ottawa, ON K1H 8M5, Canada; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Ottawa; University of Ottawa; University of Tokyo	Bennett, SAL (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Neural Regenerat Lab, Ottawa, ON K1H 8M5, Canada.	sbennet@uottawa.ca		Ryan, Scott/0000-0001-9829-4649				Asano K, 1999, BIOCHEM BIOPH RES CO, V261, P511, DOI 10.1006/bbrc.1999.1066; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Bate C, 2004, NEUROREPORT, V15, P509, DOI 10.1097/00001756-200403010-00025; Bate C, 2004, J BIOL CHEM, V279, P36405, DOI 10.1074/jbc.M404086200; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Bennett SAL, 1998, CELL DEATH DIFFER, V5, P867, DOI 10.1038/sj.cdd.4400434; BIRKLE DL, 1988, J NEUROCHEM, V51, P1900, DOI 10.1111/j.1471-4159.1988.tb01175.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; Brewer C, 2002, J NEUROCHEM, V82, P1502, DOI 10.1046/j.1471-4159.2002.01094.x; Chen CH, 2003, CIRCULATION, V107, P2102, DOI 10.1161/01.CIR.0000065220.70220.F7; Darst M, 2004, J IMMUNOL, V172, P6330, DOI 10.4049/jimmunol.172.10.6330; Dupre DJ, 2001, J PHARMACOL EXP THER, V299, P358; Fukuda Y, 2000, EUR J PHARMACOL, V390, P203, DOI 10.1016/S0014-2999(99)00920-6; GERARD NP, 1994, J IMMUNOL, V152, P793; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirashima Y, 2000, BRAIN RES, V885, P128, DOI 10.1016/S0006-8993(00)02852-3; Hostettler ME, 2002, GLIA, V38, P228, DOI 10.1002/glia.10065; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; LACHACHI H, 1985, BIOCHEM BIOPH RES CO, V132, P460, DOI 10.1016/0006-291X(85)91156-8; LAMANT V, 1987, BIOCHEM PHARMACOL, V36, P2749, DOI 10.1016/0006-2952(87)90259-0; Li T, 2003, J BIOL CHEM, V278, P16614, DOI 10.1074/jbc.M211287200; Lu J, 2004, AM J PHYSIOL-GASTR L, V286, pG340, DOI 10.1152/ajpgi.00182.2003; Ma X, 2001, CURR EYE RES, V23, P326, DOI 10.1076/ceyr.23.5.326.5445; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Manya H, 1999, J BIOL CHEM, V274, P31827, DOI 10.1074/jbc.274.45.31827; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; Marques M, 2002, J INVEST DERMATOL, V119, P913, DOI 10.1046/j.1523-1747.2002.01859.x; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Mori M, 1996, J NEUROSCI, V16, P3590; NUNEZ D, 1986, EUR J PHARMACOL, V123, P197, DOI 10.1016/0014-2999(86)90660-6; OFLAHERTY JT, 1987, BIOCHEM BIOPH RES CO, V147, P18, DOI 10.1016/S0006-291X(87)80081-5; Ogden F, 1998, J NEUROSCI RES, V53, P677, DOI 10.1002/(SICI)1097-4547(19980915)53:6<677::AID-JNR6>3.0.CO;2-2; Ohshima N, 2002, J BIOL CHEM, V277, P9722, DOI 10.1074/jbc.M112406200; OKAMOTO M, 1986, CHEM PHARM BULL, V34, P345; Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660; Pietri S, 1997, J MOL CELL CARDIOL, V29, P733, DOI 10.1006/jmcc.1996.0316; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Southall MD, 2001, J BIOL CHEM, V276, P45548, DOI 10.1074/jbc.M105978200; TERASHITA ZI, 1987, J PHARMACOL EXP THER, V242, P263; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tokuoka SM, 2003, EUR J NEUROSCI, V18, P563, DOI 10.1046/j.1460-9568.2003.02778.x; Tong N, 2001, EUR J NEUROSCI, V13, P1913, DOI 10.1046/j.0953-816x.2001.01572.x; VALONE FH, 1985, BIOCHEM BIOPH RES CO, V126, P502, DOI 10.1016/0006-291X(85)90634-5; Yoshida K, 1988, Prog Biochem Pharmacol, V22, P66	51	33	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52425	52436		10.1074/jbc.M410967200	http://dx.doi.org/10.1074/jbc.M410967200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456758	hybrid			2022-12-27	WOS:000225493400087
J	Fu, VX; Schwarze, SR; Kenowski, ML; LeBlanc, S; Svaren, J; Jarrard, DF				Fu, VX; Schwarze, SR; Kenowski, ML; LeBlanc, S; Svaren, J; Jarrard, DF			A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; BENIGN PROSTATIC HYPERPLASIA; BECKWITH-WIEDEMANN-SYNDROME; CPG-ISLAND METHYLATION; TUMOR SUPPRESSOR WT1; DNA METHYLATION; WILMS-TUMOR; COLORECTAL-CANCER; IGF2/H19 LOCUS; CTCF-BINDING	The imprinted insulin-like growth factor-2 (IGF2) gene is an auto/paracrine growth factor expressed only from the paternal allele in adult tissues. In tissues susceptible to aging-related cancers, including the prostate, a relaxation of IGF2 imprinting is found, suggesting a permissive role for epigenetic alterations in cancer development. To determine whether IGF2 imprinting is altered in cellular aging and senescence, human prostate epithelial and urothelial cells were passaged serially in culture to senescence. Allelic analyses using an IGF2 polymorphism demonstrated a complete conversion of the IGF2 imprint status from monoallelic to biallelic, in which the development of senescence was associated with a 10-fold increase in IGF2 expression. As a mechanism, a 2-fold decrease in the binding of the enhancer-blocking element CCCTC-binding factor (CTCF) within the intergenic IGF2-H19 region was found to underlie this switch to biallelic IGF2 expression in senescent cells. This decrease in CTCF binding was associated with reduced CTCF expression in senescent cells. No de novo increases in methylation at the IGF2 CTCF binding site were seen. The forced down-regulation of CTCF expression using small interfering RNA in imprinted prostate cell lines resulted in an increase in IGF2 expression and a relaxation of imprinting. Our data suggest a novel mechanism for IGF2 imprinting regulation, that is, the reduction of CTCF expression in the control of IGF2 imprinting. We also demonstrate that altered imprinting patterns contribute to changes in gene expression in aging cells.	Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Sch Vet Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Environm & Mol Toxicol, Sch Vet Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Comparat Biosci, Sch Vet Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarrard, DF (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Sch Vet Med, 600 Highland Ave,K6-530, Madison, WI 53792 USA.	jarrard@surgery.wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	NATIONAL CANCER INSTITUTE [K08CA076184, R01CA097131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA97131, K08CA76184] Funding Source: Medline; NIDDK NIH HHS [1P50DK065303] Funding Source: Medline; NIGMS NIH HHS [T32 GM08688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDFORD MT, 1987, CANCER RES, V47, P5274; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BONNET P, 1993, J CLIN ENDOCR METAB, V77, P1203, DOI 10.1210/jc.77.5.1203; Campisi J, 2000, IN VIVO, V14, P183; CATANIA J, 1991, MUTAT RES, V256, P283, DOI 10.1016/0921-8734(91)90019-8; Catchpoole D, 2000, J MED GENET, V37, P212, DOI 10.1136/jmg.37.3.212; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2001, CANCER RES, V61, P4947; Cui HM, 2002, CANCER RES, V62, P6442; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; Feinberg AP, 2000, CURR TOP MICROBIOL, V249, P87; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jarrard DF, 1999, CANCER RES, V59, P2957; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Jones BK, 2002, HUM MOL GENET, V11, P411, DOI 10.1093/hmg/11.4.411; Kaffer CR, 2001, MOL CELL BIOL, V21, P8189, DOI 10.1128/MCB.21.23.8189-8196.2001; Lee YI, 1996, DNA CELL BIOL, V15, P99, DOI 10.1089/dna.1996.15.99; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; Mazin A. L., 1993, Molekulyarnaya Biologiya (Moscow), V27, P895; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2000, INT J DEV BIOL, V44, P145; Reik W, 2001, ELECTROPHORESIS, V22, P2838, DOI 10.1002/1522-2683(200108)22:14&lt;2838::AID-ELPS2838&gt;3.0.CO;2-M; REZNIKOFF CA, 1983, IN VITRO CELL DEV B, V19, P326; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Sasaki H, 2000, J BIOCHEM, V127, P711, DOI 10.1093/oxfordjournals.jbchem.a022661; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SINGHAL RP, 1987, MECH AGEING DEV, V41, P199, DOI 10.1016/0047-6374(87)90040-6; Slater M, 2000, HISTOCHEM J, V32, P357, DOI 10.1023/A:1004065630631; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tran CP, 2002, MOL CANCER RES, V1, P113; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vu TH, 2000, GENOMICS, V64, P132, DOI 10.1006/geno.1999.6094; Zhan SL, 1998, BRAIN RES, V792, P283, DOI 10.1016/S0006-8993(98)00157-7; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	55	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52218	52226		10.1074/jbc.M405015200	http://dx.doi.org/10.1074/jbc.M405015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471867	hybrid			2022-12-27	WOS:000225493400062
J	Uchida, T; Stevens, JM; Daltrop, O; Harvat, EM; Hong, L; Ferguson, SJ; Kitagawa, T				Uchida, T; Stevens, JM; Daltrop, O; Harvat, EM; Hong, L; Ferguson, SJ; Kitagawa, T			The interaction of covalently bound heme with the cytochrome c maturation protein CcmE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CHAPERONE CCME; SERRATIA-MARCESCENS; PROXIMAL HISTIDINE; LUCINA-PECTINATA; VINYL INFLUENCES; HEMOGLOBINS-M; M IWATE	The heme chaperone CcmE is a novel protein that binds heme covalently via a histidine residue as part of its essential function in the process of cytochrome c biogenesis in many bacteria as well as plant mitochondria. In the continued absence of a structure of the holoform of CcmE, identification of the heme ligands is an important step in understanding the molecular function of this protein and the role of covalent heme binding to CcmE during the maturation of c-type cytochromes. In this work, we present spectroscopic data that provide insight into the ligation of the heme iron in the soluble domain of CcmE from Escherichia coli. Resonance Raman spectra demonstrated that one of the heme axial ligands is a histidine residue and that the other is likely to be Tyr(134). In addition, the properties of the heme resonances of the holo-protein as compared with those of a form of CcmE with non-covalently bound heme provide evidence for the modification of one of the heme vinyl side chains by the protein, most likely the 2-vinyl group.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Aichi 4448787, Japan; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Oxford	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Aichi 4448787, Japan.	teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Agrawal V, 2003, CURR PROTEIN PEPT SC, V4, P195, DOI 10.2174/1389203033487207; Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BANGCHAROENPAURPONG O, 1987, J CHEM PHYS, V87, P4273, DOI 10.1063/1.452885; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; CHOI S, 1982, J AM CHEM SOC, V104, P4337, DOI 10.1021/ja00380a005; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; Enggist E, 2003, J BACTERIOL, V185, P175, DOI 10.1128/JB.185.1.175-183.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Fee JA, 2004, BIOCHEMISTRY-US, V43, P12162, DOI 10.1021/bi048968l; Gao F, 1998, BIOCHEMISTRY-US, V37, P9751, DOI 10.1021/bi9800653; Gao F, 1999, BBA-PROTEIN STRUCT M, V1430, P203, DOI 10.1016/S0167-4838(98)00284-2; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; HARADA I, 1986, SPECTROCHIM ACTA A, V42, P307, DOI 10.1016/0584-8539(86)80193-3; HARADA I, 1986, SPECTROSCOPY BIOL SY, V13; HU SH, 1992, FEBS LETT, V314, P293, DOI 10.1016/0014-5793(92)81492-5; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Jayaraman V, 1996, BIOSPECTROSCOPY, V2, P311, DOI 10.1002/(SICI)1520-6343(1996)2:5<311::AID-BSPY4>3.3.CO;2-L; Kincaid JR, 1996, J BIOL CHEM, V271, P28805, DOI 10.1074/jbc.271.46.28805; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Ma JG, 1998, BIOCHEMISTRY-US, V37, P5118, DOI 10.1021/bi972375b; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; Nagai M, 2000, BIOCHEMISTRY-US, V39, P13093, DOI 10.1021/bi001029i; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Stevens JM, 2003, J BIOL CHEM, V278, P20500, DOI 10.1074/jbc.M212925200; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; TSUBAKI M, 1980, BIOCHEMISTRY-US, V19, P379, DOI 10.1021/bi00543a020; VERMA AL, 1988, J AM CHEM SOC, V110, P6617, DOI 10.1021/ja00228a004; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	51	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51981	51988		10.1074/jbc.M408963200	http://dx.doi.org/10.1074/jbc.M408963200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465823	hybrid			2022-12-27	WOS:000225493400034
J	Kou, I; Ikegawa, S				Kou, I; Ikegawa, S			SOX9-dependent and -independent transcriptional regulation of human cartilage link protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; II COLLAGEN GENE; RETINOIC ACID; IN-VIVO; SOX9; CHONDROGENESIS; EXPRESSION; DIFFERENTIATION; COL2A1; TRANSACTIVATION	Cartilage link protein is a key component of the cartilage extracellular matrix. The transcriptional regulation of the gene encoding cartilage link protein (CRTL1) is largely unknown, however. Here, we investigated the regulation of CRTL1 by SOX9, a key regulator of cartilage matrix genes and chondrogenesis. Knockdown of SOX9 resulted in decreased CRTL1 expression. SOX9 induced CRTL1 expression effectively in human nonchondrocytic immortalized cell lines as well as in mesenchymal stem cell and adult dermal fibroblast. These results indicate that, like other cartilage matrix genes, SOX9 is a key regulator of CRTL1. Unlike other cartilage matrix genes, however, the activation of CRTL1 by SOX9 and its known transcriptional co-activators L-SOX5 and SOX6 was cell type-dependent. Two cis-acting enhancer elements resided in the 5'-untranslated region of CRTL1. One contained a heptameric SOX binding sequence and showed SOX9-dependent enhancer activity in several cell lines. The other showed cell type-specific SOX9-independent enhancer activity. These findings suggest that the enhancer elements may mediate differential expression of CRTL1 during chondrocyte differentiation and maturation.	Univ Tokyo, Inst Med Sci, RIKEN, SNP Res Ctr,Lab Bone & Joint Dis,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Ikegawa, S (corresponding author), Univ Tokyo, Inst Med Sci, RIKEN, SNP Res Ctr,Lab Bone & Joint Dis,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sikegawa@ims.u-tokyo.ac.jp	Ikegawa, Shiro/N-6895-2015	Ikegawa, Shiro/0000-0003-0316-2147				Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bernard P, 2003, HUM MOL GENET, V12, P1755, DOI 10.1093/hmg/ddg182; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BINETTE F, 1994, J BIOL CHEM, V269, P19116; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; Czipri M, 2003, J BIOL CHEM, V278, P39214, DOI 10.1074/jbc.M303329200; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDHIA J, 1994, BIOCHEM J, V303, P329, DOI 10.1042/bj3030329; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; McKenna LA, 1998, ARTHRITIS RHEUM, V41, P157, DOI 10.1002/1529-0131(199801)41:1<157::AID-ART19>3.0.CO;2-J; MORGELIN M, 1988, BIOCHEM J, V253, P175; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; RHODES C, 1995, NUCLEIC ACIDS RES, V23, P2305, DOI 10.1093/nar/23.12.2305; RHODES C, 1991, NUCLEIC ACIDS RES, V19, P1933, DOI 10.1093/nar/19.8.1933; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Vornehm SI, 1996, MATRIX BIOL, V15, P91, DOI 10.1016/S0945-053X(96)90150-X; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	32	81	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50942	50948		10.1074/jbc.M406786200	http://dx.doi.org/10.1074/jbc.M406786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456769	hybrid			2022-12-27	WOS:000225355800037
J	Krug, A; Wendisch, VF; Bott, M				Krug, A; Wendisch, VF; Bott, M			Identification of AcnR, a TetR-type repressor of the aconitase gene acn in Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS ACONITASE; ESCHERICHIA-COLI ACONITASES; DNA MICROARRAY ANALYSES; POSTTRANSCRIPTIONAL REGULATION; BINDING PROTEIN; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; ACETATE METABOLISM; MOLECULAR ANALYSIS; RESPIRATORY-CHAIN	In Corynebacterium glutamicum, the activity of aconitase is 2.5-4-fold higher on propionate, citrate, or acetate than on glucose. Here we show that this variation is caused by transcriptional regulation. In search for putative regulators, a gene (acnR) encoding a TetR-type transcriptional regulator was found to be encoded immediately downstream of the aconitase gene (acn) in C. glutamicum. Deletion of the acnR gene led to a 5-fold increased acn-mRNA level and a 5-fold increased aconitase activity, suggesting that AcnR functions as repressor of acn expression. DNA microarray analyses indicated that acn is the primary target gene of AcnR in the C. glutamicum genome. Purified AcnR was shown to be a homodimer, which binds to the acn promoter in the region from -11 to -28 relative to the transcription start. It thus presumably acts by interfering with the binding of RNA polymerase. The acn-acnR organization is conserved in all corynebacteria and mycobacteria with known genome sequence and a putative AcnR consensus binding motif (CAGNACnnncGTACTG) was identified in the corresponding acn upstream regions. Mutations within this motif inhibited AcnR binding. Because the activities of citrate synthase and isocitrate dehydrogenase were previously reported not to be increased during growth on acetate, our data indicate that aconitase is a major control point of tricarboxylic acid cycle activity in C. glutamicum, and they identify AcnR as the first transcriptional regulator of a tricarboxylic acid cycle gene in the Corynebacterianeae.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Bott, M (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	m.bott@fz-juelich.de	Wendisch, Volker F./M-5940-2016; Bott, Michael/E-8004-2011	Wendisch, Volker F./0000-0003-3473-0012; Bott, Michael/0000-0002-4701-8254				Alen C, 1999, P NATL ACAD SCI USA, V96, P10412, DOI 10.1073/pnas.96.18.10412; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bott M, 2003, J BIOTECHNOL, V104, P129, DOI 10.1016/S0168-1656(03)00144-5; Brock M, 2002, EUR J BIOCHEM, V269, P6184, DOI 10.1046/j.1432-1033.2002.03336.x; Claes WA, 2002, J BACTERIOL, V184, P2728, DOI 10.1128/JB.184.10.2728-2739.2002; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cunningham L, 1997, MICROBIOL-UK, V143, P3795, DOI 10.1099/00221287-143-12-3795; Eggeling L, 1999, APPL MICROBIOL BIOT, V52, P146, DOI 10.1007/s002530051501; EIKMANNS BJ, 1995, J BACTERIOL, V177, P774, DOI 10.1128/jb.177.3.774-782.1995; EIKMANNS BJ, 1991, GENE, V102, P93, DOI 10.1016/0378-1119(91)90545-M; EIKMANNS BJ, 1994, MICROBIOL-SGM, V140, P1817, DOI 10.1099/13500872-140-8-1817; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engels S, 2004, MOL MICROBIOL, V52, P285, DOI 10.1111/j.1365-2958.2003.03979.x; Engohang-Ndong J, 2004, MOL MICROBIOL, V51, P175, DOI 10.1046/j.1365-2958.2003.03809.x; Gerstmeir R, 2004, J BACTERIOL, V186, P2798, DOI 10.1128/JB.186.9.2798-2809.2004; Gerstmeir R, 2003, J BIOTECHNOL, V104, P99, DOI 10.1016/S0168-1656(03)00167-6; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; Gruer MJ, 1997, TRENDS BIOCHEM SCI, V22, P3, DOI 10.1016/S0968-0004(96)10069-4; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENSON CP, 1967, J BIOL CHEM, V242, P3833; Hermann T, 2003, J BIOTECHNOL, V104, P155, DOI 10.1016/S0168-1656(03)00149-4; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Ishige T, 2003, J BACTERIOL, V185, P4519, DOI 10.1128/JB.185.15.4519-4529.2003; Jourlin-Castelli C, 2000, J MOL BIOL, V295, P865, DOI 10.1006/jmbi.1999.3420; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; Kim HJ, 2003, J BACTERIOL, V185, P1672, DOI 10.1128/JB.185.5.1672-1680.2003; Kim SI, 2003, J MOL BIOL, V334, P609, DOI 10.1016/j.jmb.2003.09.078; Kimura Eiichiro, 2003, Adv Biochem Eng Biotechnol, V79, P37; Kinoshita S., 1957, J GEN APPL MICROBIOL, V3, P193, DOI [10.2323/jgam.3.193, DOI 10.2323/JGAM.3.193]; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange C, 2003, APPL ENVIRON MICROB, V69, P2521, DOI 10.1128/AEM.69.5.2521-2532.2003; MENKEL E, 1989, APPL ENVIRON MICROB, V55, P684, DOI 10.1128/AEM.55.3.684-688.1989; Moker N, 2004, MOL MICROBIOL, V54, P420, DOI 10.1111/j.1365-2958.2004.04249.x; Molenaar D, 2000, J BACTERIOL, V182, P6884, DOI 10.1128/JB.182.24.6884-6891.2000; Molenaar D, 1998, EUR J BIOCHEM, V254, P395, DOI 10.1046/j.1432-1327.1998.2540395.x; Niebisch A, 2001, ARCH MICROBIOL, V175, P282, DOI 10.1007/s002030100262; Pfefferle Walter, 2003, Adv Biochem Eng Biotechnol, V79, P59; Polen T, 2003, APPL ENVIRON MICROB, V69, P1759, DOI 10.1128/AEM.69.3.1759-1774.2003; PRODROMOU C, 1991, J GEN MICROBIOL, V137, P2505, DOI 10.1099/00221287-137-11-2505; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schaffer S, 2001, ELECTROPHORESIS, V22, P4404, DOI 10.1002/1522-2683(200112)22:20<4404::AID-ELPS4404>3.0.CO;2-2; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Skerra A, 2000, METHOD ENZYMOL, V326, P271; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tang Y, 1999, MICROBIOL-SGM, V145, P3069, DOI 10.1099/00221287-145-11-3069; Tang Y, 2004, MOL MICROBIOL, V51, P1817, DOI 10.1111/j.1365-2958.2003.03954.x; Tang Y, 2002, MICROBIOL-SGM, V148, P1027, DOI 10.1099/00221287-148-4-1027; Textor S, 1997, ARCH MICROBIOL, V168, P428, DOI 10.1007/s002030050518; Usuda Y, 1996, MICROBIOL-UK, V142, P3347, DOI 10.1099/13500872-142-12-3347; van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557; Wendisch VF, 2003, J BIOTECHNOL, V104, P273, DOI 10.1016/S0168-1656(03)00147-0; Wendisch VF, 2001, ANAL BIOCHEM, V290, P205, DOI 10.1006/abio.2000.4982; Wendisch VF, 2000, J BACTERIOL, V182, P3088, DOI 10.1128/JB.182.11.3088-3096.2000; Wong DK, 1999, INFECT IMMUN, V67, P327, DOI 10.1128/IAI.67.1.327-336.1999	63	57	68	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					585	595		10.1074/jbc.M408271200	http://dx.doi.org/10.1074/jbc.M408271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494411	hybrid, Green Published			2022-12-27	WOS:000226025100070
J	Qing, GL; Qu, ZX; Xiao, GT				Qing, GL; Qu, ZX; Xiao, GT			Regulation of NF-kappa B2 p100 processing by its cis-acting domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IKK-ALPHA; MEDIATED ACTIVATION; KINASE; PROTEINS; BETA; GENE; GENERATION; EXPRESSION; SIGNAL	Processing of NF-kappaB2 precursor protein p100 to generate p52 is tightly regulated. However, this proteolytic event could be actively induced by the NF-kappaB-inducing kinase and the human T-cell leukemia virus-encoded oncoprotein Tax or be constitutively turned on due to the loss of the C-terminal portion of p100. Whereas NF-kappaB-inducing kinase-mediated p100 processing requires beta-transducin repeat-containing protein, constitutive processing of p100 is independent of this protein. On the other hand, Tax-induced processing of p100 appears to be both beta-transducin repeat-containing protein-dependent and -independent. We show here that, besides the C-terminal sequences, multiple functional regions, including the two alpha-helices, dimerization domain, nuclear localization sequence, and glycine-rich region, located in the N terminus of p100, also play important roles in both constitutive and inducible processing, suggesting a common mechanism for p100 processing. We further demonstrate that with the help of the C-terminal death domain and IkappaB kinase alpha-targeting serines, the C-terminal ankyrin-repeat domain of p100 strongly interacts with its N-terminal dimerization domain and nuclear localization sequence, thereby bringing the C- and N-terminal sequences together to form a three-dimensional domain. This presumptive domain is not only responsible for suppression of constitutive processing but also required for inducible processing of p100. Taken together, these studies highlight the mechanism by which the different sequences within p100 work in concert to regulate its processing and shed light on the mechanisms of how p100 processing is tightly and delicately controlled.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Lab, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Xiao, GT (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Lab, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu						Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LANOIX J, 1994, ONCOGENE, V9, P841; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; Lin L, 1996, MOL CELL BIOL, V16, P2248; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; THAKUR S, 1994, ONCOGENE, V9, P2335; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; ZHANG JD, 1994, ONCOGENE, V9, P1931	47	42	43	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					18	27		10.1074/jbc.M406619200	http://dx.doi.org/10.1074/jbc.M406619200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15485830	hybrid			2022-12-27	WOS:000226025100004
J	Deka, RK; Neil, L; Hagman, KE; Machius, M; Tomchick, DR; Brautigam, CA; Norgard, MV				Deka, RK; Neil, L; Hagman, KE; Machius, M; Tomchick, DR; Brautigam, CA; Norgard, MV			Structural evidence that the 32-kilodalton lipoprotein (Tp32) of Treponema pallidum is an L-methionine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; BORRELIA-BURGDORFERI LIPOPROTEINS; ESCHERICHIA-COLI; OUTER-MEMBRANE; PERIPLASMIC LYSINE; ABC TRANSPORTERS; ARGININE; ENCODES; SYSTEM; LIGAND	A structure-to-function approach was undertaken to gain insights into the potential function of the 32-kDa membrane lipoprotein (Tp32) of Treponema pallidum, the syphilis bacterium. The crystal structure of rTp32 (determined at a resolution of 1.85 Angstrom) shows that the organization of rTp32 is similar to other periplasmic ligand-binding proteins (PLBPs), in that it consists of two alpha/beta domains, linked by two crossovers, with a binding pocket between them. In the pocket, a molecule of L-methionine was detected in the electron density map. Residues from both domains interact with the ligand. One of the crossover regions is comprised of a 3(10)-helix, a feature not typical in other ligand-binding proteins. Sequence comparison shows strong similarity to other hypothetical methionine-binding proteins. Together, the data support the notion that rTp32 is a component of a periplasmic methionine uptake transporter system in T. pallidum.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Norgard, MV (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.norgard@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Brautigam, Chad/0000-0001-6563-1338	NIAID NIH HHS [AI 56305] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER PS, 1994, INFECT IMMUN, V62, P1381, DOI 10.1128/IAI.62.4.1381-1391.1994; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Deka RK, 2004, J BACTERIOL, V186, P2303, DOI 10.1128/JB.186.8.2303-2308.2004; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gal J, 2002, J BACTERIOL, V184, P4930, DOI 10.1128/JB.184.17.4930-4932.2002; Haake DA, 2000, MICROBIOL-SGM, V146, P1491, DOI 10.1099/00221287-146-7-1491; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hullo MF, 2004, RES MICROBIOL, V155, P80, DOI 10.1016/j.resmic.2003.11.008; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merlin C, 2002, J BACTERIOL, V184, P5513, DOI 10.1128/JB.184.19.5513-5517.2002; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido H, 1998, METHOD ENZYMOL, V292, P3; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; Ochsner UA, 1999, J BACTERIOL, V181, P1099, DOI 10.1128/JB.181.4.1099-1109.1999; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P26323; Oliver DB, 1996, ESCHERICHIA COLI SAL, P88; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; Radolf Justin D., 1994, Trends in Microbiology, V2, P307, DOI 10.1016/0966-842X(94)90446-4; Rodionov DA, 2004, NUCLEIC ACIDS RES, V32, P3340, DOI 10.1093/nar/gkh659; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P2213, DOI 10.1107/S0907444902016384; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; Zhang ZG, 2003, ARCH MICROBIOL, V180, P88, DOI 10.1007/s00203-003-0561-4	45	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55644	55650		10.1074/jbc.M409263200	http://dx.doi.org/10.1074/jbc.M409263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489229	hybrid			2022-12-27	WOS:000225960800083
J	Korkhov, VM; Farhan, H; Freissmuth, M; Sitte, HH				Korkhov, VM; Farhan, H; Freissmuth, M; Sitte, HH			Oligomerization of the gamma-aminobutyric acid transporter-1 is driven by an interplay of polar and hydrophobic interactions in transmembrane helix II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HUMAN SEROTONIN TRANSPORTER; RAT GABA TRANSPORTER-1; PLASMA-MEMBRANE; LEUCINE-ZIPPER; NEUROTRANSMITTER TRANSPORTERS; CROSS-LINKING; COILED-COIL; PROTEIN; ASSOCIATION	The available evidence indicates that members of the neurotransmitter: sodium symporter family form constitutive oligomers. Their second transmembrane helix (TM2) contains a leucine heptad repeat proposed to be involved in oligomerization. In artificial transmembrane segments, interhelical interactions are stabilized by polar residues. We searched for these hydrogen bond donors in TM2 by mutating the five polar residues in TM2 of the gamma-aminobutyric acid transporter- 1 (GAT1). We tested the ability of the resulting mutants to oligomerize by fluorescence microscopy, Foerster resonance energy transfer, and beta-lactamase fragment complementation. Of all generated mutants, only Y86A-(but not Y86F-), E101A-, E101Q-, and E101D-GAT1 were judged by these criteria to be deficient in oligomerization and were retained intracellularly. The observations are consistent with a model where the leucine heptad repeat in TM2 drives a homophilic association that is stabilized by Tyr(86) and Glu(101); Tyr(86) participates in hydrophobic stacking. Glu(101) is in the a-position of the leucine heptad repeat (where positions 1-7 are denoted a-g, and each leucine is in the central d- position). Thus, Glu(101) is in the position predicted for the hydrogen bond donor (i.e. sandwiched between Leu(97) and Leu(104), which are one helical turn above and below Glu(101)). These key residues, namely Tyr(86) and Glu(101), are conserved in related transporters from archaeae to humans; they are therefore likely to support oligomeric assembly in transporter orthologs and possibly other proteins with multiple transmembrane segments.	Vienna Med Univ, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Vienna Med Univ, Inst Pharmacol, Waehringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Sitte, Harald/O-7025-2019; Farhan, Hesso/C-7997-2012; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Farhan, Hesso/0000-0002-0889-8463; Sitte, Harald/0000-0002-1339-7444; Korkhov, Volodymyr/0000-0002-0962-9433; Freissmuth, Michael/0000-0001-9398-1765				Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Aggeli A, 1998, BIOCHEMISTRY-US, V37, P8121, DOI 10.1021/bi972112h; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Chelli R, 2002, J AM CHEM SOC, V124, P6133, DOI 10.1021/ja0121639; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Farhan H, 2004, J BIOL CHEM, V279, P28553, DOI 10.1074/jbc.M307325200; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Hahn MK, 2003, J NEUROSCI, V23, P4470; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; OKAYAMA H, 1985, MOL CELL BIOL, V5, P1136, DOI 10.1128/MCB.5.5.1136; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	35	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55728	55736		10.1074/jbc.M409449200	http://dx.doi.org/10.1074/jbc.M409449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496410	hybrid			2022-12-27	WOS:000225960800094
J	Lemonnier, M; Buckingham, ME				Lemonnier, M; Buckingham, ME			Characterization of a cardiac-specific enhancer, which directs alpha-cardiac actin gene transcription in the mouse adult heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; BINDING-FACTOR; IN-VITRO; CARG BOXES; EXPRESSION; MEF2; UPSTREAM; PROMOTER; ELEMENTS; ACTIVATION	Expression of the mouse alpha-cardiac actin gene in skeletal and cardiac muscle is regulated by enhancers lying 5' to the proximal promoter. Here we report the characterization of a cardiac-specific enhancer located within -2.354/-1.36 kbp of the gene, which is active in cardiocytes but not in C2 skeletal muscle cells. In vivo it directs reporter gene expression to the adult heart, where the proximal promoter alone is inactive. An 85-bp region within the enhancer is highly conserved between human and mouse and contains a central AT-rich site, which is essential for enhancer activity. This site binds myocyte enhancer factor (MEF)2 factors, principally MEF2D and MEF2A in cardiocyte nuclear extracts. These results are discussed in the context of MEF2 activity and of the regulation of the alpha-cardiac actin locus.	Inst Pasteur, Dept Dev Biol, CNRS, URA 2578, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buckingham, ME (corresponding author), Inst Pasteur, Dept Dev Biol, CNRS, URA 2578, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	margab@pasteur.fr						AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; BIBEN C, 1994, MOL CELL BIOL, V14, P3504, DOI 10.1128/MCB.14.5.3504; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; GARNER I, 1989, DEV BIOL, V134, P236, DOI 10.1016/0012-1606(89)90093-6; GARNER I, 1986, EMBO J, V5, P2559, DOI 10.1002/j.1460-2075.1986.tb04535.x; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; Hadchouel J, 2003, DEVELOPMENT, V130, P3415, DOI 10.1242/dev.00552; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Kelly RG, 2003, J CELL SCI, V116, P5005, DOI 10.1242/jcs.00824; Kelly RG, 1999, TRENDS CARDIOVAS MED, V9, P3, DOI 10.1016/S1050-1738(98)00034-6; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LI ZL, 1993, NEUROMUSCULAR DISORD, V3, P423, DOI 10.1016/0960-8966(93)90089-3; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MANIATIS T, 1989, MOL CLONING, P52; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTINEZ HM, 1983, NUCLEIC ACIDS RES, V11, P4629, DOI 10.1093/nar/11.13.4629; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; Molinari S, 2004, MOL CELL BIOL, V24, P2944, DOI 10.1128/MCB.24.7.2944-2957.2004; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Razeghi P, 2002, CIRCULATION, V106, P407, DOI 10.1161/01.CIR.0000026392.80723.DC; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	51	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55651	55658		10.1074/jbc.M411082200	http://dx.doi.org/10.1074/jbc.M411082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15491989	hybrid			2022-12-27	WOS:000225960800084
J	Liu, JG; Guan, XQ; Tamura, T; Ozato, K; Ma, XJ				Liu, JG; Guan, XQ; Tamura, T; Ozato, K; Ma, XJ			Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; NF-KAPPA-B; PROINFLAMMATORY CYTOKINE; IL-12 PRODUCTION; DENDRITIC CELLS; P40 EXPRESSION; C-REL; IRF-1; PROMOTER; MACROPHAGES	Interferon regulatory factor-1 (IRF-1) and interferon consensus sequence-binding protein (ICSBP or IRF-8) are two members of the IRF family of transcription factors that play critical roles in interferon signaling in a wide range of host responses to infection and malignancy. Interleukin-12 (IL-12) is a key factor in the induction of innate resistance and generation of T helper type 1 cells and cytotoxic T lymphocytes. In this work, we find that ICSBP-deficient macrophages are highly defective in the production of IL-12. The defect is also observed at the level of IL-12 p40 and p35 mRNA expression. Transcriptional analyses revealed that ICSBP is a potent activator of the IL-12 p35 gene. It acts through a site localized to -226 to -219, named ICSBP-response element (ICSBP-RE), in the human IL-12 p35 promoter through physical association with IRF-1 both in vitro and in vivo. Co-expression of ICSBP and IRF-1 synergistically stimulates the IL-12 p35 promoter activity. Mutations at the ICSBP-RE results in the loss of protein binding as well as transcriptional activation by ICSBP alone or together with IRF-1. This study provides novel mechanistic information on how signals initiated during innate and adaptive immune responses synergize to yield greater IL-12 production and sustained cellular immunity.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Ma, XJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	xim2002@med.cornell.edu			NATIONAL CANCER INSTITUTE [K01CA079772] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045899] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79772] Funding Source: Medline; NIAID NIH HHS [AI 045899] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babik JM, 1999, J IMMUNOL, V162, P4069; Carra G, 2000, J IMMUNOL, V164, P4752, DOI 10.4049/jimmunol.164.9.4752; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Edwards AD, 2002, J IMMUNOL, V169, P3652, DOI 10.4049/jimmunol.169.7.3652; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Grumont R, 2001, J EXP MED, V194, P1021, DOI 10.1084/jem.194.8.1021; Hayes MP, 1998, BLOOD, V91, P4645, DOI 10.1182/blood.V91.12.4645.412k36_4645_4651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JG, 2003, J EXP MED, V198, P1265, DOI 10.1084/jem.20030026; Lohoff M, 2000, J EXP MED, V192, P325, DOI 10.1084/jem.192.3.325; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Murphy FJ, 2000, J IMMUNOL, V164, P839, DOI 10.4049/jimmunol.164.2.839; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seki E, 2002, J IMMUNOL, V169, P3863, DOI 10.4049/jimmunol.169.7.3863; Snijders A, 1996, J IMMUNOL, V156, P1207; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tamura T, 2003, BLOOD, V102, P4547, DOI 10.1182/blood-2003-01-0291; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271	31	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55609	55617		10.1074/jbc.M406565200	http://dx.doi.org/10.1074/jbc.M406565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489234	hybrid			2022-12-27	WOS:000225960800079
J	Zhou, BR; Yi, L; Fen, D; Zheng, Z; Jie, C				Zhou, BR; Yi, L; Fen, D; Zheng, Z; Jie, C			Mixed macromolecular crowding accelerates the oxidative refolding of reduced, denatured lysozyme - Implications for protein folding in intracellular environments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; MUSCLE CREATINE-KINASE; ESCHERICHIA-COLI; HEN LYSOZYME; MASS-SPECTROMETRY; AGGREGATION; CYTOPLASM; KINETICS; VOLUME; GROEL	The oxidative refolding of reduced, denatured hen egg white lysozyme in the presence of a mixed macromolecular crowding agent containing both bovine serum albumin (BSA) and polysaccharide has been studied from a physiological point of view. When the total concentration of the mixed crowding agent is 100 g/liter, in which the weight ratio of BSA to dextran 70 is 1:9, the refolding yield of lysozyme after refolding for 4 h under this condition increases 24% compared with that in the presence of BSA and 16% compared with dextran 70. A remarkable increase in the refolding yield of lysozyme by a mixed crowding agent containing BSA and Ficoll 70 is also observed. Further folding kinetics analyses show that these two mixed crowding agents accelerate the oxidative refolding of lysozyme remarkably, compared with single crowding agents. These results suggest that the stabilization effects of mixed macromolecular crowding agents are stronger than those of single polysaccharide crowding agents such as dextran 70 and Ficoll 70, whereas the excluded volume effects of mixed macromolecular crowding agents are weaker than those of single protein crowding agents such as BSA. Both the refolding yield and the rate of the oxidative refolding of lysozyme in these two mixed crowded solutions with suitable weight ratios are higher than those in single crowded solutions, indicating that mixed macromolecular crowding agents are more favorable to lysozyme folding and can be used to simulate the intracellular environments more accurately than single crowding agents do.	Wuhan Univ, Coll Life Sci, Natl Key Lab Virol, Wuhan 430072, Peoples R China	Wuhan University	Yi, L (corresponding author), Wuhan Univ, Coll Life Sci, Natl Key Lab Virol, Wuhan 430072, Peoples R China.	liangyi@whu.edu.cn	Liang, Yi/V-1396-2017; Zhou, Bing-Rui/D-4766-2009; Zhou, Zheng/AAK-2669-2021	Liang, Yi/0000-0002-7349-8300; Zhou, Zheng/0000-0002-3124-6041; Zhou, Bing-Rui/0000-0002-5375-7977				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bushmarina NA, 2001, CHEMBIOCHEM, V2, P813, DOI 10.1002/1439-7633(20011105)2:11<813::AID-CBIC813>3.0.CO;2-W; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; Elcock AH, 2003, P NATL ACAD SCI USA, V100, P2340, DOI 10.1073/pnas.0535055100; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Flaugh SL, 2001, BIOMACROMOLECULES, V2, P538, DOI 10.1021/bm015502z; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; Galan A, 2001, J BIOL CHEM, V276, P957, DOI 10.1074/jbc.M006861200; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; Hall D, 2003, BBA-PROTEINS PROTEOM, V1649, P127, DOI 10.1016/S1570-9639(03)00167-5; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Huang BX, 2004, J AM SOC MASS SPECTR, V15, P1237, DOI 10.1016/j.jasms.2004.05.004; Kuznetsova IM, 2002, BBA-PROTEIN STRUCT M, V1596, P138, DOI 10.1016/S0167-4838(02)00212-1; Kuznetsova IM, 2002, BIOCHEMISTRY-US, V41, P13127, DOI 10.1021/bi026412x; Li J, 2001, J BIOL CHEM, V276, P34396, DOI 10.1074/jbc.M103392200; Liang Y, 2003, J BIOL CHEM, V278, P30098, DOI 10.1074/jbc.M304050200; Matagne A, 1997, J MOL BIOL, V267, P1068, DOI 10.1006/jmbi.1997.0963; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Minton AP, 2000, BIOPHYS J, V78, P101, DOI 10.1016/S0006-3495(00)76576-3; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; MINTON AP, 1992, P NATL ACAD SCI USA, V89, P10504, DOI 10.1073/pnas.89.21.10504; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Ren GP, 2003, J PROTEIN CHEM, V22, P431, DOI 10.1023/B:JOPC.0000005458.08802.11; Rival Y, 2004, ATHEROSCLEROSIS SUPP, V5, P27; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; Roux P, 1997, J BIOL CHEM, V272, P24843, DOI 10.1074/jbc.272.40.24843; Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Tokuriki N, 2004, PROTEIN SCI, V13, P125, DOI 10.1110/ps.03288104; van den Berg B, 2000, EMBO J, V19, P3870, DOI 10.1093/emboj/19.15.3870; van den Berg B, 1999, J MOL BIOL, V290, P781, DOI 10.1006/jmbi.1999.2915; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; Wenner JR, 1999, BIOPHYS J, V77, P3234, DOI 10.1016/S0006-3495(99)77154-7; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	48	87	93	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55109	55116		10.1074/jbc.M409086200	http://dx.doi.org/10.1074/jbc.M409086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494409	hybrid			2022-12-27	WOS:000225960800017
J	Lee, BY; Thulin, CD; Willardson, BM				Lee, BY; Thulin, CD; Willardson, BM			Site-specific phosphorylation of phosducin in intact retina - Dynamics of phosphorylation and effects on G protein beta gamma dimer binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DRIVEN TRANSLOCATION; ROD PHOTORECEPTOR CELLS; MICE LACKING; TRANSDUCIN; COMPLEX; SUBUNIT; MECHANISM; PHOSPHODIESTERASE; DEPHOSPHORYLATION; ADAPTATION	Phosducin (Pdc) is a G protein betagamma dimer (Gbetagamma) binding protein, highly expressed in retinal photoreceptor and pineal cells, yet whose physiological role remains elusive. Light controls the phosphorylation of Pdc in a cAMP and Ca2+-dependent manner, and phosphorylation in turn regulates the binding of Pdc to G(t)betagamma or 14-3-3 proteins in vitro. To directly examine the phosphorylation of Pdc in intact retina, we prepared antibodies specific to the three principal phosphorylation sites (Ser-54, Ser-73, and Ser-106) and measured the kinetics of phosphorylation/dephosphorylation during light/dark adaptation and the subsequent effects on G(t)betagamma binding. Ser-54 phosphorylation increased slowly (t(1/2)similar to90 min) during dark adaptation to similar to70% phosphorylated and decreased rapidly (t(1/2)similar to2 min) during light adaptation to less than 20% phosphorylated. Ser-73 phosphorylation increased much faster during dark adaptation (t(1/2)similar to3 min) to similar to50% phosphorylated and decreased more slowly during light adaptation (t(1/2)similar to9 min) to less than 20% phosphorylated. The Ca2+ chelator BAPTA-AM blocked Ser-54 phosphorylation during dark adaptation but had no effect on Ser-73 phosphorylation. In contrast, Ser-106 was not phosphorylated in either the light or dark. Importantly, Gbetagamma binding to Pdc was enhanced by Ca2+ chelation and the binding kinetics closely paralleled those of Ser-54 dephosphorylation, indicating that Ser-54 phosphorylation controls G(t)betagamma binding in vivo. These results suggest a pivotal role of Ser-54 and Ser-73 phosphorylation in determining the interactions of Pdc with its binding partners, G(t)betagamma and 14-3-3 protein, which may regulate the light-dependent translocation of the photoreceptor G protein.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Brigham Young University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	barry_willardson@byu.edu		Willardson, Barry/0000-0002-8503-2268	NATIONAL EYE INSTITUTE [R01EY012287] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BRANN MR, 1987, SCIENCE, V235, P585, DOI 10.1126/science.3101175; Brown BM, 2002, BIOCHEMISTRY-US, V41, P13526, DOI 10.1021/bi0204490; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COHEN AI, 1990, VISUAL NEUROSCI, V4, P43, DOI 10.1017/S0952523800002753; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; Granovsky AE, 2001, BIOCHEMISTRY-US, V40, P13209, DOI 10.1021/bi011127j; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Margulis A, 2002, MOL VIS, V8, P477; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; Nir I, 2002, J NEUROSCI, V22, P2063, DOI 10.1523/JNEUROSCI.22-06-02063.2002; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; REIG JA, 1990, J BIOL CHEM, V265, P5816; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Thulin CD, 1999, MOL VIS, V5, pU13; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54008	54017		10.1074/jbc.M405669200	http://dx.doi.org/10.1074/jbc.M405669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485848	hybrid			2022-12-27	WOS:000225793600016
J	Sell, DR; Monnier, VM				Sell, DR; Monnier, VM			Conversion of arginine into ornithine by advanced glycation in senescent human collagen and lens crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-ASPARTIC ACID; END-PRODUCTS; CROSS-LINKS; DIABETIC COMPLICATIONS; MAILLARD REACTION; SKIN COLLAGEN; PROTEIN; METHYLGLYOXAL; GLYCOXIDATION; PENTOSIDINE	Long lived proteins undergo age-related postsynthetic modifications that destabilize them by altering their conformation, charge, and helicity, thereby enhancing their resistance toward proteolysis and propensity to aggregate. The unexpected finding of substantial amounts of ornithine, the nonprotein amino acid, and decarbamidation product of arginine in acid hydrolysates of lens crystallins and skin collagen led us to investigate its source and mechanism of formation. In order to exclude ornithine formation as an artifact of acid hydrolysis, proteins were reductively alkylated with formaldehyde to convert ornithine to dimethyl-ornithine. The proteins were assayed for carboxymethyl-ornithine and glycated ornithine ("furornithine") by liquid chromatography coupled to electrospray ionization mass spectrometry. Ornithine in acid hydrolysates of human lens and skin proteins increased from 1 to 15 nmol/mg protein from ages 10 to 90 years, whereas dimethyl-ornithine increased from 0.5 to 15 and from 0 to 5 nmol/mg protein, respectively. Carboxymethyl-ornithine and furornithine increased with age in lens and skin from similar to0 to 60 and 0 to 180 pmol/mg protein, respectively. In collagen, ornithine was elevated above levels of nondiabetic controls only when both diabetes and end stage renal disease were present. The age-related increase of these modifications provides evidence for substantial in vivo formation of ornithine in aging human tissue proteins. The mechanism of ornithine formation is not known, but data suggest that arginine-derived advanced glycation end products might serve as precursors for the in vivo conversion of ornithine from arginine.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sell, DR (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	drs7@cwru.edu	Monnier, Vincent M/B-1371-2009		NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018629] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007099, EY07099, R01 EY007099-17, R01 EY007099-18] Funding Source: Medline; NIA NIH HHS [AG18629] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AAKESSON I, 1971, EUR J CLIN INVEST, V1, P281, DOI 10.1111/eci.1971.1.4.281; Ahmed N, 2002, BIOCHEM J, V364, P1; Ahmed N, 2003, INVEST OPHTH VIS SCI, V44, P5287, DOI 10.1167/iovs.03-0573; Bailey AJ, 2001, MECH AGEING DEV, V122, P735, DOI 10.1016/S0047-6374(01)00225-1; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x; Biemel KM, 2001, NAHRUNG, V45, P210, DOI 10.1002/1521-3803(20010601)45:3&lt;210::AID-FOOD210&gt;3.0.CO;2-L; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Boonyakiat Y, 2001, J VIROL, V75, P10000, DOI 10.1128/JVI.75.20.10000-10004.2001; BROWNLEE M, 1983, J EXP MED, V158, P1739, DOI 10.1084/jem.158.5.1739; BUONO RD, 1991, DIFFERENTIATION, V46, P97; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; Chaimbault P, 1999, J CHROMATOGR A, V855, P191, DOI 10.1016/S0021-9673(99)00685-8; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; Lindner H, 2001, EXP GERONTOL, V36, P1551, DOI 10.1016/S0531-5565(01)00140-1; Liu BF, 2004, INVEST OPHTH VIS SCI, V45, P1983, DOI 10.1167/iovs.03-0995; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; Monnier VM, 2003, ARCH BIOCHEM BIOPHYS, V419, P1, DOI 10.1016/j.abb.2003.08.014; MOORE S, 1954, J BIOL CHEM, V211, P907; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Nelson D.L., 2004, PRINCIPLES BIOCH, V4th; Paul RG, 1998, BIOCHEM J, V330, P1241, DOI 10.1042/bj3301241; PIRIE A., 1965, INVEST OPHTHALMOL, V4, P629; RAMACHANDRULA A, 1992, J CELL SCI, V101, P859; SELL DR, 1993, DIABETOLOGIA, V36, P936, DOI 10.1007/BF02374476; Sell DR, 2003, J GERONTOL A-BIOL, V58, P508; Sell DR, 2000, FASEB J, V14, P145, DOI 10.1096/fasebj.14.1.145; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; SLETTEN K, 1971, NATURE-NEW BIOL, V231, P118, DOI 10.1038/newbio231118a0; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; THORNALLEY PJ, 2005, IN PRESS P 8 INT S M; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Vlassara H, 2004, REV ENDOCR METAB DIS, V5, P181, DOI 10.1023/B:REMD.0000032406.84813.f6; Vlassara H, 2003, MT SINAI J MED, V70, P232; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; Wilker SC, 2001, ANAL BIOCHEM, V290, P353, DOI 10.1006/abio.2001.4992; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yu H, 2003, J HISTOCHEM CYTOCHEM, V51, P1151, DOI 10.1177/002215540305100905	44	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54173	54184		10.1074/jbc.M408946200	http://dx.doi.org/10.1074/jbc.M408946200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489230	hybrid			2022-12-27	WOS:000225793600036
J	Stahelin, RV; Ananthanarayanan, B; Blatner, NR; Singh, S; Bruzik, KS; Murray, D; Cho, WH				Stahelin, RV; Ananthanarayanan, B; Blatner, NR; Singh, S; Bruzik, KS; Murray, D; Cho, WH			Mechanism of membrane binding of the phospholipase D1 PX domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SURFACE-PLASMON RESONANCE; ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDIC-ACID; PH DOMAIN; STRUCTURE PREDICTION; SECONDARY STRUCTURE; INDUCED ACTIVATION; HOMOLOGY DOMAINS	Mammalian phospholipases D (PLD), which catalyze the hydrolysis of phosphatidylcholine to phosphatidic acid (PA), have been implicated in various cell signaling and vesicle trafficking processes. Mammalian PLD1 contains two different membrane-targeting domains, pleckstrin homology and Phox homology (PX) domains, but the precise roles of these domains in the membrane binding and activation of PLD1 are still unclear. To elucidate the role of the PX domain in PLD1 activation, we constructed a structural model of the PX domain by homology modeling and measured the membrane binding of this domain and selected mutants by surface plasmon resonance analysis. The PLD1 PX domain was found to have high phosphoinositide specificity, i.e. phosphatidylinositol 3,4,5-trisphosphate (PtdIns( 3,4,5) P-3) >> phosphatidylinositol 3-phosphate > phosphatidylinositol 5-phosphate >> other phosphoinositides. The PtdIns( 3,4,5) P3 binding was facilitated by the cationic residues (Lys(119), Lys(121), and Arg(179)) in the putative binding pocket. Consistent with the model structure that suggests the presence of a second lipid-binding pocket, vesicle binding studies indicated that the PLD1 PX domain could also bind with moderate affinity to PA, phosphatidylserine, and other anionic lipids, which were mediated by a cluster of cationic residues in the secondary binding site. Simultaneous occupancy of both binding pockets synergistically increases membrane affinity of the PX domain. Electrostatic potential calculations suggest that a highly positive potential near the secondary binding site may facilitate the initial adsorption of the domain to the anionic membrane, which is followed by the binding of PtdIns( 3,4,5) P3 to its binding pocket. Collectively, our results suggest that the interaction of the PLD1 PX domain with PtdIns(3,4,5) P-3 and/or PA ( or phosphatidylserine) may be an important factor in the spatiotemporal regulation and activation of PLD1.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University	Cho, WH (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM053987, R01GM068849] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68849, GM53987, GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Alexandrov N N, 1996, Pac Symp Biocomput, P53; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Banno Y, 2003, BIOCHEM J, V369, P363, DOI 10.1042/BJ20021368; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Karplus K, 2001, BIOINFORMATICS, V17, P713, DOI 10.1093/bioinformatics/17.8.713; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kozawa O, 1997, EUR J BIOCHEM, V248, P149, DOI 10.1111/j.1432-1033.1997.00149.x; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Lucocq J, 2001, EUR J CELL BIOL, V80, P508, DOI 10.1078/0171-9335-00186; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; Petrey D, 2003, PROTEINS, V53, P430, DOI 10.1002/prot.10550; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rost B, 1996, METHOD ENZYMOL, V266, P525; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wakelam MJO, 1997, SEMIN CELL DEV BIOL, V8, P305, DOI 10.1006/scdb.1997.0152; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xing Y, 2004, J BIOL CHEM, V279, P30662, DOI 10.1074/jbc.M404107200; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200	80	82	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54918	54926		10.1074/jbc.M407798200	http://dx.doi.org/10.1074/jbc.M407798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475361	hybrid			2022-12-27	WOS:000225793600121
J	Chang, CH; Svedruzic, D; Ozarowski, A; Walker, L; Yeagle, G; Britt, RD; Angerhofer, A; Richards, NGJ				Chang, CH; Svedruzic, D; Ozarowski, A; Walker, L; Yeagle, G; Britt, RD; Angerhofer, A; Richards, NGJ			EPR spectroscopic characterization of the manganese center and a free radical in the oxalate decarboxylase reaction - Identification of a tyrosyl radical during turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; COLI RIBONUCLEOTIDE REDUCTASE; ELECTRON-SPIN-RESONANCE; BACILLUS-SUBTILIS YVRK; ESCHERICHIA-COLI; BIOCHEMICAL PATHWAYS; SUPEROXIDE-DISMUTASE; HAMMERHEAD RIBOZYME; PEROXYL RADICALS; LOW-TEMPERATURE	Several molecular mechanisms for cleavage of the oxalate carbon-carbon bond by manganese-dependent oxalate decarboxylase have recently been proposed involving high oxidation states of manganese. We have examined the oxalate decarboxylase from Bacillus subtilis by electron paramagnetic resonance in perpendicular and parallel polarization configurations to test for the presence of such species in the resting state and during enzymatic turnover. Simulation and the position of the half-field Mn(II) line suggest a nearly octahedral metal geometry in the resting state. No spectroscopic signature for Mn(III) or Mn(IV) is seen in parallel mode EPR for samples frozen during turnover, consistent either with a large zero-field splitting in the oxidized metal center or undetectable levels of these putative high-valent intermediates in the steady state. A narrow, featureless g = 2.0 species was also observed in perpendicular mode in the presence of substrate, enzyme, and dioxygen. Additional splittings in the signal envelope became apparent when spectra were taken at higher temperatures. Isotopic editing resulted in an altered line shape only when tyrosine residues of the enzyme were specifically deuterated. Spectral processing confirmed multiple splittings with isotopically neutral enzyme that collapsed to a single prominent splitting in the deuterated enzyme. These results are consistent with formation of an enzyme-based tyrosyl radical upon oxalate exposure. Modestly enhanced relaxation relative to abiological tyrosyl radicals was observed, but site-directed mutagenesis indicated that conserved tyrosine residues in the active site do not host the unpaired spin. Potential roles for manganese and a peripheral tyrosyl radical during steady-state turnover are discussed.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	State University System of Florida; University of Florida; University of California System; University of California Davis	Chang, CH (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	cchang@chem.ufl.edu; richards@qtp.ufl.edu	Chang, Christopher H/A-1404-2012; Angerhofer, Alexander/E-3143-2010	Chang, Christopher H/0000-0003-3800-6021; Angerhofer, Alexander/0000-0002-8580-6024; Svedruzic, Drazenka/0000-0002-0229-7229	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK061193, R01DK053556, R56DK061666, R01DK061666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048242, R29GM048242] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61193, DK61666, DK53556] Funding Source: Medline; NIGMS NIH HHS [GM48242] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAGAM A, 1970, ELECT PARAMAGNETIC R, P454; Adam W, 2000, J AM CHEM SOC, V122, P9685, DOI 10.1021/ja0005082; Adrait A, 2002, BIOCHEMISTRY-US, V41, P6510, DOI 10.1021/bi012043d; Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; BARRY BA, 1990, J BIOL CHEM, V265, P20139; Borodine A., 1861, LIEBIGS ANN CHEM, V119, P121, DOI 10.1002/jlac.18611190113; Campbell KA, 2001, J AM CHEM SOC, V123, P5710, DOI 10.1021/ja0027463; Campbell KA, 1999, J AM CHEM SOC, V121, P4714, DOI 10.1021/ja9902219; CHANDRA SK, 1990, INORG CHEM, V29, P2423, DOI 10.1021/ic00338a008; CHENBARRETT Y, 1995, BIOCHEMISTRY-US, V34, P7847, DOI 10.1021/bi00024a008; Dunwell JM, 1998, BIOTECHNOL GENET ENG, V15, P1; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Gerfen GJ, 1998, J AM CHEM SOC, V120, P3823, DOI 10.1021/ja972166e; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Hunsdiecker H., 1942, CHEM BER, V75, P291, DOI DOI 10.1002/CBER.19420750309; JOHNSON RG, 1956, CHEM REV, V56, P219, DOI 10.1021/cr50008a002; Katterle B, 1997, J BIOL CHEM, V272, P10414; KESSISSOGLOU DP, 1987, INORG CHEM, V26, P2487, DOI 10.1021/ic00262a030; KIM HW, 1990, FEBS LETT, V272, P34, DOI 10.1016/0014-5793(90)80442-L; Kolbe H., 1849, LIEBIGS ANN CHEM, V69, P257, DOI DOI 10.1002/JLAC.18490690302; Krzystek J, 2003, INORG CHEM, V42, P4610, DOI 10.1021/ic020712l; Lassmann G, 2003, PHYS CHEM CHEM PHYS, V5, P2442, DOI 10.1039/b302601a; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lide D. R., 1997, CRC HDB CHEM PHYS, P5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; Morrissey SR, 2000, J AM CHEM SOC, V122, P3473, DOI 10.1021/ja992989z; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P5712, DOI 10.1021/bi00017a002; Rajendiran TM, 2002, INORG CHIM ACTA, V339, P497, DOI 10.1016/S0020-1693(02)00956-8; Reddy SG, 1998, BIOCHEMISTRY-US, V37, P558, DOI 10.1021/bi972086n; Reed G., 1984, BIOL MAGN RESON, V6, P73; REED GH, 1995, METHOD ENZYMOL, V258, P362; Reinhardt LA, 2003, J AM CHEM SOC, V125, P1244, DOI 10.1021/ja0286977; Rogers PA, 2001, J BIOL CHEM, V276, P30980, DOI 10.1074/jbc.M101037200; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; STALLINGS WC, 1985, J BIOL CHEM, V260, P6424; STOLL S, 2003, THESIS EIDGENOSSISCH; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Tanner A, 2000, J BACTERIOL, V182, P5271, DOI 10.1128/JB.182.18.5271-5273.2000; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; VIJH AK, 1967, CHEM REV, V67, P623, DOI 10.1021/cr60250a003; Vogt M, 2003, ACS SYM SER, V858, P193; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WEIL JA, 1994, ELECT PARAMAGNETIC R, P321; Weyhermuller T, 2002, INORG CHIM ACTA, V337, P344, DOI 10.1016/S0020-1693(02)01000-9; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; Whittaker MM, 2002, J BIOL INORG CHEM, V7, P136, DOI 10.1007/s007750100281; YANEZ J, 1987, J PHYS CHEM-US, V91, P487, DOI 10.1021/j100286a044	58	38	39	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52840	52849		10.1074/jbc.M402345200	http://dx.doi.org/10.1074/jbc.M402345200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475346	hybrid			2022-12-27	WOS:000225680600008
J	Codina, A; Benoit, G; Gooch, JT; Neuhaus, D; Perlmann, T; Schwabe, JWR				Codina, A; Benoit, G; Gooch, JT; Neuhaus, D; Perlmann, T; Schwabe, JWR			Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR ACTIVATION; COACTIVATOR RECRUITMENT; HORMONE-RECEPTORS; MEDIATES TRANSACTIVATION; MOLECULAR DETERMINANTS; COREPRESSOR BINDING; STRUCTURAL BASIS; SPECTROSCOPY; MECHANISM; ALPHA	The nuclear receptor Nurr1 is a transcription factor essential for the development of midbrain dopaminergic neurons in vertebrates. Recent crystal structures of the Nurr1 ligand binding domain (LBD) and the Drosophila orthologue dHR38 revealed that, although these receptors share the classical LBD architecture, they lack a ligand binding cavity. This volume is instead filled with bulky hydrophobic side chains. Furthermore the "canonical" non-polar co-regulator binding groove is filled with polar side chains; thus, the regulation of transcription by this sub-family of nuclear receptor LBDs may be mediated by some other interaction surface on the LBD. We report here the identification of a novel co-regulator interface on the LBD of Nurr1. We used an NMR footprinting strategy that facilitates the identification of an interaction surface without the need of a full assignment. We found that non-polar peptides derived from the co-repressors SMRT and NCoR bind to a hydrophobic patch on the LBD of Nurr1. This binding surface involves a groove between helices 11 and 12. Mutations in this site abolish activation by the Nurr1 LBD. These findings give insight into the unique mechanism of action of this class of nuclear receptors.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	MRC Laboratory Molecular Biology; Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research	Schwabe, JWR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	john.schwabe@mrc-lmb.cam.ac.uk	Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383; BENOIT, Gerard/0000-0001-9462-6570				Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Codina A, 2002, J BIOMOL NMR, V22, P295, DOI 10.1023/A:1014988206967; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Escriva H, 2000, BIOESSAYS, V22, P717; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Goodford P, 1996, J CHEMOMETR, V10, P107; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Iannone MA, 2001, CYTOMETRY, V44, P326, DOI 10.1002/1097-0320(20010801)44:4<326::AID-CYTO1124>3.0.CO;2-4; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruyama K, 1998, INT J ONCOL, V12, P1237; Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Reese ML, 2003, J AM CHEM SOC, V125, P14250, DOI 10.1021/ja037640x; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; SCHWABE J, 2004, SCI STKE; Sohn YC, 2001, J BIOL CHEM, V276, P43734, DOI 10.1074/jbc.M107208200; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	34	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53338	53345		10.1074/jbc.M409096200	http://dx.doi.org/10.1074/jbc.M409096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456745	hybrid			2022-12-27	WOS:000225680600066
J	Lee, JM; Kim, YS; Choi, DH; Bang, MS; Han, TR; Joh, TH; Kim, SY				Lee, JM; Kim, YS; Choi, DH; Bang, MS; Han, TR; Joh, TH; Kim, SY			Transglutaminase 2 induces nuclear factor-kappa B activation via a novel pathway in BV-2 microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-TYPE TRANSGLUTAMINASE; CROSS-LINKING; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; CELIAC-DISEASE; MESSENGER-RNA; EXTRACELLULAR MATRICES; INCREASED EXPRESSION; PARKINSONS-DISEASE; ELASTASE INHIBITOR	Transglutaminase 2 (TGase 2) expression is increased in inflammatory diseases. We demonstrated previously that inhibitors of TGase 2 reduce nitric oxide ( NO) generation in a lipopolysaccharide (LPS)-treated microglial cell line. However, the precise mechanism by which TGase 2 promotes inflammation remains unclear. We found that TGase 2 activates the transcriptional activator nuclear factor (NF)-kappaB and thereby enhances LPS-induced expression of inducible nitric-oxide synthase. TGase 2 activates NF-kappaB via a novel pathway. Rather than stimulating phosphorylation and degradation of the inhibitory subunit alpha of NF-kappaB (I-kappaBalpha), TGase2 induces its polymerization. This polymerization results in dissociation of NF-kappaB and its translocation to the nucleus, where it is capable of up-regulating a host of inflammatory genes, including inducible nitric-oxide synthase and tumor necrosis factor alpha (TNF-alpha). Indeed, TGase inhibitors prevent depletion of monomeric I-kappaBalpha in the cytosol of cells overexpressing TGase 2. In an LPS-induced rat brain injury model, TGase inhibitors significantly reduced TNF-alpha synthesis. The findings are consistent with a model in which LPS-induced NF-kappaB activation is the result of phosphorylation of I-kappaBalpha by I-kappaB kinase as well as I-kappaBalpha polymerization by TGase 2. Safe and stable TGase2 inhibitors may be effective agents in diseases associated with inflammation.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, White Plains, NY 10605 USA; Burke Med Res Inst, White Plains, NY 10605 USA; Seoul Natl Univ, Coll Med, Dept Rehabil Med, Seoul 110744, South Korea	Cornell University; Seoul National University (SNU)	Kim, SY (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, White Plains, NY 10605 USA.	tgase@hanmail.net	Han, Tai Ryoon/J-5712-2012; Bang, Moon Suk/J-5501-2012					Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Andringa G, 2004, FASEB J, V18, P932, DOI 10.1096/fj.03-0829fje; Antonyak MA, 2003, J BIOL CHEM, V278, P15859, DOI 10.1074/jbc.M300037200; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; BAKER H, 1993, BRAIN RES, V614, P109, DOI 10.1016/0006-8993(93)91023-L; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; Bowness JM, 1997, MOL CELL BIOCHEM, V169, P157, DOI 10.1023/A:1006846400478; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; Campisi A, 2003, BRAIN RES, V978, P24, DOI 10.1016/S0006-8993(03)02725-2; Catania A, 1998, ANN NY ACAD SCI, V856, P62, DOI 10.1111/j.1749-6632.1998.tb08313.x; Choi YC, 2000, J BIOL CHEM, V275, P8703, DOI 10.1074/jbc.275.12.8703; Choi YC, 2004, EUR NEUROL, V51, P10, DOI 10.1159/000074911; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dieterich W, 1999, J INVEST DERMATOL, V113, P133, DOI 10.1046/j.1523-1747.1999.00627.x; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Fujita K, 1998, NEUROCHEM RES, V23, P557, DOI 10.1023/A:1022442904179; Fujita K, 1998, J NEUROL SCI, V158, P53, DOI 10.1016/S0022-510X(98)00088-4; Gibson GE, 2002, BBA-MOL BASIS DIS, V1586, P177, DOI 10.1016/S0925-4439(01)00091-6; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gross SR, 2003, J INVEST DERMATOL, V121, P412, DOI 10.1046/j.1523-1747.2003.12353.x; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Kim SY, 2002, J INTERF CYTOK RES, V22, P677, DOI 10.1089/10799900260100169; Kim SY, 1997, BIOCHEM BIOPH RES CO, V233, P39, DOI 10.1006/bbrc.1997.6407; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Lampasona V, 1999, DIABETOLOGIA, V42, P1195, DOI 10.1007/s001250051291; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; LEU RW, 1982, EXP CELL RES, V141, P191, DOI 10.1016/0014-4827(82)90081-7; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; McGeer PL, 2001, ADV NEUROL, V86, P83; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; MIRZA A, 1997, AM J PHYSIOL, V272, P281; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; MURTAUGH MP, 1983, J BIOL CHEM, V258, P1074; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NOVOGRODSKY A, 1978, P NATL ACAD SCI USA, V75, P1157, DOI 10.1073/pnas.75.3.1157; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Park KC, 2004, BIOCHEM BIOPH RES CO, V323, P1055, DOI 10.1016/j.bbrc.2004.08.204; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Picarelli A, 2003, CLIN CHEM, V49, P2091, DOI 10.1373/clinchem.2003.023234; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quan N, 1997, P NATL ACAD SCI USA, V94, P10985, DOI 10.1073/pnas.94.20.10985; Roberts ES, 2003, AM J PATHOL, V162, P2041, DOI 10.1016/S0002-9440(10)64336-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sanchez D, 2000, J AUTOIMMUN, V15, P441, DOI 10.1006/jaut.2000.0452; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCOTT KFF, 1982, P NATL ACAD SCI-BIOL, V79, P4093, DOI 10.1073/pnas.79.13.4093; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200; Ueki S, 1996, J CELL SCI, V109, P2727; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; WEINBERG JB, 1991, ARTHRITIS RHEUM, V34, P996, DOI 10.1002/art.1780340809	75	148	152	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53725	53735		10.1074/jbc.M407627200	http://dx.doi.org/10.1074/jbc.M407627200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471861	hybrid			2022-12-27	WOS:000225680600110
J	Zhang, YH; Biggs, JR; Kraft, AS				Zhang, YH; Biggs, JR; Kraft, AS			Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CORE-BINDING-FACTOR; BLOCKS GRANULOCYTIC DIFFERENTIATION; IMMATURE MYELOID CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SYNERGISTICALLY ACTIVATE; GROWTH-INHIBITION; LEUKEMIC-CELLS; RUNT-DOMAIN; IN-VITRO	We find that phorbol ester (PE) treatment of K562 cells greatly stimulates promoters (T cell receptor beta, myeloperoxidase, macrophage colony-stimulating factor receptor, and granulocyte macrophage colony-stimulating factor receptor) containing AML1 transcription factor binding sites. This stimulation of AML1c transcriptional activity is mediated by direct phosphorylation of the AML1c molecule on multiple phosphorylation sites. Eleven AML1c (S/T)P sites in the transcriptional activating domain are phosphorylated at a basal level in untreated K562 cells; treatment of the K562 cells with PE results in increased phosphorylation at five of these sites (serines 276, 293, 303, 462, and threonine 300). Mutation of these five sites to alanine inhibits PE-induced transcriptional activity; mutation of the sites to an acidic amino acid, aspartic acid, stimulates constitutive activity. Single mutations in four amino acids or double mutations (serines 276 and 293 or threonine 300 and serine 303) have little effect on AML1c transcriptional activity. Inhibitor assays suggest that the ERK family of protein kinases is activated by PEs to phosphorylate the (S/T)P sites within the AML1c molecule and markedly enhance the transcriptional activity of AML1c.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina	Kraft, AS (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	Kraft@musc.edu			NCI NIH HHS [CA42533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggs JR, 1998, CELL GROWTH DIFFER, V9, P667; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gonzalez R, 1999, MELANOMA RES, V9, P599, DOI 10.1097/00008390-199912000-00010; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; MURAKAMI K, 1993, ONCOGENE, V8, P1559; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Smithgall TE, 1998, PHARMACOL REV, V50, P1; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tonks A, 2003, BLOOD, V101, P624, DOI 10.1182/blood-2002-06-1732; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WOTTON D, 1993, LEUKEMIA, V7, pS55; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	40	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53116	53125		10.1074/jbc.M405502200	http://dx.doi.org/10.1074/jbc.M405502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475366	hybrid			2022-12-27	WOS:000225680600040
J	Li, QY; Kaneko, S; Yang, L; Feldman, RI; Nicosia, SV; Chen, JD; Cheng, JQ				Li, QY; Kaneko, S; Yang, L; Feldman, RI; Nicosia, SV; Chen, JD; Cheng, JQ			Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR PROTEIN P53; HUMAN OVARIAN-CANCER; CENTROSOME AMPLIFICATION; CELL-LINES; CHROMOSOME SEGREGATION; MESSENGER-RNA; HUMAN TUMORS; KINASE; ACTIVATION; MDM2	The tumor suppressor p53 is important in the decision to either arrest cell cycle progression or induce apoptosis in response to a variety of stimuli. p53 post-translational modifications and association with other proteins have been implicated in the regulation of its stability and transactivation activity. Here we show that p53 is phosphorylated by the mitotic kinase Aurora-A at serine 215. Unlike most identified phosphorylation sites of p53 that positively associate with p53 function (Brooks, C. L., and Gu, W. (2003) Curr. Opin. Cell Biol. 15, 164-171), the phosphorylation of p53 by Aurora-A at Ser-215 abrogates p53 DNA binding and transactivation activity. Downstream target genes of p53, such as p21(Cip/WAF1) and PTEN, were inhibited by Aurora-A in a Ser-215 phosphorylation-dependent manner (i.e. phosphomimic p53-S215D lost and non-phosphorylatable p53-S215A retained normal p53 function). As a result, Aurora-A overrides the apoptosis and cell cycle arrest induced by cisplatin and gamma-irradiation, respectively. However, the effect of Aurora-A on p53 DNA binding and transactivation activity was not affected by phosphorylation of Ser-315, a recently identified Aurora-A phosphorylation site of p53 (Katayama, H., Sasai, K., Kawai, H., Yuan, Z. M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., and Sen, S. (2004) Nat. Genet. 36, 55-62). Our data indicate that phosphorylation of p53 at Ser-215 by Aurora-A is a major mechanism to inactivate p53 and can provide a molecular insight for Aurora-A function.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Berlex Labs Inc, Biosci, Dept Canc Res, Richmond, CA 94804 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC Box 11, Tampa, FL 33612 USA.	jcheng@hsc.usf.edu						Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Ausubel F., 1999, CURRENT PROTOCOLS MO; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fraser M, 2003, CANCER RES, V63, P7081; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Higuchi T, 2003, NATURE, V426, P780, DOI 10.1038/426780a; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LE GP, 1994, J BIOL CHEM, V269, P4458; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	37	94	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52175	52182		10.1074/jbc.M406802200	http://dx.doi.org/10.1074/jbc.M406802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469940	hybrid			2022-12-27	WOS:000225493400057
J	van der Sanden, MHM; Meems, H; Houweling, M; Helms, JB; Vaandrager, AB				van der Sanden, MHM; Meems, H; Houweling, M; Helms, JB; Vaandrager, AB			Induction of CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 expression during inhibition of phosphatidylcholine synthesis is mediated via activation of a C/EBP-activating transcription factor-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ENDOPLASMIC-RETICULUM STRESS; SIGNAL-TRANSDUCTION PATHWAYS; HAMSTER OVARY CELLS; N-TERMINAL KINASE; MESSENGER-RNA; PHOSPHOLIPID-METABOLISM; GENE-TRANSCRIPTION; CHOP EXPRESSION; APOPTOSIS	The gene for the proapoptotic transcription factor CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 (CHOP/GADD153) is induced by various cellular stresses. Previously, we described that inhibition of phosphatidylcholine (PC) synthesis in MT58 cells, which contain a temperature-sensitive mutation in CTP: phosphocholine cytidylyltransferase (CT), results in apoptosis preceded by the induction of CHOP. Here we report that prevention of CHOP induction, by expression of antisense CHOP, delays the PC depletion-induced apoptotic process. By mutational analysis of the conserved region in the promoter of the CHOP gene, we provide evidence that the C/EBP-ATF composite site, but not the ER stress-responsive element or the activator protein-1 site, is required for the increased expression of CHOP during PC depletion. Inhibition of PC synthesis in MT58 cells also led to an increase in phosphorylation of the stress-related transcription factor ATF2 and the stress kinase JNK after 8 and 16 h, respectively. In contrast, no phosphorylation of p38 MAPK was observed in MT58 cultured at the nonpermissive temperature. Treatment of MT58 cells with the JNK inhibitor SP600125 could rescue the cells from apoptosis but did not inhibit the phosphorylation of ATF2 or the induction of CHOP. Taken together, our results suggest that increased expression of CHOP during PC depletion depends on a C/EBP-ATF element in its promoter and might be mediated by binding of ATF2 to this element.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 TD Utrecht, Netherlands	Utrecht University; Utrecht University	Vaandrager, AB (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	A.B.Vaandrager@vet.uu.nl		Vaandrager, Arie/0000-0001-9394-9239				Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BAN N, 2000, DIABETES, V49, P3819; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; SHENG W, 2003, ONCOGENE, V22, P955; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Van der Sanden MHM, 2003, BIOCHEM J, V369, P643, DOI 10.1042/BJ20020285; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	62	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52007	52015		10.1074/jbc.M405577200	http://dx.doi.org/10.1074/jbc.M405577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466475	hybrid			2022-12-27	WOS:000225493400037
J	Asthana, N; Yadav, SP; Ghosh, JK				Asthana, N; Yadav, SP; Ghosh, JK			Dissection of antibacterial and toxic activity of melittin - A leucine zipper motif plays a crucial role in determining its hemolytic activity but not antibacterial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND MELITTIN; LIPID VESICLES; SOLID-PHASE; PHOSPHOLIPID-MEMBRANES; CONFORMATIONAL CHANGE; SELF-ASSOCIATION; PORE FORMATION; AMINO GROUPS; PEPTIDES; AGGREGATION	Melittin, a naturally occurring antimicrobial peptide, exhibits strong lytic activity against both eukaryotic and prokaryotic cells. Despite a tremendous amount of work done, very little is known about the amino acid sequence, which regulates its toxic activity. With the goal of understanding the basis of toxic activity and poor cell selectivity in melittin, a leucine zipper motif has been identified. To evaluate the possible structural and functional roles of this motif, melittin and its two analogs, after substituting the heptadic leucine by alanine, were synthesized and characterized. Functional studies indicated that alanine substitution in the leucine zipper motif resulted in a drastic reduction of the hemolytic activity of melittin. However, interestingly, both the designed analogs exhibited antibacterial activity comparable to melittin. Mutations caused a significant decrease in the membrane permeability of melittin in zwitterionic but not in negatively charged lipid vesicles. Although both the analogs exhibited similar secondary structures in the presence of negatively charged lipid vesicles as melittin, they failed to adopt a significant helical structure in the presence of zwitterionic lipid vesicles. Results suggest that the substitution of heptadic leucine by alanine impaired the assembly of melittin in an aqueous environment and its localization only in zwitterionic but not in negatively charged membrane. Altogether, the results suggest the identification of a structural element in melittin, which probably plays a prominent role in regulating its toxicity but not antibacterial activity. The results indicate that cell selectivity in some antimicrobial peptides can probably be introduced by modulating their assembly in an aqueous environment.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Ghosh, JK (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India.	jighosh@yahoo.com						ALTENBACH C, 1988, PROTEINS, V3, P230, DOI 10.1002/prot.340030404; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATENBURG AM, 1988, BIOSCIENCE REP, V8, P299, DOI 10.1007/BF01115220; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; BROWN LR, 1980, BIOCHIM BIOPHYS ACTA, V622, P231, DOI 10.1016/0005-2795(80)90034-3; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DEGRADO WF, 1981, J AM CHEM SOC, V103, P679, DOI 10.1021/ja00393a035; DEGRADO WF, 1982, BIOPHYS J, V37, P329, DOI 10.1016/S0006-3495(82)84681-X; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GEVOD VS, 1984, BIOPHYS J, V45, P1079, DOI 10.1016/S0006-3495(84)84255-1; Ghosh AK, 1997, BIOCHEMISTRY-US, V36, P14291, DOI 10.1021/bi971933j; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Ghosh JK, 1998, J BIOL CHEM, V273, P7252, DOI 10.1074/jbc.273.13.7252; Ghosh JK, 1997, BIOCHEMISTRY-US, V36, P15451, DOI 10.1021/bi971152i; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1970, H-S Z PHYSIOL CHEM, V351, P884, DOI 10.1515/bchm2.1970.351.2.884; JOHN E, 1992, BIOPHYS J, V63, P1536, DOI 10.1016/S0006-3495(92)81737-X; Juvvadi P, 1996, J AM CHEM SOC, V118, P8989, DOI 10.1021/ja9542911; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; LADOKHIN AS, 1995, BIOPHYS J, V69, P506, DOI 10.1016/S0006-3495(95)79924-6; Ladokhin AS, 2001, BBA-BIOMEMBRANES, V1514, P253, DOI 10.1016/S0005-2736(01)00382-0; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Rex S, 1998, BIOCHEMISTRY-US, V37, P2336, DOI 10.1021/bi971009p; SCHRODER E, 1971, EXPERIENTIA, V27, P764, DOI 10.1007/BF02136851; SEKHARAM KM, 1991, BIOCHIM BIOPHYS ACTA, V1063, P171, DOI 10.1016/0005-2736(91)90367-H; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Subbalakshmi C, 1999, FEBS LETT, V448, P62, DOI 10.1016/S0014-5793(99)00328-2; TALBOT JC, 1979, FEBS LETT, V102, P191, DOI 10.1016/0014-5793(79)80957-6; TATHAM AS, 1983, BIOCHEM J, V211, P683, DOI 10.1042/bj2110683; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; VOJKOVSKY T, 1995, PEPTIDE RES, V8, P236; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Yadav SP, 2003, J BIOL CHEM, V278, P51023, DOI 10.1074/jbc.M310052200; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	53	174	183	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55042	55050		10.1074/jbc.M408881200	http://dx.doi.org/10.1074/jbc.M408881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475354	hybrid			2022-12-27	WOS:000225960800009
J	Janz, JM; Farrens, DL				Janz, JM; Farrens, DL			Role of the retinal hydrogen bond network in rhodopsin Schiff base stability and hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE VISUAL PIGMENTS; PROTEIN-COUPLED-RECEPTOR; RESONANCE RAMAN-SPECTROSCOPY; NIGHT BLINDNESS MUTANT; BOVINE RHODOPSIN; METARHODOPSIN-II; TRANSDUCIN ACTIVATION; FLUORESCENCE SPECTROSCOPY; COUNTERION SWITCH; CRYSTAL-STRUCTURE	Little is known about the molecular mechanism of Schiff base hydrolysis in rhodopsin. We report here our investigation into this process focusing on the role of amino acids involved in a hydrogen bond network around the retinal Schiff base. We find conservative mutations in this network (T94I, E113Q, S186A, E181Q, Y192F, and Y268F) increase the activation energy (E-a) and abolish the concave Arrhenius plot normally seen for Schiff base hydrolysis in dark state rhodopsin. Interestingly, two mutants ( T94I and E113Q) show dramatically faster rates of Schiff base hydrolysis in dark state rhodopsin, yet slower hydrolysis rates in the active MII form. We find deuterium affects the hydrolysis process in wild-type rhodopsin, exhibiting a specific isotope effect of similar to2.5, and proton inventory studies indicate that multiple proton transfer events occur during the process of Schiff base hydrolysis for both dark state and MII forms. Taken together, our study demonstrates the importance of the retinal hydrogen bond network both in maintaining Schiff base integrity in dark state rhodopsin, as well as in catalyzing the hydrolysis and release of retinal from the MII form. Finally, we note that the dramatic alteration of Schiff base stability caused by mutation T94I may play a causative role in congenital night blindness as has been suggested by the Oprian and Garriga laboratories.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Farrens, DL (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Mail Code L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	farrensd@ohsu.edu			NEI NIH HHS [EY 12095, T32 EY 07123-09] Funding Source: Medline; NIDA NIH HHS [DA 14896] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007123, R01EY012095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; Babu KR, 2001, BIOCHEMISTRY-US, V40, P13760, DOI 10.1021/bi015584b; Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Birge RR, 2003, P NATL ACAD SCI USA, V100, P9105, DOI 10.1073/pnas.1733801100; BRUAULT M, 1976, J ORG CHEM, V41, P346; COOPER A, 1987, J AM CHEM SOC, V109, P7254, DOI 10.1021/ja00258a002; Das J, 2004, BIOCHEMISTRY-US, V43, P5532, DOI 10.1021/bi036097u; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DENG H, 1994, BIOPHYS J, V66, P1129, DOI 10.1016/S0006-3495(94)80893-8; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Ebrey TG, 2000, METHOD ENZYMOL, V315, P196; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FILIPEK S, 2002, ANNU REV PHYSIOL, V20, P20; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2009, DOI 10.1021/bi020613j; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2002, DOI 10.1021/bi020612r; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Imai H, 1997, P NATL ACAD SCI USA, V94, P2322, DOI 10.1073/pnas.94.6.2322; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Janz JM, 2003, VISION RES, V43, P2991, DOI 10.1016/j.visres.2003.08.010; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Lewis JW, 2000, METHOD ENZYMOL, V315, P164; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; Nagata T, 1998, BIOCHEMISTRY-US, V37, P17216, DOI 10.1021/bi9810149; Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSEROFF AR, 1974, BIOCHEMISTRY-US, V13, P4243, DOI 10.1021/bi00717a027; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Ramon E, 2003, J BIOL CHEM, V278, P6427, DOI 10.1074/jbc.M210929200; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHICHIDA Y, 1994, BIOCHEMISTRY-US, V33, P9040, DOI 10.1021/bi00197a002; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; STEINBERG G, 1993, BIOPHYS J, V64, P1499, DOI 10.1016/S0006-3495(93)81518-2; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Xie GF, 2003, BIOCHEMISTRY-US, V42, P1995, DOI 10.1021/bi020611z; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100; Yan ECY, 2002, BIOCHEMISTRY-US, V41, P3620, DOI 10.1021/bi0160011; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	71	58	59	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55886	55894		10.1074/jbc.M408766200	http://dx.doi.org/10.1074/jbc.M408766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475355	hybrid			2022-12-27	WOS:000225960800112
J	Kuo, PC; Liu, HF; Chao, JI				Kuo, PC; Liu, HF; Chao, JI			Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; CANCER CELLS; DNA-DAMAGE; MUTANT P53; AURORA-B; PHOSPHORYLATION; CHECKPOINT; ARREST; CYCLE	Quercetin, a ubiquitous bioactive plant flavonoid, has been shown to inhibit the proliferation of cancer cells. However, the regulation of survivin and p53 on the quercetin-induced cell growth inhibition and apoptosis in cancer cells remains unclear. In this study, we investigated the roles of survivin and p53 in the quercetin-treated human lung carcinoma cells. Quercetin (20-80 muM for 24 h) induced the cytotoxicity and apoptosis in both A549 and H1299 lung carcinoma cells in a concentration-dependent manner. Additionally, quercetin inhibited the cell growth, increased the fractions of G(2)/M phase, and raised the levels of cyclin B1 and phospho-cdc2 (threonine 161) proteins. Moreover, quercetin induced abnormal chromosome segregation in H1299 cells. The survivin proteins were highly expressed in mitotic phase and were located on the midbody of cytokinesis; however, the survivin proteins were increased and concentrated on the nuclei following quercetin treatment in the lung carcinoma cells. Transfection of a survivin antisense oligodeoxynucleotide enhanced the quercetin-induced cell growth inhibition and cytotoxicity. Subsequently, quercetin increased the levels of total p53 (DO-1), phospho-p53 (serine 15), and p21 proteins, which were translocated to the nuclei in A549 cells. Treatment with a specific p53 inhibitor, pifithrin-alpha, or transfection of a p53 antisense oligodeoxynucleotide enhanced the cytotoxicity of the quercetin-treated cells. Furthermore, transfection of a small interfering RNA of p21 enhanced the quercetin-induced cell death in A549 cells. Together, our results suggest that survivin can reduce the cell growth inhibition and apoptosis, and p53 elevates the p21 level, which may attenuate the cell death in the quercetin-treated human lung carcinoma cells.	Tzu Chi Univ, Coll Life Sci, Mol Toxicol Lab, Inst Pharmacol & Toxicol, Hualien 970, Taiwan	Tzu Chi University	Chao, JI (corresponding author), Tzu Chi Univ, Coll Life Sci, Mol Toxicol Lab, Inst Pharmacol & Toxicol, 701,Sect 3,Chung Yang Rd, Hualien 970, Taiwan.	chaoji@mail.tcu.edu.tw						AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; AVILA MA, 1994, CANCER RES, V54, P2424; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Beniston RG, 2003, ONCOGENE, V22, P5504, DOI 10.1038/sj.onc.1206848; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; CHEN JY, 1993, ONCOGENE, V8, P2159; Choi JA, 2001, INT J ONCOL, V19, P837; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Di Carlo G, 1999, LIFE SCI, V65, P337, DOI 10.1016/S0024-3205(99)00120-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gupta K, 2002, BIOCHEMISTRY-US, V41, P13029, DOI 10.1021/bi025952r; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kawamura K, 2003, DEV BIOL, V256, P331, DOI 10.1016/S0012-1606(02)00135-5; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LEA MA, 1993, CANCER LETT, V68, P231, DOI 10.1016/0304-3835(93)90151-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1995, CELL, V80, P293; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2000, CANCER RES, V60, P2805; Ong CS, 2004, ONCOL REP, V11, P727; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Plaumann B, 1996, ONCOGENE, V13, P1605; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; SMITH ML, 1995, ONCOGENE, V10, P1053; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tsai CM, 1996, CANCER RES, V56, P206; Wall NR, 2003, CANCER RES, V63, P230; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Yoshizumi M, 2001, MOL PHARMACOL, V60, P656	49	138	145	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55875	55885		10.1074/jbc.M407985200	http://dx.doi.org/10.1074/jbc.M407985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15456784	hybrid			2022-12-27	WOS:000225960800111
J	Chami, M; Prandini, A; Campanella, M; Pinton, P; Szabadkai, G; Reed, JC; Rizzuto, R				Chami, M; Prandini, A; Campanella, M; Pinton, P; Szabadkai, G; Reed, JC; Rizzuto, R			Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; CELL-DEATH; APOPTOSIS; CALCIUM; MITOCHONDRIA; PROTEIN; HOMEOSTASIS; RECEPTOR	Recent work has shown that Bcl-2 and other antiapoptotic proteins partially deplete the endoplasmic reticulum (ER) Ca2+ store and that this alteration of Ca2+ signaling reduces cellular sensitivity to apoptotic stimuli. We expressed in HeLa cells Bcl-2, Bax, and Bcl-2/Bax chimeras in which the putative pore-forming domains of the two proteins (alpha5-alpha6) were mutually swapped, comparing the effects on Ca2+ signaling of the two proteins and relating them to defined molecular domains. The results showed that only Bcl-2 reduces ER Ca2+ levels and that this effect does not depend on the alpha5-alpha6 helices of this oncoprotein. Soon after its expression, Bax increased ER Ca2+ loading, with ensuing potentiation of mitochondrial Ca2+ responses. Then the cells progressed into an apoptotic phenotype (which included drastic reductions of cytosolic and mitochondrial Ca2+ responses and alterations of organelle morphology). These results provide a coherent scenario that highlights a primary role of Ca2+ signals in deciphering apoptotic stimuli.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy; Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	University of Ferrara; University of Ferrara; Sanford Burnham Prebys Medical Discovery Institute	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via L Borsari 46, I-44100 Ferrara, Italy.	r.rizzuto@unife.it	Rizzuto, Rosario/B-6312-2008; Pinton, Paolo/J-8025-2012; Chami, Mounia/S-6471-2019; Campanella, Michelangelo/K-8172-2016	Pinton, Paolo/0000-0001-7108-6508; Chami, Mounia/0000-0003-1498-7187; Szabadkai, Gyorgy/0000-0002-3006-3577; Rizzuto, Rosario/0000-0001-7044-5097; Campanella, Michelangelo/0000-0002-6948-4184	Telethon [GTF02013] Funding Source: Medline	Telethon(Fondazione Telethon)		Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Chami M, 2003, J BIOL CHEM, V278, P31745, DOI 10.1074/jbc.M304202200; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rizzuto R, 1998, TRENDS CELL BIOL, V8, P288, DOI 10.1016/S0962-8924(98)01301-4; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208	35	91	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54581	54589		10.1074/jbc.M409663200	http://dx.doi.org/10.1074/jbc.M409663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485871	hybrid			2022-12-27	WOS:000225793600084
J	Graziani, S; Xia, YN; Gurnon, JR; Van Etten, JL; Leduc, D; Skouloubris, S; Myllykallio, H; Liebl, U				Graziani, S; Xia, YN; Gurnon, JR; Van Etten, JL; Leduc, D; Skouloubris, S; Myllykallio, H; Liebl, U			Functional analysis of FAD-dependent thymidylate synthase ThyX from Paramecium bursaria chlorella virus-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; SYNTHETASE; PROTEIN; PBCV-1; LIFE	Sequence analysis of the 330-kb double-stranded DNA genome of Paramecium bursaria chlorella virus-1 revealed an open reading frame A674R that encodes a protein with up to 53% amino acid identity to a recently discovered new class of thymidylate synthases, called ThyX. Unlike the traditional thymidylate synthase, ThyA, that uses methylenetetrahydrofolate (CH(2)H(4)folate) as both a source of the methylene group and the reductant, CH(2)H(4)folate only supplies the methylene group in ThyX-catalyzed reactions. Furthermore, ThyX only catalyzes thymidylate (dTMP) formation in the presence of reduced pyridine nucleotides and oxidized FAD. The distribution and transcription patterns of the a674r gene in Chlorella viruses were examined. The a674r gene was cloned, and the protein was expressed in Escherichia coli. Biochemical characterization of the P. bursaria chlorella virus-1 recombinant ThyX protein indicates that it is more efficient at converting dUMP to dTMP than previously studied ThyX enzymes, thus allowing more detailed mechanistic studies of the enzyme. The ThyX-dUMP complexes with bound FAD function as efficient NAD(P) H oxidases, indicating that dUMP binds to the enzyme prior to NAD(P) H. This oxidation activity is directly linked to FAD reduction. Our results indicate that ThyX-specific inhibitors can be designed that do not affect ThyA enzymes. Finally, a model is proposed for the early stages of ThyX catalysis.	Ecole Polytech, Lab Opt & Biosci, INSERM, U451,CNRS,UMR 7645, F-91128 Palaiseau, France; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA; Univ Paris 11, Inst Genet & Microbiol, Lab Genom & Microbial Physiol, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; UDICE-French Research Universities; Universite Paris Saclay	Liebl, U (corresponding author), Ecole Polytech, Lab Opt & Biosci, INSERM, U451,CNRS,UMR 7645, F-91128 Palaiseau, France.	Ursula.Liebl@polytechnique.fr	Myllykallio, Hannu/Y-5462-2019	Myllykallio, Hannu/0000-0002-0541-1197; LIEBL, Ursula/0000-0003-0869-4388; Skouloubris, Stephane/0000-0001-6660-0023	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR15635] Funding Source: Medline; NIGMS NIH HHS [GM32441] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal N, 2004, BIOCHEMISTRY-US, V43, P10295, DOI 10.1021/bi0490439; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Copeland R. A., 2004, ENZYMES PRACTICAL IN; DARON HH, 1978, J BIOL CHEM, V253, P940; Fortune JM, 2001, J BIOL CHEM, V276, P24401, DOI 10.1074/jbc.M101693200; Graves MV, 2001, VIROLOGY, V285, P332, DOI 10.1006/viro.2001.0937; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KALMAN TI, 1981, BIOCHEM BIOPH RES CO, V102, P682, DOI 10.1016/S0006-291X(81)80186-6; Kuhn P, 2002, PROTEINS, V49, P142, DOI 10.1002/prot.10202; Leduc D, 2004, P NATL ACAD SCI USA, V101, P7252, DOI 10.1073/pnas.0401365101; Mathews II, 2003, STRUCTURE, V11, P677, DOI 10.1016/S0969-2126(03)00097-2; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Myllykallio H, 2003, TRENDS MICROBIOL, V11, P220, DOI 10.1016/S0966-842X(03)00101-X; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P467, DOI 10.1021/bi00700a011; Sun LW, 2000, VIROLOGY, V276, P27, DOI 10.1006/viro.2000.0500; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; VANETTEN JL, 1984, VIROLOGY, V134, P443, DOI 10.1016/0042-6822(84)90311-8; VANETTEN JL, 1981, VIROLOGY, V113, P704, DOI 10.1016/0042-6822(81)90199-9; VANETTEN JL, 1983, VIROLOGY, V126, P117, DOI 10.1016/0042-6822(83)90466-X	19	57	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54340	54347		10.1074/jbc.M409121200	http://dx.doi.org/10.1074/jbc.M409121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471872	hybrid			2022-12-27	WOS:000225793600056
J	Han, B; Bai, XH; Lodyga, M; Xu, J; Yang, BB; Keshavjee, S; Post, M; Liu, MY				Han, B; Bai, XH; Lodyga, M; Xu, J; Yang, BB; Keshavjee, S; Post, M; Liu, MY			Conversion of mechanical force into biochemical signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENT INTEGRITY; FAMILY TYROSINE KINASES; MECHANOSENSORY TRANSDUCTION; C-SRC; CAENORHABDITIS-ELEGANS; MOLECULAR-BASIS; SHEAR-STRESS; STRETCH; CELLS; MECHANOTRANSDUCTION	Physical forces play important roles in regulating cell proliferation, differentiation, and death by activating intracellular signal transduction pathways. How cells sense mechanical stimulation, however, is largely unknown. Most studies focus on cellular membrane proteins such as ion channels, integrins, and receptors for growth factors as mechanosensory units. Here we show that mechanical stretch-induced c-Src protein tyrosine kinase activation is mediated through the actin filament-associated protein ( AFAP). Distributed along the actin filaments, AFAP can directly active c-Src through binding to its Src homology 3 and/or 2 domains. Mutations at these specific binding sites on AFAP blocked mechanical stretch-induced c-Src activation. Therefore, mechanical force can be transmitted along the cytoskeleton, and interaction between cytoskeletal associated proteins and enzymes related to signal transduction may convert physical forces into biochemical reactions. Cytoskeleton deformation-induced protein-protein interaction via specific binding sites may represent a novel intracellular mechanism for cells to sense mechanical stimulation.	Univ Hlth Network, Toronto Gen Res Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2C4, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Liu, MY (corresponding author), Univ Toronto, Toronto Gen Hosp, Rm MBRC5R422,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	mingyao.liu@utoronto.ca		Liu, Mingyao/0000-0002-9188-8417; Keshavjee, Shaf/0000-0003-4547-8094				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Chalfie M, 1997, BIOL BULL, V192, P125, DOI 10.2307/1542584; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Epstein ND, 2003, CELL, V112, P147, DOI 10.1016/S0092-8674(03)00037-0; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; Langille BL, 2001, MICROCIRCULATION, V8, P195, DOI 10.1038/sj.mn.7800085; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Sai XR, 1999, J CELL SCI, V112, P1365; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; TURNER CH, 1995, AM J PHYSIOL, V269, P438; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	42	117	124	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54793	54801		10.1074/jbc.M406880200	http://dx.doi.org/10.1074/jbc.M406880200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485829	hybrid			2022-12-27	WOS:000225793600107
J	Pan, F; Egile, C; Lipkin, T; Li, R				Pan, F; Egile, C; Lipkin, T; Li, R			ARPC1/Arc40 mediates the interaction of the actin-related protein 2 and 3 complex with Wiskott-Aldrich syndrome protein family activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ARP2/3 COMPLEX; INDIVIDUAL SUBUNITS; N-WASP; POLYMERIZATION; FILAMENTS; MOTILITY; PURIFICATION; CYTOSKELETON; NUCLEATION; HOMOLOGY	The actin-related protein 2 and 3 (Arp2/3) complex is a seven-subunit protein complex that nucleates actin filaments at the cell cortex. Despite extensive cross-linking, crystallography, genetic and biochemical studies, the contribution of each subunit to the activity of the complex remains largely unclear. In this study we characterized the function of the 40-kDa subunit, ARPC1/Arc40, of the yeast Arp2/3 complex. We showed that this subunit is indeed a stable component of the Arp2/3 complex, but its highly unusual electrophoretic mobility eluded detection in previous studies. Recombinant Arc40 bound the VCA domain of Wiskott-Aldrich syndrome protein family activators at a K-d of 0.45 muM, close to that of the full complex with VCA (0.30 muM), and this interaction was dependent on the conserved tryptophan at the COOH terminus of VCA. Using a newly constructed Deltaarc40 yeast strain, we showed that loss of Arc40 severely reduced the binding affinity of the Arp2/3 complex with VCA as well as the nucleation activity of the complex, suggesting that Arc40 contains an important contact site of the Arp2/3 complex with VCA. The Deltaarc40 cells exhibited reduced growth rate, loss of actin patches, and accumulation of cables like actin aggregates, phenotypes typical of other subunit nulls, suggesting that Arc40 functions exclusively within the Arp2/3 complex.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Li, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Bldg C2-417,240 Longwood Ave, Boston, MA 02115 USA.	rli@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066311, R01GM057063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM057063, GM66311] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Beltzner CC, 2004, J MOL BIOL, V336, P551, DOI 10.1016/j.jmb.2003.12.017; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gournier H, 2001, MOL CELL, V8, P1041, DOI 10.1016/S1097-2765(01)00393-8; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hufner K, 2001, J BIOL CHEM, V276, P35761, DOI 10.1074/jbc.M106520200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lechler T, 2001, J CELL BIOL, V155, P261, DOI 10.1083/jcb.200104094; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sherman F., 1974, METHODS YEAST GENETI; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Weaver AM, 2003, CURR OPIN CELL BIOL, V15, P23, DOI 10.1016/S0955-0674(02)00015-7; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200	34	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54629	54636		10.1074/jbc.M402357200	http://dx.doi.org/10.1074/jbc.M402357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485833	hybrid			2022-12-27	WOS:000225793600089
J	Dodd, RB; Allen, MD; Brown, SE; Sanderson, CM; Duncan, LM; Lehner, PJ; Bycroft, M; Read, RJ				Dodd, RB; Allen, MD; Brown, SE; Sanderson, CM; Duncan, LM; Lehner, PJ; Bycroft, M; Read, RJ			Solution structure of the Kaposi's sarcoma-associated herpesvirus K3N-terminal domain reveals a novel E2-binding C4HC3-type RING domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-I; MHC CLASS-I; E3 UBIQUITIN LIGASES; CRYSTAL-STRUCTURE; FINGER PROTEINS; DOWN-REGULATION; IMMUNE EVASION; PHD DOMAIN; FAMILY; MOLECULES	RING domains are found in a large number of eukaryotic proteins. Most function as E3 ubiquitin-protein ligases, catalyzing the terminal step in the ubiquitination process. Structurally, these domains have been characterized as binding two zinc ions in a stable cross-brace motif. The tumorigenic human gamma-herpesvirus Kaposi's sarcoma-associated herpesvirus encodes a ubiquitin-protein ligase termed K3, which functions as an immune evasion molecule by ubiquitinating major histocompatibility complex class I. K3 possesses at its N terminus a domain related to cellular RING domains but with an altered zinc ligand arrangement. This domain was initially characterized as a plant homeodomain, a structure not previously known to function as an E3. Here, it is conclusively demonstrated that the K3 N-terminal domain is a variant member of the RING domain family and not a plant homeodomain. The domain is found to interact with the cellular ubiquitin-conjugating enzymes UbcH5A to -C and UbcH13, which dock to the equivalent surface as on classical cellular RING domains. Interaction with UbcH13 suggests a possible role for K3 in catalyzing Lys(63)-linked ubiquitination.	Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; MRC, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England; MRC, Rosalind Franklin Ctr Gen Res, Funct Gen Grp, Cambridge CB10 1SB, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Read, RJ (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	rjr27@cam.ac.uk	Bycroft, Mark/D-9446-2017; Dodd, Roger/B-4917-2008; Read, Randy J/L-1418-2013	Read, Randy J/0000-0001-8273-0047; Lehner, Paul Joseph/0000-0001-9383-1054; Bycroft, Mark/0000-0002-0673-2216; Dodd, Roger/0000-0003-4268-1863				Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Ashley C, 2002, GENE, V285, P183, DOI 10.1016/S0378-1119(02)00409-2; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Bashford D, 1997, LECT NOTES COMPUTER, P233, DOI [10.1007/3-540-63827-X, DOI 10.1007/3-540-63827-X_66]; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Coscoy L, 2003, TRENDS CELL BIOL, V13, P287, DOI 10.1016/S0962-8924(03)00103-X; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; DeLano WL, 2002, PYMOL USERS MANUAL; Estevez AM, 2003, J BIOL CHEM, V278, P34943, DOI 10.1074/jbc.M305333200; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Haque M, 2001, J GEN VIROL, V82, P1175, DOI 10.1099/0022-1317-82-5-1175; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson ES, 2002, NAT CELL BIOL, V4, pE295, DOI 10.1038/ncb1202-e295; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Tanaka K, 1998, GENES CELLS, V3, P499, DOI 10.1046/j.1365-2443.1998.00207.x; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Wilkinson Caroline R. M., 2002, Trends in Cell Biology, V12, P545, DOI 10.1016/S0962-8924(02)02397-8; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53840	53847		10.1074/jbc.M409662200	http://dx.doi.org/10.1074/jbc.M409662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465811	hybrid			2022-12-27	WOS:000225680600122
J	Koga, H; Ohshima, T; Shimotohno, K				Koga, H; Ohshima, T; Shimotohno, K			Enhanced activation of tax-dependent transcription of human T-cell leukemia virus type I (HTLV-I) long terminal repeat by TORC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BINDING-PROTEIN; MOLECULAR-MECHANISM; CREB; TRANSACTIVATION; ONCOPROTEIN; INTERACTS; COACTIVATOR; ELEMENT; DOMAIN	Tax, a protein encoded by the env-pX gene of human T-cell leukemia virus type I (HTLV-I), interacts with various host cell transcription factors. Tax activates transcription from the long terminal repeat (LTR) of HTLV-I through association with cyclic AMP-responsive element-binding protein (CREB). Here, we present evidence that transducer of regulated cyclic AMP-response element-binding protein 3 (TORC3), a co-activator of CREB, is involved in Tax-induced transcriptional activation from the HTLV-I LTR. By using a luciferase assay system, we show that TORC3 alone can enhance transcription from the HTLV-I LTR, as well as from a cellular cyclic AMP-response element (CRE). Interestingly, we find that co-expression of TORC3 and Tax dramatically increased transcriptional activation at the HTLV-I LTR. We also show by glutathione S-transferase pull-down and co-immunoprecipitation experiments that TORC3 interacts with Tax. Using deletion mutant analysis, we identify the Tax interaction domain of TORC3 as a region spanning from amino acid 1 to 103, which contains a coiled-coil domain. These results provide important clues toward understanding the molecular mechanism of Tax-dependent transcriptional activation of the HTLV-I LTR.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068502, Japan.	kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Connor LM, 2000, VIROLOGY, V270, P328, DOI 10.1006/viro.2000.0262; Datta S, 2000, J VIROL, V74, P8277, DOI 10.1128/JVI.74.18.8277-8285.2000; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; OSAME M, 1986, LANCET, V1, P1031; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Watanabe T, 1997, INT J HEMATOL, V66, P257; YAMAOKA S, 1992, ONCOGENE, V7, P433; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Youn HG, 2003, J VIROL, V77, P10015, DOI 10.1128/JVI.77.18.10015-10027.2003	33	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52978	52983		10.1074/jbc.M409021200	http://dx.doi.org/10.1074/jbc.M409021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466468	hybrid			2022-12-27	WOS:000225680600022
J	Liang, XD; Young, JJ; Boone, SA; Waugh, DS; Duesbery, NS				Liang, XD; Young, JJ; Boone, SA; Waugh, DS; Duesbery, NS			Involvement of domain II in toxicity of anthrax lethal factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; FACTOR CLEAVES; KINASE-KINASE; TOXIN; INHIBITORS; SEQUENCE; BINDING	Anthrax lethal factor (LF) is a Zn2+-metalloprotease that cleaves and inactivates mitogen-activated protein kinase kinases (MEKs). We have used site-directed mutagenesis to identify a cluster of residues in domain II of LF that lie outside the active site and are required for cellular proteolytic activity toward MEKs. Alanine substituted for Leu(293), Lys(294), Leu(514), Asn(516), or Arg(491) caused a 10-50-fold reduction in LF toxicity. Further, whereas pairwise substitution of alanine for Leu(514) and either Leu(293), Lys(294), or Arg(491) completely abrogated LF toxicity, pairwise mutation of Leu(514) and Asn(516) resulted in toxicity comparable with N516A alone. The introduction of these mutations reduced LF-mediated cleavage of MEK2 in cell-based assays but altered neither the ability of LF to bind protective antigen nor its ability to translocate across a membrane. Interestingly, direct in vitro measurement of LF activity indicated that decreased toxicity was not always accompanied by reduced proteolytic activity. However, mutations in this region significantly reduced the ability of LF to competitively inhibit B-Raf phosphorylation of MEK. These results provide evidence that elements of domain II are involved in the association of LF into productive complex with MEKs.	Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA; NCI, Prot Engn Sect, Macromol Crystallog Lab, Ctr Canc Res, Ft Detrick, MD 21702 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	duesbery@vai.org		Young, John/0000-0001-5929-5315; Duesbery, Nicholas/0000-0002-5708-4984; DUESBERY, NICK/0000-0002-4258-5655				ARORA N, 1993, J BIOL CHEM, V268, P3334; Bardwell AJ, 2004, BIOCHEM J, V378, P569, DOI 10.1042/BJ20031382; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; BRAGG TS, 1989, GENE, V81, P45, DOI 10.1016/0378-1119(89)90335-1; CATALDI A, 1990, MOL MICROBIOL, V4, P1111, DOI 10.1111/j.1365-2958.1990.tb00685.x; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; Dell'Aica I, 2004, EMBO REP, V5, P418, DOI 10.1038/sj.embor.7400118; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Lacy DB, 2002, J BIOL CHEM, V277, P3006, DOI 10.1074/jbc.M109997200; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Min DH, 2004, NAT BIOTECHNOL, V22, P717, DOI 10.1038/nbt973; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PEZARD C, 1993, J GEN MICROBIOL, V139, P2459, DOI 10.1099/00221287-139-10-2459; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; QUINN CP, 1991, J BIOL CHEM, V266, P20124; QUINN CP, 1990, J GEN MICROBIOL, V136, P1211, DOI 10.1099/00221287-136-7-1211; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671	39	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52473	52478		10.1074/jbc.M409105200	http://dx.doi.org/10.1074/jbc.M409105200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465830	hybrid			2022-12-27	WOS:000225493400092
J	Xu, Y; Liang, XW; Chen, YH; Koehler, TM; Hook, M				Xu, Y; Liang, XW; Chen, YH; Koehler, TM; Hook, M			Identification and biochemical characterization of two novel collagen binding MSCRAMMs of Bacillus anthracis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; STAPHYLOCOCCUS-AUREUS; CIRCULAR-DICHROISM; ENTEROCOCCUS-FAECALIS; VIRULENCE FACTOR; CLUMPING FACTOR; ADHESIN; PATHOGENESIS; FIBRINOGEN; YADA	Cell wall-anchored proteins play critical roles in the pathogenesis of infections caused by Gram-positive bacteria. Through the analysis of the genome of Bacillus anthracis Ames strain, we identified two novel putative cell wall-anchored proteins, BA0871 and BA5258, which have sequence homology to CNA, a cell wall-anchored collagen adhesin of Staphylococcus aureus. The two proteins have similar domain organization to that of CNA, with typical signal peptide sequences, a non-repetitive A region followed by repeats, and a characteristic cell wall-anchoring region. They are expressed on the surface of B. anthracis. The A regions of the two proteins were predicted to adopt similar structural folds as CNA. Circular dichroism analysis of the recombinant A regions of the two proteins (rBA0871A and rBA5258A) indicate that their secondary structure compositions are similar to those of the A regions of CNA and other cell wall-anchored adhesins. We demonstrate through solid phase binding assays and surface plasmon resonance analyses that rBA0871A and rBA5258A specifically bound type I collagen in a dose-dependent and saturable manner. Their dissociation constants (K-D) for collagen are 1.6-3.2 muM for rBA0871A and 0.6-0.9 muM for rBA5258A, respectively. We further demonstrate that BA0871 and BA5258 can mediate cell attachment to collagen when expressed on the surface of a heterologous host bacterium. To our knowledge these are the first two adhesins of B. anthracis described, which may have important implications for our understanding of the pathogenic mechanisms explored by this organism.	Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Xu, Y (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, 2121 W Holcombe Blvd,Suite 603, Houston, TX 77030 USA.	yxu@ibt.tamushsc.edu		Liang, Xiaowen/0000-0002-6174-2951	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI061555, R01AI020624, U54AI057156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER; NIAID NIH HHS [AIO61555-01, U54 AI057156, AI020624-21] Funding Source: Medline; NIAMS NIH HHS [AR44415] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Ascenzi P, 2002, FEBS LETT, V531, P384, DOI 10.1016/S0014-5793(02)03609-8; Bourgogne A, 2003, INFECT IMMUN, V71, P2736, DOI 10.1128/IAI.71.5.2736-2743.2003; Deivanayagam CCS, 2000, STRUCTURE, V8, P67, DOI 10.1016/S0969-2126(00)00081-2; Deivanayagam CCS, 2002, EMBO J, V21, P6660, DOI 10.1093/emboj/cdf619; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; El Tahir Y, 2001, INT J MED MICROBIOL, V291, P209, DOI 10.1078/1438-4221-00119; Elasri MO, 2002, BONE, V30, P275, DOI 10.1016/S8756-3282(01)00632-9; GRIPENBERGLERCHE C, 1995, INFECT IMMUN, V63, P3222, DOI 10.1128/IAI.63.8.3222-3226.1995; GRIPENBERGLERCHE C, 1994, INFECT IMMUN, V62, P5568, DOI 10.1128/IAI.62.12.5568-5575.1994; Guidi-Rontani C, 2002, TRENDS MICROBIOL, V10, P405, DOI 10.1016/S0966-842X(02)02422-8; Hanna P, 1998, CURR TOP MICROBIOL, V225, P13; Hanna PC, 1999, TRENDS MICROBIOL, V7, P180, DOI 10.1016/S0966-842X(99)01507-3; Hienz SA, 1996, J INFECT DIS, V174, P83, DOI 10.1093/infdis/174.1.83; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61; Lannergard J, 2003, FEMS MICROBIOL LETT, V222, P69, DOI 10.1016/S0378-1097(03)00222-2; LEE CY, 1989, J BACTERIOL, V171, P1652, DOI 10.1128/jb.171.3.1652-1657.1989; Mamo W, 2000, MICROBIOL IMMUNOL, V44, P381, DOI 10.1111/j.1348-0421.2000.tb02509.x; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Motulsky H, 2003, PRACTICAL GUIDE CURV; Nallapareddy SR, 2003, MOL MICROBIOL, V47, P1733, DOI 10.1046/j.1365-2958.2003.03417.x; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Ponnuraj K, 2002, BBA-PROTEIN STRUCT M, V1596, P173, DOI 10.1016/S0167-4838(01)00328-4; Ponnuraj K, 2003, CELL, V115, P217, DOI 10.1016/S0092-8674(03)00809-2; Pouttu R, 1999, MOL MICROBIOL, V31, P1747, DOI 10.1046/j.1365-2958.1999.01311.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rhem MN, 2000, INFECT IMMUN, V68, P3776, DOI 10.1128/IAI.68.6.3776-3779.2000; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Ruthel G, 2004, J INFECT DIS, V189, P1313, DOI 10.1086/382656; Shimoji Y, 2003, J BACTERIOL, V185, P2739, DOI 10.1128/JB.185.9.2739-2748.2003; Sillanpaa J, 2004, MICROBIOL-SGM, V150, P2069, DOI 10.1099/mic.0.27074-0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Visai L, 2000, J BIOL CHEM, V275, P39837, DOI 10.1074/jbc.M005297200; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Xu Y, 2004, J INFECT DIS, V189, P2323, DOI 10.1086/420851; YANG JT, 1986, METHOD ENZYMOL, V130, P208	42	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51760	51768		10.1074/jbc.M406417200	http://dx.doi.org/10.1074/jbc.M406417200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456768	hybrid			2022-12-27	WOS:000225493400008
J	Pan, QH; Gollapudi, AS; Dave, VP				Pan, QH; Gollapudi, AS; Dave, VP			Biochemical evidence for the presence of a single CD3 delta and CD3 gamma chain in the surface T cell receptor/CD3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; ALPHA-BETA; TCR/CD3 COMPLEX; TCR-ALPHA; MULTIVALENT STRUCTURE; CD3-EPSILON CHAINS; CD3 COMPLEX; GAMMA; ASSOCIATION; ACTIVATION	The T cell antigen receptor (TCR) consists of an alphabeta heterodimer and associated invariant CD3gamma, delta, epsilon, and zeta chains (TCR/CD3 complex). The general stoichiometry of the receptor complex, which is believed to be one molecule each of TCRalpha, TCRbeta, CD3gamma, and CD3delta and two molecules each of CD3epsilon and CD3zeta, is not clearly understood. Although it has been shown that there are two chains of CD3epsilon and CD3zeta, the stoichiometry of CD3gamma or CD3delta chains in the surface antigen receptor complex has not been determined. In the present study, transgenic mice expressing an altered form of mouse CD3delta and CD3gamma were employed to show that the surface TCR complexes contain one molecule each of CD3delta and CD3gamma. Thymocytes from wild type and CD3 chain transgenic mice on the appropriate knockout background were surface-biotinylated and immunoprecipitated using a specific antibody. The immunoprecipitates were resolved in two dimensions under nonreducing/reducing conditions to determine the stoichiometry of CD3delta and CD3gamma in the surface antigen receptor complex. Our data clearly show the presence of one molecule each of CD3delta and CD3gamma in the surface TCR/CD3 complex.	Inst Rech Clin Montreal, Lymphocyte Dev Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Dave, VP (corresponding author), Inst Rech Clin Montreal, Lymphocyte Dev Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	vibhuti.dave@ircm.qc.ca						BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; Davis MM, 2002, CELL, V110, P285, DOI 10.1016/S0092-8674(02)00865-6; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; EXLEY M, 1995, MOL IMMUNOL, V32, P829, DOI 10.1016/0161-5890(95)00046-H; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; Hayes SM, 2002, J EXP MED, V196, P1355, DOI 10.1084/jem.20021196; Jacobs H, 1997, IMMUNOL TODAY, V18, P565; Jose ES, 1998, EUR J IMMUNOL, V28, P12; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; KEARSE KP, 1995, IMMUNITY, V2, P391; Malissen B, 1999, ADV IMMUNOL, V72, P103, DOI 10.1016/S0065-2776(08)60018-8; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; THIBAULT G, 1995, J IMMUNOL, V154, P3814; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	31	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51068	51074		10.1074/jbc.M406145200	http://dx.doi.org/10.1074/jbc.M406145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459203	hybrid			2022-12-27	WOS:000225355800052
